10076535|t|Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
10076535|a|Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer. Estramustine phosphate is metabolically activated in vivo, and its metabolites, estramustine, estromustine, estrone, and beta-estradiol inhibit the assembly of microtubules [for review see: Kreis W, In: Concepts, Mechanisms, and New Targets for Chemotherapy (Ed. Muggia FM), pp. 163-184. Kluwer Academic Publishers, Boston, 1995]. We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells. Analogous to the antiandrogens, bicalutamide and hydroxyflutamide, binding of estramustine phosphate metabolites to the androgen receptor was observed. The EC50 values (in microM) were: estramustine phosphate, > 10; estramustine, 3.129 +/- 0.312; estromustine; 2.612 +/- 0.584; estrone, 0.800 +/- 0.090; alpha-estradiol, 1.051 +/- 0.096; beta-estradiol, 0.523 +/- 0.028; bicalutamide, 4.920 +/- 0.361; and hydroxyflutamide, 0.254 +/- 0.012. The transactivation assay demonstrated that, analogous to bicalutamide, estramustine could not induce luciferase activity in either w-pAR0 or m-pARL transfected HeLa cells. In contrast, a strong induction of the reporter activity by dihydrotestosterone was observed. Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor. Exposure of LNCaP cells to estramustine for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner. The levels of PSA mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of estramustine, respectively (IC50 = 10.97 +/- 1.68 microM). Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR. Our data indicate that estramustine phosphate metabolites perform as androgen antagonists of AR, an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.
10076535	1404	1419	alpha-estradiol	CHEMICAL	10076535T10
10076535	1438	1452	beta-estradiol	CHEMICAL	10076535T11
10076535	1471	1483	bicalutamide	CHEMICAL	10076535T12
10076535	1506	1522	hydroxyflutamide	CHEMICAL	10076535T13
10076535	1599	1611	bicalutamide	CHEMICAL	10076535T14
10076535	1613	1625	estramustine	CHEMICAL	10076535T15
10076535	270	292	Estramustine phosphate	CHEMICAL	10076535T16
10076535	1774	1793	dihydrotestosterone	CHEMICAL	10076535T17
10076535	1893	1905	estramustine	CHEMICAL	10076535T18
10076535	1910	1922	bicalutamide	CHEMICAL	10076535T19
10076535	117	139	Estramustine phosphate	CHEMICAL	10076535T1
10076535	1970	1978	androgen	CHEMICAL	10076535T20
10076535	2016	2028	estramustine	CHEMICAL	10076535T21
10076535	2215	2227	estramustine	CHEMICAL	10076535T22
10076535	2285	2301	hydroxyflutamide	CHEMICAL	10076535T23
10076535	2410	2426	hydroxyflutamide	CHEMICAL	10076535T24
10076535	350	362	estramustine	CHEMICAL	10076535T25
10076535	2483	2505	estramustine phosphate	CHEMICAL	10076535T26
10076535	2529	2537	androgen	CHEMICAL	10076535T27
10076535	364	376	estromustine	CHEMICAL	10076535T28
10076535	2619	2641	estramustine phosphate	CHEMICAL	10076535T29
10076535	1132	1144	bicalutamide	CHEMICAL	10076535T2
10076535	378	385	estrone	CHEMICAL	10076535T30
10076535	391	405	beta-estradiol	CHEMICAL	10076535T31
10076535	637	657	[3H]methyltrienolone	CHEMICAL	10076535T32
10076535	687	710	triamcinolone acetonide	CHEMICAL	10076535T33
10076535	727	749	estramustine phosphate	CHEMICAL	10076535T34
10076535	771	783	estramustine	CHEMICAL	10076535T35
10076535	785	797	estromustine	CHEMICAL	10076535T36
10076535	799	806	estrone	CHEMICAL	10076535T37
10076535	812	826	beta-estradiol	CHEMICAL	10076535T38
10076535	875	890	alpha-estradiol	CHEMICAL	10076535T39
10076535	1149	1165	hydroxyflutamide	CHEMICAL	10076535T3
10076535	892	904	bicalutamide	CHEMICAL	10076535T40
10076535	910	926	hydroxyflutamide	CHEMICAL	10076535T41
10076535	943	951	androgen	CHEMICAL	10076535T42
10076535	1004	1012	androgen	CHEMICAL	10076535T43
10076535	0	8	Androgen	CHEMICAL	10076535T44
10076535	32	54	estramustine phosphate	CHEMICAL	10076535T45
10076535	56	59	EMP	CHEMICAL	10076535T46
10076535	98	106	androgen	CHEMICAL	10076535T47
10076535	1220	1237	androgen receptor	GENE-Y	10076535T48
10076535	1827	1852	prostate-specific antigen	GENE-Y	10076535T49
10076535	1178	1200	estramustine phosphate	CHEMICAL	10076535T4
10076535	1854	1857	PSA	GENE-Y	10076535T50
10076535	1874	1876	AR	GENE-Y	106862
10076535	1970	1987	androgen receptor	GENE-Y	10076535T52
10076535	2076	2079	PSA	GENE-Y	10076535T53
10076535	2131	2134	PSA	GENE-Y	10076535T54
10076535	2307	2309	AR	GENE-Y	106862
10076535	2378	2381	PSA	GENE-Y	10076535T56
10076535	2456	2458	AR	GENE-Y	106862
10076535	2553	2555	AR	GENE-Y	106862
10076535	943	960	androgen receptor	GENE-Y	10076535T59
10076535	1220	1228	androgen	CHEMICAL	10076535T5
10076535	964	966	AR	GENE-Y	106862
10076535	1004	1021	androgen receptor	GENE-Y	10076535T61
10076535	1035	1037	AR	GENE-Y	106862
10076535	98	115	androgen receptor	GENE-Y	10076535T63
10076535	1286	1308	estramustine phosphate	CHEMICAL	10076535T6
10076535	1316	1328	estramustine	CHEMICAL	10076535T7
10076535	1347	1359	estromustine	CHEMICAL	10076535T8
10076535	1378	1385	estrone	CHEMICAL	10076535T9
10076535	CPR:3	10076535T23	10076535T56
10076535	CPR:4	10076535T18	10076535T49
10076535	CPR:4	10076535T18	10076535T50
10076535	CPR:4	10076535T18	106862
10076535	CPR:4	10076535T18	10076535T52
10076535	CPR:4	10076535T19	10076535T49
10076535	CPR:4	10076535T19	10076535T50
10076535	CPR:4	10076535T19	106862
10076535	CPR:4	10076535T19	10076535T52
10076535	CPR:4	10076535T21	10076535T53
10076535	CPR:4	10076535T22	10076535T54
10076535	CPR:5	10076535T24	106862
10076535	CPR:6	10076535T26	106862
10076535	CPR:6	10076535T27	106862
10076535	CPR:6	10076535T44	10076535T63
10076535	CPR:6	10076535T45	10076535T63
10076535	CPR:6	10076535T46	10076535T63

10089512|t|Static Laue diffraction studies on acetylcholinesterase.
10089512|a|Acetylcholinesterase (AChE) is one of nature's fastest enzymes, despite the fact that its three-dimensional structure reveals its active site to be deeply sequestered within the molecule. This raises questions with respect to traffic of substrate to, and products from, the active site, which may be investigated by time-resolved crystallography. In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of Torpedo californica AChE soaked with the reversible inhibitor edrophonium, using a total X-ray exposure time of 24 ms. Electron-density maps obtained from the Laue data, which are of surprisingly good quality compared with similar maps from monochromatic data, show essentially the same features. They clearly reveal the bound ligand, as well as a structural change in the conformation of the active-site Ser200 induced upon binding.
10089512	641	652	edrophonium	CHEMICAL	10089512T1
10089512	57	77	Acetylcholinesterase	GENE-Y	10089512T2
10089512	79	83	AChE	GENE-Y	10089512T3
10089512	493	497	AChE	GENE-Y	10089512T4
10089512	579	603	Torpedo californica AChE	GENE-Y	10089512T5
10089512	35	55	acetylcholinesterase	GENE-Y	10089512T6
10089512	CPR:4	10089512T1	10089512T5

10201371|t|Synthesis of thrombin-inhibiting heparin mimetics without side effects.
10201371|a|Unwanted side effects of pharmacologically active compounds can usually be eliminated by structural modifications. But the complex heterogeneous structure of the polysaccharide heparin has limited this approach to fragmentation, leading to slightly better-tolerated heparin preparations of low molecular mass. Despite this improvement, heparin-induced thrombocytopaenia (HIT), related to an interaction with platelet factor 4 (PF4) and, to a lesser extent, haemorrhages, remain significant side effects of heparinotherapy. Breakthroughs in oligosaccharide chemistry made possible the total synthesis of the pentasaccharide antithrombin-binding site of heparin. This pentasaccharide represents a new family of potential antithrombotic drugs, devoid of thrombin inhibitory properties, and free of undesired interactions with blood and vessel components. To obtain more potent and well-tolerated antithrombotic drugs, we wished to synthesize heparin mimetics able to inhibit thrombin, that is, longer oligosaccharides. Like thrombin inhibition, undesired interactions are directly correlated to the charge and the size of the molecules, so we had to design structures that were able to discriminate between thrombin and other proteins, particularly PF4. Here we describe the use of multistep converging synthesis to obtain sulphated oligosaccharides that meet these requirements.
10201371	1093	1101	thrombin	GENE-Y	10201371T1
10201371	1276	1284	thrombin	GENE-Y	10201371T2
10201371	1318	1321	PF4	GENE-Y	111219
10201371	480	497	platelet factor 4	GENE-Y	10201371T4
10201371	499	502	PF4	GENE-Y	111219
10201371	695	707	antithrombin	GENE-Y	10201371T6
10201371	823	831	thrombin	GENE-Y	10201371T7
10201371	1044	1052	thrombin	GENE-Y	10201371T8
10201371	13	21	thrombin	GENE-Y	10201371T9

10220509|t|Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites.
10220509|a|BACKGROUND & AIMS: The critical role of cyclooxygenase (COX) products in maintenance of renal function in cirrhosis with ascites discourages the use of nonsteroidal anti-inflammatory drugs in this disease. The recent development of selective COX-2 inhibitors opens new avenues for the use of these compounds in decompensated cirrhosis. The current study evaluates the effects of a selective COX-2 inhibitor (SC-236) on renal function in cirrhotic rats with ascites. METHODS: In protocol 1, urine volume, urinary excretion of sodium and prostaglandins, glomerular filtration rate, and renal plasma flow were measured before and after administration of SC-236 (n = 12) or ketorolac (n = 10) to rats with cirrhosis. Protocol 2 was aimed at assessing the effects of COX inhibitors on renal water metabolism in 28 cirrhotic rats. RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism. CONCLUSIONS: These findings indicate that SC-236 does not significantly impair renal function in rats with cirrhosis.
10220509	67	80	prostaglandin	CHEMICAL	10220509T10
10220509	365	370	COX-2	GENE-Y	10220509T11
10220509	514	519	COX-2	GENE-Y	10220509T12
10220509	163	177	cyclooxygenase	GENE-N	10220509T13
10220509	179	182	COX	GENE-N	10220509T14
10220509	885	888	COX	GENE-N	10220509T15
10220509	1089	1094	COX-1	GENE-Y	10220509T16
10220509	1095	1100	COX-2	GENE-Y	10220509T17
10220509	24	40	cyclooxygenase 2	GENE-Y	10220509T18
10220509	1192	1206	prostaglandins	CHEMICAL	10220509T1
10220509	1340	1346	SC-236	CHEMICAL	10220509T2
10220509	531	537	SC-236	CHEMICAL	10220509T3
10220509	648	654	sodium	CHEMICAL	10220509T4
10220509	659	673	prostaglandins	CHEMICAL	10220509T5
10220509	774	780	SC-236	CHEMICAL	10220509T6
10220509	793	802	ketorolac	CHEMICAL	10220509T7
10220509	975	981	SC-236	CHEMICAL	10220509T8
10220509	1112	1121	ketorolac	CHEMICAL	10220509T9
10220509	CPR:4	10220509T3	10220509T12
10220509	CPR:4	10220509T9	10220509T16
10220509	CPR:4	10220509T9	10220509T17
10220509	CPR:9	10220509T10	10220509T18
10220509	CPR:9	10220509T1	10220509T16
10220509	CPR:9	10220509T1	10220509T17

10351938|t|Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils.
10351938|a|We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (cPLA2), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro. Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB). At 24 h, stimulated LTC4 secretion from eosinophils was unchanged; however, when corrected for cell viability, LTC4 secretion decreased from 1,429 +/- 327 pg/10(6) cells to 762 +/- 113 pg/10(6) cells for eosinophils treated for 48 h with >/= 10(-)8 M FP (p < 0.003). FMLP/CB-stimulated translocation of cPLA2 to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP. By contrast, membrane expression of annexin-1, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA). We find that FP causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by phospholipase A2 (PLA2). Inhibition of LTC4 synthesis precedes the global cytotoxic effects of FP as indicated by the simultaneous upregulation of annexin-1 expression. Inhibited stimulated secretion corresponds to inhibited translocation of cPLA2 to the nuclear envelope during cellular activation.
10351938	352	356	LTC4	CHEMICAL	10351938T10
10351938	509	511	FP	CHEMICAL	10351938T11
10351938	600	618	formyl-met-leu-phe	CHEMICAL	10351938T12
10351938	620	624	FMLP	CHEMICAL	10351938T13
10351938	628	642	cytochalasin B	CHEMICAL	10351938T14
10351938	644	646	CB	CHEMICAL	10351938T15
10351938	669	673	LTC4	CHEMICAL	10351938T16
10351938	760	764	LTC4	CHEMICAL	10351938T17
10351938	197	219	fluticasone propionate	CHEMICAL	10351938T18
10351938	900	902	FP	CHEMICAL	10351938T19
10351938	1201	1203	FP	CHEMICAL	10351938T1
10351938	916	920	FMLP	CHEMICAL	10351938T20
10351938	921	923	CB	CHEMICAL	10351938T21
10351938	221	223	FP	CHEMICAL	10351938T22
10351938	1052	1054	FP	CHEMICAL	10351938T23
10351938	38	52	leukotriene C4	CHEMICAL	10351938T24
10351938	66	88	fluticasone propionate	CHEMICAL	10351938T25
10351938	1385	1401	phospholipase A2	GENE-Y	10351938T26
10351938	1403	1407	PLA2	GENE-Y	10351938T27
10351938	1532	1541	annexin-1	GENE-Y	10351938T28
10351938	280	306	cytosolic phospholipase A2	GENE-Y	10351938T29
10351938	1223	1227	LTC4	CHEMICAL	10351938T2
10351938	1627	1632	cPLA2	GENE-Y	10351938T30
10351938	308	313	cPLA2	GENE-Y	10351938T31
10351938	540	571	human recombinant interleukin-5	GENE-Y	10351938T32
10351938	573	579	rhIL-5	GENE-Y	10351938T33
10351938	952	957	cPLA2	GENE-Y	10351938T34
10351938	1092	1101	annexin-1	GENE-Y	10351938T35
10351938	14	19	cPLA2	GENE-Y	10351938T36
10351938	1264	1280	arachidonic acid	CHEMICAL	10351938T3
10351938	1282	1284	AA	CHEMICAL	10351938T4
10351938	1300	1302	FP	CHEMICAL	10351938T5
10351938	1359	1363	LTC4	CHEMICAL	10351938T6
10351938	1424	1428	LTC4	CHEMICAL	10351938T7
10351938	1480	1482	FP	CHEMICAL	10351938T8
10351938	336	350	leukotriene C4	CHEMICAL	10351938T9
10351938	CPR:3	10351938T8	10351938T28
10351938	CPR:4	10351938T23	10351938T34
10351938	CPR:4	10351938T25	10351938T36
10351938	CPR:4	10351938T5	10351938T26
10351938	CPR:9	10351938T6	10351938T26
10351938	CPR:9	10351938T6	10351938T27

10424850|t|Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells.
10424850|a|The antidepressant desipramine has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter (NET) in vivo and in vitro, on both an acute and a chronic basis. The possible contribution of decreased NET synthesis to the chronic downregulation of the NETs has not been definitively established. In this study, we treated SK-N-SHSY5Y cells with 100 nM desipramine for 24 or 72 h, and measured 3H-nisoxetine binding (as an estimate of NETs) and NET mRNA by quantitative reverse transcription polymerase chain reaction. Similar to what has been reported previously, membrane 3H-nisoxetine binding was significantly decreased at both 24 and 72 h (approximately 50% at both time points). However, a significant decrease (64 +/- 8% of paired control) of NET mRNA was observed only at the 72-h time point. We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of desipramine to downregulate the NET.
10424850	248	251	NET	GENE-Y	10424850T10
10424850	352	355	NET	GENE-Y	10424850T11
10424850	403	407	NETs	GENE-Y	10424850T12
10424850	585	589	NETs	GENE-Y	10424850T13
10424850	595	598	NET	GENE-Y	10424850T14
10424850	900	903	NET	GENE-Y	10424850T15
10424850	978	981	NET	GENE-Y	10424850T16
10424850	1080	1083	NET	GENE-Y	10424850T17
10424850	210	246	norepinephrine re-uptake transporter	GENE-Y	10424850T18
10424850	58	84	norepinephrine transporter	GENE-Y	10424850T19
10424850	131	142	desipramine	CHEMICAL	10424850T1
10424850	503	514	desipramine	CHEMICAL	10424850T2
10424850	544	557	3H-nisoxetine	CHEMICAL	10424850T3
10424850	724	737	3H-nisoxetine	CHEMICAL	10424850T4
10424850	1048	1059	desipramine	CHEMICAL	10424850T5
10424850	210	224	norepinephrine	CHEMICAL	10424850T6
10424850	0	11	Desipramine	CHEMICAL	1139
10424850	32	45	3H-nisoxetine	CHEMICAL	10424850T8
10424850	58	72	norepinephrine	CHEMICAL	10424850T9
10424850	CPR:4	10424850T1	10424850T10
10424850	CPR:4	10424850T1	10424850T18
10424850	CPR:4	10424850T5	10424850T17
10424850	CPR:4	1139	10424850T19

10510456|t|Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.
10510456|a|1 Cisapride is a prokinetic agent which has been associated with QT prolongation, torsades de pointes and cardiac arrest. The cellular mechanism for these observations is high affinity blockade of IKr (encoded by HERG). 2 In a chronic transfection model using CHO-K1 cells, cisapride inhibited HERG tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. 4 nM at 20-22 degrees C and 23.6 nM at 37 degrees C). 3 Channel inhibition exhibited time-, voltage- and frequency-dependence. In an envelope of tails test, channel blockade increased from 27+/-8% after a 120 ms depolarizing step to 50+/-4% after a 1.0 s step. These findings suggested affinity for open and/or inactivated channel states. 4 Inactivation was significantly accelerated by cisapride in a concentration-dependent manner and there was a small (-7 mV) shift in the voltage dependence of steady state inactivation. 5 Channel blockade by cisapride was modulated by [K+]o, with a 26% reduction in the potency of channel blockade when [K+]o was increased from 1 to 10 mM. 6 In conclusion, HERG channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration. These features may have significant clinical implications with regard to the mechanism and treatment of cisapride-induced proarrhythmia.
10510456	24	29	ether	CHEMICAL	10510456T10
10510456	58	67	potassium	CHEMICAL	10510456T11
10510456	79	88	cisapride	CHEMICAL	10510456T12
10510456	1234	1238	HERG	GENE-Y	10510456T13
10510456	329	332	IKr	GENE-N	10510456T14
10510456	345	349	HERG	GENE-Y	10510456T15
10510456	426	430	HERG	GENE-Y	10510456T16
10510456	18	75	human ether-a-go-go-related gene (HERG) potassium channel	GENE-Y	10510456T17
10510456	1181	1183	K+	CHEMICAL	10510456T1
10510456	1261	1270	cisapride	CHEMICAL	10510456T2
10510456	1369	1378	potassium	CHEMICAL	10510456T3
10510456	1498	1507	cisapride	CHEMICAL	10510456T4
10510456	134	143	Cisapride	CHEMICAL	594
10510456	406	415	cisapride	CHEMICAL	10510456T6
10510456	925	934	cisapride	CHEMICAL	10510456T7
10510456	1085	1094	cisapride	CHEMICAL	10510456T8
10510456	1113	1115	K+	CHEMICAL	10510456T9
10510456	CPR:4	10510456T12	10510456T17
10510456	CPR:4	10510456T2	10510456T13
10510456	CPR:4	10510456T6	10510456T16

10516958|t|Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation.
10516958|a|Ziprasidone is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and D2 sites. While it is an antagonist at these latter receptors, ziprasidone behaves as a 5-HT1A agonist in vitro in adenylate cyclase measurements. The goal of the present study was to examine the 5-HT1A properties of ziprasidone in vivo using as a marker of central 5-HT1A activity the inhibition of firing of serotonin-containing neurons in the dorsal raphe nucleus. In anesthetized rats, ziprasidone dose-dependently slowed raphe unit activity (ED50 = 300 micrograms/kg i.v.) as did the atypical antipsychotics clozapine (ED50 = 250 micrograms/kg i.v.) and olanzapine (ED50 = 1000 micrograms/kg i.v.). Pretreatment with the 5-HT1A antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine. Because all three agents also bind to alpha 1 receptors, antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine (DMI), a NE re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity. DMI (5 mg/kg i.v.) failed to reverse the inhibitory effect of ziprasidone but produced nearly complete reversal of that of clozapine and olanzapine. These profiles suggest a mechanism of action for each agent, 5-HT1A agonism for ziprasidone and alpha 1 antagonism for clozapine and olanzapine. The 5-HT1A agonist activity reported here clearly distinguishes ziprasidone from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.
10516958	1659	1670	ziprasidone	CHEMICAL	10516958T10
10516958	1698	1707	clozapine	CHEMICAL	10516958T11
10516958	1712	1722	olanzapine	CHEMICAL	10516958T12
10516958	1788	1799	ziprasidone	CHEMICAL	10516958T13
10516958	370	381	ziprasidone	CHEMICAL	10516958T14
10516958	422	431	adenylate	CHEMICAL	10516958T15
10516958	524	535	ziprasidone	CHEMICAL	10516958T16
10516958	617	626	serotonin	CHEMICAL	10516958T17
10516958	697	708	ziprasidone	CHEMICAL	10516958T18
10516958	820	829	clozapine	CHEMICAL	10516958T19
10516958	164	175	Ziprasidone	CHEMICAL	239
10516958	866	876	olanzapine	CHEMICAL	10516958T20
10516958	951	962	WAY-100,635	CHEMICAL	10516958T21
10516958	1001	1012	ziprasidone	CHEMICAL	10516958T22
10516958	1050	1061	WAY-100,635	CHEMICAL	10516958T23
10516958	1110	1119	clozapine	CHEMICAL	10516958T24
10516958	1124	1134	olanzapine	CHEMICAL	10516958T25
10516958	38	49	ziprasidone	CHEMICAL	10516958T26
10516958	55	64	clozapine	CHEMICAL	10516958T27
10516958	69	79	olanzapine	CHEMICAL	10516958T28
10516958	1174	1191	alpha 1 receptors	GENE-N	10516958T29
10516958	1222	1231	serotonin	CHEMICAL	10516958T2
10516958	288	294	5-HT1D	GENE-Y	10516958T30
10516958	296	301	5-HT2	GENE-Y	10516958T31
10516958	307	309	D2	GENE-Y	10516958T32
10516958	1640	1646	5-HT1A	GENE-Y	10516958T33
10516958	1728	1734	5-HT1A	GENE-Y	10516958T34
10516958	395	401	5-HT1A	GENE-Y	10516958T35
10516958	422	439	adenylate cyclase	GENE-N	10516958T36
10516958	503	509	5-HT1A	GENE-Y	10516958T37
10516958	573	579	5-HT1A	GENE-Y	10516958T38
10516958	933	939	5-HT1A	GENE-Y	10516958T39
10516958	1301	1312	desipramine	CHEMICAL	10516958T3
10516958	241	257	5-HT1A receptors	GENE-Y	10516958T40
10516958	136	151	5-HT1A receptor	GENE-Y	10516958T41
10516958	1314	1317	DMI	CHEMICAL	1139
10516958	1322	1324	NE	CHEMICAL	10516958T5
10516958	1430	1433	DMI	CHEMICAL	1139
10516958	1492	1503	ziprasidone	CHEMICAL	10516958T7
10516958	1553	1562	clozapine	CHEMICAL	10516958T8
10516958	1567	1577	olanzapine	CHEMICAL	10516958T9
10516958	CPR:5	10516958T10	10516958T33
10516958	CPR:5	10516958T13	10516958T34
10516958	CPR:5	10516958T14	10516958T35
10516958	CPR:6	10516958T21	10516958T39
10516958	CPR:6	10516958T23	10516958T39

10548268|t|Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors.
10548268|a|Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence. The aim of the present study was, therefore, to evaluate several MAO inhibitors for their capacity to affect ethanol self-administration in rats trained to self-administer ethanol (10% v/v) orally in a free-choice two-lever operant task. The nonselective and irreversible MAO inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement. The reversible MAO-A inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration. However, befloxatone-induced effects leveled off at a 50% decrease. The irreversible MAO-B inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice. In conclusion, the present results showing that several MAO inhibitors decreased ethanol self-administration in rats are consistent with previous findings that synaptic levels of serotonin and dopamine play a critical role in the control of ethanol self-administration.
10548268	271	280	serotonin	CHEMICAL	10548268T10
10548268	285	293	dopamine	CHEMICAL	10548268T11
10548268	110	118	dopamine	CHEMICAL	10548268T12
10548268	364	371	alcohol	CHEMICAL	10548268T13
10548268	123	132	serotonin	CHEMICAL	10548268T14
10548268	493	500	ethanol	CHEMICAL	10548268T15
10548268	556	563	ethanol	CHEMICAL	10548268T16
10548268	672	682	phenelzine	CHEMICAL	10548268T17
10548268	697	712	tranylcypromine	CHEMICAL	10548268T18
10548268	730	739	nialamide	CHEMICAL	10548268T19
10548268	1087	1096	pargyline	CHEMICAL	10548268T1
10548268	151	158	ethanol	CHEMICAL	10548268T20
10548268	796	803	ethanol	CHEMICAL	10548268T21
10548268	851	862	befloxatone	CHEMICAL	10548268T22
10548268	916	926	clorgyline	CHEMICAL	10548268T23
10548268	955	962	ethanol	CHEMICAL	10548268T24
10548268	993	1004	befloxatone	CHEMICAL	10548268T25
10548268	18	25	ethanol	CHEMICAL	10548268T26
10548268	57	66	monoamine	CHEMICAL	10548268T27
10548268	191	208	monoamine oxidase	GENE-N	10548268T28
10548268	210	213	MAO	GENE-N	10548268T29
10548268	1112	1122	l-deprenyl	CHEMICAL	10548268T2
10548268	1357	1360	MAO	GENE-N	10548268T30
10548268	449	452	MAO	GENE-N	10548268T31
10548268	656	659	MAO	GENE-N	10548268T32
10548268	834	839	MAO-A	GENE-Y	10548268T33
10548268	899	904	MAO-A	GENE-Y	10548268T34
10548268	1069	1074	MAO-B	GENE-Y	10548268T35
10548268	57	74	monoamine oxidase	GENE-N	10548268T36
10548268	191	200	monoamine	CHEMICAL	10548268T3
10548268	1176	1183	ethanol	CHEMICAL	10548268T4
10548268	1277	1284	ethanol	CHEMICAL	10548268T5
10548268	1382	1389	ethanol	CHEMICAL	10548268T6
10548268	1480	1489	serotonin	CHEMICAL	10548268T7
10548268	1494	1502	dopamine	CHEMICAL	10548268T8
10548268	1542	1549	ethanol	CHEMICAL	10548268T9
10548268	CPR:4	10548268T17	10548268T32
10548268	CPR:4	10548268T18	10548268T32
10548268	CPR:4	10548268T19	10548268T32
10548268	CPR:4	10548268T1	10548268T35
10548268	CPR:4	10548268T22	10548268T33
10548268	CPR:4	10548268T23	10548268T34
10548268	CPR:4	10548268T2	10548268T35

10561120|t|Decreased intracellular proteolysis correlates with the maintenance of a specific isoenzyme of cytochrome P-450.
10561120|a|The rates of intracellular protein degradation, of identically labelled populations of proteins, were compared in hepatocytes cultured at 37 degrees (on an adsorbed collagen layer) and in cells preserved on gelatin gels at 10 degrees C. The half-lives of the long-lived proteins were 35.4+/-8.6 h (N=4) and 692.9+/-216.9 h (N=4) respectively. Proteolysis was substantially decreased at 10 degrees C but the rate of decrease remained constant. Hepatocytes rapidly removed resorufin from the culture medium. The resorufin was not being conjugated or accumulated within the cells. Dicumarol, a potent inhibitor of quinone oxidoreductase, at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin. The microsomal detoxifying enzyme, cytochrome P-450 1A1 remained at a constant level in the preserved hepatocyte monolayers. The results of this study strongly favour storing hepatocytes at 10 degrees C rather than at 4 degrees or 37 degrees C.
10561120	584	593	resorufin	CHEMICAL	10561120T1
10561120	623	632	resorufin	CHEMICAL	10561120T2
10561120	691	700	Dicumarol	CHEMICAL	259
10561120	724	731	quinone	CHEMICAL	10561120T4
10561120	833	842	resorufin	CHEMICAL	10561120T5
10561120	724	746	quinone oxidoreductase	GENE-N	10561120T6
10561120	879	899	cytochrome P-450 1A1	GENE-Y	10561120T7
10561120	95	111	cytochrome P-450	GENE-N	10561120T8
10561120	CPR:4	259	10561120T6

10577279|t|A novel mutation of the erythroid-specific gamma-Aminolevulinate synthase gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia.
10577279|a|A novel missense mutation, G663A, in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) was identified in a Japanese male with pyridoxine-responsive sideroblastic anemia. Activity of the mutant delta-aminolevulinate synthase protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of pyridoxal 5'-phosphate, consistent with the clinical response of the patient to pyridoxine treatment. The same mutation was also detected in genomic DNa from the oral mucosal membrane of the patiet; however, it was not detected in other family member. These findings suggest that this G663A mutation is responsible for sideroblastic anemia in the proband, and may be an index mutation in this pedigree.
10577279	182	187	G663A	GENE-N	10577279T10
10577279	206	255	erythroid-specific delta-aminolevulinate synthase	GENE-Y	10577279T11
10577279	811	816	G663A	GENE-N	10577279T12
10577279	24	73	erythroid-specific gamma-Aminolevulinate synthase	GENE-N	10577279T13
10577279	308	318	pyridoxine	CHEMICAL	10577279T1
10577279	375	396	delta-aminolevulinate	CHEMICAL	10577279T2
10577279	526	548	pyridoxal 5'-phosphate	CHEMICAL	10577279T3
10577279	606	616	pyridoxine	CHEMICAL	10577279T4
10577279	225	246	delta-aminolevulinate	CHEMICAL	10577279T5
10577279	111	121	pyridoxine	CHEMICAL	10577279T6
10577279	43	64	gamma-Aminolevulinate	CHEMICAL	10577279T7
10577279	262	267	ALAS2	GENE-Y	106714
10577279	375	405	delta-aminolevulinate synthase	GENE-Y	10577279T9
10577279	CPR:3	10577279T3	10577279T9

10587286|t|Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
10587286|a|This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. Lumbar CSF samples were collected continuously (0.1 mL x min(-1)) for 49 hours from eight healthy volunteers who took either placebo or a single oral dose of rivastigmine (3 mg). CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (BuChE) activity. Safety evaluations were performed 23 hours after drug dosing and at the end of the study. Evaluable data were obtained from six subjects. The mean time to maximal rivastigmine plasma concentration (tmax) was 0.83 +/- 0.26 hours, the mean maximal plasma concentration (Cmax) was 4.88 +/- 3.82 ng x mL(-1), the mean plasma area under the concentration versus time curve (AUC0-infinity) was 7.43 +/- 4.74 ng x hr x mL(-1), and the mean plasma t1/2 was 0.85 +/- 0.115 hours. The concentration of rivastigmine in CSF was lower than the quantification limit for assay (0.65 ng x mL(-1)), but NAP 226-90 reached a mean Cmax of 3.14 +/- 0.57 ng x mL(-1). Only minimal inhibition of erythrocyte AChE activity (approximately 3%) was observed. Inhibition of AChE in the CSF after rivastigmine administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours. Plasma BuChE activity was significantly lower after rivastigmine than after placebo, but this was not clinically relevant. BuChE activity in CSF was significantly lower after rivastigmine than after placebo for up to 3.6 hours after dosing, but this difference was not sustained. This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.
10587286	617	629	rivastigmine	CHEMICAL	10587286T10
10587286	727	739	rivastigmine	CHEMICAL	10587286T11
10587286	759	769	NAP 226-90	CHEMICAL	10587286T12
10587286	771	810	[-] [3-([1-dimethylaminolethyl)-phenol]	CHEMICAL	10587286T13
10587286	1081	1093	rivastigmine	CHEMICAL	10587286T14
10587286	68	80	rivastigmine	CHEMICAL	10587286T15
10587286	1604	1608	AChE	GENE-Y	10587286T16
10587286	1665	1669	AChE	GENE-Y	10587286T17
10587286	1838	1843	BuChE	GENE-Y	10587286T18
10587286	1954	1959	BuChE	GENE-Y	10587286T19
10587286	1410	1422	rivastigmine	CHEMICAL	10587286T1
10587286	2182	2186	AChE	GENE-Y	10587286T20
10587286	2267	2271	AChE	GENE-Y	10587286T21
10587286	2341	2345	AChE	GENE-Y	10587286T22
10587286	2395	2399	AChE	GENE-Y	10587286T23
10587286	2403	2408	BuChE	GENE-Y	10587286T24
10587286	372	376	AChE	GENE-Y	10587286T25
10587286	164	184	acetylcholinesterase	GENE-Y	10587286T26
10587286	825	829	AChE	GENE-Y	10587286T27
10587286	844	848	AChE	GENE-Y	10587286T28
10587286	878	899	butyrylcholinesterase	GENE-Y	10587286T29
10587286	1504	1514	NAP 226-90	CHEMICAL	10587286T2
10587286	901	906	BuChE	GENE-Y	10587286T30
10587286	186	190	AChE	GENE-Y	10587286T31
10587286	33	53	acetylcholinesterase	GENE-Y	10587286T32
10587286	1687	1699	rivastigmine	CHEMICAL	10587286T3
10587286	1883	1895	rivastigmine	CHEMICAL	10587286T4
10587286	280	292	rivastigmine	CHEMICAL	10587286T5
10587286	2006	2018	rivastigmine	CHEMICAL	10587286T6
10587286	294	301	ENA-713	CHEMICAL	10587286T7
10587286	303	309	Exelon	CHEMICAL	10587286T8
10587286	2232	2244	rivastigmine	CHEMICAL	10587286T9
10587286	CPR:4	10587286T15	10587286T32
10587286	CPR:4	10587286T3	10587286T17
10587286	CPR:4	10587286T4	10587286T18
10587286	CPR:4	10587286T6	10587286T19
10587286	CPR:4	10587286T9	10587286T21
10587286	CPR:4	10587286T9	10587286T22
10587286	CPR:4	10587286T9	10587286T23
10587286	CPR:4	10587286T9	10587286T24

10593931|t|Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX.
10593931|a|Activated coagulation factor XI (factor XIa) proteolytically cleaves its substrate, factor IX, in an interaction requiring the factor XI A3 domain (Sun, Y., and Gailani, D. (1996) J. Biol. Chem. 271, 29023-29028). To identify key amino acids involved in factor IX activation, recombinant factor XIa proteins containing alanine substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay. Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the N terminus and for Ser(258)-Ser(264) at the C terminus of the A3 domain markedly decreased factor XI coagulant activity. The plasma protease prekallikrein is structurally homologous to factor XI, but activated factor IX poorly. A chimeric factor XIa molecule with the A3 domain replaced with A3 from prekallikrein (FXI/PKA3) activated factor IX with a K(m) 35-fold greater than that of wild-type factor XI. FXI/PKA3 was used as a template for a series of proteins in which prekallikrein A3 sequence was replaced with factor XI sequence to restore factor IX activation. Clotting and kinetics studies using these chimeras confirmed the results obtained with alanine mutants. Amino acids between Ile(183) and Val(191) are necessary for proper factor IX activation, but additional sequence between Ser(195) and Ile(197) or between Phe(260) and Ser(265) is required for complete restoration of activation.
10593931	1149	1158	factor IX	GENE-Y	10593931T10
10593931	1342	1351	factor IX	GENE-Y	10593931T11
10593931	227	246	factor XI A3 domain	GENE-N	10593931T12
10593931	354	363	factor IX	GENE-Y	10593931T13
10593931	388	398	factor XIa	GENE-Y	10593931T14
10593931	133	143	factor XIa	GENE-Y	10593931T15
10593931	664	673	A3 domain	GENE-N	10593931T16
10593931	693	702	factor XI	GENE-Y	10593931T17
10593931	727	742	plasma protease	GENE-N	10593931T18
10593931	743	756	prekallikrein	GENE-Y	10593931T19
10593931	1258	1265	alanine	CHEMICAL	10593931T1
10593931	787	796	factor XI	GENE-Y	10593931T20
10593931	812	821	factor IX	GENE-Y	10593931T21
10593931	841	851	factor XIa	GENE-Y	10593931T22
10593931	870	879	A3 domain	GENE-N	10593931T23
10593931	902	915	prekallikrein	GENE-Y	10593931T24
10593931	917	920	FXI	GENE-Y	10593931T25
10593931	921	925	PKA3	GENE-N	10593931T26
10593931	927	946	activated factor IX	GENE-Y	10593931T27
10593931	184	193	factor IX	GENE-Y	10593931T28
10593931	998	1007	factor XI	GENE-Y	10593931T29
10593931	1275	1286	Amino acids	CHEMICAL	10593931T2
10593931	1009	1012	FXI	GENE-Y	10593931T30
10593931	1013	1017	PKA3	GENE-N	10593931T31
10593931	1075	1088	prekallikrein	GENE-Y	10593931T32
10593931	37	61	factor XI apple 3 domain	GENE-N	10593931T33
10593931	89	98	factor IX	GENE-Y	10593931T34
10593931	330	341	amino acids	CHEMICAL	10593931T3
10593931	419	426	alanine	CHEMICAL	10593931T4
10593931	602	603	N	CHEMICAL	167
10593931	646	647	C	CHEMICAL	10593931T6
10593931	18	29	amino acids	CHEMICAL	10593931T7
10593931	100	131	Activated coagulation factor XI	GENE-Y	10593931T8
10593931	1119	1128	factor XI	GENE-Y	10593931T9

10611634|t|Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
10611634|a|Herein, we evaluate the interaction of the alpha(2)-AR antagonist, yohimbine, as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats. Yohimbine displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors. In [(35)S]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites. In vivo, agonist actions of yohimbine at 5-HT(1A) sites are revealed by WAY100,635-reversible induction of hypothermia in the rat. In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611. In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs. While fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover, yohimbine also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT. Further, yohimbine decreases firing of serotonergic neurones in raphe nuclei, an action reversed by WAY100,635. Fluparoxan increases extracellular levels of DA and NAD, but not 5-HT, in frontal cortex. In analogy, yohimbine enhances FCX levels of DA and NAD, yet suppresses those of 5-HT, the latter effect being antagonized by WAY100,635. The induction by fluoxetine of FCX levels of 5-HT, DA, and NAD is potentiated by fluparoxan. Yohimbine likewise facilitates the influence of fluoxetine upon DA and NAD levels, but not those of 5-HT. In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine. However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.
10611634	1666	1676	Fluparoxan	CHEMICAL	10611634T10
10611634	1711	1713	DA	CHEMICAL	10611634T11
10611634	1718	1721	NAD	CHEMICAL	10611634T12
10611634	1731	1735	5-HT	CHEMICAL	10611634T13
10611634	1768	1777	yohimbine	CHEMICAL	10611634T14
10611634	1801	1803	DA	CHEMICAL	10611634T15
10611634	1808	1811	NAD	CHEMICAL	10611634T16
10611634	1837	1841	5-HT	CHEMICAL	10611634T17
10611634	1882	1892	WAY100,635	CHEMICAL	10611634T18
10611634	1939	1943	5-HT	CHEMICAL	10611634T19
10611634	1382	1392	fluparoxan	CHEMICAL	10611634T1
10611634	1945	1947	DA	CHEMICAL	10611634T20
10611634	1953	1956	NAD	CHEMICAL	10611634T21
10611634	1975	1985	fluparoxan	CHEMICAL	10611634T22
10611634	1987	1996	Yohimbine	CHEMICAL	1342
10611634	2035	2045	fluoxetine	CHEMICAL	10611634T24
10611634	2051	2053	DA	CHEMICAL	10611634T25
10611634	2058	2061	NAD	CHEMICAL	10611634T26
10611634	2087	2091	5-HT	CHEMICAL	10611634T27
10611634	2149	2158	yohimbine	CHEMICAL	10611634T28
10611634	2168	2170	DA	CHEMICAL	10611634T29
10611634	1426	1439	noradrenaline	CHEMICAL	10611634T2
10611634	2175	2178	NAD	CHEMICAL	10611634T30
10611634	2295	2305	fluparoxan	CHEMICAL	10611634T31
10611634	2311	2315	5-HT	CHEMICAL	10611634T32
10611634	2339	2348	yohimbine	CHEMICAL	10611634T33
10611634	2358	2362	5-HT	CHEMICAL	10611634T34
10611634	2431	2441	fluoxetine	CHEMICAL	10611634T35
10611634	2447	2451	5-HT	CHEMICAL	10611634T36
10611634	553	562	Yohimbine	CHEMICAL	1342
10611634	765	770	(35)S	CHEMICAL	10611634T38
10611634	800	809	yohimbine	CHEMICAL	10611634T39
10611634	1441	1444	NAD	CHEMICAL	10611634T3
10611634	356	365	yohimbine	CHEMICAL	10611634T40
10611634	969	978	yohimbine	CHEMICAL	10611634T41
10611634	982	986	5-HT	CHEMICAL	10611634T42
10611634	1013	1023	WAY100,635	CHEMICAL	10611634T43
10611634	1110	1119	yohimbine	CHEMICAL	10611634T44
10611634	1123	1127	5-HT	CHEMICAL	10611634T45
10611634	1196	1200	5-HT	CHEMICAL	10611634T46
10611634	1214	1222	GR46,611	CHEMICAL	10611634T47
10611634	382	392	fluparoxan	CHEMICAL	10611634T48
10611634	1242	1251	yohimbine	CHEMICAL	10611634T49
10611634	1456	1465	yohimbine	CHEMICAL	10611634T4
10611634	1253	1263	fluparoxan	CHEMICAL	10611634T50
10611634	110	119	serotonin	CHEMICAL	10611634T51
10611634	121	125	5-HT	CHEMICAL	10611634T52
10611634	132	136	5-HT	CHEMICAL	10611634T53
10611634	142	146	5-HT	CHEMICAL	10611634T54
10611634	155	163	dopamine	CHEMICAL	10611634T55
10611634	34	43	yohimbine	CHEMICAL	10611634T56
10611634	59	69	fluparoxan	CHEMICAL	10611634T57
10611634	1309	1318	h5-HT(1A)	GENE-Y	10611634T58
10611634	1361	1374	halpha(2)-ARs	GENE-N	10611634T59
10611634	1489	1497	dopamine	CHEMICAL	10611634T5
10611634	406	429	monoaminergic receptors	GENE-N	10611634T60
10611634	2112	2123	alpha(2)-AR	GENE-N	10611634T61
10611634	2271	2282	alpha(2)-AR	GENE-N	10611634T62
10611634	2311	2319	5-HT(1A)	GENE-Y	10611634T63
10611634	591	642	human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs	GENE-N	10611634T64
10611634	669	678	h5-HT(1A)	GENE-Y	10611634T65
10611634	680	689	h5-HT(1B)	GENE-Y	10611634T66
10611634	691	700	h5-HT(1D)	GENE-Y	10611634T67
10611634	706	721	hD(2) receptors	GENE-Y	10611634T68
10611634	332	354	alpha(2)-AR antagonist	GENE-N	10611634T69
10611634	1499	1501	DA	CHEMICAL	10611634T6
10611634	744	759	hD(3) receptors	GENE-Y	10611634T70
10611634	839	852	halpha(2A)-AR	GENE-Y	10611634T71
10611634	854	863	h5-HT(1B)	GENE-Y	10611634T72
10611634	865	874	h5-HT(1D)	GENE-Y	10611634T73
10611634	880	885	hD(2)	GENE-Y	10611634T74
10611634	924	933	h5-HT(1A)	GENE-Y	10611634T75
10611634	982	990	5-HT(1A)	GENE-Y	10611634T76
10611634	1123	1131	5-HT(1B)	GENE-Y	10611634T77
10611634	1196	1204	5-HT(1B)	GENE-Y	10611634T78
10611634	103	108	(AR)s	GENE-N	10611634T79
10611634	1548	1552	5-HT	CHEMICAL	10611634T7
10611634	120	130	(5-HT)(1A)	GENE-Y	10611634T80
10611634	132	140	5-HT(1B)	GENE-Y	10611634T81
10611634	142	150	5-HT(1D)	GENE-Y	10611634T82
10611634	155	187	dopamine D(2) and D(3) receptors	GENE-N	10611634T83
10611634	73	102	alpha(2)-adrenergic receptors	GENE-N	10611634T84
10611634	1563	1572	yohimbine	CHEMICAL	10611634T8
10611634	1654	1664	WAY100,635	CHEMICAL	10611634T9
10611634	CPR:5	10611634T33	10611634T63
10611634	CPR:5	10611634T39	10611634T75
10611634	CPR:5	10611634T41	10611634T76
10611634	CPR:5	10611634T47	10611634T78
10611634	CPR:5	10611634T49	10611634T58
10611634	CPR:5	10611634T50	10611634T58
10611634	CPR:5	10611634T56	10611634T79
10611634	CPR:5	10611634T56	10611634T80
10611634	CPR:5	10611634T56	10611634T81
10611634	CPR:5	10611634T56	10611634T82
10611634	CPR:5	10611634T56	10611634T84
10611634	CPR:5	10611634T57	10611634T79
10611634	CPR:5	10611634T57	10611634T84
10611634	CPR:6	10611634T28	10611634T61
10611634	CPR:6	10611634T31	10611634T62
10611634	CPR:6	10611634T39	10611634T71
10611634	CPR:6	10611634T39	10611634T72
10611634	CPR:6	10611634T39	10611634T73
10611634	CPR:6	10611634T39	10611634T74
10611634	CPR:6	10611634T40	10611634T69
10611634	CPR:6	10611634T43	10611634T76
10611634	CPR:6	10611634T44	10611634T77
10611634	CPR:6	10611634T48	10611634T69
10611634	CPR:6	10611634T49	10611634T59
10611634	CPR:6	10611634T50	10611634T59
10611634	CPR:6	10611634T56	10611634T79
10611634	CPR:6	10611634T56	10611634T80
10611634	CPR:6	10611634T56	10611634T81
10611634	CPR:6	10611634T56	10611634T82
10611634	CPR:6	10611634T56	10611634T84
10611634	CPR:6	10611634T57	10611634T79
10611634	CPR:6	10611634T57	10611634T84

10640321|t|The antitussive activity of delta-opioid receptor stimulation in guinea pigs.
10640321|a|In this study, the activity of the delta-opioid receptor subtype-selective agonist, SB 227122, was investigated in a guinea pig model of citric acid-induced cough. Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively. The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated. The delta-receptor antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.). In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.). The sigma-receptor antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122. These studies provide compelling evidence that the antitussive effects of SB 227122 in this guinea pig cough model are mediated by agonist activity at the delta-opioid receptor.
10640321	405	414	BRL 52974	CHEMICAL	10640321T10
10640321	452	463	citric acid	CHEMICAL	10640321T11
10640321	589	597	naloxone	CHEMICAL	10640321T12
10640321	653	660	codeine	CHEMICAL	10640321T13
10640321	664	673	SB 227122	CHEMICAL	10640321T14
10640321	794	803	SB 244525	CHEMICAL	10640321T15
10640321	858	867	SB 227122	CHEMICAL	10640321T16
10640321	926	945	beta-funaltrexamine	CHEMICAL	10640321T17
10640321	162	171	SB 227122	CHEMICAL	10640321T18
10640321	991	1009	norbinaltorphimine	CHEMICAL	10640321T19
10640321	1204	1213	SB 227122	CHEMICAL	10640321T1
10640321	1107	1129	mu- and kappa-receptor	GENE-N	10640321T20
10640321	1236	1250	sigma-receptor	GENE-N	10640321T21
10640321	1567	1588	delta-opioid receptor	GENE-Y	10640321T22
10640321	297	318	delta-opioid receptor	GENE-Y	10640321T23
10640321	332	350	mu-opioid receptor	GENE-Y	10640321T24
10640321	382	403	kappa-opioid receptor	GENE-Y	10640321T25
10640321	113	134	delta-opioid receptor	GENE-Y	10640321T26
10640321	561	576	opioid receptor	GENE-N	10640321T27
10640321	737	752	opioid receptor	GENE-N	10640321T28
10640321	767	781	delta-receptor	GENE-Y	10640321T29
10640321	1262	1271	rimcazole	CHEMICAL	10640321T2
10640321	947	958	mu-receptor	GENE-Y	10640321T30
10640321	1011	1025	kappa-receptor	GENE-Y	10640321T31
10640321	28	49	delta-opioid receptor	GENE-Y	10640321T32
10640321	1324	1340	dextromethorphan	CHEMICAL	10640321T3
10640321	1401	1410	SB 227122	CHEMICAL	10640321T4
10640321	215	226	citric acid	CHEMICAL	10640321T5
10640321	1486	1495	SB 227122	CHEMICAL	10640321T6
10640321	320	329	SB 227122	CHEMICAL	10640321T7
10640321	352	359	codeine	CHEMICAL	10640321T8
10640321	364	375	hydrocodone	CHEMICAL	10640321T9
10640321	CPR:5	10640321T10	10640321T25
10640321	CPR:5	10640321T13	10640321T27
10640321	CPR:5	10640321T13	10640321T28
10640321	CPR:5	10640321T14	10640321T27
10640321	CPR:5	10640321T14	10640321T28
10640321	CPR:5	10640321T16	10640321T29
10640321	CPR:5	10640321T18	10640321T26
10640321	CPR:5	10640321T3	10640321T21
10640321	CPR:5	10640321T6	10640321T22
10640321	CPR:5	10640321T7	10640321T23
10640321	CPR:5	10640321T8	10640321T24
10640321	CPR:5	10640321T9	10640321T24
10640321	CPR:6	10640321T12	10640321T27
10640321	CPR:6	10640321T15	10640321T29
10640321	CPR:6	10640321T17	10640321T30
10640321	CPR:6	10640321T19	10640321T31
10640321	CPR:6	10640321T2	10640321T21

10643177|t|COX-2-specific inhibition: implications for clinical practice.
10643177|a|Although conventional nonsteroidal anti-inflammatory drugs (NSAIDs) have long been a major therapeutic choice for the management of arthritic conditions, the potential adverse effects of these agents sometimes compromise their clinical utility. New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (COX-2)-specific inhibitors celecoxib and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.
10643177	421	430	celecoxib	CHEMICAL	10643177T1
10643177	435	444	rofecoxib	CHEMICAL	10643177T2
10643177	376	392	cyclooxygenase-2	GENE-Y	10643177T3
10643177	394	399	COX-2	GENE-Y	10643177T4
10643177	0	5	COX-2	GENE-Y	10643177T5
10643177	CPR:4	10643177T1	10643177T3
10643177	CPR:4	10643177T1	10643177T4
10643177	CPR:4	10643177T2	10643177T3
10643177	CPR:4	10643177T2	10643177T4

10658902|t|Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
10658902|a|Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate. The enzyme has been identified as or surmised to be the pharmacological target for isoxazol, triazine, cinchoninic acid and (naphtho)quinone derivatives, which exerted antiproliferative, immunosuppressive, and antiparasitic effects. Despite this broad spectrum of biological and clinical relevance, there have been no comparative studies on drug-dihydroorotate dehydrogenase interactions. Here, we describe a study of the inhibition of the purified recombinant human and rat dihydroorotate dehydrogenase by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and polyporic acid (quinone derivative) were found to function as alternative electron acceptors with 10-30% of control enzyme activity. The human and rat enzyme activity was decreased by 50% by the natural compound lawsone ( > 500 and 49 microM, respectively) and by the derivatives dichloroally-lawsone (67 and 10 nM), lapachol (618 and 61 nM) and atovaquone (15 microM and 698 nM). With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase. Atovaquone (Kic = 60 nM) was also acompetitive inhibitor of the rat enzyme. Dichloroally]-lawsone was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for mammalian dihydroorotate dehydrogenases. Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem. Pharmacol. 56 (1998) 1259-1264]. The slow binding features of this potent inhibitor (Ki* = 1.8 nM) with the human enzyme, were verified and seen to be one of the reasons for the narrow therapeutic window (efficacy versus toxicity) reported from clinical trials on its antiproliferative and immunosuppressive action. With respect to the substrate dihydroorotate, atovaquone was an uncompetitive inhibitor of human dihydroorotate dehydrogenase (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM). 1.5 mM polyporic acid, a natural quinone from fungi, influenced the activity of the human enzyme only slightly; the activity of the rat enzyme was decreased by 30%.
10658902	1521	1531	Atovaquone	CHEMICAL	1105
10658902	1597	1618	Dichloroally]-lawsone	CHEMICAL	10658902T11
10658902	1765	1779	dihydroorotate	CHEMICAL	10658902T12
10658902	1815	1824	brequinar	CHEMICAL	10658902T13
10658902	1893	1907	dihydroorotate	CHEMICAL	10658902T14
10658902	1990	2003	dihyroorotate	CHEMICAL	10658902T15
10658902	2039	2047	isoxazol	CHEMICAL	10658902T16
10658902	2052	2068	cinchoninic acid	CHEMICAL	10658902T17
10658902	164	178	dihydroorotate	CHEMICAL	10658902T18
10658902	2437	2451	dihydroorotate	CHEMICAL	10658902T19
10658902	1193	1213	dichloroally-lawsone	CHEMICAL	10658902T1
10658902	2453	2463	atovaquone	CHEMICAL	10658902T20
10658902	2504	2518	dihydroorotate	CHEMICAL	10658902T21
10658902	379	387	isoxazol	CHEMICAL	10658902T22
10658902	389	397	triazine	CHEMICAL	10658902T23
10658902	2639	2653	polyporic acid	CHEMICAL	10658902T24
10658902	2665	2672	quinone	CHEMICAL	10658902T25
10658902	399	415	cinchoninic acid	CHEMICAL	10658902T26
10658902	420	436	(naphtho)quinone	CHEMICAL	10658902T27
10658902	642	656	dihydroorotate	CHEMICAL	10658902T28
10658902	771	785	dihydroorotate	CHEMICAL	10658902T29
10658902	1230	1238	lapachol	CHEMICAL	10658902T2
10658902	818	836	1,4-Naphthoquinone	CHEMICAL	10658902T30
10658902	838	864	5,8-hydroxy-naphthoquinone	CHEMICAL	10658902T31
10658902	891	897	juglon	CHEMICAL	10658902T32
10658902	899	908	plumbagin	CHEMICAL	10658902T33
10658902	913	927	polyporic acid	CHEMICAL	10658902T34
10658902	929	936	quinone	CHEMICAL	10658902T35
10658902	1125	1132	lawsone	CHEMICAL	10658902T36
10658902	105	121	brequinar sodium	CHEMICAL	10658902T37
10658902	126	140	polyporic acid	CHEMICAL	10658902T38
10658902	40	54	dihydroorotate	CHEMICAL	10658902T39
10658902	1259	1269	atovaquone	CHEMICAL	10658902T3
10658902	72	82	atovaquone	CHEMICAL	10658902T40
10658902	84	91	lawsone	CHEMICAL	10658902T41
10658902	1342	1370	dihydroorotate dehydrogenase	GENE-Y	10658902T42
10658902	1485	1519	human dihydroorotate dehydrogenase	GENE-Y	10658902T43
10658902	1755	1794	mammalian dihydroorotate dehydrogenases	GENE-N	10658902T44
10658902	1887	1921	human dihydroorotate dehydrogenase	GENE-Y	10658902T45
10658902	1976	2017	human and rat dihyroorotate dehydrogenase	GENE-N	10658902T46
10658902	164	192	dihydroorotate dehydrogenase	GENE-Y	10658902T47
10658902	2498	2532	human dihydroorotate dehydrogenase	GENE-Y	10658902T48
10658902	642	670	dihydroorotate dehydrogenase	GENE-Y	10658902T49
10658902	1314	1321	quinone	CHEMICAL	10658902T4
10658902	194	206	EC 1.3.99.11	GENE-Y	10658902T50
10658902	757	799	human and rat dihydroorotate dehydrogenase	GENE-N	10658902T51
10658902	26	68	human and rat dihydroorotate dehydrogenase	GENE-N	10658902T52
10658902	1342	1356	dihydroorotate	CHEMICAL	10658902T5
10658902	1372	1382	atovaquone	CHEMICAL	10658902T6
10658902	1406	1426	dichloroally-lawsone	CHEMICAL	10658902T7
10658902	273	294	uridine monophosphate	CHEMICAL	10658902T8
10658902	1491	1505	dihydroorotate	CHEMICAL	10658902T9
10658902	CPR:4	10658902T11	10658902T44
10658902	CPR:4	10658902T13	10658902T45
10658902	CPR:4	10658902T16	10658902T46
10658902	CPR:4	10658902T17	10658902T46
10658902	CPR:4	10658902T19	10658902T48
10658902	CPR:4	10658902T20	10658902T48
10658902	CPR:4	10658902T37	10658902T52
10658902	CPR:4	10658902T38	10658902T52
10658902	CPR:4	10658902T40	10658902T52
10658902	CPR:4	10658902T41	10658902T52
10658902	CPR:4	10658902T6	10658902T43
10658902	CPR:4	10658902T7	10658902T43
10658902	CPR:9	10658902T4	10658902T42
10658902	CPR:9	10658902T8	10658902T47
10658902	CPR:9	10658902T8	10658902T50

10662748|t|Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts.
10662748|a|BACKGROUND: A mutation in the cardiac sodium channel gene (SCN5A) has been described in patients with the syndrome of right bundle branch block, ST-segment elevation in leads V1 to V3, and sudden death (Brugada syndrome). These electrocardiographic manifestations are transient in many patients with the syndrome. The present study examined arrhythmic risk in patients with overt and concealed forms of the disease and the effectiveness of sodium channel blockers to unmask the syndrome and, thus, identify patients at risk. METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg), procainamide (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a SCN5A mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C). Ajmaline, procainamide, or flecainide administration resulted in ST-segment elevation and right bundle branch block in all patients in group A and in all 11 patients with the mutation in group B. A similar pattern could not be elicited in the 8 patients in group B who lacked the mutation or in any person in group C. The follow-up period (37+/-33 months) revealed no differences in the incidence of arrhythmia between the 34 patients in whom the phenotypic manifestation of the syndrome was transient and the 24 patients in whom it was persistent (log-rank, 0.639). CONCLUSIONS: The data demonstrated a similar incidence of potentially lethal arrhythmias in patients displaying transient versus persistent ST-segment elevation and right bundle branch block, as well as the effectiveness of sodium channel blockers to unmask the syndrome and, thus, identify patients at risk.
10662748	0	6	Sodium	CHEMICAL	10662748T10
10662748	1855	1869	sodium channel	GENE-N	10662748T11
10662748	185	207	cardiac sodium channel	GENE-N	10662748T12
10662748	595	609	sodium channel	GENE-N	10662748T13
10662748	214	219	SCN5A	GENE-Y	112236|1172535
10662748	937	942	SCN5A	GENE-Y	112236|1172535
10662748	0	14	Sodium channel	GENE-N	10662748T16
10662748	1855	1861	sodium	CHEMICAL	10662748T1
10662748	193	199	sodium	CHEMICAL	10662748T2
10662748	595	601	sodium	CHEMICAL	10662748T3
10662748	727	735	ajmaline	CHEMICAL	10662748T4
10662748	747	759	procainamide	CHEMICAL	10662748T5
10662748	775	785	flecainide	CHEMICAL	1183
10662748	1064	1072	Ajmaline	CHEMICAL	1374
10662748	1074	1086	procainamide	CHEMICAL	10662748T8
10662748	1091	1101	flecainide	CHEMICAL	1183

10665814|t|Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels.
10665814|a|The voltage gated calcium channel family is a major target for a range of therapeutic drugs. Mibefradil (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block T-type Ca2+ channels. However, this molecule has also been shown to inhibit other Ca2+ channel subtypes. To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration. Expression of alpha1A, alpha1C, and alpha1E in tsA 201 cells resulted in Ca2+ currents with functional characteristics closely related to those of their native counterparts. Mibefradil blocked alpha1A and alpha1E with a Kd comparable to that reported for T-type channels, but had a lower affinity (approximately 30-fold) for alpha1C. For each channel, inhibition by Mibefradil was consistent with high-affinity binding to the inactivated state. Modulation of the voltage-dependent inactivation properties by the nature of the coexpressed beta subunit or the alpha1 splice variant altered block at the Mibefradil receptor site. Therefore, we conclude that the tissue and sub-cellular localization of calcium channel subunits as well as their specific associations are essential parameters to understand the in vivo effects of Mibefradil.
10665814	500	510	Mibefradil	CHEMICAL	1340
10665814	550	560	Mibefradil	CHEMICAL	1340
10665814	584	588	Ca2+	CHEMICAL	10665814T12
10665814	658	662	Ca2+	CHEMICAL	10665814T13
10665814	788	792	Ca2+	CHEMICAL	10665814T14
10665814	889	899	Mibefradil	CHEMICAL	1340
10665814	185	195	Mibefradil	CHEMICAL	1340
10665814	1081	1091	Mibefradil	CHEMICAL	1340
10665814	54	64	Mibefradil	CHEMICAL	1340
10665814	74	81	calcium	CHEMICAL	10665814T19
10665814	197	207	Ro 40-5967	CHEMICAL	10665814T1
10665814	1414	1429	calcium channel	GENE-N	10665814T20
10665814	335	355	T-type Ca2+ channels	GENE-N	10665814T21
10665814	417	429	Ca2+ channel	GENE-N	10665814T22
10665814	487	499	Ca2+ channel	GENE-N	10665814T23
10665814	96	125	voltage gated calcium channel	GENE-N	10665814T24
10665814	584	597	Ca2+ channels	GENE-N	10665814T25
10665814	970	985	T-type channels	GENE-N	10665814T26
10665814	74	90	calcium channels	GENE-N	10665814T27
10665814	1316	1326	Mibefradil	CHEMICAL	1340
10665814	1414	1421	calcium	CHEMICAL	10665814T3
10665814	1540	1550	Mibefradil	CHEMICAL	1340
10665814	110	117	calcium	CHEMICAL	10665814T5
10665814	285	289	Ca2+	CHEMICAL	10665814T6
10665814	342	346	Ca2+	CHEMICAL	10665814T7
10665814	417	421	Ca2+	CHEMICAL	10665814T8
10665814	487	491	Ca2+	CHEMICAL	10665814T9
10665814	CPR:4	1340	10665814T26
10665814	CPR:4	1340	10665814T21
10665814	CPR:4	1340	10665814T27
10665814	CPR:4	10665814T1	10665814T21

10673876|t|Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty.
10673876|a|We have investigated the effect of treatment with tranexamic acid, an inhibitor of fibrinolysis, on blood loss, blood transfusion requirements and blood coagulation in a randomized, double-blind, placebo-controlled study of 42 patients after total knee arthroplasty. Tranexamic acid 15 mg kg-1 (n = 21) or an equivalent volume of normal saline (n = 21) was given 30 min before surgery and subsequently every 8 h for 3 days. Coagulation and fibrinolysis values, blood loss and blood units administered were measured before administration of tranexamic acid, 8 h after the end of surgery and at 24 and 72 h after operation. Coagulation profile was examined (bleeding time, platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), plasminogen, beta-thromboglobulin and fibrinogen). Fibrinolysis was evaluated by measurement of concentrations of D-dimer and fibrinogen degradation products (FDP). Total blood loss in the tranexamic acid group was 678 (SD 352) ml compared with 1419 (607) ml in the control group (P < 0.001), and occurred primarily during the first 24 h after surgery. Thirteen patients received 1-5 u. of packed red blood cells in the control group compared with two patients in the tranexamic acid group, who received 3 u. (P < 0.001). Postoperative packed cell volume values were higher in the tranexamic acid group despite fewer blood transfusions. Postoperative concentrations of plasminogen were decreased significantly in the tranexamic acid group (P < 0.001). Platelet count, PT, aPTT, bleeding time, beta-thromboglobulin, fibrinogen and FDP concentrations did not differ between groups, but D-dimer concentrations were increased in the control group. Thromboembolic complications occurred in two patients in the control group compared with none in the tranexamic acid group.
10673876	1524	1535	plasminogen	GENE-Y	10673876T10
10673876	1648	1668	beta-thromboglobulin	GENE-Y	10673876T11
10673876	1670	1680	fibrinogen	GENE-N	10673876T12
10673876	1685	1688	FDP	GENE-N	10673876T13
10673876	786	797	prothrombin	GENE-Y	10673876T14
10673876	827	841	thromboplastin	GENE-Y	10673876T15
10673876	855	866	plasminogen	GENE-Y	10673876T16
10673876	868	888	beta-thromboglobulin	GENE-Y	10673876T17
10673876	893	903	fibrinogen	GENE-N	10673876T18
10673876	981	1012	fibrinogen degradation products	GENE-N	10673876T19
10673876	1323	1338	tranexamic acid	CHEMICAL	295
10673876	1014	1017	FDP	GENE-N	10673876T20
10673876	1436	1451	tranexamic acid	CHEMICAL	295
10673876	1572	1587	tranexamic acid	CHEMICAL	295
10673876	1900	1915	tranexamic acid	CHEMICAL	295
10673876	366	381	Tranexamic acid	CHEMICAL	10673876T5
10673876	149	164	tranexamic acid	CHEMICAL	295
10673876	639	654	tranexamic acid	CHEMICAL	295
10673876	1044	1059	tranexamic acid	CHEMICAL	295
10673876	7	22	tranexamic acid	CHEMICAL	295
10673876	CPR:4	295	10673876T10

10682715|t|Correlations between serotonin level and single-cell firing in the rat's nucleus raphe magnus.
10682715|a|The relation between serotonin release and electrical activity was examined in the nucleus raphe magnus of rats anesthetized with pentobarbital. Serotonin levels were monitored through a carbon-fiber microelectrode by fast cyclic voltammetry (usually at 1 Hz). Single-cell firing was recorded through the same microelectrode, except during the voltammetry waveform and associated electrical artifact (totaling about 30 ms). Multi-barrel micropipettes incorporating the voltammetry electrode were used for iontophoresis of drugs. Cells were inhibited, excited or unaffected by noxious mechanical skin stimulation. These were respectively designated as off(M) cells, on(M) cells and neutral(M) cells, M denoting mechanical. During 3 min of pinching, serotonin slowly rose near seven of 14 on(M) cells and 26 of 46 off(M) cells; it fell near two off(M) cells; it was unchanged near all other cells, including six neutral(M) cells. On a finer spatiotemporal scale, near four of seven on(M) cells, 10 of 14 off(M) cells and 0 of four neutral(M) cells, average serotonin levels fell significantly within +/- 100 ms of spontaneous spikes. Lower serotonin may have caused the higher spike probability; the converse is theoretically unlikely, since delays between release and detection are estimated to exceed 100 ms. Increased serotonin and decreased firing were always seen following iontophoresis or intravenous injection (1 mg/kg) of the serotonin re-uptake inhibitor clomipramine (n = 7). Iontophoresis of +/- propranolol, whose serotonergic actions include antagonism and partial agonism at 5-HT1 receptors, also increased serotonin and decreased firing (n=4). Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3). Iontophoresis of glutamate always lowered serotonin and increased firing (n = 4). Since serotonin levels and firing were usually inversely correlated, except near on(M) cells during pinch, we propose that serotonin is released from terminals of incoming nociceptive afferents. Prior neuroanatomical knowledge favors a midbrain origin for these afferents, while some of the drug findings suggest that their terminals possess inhibitory serotonergic autoreceptors, possibly of 5-HT1b subtype. The released serotonin could contribute to the inhibition of off(M) cells and excitation of on(M) cells by noxious stimulation, since inhibitory 5-HT1a receptors and excitatory 5-HT2 receptors, respectively, have previously been shown to dominate their serotonergic responses.
10682715	1753	1765	Methiothepin	CHEMICAL	10682715T10
10682715	1870	1879	serotonin	CHEMICAL	10682715T11
10682715	1941	1953	clomipramine	CHEMICAL	10682715T12
10682715	282	288	carbon	CHEMICAL	10682715T13
10682715	1980	1989	glutamate	CHEMICAL	10682715T14
10682715	2005	2014	serotonin	CHEMICAL	10682715T15
10682715	2051	2060	serotonin	CHEMICAL	10682715T16
10682715	2168	2177	serotonin	CHEMICAL	10682715T17
10682715	116	125	serotonin	CHEMICAL	10682715T18
10682715	2467	2476	serotonin	CHEMICAL	10682715T19
10682715	1150	1159	serotonin	CHEMICAL	10682715T1
10682715	843	852	serotonin	CHEMICAL	10682715T20
10682715	21	30	serotonin	CHEMICAL	10682715T21
10682715	1683	1688	5-HT1	GENE-N	10682715T22
10682715	1825	1830	5-HT1	GENE-N	10682715T23
10682715	1835	1840	5-HT2	GENE-N	10682715T24
10682715	2438	2444	5-HT1b	GENE-Y	10682715T25
10682715	2599	2605	5-HT1a	GENE-Y	10682715T26
10682715	2631	2636	5-HT2	GENE-N	10682715T27
10682715	1233	1242	serotonin	CHEMICAL	10682715T2
10682715	225	238	pentobarbital	CHEMICAL	10682715T3
10682715	1414	1423	serotonin	CHEMICAL	10682715T4
10682715	1528	1537	serotonin	CHEMICAL	10682715T5
10682715	240	249	Serotonin	CHEMICAL	10682715T6
10682715	1558	1570	clomipramine	CHEMICAL	10682715T7
10682715	1597	1612	+/- propranolol	CHEMICAL	10682715T8
10682715	1715	1724	serotonin	CHEMICAL	10682715T9
10682715	CPR:5	10682715T8	10682715T22
10682715	CPR:6	10682715T10	10682715T23
10682715	CPR:6	10682715T10	10682715T24
10682715	CPR:6	10682715T8	10682715T22

10701840|t|The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
10701840|a|The 90-kDa heat shock protein (Hsp90) is the most abundant molecular chaperone of eukaryotic cells. Its chaperone function in folding nascent proteins seems to be restricted to a subset of proteins including major components of signal transduction pathways (eg, nuclear hormone receptors, transcription factors, and protein kinases). Improper function of these proteins can be induced by selective disruption of their complexes with Hsp90 using the benzoquinonoid ansamycin geldanamycin. In this study, we demonstrate that geldanamycin treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes. Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase. Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT). Treatment with geldanamycin, however, does not affect the activation of lysophosphatide acyltransferase, which is a plasma membrane enzyme coupled to the T-cell receptor after T-cell stimulation. Through demonstrating the selective inhibition of kinase-related T-lymphocyte responses by geldanamycin, our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.
10701840	1223	1238	T-cell receptor	GENE-N	10701840T10
10701840	1315	1321	kinase	GENE-N	10701840T11
10701840	1416	1421	Hsp90	GENE-N	10701840T12
10701840	1422	1428	kinase	GENE-N	10701840T13
10701840	386	411	nuclear hormone receptors	GENE-N	10701840T14
10701840	155	160	Hsp90	GENE-N	10701840T15
10701840	440	455	protein kinases	GENE-N	10701840T16
10701840	128	153	90-kDa heat shock protein	GENE-N	10701840T17
10701840	557	562	Hsp90	GENE-N	10701840T18
10701840	677	695	interleukin (IL)-2	GENE-Y	10701840T19
10701840	1356	1368	geldanamycin	CHEMICAL	10701840T1
10701840	707	720	IL-2 receptor	GENE-N	10701840T20
10701840	183	202	molecular chaperone	GENE-N	10701840T21
10701840	847	850	Lck	GENE-Y	201120
10701840	855	860	Raf-1	GENE-Y	10701840T23
10701840	861	868	kinases	GENE-N	10701840T24
10701840	900	945	extracellular signal regulated kinase (ERK)-2	GENE-Y	10701840T25
10701840	946	952	kinase	GENE-N	10701840T26
10701840	985	1000	T-cell receptor	GENE-N	10701840T27
10701840	1024	1059	nuclear factor of activated T-cells	GENE-N	10701840T28
10701840	1061	1066	NF-AT	GENE-N	10701840T29
10701840	573	597	benzoquinonoid ansamycin	CHEMICAL	10701840T2
10701840	4	9	Hsp90	GENE-N	10701840T30
10701840	63	69	kinase	GENE-N	10701840T31
10701840	598	610	geldanamycin	CHEMICAL	10701840T3
10701840	647	659	geldanamycin	CHEMICAL	10701840T4
10701840	790	802	geldanamycin	CHEMICAL	10701840T5
10701840	954	966	Geldanamycin	CHEMICAL	2327
10701840	1084	1096	geldanamycin	CHEMICAL	10701840T7
10701840	29	41	geldanamycin	CHEMICAL	10701840T8
10701840	1141	1172	lysophosphatide acyltransferase	GENE-N	10701840T9
10701840	CPR:4	10701840T1	10701840T11
10701840	CPR:4	10701840T2	10701840T18
10701840	CPR:4	10701840T3	10701840T18
10701840	CPR:4	10701840T4	10701840T19
10701840	CPR:4	10701840T4	10701840T20
10701840	CPR:4	10701840T5	201120
10701840	CPR:4	10701840T5	10701840T23
10701840	CPR:4	10701840T5	10701840T24
10701840	CPR:4	10701840T5	10701840T25
10701840	CPR:4	10701840T5	10701840T26
10701840	CPR:4	2327	10701840T27
10701840	CPR:4	2327	10701840T28
10701840	CPR:4	2327	10701840T29
10701840	CPR:4	10701840T8	10701840T30
10701840	CPR:4	10701840T8	10701840T31

10709635|t|Carnitine biosynthesis. Purification of gamma-butyrobetaine hydroxylase from rat liver.
10709635|a|gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen. Initial attempts to purify the protein from rat liver showed that gamma-butyrobetaine hydroxylase is unstable. We, therefore, determined the influence of various compounds on the stability of gamma-butyrobetaine hydroxylase at different storage temperatures. The enzyme activity was best conserved by storing the protein at 4 degrees C in the presence of 200 g/l glycerol and 10 mM DTT. We subsequently purified the enzyme from rat liver to apparent homogeneity by liquid chromatography.
10709635	146	155	carnitine	CHEMICAL	10709635T10
10709635	680	683	DTT	CHEMICAL	10709635T11
10709635	187	198	L-carnitine	CHEMICAL	10709635T12
10709635	0	9	Carnitine	CHEMICAL	573
10709635	40	59	gamma-butyrobetaine	CHEMICAL	10709635T14
10709635	88	119	gamma-Butyrobetaine hydroxylase	GENE-Y	10709635T15
10709635	364	395	gamma-butyrobetaine hydroxylase	GENE-Y	10709635T16
10709635	490	521	gamma-butyrobetaine hydroxylase	GENE-Y	10709635T17
10709635	40	71	gamma-butyrobetaine hydroxylase	GENE-Y	10709635T18
10709635	88	107	gamma-Butyrobetaine	CHEMICAL	10709635T1
10709635	204	223	gamma-butyrobetaine	CHEMICAL	10709635T2
10709635	249	253	Fe2+	CHEMICAL	10709635T3
10709635	255	274	alpha-ketoglutarate	CHEMICAL	10709635T4
10709635	276	285	ascorbate	CHEMICAL	10709635T5
10709635	290	296	oxygen	CHEMICAL	10709635T6
10709635	364	383	gamma-butyrobetaine	CHEMICAL	10709635T7
10709635	490	509	gamma-butyrobetaine	CHEMICAL	10709635T8
10709635	661	669	glycerol	CHEMICAL	10709635T9
10709635	CPR:9	10709635T10	10709635T15
10709635	CPR:9	10709635T12	10709635T15
10709635	CPR:9	10709635T2	10709635T15

10727528|t|Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism.
10727528|a|Aspirin is a commonly used drug with a wide pharmacological spectrum including antiplatelet, anti-inflammatory, and neuroprotective actions. This study shows that aspirin and sodium salicylate, its major blood metabolite, reverse contractile actions of endothelin-1 (ET-1) in isolated rat aorta and human mammary arteries. They also prevent the intracellular Ca(2+) mobilizing action of ET-1 in cultured endothelial cells but not those of neuromedin B or UTP. Inhibition of the actions of ET-1 by salicylates is apparently competitive. Salicylates inhibit (125)I-ET-1 binding to recombinant rat ETA receptors. Salicylic acid promotes dissociation of (125)I-ET-1 ETA receptor complexes both in the absence and the presence of unlabeled ET-1. It has no influence on the rate of association of (125)I-ET-1 to ETA receptors. Salicylates do not promote dissociation of (125)I-ET-1 ETB receptor complexes. Salicylates potentiate relaxing actions of receptor antagonists such as bosentan. It is concluded that salicylates are allosteric inhibitors of ETA receptors. The results also suggest that: 1) irreversible ET-1 binding probably limits actions of receptor antagonists in vivo, and 2) an association of salicylates and ETA receptor antagonists should be used to evaluate the physiopathological role of ET-1 and may be of therapeutic interest in the treatment of ischemic heart disease.
10727528	709	723	Salicylic acid	CHEMICAL	926
10727528	749	755	(125)I	CHEMICAL	10727528T11
10727528	890	896	(125)I	CHEMICAL	10727528T12
10727528	920	931	Salicylates	CHEMICAL	10727528T13
10727528	963	969	(125)I	CHEMICAL	10727528T14
10727528	999	1010	Salicylates	CHEMICAL	10727528T15
10727528	1071	1079	bosentan	CHEMICAL	549
10727528	0	7	Aspirin	CHEMICAL	935
10727528	12	29	sodium salicylate	CHEMICAL	10727528T18
10727528	1143	1156	ETA receptors	GENE-Y	10727528T19
10727528	99	106	Aspirin	CHEMICAL	935
10727528	1205	1209	ET-1	GENE-Y	10727528T20
10727528	1316	1328	ETA receptor	GENE-Y	10727528T21
10727528	1399	1403	ET-1	GENE-Y	10727528T22
10727528	352	364	endothelin-1	GENE-N	10727528T23
10727528	366	370	ET-1	GENE-N	10727528T24
10727528	486	490	ET-1	GENE-Y	10727528T25
10727528	538	550	neuromedin B	GENE-Y	10727528T26
10727528	588	592	ET-1	GENE-Y	10727528T27
10727528	662	666	ET-1	GENE-Y	10727528T28
10727528	690	707	rat ETA receptors	GENE-Y	10727528T29
10727528	1102	1113	salicylates	CHEMICAL	10727528T2
10727528	756	760	ET-1	GENE-Y	10727528T30
10727528	761	773	ETA receptor	GENE-Y	10727528T31
10727528	834	838	ET-1	GENE-Y	10727528T32
10727528	897	901	ET-1	GENE-Y	10727528T33
10727528	905	918	ETA receptors	GENE-Y	10727528T34
10727528	970	974	ET-1	GENE-Y	10727528T35
10727528	975	987	ETB receptor	GENE-Y	10727528T36
10727528	49	62	ETA receptors	GENE-Y	10727528T37
10727528	1300	1311	salicylates	CHEMICAL	10727528T3
10727528	262	269	aspirin	CHEMICAL	10727528T4
10727528	274	291	sodium salicylate	CHEMICAL	10727528T5
10727528	458	464	Ca(2+)	CHEMICAL	10727528T6
10727528	596	607	salicylates	CHEMICAL	10727528T7
10727528	635	646	Salicylates	CHEMICAL	10727528T8
10727528	655	661	(125)I	CHEMICAL	10727528T9
10727528	CPR:4	10727528T7	10727528T27

10755406|t|A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C.
10755406|a|Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer. Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity. However, the role of NQO1 in metabolic activation of MMC has been disputed. In this report, we present cellular and animal models to demonstrate that NQO1 may play only a minor role in metabolic activation of MMC. We further demonstrate that bioreductive activation of MMC is catalysed by a unique cytosolic activity which is related but distinct from NQO1. Chinese hamster ovary (CHO) cells were developed that permanently express higher levels of cDNA-derived NQO1. These cells showed significantly increased protection against menadione toxicity. However, they failed to demonstrate higher cytotoxicity due to exposure to MMC under oxygen (normal air) or hypoxia, as compared to the wild-type control CHO cells. Disruption of the NQO1 gene by homologous recombination generated NQO1-/- mice that do not express the NQO1 gene resulting in the loss of NQO1 protein and activity. The cytosolic fractions from liver and colon tissues of NQO1-/- mice showed similar amounts of DNA cross-linking upon exposure to MMC, as observed in NQO1+/+ mice. The unique cytosolic activity that activated MMC in cytosolic fractions of liver and colon tissues of NQO1-/- mice was designated as cytosolic MMC reductase. This activity, like NQO1, was inhibited by dicoumarol and immunologically related to NQO1.
10755406	376	379	MMC	CHEMICAL	10755406T10
10755406	487	490	MMC	CHEMICAL	10755406T11
10755406	643	646	MMC	CHEMICAL	10755406T12
10755406	703	706	MMC	CHEMICAL	10755406T13
10755406	964	973	menadione	CHEMICAL	10755406T14
10755406	1059	1062	MMC	CHEMICAL	10755406T15
10755406	1069	1075	oxygen	CHEMICAL	10755406T16
10755406	93	104	mitomycin C	CHEMICAL	10755406T17
10755406	1167	1171	NQO1	GENE-N	108072
10755406	1215	1219	NQO1	GENE-N	108072
10755406	106	117	Mitomycin C	CHEMICAL	10755406T1
10755406	1252	1256	NQO1	GENE-N	108072
10755406	1287	1291	NQO1	GENE-N	108072
10755406	1370	1374	NQO1	GENE-N	108072
10755406	1464	1468	NQO1	GENE-N	108072
10755406	1580	1584	NQO1	GENE-N	108072
10755406	1621	1634	MMC reductase	GENE-N	10755406T25
10755406	1656	1660	NQO1	GENE-N	108072
10755406	1721	1725	NQO1	GENE-N	108072
10755406	288	319	NAD(P)H:quinone oxidoreductase1	GENE-N	10755406T28
10755406	321	325	NQO1	GENE-N	108072
10755406	119	122	MMC	CHEMICAL	10755406T2
10755406	455	459	NQO1	GENE-N	108072
10755406	584	588	NQO1	GENE-N	108072
10755406	786	790	NQO1	GENE-N	108072
10755406	896	900	NQO1	GENE-N	108072
10755406	54	58	NQO1	GENE-N	108072
10755406	1444	1447	MMC	CHEMICAL	10755406T3
10755406	1523	1526	MMC	CHEMICAL	10755406T4
10755406	255	265	dicoumarol	CHEMICAL	10755406T5
10755406	1621	1624	MMC	CHEMICAL	10755406T6
10755406	1679	1689	dicoumarol	CHEMICAL	10755406T7
10755406	288	295	NAD(P)H	CHEMICAL	10755406T8
10755406	296	303	quinone	CHEMICAL	10755406T9
10755406	CPR:4	10755406T5	10755406T28
10755406	CPR:4	10755406T5	108072
10755406	CPR:4	10755406T7	108072
10755406	CPR:9	10755406T10	10755406T28
10755406	CPR:9	10755406T10	108072
10755406	CPR:9	10755406T11	108072
10755406	CPR:9	10755406T12	108072
10755406	CPR:9	10755406T17	108072

10768100|t|Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes.
10768100|a|AIMS/HYPOTHESIS: Increased plasma plasminogen activator inhibitor-1 (PAI-1) concentrations are characteristic for subjects with insulin resistance and could contribute to the increased cardiovascular risk in this state. In this study, we investigated the effect of troglitazone, a ligand of the nuclear receptor peroxisome proliferator activated receptor-gamma, on PAI-1 expression and secretion in human adipocytes. METHODS: We used two models: in vitro differentiated subcutaneous and omental adipocytes cultured under serum-free conditions and isolated subcutaneous and omental fat cells kept in suspension culture. Plasminogen activator inhibitor-1 protein was measured by ELISA, PAI-1 mRNA by a semiquantitative RT-PCR technique. RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml troglitazone for 72 h caused a reduction of both PAI-1 secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05). In cultures from severely obese subjects, troglitazone induced a decrease of PAI-1 antigen secretion from newly differentiated omental adipocytes by 49 +/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +/- 7% (p < 0.05). Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to troglitazone induced a similar reduction of PAI-1 concentration in the culture medium (by 35 +/- 11%, p < 0.05, and 33 +/- 8%, p < 0.05 compared with control, respectively). CONCLUSION/INTERPRETATION: This study provides evidence that troglitazone reduces PAI-1 production in human adipocytes, probably at the transcriptional level. This observation could point to a new beneficial effect of troglitazone, particularly in obese subjects, which could be associated with a reduced cardiovascular risk.
10768100	1469	1474	PAI-1	GENE-Y	10768100T10
10768100	1681	1686	PAI-1	GENE-Y	10768100T11
10768100	137	177	plasma plasminogen activator inhibitor-1	GENE-Y	10768100T12
10768100	405	421	nuclear receptor	GENE-N	10768100T13
10768100	422	470	peroxisome proliferator activated receptor-gamma	GENE-Y	10768100T14
10768100	475	480	PAI-1	GENE-Y	10768100T15
10768100	729	762	Plasminogen activator inhibitor-1	GENE-Y	10768100T16
10768100	794	799	PAI-1	GENE-Y	10768100T17
10768100	179	184	PAI-1	GENE-Y	10768100T18
10768100	1014	1019	PAI-1	GENE-Y	10768100T19
10768100	1149	1161	troglitazone	CHEMICAL	10768100T1
10768100	1059	1064	PAI-1	GENE-Y	10768100T20
10768100	21	54	plasminogen activator inhibitor-1	GENE-Y	10768100T21
10768100	1425	1437	troglitazone	CHEMICAL	10768100T2
10768100	1660	1672	troglitazone	CHEMICAL	10768100T3
10768100	1817	1829	troglitazone	CHEMICAL	10768100T4
10768100	375	387	troglitazone	CHEMICAL	10768100T5
10768100	965	977	troglitazone	CHEMICAL	10768100T6
10768100	0	12	Troglitazone	CHEMICAL	190
10768100	1184	1189	PAI-1	GENE-Y	10768100T8
10768100	238	245	insulin	GENE-Y	10768100T9
10768100	CPR:4	10768100T1	10768100T8
10768100	CPR:4	10768100T2	10768100T10
10768100	CPR:4	10768100T3	10768100T11
10768100	CPR:4	10768100T6	10768100T19
10768100	CPR:4	10768100T6	10768100T20
10768100	CPR:4	190	10768100T21

10771044|t|Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs.
10771044|a|We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new alpha(1L)-adrenoceptor antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs. In the contraction study, phenylephrine and noradrenaline produced concentration-dependent contractions in canine prostate and carotid artery, respectively. In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner. The pA(2) (pK(B)) values with prostate were 8.49+/-0.07 for JTH-601, 7.94+/-0.04 for prazosin and 9.42+/-0.22 for tamsulosin. The ratio of pA(2) (carotid artery/prostate), i.e. prostatic selectivity, was 10.471 for JTH-601, 0.008 for prazosin and 0.371 for tamsulosin, respectively. In anesthetized dogs, JTH-601 (1 mg/kg, i.d.) significantly decreased urethral pressure by 15% without affecting blood pressure or heart rate. Tamsulosin (0.1 mg/kg, i.d.) decreased urethral pressure to the same extent as did JTH-601, but with a significant effect on blood pressure and heart rate. JTH-601 showed higher selectivity for canine prostate both in vitro and in vivo. In prostate, an important role of the alpha(1L)-adrenoceptor is suggested in the smooth muscle contraction mediated by alpha(1)-adrenoceptors. JTH-601 is expected to be an effective alpha(1)-adrenoceptor antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.
10771044	585	592	JTH-601	CHEMICAL	10771044T10
10771044	594	602	prazosin	CHEMICAL	10771044T11
10771044	659	669	tamsulosin	CHEMICAL	10771044T12
10771044	151	216	N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom	CHEMICAL	10771044T13
10771044	869	877	prazosin	CHEMICAL	10771044T14
10771044	898	908	tamsulosin	CHEMICAL	10771044T15
10771044	999	1006	JTH-601	CHEMICAL	10771044T16
10771044	1018	1026	prazosin	CHEMICAL	10771044T17
10771044	1041	1051	tamsulosin	CHEMICAL	10771044T18
10771044	1089	1096	JTH-601	CHEMICAL	10771044T19
10771044	1210	1220	Tamsulosin	CHEMICAL	696
10771044	1485	1507	alpha(1L)-adrenoceptor	GENE-N	10771044T20
10771044	1566	1588	alpha(1)-adrenoceptors	GENE-N	10771044T21
10771044	1629	1650	alpha(1)-adrenoceptor	GENE-N	10771044T22
10771044	299	321	alpha(1L)-adrenoceptor	GENE-N	10771044T23
10771044	620	641	alpha(1)-adrenoceptor	GENE-N	10771044T24
10771044	674	696	alpha(1A)-adrenoceptor	GENE-Y	10771044T25
10771044	27	48	alpha(1)-adrenoceptor	GENE-N	10771044T26
10771044	1293	1300	JTH-601	CHEMICAL	10771044T2
10771044	217	222	ethyl	CHEMICAL	10771044T3
10771044	1366	1373	JTH-601	CHEMICAL	10771044T4
10771044	1590	1597	JTH-601	CHEMICAL	10771044T5
10771044	246	290	4-methoxy-2,5,6-trimethylphenol hemifumarate	CHEMICAL	10771044T6
10771044	117	124	JTH-601	CHEMICAL	10771044T7
10771044	436	449	phenylephrine	CHEMICAL	10771044T8
10771044	454	467	noradrenaline	CHEMICAL	10771044T9
10771044	CPR:6	10771044T10	10771044T24
10771044	CPR:6	10771044T11	10771044T24
10771044	CPR:6	10771044T12	10771044T25
10771044	CPR:6	10771044T13	10771044T23
10771044	CPR:6	10771044T3	10771044T23
10771044	CPR:6	10771044T5	10771044T22
10771044	CPR:6	10771044T6	10771044T23
10771044	CPR:6	10771044T7	10771044T23

10831596|t|Severe impairment of salivation in Na+/K+/2Cl- cotransporter (NKCC1)-deficient mice.
10831596|a|The salivary fluid secretory mechanism is thought to require Na(+)/K(+)/2Cl(-) cotransporter-mediated Cl(-) uptake. To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter. In wild-type mice NKCC1 was localized to the basolateral membranes of parotid acinar cells, whereas expression was not detected in duct cells. The lack of functional NKCC1 resulted in a dramatic reduction (>60%) in the volume of saliva secreted in response to a muscarinic agonist, the primary in situ salivation signal. Consistent with defective Cl(-) uptake, a loss of bumetanide-sensitive Cl(-) influx was observed in parotid acinar cells from mice lacking NKCC1. Cl(-)/ HCO(3)(-) exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl(-) uptake. Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter. Furthermore, the ability of the parotid gland to conserve NaCl was abolished in NKCC1-deficient mice. This deficit was not associated with changes in the morphology of the ducts, but transcript levels for the alpha-, beta-, and gamma-subunits of the epithelial Na(+) channel were reduced. These data directly demonstrate that NKCC1 is the major Cl(-) uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.
10831596	1689	1694	Cl(-)	CHEMICAL	10831596T10
10831596	359	364	Na(+)	CHEMICAL	10831596T11
10831596	365	369	K(+)	CHEMICAL	10831596T12
10831596	370	376	2Cl(-)	CHEMICAL	10831596T13
10831596	441	446	Na(+)	CHEMICAL	10831596T14
10831596	447	451	K(+)	CHEMICAL	10831596T15
10831596	452	458	2Cl(-)	CHEMICAL	10831596T16
10831596	146	151	Na(+)	CHEMICAL	10831596T17
10831596	152	156	K(+)	CHEMICAL	10831596T18
10831596	157	163	2Cl(-)	CHEMICAL	10831596T19
10831596	187	192	Cl(-)	CHEMICAL	10831596T1
10831596	821	826	Cl(-)	CHEMICAL	10831596T20
10831596	845	855	bumetanide	CHEMICAL	877
10831596	866	871	Cl(-)	CHEMICAL	10831596T22
10831596	941	946	Cl(-)	CHEMICAL	10831596T23
10831596	948	957	HCO(3)(-)	CHEMICAL	10831596T24
10831596	35	38	Na+	CHEMICAL	10831596T25
10831596	39	41	K+	CHEMICAL	10831596T26
10831596	42	46	2Cl-	CHEMICAL	10831596T27
10831596	1104	1109	NKCC1	GENE-Y	10831596T28
10831596	1195	1221	Cl(-)/ HCO(3)(-) exchanger	GENE-N	10831596T29
10831596	1155	1160	Cl(-)	CHEMICAL	10831596T2
10831596	1222	1225	AE2	GENE-N	10831596T30
10831596	1311	1342	Na(+)/K(+)/2Cl(-) cotransporter	GENE-N	10831596T31
10831596	1424	1429	NKCC1	GENE-Y	10831596T32
10831596	1670	1675	NKCC1	GENE-Y	10831596T33
10831596	359	400	Na(+)/K(+)/2Cl(-) cotransporter isoform 1	GENE-Y	10831596T34
10831596	402	407	Nkcc1	GENE-Y	10831596T35
10831596	441	472	Na(+)/K(+)/2Cl(-) cotransporter	GENE-N	10831596T36
10831596	492	497	NKCC1	GENE-Y	10831596T37
10831596	640	645	NKCC1	GENE-Y	10831596T38
10831596	146	177	Na(+)/K(+)/2Cl(-) cotransporter	GENE-N	10831596T39
10831596	1195	1200	Cl(-)	CHEMICAL	10831596T3
10831596	934	939	NKCC1	GENE-Y	10831596T40
10831596	941	967	Cl(-)/ HCO(3)(-) exchanger	GENE-N	10831596T41
10831596	35	60	Na+/K+/2Cl- cotransporter	GENE-N	10831596T42
10831596	62	67	NKCC1	GENE-Y	10831596T43
10831596	1202	1211	HCO(3)(-)	CHEMICAL	10831596T4
10831596	1311	1316	Na(+)	CHEMICAL	10831596T5
10831596	1317	1321	K(+)	CHEMICAL	10831596T6
10831596	1322	1328	2Cl(-)	CHEMICAL	10831596T7
10831596	1402	1406	NaCl	CHEMICAL	10831596T8
10831596	1605	1610	Na(+)	CHEMICAL	10831596T9
10831596	CPR:9	10831596T10	10831596T33
10831596	CPR:9	10831596T1	10831596T39

10907719|t|Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain.
10907719|a|UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB). Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB. A similar discrepancy in sensitivity to competitors between 3H-NMPB and 3H-QNB was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the mAch receptor could not account for the observed differences in sensitivity to competition. An in vivo saturation study suggested that the apparent association rate constant (k on) of 3H-QNB binding might be changed by ligand concentration. The heterogeneity of the free ligand concentration in intact brain was assessed in relation to the ligand concentration dependency of the apparent association rate constant (k on) of 3H-QNB binding. This finding, together with the more favorable accumulation of 3H-NMPB in cerebral cortex, hippocampus, and striatum, leads us to conclude that 3H-NMPB, or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of mAch receptor occupancy by cholinergic drugs in the brain. KEYWORDS: mAch receptor, QNB, NMPB, in vivo, mouse.
10907719	401	408	3H-NMPB	CHEMICAL	10907719T10
10907719	111	124	acetylcholine	CHEMICAL	10907719T11
10907719	414	440	3H-quinuclidinyl benzilate	CHEMICAL	10907719T12
10907719	442	448	3H-QNB	CHEMICAL	10907719T13
10907719	583	590	3H-NMPB	CHEMICAL	10907719T14
10907719	646	653	3H-NMPB	CHEMICAL	10907719T15
10907719	730	741	scopolamine	CHEMICAL	10907719T16
10907719	751	757	3H-QNB	CHEMICAL	10907719T17
10907719	819	826	3H-NMPB	CHEMICAL	10907719T18
10907719	831	837	3H-QNB	CHEMICAL	10907719T19
10907719	1134	1140	3H-QNB	CHEMICAL	10907719T1
10907719	861	870	biperiden	CHEMICAL	10907719T20
10907719	44	51	3H-NMPB	CHEMICAL	10907719T21
10907719	56	62	3H-QNB	CHEMICAL	10907719T22
10907719	1644	1657	mAch receptor	GENE-N	10907719T23
10907719	1713	1726	mAch receptor	GENE-N	10907719T24
10907719	272	274	M1	GENE-Y	10907719T25
10907719	100	140	muscarinic acetylcholine (mAch) receptor	GENE-N	10907719T26
10907719	477	491	mAch receptors	GENE-N	10907719T27
10907719	630	644	mAch receptors	GENE-N	10907719T28
10907719	950	963	mAch receptor	GENE-N	10907719T29
10907719	206	217	scopolamine	CHEMICAL	10907719T2
10907719	1374	1380	3H-QNB	CHEMICAL	10907719T3
10907719	1453	1460	3H-NMPB	CHEMICAL	10907719T4
10907719	1534	1541	3H-NMPB	CHEMICAL	10907719T5
10907719	238	247	biperiden	CHEMICAL	10907719T6
10907719	1728	1731	QNB	CHEMICAL	10907719T7
10907719	1733	1737	NMPB	CHEMICAL	10907719T8
10907719	368	399	3H-N-methyl piperidyl benzilate	CHEMICAL	10907719T9
10907719	CPR:6	10907719T2	10907719T26
10907719	CPR:6	10907719T6	10907719T25

10909982|t|Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene.
10909982|a|The expression of uncoupling protein (UCP)-3 mRNA in skeletal muscle is dramatically reduced during lactation in mice. The reduction in UCP-3 mRNA levels lowers the amount of the UCP-3 protein in skeletal muscle mitochondria during lactation. Spontaneous or abrupt weaning reverses the downregulation of the UCP-3 mRNA but not the reduction in UCP-3 protein levels. In lactating and virgin mice, however, fasting increases UCP-3 mRNA levels. Changes in UCP-3 mRNA occur in parallel with modifications in the levels of free fatty acids, which are reduced in lactation and are upregulated due to weaning or fasting. Modifications in the energy nutritional stress of lactating dams achieved by manipulating litter sizes do not influence UCP-3 mRNA levels in skeletal muscle. Conversely, when mice are fed a high-fat diet after parturition, the downregulation of UCP-3 mRNA and UCP-3 protein levels due to lactation is partially reversed, as is the reduction in serum free fatty acid levels. Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice. However, in virgin mice, bezafibrate and WY-14,643 do not significantly affect UCP-3 mRNA expression, whereas troglitazone is at least as effective as it is in lactating dams. It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free fatty acids by mechanisms involving activation of PPARs. The impaired expression of the UCP-3 gene is consistent with the involvement of UCP-3 gene regulation in the reduction of the use of fatty acids as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.
10909982	714	725	fatty acids	CHEMICAL	10909982T10
10909982	1160	1170	fatty acid	CHEMICAL	10909982T11
10909982	103	115	troglitazone	CHEMICAL	10909982T12
10909982	1267	1309	peroxisome proliferator-activated receptor	GENE-N	10909982T13
10909982	1311	1315	PPAR	GENE-N	10909982T14
10909982	1325	1330	UCP-3	GENE-Y	10909982T15
10909982	1492	1502	PPAR-alpha	GENE-Y	10909982T16
10909982	1549	1554	UCP-3	GENE-Y	10909982T17
10909982	327	332	UCP-3	GENE-Y	10909982T18
10909982	1607	1617	PPAR-gamma	GENE-Y	10909982T19
10909982	1234	1245	bezafibrate	CHEMICAL	10909982T1
10909982	1648	1653	UCP-3	GENE-Y	10909982T20
10909982	1786	1791	UCP-3	GENE-Y	10909982T21
10909982	1907	1912	UCP-3	GENE-Y	10909982T22
10909982	370	375	UCP-3	GENE-Y	10909982T23
10909982	209	235	uncoupling protein (UCP)-3	GENE-Y	10909982T24
10909982	2060	2065	PPARs	GENE-N	10909982T25
10909982	2098	2103	UCP-3	GENE-Y	10909982T26
10909982	2147	2152	UCP-3	GENE-Y	10909982T27
10909982	499	504	UCP-3	GENE-Y	10909982T28
10909982	535	540	UCP-3	GENE-Y	10909982T29
10909982	1398	1453	4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid	CHEMICAL	10909982T2
10909982	614	619	UCP-3	GENE-Y	10909982T30
10909982	644	649	UCP-3	GENE-Y	10909982T31
10909982	925	930	UCP-3	GENE-Y	10909982T32
10909982	1050	1055	UCP-3	GENE-Y	10909982T33
10909982	1065	1070	UCP-3	GENE-Y	10909982T34
10909982	164	184	uncoupling protein-3	GENE-Y	10909982T35
10909982	27	47	uncoupling protein-3	GENE-Y	10909982T36
10909982	1455	1464	WY-14,643	CHEMICAL	10909982T3
10909982	1569	1581	troglitazone	CHEMICAL	10909982T4
10909982	1732	1743	bezafibrate	CHEMICAL	10909982T5
10909982	1748	1757	WY-14,643	CHEMICAL	10909982T6
10909982	1817	1829	troglitazone	CHEMICAL	10909982T7
10909982	2010	2021	fatty acids	CHEMICAL	10909982T8
10909982	2200	2211	fatty acids	CHEMICAL	10909982T9
10909982	CPR:3	10909982T12	10909982T35
10909982	CPR:3	10909982T1	10909982T13
10909982	CPR:3	10909982T1	10909982T14
10909982	CPR:3	10909982T1	10909982T15
10909982	CPR:3	10909982T2	10909982T17
10909982	CPR:3	10909982T3	10909982T17
10909982	CPR:3	10909982T4	10909982T19
10909982	CPR:3	10909982T4	10909982T20
10909982	CPR:3	10909982T8	10909982T25

10935465|t|The apoptosome: heart and soul of the cell death machine.
10935465|a|Apoptosis is a fundamental biologic process by which metazoan cells orchestrate their own self-demise. Genetic analyses of the nematode C elegans identified three core components of the suicide apparatus which include CED-3, CED-4, and CED-9. An analogous set of core constituents exists in mammalian cells and includes caspase-9, Apaf-1, and bcl-2/xL, respectively. CED-3 and CED-4, along with their mammalian counterparts, function to kill cells, whereas CED-9 and its mammalian equivalents protect cells from death. These central components biochemically intermingle in a ternary complex recently dubbed the "apoptosome." The C elegans protein EGL-1 and its mammalian counterparts, pro-apoptotic members of the bcl-2 family, induce cell death by disrupting apoptosome interactions. Thus, EGL-1 may represent a primordial signal integrator for the apoptosome. Various biochemical processes including oligomerization, adenosine triphosphate ATP/dATP binding, and cytochrome c interaction play a role in regulating the ternary death complex. Recent studies suggest that cell death receptors, such as CD95, may amplify their suicide signal by activating the apoptosome. These mutual associations by core components of the suicide apparatus provide a molecular framework in which diverse death signals likely interface. Understanding the apoptosome and its cellular connections will facilitate the design of novel therapeutic strategies for cancer and other disease states in which apoptosis plays a pivotal role.
10935465	401	409	bcl-2/xL	GENE-N	10935465T10
10935465	425	430	CED-3	GENE-Y	10935465T11
10935465	435	440	CED-4	GENE-Y	10935465T12
10935465	515	520	CED-9	GENE-Y	10935465T13
10935465	705	710	EGL-1	GENE-Y	10935465T14
10935465	772	777	bcl-2	GENE-N	10935465T15
10935465	849	854	EGL-1	GENE-Y	10935465T16
10935465	1022	1034	cytochrome c	GENE-Y	10935465T17
10935465	977	999	adenosine triphosphate	CHEMICAL	10935465T1
10935465	1000	1003	ATP	CHEMICAL	164
10935465	1133	1148	death receptors	GENE-N	10935465T3
10935465	1158	1162	CD95	GENE-Y	10935465T4
10935465	276	281	CED-3	GENE-Y	10935465T5
10935465	283	288	CED-4	GENE-Y	10935465T6
10935465	294	299	CED-9	GENE-Y	10935465T7
10935465	378	387	caspase-9	GENE-Y	10935465T8
10935465	389	395	Apaf-1	GENE-Y	10935465T9

10953053|t|Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
10953053|a|Retigabine [N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid; D-23129] is a novel anticonvulsant, unrelated to currently available antiepileptic agents, with activity in a broad range of seizure models. In the present study, we sought to determine whether retigabine could enhance current through M-like currents in PC12 cells and KCNQ2/Q3 K(+) channels expressed in Chinese hamster ovary cells (CHO-KCNQ2/Q3). In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current. The effect of retigabine was associated with a slowing of M-like tail current deactivation in these cells. Retigabine (0.1 to 10 microM) induced a potassium current and hyperpolarized CHO cells expressing KCNQ2/Q3 cells but not in wild-type cells. Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM). The mechanism by which retigabine enhanced KCNQ2/Q3 currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine). Retigabine shifted the voltage dependence of channel activation with an EC(50) value of 1.6 +/- 0.3 microM (slope factor was 1.2 +/- 0.1, n = 4 to 5 cells per concentration). Retigabine (0.1 to 10 microM) also slowed the rate of channel deactivation, predominantly by increasing the contribution of a slowly deactivating tail current component. Our findings identify KCNQ2/Q3 channels as a molecular target for retigabine and suggest that activation of KCNQ2/Q3 channels may be responsible for at least some of the anticonvulsant activity of this agent.
10953053	696	706	Retigabine	CHEMICAL	4747
10953053	736	745	potassium	CHEMICAL	10953053T11
10953053	157	164	D-23129	CHEMICAL	4747
10953053	837	847	Retigabine	CHEMICAL	4747
10953053	951	962	linopirdine	CHEMICAL	10953053T14
10953053	1005	1012	BaCl(2)	CHEMICAL	10953053T15
10953053	1045	1055	retigabine	CHEMICAL	10953053T16
10953053	0	10	Retigabine	CHEMICAL	4747
10953053	69	78	potassium	CHEMICAL	10953053T18
10953053	1596	1604	KCNQ2/Q3	GENE-N	10953053T19
10953053	89	99	Retigabine	CHEMICAL	4747
10953053	1682	1690	KCNQ2/Q3	GENE-N	10953053T20
10953053	426	434	KCNQ2/Q3	GENE-N	10953053T21
10953053	435	448	K(+) channels	GENE-N	10953053T22
10953053	495	503	KCNQ2/Q3	GENE-N	10953053T23
10953053	794	802	KCNQ2/Q3	GENE-N	10953053T24
10953053	872	880	KCNQ2/Q3	GENE-N	10953053T25
10953053	933	941	KCNQ2/Q3	GENE-N	10953053T26
10953053	1065	1073	KCNQ2/Q3	GENE-N	10953053T27
10953053	60	68	KCNQ2/Q3	GENE-N	10953053T28
10953053	69	87	potassium channels	GENE-N	10953053T29
10953053	1216	1226	retigabine	CHEMICAL	10953053T2
10953053	1229	1239	Retigabine	CHEMICAL	4747
10953053	101	155	N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid	CHEMICAL	10953053T4
10953053	1404	1414	Retigabine	CHEMICAL	4747
10953053	1640	1650	retigabine	CHEMICAL	10953053T6
10953053	435	439	K(+)	CHEMICAL	10953053T7
10953053	558	569	linopirdine	CHEMICAL	10953053T8
10953053	603	613	retigabine	CHEMICAL	10953053T9
10953053	CPR:3	4747	10953053T29

10980326|t|Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.
10980326|a|The aim of this study was to investigate [3H]paroxetine binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter (5-HTT) polymorphism (5-HTTLPR). Alcohol-dependent subjects were hypothesized to show a decreased number of bindings sites and a lower dissociation constant. 5-HTTLPR S-genotype carriers in both alcohol-dependent and control subjects were expected to show significantly fewer binding sites and a lower dissociation constant. Influences of impulsive traits, chronic daily alcohol intake, duration of alcohol dependence, age of onset and age on [3H]paroxetine binding were also investigated. Inpatients meeting DSM IV alcohol dependence criteria and of German descent were recruited to avoid ethnic stratification effects. One hundred and seventeen control subjects of similar social status were recruited from a town community. Blood samples were taken from both alcohol-dependent and control subjects to determine 5-HTTLPR genotypes using PCR of lymphocyte DNA, and to perform platelet [3H]paroxetine binding (binding capacity: B(max); and dissociation constant: K(D)). Impulsivity was assessed using the Barratt impulsiveness scale version 5 (BIS-5) in alcohol-dependent subjects only. Alcohol-dependent subjects were subdivided into low or high impulsivity groups using a median-split of the BIS-5 scale. The control group was slightly older than the alcohol-dependent group (not statistically significant). [3H]paroxetine binding was investigated in 72 control subjects and 72 patients, of which five patients met type 2 alcohol dependence criteria. Genotyping was carried out in all patients and control subjects. A significant influence of duration of alcohol dependence was found on the [3H]paroxetine binding K(D) but not B(max.) Neither alcohol-dependent nor control subjects showed any differences in B(max) or K(D). S-allele carriers did not show a decreased binding or lower dissociation constant. Furthermore, no significant interaction between B(max) and K(D) with either 5-HTTLPR genotype or impulsivity was revealed. This was the first study to investigate platelet [3H]paroxetine binding in alcohol-dependent and age-matched control subjects in relation to the 5-HTTLPR genotype. No differences concerning 5-HTTLPR-alleles were found in these groups Furthermore, no significant interaction between these parameters and impulsivity was shown in alcohol-dependent subjects. These results do not support previous results of altered [3H]paroxetine binding sites in alcohol-dependent subjects or 5-HTTLPR S-allele carriers. K(D) might be influenced by duration of alcohol dependence, but not sufficiently to yield differences between alcohol-dependent and control subjects.
10980326	2365	2379	[3H]paroxetine	CHEMICAL	10980326T10
10980326	2391	2398	alcohol	CHEMICAL	10980326T11
10980326	2644	2651	alcohol	CHEMICAL	10980326T12
10980326	2729	2743	[3H]paroxetine	CHEMICAL	10980326T13
10980326	2859	2866	alcohol	CHEMICAL	10980326T14
10980326	2929	2936	alcohol	CHEMICAL	10980326T15
10980326	579	586	alcohol	CHEMICAL	10980326T16
10980326	233	247	[3H]paroxetine	CHEMICAL	10980326T17
10980326	755	762	alcohol	CHEMICAL	10980326T18
10980326	783	790	alcohol	CHEMICAL	10980326T19
10980326	1270	1284	[3H]paroxetine	CHEMICAL	10980326T1
10980326	827	841	[3H]paroxetine	CHEMICAL	10980326T20
10980326	900	907	alcohol	CHEMICAL	10980326T21
10980326	275	282	alcohol	CHEMICAL	10980326T22
10980326	1146	1153	alcohol	CHEMICAL	10980326T23
10980326	0	9	Serotonin	CHEMICAL	10980326T24
10980326	70	84	[3H]paroxetine	CHEMICAL	10980326T25
10980326	1198	1206	5-HTTLPR	GENE-Y	10980326T26
10980326	362	383	serotonin transporter	GENE-Y	10980326T27
10980326	385	390	5-HTT	GENE-Y	10980326T28
10980326	2269	2277	5-HTTLPR	GENE-Y	10980326T29
10980326	1438	1445	alcohol	CHEMICAL	10980326T2
10980326	406	414	5-HTTLPR	GENE-Y	10980326T30
10980326	2461	2469	5-HTTLPR	GENE-Y	10980326T31
10980326	2506	2514	5-HTTLPR	GENE-Y	10980326T32
10980326	2791	2799	5-HTTLPR	GENE-Y	10980326T33
10980326	542	550	5-HTTLPR	GENE-Y	10980326T34
10980326	0	21	Serotonin transporter	GENE-Y	10980326T35
10980326	59	67	5-HTTLPR	GENE-Y	10980326T36
10980326	1471	1478	Alcohol	CHEMICAL	888
10980326	1694	1708	[3H]paroxetine	CHEMICAL	10980326T4
10980326	1808	1815	alcohol	CHEMICAL	10980326T5
10980326	362	371	serotonin	CHEMICAL	10980326T6
10980326	1941	1948	alcohol	CHEMICAL	10980326T7
10980326	1977	1991	[3H]paroxetine	CHEMICAL	10980326T8
10980326	2029	2036	alcohol	CHEMICAL	10980326T9

11006278|t|Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 (cyclooxygenase-2).
11006278|a|By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of arachidonic acid and nonsteroidal anti-inflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H(2) synthase enzyme (PGHS-2). Line shape broadening resulting from spin-spin coupling of nitroxide pairs introduced into the membrane-binding helices of PGHS-2 was used to calculate the inter-helical distances and changes in these distances that occur in response to binding various ligands. The inter-residue distances determined for the PGHS-2 holoenzyme using EPR were 1-7.9 A shorter than those of the crystal structure of the PGHS-2 holoenzyme. However, inter-helical distances calculated and determined by EPR for PGHS-2 complexed with arachidonic acid, flurbiprofen, and SC-58125 were in close agreement with those obtained from the cognate crystal structures. These results indicate that the structure of the solubilized PGHS-2 holoenzyme measured in solution differs from the crystal structure of PGHS-2 holoenzyme obtained by x-ray analysis. Furthermore, binding of ligands induces a conformational change in the holo-PGHS-2, converting it to a structure similar to those obtained by x-ray analysis. Proteolysis protection assays had previously provided circumstantial evidence that binding of heme and non-steroidal anti-inflammatory drugs alters the conformation of PGHS, but the present experiments are the first to directly measure such changes. The finding that arachidonate can also induce a conformational change in PGHS-2 was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the cyclooxygenase catalytic mechanism.
11006278	101	130	prostaglandin endoperoxide H2	CHEMICAL	11006278T10
11006278	1217	1223	PGHS-2	GENE-Y	11006278T11
11006278	1339	1345	PGHS-2	GENE-Y	11006278T12
11006278	1589	1593	PGHS	GENE-N	11006278T13
11006278	1744	1750	PGHS-2	GENE-Y	11006278T14
11006278	1856	1870	cyclooxygenase	GENE-N	11006278T15
11006278	377	430	human prostaglandin endoperoxide H(2) synthase enzyme	GENE-N	11006278T16
11006278	432	438	PGHS-2	GENE-Y	11006278T17
11006278	564	570	PGHS-2	GENE-Y	11006278T18
11006278	750	756	PGHS-2	GENE-Y	11006278T19
11006278	281	297	arachidonic acid	CHEMICAL	11006278T1
11006278	842	848	PGHS-2	GENE-Y	11006278T20
11006278	931	937	PGHS-2	GENE-Y	11006278T21
11006278	1140	1146	PGHS-2	GENE-Y	11006278T22
11006278	143	159	cyclooxygenase-2	GENE-Y	11006278T23
11006278	95	141	human prostaglandin endoperoxide H2 synthase-2	GENE-Y	11006278T24
11006278	1528	1537	steroidal	CHEMICAL	11006278T2
11006278	1688	1700	arachidonate	CHEMICAL	11006278T3
11006278	383	414	prostaglandin endoperoxide H(2)	CHEMICAL	11006278T4
11006278	500	509	nitroxide	CHEMICAL	11006278T5
11006278	953	969	arachidonic acid	CHEMICAL	11006278T6
11006278	971	983	flurbiprofen	CHEMICAL	11006278T7
11006278	989	997	SC-58125	CHEMICAL	11006278T8
11006278	0	16	Arachidonic acid	CHEMICAL	11006278T9

11054378|t|Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta.
11054378|a|BACKGROUND & AIMS: Activation of NF-kappaB/Rel has been implicated in the pathogenesis of inflammatory bowel disease (IBD). Various drugs used in the treatment of IBD, such as glucocorticoids, 5-aminosalicylic acid, and sulfasalazine, interfere with NF-kappaB/Rel signaling. The aim of this study was to define the molecular mechanism by which sulfasalazine inhibits NF-kappaB activation. METHODS: The effects of sulfasalazine and its moieties on NF-kappaB signaling were evaluated using electromobility shift, transfection, and immune complex kinase assays. The direct effect of sulfasalazine on IkappaB kinase (IKK) activity was investigated using purified recombinant IKK-alpha and -beta proteins. RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine. Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro. In contrast, the moieties of sulfasalazine, 5-aminosalicylic acid, and sulfapyridine or 4-aminosalicylic acid had no effect. Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun-N-terminal kinase (JNK) 1, and p38 was unaffected by sulfasalazine. The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of IKKs and can be antagonized by excess adenosine triphosphate. CONCLUSIONS: These data identify sulfasalazine as a direct inhibitor of IKK-alpha and -beta by antagonizing adenosine triphosphate binding. The suppression of NF-kappaB activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of sulfasalazine.
11054378	2047	2060	sulfasalazine	CHEMICAL	11054378T10
11054378	312	333	5-aminosalicylic acid	CHEMICAL	237
11054378	339	352	sulfasalazine	CHEMICAL	11054378T12
11054378	463	476	sulfasalazine	CHEMICAL	11054378T13
11054378	532	545	sulfasalazine	CHEMICAL	11054378T14
11054378	699	712	sulfasalazine	CHEMICAL	11054378T15
11054378	892	928	12-O-tetradecanoylphorbol-13-acetate	CHEMICAL	11054378T16
11054378	1089	1102	sulfasalazine	CHEMICAL	11054378T17
11054378	1104	1117	Sulfasalazine	CHEMICAL	785
11054378	37	50	sulfasalazine	CHEMICAL	11054378T19
11054378	1342	1355	sulfasalazine	CHEMICAL	11054378T1
11054378	1128	1155	tumor necrosis factor alpha	GENE-Y	11054378T20
11054378	1189	1192	IKK	GENE-N	11054378T21
11054378	1280	1289	IKK-alpha	GENE-Y	11054378T22
11054378	1294	1302	IKK-beta	GENE-Y	11054378T23
11054378	1452	1501	extracellular signal-related kinase (ERK) 1 and 2	GENE-N	11054378T24
11054378	1503	1534	c-Jun-N-terminal kinase (JNK) 1	GENE-Y	11054378T25
11054378	1540	1543	p38	GENE-N	11054378T26
11054378	1622	1641	IKK-alpha and -beta	GENE-N	11054378T27
11054378	1698	1702	IKKs	GENE-N	11054378T28
11054378	1832	1851	IKK-alpha and -beta	GENE-N	11054378T29
11054378	1357	1378	5-aminosalicylic acid	CHEMICAL	237
11054378	1919	1928	NF-kappaB	GENE-N	11054378T30
11054378	1961	1965	IKKs	GENE-N	11054378T31
11054378	369	378	NF-kappaB	GENE-N	11054378T32
11054378	379	382	Rel	GENE-Y	202852|66255
11054378	152	161	NF-kappaB	GENE-N	11054378T34
11054378	486	495	NF-kappaB	GENE-N	11054378T35
11054378	162	165	Rel	GENE-Y	202852|66255
11054378	566	575	NF-kappaB	GENE-N	11054378T37
11054378	716	730	IkappaB kinase	GENE-N	11054378T38
11054378	732	735	IKK	GENE-N	11054378T39
11054378	1384	1397	sulfapyridine	CHEMICAL	11054378T3
11054378	790	809	IKK-alpha and -beta	GENE-N	11054378T40
11054378	829	838	NF-kappaB	GENE-N	11054378T41
11054378	839	842	Rel	GENE-Y	202852|66255
11054378	863	890	tumor necrosis factor alpha	GENE-Y	11054378T43
11054378	951	976	NF-kappaB-inducing kinase	GENE-Y	11054378T44
11054378	978	987	IKK-alpha	GENE-Y	11054378T45
11054378	989	997	IKK-beta	GENE-Y	11054378T46
11054378	1024	1033	IKK-alpha	GENE-Y	11054378T47
11054378	1038	1046	IKK-beta	GENE-Y	11054378T48
11054378	15	24	NF-kappaB	GENE-N	11054378T49
11054378	1401	1422	4-aminosalicylic acid	CHEMICAL	226
11054378	87	117	IkappaB kinases alpha and beta	GENE-N	11054378T50
11054378	1509	1510	N	CHEMICAL	167
11054378	1562	1575	sulfasalazine	CHEMICAL	11054378T6
11054378	1736	1758	adenosine triphosphate	CHEMICAL	11054378T7
11054378	1793	1806	sulfasalazine	CHEMICAL	11054378T8
11054378	1868	1890	adenosine triphosphate	CHEMICAL	11054378T9
11054378	CPR:3	11054378T16	11054378T41
11054378	CPR:3	11054378T16	202852|66255
11054378	CPR:4	11054378T10	11054378T30
11054378	CPR:4	11054378T10	11054378T31
11054378	CPR:4	11054378T13	11054378T35
11054378	CPR:4	11054378T17	11054378T41
11054378	CPR:4	11054378T17	202852|66255
11054378	CPR:4	11054378T17	11054378T44
11054378	CPR:4	11054378T17	11054378T45
11054378	CPR:4	11054378T17	11054378T46
11054378	CPR:4	11054378T17	11054378T47
11054378	CPR:4	11054378T17	11054378T48
11054378	CPR:4	785	11054378T20
11054378	CPR:4	785	11054378T21
11054378	CPR:4	785	11054378T22
11054378	CPR:4	785	11054378T23
11054378	CPR:4	11054378T19	11054378T49
11054378	CPR:4	11054378T7	11054378T28

11078056|t|Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.
11078056|a|Several types of human tumors overexpress cyclooxygenase (COX) -2 but not COX-1, and gene knockout transfection experiments demonstrate a central role of COX-2 in experimental tumorigenesis. COX-2 produces prostaglandins that inhibit apoptosis and stimulate angiogenesis and invasiveness. Selective COX-2 inhibitors reduce prostaglandin synthesis, restore apoptosis, and inhibit cancer cell proliferation. In animal studies they limit carcinogen-induced tumorigenesis. In contrast, aspirin-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective COX-1 as well. Consequently, nonselective NSAIDs can cause platelet dysfunction, gastrointestinal ulceration, and kidney damage. For that reason, selective inhibition of COX-2 to treat neoplastic proliferation is preferable to nonselective inhibition. Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. For instance, meloxicam inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express COX-2 but has no effect on HCT-116 tumor cells that do not express COX-2. NS-398 induces apoptosis in COX-2 expressing LNCaP prostate cancer cells and, surprisingly, in colon cancer S/KS cells that does not express COX-2. This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of Bcl-2, as has been demonstrated for some nonselective NSAIDs, for instance, flurbiprofen. COX-2 mRNA and COX-2 protein is constitutively expressed in the kidney, brain, spinal cord, and ductus deferens, and in the uterus during implantation. In addition, COX-2 is constitutively and dominantly expressed in the pancreatic islet cells. These findings might somewhat limit the use of presently available selective COX-2 inhibitors in cancer prevention but will probably not deter their successful application for the treatment of human cancers.
11078056	633	645	indomethacin	CHEMICAL	11078056T10
11078056	1068	1077	meloxicam	CHEMICAL	11078056T11
11078056	1079	1088	celecoxib	CHEMICAL	11078056T12
11078056	1090	1098	SC-58635	CHEMICAL	11078056T13
11078056	1198	1203	COX-2	GENE-Y	11078056T14
11078056	1212	1217	COX-1	GENE-Y	11078056T15
11078056	1327	1332	COX-2	GENE-Y	11078056T16
11078056	1394	1399	COX-2	GENE-Y	11078056T17
11078056	1429	1434	COX-2	GENE-Y	11078056T18
11078056	1542	1547	COX-2	GENE-Y	11078056T19
11078056	1105	1114	rofecoxib	CHEMICAL	11078056T1
11078056	251	256	COX-2	GENE-Y	11078056T20
11078056	1666	1671	Bcl-2	GENE-Y	11078056T21
11078056	1756	1761	COX-2	GENE-Y	11078056T22
11078056	1771	1776	COX-2	GENE-Y	11078056T23
11078056	1921	1926	COX-2	GENE-Y	11078056T24
11078056	288	293	COX-2	GENE-Y	11078056T25
11078056	2078	2083	COX-2	GENE-Y	11078056T26
11078056	396	401	COX-2	GENE-Y	11078056T27
11078056	139	162	cyclooxygenase (COX) -2	GENE-Y	11078056T28
11078056	725	730	COX-2	GENE-Y	11078056T29
11078056	1116	1123	MK-0966	CHEMICAL	11078056T2
11078056	780	785	COX-1	GENE-Y	11078056T30
11078056	171	176	COX-1	GENE-Y	11078056T31
11078056	950	955	COX-2	GENE-Y	11078056T32
11078056	1042	1047	COX-2	GENE-Y	11078056T33
11078056	16	38	cyclooxygenase (COX)-2	GENE-Y	11078056T34
11078056	77	82	COX-2	GENE-Y	11078056T35
11078056	1233	1242	meloxicam	CHEMICAL	11078056T3
11078056	1401	1407	NS-398	CHEMICAL	11078056T4
11078056	1742	1754	flurbiprofen	CHEMICAL	11078056T5
11078056	303	317	prostaglandins	CHEMICAL	11078056T6
11078056	420	433	prostaglandin	CHEMICAL	11078056T7
11078056	579	586	aspirin	CHEMICAL	11078056T8
11078056	620	628	sulindac	CHEMICAL	595
11078056	CPR:4	11078056T10	11078056T29
11078056	CPR:4	11078056T10	11078056T30
11078056	CPR:4	11078056T11	11078056T14
11078056	CPR:4	11078056T11	11078056T33
11078056	CPR:4	11078056T12	11078056T14
11078056	CPR:4	11078056T12	11078056T33
11078056	CPR:4	11078056T13	11078056T14
11078056	CPR:4	11078056T13	11078056T33
11078056	CPR:4	11078056T1	11078056T14
11078056	CPR:4	11078056T1	11078056T33
11078056	CPR:4	11078056T2	11078056T14
11078056	CPR:4	11078056T2	11078056T33
11078056	CPR:4	11078056T3	11078056T16
11078056	CPR:4	11078056T5	11078056T21
11078056	CPR:4	11078056T8	11078056T29
11078056	CPR:4	11078056T8	11078056T30
11078056	CPR:4	595	11078056T29
11078056	CPR:4	595	11078056T30
11078056	CPR:9	11078056T6	11078056T25

11106255|t|The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.
11106255|a|The carcinoid tumor is an uncommon neuroendocrine neoplasm the hallmark of which is excessive serotonin production. In studying kinetics of tryptophan hydroxylase and aromatic-L-amino acid decarboxylase (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J. A. Gilbert et al, Biochem. Pharmacol., 50: 845-850, 1995), we identified one significant difference: the Vmax of carcinoid AAAD was 50-fold higher than that in normal liver. Here, we report Western and Northern analyses detecting large quantities of AAAD polypeptide and mRNA in human carcinoid primary as well as metastatic tumors compared with normal surrounding tissues. To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells. Carbidopa and MFMD were lethal (IC50 = 29 +/- 2 microM and 56 +/- 6 microM, respectively); NSD-1015 had no effect on proliferation. On exposure to other human tumor lines, carbidopa was lethal only to NCI-H146 and NCI-H209 small cell lung carcinoma (SCLC) lines (IC50 = 12 +/- 1 microM and 22 +/- 5 microM, respectively). Carbidopa (100 microM) decreased growth of (but did not kill) SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells and did not affect proliferation of DU 145 prostate, MCF7 breast, or NCI-H460 large cell lung carcinoma lines. The rank order of lines by AAAD activity was NCI-H146 > NCI-H209 > SK-N-SH > NCI-H727, whereas A204, DU 145, MCF7, and NCI-H460 had no measurable activity. For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), AAAD activity was correlated with the potency of carbidopa-induced cytotoxicity. However, carcinoid cell death was not solely attributable to complete inhibition of either AAAD activity or the serotonin synthetic pathway. In further evaluating potential applications of these findings with carbidopa, we determined that sublethal doses of carbidopa produced additive cytotoxic effects in carcinoid cells in combination with etoposide and cytotoxic synergy in SCLC cells when coincubated with topotecan.
11106255	2354	2363	topotecan	CHEMICAL	1019
11106255	899	908	carbidopa	CHEMICAL	11106255T11
11106255	910	936	alpha-methyl-dopahydrazine	CHEMICAL	11106255T12
11106255	939	965	alpha-monofluoromethyldopa	CHEMICAL	11106255T13
11106255	967	971	MFMD	CHEMICAL	11106255T14
11106255	978	1002	3-hydroxybenzylhydrazine	CHEMICAL	11106255T15
11106255	1004	1012	NSD-1015	CHEMICAL	11106255T16
11106255	1078	1087	Carbidopa	CHEMICAL	183
11106255	245	254	serotonin	CHEMICAL	11106255T18
11106255	1092	1096	MFMD	CHEMICAL	11106255T19
11106255	1169	1177	NSD-1015	CHEMICAL	11106255T1
11106255	4	25	aromatic-L-amino acid	CHEMICAL	11106255T20
11106255	291	313	tryptophan hydroxylase	GENE-N	11106255T21
11106255	1654	1658	AAAD	GENE-Y	11106255T22
11106255	318	353	aromatic-L-amino acid decarboxylase	GENE-Y	11106255T23
11106255	1862	1866	AAAD	GENE-Y	11106255T24
11106255	2034	2038	AAAD	GENE-Y	11106255T25
11106255	355	359	AAAD	GENE-Y	11106255T26
11106255	552	556	AAAD	GENE-Y	11106255T27
11106255	679	683	AAAD	GENE-Y	11106255T28
11106255	853	857	AAAD	GENE-Y	11106255T29
11106255	1250	1259	carbidopa	CHEMICAL	11106255T2
11106255	883	887	AAAD	GENE-Y	11106255T30
11106255	4	39	aromatic-L-amino acid decarboxylase	GENE-Y	11106255T31
11106255	1400	1409	Carbidopa	CHEMICAL	183
11106255	291	301	tryptophan	CHEMICAL	11106255T4
11106255	318	339	aromatic-L-amino acid	CHEMICAL	11106255T5
11106255	1911	1920	carbidopa	CHEMICAL	11106255T6
11106255	2055	2064	serotonin	CHEMICAL	11106255T7
11106255	2152	2161	carbidopa	CHEMICAL	11106255T8
11106255	2201	2210	carbidopa	CHEMICAL	11106255T9
11106255	CPR:4	11106255T11	11106255T30
11106255	CPR:4	11106255T12	11106255T30
11106255	CPR:4	11106255T13	11106255T30
11106255	CPR:4	11106255T14	11106255T30
11106255	CPR:4	11106255T15	11106255T30
11106255	CPR:4	11106255T16	11106255T30

11141093|t|Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors.
11141093|a|In a search for less flexible analogues of caproctamine (1), a diamine diamide endowed with an interesting AChE affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system. Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE. The 6-carbamate 4 was almost as potent as physostigmine and was 60- and 550-fold more potent than the 7-carbamate 5 and the 8-carbamate 6, respectively. The two enantiomers of 4, (-)-4 and (+)-4, did not show a marked enantioselectivity. Finally, a similar time-dependent pattern of inhibition of AChE was observed for 3 and 4.
11141093	151	158	diamide	CHEMICAL	11141093T10
11141093	0	31	Hexahydrochromeno[4,3-b]pyrrole	CHEMICAL	11141093T11
11141093	187	191	AChE	GENE-Y	11141093T12
11141093	367	371	AChE	GENE-Y	11141093T13
11141093	629	639	human AChE	GENE-Y	11141093T14
11141093	644	648	BChE	GENE-Y	11141093T15
11141093	947	951	AChE	GENE-Y	11141093T16
11141093	47	67	acetylcholinesterase	GENE-Y	11141093T17
11141093	258	273	2-methoxybenzyl	CHEMICAL	11141093T1
11141093	316	325	tricyclic	CHEMICAL	11141093T2
11141093	400	431	hexahydrochromeno[4,3-b]pyrrole	CHEMICAL	11141093T3
11141093	461	507	hexahydropyrrolo[2,3-b]indole of physostigmine	CHEMICAL	11141093T4
11141093	123	135	caproctamine	CHEMICAL	11141093T5
11141093	546	556	carbamates	CHEMICAL	11141093T6
11141093	654	665	6-carbamate	CHEMICAL	11141093T7
11141093	692	705	physostigmine	CHEMICAL	11141093T8
11141093	143	150	diamine	CHEMICAL	11141093T9
11141093	CPR:4	11141093T11	11141093T17
11141093	CPR:4	11141093T3	11141093T13
11141093	CPR:4	11141093T4	11141093T13

11155778|t|Brugada syndrome without mutation of the cardiac sodium channel gene in a Taiwanese patient.
11155778|a|We describe a 45-year-old Taiwanese man with specific features of Brugada syndrome but no clinical features of structural heart disease. He was successfully treated with an implantable cardioverter-defibrillator. His electrocardiogram (ECG) patterns changed intermittently. Alpha-adrenoceptor stimulation and beta-adrenoceptor blockade augmented the characteristic ST-segment elevation, whereas alpha-adrenoceptor blockade and beta-adrenoceptor stimulation mitigated the ST-segment elevation. Intravenous procainamide administration did not aggravate ST-segment elevation when ECG had shown coved ST elevation in the right precordial leads. Molecular study did not reveal the same mutations in the cardiac sodium channel gene (SCN5A) as previously reported in Brugada syndrome. This case demonstrates the genetic heterogeneity of SCN5A in Brugada syndrome.
11155778	923	928	SCN5A	GENE-Y	112236|1172535
11155778	41	63	cardiac sodium channel	GENE-Y	11155778T11
11155778	598	610	procainamide	CHEMICAL	11155778T1
11155778	799	805	sodium	CHEMICAL	11155778T2
11155778	49	55	sodium	CHEMICAL	11155778T3
11155778	367	385	Alpha-adrenoceptor	GENE-N	11155778T4
11155778	402	419	beta-adrenoceptor	GENE-N	11155778T5
11155778	488	506	alpha-adrenoceptor	GENE-N	11155778T6
11155778	520	537	beta-adrenoceptor	GENE-N	11155778T7
11155778	791	813	cardiac sodium channel	GENE-Y	11155778T8
11155778	820	825	SCN5A	GENE-Y	112236|1172535

11161433|t|Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma.
11161433|a|The association between the balance of Th1/Th2 cell responses and CYP11A1 expression in CD4+ T cells was investigated in a murine model implanted with highly metastatic B16F10 melanoma cells (B16F10 mice). When 2 x 10(5) cells/mouse of B16F10 cells were inoculated into C57BL/6 mice, Th2 cell responses and pulmonary metastasis were increased. In addition, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression (mRNA encoding cholesterol side-chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice. When the anti-corticosterone drug aminoglutethimide (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation. In addition, Th1 cell responses were restored and pulmonary metastasis was reduced by aminoglutethimide. These results indicated that the breakdown of Th cell responses and increase of pulmonary metastasis were due to an increase in steroidogenic CYP11A1 mRNA expression in CD4+ T cells. Moreover, it was suggested that promotion of CYP11A1 mRNA expression in Th2 cells was partially involved due to an increase in level of corticosterone in splenic tissue and the breakdown of Th cell responses locally in the splenic tissue, which then affected the maintenance of Th2 cell functions in the microenvironment of tumor-bearing mice.
11161433	587	630	cholesterol side-chain cleavage p450 enzyme	GENE-Y	11161433T10
11161433	731	738	CYP11A1	GENE-Y	107955
11161433	204	211	CYP11A1	GENE-Y	107955
11161433	836	843	CYP11A1	GENE-Y	107955
11161433	56	63	CYP11A1	GENE-Y	107955
11161433	1335	1349	corticosterone	CHEMICAL	11161433T1
11161433	495	509	corticosterone	CHEMICAL	11161433T2
11161433	587	598	cholesterol	CHEMICAL	11161433T3
11161433	712	729	aminoglutethimide	CHEMICAL	11161433T4
11161433	783	797	corticosterone	CHEMICAL	11161433T5
11161433	997	1014	aminoglutethimide	CHEMICAL	11161433T6
11161433	1158	1165	CYP11A1	GENE-Y	107955
11161433	1244	1251	CYP11A1	GENE-Y	107955
11161433	548	555	CYP11A1	GENE-Y	107955
11161433	CPR:4	11161433T4	107955
11161433	CPR:4	11161433T4	107955

11181577|t|A nonsense mutation in the NDUFS4 gene encoding the 18 kDa (AQDQ) subunit of complex I abolishes assembly and activity of the complex in a patient with Leigh-like syndrome.
11181577|a|Sequence analysis of mitochondrial and nuclear candidate genes of complex I in children with deficiency of this complex and exhibiting Leigh-like syndrome has revealed, in one of them, a novel mutation in the NDUFS4 gene encoding the 18 kDa subunit. Phosphorylation of this subunit by cAMP-dependent protein kinase has previously been found to activate the complex. The present mutation consists of a homozygous G-->A transition at nucleotide position +44 of the coding sequence of the gene, resulting in the change of a tryptophan codon to a stop codon. Such mutation causes premature termination of the protein after only 14 amino acids of the putative mitochondrial targeting peptide. Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive NADH-->UQ oxidoreductase activity of complex I, which was insensitive to cAMP stimulation. Two-dimensional electrophoresis showed the absence of detectable normally assembled complex I in the inner mitochondrial membrane. These findings show that the expression of the NDUFS4 gene is essential for the assembly of a functional complex I.
11181577	239	248	complex I	GENE-N	11181577T10
11181577	951	975	NADH-->UQ oxidoreductase	GENE-N	11181577T11
11181577	988	997	complex I	GENE-N	11181577T12
11181577	1126	1135	complex I	GENE-N	11181577T13
11181577	27	33	NDUFS4	GENE-Y	110803
11181577	52	86	18 kDa (AQDQ) subunit of complex I	GENE-Y	11181577T15
11181577	458	462	cAMP	CHEMICAL	2424
11181577	694	704	tryptophan	CHEMICAL	11181577T2
11181577	800	811	amino acids	CHEMICAL	11181577T3
11181577	951	955	NADH	CHEMICAL	151
11181577	1024	1028	cAMP	CHEMICAL	2424
11181577	1220	1226	NDUFS4	GENE-Y	110803
11181577	1278	1287	complex I	GENE-N	11181577T7
11181577	382	388	NDUFS4	GENE-Y	110803
11181577	458	487	cAMP-dependent protein kinase	GENE-N	11181577T9

11212269|t|Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
11212269|a|Chemotherapeutic agents produce cytotoxicity via induction of apoptosis and cell cycle arrest. Rapidly proliferating cells in the bone marrow and intestinal crypts are highly susceptible to chemotherapy, and damage to these cellular compartments may preclude maximally effective chemotherapy administration. Glucagon-like peptide (GLP)-2 is an enteroendocrine-derived regulatory peptide that inhibits crypt cell apoptosis after administration of agents that damage the intestinal epithelium. We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan. Furthermore, h[Gly2]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(ADP-ribose) polymerase cleavage in heterologous cells transfected with the GLP-2 receptor. These observations demonstrate that the antiapoptotic effects of GLP-2 on intestinal crypt cells may be useful for the attenuation of chemotherapy-induced intestinal mucositis.
11212269	1358	1372	GLP-2 receptor	GENE-Y	11212269T10
11212269	1439	1444	GLP-2	GENE-Y	11212269T11
11212269	457	486	Glucagon-like peptide (GLP)-2	GENE-Y	11212269T12
11212269	691	696	GLP-2	GENE-Y	11212269T13
11212269	715	720	GLP-2	GENE-Y	11212269T14
11212269	894	909	topoisomerase I	GENE-Y	11212269T15
11212269	991	996	GLP-2	GENE-Y	11212269T16
11212269	0	29	Glucagon-like peptide (GLP)-2	GENE-Y	11212269T17
11212269	133	147	GLP-2 receptor	GENE-Y	11212269T18
11212269	1170	1174	Gly2	CHEMICAL	11212269T1
11212269	1283	1293	ADP-ribose	CHEMICAL	11212269T2
11212269	709	713	Gly2	CHEMICAL	11212269T3
11212269	920	944	irinotecan hydrochloride	CHEMICAL	11212269T4
11212269	967	981	5-fluorouracil	CHEMICAL	11212269T5
11212269	985	989	Gly2	CHEMICAL	11212269T6
11212269	1176	1181	GLP-2	GENE-Y	11212269T7
11212269	1246	1262	caspase-8 and -3	GENE-N	11212269T8
11212269	1278	1305	poly(ADP-ribose) polymerase	GENE-N	11212269T9
11212269	CPR:4	11212269T1	11212269T9
11212269	CPR:4	11212269T4	11212269T15

11255924|t|On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns.
11255924|a|RATIONALE: Drugs that are self-administered appear to vary in their potency and effectiveness as positive reinforcers. Understanding mechanisms that determine relative effectiveness of drugs as reinforcers will enhance our understanding of drug abuse. OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors. Accordingly, self-administration of a group of local anesthetics that are DAT ligands was compared to their effects as DA uptake blockers in vitro in brain tissue. METHODS: Rhesus monkeys were allowed to self-administer cocaine and other local anesthetics i.v. under a progressive-ratio schedule. The same compounds were compared in standard in vitro DA uptake assays using monkey caudate tissue. RESULTS: The rank order of both potency and effectiveness as reinforcers was cocaine > dimethocaine > procaine > chloroprocaine. Tetracaine did not maintain self-administration. For inhibiting DA uptake, the potency order was cocaine > dimethocaine > tetracaine > procaine > chloro-procaine. At maximum, these compounds were equally effective in blocking DA uptake. Lidocaine did not inhibit DA uptake. CONCLUSIONS: The potency of local anesthetics as positive reinforcers is likely related to their potency as DA uptake inhibitors. Variation in their effectiveness as positive reinforcers was not a function of differences in effectiveness as DA uptake blockers, but may be related to relative potency over the concentrations that are achieved in vivo. Effects at sodium channels may limit the reinforcing effects of local anesthetics.
11255924	1430	1432	DA	CHEMICAL	11255924T10
11255924	1549	1551	DA	CHEMICAL	11255924T11
11255924	1682	1684	DA	CHEMICAL	11255924T12
11255924	1803	1809	sodium	CHEMICAL	11255924T13
11255924	484	492	dopamine	CHEMICAL	11255924T14
11255924	619	621	DA	CHEMICAL	11255924T15
11255924	760	762	DA	CHEMICAL	11255924T16
11255924	861	868	cocaine	CHEMICAL	11255924T17
11255924	992	994	DA	CHEMICAL	11255924T18
11255924	1115	1122	cocaine	CHEMICAL	11255924T19
11255924	1167	1177	Tetracaine	CHEMICAL	7831
11255924	1125	1137	dimethocaine	CHEMICAL	11255924T20
11255924	1140	1148	procaine	CHEMICAL	11255924T21
11255924	1151	1165	chloroprocaine	CHEMICAL	11255924T22
11255924	32	40	dopamine	CHEMICAL	11255924T23
11255924	1803	1818	sodium channels	GENE-N	11255924T24
11255924	484	504	dopamine transporter	GENE-N	11255924T25
11255924	506	509	DAT	GENE-N	11255924T26
11255924	715	718	DAT	GENE-N	11255924T27
11255924	32	52	dopamine transporter	GENE-N	11255924T28
11255924	1231	1233	DA	CHEMICAL	11255924T2
11255924	1264	1271	cocaine	CHEMICAL	11255924T3
11255924	1274	1286	dimethocaine	CHEMICAL	11255924T4
11255924	1289	1299	tetracaine	CHEMICAL	11255924T5
11255924	1302	1310	procaine	CHEMICAL	11255924T6
11255924	1313	1328	chloro-procaine	CHEMICAL	11255924T7
11255924	1393	1395	DA	CHEMICAL	11255924T8
11255924	1404	1413	Lidocaine	CHEMICAL	274
11255924	CPR:9	11255924T15	11255924T25
11255924	CPR:9	11255924T15	11255924T26
11255924	CPR:9	11255924T16	11255924T27

11292635|t|Contribution of the Na+-K+-2Cl- cotransporter NKCC1 to Cl- secretion in rat OMCD.
11292635|a|In rat kidney the "secretory" isoform of the Na+-K+-2Cl- cotransporter (NKCC1) localizes to the basolateral membrane of the alpha-intercalated cell. The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by NKCC1 in series with Cl- efflux across the apical membrane. OMCD tubules from rats treated with deoxycorticosterone pivalate were perfused in vitro in symmetrical HCO/CO2-buffered solutions. Cl- secretion was observed in this segment, accompanied by a lumen positive transepithelial potential. Bumetanide (100 microM), when added to the bath, reduced Cl- secretion by 78%, although the lumen positive transepithelial potential and fluid flux were unchanged. Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of NKCC1-mediated Cl- transport. In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through NKCC1-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane. The physiological role of NKCC1-mediated Cl- uptake remains to be determined. However, the role of NKCC1 in the process of fluid secretion could not be demonstrated.
11292635	127	130	Na+	CHEMICAL	11292635T10
11292635	556	584	deoxycorticosterone pivalate	CHEMICAL	11292635T11
11292635	131	133	K+	CHEMICAL	11292635T12
11292635	134	138	2Cl-	CHEMICAL	11292635T13
11292635	623	626	HCO	CHEMICAL	11292635T14
11292635	627	630	CO2	CHEMICAL	11292635T15
11292635	651	654	Cl-	CHEMICAL	11292635T16
11292635	754	764	Bumetanide	CHEMICAL	877
11292635	811	814	Cl-	CHEMICAL	11292635T18
11292635	918	928	Bumetanide	CHEMICAL	877
11292635	1110	1138	deoxycorticosterone pivalate	CHEMICAL	11292635T1
11292635	939	942	Cl-	CHEMICAL	11292635T20
11292635	984	987	Na+	CHEMICAL	11292635T21
11292635	999	1001	K+	CHEMICAL	11292635T22
11292635	1005	1007	NH	CHEMICAL	11292635T23
11292635	1062	1065	Cl-	CHEMICAL	11292635T24
11292635	20	23	Na+	CHEMICAL	11292635T25
11292635	24	26	K+	CHEMICAL	11292635T26
11292635	27	31	2Cl-	CHEMICAL	11292635T27
11292635	55	58	Cl-	CHEMICAL	11292635T28
11292635	1195	1200	NKCC1	GENE-Y	11292635T29
11292635	1160	1163	Cl-	CHEMICAL	11292635T2
11292635	1333	1338	NKCC1	GENE-Y	11292635T30
11292635	1406	1411	NKCC1	GENE-Y	11292635T31
11292635	460	465	NKCC1	GENE-Y	11292635T32
11292635	127	152	Na+-K+-2Cl- cotransporter	GENE-N	11292635T33
11292635	154	159	NKCC1	GENE-Y	11292635T34
11292635	1047	1052	NKCC1	GENE-Y	11292635T35
11292635	20	45	Na+-K+-2Cl- cotransporter	GENE-N	11292635T36
11292635	46	51	NKCC1	GENE-Y	11292635T37
11292635	1210	1213	Cl-	CHEMICAL	11292635T3
11292635	1268	1271	Cl-	CHEMICAL	11292635T4
11292635	1348	1351	Cl-	CHEMICAL	11292635T5
11292635	334	337	Cl-	CHEMICAL	11292635T6
11292635	366	369	Cl-	CHEMICAL	11292635T7
11292635	405	408	Cl-	CHEMICAL	11292635T8
11292635	481	484	Cl-	CHEMICAL	11292635T9
11292635	CPR:9	11292635T24	11292635T35
11292635	CPR:9	11292635T28	11292635T36
11292635	CPR:9	11292635T28	11292635T37
11292635	CPR:9	11292635T2	11292635T29
11292635	CPR:9	11292635T3	11292635T29
11292635	CPR:9	11292635T4	11292635T29
11292635	CPR:9	11292635T5	11292635T30
11292635	CPR:9	11292635T8	11292635T32
11292635	CPR:9	11292635T9	11292635T32

11344206|t|Evidence for genetic heterogeneity of pseudohypoaldosteronism type 1: identification of a novel mutation in the human mineralocorticoid receptor in one sporadic case and no mutations in two autosomal dominant kindreds.
11344206|a|Pseudohypoaldosteronism type 1 (PHA1) is characterized by neonatal salt wasting resistant to mineralocorticoids. There are 2 forms of PHA1: the autosomal recessive form with symptoms persisting into adulthood, caused by mutations in the amiloride-sensitive luminal sodium channel, and the autosomal dominant or sporadic form, which shows milder symptoms that remit with age. Mutations in the gene encoding the human mineralocorticoid receptor (hMR) are, at least in some patients, responsible for the latter form of PHA1. We here report the results of a genetic study in a sporadic case and in 5 affected patients from 2 families with autosomal dominant PHA1. In the sporadic case we identified a new frameshift mutation, Ins2871C, in exon 9 of the hMR gene. Family members were asymptomatic and had no mutation. This mutation is the first described in exon 9 and impairs the last 27 amino acids of the hormone-binding domain. In 2 kindreds with autosomal dominant PHA1 we found no mutation of the hMR gene. Our results confirm the hypothesis that autosomal dominant or sporadic PHA1 is a genetically heterogeneous disease involving other, as yet unidentified, genes.
11344206	1217	1220	hMR	GENE-Y	11344206T10
11344206	112	144	human mineralocorticoid receptor	GENE-Y	11344206T11
11344206	456	465	amiloride	CHEMICAL	11344206T1
11344206	484	490	sodium	CHEMICAL	11344206T2
11344206	1103	1114	amino acids	CHEMICAL	11344206T3
11344206	456	498	amiloride-sensitive luminal sodium channel	GENE-N	11344206T4
11344206	629	661	human mineralocorticoid receptor	GENE-Y	11344206T5
11344206	663	666	hMR	GENE-Y	11344206T6
11344206	941	949	Ins2871C	GENE-N	11344206T7
11344206	968	971	hMR	GENE-Y	11344206T8
11344206	1122	1144	hormone-binding domain	GENE-N	11344206T9

11350861|t|The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
11350861|a|The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent dopamine D2, D3 and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study. In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a 5-HT3 receptor agonist (pA2 value of 7.04). Other 5-HT3 receptor antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>>metoclopramide. In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.). Domperidone and haloperidol, which have affinity for dopamine D3 receptor, also inhibited R(+)-7-OH-DPAT-induced hypothermia. In ferrets or dogs, AS-8112 dose-dependently inhibited emesis induced by R(+)-7-OH-DPAT, apomorphine, morphine or cisplatin with ID50 values of 2.22 microg kg(-1) s.c., 10.5 microg kg(-1) s.c., 14.2 microg kg(-1) i.v. and 17.6 microg kg(-1) i.v., respectively. Moreover, oral administration of AS-8112 significantly inhibited emesis induced by these emetogens. AS-8112 (0.3 mg kg(-1) i.v.) significantly inhibited emesis induced by cyclophosphamide and doxorubicin. In conclusion, AS-8112 is a potent dopamine D2, D3 and 5-HT3 receptors antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity. These results suggest that this compound is worthy of clinical investigation.
11350861	1568	1576	dopamine	CHEMICAL	11350861T10
11350861	306	314	dopamine	CHEMICAL	11350861T11
11350861	326	345	5-hydroxytryptamine	CHEMICAL	11350861T12
11350861	443	450	AS-8112	CHEMICAL	7951
11350861	518	530	2-methyl-5HT	CHEMICAL	11350861T14
11350861	155	162	AS-8112	CHEMICAL	7951
11350861	164	284	(R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate	CHEMICAL	11350861T16
11350861	683	694	granisetron	CHEMICAL	11350861T17
11350861	696	707	ondansetron	CHEMICAL	11350861T18
11350861	708	715	AS-8112	CHEMICAL	7951
11350861	1140	1154	R(+)-7-OH-DPAT	CHEMICAL	11350861T1
11350861	717	731	metoclopramide	CHEMICAL	11350861T20
11350861	742	749	AS-8112	CHEMICAL	7951
11350861	823	831	dopamine	CHEMICAL	11350861T22
11350861	853	867	R(+)-7-OH-DPAT	CHEMICAL	11350861T23
11350861	869	917	R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline	CHEMICAL	11350861T24
11350861	941	952	Domperidone	CHEMICAL	1172
11350861	957	968	haloperidol	CHEMICAL	11350861T26
11350861	994	1002	dopamine	CHEMICAL	11350861T27
11350861	1031	1045	R(+)-7-OH-DPAT	CHEMICAL	11350861T28
11350861	1087	1094	AS-8112	CHEMICAL	7951
11350861	1156	1167	apomorphine	CHEMICAL	11350861T2
11350861	43	50	AS-8112	CHEMICAL	7951
11350861	60	68	dopamine	CHEMICAL	11350861T31
11350861	1568	1583	dopamine D2, D3	GENE-N	11350861T32
11350861	1588	1603	5-HT3 receptors	GENE-Y	11350861T33
11350861	306	321	dopamine D2, D3	GENE-N	11350861T34
11350861	326	365	5-hydroxytryptamine-3 (5-HT3) receptors	GENE-Y	11350861T35
11350861	534	548	5-HT3 receptor	GENE-Y	11350861T36
11350861	584	598	5-HT3 receptor	GENE-Y	11350861T37
11350861	823	843	dopamine D3 receptor	GENE-Y	11350861T38
11350861	994	1014	dopamine D3 receptor	GENE-Y	11350861T39
11350861	1169	1177	morphine	CHEMICAL	11350861T3
11350861	60	75	dopamine D2, D3	GENE-N	11350861T40
11350861	80	95	5-HT3 receptors	GENE-Y	11350861T41
11350861	1181	1190	cisplatin	CHEMICAL	11350861T4
11350861	1361	1368	AS-8112	CHEMICAL	7951
11350861	1428	1435	AS-8112	CHEMICAL	7951
11350861	1499	1515	cyclophosphamide	CHEMICAL	11350861T7
11350861	1520	1531	doxorubicin	CHEMICAL	11350861T8
11350861	1548	1555	AS-8112	CHEMICAL	7951
11350861	CPR:4	7951	11350861T38
11350861	CPR:5	11350861T14	11350861T36
11350861	CPR:5	11350861T23	11350861T38
11350861	CPR:5	11350861T24	11350861T38
11350861	CPR:6	7951	11350861T36
11350861	CPR:6	11350861T17	11350861T37
11350861	CPR:6	11350861T18	11350861T37
11350861	CPR:6	7951	11350861T37
11350861	CPR:6	11350861T20	11350861T37
11350861	CPR:6	7951	11350861T41
11350861	CPR:6	7951	11350861T33

11369259|t|Heparin-binding exosite of factor Xa.
11369259|a|Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium. Binding of a full-length heparin chain to this site of factor Xa in the presence of calcium makes a significant contribution to acceleration of the proteinase inhibition by antithrombin through a ternary complex bridging or template mechanism. Moreover, certain basic residues of this site, particularly Arg(165) and Lys(169), play a key role in factor Va and/or prothrombin recognition by factor Xa in the prothrombinase complex. This article reviews recent structural, mutagenesis and kinetic data that lead to identification of this exosite and discusses how the binding of protein or polysaccharide cofactors to this site of factor Xa can modulate the specificity and physiological function of this key coagulant enzyme in plasma.
11369259	110	113	Arg	CHEMICAL	119
11369259	120	123	Arg	CHEMICAL	119
11369259	130	133	Lys	CHEMICAL	11369259T12
11369259	164	176	chymotrypsin	GENE-N	11369259T13
11369259	237	246	factor Xa	GENE-Y	11369259T14
11369259	300	321	N-terminal Gla domain	GENE-N	11369259T15
11369259	329	339	proteinase	GENE-N	11369259T16
11369259	447	456	factor Xa	GENE-Y	11369259T17
11369259	540	550	proteinase	GENE-N	11369259T18
11369259	565	577	antithrombin	GENE-Y	11369259T19
11369259	140	143	Lys	CHEMICAL	11369259T1
11369259	738	747	factor Va	GENE-Y	11369259T20
11369259	755	766	prothrombin	GENE-Y	11369259T21
11369259	782	791	factor Xa	GENE-Y	11369259T22
11369259	1021	1030	factor Xa	GENE-Y	11369259T23
11369259	27	36	factor Xa	GENE-Y	11369259T24
11369259	154	157	Arg	CHEMICAL	119
11369259	300	301	N	CHEMICAL	167
11369259	383	390	calcium	CHEMICAL	11369259T4
11369259	476	483	calcium	CHEMICAL	11369259T5
11369259	92	95	Arg	CHEMICAL	119
11369259	101	104	Lys	CHEMICAL	11369259T7
11369259	696	699	Arg	CHEMICAL	119
11369259	709	712	Lys	CHEMICAL	11369259T9

11398914|t|Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
11398914|a|Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day. Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin. In well-controlled clinical trials, rofecoxib 12.5 to 500 mg/day has been evaluated for its efficacy in the treatment of osteoarthritis, acute pain and rheumatoid arthritis [lower dosages (5 to 125 mg/day) were generally used in the chronic pain indications]. In the treatment of patients with osteoarthritis, rofecoxib was more effective in providing symptomatic relief than placebo, paracetamol (acetaminophen) and celecoxib and was similar in efficacy to ibuprofen, diclofenac, naproxen and nabumetone. Overall, both the physician's assessment of disease status and the patient's assessment of response to therapy tended to favour rofecoxib. In patients with postsurgical dental pain, pain after spinal fusion or orthopaedic surgery, or primary dysmenorrhoea, rofecoxib provided more rapid and more sustained pain relief and reduced requirements for supplemental morphine use after surgery than placebo. Rofecoxib was more efficacious than celecoxib in patients with acute dental pain and pain after spinal fusion surgery, although celecoxib may have been used at a subtherapeutic dose. In comparison with traditional nonsteroidal anti-inflammatory drugs (NSAIDs) ibuprofen, diclofenac and naproxen sodium, rofecoxib was similar in efficacy in the treatment of acute pain. Although naproxen sodium provided more rapid pain relief than rofecoxib in patients with primary dysmenorrhoea, the reverse was true after orthopaedic surgery: rofecoxib provided more rapid pain relief and less supplemental morphine was needed. Rofecoxib was as effective as naproxen in providing symptomatic relief for over 8700 patients with rheumatoid arthritis. Compared with traditional NSAID therapy, rofecoxib had a significantly lower incidence of endoscopically confirmed gastroduodenal ulceration and, in approximately 13,000 patients with osteoarthritis and rheumatoid arthritis, a lower incidence of gastrointestinal (GI) adverse events. Rofecoxib was generally well tolerated in all indications with an overall tolerability profile similar to traditional NSAIDs. The most common adverse events in rofecoxib recipients were nausea, dizziness and headache. In conclusion, rofecoxib is at least as effective as traditional NSAID therapy in providing pain relief for both chronic and acute pain conditions. Rofecoxib provides an alternative treatment option to traditional NSAID therapy in the management of symptomatic pain relief in patients with osteoarthritis. Initial data from patients with primary dysmenorrhoea and postoperative pain are promising and further trials may confirm its place in the treatment of these indications. Rofecoxib has also shown promising results in patients with rheumatoid arthritis and is likely to become a valuable addition to current drug therapy for this patient population. Importantly, rofecoxib is associated with a lower incidence of GI adverse events than traditional NSAIDs making it a primary treatment option in patients at risk of developing GI complications or patients with chronic conditions requiring long term treatment.
11398914	1555	1564	rofecoxib	CHEMICAL	11398914T10
11398914	1630	1645	naproxen sodium	CHEMICAL	11398914T11
11398914	1683	1692	rofecoxib	CHEMICAL	11398914T12
11398914	1781	1790	rofecoxib	CHEMICAL	11398914T13
11398914	1845	1853	morphine	CHEMICAL	11398914T14
11398914	1866	1875	Rofecoxib	CHEMICAL	523
11398914	1896	1904	naproxen	CHEMICAL	11398914T16
11398914	294	303	celecoxib	CHEMICAL	11398914T17
11398914	2028	2037	rofecoxib	CHEMICAL	11398914T18
11398914	305	314	meloxicam	CHEMICAL	11398914T19
11398914	105	114	Rofecoxib	CHEMICAL	523
11398914	316	326	diclofenac	CHEMICAL	11398914T20
11398914	2271	2280	Rofecoxib	CHEMICAL	523
11398914	331	343	indomethacin	CHEMICAL	11398914T22
11398914	2431	2440	rofecoxib	CHEMICAL	11398914T23
11398914	2504	2513	rofecoxib	CHEMICAL	11398914T24
11398914	2637	2646	Rofecoxib	CHEMICAL	523
11398914	381	390	rofecoxib	CHEMICAL	11398914T26
11398914	2966	2975	Rofecoxib	CHEMICAL	523
11398914	3157	3166	rofecoxib	CHEMICAL	11398914T28
11398914	655	664	rofecoxib	CHEMICAL	11398914T29
11398914	1108	1117	rofecoxib	CHEMICAL	11398914T2
11398914	730	741	paracetamol	CHEMICAL	11398914T30
11398914	743	756	acetaminophen	CHEMICAL	11398914T31
11398914	762	771	celecoxib	CHEMICAL	11398914T32
11398914	803	812	ibuprofen	CHEMICAL	11398914T33
11398914	814	824	diclofenac	CHEMICAL	11398914T34
11398914	826	834	naproxen	CHEMICAL	11398914T35
11398914	839	849	nabumetone	CHEMICAL	11398914T36
11398914	979	988	rofecoxib	CHEMICAL	11398914T37
11398914	0	9	Rofecoxib	CHEMICAL	523
11398914	283	288	COX-2	GENE-Y	11398914T39
11398914	1252	1261	Rofecoxib	CHEMICAL	523
11398914	130	153	cyclo-oxygenase (COX)-2	GENE-Y	11398914T40
11398914	201	206	COX-1	GENE-Y	11398914T41
11398914	1288	1297	celecoxib	CHEMICAL	11398914T4
11398914	1380	1389	celecoxib	CHEMICAL	11398914T5
11398914	245	254	Rofecoxib	CHEMICAL	523
11398914	1512	1521	ibuprofen	CHEMICAL	11398914T7
11398914	1523	1533	diclofenac	CHEMICAL	11398914T8
11398914	1538	1553	naproxen sodium	CHEMICAL	11398914T9
11398914	CPR:4	523	11398914T40
11398914	CPR:4	523	11398914T39

11456284|t|Clinical, biochemical and molecular genetic data in five children with Gitelman's syndrome.
11456284|a|Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the thiazide-sensitive NaCl co-transporter (NCCT). The main clinical symptoms are: muscular weakness, carpopedal spasm, constipation and short stature. The diagnosis was suspected in five children according to clinical criteria. All patients exhibited carpopedal spasm during febrile illness, three patients had short stature. Biochemical features were: metabolic alkalosis, hypokalemia, hypomagnesemia, low IGF-I levels, hyperkaliuria, hypernatriuria, hypocalciuria and normoprostaglandinuria. Three patients had elevated plasma renin activity and hyperaldosteronism. Mutational analysis of the NCCT gene confirmed the diagnosis in all five patients. Different forms of therapy, potassium and magnesium substitution, spironolactone and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized IGF-I levels in the three patients with short stature. During therapy, clinical symptoms disappeared. We conclude that Gitelman's syndrome is a disorder with a variable symptom profile, but can be suspected on clinical signs already in early childhood. The early diagnosis is essential in preventing complications.
11456284	722	727	renin	GENE-Y	11456284T10
11456284	788	792	NCCT	GENE-Y	11456284T11
11456284	1051	1056	IGF-I	GENE-Y	11456284T12
11456284	196	204	thiazide	CHEMICAL	11456284T1
11456284	215	219	NaCl	CHEMICAL	11456284T2
11456284	872	881	potassium	CHEMICAL	11456284T3
11456284	886	895	magnesium	CHEMICAL	11456284T4
11456284	910	924	spironolactone	CHEMICAL	11456284T5
11456284	929	941	indomethacin	CHEMICAL	11456284T6
11456284	196	234	thiazide-sensitive NaCl co-transporter	GENE-Y	11456284T7
11456284	236	240	NCCT	GENE-Y	11456284T8
11456284	600	605	IGF-I	GENE-Y	11456284T9

11474486|t|Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat.
11474486|a|Fibrates and thiazolidinediones are used clinically to treat hypertriglyceridemia and hyperglycemia, respectively. Fibrates bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and thiazolidinediones are ligands of PPAR-gamma. These intracellular receptors form heterodimers with retinoid X receptor to modulate gene transcription. To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction. All 3 compounds decreased serum glucose and triglyceride levels. Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs. Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue. We identified a novel target in liver, mitogen-activated phosphokinase phosphatase 1, whose down-regulation by PPAR-alpha agonists may improve insulin sensitivity in that tissue by prolonging insulin responses. The results of these studies suggest that activation of PPAR-alpha as well as PPAR-gamma in therapy for type 2 diabetes will enhance glucose and triglyceride control by combining actions in hepatic and peripheral tissues.
11474486	648	659	fenofibrate	CHEMICAL	11474486T10
11474486	691	704	rosiglitazone	CHEMICAL	11474486T11
11474486	741	747	GW2331	CHEMICAL	11474486T12
11474486	888	895	glucose	CHEMICAL	11474486T13
11474486	900	912	triglyceride	CHEMICAL	11474486T14
11474486	921	932	Fenofibrate	CHEMICAL	1028
11474486	937	943	GW2331	CHEMICAL	11474486T16
11474486	966	981	acyl-coenzyme A	CHEMICAL	11474486T17
11474486	983	986	CoA	CHEMICAL	1916
11474486	1000	1009	enoyl-CoA	CHEMICAL	11474486T19
11474486	147	155	Fibrates	CHEMICAL	11474486T1
11474486	1057	1076	phosphoenolpyruvate	CHEMICAL	11474486T20
11474486	1098	1111	Rosiglitazone	CHEMICAL	404
11474486	1255	1276	glucose transporter 4	GENE-Y	11474486T22
11474486	1281	1314	phosphoenolpyruvate carboxykinase	GENE-N	11474486T23
11474486	1373	1418	mitogen-activated phosphokinase phosphatase 1	GENE-Y	11474486T24
11474486	1445	1455	PPAR-alpha	GENE-Y	11474486T25
11474486	1477	1484	insulin	GENE-N	11474486T26
11474486	283	338	peroxisome proliferator-activated receptor (PPAR)-alpha	GENE-Y	11474486T27
11474486	1526	1533	insulin	GENE-N	11474486T28
11474486	1601	1611	PPAR-alpha	GENE-Y	11474486T29
11474486	1255	1262	glucose	CHEMICAL	11474486T2
11474486	1623	1633	PPAR-gamma	GENE-Y	11474486T30
11474486	378	388	PPAR-gamma	GENE-Y	11474486T31
11474486	443	462	retinoid X receptor	GENE-N	11474486T32
11474486	618	628	PPAR-alpha	GENE-Y	11474486T33
11474486	663	673	PPAR-gamma	GENE-Y	11474486T34
11474486	712	729	PPAR-alpha/-gamma	GENE-N	11474486T35
11474486	966	995	acyl-coenzyme A (CoA) oxidase	GENE-N	11474486T36
11474486	1000	1019	enoyl-CoA hydratase	GENE-Y	11474486T37
11474486	1032	1052	apolipoprotein C-III	GENE-Y	11474486T38
11474486	1057	1090	phosphoenolpyruvate carboxykinase	GENE-N	11474486T39
11474486	1281	1300	phosphoenolpyruvate	CHEMICAL	11474486T3
11474486	1131	1151	apolipoprotein C-III	GENE-Y	11474486T40
11474486	0	42	Peroxisome proliferator-activated receptor	GENE-N	11474486T41
11474486	262	270	Fibrates	CHEMICAL	11474486T4
11474486	160	178	thiazolidinediones	CHEMICAL	11474486T5
11474486	1678	1685	glucose	CHEMICAL	11474486T6
11474486	1690	1702	triglyceride	CHEMICAL	11474486T7
11474486	344	362	thiazolidinediones	CHEMICAL	11474486T8
11474486	443	451	retinoid	CHEMICAL	11474486T9
11474486	CPR:3	1028	11474486T36
11474486	CPR:3	1028	11474486T37
11474486	CPR:3	11474486T16	11474486T36
11474486	CPR:3	11474486T16	11474486T37
11474486	CPR:3	404	11474486T22
11474486	CPR:3	404	11474486T23
11474486	CPR:3	404	11474486T40
11474486	CPR:4	1028	11474486T38
11474486	CPR:4	1028	11474486T39
11474486	CPR:4	11474486T16	11474486T38
11474486	CPR:4	11474486T16	11474486T39

11513839|t|Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain.
11513839|a|In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists eletriptan, zolmitriptan and sumatriptan in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), 5-HT(1D) and 5-HT(1A) receptors. In vitro studies showed that all three triptans are high affinity, full agonists at 5-HT(1B/1D) receptors, but that sumatriptan is functionally less potent as a 5-HT(1B/1D) agonist than zolmitriptan and eletriptan. Local intracortical perfusion with the compounds via the dialysis probe decreased cortical 5-HT (5-hydroxytryptamine, serotonin) release with ED(50) values of approximately 0.1 microM for eletriptan and zolmitriptan and 0.5 microM for sumatriptan. At 3.2 mg/kg i.v., both eletriptan and zolmitriptan decreased 5-HT levels by about 35%, while sumatriptan had no effect, despite the fact that maximal sumatriptan concentrations in cortical dialysates were higher (8.8 nM at 20 min) than those of zolmitriptan (5.9 nM at 20 min) and eletriptan (2.6 nM at 40 min). The observation that eletriptan and zolmitriptan produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional 5-HT(1B/1D) receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg/kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg/kg i.v. sumatriptan is likely due to its weaker functional 5-HT(1B/1D) receptor agonist potency than eletriptan and zolmitriptan, rather than lower brain levels, consistent with sumatriptan's fivefold lower potency after intracerebral administration.
11513839	281	292	sumatriptan	CHEMICAL	11513839T10
11513839	510	518	triptans	CHEMICAL	11513839T11
11513839	587	598	sumatriptan	CHEMICAL	11513839T12
11513839	657	669	zolmitriptan	CHEMICAL	11513839T13
11513839	674	684	eletriptan	CHEMICAL	11513839T14
11513839	777	781	5-HT	CHEMICAL	11513839T15
11513839	783	802	5-hydroxytryptamine	CHEMICAL	11513839T16
11513839	804	813	serotonin	CHEMICAL	11513839T17
11513839	874	884	eletriptan	CHEMICAL	11513839T18
11513839	889	901	zolmitriptan	CHEMICAL	11513839T19
11513839	1180	1192	zolmitriptan	CHEMICAL	11513839T1
11513839	921	932	sumatriptan	CHEMICAL	11513839T20
11513839	958	968	eletriptan	CHEMICAL	11513839T21
11513839	973	985	zolmitriptan	CHEMICAL	11513839T22
11513839	996	1000	5-HT	CHEMICAL	11513839T23
11513839	1028	1039	sumatriptan	CHEMICAL	11513839T24
11513839	1085	1096	sumatriptan	CHEMICAL	11513839T25
11513839	55	65	eletriptan	CHEMICAL	11513839T26
11513839	67	79	zolmitriptan	CHEMICAL	11513839T27
11513839	84	95	sumatriptan	CHEMICAL	11513839T28
11513839	222	233	5-HT(1B/1D)	GENE-N	11513839T29
11513839	1216	1226	eletriptan	CHEMICAL	11513839T2
11513839	1462	1473	5-HT(1B/1D)	GENE-N	11513839T30
11513839	1696	1707	5-HT(1B/1D)	GENE-N	11513839T31
11513839	428	436	5-HT(1B)	GENE-Y	11513839T32
11513839	438	446	5-HT(1D)	GENE-Y	11513839T33
11513839	451	459	5-HT(1A)	GENE-Y	11513839T34
11513839	555	566	5-HT(1B/1D)	GENE-N	11513839T35
11513839	632	643	5-HT(1B/1D)	GENE-N	11513839T36
11513839	1268	1278	eletriptan	CHEMICAL	11513839T3
11513839	1283	1295	zolmitriptan	CHEMICAL	11513839T4
11513839	252	262	eletriptan	CHEMICAL	11513839T5
11513839	1645	1656	sumatriptan	CHEMICAL	11513839T6
11513839	264	276	zolmitriptan	CHEMICAL	11513839T7
11513839	1738	1748	eletriptan	CHEMICAL	11513839T8
11513839	1753	1765	zolmitriptan	CHEMICAL	11513839T9

11544332|t|Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active.
11544332|a|We have previously isolated from human hemofiltrate an N-terminally truncated form of the hemofiltrate CC chemokine 1 (HCC-1), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent CCR3. In this study, we show that conditioned media from human tumor cell lines PC-3 and 143B contain proteolytic activities that convert HCC-1 into the [9-74] form. This activity was fully inhibited by inhibitors of urokinase-type plasminogen activator (uPA), including PA inhibitor-1, an anti-uPA mAb, and amiloride. Pure preparations of uPA processed HCC-1 with high efficiency, without further degrading HCC-1[9-74]. Plasmin could also generate HCC-1[9-74], but degraded the active product as well. The kinetics of HCC-1 cleavage by uPA and plasmin (Michaelis constant, K(m), of 0.76 +/- 0.4 microM for uPA, and 0.096 +/- 0.05 microM for plasmin; catalytic rate constant, k(cat): 3.36 +/- 0.96 s(-1) for uPA and 6 +/- 3.6 s(-1) for plasmin) are fully compatible with a role in vivo. The activation of an abundant inactive precursor into a broad-spectrum chemokine by uPA and plasmin directly links the production of uPA by numerous tumors and their ability to recruit mononuclear leukocytes, without the need for the transcriptional activation of chemokine genes.
11544332	323	327	CCR3	GENE-Y	107637|10077
11544332	461	466	HCC-1	GENE-Y	11544332T11
11544332	540	576	urokinase-type plasminogen activator	GENE-Y	11544332T12
11544332	578	581	uPA	GENE-Y	11544332T13
11544332	594	608	PA inhibitor-1	GENE-Y	11544332T14
11544332	618	621	uPA	GENE-Y	11544332T15
11544332	663	666	uPA	GENE-Y	11544332T16
11544332	677	682	HCC-1	GENE-Y	11544332T17
11544332	731	742	HCC-1[9-74]	GENE-Y	11544332T18
11544332	744	751	Plasmin	GENE-Y	11544332T19
11544332	164	165	N	CHEMICAL	167
11544332	772	783	HCC-1[9-74]	GENE-Y	11544332T20
11544332	842	847	HCC-1	GENE-Y	11544332T21
11544332	860	863	uPA	GENE-Y	11544332T22
11544332	868	875	plasmin	GENE-Y	11544332T23
11544332	930	933	uPA	GENE-Y	11544332T24
11544332	965	972	plasmin	GENE-Y	11544332T25
11544332	199	226	hemofiltrate CC chemokine 1	GENE-Y	11544332T26
11544332	1031	1034	uPA	GENE-Y	11544332T27
11544332	1059	1066	plasmin	GENE-Y	11544332T28
11544332	0	31	Urokinase plasminogen activator	GENE-Y	11544332T29
11544332	1194	1197	uPA	GENE-Y	11544332T2
11544332	36	43	plasmin	GENE-Y	11544332T30
11544332	64	91	hemofiltrate CC chemokine 1	GENE-Y	11544332T31
11544332	1202	1209	plasmin	GENE-Y	11544332T3
11544332	1243	1246	uPA	GENE-Y	11544332T4
11544332	228	233	HCC-1	GENE-Y	11544332T5
11544332	1374	1383	chemokine	GENE-N	11544332T6
11544332	254	265	HCC-1[9-74]	GENE-Y	11544332T7
11544332	289	293	CCR1	GENE-Y	15362|107635
11544332	295	299	CCR5	GENE-Y	107639

11551210|t|Cembranoid and long-chain alkanol sites on the nicotinic acetylcholine receptor and their allosteric interaction.
11551210|a|Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (AChR) by binding to one or more specific sites on the AChR. Cembranoids are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal AChRs, which have no demonstrable general anesthetic activity in vivo. In this study, [3H]tenocyclidine ([3H]TCP), an analogue of the cationic noncompetitive inhibitor phencyclidine (PCP), was used to characterize the cembranoid and long-chain alkanol sites on the desensitized Torpedo californica AChR and to investigate if these sites interact. These studies confirm that there is a single cembranoid site which sterically overlaps the [3H]TCP channel site. This cembranoid site probably also overlaps the sites for the cationic noncompetitive inhibitors, procaine and quinacrine. Evidence is also presented for one or more allosteric cembranoid sites which negatively modulate cembranoid affinity for the inhibitory site. In contrast, long-chain alkanols inhibit [3H]TCP binding through an allosteric mechanism involving two or more alkanol sites which display positive cooperativity toward each other. Double inhibitor studies show that the cembranoid inhibitory site and the alkanol sites are not independent of each other but interfere allosterically with each other's inhibition of [3H]TCP binding. The simplest models consistent with the observed data are presented and discussed.
11551210	514	531	[3H]tenocyclidine	CHEMICAL	11551210T10
11551210	533	540	[3H]TCP	CHEMICAL	11551210T11
11551210	596	609	phencyclidine	CHEMICAL	11551210T12
11551210	611	614	PCP	CHEMICAL	3424
11551210	646	656	cembranoid	CHEMICAL	11551210T14
11551210	661	679	long-chain alkanol	CHEMICAL	11551210T15
11551210	866	873	[3H]TCP	CHEMICAL	11551210T16
11551210	893	903	cembranoid	CHEMICAL	11551210T17
11551210	986	994	procaine	CHEMICAL	11551210T18
11551210	999	1009	quinacrine	CHEMICAL	11551210T19
11551210	114	133	Long-chain alkanols	CHEMICAL	11551210T1
11551210	1108	1118	cembranoid	CHEMICAL	11551210T20
11551210	0	10	Cembranoid	CHEMICAL	11551210T21
11551210	15	33	long-chain alkanol	CHEMICAL	11551210T22
11551210	57	70	acetylcholine	CHEMICAL	11551210T23
11551210	234	266	nicotinic acetylcholine receptor	GENE-N	11551210T24
11551210	268	272	AChR	GENE-N	11551210T25
11551210	322	326	AChR	GENE-N	11551210T26
11551210	428	433	AChRs	GENE-N	11551210T27
11551210	726	730	AChR	GENE-N	11551210T28
11551210	47	79	nicotinic acetylcholine receptor	GENE-N	11551210T29
11551210	1166	1185	long-chain alkanols	CHEMICAL	11551210T2
11551210	1194	1201	[3H]TCP	CHEMICAL	11551210T3
11551210	1264	1271	alkanol	CHEMICAL	11551210T4
11551210	1373	1383	cembranoid	CHEMICAL	11551210T5
11551210	1408	1415	alkanol	CHEMICAL	11551210T6
11551210	244	257	acetylcholine	CHEMICAL	11551210T7
11551210	1517	1524	[3H]TCP	CHEMICAL	11551210T8
11551210	328	339	Cembranoids	CHEMICAL	11551210T9
11551210	CPR:4	11551210T1	11551210T24
11551210	CPR:4	11551210T9	11551210T27

11587223|t|Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug.
11587223|a|Although cyst(e)ine is nutritionally a non-essential amino acid, lymphoid cells cannot synthesize it, rendering their growth dependent on uptake of cyst(e)ine from their microenvironment. Accordingly, we previously suggested that the x(c)- plasma membrane cystine transporter provided a target for lymphoid cancer therapy. Its inhibition could lead to cyst(e)ine deficiency in lymphoma cells via reduction of both their cystine uptake and cysteine supply by somatic cells. In this study, using rat Nb2 lymphoma cultures, drugs were screened for growth arrest based on x(c)- inhibition. Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the x(c)- transporter. It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid. Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures. In rats (n = 13), sulfasalazine (i.p.) markedly inhibited growth of well-developed, rapidly growing rat Nb2 lymphoma transplants without apparent side-effects. Reduced, macrophage-mediated supply of cysteine was probably involved. In five rats, 90-100% tumor growth suppression, relative to controls, was obtained. The x(c)- cystine transporter represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.
11587223	552	559	cystine	CHEMICAL	11587223T10
11587223	571	579	cysteine	CHEMICAL	11587223T11
11587223	718	731	Sulfasalazine	CHEMICAL	785
11587223	956	963	cystine	CHEMICAL	11587223T13
11587223	1012	1025	sulfapyridine	CHEMICAL	11587223T14
11587223	1030	1051	5-aminosalicylic acid	CHEMICAL	237
11587223	141	151	cyst(e)ine	CHEMICAL	11587223T16
11587223	1053	1066	Sulfasalazine	CHEMICAL	785
11587223	0	13	Sulfasalazine	CHEMICAL	785
11587223	81	88	cystine	CHEMICAL	11587223T19
11587223	1164	1177	sulfasalazine	CHEMICAL	11587223T1
11587223	1465	1490	x(c)- cystine transporter	GENE-Y	11587223T20
11587223	366	407	x(c)- plasma membrane cystine transporter	GENE-Y	11587223T21
11587223	700	704	x(c)	GENE-Y	11587223T22
11587223	794	811	x(c)- transporter	GENE-Y	11587223T23
11587223	941	945	x(c)	GENE-Y	11587223T24
11587223	75	100	x(c)- cystine transporter	GENE-Y	11587223T25
11587223	1345	1353	cysteine	CHEMICAL	11587223T2
11587223	1471	1478	cystine	CHEMICAL	11587223T3
11587223	1521	1534	sulfasalazine	CHEMICAL	11587223T4
11587223	280	290	cyst(e)ine	CHEMICAL	11587223T5
11587223	1660	1670	cyst(e)ine	CHEMICAL	11587223T6
11587223	388	395	cystine	CHEMICAL	11587223T7
11587223	484	494	cyst(e)ine	CHEMICAL	11587223T8
11587223	171	195	non-essential amino acid	CHEMICAL	11587223T9
11587223	CPR:4	785	11587223T23
11587223	CPR:4	11587223T14	11587223T24
11587223	CPR:4	237	11587223T24
11587223	CPR:4	785	11587223T25
11587223	CPR:9	11587223T13	11587223T24
11587223	CPR:9	11587223T6	11587223T20

11588409|t|Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat, a vasopeptidase inhibitor.
11588409|a|The preferred initial agents for the treatment of high blood pressure are low-dose thiazide diuretics, beta blockers, calcium antagonists, and angiotensin-converting enzyme (ACE) inhibitors. In high-risk patients, including those with diabetes, renal insufficiency, left ventricular dysfunction, and atherosclerosis, ACE inhibitors may have specific benefit in reducing cardiovascular morbidity and mortality. Omapatrilat, the prototypical vasopeptidase inhibitor, inhibits not only ACE but also neutral endopeptidase. Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin. Effective blood pressure control, especially in the high-risk patient, usually necessitates combination therapy. A recent study randomized 274 subjects with mild to severe hypertension (stages 1-3 diastolic blood pressure elevation) and confirmed the benefits of omapatrilat combined with hydrochlorothiazide in patients not controlled on hydrochlorothiazide alone. The frequencies of adverse events, serious adverse events, and discontinuation attributed to adverse events were similar for omapatrilat and placebo. Furthermore, there were no clinically significant changes in serum creatinine, potassium, or other laboratory parameters. Adding omapatrilat to the background of hydrochlorothiazide treatment produced statistically significant additional reductions in trough diastolic and systolic blood pressures at weeks 4 and 8.
11588409	703	714	omapatrilat	CHEMICAL	11588409T10
11588409	848	858	bradykinin	CHEMICAL	11588409T11
11588409	233	241	thiazide	CHEMICAL	11588409T12
11588409	1123	1134	omapatrilat	CHEMICAL	11588409T13
11588409	1149	1168	hydrochlorothiazide	CHEMICAL	11588409T14
11588409	110	121	omapatrilat	CHEMICAL	11588409T15
11588409	71	79	thiazide	CHEMICAL	11588409T16
11588409	293	322	angiotensin-converting enzyme	GENE-Y	11588409T17
11588409	324	327	ACE	GENE-Y	108004
11588409	467	470	ACE	GENE-Y	108004
11588409	1199	1218	hydrochlorothiazide	CHEMICAL	11588409T1
11588409	590	603	vasopeptidase	GENE-N	11588409T20
11588409	633	636	ACE	GENE-Y	108004
11588409	646	667	neutral endopeptidase	GENE-Y	11588409T22
11588409	687	690	ACE	GENE-Y	108004
11588409	806	843	atrial and brain natriuretic peptides	GENE-N	11588409T24
11588409	848	858	bradykinin	GENE-Y	11588409T25
11588409	125	138	vasopeptidase	GENE-N	11588409T26
11588409	268	275	calcium	CHEMICAL	11588409T2
11588409	1351	1362	omapatrilat	CHEMICAL	11588409T3
11588409	1443	1453	creatinine	CHEMICAL	11588409T4
11588409	1455	1464	potassium	CHEMICAL	11588409T5
11588409	1505	1516	omapatrilat	CHEMICAL	11588409T6
11588409	1538	1557	hydrochlorothiazide	CHEMICAL	11588409T7
11588409	293	304	angiotensin	CHEMICAL	11588409T8
11588409	560	571	Omapatrilat	CHEMICAL	876
11588409	CPR:3	11588409T10	11588409T24
11588409	CPR:3	11588409T10	11588409T25
11588409	CPR:4	11588409T10	108004
11588409	CPR:4	11588409T15	11588409T26
11588409	CPR:4	876	11588409T20
11588409	CPR:4	876	108004
11588409	CPR:4	876	11588409T22

11688549|t|Neonatal red blood cells: amiloride-insensitive Na+-H+ transport isoform would express Na+-Li+ exchange.
11688549|a|Neonatal red cells (umbilical cord blood) were in vitro incubated in isotonic media (thiocyanate as predominant anion). This experimental condition was selected as it was known that this chaotropic anion induced activation of Na+-H+ exchange. The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-H+ exchange (NHE1 isoform). However, the Na+-Li+ exchange, also determined in the cells in the above-mentioned medium was not affected by amiloride. The present data suggest that an amiloride insensitive Na+-H+ exchange isoform would express Na+-Li+ countertransport in these cells.
11688549	697	700	Na+	CHEMICAL	11688549T10
11688549	701	703	H+	CHEMICAL	11688549T11
11688549	735	738	Na+	CHEMICAL	11688549T12
11688549	739	742	Li+	CHEMICAL	11688549T13
11688549	190	201	thiocyanate	CHEMICAL	11688549T14
11688549	26	35	amiloride	CHEMICAL	11688549T15
11688549	48	51	Na+	CHEMICAL	11688549T16
11688549	52	54	H+	CHEMICAL	11688549T17
11688549	87	90	Na+	CHEMICAL	11688549T18
11688549	91	94	Li+	CHEMICAL	11688549T19
11688549	331	334	Na+	CHEMICAL	11688549T1
11688549	506	510	NHE1	GENE-Y	11688549T20
11688549	335	337	H+	CHEMICAL	11688549T2
11688549	362	371	amiloride	CHEMICAL	11688549T3
11688549	489	492	Na+	CHEMICAL	11688549T4
11688549	493	495	H+	CHEMICAL	11688549T5
11688549	534	537	Na+	CHEMICAL	11688549T6
11688549	538	541	Li+	CHEMICAL	11688549T7
11688549	631	640	amiloride	CHEMICAL	11688549T8
11688549	675	684	amiloride	CHEMICAL	11688549T9
11688549	CPR:9	11688549T4	11688549T20
11688549	CPR:9	11688549T5	11688549T20

11689471|t|Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts.
11689471|a|Salicylic acid (SA), an endogenous signaling molecule of plants, possesses anti-inflammatory and anti-neoplastic actions in human. Its derivative, aspirin, is the most commonly used anti-inflammatory and analgesic drug. Aspirin and sodium salicylate (salicylates) have been reported to have multiple pharmacological actions. However, it is unclear whether they bind to a cellular protein. Here, we report for the first time the purification from human fibroblasts of a approximately 78 kDa salicylate binding protein with sequence identity to immunoglobulin heavy chain binding protein (BiP). The Kd values of SA binding to crude extract and to recombinant BiP were 45.2 and 54.6 microM, respectively. BiP is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an ATP binding site. A heptapeptide with the specific sequence displaced SA binding in a concentration-dependent manner whereas a control heptapeptide did not. Salicylates inhibited ATPase activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression. These results indicate that salicylates bind specifically to the polypeptide binding site of BiP in human cells that may interfere with folding and transport of proteins important in inflammation.
11689471	1021	1023	SA	CHEMICAL	252
11689471	1108	1119	Salicylates	CHEMICAL	11689471T11
11689471	0	7	Aspirin	CHEMICAL	935
11689471	12	22	salicylate	CHEMICAL	11689471T13
11689471	1227	1230	BiP	GENE-Y	11689471T14
11689471	1336	1339	BiP	GENE-Y	11689471T15
11689471	624	650	salicylate binding protein	GENE-N	11689471T16
11689471	677	719	immunoglobulin heavy chain binding protein	GENE-Y	11689471T17
11689471	721	724	BiP	GENE-Y	11689471T18
11689471	791	794	BiP	GENE-Y	11689471T19
11689471	134	148	Salicylic acid	CHEMICAL	926
11689471	836	839	BiP	GENE-Y	11689471T20
11689471	845	862	chaperone protein	GENE-N	11689471T21
11689471	922	943	heptapeptide sequence	GENE-N	11689471T22
11689471	951	967	ATP binding site	GENE-N	11689471T23
11689471	1130	1136	ATPase	GENE-N	11689471T24
11689471	31	73	immunoglobulin heavy chain binding protein	GENE-Y	11689471T25
11689471	75	78	BiP	GENE-Y	11689471T26
11689471	96	102	ATPase	GENE-N	11689471T27
11689471	1205	1208	ATP	CHEMICAL	164
11689471	1271	1282	salicylates	CHEMICAL	11689471T3
11689471	150	152	SA	CHEMICAL	252
11689471	354	361	Aspirin	CHEMICAL	935
11689471	366	383	sodium salicylate	CHEMICAL	11689471T6
11689471	385	396	salicylates	CHEMICAL	11689471T7
11689471	744	746	SA	CHEMICAL	252
11689471	951	954	ATP	CHEMICAL	164
11689471	CPR:4	11689471T11	11689471T24
11689471	CPR:4	935	11689471T27
11689471	CPR:4	11689471T13	11689471T27

11691635|t|Compensatory changes in enzymes of arginine metabolism during renal hypertrophy in mice.
11691635|a|The present study investigates enzyme activities of the urea cycle, transamidinase and ornithine-proline inter-conversion in the hypertrophied kidney after unilateral nephrectomy in mice. Surgical removal of the left kidney in mice led to compensatory enlargement of the right kidney after 1 and 14 days. This renal growth was associated with an increase in glomerular volume (but not number) and enlargement of the proximal convoluted tubules. The total renal protein content increased in proportion to the increase in kidney weight, but the protein per gram weight of kidney did not change. The specific activity of only ornithine aminotransferase (OAT), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy. The specific activity of all other enzymes was unchanged. However, the total enzyme activity per kidney of all the enzymes, without exception, was elevated in the hypertrophied kidney. While the increase in total OAT activity was much more than the increase in kidney weight, all other enzymes increased more or less in proportion to the increase in renal mass. The results suggest that compensation in OAT activity to chronic reduction in renal mass was complete, but only partial in the case of other enzymes.
11691635	157	171	transamidinase	GENE-Y	11691635T10
11691635	1064	1067	OAT	GENE-Y	110996
11691635	712	721	ornithine	CHEMICAL	11691635T1
11691635	792	801	ornithine	CHEMICAL	11691635T2
11691635	805	812	proline	CHEMICAL	11691635T3
11691635	176	185	ornithine	CHEMICAL	11691635T4
11691635	186	193	proline	CHEMICAL	11691635T5
11691635	35	43	arginine	CHEMICAL	11691635T6
11691635	1254	1257	OAT	GENE-Y	110996
11691635	712	738	ornithine aminotransferase	GENE-Y	11691635T8
11691635	740	743	OAT	GENE-Y	110996
11691635	CPR:9	11691635T2	11691635T8
11691635	CPR:9	11691635T2	110996
11691635	CPR:9	11691635T3	11691635T8
11691635	CPR:9	11691635T3	110996

11695255|t|Analgesia and COX-2 inhibition.
11695255|a|While non-steroidal anti-inflammatory drugs (NSAIDs) are the mainstay of therapy for the management of acute pain and rheumatoid arthritis, toxicity associated with chronic administration limits their benefit-to-risk relationship in many patients. A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac). Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain. The time course of PGE2 production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression. Ketorolac 30 mg at pain onset suppressed both pain and peripheral PGE2 levels. Ketorolac 1 mg either at the site of injury or intramuscularly also produced analgesia but without any effect on peripheral PGE2 levels. Celecoxib selectively suppressed PGE2 but not TxB2 at time points consistent with COX-2 activity, while producing analgesia. These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of COX-2 mediated PGE2 is temporally related to NSAID analgesia.
11695255	497	506	celecoxib	CHEMICAL	11695255T10
11695255	555	564	ketorolac	CHEMICAL	11695255T11
11695255	702	718	prostaglandin E2	CHEMICAL	11695255T12
11695255	720	724	PGE2	CHEMICAL	907
11695255	765	779	thromboxane B2	CHEMICAL	11695255T14
11695255	870	874	PGE2	CHEMICAL	907
11695255	1332	1337	COX-2	GENE-Y	11695255T16
11695255	1464	1469	COX-2	GENE-Y	11695255T17
11695255	1521	1526	COX-2	GENE-Y	11695255T18
11695255	351	360	cytokines	GENE-N	11695255T19
11695255	1034	1043	Ketorolac	CHEMICAL	457
11695255	463	485	cyclooxygenase (COX)-2	GENE-Y	11695255T20
11695255	532	537	COX-1	GENE-Y	11695255T21
11695255	538	543	COX-2	GENE-Y	11695255T22
11695255	744	749	COX-1	GENE-Y	11695255T23
11695255	754	759	COX-2	GENE-Y	11695255T24
11695255	800	805	COX-1	GENE-Y	11695255T25
11695255	927	932	COX-1	GENE-Y	11695255T26
11695255	1016	1021	COX-2	GENE-Y	11695255T27
11695255	14	19	COX-2	GENE-Y	11695255T28
11695255	42	51	steroidal	CHEMICAL	11695255T2
11695255	1100	1104	PGE2	CHEMICAL	907
11695255	1113	1122	Ketorolac	CHEMICAL	457
11695255	1237	1241	PGE2	CHEMICAL	907
11695255	1250	1259	Celecoxib	CHEMICAL	474
11695255	1283	1287	PGE2	CHEMICAL	907
11695255	1296	1300	TxB2	CHEMICAL	11695255T8
11695255	1536	1540	PGE2	CHEMICAL	907
11695255	CPR:4	11695255T10	11695255T20
11695255	CPR:4	11695255T11	11695255T21
11695255	CPR:4	11695255T11	11695255T22
11695255	CPR:4	474	11695255T16
11695255	CPR:9	11695255T12	11695255T23
11695255	CPR:9	11695255T12	11695255T24
11695255	CPR:9	907	11695255T23
11695255	CPR:9	907	11695255T24
11695255	CPR:9	907	11695255T26
11695255	CPR:9	907	11695255T27
11695255	CPR:9	907	11695255T16
11695255	CPR:9	907	11695255T18

11698075|t|[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.
11698075|a|The pharmacological characteristics of [3H]dofetilide binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing human ether-a-go-go related gene (HERG) K+ channels. The classIII antiarrhythmic compounds dofetilide, clofilium, 4'-[[1-[2-(6-methyl-2-pyridyl)ethyl]-4-piperidyl]carbonyl]methanesulfonanilide (E-4031), N-methyl-N-[2-[methyl-(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfo nyl)amino]benzene-sulfonamide (WAY-123,398) and d-sotalol all inhibited [3H]dofetilide binding. In addition, the structurally unrelated compounds pimozide, terfenadine and haloperidol, all of which prolong the QT interval in man, also inhibited binding. These data indicate that a [3H]dofetilide binding assay using HERG membranes may help identify compounds that prolong the QT interval.
11698075	594	603	d-sotalol	CHEMICAL	11698075T10
11698075	618	632	[3H]dofetilide	CHEMICAL	11698075T11
11698075	692	700	pimozide	CHEMICAL	11698075T12
11698075	702	713	terfenadine	CHEMICAL	11698075T13
11698075	718	729	haloperidol	CHEMICAL	11698075T14
11698075	827	841	[3H]dofetilide	CHEMICAL	11698075T15
11698075	0	14	[3H]dofetilide	CHEMICAL	11698075T16
11698075	261	312	human ether-a-go-go related gene (HERG) K+ channels	GENE-Y	11698075T17
11698075	862	866	HERG	GENE-Y	11698075T18
11698075	26	30	HERG	GENE-Y	11698075T19
11698075	267	272	ether	CHEMICAL	11698075T1
11698075	301	303	K+	CHEMICAL	11698075T2
11698075	352	362	dofetilide	CHEMICAL	197
11698075	364	373	clofilium	CHEMICAL	11698075T4
11698075	375	453	4'-[[1-[2-(6-methyl-2-pyridyl)ethyl]-4-piperidyl]carbonyl]methanesulfonanilide	CHEMICAL	11698075T5
11698075	455	461	E-4031	CHEMICAL	11698075T6
11698075	464	575	N-methyl-N-[2-[methyl-(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfo nyl)amino]benzene-sulfonamide	CHEMICAL	11698075T7
11698075	141	155	[3H]dofetilide	CHEMICAL	11698075T8
11698075	577	588	WAY-123,398	CHEMICAL	11698075T9

11775064|t|Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain.
11775064|a|1. Phenelzine (PLZ) is an antidepressant with anxiolytic properties. Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (GABA-T). 2. Previous preliminary reports have indicated that acute PLZ treatment also elevates brain alanine levels. As with GABA, the metabolism of alanine involves a pyridoxal phosphate-dependent transaminase. 3. In the study reported here, the effects of acute PLZ treatment on the levels of various amino acids, some of which are also metabolized by pyridoxal phosphate-dependent transaminases were compared in rat whole brain. Of the 6 amino acids investigated, only GABA and alanine levels were elevated (in a time- and dose-dependent manner). 4. The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced. In addition, we also showed that the elevation in alanine levels and the inhibition of alanine transaminase in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine. 5. These results are discussed in terms of their relevance to synaptic function and to the pharmacological profile of PLZ.
11775064	339	343	GABA	CHEMICAL	11775064T10
11775064	109	119	Phenelzine	CHEMICAL	770
11775064	425	428	PLZ	CHEMICAL	11775064T12
11775064	459	466	alanine	CHEMICAL	11775064T13
11775064	483	487	GABA	CHEMICAL	11775064T14
11775064	507	514	alanine	CHEMICAL	11775064T15
11775064	526	545	pyridoxal phosphate	CHEMICAL	11775064T16
11775064	622	625	PLZ	CHEMICAL	11775064T17
11775064	661	672	amino acids	CHEMICAL	11775064T18
11775064	712	731	pyridoxal phosphate	CHEMICAL	11775064T19
11775064	1233	1240	alanine	CHEMICAL	11775064T1
11775064	799	810	amino acids	CHEMICAL	11775064T20
11775064	830	834	GABA	CHEMICAL	11775064T21
11775064	839	846	alanine	CHEMICAL	11775064T22
11775064	934	941	alanine	CHEMICAL	11775064T23
11775064	193	196	PLZ	CHEMICAL	11775064T24
11775064	1038	1041	PLZ	CHEMICAL	11775064T25
11775064	1045	1052	alanine	CHEMICAL	11775064T26
11775064	1067	1070	ALA	CHEMICAL	126|154|845
11775064	1092	1096	GABA	CHEMICAL	11775064T28
11775064	45	55	phenelzine	CHEMICAL	11775064T29
11775064	1270	1277	alanine	CHEMICAL	11775064T2
11775064	59	66	alanine	CHEMICAL	11775064T30
11775064	71	78	alanine	CHEMICAL	11775064T31
11775064	1270	1290	alanine transaminase	GENE-N	11775064T32
11775064	339	356	GABA transaminase	GENE-Y	11775064T33
11775064	358	364	GABA-T	GENE-Y	11775064T34
11775064	526	568	pyridoxal phosphate-dependent transaminase	GENE-N	11775064T35
11775064	712	755	pyridoxal phosphate-dependent transaminases	GENE-N	11775064T36
11775064	1045	1065	alanine transaminase	GENE-N	11775064T37
11775064	1067	1072	ALA-T	GENE-N	11775064T38
11775064	71	91	alanine transaminase	GENE-N	11775064T39
11775064	227	231	GABA	CHEMICAL	11775064T3
11775064	1334	1337	PLZ	CHEMICAL	11775064T4
11775064	1358	1361	PLZ	CHEMICAL	11775064T5
11775064	1416	1423	alanine	CHEMICAL	11775064T6
11775064	1543	1546	PLZ	CHEMICAL	11775064T7
11775064	121	124	PLZ	CHEMICAL	11775064T8
11775064	313	317	GABA	CHEMICAL	11775064T9
11775064	CPR:4	11775064T24	11775064T33
11775064	CPR:4	11775064T24	11775064T34
11775064	CPR:4	11775064T25	11775064T37
11775064	CPR:4	11775064T25	11775064T38
11775064	CPR:4	11775064T4	11775064T32
11775064	CPR:9	11775064T15	11775064T35
11775064	CPR:9	11775064T18	11775064T36
11775064	CPR:9	11775064T1	11775064T32
11775064	CPR:9	11775064T23	11775064T37
11775064	CPR:9	11775064T23	11775064T38
11775064	CPR:9	11775064T9	11775064T33
11775064	CPR:9	11775064T9	11775064T34

11811354|t|Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites.
11811354|a|Nicotine caused a contraction of the rat coronary artery in the presence of Nomega-nitro-L-arginine methyl ester (L-NAME) and arachidonic acid, and did not in the absence of these agents. The present experiments were undertaken to pharmacologically characterize the nicotine-induced contraction in ring preparations of the rat coronary artery. The contraction was abolished by chemical removal of endothelium saponin. Oxygen radical scavengers, superoxide dismutase and catalase, significantly attenuated the contraction. Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction. A TXA2 synthetase inhibitor (OKY-046) attenuated the contraction to a small extent only at high concentrations. A TXA2 receptor antagonist (S-1452) attenuated the contraction in a concentration-dependent manner. A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction. From these results, it was suggested that the contraction induced by nicotine in the rat coronary artery in the presence of L-NAME and arachidonic acid is endothelium dependent, and involves reactive oxygen species and endothelial COX-1 metabolites of arachidonic acid. Part of the contraction is probably due to release of norepinephrine.
11811354	1578	1594	arachidonic acid	CHEMICAL	11811354T10
11811354	1650	1664	norepinephrine	CHEMICAL	11811354T11
11811354	411	419	nicotine	CHEMICAL	11811354T12
11811354	554	561	saponin	CHEMICAL	11811354T13
11811354	563	569	Oxygen	CHEMICAL	11811354T14
11811354	704	716	flurbiprofen	CHEMICAL	11811354T15
11811354	718	728	ketoprofen	CHEMICAL	11811354T16
11811354	733	742	ketrolack	CHEMICAL	11811354T17
11811354	759	767	nicotine	CHEMICAL	11811354T18
11811354	889	899	nimesulide	CHEMICAL	11811354T19
11811354	145	153	Nicotine	CHEMICAL	177
11811354	904	910	NS-389	CHEMICAL	11811354T20
11811354	221	257	Nomega-nitro-L-arginine methyl ester	CHEMICAL	11811354T21
11811354	951	955	TXA2	CHEMICAL	11811354T22
11811354	978	985	OKY-046	CHEMICAL	11811354T23
11811354	1063	1067	TXA2	CHEMICAL	11811354T24
11811354	1089	1095	S-1452	CHEMICAL	11811354T25
11811354	0	8	Nicotine	CHEMICAL	177
11811354	107	113	oxygen	CHEMICAL	11811354T27
11811354	1163	1181	nicotinic receptor	GENE-N	11811354T28
11811354	1251	1269	alpha-adrenoceptor	GENE-N	11811354T29
11811354	1194	1207	hexamethonium	CHEMICAL	11811354T2
11811354	1557	1562	COX-1	GENE-Y	11811354T30
11811354	590	610	superoxide dismutase	GENE-N	11811354T31
11811354	615	623	catalase	GENE-Y	11811354T32
11811354	667	683	Cyclooxygenase-1	GENE-Y	11811354T33
11811354	685	690	COX-1	GENE-Y	11811354T34
11811354	829	845	cyclooxygenase-2	GENE-Y	11811354T35
11811354	847	852	COX-2	GENE-Y	11811354T36
11811354	951	966	TXA2 synthetase	GENE-Y	11811354T37
11811354	1063	1076	TXA2 receptor	GENE-Y	11811354T38
11811354	126	131	COX-1	GENE-Y	11811354T39
11811354	1282	1290	prazosin	CHEMICAL	11811354T3
11811354	259	265	L-NAME	CHEMICAL	11811354T4
11811354	1395	1403	nicotine	CHEMICAL	11811354T5
11811354	271	287	arachidonic acid	CHEMICAL	11811354T6
11811354	1450	1456	L-NAME	CHEMICAL	11811354T7
11811354	1461	1477	arachidonic acid	CHEMICAL	11811354T8
11811354	1526	1532	oxygen	CHEMICAL	11811354T9
11811354	CPR:4	11811354T15	11811354T33
11811354	CPR:4	11811354T15	11811354T34
11811354	CPR:4	11811354T16	11811354T33
11811354	CPR:4	11811354T16	11811354T34
11811354	CPR:4	11811354T17	11811354T33
11811354	CPR:4	11811354T17	11811354T34
11811354	CPR:4	11811354T19	11811354T35
11811354	CPR:4	11811354T19	11811354T36
11811354	CPR:4	11811354T20	11811354T35
11811354	CPR:4	11811354T20	11811354T36
11811354	CPR:4	11811354T23	11811354T37
11811354	CPR:6	11811354T25	11811354T38
11811354	CPR:6	11811354T2	11811354T28
11811354	CPR:6	11811354T3	11811354T29

11858481|t|Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
11858481|a|The present study was initiated to evaluate the safety and efficacy of Haemate-P (Humate-P in North America) (anti-hemophilic FVIII/VWF complex [human] dried, pasteurized) dosed in ristocetin cofactor units (VWF:RCo) in the treatment of von Willebrand disease (VWD) patients in Canada. This retrospective data collection reviewed the medical records of VWD patients treated under the Canadian Emergency Drug Release Program from November 22, 1991, to April 30, 1996. Data collection was accomplished by on-site retrieval from source data for 97 patients. Dosing was based on the German package insert, which lists only Factor VIII:C (FVIII:C) units, which were converted in the study analysis to VWF:RCo units based on the analysis of the individual manufactured lots of product used in these patients (average ratio of 2.6 IU VWF:RCo per IU FVIII:C). Twenty five different lots of Haemate-P/Humate-P were used to treat 437 different events in the 97 study patients (344 hemorrhagic events, 73 surgical interventions and 20 prophylactic infusion cycles). Overall, the median dose of concentrate per infusion used to treat surgical events was 69.1 IU VWF:RCo/kg (range 11.9-222.8); bleeding events 55.3 IU VWF:RCo/kg (range 17.1-227.5) and prophylaxis 41.6 IU VWF:RCo/kg (range 34.6-81.0). Treatment periods varied, with the majority of events treated for < or = 10 days (91%). Fifty percent of events that were treated longer than 10 days were given for prophylactic reasons. Efficacy was determined in a standardized manner by the physician, based on dosing in VWF:RCo activity. An overall clinical result of "excellent" or "good" was reported in 97% (424/437) of treatment events. A pediatric sub-population analysis of the patient population reported "excellent/good" efficacy in 100% (17/17) of treatment events in infants, 95% (155/164) in children, and 94% (76/81) in adolescent patients. Related adverse events (AEs) were observed in only 4 (4%) patients and were not deemed to be serious. The findings in this study confirm the safety and efficacy of Haemate-P/Humate-P using VWF:RCo dosing in pediatric and adult patients with various types of VWD.
11858481	39	60	von Willebrand factor	GENE-Y	11858481T10
11858481	348	358	ristocetin	CHEMICAL	11858481T1
11858481	94	104	ristocetin	CHEMICAL	11858481T2
11858481	293	298	FVIII	GENE-Y	11858481T3
11858481	299	302	VWF	GENE-Y	113289
11858481	2251	2254	VWF	GENE-Y	113289
11858481	786	799	Factor VIII:C	GENE-Y	11858481T6
11858481	801	808	FVIII:C	GENE-Y	11858481T7
11858481	1009	1016	FVIII:C	GENE-Y	11858481T8
11858481	27	38	factor VIII	GENE-Y	11858481T9

11885959|t|Differential binding mode of diverse cyclooxygenase inhibitors.
11885959|a|Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid. There are at least two different isoforms of the enzyme known as COX-1 and -2. Site directed mutagenesis studies suggest that non-selective COX inhibitors of diverse chemical families exhibit differential binding modes to the two isozymes. These results cannot clearly be explained from the sole analysis of the crystal structures of COX available from X-ray diffraction studies. With the aim to elucidate the structural features governing the differential inhibitory binding behavior of these inhibitors, molecular modeling studies were undertaken to generate atomic models compatible with the experimental data available. Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program. The results of the present study provide new insights into a better understanding of the differential binding mode of diverse families of COX inhibitors, and are expected to contribute to the design of new selective compounds.
11885959	1024	1033	zomepirac	CHEMICAL	11885959T10
11885959	1035	1047	indomethacin	CHEMICAL	11885959T11
11885959	1049	1059	diclofenac	CHEMICAL	11885959T12
11885959	1261	1264	COX	GENE-N	11885959T13
11885959	324	336	COX-1 and -2	GENE-N	11885959T14
11885959	399	402	COX	GENE-N	11885959T15
11885959	593	596	COX	GENE-N	11885959T16
11885959	141	155	cyclooxygenase	GENE-N	11885959T17
11885959	917	920	COX	GENE-N	11885959T18
11885959	157	160	COX	GENE-N	11885959T19
11885959	1064	1081	meclofenamic acid	CHEMICAL	11885959T1
11885959	37	51	cyclooxygenase	GENE-N	11885959T20
11885959	204	218	prostaglandins	CHEMICAL	11885959T2
11885959	223	235	thromboxanes	CHEMICAL	11885959T3
11885959	241	257	arachidonic acid	CHEMICAL	11885959T4
11885959	68	77	steroidal	CHEMICAL	11885959T5
11885959	980	989	rofecoxib	CHEMICAL	11885959T6
11885959	991	1001	ketoprofen	CHEMICAL	11885959T7
11885959	1003	1011	suprofen	CHEMICAL	11885959T8
11885959	1013	1022	carprofen	CHEMICAL	11885959T9
11885959	CPR:4	11885959T10	11885959T18
11885959	CPR:4	11885959T11	11885959T18
11885959	CPR:4	11885959T12	11885959T18
11885959	CPR:4	11885959T1	11885959T18
11885959	CPR:4	11885959T5	11885959T17
11885959	CPR:4	11885959T5	11885959T19
11885959	CPR:4	11885959T6	11885959T18
11885959	CPR:4	11885959T7	11885959T18
11885959	CPR:4	11885959T8	11885959T18
11885959	CPR:4	11885959T9	11885959T18
11885959	CPR:9	11885959T2	11885959T17
11885959	CPR:9	11885959T2	11885959T19
11885959	CPR:9	11885959T3	11885959T17
11885959	CPR:9	11885959T3	11885959T19
11885959	CPR:9	11885959T4	11885959T17
11885959	CPR:9	11885959T4	11885959T19

11922402|t|Pure antiestrogens and breast cancer.
11922402|a|Tamoxifen, which is the most commonly used drug for treatment of breast cancer, has both estrogen agonist and antagonist actions. Pure antiestrogens are devoid of any estrogen agonist effects. ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor (ER). Preclinical and clinical studies show that fulvestrant and ICI 164,384 are more potent than tamoxifen in inhibiting the growth of breast cancer cells. They are devoid of any estrogen-agonist action on the uterus and vagina but lack the beneficial effects of tamoxifen on the bone and serum lipid profile. Fulvestrant is the first pure antiestrogen to complete phase III clinical trials. Such studies have shown that fulvestrant is at least as good as anastrozole in the treatment of post-menopausal women with advanced breast cancer who had relapsed or progressed on prior endocrine therapy. The drug was well tolerated and only minor side-effects were reported. Its potential role in the adjuvant setting will be determined by its adverse effects on bone mass and serum lipids. EM-800 and EM-652 are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to ER. They have no stimulatory effects on the uterus or vagina. It seems reasonable to expect that pure antiestrogens will be good alternatives to tamoxifen and aromatase inhibitors in the treatment of breast cancer.
11922402	272	283	ICI 164,384	CHEMICAL	11922402T10
11922402	314	322	estrogen	CHEMICAL	11922402T11
11922402	341	349	estrogen	CHEMICAL	11922402T12
11922402	408	419	fulvestrant	CHEMICAL	11922402T13
11922402	424	435	ICI 164,384	CHEMICAL	11922402T14
11922402	457	466	tamoxifen	CHEMICAL	11922402T15
11922402	539	547	estrogen	CHEMICAL	11922402T16
11922402	623	632	tamoxifen	CHEMICAL	11922402T17
11922402	670	681	Fulvestrant	CHEMICAL	937
11922402	700	712	antiestrogen	CHEMICAL	11922402T19
11922402	38	47	Tamoxifen	CHEMICAL	665
11922402	781	792	fulvestrant	CHEMICAL	11922402T20
11922402	816	827	anastrozole	CHEMICAL	11922402T21
11922402	127	135	estrogen	CHEMICAL	11922402T22
11922402	1261	1263	ER	GENE-Y	16226|2525
11922402	341	358	estrogen receptor	GENE-Y	11922402T24
11922402	360	362	ER	GENE-Y	16226|2525
11922402	1144	1150	EM-800	CHEMICAL	11922402T2
11922402	1155	1161	EM-652	CHEMICAL	11922402T3
11922402	1205	1211	EM-652	CHEMICAL	11922402T4
11922402	1406	1415	tamoxifen	CHEMICAL	11922402T5
11922402	205	213	estrogen	CHEMICAL	11922402T6
11922402	231	242	ICI 182,780	CHEMICAL	937
11922402	244	255	fulvestrant	CHEMICAL	11922402T8
11922402	258	266	Faslodex	CHEMICAL	11922402T9

12016548|t|Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.
12016548|a|Hepatotoxic adverse drug reactions have contributed to the decline of many promising therapies, even among mainstream medication classes (bromfenac and troglitazone are recent examples). The spectrum of nonsteroidal anti-inflammatory drug-related liver toxicity continues to expand, with reports in children, interactive toxicity in persons with hepatitis C, and recognition of the toxicity of both the preferential and selective cyclooxygenase-2 inhibitors. Of the antihypertensive agents, methyldopa is now rarely prescribed and adverse effects are reported infrequently, whereas cases of liver injury associated with the angiotensin receptor and converting enzyme inhibitors are increasingly reported. Of the antidiabetic agents, acarbose, gliclazide, metformin, and human insulin have been implicated in causing liver injury. To date, the newer thiazolidinediones do not appear to share the hepatotoxic potential of troglitazone, although a few reports of acute hepatitis have accrued. Although liver injury has been associated with the "statins," the frequency of such toxicity is lower than that of the background population and the value of biochemical monitoring remains unproved. Newer concepts in anticonvulsant hepatotoxicity have been the recognition of the reactive metabolite syndrome, delineation of the risk factors for valproic acid toxicity, the potential role of carnitine in preventing valproic acid hepatotoxicity, and the toxicity of second-line antiepileptic drugs. Liver injury associated with newer psychotropic agents, particularly the selective serotonin reuptake inhibitors, is also discussed. The focus of the review is the hepatotoxicity of commonly used drugs with particular reference to recent and novel reports of toxicity. Well-known causes of liver injury such as chlorpromazine, phenytoin, and methyldopa are not discussed.
12016548	801	812	angiotensin	CHEMICAL	12016548T10
12016548	910	918	acarbose	CHEMICAL	277
12016548	920	930	gliclazide	CHEMICAL	12016548T12
12016548	932	941	metformin	CHEMICAL	12016548T13
12016548	1026	1044	thiazolidinediones	CHEMICAL	12016548T14
12016548	1097	1109	troglitazone	CHEMICAL	12016548T15
12016548	607	623	cyclooxygenase-2	GENE-Y	12016548T16
12016548	801	821	angiotensin receptor	GENE-N	12016548T17
12016548	826	843	converting enzyme	GENE-Y	12016548T18
12016548	947	960	human insulin	GENE-Y	12016548T19
12016548	1513	1526	valproic acid	CHEMICAL	12016548T1
12016548	315	324	bromfenac	CHEMICAL	12016548T2
12016548	1559	1568	carnitine	CHEMICAL	12016548T3
12016548	1583	1596	valproic acid	CHEMICAL	12016548T4
12016548	329	341	troglitazone	CHEMICAL	12016548T5
12016548	1749	1758	serotonin	CHEMICAL	12016548T6
12016548	1977	1991	chlorpromazine	CHEMICAL	12016548T7
12016548	1993	2002	phenytoin	CHEMICAL	12016548T8
12016548	2008	2018	methyldopa	CHEMICAL	12016548T9

12046981|t|Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
12046981|a|Olopatadine hydrochloride (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/histamine H1-receptor antagonistic drug that was synthesized and evaluated in our laboratories. Oral administration of olopatadine at doses of 0.03 mg/kg or higher inhibited the symptoms of experimental allergic skin responses, rhinoconjunctivitis and bronchial asthma in sensitized guinea pigs and rats. Olopatadine is a selective histamine H1-receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils. Olopatadine also inhibited the tachykininergic contraction in the guinea pig bronchi by prejunctional inhibition of peripheral sensory nerves. Olopatadine exerted no significant effects on action potential duration in isolated guinea pig ventricular myocytes, myocardium and human ether-a-go-go-related gene channel. Olopatadine was highly and rapidly absorbed in healthy human volunteers. The urinary excretion of olopatadine accounted for not less than 58% and the contribution of metabolism was considerably low in the clearance of olopatadine in humans. Olopatadine is one of the few renal clearance drugs in antiallergic drugs. Olopatadine was shown to be useful for the treatment of allergic rhinitis and chronic urticaria in double-blind clinical trials. Olopatadine was approved in Japan for the treatment of allergic rhinitis, chronic urticaria, eczema dermatitis, prurigo, pruritus cutaneous, psoriasis vulgaris and erythema exsudativum multiforme in December, 2000. Ophthalmic solution of olopatadine was also approved in the United States for the treatment of seasonal allergic conjunctivitis in December, 1996 (Appendix: also in the European Union, it was approved in February 2002).
12046981	139	150	olopatadine	CHEMICAL	12046981T10
12046981	396	407	olopatadine	CHEMICAL	12046981T11
12046981	152	251	11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride	CHEMICAL	12046981T12
12046981	582	593	Olopatadine	CHEMICAL	758
12046981	609	618	histamine	CHEMICAL	12046981T14
12046981	727	738	leukotriene	CHEMICAL	12046981T15
12046981	743	754	thromboxane	CHEMICAL	12046981T16
12046981	812	823	Olopatadine	CHEMICAL	758
12046981	955	966	Olopatadine	CHEMICAL	758
12046981	60	85	olopatadine hydrochloride	CHEMICAL	12046981T19
12046981	112	137	Olopatadine hydrochloride	CHEMICAL	12046981T1
12046981	277	298	histamine H1-receptor	GENE-Y	12046981T20
12046981	609	630	histamine H1-receptor	GENE-Y	12046981T21
12046981	1087	1127	human ether-a-go-go-related gene channel	GENE-Y	12046981T22
12046981	1129	1140	Olopatadine	CHEMICAL	758
12046981	1227	1238	olopatadine	CHEMICAL	12046981T3
12046981	1347	1358	olopatadine	CHEMICAL	12046981T4
12046981	1370	1381	Olopatadine	CHEMICAL	758
12046981	1445	1456	Olopatadine	CHEMICAL	758
12046981	1574	1585	Olopatadine	CHEMICAL	758
12046981	277	286	histamine	CHEMICAL	12046981T8
12046981	1812	1823	olopatadine	CHEMICAL	12046981T9
12046981	CPR:6	12046981T10	12046981T20
12046981	CPR:6	12046981T12	12046981T20
12046981	CPR:6	758	12046981T21
12046981	CPR:6	12046981T1	12046981T20

12057823|t|Serotonin transporter polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals.
12057823|a|Considerable evidence indicates that serotonergic mechanisms, particularly the serotonin transporter (5HTT), may mediate central effects of cocaine and may also be involved in impulsive and aggressive behavior. We investigated whether polymorphisms in the 5HTT gene were related to traits of impulsivity, sensation seeking, and aggression among cocaine abusers. Standardized measures of these personality traits were obtained in a sample of 105 severely affected cocaine-dependent African-American subjects and 44 African-American controls. Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among cocaine patients. No significant relationships were observed between polymorphic variants of the 5HTTLPR and VNTR regions and scores on any of the trait measures. Similarly, demographic variables and measures of severity of substance use and depression were unrelated to allele frequencies or genotype distributions of the variants among cocaine patients. As expected, cocaine patients scored significantly higher on total scores of impulsivity, aggression, and sensation seeking compared to controls. The findings do not seem to support an association between these polymorphisms in the 5HTT gene and impulsive-aggressive traits among cocaine-dependent African-American individuals.
12057823	122	129	cocaine	CHEMICAL	12057823T10
12057823	255	259	5HTT	GENE-Y	12057823T11
12057823	1443	1447	5HTT	GENE-Y	12057823T12
12057823	409	413	5HTT	GENE-Y	12057823T13
12057823	719	723	5HTT	GENE-Y	12057823T14
12057823	770	777	5HTTLPR	GENE-N	12057823T15
12057823	805	834	variable-number-tandem-repeat	GENE-N	12057823T16
12057823	836	840	VNTR	GENE-N	12057823T17
12057823	232	253	serotonin transporter	GENE-Y	12057823T18
12057823	952	959	5HTTLPR	GENE-N	12057823T19
12057823	1193	1200	cocaine	CHEMICAL	12057823T1
12057823	964	968	VNTR	GENE-N	12057823T20
12057823	0	21	Serotonin transporter	GENE-Y	12057823T21
12057823	1224	1231	cocaine	CHEMICAL	12057823T2
12057823	1491	1498	cocaine	CHEMICAL	12057823T3
12057823	293	300	cocaine	CHEMICAL	12057823T4
12057823	498	505	cocaine	CHEMICAL	12057823T5
12057823	616	623	cocaine	CHEMICAL	12057823T6
12057823	855	862	cocaine	CHEMICAL	12057823T7
12057823	232	241	serotonin	CHEMICAL	12057823T8
12057823	0	9	Serotonin	CHEMICAL	12057823T9

12070353|t|A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.
12070353|a|The molecular mechanism for the anti-inflammatory action of theophylline is currently unknown, but low-dose theophylline is an effective add-on therapy to corticosteroids in controlling asthma. Corticosteroids act, at least in part, by recruitment of histone deacetylases (HDACs) to the site of active inflammatory gene transcription. They thereby inhibit the acetylation of core histones that is necessary for inflammatory gene transcription. We show both in vitro and in vivo that low-dose theophylline enhances HDAC activity in epithelial cells and macrophages. This increased HDAC activity is then available for corticosteroid recruitment and predicts a cooperative interaction between corticosteroids and theophylline. This mechanism occurs at therapeutic concentrations of theophylline and is dissociated from phosphodiesterase inhibition (the mechanism of bronchodilation) or the blockade of adenosine receptors, which are partially responsible for its side effects. Thus we have shown that low-dose theophylline exerts an anti-asthma effect through increasing activation of HDAC which is subsequently recruited by corticosteroids to suppress inflammatory genes.
12070353	912	924	theophylline	CHEMICAL	12070353T10
12070353	1032	1041	adenosine	CHEMICAL	12070353T11
12070353	35	47	theophylline	CHEMICAL	12070353T12
12070353	1215	1219	HDAC	GENE-N	12070353T13
12070353	384	404	histone deacetylases	GENE-N	12070353T14
12070353	406	411	HDACs	GENE-N	12070353T15
12070353	647	651	HDAC	GENE-N	12070353T16
12070353	713	717	HDAC	GENE-N	12070353T17
12070353	949	966	phosphodiesterase	GENE-N	12070353T18
12070353	1032	1051	adenosine receptors	GENE-N	12070353T19
12070353	1140	1152	theophylline	CHEMICAL	12070353T1
12070353	62	81	histone deacetylase	GENE-N	12070353T20
12070353	241	253	theophylline	CHEMICAL	12070353T2
12070353	1255	1270	corticosteroids	CHEMICAL	12070353T3
12070353	327	342	Corticosteroids	CHEMICAL	12070353T4
12070353	625	637	theophylline	CHEMICAL	12070353T5
12070353	193	205	theophylline	CHEMICAL	12070353T6
12070353	749	763	corticosteroid	CHEMICAL	12070353T7
12070353	823	838	corticosteroids	CHEMICAL	12070353T8
12070353	843	855	theophylline	CHEMICAL	12070353T9
12070353	CPR:3	12070353T12	12070353T20
12070353	CPR:3	12070353T1	12070353T13
12070353	CPR:3	12070353T5	12070353T16

12085361|t|Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
12085361|a|The antibiotics rifamycin SV and rifampicin substantially reduce sulfobromophthalein (BSP) elimination in humans. In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2. Therefore, we investigated the effects of rifamycin SV and rifampicin on the OATPs of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers. In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. In the presence of 100 micromol/L rifamycin SV, BSP uptake was almost completely abolished. Approximate K(i) values were 2 micromol/L for OATP-C, 3 micromol/L for OATP8, 3 micromol/L for OATP-B and 11 micromol/L for OATP-A. Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively. The corresponding K(i) values were 17 micromol/L for OATP-C, 5 micromol/L for OATP8, and 51 micromol/L for OATP-A. Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L). In conclusion, these results show that rifamycin SV and rifampicin interact with OATP-mediated substrate transport to different extents. Inhibition of human liver OATPs can explain the previously observed effects of rifamycin SV and rifampicin on hepatic organic anion elimination.
12085361	1839	1851	rifamycin SV	CHEMICAL	12085361T10
12085361	1856	1866	rifampicin	CHEMICAL	12085361T11
12085361	2016	2028	rifamycin SV	CHEMICAL	12085361T12
12085361	2033	2043	rifampicin	CHEMICAL	12085361T13
12085361	423	435	rifamycin SV	CHEMICAL	12085361T14
12085361	127	137	rifampicin	CHEMICAL	12085361T15
12085361	440	450	rifampicin	CHEMICAL	12085361T16
12085361	502	512	rifampicin	CHEMICAL	12085361T17
12085361	624	636	rifamycin SV	CHEMICAL	12085361T18
12085361	159	178	sulfobromophthalein	CHEMICAL	12085361T19
12085361	1268	1278	Rifampicin	CHEMICAL	1034
12085361	180	183	BSP	CHEMICAL	12085361T20
12085361	1078	1090	rifamycin SV	CHEMICAL	12085361T21
12085361	1092	1095	BSP	CHEMICAL	12085361T22
12085361	16	28	rifamycin SV	CHEMICAL	12085361T23
12085361	33	43	rifampicin	CHEMICAL	12085361T24
12085361	1182	1188	OATP-C	GENE-Y	12085361T25
12085361	1207	1212	OATP8	GENE-Y	12085361T26
12085361	1231	1237	OATP-B	GENE-Y	12085361T27
12085361	1260	1266	OATP-A	GENE-Y	12085361T28
12085361	1305	1310	OATP8	GENE-Y	12085361T29
12085361	1320	1323	BSP	CHEMICAL	12085361T2
12085361	1361	1367	OATP-C	GENE-Y	12085361T30
12085361	1370	1376	OATP-B	GENE-Y	12085361T31
12085361	1383	1389	OATP-A	GENE-Y	12085361T32
12085361	1464	1470	OATP-C	GENE-Y	12085361T33
12085361	1476	1481	OATP8	GENE-Y	12085361T34
12085361	1484	1490	OATP-B	GENE-Y	12085361T35
12085361	1496	1502	OATP-A	GENE-Y	12085361T36
12085361	1617	1623	OATP-C	GENE-Y	12085361T37
12085361	1642	1647	OATP8	GENE-Y	12085361T38
12085361	1671	1677	OATP-A	GENE-Y	12085361T39
12085361	217	229	rifamycin SV	CHEMICAL	12085361T3
12085361	1729	1735	OATP-C	GENE-Y	12085361T40
12085361	1776	1781	OATP8	GENE-Y	12085361T41
12085361	1881	1885	OATP	GENE-N	12085361T42
12085361	1951	1968	human liver OATPs	GENE-N	12085361T43
12085361	324	363	organic anion transporting polypeptides	GENE-N	12085361T44
12085361	364	369	Oatp1	GENE-Y	12085361T45
12085361	374	379	Oatp2	GENE-Y	12085361T46
12085361	458	463	OATPs	GENE-N	12085361T47
12085361	667	713	human organic anion transporting polypeptide C	GENE-Y	12085361T48
12085361	715	722	SLC21A6	GENE-Y	12085361T49
12085361	1399	1402	BSP	CHEMICAL	12085361T4
12085361	725	731	OATP-C	GENE-Y	12085361T50
12085361	734	780	human organic anion transporting polypeptide 8	GENE-Y	12085361T51
12085361	782	789	SLC21A8	GENE-Y	12085361T52
12085361	792	797	OATP8	GENE-Y	12085361T53
12085361	800	846	human organic anion transporting polypeptide B	GENE-Y	12085361T54
12085361	848	855	SLC21A9	GENE-Y	12085361T55
12085361	858	864	OATP-B	GENE-Y	12085361T56
12085361	871	917	human organic anion transporting polypeptide A	GENE-Y	12085361T57
12085361	919	926	SLC21A3	GENE-Y	12085361T58
12085361	929	935	OATP-A	GENE-Y	12085361T59
12085361	1443	1453	rifampicin	CHEMICAL	12085361T5
12085361	234	244	rifampicin	CHEMICAL	12085361T6
12085361	1512	1515	BSP	CHEMICAL	12085361T7
12085361	1699	1709	rifampicin	CHEMICAL	12085361T8
12085361	110	122	rifamycin SV	CHEMICAL	12085361T9
12085361	CPR:4	12085361T12	12085361T43
12085361	CPR:4	12085361T13	12085361T43
12085361	CPR:4	12085361T18	12085361T48
12085361	CPR:4	12085361T18	12085361T49
12085361	CPR:4	12085361T18	12085361T50
12085361	CPR:4	12085361T18	12085361T51
12085361	CPR:4	12085361T18	12085361T52
12085361	CPR:4	12085361T18	12085361T53
12085361	CPR:4	12085361T18	12085361T54
12085361	CPR:4	12085361T18	12085361T55
12085361	CPR:4	12085361T18	12085361T56
12085361	CPR:4	12085361T18	12085361T57
12085361	CPR:4	12085361T18	12085361T58
12085361	CPR:4	12085361T18	12085361T59
12085361	CPR:4	1034	12085361T29
12085361	CPR:4	1034	12085361T30
12085361	CPR:4	1034	12085361T31
12085361	CPR:4	1034	12085361T32
12085361	CPR:4	12085361T3	12085361T44
12085361	CPR:4	12085361T3	12085361T45
12085361	CPR:4	12085361T3	12085361T46
12085361	CPR:4	12085361T5	12085361T33
12085361	CPR:4	12085361T5	12085361T34
12085361	CPR:4	12085361T5	12085361T35
12085361	CPR:4	12085361T5	12085361T36
12085361	CPR:4	12085361T6	12085361T44
12085361	CPR:4	12085361T6	12085361T45
12085361	CPR:4	12085361T6	12085361T46
12085361	CPR:9	12085361T2	12085361T29
12085361	CPR:9	12085361T4	12085361T30
12085361	CPR:9	12085361T4	12085361T31
12085361	CPR:9	12085361T4	12085361T32
12085361	CPR:9	12085361T7	12085361T33
12085361	CPR:9	12085361T7	12085361T34
12085361	CPR:9	12085361T7	12085361T35
12085361	CPR:9	12085361T7	12085361T36
12085361	CPR:9	12085361T8	12085361T40
12085361	CPR:9	12085361T8	12085361T41

12086935|t|Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.
12086935|a|Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK alpha2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK alpha2.
12086935	361	364	AMP	CHEMICAL	125|407
12086935	526	533	glucose	CHEMICAL	12086935T11
12086935	654	663	metformin	CHEMICAL	12086935T12
12086935	173	180	glucose	CHEMICAL	12086935T13
12086935	749	756	glucose	CHEMICAL	12086935T14
12086935	833	842	metformin	CHEMICAL	12086935T15
12086935	908	917	Metformin	CHEMICAL	323
12086935	1097	1107	acetyl-CoA	CHEMICAL	12086935T17
12086935	0	9	Metformin	CHEMICAL	323
12086935	20	23	AMP	CHEMICAL	125|407
12086935	111	120	Metformin	CHEMICAL	323
12086935	1148	1159	AMPK alpha2	GENE-Y	12086935T20
12086935	1336	1340	AMPK	GENE-N	12086935T21
12086935	1573	1584	AMPK alpha2	GENE-Y	12086935T22
12086935	361	389	AMP-activated protein kinase	GENE-N	12086935T23
12086935	391	395	AMPK	GENE-N	12086935T24
12086935	633	637	AMPK	GENE-N	12086935T25
12086935	852	856	AMPK	GENE-N	12086935T26
12086935	965	976	AMPK alpha2	GENE-Y	12086935T27
12086935	1068	1072	AMPK	GENE-N	12086935T28
12086935	1097	1121	acetyl-CoA carboxylase-2	GENE-Y	12086935T29
12086935	218	225	glucose	CHEMICAL	12086935T2
12086935	20	48	AMP-activated protein kinase	GENE-N	12086935T30
12086935	1228	1231	ATP	CHEMICAL	164
12086935	1236	1251	phosphocreatine	CHEMICAL	12086935T4
12086935	1284	1293	metformin	CHEMICAL	12086935T5
12086935	1305	1314	Metformin	CHEMICAL	323
12086935	1387	1394	glucose	CHEMICAL	12086935T7
12086935	252	259	glucose	CHEMICAL	12086935T8
12086935	320	329	metformin	CHEMICAL	12086935T9
12086935	CPR:3	12086935T12	12086935T25
12086935	CPR:3	12086935T15	12086935T26
12086935	CPR:3	323	12086935T27
12086935	CPR:3	323	12086935T28
12086935	CPR:3	323	12086935T30
12086935	CPR:3	12086935T5	12086935T20
12086935	CPR:3	323	12086935T21
12086935	CPR:4	323	12086935T29
12086935	CPR:9	12086935T11	12086935T23
12086935	CPR:9	12086935T11	12086935T24

12105857|t|Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production.
12105857|a|BACKGROUND & AIMS: Sensitization of Kupffer cells (KCs) to lipopolysaccharide (LPS) and overproduction of tumor necrosis factor (TNF) alpha are critical for progression of alcoholic liver injury. Thalidomide has been shown to suppress TNF-alpha production from macrophages. Accordingly, the purpose of this study was to determine whether thalidomide could prevent alcohol-induced liver injury. METHODS: Rats were given ethanol (5 g/kg body wt) and thalidomide (5 mg/kg) once every 24 hours intragastrically. To assess the sensitization of Kupffer cells, LPS (5 mg/kg intravenously) was administered and liver histology was evaluated 24 hours later. KCs were isolated after 4 weeks of ethanol treatment and intracellular Ca2+ ([Ca2+]i) was measured using fura-2, whereas TNF-alpha was evaluated by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay. CD14 was determined by Western and fluorescence staining. RESULTS: Treatment with ethanol for 8 weeks caused marked steatosis, necrosis, and inflammation in the liver. These pathologic parameters were diminished markedly by treatment with thalidomide. In the 4-week ethanol group, the LPS-induced liver damage was aggravated and KCs were sensitized to LPS. Coadministration of thalidomide with ethanol prevented the KC sensitization completely. Furthermore, thalidomide abolished the LPS-induced increase in CD14 expression and [Ca2+]i elevation in KCs. Gut permeability was increased about 10-fold after 4 weeks of ethanol exposure, which was not affected by thalidomide. Moreover, thalidomide reduced the LPS-induced TNF-alpha production by KCs by decreasing TNF-alpha messenger RNA. CONCLUSIONS: These results collectively indicate that thalidomide prevents alcoholic liver injury through suppression of TNF-alpha production and abolishment of KC sensitization.
12105857	300	309	alcoholic	CHEMICAL	12105857T10
12105857	1852	1863	thalidomide	CHEMICAL	8562
12105857	324	335	Thalidomide	CHEMICAL	1030
12105857	466	477	thalidomide	CHEMICAL	8562
12105857	492	499	alcohol	CHEMICAL	12105857T14
12105857	547	554	ethanol	CHEMICAL	12105857T15
12105857	576	587	thalidomide	CHEMICAL	8562
12105857	812	819	ethanol	CHEMICAL	12105857T17
12105857	848	852	Ca2+	CHEMICAL	12105857T18
12105857	855	859	Ca2+	CHEMICAL	12105857T19
12105857	1251	1262	thalidomide	CHEMICAL	8562
12105857	1094	1101	ethanol	CHEMICAL	12105857T20
12105857	0	11	Thalidomide	CHEMICAL	1030
12105857	21	30	alcoholic	CHEMICAL	12105857T22
12105857	234	267	tumor necrosis factor (TNF) alpha	GENE-Y	12105857T23
12105857	1520	1524	CD14	GENE-Y	107367
12105857	1731	1740	TNF-alpha	GENE-Y	12105857T25
12105857	1773	1782	TNF-alpha	GENE-Y	12105857T26
12105857	1919	1928	TNF-alpha	GENE-Y	12105857T27
12105857	363	372	TNF-alpha	GENE-Y	12105857T28
12105857	898	907	TNF-alpha	GENE-Y	12105857T29
12105857	1278	1285	ethanol	CHEMICAL	12105857T2
12105857	1012	1016	CD14	GENE-Y	107367
12105857	106	115	TNF-alpha	GENE-Y	12105857T31
12105857	1389	1400	thalidomide	CHEMICAL	8562
12105857	1406	1413	ethanol	CHEMICAL	12105857T4
12105857	1470	1481	thalidomide	CHEMICAL	8562
12105857	1541	1545	Ca2+	CHEMICAL	12105857T6
12105857	1628	1635	ethanol	CHEMICAL	12105857T7
12105857	1672	1683	thalidomide	CHEMICAL	8562
12105857	1695	1706	thalidomide	CHEMICAL	8562
12105857	CPR:4	8562	12105857T27
12105857	CPR:4	1030	12105857T28
12105857	CPR:4	1030	12105857T31
12105857	CPR:4	8562	107367
12105857	CPR:4	8562	12105857T25
12105857	CPR:4	8562	12105857T26

12141946|t|Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin.
12141946|a|During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively. In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves spermine in the absence of prior acetylation by SSAT. A BLAST search using maize PAO sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 amino acids. When either cDNA was transiently transfected into HEK-293 cells, intracellular spermine pools decreased by 75% while spermidine and N (1)-acetylspermidine pools increased, suggesting that spermine was selectively and directly oxidized by the enzyme. Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine. The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction. Overall, the data indicate that the enzyme represents a novel mammalian oxidase which, on the basis of substrate specificity, we have designated spermine oxidase in order to distinguish it from the PAO involved in polyamine back-conversion. The identification of an enzyme capable of directly oxidizing spermine to spermidine has important implications for understanding polyamine homoeostasis and for interpreting metabolic and cellular responses to clinically relevant polyamine analogues and inhibitors.
12141946	1745	1753	spermine	CHEMICAL	12141946T10
12141946	1757	1767	spermidine	CHEMICAL	12141946T11
12141946	1913	1922	polyamine	CHEMICAL	12141946T12
12141946	299	309	spermidine	CHEMICAL	12141946T13
12141946	314	324	putrescine	CHEMICAL	12141946T14
12141946	137	145	spermine	CHEMICAL	12141946T15
12141946	467	475	spermine	CHEMICAL	12141946T16
12141946	150	160	spermidine	CHEMICAL	12141946T17
12141946	693	704	amino acids	CHEMICAL	12141946T18
12141946	785	793	spermine	CHEMICAL	12141946T19
12141946	1154	1176	N (1)-acetylspermidine	CHEMICAL	12141946T1
12141946	823	833	spermidine	CHEMICAL	12141946T20
12141946	115	124	polyamine	CHEMICAL	12141946T21
12141946	838	860	N (1)-acetylspermidine	CHEMICAL	12141946T22
12141946	185	195	spermidine	CHEMICAL	12141946T23
12141946	894	902	spermine	CHEMICAL	12141946T24
12141946	196	204	spermine	CHEMICAL	12141946T25
12141946	205	206	N	CHEMICAL	167
12141946	1090	1098	spermine	CHEMICAL	12141946T27
12141946	1104	1124	N (1)-acetylspermine	CHEMICAL	12141946T28
12141946	47	53	flavin	CHEMICAL	12141946T29
12141946	1178	1188	spermidine	CHEMICAL	12141946T2
12141946	65	73	spermine	CHEMICAL	12141946T30
12141946	1206	1209	PAO	GENE-Y	12141946T31
12141946	1257	1260	PAO	GENE-Y	12141946T32
12141946	229	233	SSAT	GENE-Y	12141946T33
12141946	1357	1360	PAO	GENE-Y	12141946T34
12141946	1504	1521	mammalian oxidase	GENE-N	12141946T35
12141946	1587	1603	spermine oxidase	GENE-N	12141946T36
12141946	1640	1643	PAO	GENE-N	12141946T37
12141946	264	281	polyamine oxidase	GENE-Y	12141946T38
12141946	283	286	PAO	GENE-Y	12141946T39
12141946	1221	1251	N (1), N (12)-diacetylspermine	CHEMICAL	12141946T3
12141946	367	370	PAO	GENE-Y	12141946T40
12141946	431	438	oxidase	GENE-N	12141946T41
12141946	515	519	SSAT	GENE-Y	12141946T42
12141946	542	551	maize PAO	GENE-Y	12141946T43
12141946	185	227	spermidine/spermine N(1)-acetyltransferase	GENE-Y	12141946T44
12141946	995	1002	oxidase	GENE-N	12141946T45
12141946	1064	1071	oxidase	GENE-N	12141946T46
12141946	65	81	spermine oxidase	GENE-N	12141946T47
12141946	1272	1282	MDL-72,527	CHEMICAL	12141946T4
12141946	1320	1328	spermine	CHEMICAL	12141946T5
12141946	1372	1407	N (1)-( n -octanesulphonyl)spermine	CHEMICAL	12141946T6
12141946	1587	1595	spermine	CHEMICAL	12141946T7
12141946	1656	1665	polyamine	CHEMICAL	12141946T8
12141946	264	273	polyamine	CHEMICAL	12141946T9
12141946	CPR:4	12141946T4	12141946T32
12141946	CPR:9	12141946T13	12141946T38
12141946	CPR:9	12141946T13	12141946T39
12141946	CPR:9	12141946T14	12141946T38
12141946	CPR:9	12141946T14	12141946T39
12141946	CPR:9	12141946T15	12141946T33
12141946	CPR:9	12141946T15	12141946T44
12141946	CPR:9	12141946T16	12141946T42
12141946	CPR:9	12141946T17	12141946T33
12141946	CPR:9	12141946T17	12141946T44
12141946	CPR:9	12141946T21	12141946T33
12141946	CPR:9	12141946T21	12141946T44
12141946	CPR:9	12141946T27	12141946T46
12141946	CPR:9	12141946T28	12141946T46
12141946	CPR:9	12141946T3	12141946T31
12141946	CPR:9	12141946T6	12141946T34

12165285|t|Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.
12165285|a|The human platelet antigen-1 (HPA-1, Pl(A)) polymorphism has been proposed to influence the inhibitory actions of abciximab. Thus, we hypothesized that this polymorphism might also be the cause for paradoxical activation of platelets by GPIIb/IIIa inhibitors. The effects of abciximab (1-10 microg/ml), tirofiban (3-30 nM), or eptifibatide (0.3-3 microg/ml) on basal and ADP (3 microM)-induced CD62P externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease. All subjects were genotyped for the human platelet antigen-1 (HPA-1, Pl(A)) polymorphism by GALIOS(R) and fluorescence correlation spectroscopy. Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or ADP-induced CD62P expression. A moderate (twofold) stimulation of CD62P expression by abciximab but not by tirofiban or eptifibatide was observed in one patient. Interestingly, this patient carried the HPA-1 b/b genotype. In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or ADP-stimulated CD62P expression. It is concluded that paradoxical platelet activation by abciximab is a rare (<2%) phenomenon. HPA-1 b/b genotype might be a contributing factor but clearly does not predict platelet activation by GP IIb/IIIa inhibitors.
12165285	1290	1301	GP IIb/IIIa	GENE-N	12165285T10
12165285	1340	1345	CD62P	GENE-Y	12165285T11
12165285	1452	1457	HPA-1	GENE-N	12165285T12
12165285	1554	1565	GP IIb/IIIa	GENE-N	12165285T13
12165285	323	333	GPIIb/IIIa	GENE-N	12165285T14
12165285	116	121	HPA-1	GENE-N	12165285T15
12165285	123	128	Pl(A)	GENE-N	12165285T16
12165285	480	485	CD62P	GENE-Y	12165285T17
12165285	90	114	human platelet antigen-1	GENE-N	12165285T18
12165285	637	661	human platelet antigen-1	GENE-N	12165285T19
12165285	1325	1328	ADP	CHEMICAL	12165285T1
12165285	663	668	HPA-1	GENE-N	12165285T20
12165285	670	675	Pl(A)	GENE-N	12165285T21
12165285	828	833	HPA-1	GENE-N	12165285T22
12165285	882	887	CD62P	GENE-Y	12165285T23
12165285	936	941	CD62P	GENE-Y	12165285T24
12165285	1072	1077	HPA-1	GENE-N	12165285T25
12165285	52	73	glycoprotein IIb/IIIa	GENE-N	12165285T26
12165285	389	398	tirofiban	CHEMICAL	12165285T2
12165285	413	425	eptifibatide	CHEMICAL	62
12165285	457	460	ADP	CHEMICAL	12165285T4
12165285	870	873	ADP	CHEMICAL	12165285T5
12165285	977	986	tirofiban	CHEMICAL	12165285T6
12165285	990	1002	eptifibatide	CHEMICAL	62
12165285	1143	1154	GP IIb/IIIa	GENE-N	12165285T8
12165285	1243	1248	HPA-1	GENE-N	12165285T9
12165285	CPR:3	12165285T1	12165285T11
12165285	CPR:3	12165285T5	12165285T23

12167474|t|Toxic, halogenated cysteine S-conjugates and targeting of mitochondrial enzymes of energy metabolism.
12167474|a|Several haloalkenes are metabolized in part to nephrotoxic cysteine S-conjugates; for example, trichloroethylene and tetrafluoroethylene are converted to S-(1,2-dichlorovinyl)-L-cysteine (DCVC) and S-(1,1,2,2-tetrafluoroethyl)-L-cysteine (TFEC), respectively. Although DCVC-induced toxicity has been investigated since the 1950s, the toxicity of TFEC and other haloalkene-derived cysteine S-conjugates has been studied more recently. Some segments of the US population are exposed to haloalkenes either through drinking water or in the workplace. Therefore, it is important to define the toxicological consequences of such exposures. Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins. Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)). Most of the cysteine S-conjugate beta-lyases are syncatalytically inactivated. TFEC-induced toxicity is associated with covalent modification of several mitochondrial enzymes of energy metabolism. Interestingly, the alpha-ketoglutarate- and branched-chain alpha-keto acid dehydrogenase complexes (KGDHC and BCDHC), but not the pyruvate dehydrogenase complex (PDHC), are susceptible to inactivation. mitAspAT and BCAT(m) may form metabolons with KGDHC and BCDHC, respectively, but no PLP enzyme is known to associate with PDHC. Consequently, we hypothesize that not only do these metabolons facilitate substrate channeling, but they also facilitate toxicant channeling, thereby promoting the inactivation of proximate mitochondrial enzymes and the induction of mitochondrial dysfunction.
12167474	256	288	S-(1,2-dichlorovinyl)-L-cysteine	CHEMICAL	12167474T10
12167474	1795	1798	PLP	CHEMICAL	109
12167474	290	294	DCVC	CHEMICAL	12167474T12
12167474	300	339	S-(1,1,2,2-tetrafluoroethyl)-L-cysteine	CHEMICAL	12167474T13
12167474	341	345	TFEC	CHEMICAL	12167474T14
12167474	371	375	DCVC	CHEMICAL	12167474T15
12167474	448	452	TFEC	CHEMICAL	12167474T16
12167474	463	503	haloalkene-derived cysteine S-conjugates	CHEMICAL	12167474T17
12167474	586	597	haloalkenes	CHEMICAL	12167474T18
12167474	161	182	cysteine S-conjugates	CHEMICAL	12167474T19
12167474	1134	1154	cysteine S-conjugate	CHEMICAL	12167474T1
12167474	753	774	cysteine S-conjugates	CHEMICAL	12167474T20
12167474	794	814	cysteine S-conjugate	CHEMICAL	12167474T21
12167474	830	838	pyruvate	CHEMICAL	12167474T22
12167474	840	847	ammonia	CHEMICAL	12167474T23
12167474	856	879	alpha-chloroenethiolate	CHEMICAL	12167474T24
12167474	886	890	DCVC	CHEMICAL	12167474T25
12167474	898	925	alpha-difluoroalkylthiolate	CHEMICAL	12167474T26
12167474	110	121	haloalkenes	CHEMICAL	12167474T27
12167474	932	936	TFEC	CHEMICAL	12167474T28
12167474	957	963	halide	CHEMICAL	12167474T29
12167474	1201	1210	aspartate	CHEMICAL	12167474T2
12167474	974	989	thioacyl halide	CHEMICAL	12167474T30
12167474	1009	1022	epsilon-amino	CHEMICAL	12167474T31
12167474	1033	1039	lysine	CHEMICAL	12167474T32
12167474	197	214	trichloroethylene	CHEMICAL	12167474T33
12167474	1077	1099	pyridoxal 5'-phosphate	CHEMICAL	12167474T34
12167474	1101	1104	PLP	CHEMICAL	109
12167474	19	40	cysteine S-conjugates	CHEMICAL	12167474T36
12167474	1155	1165	beta-lyase	GENE-N	12167474T37
12167474	1187	1227	mitochondrial aspartate aminotransferase	GENE-Y	12167474T38
12167474	1229	1237	mitAspAT	GENE-Y	12167474T39
12167474	1258	1283	branched-chain amino acid	CHEMICAL	12167474T3
12167474	1244	1300	mitochondrial branched-chain amino acid aminotransferase	GENE-Y	12167474T40
12167474	1302	1309	BCAT(m)	GENE-Y	12167474T41
12167474	1345	1356	beta-lyases	GENE-N	12167474T42
12167474	1528	1607	alpha-ketoglutarate- and branched-chain alpha-keto acid dehydrogenase complexes	GENE-N	12167474T43
12167474	1609	1614	KGDHC	GENE-N	12167474T44
12167474	1619	1624	BCDHC	GENE-N	12167474T45
12167474	1639	1669	pyruvate dehydrogenase complex	GENE-N	12167474T46
12167474	1671	1675	PDHC	GENE-N	12167474T47
12167474	1711	1719	mitAspAT	GENE-Y	12167474T48
12167474	1724	1731	BCAT(m)	GENE-Y	12167474T49
12167474	219	238	tetrafluoroethylene	CHEMICAL	12167474T4
12167474	1757	1762	KGDHC	GENE-N	12167474T50
12167474	1767	1772	BCDHC	GENE-N	12167474T51
12167474	1795	1805	PLP enzyme	GENE-N	12167474T52
12167474	1833	1837	PDHC	GENE-N	12167474T53
12167474	815	826	beta-lyases	GENE-N	12167474T54
12167474	1324	1344	cysteine S-conjugate	CHEMICAL	12167474T5
12167474	1391	1395	TFEC	CHEMICAL	12167474T6
12167474	1528	1547	alpha-ketoglutarate	CHEMICAL	12167474T7
12167474	1553	1583	branched-chain alpha-keto acid	CHEMICAL	12167474T8
12167474	1639	1647	pyruvate	CHEMICAL	12167474T9
12167474	CPR:9	12167474T20	12167474T54
12167474	CPR:9	12167474T22	12167474T54
12167474	CPR:9	12167474T23	12167474T54
12167474	CPR:9	12167474T24	12167474T54
12167474	CPR:9	12167474T25	12167474T54
12167474	CPR:9	12167474T26	12167474T54
12167474	CPR:9	12167474T28	12167474T54

12175785|t|A heterozygote phenotype is present in the jvs +/- mutant mouse livers.
12175785|a|The juvenile visceral steatosis (jvs) mouse, having a mutation in the carnitine transporter gene Octn2, is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140). Like humans with SCD, homozygous jvs -/- mice have hepatic and cardiac steatoses, reduced plasma and tissue carnitines, and increased urinary carnitine clearance. Because symptomatic heterozygotes have been reported for some fatty acid oxidation disorders, including SCD, we compared the jvs heterozygotes to normal control mice. We measured the free and esterified carnitine, total cholesterol, and triglycerides in adult liver samples, myocardium, and skeletal muscle. Our results indicate significant differences between the livers of nonfasting adult normal (n = 8) vs jvs heterozygotes (n = 8) (means +/- SEM, p < 0.01) for the following parameters: free carnitine, 2.28 +/- 0.36 nmol/mg protein vs 0.41 +/- 0.13; total carnitine, 3.48 +/- 0.36 vs 1.27 +/- 0.25; triglycerides, 0.14 +/- 0.04 vs 0.39 +/- 0.02; and total cholesterol, 0.21 +/- 0.02 vs 0.39 +/- 0.04, but not for esterified carnitine, 1.18 +/- 0.17 vs 0.90 +/- 0.17 (p > 0.05). There is also a negative correlation between hepatic free carnitine and triglycerides from jvs heterozygotes (p < 0.05). Similar results were obtained with myocardium and skeletal muscle. We conclude that free and total carnitine levels are significantly lower in the heterozygote mouse liver and heart while triglyceride and total cholesterol levels are significantly higher. We speculate that in situations of lipolytic stress, some SCD heterozygotes might develop clinical symptoms of carnitine deficiency.
12175785	366	376	carnitines	CHEMICAL	12175785T10
12175785	400	409	carnitine	CHEMICAL	12175785T11
12175785	483	493	fatty acid	CHEMICAL	12175785T12
12175785	624	633	carnitine	CHEMICAL	12175785T13
12175785	641	652	cholesterol	CHEMICAL	12175785T14
12175785	658	671	triglycerides	CHEMICAL	12175785T15
12175785	142	151	carnitine	CHEMICAL	12175785T16
12175785	918	927	carnitine	CHEMICAL	12175785T17
12175785	983	992	carnitine	CHEMICAL	12175785T18
12175785	1026	1039	triglycerides	CHEMICAL	12175785T19
12175785	1083	1094	cholesterol	CHEMICAL	12175785T1
12175785	169	174	Octn2	GENE-Y	12175785T20
12175785	1151	1160	carnitine	CHEMICAL	12175785T2
12175785	1263	1272	carnitine	CHEMICAL	12175785T3
12175785	1277	1290	triglycerides	CHEMICAL	12175785T4
12175785	207	216	carnitine	CHEMICAL	12175785T5
12175785	1425	1434	carnitine	CHEMICAL	12175785T6
12175785	1514	1526	triglyceride	CHEMICAL	12175785T7
12175785	1537	1548	cholesterol	CHEMICAL	12175785T8
12175785	1693	1702	carnitine	CHEMICAL	12175785T9
12175785	CPR:9	12175785T16	12175785T20

12181285|t|Organic cation transporter mRNA and function in the rat superior cervical ganglion.
12181285|a|Reuptake of extracellular noradrenaline (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (NAT, uptake 1). We now demonstrate by single-cell RT-PCR that mRNA of the organic cation transporter 3 (OCT3, uptake 2) occurs in rat SCG neurones as well. Furthermore, our RT-PCR analyses reveal the presence of mRNA for novel organic cation transporters 1 and 2 (OCTN1 and OCTN2), but not for OCT1 or OCT2 in the ganglion. Making use of the NAT as a powerful, neurone-specific transporter system, we loaded[3H]-N-methyl-4-phenylpyridinium ([3H]-MPP+) into cultured rat SCG neurones. The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the OCT3 inhibitors cyanine 863, oestradiol and corticosterone. In contrast, cyanine 863 enhanced the radioactive outflow from cultures preloaded with [3H]-NA. Two observations suggest that a depletion of storage vesicles by cyanine 863 accounts for the latter phenomenon: first, the primary radioactive product isolated from supernatants of cultures loaded with [3H]-NA was the metabolite [3H]-DHPG; and second, inhibition of MAO significantly reduced the radioactive outflow in response to cyanine 863. The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related transmembrane transporters. However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action. The MPP+-induced release of [3H]-MPP+ was fully prevented by a combined application of desipramine and cyanine 863. No trans-stimulation of [3H]-MPP+ outflow was observed by the OCTN1 and OCTN2 substrate carnitine at 100 microM. Our observations indicate an OCT-mediated transmembrane transport of [3H]-MPP+. Amongst the three OCTs expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [3H]-MPP+ release.
12181285	1671	1675	MPP+	CHEMICAL	12181285T10
12181285	1748	1752	MPP+	CHEMICAL	12181285T11
12181285	1772	1781	[3H]-MPP+	CHEMICAL	12181285T12
12181285	1831	1842	desipramine	CHEMICAL	12181285T13
12181285	1884	1893	[3H]-MPP+	CHEMICAL	12181285T14
12181285	2042	2051	[3H]-MPP+	CHEMICAL	12181285T15
12181285	2223	2232	[3H]-MPP+	CHEMICAL	12181285T16
12181285	110	123	noradrenaline	CHEMICAL	12181285T17
12181285	125	127	NA	CHEMICAL	12181285T18
12181285	638	670	[3H]-N-methyl-4-phenylpyridinium	CHEMICAL	12181285T19
12181285	1221	1228	[3H]-NA	CHEMICAL	12181285T1
12181285	672	681	[3H]-MPP+	CHEMICAL	12181285T20
12181285	783	794	desipramine	CHEMICAL	12181285T21
12181285	799	808	reserpine	CHEMICAL	12181285T22
12181285	842	853	desipramine	CHEMICAL	12181285T23
12181285	891	901	oestradiol	CHEMICAL	12181285T24
12181285	906	920	corticosterone	CHEMICAL	12181285T25
12181285	1009	1016	[3H]-NA	CHEMICAL	12181285T26
12181285	1285	1288	MAO	GENE-N	12181285T27
12181285	204	229	noradrenaline transporter	GENE-Y	12181285T28
12181285	1486	1489	OCT	GENE-N	12181285T29
12181285	1248	1257	[3H]-DHPG	CHEMICAL	12181285T2
12181285	1498	1524	transmembrane transporters	GENE-N	12181285T30
12181285	231	234	NAT	GENE-Y	12181285T31
12181285	1692	1695	NAT	GENE-Y	12181285T32
12181285	1707	1710	OCT	GENE-N	12181285T33
12181285	1922	1927	OCTN1	GENE-Y	12181285T34
12181285	1932	1937	OCTN2	GENE-Y	12181285T35
12181285	2002	2005	OCT	GENE-N	12181285T36
12181285	2071	2075	OCTs	GENE-N	12181285T37
12181285	2098	2102	OCT3	GENE-Y	12181285T38
12181285	305	333	organic cation transporter 3	GENE-Y	12181285T39
12181285	204	217	noradrenaline	CHEMICAL	12181285T3
12181285	335	339	OCT3	GENE-Y	12181285T40
12181285	452	493	novel organic cation transporters 1 and 2	GENE-N	12181285T41
12181285	495	500	OCTN1	GENE-Y	12181285T42
12181285	505	510	OCTN2	GENE-Y	12181285T43
12181285	525	529	OCT1	GENE-Y	34002
12181285	533	537	OCT2	GENE-Y	12181285T45
12181285	573	576	NAT	GENE-Y	12181285T46
12181285	862	866	OCT3	GENE-Y	12181285T47
12181285	0	26	Organic cation transporter	GENE-N	12181285T48
12181285	1378	1387	[3H]-MPP+	CHEMICAL	12181285T4
12181285	1418	1422	MPP+	CHEMICAL	12181285T5
12181285	1424	1433	guanidine	CHEMICAL	12181285T6
12181285	1435	1442	choline	CHEMICAL	12181285T7
12181285	1447	1457	amantadine	CHEMICAL	12181285T8
12181285	1535	1546	desipramine	CHEMICAL	12181285T9
12181285	CPR:4	12181285T24	12181285T47
12181285	CPR:4	12181285T25	12181285T47
12181285	CPR:9	12181285T10	12181285T32
12181285	CPR:9	12181285T15	12181285T36
12181285	CPR:9	12181285T16	12181285T37
12181285	CPR:9	12181285T16	12181285T38
12181285	CPR:9	12181285T17	12181285T28
12181285	CPR:9	12181285T17	12181285T31
12181285	CPR:9	12181285T18	12181285T28
12181285	CPR:9	12181285T18	12181285T31
12181285	CPR:9	12181285T4	12181285T29
12181285	CPR:9	12181285T4	12181285T30
12181285	CPR:9	12181285T5	12181285T29
12181285	CPR:9	12181285T5	12181285T30
12181285	CPR:9	12181285T6	12181285T29
12181285	CPR:9	12181285T6	12181285T30
12181285	CPR:9	12181285T7	12181285T29
12181285	CPR:9	12181285T7	12181285T30
12181285	CPR:9	12181285T8	12181285T29
12181285	CPR:9	12181285T8	12181285T30

12200198|t|Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes.
12200198|a|In Parkinson's disease (PD), therapies to delay or suppress the progression of cell death in nigrostriatal dopamine neurons have been proposed by use of various agents. An inhibitor of type B monoamine oxidase (MAO-B), (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it. However, the animal and cellular models of PD proved that selegiline protects neurons from cell death. Among selegiline-related propargylamines, (R)(+)-N-propargyl-1-aminoindan (rasagiline) was the most effective to suppress the cell death in in vivo and in vitro experiments. In this paper, the mechanism of the neuroprotection by rasagiline was examined using human dopaminergic SH-SY5Y cells against cell death induced by an endogenous dopaminergic neurotoxin N-methyl(R)salsolinol (NM(R)Sal). NM(R)Sal induced apoptosis (but not necrosis) in SH-SY5Y cells, and the apoptotic cascade was initiated by mitochondrial permeability transition (PT) and activated by stepwise reactions. Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF). Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and catalase in the brain regions containing dopamine neurons. Rasagiline and related propargylamines may rescue degenerating dopamine neurons through inhibiting death signal transduction initiated by mitochondria PT.
12200198	339	350	(-)deprenyl	CHEMICAL	12200198T10
12200198	352	362	selegiline	CHEMICAL	12200198T11
12200198	512	522	selegiline	CHEMICAL	12200198T12
12200198	563	573	selegiline	CHEMICAL	12200198T13
12200198	582	597	propargylamines	CHEMICAL	12200198T14
12200198	599	630	(R)(+)-N-propargyl-1-aminoindan	CHEMICAL	12200198T15
12200198	632	642	rasagiline	CHEMICAL	12200198T16
12200198	786	796	rasagiline	CHEMICAL	12200198T17
12200198	917	938	N-methyl(R)salsolinol	CHEMICAL	12200198T18
12200198	940	948	NM(R)Sal	CHEMICAL	12200198T19
12200198	1138	1148	Rasagiline	CHEMICAL	1329
12200198	951	959	NM(R)Sal	CHEMICAL	12200198T20
12200198	19	34	propargylamines	CHEMICAL	12200198T21
12200198	1246	1251	Bcl-2	GENE-Y	12200198T22
12200198	1258	1277	neurotrophic factor	GENE-N	12200198T23
12200198	1279	1322	glial cell line-derived neurotrophic factor	GENE-Y	12200198T24
12200198	1324	1328	GDNF	GENE-Y	108936
12200198	1433	1453	superoxide dismutase	GENE-N	12200198T26
12200198	1455	1458	SOD	GENE-N	12200198T27
12200198	1464	1472	catalase	GENE-Y	12200198T28
12200198	305	329	type B monoamine oxidase	GENE-Y	12200198T29
12200198	227	235	dopamine	CHEMICAL	12200198T2
12200198	331	336	MAO-B	GENE-Y	12200198T30
12200198	1359	1374	propargylamines	CHEMICAL	12200198T3
12200198	1433	1443	superoxide	CHEMICAL	12200198T4
12200198	1505	1513	dopamine	CHEMICAL	12200198T5
12200198	1523	1533	Rasagiline	CHEMICAL	1329
12200198	1546	1561	propargylamines	CHEMICAL	12200198T7
12200198	1586	1594	dopamine	CHEMICAL	12200198T8
12200198	312	321	monoamine	CHEMICAL	12200198T9
12200198	CPR:3	1329	12200198T22
12200198	CPR:3	1329	12200198T23
12200198	CPR:3	1329	12200198T24
12200198	CPR:3	1329	108936
12200198	CPR:3	12200198T3	12200198T26
12200198	CPR:3	12200198T3	12200198T27
12200198	CPR:3	12200198T3	12200198T28
12200198	CPR:4	12200198T10	12200198T29
12200198	CPR:4	12200198T10	12200198T30
12200198	CPR:4	12200198T11	12200198T29
12200198	CPR:4	12200198T11	12200198T30

12213119|t|Pharmacodynamics and pharmacokinetics of phenylbutazone in calves.
12213119|a|Phenylbutazone (PBZ) was administered to six calves intravenously (i.v.) and orally at a dose rate of 4.4 mg/kg in a three-period cross-over study incorporating a placebo treatment to establish its pharmacokinetic and pharmacodynamic properties. Extravascular distribution was determined by measuring penetration into tissue chamber fluid in the absence of stimulation (transudate) and after stimulation of chamber tissue with the mild irritant carrageenan (exudate). PBZ pharmacokinetics after i.v. dosage was characterized by slow clearance (1.29 mL/kg/h), long-terminal half-life (53.4 h), low distribution volume (0.09 L/kg) and low concentrations in plasma of the metabolite oxyphenbutazone (OPBZ), confirming previously published data for adult cattle. After oral dosage bioavailability (F) was 66%. Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL. These concentrations were approximately 15-20 (plasma) and nine (exudate) times greater than those previously reported in horses (receiving the same dose rate of PBZ). In the horse, the lower concentrations had produced marked inhibition of eicosanoid synthesis and suppressed the inflammatory response. The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling. These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (COX) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors. To achieve clinical efficacy with single doses of PBZ in calves, higher dosages than 4.4 mg/kg will be probably required.
12213119	1904	1907	PBZ	CHEMICAL	782
12213119	1920	1924	OPBZ	CHEMICAL	12213119T11
12213119	1961	1964	PBZ	CHEMICAL	782
12213119	2040	2043	PBZ	CHEMICAL	782
12213119	2191	2194	PBZ	CHEMICAL	782
12213119	535	538	PBZ	CHEMICAL	782
12213119	747	762	oxyphenbutazone	CHEMICAL	12213119T16
12213119	764	768	OPBZ	CHEMICAL	12213119T17
12213119	41	55	phenylbutazone	CHEMICAL	12213119T18
12213119	1616	1634	beta-glucuronidase	GENE-Y	12213119T19
12213119	67	81	Phenylbutazone	CHEMICAL	802
12213119	1714	1724	bradykinin	GENE-Y	12213119T20
12213119	2051	2066	cyclo-oxygenase	GENE-N	12213119T21
12213119	2068	2071	COX	GENE-N	12213119T22
12213119	2085	2090	COX-1	GENE-Y	12213119T23
12213119	2095	2100	COX-2	GENE-Y	12213119T24
12213119	1336	1339	PBZ	CHEMICAL	782
12213119	1565	1581	prostaglandin E2	CHEMICAL	12213119T3
12213119	1583	1587	PGE2	CHEMICAL	907
12213119	1590	1604	leukotriene B4	CHEMICAL	12213119T5
12213119	1606	1610	LTB4	CHEMICAL	12213119T6
12213119	83	86	PBZ	CHEMICAL	782
12213119	1687	1701	thromboxane B2	CHEMICAL	12213119T8
12213119	1703	1707	TxB2	CHEMICAL	12213119T9

12227806|t|Practical asymmetric synthesis of aprepitant, a potent human NK-1 receptor antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.
12227806|a|A streamlined and high-yielding synthesis of aprepitant (1), a potent substance P (SP) receptor antagonist, is described. The enantiopure oxazinone 16 starting material was synthesized via a novel crystallization-induced dynamic resolution process. Conversion of 16 to the penultimate intermediate cis-sec-amine 9 features a highly stereoselective Lewis acid-catalyzed trans acetalization of chiral alcohol 3 with trichloroacetimidate 18 followed by inversion of the adjacent chiral center on the morpholine ring. The six-step process for the synthesis of 9 was accomplished in extremely high overall yield (81%) and with only two isolations.
12227806	230	255	substance P (SP) receptor	GENE-Y	12227806T10
12227806	61	74	NK-1 receptor	GENE-Y	12227806T11
12227806	298	307	oxazinone	CHEMICAL	12227806T1
12227806	458	471	cis-sec-amine	CHEMICAL	12227806T2
12227806	552	566	chiral alcohol	CHEMICAL	12227806T3
12227806	574	594	trichloroacetimidate	CHEMICAL	12227806T4
12227806	205	215	aprepitant	CHEMICAL	663
12227806	657	667	morpholine	CHEMICAL	12227806T6
12227806	230	241	substance P	CHEMICAL	12227806T7
12227806	243	245	SP	CHEMICAL	12227806T8
12227806	34	44	aprepitant	CHEMICAL	663
12227806	CPR:6	663	12227806T10
12227806	CPR:6	663	12227806T11

12297509|t|Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors.
12297509|a|Platelet responses at sites of vascular injury are regulated by intracellular cAMP levels, which rise rapidly when prostacyclin (PGI(2)) is released from endothelial cells. Platelet agonists such as ADP and epinephrine suppress PGI(2)-stimulated cAMP formation by activating receptors coupled to G(i) family members, four of which are present in platelets. To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP. As reported previously, loss of G(i2)alpha or G(z)alpha inhibited aggregation in response to ADP and epinephrine, respectively, producing defects that could not be reversed by adding an adenylyl cyclase inhibitor. Platelets that lacked both G(i2)alpha and G(z)alpha showed impaired responses to both agonists, but the impairment was no greater than in the individual knockouts. Loss of G(i3)alpha had no effect either alone or in combination with G(z)alpha. Loss of either G(z)alpha or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not. Conversely, deletion of IP abolished responses to PGI(2) and caused cAMP levels to fall by 30%, effects that did not translate into enhanced responsiveness to agonists ex vivo. From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3). Finally, the failure of ADP and epinephrine to inhibit basal, as opposed to PGI(2)-stimulated, cAMP formation highlights the need during platelet activation for G(i) signaling pathways that involve effectors other than adenylyl cyclase.
12297509	1813	1817	cAMP	CHEMICAL	2424
12297509	1932	1943	epinephrine	CHEMICAL	12297509T11
12297509	1971	1974	ADP	CHEMICAL	12297509T12
12297509	335	338	ADP	CHEMICAL	12297509T13
12297509	2164	2167	ADP	CHEMICAL	12297509T14
12297509	2172	2183	epinephrine	CHEMICAL	12297509T15
12297509	2216	2222	PGI(2)	CHEMICAL	12297509T16
12297509	2235	2239	cAMP	CHEMICAL	2424
12297509	2359	2367	adenylyl	CHEMICAL	12297509T18
12297509	364	370	PGI(2)	CHEMICAL	12297509T19
12297509	251	263	prostacyclin	CHEMICAL	12297509T1
12297509	382	386	cAMP	CHEMICAL	2424
12297509	586	590	cAMP	CHEMICAL	2424
12297509	676	684	adenylyl	CHEMICAL	12297509T22
12297509	896	902	PGI(2)	CHEMICAL	12297509T23
12297509	214	218	cAMP	CHEMICAL	2424
12297509	1010	1013	ADP	CHEMICAL	12297509T25
12297509	1018	1029	epinephrine	CHEMICAL	12297509T26
12297509	1103	1111	adenylyl	CHEMICAL	12297509T27
12297509	98	106	adenylyl	CHEMICAL	12297509T28
12297509	1158	1168	G(i2)alpha	GENE-Y	12297509T29
12297509	265	271	PGI(2)	CHEMICAL	12297509T2
12297509	1173	1182	G(z)alpha	GENE-Y	12297509T30
12297509	1303	1313	G(i3)alpha	GENE-Y	12297509T31
12297509	1364	1373	G(z)alpha	GENE-Y	12297509T32
12297509	1390	1399	G(z)alpha	GENE-Y	12297509T33
12297509	1403	1413	G(i2)alpha	GENE-Y	12297509T34
12297509	1487	1503	adenylyl cyclase	GENE-N	12297509T35
12297509	1577	1587	G(i3)alpha	GENE-Y	12297509T36
12297509	1621	1623	IP	GENE-Y	12297509T37
12297509	1884	1889	G(i2)	GENE-N	12297509T38
12297509	1891	1895	G(z)	GENE-N	12297509T39
12297509	1438	1441	ADP	CHEMICAL	12297509T3
12297509	1901	1903	IP	GENE-Y	12297509T40
12297509	1913	1918	G(i3)	GENE-N	12297509T41
12297509	1944	1965	(alpha(2A)-adrenergic	GENE-Y	12297509T42
12297509	1976	1981	P2Y12	GENE-Y	12297509T43
12297509	2026	2030	G(i)	GENE-N	12297509T44
12297509	2133	2138	G(i3)	GENE-N	12297509T45
12297509	2301	2305	G(i)	GENE-N	12297509T46
12297509	2359	2375	adenylyl cyclase	GENE-N	12297509T47
12297509	432	436	G(i)	GENE-N	12297509T48
12297509	548	557	G protein	GENE-N	12297509T49
12297509	1446	1457	epinephrine	CHEMICAL	12297509T4
12297509	633	637	G(i)	GENE-N	12297509T50
12297509	676	692	adenylyl cyclase	GENE-N	12297509T51
12297509	810	814	G(i)	GENE-N	12297509T52
12297509	896	911	PGI(2) receptor	GENE-Y	12297509T53
12297509	913	915	IP	GENE-Y	12297509T54
12297509	949	959	G(i2)alpha	GENE-Y	12297509T55
12297509	963	972	G(z)alpha	GENE-Y	12297509T56
12297509	1103	1119	adenylyl cyclase	GENE-N	12297509T57
12297509	18	20	Gi	GENE-N	12297509T58
12297509	98	114	adenylyl cyclase	GENE-N	12297509T59
12297509	1469	1475	PGI(2)	CHEMICAL	12297509T5
12297509	1487	1495	adenylyl	CHEMICAL	12297509T6
12297509	1548	1552	cAMP	CHEMICAL	2424
12297509	1647	1653	PGI(2)	CHEMICAL	12297509T8
12297509	1665	1669	cAMP	CHEMICAL	2424

12375053|t|Effects of pentosan polysulfate sodium on the estrogen-induced pituitary prolactinoma in Fischer 344 rats.
12375053|a|The development of estrogen-induced pituitary prolactinoma in Fischer 344 (F344) rats is associated with enhanced neovascularization. This type of tumor is a rich source of basic fibroblast growth factor (bFGF), which possesses strong mitogenic and angiogenic properties. Pentosan polysulfate sodium (PPS) has been shown to exert antitumor activity by antagonizing the binding of bFGF to cell surface receptors. We have examined the effects of pentosan on tumor growth, hyperprolactinemia and angiogenesis in diethylstilbestrol-induced anterior pituitary adenoma in F344 rats. Chronic treatment with PPS did not cause any changes in the pituitary weight and serum prolactin concentration in comparison with untreated animals. The density of microvessels identified by CD-31 was also not affected by the tested drug. On the other hand, pentosan has been found to decrease cell proliferation evaluated by a number of PCNA-positive stained cell nuclei. Moreover, the TUNEL method has revealed an increased number of apoptotic bodies within the anterior pituitary after treatment with PPS. Despite the antiproliferative and proapoptotic activity of pentosan, the drug failed to inhibit tumor growth. This fact might be due to the lack of antiangiogenic activity of PPS in this experimental design.
12375053	126	134	estrogen	CHEMICAL	12375053T1
12375053	400	406	sodium	CHEMICAL	12375053T2
12375053	616	634	diethylstilbestrol	CHEMICAL	12375053T3
12375053	32	38	sodium	CHEMICAL	12375053T4
12375053	46	54	estrogen	CHEMICAL	12375053T5
12375053	280	310	basic fibroblast growth factor	GENE-Y	12375053T6
12375053	312	316	bFGF	GENE-Y	12375053T7
12375053	487	491	bFGF	GENE-Y	12375053T8
12375053	CPR:6	12375053T2	12375053T8

12388412|t|Localization of the ammonium transporter proteins RhBG and RhCG in mouse kidney.
12388412|a|Ammonia is both produced and transported by renal epithelial cells, and it regulates renal ion transport. Recent studies have identified a family of putative ammonium transporters; mRNA for two members of this family, Rh B-glycoprotein (RhBG) and Rh C-glycoprotein (RhCG), is expressed in the kidney. The purpose of this study was to determine the cellular location of RhBG and RhCG protein in the mouse kidney. We generated RhBG- and RhCG-specific anti-peptide antibodies. Immunoblot analysis confirmed that both proteins were expressed in the mouse kidney. RhBG localization with immunohistochemistry revealed discrete basolateral labeling in the connecting segment (CNT) and in the majority of initial collecting tubule (ICT) and cortical collecting duct (CCD) cells. In the outer medullary collecting duct (OMCD) and inner medullary collecting duct (IMCD) only a subpopulation of cells exhibited basolateral immunoreactivity. Colocalization of RhBG with carbonic anhydrase II, the thiazide-sensitive transporter, and the anion exchangers AE1 and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells. In the ICT and CCD, basolateral RhBG immunoreactivity is also present in A-type intercalated cells but not in pendrin-positive CCD intercalated cells. In the OMCD and IMCD, only intercalated cells exhibit RhBG immunoreactivity. Immunoreactivity for a second putative ammonium transporter, RhCG, was present in the apical region of cells with almost the same distribution as RhBG. However, RhCG immunoreactivity was present in all CCD cells, and it was present in outer stripe OMCD principal cells, in addition to OMCD and IMCD intercalated cells. Thus the majority of RhBG and RhCG protein expression is present in the same epithelial cell types in the CNT and collecting duct but with opposite polarity. These findings suggest that RhBG and RhCG may play important and cell-specific roles in ammonium transport and signaling in these regions of the kidney.
12388412	1152	1156	RhBG	GENE-Y	12388412T10
12388412	1260	1264	RhBG	GENE-Y	12388412T11
12388412	1338	1345	pendrin	GENE-Y	12388412T12
12388412	1433	1437	RhBG	GENE-Y	12388412T13
12388412	1495	1515	ammonium transporter	GENE-N	12388412T14
12388412	1517	1521	RhCG	GENE-Y	12388412T15
12388412	1602	1606	RhBG	GENE-Y	12388412T16
12388412	1617	1621	RhCG	GENE-Y	12388412T17
12388412	239	260	ammonium transporters	GENE-N	12388412T18
12388412	1796	1800	RhBG	GENE-Y	12388412T19
12388412	81	88	Ammonia	CHEMICAL	12388412T1
12388412	1805	1809	RhCG	GENE-Y	12388412T20
12388412	1961	1965	RhBG	GENE-Y	12388412T21
12388412	1970	1974	RhCG	GENE-Y	12388412T22
12388412	299	316	Rh B-glycoprotein	GENE-Y	12388412T23
12388412	318	322	RhBG	GENE-Y	12388412T24
12388412	328	345	Rh C-glycoprotein	GENE-Y	12388412T25
12388412	347	351	RhCG	GENE-Y	12388412T26
12388412	450	454	RhBG	GENE-Y	12388412T27
12388412	459	463	RhCG	GENE-Y	12388412T28
12388412	506	510	RhBG	GENE-Y	12388412T29
12388412	1495	1503	ammonium	CHEMICAL	12388412T2
12388412	516	520	RhCG	GENE-Y	12388412T30
12388412	640	644	RhBG	GENE-Y	12388412T31
12388412	1029	1033	RhBG	GENE-Y	12388412T32
12388412	1039	1060	carbonic anhydrase II	GENE-Y	12388412T33
12388412	20	49	ammonium transporter proteins	GENE-N	12388412T34
12388412	50	54	RhBG	GENE-Y	12388412T35
12388412	59	63	RhCG	GENE-Y	12388412T36
12388412	239	247	ammonium	CHEMICAL	12388412T3
12388412	2021	2029	ammonium	CHEMICAL	12388412T4
12388412	1066	1074	thiazide	CHEMICAL	12388412T5
12388412	20	28	ammonium	CHEMICAL	12388412T6
12388412	1106	1122	anion exchangers	GENE-N	12388412T7
12388412	1123	1126	AE1	GENE-Y	12388412T8
12388412	1131	1138	pendrin	GENE-Y	12388412T9
12388412	CPR:9	12388412T4	12388412T21
12388412	CPR:9	12388412T4	12388412T22

12414329|t|Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
12414329|a|The scientific rationale of pharmacologically inhibiting phosphodiesterase type 5 (PDE5) in the treatment of erectile dysfunction (ED) is reviewed. Published literature on the nitric oxide-cyclic guanosine monophosphate (cGMP) pathway for penile erection and on PDE5 inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed. The key second messenger in the mediation of penile erection is cGMP. PDE5 is the predominant PDE in the corpus cavernosum, and cGMP is its primary substrate. Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of cGMP-specific PDE5 is a means of improving erectile function at minimal risk of adverse events. This approach is validated by the clinical efficacy and safety of sildenafil, the pioneering drug for selective PDE5 inhibitor therapy for ED. Sildenafil exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods. Thus, its pharmacologic profile is predictable, with close correlation between pharmacodynamic and pharmacokinetic properties. Clinically, sildenafil improves erectile function in a large percentage of men with ED. The most common adverse events are due to PDE5 inhibition in vascular and visceral smooth muscle; similar adverse events are expected during therapeutic use of all PDE5 inhibitors. As free sildenafil plasma concentrations approach concentrations sufficient to inhibit retinal PDE6, usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently. Selective inhibition of PDE5 is a rational therapeutic approach in ED, as proved by the clinical success of sildenafil.
12414329	854	864	sildenafil	CHEMICAL	12414329T10
12414329	931	941	Sildenafil	CHEMICAL	196
12414329	1083	1086	PDE	GENE-N	12414329T12
12414329	1386	1390	PDE5	GENE-Y	12414329T13
12414329	1508	1512	PDE5	GENE-Y	12414329T14
12414329	1620	1624	PDE6	GENE-N	12414329T15
12414329	1763	1767	PDE5	GENE-Y	12414329T16
12414329	338	342	PDE5	GENE-Y	12414329T17
12414329	402	406	PDE5	GENE-Y	12414329T18
12414329	502	506	PDE5	GENE-Y	12414329T19
12414329	1268	1278	sildenafil	CHEMICAL	12414329T1
12414329	526	529	PDE	GENE-N	12414329T20
12414329	133	157	phosphodiesterase type 5	GENE-Y	12414329T21
12414329	706	710	PDE5	GENE-Y	12414329T22
12414329	900	904	PDE5	GENE-Y	12414329T23
12414329	159	163	PDE5	GENE-Y	12414329T24
12414329	978	982	PDE5	GENE-Y	12414329T25
12414329	1061	1065	PDE6	GENE-N	12414329T26
12414329	0	24	Phosphodiesterase type 5	GENE-Y	12414329T27
12414329	1533	1543	sildenafil	CHEMICAL	12414329T2
12414329	252	264	nitric oxide	CHEMICAL	12414329T3
12414329	1847	1857	sildenafil	CHEMICAL	12414329T4
12414329	265	295	cyclic guanosine monophosphate	CHEMICAL	12414329T5
12414329	297	301	cGMP	CHEMICAL	12414329T6
12414329	560	564	cGMP	CHEMICAL	12414329T7
12414329	631	635	cGMP	CHEMICAL	12414329T8
12414329	692	696	cGMP	CHEMICAL	12414329T9
12414329	CPR:4	12414329T10	12414329T23
12414329	CPR:4	196	12414329T12
12414329	CPR:4	196	12414329T25
12414329	CPR:4	196	12414329T26
12414329	CPR:4	12414329T2	12414329T15
12414329	CPR:4	12414329T4	12414329T16
12414329	CPR:4	12414329T9	12414329T22
12414329	CPR:9	12414329T7	12414329T19
12414329	CPR:9	12414329T7	12414329T20

12421359|t|Study of the nematode putative GABA type-A receptor subunits: evidence for modulation by ivermectin.
12421359|a|Two alleles of the HG1 gene, which encodes a putative GABA receptor alpha/gamma subunit, were isolated from Haemonchus contortus. These two alleles were shown previously to be associated with ivermectin susceptibility (HG1A) and resistance (HG1E), respectively. Sequence analysis indicates that they differ in four amino acids. To explore the functional properties of the two alleles, a full-length cDNA encoding the beta subunit, a key functional component of the GABA receptor, was isolated from Caenorhabditis elegans (gab-1, corresponding to the GenBank locus ZC482.1) and coexpressed in Xenopus oocytes with the HG1 alleles. When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid (GABA)-responsive channels with different sensitivity to the agonist were formed. The effects of ivermectin on the hetero-oligomeric receptors were determined. Application of ivermectin alone had no effect on the receptors. However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor. We demonstrated that the coexpressed HG1 and GAB-1 receptors are GABA-responsive, and provide evidence for the possible involvement of GABA receptors in the mechanism of ivermectin resistance.
12421359	566	570	GABA	CHEMICAL	12421359T10
12421359	155	159	GABA	CHEMICAL	12421359T11
12421359	825	848	gamma-aminobutyric acid	CHEMICAL	12421359T12
12421359	850	854	GABA	CHEMICAL	12421359T13
12421359	946	956	ivermectin	CHEMICAL	592
12421359	1024	1034	ivermectin	CHEMICAL	592
12421359	31	35	GABA	CHEMICAL	12421359T16
12421359	89	99	ivermectin	CHEMICAL	592
12421359	1173	1178	GAB-1	GENE-Y	12421359T18
12421359	1179	1183	HG1A	GENE-Y	12421359T19
12421359	1113	1117	GABA	CHEMICAL	12421359T1
12421359	1234	1239	GAB-1	GENE-Y	12421359T20
12421359	1240	1244	HG1E	GENE-Y	12421359T21
12421359	1292	1295	HG1	GENE-Y	12421359T22
12421359	1300	1305	GAB-1	GENE-Y	12421359T23
12421359	1390	1404	GABA receptors	GENE-N	12421359T24
12421359	120	123	HG1	GENE-Y	12421359T25
12421359	320	324	HG1A	GENE-Y	12421359T26
12421359	342	346	HG1E	GENE-Y	12421359T27
12421359	566	579	GABA receptor	GENE-N	12421359T28
12421359	623	628	gab-1	GENE-Y	41867
12421359	1119	1129	ivermectin	CHEMICAL	592
12421359	155	180	GABA receptor alpha/gamma	GENE-N	12421359T30
12421359	651	672	GenBank locus ZC482.1	GENE-Y	12421359T31
12421359	718	721	HG1	GENE-Y	12421359T32
12421359	736	741	gab-1	GENE-Y	41867
12421359	774	778	HG1A	GENE-Y	12421359T34
12421359	793	797	HG1E	GENE-Y	12421359T35
12421359	825	875	gamma-aminobutyric acid (GABA)-responsive channels	GENE-N	12421359T36
12421359	31	51	GABA type-A receptor	GENE-N	12421359T37
12421359	1146	1150	GABA	CHEMICAL	12421359T3
12421359	1213	1217	GABA	CHEMICAL	12421359T4
12421359	1320	1324	GABA	CHEMICAL	12421359T5
12421359	1390	1394	GABA	CHEMICAL	12421359T6
12421359	1425	1435	ivermectin	CHEMICAL	592
12421359	293	303	ivermectin	CHEMICAL	592
12421359	416	427	amino acids	CHEMICAL	12421359T9
12421359	CPR:3	592	12421359T18
12421359	CPR:3	592	12421359T19
12421359	CPR:4	592	12421359T20
12421359	CPR:4	592	12421359T21

12438517|t|Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype.
12438517|a|Yohimbine is a potent and selective alpha2- versus alpha1-adrenoceptor antagonist. To date, drugs with high specificity for the alpha2-adrenoceptor show marginal selectivity among the three alpha2-adrenoceptor subtypes. Initial studies showed that yohimbine was about 4- and 15-fold more selective for the human alpha2C-adrenoceptor in comparison with the alpha2A- and alpha2B-adrenoceptors, respectively. To improve on this alpha2-adrenoceptor subtype selectivity, a series of yohimbine dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on human alpha2-adrenoceptor subtypes expressed in Chinese hamster ovary cells. Each dimeric analog showed higher affinities for alpha2A- and alpha2C-adrenoceptor versus the alpha2B-adrenoceptor; and yohimbine dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the alpha2C-adrenoceptor. The yohimbine dimers n = 3 and n = 24 showed the highest potency and selectivity (32- and 82-fold. respectively) for the alpha2C-adrenoceptor in receptor binding and in functional studies (42- and 29-fold, respectively) measuring cAMP changes using a cell-based luciferase reporter gene assay. The dimers (n = 3 and n = 24) had high selectivity (>1000-fold) for the alpha2C-adrenoceptor compared with the three alpha1-adrenoceptor subtypes. These findings demonstrate that the addition of spacer linkages to bivalent yohimbine molecules provides a successful approach to the development of ligands that are potent and highly selective for the alpha2C-adrenoceptor.
12438517	1344	1364	alpha2C-adrenoceptor	GENE-Y	12438517T10
12438517	213	232	alpha2-adrenoceptor	GENE-N	12438517T11
12438517	1389	1408	alpha1-adrenoceptor	GENE-N	12438517T12
12438517	1621	1641	alpha2C-adrenoceptor	GENE-Y	12438517T13
12438517	275	294	alpha2-adrenoceptor	GENE-N	12438517T14
12438517	391	417	human alpha2C-adrenoceptor	GENE-Y	12438517T15
12438517	441	475	alpha2A- and alpha2B-adrenoceptors	GENE-N	12438517T16
12438517	121	155	alpha2- versus alpha1-adrenoceptor	GENE-N	12438517T17
12438517	510	529	alpha2-adrenoceptor	GENE-N	12438517T18
12438517	672	697	human alpha2-adrenoceptor	GENE-N	12438517T19
12438517	85	94	Yohimbine	CHEMICAL	1342
12438517	798	831	alpha2A- and alpha2C-adrenoceptor	GENE-N	12438517T20
12438517	843	863	alpha2B-adrenoceptor	GENE-Y	12438517T21
12438517	956	976	alpha2C-adrenoceptor	GENE-Y	12438517T22
12438517	48	75	human alpha 2C-adrenoceptor	GENE-Y	12438517T23
12438517	1208	1212	cAMP	CHEMICAL	2424
12438517	1495	1504	yohimbine	CHEMICAL	12438517T3
12438517	333	342	yohimbine	CHEMICAL	12438517T4
12438517	563	572	yohimbine	CHEMICAL	12438517T5
12438517	869	878	yohimbine	CHEMICAL	12438517T6
12438517	982	991	yohimbine	CHEMICAL	12438517T7
12438517	0	9	Yohimbine	CHEMICAL	1342
12438517	1099	1119	alpha2C-adrenoceptor	GENE-Y	12438517T9
12438517	CPR:6	1342	12438517T17

12470615|t|Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
12470615|a|The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans. Recently, it was shown that plasmacytoid dendritic cells (pDC) are the primary interferon-producing cells in the blood in response to viral infections. Here, we characterize the activation of human pDC with the TLR7 agonists imiquimod and resiquimod. Results indicate that imiquimod and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood. Resiquimod-stimulated pDC also produce a number of other cytokines including TNF-alpha and IP-10. Resiquimod enhances co-stimulatory marker expression, CCR7 expression, and pDC viability. Resiquimod was compared throughout the study to the pDC survival factors, IL-3 and IFN-alpha; resiquimod more effectively matures pDC than either IL-3 or IFN-alpha alone. These results demonstrate that imidazoquinoline molecules directly induce pDC maturation as determined by cytokine induction, CCR7 and co-stimulatory marker expression and prolonging viability.
12470615	952	962	resiquimod	CHEMICAL	12470615T10
12470615	1060	1076	imidazoquinoline	CHEMICAL	12470615T11
12470615	106	116	resiquimod	CHEMICAL	12470615T12
12470615	92	101	imiquimod	CHEMICAL	12470615T13
12470615	1135	1143	cytokine	GENE-N	12470615T14
12470615	1155	1159	CCR7	GENE-Y	107641
12470615	341	351	interferon	GENE-N	12470615T16
12470615	473	477	TLR7	GENE-Y	119436
12470615	567	576	IFN-alpha	GENE-N	12470615T18
12470615	581	590	IFN-omega	GENE-N	12470615T19
12470615	149	158	imiquimod	CHEMICAL	12470615T1
12470615	636	639	IFN	GENE-N	12470615T20
12470615	727	736	cytokines	GENE-N	12470615T21
12470615	179	183	TLR7	GENE-Y	119436
12470615	747	756	TNF-alpha	GENE-Y	12470615T23
12470615	761	766	IP-10	GENE-Y	12470615T24
12470615	822	826	CCR7	GENE-Y	107641
12470615	932	936	IL-3	GENE-Y	12470615T26
12470615	941	950	IFN-alpha	GENE-N	12470615T27
12470615	205	222	type I interferon	GENE-N	12470615T28
12470615	1004	1008	IL-3	GENE-Y	12470615T29
12470615	487	496	imiquimod	CHEMICAL	12470615T2
12470615	1012	1021	IFN-alpha	GENE-N	12470615T30
12470615	37	46	cytokines	GENE-N	12470615T31
12470615	77	81	TLR7	GENE-Y	119436
12470615	501	511	resiquimod	CHEMICAL	12470615T3
12470615	535	544	imiquimod	CHEMICAL	12470615T4
12470615	549	559	resiquimod	CHEMICAL	12470615T5
12470615	163	173	resiquimod	CHEMICAL	12470615T6
12470615	670	680	Resiquimod	CHEMICAL	12470615T7
12470615	768	778	Resiquimod	CHEMICAL	12470615T8
12470615	858	868	Resiquimod	CHEMICAL	12470615T9
12470615	CPR:3	12470615T11	12470615T14
12470615	CPR:3	12470615T1	12470615T28
12470615	CPR:3	12470615T4	12470615T18
12470615	CPR:3	12470615T4	12470615T19
12470615	CPR:3	12470615T6	12470615T28
12470615	CPR:3	12470615T7	12470615T21
12470615	CPR:3	12470615T7	12470615T23
12470615	CPR:3	12470615T7	12470615T24
12470615	CPR:3	12470615T8	107641
12470615	CPR:5	12470615T12	119436
12470615	CPR:5	12470615T13	119436
12470615	CPR:5	12470615T1	119436
12470615	CPR:5	12470615T2	119436
12470615	CPR:5	12470615T3	119436
12470615	CPR:5	12470615T6	119436

12472888|t|Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.
12472888|a|Induction of heat shock proteins (HSPs) protects cells from oxidative injury. Here Hsp72, Hsp27 and heme oxygenase-1 (HO-1) were induced in cultured rat astrocytes, and protection against oxidative stress was investigated. Astrocytes were treated with sodium arsenite (20-50 micro m) for 1 h, which was non-toxic to cells, 24 h later they were exposed to 400 micro m H2O2 for 1 h, and cell death was evaluated at different time points. Arsenite triggered strong induction of HSPs, which was prevented by 1 micro g/mL cycloheximide (CXH). H2O2 caused cell loss and increased cell death with features of apoptosis, i.e. TdT-mediated dUTP nick-end labelling (TUNEL) reaction and caspase-3 activation. These features were abrogated by pre-treatment with arsenite, which prevented cell loss and significantly reduced the number of dead cells. The protective effect of arsenite was not detected in the presence of CHX. Pre-treatment with arsenite increased protein kinase B (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after H2O2. However, while Akt phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by CHX. The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2. It is suggested that HSP expression at the time of H2O2 exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro-survival Akt.
12472888	654	667	cycloheximide	CHEMICAL	12472888T10
12472888	669	672	CXH	CHEMICAL	12472888T11
12472888	675	679	H2O2	CHEMICAL	12472888T12
12472888	887	895	arsenite	CHEMICAL	12472888T13
12472888	1000	1008	arsenite	CHEMICAL	12472888T14
12472888	1045	1048	CHX	CHEMICAL	12472888T15
12472888	43	58	sodium arsenite	CHEMICAL	12472888T16
12472888	99	116	hydrogen peroxide	CHEMICAL	12472888T17
12472888	237	253	heme oxygenase-1	GENE-Y	12472888T18
12472888	1158	1164	ERK1/2	GENE-N	12472888T19
12472888	1188	1192	H2O2	CHEMICAL	12472888T1
12472888	1209	1212	Akt	GENE-N	12472888T20
12472888	1251	1257	Erk1/2	GENE-N	12472888T21
12472888	255	259	HO-1	GENE-Y	12472888T22
12472888	1366	1371	Hsp72	GENE-Y	12472888T23
12472888	1373	1377	HO-1	GENE-Y	12472888T24
12472888	1403	1408	Hsp27	GENE-Y	64473
12472888	150	169	heat shock proteins	GENE-N	12472888T26
12472888	1489	1492	Akt	GENE-N	12472888T27
12472888	1530	1533	HSP	GENE-N	12472888T28
12472888	1666	1669	Akt	GENE-N	12472888T29
12472888	1298	1301	CHX	CHEMICAL	12472888T2
12472888	171	175	HSPs	GENE-N	12472888T30
12472888	612	616	HSPs	GENE-N	12472888T31
12472888	813	822	caspase-3	GENE-Y	12472888T32
12472888	220	225	Hsp72	GENE-Y	12472888T33
12472888	227	232	Hsp27	GENE-Y	64473
12472888	1088	1104	protein kinase B	GENE-N	12472888T35
12472888	1106	1109	Akt	GENE-N	12472888T36
12472888	1115	1156	extracellular signal regulated kinase 1/2	GENE-N	12472888T37
12472888	13	32	heat shock proteins	GENE-N	12472888T38
12472888	34	38	HSPs	GENE-N	12472888T39
12472888	1335	1343	arsenite	CHEMICAL	12472888T3
12472888	1421	1425	H2O2	CHEMICAL	12472888T4
12472888	1503	1507	H2O2	CHEMICAL	12472888T5
12472888	1560	1564	H2O2	CHEMICAL	12472888T6
12472888	389	404	sodium arsenite	CHEMICAL	12472888T7
12472888	504	508	H2O2	CHEMICAL	12472888T8
12472888	573	581	Arsenite	CHEMICAL	12472888T9
12472888	CPR:3	12472888T12	12472888T32
12472888	CPR:3	12472888T16	12472888T38
12472888	CPR:3	12472888T16	12472888T39
12472888	CPR:3	12472888T1	12472888T35
12472888	CPR:3	12472888T1	12472888T36
12472888	CPR:3	12472888T3	12472888T23
12472888	CPR:3	12472888T3	12472888T24
12472888	CPR:3	12472888T3	64473
12472888	CPR:3	12472888T3	12472888T27
12472888	CPR:3	12472888T5	12472888T27
12472888	CPR:3	12472888T9	12472888T31
12472888	CPR:4	12472888T10	12472888T31
12472888	CPR:4	12472888T11	12472888T31
12472888	CPR:4	12472888T2	12472888T20

12487427|t|Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat.
12487427|a|Several studies have suggested that the accumulation of bradykinin, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various ACEi. In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial. In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe. In the presence of inhibitors, however, the levels of these resultant metabolites were different. Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found. In addition the production of BrBK1-8 was enhanced in the presence of these inhibitors with a greater accumulation being observed with omapatrilat. The production of Br-Phe5 was reduced with GW660511X while no significant change was observed with omapatrilat after 4 h of incubation. In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma. GW660511X and omapatrilat reduced the production of BrBK1-5 and BrBK1-7 with more effect being observed with omapatrilat. GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8. This study shows that the potency of GW660511X in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/NEP inhibition in relation to effects in humans.
12487427	1654	1661	BrBK1-8	CHEMICAL	12487427T10
12487427	1663	1670	BrBK1-7	CHEMICAL	12487427T11
12487427	1672	1679	BrBK1-5	CHEMICAL	12487427T12
12487427	1684	1691	Br-Phe5	CHEMICAL	12487427T13
12487427	1697	1704	BrBK2-9	CHEMICAL	12487427T14
12487427	1706	1713	BrBK4-8	CHEMICAL	12487427T15
12487427	1718	1725	BrBK2-8	CHEMICAL	12487427T16
12487427	1765	1774	GW660511X	CHEMICAL	12487427T17
12487427	1779	1790	omapatrilat	CHEMICAL	12487427T18
12487427	1817	1824	BrBK1-5	CHEMICAL	12487427T19
12487427	1186	1193	BrBK1-8	CHEMICAL	12487427T1
12487427	1829	1836	BrBK1-7	CHEMICAL	12487427T20
12487427	1874	1885	omapatrilat	CHEMICAL	12487427T21
12487427	1887	1896	GW660511X	CHEMICAL	12487427T22
12487427	1901	1912	omapatrilat	CHEMICAL	12487427T23
12487427	1946	1953	BrBK1-8	CHEMICAL	12487427T24
12487427	1958	1965	Br-Phe5	CHEMICAL	12487427T25
12487427	1982	1989	BrBK4-8	CHEMICAL	12487427T26
12487427	1994	2001	BrBK2-8	CHEMICAL	12487427T27
12487427	2040	2049	GW660511X	CHEMICAL	12487427T28
12487427	2069	2080	omapatrilat	CHEMICAL	12487427T29
12487427	1291	1302	omapatrilat	CHEMICAL	12487427T2
12487427	499	501	BK	CHEMICAL	12487427T30
12487427	509	516	Br-Phe5	CHEMICAL	12487427T31
12487427	518	522	BrBK	CHEMICAL	12487427T32
12487427	575	584	GW660511X	CHEMICAL	12487427T33
12487427	589	600	omapatrilat	CHEMICAL	12487427T34
12487427	654	658	BrBK	CHEMICAL	12487427T35
12487427	193	203	bradykinin	CHEMICAL	12487427T36
12487427	713	722	GW660511X	CHEMICAL	12487427T37
12487427	739	750	omapatrilat	CHEMICAL	12487427T38
12487427	831	835	BrBK	CHEMICAL	12487427T39
12487427	1322	1329	Br-Phe5	CHEMICAL	12487427T3
12487427	854	861	BrBK1-8	CHEMICAL	12487427T40
12487427	863	870	BrBK1-7	CHEMICAL	12487427T41
12487427	872	879	BrBK1-5	CHEMICAL	12487427T42
12487427	884	890	Br-Phe	CHEMICAL	12487427T43
12487427	997	1006	GW660511X	CHEMICAL	12487427T44
12487427	1008	1019	omapatrilat	CHEMICAL	12487427T45
12487427	1048	1055	BrBK1-5	CHEMICAL	12487427T46
12487427	1060	1067	BrBK1-7	CHEMICAL	12487427T47
12487427	1116	1125	GW660511X	CHEMICAL	12487427T48
12487427	110	119	GW660511X	CHEMICAL	12487427T49
12487427	1347	1356	GW660511X	CHEMICAL	12487427T4
12487427	124	135	omapatrilat	CHEMICAL	12487427T50
12487427	17	27	bradykinin	CHEMICAL	12487427T51
12487427	1186	1193	BrBK1-8	GENE-Y	12487427T52
12487427	1322	1329	Br-Phe5	GENE-Y	12487427T53
12487427	1458	1462	BrBK	GENE-Y	12487427T54
12487427	1631	1635	BrBK	GENE-Y	12487427T55
12487427	1654	1661	BrBK1-8	GENE-Y	12487427T56
12487427	1663	1670	BrBK1-7	GENE-Y	12487427T57
12487427	1672	1679	BrBK1-5	GENE-Y	12487427T58
12487427	1684	1691	Br-Phe5	GENE-Y	12487427T59
12487427	1403	1414	omapatrilat	CHEMICAL	12487427T5
12487427	1697	1704	BrBK2-9	GENE-Y	12487427T60
12487427	1706	1713	BrBK4-8	GENE-Y	12487427T61
12487427	1718	1725	BrBK2-8	GENE-N	12487427T62
12487427	1817	1824	BrBK1-5	GENE-Y	12487427T63
12487427	1829	1836	BrBK1-7	GENE-Y	12487427T64
12487427	1946	1953	BrBK1-8	GENE-N	12487427T65
12487427	1958	1965	Br-Phe5	GENE-N	12487427T66
12487427	1982	1989	BrBK4-8	GENE-N	12487427T67
12487427	1994	2001	BrBK2-8	GENE-N	12487427T68
12487427	335	338	ACE	GENE-Y	108004
12487427	1458	1462	BrBK	CHEMICAL	12487427T6
12487427	2240	2243	ACE	GENE-Y	108004
12487427	2244	2247	NEP	GENE-Y	12487427T71
12487427	499	501	BK	GENE-N	12487427T72
12487427	503	516	79/81 Br-Phe5	GENE-N	12487427T73
12487427	518	522	BrBK	GENE-N	12487427T74
12487427	555	558	ACE	GENE-N	108004
12487427	559	562	NEP	GENE-N	12487427T76
12487427	654	658	BrBK	GENE-Y	12487427T77
12487427	193	203	bradykinin	GENE-Y	12487427T78
12487427	831	835	BrBK	GENE-Y	12487427T79
12487427	1517	1526	GW660511X	CHEMICAL	12487427T7
12487427	854	861	BrBK1-8	GENE-Y	12487427T80
12487427	863	870	BrBK1-7	GENE-Y	12487427T81
12487427	872	879	BrBK1-5	GENE-Y	12487427T82
12487427	884	890	Br-Phe	GENE-Y	12487427T83
12487427	1048	1055	BrBK1-5	GENE-Y	12487427T84
12487427	1060	1067	BrBK1-7	GENE-Y	12487427T85
12487427	1089	1092	ACE	GENE-Y	108004
12487427	1132	1135	NEP	GENE-Y	12487427T87
12487427	17	27	bradykinin	GENE-N	12487427T88
12487427	91	94	ACE	GENE-N	108004
12487427	1539	1550	omapatrilat	CHEMICAL	12487427T8
12487427	95	98	NEP	GENE-N	12487427T90
12487427	1631	1635	BrBK	CHEMICAL	12487427T9
12487427	CPR:3	12487427T22	12487427T65
12487427	CPR:3	12487427T22	12487427T66
12487427	CPR:3	12487427T23	12487427T65
12487427	CPR:3	12487427T23	12487427T66
12487427	CPR:3	12487427T2	12487427T52
12487427	CPR:4	12487427T17	12487427T63
12487427	CPR:4	12487427T17	12487427T64
12487427	CPR:4	12487427T18	12487427T63
12487427	CPR:4	12487427T18	12487427T64
12487427	CPR:4	12487427T21	12487427T63
12487427	CPR:4	12487427T21	12487427T64
12487427	CPR:4	12487427T28	108004
12487427	CPR:4	12487427T28	12487427T71
12487427	CPR:4	12487427T29	12487427T71
12487427	CPR:4	12487427T33	108004
12487427	CPR:4	12487427T33	12487427T76
12487427	CPR:4	12487427T34	108004
12487427	CPR:4	12487427T34	12487427T76
12487427	CPR:4	12487427T45	12487427T84
12487427	CPR:4	12487427T45	12487427T85
12487427	CPR:4	12487427T45	108004
12487427	CPR:4	12487427T48	108004
12487427	CPR:4	12487427T49	108004
12487427	CPR:4	12487427T49	12487427T90
12487427	CPR:4	12487427T4	12487427T53
12487427	CPR:4	12487427T50	108004
12487427	CPR:4	12487427T50	12487427T90

12513698|t|Activity of opioid ligands in cells expressing cloned mu opioid receptors.
12513698|a|BACKGROUND: The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (cAMP) production. Efficacies and potencies of these ligands were determined relative to the endogenous ligand beta-endorphin and the common mu agonist, morphine. RESULTS: Among the ligands studied naltrexone, WIN 44,441 and SKF 10047, were classified as antagonists, while the remaining ligands were agonists. Agonist efficacy was assessed by determining the extent of inhibition of forskolin-stimulated cAMP production. The rank order of efficacy of the agonists was fentanyl = hydromorphone = beta-endorphin > etorphine = lofentanil = butorphanol = morphine = nalbuphine = nalorphine > cyclazocine = dezocine = metazocine >or= xorphanol. The rank order of potency of these ligands was different from that of their efficacies; etorphine > hydromorphone > dezocine > xorphanol = nalorphine = butorphanol = lofentanil > metazocine > nalbuphine > cyclazocine > fentanyl > morphine >>>> beta-endorphin. CONCLUSION: These results elucidate the relative activities of a set of opioid ligands at mu opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of opioid ligands at this receptor. Furthermore, these results can assist in understanding the physiological effect of many opioid ligands acting through mu opioid receptors.
12513698	1216	1227	cyclazocine	CHEMICAL	12513698T10
12513698	1230	1238	fentanyl	CHEMICAL	12513698T11
12513698	1241	1249	morphine	CHEMICAL	12513698T12
12513698	317	326	forskolin	CHEMICAL	12513698T13
12513698	338	369	cyclic adenosine mono phosphate	CHEMICAL	12513698T14
12513698	371	375	cAMP	CHEMICAL	2424
12513698	523	531	morphine	CHEMICAL	12513698T16
12513698	568	578	naltrexone	CHEMICAL	12513698T17
12513698	580	590	WIN 44,441	CHEMICAL	12513698T18
12513698	595	604	SKF 10047	CHEMICAL	12513698T19
12513698	1099	1108	etorphine	CHEMICAL	12513698T1
12513698	754	763	forskolin	CHEMICAL	12513698T20
12513698	775	779	cAMP	CHEMICAL	2424
12513698	839	847	fentanyl	CHEMICAL	12513698T22
12513698	850	863	hydromorphone	CHEMICAL	12513698T23
12513698	883	892	etorphine	CHEMICAL	12513698T24
12513698	895	905	lofentanil	CHEMICAL	12513698T25
12513698	908	919	butorphanol	CHEMICAL	12513698T26
12513698	922	930	morphine	CHEMICAL	12513698T27
12513698	933	943	nalbuphine	CHEMICAL	12513698T28
12513698	946	956	nalorphine	CHEMICAL	12513698T29
12513698	1111	1124	hydromorphone	CHEMICAL	12513698T2
12513698	959	970	cyclazocine	CHEMICAL	12513698T30
12513698	973	981	dezocine	CHEMICAL	12513698T31
12513698	984	994	metazocine	CHEMICAL	12513698T32
12513698	1000	1009	xorphanol	CHEMICAL	12513698T33
12513698	1361	1379	mu opioid receptor	GENE-Y	12513698T34
12513698	1637	1656	mu opioid receptors	GENE-Y	12513698T35
12513698	232	251	mu opioid receptors	GENE-Y	12513698T36
12513698	481	495	beta-endorphin	GENE-Y	12513698T37
12513698	54	73	mu opioid receptors	GENE-Y	12513698T38
12513698	1127	1135	dezocine	CHEMICAL	12513698T3
12513698	1138	1147	xorphanol	CHEMICAL	12513698T4
12513698	1150	1160	nalorphine	CHEMICAL	12513698T5
12513698	1163	1174	butorphanol	CHEMICAL	12513698T6
12513698	1177	1187	lofentanil	CHEMICAL	12513698T7
12513698	1190	1200	metazocine	CHEMICAL	12513698T8
12513698	1203	1213	nalbuphine	CHEMICAL	12513698T9

12604879|t|Ventricular tachyarrhythmias in a canine model of LQT3: arrhythmogenic effects of sympathetic activity and therapeutic effects of mexiletine.
12604879|a|The ventricular tachyarrhythmias associated with the LQT3 syndrome are typically bradycardia-dependent. However, some episodes can be associated with exercise or emotional stress, suggesting a different arrhythmogenic mechanism when sympathetic activity predominates. This study examined the potential arrhythmogenic mechanisms during periods of autonomically mediated transient heart rate acceleration in a canine anthopleurin-A model of LQT3 syndrome. Using plunge needle electrodes, transmural unipolar electrograms of the left ventricle were recorded from endocardial (Endo), mid-myocardial (Mid) and epicardial (Epi) sites. The activation-recovery interval (ARI) was measured to estimate local refractoriness. The cardiac cycle length was gradually shortened by cessation of vagal stimulation (vagal stimulation protocol (VSP)), and intramural electrograms and onset mode of ventricular tachyarrhythmias were analyzed in 7 experiments. The VSP was performed 8 times before and 5 times after administration of mexiletine in each experiment. Before mexiletine, vagal stimulation slowed the heart rate and created large transmural ARI dispersion because of a greater ARI prolongation at Mid rather than Epi/Endo sites. After cessation of vagal stimulation, unipolar electrograms started to show ARI alternans and ventricular premature beats developed sporadically. Sustained ventricular tachyarrhythmias were induced in 12 of the 56 trials of the VSP. Initiation of ventricular tachyarrhythmias was associated with delayed conduction at Mid/Endo sites. Mexiletine attenuated transmural ARI dispersion, and neither ARI alternans nor ventricular tachyarrhythmias was observed during all 35 trials of the VSP after mexiletine administration. Heart rate acceleration induced by an abrupt shift to a state of predominant sympathetic activity enhances arrhythmias in this LQT3 model. Mexiletine homogenizes ventricular repolarization, suppresses premature complexes and was antiarrhythmic during ventricular tachyarrhythmias induced by the VSP.
12604879	1156	1166	mexiletine	CHEMICAL	12604879T1
12604879	1194	1204	mexiletine	CHEMICAL	12604879T2
12604879	1697	1707	Mexiletine	CHEMICAL	371
12604879	1856	1866	mexiletine	CHEMICAL	12604879T4
12604879	2022	2032	Mexiletine	CHEMICAL	371
12604879	130	140	mexiletine	CHEMICAL	12604879T6
12604879	557	571	anthopleurin-A	GENE-Y	12604879T7

12636181|t|Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
12636181|a|Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels. However, BuChE activity progressively increases in patients with Alzheimer's disease (AD), while AChE activity remains unchanged or declines. Both enzymes therefore represent legitimate therapeutic targets for ameliorating the cholinergic deficit considered to be responsible for the declines in cognitive, behavioral and global functioning characteristic of AD. The two enzymes differ in substrate specificity, kinetics and activity in different brain regions. Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. Recent evidence suggests that both AChE and BuChE may have roles in the aetiology and progression of AD beyond regulation of synaptic ACh levels. The development of specific BuChE inhibitors and further experience with the dual enzyme inhibitor rivastigmine will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.
12636181	101	105	AChE	GENE-Y	12636181T10
12636181	354	358	AChE	GENE-Y	12636181T11
12636181	147	168	butyrylcholinesterase	GENE-Y	12636181T12
12636181	794	799	BuChE	GENE-Y	12636181T13
12636181	862	866	AChE	GENE-Y	12636181T14
12636181	871	876	BuChE	GENE-Y	12636181T15
12636181	952	956	AChE	GENE-Y	12636181T16
12636181	961	966	BuChE	GENE-Y	12636181T17
12636181	170	175	BuChE	GENE-Y	12636181T18
12636181	1031	1035	AChE	GENE-Y	12636181T19
12636181	1241	1253	rivastigmine	CHEMICAL	12636181T1
12636181	1040	1045	BuChE	GENE-Y	12636181T20
12636181	0	21	Butyrylcholinesterase	GENE-Y	12636181T21
12636181	229	242	acetylcholine	CHEMICAL	12636181T2
12636181	244	247	ACh	CHEMICAL	12636181T3
12636181	801	810	cymserine	CHEMICAL	12636181T4
12636181	822	829	MF-8622	CHEMICAL	12636181T5
12636181	878	890	rivastigmine	CHEMICAL	12636181T6
12636181	79	99	Acetylcholinesterase	GENE-Y	12636181T7
12636181	1170	1175	BuChE	GENE-Y	12636181T8
12636181	266	271	BuChE	GENE-Y	12636181T9
12636181	CPR:4	12636181T1	12636181T8
12636181	CPR:4	12636181T6	12636181T14
12636181	CPR:4	12636181T6	12636181T15
12636181	CPR:4	12636181T6	12636181T16
12636181	CPR:4	12636181T6	12636181T17
12636181	CPR:9	12636181T2	12636181T10
12636181	CPR:9	12636181T2	12636181T12
12636181	CPR:9	12636181T2	12636181T18
12636181	CPR:9	12636181T2	12636181T7
12636181	CPR:9	12636181T3	12636181T10
12636181	CPR:9	12636181T3	12636181T12
12636181	CPR:9	12636181T3	12636181T18
12636181	CPR:9	12636181T3	12636181T7

12710892|t|A low toxicity maintenance regime, using eicosapentaenoic acid and readily available drugs, for mantle cell lymphoma and other malignancies with excess cyclin D1 levels.
12710892|a|Mantle cell lymphoma is a difficult to treat non-Hodgkin's lymphoma (NHL) whose biochemistry is unusually well characterised. Almost all and perhaps all patients overexpress the cyclin D1 protein which is crucial in driving cells from the G1 to the S phase. This overexpression may be responsible for the refractoriness. Despite this understanding, treatments for mantle cell lymphoma are based on standard NHL regimes of cyclophosphamide, doxorubicin, vincristine and prednisone, perhaps supplemented with the monoclonal antibody rituximab. There has never been any attempt to direct treatment to the cyclin D1 mechanism or to angiogenesis which is now known to be important in all lymphomas. Both these targets lend themselves to long-term maintenance regimes of relatively low toxicity which can be used as adjuvants to standard therapy. Agents which have recently been shown to block cyclin D1 translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole. Two types of agent which have been shown to inhibit angiogenesis are the teratogen, thalidomide, and the selective inhibitors of cyclo-oxygenase 2 (COX-2). Retinoids exert synergistic effects with EPA and have been shown to inhibit both tumour growth and angiogenesis. The mechanisms of action of these various agents are discussed, and specific suggestions are made for low toxicity maintenance therapy of mantle cell lymphoma and of other tumours which overexpress cyclin D1.
12710892	639	649	prednisone	CHEMICAL	12710892T10
12710892	1117	1149	unsaturated essential fatty acid	CHEMICAL	12710892T11
12710892	1151	1172	eicosapentaenoic acid	CHEMICAL	12710892T12
12710892	41	62	eicosapentaenoic acid	CHEMICAL	12710892T13
12710892	1386	1403	cyclo-oxygenase 2	GENE-Y	12710892T14
12710892	1405	1410	COX-2	GENE-Y	12710892T15
12710892	1724	1733	cyclin D1	GENE-Y	12710892T16
12710892	348	357	cyclin D1	GENE-Y	12710892T17
12710892	772	781	cyclin D1	GENE-Y	12710892T18
12710892	1058	1067	cyclin D1	GENE-Y	12710892T19
12710892	1174	1177	EPA	CHEMICAL	153
12710892	152	161	cyclin D1	GENE-Y	12710892T20
12710892	1197	1215	thiazolidinediones	CHEMICAL	12710892T2
12710892	1243	1255	clotrimazole	CHEMICAL	12710892T3
12710892	1341	1352	thalidomide	CHEMICAL	8562
12710892	1413	1422	Retinoids	CHEMICAL	12710892T5
12710892	1454	1457	EPA	CHEMICAL	153
12710892	592	608	cyclophosphamide	CHEMICAL	12710892T7
12710892	610	621	doxorubicin	CHEMICAL	12710892T8
12710892	623	634	vincristine	CHEMICAL	12710892T9
12710892	CPR:4	12710892T11	12710892T19
12710892	CPR:4	12710892T12	12710892T19
12710892	CPR:4	153	12710892T19
12710892	CPR:4	12710892T2	12710892T19
12710892	CPR:4	12710892T3	12710892T19

12719755|t|Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex.
12719755|a|Modulation at the level of the nucleus tractus solitarii (NTS) appears to be an effective way of controlling cardiovascular reflexes. Angiotensin II acting on angiotensin AT1 receptors at the central nervous system appears to have an important role in these modulatory processes. The hypothalamic defence area (HDA) is a potential source of descending fibres containing angiotensin II that innervate the NTS. We investigated the effect of AT1 receptor blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent pancuronium bromide. The characteristic increase in heart rate, blood pressure and phrenic nerve activity evoked by electrical stimulation of HDA is decreased by the microinjection of the AT1 receptor antagonist losartan into the NTS and the cardiovascular response to carotid body chemical stimulation is also reduced. These results support the hypothesis that AT1 receptors in the NTS play a role in the modulation of cardiovascular reflexes, and modify the influence exerted on the processing of these reflexes by other areas of the central nervous system.
12719755	570	582	AT1 receptor	GENE-Y	12719755T10
12719755	897	909	AT1 receptor	GENE-Y	12719755T11
12719755	1071	1084	AT1 receptors	GENE-Y	12719755T12
12719755	0	24	Angiotensin AT1 receptor	GENE-Y	12719755T13
12719755	265	279	Angiotensin II	CHEMICAL	12719755T1
12719755	290	301	angiotensin	CHEMICAL	12719755T2
12719755	501	515	angiotensin II	CHEMICAL	12719755T3
12719755	709	728	pancuronium bromide	CHEMICAL	1303
12719755	0	11	Angiotensin	CHEMICAL	12719755T5
12719755	36	44	losartan	CHEMICAL	12719755T6
12719755	265	279	Angiotensin II	GENE-Y	12719755T7
12719755	290	315	angiotensin AT1 receptors	GENE-Y	12719755T8
12719755	501	515	angiotensin II	GENE-Y	12719755T9
12719755	CPR:4	1303	12719755T10
12719755	CPR:6	12719755T6	12719755T13

12720300|t|Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
12720300|a|High levels of the cell growth inhibitor transforming growth factor-beta1 (TGF-beta1) are often found in a variety of human cancers. However, the physiological significance of this overexpression depends on the availability of the biologically active form of TGF-beta1 within the extracellular matrix of the tumor microenvironment. To determine the expression and activation status of TGF-beta1 in chemically induced tumors, 6-wk-old A/J mice were injected intraperitoneally with either azoxymethane (AOM) (10 mg/kg body weight, once a week for 6 wk) or normal saline solution, and colon tumors were isolated 24 wk following the last injection. An enzyme-linked immunosorbent assay for TGF-beta1 revealed a significant increase (1.7-fold, P < 0.05) in total TGF-beta1 protein in tumors. Interestingly, while 80% of the total TGF-beta1 in the control colon tissues was in the active form, only 50% was found to be active in tumors. Together with our earlier observations that TGF-beta1 mRNA levels are unchanged in A/J tumors, these data further support a mechanism whereby elevated TGF-beta1 levels result from a defective activation and turnover of this protein. Because plasmin is known to be a major activator of TGF-beta1 in vivo, we hypothesized that reduced plasmin activity may be responsible for the observed dysregulation of TGF-beta1 processing in these behaviorally benign tumors. With a fluorogenic peptide substrate for serine proteases, a deficiency in plasmin activity was found in the tumors. Furthermore, semiquantitative reverse transcription (RT)-polymerase chain reaction (PCR) analysis of a panel of genes involved in the plasminogen activation system, including plasminogen activator inhibitor-1 (PAI-1), urokinase-plasminogen activator (u-PA), and urokinase-receptor (u-PAR-1), demonstrated a significant upregulation (approximately fourfold to sixfold, P < 0.05) in the expression of each of these genes in the tumor tissue. In addition, no significant changes were observed in the expression levels of thrombospondin-1 (TSP-1) and insulin-like growth factor type II receptor (IGF-IIR), which also mediate the activation of latent TGF-beta1. To gain further insight into the functionality of the TGF-beta1 pathway, cDNA microarrays were performed and the expression levels of a panel of 21 TGF-beta1-specific target genes were determined in AOM-induced tumors that overexpress the ligand. A significant dysregulation in the expression of each of these targets was observed, providing evidence of aberrant TGF-beta1 signaling in tumors. Overall, the present study demonstrates a very low plasmin activity in A/J colon tumors, possibly as a result of the potent inhibitory effect of PAI-1 on the plasminogen activation cascade. The observed deficiency in plasmin activity may not be sufficiently compensated for by other mechanisms of latent TGF-beta1 activation, including TSP-1 and IGF-IIR, thereby resulting in a decreased fraction of the biologically active form of TGF-beta1 and subsequent aberration in TGF-beta1-specific gene regulation in A/J tumors.
12720300	1439	1448	TGF-beta1	GENE-Y	12720300T10
12720300	1538	1554	serine proteases	GENE-N	12720300T11
12720300	1572	1579	plasmin	GENE-Y	12720300T12
12720300	1748	1759	plasminogen	GENE-Y	12720300T13
12720300	1789	1822	plasminogen activator inhibitor-1	GENE-Y	12720300T14
12720300	1824	1829	PAI-1	GENE-Y	12720300T15
12720300	1832	1863	urokinase-plasminogen activator	GENE-Y	12720300T16
12720300	1865	1869	u-PA	GENE-Y	12720300T17
12720300	1876	1894	urokinase-receptor	GENE-Y	12720300T18
12720300	1896	1903	u-PAR-1	GENE-Y	12720300T19
12720300	1538	1544	serine	CHEMICAL	12720300T1
12720300	2132	2148	thrombospondin-1	GENE-Y	12720300T20
12720300	2150	2155	TSP-1	GENE-Y	12720300T21
12720300	2161	2204	insulin-like growth factor type II receptor	GENE-Y	12720300T22
12720300	2206	2213	IGF-IIR	GENE-Y	12720300T23
12720300	2260	2269	TGF-beta1	GENE-Y	12720300T24
12720300	2325	2334	TGF-beta1	GENE-Y	12720300T25
12720300	2419	2428	TGF-beta1	GENE-Y	12720300T26
12720300	2634	2643	TGF-beta1	GENE-Y	12720300T27
12720300	364	373	TGF-beta1	GENE-Y	12720300T28
12720300	2716	2723	plasmin	GENE-Y	12720300T29
12720300	2470	2473	AOM	CHEMICAL	12720300T2
12720300	2810	2815	PAI-1	GENE-Y	12720300T30
12720300	2823	2834	plasminogen	GENE-Y	12720300T31
12720300	2882	2889	plasmin	GENE-Y	12720300T32
12720300	2969	2978	TGF-beta1	GENE-Y	12720300T33
12720300	3001	3006	TSP-1	GENE-Y	12720300T34
12720300	3011	3018	IGF-IIR	GENE-Y	12720300T35
12720300	3097	3106	TGF-beta1	GENE-Y	12720300T36
12720300	3136	3145	TGF-beta1	GENE-Y	12720300T37
12720300	490	499	TGF-beta1	GENE-Y	12720300T38
12720300	146	178	transforming growth factor-beta1	GENE-Y	12720300T39
12720300	592	604	azoxymethane	CHEMICAL	12720300T3
12720300	791	800	TGF-beta1	GENE-Y	12720300T40
12720300	180	189	TGF-beta1	GENE-Y	12720300T41
12720300	863	872	TGF-beta1	GENE-Y	12720300T42
12720300	930	939	TGF-beta1	GENE-Y	12720300T43
12720300	1080	1089	TGF-beta1	GENE-Y	12720300T44
12720300	28	60	transforming growth factor-beta1	GENE-Y	12720300T45
12720300	606	609	AOM	CHEMICAL	12720300T4
12720300	64	76	azoxymethane	CHEMICAL	12720300T5
12720300	1187	1196	TGF-beta1	GENE-Y	12720300T6
12720300	1277	1284	plasmin	GENE-Y	12720300T7
12720300	1321	1330	TGF-beta1	GENE-Y	12720300T8
12720300	1369	1376	plasmin	GENE-Y	12720300T9

1279186|t|Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals.
1279186|a|BACKGROUND: In a proliferating tumor, locally secreted polypeptide growth factors, which have autocrine and paracrine functions, induce vascularization essential for tumor growth and metastasis. These growth factors may serve as targets for tumor therapy. We have shown that the heparinoid pentosan polysulfate (PPS) can block growth of subcutaneous human tumor xenografts in nude mice and angiogenesis induced by the heparin-binding, Kaposi's sarcoma-derived fibroblast growth factor (K-FGF). PURPOSE: The purpose of this study was to determine whether PPS might also interfere with stimulation of endothelial cells by other growth factors released from tumor cells and whether the promising antitumor effects of PPS extend to other human tumor cell lines. We studied the effects of PPS on stimulation by heparin-binding growth factors released from seven human tumor cell lines in vitro and on tumors growing from these cell lines in athymic nude mice. METHODS: Seven human cell lines established from breast, prostate, epidermoid, and lung carcinomas and rhabdomyosarcoma were used in in vivo as well as in vitro studies of the effects of PPS. We also studied in vitro the effects of PPS on growth factor-induced colony formation of normal rat kidney fibroblasts and human adrenal carcinoma cells. RESULTS: The tumor cell lines released growth factors into their media that stimulated growth of endothelial and epithelial cells as well as fibroblasts. Heparin-affinity chromatography showed that heparin-binding growth factors contributed substantially to this paracrine activity and that PPS inhibited this stimulus. Six of the seven tumor cell lines were resistant to PPS in soft-agar cloning assays and hence did not appear to depend on autocrine stimulation by the heparin-binding growth factors. In contrast to this in vitro resistance, subcutaneous growth of tumors from all cell lines in athymic nude mice was inhibited in a dose-dependent fashion by daily intraperitoneal injections of PPS. CONCLUSIONS: We conclude that heparin-binding growth factors contribute substantially to tumor growth in vivo and that PPS acts by blocking the paracrine effects of heparin-binding growth factors released from the tumor cells. IMPLICATION: PPS could become a novel treatment tool targeting tumor growth factors.
1279186	1648	1678	heparin-binding growth factors	GENE-N	1279186T1
1279186	1921	1951	heparin-binding growth factors	GENE-N	1279186T2
1279186	2181	2211	heparin-binding growth factors	GENE-N	1279186T3
1279186	2316	2346	heparin-binding growth factors	GENE-N	1279186T4
1279186	584	633	Kaposi's sarcoma-derived fibroblast growth factor	GENE-N	1279186T5
1279186	635	640	K-FGF	GENE-N	1279186T6
1279186	955	985	heparin-binding growth factors	GENE-N	1279186T7
1279186	44	74	heparin-binding growth factors	GENE-N	1279186T8

12842269|t|Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors.
12842269|a|Utilizing agonist-stimulated GTPgammaS autoradiography, we analyzed the ability of preproorphanin FQ (ppOFQ) peptides to stimulate [35S]-GTPgammaS binding in adult rat brain. Orphanin FQ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor. The ppOFQ peptides nocistatin and orphanin FQ2 (OFQ II(1-17)) had no effect, suggesting that they do not mediate their reported analgesic effects via a G(i/o)-coupled receptor (i.e. opioid or ORL1). Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone. To explore these observations, we evaluated the receptor binding profile of OFQ II(1-28) at the cloned ORL1 and mu opioid receptors. OFQ II(1-28) had no specific binding at either ORL1 or mu opioid receptors at concentrations up to 50 microM. This lack of affinity was not consistent with a mu-mediated effect, as suggested by preliminary observation using functional autoradiography in rat brain sections. Although behavioral studies suggest that OFQ II(1-28) possesses analgesic activity, this effect does not appear to be mediated via direct binding at the mu opioid receptor. Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate [35S]-GTPgammaS binding in cells expressing the mu opioid receptor.
12842269	1318	1330	OFQ II(1-28)	GENE-Y	12842269T10
12842269	1430	1448	mu opioid receptor	GENE-Y	12842269T11
12842269	1507	1510	OFQ	GENE-Y	12842269T12
12842269	1523	1528	ppOFQ	GENE-N	12842269T13
12842269	1569	1573	ORL1	GENE-N	12842269T14
12842269	1591	1603	OFQ II(1-28)	GENE-Y	12842269T15
12842269	1679	1697	mu opioid receptor	GENE-Y	12842269T16
12842269	302	313	Orphanin FQ	GENE-Y	12842269T17
12842269	315	318	OFQ	GENE-Y	12842269T18
12842269	405	408	OFQ	GENE-Y	12842269T19
12842269	258	273	[35S]-GTPgammaS	CHEMICAL	12842269T1
12842269	427	463	opioid receptor-like (ORL1) receptor	GENE-Y	12842269T20
12842269	469	474	ppOFQ	GENE-N	12842269T21
12842269	499	511	orphanin FQ2	GENE-Y	12842269T22
12842269	513	525	OFQ II(1-17)	GENE-Y	12842269T23
12842269	617	640	G(i/o)-coupled receptor	GENE-N	12842269T24
12842269	657	661	ORL1	GENE-Y	12842269T25
12842269	671	683	OFQ II(1-17)	GENE-Y	12842269T26
12842269	734	746	OFQ II(1-28)	GENE-Y	12842269T27
12842269	788	811	mu (mu) opioid receptor	GENE-Y	12842269T28
12842269	946	958	OFQ II(1-28)	GENE-Y	12842269T29
12842269	1631	1646	[35S]-GTPgammaS	CHEMICAL	12842269T2
12842269	210	244	preproorphanin FQ (ppOFQ) peptides	GENE-N	12842269T30
12842269	973	977	ORL1	GENE-Y	12842269T31
12842269	982	1001	mu opioid receptors	GENE-Y	12842269T32
12842269	1003	1015	OFQ II(1-28)	GENE-Y	12842269T33
12842269	1050	1054	ORL1	GENE-Y	12842269T34
12842269	1058	1077	mu opioid receptors	GENE-Y	12842269T35
12842269	100	104	ORL1	GENE-Y	12842269T36
12842269	109	125	opioid receptors	GENE-N	12842269T37
12842269	51	83	preproorphanin precursor peptide	GENE-N	12842269T38
12842269	331	346	[35S]-GTPgammaS	CHEMICAL	12842269T3
12842269	399	403	125I	CHEMICAL	12842269T4
12842269	156	165	GTPgammaS	CHEMICAL	12842269T5
12842269	712	713	C	CHEMICAL	12842269T6
12842269	759	774	[35S]-GTPgammaS	CHEMICAL	12842269T7
12842269	860	868	naloxone	CHEMICAL	12842269T8
12842269	12	21	GTPgammaS	CHEMICAL	12842269T9

12852767|t|Tethered dimers as NAD synthetase inhibitors with antibacterial activity.
12852767|a|The solution-phase parallel synthesis of tethered dimers was employed to identify lead inhibitors of bacterial NAD synthetase. Active dimers contained two aromatic end groups joined by a polymethylene linker, with one end group containing a permanent positive charge. Effective inhibitors of NAD synthetase also inhibited the growth of Gram-positive (but not Gram-negative) bacteria, including antibiotic-resistant strains. The desmethyl precursors of active inhibitors lacked a permanent positive charge and were inactive as either enzyme inhibitors or antibacterial agents. Similarly, a close structural analogue of the most active inhibitors contained two additional ether oxygens in the tether and was inactive in both assays. These results are consistent with the premise that NAD synthetase inhibition is responsible for the antibacterial actions and support further studies on NAD synthetase as a new target for antibacterial agents.
12852767	958	972	NAD synthetase	GENE-N	12852767T10
12852767	19	33	NAD synthetase	GENE-N	12852767T11
12852767	185	188	NAD	CHEMICAL	12852767T1
12852767	366	369	NAD	CHEMICAL	12852767T2
12852767	750	757	oxygens	CHEMICAL	12852767T3
12852767	856	859	NAD	CHEMICAL	12852767T4
12852767	958	961	NAD	CHEMICAL	12852767T5
12852767	19	22	NAD	CHEMICAL	12852767T6
12852767	175	199	bacterial NAD synthetase	GENE-N	12852767T7
12852767	366	380	NAD synthetase	GENE-N	12852767T8
12852767	856	870	NAD synthetase	GENE-N	12852767T9

12897749|t|Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.
12897749|a|BACKGROUND: Prior investigations have demonstrated that beta(2)-adrenoceptor stimulation is ineffective in inhibiting synthesis of eicosanoids in human eosinophils. This effect has been postulated to relate to density or structural differences in the beta(2)-adrenoceptor or its coupled G-protein. However, recent reports indicate that cAMP-specific PDE4 activity in eosinophils is 10-fold that of other inflammatory cells. We postulated that selective blockade of PDE4 in eosinophils would unmask the inhibitory effect of beta(2)-adrenoceptor stimulation and that this inhibition would result from decreased phosphor-ylation of cytosolic group IV-PLA(2) (gIV-PLA(2)). OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP. METHODS: Human eosinophils were pretreated with buffer, salmeterol or rolipram (singly or combination) before FMLP/B activation. Release of AA and LTC(4), intracellular cAMP concentration, and phosphorylation and activation of gIV-PLA(2) were determined. RESULTS: Rolipram unmasked the inhibitory effect of beta(2)-adrenoceptor stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4). Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of gIV-PLA(2) in FMLP/B-activated eosinophils. CONCLUSIONS: Inhibition of PDE4 by rolipram unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.
12897749	1558	1566	Rolipram	CHEMICAL	1878
12897749	1639	1649	salmeterol	CHEMICAL	12897749T11
12897749	1705	1707	AA	CHEMICAL	12897749T12
12897749	1723	1729	LTC(4)	CHEMICAL	12897749T13
12897749	1768	1772	cAMP	CHEMICAL	2424
12897749	1794	1802	rolipram	CHEMICAL	12897749T15
12897749	1812	1820	rolipram	CHEMICAL	12897749T16
12897749	1826	1836	salmeterol	CHEMICAL	12897749T17
12897749	1974	1978	PDE4	CHEMICAL	12897749T18
12897749	1982	1990	rolipram	CHEMICAL	12897749T19
12897749	1161	1165	cAMP	CHEMICAL	2424
12897749	2030	2036	LTC(4)	CHEMICAL	12897749T20
12897749	485	489	cAMP	CHEMICAL	2424
12897749	499	503	PDE4	CHEMICAL	12897749T22
12897749	614	618	PDE4	CHEMICAL	12897749T23
12897749	854	858	PDE4	CHEMICAL	12897749T24
12897749	881	889	rolipram	CHEMICAL	12897749T25
12897749	912	928	arachidonic acid	CHEMICAL	12897749T26
12897749	930	932	AA	CHEMICAL	12897749T27
12897749	938	954	leukotriene C(4)	CHEMICAL	12897749T28
12897749	956	962	LTC(4)	CHEMICAL	12897749T29
12897749	1248	1250	AA	CHEMICAL	12897749T2
12897749	1005	1023	formyl-met-leu-phe	CHEMICAL	12897749T30
12897749	1029	1043	cytochalasin B	CHEMICAL	12897749T31
12897749	1074	1078	PDE4	CHEMICAL	12897749T32
12897749	111	115	PDE4	CHEMICAL	12897749T33
12897749	12	16	LTC4	CHEMICAL	12897749T34
12897749	96	106	salmeterol	CHEMICAL	12897749T35
12897749	1521	1531	gIV-PLA(2)	GENE-N	12897749T36
12897749	1601	1621	beta(2)-adrenoceptor	GENE-N	12897749T37
12897749	1903	1913	gIV-PLA(2)	GENE-N	12897749T38
12897749	1974	1978	PDE4	GENE-N	12897749T39
12897749	1255	1261	LTC(4)	CHEMICAL	12897749T3
12897749	1999	2017	beta(2)-adrenergic	GENE-Y	12897749T40
12897749	400	420	beta(2)-adrenoceptor	GENE-Y	12897749T41
12897749	436	445	G-protein	GENE-N	12897749T42
12897749	485	503	cAMP-specific PDE4	GENE-N	12897749T43
12897749	614	618	PDE4	GENE-N	12897749T44
12897749	672	692	beta(2)-adrenoceptor	GENE-Y	12897749T45
12897749	205	225	beta(2)-adrenoceptor	GENE-Y	12897749T46
12897749	778	803	cytosolic group IV-PLA(2)	GENE-N	12897749T47
12897749	805	815	gIV-PLA(2)	GENE-N	12897749T48
12897749	854	858	PDE4	GENE-N	12897749T49
12897749	1288	1292	cAMP	CHEMICAL	2424
12897749	1074	1078	PDE4	GENE-N	12897749T50
12897749	1095	1115	beta(2)-adrenoceptor	GENE-Y	12897749T51
12897749	111	115	PDE4	GENE-N	12897749T52
12897749	60	68	gIV-PLA2	GENE-N	12897749T53
12897749	1350	1360	salmeterol	CHEMICAL	12897749T5
12897749	1364	1372	rolipram	CHEMICAL	12897749T6
12897749	1434	1436	AA	CHEMICAL	12897749T7
12897749	1441	1447	LTC(4)	CHEMICAL	12897749T8
12897749	1463	1467	cAMP	CHEMICAL	2424
12897749	CPR:3	12897749T11	12897749T37
12897749	CPR:4	12897749T16	12897749T38
12897749	CPR:4	12897749T17	12897749T38
12897749	CPR:4	12897749T19	12897749T39
12897749	CPR:4	12897749T25	12897749T49
12897749	CPR:9	12897749T34	12897749T53

12942109|t|A phase 1 study of tazarotene in adults with advanced cancer.
12942109|a|Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and RARgamma. The safety, toxicity and pharmacokinetics of oral tazarotene were determined over 12 weeks of treatment in 34 patients with advanced cancer. Commonly seen toxicities were mucocutaneous symptoms, musculoskeletal pain and headache. Dose-limiting toxicities were hypercalcaemia, hypertriglyceridaemia and musculoskeletal pain. The maximum tolerated dose of tazarotene in this schedule is 25.2 mg day(-1). Plasma concentrations of tazarotenic acid were found to peak rapidly within 1-3 h of dosing and thereafter declined quickly. The C(max) and AUC values on day 0, and weeks 2 and 4 were similar indicating no drug accumulation. The dose-normalised C(max) and AUC values at different dose levels and different study days appeared to be similar indicating linear pharmacokinetics. No objective responses were seen, although stable disease was seen in six out of eight evaluable patients receiving the three highest dose levels of tazarotene (16.8, 25.2 or 33.4 mg day(-1)). We conclude that oral tazarotene is well tolerated when administered daily for 12 weeks, has a favourable toxicity profile compared with other retinoids and merits further investigation as an anticancer therapy.
12942109	123	139	tazarotenic acid	CHEMICAL	12942109T10
12942109	19	29	tazarotene	CHEMICAL	12942109T11
12942109	175	193	retinoid receptors	GENE-N	12942109T12
12942109	194	201	RARbeta	GENE-Y	12942109T13
12942109	206	214	RARgamma	GENE-Y	12942109T14
12942109	62	72	Tazarotene	CHEMICAL	789
12942109	1143	1153	tazarotene	CHEMICAL	12942109T2
12942109	175	183	retinoid	CHEMICAL	12942109T3
12942109	1209	1219	tazarotene	CHEMICAL	12942109T4
12942109	1330	1339	retinoids	CHEMICAL	12942109T5
12942109	79	98	acetylenic retinoid	CHEMICAL	12942109T6
12942109	266	276	tazarotene	CHEMICAL	12942109T7
12942109	570	580	tazarotene	CHEMICAL	12942109T8
12942109	643	659	tazarotenic acid	CHEMICAL	12942109T9

1322047|t|Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation.
1322047|a|The potent anabolic effects of the beta 2-adrenoceptor agonist clenbuterol on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors. In the present study clenbuterol, presented to rats in the diet (4 mg/kg), caused significant increases in gastrocnemius muscle mass, protein, and RNA content and a decrease in epididymal fat pad mass. These effects were not mimicked by oral administration of the beta 2-adrenoceptor agonist salbutamol even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet). However, the selective beta 2-antagonist ICI-118,551 (200 mg/kg diet) reversed the anabolic effects of clenbuterol, and a high dose of DL-propranolol (1,000 mg/kg diet) also inhibited these actions of clenbuterol. Furthermore, continuous infusion of salbutamol (1.15 mg.kg body wt-1.day-1) via miniosmotic pumps did cause significant increases in muscle mass, protein, and RNA content. These results indicate that the anabolic effects of clenbuterol are dependent on interaction with the beta 2-adrenoceptor. However, a long duration of action appears to be required to induce the anabolic effects of beta 2-agonists.
1322047	901	912	clenbuterol	CHEMICAL	1322047T10
1322047	950	960	salbutamol	CHEMICAL	1322047T11
1322047	20	31	clenbuterol	CHEMICAL	1322047T12
1322047	1188	1207	beta 2-adrenoceptor	GENE-Y	1322047T13
1322047	244	262	beta-adrenoceptors	GENE-N	1322047T14
1322047	134	153	beta 2-adrenoceptor	GENE-Y	1322047T15
1322047	528	547	beta 2-adrenoceptor	GENE-Y	1322047T16
1322047	67	86	beta 2-adrenoceptor	GENE-Y	1322047T17
1322047	1138	1149	clenbuterol	CHEMICAL	1322047T1
1322047	285	296	clenbuterol	CHEMICAL	1322047T2
1322047	556	566	salbutamol	CHEMICAL	1322047T3
1322047	621	632	clenbuterol	CHEMICAL	1322047T4
1322047	667	681	DL-propranolol	CHEMICAL	1322047T5
1322047	162	173	clenbuterol	CHEMICAL	1322047T6
1322047	741	752	ICI-118,551	CHEMICAL	1322047T7
1322047	803	814	clenbuterol	CHEMICAL	1322047T8
1322047	835	849	DL-propranolol	CHEMICAL	1322047T9
1322047	CPR:3	1322047T12	1322047T17
1322047	CPR:5	1322047T3	1322047T16
1322047	CPR:5	1322047T4	1322047T16
1322047	CPR:5	1322047T6	1322047T15

1356794|t|Evidence that an alpha 2A-adrenoceptor subtype mediates antinociception in mice.
1356794|a|In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408. In contrast, the preferential alpha 2B- (and alpha 2C)-adrenoceptor ligands ('antagonists'), ARC-239, BRL 41992 and prazosin were inactive. The preferential alpha 2A-adrenoceptor partial agonist, guanfacine, partially inhibited UK 14,304-induced antinociception. Further, guanfacine BRL 44408 reversibly elicited submaximal antinociception. It is concluded that alpha 2A-adrenoceptors mediate antinociception in mice.
1356794	655	664	BRL 44408	CHEMICAL	1356794T10
1356794	176	185	UK 14,304	CHEMICAL	1356794T11
1356794	208	228	alpha 2-adrenoceptor	GENE-N	1356794T12
1356794	262	283	alpha 2A-adrenoceptor	GENE-Y	1356794T13
1356794	327	348	alpha 2A-adrenoceptor	GENE-Y	1356794T14
1356794	402	439	alpha 2B- (and alpha 2C)-adrenoceptor	GENE-N	1356794T15
1356794	529	550	alpha 2A-adrenoceptor	GENE-Y	1356794T16
1356794	734	756	alpha 2A-adrenoceptors	GENE-Y	1356794T17
1356794	146	166	alpha 2-adrenoceptor	GENE-N	1356794T18
1356794	17	38	alpha 2A-adrenoceptor	GENE-Y	1356794T19
1356794	241	249	idazoxan	CHEMICAL	1356794T1
1356794	296	305	RX 821002	CHEMICAL	1356794T2
1356794	361	370	BRL 44408	CHEMICAL	1356794T3
1356794	465	472	ARC-239	CHEMICAL	1356794T4
1356794	474	483	BRL 41992	CHEMICAL	1356794T5
1356794	488	496	prazosin	CHEMICAL	1356794T6
1356794	568	578	guanfacine	CHEMICAL	1008
1356794	600	609	UK 14,304	CHEMICAL	1356794T8
1356794	644	654	guanfacine	CHEMICAL	1008
1356794	CPR:5	1356794T11	1356794T18
1356794	CPR:5	1008	1356794T16
1356794	CPR:5	1356794T8	1356794T16
1356794	CPR:6	1356794T1	1356794T12
1356794	CPR:6	1356794T2	1356794T13
1356794	CPR:6	1356794T3	1356794T14

14596599|t|Crystal structure of serine dehydratase from rat liver.
14596599|a|SDH (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia. Liver SDH plays an important role in gluconeogenesis. Formation of pyruvate by SDH is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate. The crystal structure of rat liver apo-SDH was determined by single isomorphous replacement at 2.8 A resolution. The holo-SDH crystallized with O-methylserine (OMS) was also determined at 2.6 A resolution by molecular replacement. SDH is composed of two domains, and each domain has a typical alphabeta-open structure. The active site is located in the cleft between the two domains. The holo-SDH contained PLP-OMS aldimine in the active site, indicating that OMS can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur. Apo-SDH forms a dimer by inserting the small domain into the catalytic cleft of the partner subunit so that the active site is closed. Holo-SDH also forms a dimer by making contacts at the back of the clefts so that the dimerization does not close the catalytic cleft. The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated. N(1) of PLP participates in a hydrogen bond with Cys303, and similar hydrogen bonds with N(1) participating are seen in other beta-elimination enzymes. These hydrogen bonding schemes indicate that N(1) is not protonated, and thus, the pyridine ring cannot take a quinone-like structure. These characteristics of the bound PLP suggest that SDH catalysis is not facilitated by forming the resonance-stabilized structure of the PLP-Ser aldimine as seen in aminotransferases. A possible catalytic mechanism involves the phosphate group, surrounded by the characteristic sequence, acting as a general acid to donate a proton to the leaving hydroxyl group of serine.
14596599	1531	1534	PLP	CHEMICAL	109
14596599	1553	1561	hydrogen	CHEMICAL	14596599T11
14596599	1592	1600	hydrogen	CHEMICAL	14596599T12
14596599	1681	1689	hydrogen	CHEMICAL	14596599T13
14596599	1758	1766	pyridine	CHEMICAL	14596599T14
14596599	1786	1793	quinone	CHEMICAL	14596599T15
14596599	1845	1848	PLP	CHEMICAL	109
14596599	1948	1964	PLP-Ser aldimine	CHEMICAL	14596599T17
14596599	2039	2048	phosphate	CHEMICAL	14596599T18
14596599	2158	2166	hydroxyl	CHEMICAL	14596599T19
14596599	164	172	L-serine	CHEMICAL	14596599T1
14596599	2176	2182	serine	CHEMICAL	14596599T20
14596599	271	279	pyruvate	CHEMICAL	14596599T21
14596599	323	331	hydroxyl	CHEMICAL	14596599T22
14596599	341	347	serine	CHEMICAL	14596599T23
14596599	370	383	aminoacrylate	CHEMICAL	14596599T24
14596599	398	411	aminoacrylate	CHEMICAL	14596599T25
14596599	464	472	pyruvate	CHEMICAL	14596599T26
14596599	61	69	L-serine	CHEMICAL	14596599T27
14596599	110	132	pyridoxal 5'-phosphate	CHEMICAL	14596599T28
14596599	618	632	O-methylserine	CHEMICAL	14596599T29
14596599	182	190	pyruvate	CHEMICAL	14596599T2
14596599	634	637	OMS	CHEMICAL	14596599T30
14596599	134	137	PLP	CHEMICAL	109
14596599	889	897	aldimine	CHEMICAL	14596599T32
14596599	934	937	OMS	CHEMICAL	14596599T33
14596599	951	962	Schiff base	CHEMICAL	14596599T34
14596599	976	979	PLP	CHEMICAL	109
14596599	21	27	serine	CHEMICAL	14596599T36
14596599	56	59	SDH	GENE-Y	14596599T37
14596599	1162	1170	Holo-SDH	GENE-Y	14596599T38
14596599	1357	1372	G-rich sequence	GENE-N	14596599T39
14596599	1319	1322	PLP	CHEMICAL	109
14596599	1379	1384	GGGGL	GENE-N	14596599T40
14596599	210	213	SDH	GENE-Y	14596599T41
14596599	1862	1865	SDH	GENE-Y	14596599T42
14596599	1976	1993	aminotransferases	GENE-N	14596599T43
14596599	283	286	SDH	GENE-Y	14596599T44
14596599	83	94	EC 4.3.1.17	GENE-Y	14596599T45
14596599	60	81	(L-serine dehydratase	GENE-Y	14596599T46
14596599	499	516	rat liver apo-SDH	GENE-Y	14596599T47
14596599	591	599	holo-SDH	GENE-Y	14596599T48
14596599	705	708	SDH	GENE-Y	14596599T49
14596599	1379	1384	GGGGL	CHEMICAL	14596599T4
14596599	862	870	holo-SDH	GENE-Y	14596599T50
14596599	1027	1034	Apo-SDH	GENE-Y	14596599T51
14596599	21	39	serine dehydratase	GENE-Y	14596599T52
14596599	1401	1409	hydrogen	CHEMICAL	14596599T5
14596599	1425	1430	amide	CHEMICAL	14596599T6
14596599	1447	1457	amino acid	CHEMICAL	14596599T7
14596599	195	202	ammonia	CHEMICAL	14596599T8
14596599	1488	1497	phosphate	CHEMICAL	14596599T9
14596599	CPR:9	14596599T1	14596599T37
14596599	CPR:9	14596599T1	14596599T45
14596599	CPR:9	14596599T1	14596599T46
14596599	CPR:9	14596599T21	14596599T44
14596599	CPR:9	14596599T24	14596599T44
14596599	CPR:9	14596599T26	14596599T44
14596599	CPR:9	14596599T2	14596599T37
14596599	CPR:9	14596599T2	14596599T45
14596599	CPR:9	14596599T2	14596599T46
14596599	CPR:9	14596599T8	14596599T37
14596599	CPR:9	14596599T8	14596599T45
14596599	CPR:9	14596599T8	14596599T46

14633707|t|Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance.
14633707|a|Oncogenic forms of the small GTPase Ras increase the resistance of cells to killing by ionizing radiation (IR). Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by phosphatidylinositol 3'-kinase (PI3-K) and Raf. Nevertheless, PI3-K and Raf together are not sufficient to reconstitute all of the resistance conferred by Ras, indicating that other effectors must also contribute. We show here that Ras-driven autocrine signaling through the epidermal growth factor receptor (EGFR) also contributes to radioresistance in Ras-transformed cells. Conditioned media (CM) collected from RIE-1 rat intestinal epithelial cells expressing oncogenic Ras increased the survival of irradiated cells. Ras-CM contains elevated levels of the EGFR ligand transforming growth factor alpha (TGF-alpha). Both Ras-CM and TGF-alpha stimulated EGFR phosphorylation, and exogenous TGF-alpha mimicked the effects of Ras-CM to increase radioresistance. Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells. Ras-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016. Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer. The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.
14633707	1320	1323	Ras	GENE-N	14633707T10
14633707	1416	1419	Ras	GENE-N	14633707T11
14633707	1427	1436	TGF-alpha	GENE-Y	14633707T12
14633707	1451	1456	PI3-K	GENE-N	14633707T13
14633707	1484	1488	EGFR	GENE-Y	108276|3932452|676741
14633707	1573	1576	Ras	GENE-N	14633707T15
14633707	1614	1618	EGFR	GENE-Y	108276|3932452|676741
14633707	1656	1660	EGFR	GENE-Y	108276|3932452|676741
14633707	1721	1724	Ras	GENE-N	14633707T18
14633707	1826	1830	EGFR	GENE-Y	108276|3932452|676741
14633707	1260	1268	GW572016	CHEMICAL	14633707T1
14633707	1927	1930	Ras	GENE-N	14633707T20
14633707	1966	1970	EGFR	GENE-Y	108276|3932452|676741
14633707	345	348	Ras	GENE-N	14633707T22
14633707	160	166	GTPase	GENE-N	14633707T23
14633707	432	462	phosphatidylinositol 3'-kinase	GENE-N	14633707T24
14633707	464	469	PI3-K	GENE-N	14633707T25
14633707	475	478	Raf	GENE-N	14633707T26
14633707	494	499	PI3-K	GENE-N	14633707T27
14633707	167	170	Ras	GENE-N	14633707T28
14633707	504	507	Raf	GENE-N	14633707T29
14633707	1557	1565	GW572016	CHEMICAL	14633707T2
14633707	587	590	Ras	GENE-N	14633707T30
14633707	664	667	Ras	GENE-N	14633707T31
14633707	707	739	epidermal growth factor receptor	GENE-Y	14633707T32
14633707	741	745	EGFR	GENE-Y	108276|3932452|676741
14633707	786	789	Ras	GENE-N	14633707T34
14633707	906	909	Ras	GENE-N	14633707T35
14633707	954	957	Ras	GENE-N	14633707T36
14633707	993	997	EGFR	GENE-Y	108276|3932452|676741
14633707	1005	1037	transforming growth factor alpha	GENE-Y	14633707T38
14633707	1039	1048	TGF-alpha	GENE-Y	14633707T39
14633707	1664	1672	GW572016	CHEMICAL	14633707T3
14633707	1056	1059	Ras	GENE-N	14633707T40
14633707	1067	1076	TGF-alpha	GENE-Y	14633707T41
14633707	1088	1092	EGFR	GENE-Y	108276|3932452|676741
14633707	1124	1133	TGF-alpha	GENE-Y	14633707T43
14633707	0	32	Epidermal growth factor receptor	GENE-Y	14633707T44
14633707	87	90	Ras	GENE-N	14633707T45
14633707	1799	1807	GW572016	CHEMICAL	14633707T4
14633707	432	452	phosphatidylinositol	CHEMICAL	14633707T5
14633707	1158	1161	Ras	GENE-N	14633707T6
14633707	1203	1207	EGFR	GENE-Y	108276|3932452|676741
14633707	1227	1231	EGFR	GENE-Y	108276|3932452|676741
14633707	1232	1237	HER-2	GENE-Y	14633707T9
14633707	CPR:4	14633707T1	14633707T10
14633707	CPR:4	14633707T1	108276|3932452|676741
14633707	CPR:4	14633707T1	108276|3932452|676741
14633707	CPR:4	14633707T1	14633707T9
14633707	CPR:4	14633707T2	14633707T13
14633707	CPR:4	14633707T2	108276|3932452|676741
14633707	CPR:4	14633707T3	14633707T15
14633707	CPR:4	14633707T3	108276|3932452|676741
14633707	CPR:4	14633707T4	14633707T18
14633707	CPR:4	14633707T4	108276|3932452|676741

14660028|t|Characterization of beta 3-adrenoceptor-mediated relaxation in rat abdominal aorta smooth muscle.
14660028|a|The present study was carried out to characterize beta-adrenoceptor subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations. Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors. In the presence of CGP20712A and ICI-118,551 (0.1 microM for each), the concentration-response curves for (-)-isoprenaline and (+/-)-CGP12177A were shifted to the right by a nonselective beta(1)-, beta(2)- and beta(3)-adrenoceptor antagonist, (+/-)-bupranolol (3 and 10 microM). These results clearly suggest that beta(3)-adrenoceptors are involved in beta-adrenoceptor-mediated relaxation of rat abdominal aorta smooth muscle.
14660028	577	718	(+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate	CHEMICAL	14660028T10
14660028	720	729	CGP20712A	CHEMICAL	14660028T11
14660028	780	879	(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride	CHEMICAL	14660028T12
14660028	881	893	ICI-118,5511	CHEMICAL	14660028T13
14660028	1037	1053	(-)-isoprenaline	CHEMICAL	14660028T14
14660028	1094	1109	(+/-)-CGP12177A	CHEMICAL	14660028T15
14660028	1144	1178	beta(1)- and beta(2)-adrenoceptors	GENE-N	14660028T16
14660028	1367	1410	beta(1)-, beta(2)- and beta(3)-adrenoceptor	GENE-N	14660028T17
14660028	1494	1515	beta(3)-adrenoceptors	GENE-Y	14660028T18
14660028	1532	1549	beta-adrenoceptor	GENE-N	14660028T19
14660028	1199	1208	CGP20712A	CHEMICAL	14660028T1
14660028	273	293	beta(3)-adrenoceptor	GENE-Y	14660028T20
14660028	148	165	beta-adrenoceptor	GENE-N	14660028T21
14660028	743	763	beta(1)-adrenoceptor	GENE-Y	14660028T22
14660028	907	927	beta(2)-adrenoceptor	GENE-Y	14660028T23
14660028	20	39	beta 3-adrenoceptor	GENE-Y	14660028T24
14660028	1213	1224	ICI-118,551	CHEMICAL	14660028T2
14660028	1286	1302	(-)-isoprenaline	CHEMICAL	14660028T3
14660028	1307	1322	(+/-)-CGP12177A	CHEMICAL	14660028T4
14660028	1423	1439	(+/-)-bupranolol	CHEMICAL	14660028T5
14660028	234	250	(-)-Isoprenaline	CHEMICAL	14660028T6
14660028	303	409	(+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride	CHEMICAL	14660028T7
14660028	411	426	(+/-)-CGP12177A	CHEMICAL	14660028T8
14660028	475	492	(-)-phenylephrine	CHEMICAL	14660028T9
14660028	CPR:5	14660028T7	14660028T20
14660028	CPR:5	14660028T8	14660028T20
14660028	CPR:6	14660028T10	14660028T22
14660028	CPR:6	14660028T11	14660028T22
14660028	CPR:6	14660028T12	14660028T23
14660028	CPR:6	14660028T13	14660028T23

14716684|t|Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells.
14716684|a|BACKGROUND: The norepinephrine transporter (NET) is a high-affinity transporter for catecholamines. Its expression is almost exclusively restricted to the sympathetic nervous system. In this study we evaluated whether the NET can be used as a reporter gene for non-invasive imaging of genetically modified cells with radiolabeled probes. METHODS: Human A431, HT1080 and murine CMS-5 cells were retrovirally transduced with bovine NET cDNA. Transduced and parental cells were incubated in vitro with [(131)I]meta-iodobenzylguanidine ([(131)I]MIBG). The specificity of tracer uptake was determined by adding the NET inhibitor imipramine. Rat PC12 cells served as positive controls. Parental and A431NET cells were xenotransplanted into nude mice and tumor uptake of [(123)I]MIBG in vivo was determined after tracer administration. RESULTS: In vitro stably transduced cells showed a 66- to 120-fold higher [(131)I]MIBG uptake than parental cells. Incubation with imipramine reduced [(131)I]MIBG uptake of transduced cells to the level found in parental cells. More than 70% of the initial radioactivity was retained in all transduced cell lines after 2 h incubation with tracer-free medium. [(131)I]MIBG uptake in PC12 cells, which express the NET endogenously, was 20- to 28-fold lower than in transduced cells. In vivo, A431NET tumors demonstrated a 33-fold higher [(123)I]MIBG uptake than parental tumors. Gamma camera images 24 h after tracer injection showed no tracer uptake in parental A431 tumors, but clear images of A431NET tumors. CONCLUSIONS: Transduction of tumor cells with NET cDNA causes highly specific uptake and significant retention of catecholamine analogs in vitro and in vivo. These characteristics make the NET suitable as a reporter gene for non-invasive monitoring of gene transfer.
14716684	1016	1028	[(131)I]MIBG	CHEMICAL	14716684T10
14716684	1073	1083	imipramine	CHEMICAL	14716684T11
14716684	1092	1104	[(131)I]MIBG	CHEMICAL	14716684T12
14716684	11	25	norepinephrine	CHEMICAL	14716684T13
14716684	1354	1357	NET	GENE-Y	14716684T14
14716684	1436	1439	NET	GENE-Y	14716684T15
14716684	1640	1643	NET	GENE-Y	14716684T16
14716684	1698	1701	NET	GENE-Y	14716684T17
14716684	129	155	norepinephrine transporter	GENE-Y	14716684T18
14716684	1841	1844	NET	GENE-Y	14716684T19
14716684	1301	1313	[(131)I]MIBG	CHEMICAL	14716684T1
14716684	335	338	NET	GENE-Y	14716684T20
14716684	536	546	bovine NET	GENE-Y	14716684T21
14716684	157	160	NET	GENE-Y	14716684T22
14716684	723	726	NET	GENE-Y	14716684T23
14716684	810	813	NET	GENE-Y	14716684T24
14716684	11	37	norepinephrine transporter	GENE-Y	14716684T25
14716684	1477	1489	[(123)I]MIBG	CHEMICAL	14716684T2
14716684	129	143	norepinephrine	CHEMICAL	14716684T3
14716684	1766	1779	catecholamine	CHEMICAL	14716684T4
14716684	612	644	[(131)I]meta-iodobenzylguanidine	CHEMICAL	14716684T5
14716684	646	658	[(131)I]MIBG	CHEMICAL	14716684T6
14716684	737	747	imipramine	CHEMICAL	14716684T7
14716684	877	889	[(123)I]MIBG	CHEMICAL	14716684T8
14716684	197	211	catecholamines	CHEMICAL	14716684T9
14716684	CPR:4	14716684T7	14716684T23
14716684	CPR:9	14716684T1	14716684T14
14716684	CPR:9	14716684T2	14716684T15

14730417|t|Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
14730417|a|Although many beta1-receptor antagonists and beta2-receptor agonists have been used in pharmacotherapy for many years their pharmacological properties at all three known subtypes of beta-adrenergic receptors are not always well characterized. The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background. We generated Chinese hamster ovary (CHO) cells stably expressing the three beta-adrenergic receptor subtypes at comparable levels. We characterized these receptor subtypes and analyzed the affinity of routinely used drugs as well as experimental compounds in competition binding studies, using the non-selective antagonist 125I-cyanopindolol as a radioligand. Furthermore, we analyzed the beta-receptor-mediated adenylyl cyclase activity in isolated membranes from these cell lines. The results from our experiments show that all compounds exhibit distinct patterns of selectivity and activity at the three beta-receptor subtypes. In particular, a number of beta2- or beta3-receptor agonists that are inverse agonists at the other subtypes were identified. In addition, beta1-receptor antagonists with agonistic activity at beta2- and beta3-receptors were found. These specific mixtures of agonism, antagonism, and inverse agonism at different subtypes may have important implications for the therapeutic use of the respective compounds.
14730417	564	574	formoterol	CHEMICAL	14730417T10
14730417	576	586	broxaterol	CHEMICAL	14730417T11
14730417	605	616	propranolol	CHEMICAL	14730417T12
14730417	618	628	alprenolol	CHEMICAL	14730417T13
14730417	630	638	atenolol	CHEMICAL	14730417T14
14730417	640	650	metoprolol	CHEMICAL	14730417T15
14730417	652	662	bisoprolol	CHEMICAL	14730417T16
14730417	664	674	carvedilol	CHEMICAL	14730417T17
14730417	676	684	pindolol	CHEMICAL	14730417T18
14730417	686	695	BRL 37344	CHEMICAL	14730417T19
14730417	1159	1177	125I-cyanopindolol	CHEMICAL	14730417T1
14730417	697	706	CGP 20712	CHEMICAL	14730417T20
14730417	708	717	SR 59230A	CHEMICAL	14730417T21
14730417	719	728	CGP 12177	CHEMICAL	14730417T22
14730417	730	740	ICI 118551	CHEMICAL	14730417T23
14730417	1225	1238	beta-receptor	GENE-N	14730417T24
14730417	1248	1264	adenylyl cyclase	GENE-N	14730417T25
14730417	1443	1456	beta-receptor	GENE-N	14730417T26
14730417	1494	1518	beta2- or beta3-receptor	GENE-N	14730417T27
14730417	146	160	beta1-receptor	GENE-Y	14730417T28
14730417	1606	1620	beta1-receptor	GENE-Y	14730417T29
14730417	1248	1256	adenylyl	CHEMICAL	14730417T2
14730417	1660	1686	beta2- and beta3-receptors	GENE-N	14730417T30
14730417	314	339	beta-adrenergic receptors	GENE-N	14730417T31
14730417	177	191	beta2-receptor	GENE-Y	14730417T32
14730417	767	798	human beta-adrenergic receptors	GENE-N	14730417T33
14730417	911	935	beta-adrenergic receptor	GENE-N	14730417T34
14730417	28	58	human beta-adrenergic receptor	GENE-N	14730417T35
14730417	473	484	epinephrine	CHEMICAL	14730417T3
14730417	486	500	norepinephrine	CHEMICAL	14730417T4
14730417	502	515	isoproterenol	CHEMICAL	14730417T5
14730417	517	526	fenoterol	CHEMICAL	14730417T6
14730417	528	538	salbutamol	CHEMICAL	14730417T7
14730417	540	550	salmeterol	CHEMICAL	14730417T8
14730417	552	562	terbutalin	CHEMICAL	14730417T9
14730417	CPR:5	14730417T10	14730417T33
14730417	CPR:5	14730417T11	14730417T33
14730417	CPR:5	14730417T3	14730417T33
14730417	CPR:5	14730417T4	14730417T33
14730417	CPR:5	14730417T5	14730417T33
14730417	CPR:5	14730417T6	14730417T33
14730417	CPR:5	14730417T7	14730417T33
14730417	CPR:5	14730417T8	14730417T33
14730417	CPR:5	14730417T9	14730417T33
14730417	CPR:6	14730417T12	14730417T33
14730417	CPR:6	14730417T13	14730417T33
14730417	CPR:6	14730417T14	14730417T33
14730417	CPR:6	14730417T15	14730417T33
14730417	CPR:6	14730417T16	14730417T33
14730417	CPR:6	14730417T17	14730417T33
14730417	CPR:6	14730417T18	14730417T33
14730417	CPR:6	14730417T19	14730417T33
14730417	CPR:6	14730417T20	14730417T33
14730417	CPR:6	14730417T21	14730417T33
14730417	CPR:6	14730417T22	14730417T33
14730417	CPR:6	14730417T23	14730417T33

14733708|t|Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.
14733708|a|Natural prostaglandins (PGs) such as PGD2, PGE2, PGF2(2alpha), and PGI2 exhibited the highest affinity for their respective cognate receptors, but were the least selective agents when tested in receptor binding assays. Travoprost acid ([+]-fluprostenol) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors. Travoprost acid was the most potent PG analog tested in FP receptor functional phosphoinositide turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM). Although latanoprost acid exhibited a relatively high affinity for the FP receptor (Ki = 98 nM), it had significant functional activity at FP (EC50 = 32-124 nM) and EP1 (EC50 = 119 nM) receptors. Bimatoprost acid was less selective, exhibiting a relatively high affinity for the FP (Ki = 83 nM), EP1 (Ki = 95 nM), and EP3 (Ki = 387 nM) receptors. Bimatoprost acid exhibited functional activity at the EP1 (EC50 = 2.7 nM) and FP (EC50 = 2.8-3.8 nM in most cells) receptors. Bimatoprost (nonhydrolyzed amide) also behaved as an FP agonist at the cloned human FP receptor (EC50 = 681 nM), in h-TM (EC50 = 3245 nM) and other cell types. Unoprostone and S-1033 bound with low affinity (Ki = 5.9 microM to > 22 microM) to the FP receptor, were not selective, but activated the FP receptor. In conclusion, travoprost acid has the highest affinity, the highest FP-receptor-selectivity, and the highest potency at the FP receptor as compared to the other ocular hypotensive PG analogs known so far, including free acids of latanoprost, bimatoprost, and unoprostone isopropyl ester.
14733708	202	205	PGs	CHEMICAL	14733708T10
14733708	215	219	PGD2	CHEMICAL	14733708T11
14733708	221	225	PGE2	CHEMICAL	907
14733708	227	239	PGF2(2alpha)	CHEMICAL	14733708T13
14733708	709	724	Travoprost acid	CHEMICAL	14733708T14
14733708	745	747	PG	CHEMICAL	1041
14733708	788	804	phosphoinositide	CHEMICAL	14733708T16
14733708	245	249	PGI2	CHEMICAL	1228
14733708	186	200	prostaglandins	CHEMICAL	14733708T18
14733708	1014	1030	latanoprost acid	CHEMICAL	14733708T19
14733708	1201	1217	Bimatoprost acid	CHEMICAL	14733708T1
14733708	146	148	PG	CHEMICAL	1041
14733708	22	35	prostaglandin	CHEMICAL	14733708T21
14733708	37	39	PG	CHEMICAL	1041
14733708	50	52	PG	CHEMICAL	1041
14733708	1284	1286	FP	GENE-Y	14733708T24
14733708	1301	1304	EP1	GENE-Y	13705
14733708	1323	1326	EP3	GENE-Y	14733708T26
14733708	1406	1409	EP1	GENE-N	13705
14733708	1430	1432	FP	GENE-Y	14733708T28
14733708	1531	1533	FP	GENE-Y	14733708T29
14733708	1352	1368	Bimatoprost acid	CHEMICAL	14733708T2
14733708	1556	1573	human FP receptor	GENE-Y	14733708T30
14733708	1725	1736	FP receptor	GENE-Y	14733708T31
14733708	1776	1787	FP receptor	GENE-Y	14733708T32
14733708	1858	1869	FP-receptor	GENE-Y	14733708T33
14733708	1914	1925	FP receptor	GENE-Y	14733708T34
14733708	445	456	FP-receptor	GENE-Y	14733708T35
14733708	531	542	FP receptor	GENE-Y	14733708T36
14733708	569	571	DP	GENE-N	14733708T37
14733708	590	593	EP1	GENE-Y	13705
14733708	610	613	EP3	GENE-Y	14733708T39
14733708	1478	1489	Bimatoprost	CHEMICAL	895
14733708	630	633	EP4	GENE-Y	14733708T40
14733708	652	654	IP	GENE-Y	14733708T41
14733708	677	679	TP	GENE-Y	14733708T42
14733708	765	776	FP receptor	GENE-Y	14733708T43
14733708	1076	1087	FP receptor	GENE-Y	14733708T44
14733708	1144	1146	FP	GENE-Y	14733708T45
14733708	1170	1173	EP1	GENE-Y	13705
14733708	133	135	FP	GENE-Y	14733708T47
14733708	146	158	PG receptors	GENE-N	14733708T48
14733708	50	61	PG receptor	GENE-N	14733708T49
14733708	1638	1649	Unoprostone	CHEMICAL	14733708T4
14733708	1654	1660	S-1033	CHEMICAL	14733708T5
14733708	1804	1819	travoprost acid	CHEMICAL	14733708T6
14733708	2005	2076	free acids of latanoprost, bimatoprost, and unoprostone isopropyl ester	CHEMICAL	14733708T7
14733708	397	412	Travoprost acid	CHEMICAL	14733708T8
14733708	414	430	[+]-fluprostenol	CHEMICAL	14733708T9

14734046|t|Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger.
14734046|a|Increased Na+/Ca(2+)-exchanger (NCX) and altered beta-adrenoceptor (betaAR) responses are observed in failing human heart. To determine the possible interaction between these changes, we investigated the effect of NCX overexpression on responses to isoproterenol in adult rat ventricular myocytes. Responses to isoproterenol were largely mediated through the beta1AR in control myocytes. Adenovirally-mediated overexpression of NCX, at levels, which did not alter basal contraction of myocytes, markedly depressed the isoproterenol concentration-response curve. Responses to isoproterenol could be restored to normal by beta2AR blockade, suggesting a beta2AR-mediated inhibition of beta1AR signalling. Pertussis toxin normalised isoproterenol responses in NCX cells, indicating that beta2AR effects were mediated by Gi. Negative-inotropic effects of high concentrations of ICI 118,551, previously shown to be due to beta2AR-Gi coupling, were increased in NCX cells. We conclude that NCX upregulation can markedly alter the consequences of betaAR stimulation and that this may contribute to the alterations in betaAR response seen in failing human heart.
14734046	1127	1133	betaAR	GENE-N	14734046T10
14734046	1197	1203	betaAR	GENE-N	14734046T11
14734046	302	305	NCX	GENE-N	14734046T12
14734046	120	123	NCX	GENE-N	14734046T13
14734046	447	454	beta1AR	GENE-Y	14734046T14
14734046	516	519	NCX	GENE-N	14734046T15
14734046	137	154	beta-adrenoceptor	GENE-N	14734046T16
14734046	708	715	beta2AR	GENE-Y	14734046T17
14734046	739	746	beta2AR	GENE-Y	14734046T18
14734046	770	777	beta1AR	GENE-Y	14734046T19
14734046	98	101	Na+	CHEMICAL	14734046T1
14734046	156	162	betaAR	GENE-N	14734046T20
14734046	790	805	Pertussis toxin	GENE-N	14734046T21
14734046	844	847	NCX	GENE-N	14734046T22
14734046	871	878	beta2AR	GENE-Y	14734046T23
14734046	904	906	Gi	GENE-N	14734046T24
14734046	1004	1011	beta2AR	GENE-Y	14734046T25
14734046	1012	1014	Gi	GENE-N	14734046T26
14734046	1043	1046	NCX	GENE-N	14734046T27
14734046	1071	1074	NCX	GENE-N	14734046T28
14734046	66	86	Na+/Ca(2+)-exchanger	GENE-N	14734046T29
14734046	102	108	Ca(2+)	CHEMICAL	14734046T2
14734046	8	25	beta-adrenoceptor	GENE-N	14734046T30
14734046	399	412	isoproterenol	CHEMICAL	14734046T3
14734046	606	619	isoproterenol	CHEMICAL	14734046T4
14734046	663	676	isoproterenol	CHEMICAL	14734046T5
14734046	817	830	isoproterenol	CHEMICAL	14734046T6
14734046	66	69	Na+	CHEMICAL	14734046T7
14734046	70	76	Ca(2+)	CHEMICAL	14734046T8
14734046	98	118	Na+/Ca(2+)-exchanger	GENE-N	14734046T9

14741265|t|Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors.
14741265|a|The nonsteroidal anti-inflammatory drugs flurbiprofen and ibuprofen were modified in an attempt to alter the kinetics of inhibitor binding by COX-1. Contrary to prior predictions, a halogen substituent is not sufficient to confer slow tight-binding behavior. Conversion of the carboxylate moiety of flurbiprofen to an ester or amide abolishes slow tight-binding behavior, regardless of halogenation state.
14741265	58	72	cyclooxygenase	GENE-N	14741265T10
14741265	267	274	halogen	CHEMICAL	14741265T1
14741265	362	373	carboxylate	CHEMICAL	14741265T2
14741265	384	396	flurbiprofen	CHEMICAL	14741265T3
14741265	403	408	ester	CHEMICAL	14741265T4
14741265	412	417	amide	CHEMICAL	14741265T5
14741265	126	138	flurbiprofen	CHEMICAL	14741265T6
14741265	143	152	ibuprofen	CHEMICAL	14741265T7
14741265	36	57	2-aryl propionic acid	CHEMICAL	14741265T8
14741265	227	232	COX-1	GENE-Y	14741265T9
14741265	CPR:4	14741265T8	14741265T10

14751502|t|Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
14751502|a|PURPOSE: Two members of the epidermal growth factor receptor family, EGFR and HER2, have been implicated in radioresistance in breast cancer and other malignancies. To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/HER2 inhibitor, GW572016, on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines. METHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress EGFR or HER2 and luminal mammary epithelial H16N2 cells stably transfected with HER2 were evaluated for the effect of GW572016 on inhibition of ligand-induced or constitutive receptor phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling. RESULTS: GW572016 inhibited constitutive and/or ligand-induced EGFR or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line. GW572016 radiosensitized EGFR-overexpressing cell lines, but HER2-overexpressing cells were unable to form colonies after brief exposure to GW572016 even in the absence of radiation, and thus could not be evaluated for radiosensitization. One cell line was resistant to the antiproliferative and radiosensitizing effects of GW572016, despite receptor inhibition. Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of GW572016 to inhibit downstream ERK and Akt activation, despite inhibition of HER2 phosphorylation. In contrast, sensitive HER2-overexpressing cell lines demonstrated inhibition of both ERK and Akt phosphorylation. CONCLUSION: GW572016 potently inhibits receptor phosphorylation in either EGFR- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects. Resistance to GW572016 was not due to a lack of receptor inhibition, but rather with a lack of inhibition of ERK and Akt, suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation. The SUM185 cell line provides a valuable model for studying mechanisms of resistance of EGFR/HER2 inhibitor therapy.
14751502	1078	1086	tyrosine	CHEMICAL	14751502T10
14751502	42	50	GW572016	CHEMICAL	14751502T11
14751502	1231	1235	EGFR	GENE-Y	108276|3932452|676741
14751502	1267	1271	HER2	GENE-Y	35473
14751502	1686	1689	ERK	GENE-N	14751502T14
14751502	1694	1697	Akt	GENE-N	14751502T15
14751502	1732	1736	HER2	GENE-Y	35473
14751502	1777	1781	HER2	GENE-Y	35473
14751502	1840	1843	ERK	GENE-N	14751502T18
14751502	1848	1851	Akt	GENE-N	14751502T19
14751502	1206	1214	GW572016	CHEMICAL	14751502T1
14751502	1943	1947	EGFR	GENE-Y	108276|3932452|676741
14751502	1952	1956	HER2	GENE-Y	35473
14751502	2153	2156	ERK	GENE-N	14751502T22
14751502	2161	2164	Akt	GENE-N	14751502T23
14751502	382	386	EGFR	GENE-Y	108276|3932452|676741
14751502	2399	2403	EGFR	GENE-Y	108276|3932452|676741
14751502	2404	2408	HER2	GENE-N	35473
14751502	391	395	HER2	GENE-Y	35473
14751502	488	492	EGFR	GENE-Y	108276|3932452|676741
14751502	493	497	HER2	GENE-Y	35473
14751502	1346	1354	GW572016	CHEMICAL	14751502T2
14751502	573	577	EGFR	GENE-Y	108276|3932452|676741
14751502	582	586	HER2	GENE-Y	35473
14751502	726	730	EGFR	GENE-Y	108276|3932452|676741
14751502	734	738	HER2	GENE-Y	35473
14751502	806	810	HER2	GENE-Y	35473
14751502	228	232	EGFR	GENE-Y	108276|3932452|676741
14751502	888	909	constitutive receptor	GENE-N	14751502T36
14751502	237	241	HER2	GENE-Y	35473
14751502	1065	1069	EGFR	GENE-Y	108276|3932452|676741
14751502	1073	1077	HER2	GENE-Y	35473
14751502	1530	1538	GW572016	CHEMICAL	14751502T3
14751502	15	19	EGFR	GENE-Y	108276|3932452|676741
14751502	20	24	HER2	GENE-Y	35473
14751502	25	31	kinase	GENE-N	14751502T42
14751502	54	58	EGFR	GENE-Y	108276|3932452|676741
14751502	64	68	HER2	GENE-Y	35473
14751502	1655	1663	GW572016	CHEMICAL	14751502T4
14751502	1881	1889	GW572016	CHEMICAL	14751502T5
14751502	2058	2066	GW572016	CHEMICAL	14751502T6
14751502	509	517	GW572016	CHEMICAL	14751502T7
14751502	844	852	GW572016	CHEMICAL	14751502T8
14751502	1011	1019	GW572016	CHEMICAL	14751502T9
14751502	CPR:4	14751502T11	108276|3932452|676741
14751502	CPR:4	14751502T11	35473
14751502	CPR:4	14751502T11	14751502T42
14751502	CPR:4	14751502T4	35473
14751502	CPR:4	14751502T5	108276|3932452|676741
14751502	CPR:4	14751502T5	35473
14751502	CPR:4	14751502T7	108276|3932452|676741
14751502	CPR:4	14751502T7	35473
14751502	CPR:4	14751502T9	108276|3932452|676741
14751502	CPR:4	14751502T9	35473

14753499|t|Aquaporin-1 deletion reduces osmotic water permeability and cerebrospinal fluid production.
14753499|a|Aquaporin-1 (AQP1) is a water channel that is strongly expressed at the ventricular-facing surface of choroid plexus epithelium. Using wildtype and AQP1 null mice, we developed novel methods to compare the water permeability in isolated choroid plexus, and cerebrospinal fluid (CSF) production in living mice. Osmotically-induced water transport was rapid in freshly isolated choroid plexus from wildtype mice as measured by a spatial-filtering optical method, and reduced by 5-fold by AQP1 deletion. CSF production, an isosmolar fluid secretion process, was measured by a dye dilution method involving fluid collections using a second microneedle introduced into the cisterna magna. CSF production in wildtype mice was (in microl/min) 0.37 +/- 0.04 microl/min (control), 0.16 +/- 0.03 microl/min (acetazolamide-treated) and 1.14 +/- 0.15 microl/min (forskolin-treated), and reduced by up to 25% in AQP1 null mice. The impaired CSF production in AQP1 null mice provides direct functional evidence for the involvement of AQP1 in CSF formation.
14753499	1038	1042	AQP1	GENE-Y	106854
14753499	0	11	Aquaporin-1	GENE-Y	14753499T11
14753499	890	903	acetazolamide	CHEMICAL	14753499T1
14753499	943	952	forskolin	CHEMICAL	14753499T2
14753499	92	103	Aquaporin-1	GENE-Y	14753499T3
14753499	1112	1116	AQP1	GENE-Y	106854
14753499	105	109	AQP1	GENE-Y	106854
14753499	240	244	AQP1	GENE-Y	106854
14753499	116	129	water channel	GENE-N	14753499T7
14753499	578	582	AQP1	GENE-Y	106854
14753499	991	995	AQP1	GENE-Y	106854

14871885|t|Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion.
14871885|a|Metformin, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (AMPK). Whether metformin or the satiety factor leptin, which also stimulates AMPK in muscle, regulates this enzyme in pancreatic islets is unknown. We have recently shown that forced increases in AMPK activity inhibit insulin secretion from MIN6 cells (da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, and Rutter GA. Biochem J 371: 761-774, 2003). Here, we explore whether 1) glucose, metformin, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate insulin secretion from human islets. Increases in glucose concentration from 0 to 3 and from 3 to 17 mM inhibited AMPK activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells. Incubation with metformin (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells. These studies demonstrate that AMPK activity is subject to regulation by both glucose and metformin in pancreatic islets and clonal beta-cells. The inhibitory effects of metformin on insulin secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.
14871885	1098	1107	metformin	CHEMICAL	14871885T10
14871885	0	9	Metformin	CHEMICAL	323
14871885	37	40	AMP	CHEMICAL	125|407
14871885	98	105	glucose	CHEMICAL	14871885T13
14871885	1209	1216	insulin	GENE-N	14871885T14
14871885	1320	1324	AMPK	GENE-N	14871885T15
14871885	1472	1479	insulin	GENE-N	14871885T16
14871885	297	325	AMP-activated protein kinase	GENE-N	14871885T17
14871885	327	331	AMPK	GENE-N	14871885T18
14871885	404	408	AMPK	GENE-N	14871885T19
14871885	136	145	Metformin	CHEMICAL	323
14871885	523	527	AMPK	GENE-N	14871885T20
14871885	545	552	insulin	GENE-N	14871885T21
14871885	754	758	AMPK	GENE-N	14871885T22
14871885	835	839	AMPK	GENE-N	14871885T23
14871885	858	865	insulin	GENE-Y	14871885T24
14871885	972	976	AMPK	GENE-N	14871885T25
14871885	1129	1133	AMPK	GENE-N	14871885T26
14871885	117	124	insulin	GENE-N	14871885T27
14871885	37	65	AMP-activated protein kinase	GENE-N	14871885T28
14871885	1367	1374	glucose	CHEMICAL	14871885T2
14871885	1379	1388	metformin	CHEMICAL	14871885T3
14871885	1459	1468	metformin	CHEMICAL	14871885T4
14871885	297	300	AMP	CHEMICAL	125|407
14871885	342	351	metformin	CHEMICAL	14871885T6
14871885	714	721	glucose	CHEMICAL	14871885T7
14871885	723	732	metformin	CHEMICAL	14871885T8
14871885	908	915	glucose	CHEMICAL	14871885T9
14871885	CPR:3	14871885T10	14871885T26
14871885	CPR:3	14871885T13	14871885T27
14871885	CPR:3	323	14871885T17
14871885	CPR:3	323	14871885T18
14871885	CPR:3	14871885T6	14871885T19
14871885	CPR:4	14871885T10	14871885T14
14871885	CPR:4	14871885T4	14871885T16
14871885	CPR:4	14871885T9	14871885T25

14993281|t|A novel retinoic acid-responsive element regulates retinoic acid-induced BLR1 expression.
14993281|a|The mechanism of action of retinoic acid (RA) is of broad relevance to cell and developmental biology, nutrition, and cancer chemotherapy. RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA. The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma. Treatment with RAR- and RXR-selective ligands showed that RARalpha synergized with RXRalpha to transcriptionally activate blr1 expression. A 5'-flanking region capable of supporting RA-induced blr1 activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA. Within this sequence DNase I footprinting revealed that RA induced binding of a nuclear protein complex to an element containing two GT boxes. Electromobility shift assays (EMSAs) and supershift assays showed that this element bound recombinant RARalpha and RXRalpha. Without RA there was neither complex binding nor transcriptional activation. Both GT boxes were needed for binding the complex, and mutation of either GT box caused the loss of transcriptional activation by RA. The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary. Each of these sites bound its corresponding transcription factor. A transcription factor-transcription factor binding array analysis of nuclear lysate from RA-treated cells indicated several prominent RARalpha binding partners; among these, Oct1, NFATc3, and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex. RA upregulated expression of these three factors. In sum the results of the present study indicate that RA-induced expression of blr1 expression depends on a novel RA response element. This cis-acting element approximately 1 kb upstream of the transcriptional start consists of two GT boxes that bind RAR and RXR in a nuclear protein complex that also contains Oct1, NFATc3, and CREB2 bound to their cognate downstream consensus binding sites.
14993281	2485	2487	RA	CHEMICAL	14993281T10
14993281	117	130	retinoic acid	CHEMICAL	14993281T11
14993281	502	504	RA	CHEMICAL	14993281T12
14993281	510	512	RA	CHEMICAL	14993281T13
14993281	132	134	RA	CHEMICAL	14993281T14
14993281	557	559	RA	CHEMICAL	14993281T15
14993281	579	587	retinoid	CHEMICAL	14993281T16
14993281	848	850	RA	CHEMICAL	14993281T17
14993281	1004	1006	RA	CHEMICAL	14993281T18
14993281	1064	1066	RA	CHEMICAL	14993281T19
14993281	1284	1286	RA	CHEMICAL	14993281T1
14993281	51	64	retinoic acid	CHEMICAL	14993281T20
14993281	8	21	retinoic acid	CHEMICAL	14993281T21
14993281	1141	1149	GT boxes	GENE-N	14993281T22
14993281	1253	1261	RARalpha	GENE-Y	14993281T23
14993281	1266	1274	RXRalpha	GENE-Y	14993281T24
14993281	1358	1366	GT boxes	GENE-N	14993281T25
14993281	1427	1433	GT box	GENE-N	14993281T26
14993281	1518	1541	RAR-RXR binding element	GENE-N	14993281T27
14993281	1633	1663	octamer transcription factor 1	GENE-Y	14993281T28
14993281	1665	1669	Oct1	GENE-Y	14993281T29
14993281	229	231	RA	CHEMICAL	14993281T2
14993281	1682	1717	nuclear factor of activated T cells	GENE-Y	14993281T30
14993281	1719	1724	NFATc	GENE-Y	14993281T31
14993281	1796	1838	cyclic AMP response element binding factor	GENE-N	14993281T32
14993281	1840	1844	CREB	GENE-N	14993281T33
14993281	269	298	Burkitt's lymphoma receptor 1	GENE-Y	14993281T34
14993281	1907	1911	blr1	GENE-Y	14993281T35
14993281	2135	2143	RARalpha	GENE-Y	14993281T36
14993281	2175	2179	Oct1	GENE-Y	14993281T37
14993281	2181	2187	NFATc3	GENE-Y	14993281T38
14993281	300	304	BLR1	GENE-Y	14993281T39
14993281	1483	1485	RA	CHEMICAL	14993281T3
14993281	2193	2198	CREB2	GENE-Y	14993281T40
14993281	2450	2454	blr1	GENE-Y	14993281T41
14993281	2485	2504	RA response element	GENE-N	14993281T42
14993281	2603	2611	GT boxes	GENE-N	14993281T43
14993281	2622	2625	RAR	GENE-N	14993281T44
14993281	2630	2633	RXR	GENE-N	14993281T45
14993281	2639	2662	nuclear protein complex	GENE-N	14993281T46
14993281	2682	2686	Oct1	GENE-Y	14993281T47
14993281	2688	2694	NFATc3	GENE-Y	14993281T48
14993281	2700	2705	CREB2	GENE-Y	14993281T49
14993281	1583	1585	RA	CHEMICAL	14993281T4
14993281	483	487	blr1	GENE-Y	14993281T50
14993281	557	568	RA receptor	GENE-N	14993281T51
14993281	570	573	RAR	GENE-N	14993281T52
14993281	579	598	retinoid X receptor	GENE-N	14993281T53
14993281	600	603	RXR	GENE-N	14993281T54
14993281	656	664	RXRgamma	GENE-Y	14993281T55
14993281	681	684	RAR	GENE-N	14993281T56
14993281	690	693	RXR	GENE-N	14993281T57
14993281	724	732	RARalpha	GENE-Y	14993281T58
14993281	749	757	RXRalpha	GENE-Y	14993281T59
14993281	1796	1806	cyclic AMP	CHEMICAL	14993281T5
14993281	788	792	blr1	GENE-Y	14993281T60
14993281	859	863	blr1	GENE-Y	14993281T61
14993281	1029	1036	DNase I	GENE-Y	14993281T62
14993281	1088	1111	nuclear protein complex	GENE-N	14993281T63
14993281	73	77	BLR1	GENE-N	14993281T64
14993281	8	40	retinoic acid-responsive element	GENE-N	14993281T65
14993281	2090	2092	RA	CHEMICAL	14993281T6
14993281	2321	2323	RA	CHEMICAL	14993281T7
14993281	2425	2427	RA	CHEMICAL	14993281T8
14993281	325	327	RA	CHEMICAL	14993281T9
14993281	CPR:3	14993281T12	14993281T50
14993281	CPR:3	14993281T17	14993281T61
14993281	CPR:3	14993281T20	14993281T64
14993281	CPR:3	14993281T2	14993281T34
14993281	CPR:3	14993281T2	14993281T39
14993281	CPR:3	14993281T8	14993281T41
14993281	CPR:4	14993281T4	14993281T30

15002740|t|The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.
15002740|a|The present study examined the potential membrane retention of desipramine (DMI) following exposures of 293-hNET cells to DMI, and its effect on [3H]NE uptake. Incubation of cells with 500 nM DMI for 1 h or 1 day persistently inhibited the uptake of [3H]NE up to 7 days, despite daily repeated washing of cells with drug-free medium. Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI. [3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET. A similar cellular retention was observed following incubation of cells with nisoxetine. The results demonstrate that DMI and nisoxetine are persistently retained in cell membranes, at least partly in association with the NET. The retention and slow diffusion of DMI and nisoxetine from membranes may contribute to their pharmacological and modulatory action on NET.
15002740	777	784	[3H]DMI	CHEMICAL	15002740T10
15002740	876	886	nisoxetine	CHEMICAL	15002740T11
15002740	191	194	DMI	CHEMICAL	1139
15002740	917	920	DMI	CHEMICAL	1139
15002740	925	935	nisoxetine	CHEMICAL	15002740T14
15002740	1062	1065	DMI	CHEMICAL	1139
15002740	1070	1080	nisoxetine	CHEMICAL	15002740T16
15002740	37	48	desipramine	CHEMICAL	15002740T17
15002740	78	92	norepinephrine	CHEMICAL	15002740T18
15002740	1161	1164	NET	GENE-Y	15002740T19
15002740	237	240	DMI	CHEMICAL	1139
15002740	223	227	hNET	GENE-Y	15002740T20
15002740	680	683	NET	GENE-Y	15002740T21
15002740	794	797	NET	GENE-Y	15002740T22
15002740	1021	1024	NET	GENE-Y	15002740T23
15002740	78	104	norepinephrine transporter	GENE-Y	15002740T24
15002740	260	266	[3H]NE	CHEMICAL	15002740T2
15002740	307	310	DMI	CHEMICAL	1139
15002740	365	371	[3H]NE	CHEMICAL	15002740T4
15002740	509	512	DMI	CHEMICAL	1139
15002740	595	602	[3H]DMI	CHEMICAL	15002740T6
15002740	604	611	[3H]DMI	CHEMICAL	15002740T7
15002740	695	705	nisoxetine	CHEMICAL	15002740T8
15002740	178	189	desipramine	CHEMICAL	15002740T9
15002740	CPR:4	15002740T17	15002740T24
15002740	CPR:4	15002740T8	15002740T21

15030294|t|AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
15030294|a|Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor). This compound lowers blood pressure dose-dependently in hypertensive patients and has a placebo-like tolerability. The antihypertensive efficacy of irbesartan is greatly enhanced by the coadministration of a diuretic, and fixed-dose combinations of irbesartan and hydrochlorothiazide are now available. Irbesartan-based treatment appears especially effective for high-risk patients, such as those with diabetes, renal disease and cardiac hypertrophy. In patients with Type 2 diabetes, irbesartan delays the development of nephropathy as well as the progression of renal failure. Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II. Irbesartan given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients.
15030294	68	78	irbesartan	CHEMICAL	15030294T10
15030294	199	202	AT1	GENE-Y	15030294T11
15030294	108	122	angiotensin II	GENE-Y	15030294T12
15030294	908	911	AT1	GENE-Y	15030294T13
15030294	1033	1047	angiotensin II	GENE-Y	15030294T14
15030294	0	3	AT1	GENE-Y	15030294T15
15030294	80	90	Irbesartan	CHEMICAL	1018
15030294	362	372	irbesartan	CHEMICAL	15030294T2
15030294	108	122	angiotensin II	CHEMICAL	15030294T3
15030294	463	473	irbesartan	CHEMICAL	15030294T4
15030294	478	497	hydrochlorothiazide	CHEMICAL	15030294T5
15030294	517	527	Irbesartan	CHEMICAL	1018
15030294	699	709	irbesartan	CHEMICAL	15030294T7
15030294	793	803	Irbesartan	CHEMICAL	1018
15030294	1033	1047	angiotensin II	CHEMICAL	15030294T9
15030294	CPR:4	1018	15030294T13
15030294	CPR:4	1018	15030294T14
15030294	CPR:6	1018	15030294T12

15060759|t|Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
15060759|a|To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177. We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of (-)-isoprenaline and (-)-CGP12177.(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the beta(1)-adrenoceptors with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9. The beta-blockers antagonised the effects of (-)-isoprenaline more than the effects of (-)-CGP12177 with potency ratios: (-)-atenolol 1,000, (+/-)-metropolol 676, (-)-pindolol 631, (-)-timolol 589, (+/-)-carvedilol 204, (+/-)-oxprenolol 138, (+/-)-sotalol 132, (-)-propranolol 120, (+/-)-bisoprolol 95, (+/-)-alprenolol 81, (+/-)-nadolol 68 and (-)-bupranolol 56. In intact cells the binding constants of beta-blockers, estimated from competition with 3-5 nM (-)-[(3)H]-CGP12177 (binding to the H-site), correlated with the corresponding affinities estimated from antagonism of the (-)-isoprenaline effects. We conclude that (-)-[(3)H]-CGP12177 binds at two sites in the recombinant beta(1)-adrenoceptor. (-)-CGP12177 is an antagonist of catecholamine effects through the H-site and a non-conventional partial agonist through the L-site. beta-blockers are more potent antagonists through the H-site than the L-site.
15060759	1321	1337	(+/-)-bisoprolol	CHEMICAL	15060759T10
15060759	1342	1358	(+/-)-alprenolol	CHEMICAL	15060759T11
15060759	1363	1376	(+/-)-nadolol	CHEMICAL	15060759T12
15060759	1384	1398	(-)-bupranolol	CHEMICAL	15060759T13
15060759	1498	1517	(-)-[(3)H]-CGP12177	CHEMICAL	15060759T14
15060759	1621	1637	(-)-isoprenaline	CHEMICAL	15060759T15
15060759	1664	1683	(-)-[(3)H]-CGP12177	CHEMICAL	15060759T16
15060759	1744	1756	(-)-CGP12177	CHEMICAL	15060759T17
15060759	1777	1790	catecholamine	CHEMICAL	15060759T18
15060759	313	332	(-)-[(3)H]-CGP12177	CHEMICAL	15060759T19
15060759	1126	1138	(-)-CGP12177	CHEMICAL	15060759T1
15060759	438	448	cyclic AMP	CHEMICAL	15060759T20
15060759	470	486	(-)-isoprenaline	CHEMICAL	15060759T21
15060759	491	503	(-)-CGP12177	CHEMICAL	15060759T22
15060759	504	523	(-)-[(3)H]-CGP12177	CHEMICAL	15060759T23
15060759	613	632	(-)-[(3)H]-CGP12177	CHEMICAL	15060759T24
15060759	187	199	(-)-CGP12177	CHEMICAL	15060759T25
15060759	828	844	(-)-Isoprenaline	CHEMICAL	15060759T26
15060759	849	861	(-)-CGP12177	CHEMICAL	15060759T27
15060759	910	920	cyclic AMP	CHEMICAL	15060759T28
15060759	961	973	(-)-CGP12177	CHEMICAL	15060759T29
15060759	1160	1172	(-)-atenolol	CHEMICAL	15060759T2
15060759	1001	1017	(-)-isoprenaline	CHEMICAL	15060759T30
15060759	1084	1100	(-)-isoprenaline	CHEMICAL	15060759T31
15060759	11	28	(-)-[3H]-CGP12177	CHEMICAL	15060759T32
15060759	241	268	human beta(1)-adrenoceptors	GENE-Y	15060759T33
15060759	1722	1742	beta(1)-adrenoceptor	GENE-Y	15060759T34
15060759	654	675	beta(1)-adrenoceptors	GENE-Y	15060759T35
15060759	213	233	beta(1)-adrenoceptor	GENE-Y	15060759T36
15060759	57	83	human beta 1-adrenoceptors	GENE-Y	15060759T37
15060759	1180	1196	(+/-)-metropolol	CHEMICAL	15060759T3
15060759	1202	1214	(-)-pindolol	CHEMICAL	15060759T4
15060759	1220	1231	(-)-timolol	CHEMICAL	15060759T5
15060759	1237	1253	(+/-)-carvedilol	CHEMICAL	15060759T6
15060759	1259	1275	(+/-)-oxprenolol	CHEMICAL	15060759T7
15060759	1281	1294	(+/-)-sotalol	CHEMICAL	15060759T8
15060759	1300	1315	(-)-propranolol	CHEMICAL	15060759T9
15060759	CPR:5	15060759T25	15060759T33
15060759	CPR:5	15060759T25	15060759T36

15072849|t|Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro.
15072849|a|Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo. Physiologically, the immune system is using perforin-containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose. This functional synergism prompted our current experiments addressing the question whether IMQ may influence perforin-release and/or induce perforin in CTLs in vitro. In peripheral lymphocytes of healthy and diseased subjects, IMQ induced a significant increase of perforin(+) CTLs within 12h in all experiments performed. This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected] IMQ. Perforin release from peripheral blood CTLs after PMA/ionomycin-stimulation was not influenced significantly by IMQ. Thus, the biological activity of IMQ appears to exceed its previously known functions, inasmuch as it boosts up significantly the perforin-granule system.
15072849	283	291	perforin	GENE-Y	15072849T10
15072849	130	150	Toll-like receptor-7	GENE-Y	15072849T11
15072849	491	499	perforin	GENE-Y	15072849T12
15072849	522	530	perforin	GENE-Y	15072849T13
15072849	647	655	perforin	GENE-Y	15072849T14
15072849	152	157	TLR-7	GENE-Y	15072849T15
15072849	822	830	perforin	GENE-Y	15072849T16
15072849	858	866	perforin	GENE-Y	15072849T17
15072849	925	933	perforin	GENE-Y	15072849T18
15072849	989	997	Perforin	GENE-Y	15072849T19
15072849	97	106	Imiquimod	CHEMICAL	714
15072849	13	33	Toll-like receptor-7	GENE-Y	15072849T20
15072849	51	59	perforin	GENE-Y	15072849T21
15072849	1101	1104	IMQ	CHEMICAL	15072849T2
15072849	1139	1142	IMQ	CHEMICAL	15072849T3
15072849	108	111	IMQ	CHEMICAL	15072849T4
15072849	473	476	IMQ	CHEMICAL	15072849T5
15072849	609	612	IMQ	CHEMICAL	15072849T6
15072849	984	987	IMQ	CHEMICAL	15072849T7
15072849	0	9	Imiquimod	CHEMICAL	714
15072849	1236	1244	perforin	GENE-Y	15072849T9
15072849	CPR:3	714	15072849T11
15072849	CPR:3	714	15072849T15
15072849	CPR:3	15072849T3	15072849T9
15072849	CPR:3	15072849T4	15072849T11
15072849	CPR:3	15072849T4	15072849T15
15072849	CPR:3	15072849T6	15072849T14
15072849	CPR:3	15072849T7	15072849T18
15072849	CPR:3	714	15072849T21
15072849	CPR:5	714	15072849T20

15095008|t|Caffeine as a psychomotor stimulant: mechanism of action.
15095008|a|The popularity of caffeine as a psychoactive drug is due to its stimulant properties, which depend on its ability to reduce adenosine transmission in the brain. Adenosine A(1) and A(2A) receptors are expressed in the basal ganglia, a group of structures involved in various aspects of motor control. Caffeine acts as an antagonist to both types of receptors. Increasing evidence indicates that the psychomotor stimulant effect of caffeine is generated by affecting a particular group of projection neurons located in the striatum, the main receiving area of the basal ganglia. These cells express high levels of adenosine A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the dopamine- and cyclic AMP-regulated 32-kDa phosphoprotein DARPP-32. The present review focuses on the effects of caffeine on striatal signal transduction and on their involvement in caffeine-mediated motor stimulation.
15095008	1005	1013	caffeine	CHEMICAL	15095008T10
15095008	0	8	Caffeine	CHEMICAL	194
15095008	219	253	Adenosine A(1) and A(2A) receptors	GENE-N	15095008T12
15095008	670	695	adenosine A(2A) receptors	GENE-Y	15095008T13
15095008	824	880	dopamine- and cyclic AMP-regulated 32-kDa phosphoprotein	GENE-Y	15095008T14
15095008	881	889	DARPP-32	GENE-Y	15095008T15
15095008	182	191	adenosine	CHEMICAL	15095008T1
15095008	219	228	Adenosine	CHEMICAL	630
15095008	76	84	caffeine	CHEMICAL	15095008T3
15095008	358	366	Caffeine	CHEMICAL	194
15095008	488	496	caffeine	CHEMICAL	15095008T5
15095008	670	679	adenosine	CHEMICAL	15095008T6
15095008	824	832	dopamine	CHEMICAL	15095008T7
15095008	838	848	cyclic AMP	CHEMICAL	15095008T8
15095008	936	944	caffeine	CHEMICAL	15095008T9

15133856|t|Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats.
15133856|a|AIM: To investigate the remodeling of mesenteric artery and the expression of TGF-beta1, c-Jun in mesenteric artery and effects of imidapril and irbesartan on the remodeling in spontaneously hypertensive rats (SHR). METHODS: Thirty SHR (male/female, 21/9), aged 13 wk, were randomly divided into 3 groups (7 male rats and 3 female rats each group): SHR group, imidapril group (imidapril 3 mg/kg.d was given in drinking water for 14 wk), and irbesartan group (irbesartan 50 mg/kg.d was given in drinking water foe 14 wk). Ten homogeneous Wistar Kyoto rats, 5 males and 5 females, weighing 206+/-49 g, were selected as normal control group (WKY group). Systolic pressure was measured on d 1, 2, 4, 6, 8, 10, 12 and 14 during the experiment and the rats were killed at the end of the experiment. Angiotensin II (Ang II) level in plasma and mesenteric arteries was measured by radioimmunoassay. The morphology of the secondary branches of mesenteric artery were examined by light microscopy and electron microscopy. Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the expression of transforming growth factor TGF-beta1 and c-Jun mRNA. RESULTS: Compared with imidapril group and irbesartan group, the blood pressure was remarkably increased in SHR group. Ang II level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in imidapril group. The remodeling of mesenteric arteries in SHR group was mostly obvious among the 4 groups. The ratio of TGF-beta1 absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01). Ang II level in plasma and mesenteric arteries in imidapril group was significantly lower than that in irbesartan group (P<0.05). The c-Jun absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05). CONCLUSION: Imidapril and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, c-Jun in SHR. Imidapril is more effective than irbesartan.
15133856	1944	1950	Ang II	CHEMICAL	15133856T10
15133856	1994	2003	imidapril	CHEMICAL	15133856T11
15133856	2047	2057	irbesartan	CHEMICAL	15133856T12
15133856	2244	2253	imidapril	CHEMICAL	15133856T13
15133856	2259	2269	irbesartan	CHEMICAL	15133856T14
15133856	2381	2390	imidapril	CHEMICAL	15133856T15
15133856	2405	2415	irbesartan	CHEMICAL	15133856T16
15133856	2444	2453	Imidapril	CHEMICAL	15133856T17
15133856	2458	2468	irbesartan	CHEMICAL	15133856T18
15133856	2601	2610	Imidapril	CHEMICAL	15133856T19
15133856	1293	1302	imidapril	CHEMICAL	15133856T1
15133856	2634	2644	irbesartan	CHEMICAL	15133856T20
15133856	471	480	imidapril	CHEMICAL	15133856T21
15133856	488	497	imidapril	CHEMICAL	15133856T22
15133856	552	562	irbesartan	CHEMICAL	15133856T23
15133856	570	580	irbesartan	CHEMICAL	15133856T24
15133856	904	918	Angiotensin II	CHEMICAL	15133856T25
15133856	920	926	Ang II	CHEMICAL	15133856T26
15133856	44	53	imidapril	CHEMICAL	15133856T27
15133856	58	68	irbesartan	CHEMICAL	15133856T28
15133856	1217	1243	transforming growth factor	GENE-Y	15133856T29
15133856	1313	1323	irbesartan	CHEMICAL	15133856T2
15133856	1244	1253	TGF-beta1	GENE-Y	15133856T30
15133856	1258	1263	c-Jun	GENE-Y	15133856T31
15133856	1389	1395	Ang II	GENE-Y	15133856T32
15133856	1663	1672	TGF-beta1	GENE-Y	15133856T33
15133856	1697	1702	GAPDH	GENE-Y	108868|675216|1172097|158540|1207532
15133856	1944	1950	Ang II	GENE-Y	15133856T35
15133856	2078	2083	c-Jun	GENE-Y	15133856T36
15133856	2105	2110	GAPDH	GENE-Y	108868|675216|1172097|158540|1207532
15133856	2576	2585	TGF-beta1	GENE-Y	15133856T38
15133856	2587	2592	c-Jun	GENE-Y	15133856T39
15133856	1389	1395	Ang II	CHEMICAL	15133856T3
15133856	189	198	TGF-beta1	GENE-Y	15133856T40
15133856	904	918	Angiotensin II	GENE-Y	15133856T41
15133856	920	926	Ang II	GENE-Y	15133856T42
15133856	200	205	c-Jun	GENE-Y	15133856T43
15133856	242	251	imidapril	CHEMICAL	15133856T4
15133856	1513	1523	irbesartan	CHEMICAL	15133856T5
15133856	1543	1552	imidapril	CHEMICAL	15133856T6
15133856	256	266	irbesartan	CHEMICAL	15133856T7
15133856	1815	1824	imidapril	CHEMICAL	15133856T8
15133856	1836	1846	irbesartan	CHEMICAL	15133856T9
15133856	CPR:3	15133856T12	15133856T35
15133856	CPR:3	15133856T13	15133856T36
15133856	CPR:3	15133856T13	108868|675216|1172097|158540|1207532
15133856	CPR:3	15133856T14	15133856T36
15133856	CPR:3	15133856T14	108868|675216|1172097|158540|1207532
15133856	CPR:3	15133856T5	15133856T32
15133856	CPR:3	15133856T8	15133856T33
15133856	CPR:3	15133856T8	108868|675216|1172097|158540|1207532
15133856	CPR:3	15133856T9	15133856T33
15133856	CPR:3	15133856T9	108868|675216|1172097|158540|1207532
15133856	CPR:4	15133856T11	15133856T35
15133856	CPR:4	15133856T17	15133856T38
15133856	CPR:4	15133856T17	15133856T39
15133856	CPR:4	15133856T18	15133856T38
15133856	CPR:4	15133856T18	15133856T39
15133856	CPR:4	15133856T6	15133856T32

15184278|t|Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles.
15184278|a|BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process. METHODS AND RESULTS: Duloxetine was administered in a randomized, placebo-controlled study in 15 healthy volunteers. Plasma from duloxetine-treated subjects (ex vivo effect) dose-dependently decreased radioligand binding to human NET (maximum inhibition was 60%) (P=0.02). The dose of intravenous tyramine required to raise systolic blood pressure by 30 mm Hg (PD30) increased dose-dependently with duloxetine and was significant at the end of the 120-mg/d dosage (P<0.001). The plasma dihydoxyphenylglycol to NE (DHPG/NE) ratio was reduced significantly at 2 weeks of treatment with 80 mg/d duloxetine (11.3 at baseline, 3.4 at 240 mg/d, P<0.001). Plasma NE was significantly increased starting at 120 mg/d duloxetine. Urine results (corrected for 24-hour creatinine excretion) showed a dose-dependent change from the baseline urinary excretion for NE, DHPG, and the DHPG/NE ratio. The most sensitive measure, the DHPG/NE ratio, was significant at the 80-mg dose. Urinary NE excretion was significantly raised after 2 weeks of treatment with 80 mg/d duloxetine (P<0.001), the lowest dose used in the study. CONCLUSIONS: These findings suggest that the degree of NET blockade can be assessed with the plasma or urine DHPG/NE ratio and the pressor effect of tyramine. Also, the DHPG/NE ratio is more sensitive at the lower end of NET inhibition, whereas tyramine exhibits a linear relation, with NET inhibition commencing at a higher dose.
15184278	236	238	NE	CHEMICAL	15184278T10
15184278	1405	1407	NE	CHEMICAL	15184278T11
15184278	1483	1493	duloxetine	CHEMICAL	15184278T12
15184278	1649	1653	DHPG	CHEMICAL	15184278T13
15184278	1654	1656	NE	CHEMICAL	15184278T14
15184278	1709	1713	DHPG	CHEMICAL	15184278T15
15184278	1714	1716	NE	CHEMICAL	15184278T16
15184278	322	332	duloxetine	CHEMICAL	15184278T17
15184278	334	391	(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine	CHEMICAL	15184278T18
15184278	411	413	NE	CHEMICAL	15184278T19
15184278	1140	1150	duloxetine	CHEMICAL	15184278T1
15184278	453	463	Duloxetine	CHEMICAL	468
15184278	561	571	duloxetine	CHEMICAL	15184278T21
15184278	918	938	dihydoxyphenylglycol	CHEMICAL	15184278T22
15184278	942	944	NE	CHEMICAL	15184278T23
15184278	946	950	DHPG	CHEMICAL	15184278T24
15184278	951	953	NE	CHEMICAL	15184278T25
15184278	1024	1034	duloxetine	CHEMICAL	15184278T26
15184278	1088	1090	NE	CHEMICAL	15184278T27
15184278	23	37	norepinephrine	CHEMICAL	15184278T28
15184278	220	251	norepinephrine (NE) transporter	GENE-Y	15184278T29
15184278	1189	1199	creatinine	CHEMICAL	15184278T2
15184278	253	256	NET	GENE-Y	15184278T30
15184278	1595	1598	NET	GENE-Y	15184278T31
15184278	1761	1764	NET	GENE-Y	15184278T32
15184278	1827	1830	NET	GENE-Y	15184278T33
15184278	295	298	NET	GENE-Y	15184278T34
15184278	656	665	human NET	GENE-Y	15184278T35
15184278	23	49	norepinephrine transporter	GENE-Y	15184278T36
15184278	220	234	norepinephrine	CHEMICAL	15184278T3
15184278	1282	1284	NE	CHEMICAL	15184278T4
15184278	1286	1290	DHPG	CHEMICAL	15184278T5
15184278	1300	1304	DHPG	CHEMICAL	15184278T6
15184278	1305	1307	NE	CHEMICAL	15184278T7
15184278	1347	1351	DHPG	CHEMICAL	15184278T8
15184278	1352	1354	NE	CHEMICAL	15184278T9
15184278	CPR:6	15184278T17	15184278T34
15184278	CPR:6	15184278T18	15184278T34
15184278	CPR:9	15184278T19	15184278T34

15191400|t|Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart.
15191400|a|Auranofin, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and glutathione peroxidase. These enzymes play an important role in protecting cardiac tissue from oxidative stress generated during ischaemia-reperfusion. Auranofin (100 mg/kg) was administered to rats and their hearts were subjected to an in vitro model of ischaemia-reperfusion. The activity of thioredoxin reductase and glutathione peroxidase was determined in liver and heart tissues in an attempt to correlate enzymatic activity with heart recovery after ischaemia-reperfusion. There was significantly less thioredoxin reductase activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of auranofin used was able to selectively inhibit one of these enzyme systems. Rats administered auranofin displayed significantly impaired recovery from ischaemic insult. The end diastolic pressure was increased, whereas the rate pressure product was significantly decreased. The level of postischaemic apoptosis was also assessed by examining caspase-3 activity in tissue homogenates. Auranofin significantly increased the degree of postischaemic apoptosis, leading to poor postischaemic recovery.
15191400	0	9	Auranofin	CHEMICAL	985
15191400	1208	1217	caspase-3	GENE-Y	15191400T11
15191400	210	232	glutathione peroxidase	GENE-N	15191400T12
15191400	504	525	thioredoxin reductase	GENE-Y	15191400T13
15191400	530	552	glutathione peroxidase	GENE-N	15191400T14
15191400	152	174	selenocysteine enzymes	GENE-N	15191400T15
15191400	719	740	thioredoxin reductase	GENE-Y	15191400T16
15191400	184	205	thioredoxin reductase	GENE-Y	15191400T17
15191400	90	99	Auranofin	CHEMICAL	985
15191400	1250	1259	Auranofin	CHEMICAL	985
15191400	210	221	glutathione	CHEMICAL	15191400T3
15191400	362	371	Auranofin	CHEMICAL	985
15191400	530	541	glutathione	CHEMICAL	15191400T5
15191400	152	166	selenocysteine	CHEMICAL	15191400T6
15191400	794	805	glutathione	CHEMICAL	15191400T7
15191400	866	875	auranofin	CHEMICAL	15191400T8
15191400	960	969	auranofin	CHEMICAL	15191400T9
15191400	CPR:4	985	15191400T12
15191400	CPR:4	985	15191400T15
15191400	CPR:4	985	15191400T17
15191400	CPR:4	15191400T8	15191400T16

15206110|t|Gallium and other main group metal compounds as antitumor agents.
15206110|a|Gallium has been the second metal to show activity against malignant tumors in humans soon after the establishment of platinum drugs in routine clinical practice. It has the unique property of inhibiting tumor growth as a simple cation, mainly because of its close resemblance to ferric iron. Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and transferrin receptor-mediated endocytosis. Furthermore, gallium also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on vacuolar-type H(+)-ATPases. Apart from the consequences of iron deprivation, gallium exerts cytotoxic effects by direct interaction with the iron-dependent enzyme ribonucleotide reductase, resulting in reduced dNTP pools and inhibition of DNA synthesis. Both the abundance of transferrin receptors and upregulation of ribonucleotide reductase render tumors susceptible to gallium-induced cytotoxicity. However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting tubulin polymerization. The limitations experienced with gallium nitrate and gallium chloride, which call for a prolonged exposure to low steady-state gallium levels in blood in order to adequately exploit the affinity of gallium to tumor tissues and to avoid severe toxic effects, may be overcome by oral gallium complexes such as tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium(III) (gallium maltolate) or tris(8-quinolinolato)gallium(III) (KP46), which are currently being evaluated in clinical trials and show promise to initiate a revival of gallium in the clinical setting. These two investigational drugs, albeit differing in their complex stability, have both been developed with the intention of providing gallium in a form which allows sufficient intestinal absorption, but without altering its pharmacodynamic effects. Gallium complexes based on other rationales are scarce and, with regard to the well-known antineoplastic potential of this metal, noticeably under-explored. With the recent approval of arsenic trioxide for the second-line treatment of acute promyelocytic leukemia, the clinical revival of arsenic compounds, which have been the mainstay of antileukemic therapy before the age of modern cancer chemotherapy, has already begun. Currently, strong efforts are being made to explore the activity spectrum in other (less rare) malignancies and to gain a deeper insight into the mode of action. Although this development is currently focusing on arsenic trioxide, it should be suited to stimulate investigations into the therapeutic potential of other arsenic compounds as well.
15206110	1764	1771	gallium	CHEMICAL	15206110T10
15206110	1848	1855	gallium	CHEMICAL	15206110T11
15206110	1874	1927	tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium(III)	CHEMICAL	15206110T12
15206110	1929	1946	gallium maltolate	CHEMICAL	15206110T13
15206110	1951	1984	tris(8-quinolinolato)gallium(III)	CHEMICAL	15206110T14
15206110	1986	1990	KP46	CHEMICAL	15206110T15
15206110	2090	2097	gallium	CHEMICAL	15206110T16
15206110	2258	2265	gallium	CHEMICAL	15206110T17
15206110	2373	2380	Gallium	CHEMICAL	15206110T18
15206110	2566	2574	trioxide	CHEMICAL	15206110T19
15206110	66	73	Gallium	CHEMICAL	15206110T1
15206110	2662	2669	arsenic	CHEMICAL	15206110T20
15206110	346	357	ferric iron	CHEMICAL	15206110T21
15206110	3012	3028	arsenic trioxide	CHEMICAL	15206110T22
15206110	3118	3125	arsenic	CHEMICAL	15206110T23
15206110	462	469	gallium	CHEMICAL	15206110T24
15206110	484	488	iron	CHEMICAL	15206110T25
15206110	688	695	gallium	CHEMICAL	15206110T26
15206110	747	751	iron	CHEMICAL	15206110T27
15206110	844	848	H(+)	CHEMICAL	15206110T28
15206110	889	893	iron	CHEMICAL	15206110T29
15206110	1148	1162	ribonucleotide	CHEMICAL	15206110T2
15206110	907	914	gallium	CHEMICAL	15206110T30
15206110	971	975	iron	CHEMICAL	15206110T31
15206110	993	1007	ribonucleotide	CHEMICAL	15206110T32
15206110	0	7	Gallium	CHEMICAL	15206110T33
15206110	1106	1127	transferrin receptors	GENE-N	15206110T34
15206110	1148	1172	ribonucleotide reductase	GENE-N	15206110T35
15206110	1542	1549	tubulin	GENE-N	15206110T36
15206110	616	627	transferrin	GENE-Y	15206110T37
15206110	632	652	transferrin receptor	GENE-N	15206110T38
15206110	830	856	vacuolar-type H(+)-ATPases	GENE-N	15206110T39
15206110	1202	1209	gallium	CHEMICAL	15206110T3
15206110	993	1017	ribonucleotide reductase	GENE-N	15206110T40
15206110	184	192	platinum	CHEMICAL	15206110T4
15206110	1328	1332	iron	CHEMICAL	15206110T5
15206110	1357	1364	gallium	CHEMICAL	15206110T6
15206110	1599	1614	gallium nitrate	CHEMICAL	15206110T7
15206110	1619	1635	gallium chloride	CHEMICAL	15206110T8
15206110	1693	1700	gallium	CHEMICAL	15206110T9
15206110	CPR:4	15206110T26	15206110T39
15206110	CPR:4	15206110T5	15206110T36
15206110	CPR:4	15206110T6	15206110T36

15210974|t|The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
15210974|a|Here, we show that the synaptic vesicle protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. The LEV-binding site is enriched in synaptic vesicles, and photoaffinity labeling of purified synaptic vesicles confirms that it has an apparent molecular mass of approximately 90 kDa. Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative, indicating that SV2A is necessary for LEV binding. LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding. No binding was observed to the related isoforms SV2B and SV2C. Furthermore, there is a high degree of correlation between binding affinities of a series of LEV derivatives to SV2A in fibroblasts and to the LEV-binding site in brain. Finally, there is a strong correlation between the affinity of a compound for SV2A and its ability to protect against seizures in an audiogenic mouse animal model of epilepsy. These experimental results suggest that SV2A is the binding site of LEV in the brain and that LEV acts by modulating the function of SV2A, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs. Further, these results indicate that proteins involved in vesicle exocytosis, and SV2 in particular, are promising targets for the development of new CNS drug therapies.
15210974	178	191	levetiracetam	CHEMICAL	15210974T10
15210974	966	969	LEV	CHEMICAL	15210974T11
15210974	193	196	LEV	CHEMICAL	15210974T12
15210974	81	94	levetiracetam	CHEMICAL	15210974T13
15210974	1209	1213	SV2A	GENE-Y	115229
15210974	1302	1306	SV2A	GENE-Y	115229
15210974	1512	1515	SV2	GENE-N	15210974T16
15210974	119	148	synaptic vesicle protein SV2A	GENE-Y	15210974T17
15210974	547	551	SV2A	GENE-Y	115229
15210974	608	612	SV2A	GENE-Y	115229
15210974	1237	1240	LEV	CHEMICAL	15210974T1
15210974	677	681	SV2A	GENE-Y	115229
15210974	724	728	SV2A	GENE-Y	115229
15210974	808	812	SV2B	GENE-Y	115228|183625
15210974	817	821	SV2C	GENE-Y	116636
15210974	935	939	SV2A	GENE-Y	115229
15210974	1071	1075	SV2A	GENE-Y	115229
15210974	4	33	synaptic vesicle protein SV2A	GENE-Y	15210974T26
15210974	1263	1266	LEV	CHEMICAL	15210974T2
15210974	1345	1348	LEV	CHEMICAL	15210974T3
15210974	301	304	LEV	CHEMICAL	15210974T4
15210974	576	579	LEV	CHEMICAL	15210974T5
15210974	630	633	LEV	CHEMICAL	15210974T6
15210974	643	646	LEV	CHEMICAL	15210974T7
15210974	747	750	LEV	CHEMICAL	15210974T8
15210974	916	919	LEV	CHEMICAL	15210974T9

15240758|t|Electrophysiological properties of mouse horizontal cell GABAA receptors.
15240758|a|GABA-induced currents have been characterized in isolated horizontal cells from lower vertebrates but not in mammalian horizontal cells. Therefore horizontal cells were isolated after enzymatical and mechanical dissociation of the adult mouse retina and visually identified. We recorded from horizontal cell bodies using the whole cell and outside-out configuration of the patch-clamp technique. Extracellular application of GABA induced inward currents carried by chloride ions. GABA-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist bicuculline (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors. Their affinity for GABA was moderate (EC50 = 30 microM), and the Hill coefficient was 1.3, corresponding to two GABA binding sites. GABA responses were partially reduced by picrotoxin with differential effects on peak and steady-state current values. Zinc blocked the GABA response with an IC50 value of 7.3 microM in a noncompetitive manner. Furthermore, GABA receptors of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors. GABA-evoked single-channel currents were characterized by a main conductance state of 29.8 pS and two subconductance states (20.2 and 10.8 pS, respectively). Kinetic analysis of single-channel events within bursts revealed similar mean open and closed times for the main conductance and the 20.2-pS subconductance state, resulting in open probabilities of 44.6 and 42.7%, respectively. The ratio of open to closed times, however, was significantly different for the 10.8-pS subconductance state with an open probability of 57.2%.
15240758	539	547	chloride	CHEMICAL	15240758T10
15240758	554	558	GABA	CHEMICAL	15240758T11
15240758	659	670	bicuculline	CHEMICAL	15240758T12
15240758	767	771	GABA	CHEMICAL	15240758T13
15240758	860	864	GABA	CHEMICAL	15240758T14
15240758	880	884	GABA	CHEMICAL	15240758T15
15240758	921	931	picrotoxin	CHEMICAL	15240758T16
15240758	999	1003	Zinc	CHEMICAL	15240758T17
15240758	1016	1020	GABA	CHEMICAL	15240758T18
15240758	1104	1118	GABA receptors	GENE-N	15240758T19
15240758	74	78	GABA	CHEMICAL	15240758T1
15240758	1340	1355	GABAA receptors	GENE-N	15240758T20
15240758	633	647	GABAA receptor	GENE-N	15240758T21
15240758	717	722	GABAA	GENE-N	15240758T22
15240758	731	746	GABAC receptors	GENE-N	15240758T23
15240758	860	878	GABA binding sites	GENE-N	15240758T24
15240758	57	72	GABAA receptors	GENE-N	15240758T25
15240758	1104	1108	GABA	CHEMICAL	15240758T2
15240758	1186	1194	diazepam	CHEMICAL	15240758T3
15240758	1196	1204	zolpidem	CHEMICAL	15240758T4
15240758	1206	1251	methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate	CHEMICAL	15240758T5
15240758	1253	1266	pentobarbital	CHEMICAL	15240758T6
15240758	1272	1283	alphaxalone	CHEMICAL	15240758T7
15240758	1357	1361	GABA	CHEMICAL	15240758T8
15240758	499	503	GABA	CHEMICAL	15240758T9
15240758	CPR:6	15240758T12	15240758T21

15255990|t|Decreased histamine H1 receptor binding in the brain of depressed patients.
15255990|a|The central histaminergic neuron system modulates the wakefulness, sleep-awake cycle, appetite control, learning and memory, and emotion. Previous studies have reported changes in neuronal histamine release and its metabolism under stress conditions in the mammalian brain. In this study, we examined, using positron emission tomography (PET) and [(11)C]-doxepin, whether the histaminergic neuron system is involved in human depression. Cerebral histamine H1 receptor (H(1)R) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [(11)C]-doxepin. Data were calculated by a graphical analysis on voxel-by-voxel and ROI (region of interests) basis. Binding potential (BP) values for [(11)C]-doxepin binding in the frontal and prefrontal cortices, and cingulate gyrus were significantly lower in the depressed patients than those in the normal control subjects. There was no area of the brain where [(11)C]-doxepin binding was significantly higher in the depressed patients than in the controls. ROI-based analysis also revealed that BP values for [(11)C]-doxepin binding in the frontal cortex and cingulate gyrus decreased in proportion to self-rating depressive scales scores. The results of this study demonstrate that depressed patients have decreased brain H(1)R binding and that this decrease correlates with the severity of depression symptoms. It is therefore suggested that the histaminergic neuron system plays an important role in the pathophysiology of depression and that its modulation may prove to be useful in the treatment of depression.
15255990	522	543	histamine H1 receptor	GENE-Y	15255990T10
15255990	545	550	H(1)R	GENE-Y	15255990T11
15255990	10	31	histamine H1 receptor	GENE-Y	15255990T12
15255990	1177	1192	[(11)C]-doxepin	CHEMICAL	15255990T1
15255990	265	274	histamine	CHEMICAL	15255990T2
15255990	423	438	[(11)C]-doxepin	CHEMICAL	15255990T3
15255990	522	531	histamine	CHEMICAL	15255990T4
15255990	662	677	[(11)C]-doxepin	CHEMICAL	15255990T5
15255990	813	828	[(11)C]-doxepin	CHEMICAL	15255990T6
15255990	1028	1043	[(11)C]-doxepin	CHEMICAL	15255990T7
15255990	10	19	histamine	CHEMICAL	15255990T8
15255990	1391	1396	H(1)R	GENE-Y	15255990T9

15286093|t|Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography.
15286093|a|Histamine H1-receptor (H1R) antagonists, or antihistamines, often induce sedative side effects when used for the treatment of allergic disorders. This study compared the sedative profiles of the second-generation antihistamines, fexofenadine and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of histamine H1-receptor occupancy (H1RO) in the brain. Subjective sleepiness and psychomotor performance were measured in 20 healthy Japanese volunteers at baseline and 90 min after administration of fexofenadine 120 mg or cetirizine 20 mg in a double-blind, placebo-controlled crossover study. Hydroxyzine 30 mg was included as a positive control. H1RO was measured using positron emission tomography (PET) with (11)C-doxepin in 12 of the 20 subjects, and a further 11 volunteers were recruited to act as controls. In psychomotor tests, fexofenadine was not significantly different from placebo and significantly less impairing than cetirizine on some tasks, as well as significantly less impairing than hydroxyzine on all tasks. For subjective sleepiness, fexofenadine was not significantly different from placebo, whereas cetirizine showed a trend toward increased sleepiness compared with fexofenadine and placebo. H1RO was negligible with fexofenadine (-0.1%) but moderately high with cetirizine (26.0%). In conclusion, fexofenadine 120 mg is distinguishable from cetirizine 20 mg, as assessed by H1RO and psychomotor testing.
15286093	1730	1742	fexofenadine	CHEMICAL	15286093T10
15286093	1774	1784	cetirizine	CHEMICAL	15286093T11
15286093	414	428	antihistamines	CHEMICAL	15286093T12
15286093	430	442	fexofenadine	CHEMICAL	15286093T13
15286093	447	457	cetirizine	CHEMICAL	15286093T14
15286093	245	259	antihistamines	CHEMICAL	15286093T15
15286093	707	716	histamine	CHEMICAL	15286093T16
15286093	905	917	fexofenadine	CHEMICAL	15286093T17
15286093	928	938	cetirizine	CHEMICAL	15286093T18
15286093	1000	1011	Hydroxyzine	CHEMICAL	547
15286093	201	210	Histamine	CHEMICAL	15286093T1
15286093	1118	1131	(11)C-doxepin	CHEMICAL	15286093T20
15286093	121	130	histamine	CHEMICAL	15286093T21
15286093	159	170	11C-doxepin	CHEMICAL	15286093T22
15286093	19	31	fexofenadine	CHEMICAL	15286093T23
15286093	36	46	cetirizine	CHEMICAL	15286093T24
15286093	201	222	Histamine H1-receptor	GENE-Y	15286093T25
15286093	224	227	H1R	GENE-Y	15286093T26
15286093	707	728	histamine H1-receptor	GENE-Y	15286093T27
15286093	121	142	histamine H1-receptor	GENE-Y	15286093T28
15286093	1243	1255	fexofenadine	CHEMICAL	15286093T2
15286093	1339	1349	cetirizine	CHEMICAL	15286093T3
15286093	1410	1421	hydroxyzine	CHEMICAL	15286093T4
15286093	1463	1475	fexofenadine	CHEMICAL	15286093T5
15286093	1530	1540	cetirizine	CHEMICAL	15286093T6
15286093	1598	1610	fexofenadine	CHEMICAL	15286093T7
15286093	1649	1661	fexofenadine	CHEMICAL	15286093T8
15286093	1695	1705	cetirizine	CHEMICAL	15286093T9
15286093	CPR:6	15286093T15	15286093T25
15286093	CPR:6	15286093T15	15286093T26

15352500|t|A novel membrane sensor for histamine H1-receptor antagonist "fexofenadine".
15352500|a|The construction and general performance of thirteen new polymeric membrane sensors for the determination of fexofenadine hydrochloride based on its ion exchange with reineckate, tetraphenylborate and tetraiodomercurate have been studied. The effects of membrane composition, type of plasticizer, pH value of sample solution and concentration of the analyte in the sensor internal solution have been thoroughly investigated. The novel sensor based on reineckate exchanger shows a stable, potentiometric response for fexofenadine in the concentration range of 1 x 10(-2) - 2.5 x 10(-6) M at 25 degrees C that is independent of pH in the range of 2.0 - 4.5. The sensor possesses a Nernstian cationic slope of 62.3+/-0.7 mV/concentration decade and a lower detection limit of 1.3 x 10(-6) M with a fast response time of 20 - 40 s. Selectivity coefficients for a number of interfering ions and excipients relative to fexofenadine were investigated. There is negligible interference from almost all studied cations, anions, and pharmaceutical excipients, however, citrizine that has a structure homologous to that of fexofenadine was found to interfere. The determination of fexofenadine in aqueous solution shows an average recovery of 99.83% with a mean relative standard deviation (RSD) of 0.5%. Direct potentiometric determination of fexofenadine in tablets gave results that compare favorably with those obtained by standard spectrophotometric methods. Potentiometric titration of fexofenadine with phosphomolybdic acid as a titrant has been monitored with the proposed sensor as an end point indicator electrode.
15352500	593	605	fexofenadine	CHEMICAL	15352500T10
15352500	990	1002	fexofenadine	CHEMICAL	15352500T11
15352500	28	37	histamine	CHEMICAL	15352500T12
15352500	62	74	fexofenadine	CHEMICAL	15352500T13
15352500	28	49	histamine H1-receptor	GENE-Y	15352500T14
15352500	1136	1145	citrizine	CHEMICAL	15352500T1
15352500	186	212	fexofenadine hydrochloride	CHEMICAL	15352500T2
15352500	1189	1201	fexofenadine	CHEMICAL	15352500T3
15352500	1247	1259	fexofenadine	CHEMICAL	15352500T4
15352500	1410	1422	fexofenadine	CHEMICAL	15352500T5
15352500	1558	1570	fexofenadine	CHEMICAL	15352500T6
15352500	1576	1596	phosphomolybdic acid	CHEMICAL	15352500T7
15352500	256	273	tetraphenylborate	CHEMICAL	15352500T8
15352500	278	296	tetraiodomercurate	CHEMICAL	15352500T9
15352500	CPR:6	15352500T13	15352500T14

15353299|t|Thymidylate synthase: a critical target in cancer therapy?
15353299|a|For the last four decades, synthesis and testing of potentially active drugs (e.g., antimetabolites) have focused on structural modification of existing metabolites as precursors of DNA and RNA synthesis. In recent years, the focus has shifted to synthesis of target-specific agents. Thus, the current emphasis of drug development is directed at inhibiting specific target(s) expressed preferentially, if not exclusively, in tumor tissues, with the ultimate goal of improving the therapeutic efficacy and selectivity of these new agents. Preclinically, proof-of-principle studies were carried out in tumors with specific expression of the intended target. With the hope of translating preclinical findings to the design of implementation of clinical trials. Thymidylate synthase (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis. While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent TS inhibitors. Thus, it is hoped that pronounced and sustained inhibition of this enzyme could result in downstream regulation of molecular markers associated with sensitivity and resistance to these agents. It is also critical to recognize that the degree and duration of inhibition of the target enzyme may depend on the expression level of the target enzyme, thymidylate synthase. Correlative studies in preclinical and clinical systems demonstrated a close relationship between the enzyme level (mRNA and protein) and response to therapy of colorectal cancer patients treated with fluoropyrimidine or Tomudex. However, significant overlap was demonstrated between responders and non-responders. These data are consistent with the hypothesis that prediction of response to anticancer drugs is multifactorial, and TS is one target. Clinically, although overall response of colorectal cancer patients to a variety of TS inhibitors is similar, toxicity profiles are different. The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that thymidine phosphorylase, the activating enzyme for 5-FU, is expressed at a higher level in tumor tissue compared with normal tissue counterparts. It is likely that successful application of TS inhibitors will not only be based on measurement of the TS level in tumors vs. normal tissues, but on the delineation of the consequences of this inhibition on molecular markers associated with cellular proliferation, apoptosis and cell cycle regulation.
15353299	2362	2371	thymidine	CHEMICAL	15353299T10
15353299	2413	2417	5-FU	CHEMICAL	534
15353299	817	828	Thymidylate	CHEMICAL	1580
15353299	881	895	5-fluorouracil	CHEMICAL	15353299T13
15353299	897	901	5-FU	CHEMICAL	534
15353299	921	924	UFT	CHEMICAL	15353299T15
15353299	925	927	LV	CHEMICAL	15353299T16
15353299	929	934	Orzel	CHEMICAL	15353299T17
15353299	937	949	capecitabine	CHEMICAL	1089
15353299	951	957	Xeloda	CHEMICAL	1089
15353299	1104	1120	fluoropyrimidine	CHEMICAL	15353299T1
15353299	964	967	S-1	CHEMICAL	15353299T20
15353299	1033	1065	2-deoxythymidine-5-monophosphate	CHEMICAL	15353299T21
15353299	0	11	Thymidylate	CHEMICAL	1580
15353299	1257	1259	TS	GENE-Y	15353299T23
15353299	1619	1639	thymidylate synthase	GENE-Y	15353299T24
15353299	2073	2075	TS	GENE-Y	15353299T25
15353299	2175	2177	TS	GENE-Y	15353299T26
15353299	2362	2385	thymidine phosphorylase	GENE-Y	15353299T27
15353299	2552	2554	TS	GENE-Y	15353299T28
15353299	2611	2613	TS	GENE-Y	15353299T29
15353299	1177	1183	ZD1694	CHEMICAL	286
15353299	817	837	Thymidylate synthase	GENE-Y	15353299T30
15353299	839	841	TS	GENE-Y	15353299T31
15353299	0	20	Thymidylate synthase	GENE-Y	15353299T32
15353299	1185	1196	raltitrexed	CHEMICAL	15353299T3
15353299	1198	1205	Tomudex	CHEMICAL	286
15353299	1211	1216	AG337	CHEMICAL	15353299T5
15353299	1218	1226	Thymitag	CHEMICAL	15353299T6
15353299	1842	1858	fluoropyrimidine	CHEMICAL	15353299T7
15353299	1862	1869	Tomudex	CHEMICAL	286
15353299	2258	2262	5-FU	CHEMICAL	534
15353299	CPR:4	286	15353299T23
15353299	CPR:4	15353299T3	15353299T23
15353299	CPR:4	286	15353299T23
15353299	CPR:4	15353299T5	15353299T23
15353299	CPR:4	15353299T6	15353299T23
15353299	CPR:9	534	15353299T27
15353299	CPR:9	15353299T21	15353299T30
15353299	CPR:9	15353299T21	15353299T31

15382615|t|[Pharmacological treatment of obesity].
15382615|a|The pharmacological treatment of obesity should be considered when cannot be achieved a 10% weight loss with diet therapy and physical activity. The drugs effective in obesity treatment may act by different mechanisms such as reduction in food intake, inhibition of fat absorption, increase of thermogenesis and stimulation of adipocyte apoptosis. At present, we only have two marketed drugs for obesity treatment. Sibutramine is an inhibitor of norepinephrine, dopamine and serotonina reuptake which inhibits food intake and increases thermogenesis. Sibutramine administration for a year can induce a weight loss of 4-7%. Its main side effects are hypertension, headache, insomnia and constipation. Orlistat is an inhibitor of pancreatic lipase which is able to block the absorption of 30% of ingested fat. Its administration induces weight loss and reduction of ulterior weight regain. Also, this drug improves hypertension dyslipdaemia and helps to prevent diabetes in 52% of cases when administered over four years. The increase in frequency of stools and interference with vitamin absorption are its main side effects. Glucagon-like peptide 1, which increases insulin sensitivity and satiety, adiponectin and PPAR-gamma agonists which reduce insulin resistance and modulates adipocyte generation are the basis for future therapeutic approaches of obesity. Phosphatase inhibitors induce PPAR-gamma phosphorylation and UCP-1 expression leading to an increase in thermogenesis and reduction in appetite.
15382615	1287	1294	insulin	GENE-Y	15382615T10
15382615	1401	1412	Phosphatase	GENE-N	15382615T11
15382615	1431	1441	PPAR-gamma	GENE-Y	15382615T12
15382615	1462	1467	UCP-1	GENE-Y	15382615T13
15382615	768	785	pancreatic lipase	GENE-N	15382615T14
15382615	455	466	Sibutramine	CHEMICAL	1093
15382615	486	500	norepinephrine	CHEMICAL	15382615T2
15382615	502	510	dopamine	CHEMICAL	15382615T3
15382615	591	602	Sibutramine	CHEMICAL	1093
15382615	740	748	Orlistat	CHEMICAL	1071
15382615	1164	1187	Glucagon-like peptide 1	GENE-Y	15382615T6
15382615	1205	1212	insulin	GENE-Y	15382615T7
15382615	1238	1249	adiponectin	GENE-Y	15382615T8
15382615	1254	1264	PPAR-gamma	GENE-Y	15382615T9
15382615	CPR:4	1071	15382615T14

15465654|t|Viability assessment in sandwich-cultured rat hepatocytes after xenobiotic exposure.
15465654|a|Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile. Sandwich-cultured rat hepatocytes maintain functional sodium taurocholate co-transporting polypeptide and Bsep transport proteins, and may be useful to study inhibition of transport by xenobiotics at concentrations below the lowest observable adverse effect level (LOAEL). The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system. The neutral red assay was not amenable to use in this model due to crystal formation on the collagen. Troglitazone decreased viability in every assay examined, with a LOAEL approximately 100 microM. Bosentan also decreased viability as measured by the LDH, MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay. Glibenclamide did not decrease viability with any assay at the xenobiotic concentrations examined in this study. Based on the results of this study, the LDH or propidium iodide assays would be the methods of choice to assess viability in sandwich-cultured rat hepatocytes after xenobiotic exposure.
15465654	577	584	lactate	CHEMICAL	15465654T10
15465654	606	617	alamar blue	CHEMICAL	15465654T11
15465654	619	679	3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide	CHEMICAL	15465654T12
15465654	681	684	MTT	CHEMICAL	15465654T13
15465654	690	706	propidium iodide	CHEMICAL	15465654T14
15465654	972	984	Troglitazone	CHEMICAL	190
15465654	1069	1077	Bosentan	CHEMICAL	549
15465654	184	196	taurocholate	CHEMICAL	15465654T17
15465654	1122	1125	LDH	GENE-N	15465654T18
15465654	1442	1445	LDH	GENE-N	15465654T19
15465654	85	97	Troglitazone	CHEMICAL	190
15465654	262	309	sodium taurocholate co-transporting polypeptide	GENE-Y	15465654T20
15465654	314	318	Bsep	GENE-Y	15465654T21
15465654	577	598	lactate dehydrogenase	GENE-N	15465654T22
15465654	600	603	LDH	GENE-N	15465654T23
15465654	138	159	bile salt export pump	GENE-Y	15465654T24
15465654	802	806	Bsep	GENE-Y	15465654T25
15465654	161	165	Bsep	GENE-Y	15465654T26
15465654	962	970	collagen	GENE-N	15465654T27
15465654	1127	1130	MTT	CHEMICAL	15465654T2
15465654	1135	1151	propidium iodide	CHEMICAL	15465654T3
15465654	1270	1281	alamar blue	CHEMICAL	15465654T4
15465654	1289	1302	Glibenclamide	CHEMICAL	1006
15465654	1449	1465	propidium iodide	CHEMICAL	15465654T6
15465654	99	107	bosentan	CHEMICAL	549
15465654	262	281	sodium taurocholate	CHEMICAL	15465654T8
15465654	112	125	glibenclamide	CHEMICAL	15465654T9
15465654	CPR:4	190	15465654T24
15465654	CPR:4	190	15465654T26
15465654	CPR:4	549	15465654T24
15465654	CPR:4	549	15465654T26
15465654	CPR:4	15465654T9	15465654T24
15465654	CPR:4	15465654T9	15465654T26
15465654	CPR:9	15465654T17	15465654T24
15465654	CPR:9	15465654T17	15465654T26

15494548|t|Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
15494548|a|The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing prostaglandin formation from COX-1. Celecoxib and rofecoxib were among the molecules developed from these efforts. We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied. Recombinant human COX-1 and COX-2 were used to screen for new highly potent and in vitro selective COX-2 inhibitors and compare kinetic mechanisms of binding and enzyme inhibition with other COX inhibitors. Valdecoxib potently inhibits recombinant COX-2, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib. Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib). The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min). Valdecoxib inhibits COX-1 in a competitive fashion only at very high concentrations (IC(50) = 150 microM). Collectively, these data provide a mechanistic basis for the potency and in vitro selectivity of valdecoxib for COX-2. Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM). We also determined whether this in vitro potency and selectivity translated to significant potency in vivo. In rats, valdecoxib demonstrated marked potency in acute and chronic models of inflammation (air pouch ED(50) = 0.06 mg/kg; paw edema ED(50) = 5.9 mg/kg; adjuvant arthritis ED(50) = 0.03 mg/kg). In these same animals, COX-1 was spared at doses greater than 200 mg/kg. These data provide a basis for the observed potent anti-inflammatory activity of valdecoxib in humans.
15494548	219	232	prostaglandin	CHEMICAL	15494548T10
15494548	1800	1810	valdecoxib	CHEMICAL	15494548T11
15494548	255	264	Celecoxib	CHEMICAL	474
15494548	269	278	rofecoxib	CHEMICAL	15494548T13
15494548	2140	2150	valdecoxib	CHEMICAL	15494548T14
15494548	418	428	valdecoxib	CHEMICAL	15494548T15
15494548	740	750	Valdecoxib	CHEMICAL	570
15494548	868	877	celecoxib	CHEMICAL	15494548T17
15494548	894	903	rofecoxib	CHEMICAL	15494548T18
15494548	922	932	etoricoxib	CHEMICAL	15494548T19
15494548	1079	1088	rofecoxib	CHEMICAL	15494548T1
15494548	965	975	valdecoxib	CHEMICAL	15494548T20
15494548	0	10	Valdecoxib	CHEMICAL	570
15494548	1161	1166	COX-2	GENE-Y	15494548T22
15494548	189	194	COX-2	GENE-Y	15494548T23
15494548	1349	1354	COX-1	GENE-Y	15494548T24
15494548	1548	1553	COX-2	GENE-Y	15494548T25
15494548	1597	1618	human whole-blood COX	GENE-N	15494548T26
15494548	1626	1631	COX-2	GENE-Y	15494548T27
15494548	1654	1659	COX-1	GENE-Y	15494548T28
15494548	248	253	COX-1	GENE-Y	15494548T29
15494548	1104	1114	etoricoxib	CHEMICAL	15494548T2
15494548	2009	2014	COX-1	GENE-Y	15494548T30
15494548	87	119	second isoform of cyclooxygenase	GENE-Y	15494548T31
15494548	401	406	COX-2	GENE-Y	15494548T32
15494548	494	499	COX-2	GENE-Y	15494548T33
15494548	545	556	human COX-1	GENE-Y	15494548T34
15494548	561	566	COX-2	GENE-Y	15494548T35
15494548	121	124	COX	GENE-N	15494548T36
15494548	632	637	COX-2	GENE-Y	15494548T37
15494548	724	727	COX	GENE-N	15494548T38
15494548	781	786	COX-2	GENE-Y	15494548T39
15494548	1170	1180	valdecoxib	CHEMICAL	15494548T3
15494548	981	986	COX-2	GENE-Y	15494548T40
15494548	1033	1038	COX-2	GENE-Y	15494548T41
15494548	26	42	cyclooxygenase-2	GENE-Y	15494548T42
15494548	1217	1226	celecoxib	CHEMICAL	15494548T4
15494548	1238	1247	rofecoxib	CHEMICAL	15494548T5
15494548	1264	1274	etoricoxib	CHEMICAL	15494548T6
15494548	1329	1339	Valdecoxib	CHEMICAL	570
15494548	1533	1543	valdecoxib	CHEMICAL	15494548T8
15494548	1555	1565	Valdecoxib	CHEMICAL	570
15494548	CPR:4	15494548T15	15494548T32
15494548	CPR:4	15494548T15	15494548T33
15494548	CPR:4	570	15494548T39
15494548	CPR:4	15494548T17	15494548T39
15494548	CPR:4	15494548T18	15494548T39
15494548	CPR:4	15494548T19	15494548T39
15494548	CPR:4	15494548T20	15494548T41
15494548	CPR:4	570	15494548T24
15494548	CPR:4	570	15494548T26
15494548	CPR:4	570	15494548T27
15494548	CPR:4	570	15494548T28
15494548	CPR:9	15494548T10	15494548T29

15498586|t|An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.
15498586|a|Evidence has accumulated that some of the angiotensin II AT1 receptor antagonists have insulin-sensitizing property. We thus examined the effect of telmisartan on insulin action using 3T3-L1 adipocytes. With standard differentiation inducers, a higher dose of telmisartan effectively facilitated differentiation of 3T3-L1 preadipocytes. Treatment of both differentiating adipocytes and fully differentiated adipocytes with telmisartan caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and adiponectin. By contrast, telmisartan attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differentiated adipocytes. Of note, we demonstrated for the first time that telmisartan augmented GLUT4 protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.
15498586	43	54	telmisartan	CHEMICAL	956
15498586	64	71	glucose	CHEMICAL	15498586T11
15498586	293	300	insulin	GENE-N	15498586T12
15498586	172	199	angiotensin II AT1 receptor	GENE-Y	15498586T13
15498586	617	626	PPARgamma	GENE-Y	15498586T14
15498586	648	651	aP2	GENE-Y	15498586T15
15498586	656	667	adiponectin	GENE-Y	15498586T16
15498586	705	747	11beta-hydroxysteroid dehydrogenase type 1	GENE-Y	15498586T17
15498586	860	865	GLUT4	GENE-Y	15498586T18
15498586	930	937	insulin	GENE-N	15498586T19
15498586	278	289	telmisartan	CHEMICAL	956
15498586	217	224	insulin	GENE-N	15498586T20
15498586	1016	1023	insulin	GENE-N	15498586T21
15498586	3	30	angiotensin II AT1 receptor	GENE-Y	15498586T22
15498586	83	88	GLUT4	GENE-Y	15498586T23
15498586	390	401	telmisartan	CHEMICAL	956
15498586	553	564	telmisartan	CHEMICAL	956
15498586	172	186	angiotensin II	CHEMICAL	15498586T4
15498586	682	693	telmisartan	CHEMICAL	956
15498586	705	726	11beta-hydroxysteroid	CHEMICAL	15498586T6
15498586	838	849	telmisartan	CHEMICAL	956
15498586	889	904	2-deoxy glucose	CHEMICAL	15498586T8
15498586	3	17	angiotensin II	CHEMICAL	15498586T9
15498586	CPR:3	956	15498586T23
15498586	CPR:3	956	15498586T14
15498586	CPR:3	956	15498586T15
15498586	CPR:3	956	15498586T16
15498586	CPR:3	956	15498586T17
15498586	CPR:3	956	15498586T18
15498586	CPR:6	956	15498586T22
15498586	CPR:9	15498586T11	15498586T23
15498586	CPR:9	15498586T8	15498586T18

15557128|t|Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma.
15557128|a|BACKGROUND: In the United States, Puerto Ricans and Mexicans have the highest and lowest asthma prevalence, morbidity, and mortality, respectively. Ethnic-specific differences in the response to drug treatment may contribute to differences in disease outcomes. Genetic variants at the beta(2)-adrenergic receptor (beta(2)AR) may modify asthma severity and albuterol responsiveness. We tested the association of beta(2)AR genotypes with asthma severity and bronchodilator response to albuterol in Puerto Ricans and Mexicans with asthma. METHODS: We used both family-based and cross-sectional tests of association with 8 beta(2)AR single nucleotide polymorphisms in 684 Puerto Rican and Mexican families. Regression analyses were used to determine the interaction between genotype, asthma severity, and bronchodilator drug responsiveness. RESULTS: Among Puerto Ricans with asthma, the arginine (Arg) 16 allele was associated with greater bronchodilator response using both family-based and cross-sectional tests (p = 0.00001-0.01). We found a strong interaction of baseline FEV(1) with the Arg16Glycine (Gly) polymorphism in predicting bronchodilator response. Among Puerto Ricans with asthma with baseline FEV(1) < 80% of predicted, but not in those with FEV(1) > 80%, there was a very strong association between the Arg16 genotype and greater bronchodilator responsiveness. No association was observed between Arg16Gly genotypes and drug responsiveness among Mexicans with asthma. CONCLUSIONS: Ethnic-specific pharmacogenetic differences exist between Arg16Gly genotypes, asthma severity, and bronchodilator response in Puerto Ricans and Mexicans with asthma. These findings underscore the need for additional research on racial/ethnic differences in asthma morbidity and drug responsiveness.
15557128	1653	1661	Arg16Gly	GENE-N	15557128T10
15557128	386	413	beta(2)-adrenergic receptor	GENE-Y	15557128T11
15557128	415	424	beta(2)AR	GENE-Y	15557128T12
15557128	512	521	beta(2)AR	GENE-Y	15557128T13
15557128	720	729	beta(2)AR	GENE-Y	15557128T14
15557128	1203	1206	Gly	CHEMICAL	139
15557128	457	466	albuterol	CHEMICAL	15557128T2
15557128	584	593	albuterol	CHEMICAL	15557128T3
15557128	737	747	nucleotide	CHEMICAL	15557128T4
15557128	984	992	arginine	CHEMICAL	15557128T5
15557128	994	997	Arg	CHEMICAL	119
15557128	43	52	albuterol	CHEMICAL	15557128T7
15557128	1189	1201	Arg16Glycine	GENE-N	15557128T8
15557128	1511	1519	Arg16Gly	GENE-N	15557128T9

15577244|t|Tyrosinase inhibitors from Rhododendron collettianum and their structure-activity relationship (SAR) studies.
15577244|a|A new coumarinolignoid 8'-epi-cleomiscosin A (1) together with the new glycoside 8-O-beta-D-glucopyranosyl-6-hydroxy-2-methyl-4H-1-benzopyrane-4-one (2) have been isolated from the aerial parts of Rhododendron collettianum and their structures determined on the basis of spectroscopic evidences. Tyrosinase inhibition study of these compounds and their structure-activity relationship (SAR) were also investigated. The compounds exhibited potent to mild inhibition activity against the enzyme. Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme tyrosinase, as compared to the standard tyrosinase inhibitors kojic acid (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.
15577244	133	154	8'-epi-cleomiscosin A	CHEMICAL	15577244T1
15577244	116	132	coumarinolignoid	CHEMICAL	15577244T2
15577244	756	766	kojic acid	CHEMICAL	15577244T3
15577244	791	801	L-mimosine	CHEMICAL	15577244T4
15577244	191	258	8-O-beta-D-glucopyranosyl-6-hydroxy-2-methyl-4H-1-benzopyrane-4-one	CHEMICAL	15577244T5
15577244	406	416	Tyrosinase	GENE-Y	15577244T6
15577244	694	704	tyrosinase	GENE-Y	15577244T7
15577244	0	10	Tyrosinase	GENE-Y	15577244T8
15577244	CPR:4	15577244T3	15577244T7
15577244	CPR:4	15577244T4	15577244T7

15646817|t|In vivo activity of the potent oxytocin antagonist on uterine activity in the rat.
15646817|a|Oxytocin antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates. The purpose of the present study was to confirm the duration of TT-235 to block oxytocin-induced uterine contractions in estrous rats. In Experiment 1, the time-response of the three OTAs on uterine contractility was examined. The rats were anesthetized and cannulas were placed in the jugular vein for infusing vehicle (sterile saline), Antag I, Antag II and TT-235. The uterine activity was monitored through a water-filled balloon-tipped cannula placed in the uterine horn. The uterine contractile activity was determined as the integrated area for 10 minutes. Each OTA was administered as a single bolus injection of 5 microg, followed by 100 mU of oxytocin 5 minutes later, also done as a single bolus. Oxytocin injection of the same dosage was repeated every hour for 5 hours. Experiment 2 determined the effect of the three OTAs on uterine oxytocin receptor number (Rn) and binding affinity (Kd). Rats treated with either OTA or vehicle were sacrificed at 0.5 and 4 hours for receptor assay. In Experiment 1, Antag I, Antag II and TT-235 inhibited the integrated uterine response to oxytocin at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05). Two hours after injecting Antag I, inhibition of uterine contractility was 55% lower than controls (p<0.05). At 3 hours, uterine contractility was no longer affected in rats treated with Antag I compared with controls. The suppressive uterine activity with Antag II continued up to 3 hours. However, uterine contractility remained lower (53%) in rats treated with TT-235 5 hours later. In Experiment 2, TT-235 induced a significant decrease (p<0.05) in oxytocin receptor number and binding affinity at both 0.5 and 4 hours compared with controls. Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time point studied compared with controls. In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.
15646817	1674	1682	Antag II	CHEMICAL	15646817T10
15646817	1781	1787	TT-235	CHEMICAL	15646817T11
15646817	1820	1826	TT-235	CHEMICAL	15646817T12
15646817	1870	1878	oxytocin	CHEMICAL	102
15646817	1964	1971	Antag I	CHEMICAL	15646817T14
15646817	1976	1984	Antag II	CHEMICAL	15646817T15
15646817	1999	2007	oxytocin	CHEMICAL	102
15646817	2124	2130	TT-235	CHEMICAL	15646817T17
15646817	2167	2175	oxytocin	CHEMICAL	102
15646817	2190	2198	oxytocin	CHEMICAL	102
15646817	83	91	Oxytocin	CHEMICAL	102
15646817	2220	2228	oxytocin	CHEMICAL	102
15646817	2281	2289	oxytocin	CHEMICAL	102
15646817	303	309	TT-235	CHEMICAL	15646817T22
15646817	2313	2319	TT-235	CHEMICAL	15646817T23
15646817	319	327	oxytocin	CHEMICAL	102
15646817	110	116	TT-235	CHEMICAL	15646817T25
15646817	577	584	Antag I	CHEMICAL	15646817T26
15646817	586	594	Antag II	CHEMICAL	15646817T27
15646817	599	605	TT-235	CHEMICAL	15646817T28
15646817	892	900	oxytocin	CHEMICAL	102
15646817	1086	1094	oxytocin	CHEMICAL	102
15646817	947	955	Oxytocin	CHEMICAL	102
15646817	31	39	oxytocin	CHEMICAL	102
15646817	83	91	Oxytocin	GENE-Y	15646817T32
15646817	1086	1103	oxytocin receptor	GENE-Y	15646817T33
15646817	188	196	oxytocin	GENE-Y	15646817T34
15646817	1329	1337	oxytocin	GENE-Y	15646817T35
15646817	1870	1887	oxytocin receptor	GENE-Y	15646817T36
15646817	1999	2016	oxytocin receptor	GENE-Y	15646817T37
15646817	2167	2175	oxytocin	GENE-Y	15646817T38
15646817	2190	2207	oxytocin receptor	GENE-Y	15646817T39
15646817	188	196	oxytocin	CHEMICAL	102
15646817	2220	2228	oxytocin	GENE-Y	15646817T40
15646817	2281	2289	oxytocin	GENE-Y	15646817T41
15646817	319	327	oxytocin	GENE-Y	15646817T42
15646817	892	900	oxytocin	GENE-Y	15646817T43
15646817	947	955	Oxytocin	GENE-Y	15646817T44
15646817	31	39	oxytocin	GENE-Y	15646817T45
15646817	1255	1262	Antag I	CHEMICAL	15646817T4
15646817	1264	1272	Antag II	CHEMICAL	15646817T5
15646817	1277	1283	TT-235	CHEMICAL	15646817T6
15646817	1329	1337	oxytocin	CHEMICAL	102
15646817	1443	1450	Antag I	CHEMICAL	15646817T8
15646817	1604	1611	Antag I	CHEMICAL	15646817T9
15646817	CPR:4	15646817T12	15646817T36
15646817	CPR:4	15646817T17	15646817T38
15646817	CPR:4	15646817T17	15646817T39
15646817	CPR:4	15646817T22	15646817T42
15646817	CPR:4	15646817T25	15646817T34
15646817	CPR:4	15646817T4	15646817T35
15646817	CPR:4	15646817T5	15646817T35
15646817	CPR:4	15646817T6	15646817T35
15646817	CPR:6	15646817T23	15646817T41
15646817	CPR:6	15646817T25	15646817T32

15655513|t|Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
15655513|a|1. This manuscript presents the preclinical profile of lumiracoxib, a novel cyclooxygenase-2 (COX-2) selective inhibitor. 2. Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively. In cellular assays, lumiracoxib had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1). 3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515). 4. Lumiracoxib was rapidly absorbed following oral administration in rats with peak plasma levels being reached between 0.5 and 1 h. 5. Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6. Efficacy of lumiracoxib in rat models of hyperalgesia, oedema, pyresis and arthritis was dose-dependent and similar to diclofenac. However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05). 7. Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.
15655513	145	156	lumiracoxib	CHEMICAL	15655513T10
15655513	684	695	Lumiracoxib	CHEMICAL	1270
15655513	826	837	lumiracoxib	CHEMICAL	15655513T12
15655513	862	878	thromboxane B(2)	CHEMICAL	15655513T13
15655513	880	886	TxB(2)	CHEMICAL	15655513T14
15655513	967	985	prostaglandin E(2)	CHEMICAL	15655513T15
15655513	987	993	PGE(2)	CHEMICAL	15655513T16
15655513	28	39	lumiracoxib	CHEMICAL	15655513T17
15655513	1267	1272	COX-1	GENE-Y	15655513T18
15655513	1459	1464	COX-2	GENE-Y	15655513T19
15655513	1115	1126	lumiracoxib	CHEMICAL	15655513T1
15655513	246	251	COX-1	GENE-Y	15655513T20
15655513	256	261	COX-2	GENE-Y	15655513T21
15655513	379	384	COX-2	GENE-Y	15655513T22
15655513	444	449	COX-1	GENE-Y	15655513T23
15655513	516	527	human COX-1	GENE-N	15655513T24
15655513	614	619	COX-2	GENE-Y	15655513T25
15655513	638	643	COX-1	GENE-Y	15655513T26
15655513	645	650	COX-1	GENE-Y	15655513T27
15655513	651	656	COX-2	GENE-Y	15655513T28
15655513	848	853	COX-1	GENE-Y	15655513T29
15655513	1222	1232	diclofenac	CHEMICAL	15655513T2
15655513	166	182	cyclooxygenase-2	GENE-Y	15655513T30
15655513	939	944	COX-2	GENE-Y	15655513T31
15655513	184	189	COX-2	GENE-Y	15655513T32
15655513	72	88	cyclooxygenase-2	GENE-Y	15655513T33
15655513	1294	1305	lumiracoxib	CHEMICAL	15655513T3
15655513	215	226	Lumiracoxib	CHEMICAL	1270
15655513	1401	1411	diclofenac	CHEMICAL	15655513T5
15655513	1425	1436	Lumiracoxib	CHEMICAL	1270
15655513	1552	1562	diclofenac	CHEMICAL	15655513T7
15655513	335	346	lumiracoxib	CHEMICAL	15655513T8
15655513	581	592	lumiracoxib	CHEMICAL	15655513T9
15655513	CPR:4	15655513T10	15655513T30
15655513	CPR:4	15655513T10	15655513T32
15655513	CPR:4	15655513T12	15655513T29
15655513	CPR:4	15655513T17	15655513T33
15655513	CPR:4	15655513T3	15655513T18
15655513	CPR:4	1270	15655513T20
15655513	CPR:4	1270	15655513T21
15655513	CPR:4	15655513T5	15655513T18
15655513	CPR:4	1270	15655513T19
15655513	CPR:4	15655513T7	15655513T19
15655513	CPR:4	15655513T8	15655513T22
15655513	CPR:4	15655513T9	15655513T25
15655513	CPR:4	15655513T9	15655513T26
15655513	CPR:4	15655513T9	15655513T27
15655513	CPR:4	15655513T9	15655513T28
15655513	CPR:9	15655513T13	15655513T29
15655513	CPR:9	15655513T14	15655513T29
15655513	CPR:9	15655513T15	15655513T31
15655513	CPR:9	15655513T16	15655513T31

15664409|t|Cloning, sequencing, structural and molecular biological characterization of placental protein 20 (PP20)/human thiamin pyrophosphokinase (hTPK).
15664409|a|Full-length cDNAs of placental protein 20 (PP20) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human thiamin pyrophosphokinase (hTPK) as confirmed by protein sequence analysis. Genomic alignment showed that the PP20/hTPK gene contains 9 exons. It is abundantly expressed in placenta, as numerous EST clones were identified. As thiamine metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20/hTPK may have a role in placental diseases. Analysis of the 1kb promoter region showed numerous putative transcription factor binding sites, which might be responsible for the ubiquitous PP20/hTPK expression. This may also be in accordance with the presence of the protein in tissues responsible for the regulation of the exquisite balance between cell division, differentiation and survival. TPK activity of the purified and recombinant protein was proved by mass spectrometry with electrospray ionization. By Western blot, PP20/hTPK was found in all human normal and tumorous adult and fetal tissues in nearly equal amounts, but not in sera. By immunohistochemical and immunofluorescent confocal imaging methods, diffuse labelling in the cytoplasm of the syncytiotrophoblasts and weak staining of the trophoblasts were observed, and the amount of PP20/hTPK decreased from the first trimester to the end of gestation. A 3D model of PP20/hTPK was computed (PDB No.: 1OLY) by homology modelling. A high degree of structural homology showed that the thiamin binding site was highly similar to that of the mouse enzyme, but highly different from the bacterial ones. Comparison of the catalytic centre sequences revealed differences, raising the possibility of designing new drugs which specifically inhibit bacterial and fungal enzymes without affecting PP20/hTPK and offering the possibility for safe antimicrobial therapy during pregnancy.
15664409	1580	1584	hTPK	GENE-Y	15664409T10
15664409	303	334	human thiamin pyrophosphokinase	GENE-Y	15664409T11
15664409	1993	1997	PP20	GENE-Y	15664409T12
15664409	1998	2002	hTPK	GENE-Y	15664409T13
15664409	336	340	hTPK	GENE-Y	15664409T14
15664409	166	186	placental protein 20	GENE-Y	15664409T15
15664409	419	423	PP20	GENE-Y	15664409T16
15664409	424	428	hTPK	GENE-Y	15664409T17
15664409	188	192	PP20	GENE-Y	15664409T18
15664409	637	641	PP20	GENE-Y	15664409T19
15664409	1690	1697	thiamin	CHEMICAL	15664409T1
15664409	642	646	hTPK	GENE-Y	15664409T20
15664409	829	833	PP20	GENE-Y	15664409T21
15664409	834	838	hTPK	GENE-Y	15664409T22
15664409	1035	1038	TPK	GENE-Y	15664409T23
15664409	105	136	human thiamin pyrophosphokinase	GENE-Y	15664409T24
15664409	138	142	hTPK	GENE-Y	15664409T25
15664409	77	97	placental protein 20	GENE-Y	15664409T26
15664409	99	103	PP20	GENE-Y	15664409T27
15664409	309	316	thiamin	CHEMICAL	15664409T2
15664409	535	543	thiamine	CHEMICAL	15664409T3
15664409	111	118	thiamin	CHEMICAL	15664409T4
15664409	1167	1171	PP20	GENE-Y	15664409T5
15664409	1172	1176	hTPK	GENE-Y	15664409T6
15664409	1491	1495	PP20	GENE-Y	15664409T7
15664409	1496	1500	hTPK	GENE-Y	15664409T8
15664409	1575	1579	PP20	GENE-Y	15664409T9
15664409	CPR:9	15664409T3	15664409T19
15664409	CPR:9	15664409T3	15664409T20

15704203|t|Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
15704203|a|Denufosol tetrasodium (INS37217) is a selective P2Y(2) agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF. The Cl(-) secretory response is mediated via a non-CFTR pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport. Denufosol is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated P2Y(2) agonists. The goal of this phase 1/phase 2 study was to assess the safety and tolerability of single and repeated doses of aerosolized denufosol in subjects with CF. The study was a double-blind, placebo-controlled, multicenter comparison of ascending single doses of denufosol (10, 20, 40, and 60 mg, administered by inhalation via the Pari LC Star nebulizer) vs. placebo (normal saline), followed by a comparison of twice-daily administration of the maximum tolerated dose (MTD) of denufosol or placebo for 5 days. Thirty-seven adult (18 years of age or older) and 24 pediatric (5-17 years of age) subjects with CF were evaluated in five cohorts. Subjects were randomized in a 3:1 ratio to receive either denufosol or placebo within each cohort. The percent of subjects experiencing adverse events was similar between the denufosol and placebo groups. The most common adverse event in subjects receiving denufosol was chest tightness in adult subjects (39%) and cough in pediatric subjects (56%). Three (7%) subjects receiving denufosol and one (7%) subject receiving placebo experienced a serious adverse event. Forced expiratory volume in 1 sec (FEV(1)) profiles following dosing were similar across treatment groups, with some acute, reversible decline seen in both groups, most notably in subjects with lower lung function at baseline. In conclusion, doses up to 60 mg of denufosol inhalation solution were well-tolerated in most subjects. Some intolerability was noted among subjects with lower baseline lung function. Based on the results of this phase 1/phase 2 study, the Therapeutics Development Network (TDN) of the Cystic Fibrosis Foundation (CFF) and Inspire Pharmaceuticals, Inc., recently completed a multicenter, 28-day, phase 2 safety and efficacy clinical trial of denufosol inhalation solution in CF subjects with mild lung disease.
15704203	422	427	Cl(-)	CHEMICAL	15704203T10
15704203	2563	2572	denufosol	CHEMICAL	15704203T11
15704203	509	514	Cl(-)	CHEMICAL	15704203T12
15704203	599	604	Na(+)	CHEMICAL	15704203T13
15704203	616	625	Denufosol	CHEMICAL	4775
15704203	914	923	denufosol	CHEMICAL	15704203T15
15704203	1047	1056	denufosol	CHEMICAL	15704203T16
15704203	27	48	denufosol tetrasodium	CHEMICAL	15704203T17
15704203	469	473	CFTR	GENE-Y	107506
15704203	554	560	P2Y(2)	GENE-Y	15704203T19
15704203	185	206	Denufosol tetrasodium	CHEMICAL	15704203T1
15704203	233	239	P2Y(2)	GENE-Y	15704203T20
15704203	772	778	P2Y(2)	GENE-Y	15704203T21
15704203	78	91	P2Y2 receptor	GENE-Y	15704203T22
15704203	291	296	Cl(-)	CHEMICAL	15704203T2
15704203	1263	1272	denufosol	CHEMICAL	15704203T3
15704203	1486	1495	denufosol	CHEMICAL	15704203T4
15704203	1603	1612	denufosol	CHEMICAL	15704203T5
15704203	1685	1694	denufosol	CHEMICAL	15704203T6
15704203	1808	1817	denufosol	CHEMICAL	15704203T7
15704203	2157	2166	denufosol	CHEMICAL	15704203T8
15704203	208	216	INS37217	CHEMICAL	15704203T9
15704203	CPR:5	4775	15704203T21
15704203	CPR:5	15704203T17	15704203T22
15704203	CPR:5	15704203T1	15704203T20
15704203	CPR:5	15704203T9	15704203T20
15704203	CPR:9	15704203T10	107506

15723099|t|The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.
15723099|a|In a previous study, we demonstrated that a dextromethorphan analog, dimemorfan, has neuroprotective effects. Dextromethorphan and dimemorfan are high-affinity ligands at sigma1 receptors. Dextromethorphan has moderate affinities for phencyclidine sites, while dimemorfan has very low affinities for such sites, suggesting that these sites are not essential for the anticonvulsant actions of dimemorfan. Kainate (KA) administration (10 mg kg(-1), i.p.) produced robust convulsions lasting 4-6 h in rats. Pre-treatment with dimemorfan (12 or 24 mg kg(-1)) reduced seizures in a dose-dependent manner. Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. These effects of dimemorfan were comparable to those of dextromethorphan. The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors. We asked whether dimemorfan produces the behavioral side effects seen with dextromethorphan or dextrorphan (a phencyclidine-like metabolite of dextromethorphan). Conditioned place preference and circling behaviors were significantly increased in mice treated with phencyclidine, dextrorphan or dextromethorphan, while mice treated with dimemorfan showed no behavioral side effects. Our results suggest that dimemorfan is equipotent to dextromethorphan in preventing KA-induced seizures, while it may lack behavioral effects, such as psychotomimetic reactions.
15723099	1496	1512	dextromethorphan	CHEMICAL	15723099T10
15723099	1617	1630	phencyclidine	CHEMICAL	15723099T11
15723099	1632	1643	dextrorphan	CHEMICAL	15723099T12
15723099	1647	1663	dextromethorphan	CHEMICAL	15723099T13
15723099	1760	1770	dimemorfan	CHEMICAL	15723099T14
15723099	1788	1804	dextromethorphan	CHEMICAL	15723099T15
15723099	1819	1821	KA	CHEMICAL	15723099T16
15723099	345	361	Dextromethorphan	CHEMICAL	504
15723099	390	403	phencyclidine	CHEMICAL	15723099T18
15723099	417	427	dimemorfan	CHEMICAL	15723099T19
15723099	1167	1174	BD 1047	CHEMICAL	15723099T1
15723099	548	558	dimemorfan	CHEMICAL	15723099T20
15723099	560	567	Kainate	CHEMICAL	15723099T21
15723099	569	571	KA	CHEMICAL	15723099T22
15723099	200	216	dextromethorphan	CHEMICAL	15723099T23
15723099	679	689	dimemorfan	CHEMICAL	15723099T24
15723099	756	766	Dimemorfan	CHEMICAL	15723099T25
15723099	801	803	KA	CHEMICAL	15723099T26
15723099	225	235	dimemorfan	CHEMICAL	15723099T27
15723099	977	987	dimemorfan	CHEMICAL	15723099T28
15723099	1016	1032	dextromethorphan	CHEMICAL	15723099T29
15723099	1221	1237	dextromethorphan	CHEMICAL	15723099T2
15723099	1063	1079	dextromethorphan	CHEMICAL	15723099T30
15723099	1083	1093	dimemorfan	CHEMICAL	15723099T31
15723099	138	154	dextromethorphan	CHEMICAL	15723099T32
15723099	28	38	dimemorfan	CHEMICAL	15723099T33
15723099	4	20	dextromethorphan	CHEMICAL	15723099T34
15723099	1285	1300	sigma1 receptor	GENE-Y	15723099T35
15723099	1325	1329	AP-1	GENE-Y	15723099T36
15723099	327	343	sigma1 receptors	GENE-Y	15723099T37
15723099	825	830	c-fos	GENE-Y	15723099T38
15723099	831	836	c-jun	GENE-Y	15723099T39
15723099	1241	1251	dimemorfan	CHEMICAL	15723099T3
15723099	849	873	activator protein (AP)-1	GENE-Y	15723099T40
15723099	1140	1155	sigma1 receptor	GENE-Y	15723099T41
15723099	79	94	sigma1 receptor	GENE-Y	15723099T42
15723099	266	282	Dextromethorphan	CHEMICAL	504
15723099	1370	1380	dimemorfan	CHEMICAL	15723099T5
15723099	1428	1444	dextromethorphan	CHEMICAL	15723099T6
15723099	1448	1459	dextrorphan	CHEMICAL	15723099T7
15723099	1463	1476	phencyclidine	CHEMICAL	15723099T8
15723099	287	297	dimemorfan	CHEMICAL	15723099T9
15723099	CPR:3	15723099T26	15723099T38
15723099	CPR:3	15723099T26	15723099T39
15723099	CPR:3	15723099T26	15723099T40
15723099	CPR:3	15723099T33	15723099T42
15723099	CPR:3	15723099T34	15723099T42
15723099	CPR:4	15723099T25	15723099T38
15723099	CPR:4	15723099T25	15723099T39
15723099	CPR:4	15723099T25	15723099T40
15723099	CPR:6	15723099T1	15723099T41

15740719|t|Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
15740719|a|We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin. For this purpose, chimeric 'gain-in function' oxytocin/vasopressin V2 receptors were expressed in COS-7 cells. These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996. Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V2 vasopressin receptor. J. Biol. Chem. 271, 31593-31601). In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg8]vasopressin, carbetocin, and atosiban. The binding profiles for the agonists oxytocin and carbetocin were found to be similar. For both agonists, important binding domains were the extracellular N-terminus (=E1) and the extracellular loops E2 and E3 from the oxytocin receptor. For the vasopressin V1A/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor. In contrast, the binding of barusiban was significantly improved when the transmembrane domains 1 and 2 were transferred from the oxytocin receptor to the vasopressin V2 receptor. The binding domain of barusiban differs from the binding domain of the agonists and the nonselective oxytocin receptor antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies. Overall, the data supported the concept of a central pocket site within the oxytocin receptor.
15740719	1596	1607	vasopressin	CHEMICAL	15740719T10
15740719	1649	1658	barusiban	CHEMICAL	15740719T11
15740719	305	316	vasopressin	CHEMICAL	15740719T12
15740719	1751	1759	oxytocin	CHEMICAL	102
15740719	1776	1787	vasopressin	CHEMICAL	15740719T14
15740719	1823	1832	barusiban	CHEMICAL	15740719T15
15740719	1902	1910	oxytocin	CHEMICAL	102
15740719	1931	1973	d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin	CHEMICAL	15740719T17
15740719	2090	2098	oxytocin	CHEMICAL	102
15740719	350	358	atosiban	CHEMICAL	15740719T19
15740719	1166	1176	carbetocin	CHEMICAL	15740719T1
15740719	376	384	oxytocin	CHEMICAL	102
15740719	389	399	carbetocin	CHEMICAL	15740719T21
15740719	447	455	oxytocin	CHEMICAL	102
15740719	456	467	vasopressin	CHEMICAL	15740719T23
15740719	193	201	oxytocin	CHEMICAL	102
15740719	591	599	oxytocin	CHEMICAL	102
15740719	626	637	vasopressin	CHEMICAL	15740719T26
15740719	750	758	oxytocin	CHEMICAL	102
15740719	215	224	barusiban	CHEMICAL	15740719T28
15740719	876	884	oxytocin	CHEMICAL	102
15740719	1182	1190	atosiban	CHEMICAL	15740719T2
15740719	932	943	vasopressin	CHEMICAL	15740719T30
15740719	1073	1082	barusiban	CHEMICAL	15740719T31
15740719	245	253	oxytocin	CHEMICAL	102
15740719	1137	1145	oxytocin	CHEMICAL	102
15740719	1147	1164	[Arg8]vasopressin	CHEMICAL	15740719T34
15740719	128	136	oxytocin	CHEMICAL	102
15740719	141	151	carbetocin	CHEMICAL	15740719T36
15740719	23	31	oxytocin	CHEMICAL	102
15740719	59	67	oxytocin	CHEMICAL	102
15740719	88	97	barusiban	CHEMICAL	15740719T39
15740719	1230	1238	oxytocin	CHEMICAL	102
15740719	1153	1164	vasopressin	GENE-Y	15740719T40
15740719	1230	1238	oxytocin	GENE-Y	15740719T41
15740719	1412	1429	oxytocin receptor	GENE-Y	15740719T42
15740719	1439	1472	vasopressin V1A/oxytocin receptor	GENE-N	15740719T43
15740719	1596	1619	vasopressin V2 receptor	GENE-Y	15740719T44
15740719	305	338	vasopressin V1A/oxytocin receptor	GENE-N	15740719T45
15740719	1776	1799	vasopressin V2 receptor	GENE-Y	15740719T46
15740719	1902	1919	oxytocin receptor	GENE-Y	15740719T47
15740719	1964	1973	vasotocin	GENE-N	15740719T48
15740719	2090	2107	oxytocin receptor	GENE-Y	15740719T49
15740719	1243	1253	carbetocin	CHEMICAL	15740719T4
15740719	376	384	oxytocin	GENE-Y	15740719T50
15740719	447	480	oxytocin/vasopressin V2 receptors	GENE-N	15740719T51
15740719	193	210	oxytocin receptor	GENE-Y	15740719T52
15740719	591	608	oxytocin receptor	GENE-Y	15740719T53
15740719	626	649	vasopressin V2 receptor	GENE-Y	15740719T54
15740719	750	767	oxytocin receptor	GENE-Y	15740719T55
15740719	876	893	oxytocin receptor	GENE-Y	15740719T56
15740719	929	952	V2 vasopressin receptor	GENE-Y	15740719T57
15740719	245	262	oxytocin receptor	GENE-Y	15740719T58
15740719	1137	1145	oxytocin	GENE-Y	15740719T59
15740719	1348	1349	N	CHEMICAL	167
15740719	128	136	oxytocin	GENE-Y	15740719T60
15740719	23	40	oxytocin receptor	GENE-Y	15740719T61
15740719	59	76	oxytocin receptor	GENE-Y	15740719T62
15740719	1412	1420	oxytocin	CHEMICAL	102
15740719	1439	1450	vasopressin	CHEMICAL	15740719T7
15740719	1455	1463	oxytocin	CHEMICAL	102
15740719	1484	1492	atosiban	CHEMICAL	15740719T9
15740719	CPR:5	102	15740719T45
15740719	CPR:5	15740719T21	15740719T45
15740719	CPR:5	102	15740719T62
15740719	CPR:5	15740719T36	15740719T62
15740719	CPR:6	15740719T17	15740719T47
15740719	CPR:6	15740719T19	15740719T45
15740719	CPR:6	15740719T28	15740719T58
15740719	CPR:6	15740719T39	15740719T62
15740719	CPR:6	15740719T9	15740719T43

15772097|t|Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase.
15772097|a|In the mouse, neurotransmitter metabolism can be regulated by modulation of the synthesis of pyridoxal 5'-phosphate and failure to maintain pyridoxal phosphate (PLP) levels results in epilepsy. This study of five patients with neonatal epileptic encephalopathy suggests that the same is true in man. Cerebrospinal fluid and urine analyses indicated reduced activity of aromatic L-amino acid decarboxylase and other PLP-dependent enzymes. Seizures ceased with the administration of PLP, having been resistant to treatment with pyridoxine, suggesting a defect of pyridox(am)ine 5'-phosphate oxidase (PNPO). Sequencing of the PNPO gene identified homozygous missense, splice site and stop codon mutations. Expression studies in Chinese hamster ovary cells showed that the splice site (IVS3-1g>a) and stop codon (X262Q) mutations were null activity mutations and that the missense mutation (R229W) markedly reduced pyridox(am)ine phosphate oxidase activity. Maintenance of optimal PLP levels in the brain may be important in many neurological disorders in which neurotransmitter metabolism is disturbed (either as a primary or as a secondary phenomenon).
15772097	80	107	pyridox(am)ine 5'-phosphate	CHEMICAL	15772097T10
15772097	486	521	aromatic L-amino acid decarboxylase	GENE-Y	15772097T11
15772097	678	713	pyridox(am)ine 5'-phosphate oxidase	GENE-Y	15772097T12
15772097	715	719	PNPO	GENE-Y	120463
15772097	740	744	PNPO	GENE-Y	120463
15772097	905	908	g>a	GENE-N	15772097T15
15772097	1004	1009	R229W	GENE-N	15772097T16
15772097	1028	1060	pyridox(am)ine phosphate oxidase	GENE-Y	15772097T17
15772097	61	65	PNPO	GENE-Y	120463
15772097	80	115	pyridox(am)ine 5'-phosphate oxidase	GENE-Y	15772097T19
15772097	257	276	pyridoxal phosphate	CHEMICAL	15772097T1
15772097	278	281	PLP	CHEMICAL	109
15772097	486	507	aromatic L-amino acid	CHEMICAL	15772097T3
15772097	532	535	PLP	CHEMICAL	109
15772097	598	601	PLP	CHEMICAL	109
15772097	678	705	pyridox(am)ine 5'-phosphate	CHEMICAL	15772097T6
15772097	1028	1052	pyridox(am)ine phosphate	CHEMICAL	15772097T7
15772097	210	232	pyridoxal 5'-phosphate	CHEMICAL	15772097T8
15772097	1094	1097	PLP	CHEMICAL	109

15795105|t|Effect of 5-azacytidine and procainamide on CD3-zeta chain expression in Jurkat T cells.
15795105|a|It has been observed that decrease of DNA methyltransferase 1 (DNMT1) activity is associated with low content of the CD3-zeta (zeta) chain in T cell receptor (TCR)/CD3 complex of T cells in systemic lupus erythematosus (SLE) patients. The CD3-zeta chain plays a pivotal role in intracellular signal transmission between TCR/CD3 complex and nuclei. The compounds 5'-azacytidine (AZC) and procainamide (PCA) belong to inhibitors of DNMT1, whose low activity correlates with increase in transcription of various genes. Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that AZC and PCA did not profoundly affect on CD3-zeta chain transcription in Jurkat T leukemia cells clone E6-1. However, the flowcytometric analysis revealed that AZC and PCA decreased intracellular contents of CD3-zeta chain in these cells in dose dependent manner. Our results suggest that decrease of DNMT1 activity may alter intracellular signal transmission without effect on transcription level of CD3-zeta chain.
15795105	28	40	procainamide	CHEMICAL	15795105T10
15795105	1106	1120	CD3-zeta chain	GENE-Y	15795105T11
15795105	206	227	CD3-zeta (zeta) chain	GENE-Y	15795105T12
15795105	231	246	T cell receptor	GENE-N	15795105T13
15795105	248	251	TCR	GENE-N	15795105T14
15795105	253	256	CD3	GENE-N	15795105T15
15795105	328	342	CD3-zeta chain	GENE-Y	15795105T16
15795105	409	412	TCR	GENE-N	15795105T17
15795105	413	416	CD3	GENE-N	15795105T18
15795105	127	150	DNA methyltransferase 1	GENE-Y	15795105T19
15795105	451	465	5'-azacytidine	CHEMICAL	15795105T1
15795105	519	524	DNMT1	GENE-Y	108123|158481
15795105	152	157	DNMT1	GENE-Y	108123|158481
15795105	746	760	CD3-zeta chain	GENE-Y	15795105T22
15795105	913	927	CD3-zeta chain	GENE-Y	15795105T23
15795105	1006	1011	DNMT1	GENE-Y	108123|158481
15795105	44	58	CD3-zeta chain	GENE-Y	15795105T25
15795105	467	470	AZC	CHEMICAL	15795105T2
15795105	476	488	procainamide	CHEMICAL	15795105T3
15795105	490	493	PCA	CHEMICAL	15795105T4
15795105	705	708	AZC	CHEMICAL	15795105T5
15795105	713	716	PCA	CHEMICAL	15795105T6
15795105	865	868	AZC	CHEMICAL	15795105T7
15795105	873	876	PCA	CHEMICAL	15795105T8
15795105	10	23	5-azacytidine	CHEMICAL	15795105T9
15795105	CPR:4	15795105T1	108123|158481
15795105	CPR:4	15795105T2	108123|158481
15795105	CPR:4	15795105T3	108123|158481
15795105	CPR:4	15795105T4	108123|158481
15795105	CPR:4	15795105T7	15795105T23
15795105	CPR:4	15795105T8	15795105T23

15805545|t|Changes in gene expression associated with loss of function of the NSDHL sterol dehydrogenase in mouse embryonic fibroblasts.
15805545|a|Seven human disorders of postsqualene cholesterol biosynthesis have been described. One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene NADH sterol dehydrogenase-like (NSDHL) encoding a sterol dehydrogenase. A series of mutant alleles of the murine Nsdhl gene are carried by bare patches (Bpa) mice, with Bpa(1H) representing a null allele. Heterozygous Bpa(1H) females display skin and skeletal abnormalities in a distribution reflecting random X inactivation, whereas hemizygous male embryos die before embryonic day 10.5. To investigate the molecular basis of defects associated with perturbations in cholesterol biosynthesis, microarray analysis was performed comparing gene expression in embryonic fibroblasts expressing the Bpa(1H) allele versus wild-type (wt) cells. Labeled cDNAs from cells grown in normal serum or lipid-depleted serum (LDS) were hybridized to microarrays containing 22,000 mouse genes. Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in fatty acid synthesis, 3 (Srebp2, Insig1, and Orf11) encode sterol-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters. Of the 21 remaining genes, 16 are known genes, some of which have been implicated previously in cholesterol homeostasis or lipid-mediated signaling, and 5 are uncharacterized cDNA clones.
15805545	73	79	sterol	CHEMICAL	15805545T10
15805545	1304	1310	Srebp2	GENE-Y	15805545T11
15805545	1312	1318	Insig1	GENE-Y	15805545T12
15805545	1324	1329	Orf11	GENE-N	15805545T13
15805545	1373	1377	Ldlr	GENE-Y	201133
15805545	1382	1388	StarD4	GENE-Y	15805545T15
15805545	353	383	NADH sterol dehydrogenase-like	GENE-Y	15805545T16
15805545	385	390	NSDHL	GENE-Y	119131
15805545	403	423	sterol dehydrogenase	GENE-N	15805545T18
15805545	466	471	Nsdhl	GENE-Y	201856
15805545	1235	1246	cholesterol	CHEMICAL	15805545T1
15805545	67	72	NSDHL	GENE-Y	119131
15805545	73	93	sterol dehydrogenase	GENE-N	15805545T21
15805545	1279	1289	fatty acid	CHEMICAL	15805545T2
15805545	1338	1344	sterol	CHEMICAL	15805545T3
15805545	1510	1521	cholesterol	CHEMICAL	15805545T4
15805545	353	357	NADH	CHEMICAL	151
15805545	358	364	sterol	CHEMICAL	15805545T6
15805545	403	409	sterol	CHEMICAL	15805545T7
15805545	164	175	cholesterol	CHEMICAL	15805545T8
15805545	821	832	cholesterol	CHEMICAL	15805545T9

15866500|t|Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
15866500|a|A novel method employing high-performance liquid chromatograph-mass spectrometry (LC-MS) has been developed and validated for the quantitation of plasma 2'-deoxyuridine (UdR). It involves a plasma clean-up step with strong anion-exchange solid-phase extraction (SAX-SPE) followed by HPLC separation and atmospheric pressure chemical ionization mass spectrometry detection (APCI-MS) in a selected-ion monitoring (SIM) mode. The ionization conditions were optimised in negative ion mode to give the best intensity of the dominant formate adduct [M+HCOO]- at m/z 273. Retention times were 7.5 and 12.5 min for 2'-deoxyuridine and 5-iodo-2'-deoxyuridine, an iodinated analogue internal standard (IS), respectively. Peak area ratios of 2'-deoxyuridine to IS were used for regression analysis of the calibration curve. The latter was linear from 5 to 400 nmol/l using 1 ml sample volume of plasma. The average recovery was 81.5% and 78.6% for 2'-deoxyuridine and 5-iodo-deoxyuridine, respectively. The method provides sufficient sensitivity, precision, accuracy and selectivity for routine analysis of human plasma 2'-deoxyuridine concentration with the lowest limit of quantitation (LLOQ) of 5 nmol/l. Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS). These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to TS inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP). Monitoring of plasma UdR concentrations have the potential to help clinicians to guide scheduling of capecitabine or other TS inhibitors in clinical trials. Marked differences of plasma 2'-deoxyuridine between human and rodents have also been confirmed. In conclusion, the LC-MS method developed is simple, highly selective and sensitive and permits pharmacodynamic studies of TS inhibitors in several species.
15866500	1899	1904	FdUMP	CHEMICAL	15866500T10
15866500	383	386	UdR	CHEMICAL	15866500T11
15866500	1928	1931	UdR	CHEMICAL	15866500T12
15866500	2008	2020	capecitabine	CHEMICAL	1089
15866500	2093	2108	2'-deoxyuridine	CHEMICAL	15866500T14
15866500	741	748	formate	CHEMICAL	15866500T15
15866500	759	763	HCOO	CHEMICAL	15866500T16
15866500	820	835	2'-deoxyuridine	CHEMICAL	15866500T17
15866500	840	862	5-iodo-2'-deoxyuridine	CHEMICAL	242
15866500	944	959	2'-deoxyuridine	CHEMICAL	15866500T19
15866500	1322	1337	2'-deoxyuridine	CHEMICAL	15866500T1
15866500	1150	1165	2'-deoxyuridine	CHEMICAL	15866500T20
15866500	1170	1189	5-iodo-deoxyuridine	CHEMICAL	15866500T21
15866500	29	44	2'-deoxyuridine	CHEMICAL	15866500T22
15866500	1670	1690	thymidylate synthase	GENE-Y	15866500T23
15866500	1692	1694	TS	GENE-Y	15866500T24
15866500	1811	1813	TS	GENE-Y	15866500T25
15866500	2030	2032	TS	GENE-Y	15866500T26
15866500	2284	2286	TS	GENE-N	15866500T27
15866500	1467	1483	fluoropyrimidine	CHEMICAL	15866500T2
15866500	1493	1505	capecitabine	CHEMICAL	1089
15866500	1507	1545	N4-pentoxycarbonyl-5'-5-fluorocytidine	CHEMICAL	15866500T4
15866500	1570	1585	2'-deoxyuridine	CHEMICAL	15866500T5
15866500	1670	1681	thymidylate	CHEMICAL	15866500T6
15866500	366	381	2'-deoxyuridine	CHEMICAL	15866500T7
15866500	1772	1784	capecitabine	CHEMICAL	1089
15866500	1859	1897	5-fluoro-2'-deoxyuridine monophosphate	CHEMICAL	15866500T9
15866500	CPR:4	15866500T10	15866500T25
15866500	CPR:4	15866500T2	15866500T23
15866500	CPR:4	15866500T2	15866500T24
15866500	CPR:4	1089	15866500T23
15866500	CPR:4	1089	15866500T24
15866500	CPR:4	15866500T4	15866500T23
15866500	CPR:4	15866500T4	15866500T24
15866500	CPR:4	15866500T5	15866500T23
15866500	CPR:4	15866500T5	15866500T24
15866500	CPR:4	1089	15866500T25
15866500	CPR:4	15866500T9	15866500T25

15887238|t|Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
15887238|a|Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases. Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively. In this report, we describe other cellular targets for imatinib. Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of imatinib-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (EGFR) activation. Imatinib-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of EGFR in this process. Western blot analysis of cells incubated with imatinib demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2. An in vitro kinase assay showed that imatinib did not directly affect EGFR kinase activity, suggesting involvement of EGFR-activating molecules. Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced imatinib-mediated mitogen activated protein kinase (MAPK) activation. Imatinib stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation. Together, these results suggested that imatinib affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous EGFR-activating ligands. Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors. This finding demonstrates the need for careful use of this drug in cancer patients.
15887238	675	683	Imatinib	CHEMICAL	609
15887238	855	863	imatinib	CHEMICAL	15887238T11
15887238	1102	1110	imatinib	CHEMICAL	15887238T12
15887238	86	103	imatinib mesylate	CHEMICAL	609
15887238	1140	1146	kinase	GENE-N	15887238T14
15887238	240	245	PDGFR	GENE-Y	15887238T15
15887238	1183	1187	EGFR	GENE-Y	108276|3932452|676741
15887238	1257	1315	heparin-binding epidermal growth factor-like growth factor	GENE-Y	15887238T17
15887238	252	257	c-kit	GENE-Y	15887238T18
15887238	1317	1323	HB-EGF	GENE-Y	15887238T19
15887238	138	155	Imatinib mesylate	CHEMICAL	15887238T1
15887238	258	265	kinases	GENE-N	15887238T20
15887238	1349	1381	transforming growth factor-alpha	GENE-Y	15887238T21
15887238	1409	1441	mitogen activated protein kinase	GENE-N	15887238T22
15887238	1443	1447	MAPK	GENE-N	15887238T23
15887238	1510	1516	HB-EGF	GENE-Y	15887238T24
15887238	1564	1570	HB-EGF	GENE-Y	15887238T25
15887238	281	284	BCR	GENE-Y	107083
15887238	1603	1607	MAPK	GENE-N	15887238T27
15887238	285	288	ABL	GENE-Y	15887238T28
15887238	1676	1680	EGFR	GENE-Y	108276|3932452|676741
15887238	1391	1399	imatinib	CHEMICAL	15887238T2
15887238	293	298	c-kit	GENE-Y	15887238T30
15887238	1776	1780	EGFR	GENE-Y	108276|3932452|676741
15887238	1839	1855	tyrosine kinases	GENE-N	15887238T32
15887238	1892	1896	EGFR	GENE-Y	108276|3932452|676741
15887238	1897	1912	tyrosine kinase	GENE-N	15887238T34
15887238	161	176	tyrosine kinase	GENE-N	15887238T35
15887238	623	655	epidermal growth factor receptor	GENE-Y	15887238T36
15887238	657	661	EGFR	GENE-Y	108276|3932452|676741
15887238	194	197	ABL	GENE-Y	15887238T38
15887238	722	726	EGFR	GENE-Y	108276|3932452|676741
15887238	1461	1469	Imatinib	CHEMICAL	609
15887238	199	238	platelet-derived growth factor receptor	GENE-Y	15887238T40
15887238	787	791	EGFR	GENE-Y	108276|3932452|676741
15887238	891	895	EGFR	GENE-Y	108276|3932452|676741
15887238	955	1027	mitogen-activated protein/extracellular signal-regulated kinase kinase 1	GENE-Y	15887238T43
15887238	1029	1033	MEK1	GENE-Y	34736|14000
15887238	1039	1043	EGFR	GENE-Y	108276|3932452|676741
15887238	1053	1057	Her2	GENE-Y	15887238T46
15887238	1058	1063	ErbB2	GENE-Y	15887238T47
15887238	1077	1083	kinase	GENE-N	15887238T48
15887238	1135	1139	EGFR	GENE-Y	108276|3932452|676741
15887238	1659	1667	imatinib	CHEMICAL	15887238T4
15887238	13	51	heparin-binding EGF-like growth factor	GENE-Y	15887238T50
15887238	70	82	EGF receptor	GENE-Y	15887238T51
15887238	1811	1819	imatinib	CHEMICAL	15887238T5
15887238	1897	1905	tyrosine	CHEMICAL	15887238T6
15887238	161	169	tyrosine	CHEMICAL	15887238T7
15887238	428	436	imatinib	CHEMICAL	15887238T8
15887238	533	541	imatinib	CHEMICAL	15887238T9
15887238	CPR:3	609	108276|3932452|676741
15887238	CPR:3	15887238T11	108276|3932452|676741
15887238	CPR:3	609	15887238T51
15887238	CPR:3	15887238T2	15887238T22
15887238	CPR:3	15887238T2	15887238T23
15887238	CPR:3	609	15887238T24
15887238	CPR:3	609	15887238T25
15887238	CPR:3	609	15887238T27
15887238	CPR:3	15887238T4	108276|3932452|676741
15887238	CPR:3	15887238T5	108276|3932452|676741
15887238	CPR:3	15887238T5	15887238T34
15887238	CPR:3	15887238T9	15887238T36
15887238	CPR:3	15887238T9	108276|3932452|676741
15887238	CPR:4	15887238T1	15887238T15
15887238	CPR:4	15887238T1	15887238T18
15887238	CPR:4	15887238T1	15887238T20
15887238	CPR:4	15887238T1	15887238T35
15887238	CPR:4	15887238T1	15887238T38
15887238	CPR:4	15887238T1	15887238T40
15887238	CPR:4	15887238T5	15887238T32

15894928|t|Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity.
15894928|a|The authors report a unique case of an intra-abdominal, epithelioid mesenchymal tumor that had an activating mutation of PDGFRA and a strong PDGFRA immunoreactivity but lacked both c-kit mutation and c-kit protein (CD117) expression. IHC study showed that the tumor cells were diffusely and strongly positive for PDGFRA, vimentin, CD34, and Bcl-2 but completely negative for CD117 as well as for muscle, epithelial, endothelial, endocrine, mesothelial, neural, and melanocytic cell markers. Molecular study revealed a mutation at the juxtamembrane domain of exon 12 in PDGFRA gene with GTC to GAC transition at codon 561 (V561D), as shown in the previous mutational studies on gastrointestinal stromal tumor (GIST). This case likely represents an example of GIST with PDGFRA activating mutation and PDGFRA immunoreactivity without CD117 positivity, which has not been documented in the literature. STI 571 (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and c-kit oncoproteins.
15894928	297	302	c-kit	GENE-Y	15894928T10
15894928	312	317	CD117	GENE-Y	15894928T11
15894928	410	416	PDGFRA	GENE-Y	111182
15894928	418	426	vimentin	GENE-Y	15894928T13
15894928	428	432	CD34	GENE-Y	107385
15894928	438	443	Bcl-2	GENE-Y	15894928T15
15894928	472	477	CD117	GENE-Y	15894928T16
15894928	666	672	PDGFRA	GENE-Y	111182
15894928	683	693	GTC to GAC	GENE-N	15894928T18
15894928	719	724	V561D	GENE-N	15894928T19
15894928	995	1002	STI 571	CHEMICAL	609
15894928	865	871	PDGFRA	GENE-Y	111182
15894928	896	902	PDGFRA	GENE-Y	111182
15894928	928	933	CD117	GENE-Y	15894928T22
15894928	48	54	PDGFRA	GENE-Y	111182
15894928	1004	1021	imatinib mesylate	CHEMICAL	609
15894928	1023	1030	Gleevec	CHEMICAL	15894928T3
15894928	1083	1090	Gleevec	CHEMICAL	15894928T4
15894928	1104	1110	PDGFRA	GENE-Y	111182
15894928	1115	1120	c-kit	GENE-Y	15894928T6
15894928	218	224	PDGFRA	GENE-Y	111182
15894928	238	244	PDGFRA	GENE-Y	111182
15894928	278	283	c-kit	GENE-Y	15894928T9

1590750|t|Genetic polymorphism and activities of human lung alcohol and aldehyde dehydrogenases: implications for ethanol metabolism and cytotoxicity.
1590750|a|Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) exhibit genetic polymorphism and tissue specificity. ADH and ALDH isozyme phenotypes from 39 surgical Chinese lung specimens were identified by agarose isoelectric focusing. The identity of the lung beta-ADHs was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline. The beta 2 allele, coding for beta 2 polypeptide, was found to be predominant in the lung specimens studied. The ADH activities in the lungs with the homozygous phenotype ADH2 2-2 (exhibiting beta 2 beta 2) and ADH2 1-1 (exhibiting beta 1 beta 1) and the heterozygous phenotype ADH2 2-1 (exhibiting beta 2 beta 2, beta 2 beta 1, and beta 1 beta 1) were determined to be 999 +/- 77, 48 +/- 17, and 494 +/- 61 nmol/min/g tissue, respectively. Fifty-one percent of the specimens studied lacked the ALDH2 activity band on the isoelectric focusing gels. The activities in the lung tissues with the ALDH2-active phenotype and the inactive phenotype were determined to be 30 +/- 3 and 17 +/- 1 nmol/min/g tissue, respectively. These findings indicate that human pulmonary ethanol-metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the ALDH2 loci. The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.
1590750	632	643	polypeptide	CHEMICAL	1590750T10
1590750	104	111	ethanol	CHEMICAL	1590750T11
1590750	50	57	alcohol	CHEMICAL	1590750T12
1590750	62	70	aldehyde	CHEMICAL	1590750T13
1590750	141	162	Alcohol dehydrogenase	GENE-N	1590750T14
1590750	1188	1193	ALDH2	GENE-Y	106719
1590750	256	259	ADH	GENE-N	1590750T16
1590750	264	268	ALDH	GENE-N	1590750T17
1590750	1462	1466	ADH2	GENE-Y	35483|1223845
1590750	1475	1480	ALDH2	GENE-Y	106719
1590750	141	148	Alcohol	CHEMICAL	888
1590750	1539	1549	beta 2-ADH	GENE-Y	1590750T20
1590750	1588	1593	ALDH2	GENE-Y	106719
1590750	164	167	ADH	GENE-N	1590750T22
1590750	402	411	beta-ADHs	GENE-N	1590750T23
1590750	173	195	aldehyde dehydrogenase	GENE-N	1590750T24
1590750	197	201	ALDH	GENE-N	1590750T25
1590750	708	711	ADH	GENE-N	1590750T26
1590750	766	774	ADH2 2-2	GENE-Y	1590750T27
1590750	806	814	ADH2 1-1	GENE-Y	1590750T28
1590750	873	881	ADH2 2-1	GENE-Y	1590750T29
1590750	1360	1367	ethanol	CHEMICAL	1590750T2
1590750	1090	1095	ALDH2	GENE-Y	106719
1590750	39	85	human lung alcohol and aldehyde dehydrogenases	GENE-N	1590750T31
1590750	1671	1683	acetaldehyde	CHEMICAL	1590750T3
1590750	1704	1711	alcohol	CHEMICAL	1590750T4
1590750	173	181	aldehyde	CHEMICAL	1590750T5
1590750	486	493	ethanol	CHEMICAL	1590750T6
1590750	527	534	ethanol	CHEMICAL	1590750T7
1590750	554	570	4-methylpyrazole	CHEMICAL	1201
1590750	574	593	1,10-phenanthroline	CHEMICAL	1590750T9
1590750	CPR:4	1201	1590750T23
1590750	CPR:4	1590750T9	1590750T23
1590750	CPR:9	1590750T2	35483|1223845
1590750	CPR:9	1590750T2	106719
1590750	CPR:9	1590750T3	1590750T20
1590750	CPR:9	1590750T3	106719
1590750	CPR:9	1590750T4	1590750T20
1590750	CPR:9	1590750T4	106719
1590750	CPR:9	1590750T6	1590750T23
1590750	CPR:9	1590750T7	1590750T23

15936988|t|Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells.
15936988|a|The effects of statins on immune response depend on the inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and leukocyte function-associated antigen (LFA)-1, which is a ligand of intercellular adhesion molecule (ICAM)-1. Simvastatin, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC). The IL-18 production is located upstream of the cytokine cascade activated by simvastatin. Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes. In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. The effects of simvastatin were abolished by the addition of the product of the HMG-CoA reductase, mevalonate, indicating the involvement of HMG-CoA reductase in the action of simvastatin.
15936988	817	828	simvastatin	CHEMICAL	15936988T10
15936988	991	1002	simvastatin	CHEMICAL	15936988T11
15936988	1019	1030	simvastatin	CHEMICAL	15936988T12
15936988	1084	1091	HMG-CoA	CHEMICAL	15936988T13
15936988	0	11	Simvastatin	CHEMICAL	631
15936988	1145	1162	HMG-CoA reductase	GENE-Y	15936988T15
15936988	223	268	leukocyte function-associated antigen (LFA)-1	GENE-Y	15936988T16
15936988	291	331	intercellular adhesion molecule (ICAM)-1	GENE-Y	15936988T17
15936988	349	366	HMG-CoA reductase	GENE-Y	15936988T18
15936988	401	406	LFA-1	GENE-Y	15936988T19
15936988	1103	1113	mevalonate	CHEMICAL	15936988T1
15936988	434	453	interleukin (IL)-18	GENE-Y	15936988T20
15936988	455	488	tumor necrosis factor (TNF)-alpha	GENE-Y	15936988T21
15936988	493	515	interferon (IFN)-gamma	GENE-Y	15936988T22
15936988	572	577	IL-18	GENE-Y	15936988T23
15936988	616	624	cytokine	GENE-N	15936988T24
15936988	735	741	ICAM-1	GENE-Y	15936988T25
15936988	772	776	CD40	GENE-Y	107396
15936988	161	218	3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase	GENE-Y	15936988T27
15936988	810	815	IL-18	GENE-Y	15936988T28
15936988	858	864	ICAM-1	GENE-Y	15936988T29
15936988	1145	1152	HMG-CoA	CHEMICAL	15936988T2
15936988	869	873	CD40	GENE-Y	107396
15936988	903	908	IL-12	GENE-N	15936988T31
15936988	910	919	TNF-alpha	GENE-Y	15936988T32
15936988	924	933	IFN-gamma	GENE-Y	15936988T33
15936988	1084	1101	HMG-CoA reductase	GENE-Y	15936988T34
15936988	20	34	interleukin-18	GENE-Y	15936988T35
15936988	1180	1191	simvastatin	CHEMICAL	15936988T3
15936988	200	207	HMG-CoA	CHEMICAL	15936988T4
15936988	333	344	Simvastatin	CHEMICAL	631
15936988	349	356	HMG-CoA	CHEMICAL	15936988T6
15936988	646	657	simvastatin	CHEMICAL	15936988T7
15936988	669	680	simvastatin	CHEMICAL	15936988T8
15936988	161	198	3-hydroxy-3-methylglutaryl coenzyme-A	CHEMICAL	15936988T9
15936988	CPR:3	15936988T10	15936988T31
15936988	CPR:3	15936988T10	15936988T32
15936988	CPR:3	15936988T10	15936988T33
15936988	CPR:3	631	15936988T35
15936988	CPR:3	631	15936988T20
15936988	CPR:3	631	15936988T21
15936988	CPR:3	631	15936988T22
15936988	CPR:3	15936988T7	15936988T23
15936988	CPR:3	15936988T7	15936988T24
15936988	CPR:3	15936988T8	107396
15936988	CPR:4	15936988T10	15936988T29
15936988	CPR:4	15936988T10	107396
15936988	CPR:4	631	15936988T18
15936988	CPR:4	631	15936988T19
15936988	CPR:4	15936988T8	15936988T25
15936988	CPR:9	15936988T1	15936988T34

15939622|t|COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.
15939622|a|We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and flunixin, on blood cyclooxygenases in the horse using in vitro enzyme-linked assays. As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of COX-2 than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined. However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50. We therefore propose that the selectivity of NSAIDs should be assessed at the 80% as well as 50% inhibition level.
15939622	646	655	carprofen	CHEMICAL	15939622T10
15939622	180	189	carprofen	CHEMICAL	15939622T11
15939622	191	205	phenylbutazone	CHEMICAL	15939622T12
15939622	210	218	flunixin	CHEMICAL	15939622T13
15939622	45	59	phenylbutazone	CHEMICAL	15939622T14
15939622	61	69	flunixin	CHEMICAL	15939622T15
15939622	71	80	carprofen	CHEMICAL	15939622T16
15939622	85	94	meloxicam	CHEMICAL	15939622T17
15939622	229	244	cyclooxygenases	GENE-N	15939622T18
15939622	399	404	COX-2	GENE-Y	15939622T19
15939622	342	351	meloxicam	CHEMICAL	15939622T1
15939622	587	592	COX-2	GENE-Y	15939622T20
15939622	675	680	COX-2	GENE-Y	15939622T21
15939622	0	5	COX-1	GENE-Y	15939622T22
15939622	10	15	COX-2	GENE-Y	15939622T23
15939622	356	365	carprofen	CHEMICAL	15939622T2
15939622	410	424	phenylbutazone	CHEMICAL	15939622T3
15939622	429	437	flunixin	CHEMICAL	15939622T4
15939622	439	448	meloxicam	CHEMICAL	15939622T5
15939622	528	542	phenylbutazone	CHEMICAL	15939622T6
15939622	557	565	flunixin	CHEMICAL	15939622T7
15939622	623	632	meloxicam	CHEMICAL	15939622T8
15939622	169	178	meloxicam	CHEMICAL	15939622T9
15939622	CPR:4	15939622T10	15939622T21
15939622	CPR:4	15939622T11	15939622T18
15939622	CPR:4	15939622T12	15939622T18
15939622	CPR:4	15939622T13	15939622T18
15939622	CPR:4	15939622T14	15939622T22
15939622	CPR:4	15939622T14	15939622T23
15939622	CPR:4	15939622T15	15939622T22
15939622	CPR:4	15939622T15	15939622T23
15939622	CPR:4	15939622T16	15939622T22
15939622	CPR:4	15939622T16	15939622T23
15939622	CPR:4	15939622T17	15939622T22
15939622	CPR:4	15939622T17	15939622T23
15939622	CPR:4	15939622T1	15939622T19
15939622	CPR:4	15939622T2	15939622T19
15939622	CPR:4	15939622T3	15939622T19
15939622	CPR:4	15939622T4	15939622T19
15939622	CPR:4	15939622T6	15939622T20
15939622	CPR:4	15939622T7	15939622T20
15939622	CPR:4	15939622T8	15939622T21
15939622	CPR:4	15939622T9	15939622T18

15942707|t|Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
15942707|a|The use of beta-blockers has emerged as a beneficial treatment for cardiac hypertrophy. Hypoxia-inducible factor-1alpha (HIF-1alpha) is tightly regulated in the ventricular myocardium. However, the expression of HIF-1alpha in cardiac hypertrophy due to pressure overload and after treatment with beta-blocker is little known. To evaluate the effect of carvedilol on both myocardial HIF-1alpha expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Carvedilol at 50 mg/kg body weight per day after surgery was given. Heart weight and the ratio of heart weight and body weight increased significantly after aortic banding for 4 weeks in the absence of drug treatment. Mean arterial pressure increased from 80 +/- 9 mmHg in the sham group to 94 +/-5 mmHg (p < 0.001) in the banding group. Echocardiography showed concentric hypertrophy after aortic banding. Mean arterial pressure decreased after treatment with carvedilol. The increased wall thickness and heart weight was reversed to normal by carvedilol. Western blot showed that HIF-1alpha, vascular endothelial growth factor (VEGF) and brain natriuretic peptide (BNP) proteins were up-regulated and nerve growth factor-beta (NGF-beta) down-regulated in the banding group. Treatment with valsartan, doxazosin, or N-acetylcysteine did not significantly affect HIF-1alpha and VEGF proteins expression in the banding groups. Real-time polymerase chain reaction showed that mRNA of HIF-1alpha, VEGF and BNP increased and mRNA of NGF-beta decreased in the banding group. Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values. Increased immunohistochemical labeling of HIF-1alpha, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling. In conclusion, HIF-1alpha, VEGF, and BNP mRNA and protein expression were up-regulated, while NGF-beta mRNA and protein was downregulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, BNP, and NGF-beta in the hypertrophic myocardium.
15942707	709	719	Carvedilol	CHEMICAL	1124
15942707	0	10	Carvedilol	CHEMICAL	1124
15942707	1291	1301	HIF-1alpha	GENE-Y	15942707T12
15942707	1303	1337	vascular endothelial growth factor	GENE-Y	15942707T13
15942707	1339	1343	VEGF	GENE-Y	15942707T14
15942707	1349	1374	brain natriuretic peptide	GENE-Y	15942707T15
15942707	1376	1379	BNP	GENE-Y	15942707T16
15942707	288	298	HIF-1alpha	GENE-Y	15942707T17
15942707	1412	1436	nerve growth factor-beta	GENE-Y	15942707T18
15942707	1438	1446	NGF-beta	GENE-Y	15942707T19
15942707	1170	1180	carvedilol	CHEMICAL	15942707T1
15942707	1571	1581	HIF-1alpha	GENE-Y	15942707T20
15942707	1586	1590	VEGF	GENE-Y	15942707T21
15942707	1690	1700	HIF-1alpha	GENE-Y	15942707T22
15942707	1702	1706	VEGF	GENE-Y	15942707T23
15942707	1711	1714	BNP	GENE-Y	15942707T24
15942707	1737	1745	NGF-beta	GENE-Y	15942707T25
15942707	1838	1848	HIF-1alpha	GENE-Y	15942707T26
15942707	1850	1854	VEGF	GENE-Y	15942707T27
15942707	1856	1859	BNP	GENE-Y	15942707T28
15942707	1865	1873	NGF-beta	GENE-Y	15942707T29
15942707	1254	1264	carvedilol	CHEMICAL	15942707T2
15942707	1940	1950	HIF-1alpha	GENE-Y	15942707T30
15942707	1952	1956	VEGF	GENE-Y	15942707T31
15942707	1962	1965	BNP	GENE-Y	15942707T32
15942707	2091	2101	HIF-1alpha	GENE-Y	15942707T33
15942707	2103	2107	VEGF	GENE-Y	15942707T34
15942707	2113	2116	BNP	GENE-Y	15942707T35
15942707	2170	2178	NGF-beta	GENE-Y	15942707T36
15942707	379	389	HIF-1alpha	GENE-Y	15942707T37
15942707	2357	2367	HIF-1alpha	GENE-Y	15942707T38
15942707	2369	2373	VEGF	GENE-Y	15942707T39
15942707	1500	1509	valsartan	CHEMICAL	15942707T3
15942707	2375	2378	BNP	GENE-Y	15942707T40
15942707	2384	2392	NGF-beta	GENE-Y	15942707T41
15942707	549	559	HIF-1alpha	GENE-Y	15942707T42
15942707	255	286	Hypoxia-inducible factor-1alpha	GENE-Y	15942707T43
15942707	62	93	hypoxia-inducible factor-1alpha	GENE-Y	15942707T44
15942707	98	132	vascular endothelial growth factor	GENE-Y	15942707T45
15942707	1511	1520	doxazosin	CHEMICAL	15942707T4
15942707	1525	1541	N-acetylcysteine	CHEMICAL	5519
15942707	1793	1803	carvedilol	CHEMICAL	15942707T6
15942707	2034	2044	carvedilol	CHEMICAL	15942707T7
15942707	2290	2300	carvedilol	CHEMICAL	15942707T8
15942707	519	529	carvedilol	CHEMICAL	15942707T9
15942707	CPR:3	15942707T6	15942707T29
15942707	CPR:4	1124	15942707T44
15942707	CPR:4	1124	15942707T45
15942707	CPR:4	15942707T6	15942707T26
15942707	CPR:4	15942707T6	15942707T27
15942707	CPR:4	15942707T6	15942707T28
15942707	CPR:4	15942707T7	15942707T30
15942707	CPR:4	15942707T7	15942707T31
15942707	CPR:4	15942707T7	15942707T32
15942707	CPR:4	15942707T8	15942707T38
15942707	CPR:4	15942707T8	15942707T39
15942707	CPR:4	15942707T8	15942707T40

15946589|t|Imatinib resistance in gastrointestinal stromal tumors.
15946589|a|Conventional chemotherapeutic drugs are ineffective in treatment of gastrointestinal stromal tumors (GISTs). Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. Unfortunately, imatinib resistance has emerged. The reported mechanism of imatinib resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile, Tyr823Asp, and Val654Ala. The established mechanisms and potential mechanisms of imatinib resistance in GISTs, the imaging studies indicative of early development of imatinib resistance, and the management of imatinib-resistant GISTs are discussed.
15946589	0	8	Imatinib	CHEMICAL	609
15946589	270	273	KIT	GENE-Y	110015
15946589	275	278	ABL	GENE-Y	15946589T12
15946589	280	283	BCR	GENE-Y	107083
15946589	284	287	ABL	GENE-Y	15946589T14
15946589	289	295	PDGFRA	GENE-Y	111182
15946589	301	308	PDGFRB,	GENE-Y	15946589T16
15946589	593	606	kinase domain	GENE-N	15946589T17
15946589	610	614	KIT,	GENE-N	15946589T18
15946589	625	634	Thr670Ile	GENE-N	15946589T19
15946589	165	173	Imatinib	CHEMICAL	609
15946589	636	645	Tyr823Asp	GENE-N	15946589T20
15946589	651	660	Val654Ala	GENE-N	15946589T21
15946589	175	181	STI571	CHEMICAL	15946589T2
15946589	183	190	Gleevec	CHEMICAL	15946589T3
15946589	192	198	Glivec	CHEMICAL	15946589T4
15946589	471	479	imatinib	CHEMICAL	15946589T5
15946589	530	538	imatinib	CHEMICAL	15946589T6
15946589	717	725	imatinib	CHEMICAL	15946589T7
15946589	802	810	imatinib	CHEMICAL	15946589T8
15946589	845	853	imatinib	CHEMICAL	15946589T9
15946589	CPR:4	609	110015
15946589	CPR:4	609	15946589T12
15946589	CPR:4	609	107083
15946589	CPR:4	609	15946589T14
15946589	CPR:4	609	111182
15946589	CPR:4	609	15946589T16
15946589	CPR:4	15946589T2	110015
15946589	CPR:4	15946589T2	15946589T12
15946589	CPR:4	15946589T2	107083
15946589	CPR:4	15946589T2	15946589T14
15946589	CPR:4	15946589T2	111182
15946589	CPR:4	15946589T2	15946589T16
15946589	CPR:4	15946589T3	110015
15946589	CPR:4	15946589T3	15946589T12
15946589	CPR:4	15946589T3	107083
15946589	CPR:4	15946589T3	15946589T14
15946589	CPR:4	15946589T3	111182
15946589	CPR:4	15946589T3	15946589T16
15946589	CPR:4	15946589T4	110015
15946589	CPR:4	15946589T4	15946589T12
15946589	CPR:4	15946589T4	107083
15946589	CPR:4	15946589T4	15946589T14
15946589	CPR:4	15946589T4	111182
15946589	CPR:4	15946589T4	15946589T16

15947036|t|Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
15947036|a|The histamine H(4) receptor (H(4)R) is involved in the chemotaxis of leukocytes and mast cells to sites of inflammation and is suggested to be a potential drug target for asthma and allergy. So far, selective H(4)R agonists have not been identified. In the present study, we therefore evaluated the human H(4)R (hH(4)R) for its interaction with various known histaminergic ligands. Almost all of the tested H(1)R and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific [(3)H]histamine binding to the hH(4)R at concentrations up to 10 microM. Most of the tested H(2)R agonists and imidazole-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists. Interestingly, we identified 4-methylhistamine as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other histamine receptor subtypes. Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8). The identification of 4-methylhistamine as a potent H(4)R agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.
15947036	112	129	4-methylhistamine	CHEMICAL	15947036T10
15947036	14	23	histamine	CHEMICAL	15947036T11
15947036	71	80	histamine	CHEMICAL	15947036T12
15947036	1240	1246	hH(4)R	GENE-Y	15947036T13
15947036	1348	1353	H(4)R	GENE-Y	15947036T14
15947036	1503	1508	H(4)R	GENE-Y	15947036T15
15947036	1601	1606	H(4)R	GENE-Y	15947036T16
15947036	394	399	H(4)R	GENE-Y	15947036T17
15947036	214	219	H(4)R	GENE-Y	15947036T18
15947036	484	495	human H(4)R	GENE-Y	15947036T19
15947036	1199	1216	4-methylhistamine	CHEMICAL	15947036T1
15947036	497	503	hH(4)R	GENE-Y	15947036T20
15947036	592	597	H(1)R	GENE-Y	15947036T21
15947036	602	607	H(2)R	GENE-Y	15947036T22
15947036	189	212	histamine H(4) receptor	GENE-Y	15947036T23
15947036	730	736	hH(4)R	GENE-Y	15947036T24
15947036	791	796	H(2)R	GENE-Y	15947036T25
15947036	826	831	H(3)R	GENE-Y	15947036T26
15947036	875	881	hH(4)R	GENE-Y	15947036T27
15947036	936	942	hH(4)R	GENE-Y	15947036T28
15947036	1069	1074	H(4)R	GENE-Y	15947036T29
15947036	1365	1376	JNJ 7777120	CHEMICAL	15947036T2
15947036	1138	1144	hH(4)R	GENE-Y	15947036T30
15947036	1160	1178	histamine receptor	GENE-N	15947036T31
15947036	14	49	histamine H1-, H2-, and H3-receptor	GENE-N	15947036T32
15947036	164	175	H4 receptor	GENE-Y	15947036T33
15947036	65	92	human histamine H4 receptor	GENE-Y	15947036T34
15947036	1378	1434	1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine	CHEMICAL	15947036T3
15947036	1473	1490	4-methylhistamine	CHEMICAL	15947036T4
15947036	189	198	histamine	CHEMICAL	15947036T5
15947036	699	714	[(3)H]histamine	CHEMICAL	15947036T6
15947036	810	819	imidazole	CHEMICAL	15947036T7
15947036	1032	1049	4-methylhistamine	CHEMICAL	15947036T8
15947036	1160	1169	histamine	CHEMICAL	15947036T9
15947036	CPR:3	15947036T1	15947036T13
15947036	CPR:5	15947036T10	15947036T33
15947036	CPR:5	15947036T4	15947036T15
15947036	CPR:5	15947036T7	15947036T28
15947036	CPR:6	15947036T2	15947036T14
15947036	CPR:6	15947036T3	15947036T14

15975002|t|Novel agents that potentially inhibit irinotecan-induced diarrhea.
15975002|a|Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (Topo I). However, severe and unpredictable dosing-limiting toxicities (mainly myelosuppression and severe diarrhea) hinder its clinical use. The latter consists of early and late-onset diarrhea, occurring within 24 hr or > or = 24 hr after CPT-11 administration, respectively. This review highlights novel agents potentially inhibiting CPT-11-induced diarrhea, which are designed and tested under guidance of disposition pathways and potential toxicity mechanisms. Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of acetylcholinesterase activity, which can be eliminated by administration of atropine. Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to Topo I and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa. CPT-11 and SN-38 may also stimulate the production of pro-inflammatory cytokines and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-). Early treatment of severe late-onset diarrhea with oral high-dose loperamide has decreased patient morbidity. Extensive studies have been conducted to identify other potential agents to ameliorate diarrhea in preclinical and clinical models. These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, P-glycoprotein (PgP) inhibitors, cyclooxygenase-2 (COX-2) inhibitors, tumor necrosis factor-alpha (TNF-alpha) inhibitors, or blockers of biliary excretion of SN-38. Further studies are needed to identify the molecular targets associated with CPT-11 toxicity and safe and effective agents for alleviating CPT-11-induced diarrhea.
15975002	1856	1861	SN-38	CHEMICAL	15975002T10
15975002	1940	1946	CPT-11	CHEMICAL	15975002T11
15975002	2002	2008	CPT-11	CHEMICAL	15975002T12
15975002	87	153	7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin	CHEMICAL	15975002T13
15975002	503	509	CPT-11	CHEMICAL	15975002T14
15975002	599	605	CPT-11	CHEMICAL	15975002T15
15975002	779	785	CPT-11	CHEMICAL	15975002T16
15975002	909	917	atropine	CHEMICAL	15975002T17
15975002	992	997	SN-38	CHEMICAL	15975002T18
15975002	999	1029	7-ethyl-10-hydroxycamptothecin	CHEMICAL	15975002T19
15975002	67	77	Irinotecan	CHEMICAL	752
15975002	1063	1069	CPT-11	CHEMICAL	15975002T20
15975002	38	48	irinotecan	CHEMICAL	15975002T21
15975002	1089	1095	Topo I	GENE-Y	15975002T22
15975002	1293	1302	cytokines	GENE-N	15975002T23
15975002	1698	1712	P-glycoprotein	GENE-N	15975002T24
15975002	1714	1717	PgP	GENE-N	15975002T25
15975002	1731	1747	cyclooxygenase-2	GENE-Y	15975002T26
15975002	1749	1754	COX-2	GENE-Y	15975002T27
15975002	1768	1795	tumor necrosis factor-alpha	GENE-Y	15975002T28
15975002	1797	1806	TNF-alpha	GENE-Y	15975002T29
15975002	1222	1228	CPT-11	CHEMICAL	15975002T2
15975002	242	261	DNA topoisomerase I	GENE-Y	15975002T30
15975002	263	269	Topo I	GENE-Y	15975002T31
15975002	833	853	acetylcholinesterase	GENE-Y	15975002T32
15975002	1233	1238	SN-38	CHEMICAL	15975002T3
15975002	79	85	CPT-11	CHEMICAL	15975002T4
15975002	1307	1321	prostaglandins	CHEMICAL	15975002T5
15975002	1323	1326	PGs	CHEMICAL	15975002T6
15975002	1360	1365	Na(+)	CHEMICAL	15975002T7
15975002	1370	1375	Cl(-)	CHEMICAL	15975002T8
15975002	1443	1453	loperamide	CHEMICAL	15975002T9
15975002	CPR:3	15975002T17	15975002T32
15975002	CPR:3	15975002T2	15975002T23
15975002	CPR:3	15975002T3	15975002T23
15975002	CPR:4	15975002T13	15975002T30
15975002	CPR:4	15975002T13	15975002T31
15975002	CPR:4	15975002T16	15975002T32
15975002	CPR:4	752	15975002T30
15975002	CPR:4	752	15975002T31
15975002	CPR:4	15975002T4	15975002T30
15975002	CPR:4	15975002T4	15975002T31

15985434|t|Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives.
15985434|a|Pyridoxal kinase (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+. This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections. Affinity chromatography investigations have shown that (R)-roscovitine also interacts with PDXK. To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs. Structural analysis revealed that these three roscovitines bind similarly in the pyridoxal-binding site of PDXK rather than in the anticipated ATP-binding site. The pyridoxal pocket has thus an unexpected ability to accommodate molecules different from and larger than pyridoxal. This work provides detailed structural information on the interactions between PDXK and roscovitine and analogs. It could also aid in the design of roscovitine derivatives displaying strict selectivity for either PDXK or CDKs.
15985434	317	327	vitamin B6	CHEMICAL	15985434T10
15985434	362	377	(R)-Roscovitine	CHEMICAL	15985434T11
15985434	379	385	CYC202	CHEMICAL	15985434T12
15985434	387	397	Seliciclib	CHEMICAL	15985434T13
15985434	651	666	(R)-roscovitine	CHEMICAL	15985434T14
15985434	140	149	pyridoxal	CHEMICAL	15985434T15
15985434	151	163	pyridoxamine	CHEMICAL	15985434T16
15985434	785	800	(R)-roscovitine	CHEMICAL	15985434T17
15985434	802	827	N6-methyl-(R)-roscovitine	CHEMICAL	15985434T18
15985434	833	851	O6-(R)-roscovitine	CHEMICAL	15985434T19
15985434	83	92	Pyridoxal	CHEMICAL	141
15985434	169	179	pyridoxine	CHEMICAL	15985434T20
15985434	974	986	roscovitines	CHEMICAL	15985434T21
15985434	1009	1018	pyridoxal	CHEMICAL	15985434T22
15985434	1071	1074	ATP	CHEMICAL	164
15985434	21	30	pyridoxal	CHEMICAL	15985434T24
15985434	54	65	roscovitine	CHEMICAL	15985434T25
15985434	83	99	Pyridoxal kinase	GENE-Y	15985434T26
15985434	1287	1291	PDXK	GENE-Y	114135
15985434	1421	1425	PDXK	GENE-Y	114135
15985434	1429	1433	CDKs	GENE-N	15985434T29
15985434	1093	1102	pyridoxal	CHEMICAL	15985434T2
15985434	101	105	PDXK	GENE-Y	114135
15985434	438	462	cyclin-dependent kinases	GENE-N	15985434T31
15985434	464	468	CDKs	GENE-N	15985434T32
15985434	687	691	PDXK	GENE-Y	114135
15985434	764	768	PDXK	GENE-Y	114135
15985434	906	910	PDXK	GENE-Y	114135
15985434	922	926	CDKs	GENE-N	15985434T36
15985434	1035	1039	PDXK	GENE-Y	114135
15985434	21	37	pyridoxal kinase	GENE-Y	15985434T38
15985434	1197	1206	pyridoxal	CHEMICAL	15985434T3
15985434	199	202	ATP	CHEMICAL	164
15985434	1296	1307	roscovitine	CHEMICAL	15985434T5
15985434	207	211	Zn2+	CHEMICAL	15985434T6
15985434	1356	1367	roscovitine	CHEMICAL	15985434T7
15985434	268	290	pyridoxal 5'-phosphate	CHEMICAL	15985434T8
15985434	292	295	PLP	CHEMICAL	109
15985434	CPR:4	15985434T11	15985434T31
15985434	CPR:4	15985434T11	15985434T32
15985434	CPR:4	15985434T12	15985434T31
15985434	CPR:4	15985434T12	15985434T32
15985434	CPR:4	15985434T13	15985434T31
15985434	CPR:4	15985434T13	15985434T32
15985434	CPR:9	15985434T15	15985434T26
15985434	CPR:9	15985434T15	114135
15985434	CPR:9	15985434T16	15985434T26
15985434	CPR:9	15985434T16	114135
15985434	CPR:9	15985434T20	15985434T26
15985434	CPR:9	15985434T20	114135

15985706|t|Gastric mucin secretion in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation.
15985706|a|In many systems, the integration of converging regulatory signals that relay on G protein-coupled receptor (GPCR) activation into functional cellular pathways requires the involvement of receptor tyrosine kinase. In this report, we provide evidence that activation of GPCR by beta-adrenergic agonist leading to stimulation in gastric mucin secretion requires epidermal growth factor receptor (EGFR) participation. Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K. Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin. The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059. The inhibition of ERK, moreover, did not cause attenuation in mucin secretion in response to cAMP and forskolin. The findings underline the role of EGFR as a convergence point in gastric mucin secretion triggered by beta-adrenergic GPCR activation, and demonstrate the requirement for Src kinase in EGFR transactivation.
15985706	1010	1019	forskolin	CHEMICAL	15985706T10
15985706	1062	1075	isoproterenol	CHEMICAL	15985706T11
15985706	1108	1111	PP2	CHEMICAL	15985706T12
15985706	1138	1146	tyrosine	CHEMICAL	15985706T13
15985706	1193	1197	EGFR	GENE-Y	108276|3932452|676741
15985706	1230	1233	ERK	GENE-N	15985706T15
15985706	287	291	GPCR	GENE-N	26950
15985706	1272	1275	ERK	GENE-N	15985706T17
15985706	1316	1321	mucin	GENE-N	15985706T18
15985706	1402	1406	EGFR	GENE-Y	108276|3932452|676741
15985706	1245	1252	PD98059	CHEMICAL	15985706T1
15985706	1433	1446	gastric mucin	GENE-N	15985706T20
15985706	1470	1490	beta-adrenergic GPCR	GENE-N	15985706T21
15985706	1539	1542	Src	GENE-Y	203491|249840
15985706	1543	1549	kinase	GENE-N	15985706T23
15985706	1553	1557	EGFR	GENE-Y	108276|3932452|676741
15985706	366	390	receptor tyrosine kinase	GENE-N	15985706T25
15985706	447	451	GPCR	GENE-N	26950
15985706	505	518	gastric mucin	GENE-N	15985706T27
15985706	538	570	epidermal growth factor receptor	GENE-Y	15985706T28
15985706	572	576	EGFR	GENE-Y	108276|3932452|676741
15985706	1347	1351	cAMP	CHEMICAL	2424
15985706	726	731	mucin	GENE-N	15985706T30
15985706	759	763	EGFR	GENE-Y	108276|3932452|676741
15985706	764	770	kinase	GENE-N	15985706T32
15985706	839	843	PI3K	GENE-N	15985706T33
15985706	884	889	mucin	GENE-N	15985706T34
15985706	259	285	G protein-coupled receptor	GENE-N	15985706T35
15985706	981	998	adenylate cyclase	GENE-N	15985706T36
15985706	1025	1038	gastric mucin	GENE-N	15985706T37
15985706	1138	1153	tyrosine kinase	GENE-N	15985706T38
15985706	1154	1157	Src	GENE-Y	203491|249840
15985706	1356	1365	forskolin	CHEMICAL	15985706T3
15985706	0	13	Gastric mucin	GENE-N	15985706T40
15985706	108	111	SRC	GENE-Y	112592|676691|192317
15985706	112	118	kinase	GENE-N	15985706T42
15985706	129	161	epidermal growth factor receptor	GENE-Y	15985706T43
15985706	39	81	beta-adrenergic G protein-coupled receptor	GENE-N	15985706T44
15985706	375	383	tyrosine	CHEMICAL	15985706T4
15985706	599	616	[(3)H]glucosamine	CHEMICAL	15985706T5
15985706	782	790	PD153035	CHEMICAL	15985706T6
15985706	803	813	wortmannin	CHEMICAL	15985706T7
15985706	965	969	cAMP	CHEMICAL	2424
15985706	981	990	adenylate	CHEMICAL	15985706T9
15985706	CPR:3	15985706T10	15985706T36
15985706	CPR:3	15985706T12	108276|3932452|676741
15985706	CPR:4	15985706T10	15985706T34
15985706	CPR:4	15985706T12	15985706T37
15985706	CPR:4	15985706T12	15985706T38
15985706	CPR:4	15985706T12	203491|249840
15985706	CPR:4	15985706T1	15985706T15
15985706	CPR:4	2424	15985706T17
15985706	CPR:4	15985706T3	15985706T17
15985706	CPR:4	15985706T6	15985706T30
15985706	CPR:4	15985706T6	108276|3932452|676741
15985706	CPR:4	15985706T6	15985706T32
15985706	CPR:4	15985706T7	15985706T30
15985706	CPR:4	15985706T7	15985706T33
15985706	CPR:9	2424	15985706T36

15991937|t|Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure.
15991937|a|Losartan (COZAAR) is the prototype of a new class of potent and selective angiotensin II (AII) type 1 (AT(1)) receptor antagonists with the largest published preclinical and clinical data base. Since all of the AII antagonists are selective for the AT(1) receptor, these drugs should exhibit similar cardiovascular effects. However, since the pharmacokinetic/pharmacodynamic profiles of these agents and their degree of affinity for the AT(1) receptor differ, it is likely that differences in clinical profiles between these drugs exist and will require investigation. Losartan (parent compound), has moderate affinity for the AT(1) receptor (competitive inhibition). Losartan is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the AT(1) receptor (non-competitive inhibition). E3174 has a half-life of 6 - 9 h; elimination is via renal and hepatic routes. Antihypertensive and, in heart failure patients, haemodynamic activity is observed over a 24 h period with once daily dosing. Over 6 million patients have been treated for hypertension with continued excellent tolerability. Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the angiotensin-converting-enzyme inhibitor class with proven benefit in this population. The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the AT(1) receptor with losartan compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.
15991937	1928	1936	Losartan	CHEMICAL	668
15991937	1983	1991	Losartan	CHEMICAL	668
15991937	317	320	AII	CHEMICAL	15991937T12
15991937	675	683	Losartan	CHEMICAL	668
15991937	774	782	Losartan	CHEMICAL	668
15991937	180	194	angiotensin II	CHEMICAL	15991937T15
15991937	196	199	AII	CHEMICAL	15991937T16
15991937	0	8	Losartan	CHEMICAL	668
15991937	22	36	angiotensin II	CHEMICAL	15991937T18
15991937	1469	1498	angiotensin-converting-enzyme	GENE-Y	15991937T19
15991937	106	114	Losartan	CHEMICAL	668
15991937	1735	1749	AT(1) receptor	GENE-Y	15991937T20
15991937	317	320	AII	GENE-Y	15991937T21
15991937	355	369	AT(1) receptor	GENE-Y	15991937T22
15991937	543	557	AT(1) receptor	GENE-Y	15991937T23
15991937	733	747	AT(1) receptor	GENE-Y	15991937T24
15991937	180	224	angiotensin II (AII) type 1 (AT(1)) receptor	GENE-Y	15991937T25
15991937	979	993	AT(1) receptor	GENE-Y	15991937T26
15991937	22	58	angiotensin II type 1 (AT1) receptor	GENE-Y	15991937T27
15991937	116	122	COZAAR	CHEMICAL	15991937T2
15991937	1426	1434	losartan	CHEMICAL	15991937T3
15991937	1442	1451	captopril	CHEMICAL	15991937T4
15991937	1469	1480	angiotensin	CHEMICAL	15991937T5
15991937	1581	1589	losartan	CHEMICAL	15991937T6
15991937	1755	1763	losartan	CHEMICAL	15991937T7
15991937	1801	1809	Losartan	CHEMICAL	668
15991937	1858	1866	Losartan	CHEMICAL	668
15991937	CPR:4	668	15991937T26
15991937	CPR:4	15991937T3	15991937T19
15991937	CPR:4	15991937T4	15991937T19
15991937	CPR:4	15991937T7	15991937T20
15991937	CPR:6	668	15991937T27
15991937	CPR:6	668	15991937T25
15991937	CPR:6	15991937T2	15991937T25

1611705|t|Effect of amrinone on tumor necrosis factor production in endotoxic shock.
1611705|a|Tumor necrosis factor (TNF) is a macrophage-derived mediator responsible for many of the pathophysiologic manifestations of endotoxic shock. We now demonstrate that amrinone, a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced TNF production at concentrations readily achieved in vivo. This inhibition is apparent in murine macrophages, in macrophage cell lines, in vivo, and in cell lines containing a reporter gene construct that substitutes the chloramphenicol acetyl transferase (CAT) coding sequence for the TNF coding sequence and introns. Inhibition by amrinone (like inhibition by pentoxifylline) is manifested at the level of mRNA accumulation, in contrast to inhibition caused by dexamethasone. Combined application of dexamethasone and amrinone caused additive inhibition of TNF biosynthesis in vitro. Furthermore, treatment of mice with amrinone immediately prior to endotoxin challenge led to significantly improved survival. These findings suggest that amrinone possesses antiinflammatory as well as inotropic properties that may make it an appropriate agent for use in septic shock or other serious bacterial infections. Abrupt removal of amrinone or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented TNF production. Therefore, amrinone and other phosphodiesterase inhibitors may also enhance sensitivity to LPS during a period of time following discontinuation of therapy.
1611705	947	955	amrinone	CHEMICAL	1611705T10
1611705	1065	1073	amrinone	CHEMICAL	1611705T11
1611705	10	18	amrinone	CHEMICAL	1611705T12
1611705	75	96	Tumor necrosis factor	GENE-Y	1611705T13
1611705	1369	1372	TNF	GENE-Y	112979
1611705	1415	1432	phosphodiesterase	GENE-N	1611705T15
1611705	98	101	TNF	GENE-Y	112979
1611705	325	328	TNF	GENE-Y	112979
1611705	611	614	TNF	GENE-Y	112979
1611705	884	887	TNF	GENE-Y	112979
1611705	1252	1260	amrinone	CHEMICAL	1611705T1
1611705	22	43	tumor necrosis factor	GENE-Y	1611705T20
1611705	1264	1278	pentoxifylline	CHEMICAL	1611705T2
1611705	1396	1404	amrinone	CHEMICAL	1611705T3
1611705	240	248	amrinone	CHEMICAL	1611705T4
1611705	658	666	amrinone	CHEMICAL	1611705T5
1611705	687	701	pentoxifylline	CHEMICAL	1611705T6
1611705	788	801	dexamethasone	CHEMICAL	1611705T7
1611705	827	840	dexamethasone	CHEMICAL	1611705T8
1611705	845	853	amrinone	CHEMICAL	1611705T9
1611705	CPR:3	1611705T1	112979
1611705	CPR:3	1611705T2	112979
1611705	CPR:4	1611705T4	112979
1611705	CPR:4	1611705T8	112979
1611705	CPR:4	1611705T9	112979

16207494|t|Age-dependent changes of pyridoxal phosphate synthesizing enzymes immunoreactivities and activities in the gerbil hippocampal CA1 region.
16207494|a|In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper. Significant age-dependent changes in PLK and PNPO immunoreactivities were found in the CA1 region, but not in the CA2/3 region. In the postnatal month 1 (PM 1) group, PLK and PNPO immunoreactivities were detected mainly in the stratum pyramidale of the CA1 region. PLK and PNPO immunoreactivities and their protein contents were highest in the PM 6 group, showing that many CA1 pyramidal cells had strong PLK and PNPO immunoreactivities. Thereafter, PLK and PNPO immunoreactivities started to decrease and were very low at PM 24. Alterations in the change patterns in protein contents and total activities of PLK and PNPO corresponded to the immunohistochemical data, but their specific activities were not altered in any experimental group. Based on double immunofluorescence study, PLK and PNPO immunoreactive cells in the strata oriens and radiatum were identified as GABAergic cells. Therefore, decreases of PLK and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (GABA) function.
16207494	252	255	PLK	GENE-N	16207494T10
16207494	1299	1302	PLK	GENE-N	16207494T11
16207494	1307	1311	PNPO	GENE-N	120463
16207494	261	292	pyridoxine 5'-phosphate oxidase	GENE-N	16207494T13
16207494	294	298	PNPO	GENE-N	120463
16207494	424	427	PLK	GENE-N	16207494T15
16207494	432	436	PNPO	GENE-N	120463
16207494	554	557	PLK	GENE-N	16207494T17
16207494	562	566	PNPO	GENE-N	120463
16207494	652	655	PLK	GENE-N	16207494T19
16207494	261	284	pyridoxine 5'-phosphate	CHEMICAL	16207494T1
16207494	660	664	PNPO	GENE-N	120463
16207494	792	795	PLK	GENE-N	16207494T21
16207494	800	804	PNPO	GENE-N	120463
16207494	837	840	PLK	GENE-N	16207494T23
16207494	845	849	PNPO	GENE-N	120463
16207494	996	999	PLK	GENE-N	16207494T25
16207494	1004	1008	PNPO	GENE-N	120463
16207494	234	250	pyridoxal kinase	GENE-N	16207494T27
16207494	1405	1428	gamma-aminobutyric acid	CHEMICAL	16207494T2
16207494	1430	1434	GABA	CHEMICAL	16207494T3
16207494	183	205	pyridoxal 5'-phosphate	CHEMICAL	16207494T4
16207494	207	210	PLP	CHEMICAL	109
16207494	234	243	pyridoxal	CHEMICAL	16207494T6
16207494	25	44	pyridoxal phosphate	CHEMICAL	16207494T7
16207494	1171	1174	PLK	GENE-N	16207494T8
16207494	1179	1183	PNPO	GENE-N	120463
16207494	CPR:4	16207494T2	16207494T11
16207494	CPR:4	16207494T2	120463
16207494	CPR:4	16207494T3	16207494T11
16207494	CPR:4	16207494T3	120463
16207494	CPR:9	16207494T4	16207494T10
16207494	CPR:9	16207494T4	16207494T13
16207494	CPR:9	16207494T4	120463
16207494	CPR:9	16207494T4	16207494T27
16207494	CPR:9	109	16207494T10
16207494	CPR:9	109	16207494T13
16207494	CPR:9	109	120463
16207494	CPR:9	109	16207494T27

16213084|t|Functional characteristics of H+ -dependent nicotinate transport in primary cultures of astrocytes from rat cerebral cortex.
16213084|a|In the present study, we report the characteristics of H(+)-coupled nicotinate transport in primary cultures of astrocytes from rat cerebral cortex. The [(3)H]nicotinate transport in rat astrocytes increased up to a pH 5.5. The nicotinic acid uptake at pH 6.0 was both energy-dependent and saturable with a Michaelis constant (K(t)) of 2.8+/-0.4 mM and the maximal uptake rate (V(max)) of 31+/-3.2 nmol/mg protein/10 min. This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM). On the other hand, the uptake process of l-lactic acid was also saturable with a high-affinity component (K(t)=0.27 mM) and a low-affinity component (K(t)=35.9 mM). Reverse transcription-PCR and Western blot analyses revealed that three MCT subtypes, MCT1/Slc16a1, MCT2/Slc16a7, and MCT4/Slc16a3, were expressed in these cells. Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or MCT2. These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.
16213084	353	367	nicotinic acid	CHEMICAL	16213084T10
16213084	591	640	carbonylcyanide p-trifluoromethoxyphenylhydrazone	CHEMICAL	16213084T11
16213084	656	671	monocarboxylate	CHEMICAL	16213084T12
16213084	180	184	H(+)	CHEMICAL	16213084T13
16213084	701	735	alpha-cyano-4-hydroxycinnamic acid	CHEMICAL	16213084T14
16213084	753	763	nicotinate	CHEMICAL	16213084T15
16213084	804	808	H(+)	CHEMICAL	16213084T16
16213084	193	203	nicotinate	CHEMICAL	16213084T17
16213084	817	832	monocarboxylate	CHEMICAL	16213084T18
16213084	851	867	[(3)H]Nicotinate	CHEMICAL	16213084T19
16213084	1376	1385	l-lactate	CHEMICAL	16213084T1
16213084	935	955	monocarboxylic acids	CHEMICAL	16213084T20
16213084	964	977	l-lactic acid	CHEMICAL	16213084T21
16213084	982	994	pyruvic acid	CHEMICAL	16213084T22
16213084	1081	1094	l-lactic acid	CHEMICAL	16213084T23
16213084	30	32	H+	CHEMICAL	16213084T24
16213084	44	54	nicotinate	CHEMICAL	16213084T25
16213084	1277	1280	MCT	GENE-N	16213084T26
16213084	1291	1295	MCT1	GENE-Y	34615
16213084	1296	1303	Slc16a1	GENE-Y	247107|203282
16213084	1305	1309	MCT2	GENE-Y	16213084T29
16213084	1408	1418	nicotinate	CHEMICAL	16213084T2
16213084	1310	1317	Slc16a7	GENE-Y	203284
16213084	1323	1327	MCT4	GENE-Y	16213084T31
16213084	1328	1335	Slc16a3	GENE-Y	219825
16213084	1511	1515	MCT1	GENE-Y	34615
16213084	1523	1527	MCT2	GENE-Y	16213084T34
16213084	1639	1679	low-affinity monocarboxylate transporter	GENE-N	16213084T35
16213084	1680	1684	MCT4	GENE-Y	16213084T36
16213084	1702	1747	H(+)-coupled monocarboxylate transport system	GENE-N	16213084T37
16213084	656	683	monocarboxylate transporter	GENE-N	16213084T38
16213084	685	688	MCT	GENE-N	16213084T39
16213084	1460	1470	nicotinate	CHEMICAL	16213084T3
16213084	817	849	monocarboxylate transport system	GENE-N	16213084T40
16213084	1577	1581	H(+)	CHEMICAL	16213084T4
16213084	1652	1667	monocarboxylate	CHEMICAL	16213084T5
16213084	278	294	[(3)H]nicotinate	CHEMICAL	16213084T6
16213084	1702	1706	H(+)	CHEMICAL	16213084T7
16213084	1715	1730	monocarboxylate	CHEMICAL	16213084T8
16213084	1753	1763	nicotinate	CHEMICAL	16213084T9
16213084	CPR:4	16213084T14	16213084T38
16213084	CPR:4	16213084T14	16213084T39
16213084	CPR:9	16213084T15	16213084T40
16213084	CPR:9	16213084T3	34615
16213084	CPR:9	16213084T3	16213084T34
16213084	CPR:9	16213084T9	16213084T35
16213084	CPR:9	16213084T9	16213084T36
16213084	CPR:9	16213084T9	16213084T37

16220064|t|A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker.
16220064|a|The angiotensin II (A-II) type 1 (AT1) receptor-mediated effects of A-II play a key role in the pathophysiology of hypertension. Effective inhibition of A-II is provided by the latest class of antihypertensive medications, the AT1 receptor blockers (ARBs). These orally available agents were developed around a common imidazole-based structural core. The most recent member of this drug class to be approved by the Food and Drug Administration, olmesartan medoxomil, contains unique features that may explain its clinical efficacy. Key structural elements of olmesartan medoxomil include a hydroxyalkyl substituent at the imidazole 4-position and a hydrolyzable ester group at the imidazole 5-position. Inter- and intramolecular hydrogen bonding involving these groups may contribute to the potentiation of antagonist activity. After oral administration, olmesartan medoxomil is deesterified in the intestinal tract to produce the active metabolite olmesartan, which undergoes no additional metabolic change. The marked antihypertensive efficacy of olmesartan medoxomil may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of A-II. This review article characterizes the structural features of olmesartan that may be responsible for its clinical efficacy. Inferential pharmacological studies compare and contrast the effects of olmesartan to those of other ARBs in comparable preclinical animal models.
16220064	54	74	olmesartan medoxomil	CHEMICAL	16220064T10
16220064	1253	1256	AT1	GENE-Y	16220064T11
16220064	1331	1335	A-II	GENE-Y	16220064T12
16220064	262	266	A-II	GENE-Y	16220064T13
16220064	336	339	AT1	GENE-Y	16220064T14
16220064	113	156	angiotensin II (A-II) type 1 (AT1) receptor	GENE-Y	16220064T15
16220064	177	181	A-II	GENE-Y	16220064T16
16220064	79	99	angiotensin receptor	GENE-N	16220064T17
16220064	1158	1178	olmesartan medoxomil	CHEMICAL	16220064T1
16220064	1331	1335	A-II	CHEMICAL	16220064T2
16220064	262	266	A-II	CHEMICAL	16220064T3
16220064	129	133	A-II	CHEMICAL	16220064T4
16220064	113	127	angiotensin II	CHEMICAL	16220064T5
16220064	554	574	olmesartan medoxomil	CHEMICAL	16220064T6
16220064	668	688	olmesartan medoxomil	CHEMICAL	16220064T7
16220064	177	181	A-II	CHEMICAL	16220064T8
16220064	964	984	olmesartan medoxomil	CHEMICAL	16220064T9
16220064	CPR:4	16220064T10	16220064T17
16220064	CPR:4	16220064T1	16220064T12

16245075|t|Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046) on acid-induced lung injury in rats.
16245075|a|It has been suggested that neutrophils play an important role in acid-aspirated lung injury. We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific neutrophil elastase inhibitor (ONO-5046) on acid lung injury in rats. Animals were anesthetized and normal saline (NS, 2 mL kg(-1)) or hydrochloric acid (HCl, 0.1 N 2 mL kg(-1)) was then instilled into trachea. Thirty minutes before HCl instillation, G-CSF (150 microg kg(-1)) was injected subcutaneously or ONO-5046 (10 mg kg(-1) h(-1)) was infused continuously into the right jugular vein. Animals were ventilated during the experiments. Five hours after HCl or NS instillation, bronchoalveolar lavage fluid (BALF) and lung tissue samples were obtained. Total nuclear cell count, absorbance, albumin, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, cytokine-induced neutrophil chemoattractant (CINC), neutrophil elastase in BALF, wet-to-dry (W/D) ratio were measured. HCl aspiration markedly increased these values in BALF and W/D ratio. Both ONO-5046 and G-CSF attenuated the parameters increased by acid-induced lung injury in rats. The data suggests that neutrophils play an important role in acid-induced lung injury. However, high-dose G-CSF does not exacerbate acid-aspirated lung injury in rats, although this agent causes an increase in peripheral neutrophils.
16245075	1258	1263	G-CSF	GENE-Y	16245075T10
16245075	1443	1448	G-CSF	GENE-Y	16245075T11
16245075	276	313	granulocyte-colony stimulating factor	GENE-Y	16245075T12
16245075	315	320	G-CSF	GENE-Y	16245075T13
16245075	393	412	neutrophil elastase	GENE-Y	16245075T14
16245075	644	649	G-CSF	GENE-Y	16245075T15
16245075	987	994	albumin	GENE-Y	16245075T16
16245075	996	1029	tumor necrosis factor (TNF)-alpha	GENE-Y	16245075T17
16245075	1031	1049	interleukin (IL)-6	GENE-Y	16245075T18
16245075	1051	1094	cytokine-induced neutrophil chemoattractant	GENE-N	16245075T19
16245075	1170	1173	HCl	CHEMICAL	16245075T1
16245075	1096	1100	CINC	GENE-N	16245075T20
16245075	1103	1122	neutrophil elastase	GENE-Y	16245075T21
16245075	11	48	granulocyte colony-stimulating factor	GENE-Y	16245075T22
16245075	50	55	G-CSF	GENE-Y	16245075T23
16245075	61	80	neutrophil elastase	GENE-Y	16245075T24
16245075	1245	1253	ONO-5046	CHEMICAL	16245075T2
16245075	424	432	ONO-5046	CHEMICAL	16245075T3
16245075	528	545	hydrochloric acid	CHEMICAL	16245075T4
16245075	547	550	HCl	CHEMICAL	16245075T5
16245075	626	629	HCl	CHEMICAL	16245075T6
16245075	701	709	ONO-5046	CHEMICAL	16245075T7
16245075	850	853	HCl	CHEMICAL	16245075T8
16245075	92	100	ONO-5046	CHEMICAL	16245075T9
16245075	CPR:4	16245075T3	16245075T14
16245075	CPR:4	16245075T9	16245075T22
16245075	CPR:4	16245075T9	16245075T23
16245075	CPR:4	16245075T9	16245075T24

16247743|t|Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
16247743|a|Type 1 Gaucher disease (GD) is a progressive lysosomal storage disorder due to an autosomal recessive deficiency of glucocerebrosidase. Clinical manifestations include anemia, thrombocytopenia, hepatosplenomegaly, and bone and pulmonary disease. Intravenous enzyme replacement (ERT) with imiglucerase is the accepted standard for treatment of symptomatic patients. More than 3,500 patients worldwide have received ERT with well-documented beneficial effects on the hematological, visceral, skeletal, and pulmonary manifestations, and with resultant improvement in health-related quality of life. Miglustat, an imino sugar that reversibly inhibits glucosylceramide synthase and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option. Because responses to miglustat are slower and less robust than those observed with ERT, and because miglustat is associated with significant side effects, clinicians who care for patients with GD should become familiar with the limited indications for miglustat use and the circumstances when it may be prescribed appropriately. This review article and position statement represents the current opinion of American physicians with extensive expertise in GD regarding patient management in the context of the availability of standard imiglucerase treatment and the recent introduction of miglustat.
16247743	1100	1109	miglustat	CHEMICAL	411
16247743	1252	1261	miglustat	CHEMICAL	411
16247743	1587	1596	miglustat	CHEMICAL	411
16247743	680	689	Miglustat	CHEMICAL	411
16247743	694	705	imino sugar	CHEMICAL	16247743T5
16247743	1021	1030	miglustat	CHEMICAL	411
16247743	23	32	miglustat	CHEMICAL	411
16247743	200	218	glucocerebrosidase	GENE-Y	16247743T8
16247743	731	756	glucosylceramide synthase	GENE-Y	16247743T9
16247743	CPR:4	411	16247743T9
16247743	CPR:4	16247743T5	16247743T9

16248990|t|Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors.
16248990|a|The main goal of the present study was to analyse the effects of (+/-)-huprine X ((+/-)-HX) and galantamine (GAL), with potentiating action on nicotinic receptors, and huperzine A (HPA), devoid of nicotinic activity, on [3H]-acetylcholine ([3H]-ACh) release in striatal slices of rat brain. All compounds are non-covalent and reversible inhibitors of AChE. Addition of (+/-)-HX (0.01 microM), GAL (10 microM) and HPA (0.1 microM) to the superfusion medium decreased the release of the ACh neurotransmitter to a similar extent: 36%, 30% and 34%, respectively (P<0.01). This effect was reverted in the presence of atropine (ATR; 0.1 microM), which blocks the pre-synaptic muscarinic M2 receptor. After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist. In these conditions, a dose-dependent increase of [3H]-ACh release was observed in the presence of (+/-)-HX, GAL and HPA. To test the role of nicotinic receptors in the drugs' effects on [3H]-ACh release, mecamylamine (MEC) 100 microM was used to block such receptors. MEC alone significantly decreased neurotransmitter release by 18% (P<0.05), but no change was obtained in the presence of both ATR and MEC. Under these conditions, (+/-)-HX, GAL and HPA increased the release of [3H]-ACh by 37%, 25% and 38%, respectively (P<0.01). Taking into account all of these data, the present results suggest that the effects induced by (+/-)-HX and GAL nicotinic-receptor potentiators seem to be mainly due to their ability in inhibiting acetylcholinesterase activity, but not by interaction on the nicotinic receptors.
16248990	636	639	ACh	CHEMICAL	16248990T10
16248990	763	771	atropine	CHEMICAL	16248990T11
16248990	773	776	ATR	CHEMICAL	16248990T12
16248990	917	920	ATR	CHEMICAL	16248990T13
16248990	966	977	haloperidol	CHEMICAL	16248990T14
16248990	979	982	HAL	CHEMICAL	16248990T15
16248990	1000	1008	dopamine	CHEMICAL	16248990T16
16248990	1074	1082	[3H]-ACh	CHEMICAL	16248990T17
16248990	52	63	galantamine	CHEMICAL	16248990T18
16248990	74	77	ACh	CHEMICAL	16248990T19
16248990	1211	1219	[3H]-ACh	CHEMICAL	16248990T1
16248990	1166	1185	nicotinic receptors	GENE-N	16248990T20
16248990	294	313	nicotinic receptors	GENE-N	16248990T21
16248990	1669	1687	nicotinic-receptor	GENE-N	16248990T22
16248990	1754	1774	acetylcholinesterase	GENE-Y	16248990T23
16248990	1815	1834	nicotinic receptors	GENE-N	16248990T24
16248990	502	506	AChE	GENE-Y	16248990T25
16248990	821	843	muscarinic M2 receptor	GENE-Y	16248990T26
16248990	1000	1011	dopamine D2	GENE-Y	16248990T27
16248990	0	18	Nicotinic-receptor	GENE-N	16248990T28
16248990	130	149	nicotinic receptors	GENE-N	16248990T29
16248990	1229	1241	mecamylamine	CHEMICAL	16248990T2
16248990	98	102	AChE	GENE-Y	16248990T30
16248990	1243	1246	MEC	CHEMICAL	16248990T3
16248990	1293	1296	MEC	CHEMICAL	16248990T4
16248990	1420	1423	ATR	CHEMICAL	16248990T5
16248990	1428	1431	MEC	CHEMICAL	16248990T6
16248990	1504	1512	[3H]-ACh	CHEMICAL	16248990T7
16248990	371	389	[3H]-acetylcholine	CHEMICAL	16248990T8
16248990	391	399	[3H]-ACh	CHEMICAL	16248990T9
16248990	CPR:4	16248990T11	16248990T26
16248990	CPR:4	16248990T12	16248990T26
16248990	CPR:4	16248990T18	16248990T30
16248990	CPR:4	16248990T2	16248990T20
16248990	CPR:4	16248990T3	16248990T20
16248990	CPR:6	16248990T14	16248990T27
16248990	CPR:6	16248990T15	16248990T27

16253547|t|Rat hepatic stellate cells become retinoid unresponsive during activation.
16253547|a|Hepatic stellate cells (HSC) play an essential role in fibrogenesis. Many stimuli cause HSC to activate, lose their Vitamin A and produce collagen. It is unclear whether Vitamin A loss causes activation, potentiates it or is simply an event in the cascade of activation changes. We determine if exogenous retinoids prevent the activation of freshly isolated rat HSC activated by plating on plastic. We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC nuclear receptors for retinoic acid (RAR) in HSC that are becoming activated or are chronically activated. Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation. RAR-alpha, RAR-beta and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after retinoic acid supplementation. Activation markers in chronically activated HSC were only slightly decreased after retinoid exposure. We conclude that exposure of HSC to extracellular retinoids diminishes some markers of activation but does not prevent HSC activation.
16253547	799	806	retinol	CHEMICAL	16253547T10
16253547	810	823	retinoic acid	CHEMICAL	16253547T11
16253547	849	857	retinoid	CHEMICAL	16253547T12
16253547	950	963	retinoic acid	CHEMICAL	16253547T13
16253547	1027	1035	retinoid	CHEMICAL	16253547T14
16253547	34	42	retinoid	CHEMICAL	16253547T15
16253547	1077	1086	RAR-gamma	GENE-Y	16253547T16
16253547	1096	1104	RAR-beta	GENE-N	16253547T17
16253547	213	221	collagen	GENE-N	16253547T18
16253547	621	656	nuclear receptors for retinoic acid	GENE-N	16253547T19
16253547	1185	1198	retinoic acid	CHEMICAL	16253547T1
16253547	658	661	RAR	GENE-N	16253547T20
16253547	889	898	RAR-alpha	GENE-Y	16253547T21
16253547	900	908	RAR-beta	GENE-Y	16253547T22
16253547	913	922	RAR-gamma	GENE-Y	16253547T23
16253547	928	945	nuclear receptors	GENE-N	16253547T24
16253547	1053	1062	RAR-alpha	GENE-Y	16253547T25
16253547	1064	1072	RAR-beta	GENE-Y	16253547T26
16253547	191	200	Vitamin A	CHEMICAL	156
16253547	1299	1307	retinoid	CHEMICAL	16253547T3
16253547	1368	1377	retinoids	CHEMICAL	16253547T4
16253547	245	254	Vitamin A	CHEMICAL	156
16253547	380	389	retinoids	CHEMICAL	16253547T6
16253547	495	504	retinoids	CHEMICAL	16253547T7
16253547	573	581	retinoid	CHEMICAL	16253547T8
16253547	643	656	retinoic acid	CHEMICAL	16253547T9
16253547	CPR:4	16253547T14	16253547T21
16253547	CPR:4	16253547T14	16253547T22
16253547	CPR:4	16253547T14	16253547T23
16253547	CPR:4	16253547T14	16253547T24

16324695|t|Protein kinase C potentiates homologous desensitization of the beta2-adrenoceptor in bovine tracheal smooth muscle.
16324695|a|Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the beta(2)-adrenoceptor. Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization. To investigate the capacity of activated PKC to regulate homologous desensitization, we incubated the smooth muscle strips with the combination of both 1 microM PMA and 1 microM fenoterol. This combined treatment synergistically decreased the isoprenaline-induced maximal relaxation, as compared to the individual effects of PMA and fenoterol alone, indicating a common pathway for heterologous and homologous desensitization. Moreover, the specific PKC-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented. In conclusion, the present study demonstrates that homologous desensitization of the beta(2)-adrenergic receptor can be enhanced by PKC activation. For the first time we have provided evidence that this concept is functionally operative in airway smooth muscle, and it may explain the reduced bronchodilator response to beta(2)-adrenoceptor agonists in patients with asthma during a severe exacerbation.
16324695	530	533	PMA	CHEMICAL	16324695T10
16324695	578	590	isoprenaline	CHEMICAL	16324695T11
16324695	870	879	fenoterol	CHEMICAL	16324695T12
16324695	935	947	isoprenaline	CHEMICAL	16324695T13
16324695	1017	1020	PMA	CHEMICAL	16324695T14
16324695	1025	1034	fenoterol	CHEMICAL	16324695T15
16324695	1142	1145	PKC	GENE-N	16324695T16
16324695	1515	1542	beta(2)-adrenergic receptor	GENE-Y	16324695T17
16324695	1562	1565	PKC	GENE-N	16324695T18
16324695	1750	1770	beta(2)-adrenoceptor	GENE-Y	16324695T19
16324695	1156	1227	2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide	CHEMICAL	16324695T1
16324695	407	427	beta(2)-adrenoceptor	GENE-Y	16324695T20
16324695	464	480	protein kinase C	GENE-N	16324695T21
16324695	482	485	PKC	GENE-N	16324695T22
16324695	628	631	PKC	GENE-N	16324695T23
16324695	654	674	beta(2)-adrenoceptor	GENE-Y	16324695T24
16324695	733	736	PKC	GENE-N	16324695T25
16324695	0	16	Protein kinase C	GENE-N	16324695T26
16324695	63	81	beta2-adrenoceptor	GENE-Y	16324695T27
16324695	226	235	fenoterol	CHEMICAL	16324695T2
16324695	1229	1239	GF 109203X	CHEMICAL	16324695T3
16324695	1286	1298	isoprenaline	CHEMICAL	16324695T4
16324695	1385	1388	PMA	CHEMICAL	16324695T5
16324695	1393	1402	fenoterol	CHEMICAL	16324695T6
16324695	246	258	isoprenaline	CHEMICAL	16324695T7
16324695	298	310	methacholine	CHEMICAL	16324695T8
16324695	497	528	phorbol 12-myristate 13-acetate	CHEMICAL	16324695T9
16324695	CPR:3	16324695T10	16324695T21
16324695	CPR:3	16324695T10	16324695T22
16324695	CPR:3	16324695T10	16324695T23
16324695	CPR:3	16324695T9	16324695T21
16324695	CPR:3	16324695T9	16324695T22
16324695	CPR:3	16324695T9	16324695T23
16324695	CPR:4	16324695T10	16324695T24
16324695	CPR:4	16324695T1	16324695T16
16324695	CPR:4	16324695T2	16324695T20
16324695	CPR:4	16324695T3	16324695T16
16324695	CPR:4	16324695T9	16324695T24
16324695	CPR:5	16324695T11	16324695T24
16324695	CPR:5	16324695T7	16324695T20

16336752|t|Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
16336752|a|The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancers. As more is learned about the molecular details of EGFR signaling, antibodies can be designed to interfere with specific domains of the EGFR molecule. In this review, we analyze preclinical and current clinical data on EGFR-targeting molecules and their potential role in the treatment of colorectal cancer. Cetuximab binds to domain III of EGFR and hinders ligand binding. It is now approved by the US Food and Drug Administration for metastatic colorectal cancer treatment. Panitumumab is another widely studied anti-EGFR antibody with similar properties. Bispecific antibodies are modified immunoglobulin molecules containing 2 different binding specificities. These antibodies can redirect the immune response against tumor cells by tethering effector cells such as CD3e-expressing T cells or CD16-expressing natural killer cells and granulocytes to the surface of cancer cells. Tyrosine kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling. The presence of skin rash and EGFR gene amplification have been advanced as possible predictors of clinical effectiveness of targeted anti-EGFR therapies.
16336752	1527	1531	EGFR	GENE-Y	108276|3932452|676741
16336752	1636	1640	EGFR	GENE-Y	108276|3932452|676741
16336752	311	315	EGFR	GENE-Y	108276|3932452|676741
16336752	396	400	EGFR	GENE-Y	108276|3932452|676741
16336752	479	483	EGFR	GENE-Y	108276|3932452|676741
16336752	169	173	EGFR	GENE-Y	108276|3932452|676741
16336752	135	167	epidermal growth factor receptor	GENE-Y	16336752T16
16336752	601	605	EGFR	GENE-Y	108276|3932452|676741
16336752	779	783	EGFR	GENE-Y	108276|3932452|676741
16336752	853	867	immunoglobulin	GENE-N	16336752T19
16336752	1143	1151	Tyrosine	CHEMICAL	16336752T1
16336752	1030	1034	CD3e	GENE-Y	16336752T20
16336752	1057	1061	CD16	GENE-N	16336752T21
16336752	68	100	epidermal growth factor receptor	GENE-Y	16336752T22
16336752	1174	1185	quinazoline	CHEMICAL	16336752T2
16336752	1269	1277	tyrosine	CHEMICAL	16336752T3
16336752	1143	1158	Tyrosine kinase	GENE-N	16336752T4
16336752	1269	1291	tyrosine kinase domain	GENE-N	16336752T5
16336752	1324	1328	EGFR	GENE-Y	108276|3932452|676741
16336752	1330	1334	Erb2	GENE-Y	16336752T7
16336752	1340	1383	vascular endothelial growth factor receptor	GENE-N	16336752T8
16336752	1481	1485	EGFR	GENE-Y	108276|3932452|676741
16336752	CPR:4	16336752T2	16336752T4
16336752	CPR:4	16336752T2	16336752T5
16336752	CPR:4	16336752T2	108276|3932452|676741
16336752	CPR:4	16336752T2	16336752T7
16336752	CPR:4	16336752T2	16336752T8
16336752	CPR:4	16336752T2	108276|3932452|676741

16373326|t|Isolation and function of the amino acid transporter PAT1 (slc36a1) from rabbit and discrimination between transport via PAT1 and system IMINO in renal brush-border membrane vesicles.
16373326|a|Reabsorption of amino acids is an important function of the renal proximal tubule. pH-dependent amino acid transport has been measured previously using rabbit renal brush-border membrane vesicles (BBMV). The purpose of this investigation was to determine whether this pH-dependent uptake represents H(+)/amino acid cotransport via a PAT1-like transport system. The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475 amino acids (92% identity to human PAT1). Rabbit PAT1 mRNA was found in all tissues investigated including kidney. When expressed heterologously in a mammalian cell line, rabbit PAT1 mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and alpha-(methylamino)isobutyric acid. Proline uptake was maximal at pH 5.0 (K(m) 2.2+/-0.7 mM). A transport system with identical characteristics (ion dependency, substrate specificity) was detected in rabbit renal BBMV where an overshoot was observed in the absence of Na+ but in the presence of an inwardly directed H+ gradient. In the presence of Na+ and under conditions in which PAT1 transport function was suppressed, a second proline uptake system was detected that exhibited functional characteristics similar to those of the IMINO system. The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that PAT1 is the low-affinity transporter of proline, glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.
16373326	488	498	amino acid	CHEMICAL	16373326T10
16373326	705	716	amino acids	CHEMICAL	16373326T11
16373326	911	916	Na(+)	CHEMICAL	16373326T12
16373326	939	946	proline	CHEMICAL	16373326T13
16373326	948	955	glycine	CHEMICAL	16373326T14
16373326	957	966	l-alanine	CHEMICAL	16373326T15
16373326	971	1005	alpha-(methylamino)isobutyric acid	CHEMICAL	16373326T16
16373326	1007	1014	Proline	CHEMICAL	16373326T17
16373326	280	290	amino acid	CHEMICAL	16373326T18
16373326	30	40	amino acid	CHEMICAL	16373326T19
16373326	1239	1242	Na+	CHEMICAL	16373326T1
16373326	1353	1357	PAT1	GENE-Y	31052|20114
16373326	1503	1515	IMINO system	GENE-N	16373326T21
16373326	1551	1562	rabbit PAT1	GENE-Y	16373326T22
16373326	1616	1620	PAT1	GENE-Y	31052|20114
16373326	517	521	PAT1	GENE-Y	31052|20114
16373326	549	560	rabbit PAT1	GENE-Y	16373326T25
16373326	637	650	poly(A) tail)	GENE-N	16373326T26
16373326	659	677	open reading frame	GENE-N	16373326T27
16373326	734	744	human PAT1	GENE-Y	16373326T28
16373326	747	758	Rabbit PAT1	GENE-Y	16373326T29
16373326	1287	1289	H+	CHEMICAL	16373326T2
16373326	876	887	rabbit PAT1	GENE-Y	16373326T30
16373326	121	125	PAT1	GENE-Y	31052|20114
16373326	130	142	system IMINO	GENE-N	16373326T32
16373326	30	57	amino acid transporter PAT1	GENE-Y	16373326T33
16373326	59	66	slc36a1	GENE-Y	16373326T34
16373326	1319	1322	Na+	CHEMICAL	16373326T3
16373326	1402	1409	proline	CHEMICAL	16373326T4
16373326	1656	1663	proline	CHEMICAL	16373326T5
16373326	1665	1672	glycine	CHEMICAL	16373326T6
16373326	1677	1691	hydroxyproline	CHEMICAL	16373326T7
16373326	200	211	amino acids	CHEMICAL	16373326T8
16373326	483	487	H(+)	CHEMICAL	16373326T9
16373326	CPR:9	16373326T13	16373326T30
16373326	CPR:9	16373326T14	16373326T30
16373326	CPR:9	16373326T15	16373326T30
16373326	CPR:9	16373326T16	16373326T30
16373326	CPR:9	16373326T4	31052|20114
16373326	CPR:9	16373326T5	31052|20114
16373326	CPR:9	16373326T6	31052|20114
16373326	CPR:9	16373326T7	31052|20114

16388933|t|Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade.
16388933|a|In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood. In addition, we examined the ability of trimipramine; a tricyclic antidepressant that is devoid of monoamine reuptake inhibitory properties on cytokine production. Lipopolysaccharide (LPS) was used to stimulate monocyte-derived pro-inflammatory (IL-1beta, TNF-alpha, IL-12) and anti-inflammatory (IL-10) cytokines, whilst concanavalin A (Con A) was used to stimulate T-cell (Th(1): IFN-gamma and Th(2/3): IL-10) cytokines. All of the antidepressants suppressed IFN-gamma production in the 10-50 microM concentration range, irrespective of their preference for serotonin or noradrenaline transporters. This suppression of IFN-gamma production was paralleled by reduced T-cell proliferation, therefore we suggest that the ability of antidepressants to suppress IFN-gamma production may be related to their anti-proliferative properties. The fact that trimipramine also suppressed IFN-gamma production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake. Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived IL-10 production, with significant effects elicited by the noradrenaline reuptake inhibitors reboxetine and desipramine. In contrast to the robust actions of antidepressants on T-cell derived cytokine production, they failed to induce any consistent change in LPS-induced monocyte cytokine production. Overall, our results indicate that IFN-gamma producing T-cells (Th(1) cells) are the major target for the immunomodulatory actions of antidepressants, and provide evidence questioning the relationship between the monoaminergic reuptake properties of antidepressants and their immunomodulatory effects. The potential clinical significance of the anti-inflammatory actions of antidepressants is discussed.
16388933	455	464	tricyclic	CHEMICAL	16388933T10
16388933	498	507	monoamine	CHEMICAL	16388933T11
16388933	177	190	noradrenaline	CHEMICAL	16388933T12
16388933	959	968	serotonin	CHEMICAL	16388933T13
16388933	204	214	reboxetine	CHEMICAL	16388933T14
16388933	972	985	noradrenaline	CHEMICAL	16388933T15
16388933	219	230	desipramine	CHEMICAL	16388933T16
16388933	89	98	monoamine	CHEMICAL	16388933T17
16388933	1158	1167	IFN-gamma	GENE-Y	16388933T18
16388933	1277	1286	IFN-gamma	GENE-Y	16388933T19
16388933	1248	1260	trimipramine	CHEMICAL	16388933T1
16388933	240	261	serotonin transporter	GENE-Y	16388933T20
16388933	1568	1573	IL-10	GENE-Y	16388933T21
16388933	1760	1768	cytokine	GENE-N	16388933T22
16388933	1849	1857	cytokine	GENE-N	16388933T23
16388933	1905	1914	IFN-gamma	GENE-Y	16388933T24
16388933	364	372	cytokine	GENE-N	16388933T25
16388933	542	550	cytokine	GENE-N	16388933T26
16388933	645	653	IL-1beta	GENE-Y	16388933T27
16388933	655	664	TNF-alpha	GENE-Y	16388933T28
16388933	666	671	IL-12	GENE-N	16388933T29
16388933	240	249	serotonin	CHEMICAL	16388933T2
16388933	177	202	noradrenaline transporter	GENE-Y	16388933T30
16388933	696	701	IL-10	GENE-Y	16388933T31
16388933	703	712	cytokines	GENE-N	16388933T32
16388933	781	790	IFN-gamma	GENE-Y	16388933T33
16388933	804	809	IL-10	GENE-Y	16388933T34
16388933	811	820	cytokines	GENE-N	16388933T35
16388933	860	869	IFN-gamma	GENE-Y	16388933T36
16388933	959	998	serotonin or noradrenaline transporters	GENE-N	16388933T37
16388933	1020	1029	IFN-gamma	GENE-Y	16388933T38
16388933	47	55	cytokine	GENE-N	16388933T39
16388933	1431	1440	monoamine	CHEMICAL	16388933T3
16388933	56	72	interferon-gamma	GENE-Y	16388933T40
16388933	89	110	monoamine transporter	GENE-N	16388933T41
16388933	263	273	fluoxetine	CHEMICAL	16388933T4
16388933	1627	1640	noradrenaline	CHEMICAL	16388933T5
16388933	1661	1671	reboxetine	CHEMICAL	16388933T6
16388933	1676	1687	desipramine	CHEMICAL	16388933T7
16388933	278	290	clomipramine	CHEMICAL	16388933T8
16388933	439	451	trimipramine	CHEMICAL	16388933T9
16388933	CPR:4	16388933T1	16388933T19

16418149|t|Effect of cyproheptadine on serum leptin levels.
16418149|a|Leptin is a 167 amino acid protein encoded by the obesity gene that is synthesized in adipose tissue and interacts with receptors in the hypothalamus linked to the regulation of appetite and metabolism. It is known to suppress appetite and increase energy expenditure. Cyproheptadine is a piperidine antihistamine that increases appetite through its antiserotonergic effect on 5-HT2 receptors in the brain. Although both leptin and cyproheptadine are effective in controlling appetite, their interaction has not been addressed in clinical studies. This study evaluated serum leptin concentrations in patients who received cyproheptadine to treat a variety of disorders. Sixteen patients aged 7 to 71 years (mean, 26.25 years) were given cyproheptadine 2 to 6 mg/day for a minimum of 7 days. Body weight was measured and blood samples were obtained at baseline and after 1 week of treatment. Serum leptin levels were determined by leptin radioimmunoassay. The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean leptin level after 1 week of treatment with cyproheptadine (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05). This increase may suggest that both leptin and cyproheptadine may affect appetite via similar receptors and that cyproheptadine does not impair leptin activity through these receptors. Further study will be necessary to clarify this relationship.
16418149	786	800	cyproheptadine	CHEMICAL	16418149T10
16418149	10	24	cyproheptadine	CHEMICAL	16418149T11
16418149	49	55	Leptin	GENE-Y	16418149T12
16418149	1147	1153	leptin	GENE-Y	16418149T13
16418149	1317	1323	leptin	GENE-Y	16418149T14
16418149	426	431	5-HT2	GENE-Y	16418149T15
16418149	470	476	leptin	GENE-Y	16418149T16
16418149	946	952	leptin	GENE-Y	16418149T17
16418149	979	985	leptin	GENE-Y	16418149T18
16418149	34	40	leptin	GENE-Y	16418149T19
16418149	1191	1205	cyproheptadine	CHEMICAL	16418149T1
16418149	1328	1342	cyproheptadine	CHEMICAL	16418149T2
16418149	1394	1408	cyproheptadine	CHEMICAL	16418149T3
16418149	65	75	amino acid	CHEMICAL	16418149T4
16418149	318	332	Cyproheptadine	CHEMICAL	426
16418149	338	348	piperidine	CHEMICAL	16418149T6
16418149	349	362	antihistamine	CHEMICAL	16418149T7
16418149	481	495	cyproheptadine	CHEMICAL	16418149T8
16418149	671	685	cyproheptadine	CHEMICAL	16418149T9
16418149	CPR:3	16418149T1	16418149T13

16424790|t|Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice.
16424790|a|To examine the role of sulfhydryl (-SH) group in improvement of endothelial dysfunction with angiotensin-converting enzyme (ACE) inhibitors in experimental high dose of methionine dieted rats. We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats. Male Sprague-Dawley rats were divided randomly into seven groups: control group, L-methionine group, low dose Captopril (15 mg/kg), middle dose Captopril (30 mg/kg), high dose Captopril (45 mg/kg), enalapril (20 mg/kg), N-acetylcysteine (200 mg/kg); control group were intragastric gavaged by water and others groups were intragastric gavaged by L-methionine and drugs in water one time every day. Acetylcholine (ACh)-induced endothelium-dependent relaxation (EDR), sodium nitroprusside (SNP)-induced endothelium-independent relaxation of aortic rings were examined. Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed. It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group. Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and SOD in serum by single intragastric gavaged L-methionine. However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and N-acetylcysteine particular in the activity of PON1 and ACE. These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in PON1 activity and NO levels. Furthermore, this protective effect may be concerned with the sulfhydryl group.
16424790	1775	1784	Captopril	CHEMICAL	1185
16424790	343	353	methionine	CHEMICAL	16424790T11
16424790	1872	1875	ACh	CHEMICAL	16424790T12
16424790	1915	1930	malondialdehyde	CHEMICAL	16424790T13
16424790	1955	1957	NO	CHEMICAL	427
16424790	2024	2036	L-methionine	CHEMICAL	16424790T15
16424790	2093	2102	Captopril	CHEMICAL	1185
16424790	2127	2136	enalapril	CHEMICAL	16424790T17
16424790	2153	2169	N-acetylcysteine	CHEMICAL	5519
16424790	2243	2252	Captopril	CHEMICAL	1185
16424790	1238	1253	malondialdehyde	CHEMICAL	16424790T1
16424790	2321	2333	L-methionine	CHEMICAL	16424790T20
16424790	2373	2382	Captopril	CHEMICAL	1185
16424790	394	403	Captopril	CHEMICAL	1185
16424790	2447	2449	NO	CHEMICAL	427
16424790	197	207	sulfhydryl	CHEMICAL	16424790T24
16424790	2520	2530	sulfhydryl	CHEMICAL	16424790T25
16424790	428	430	SH	CHEMICAL	16424790T26
16424790	439	448	enalapril	CHEMICAL	16424790T27
16424790	476	478	SH	CHEMICAL	16424790T28
16424790	487	503	N-acetylcysteine	CHEMICAL	5519
16424790	1255	1258	MDA	CHEMICAL	16424790T2
16424790	511	513	SH	CHEMICAL	16424790T30
16424790	210	212	SH	CHEMICAL	16424790T31
16424790	577	587	methionine	CHEMICAL	16424790T32
16424790	714	726	L-methionine	CHEMICAL	16424790T33
16424790	743	752	Captopril	CHEMICAL	1185
16424790	777	786	Captopril	CHEMICAL	1185
16424790	809	818	Captopril	CHEMICAL	1185
16424790	831	840	enalapril	CHEMICAL	16424790T37
16424790	853	869	N-acetylcysteine	CHEMICAL	5519
16424790	979	991	L-methionine	CHEMICAL	16424790T39
16424790	1261	1273	nitric oxide	CHEMICAL	16424790T3
16424790	1031	1044	Acetylcholine	CHEMICAL	2997
16424790	1046	1049	ACh	CHEMICAL	16424790T41
16424790	1099	1119	sodium nitroprusside	CHEMICAL	16424790T42
16424790	267	278	angiotensin	CHEMICAL	16424790T43
16424790	1121	1124	SNP	CHEMICAL	16424790T44
16424790	14	23	captopril	CHEMICAL	16424790T45
16424790	157	167	methionine	CHEMICAL	16424790T46
16424790	28	37	enalapril	CHEMICAL	16424790T47
16424790	63	73	sulfhydryl	CHEMICAL	16424790T48
16424790	1200	1212	Paraoxonase1	GENE-Y	16424790T49
16424790	1275	1277	NO	CHEMICAL	427
16424790	1214	1218	PON1	GENE-Y	111440
16424790	1224	1227	ACE	GENE-Y	108004
16424790	1280	1300	superoxide dismutase	GENE-N	16424790T52
16424790	1302	1305	SOD	GENE-N	16424790T53
16424790	298	301	ACE	GENE-Y	108004
16424790	1538	1542	PON1	GENE-Y	111440
16424790	1547	1550	SOD	GENE-N	16424790T56
16424790	1663	1692	angiotensin-converting enzyme	GENE-Y	16424790T57
16424790	1971	1975	PON1	GENE-Y	111440
16424790	1980	1983	SOD	GENE-N	16424790T59
16424790	1280	1290	superoxide	CHEMICAL	16424790T5
16424790	2200	2204	PON1	GENE-Y	111440
16424790	2209	2212	ACE	GENE-Y	108004
16424790	2429	2433	PON1	GENE-Y	111440
16424790	408	411	ACE	GENE-Y	108004
16424790	453	456	ACE	GENE-Y	108004
16424790	524	527	ACE	GENE-Y	108004
16424790	267	296	angiotensin-converting enzyme	GENE-Y	16424790T66
16424790	127	130	ACE	GENE-Y	108004
16424790	1381	1393	L-methionine	CHEMICAL	16424790T6
16424790	1492	1507	malondialdehyde	CHEMICAL	16424790T7
16424790	1585	1587	NO	CHEMICAL	427
16424790	1663	1674	angiotensin	CHEMICAL	16424790T9
16424790	CPR:3	1185	111440
16424790	CPR:3	1185	16424790T59
16424790	CPR:3	1185	111440
16424790	CPR:4	16424790T20	111440
16424790	CPR:4	1185	108004
16424790	CPR:4	16424790T26	108004
16424790	CPR:4	16424790T27	108004
16424790	CPR:4	16424790T45	108004
16424790	CPR:4	16424790T47	108004
16424790	CPR:4	16424790T48	108004
16424790	CPR:4	16424790T6	111440
16424790	CPR:4	16424790T6	16424790T56

16474853|t|Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
16474853|a|Tumor survival, growth and metastasis depend on efficient tumor cell proliferation and tumor angiogenesis, and targeting both of these processes simultaneously could prove to be therapeutically relevant. The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation, and angiogenesis and is often aberrantly activated in human tumors due to the presence of activated Ras or mutant B-Raf, or elevation of growth factor receptors. Sorafenib, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable kinase selectivity profile. Further characterization showed that sorafenib suppresses both wild-type and V599E mutant B-Raf activity in vitro. In addition, sorafenib demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT. Preclinically, sorafenib showed broad-spectrum antitumor activity in colon, breast and non-small-cell lung cancer xenograft models. A total of four phase I studies using oral sorafenib as a single agent have been completed, and the compound showed a favorable safety profile with mild to moderate diarrhea being the most common treatment-related adverse event. The maximum tolerated dose was 400 mg b.i.d. continuous. Single-agent phase II trials reported so far demonstrated antitumor activity of sorafenib in patients with hepatocellular carcinoma, sarcoma and renal cell cancer (RCC). Based on phase II results in RCC patients, a placebo-controlled phase III study was performed, which randomized a total of 905 patients, most of whom were treated previously. The partial response rate was 2% for sorafenib and 0% for placebo. Stable disease was observed in 78% and 55% of patients on sorafenib and placebo, respectively. Sorafenib significantly prolonged median progression-free survival (24 weeks) compared with placebo (12 weeks) in all subsets of patients evaluated. Approval of sorafenib by the U.S. Food and Drug Administration for this indication is pending. A first-line phase III study in RCC as well as phase III studies in hepatocellular carcinoma and metastatic melanoma have been initiated.
16474853	815	824	sorafenib	CHEMICAL	16474853T10
16474853	906	915	sorafenib	CHEMICAL	16474853T11
16474853	975	983	tyrosine	CHEMICAL	16474853T12
16474853	71	80	sorafenib	CHEMICAL	16474853T13
16474853	1102	1109	VEGFR-3	GENE-Y	16474853T14
16474853	1111	1154	platelet-derived growth factor (PDGFR)-beta	GENE-Y	16474853T15
16474853	1155	1160	Flt-3	GENE-Y	16474853T16
16474853	1166	1171	c-KIT	GENE-Y	16474853T17
16474853	310	313	RAS	GENE-N	16474853T18
16474853	314	317	RAF	GENE-Y	16474853T19
16474853	1188	1197	sorafenib	CHEMICAL	16474853T1
16474853	490	493	Ras	GENE-N	16474853T20
16474853	504	509	B-Raf	GENE-Y	16474853T21
16474853	527	550	growth factor receptors	GENE-N	16474853T22
16474853	726	731	Raf-1	GENE-Y	16474853T23
16474853	750	756	kinase	GENE-N	16474853T24
16474853	855	860	V599E	GENE-N	16474853T25
16474853	868	873	B-Raf	GENE-Y	16474853T26
16474853	966	991	receptor tyrosine kinases	GENE-N	16474853T27
16474853	1056	1100	vascular-endothelial growth factor (VEGFR)-2	GENE-Y	16474853T28
16474853	1348	1357	sorafenib	CHEMICAL	16474853T2
16474853	1671	1680	sorafenib	CHEMICAL	16474853T3
16474853	1973	1982	sorafenib	CHEMICAL	16474853T4
16474853	2061	2070	sorafenib	CHEMICAL	16474853T5
16474853	2098	2107	Sorafenib	CHEMICAL	390
16474853	2259	2268	sorafenib	CHEMICAL	16474853T7
16474853	552	561	Sorafenib	CHEMICAL	390
16474853	624	638	bis-aryl ureas	CHEMICAL	16474853T9
16474853	CPR:3	16474853T11	16474853T14
16474853	CPR:3	16474853T11	16474853T15
16474853	CPR:3	16474853T11	16474853T16
16474853	CPR:3	16474853T11	16474853T17
16474853	CPR:3	16474853T11	16474853T27
16474853	CPR:3	16474853T11	16474853T28
16474853	CPR:4	16474853T10	16474853T25
16474853	CPR:4	16474853T10	16474853T26
16474853	CPR:4	390	16474853T23
16474853	CPR:4	390	16474853T24
16474853	CPR:4	16474853T9	16474853T23
16474853	CPR:4	16474853T9	16474853T24

16495926|t|A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.
16495926|a|The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours. In the experimental lung metastasis xenograft models, treatment with bexarotene inhibited the development of the lung tumour nodule formation compared to control. In vivo angiogenesis assay utilising gelfoam sponges, bexarotene reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic fibroblast growth factor to various extent. To determine the basis of these observations, human breast and non-small-cell lung cancer cells were subjected to migration and invasion assays in the presence of bexarotene. Our data showed that bexarotene decrease migration and invasiveness of tumour cells in a dose-dependent manner. Furthermore, bexarotene inhibited angiogenesis by directly inhibiting human umbilical vein endothelial cell growth and indirectly inhibiting tumour cell-mediated migration of human umbilical vein endothelial cells through Matrigel matrix. Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases. The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma. Collectively, our results suggest a role of bexarotene in treatment of angiogenesis and metastasis in solid tumours.
16495926	948	958	bexarotene	CHEMICAL	300
16495926	12	20	retinoid	CHEMICAL	16495926T11
16495926	40	50	bexarotene	CHEMICAL	300
16495926	52	59	LGD1069	CHEMICAL	16495926T13
16495926	61	70	targretin	CHEMICAL	300
16495926	1288	1313	matrix metalloproteinases	GENE-N	16495926T15
16495926	1352	1377	matrix metalloproteinases	GENE-N	16495926T16
16495926	1506	1554	peroxisome proliferator-activated receptor gamma	GENE-Y	16495926T17
16495926	534	568	vascular endothelial growth factor	GENE-Y	16495926T18
16495926	570	593	epidermal growth factor	GENE-Y	16495926T19
16495926	1227	1237	bexarotene	CHEMICAL	300
16495926	604	628	fibroblast growth factor	GENE-N	16495926T20
16495926	175	194	retinoid X receptor	GENE-N	16495926T21
16495926	12	31	retinoid X receptor	GENE-N	16495926T22
16495926	1394	1404	bexarotene	CHEMICAL	300
16495926	1600	1610	bexarotene	CHEMICAL	300
16495926	332	342	bexarotene	CHEMICAL	300
16495926	480	490	bexarotene	CHEMICAL	300
16495926	175	183	retinoid	CHEMICAL	16495926T6
16495926	811	821	bexarotene	CHEMICAL	300
16495926	844	854	bexarotene	CHEMICAL	300
16495926	203	213	bexarotene	CHEMICAL	300
16495926	CPR:3	300	16495926T16
16495926	CPR:3	300	16495926T17
16495926	CPR:4	300	16495926T15
16495926	CPR:5	300	16495926T22
16495926	CPR:5	16495926T13	16495926T22
16495926	CPR:5	300	16495926T22
16495926	CPR:5	300	16495926T21

16513877|t|DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
16513877|a|OBJECTIVE: All antipsychotics act on the dopamine D(2) receptor. The present study extends prior pharmacogenetic investigations of the D(2) receptor gene (DRD2) by examining, in first-episode schizophrenia patients, promoter region variation as a predictor of response time to two first-line atypical antipsychotics. METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine. Time until sustained response (two consecutive ratings without significant positive symptoms) for rare allele carriers versus wild types was examined by using Kaplan-Meier curves. RESULTS: Relative to wild type homozygotes, G carriers (A-241G) exhibited a significantly faster time until response, whereas -141C Del carriers took a significantly longer time to respond. Diplotype analysis revealed similar results. CONCLUSIONS: These findings suggest that variation in the D(2) receptor gene can, in part, explain variation in the timing of clinical response to antipsychotics in patients with first-episode schizophrenia.
16513877	948	954	A-241G	GENE-N	16513877T10
16513877	0	13	DRD2 promoter	GENE-N	16513877T11
16513877	178	186	dopamine	CHEMICAL	16513877T1
16513877	685	696	risperidone	CHEMICAL	16513877T2
16513877	700	710	olanzapine	CHEMICAL	16513877T3
16513877	1185	1198	D(2) receptor	GENE-Y	16513877T4
16513877	272	285	D(2) receptor	GENE-Y	16513877T5
16513877	292	296	DRD2	GENE-Y	108147
16513877	551	564	DRD2 promoter	GENE-N	16513877T7
16513877	178	200	dopamine D(2) receptor	GENE-Y	16513877T8
16513877	587	593	A-241G	GENE-N	16513877T9

16532916|t|Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea.
16532916|a|BACKGROUND: A model to study the effect of vasopressin V1a antagonist in dysmenorrhea. METHODS: A double-blind, randomized, placebo-controlled, cross-over trial was performed. Eight patients with primary dysmenorrhea and eight tuballigated, healthy subjects participated on days 1-2 of two consecutive menstruations. At each menstruation a bolus injection of 10 pmol/kg of vasopressin was administered before and during infusion of either 300 microg/min of atosiban or placebo. Intrauterine pressure was measured as area under the curve throughout the experiments. Ischemia markers in plasma and pain recorded by a visual analog scale were measured before and after each vasopressin injection as well as before and after the start of either atosiban or placebo infusion. RESULTS: Vasopressin injections elevated area under the curve in both healthy volunteers and dysmenorrhea subjects. The vasopressin-induced rise in area under the curve was lower during atosiban administration than during infusion of placebo in both groups. None of the ischemia markers differed between or within groups at vasopressin injections or atosiban/placebo infusions. In subjects with dysmenorrhea the increase in pain following the administration of vasopressin was significantly lower during atosiban than during placebo infusion. Healthy volunteers experienced only slight discomfort after the vasopressin injections. CONCLUSIONS: Atosiban reduces vasopressin-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea. The ischemia markers are not a useful biomarker index in women with dysmenorrhea. The dysmenorrhea pain evoked by vasopressin correlated poorly with area under the curve, which may suggest that the effect is mediated by more than one V1a-like receptor. We conclude that this model with recordings in healthy women is useful in the evaluation of drug candidates for primary dysmenorrhea.
16532916	221	232	vasopressin	CHEMICAL	16532916T10
16532916	635	643	atosiban	CHEMICAL	16532916T11
16532916	849	860	vasopressin	CHEMICAL	16532916T12
16532916	919	927	atosiban	CHEMICAL	16532916T13
16532916	958	969	Vasopressin	CHEMICAL	66
16532916	1069	1080	vasopressin	CHEMICAL	16532916T15
16532916	1135	1143	atosiban	CHEMICAL	16532916T16
16532916	144	155	vasopressin	CHEMICAL	16532916T17
16532916	89	100	vasopressin	CHEMICAL	16532916T18
16532916	1410	1421	vasopressin	GENE-Y	16532916T19
16532916	1273	1284	vasopressin	CHEMICAL	16532916T1
16532916	1556	1567	vasopressin	GENE-Y	16532916T20
16532916	1610	1621	vasopressin	GENE-Y	16532916T21
16532916	1862	1873	vasopressin	GENE-Y	16532916T22
16532916	1982	1999	V1a-like receptor	GENE-Y	16532916T23
16532916	551	562	vasopressin	GENE-Y	16532916T24
16532916	221	236	vasopressin V1a	GENE-Y	16532916T25
16532916	849	860	vasopressin	GENE-Y	16532916T26
16532916	958	969	Vasopressin	GENE-Y	16532916T27
16532916	144	155	vasopressin	GENE-Y	16532916T28
16532916	89	113	vasopressin V1a receptor	GENE-Y	16532916T29
16532916	1299	1307	atosiban	CHEMICAL	16532916T2
16532916	1410	1421	vasopressin	CHEMICAL	16532916T3
16532916	1453	1461	atosiban	CHEMICAL	16532916T4
16532916	1556	1567	vasopressin	CHEMICAL	16532916T5
16532916	1593	1601	Atosiban	CHEMICAL	16532916T6
16532916	1610	1621	vasopressin	CHEMICAL	16532916T7
16532916	1862	1873	vasopressin	CHEMICAL	16532916T8
16532916	551	562	vasopressin	CHEMICAL	16532916T9
16532916	CPR:4	16532916T4	16532916T19
16532916	CPR:4	16532916T6	16532916T21

16538493|t|Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?
16538493|a|BACKGROUND AND AIMS: Thymidylate synthase (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU). Its expression may determine the outcome of patients with gastrointestinal cancers. We examined the prognostic and predictive value of TS-protein expression in patients with ductal adenocarcinoma of the pancreas. METHODS: TS expression from 131 patients with ductal adenocarcinoma of the pancreas was analyzed by immunohistochemistry in paraffin-embedded primary tumour specimens or biopsies. RESULTS: The median disease-specific survival among all patients (n=131) was 13 months. The invasion depth, the presence of metastases, grading and Union Internationale Contre le Cancer [International Union Against Cancer] (UICC) stage were associated with survival. Among resected patients (n=98), a difference in median survival was seen in the group receiving postoperative adjuvant treatment (21.1 months) compared with the group treated by surgery alone (12.4 months) (p=0.025). Low- and high-TS immunoreactivity was present in 74 (56%) and 56 (43%) of the cancers, respectively. One sample was not evaluable. No difference in median survival was observed among low- and high-TS-expressing tumours. Among patients undergoing resection and receiving postoperative intra-arterial chemotherapy (n=23), a marked trend to a longer median survival was seen for the group with low-TS-expressing tumours compared with the corresponding high-TS group (25.0 vs 16.0 months) (p=0.3834). There was no difference in survival among all palliative treated patients with low- and high-TS-expressing tumours. CONCLUSION: Especially patients undergoing tumour resection with low-TS values seemed to have taken advantage from an intensified postoperative chemotherapeutic protocol. However due to the heterogeneous group of patients in the present report, larger trials of more homogenous patient populations will be necessary to confirm this hypothesis.
16538493	1812	1814	TS	GENE-Y	16538493T10
16538493	144	164	Thymidylate synthase	GENE-Y	16538493T11
16538493	388	390	TS	GENE-Y	16538493T12
16538493	475	477	TS	GENE-Y	16538493T13
16538493	166	168	TS	GENE-Y	16538493T14
16538493	0	20	Thymidylate synthase	GENE-Y	16538493T15
16538493	230	244	5-fluorouracil	CHEMICAL	16538493T1
16538493	246	250	5-FU	CHEMICAL	534
16538493	144	155	Thymidylate	CHEMICAL	1580
16538493	0	11	Thymidylate	CHEMICAL	1580
16538493	1144	1146	TS	GENE-Y	16538493T5
16538493	1327	1329	TS	GENE-Y	16538493T6
16538493	1525	1527	TS	GENE-Y	16538493T7
16538493	1584	1586	TS	GENE-Y	16538493T8
16538493	1720	1722	TS	GENE-Y	16538493T9

16580895|t|Enzymatic and biochemical properties of a novel human serine dehydratase isoform.
16580895|a|A cDNA clone similar to human serine dehydratase (SDH) is deposited in the GenBank/EMBL databases, but its structural and functional bases remain unknown. Despite the occurrence of mRNA, the expected protein level was found to be low in cultured cells. To learn about physicochemical properties of the protein, we expressed the cDNA in Escherichia coli, and compared the expressed protein with that of a hepatic SDH. The purified protein showed l-serine and l-threonine dehydratase activity, demonstrating to be an isoform of SDH. However, their Km and Vmax constants were different in a range of two-order. Removal of Pro128 from the hepatic SDH consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for pyridoxal 5'-phosphate, whereas addition of a proline residue to the isoform was without effect. These findings suggest the difference in the structures of the active sites of the two enzymes. Another striking feature was that the expressed level of the isoform in E. coli was 7-fold lower than that of the hepatic SDH. Substitution of Val for Leu287 in the isoform dramatically increased the protein level. The high yield of the mutated isoform was also confirmed by the in vitro transcription and translation experiment. The poor expression of the isoform could be explained by the more stable secondary structure of the mRNA than that of the hepatic SDH mRNA. The present findings may provide a clue as to why the protein level in cultured cells is low.
16580895	106	130	human serine dehydratase	GENE-Y	16580895T10
16580895	494	497	SDH	GENE-Y	16580895T11
16580895	527	563	l-serine and l-threonine dehydratase	GENE-Y	16580895T12
16580895	132	135	SDH	GENE-Y	16580895T13
16580895	608	611	SDH	GENE-Y	16580895T14
16580895	725	728	SDH	GENE-Y	16580895T15
16580895	48	72	human serine dehydratase	GENE-Y	16580895T16
16580895	112	118	serine	CHEMICAL	16580895T1
16580895	527	535	l-serine	CHEMICAL	16580895T2
16580895	540	551	l-threonine	CHEMICAL	16580895T3
16580895	910	932	pyridoxal 5'-phosphate	CHEMICAL	16580895T4
16580895	956	963	proline	CHEMICAL	16580895T5
16580895	54	60	serine	CHEMICAL	16580895T6
16580895	1225	1228	SDH	GENE-Y	16580895T7
16580895	1246	1260	Val for Leu287	GENE-N	16580895T8
16580895	1563	1566	SDH	GENE-Y	16580895T9

16599255|t|Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents.
16599255|a|Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine. H3 receptor antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease. Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of butyrylcholinesterase which is another catalytic enzyme hydrolysing acetylcholine. Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine. Preliminary structure-activity relationships could already be drawn from the small number of compounds. The compounds acting as hybrid drugs simultaneously on four different targets to enhance cognitive functions via different pathways are promising lead structures for a new approach in the treatment of Alzheimer's disease.
16599255	31	40	histamine	CHEMICAL	16599255T10
16599255	240	259	N-methyltransferase	GENE-N	16599255T11
16599255	119	140	histamine H3 receptor	GENE-Y	16599255T12
16599255	304	324	acetylcholinesterase	GENE-Y	16599255T13
16599255	344	355	H3 receptor	GENE-Y	16599255T14
16599255	712	732	acetylcholinesterase	GENE-Y	16599255T15
16599255	740	761	butyrylcholinesterase	GENE-Y	16599255T16
16599255	963	977	cholinesterase	GENE-N	16599255T17
16599255	31	52	histamine H3 receptor	GENE-Y	16599255T18
16599255	240	241	N	CHEMICAL	167
16599255	119	128	histamine	CHEMICAL	16599255T2
16599255	335	342	tacrine	CHEMICAL	16599255T3
16599255	409	418	histamine	CHEMICAL	16599255T4
16599255	458	471	acetylcholine	CHEMICAL	16599255T5
16599255	808	821	acetylcholine	CHEMICAL	16599255T6
16599255	876	885	histamine	CHEMICAL	16599255T7
16599255	1024	1031	tacrine	CHEMICAL	16599255T8
16599255	196	205	histamine	CHEMICAL	16599255T9
16599255	CPR:4	16599255T3	16599255T13
16599255	CPR:9	16599255T6	16599255T15
16599255	CPR:9	16599255T6	16599255T16
16599255	CPR:9	16599255T9	16599255T11

16609060|t|Chemotherapy and targeted therapy combinations in advanced melanoma.
16609060|a|For three decades, clinical trials with chemotherapy in melanoma have failed to show superiority of any one regimen over another. Dacarbazine remains the only "standard" agent. With response rates of <10% and median progression-free survival of 2 months or less in contemporary trials, there is a need to improve systemic therapy. Combination chemotherapy is associated with higher response rates than single-agent therapy but this has not translated into improved survival. An increasing number of potential therapeutic targets have been identified. For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors. Several multitargeted kinase inhibitors have potency against the fibroblast growth factor receptor, c-kit, and platelet-derived growth factor receptor. Small-molecule inhibitors of c-met and Akt are in preclinical development. Another class of agents indirectly affect aberrant signaling, including inhibitors of chaperones and proteasomes. Several targeted agents seem to enhance the cytotoxicity of chemotherapy in preclinical models. The mechanism by which signaling inhibition might synergize with chemotherapy requires more study so that rational combinations move forward. Very few targeted agents have been studied rigorously in this fashion.
16609060	1287	1297	chaperones	GENE-N	16609060T10
16609060	1302	1313	proteasomes	GENE-N	16609060T11
16609060	694	698	BRAF	GENE-Y	107141|676499
16609060	700	719	farnesyltransferase	GENE-N	16609060T13
16609060	735	739	NRAS	GENE-Y	110952
16609060	756	788	mitogen-activated protein kinase	GENE-N	16609060T15
16609060	789	833	extracellular signal-regulated kinase kinase	GENE-N	16609060T16
16609060	859	888	mammalian target of rapamycin	GENE-Y	16609060T17
16609060	921	955	vascular endothelial growth factor	GENE-Y	16609060T18
16609060	996	1002	kinase	GENE-N	16609060T19
16609060	199	210	Dacarbazine	CHEMICAL	841
16609060	1039	1072	fibroblast growth factor receptor	GENE-N	16609060T20
16609060	680	689	sorafenib	CHEMICAL	16609060T2
16609060	741	751	PD-0325901	CHEMICAL	16609060T3
16609060	835	844	rapamycin	CHEMICAL	16609060T4
16609060	879	888	rapamycin	CHEMICAL	16609060T5
16609060	1074	1079	c-kit	GENE-Y	16609060T6
16609060	1085	1124	platelet-derived growth factor receptor	GENE-N	16609060T7
16609060	1155	1160	c-met	GENE-Y	16609060T8
16609060	1165	1168	Akt	GENE-N	16609060T9
16609060	CPR:4	16609060T2	107141|676499
16609060	CPR:4	16609060T3	16609060T15
16609060	CPR:4	16609060T3	16609060T16
16609060	CPR:4	16609060T4	16609060T17

16618126|t|Lipid specific activation of the murine P4-ATPase Atp8a1 (ATPase II).
16618126|a|The asymmetric transbilayer distribution of phosphatidylserine (PS) in the mammalian plasma membrane and secretory vesicles is maintained, in part, by an ATP-dependent transporter. This aminophospholipid "flippase" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents. Although the flippase has not been positively identified, a subfamily of P-type ATPases has been proposed to function as transporters of amphipaths, including PS and other phospholipids. A candidate PS flippase ATP8A1 (ATPase II), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the yeast protein Drs2, which has been linked to ribosomal assembly, the formation of Golgi-coated vesicles, and the maintenance of PS asymmetry. To determine if ATP8A1 has biochemical characteristics consistent with a PS flippase, a murine homologue of this enzyme was expressed in insect cells and purified. The purified Atp8a1 is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS. The selectivity for PS is dependent upon multiple elements of the lipid structure. Similar to the plasma membrane PS transporter, Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the sn-2,3-glycerol stereoisomer. Both flippase and Atp8a1 activities are insensitive to the stereochemistry of the serine headgroup. Most modifications of the PS headgroup structure decrease recognition by the plasma membrane PS flippase. Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1. Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak Atp8a1 activators. However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity. These results indicate that the ATPase activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.
16618126	1563	1578	sn-1,2-glycerol	CHEMICAL	16618126T10
16618126	1604	1619	sn-2,3-glycerol	CHEMICAL	16618126T11
16618126	224	227	ATP	CHEMICAL	164
16618126	1760	1762	PS	CHEMICAL	138
16618126	1827	1829	PS	CHEMICAL	138
16618126	1901	1934	phosphatidylserine-O-methyl ester	CHEMICAL	16618126T15
16618126	1936	1958	lysophosphatidylserine	CHEMICAL	16618126T16
16618126	1960	1980	glycerophosphoserine	CHEMICAL	16618126T17
16618126	1986	1999	phosphoserine	CHEMICAL	16618126T18
16618126	2112	2114	PE	CHEMICAL	16618126T19
16618126	1201	1220	phosphatidylcholine	CHEMICAL	16618126T1
16618126	2116	2145	phosphatidylhydroxypropionate	CHEMICAL	16618126T20
16618126	2151	2173	phosphatidylhomoserine	CHEMICAL	16618126T21
16618126	2217	2244	N-methyl-phosphatidylserine	CHEMICAL	16618126T22
16618126	2323	2325	PS	CHEMICAL	138
16618126	308	310	PS	CHEMICAL	138
16618126	2526	2528	PS	CHEMICAL	138
16618126	2558	2566	glycerol	CHEMICAL	16618126T26
16618126	2575	2581	serine	CHEMICAL	16618126T27
16618126	371	379	vanadate	CHEMICAL	16618126T28
16618126	381	387	Ca(2+)	CHEMICAL	16618126T29
16618126	1222	1239	phosphatidic acid	CHEMICAL	16618126T2
16618126	409	419	sulfhydryl	CHEMICAL	16618126T30
16618126	114	132	phosphatidylserine	CHEMICAL	16618126T31
16618126	629	631	PS	CHEMICAL	138
16618126	134	136	PS	CHEMICAL	138
16618126	1030	1032	PS	CHEMICAL	138
16618126	1134	1140	Atp8a1	GENE-Y	252971|198270
16618126	1479	1509	plasma membrane PS transporter	GENE-N	16618126T36
16618126	1511	1517	Atp8a1	GENE-Y	252971|198270
16618126	1639	1647	flippase	GENE-N	16618126T38
16618126	1652	1658	Atp8a1	GENE-Y	252971|198270
16618126	1244	1264	phosphatidylinositol	CHEMICAL	16618126T3
16618126	1827	1838	PS flippase	GENE-N	16618126T40
16618126	1854	1860	Atp8a1	GENE-Y	252971|198270
16618126	2076	2082	Atp8a1	GENE-Y	252971|198270
16618126	275	283	flippase	GENE-N	16618126T43
16618126	2189	2195	Atp8a1	GENE-Y	252971|198270
16618126	2290	2298	flippase	GENE-N	16618126T45
16618126	2354	2360	Atp8a1	GENE-Y	252971|198270
16618126	2403	2409	ATPase	GENE-N	16618126T47
16618126	2444	2450	Atp8a1	GENE-Y	252971|198270
16618126	2729	2737	flippase	GENE-N	16618126T49
16618126	1292	1312	phosphatidylglycerol	CHEMICAL	16618126T4
16618126	443	451	flippase	GENE-N	16618126T50
16618126	503	517	P-type ATPases	GENE-N	16618126T51
16618126	629	647	PS flippase ATP8A1	GENE-Y	16618126T52
16618126	649	658	ATPase II	GENE-Y	16618126T53
16618126	815	833	yeast protein Drs2	GENE-Y	16618126T54
16618126	973	979	ATP8A1	GENE-Y	115668
16618126	1030	1041	PS flippase	GENE-N	16618126T56
16618126	33	49	murine P4-ATPase	GENE-N	16618126T57
16618126	50	56	Atp8a1	GENE-Y	252971|198270
16618126	58	67	ATPase II	GENE-Y	16618126T59
16618126	1316	1340	phosphatidylethanolamine	CHEMICAL	16618126T5
16618126	1342	1344	PE	CHEMICAL	16618126T6
16618126	1377	1379	PS	CHEMICAL	138
16618126	1401	1403	PS	CHEMICAL	138
16618126	1495	1497	PS	CHEMICAL	138
16618126	CPR:3	16618126T10	16618126T36
16618126	CPR:3	16618126T10	252971|198270
16618126	CPR:3	16618126T19	252971|198270
16618126	CPR:3	16618126T20	252971|198270
16618126	CPR:3	16618126T21	252971|198270
16618126	CPR:3	138	16618126T47
16618126	CPR:3	138	252971|198270
16618126	CPR:3	16618126T4	252971|198270
16618126	CPR:3	16618126T5	252971|198270
16618126	CPR:3	16618126T6	252971|198270
16618126	CPR:3	138	252971|198270
16618126	CPR:4	16618126T15	252971|198270
16618126	CPR:4	16618126T16	252971|198270
16618126	CPR:4	16618126T17	252971|198270
16618126	CPR:4	16618126T18	252971|198270
16618126	CPR:9	16618126T22	16618126T45
16618126	CPR:9	138	16618126T43

16622728|t|Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody.
16622728|a|We report that a-63-year-old woman developed Pneumocystis jiroveci pneumonia (PCP) as a complication from treatment with infliximab for rheumatoid arthritis. Although there was neither symptoms of dyspnea nor typical observations on a chest X-ray examination, low levels of oxygen saturation and findings of high-resolution chest computed tomographic scanning suggested a possibility of interstitial pneumonia. A polymerase chain reaction-based detection of Pneumocystis jiroveci in induced sputum allowed an early diagnosis of PCP and subsequent effective treatment.
16622728	449	455	oxygen	CHEMICAL	16622728T1
16622728	124	151	tumor necrosis factor alpha	GENE-Y	16622728T2

16647263|t|High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates.
16647263|a|Various high-mannose-type glycan modifications of dihydrofolate reductase (DHFR) were achieved by ligand-based approach using glycan-methotrexate (MTX) conjugates as tight binding glycan bearing ligands for DHFR. The resulting glycan-MTX conjugates and the corresponding artificial glycoproteins could be useful as oligosaccharide- and glycoprotein-probes to perform quantitative analysis of glycan recognizing protein such as lectins, glycosyltransferases or glycosidases. Moreover, artificial glycoproteins having two different high-mannose-type glycans were developed for the first time by a combination of two different types of glycan modification strategies.
16647263	311	315	DHFR	GENE-Y	108065
16647263	496	522	glycan recognizing protein	GENE-N	16647263T11
16647263	531	538	lectins	GENE-N	16647263T12
16647263	540	560	glycosyltransferases	GENE-N	16647263T13
16647263	564	576	glycosidases	GENE-N	16647263T14
16647263	154	177	dihydrofolate reductase	GENE-Y	16647263T15
16647263	179	183	DHFR	GENE-Y	108065
16647263	42	65	dihydrofolate reductase	GENE-Y	16647263T17
16647263	117	124	mannose	CHEMICAL	16647263T1
16647263	237	249	methotrexate	CHEMICAL	16647263T2
16647263	251	254	MTX	CHEMICAL	553
16647263	338	341	MTX	CHEMICAL	553
16647263	154	167	dihydrofolate	CHEMICAL	16647263T5
16647263	639	646	mannose	CHEMICAL	16647263T6
16647263	42	55	dihydrofolate	CHEMICAL	16647263T7
16647263	5	12	mannose	CHEMICAL	16647263T8
16647263	79	91	methotrexate	CHEMICAL	16647263T9

16719808|t|NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.
16719808|a|Glutamate receptors of the N-methyl-D-asparate (NMDA-) subtype are tetrameric allosteric and ligand-gated calcium channels. They are modulated by a variety of endogenous ligands and ions and play a pivotal role in memory-related signal transduction due to a voltage-dependent block by magnesium, which makes them Hebbian coincidence detectors. On the structural level NMDA receptors have an enormous flexibility due to seven genes (NR1, NR2A-D and NR3A-B), alternative splicing, RNA-editing and extensive posttranslational modifications, like phosphorylation and glycosylation. NMDA receptors are thought to be responsible for excitotoxicity and subsequent downstream events like neuroinflammation and apoptosis and thus have been implicated in many important human pathologies, ranging from amyotrophic lateral sclerosis, Alzheimer's and Parkinson' disease, depression, epilepsy, trauma and stroke to schizophrenia. This fundamental significance of NMDA receptor-related excitotoxicity is discussed in the context of the developing clinical success of Memantine, but moreover set into relation to various proteomic and genetic markers of said diseases. The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD). The flexibility and multitude of interaction partners and possibilities of these highly dynamic molecular systems are discussed in terms of drug development strategies, in particular comparing high affinity and sub-type specific ligands to currently successful or promising therapies.
16719808	259	263	NMDA	CHEMICAL	1209
16719808	789	793	NMDA	CHEMICAL	1209
16719808	1161	1165	NMDA	CHEMICAL	1209
16719808	0	4	NMDA	CHEMICAL	1209
16719808	118	129	cholesterol	CHEMICAL	16719808T14
16719808	189	198	glutamate	CHEMICAL	16719808T15
16719808	52	56	NMDA	CHEMICAL	1209
16719808	211	230	Glutamate receptors	GENE-N	16719808T17
16719808	1426	1440	NMDA receptors	GENE-N	16719808T18
16719808	1468	1479	neuregulins	GENE-N	16719808T19
16719808	211	220	Glutamate	CHEMICAL	16719808T1
16719808	1484	1509	receptor tyrosine kinases	GENE-N	16719808T20
16719808	1648	1654	PSD-95	GENE-Y	16719808T21
16719808	1656	1694	post-synaptic density protein of 95 kD	GENE-Y	16719808T22
16719808	579	593	NMDA receptors	GENE-N	16719808T23
16719808	643	646	NR1	GENE-Y	16719808T24
16719808	648	654	NR2A-D	GENE-N	16719808T25
16719808	659	665	NR3A-B	GENE-N	16719808T26
16719808	789	803	NMDA receptors	GENE-N	16719808T27
16719808	304	333	ligand-gated calcium channels	GENE-N	16719808T28
16719808	1161	1174	NMDA receptor	GENE-N	16719808T29
16719808	1264	1273	Memantine	CHEMICAL	1032
16719808	0	14	NMDA receptors	GENE-N	16719808T30
16719808	108	151	transient cholesterol-rich membrane domains	GENE-N	16719808T31
16719808	52	65	NMDA receptor	GENE-N	16719808T32
16719808	92	103	neuregulins	GENE-N	16719808T33
16719808	1426	1430	NMDA	CHEMICAL	1209
16719808	1493	1501	tyrosine	CHEMICAL	16719808T4
16719808	1513	1524	cholesterol	CHEMICAL	16719808T5
16719808	1562	1569	calcium	CHEMICAL	16719808T6
16719808	238	257	N-methyl-D-asparate	CHEMICAL	16719808T7
16719808	496	505	magnesium	CHEMICAL	16719808T8
16719808	579	583	NMDA	CHEMICAL	1209

16729906|t|Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
16729906|a|Metastatic renal cell carcinoma does not respond favorably to conventional treatment strategies and is not very responsive to cytokine therapy. Therefore, novel targeted treatment approaches have been explored for patients with renal cancer who have chemotherapy-refractory disease. Sorafenib (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of tyrosine kinases that are known to be involved in tumor cell proliferation and tumor angiogenesis. These kinases include vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor, Flt-3, c-kit, and Raf kinases. Based on the significant improvement in progression-free survival, sorafenib received Food and Drug Administration approval in December 2005 for the treatment of renal cell carcinoma. In combination studies, sorafenib with other antitumor agents has demonstrated significant clinical activity in patients with renal cell carcinoma. As discussed in this mini-review, the clinical potency of sorafenib as a single agent or in combination with other antitumor agents is being evaluated in several ongoing clinical trials in patients with renal carcinoma.
16729906	670	723	vascular endothelial growth factor receptor (VEGFR)-1	GENE-Y	16729906T10
16729906	725	732	VEGFR-2	GENE-Y	16729906T11
16729906	734	741	VEGFR-3	GENE-Y	16729906T12
16729906	743	782	platelet-derived growth factor receptor	GENE-Y	16729906T13
16729906	784	789	Flt-3	GENE-Y	16729906T14
16729906	791	796	c-kit	GENE-Y	16729906T15
16729906	802	805	Raf	GENE-Y	16729906T16
16729906	806	813	kinases	GENE-N	16729906T17
16729906	79	96	interferon-alpha2	GENE-Y	16729906T18
16729906	1205	1214	sorafenib	CHEMICAL	16729906T1
16729906	434	443	Sorafenib	CHEMICAL	390
16729906	445	456	BAY 43-9006	CHEMICAL	16729906T3
16729906	549	557	tyrosine	CHEMICAL	16729906T4
16729906	882	891	sorafenib	CHEMICAL	16729906T5
16729906	1023	1032	sorafenib	CHEMICAL	16729906T6
16729906	0	9	Sorafenib	CHEMICAL	390
16729906	549	565	tyrosine kinases	GENE-N	16729906T8
16729906	654	661	kinases	GENE-N	16729906T9
16729906	CPR:4	390	16729906T8
16729906	CPR:4	16729906T3	16729906T8

16781459|t|Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.
16781459|a|Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored. Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (ERK). Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced iNOS expression and NO production. Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid. While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1. CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB. Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.
16781459	338	348	L-cysteine	CHEMICAL	16781459T10
16781459	1895	1910	carbon monoxide	CHEMICAL	16781459T11
16781459	1912	1914	CO	CHEMICAL	16781459T12
16781459	1941	1943	CO	CHEMICAL	16781459T13
16781459	1981	1983	NO	CHEMICAL	427
16781459	350	355	L-Cys	CHEMICAL	145
16781459	186	191	H(2)S	CHEMICAL	16781459T16
16781459	2089	2094	H(2)S	CHEMICAL	16781459T17
16781459	2107	2109	NO	CHEMICAL	427
16781459	2229	2231	CO	CHEMICAL	16781459T19
16781459	168	184	Hydrogen sulfide	CHEMICAL	16781459T1
16781459	412	424	nitric oxide	CHEMICAL	16781459T20
16781459	426	428	NO	CHEMICAL	427
16781459	507	512	H(2)S	CHEMICAL	16781459T22
16781459	533	535	NO	CHEMICAL	427
16781459	561	563	NO	CHEMICAL	427
16781459	699	704	H(2)S	CHEMICAL	16781459T25
16781459	740	745	H(2)S	CHEMICAL	16781459T26
16781459	754	758	NaSH	CHEMICAL	16781459T27
16781459	762	767	H(2)S	CHEMICAL	16781459T28
16781459	909	914	H(2)S	CHEMICAL	16781459T29
16781459	1196	1216	beta-cyano-L-alanine	CHEMICAL	16781459T2
16781459	918	922	NaHS	CHEMICAL	16781459T30
16781459	979	981	NO	CHEMICAL	427
16781459	1004	1006	NO	CHEMICAL	427
16781459	260	273	cystathionine	CHEMICAL	16781459T33
16781459	1122	1127	L-Cys	CHEMICAL	145
16781459	1145	1150	H(2)S	CHEMICAL	16781459T35
16781459	0	16	Hydrogen sulfide	CHEMICAL	16781459T36
16781459	26	38	nitric oxide	CHEMICAL	16781459T37
16781459	1182	1185	CSE	GENE-Y	16781459T38
16781459	1232	1235	CBS	GENE-Y	107321
16781459	1246	1265	aminooxyacetic acid	CHEMICAL	16781459T3
16781459	1292	1294	HO	GENE-Y	31883
16781459	1311	1313	HO	GENE-Y	31883
16781459	287	290	CSE	GENE-Y	16781459T42
16781459	1370	1374	HO-1	GENE-Y	16781459T43
16781459	1389	1393	HO-1	GENE-Y	16781459T44
16781459	1468	1472	iNOS	GENE-Y	16781459T45
16781459	299	326	cystathionine beta-synthase	GENE-Y	16781459T46
16781459	1503	1507	HO-1	GENE-Y	16781459T47
16781459	1610	1621	(NF)-kappaB	GENE-N	16781459T48
16781459	1746	1755	NF-kappaB	GENE-N	16781459T49
16781459	1459	1464	H(2)S	CHEMICAL	16781459T4
16781459	328	331	CBS	GENE-Y	107321
16781459	1815	1819	HO-1	GENE-Y	16781459T51
16781459	1854	1858	HO-1	GENE-Y	16781459T52
16781459	1935	1939	HO-1	GENE-Y	16781459T53
16781459	1999	2003	iNOS	GENE-Y	16781459T54
16781459	2039	2048	NF-kappaB	GENE-N	16781459T55
16781459	2125	2134	NF-kappaB	GENE-N	16781459T56
16781459	2224	2228	HO-1	GENE-Y	16781459T57
16781459	551	572	inducible NO synthase	GENE-Y	16781459T58
16781459	574	578	iNOS	GENE-Y	16781459T59
16781459	299	312	cystathionine	CHEMICAL	16781459T5
16781459	595	609	heme oxygenase	GENE-N	16781459T60
16781459	611	615	HO-1	GENE-Y	16781459T61
16781459	800	804	HO-1	GENE-Y	16781459T62
16781459	846	883	extracellular signal-regulated kinase	GENE-N	16781459T63
16781459	885	888	ERK	GENE-N	16781459T64
16781459	959	963	iNOS	GENE-Y	16781459T65
16781459	1068	1071	CSE	GENE-Y	16781459T66
16781459	260	285	cystathionine gamma-lyase	GENE-Y	16781459T67
16781459	54	75	nuclear factor-kappaB	GENE-N	16781459T68
16781459	80	96	heme oxygenase-1	GENE-Y	16781459T69
16781459	1488	1490	NO	CHEMICAL	427
16781459	1563	1568	H(2)S	CHEMICAL	16781459T7
16781459	1690	1695	H(2)S	CHEMICAL	16781459T8
16781459	1737	1742	H(2)S	CHEMICAL	16781459T9
16781459	CPR:3	16781459T25	16781459T62
16781459	CPR:3	16781459T25	16781459T63
16781459	CPR:3	16781459T25	16781459T64
16781459	CPR:4	16781459T13	16781459T54
16781459	CPR:4	16781459T13	16781459T55
16781459	CPR:4	16781459T17	16781459T56
16781459	CPR:4	16781459T22	16781459T58
16781459	CPR:4	16781459T22	16781459T59
16781459	CPR:4	16781459T29	16781459T65
16781459	CPR:4	16781459T2	16781459T38
16781459	CPR:4	16781459T30	16781459T65
16781459	CPR:4	16781459T36	16781459T68
16781459	CPR:4	16781459T3	107321
16781459	CPR:4	16781459T4	16781459T45
16781459	CPR:4	16781459T8	16781459T48
16781459	CPR:4	16781459T9	16781459T49
16781459	CPR:9	16781459T10	16781459T42
16781459	CPR:9	16781459T10	16781459T46
16781459	CPR:9	16781459T10	107321
16781459	CPR:9	16781459T10	16781459T67
16781459	CPR:9	16781459T11	16781459T53
16781459	CPR:9	16781459T12	16781459T53
16781459	CPR:9	427	16781459T54
16781459	CPR:9	145	16781459T42
16781459	CPR:9	145	16781459T46
16781459	CPR:9	145	107321
16781459	CPR:9	145	16781459T67
16781459	CPR:9	16781459T16	16781459T42
16781459	CPR:9	16781459T16	16781459T46
16781459	CPR:9	16781459T16	107321
16781459	CPR:9	16781459T16	16781459T67
16781459	CPR:9	16781459T19	16781459T57
16781459	CPR:9	16781459T1	16781459T42
16781459	CPR:9	16781459T1	16781459T46
16781459	CPR:9	16781459T1	107321
16781459	CPR:9	16781459T1	16781459T67
16781459	CPR:9	427	16781459T58
16781459	CPR:9	427	16781459T59
16781459	CPR:9	427	16781459T65
16781459	CPR:9	145	16781459T66
16781459	CPR:9	427	16781459T45

16809898|t|Effect of chronic renal failure on arginase and argininosuccinate synthetase expression.
16809898|a|BACKGROUND: L-arginine (L-arg) participates in numerous biological functions including urea and nitric oxide synthesis. Sources of L-arg include dietary proteins and endogenous synthesis by argininosuccinate synthetase and argininosuccinate lyase. L-arg is converted to urea by arginase I in the liver and arginase II in the kidney. Normally, the liver fully consumes L-arg for urea generation and does not contribute to its circulating pool. Instead, much of the circulating L-arg is produced by the kidney. If true, plasma L-arg should be severely reduced in chronic renal failure (CRF); however, plasma L-arg is frequently unchanged in CRF. We hypothesized that preservation of plasma L-arg in CRF may be, partly, due to downregulation/inhibition of arginase. METHODS: Argininosuccinate synthetase, arginase I and II protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5/6 nephrectomy or sham operation. In addition, arginase activity was measured in the presence of different urea concentrations to simulate azotemia in vitro. RESULTS: Arginases I and II protein abundance as well as arginase activity in the liver, measured in the physiological buffer, were similar among the CRF and control groups. However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of arginase activity by urea in the tissue lysates. CRF had no significant effect on argininosuccinate synthetase abundance in the kidney, liver, spleen or intestine. CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of arginase, the inherent rise in urea concentration inhibits its enzymatic activity. The latter, in turn, attenuates L-arg catabolism and urea production and, thereby, mitigates the fall in plasma L-arg.
16809898	312	329	argininosuccinate	CHEMICAL	16809898T10
16809898	113	118	L-arg	CHEMICAL	16809898T11
16809898	337	342	L-arg	CHEMICAL	16809898T12
16809898	359	363	urea	CHEMICAL	16809898T13
16809898	457	462	L-arg	CHEMICAL	16809898T14
16809898	467	471	urea	CHEMICAL	16809898T15
16809898	565	570	L-arg	CHEMICAL	16809898T16
16809898	614	619	L-arg	CHEMICAL	16809898T17
16809898	695	700	L-arg	CHEMICAL	16809898T18
16809898	777	782	L-arg	CHEMICAL	16809898T19
16809898	1109	1113	urea	CHEMICAL	16809898T1
16809898	861	878	Argininosuccinate	CHEMICAL	2176
16809898	176	180	urea	CHEMICAL	16809898T21
16809898	185	197	nitric oxide	CHEMICAL	16809898T22
16809898	48	65	argininosuccinate	CHEMICAL	16809898T23
16809898	1169	1187	Arginases I and II	GENE-N	16809898T24
16809898	1217	1225	arginase	GENE-N	16809898T25
16809898	1447	1455	arginase	GENE-N	16809898T26
16809898	1529	1557	argininosuccinate synthetase	GENE-Y	16809898T27
16809898	1694	1702	arginase	GENE-N	16809898T28
16809898	279	307	argininosuccinate synthetase	GENE-Y	16809898T29
16809898	101	111	L-arginine	CHEMICAL	16809898T2
16809898	312	335	argininosuccinate lyase	GENE-Y	16809898T30
16809898	367	377	arginase I	GENE-Y	16809898T31
16809898	395	406	arginase II	GENE-Y	16809898T32
16809898	842	850	arginase	GENE-N	16809898T33
16809898	861	889	Argininosuccinate synthetase	GENE-Y	16809898T34
16809898	891	908	arginase I and II	GENE-N	16809898T35
16809898	1049	1057	arginase	GENE-N	16809898T36
16809898	35	43	arginase	GENE-N	16809898T37
16809898	48	76	argininosuccinate synthetase	GENE-Y	16809898T38
16809898	220	225	L-arg	CHEMICAL	16809898T3
16809898	1468	1472	urea	CHEMICAL	16809898T4
16809898	1529	1546	argininosuccinate	CHEMICAL	16809898T5
16809898	1725	1729	urea	CHEMICAL	16809898T6
16809898	1809	1814	L-arg	CHEMICAL	16809898T7
16809898	1889	1894	L-arg	CHEMICAL	16809898T8
16809898	279	296	argininosuccinate	CHEMICAL	16809898T9
16809898	CPR:4	16809898T4	16809898T26
16809898	CPR:4	16809898T6	16809898T28
16809898	CPR:9	16809898T12	16809898T31
16809898	CPR:9	16809898T12	16809898T32
16809898	CPR:9	16809898T13	16809898T31
16809898	CPR:9	16809898T13	16809898T32
16809898	CPR:9	16809898T19	16809898T33
16809898	CPR:9	16809898T3	16809898T29
16809898	CPR:9	16809898T3	16809898T30

16814387|t|Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
16814387|a|Epratuzumab is a humanized anti-CD22 monoclonal antibody currently in clinical trials for treatment of non-Hodgkin lymphoma (NHL) and certain autoimmune diseases. Here we report the results of investigations of epratuzumab's mode of action in comparison to and in combination with the anti-CD20 mAb, rituximab. In vitro cell growth inhibition, induction of apoptosis, and the ability of the mAbs to mediate complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) were evaluated. We also investigated the potential activity of epratuzumab in the regulation of B-cell antigen receptor (BCR) activation. Epratuzumab and rituximab displayed very distinct modes of action; epratuzumab acts as an immunomodulatory agent, while rituximab is an acutely cytotoxic therapeutic antibody. Epratuzumab has distinct effects on cell growth from rituximab. For example, rituximab+anti-human IgG Fcgamma yielded marked inhibition of proliferation in human NHL cell lines, while epratuzumab had little or no effect in this assay. However, when cells were immobilized and stimulated with anti-IgM, epratuzumab, but not rituximab, caused a significant antiproliferative effect. Unlike rituximab, no CDC could be detected, and ADCC was modest but significant with epratuzumab. Importantly, combining rituximab and epratuzumab did not decrease rituximab's ability to induce apoptosis, CDC, and ADCC. In fact, the combination is more effective than rituximab alone in inhibiting proliferation of Daudi Burkitt lymphoma cells in the presence of second antibody, and at least equally effective to rituximab in the absence of crosslinking. These observations suggest that it may be possible to enhance clinical efficacy by combination therapy comprised of anti-CD20 and anti-CD22 mAbs.
16814387	15	19	CD22	GENE-Y	107371
16814387	1219	1222	IgM	GENE-N	16814387T1
16814387	1880	1884	CD20	GENE-Y	16814387T2
16814387	1894	1898	CD22	GENE-Y	107371
16814387	399	403	CD20	GENE-Y	16814387T4
16814387	141	145	CD22	GENE-Y	107371
16814387	516	526	complement	GENE-N	16814387T6
16814387	704	727	B-cell antigen receptor	GENE-N	16814387T7
16814387	729	732	BCR	GENE-N	107083
16814387	1020	1031	IgG Fcgamma	GENE-N	16814387T9

16843091|t|Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
16843091|a|Hyponatremia is the most frequent electrolyte disorder encountered in hospitalized patients. It is a state of relative water excess due to stimulated arginine vasopressin (AVP) and fluid intake greater than obligatory losses. This kind of hyponatremia occurs in the syndrome of inappropriate antidiuretic hormone secretion, congestive heart failure, and liver cirrhosis. Fluid restriction is the presently recommended treatment for hyponatremia. However, fluid restriction may be very difficult for patients to achieve, is slow to work, and does not allow a graded therapeutic approach. More efficient and specific treatments of hyponatremia are needed. In this respect, pharmacologic research has yielded a number of compounds exhibiting antagonistic qualities at the vasopressin V2 receptor. Among these agents, peptidic derivatives of AVP turned out to have intrinsic antidiuretic properties in vivo when given over days or weeks. The development of such agents for use in patients has not been pursued. However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463. Prospective, randomized, placebo-controlled trials performed with these agents found that they corrected hyponatremia efficiently and safely. Most of the studies were conducted over a 4- to 28-day period. Long-term studies will be needed in the future to address such issues as the eventual benefit to patients and the effects of vasopressin antagonists on morbidity and mortality of patients with hyponatremia.
16843091	251	254	AVP	CHEMICAL	66
16843091	848	859	vasopressin	CHEMICAL	16843091T11
16843091	917	920	AVP	CHEMICAL	66
16843091	0	11	Vasopressin	CHEMICAL	66
16843091	1125	1145	vasopressin receptor	GENE-N	16843091T14
16843091	229	249	arginine vasopressin	GENE-Y	16843091T15
16843091	251	254	AVP	GENE-Y	107032
16843091	371	391	antidiuretic hormone	GENE-Y	16843091T17
16843091	848	871	vasopressin V2 receptor	GENE-Y	16843091T18
16843091	917	920	AVP	GENE-Y	107032
16843091	1196	1203	VPA-985	CHEMICAL	16843091T1
16843091	0	11	Vasopressin	GENE-Y	16843091T20
16843091	1205	1215	lixivaptan	CHEMICAL	16843091T2
16843091	1218	1224	YM-087	CHEMICAL	16843091T3
16843091	1226	1236	conivaptan	CHEMICAL	16843091T4
16843091	1239	1248	OPC-41061	CHEMICAL	16843091T5
16843091	1250	1259	tolvaptan	CHEMICAL	16843091T6
16843091	1266	1275	SR-121463	CHEMICAL	16843091T7
16843091	229	249	arginine vasopressin	CHEMICAL	16843091T8
16843091	1607	1618	vasopressin	CHEMICAL	16843091T9
16843091	CPR:6	16843091T1	16843091T14
16843091	CPR:6	16843091T2	16843091T14
16843091	CPR:6	16843091T3	16843091T14
16843091	CPR:6	16843091T4	16843091T14
16843091	CPR:6	16843091T5	16843091T14
16843091	CPR:6	16843091T6	16843091T14
16843091	CPR:6	16843091T7	16843091T14

1686208|t|Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene.
1686208|a|1. The effects of 10 mg (+)- and (-)-chlorpheniramine and 5 mg (+)- and (-)-dimethindene on daytime sleep latencies, digit symbol substitution and subjective assessments of mood and well-being were studied in 6 healthy young adult humans. Each subject also took 5 mg triprolidine hydrochloride as an active control and two placebos. 2. Daytime sleep latencies were reduced with triprolidine, (+)-chlorpheniramine and (-)-dimethindene, and subjects also reported that they felt more sleepy after (+)-chlorpheniramine and (-)-dimethindene. Performance on digit symbol substitution was impaired with (+)-chlorpheniramine. 3. Changes in measures with (-)-chlorpheniramine and (+)-dimethindene were not different from changes with placebo. 4. In the present study, changes in measures of drowsiness and performance were limited to the enantiomers with high affinity for the histamine H1-receptor. These findings strongly suggest that sedation can arise from H1-receptor antagonism alone, and provide further support for the belief that the histaminergic system is concerned with the regulation of alertness in man.
1686208	768	788	(-)-chlorpheniramine	CHEMICAL	1686208T10
1686208	793	809	(+)-dimethindene	CHEMICAL	1686208T11
1686208	990	999	histamine	CHEMICAL	1686208T12
1686208	107	119	dimethindene	CHEMICAL	1686208T13
1686208	13	22	histamine	CHEMICAL	1686208T14
1686208	86	102	chlorpheniramine	CHEMICAL	1686208T15
1686208	990	1011	histamine H1-receptor	GENE-Y	1686208T16
1686208	1074	1085	H1-receptor	GENE-Y	1686208T17
1686208	13	34	histamine H1-receptor	GENE-Y	1686208T18
1686208	145	174	(+)- and (-)-chlorpheniramine	CHEMICAL	1686208T1
1686208	388	414	triprolidine hydrochloride	CHEMICAL	1686208T2
1686208	499	511	triprolidine	CHEMICAL	1686208T3
1686208	513	533	(+)-chlorpheniramine	CHEMICAL	1686208T4
1686208	538	554	(-)-dimethindene	CHEMICAL	1686208T5
1686208	616	636	(+)-chlorpheniramine	CHEMICAL	1686208T6
1686208	641	657	(-)-dimethindene	CHEMICAL	1686208T7
1686208	718	738	(+)-chlorpheniramine	CHEMICAL	1686208T8
1686208	184	209	(+)- and (-)-dimethindene	CHEMICAL	1686208T9
1686208	CPR:6	1686208T13	1686208T18
1686208	CPR:6	1686208T15	1686208T18

16866189|t|Anti-clastogenic effect of beta-glucan extracted from barley towards chemically induced DNA damage in rodent cells.
16866189|a|beta-Glucan (BG) was tested in vitro to determine its potential clastogenic and/or anti-clastogenic activity, and attempts were made to elucidate its possible mechanism of action by using combinations with an inhibitor of DNA polymerase. The study was carried out on cells deficient (CHO-k1) and cells proficient (HTC) in phases I and II enzymes, and the DNA damage was assessed by the chromosomal aberration assay. BG did not show a clastogenic effect, but was anti-clastogenic in both cell lines used, and at all concentrations tested (2.5, 5 and 10 microg/mL) in combination with damage inducing agents (methylmethane sulfonate in cell line CHO-k1, and methylmethane sulfonate or 2-aminoanthracene in cell line HTC). BG also showed a protective effect in the presence of a DNA polymerase beta inhibitor (cytosine arabinoside-3-phosphate, Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.
16866189	723	746	methylmethane sulfonate	CHEMICAL	16866189T1
16866189	772	795	methylmethane sulfonate	CHEMICAL	16866189T2
16866189	799	816	2-aminoanthracene	CHEMICAL	16866189T3
16866189	923	955	cytosine arabinoside-3-phosphate	CHEMICAL	16866189T4
16866189	957	962	Ara-C	CHEMICAL	977
16866189	338	352	DNA polymerase	GENE-N	16866189T6
16866189	892	911	DNA polymerase beta	GENE-Y	16866189T7
16866189	1056	1075	DNA polymerase beta	GENE-Y	16866189T8
16866189	CPR:4	16866189T4	16866189T7
16866189	CPR:4	977	16866189T7

16867246|t|Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
16867246|a|AIM: Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor. Recently, many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression. In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients. METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks. The alleles of all loci were determined by PCR (polymerase chain reaction). RESULTS: Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study. No statistical significance was found in the allele distribution of -141Cins>del, TaqIB, rs6275 and TaqIA or in the estimated haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequilibrium between the two groups. CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia. Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians.
16867246	562	566	DRD2	GENE-Y	108147
16867246	724	733	Ser311Cys	GENE-N	16867246T11
16867246	768	772	DRD2	GENE-Y	108147
16867246	1029	1038	Ser311Cys	GENE-N	16867246T13
16867246	15	19	DRD2	GENE-Y	108147
16867246	1531	1545	chlorpromazine	CHEMICAL	16867246T1
16867246	576	590	chlorpromazine	CHEMICAL	16867246T2
16867246	670	680	nucleotide	CHEMICAL	16867246T3
16867246	893	907	chlorpromazine	CHEMICAL	16867246T4
16867246	38	52	chlorpromazine	CHEMICAL	16867246T5
16867246	247	258	D2 receptor	GENE-Y	16867246T6
16867246	1447	1451	DRD2	GENE-Y	108147
16867246	1663	1667	DRD2	GENE-Y	108147
16867246	372	376	DRD2	GENE-Y	108147

16879709|t|Activity-dependent cleavage of brain glutamic acid decarboxylase 65 by calpain.
16879709|a|Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69). However, whether such a truncated form is also present under certain physiological conditions remains elusive. In the present study, we showed that, upon sustained neuronal stimulation, GAD65 could be cleaved into a truncated form in a rat synaptosomal preparation. This truncated form had similar electrophoretic mobility to purified recombinant human GAD65(Delta1-69). Furthermore, we demonstrated that this conversion was calcium dependent. Calcium-chelating reagents such as EDTA and 1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester prevented the cleavage of GAD65. In addition, our data suggested that calpain, a calcium-dependent cysteine protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated GAD65 in the brain. Moreover, calpain inhibitors such as calpain inhibitor I or calpastatin could block the cleavage. Results of our in vitro cleavage assay using purified calpain and immunopurified rat GAD65 also supported the idea that GAD65 could be directly cleaved by calpain.
16879709	37	50	glutamic acid	CHEMICAL	16879709T10
16879709	1095	1100	GAD65	GENE-Y	16879709T11
16879709	1125	1132	calpain	GENE-N	16879709T12
16879709	1175	1186	calpastatin	GENE-Y	16879709T13
16879709	1267	1274	calpain	GENE-N	16879709T14
16879709	1294	1303	rat GAD65	GENE-Y	16879709T15
16879709	1333	1338	GAD65	GENE-Y	16879709T16
16879709	1368	1375	calpain	GENE-N	16879709T17
16879709	268	284	GAD65(Delta1-69)	GENE-Y	16879709T18
16879709	109	149	l-glutamic acid decarboxylase isoform 65	GENE-Y	16879709T19
16879709	231	241	amino acid	CHEMICAL	16879709T1
16879709	472	477	GAD65	GENE-Y	16879709T20
16879709	633	654	human GAD65(Delta1-69	GENE-Y	16879709T21
16879709	151	156	GAD65	GENE-Y	16879709T22
16879709	886	891	GAD65	GENE-Y	16879709T23
16879709	930	937	calpain	GENE-N	16879709T24
16879709	941	976	calcium-dependent cysteine protease	GENE-N	16879709T25
16879709	1076	1081	GAD65	GENE-Y	16879709T26
16879709	37	67	glutamic acid decarboxylase 65	GENE-Y	16879709T27
16879709	71	78	calpain	GENE-N	16879709T28
16879709	256	257	N	CHEMICAL	167
16879709	109	124	l-glutamic acid	CHEMICAL	16879709T3
16879709	711	718	calcium	CHEMICAL	16879709T4
16879709	730	737	Calcium	CHEMICAL	1332
16879709	765	769	EDTA	CHEMICAL	16879709T6
16879709	774	859	1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester	CHEMICAL	16879709T7
16879709	941	948	calcium	CHEMICAL	16879709T8
16879709	959	967	cysteine	CHEMICAL	16879709T9

16901402|t|Therapeutic targets in melanoma: map kinase pathway.
16901402|a|Recent progress in our understanding of the genetic alterations that occur in the pathogenesis of melanoma provides exciting opportunities for therapy. The most important signaling pathways in melanoma lie downstream of NRAS: the RAS-BRAF-MAPK pathway. A great deal of attention has been focused on the high mutation rate in the BRAF oncogene, which approaches 60%, because BRAF itself is an appealing drug substrate and because of the central contribution of BRAF function to melanoma development that the mutation rate signifies. Agents that specifically target BRAF, such as sorafenib, as well as new molecules that function both upstream and downstream of BRAF, are being actively investigated.
16901402	713	717	BRAF	GENE-Y	107141|676499
16901402	33	43	map kinase	GENE-N	16901402T11
16901402	631	640	sorafenib	CHEMICAL	16901402T1
16901402	273	277	NRAS	GENE-Y	110952
16901402	283	286	RAS	GENE-N	16901402T3
16901402	287	291	BRAF	GENE-Y	107141|676499
16901402	292	296	MAPK	GENE-N	16901402T5
16901402	382	386	BRAF	GENE-Y	107141|676499
16901402	427	431	BRAF	GENE-Y	107141|676499
16901402	513	517	BRAF	GENE-Y	107141|676499
16901402	617	621	BRAF	GENE-Y	107141|676499

16901636|t|Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
16901636|a|Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker candesartan and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats. L-NAME was used to test whether any potential effect was due to activation of endothelial nitric oxide synthase (eNOS). Therefore, the middle cerebral artery was occluded for 1 h (MCAO) followed by 7 days reperfusion. Rats received candesartan 2h before and daily after MCAO (pretreatment) or daily after MCAO (posttreatment); rosuvastatin was given daily for 7 days before MCAO without or with candesartan pre- and posttreatment. In addition, candesartan and rosuvastatin were combined with L-NAME. Infarct size and neuroscore at day 7 were compared to those of controls. As result, compared to controls (109+/-12 mm(3)) infarct size with candesartan (pretreatment: 21+/-5 mm(3); posttreatment: 68+/-29 mm(3); P<0.05) or rosuvastatin (69+/-14 mm(3); P<0.05) was smaller. Combined treatment also reduced infarct size (pretreatment: 37+/-15 mm(3); posttreatment 57+/-20mm(3); P<0.05); but there was no benefit of combined treatment over candesartan pretreatment alone. Compared to controls (2.08+/-0.28) only candesartan pretreatment and combined treatment improved the neuroscore (0.97+/-0.05, 1.10+/-0.33; P<0.05). L-NAME abolished the reduction in infarct size and improvement in neuroscore. In conclusion, both, candesartan or rosuvastatin treatment alone reduced infarct size in transient cerebral ischemia, and the best result was achieved with candesartan pretreatment. Combined treatment was superior to rosuvastatin alone, but not to candesartan. The therapeutic benefit of both agents was at least in parts mediated by eNOS-activation.
16901636	1821	1833	rosuvastatin	CHEMICAL	16901636T10
16901636	1852	1863	candesartan	CHEMICAL	16901636T11
16901636	410	416	L-NAME	CHEMICAL	16901636T12
16901636	500	512	nitric oxide	CHEMICAL	16901636T13
16901636	642	653	candesartan	CHEMICAL	16901636T14
16901636	737	749	rosuvastatin	CHEMICAL	16901636T15
16901636	805	816	candesartan	CHEMICAL	16901636T16
16901636	854	865	candesartan	CHEMICAL	16901636T17
16901636	870	882	rosuvastatin	CHEMICAL	16901636T18
16901636	902	908	L-NAME	CHEMICAL	16901636T19
16901636	278	289	candesartan	CHEMICAL	16901636T1
16901636	1050	1061	candesartan	CHEMICAL	16901636T20
16901636	1132	1144	rosuvastatin	CHEMICAL	16901636T21
16901636	108	120	rosuvastatin	CHEMICAL	16901636T22
16901636	63	74	candesartan	CHEMICAL	16901636T23
16901636	80	87	HMG-CoA	CHEMICAL	16901636T24
16901636	298	315	HMG-CoA reductase	GENE-Y	16901636T25
16901636	1938	1942	eNOS	GENE-Y	16901636T26
16901636	488	521	endothelial nitric oxide synthase	GENE-Y	16901636T27
16901636	523	527	eNOS	GENE-Y	16901636T28
16901636	255	260	AT(1)	GENE-N	16901636T29
16901636	1346	1357	candesartan	CHEMICAL	16901636T2
16901636	42	45	AT1	GENE-N	16901636T30
16901636	80	97	HMG-CoA reductase	GENE-Y	16901636T31
16901636	298	305	HMG-CoA	CHEMICAL	16901636T3
16901636	1418	1429	candesartan	CHEMICAL	16901636T4
16901636	1526	1532	L-NAME	CHEMICAL	16901636T5
16901636	1625	1636	candesartan	CHEMICAL	16901636T6
16901636	1640	1652	rosuvastatin	CHEMICAL	16901636T7
16901636	326	338	rosuvastatin	CHEMICAL	16901636T8
16901636	1760	1771	candesartan	CHEMICAL	16901636T9
16901636	CPR:4	16901636T1	16901636T29
16901636	CPR:4	16901636T22	16901636T31
16901636	CPR:4	16901636T23	16901636T30
16901636	CPR:4	16901636T8	16901636T25

16902423|t|ABCA12 is the major harlequin ichthyosis gene.
16902423|a|Harlequin ichthyosis (HI) is the most severe form of autosomal-recessive, congenital ichthyosis. Affected infants have markedly impaired barrier function and are more susceptible to infection. Abnormalities in the localization of epidermal lipids as well as abnormal lamellar granule formation are features of HI skin. Previously, we and others have shown that mutations in the ABCA12 gene encoding an adenosine triphosphate-binding cassette (ABC) transporter underlie the skin disease HI. In this study, we have sequenced the ABCA12 gene in an additional 14 patients and show that all contain mutations, with the majority being either nonsense substitution or frameshift mutations. Eleven HI patients had bi-allelic ABCA12 mutations, whereas in the remaining three HI patients in this study, ABCA12 mutations were detected on only one allele by sequencing. In addition, the one patient from the previous study where no sequence mutations were detected was screened for heterozygous deletions. A combination of oligonucleotide arrays, multiplex PCR analysis and single-nucleotide polymorphism genotyping revealed a heterozygous intragenic deletion in exon 8. These mutation data establish ABCA12 as the major HI gene.
16902423	1116	1126	nucleotide	CHEMICAL	16902423T1
16902423	449	471	adenosine triphosphate	CHEMICAL	16902423T2
16902423	1236	1242	ABCA12	GENE-Y	117585
16902423	425	431	ABCA12	GENE-Y	117585
16902423	449	506	adenosine triphosphate-binding cassette (ABC) transporter	GENE-N	16902423T5
16902423	574	580	ABCA12	GENE-Y	117585
16902423	764	770	ABCA12	GENE-Y	117585
16902423	840	846	ABCA12	GENE-Y	117585
16902423	0	6	ABCA12	GENE-Y	117585

16905533|t|Phosphorylation and up-regulation of diacylglycerol kinase gamma via its interaction with protein kinase C gamma.
16905533|a|Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (DGK). Therefore, DGK is thought to be a negative regulator of PKC activation. Here we show molecular mechanisms of functional coupling of the two kinases. gammaPKC directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/diolein in vitro. Mass spectrometric analysis and mutation studies revealed that gammaPKC phosphorylated Ser-776 and Ser-779 in the AD of DGKgamma. The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant. Importantly, the interaction of the two kinases and the phosphorylation of DGKgamma by gammaPKC could be confirmed in vivo, and overexpression of the AD of DGKgamma inhibited re-translocation of gammaPKC. These results demonstrate that localization and activation of the functionally correlated kinases, gammaPKC and DGKgamma, are spatio-temporally orchestrated by their direct association and phosphorylation, contributing to subtype-specific regulation of DGKgamma and DAG signaling.
16905533	819	832	glutamic acid	CHEMICAL	16905533T10
16905533	213	230	phosphatidic acid	CHEMICAL	16905533T11
16905533	37	51	diacylglycerol	CHEMICAL	16905533T12
16905533	1130	1138	DGKgamma	GENE-Y	16905533T13
16905533	1169	1177	gammaPKC	GENE-Y	16905533T14
16905533	1269	1276	kinases	GENE-N	16905533T15
16905533	1278	1286	gammaPKC	GENE-Y	16905533T16
16905533	1291	1299	DGKgamma	GENE-Y	16905533T17
16905533	234	244	DAG kinase	GENE-N	16905533T18
16905533	1432	1440	DGKgamma	GENE-Y	16905533T19
16905533	114	128	Diacylglycerol	CHEMICAL	16905533T1
16905533	246	249	DGK	GENE-N	16905533T20
16905533	263	266	DGK	GENE-N	16905533T21
16905533	308	311	PKC	GENE-N	16905533T22
16905533	392	399	kinases	GENE-N	16905533T23
16905533	401	409	gammaPKC	GENE-Y	16905533T24
16905533	435	443	DGKgamma	GENE-Y	16905533T25
16905533	608	616	gammaPKC	GENE-Y	16905533T26
16905533	665	673	DGKgamma	GENE-Y	16905533T27
16905533	170	186	protein kinase C	GENE-N	16905533T28
16905533	698	706	gammaPKC	GENE-Y	16905533T29
16905533	130	133	DAG	CHEMICAL	16905533T2
16905533	733	741	DGKgamma	GENE-Y	16905533T30
16905533	752	760	DGKgamma	GENE-Y	16905533T31
16905533	188	191	PKC	GENE-N	16905533T32
16905533	922	930	DGKgamma	GENE-Y	16905533T33
16905533	957	965	DGKgamma	GENE-Y	16905533T34
16905533	1014	1021	kinases	GENE-N	16905533T35
16905533	1049	1057	DGKgamma	GENE-Y	16905533T36
16905533	1061	1069	gammaPKC	GENE-Y	16905533T37
16905533	37	64	diacylglycerol kinase gamma	GENE-Y	16905533T38
16905533	90	112	protein kinase C gamma	GENE-Y	16905533T39
16905533	492	496	Ca2+	CHEMICAL	16905533T3
16905533	508	526	phosphatidylserine	CHEMICAL	16905533T4
16905533	527	534	diolein	CHEMICAL	16905533T5
16905533	617	635	phosphorylated Ser	CHEMICAL	16905533T6
16905533	644	647	Ser	CHEMICAL	127
16905533	777	780	Ser	CHEMICAL	127
16905533	789	792	Ser	CHEMICAL	127
16905533	CPR:9	16905533T11	16905533T18
16905533	CPR:9	16905533T11	16905533T20
16905533	CPR:9	16905533T1	16905533T18
16905533	CPR:9	16905533T1	16905533T20
16905533	CPR:9	16905533T2	16905533T18
16905533	CPR:9	16905533T2	16905533T20

1692236|t|Differences in conformational stability between native and phosphorylated acetylcholinesterase as evidenced by a monoclonal antibody.
1692236|a|Monoclonal antibody 25B1 generated against diisopropyl phosphorofluoridate inhibited fetal bovine serum acetylcholinesterase has been extensively characterized with respect to its anticholinesterase properties. This antibody demonstrated considerably different properties from previously reported inhibitory antibodies raised against acetylcholinesterase in terms of the degree of inhibition (greater than 98%), the high degree of specificity, and the stability of the antigen-antibody complex. Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of acetylcholinesterase against denaturation by heat or guanidine following phosphorylation by organophosphorus anticholinesterase compounds. This approach allowed the determination of stability rank order of various phosphorylated acetylcholinesterases. Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)-AChE, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.
1692236	314	332	anticholinesterase	GENE-Y	1692236T10
1692236	468	488	acetylcholinesterase	GENE-Y	1692236T11
1692236	862	882	acetylcholinesterase	GENE-Y	1692236T12
1692236	971	989	anticholinesterase	GENE-Y	1692236T13
1692236	225	258	bovine serum acetylcholinesterase	GENE-Y	1692236T14
1692236	1076	1112	phosphorylated acetylcholinesterases	GENE-N	1692236T15
1692236	59	94	phosphorylated acetylcholinesterase	GENE-Y	1692236T16
1692236	1212	1218	oxygen	CHEMICAL	1692236T1
1692236	1235	1236	P	CHEMICAL	165
1692236	1243	1254	CH3P(O)(O-)	CHEMICAL	1692236T3
1692236	1333	1349	organophosphoryl	CHEMICAL	1692236T4
1692236	177	208	diisopropyl phosphorofluoridate	CHEMICAL	1692236T5
1692236	915	924	guanidine	CHEMICAL	1692236T6
1692236	1128	1144	organophosphates	CHEMICAL	1692236T7
1692236	1255	1259	AChE	GENE-Y	1692236T8
1692236	1364	1384	acetylcholinesterase	GENE-Y	1692236T9
1692236	CPR:4	1692236T5	1692236T14
1692236	CPR:4	1692236T6	1692236T12

16950805|t|Effects of folic acid deficiency and MTHFR C677T polymorphism on spontaneous and radiation-induced micronuclei in human lymphocytes.
16950805|a|Folic acid plays a key role in the maintenance of genomic stability, providing methyl groups for the conversion of uracil to thymine and for DNA methylation. Besides dietary habits, folic acid metabolism is influenced by genetic polymorphism. The C677T polymorphism of the methylene-tetrahydrofolate reductase (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status. In this work the effect of folic acid deficiency on genome stability and radiosensitivity has been investigated in cultured lymphocytes of 12 subjects with different MTHFR genotype (four for each genotype). Cells were grown for 9 days with 12, 24 and 120 nM folic acid and analyzed in a comprehensive micronucleus test coupled with centromere characterization by CREST immunostaining. In other experiments, cells were grown with various folic acid concentrations, irradiated with 0.5 Gy of gamma rays and analyzed in the micronucleus test. The results obtained indicate that folic acid deficiency induces to a comparable extent chromosome loss and breakage, irrespective of the MTHFR genotype. The effect of folic acid was highly significant (P < 0.001) and explained >50% of variance of both types of micronuclei. Also nucleoplasmic bridges and buds were significantly increased under low folate supply; the increase in bridges was mainly observed in TT cells, highlighting a significant effect of the MTHFR genotype (P = 0.006) on this biomarker. Folic acid concentration significantly affected radiation-induced micronuclei (P < 0.001): the increased incidence of radiation-induced micronuclei with low folic acid was mainly accounted for by carriers of the variant MTHFR allele (both homozygotes and heterozygotes), but the overall effect of genotype did not attain statistical significance. Treatment with ionizing radiations also increased the frequency of nucleoplasmic bridges. The effect of folic acid level on this end-point was modulated by the MTHFR genotype (P for interaction = 0.02), with TT cells grown at low folic acid concentration apparently resistant to the induction of radiation-induced bridges. Finally, the effect of in vitro folate deprivation on global DNA methylation was evaluated in lymphocytes of six homozygous subjects (three CC and three TT). The results obtained suggest that, under the conditions of this work, folic acid deprivation is associated with global DNA hypermethylation.
16950805	2088	2098	folic acid	CHEMICAL	16950805T10
16950805	2214	2224	folic acid	CHEMICAL	16950805T11
16950805	2339	2345	folate	CHEMICAL	16950805T12
16950805	2535	2545	folic acid	CHEMICAL	16950805T13
16950805	406	432	methylene-tetrahydrofolate	CHEMICAL	16950805T14
16950805	573	579	folate	CHEMICAL	16950805T15
16950805	615	625	folic acid	CHEMICAL	16950805T16
16950805	846	856	folic acid	CHEMICAL	16950805T17
16950805	1025	1035	folic acid	CHEMICAL	16950805T18
16950805	11	21	folic acid	CHEMICAL	16950805T19
16950805	133	143	Folic acid	CHEMICAL	152
16950805	1266	1271	MTHFR	GENE-Y	110624
16950805	1591	1596	MTHFR	GENE-Y	110624
16950805	1857	1862	MTHFR	GENE-Y	110624
16950805	2144	2149	MTHFR	GENE-Y	110624
16950805	380	385	C677T	GENE-N	16950805T24
16950805	406	442	methylene-tetrahydrofolate reductase	GENE-Y	16950805T25
16950805	444	449	MTHFR	GENE-Y	110624
16950805	754	759	MTHFR	GENE-Y	110624
16950805	37	42	MTHFR	GENE-Y	110624
16950805	43	48	C677T	GENE-N	16950805T29
16950805	1163	1173	folic acid	CHEMICAL	16950805T2
16950805	248	254	uracil	CHEMICAL	16950805T3
16950805	1296	1306	folic acid	CHEMICAL	16950805T4
16950805	258	265	thymine	CHEMICAL	16950805T5
16950805	1478	1484	folate	CHEMICAL	16950805T6
16950805	1637	1647	Folic acid	CHEMICAL	152
16950805	1794	1804	folic acid	CHEMICAL	16950805T8
16950805	315	325	folic acid	CHEMICAL	16950805T9

16964330|t|Antifungal agents: mode of action in yeast cells.
16964330|a|Different kinds of mycoses, especially invasive, have become an important public health problem as their incidence has increased dramatically in the last decades in relation to AIDS, hematological malignancies, transplant recipients and other immunosuppressed individuals. Management of fungal infections is markedly limited by problems of drug safety, resistance and effectiveness profile. Current therapy for invasive mycoses uses a relatively reduced number of antifungal drugs, such as amphotericin B, fluconazole and itraconazole. Other new antifungal agents from old and new chemical families, like voriconazole, posaconazole, ravuconazole, caspofungin and micafungin, have been introduced into the armamentarium for fungal infections management. This review is focused on the mode of action of those antifungal drugs used against pathogenic yeasts. The interaction of amphotericin B with ergosterol and other membrane sterols results in the production of aqueous pores of drug and the ergosterol biosynthetic pathway is the target of the allylamines, phenylmorpholines and azole antifungal agents. The main molecular target of azole antifungals is the cytochrome P-450 protein Erg11p/Cyp51p. Echinocandins, a new class of antifungal drugs, are fungal secondary metabolites that act against beta-1-3-D-glucan synthesis. The phenylmorpholines, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase). The sordarins group are protein synthesis inhibitors that work by blocking the function of fungal translation elongation factor 2. Other protein inhibitors are zofimarin, BE31045, SCH57504, xylarin, hypoxysordarin and GR135402. In order to overcome the problems derived from the exploitation of azole drugs, macrolides and echinocandins, novel targets were explored. Proposed antifungal drugs have been developed against potential targets like the N-myristylation of fungal proteins, with inhibitors like myristate and histidine analogues or myristoylpeptide derivatives, aminobenzothiazoles, quinolines and benzofurans. Polymerization of cell wall carbohydrates from uridine di-phospho sugars is another potential target.
16964330	1757	1765	SCH57504	CHEMICAL	16964330T10
16964330	1767	1774	xylarin	CHEMICAL	16964330T11
16964330	1776	1790	hypoxysordarin	CHEMICAL	16964330T12
16964330	1795	1803	GR135402	CHEMICAL	16964330T13
16964330	1872	1877	azole	CHEMICAL	16964330T14
16964330	1900	1913	echinocandins	CHEMICAL	16964330T15
16964330	2025	2026	N	CHEMICAL	167
16964330	2082	2091	myristate	CHEMICAL	16964330T17
16964330	2096	2105	histidine	CHEMICAL	16964330T18
16964330	2149	2168	aminobenzothiazoles	CHEMICAL	16964330T19
16964330	1095	1106	allylamines	CHEMICAL	16964330T1
16964330	2170	2180	quinolines	CHEMICAL	16964330T20
16964330	2185	2196	benzofurans	CHEMICAL	16964330T21
16964330	2245	2270	uridine di-phospho sugars	CHEMICAL	16964330T22
16964330	540	554	amphotericin B	CHEMICAL	16964330T23
16964330	556	567	fluconazole	CHEMICAL	16964330T24
16964330	572	584	itraconazole	CHEMICAL	16964330T25
16964330	655	667	voriconazole	CHEMICAL	16964330T26
16964330	669	681	posaconazole	CHEMICAL	16964330T27
16964330	683	695	ravuconazole	CHEMICAL	16964330T28
16964330	697	708	caspofungin	CHEMICAL	16964330T29
16964330	1108	1125	phenylmorpholines	CHEMICAL	16964330T2
16964330	713	723	micafungin	CHEMICAL	16964330T30
16964330	925	939	amphotericin B	CHEMICAL	16964330T31
16964330	945	955	ergosterol	CHEMICAL	16964330T32
16964330	975	982	sterols	CHEMICAL	16964330T33
16964330	1042	1052	ergosterol	CHEMICAL	16964330T34
16964330	1209	1225	cytochrome P-450	GENE-N	16964330T35
16964330	1234	1240	Erg11p	GENE-N	16964330T36
16964330	1241	1247	Cyp51p	GENE-N	16964330T37
16964330	1510	1516	Erg24p	GENE-N	16964330T38
16964330	1518	1536	delta 14 reductase	GENE-N	16964330T39
16964330	1130	1135	azole	CHEMICAL	16964330T3
16964330	1542	1547	Erg2p	GENE-N	16964330T40
16964330	1549	1574	delta 8-delta 7 isomerase	GENE-N	16964330T41
16964330	1668	1706	fungal translation elongation factor 2	GENE-N	16964330T42
16964330	1184	1189	azole	CHEMICAL	16964330T4
16964330	1380	1397	phenylmorpholines	CHEMICAL	16964330T5
16964330	1408	1418	amorolfine	CHEMICAL	16964330T6
16964330	1581	1590	sordarins	CHEMICAL	16964330T7
16964330	1737	1746	zofimarin	CHEMICAL	16964330T8
16964330	1748	1755	BE31045	CHEMICAL	16964330T9
16964330	CPR:4	16964330T7	16964330T42

16965760|t|D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation.
16965760|a|Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays. A specific detection of IP3 production was also established using IP3 binding proteins. The short lifetime of IP3 makes this detection very challenging in measuring GPCR responses. Indeed, this IP3 rapidly enters the metabolic inositol phosphate cascade. It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade. We show here that IP1 can be used as a surrogate of IP3 to monitor GPCR activation. We developed a novel homogeneous time-resolved fluorescence (HTRF) assay that correlates perfectly with existing methods and is easily amenable to high-throughput screening. The IP-One assay was validated on various GPCR models. It has the advantage over the traditional Ca2+ assay of allowing the measurement of inverse agonist activity as well as the analysis of PLC-beta activity in any nontransfected primary cultures. Finally, the high assay specificity for D-myo-inositol 1 monophosphate (IP1(1)) opens new possibilities in developing selective assays to study the functional roles of the various isoforms of inositol phosphates.
16965760	503	506	IP3	CHEMICAL	16965760T10
16965760	547	550	IP3	CHEMICAL	16965760T11
16965760	631	634	IP3	CHEMICAL	16965760T12
16965760	664	682	inositol phosphate	CHEMICAL	16965760T13
16965760	727	743	lithium chloride	CHEMICAL	16965760T14
16965760	745	749	LiCl	CHEMICAL	16965760T15
16965760	760	786	D-myo-inositol 1-phosphate	CHEMICAL	16965760T16
16965760	883	886	IP3	CHEMICAL	16965760T17
16965760	924	927	IP1	CHEMICAL	16965760T18
16965760	958	961	IP3	CHEMICAL	16965760T19
16965760	1261	1265	Ca2+	CHEMICAL	16965760T1
16965760	0	26	D-myo-inositol 1-phosphate	CHEMICAL	16965760T20
16965760	45	80	D-myo-inositol 1,4,5-tris phosphate	CHEMICAL	16965760T21
16965760	131	151	Phospholipase C beta	GENE-N	16965760T22
16965760	1206	1210	GPCR	GENE-N	26950
16965760	1355	1363	PLC-beta	GENE-N	16965760T24
16965760	318	326	PLC-beta	GENE-N	16965760T25
16965760	153	161	PLC-beta	GENE-N	16965760T26
16965760	171	197	G protein-coupled receptor	GENE-N	16965760T27
16965760	602	606	GPCR	GENE-N	26950
16965760	803	807	GPCR	GENE-N	26950
16965760	256	260	Ca2+	CHEMICAL	16965760T2
16965760	199	203	GPCR	GENE-N	26950
16965760	833	857	inositol monophosphatase	GENE-N	16965760T31
16965760	973	977	GPCR	GENE-N	26950
16965760	92	118	G protein-coupled receptor	GENE-N	16965760T33
16965760	1453	1483	D-myo-inositol 1 monophosphate	CHEMICAL	16965760T3
16965760	1485	1488	IP1	CHEMICAL	16965760T4
16965760	274	308	D-myo-inositol 1,4,5-trisphosphate	CHEMICAL	16965760T5
16965760	1605	1624	inositol phosphates	CHEMICAL	16965760T6
16965760	310	313	IP3	CHEMICAL	16965760T7
16965760	381	399	inositol phosphate	CHEMICAL	16965760T8
16965760	461	464	IP3	CHEMICAL	16965760T9
16965760	CPR:3	16965760T14	26950
16965760	CPR:3	16965760T15	26950
16965760	CPR:4	16965760T14	16965760T31
16965760	CPR:4	16965760T15	16965760T31
16965760	CPR:9	16965760T16	16965760T31
16965760	CPR:9	16965760T17	16965760T31
16965760	CPR:9	16965760T5	16965760T25
16965760	CPR:9	16965760T7	16965760T25
16965760	CPR:9	16965760T8	16965760T25

16970975|t|Non-enzymatic interactions of glyoxylate with lysine, arginine, and glucosamine: a study of advanced non-enzymatic glycation like compounds.
16970975|a|Glyoxylate is a 2 carbon aldo acid that is formed in hepatic tissue from glycolate. Once formed, the molecule can be converted to glycine by alanine-glyoxylate aminotransferase (AGAT). In defects of AGAT, glyoxylate is transformed to oxalate, resulting in high levels of oxalate in the body. The objective of this study was 2-fold. First, it was to determine, if akin to D-glucose, D-fructose or DL-glyceraldehyde, glyoxylate was susceptible to non-enzymatic attack by amino containing molecules such as lysine, arginine or glucosamine. Second, if by virtue of its molecular structure and size, glyoxylate was as reactive a reagent in non-enzymatic reactions as DL-glyceraldehyde; i.e., a glycose that we previously demonstrated to be a more effective glycating agent than D-glucose or D-fructose. Using capillary electrophoresis (CE), high performance liquid chromatography and UV and fluorescence spectroscopy, glyoxylate was found to be a highly reactive precursor of advanced glycation like end products (AGLEs) and a more effective promoter of non-enzymatic end products than D-glucose, D-fructose or DL-glyceraldehyde.
16970975	375	382	oxalate	CHEMICAL	16970975T10
16970975	412	419	oxalate	CHEMICAL	16970975T11
16970975	512	521	D-glucose	CHEMICAL	16970975T12
16970975	523	533	D-fructose	CHEMICAL	16970975T13
16970975	537	554	DL-glyceraldehyde	CHEMICAL	16970975T14
16970975	556	566	glyoxylate	CHEMICAL	16970975T15
16970975	610	615	amino	CHEMICAL	16970975T16
16970975	645	651	lysine	CHEMICAL	16970975T17
16970975	653	661	arginine	CHEMICAL	16970975T18
16970975	665	676	glucosamine	CHEMICAL	16970975T19
16970975	141	151	Glyoxylate	CHEMICAL	16970975T1
16970975	736	746	glyoxylate	CHEMICAL	16970975T20
16970975	803	820	DL-glyceraldehyde	CHEMICAL	16970975T21
16970975	830	837	glycose	CHEMICAL	16970975T22
16970975	214	223	glycolate	CHEMICAL	16970975T23
16970975	914	923	D-glucose	CHEMICAL	16970975T24
16970975	927	937	D-fructose	CHEMICAL	16970975T25
16970975	1054	1064	glyoxylate	CHEMICAL	16970975T26
16970975	30	40	glyoxylate	CHEMICAL	16970975T27
16970975	46	52	lysine	CHEMICAL	16970975T28
16970975	54	62	arginine	CHEMICAL	16970975T29
16970975	1222	1231	D-glucose	CHEMICAL	16970975T2
16970975	68	79	glucosamine	CHEMICAL	16970975T30
16970975	282	317	alanine-glyoxylate aminotransferase	GENE-Y	16970975T31
16970975	319	323	AGAT	GENE-Y	16970975T32
16970975	340	344	AGAT	GENE-Y	16970975T33
16970975	1233	1243	D-fructose	CHEMICAL	16970975T3
16970975	1247	1264	DL-glyceraldehyde	CHEMICAL	16970975T4
16970975	271	278	glycine	CHEMICAL	16970975T5
16970975	282	289	alanine	CHEMICAL	16970975T6
16970975	290	300	glyoxylate	CHEMICAL	16970975T7
16970975	159	175	carbon aldo acid	CHEMICAL	16970975T8
16970975	346	356	glyoxylate	CHEMICAL	16970975T9
16970975	CPR:9	16970975T5	16970975T31
16970975	CPR:9	16970975T5	16970975T32

16980198|t|Cortisol metabolism in hypertension.
16980198|a|Corticosteroids are critically involved in blood pressure regulation. Lack of adrenal steroids in Addison's disease causes life-threatening hypotension, whereas glucocorticoid excess in Cushing's syndrome invariably results in high blood pressure. At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action. By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol. Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia. Ingestion of competitive inhibitors of 11beta-HSD2 such as liquorice and carbenoxolone result in a similar but milder clinical phenotype. Epidemiological data suggests that polymorphic variability in the HSD11B2 gene determines salt sensitivity in the general population, which is a key predisposing factor to adult onset hypertension in some patients. Extrarenal sites of glucocorticoid action and metabolism that might impact on blood pressure include the vasculature and the central nervous system. Intriguingly, increased exposure to glucocorticoids during fetal life promotes high blood pressure in adulthood suggesting an early programming effect. Thus, metabolism and action in many peripheral tissues might contribute to the pathophysiology of human hypertension.
16980198	123	131	steroids	CHEMICAL	16980198T10
16980198	1034	1047	carbenoxolone	CHEMICAL	16980198T11
16980198	0	8	Cortisol	CHEMICAL	731
16980198	1165	1172	HSD11B2	GENE-Y	109524
16980198	348	384	11beta-hydroxysteroid dehydrogenases	GENE-N	16980198T14
16980198	386	397	11beta-HSDs	GENE-N	16980198T15
16980198	400	411	11Beta-HSD1	GENE-Y	16980198T16
16980198	458	481	glucocorticoid receptor	GENE-Y	16980198T17
16980198	483	485	GR	GENE-Y	9947
16980198	517	528	11beta-HSD2	GENE-Y	16980198T19
16980198	37	52	Corticosteroids	CHEMICAL	16980198T1
16980198	695	721	mineralocorticoid receptor	GENE-Y	16980198T20
16980198	723	725	MR	GENE-Y	16980198T21
16980198	757	768	11beta-HSD2	GENE-Y	16980198T22
16980198	908	910	MR	GENE-Y	16980198T23
16980198	1000	1011	11beta-HSD2	GENE-Y	16980198T24
16980198	348	369	11beta-hydroxysteroid	CHEMICAL	16980198T2
16980198	422	431	cortisone	CHEMICAL	16980198T3
16980198	435	443	cortisol	CHEMICAL	16980198T4
16980198	553	564	aldosterone	CHEMICAL	16980198T5
16980198	643	651	cortisol	CHEMICAL	16980198T6
16980198	655	664	cortisone	CHEMICAL	16980198T7
16980198	730	738	cortisol	CHEMICAL	16980198T8
16980198	885	893	cortisol	CHEMICAL	16980198T9
16980198	CPR:3	16980198T8	16980198T20
16980198	CPR:3	16980198T8	16980198T21
16980198	CPR:3	16980198T9	16980198T23
16980198	CPR:4	16980198T11	16980198T24
16980198	CPR:9	16980198T3	16980198T16
16980198	CPR:9	16980198T4	16980198T16
16980198	CPR:9	16980198T6	16980198T19
16980198	CPR:9	16980198T7	16980198T19

16982809|t|PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells.
16982809|a|Dendritic cells (DCs) expressing CD1d, a molecule responsible for lipid antigen presentation, are capable of enhancing natural killer T (iNKT) cell proliferation. The signals controlling CD1 expression and lipid antigen presentation are poorly defined. We have shown previously that stimulation of the lipid-activated transcription factor, peroxisome proliferator-activated receptor (PPAR)gamma, indirectly regulates CD1d expression. Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2). PPARgamma-regulated expression of these enzymes leads to an increase in the intracellular generation of all-trans retinoic acid (ATRA) from retinol. ATRA regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates CD1d expression. The retinoic acid-induced elevated expression of CD1d is coupled to enhanced iNKT cell activation. Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit retinoid signaling leading to CD1d up-regulation. These data show that regulation of retinoid metabolism and signaling is part of the PPARgamma-controlled transcriptional events in DCs. The uncovered mechanisms allow the DCs to respond to altered lipid homeostasis by changing CD1 gene expression.
16982809	906	913	retinol	CHEMICAL	16982809T10
16982809	915	919	ATRA	CHEMICAL	745
16982809	972	985	retinoic acid	CHEMICAL	16982809T12
16982809	1072	1085	retinoic acid	CHEMICAL	16982809T13
16982809	49	62	retinoic acid	CHEMICAL	16982809T14
16982809	1117	1121	CD1d	GENE-Y	16982809T15
16982809	1291	1295	CD1d	GENE-Y	16982809T16
16982809	1395	1404	PPARgamma	GENE-Y	16982809T17
16982809	1538	1541	CD1	GENE-N	16982809T18
16982809	297	300	CD1	GENE-N	16982809T19
16982809	1261	1269	retinoid	CHEMICAL	16982809T1
16982809	412	448	lipid-activated transcription factor	GENE-N	16982809T20
16982809	143	147	CD1d	GENE-Y	16982809T21
16982809	450	504	peroxisome proliferator-activated receptor (PPAR)gamma	GENE-Y	16982809T22
16982809	527	531	CD1d	GENE-Y	16982809T23
16982809	569	578	PPARgamma	GENE-Y	16982809T24
16982809	692	716	retinol dehydrogenase 10	GENE-Y	16982809T25
16982809	721	755	retinaldehyde dehydrogenase type 2	GENE-Y	16982809T26
16982809	757	763	RALDH2	GENE-Y	16982809T27
16982809	766	775	PPARgamma	GENE-Y	16982809T28
16982809	972	1005	retinoic acid receptor (RAR)alpha	GENE-Y	16982809T29
16982809	1346	1354	retinoid	CHEMICAL	16982809T2
16982809	1024	1032	RARalpha	GENE-Y	16982809T30
16982809	1051	1055	CD1d	GENE-Y	16982809T31
16982809	0	9	PPARgamma	GENE-Y	16982809T32
16982809	19	23	CD1d	GENE-Y	16982809T33
16982809	589	602	retinoic acid	CHEMICAL	16982809T3
16982809	643	650	retinol	CHEMICAL	16982809T4
16982809	655	662	retinal	CHEMICAL	16982809T5
16982809	692	699	retinol	CHEMICAL	16982809T6
16982809	721	734	retinaldehyde	CHEMICAL	16982809T7
16982809	870	893	all-trans retinoic acid	CHEMICAL	16982809T8
16982809	895	899	ATRA	CHEMICAL	745
16982809	CPR:3	745	16982809T29
16982809	CPR:3	745	16982809T30
16982809	CPR:3	745	16982809T31
16982809	CPR:3	16982809T13	16982809T15
16982809	CPR:3	16982809T1	16982809T16
16982809	CPR:9	16982809T3	16982809T25
16982809	CPR:9	16982809T3	16982809T26
16982809	CPR:9	16982809T3	16982809T27
16982809	CPR:9	16982809T4	16982809T25
16982809	CPR:9	16982809T4	16982809T26
16982809	CPR:9	16982809T4	16982809T27
16982809	CPR:9	16982809T5	16982809T25
16982809	CPR:9	16982809T5	16982809T26
16982809	CPR:9	16982809T5	16982809T27

17015817|t|Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
17015817|a|CONTEXT: Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment. Most approved insomnia medications have potential for abuse and cause motor and cognitive impairment. OBJECTIVE: To evaluate the potential for abuse, subjective effects, and motor and cognitive-impairing effects of ramelteon compared with triazolam, a classic benzodiazepine sedative-hypnotic drug. DESIGN: In this double-blind crossover study, each participant received oral doses of ramelteon (16, 80, or 160 mg), triazolam (0.25, 0.5, or 0.75 mg), and placebo during approximately 18 days. All participants received each treatment on different days. Most outcome measures were assessed at 0.5 hours before drug administration and repeatedly up to 24 hours after drug administration. SETTING: Residential research facility. PARTICIPANTS: Fourteen adults with histories of sedative abuse. MAIN OUTCOME MEASURES: Subject-rated measures included items relevant to potential for abuse (eg, drug liking, street value, and pharmacological classification), as well as assessments of a broad range of stimulant and sedative subjective effects. Observer-rated measures included assessments of sedation and impairment. Motor and cognitive performance measures included psychomotor and memory tasks and a standing balance task. RESULTS: Compared with placebo, ramelteon (16, 80, and 160 mg) showed no significant effect on any of the subjective effect measures, including those related to potential for abuse. In the pharmacological classification, 79% (11/14) of subjects identified the highest dose of ramelteon as placebo. Similarly, compared with placebo, ramelteon had no effect at any dose on any observer-rated or motor and cognitive performance measure. In contrast, triazolam showed dose-related effects on a wide range of subject-rated, observer-rated, and motor and cognitive performance measures, consistent with its profile as a sedative drug with abuse liability. CONCLUSION: Ramelteon demonstrated no significant effects indicative of potential for abuse or motor and cognitive impairment at up to 20 times the recommended therapeutic dose and may represent a useful alternative to existing insomnia medications.
17015817	619	628	triazolam	CHEMICAL	17015817T10
17015817	91	100	Ramelteon	CHEMICAL	970
17015817	0	9	Ramelteon	CHEMICAL	970
17015817	112	115	MT1	GENE-Y	17015817T13
17015817	120	142	MT2 melatonin receptor	GENE-Y	17015817T14
17015817	1454	1463	ramelteon	CHEMICAL	17015817T1
17015817	1698	1707	ramelteon	CHEMICAL	17015817T2
17015817	1754	1763	ramelteon	CHEMICAL	17015817T3
17015817	1869	1878	triazolam	CHEMICAL	17015817T4
17015817	2084	2093	Ramelteon	CHEMICAL	970
17015817	418	427	ramelteon	CHEMICAL	17015817T6
17015817	442	451	triazolam	CHEMICAL	17015817T7
17015817	463	477	benzodiazepine	CHEMICAL	17015817T8
17015817	588	597	ramelteon	CHEMICAL	17015817T9
17015817	CPR:5	970	17015817T13
17015817	CPR:5	970	17015817T14

17016511|t|Inhibition of cardiac voltage-gated sodium channels by grape polyphenols.
17016511|a|BACKGROUND AND PURPOSE: The cardiovascular benefits of red wine consumption are often attributed to the antioxidant effects of its polyphenolic constituents, including quercetin, catechin and resveratrol. Inhibition of cardiac voltage-gated sodium channels (VGSCs) is antiarrhythmic and cardioprotective. As polyphenols may also modulate ion channels, and possess structural similarities to several antiarrhythmic VGSC inhibitors, we hypothesised that VGSC inhibition may contribute to cardioprotection by these polyphenols. EXPERIMENTAL APPROACH: The whole-cell voltage-clamp technique was used to record peak and late VGSC currents (INa) from recombinant human heart NaV1.5 channels expressed in tsA201 cells. Right ventricular myocytes from rat heart were isolated and single myocytes were field-stimulated. Either calcium transients or contractility were measured using the calcium-sensitive dye Calcium-Green 1AM or video edge detection, respectively. KEY RESULTS: The red grape polyphenols quercetin, catechin and resveratrol blocked peak INa with IC50s of 19.4 microM, 76.8 microM and 77.3 microM, respectively. In contrast to lidocaine, resveratrol did not exhibit any frequency-dependence of peak INa block. Late INa induced by the VGSC long QT mutant R1623Q was reduced by resveratrol and quercetin. Resveratrol and quercetin also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively. In field-stimulated myocytes, ATXII-induced increases in diastolic calcium were prevented and reversed by resveratrol. ATXII-induced contractile dysfunction was delayed and reduced by resveratrol. CONCLUSIONS AND IMPLICATIONS: Our results indicate that several red grape polyphenols inhibit cardiac VGSCs and that this effect may contribute to the documented cardioprotective efficacy of red grape products.
17016511	1625	1636	resveratrol	CHEMICAL	17016511T10
17016511	1703	1714	resveratrol	CHEMICAL	17016511T11
17016511	242	251	quercetin	CHEMICAL	17016511T12
17016511	253	261	catechin	CHEMICAL	17016511T13
17016511	266	277	resveratrol	CHEMICAL	17016511T14
17016511	315	321	sodium	CHEMICAL	17016511T15
17016511	892	899	calcium	CHEMICAL	17016511T16
17016511	952	959	calcium	CHEMICAL	17016511T17
17016511	974	981	Calcium	CHEMICAL	1332
17016511	1070	1079	quercetin	CHEMICAL	17016511T19
17016511	1081	1089	catechin	CHEMICAL	17016511T1
17016511	36	42	sodium	CHEMICAL	17016511T20
17016511	1315	1319	VGSC	GENE-N	17016511T21
17016511	1335	1341	R1623Q	GENE-N	17016511T22
17016511	1818	1823	VGSCs	GENE-N	17016511T23
17016511	301	330	voltage-gated sodium channels	GENE-N	17016511T24
17016511	332	337	VGSCs	GENE-N	17016511T25
17016511	488	492	VGSC	GENE-N	17016511T26
17016511	526	530	VGSC	GENE-N	17016511T27
17016511	694	698	VGSC	GENE-N	17016511T28
17016511	731	749	human heart NaV1.5	GENE-Y	17016511T29
17016511	1094	1105	resveratrol	CHEMICAL	17016511T2
17016511	22	51	voltage-gated sodium channels	GENE-N	17016511T30
17016511	1208	1217	lidocaine	CHEMICAL	17016511T3
17016511	1219	1230	resveratrol	CHEMICAL	17016511T4
17016511	1357	1368	resveratrol	CHEMICAL	17016511T5
17016511	1373	1382	quercetin	CHEMICAL	17016511T6
17016511	1384	1395	Resveratrol	CHEMICAL	2597
17016511	1400	1409	quercetin	CHEMICAL	17016511T8
17016511	1586	1593	calcium	CHEMICAL	17016511T9
17016511	CPR:4	17016511T5	17016511T21
17016511	CPR:4	17016511T5	17016511T22
17016511	CPR:4	17016511T6	17016511T21
17016511	CPR:4	17016511T6	17016511T22

17016621|t|Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.
17016621|a|The effects of amrubicin (AMR) and its active metabolite, amrubicinol (AMROH), on the sensitivity of human lung adenocarcinoma A549 cells to ionizing radiation were investigated in vitro. Further, the kinetics of apoptosis and necrosis induction were also analyzed. The cytocidal effects of X-ray irradiation on A549 cells resulted in a low level of radiosensitivity with a D0 value of 12 Gy. The slopes of the survival curves in the exponential phase were plotted on semilogarithmic paper for radiation combined with AMR (2.5 microg/ml) and AMROH (0.02 microg/ml) treatment, and were shown to be approximately parallel to treatment with irradiation alone. The initial shoulder-shape portion of the survival curve for radiation alone, indicating the repair of sublethal damage, was reduced as compared to that for sequential combined treatment with AMR or AMROH. Sequential treatments with AMR or AMROH prior to ionizing radiation resulted in an additive radio-enhancement effect that reduced not only survival, but also the shoulder width. Fractionated irradiation with 2 Gy per fraction of A549 cells was carried out in vitro similar to that commonly performed in clinical radiotherapy and the radio-resistance of the cells was shown to be inhibited by AMR and AMROH. Similar to AMR and AMROH, adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors. The effects of these 4 agents on cells that received X-ray irradiation were compared and all of the agents exhibited comparable radio-enhancement effects. The induction of apoptosis was investigated at 48 and 72 h after administration of AMROH, radiation or combined treatment, and apoptosis was not significantly induced after any of the treatments. We also examined the induction of necrosis, and found that the incidence of necrosis following combined treatment was approximately 2 times higher than that with either of the single treatments.
17016621	206	209	AMR	CHEMICAL	17016621T10
17016621	698	701	AMR	CHEMICAL	17016621T11
17016621	722	727	AMROH	CHEMICAL	17016621T12
17016621	238	249	amrubicinol	CHEMICAL	17016621T13
17016621	251	256	AMROH	CHEMICAL	17016621T14
17016621	1029	1032	AMR	CHEMICAL	17016621T15
17016621	1036	1041	AMROH	CHEMICAL	17016621T16
17016621	1070	1073	AMR	CHEMICAL	17016621T17
17016621	1077	1082	AMROH	CHEMICAL	17016621T18
17016621	63	72	amrubicin	CHEMICAL	17016621T19
17016621	1435	1438	AMR	CHEMICAL	17016621T1
17016621	77	88	amrubicinol	CHEMICAL	17016621T20
17016621	1513	1533	DNA topoisomerase II	GENE-Y	17016621T21
17016621	35	51	topoisomerase II	GENE-Y	17016621T22
17016621	1443	1448	AMROH	CHEMICAL	17016621T2
17016621	1461	1464	AMR	CHEMICAL	17016621T3
17016621	1469	1474	AMROH	CHEMICAL	17016621T4
17016621	1476	1486	adriamycin	CHEMICAL	17016621T5
17016621	1491	1500	etoposide	CHEMICAL	17016621T6
17016621	1502	1507	VP-16	CHEMICAL	763
17016621	195	204	amrubicin	CHEMICAL	17016621T8
17016621	1784	1789	AMROH	CHEMICAL	17016621T9
17016621	CPR:4	17016621T19	17016621T22
17016621	CPR:4	17016621T20	17016621T22
17016621	CPR:4	17016621T3	17016621T21
17016621	CPR:4	17016621T4	17016621T21
17016621	CPR:4	17016621T5	17016621T21
17016621	CPR:4	17016621T6	17016621T21
17016621	CPR:4	763	17016621T21

17033106|t|Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals.
17033106|a|Helicobacter pylori (H. pylori) and non-steroidal anti-inflammatory drugs (NSAID) are major pathogenic factors in peptic ulcer disease but whether these two factors exert synergistic or antagonistic action on the gastric mucosa has been a subject of controversy. The classic concept states that there is an increased ulcer occurrence and bleeding in patients with both H. pylori infection and NSAID use. However, the question whether the H. pylori eradication therapy in NSAID users reduces the occurrence of peptic ulcer has not been fully addressed. Studies on secondary prevention of NSAID-associated ulcers in H. pylori patients have indicated that H. pylori eradication results in impaired ulcer healing with an effect on the rate of peptic ulcer occurrence. On the other hand, the treatment of H. pylori in patients with no prior history of chronic NSAID therapy has been shown to decrease the risk of peptic ulcer. Studies in experimental animals revealed for instance, that the H. pylori infection augments the gastric mucosal damage induced by NSAID in Mongolian gerbils. In rats with preexisting chromic gastric ulcers, H. pylori infection attenuated significantly the aspirin-induced inhibition of ulcer healing and accompanying fall in the gastric blood flow at the margin of these ulcers, suggesting negative interaction between aspirin and H. pylori on ulcerogenesis. Accumulated evidence in humans and animals shows that both aspirin and H. pylori upregulate the expression of cyclooxygenase (COX)-2 both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1. It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF. The present review summarizes and further addresses the issue of the interaction between these two major ulcer risk factors determined in the stomach of humans and experimental animals.
17033106	2034	2043	TGF alpha	GENE-N	17033106T10
17033106	2048	2052	VEGF	GENE-N	17033106T11
17033106	1315	1322	aspirin	CHEMICAL	17033106T1
17033106	1478	1485	aspirin	CHEMICAL	17033106T2
17033106	1577	1584	aspirin	CHEMICAL	17033106T3
17033106	1825	1832	aspirin	CHEMICAL	17033106T4
17033106	1923	1929	PGE(2)	CHEMICAL	17033106T5
17033106	176	185	steroidal	CHEMICAL	17033106T6
17033106	1628	1650	cyclooxygenase (COX)-2	GENE-N	17033106T7
17033106	1750	1755	COX-1	GENE-N	17033106T8
17033106	1952	1957	COX-2	GENE-N	17033106T9
17033106	CPR:3	17033106T3	17033106T7
17033106	CPR:3	17033106T4	17033106T10
17033106	CPR:3	17033106T4	17033106T11
17033106	CPR:3	17033106T4	17033106T9
17033106	CPR:9	17033106T5	17033106T9

17041099|t|The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
17041099|a|Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis. Methylthioadenosine phosphorylase (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma. The current study addresses the effect of MTAP on pemetrexed activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the MTAP(+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines. Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations. ImmA had no effect on pemetrexed activity but, when thymidine was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in MTAP(+) H28 cells with no effect in MTAP(-) H2052 cells. Conversely, the transfection of MTAP into H2052 cells increased the pemetrexed IC(50) by nearly 3-fold but only in the presence of thymidine; this was reversed by ImmA. An MTAP-specific short interfering RNA produced a 2-fold decrease in pemetrexed IC(50) in MTAP(+) HeLa cells in the presence of thymidine. These data indicate that suppression of constitutive MTAP has no effect on pemetrexed activity when the primary target is TS. There is a modest salutary effect when the pemetrexed target is GARFT alone.
17041099	356	363	purines	CHEMICAL	17041099T10
17041099	377	384	adenine	CHEMICAL	17041099T11
17041099	390	409	methylthioadenosine	CHEMICAL	17041099T12
17041099	498	508	pemetrexed	CHEMICAL	632
17041099	165	176	thymidylate	CHEMICAL	17041099T14
17041099	766	776	pemetrexed	CHEMICAL	632
17041099	857	867	pemetrexed	CHEMICAL	632
17041099	906	916	pemetrexed	CHEMICAL	632
17041099	936	945	thymidine	CHEMICAL	17041099T18
17041099	961	971	pemetrexed	CHEMICAL	632
17041099	1148	1158	pemetrexed	CHEMICAL	632
17041099	52	71	methylthioadenosine	CHEMICAL	17041099T20
17041099	89	99	pemetrexed	CHEMICAL	632
17041099	1112	1116	MTAP	GENE-Y	110611
17041099	217	258	glycinamide ribonucleotide transformylase	GENE-Y	17041099T23
17041099	1252	1256	MTAP	GENE-Y	110611
17041099	1339	1343	MTAP	GENE-Y	110611
17041099	1441	1445	MTAP	GENE-Y	110611
17041099	1510	1512	TS	GENE-Y	17041099T27
17041099	1578	1583	GARFT	GENE-Y	17041099T28
17041099	260	265	GARFT	GENE-Y	17041099T29
17041099	217	243	glycinamide ribonucleotide	CHEMICAL	17041099T2
17041099	306	339	Methylthioadenosine phosphorylase	GENE-Y	17041099T30
17041099	341	345	MTAP	GENE-Y	110611
17041099	490	494	MTAP	GENE-Y	110611
17041099	570	574	MTAP	GENE-Y	110611
17041099	630	634	MTAP	GENE-Y	110611
17041099	650	654	MTAP	GENE-Y	110611
17041099	165	185	thymidylate synthase	GENE-Y	17041099T36
17041099	735	737	TS	GENE-Y	17041099T37
17041099	808	813	GARFT	GENE-Y	17041099T38
17041099	187	189	TS	GENE-Y	17041099T39
17041099	1211	1220	thymidine	CHEMICAL	17041099T3
17041099	1023	1027	MTAP	GENE-Y	110611
17041099	1059	1063	MTAP	GENE-Y	110611
17041099	52	85	methylthioadenosine phosphorylase	GENE-Y	17041099T42
17041099	1318	1328	pemetrexed	CHEMICAL	632
17041099	1377	1386	thymidine	CHEMICAL	17041099T5
17041099	1463	1473	pemetrexed	CHEMICAL	632
17041099	1557	1567	pemetrexed	CHEMICAL	632
17041099	288	294	purine	CHEMICAL	17041099T8
17041099	306	325	Methylthioadenosine	CHEMICAL	17041099T9
17041099	CPR:4	632	17041099T38
17041099	CPR:9	17041099T11	17041099T30
17041099	CPR:9	17041099T11	110611
17041099	CPR:9	17041099T12	17041099T30
17041099	CPR:9	17041099T12	110611

17082235|t|Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach.
17082235|a|Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones). Our work shows that sulfonylureas and glinides additionally bind to PPARgamma and exhibit PPARgamma agonistic activity. This activity was predicted in silico by virtual screening and confirmed in vitro in a binding assay, a transactivation assay, and by measuring the expression of PPARgamma target genes. Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit PPARgamma agonistic activity at concentrations comparable with those reached under pharmacological treatment. The most active of these compounds, gliquidone, is shown to be as potent as pioglitazone at inducing PPARgamma target gene expression. This dual mode of action of sulfonylureas and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the sulfonylurea receptor and PPARgamma. Targeting both receptors could increase pancreatic insulin secretion and improve insulin resistance. Glinides, sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new PPARgamma agonists. In addition, we provide a unified concept of the PPARgamma binding ability of seemingly disparate compound classes.
17082235	771	781	gliquidone	CHEMICAL	17082235T10
17082235	786	795	glipizide	CHEMICAL	1055
17082235	801	814	sulfonylureas	CHEMICAL	17082235T12
17082235	828	839	nateglinide	CHEMICAL	17082235T13
17082235	843	850	glinide	CHEMICAL	17082235T14
17082235	238	250	sulfonylurea	CHEMICAL	17082235T15
17082235	1007	1017	gliquidone	CHEMICAL	17082235T16
17082235	1047	1059	pioglitazone	CHEMICAL	17082235T17
17082235	1134	1147	sulfonylureas	CHEMICAL	17082235T18
17082235	1152	1160	glinides	CHEMICAL	17082235T19
17082235	1318	1330	sulfonylurea	CHEMICAL	17082235T1
17082235	0	13	Sulfonylureas	CHEMICAL	17082235T20
17082235	18	26	glinides	CHEMICAL	17082235T21
17082235	1318	1339	sulfonylurea receptor	GENE-N	17082235T22
17082235	272	279	insulin	GENE-Y	17082235T23
17082235	1344	1353	PPARgamma	GENE-Y	17082235T24
17082235	1406	1413	insulin	GENE-Y	17082235T25
17082235	1436	1443	insulin	GENE-Y	17082235T26
17082235	1563	1572	PPARgamma	GENE-Y	17082235T27
17082235	1632	1641	PPARgamma	GENE-Y	17082235T28
17082235	329	371	peroxisome proliferator-activated receptor	GENE-N	17082235T29
17082235	1456	1464	Glinides	CHEMICAL	17082235T2
17082235	373	382	PPARgamma	GENE-Y	17082235T30
17082235	394	401	insulin	GENE-Y	17082235T31
17082235	503	512	PPARgamma	GENE-Y	17082235T32
17082235	525	534	PPARgamma	GENE-Y	17082235T33
17082235	717	726	PPARgamma	GENE-Y	17082235T34
17082235	861	870	PPARgamma	GENE-Y	17082235T35
17082235	238	259	sulfonylurea receptor	GENE-N	17082235T36
17082235	1072	1081	PPARgamma	GENE-Y	17082235T37
17082235	35	83	peroxisome proliferator-activated receptor gamma	GENE-Y	17082235T38
17082235	1466	1479	sulfonylureas	CHEMICAL	17082235T3
17082235	1491	1513	acidified sulfonamides	CHEMICAL	17082235T4
17082235	289	302	sulfonylureas	CHEMICAL	17082235T5
17082235	304	312	glinides	CHEMICAL	17082235T6
17082235	414	432	thiazolidinediones	CHEMICAL	17082235T7
17082235	455	468	sulfonylureas	CHEMICAL	17082235T8
17082235	473	481	glinides	CHEMICAL	17082235T9
17082235	CPR:3	17082235T16	17082235T37
17082235	CPR:3	17082235T17	17082235T37
17082235	CPR:3	17082235T5	17082235T23
17082235	CPR:3	17082235T6	17082235T23
17082235	CPR:5	17082235T10	17082235T35
17082235	CPR:5	1055	17082235T35
17082235	CPR:5	17082235T12	17082235T35
17082235	CPR:5	17082235T13	17082235T35
17082235	CPR:5	17082235T14	17082235T35
17082235	CPR:5	17082235T2	17082235T27
17082235	CPR:5	17082235T3	17082235T27
17082235	CPR:5	17082235T4	17082235T27
17082235	CPR:5	17082235T8	17082235T33
17082235	CPR:5	17082235T9	17082235T33

17088426|t|PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases.
17088426|a|There is a growing appreciation that the cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) signaling pathway is organized to form transduction units that function to deliver specific messages. Such organization results in the local activation of PKA subsets through the generation of confined intracellular gradients of cAMP, but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified. In this study, by performing real-time imaging of cAMP, we show that prostaglandin 1 stimulation generates multiple contiguous, intracellular domains with different cAMP concentration in human embryonic kidney 293 cells. By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and PDE4D are responsible for selectively modulating the concentration of cAMP in individual subcellular compartments. We propose a model whereby compartmentalized PDEs, rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of cAMP synthesis.
17088426	996	1000	cAMP	CHEMICAL	2424
17088426	1141	1145	cAMP	CHEMICAL	2424
17088426	0	6	PGE(1)	CHEMICAL	17088426T12
17088426	89	93	cAMP	CHEMICAL	2424
17088426	399	402	PKA	GENE-N	17088426T14
17088426	851	869	phosphodiesterases	GENE-N	17088426T15
17088426	871	875	PDEs	GENE-N	17088426T16
17088426	916	921	PDE4B	GENE-Y	111168
17088426	926	931	PDE4D	GENE-Y	111170
17088426	221	237	protein kinase A	GENE-N	17088426T19
17088426	1288	1292	cAMP	CHEMICAL	2424
17088426	1086	1090	PDEs	GENE-N	17088426T20
17088426	239	242	PKA	GENE-N	17088426T21
17088426	1356	1360	cAMP	CHEMICAL	2424
17088426	473	477	cAMP	CHEMICAL	2424
17088426	540	544	cAMP	CHEMICAL	2424
17088426	183	213	cyclic adenosine monophosphate	CHEMICAL	17088426T5
17088426	627	631	cAMP	CHEMICAL	2424
17088426	646	661	prostaglandin 1	CHEMICAL	17088426T7
17088426	742	746	cAMP	CHEMICAL	2424
17088426	215	219	cAMP	CHEMICAL	2424
17088426	CPR:3	2424	17088426T14
17088426	CPR:9	2424	111168
17088426	CPR:9	2424	111170
17088426	CPR:9	2424	17088426T20
17088426	CPR:9	2424	17088426T20

17089011|t|DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
17089011|a|Fatty acid synthase (FAS), the key metabolic multi-enzyme that is responsible for the terminal catalytic step in the de novo fatty acid biosynthesis, plays an active role in the development, maintenance, and enhancement of the malignant phenotype in a subset of breast carcinomas. We recently described that a molecular bi-directional cross-talk between FAS and the Her-2/neu (erbB-2) oncogene is taking place at the level of transcription, translation, and activity in breast cancer cells. Because Her-2/neu has been linked with altered sensitivity to cytotoxic drugs, we envisioned that FAS gene expression may represent a novel predictive molecular factor for breast cancer response to chemotherapy in a Her-2/neu-related manner. We herein evaluated whether chemotherapy-induced cell damage acts in an epigenetic fashion by inducing changes in the transcriptional activation of FAS gene in breast cancer cells. To evaluate this option, FAS- and Her-2/neu-overexpressing SK-Br3 breast cancer cells were transiently transfected with a FAS promoter-reporter construct (FAS-Luciferase) harboring all the elements necessary for high level expression in cancer cells. SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions. We failed to observe any significant activation of FAS promoter following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and vincristine. Moreover, the up-regulatory effects of TOP2A inhibitors on the transcriptional activation of FAS gene expression were not significantly decreased when the FAS promoter was damaged at the sterol regulatory element binding protein (SREBP)-binding site. Considering that FAS inhibition produces profound inhibition of DNA replication and S-phase progression in cancer cells, we finally asked whether a cross-talk between TOP2A and FAS could exhibit a Her-2/neu-related bi-directional nature. TOP2A protein levels were decreased during treatment with the anti-Her-2/neu antibody trastuzumab while, concomitantly, FAS promoter activity and FAS protein expression were significantly reduced. Of note, when the expression levels of TOP2A protein were analyzed following exposure of SK-Br3 cells to increasing concentrations of the novel slow-binding FAS inhibitor C75, a dose-dependent reduction in TOP2A expression was observed. Although FAS gene is not physically located in the Her-2/neu-TOP2A amplicon, our present findings strongly suggest that a tight functional association between FAS, Her-2/neu and TOP2A genes is taking place in a subset of breast carcinoma cells.
17089011	212	231	Fatty acid synthase	GENE-Y	17089011T10
17089011	1248	1260	FAS promoter	GENE-N	17089011T11
17089011	1281	1284	FAS	GENE-Y	106851
17089011	1418	1439	topoisomerase IIalpha	GENE-Y	17089011T13
17089011	1441	1446	TOP2A	GENE-Y	113006
17089011	1533	1545	FAS promoter	GENE-N	17089011T15
17089011	1680	1692	FAS promoter	GENE-N	17089011T16
17089011	1887	1892	TOP2A	GENE-Y	113006
17089011	1941	1944	FAS	GENE-Y	106851
17089011	2003	2015	FAS promoter	GENE-N	17089011T19
17089011	212	222	Fatty acid	CHEMICAL	17089011T1
17089011	2035	2076	sterol regulatory element binding protein	GENE-N	17089011T20
17089011	2078	2083	SREBP	GENE-N	17089011T21
17089011	2116	2119	FAS	GENE-Y	106851
17089011	2266	2271	TOP2A	GENE-Y	113006
17089011	2276	2279	FAS	GENE-Y	106851
17089011	2296	2301	Her-2	GENE-Y	17089011T25
17089011	2302	2305	neu	GENE-Y	17089011T26
17089011	233	236	FAS	GENE-Y	106851
17089011	2337	2342	TOP2A	GENE-Y	113006
17089011	2404	2409	Her-2	GENE-Y	17089011T29
17089011	1459	1470	doxorubicin	CHEMICAL	17089011T2
17089011	2410	2413	neu	GENE-Y	17089011T30
17089011	2457	2469	FAS promoter	GENE-N	17089011T31
17089011	2483	2486	FAS	GENE-Y	106851
17089011	2573	2578	TOP2A	GENE-Y	113006
17089011	2691	2694	FAS	GENE-Y	106851
17089011	2740	2745	TOP2A	GENE-Y	113006
17089011	2780	2783	FAS	GENE-Y	106851
17089011	2822	2827	Her-2	GENE-Y	17089011T37
17089011	2828	2831	neu	GENE-Y	17089011T38
17089011	2832	2837	TOP2A	GENE-Y	113006
17089011	1475	1484	etopoxide	CHEMICAL	17089011T3
17089011	2930	2933	FAS	GENE-Y	106851
17089011	2935	2940	Her-2	GENE-Y	17089011T41
17089011	2941	2944	neu	GENE-Y	17089011T42
17089011	2949	2954	TOP2A	GENE-Y	113006
17089011	566	569	FAS	GENE-Y	106851
17089011	578	583	Her-2	GENE-Y	17089011T45
17089011	584	587	neu	GENE-Y	17089011T46
17089011	589	595	erbB-2	GENE-Y	17089011T47
17089011	711	716	Her-2	GENE-Y	17089011T48
17089011	717	720	neu	GENE-Y	17089011T49
17089011	1486	1491	VP-16	CHEMICAL	763
17089011	801	804	FAS	GENE-Y	106851
17089011	919	924	Her-2	GENE-Y	17089011T51
17089011	925	928	neu	GENE-Y	17089011T52
17089011	1093	1096	FAS	GENE-Y	106851
17089011	1151	1154	FAS	GENE-Y	106851
17089011	1160	1165	Her-2	GENE-Y	17089011T55
17089011	1166	1169	neu	GENE-Y	17089011T56
17089011	0	25	DNA topoisomerase IIalpha	GENE-Y	17089011T57
17089011	180	183	FAS	GENE-Y	106851
17089011	185	190	Her-2	GENE-Y	17089011T59
17089011	1735	1749	5-fluorouracil	CHEMICAL	17089011T5
17089011	191	194	neu	GENE-Y	17089011T60
17089011	199	204	TOP2A	GENE-Y	113006
17089011	27	32	TOP2A	GENE-Y	113006
17089011	57	76	fatty acid synthase	GENE-Y	17089011T63
17089011	1771	1780	cisplatin	CHEMICAL	17089011T6
17089011	1820	1830	paclitaxel	CHEMICAL	17089011T7
17089011	1835	1846	vincristine	CHEMICAL	17089011T8
17089011	57	67	fatty acid	CHEMICAL	17089011T9
17089011	CPR:3	17089011T2	17089011T15
17089011	CPR:3	17089011T3	17089011T15
17089011	CPR:3	763	17089011T15
17089011	CPR:4	17089011T2	17089011T13
17089011	CPR:4	17089011T2	113006
17089011	CPR:4	17089011T3	17089011T13
17089011	CPR:4	17089011T3	113006
17089011	CPR:4	763	17089011T13
17089011	CPR:4	763	113006

17094978|t|Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate.
17094978|a|OBJECTIVE: To evaluate the effect of mifepristone on the expression of endometrial steroid receptors and their co-factors in depot medroxyprogesterone acetate (DMPA) users. DESIGN: A prospective, randomized, placebo-controlled trial. SETTING: Reproductive research center. PATIENT(S): Fifty healthy women with regular menstrual cycle. INTERVENTION(S): One hundred fifty milligrams of DMPA were given every 3 months. Two pills (25 mg each) of placebo or mifepristone were administered every 14 days during the DMPA therapy. Four endometrial biopsy specimens were obtained from each patient. MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively. Steroid receptor coactivator 1 (SRC-1), silencing mediator for retinoid and thyroid-hormone receptors, and cell proliferation were evaluated by immunohistochemistry. RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and SRC-1 was increased significantly after 1 week of mifepristone, but the increase was no longer seen after 10 weeks. A positive correlation between endometrial ERalpha, PRAB, PRB, and SRC-1 production and proliferation was demonstrated. CONCLUSION(S): Short-term exposure of mifepristone in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and SRC-1 and promotes cell proliferation. Prolonged exposure to mifepristone does not alter the suppression of these receptors that are caused by DMPA and continues to result in endometrial atrophy.
17094978	1013	1020	Steroid	CHEMICAL	17094978T10
17094978	1076	1084	retinoid	CHEMICAL	17094978T11
17094978	1089	1104	thyroid-hormone	CHEMICAL	17094978T12
17094978	0	12	Mifepristone	CHEMICAL	824
17094978	100	127	medroxyprogesterone acetate	CHEMICAL	17094978T14
17094978	46	53	steroid	CHEMICAL	17094978T15
17094978	1220	1227	ERalpha	GENE-Y	17094978T16
17094978	1229	1233	PRAB	GENE-N	17094978T17
17094978	1235	1238	PRB	GENE-Y	17094978T18
17094978	1244	1249	SRC-1	GENE-Y	17094978T19
17094978	1294	1306	mifepristone	CHEMICAL	17094978T1
17094978	1403	1410	ERalpha	GENE-Y	17094978T20
17094978	1412	1416	PRAB	GENE-N	17094978T21
17094978	1418	1421	PRB	GENE-Y	17094978T22
17094978	1427	1432	SRC-1	GENE-Y	17094978T23
17094978	1595	1602	ERalpha	GENE-Y	17094978T24
17094978	1604	1608	PRAB	GENE-N	17094978T25
17094978	1610	1613	PRB	GENE-Y	17094978T26
17094978	1619	1624	SRC-1	GENE-Y	17094978T27
17094978	762	803	estrogen receptor subtypes alpha and beta	GENE-N	17094978T28
17094978	805	812	ERalpha	GENE-Y	17094978T29
17094978	260	287	medroxyprogesterone acetate	CHEMICAL	17094978T2
17094978	817	823	ERbeta	GENE-Y	17094978T30
17094978	826	856	progesterone receptors A and B	GENE-N	17094978T31
17094978	858	862	PRAB	GENE-N	17094978T32
17094978	867	870	PRB	GENE-Y	17094978T33
17094978	877	894	androgen receptor	GENE-N	17094978T34
17094978	212	229	steroid receptors	GENE-N	17094978T35
17094978	1013	1043	Steroid receptor coactivator 1	GENE-Y	17094978T36
17094978	1045	1050	SRC-1	GENE-Y	17094978T37
17094978	1076	1114	retinoid and thyroid-hormone receptors	GENE-N	17094978T38
17094978	46	63	steroid receptors	GENE-N	17094978T39
17094978	1518	1530	mifepristone	CHEMICAL	17094978T3
17094978	1680	1692	mifepristone	CHEMICAL	17094978T4
17094978	582	594	mifepristone	CHEMICAL	17094978T5
17094978	762	770	estrogen	CHEMICAL	17094978T6
17094978	826	838	progesterone	CHEMICAL	17094978T7
17094978	877	885	androgen	CHEMICAL	17094978T8
17094978	212	219	steroid	CHEMICAL	17094978T9
17094978	CPR:3	17094978T1	17094978T16
17094978	CPR:3	17094978T1	17094978T17
17094978	CPR:3	17094978T1	17094978T18
17094978	CPR:3	17094978T1	17094978T19
17094978	CPR:3	17094978T3	17094978T24
17094978	CPR:3	17094978T3	17094978T25
17094978	CPR:3	17094978T3	17094978T26
17094978	CPR:3	17094978T3	17094978T27

17097861|t|Characterization of the molecular mechanisms involved in the increased insulin secretion in rats with acute liver failure.
17097861|a|To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of d-galactosamine (GalN), we focused on the role of polyprimidine tract-binding protein (PTB) in islet insulin synthesis. Recent reports indicate that PTB binds and stabilizes mRNA encoding insulin and insulin secretory granule proteins, including islet cell autoantigen 512 (ICA512), prohormone convertase 1/3 (PC1/3), and PC2. In the present study, glucose-stimulated insulin secretion was significantly increased in GalN-treated rats compared to controls. Levels of mRNA encoding insulin 1, ICA512, and PC1/3 were increased in the pancreatic islets of GalN-treated rats. This mRNA level elevation was not prevented by pretreatment with actinomycin D. When the PTB-binding site in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from GalN-treated rats compared to the level in control rats. The cytosolic fraction obtained from pancreatic islets obtained from GalN-treated rats had an increased PTB level compared to the levels obtained from the pancreatic islets of control rats. These findings suggest that, in rats with acute liver failure, cytosolic PTB binds and stabilizes mRNA encoding insulin and its secretory granule proteins.
17097861	1388	1391	PTB	GENE-Y	17097861T10
17097861	1427	1434	insulin	GENE-N	17097861T11
17097861	1443	1469	secretory granule proteins	GENE-N	17097861T12
17097861	289	324	polyprimidine tract-binding protein	GENE-Y	17097861T13
17097861	326	329	PTB	GENE-Y	17097861T14
17097861	340	347	insulin	GENE-N	17097861T15
17097861	388	391	PTB	GENE-Y	17097861T16
17097861	427	434	insulin	GENE-N	17097861T17
17097861	439	473	insulin secretory granule proteins	GENE-N	17097861T18
17097861	485	511	islet cell autoantigen 512	GENE-Y	17097861T19
17097861	1194	1198	GalN	CHEMICAL	17097861T1
17097861	513	519	ICA512	GENE-Y	17097861T20
17097861	522	547	prohormone convertase 1/3	GENE-N	17097861T21
17097861	549	554	PC1/3	GENE-N	17097861T22
17097861	561	564	PC2	GENE-Y	17097861T23
17097861	607	614	insulin	GENE-N	17097861T24
17097861	720	729	insulin 1	GENE-Y	17097861T25
17097861	731	737	ICA512	GENE-Y	17097861T26
17097861	743	748	PC1/3	GENE-N	17097861T27
17097861	900	916	PTB-binding site	GENE-N	17097861T28
17097861	920	929	insulin 1	GENE-Y	17097861T29
17097861	239	254	d-galactosamine	CHEMICAL	17097861T2
17097861	71	78	insulin	GENE-N	17097861T30
17097861	256	260	GalN	CHEMICAL	17097861T3
17097861	588	595	glucose	CHEMICAL	17097861T4
17097861	656	660	GalN	CHEMICAL	17097861T5
17097861	792	796	GalN	CHEMICAL	17097861T6
17097861	876	889	actinomycin D	CHEMICAL	17097861T7
17097861	1068	1072	GalN	CHEMICAL	17097861T8
17097861	1229	1232	PTB	GENE-Y	17097861T9
17097861	CPR:3	17097861T1	17097861T9
17097861	CPR:3	17097861T4	17097861T24
17097861	CPR:3	17097861T5	17097861T24
17097861	CPR:3	17097861T6	17097861T25
17097861	CPR:3	17097861T6	17097861T26
17097861	CPR:3	17097861T8	17097861T28
17097861	CPR:3	17097861T8	17097861T29

17112405|t|Cysteinyl leukotriene receptor 1 is involved in N-methyl-D-aspartate-mediated neuronal injury in mice.
17112405|a|AIM: To determine whether cysteinyl leukotriene receptor 1 (CysLT1 receptor) is involved in N-methyl-D-aspartate (NMDA)-induced excitotoxic injury in the mouse brain. METHODS: Brain injury was induced by NMDA microinjection (50-150 nmol in 0.5 microL) into the cerebral cortex. The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed. RESULTS: In the NMDA-injured brain, the CysLT1 receptor mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes. Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor. CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.
17112405	652	656	NMDA	CHEMICAL	1209
17112405	819	829	Pranlukast	CHEMICAL	1360
17112405	831	839	ketamine	CHEMICAL	17112405T12
17112405	844	853	edaravone	CHEMICAL	17112405T13
17112405	864	868	NMDA	CHEMICAL	1209
17112405	885	895	pranlukast	CHEMICAL	17112405T15
17112405	912	920	ketamine	CHEMICAL	17112405T16
17112405	195	215	N-methyl-D-aspartate	CHEMICAL	17112405T17
17112405	1053	1057	NMDA	CHEMICAL	1209
17112405	1073	1077	NMDA	CHEMICAL	1209
17112405	1203	1207	NMDA	CHEMICAL	1209
17112405	0	21	Cysteinyl leukotriene	CHEMICAL	17112405T20
17112405	48	68	N-methyl-D-aspartate	CHEMICAL	17112405T21
17112405	1113	1128	CysLT1 receptor	GENE-Y	17112405T22
17112405	1172	1187	CysLT1 receptor	GENE-Y	17112405T23
17112405	129	161	cysteinyl leukotriene receptor 1	GENE-Y	17112405T24
17112405	396	411	CysLT1 receptor	GENE-Y	17112405T25
17112405	470	485	CysLT1 receptor	GENE-Y	17112405T26
17112405	534	547	NMDA receptor	GENE-N	17112405T27
17112405	676	691	CysLT1 receptor	GENE-Y	17112405T28
17112405	163	178	CysLT1 receptor	GENE-Y	17112405T29
17112405	217	221	NMDA	CHEMICAL	1209
17112405	965	980	CysLT1 receptor	GENE-Y	17112405T30
17112405	994	1009	CysLT1 receptor	GENE-Y	17112405T31
17112405	0	32	Cysteinyl leukotriene receptor 1	GENE-Y	17112405T32
17112405	307	311	NMDA	CHEMICAL	1209
17112405	129	150	cysteinyl leukotriene	CHEMICAL	17112405T4
17112405	434	438	NMDA	CHEMICAL	1209
17112405	498	508	pranlukast	CHEMICAL	17112405T6
17112405	534	538	NMDA	CHEMICAL	1209
17112405	560	568	ketamine	CHEMICAL	17112405T8
17112405	601	610	edaravone	CHEMICAL	17112405T9
17112405	CPR:3	1209	17112405T28
17112405	CPR:3	1209	17112405T31
17112405	CPR:3	1209	17112405T23
17112405	CPR:4	17112405T15	17112405T30
17112405	CPR:4	17112405T16	17112405T30
17112405	CPR:6	17112405T6	17112405T26
17112405	CPR:6	17112405T8	17112405T27

17119350|t|Bcl-2 phosphorylation has pathological significance in human breast cancer.
17119350|a|The anti-apoptotic molecule, Bcl-2, is well known to play an important role in the chemoresistance of breast cancer. We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel. In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens. Expression of P-Bcl-2 was found to significantly correlate with lymphatic invasion, lymph node metastasis, but not histological differentiation, tumor grade or vascular and fatty invasion. The positivity of P-Bcl-2 was also significantly correlated to that of P-FADD/JNK. Thus, P-Bcl-2 as well as the P-FADD/JNK parameter might be useful markers for cancer progression, independent of the hormone receptor status, in human breast cancers.
17119350	1158	1161	JNK	GENE-N	17119350T10
17119350	249	295	Fas-associated death domain-containing protein	GENE-Y	17119350T11
17119350	297	301	FADD	GENE-Y	114302
17119350	325	350	c-jun NH2-terminal kinase	GENE-N	17119350T13
17119350	352	355	JNK	GENE-N	17119350T14
17119350	105	110	Bcl-2	GENE-Y	17119350T15
17119350	472	477	Bcl-2	GENE-Y	17119350T16
17119350	508	511	JNK	GENE-N	17119350T17
17119350	512	516	FADD	GENE-Y	114302
17119350	637	657	phosphorylated Bcl-2	GENE-Y	17119350T19
17119350	310	316	serine	CHEMICAL	17119350T1
17119350	659	666	P-Bcl-2	GENE-Y	17119350T20
17119350	673	715	estrogen, progesterone, c-erbB-2 receptors	GENE-N	17119350T21
17119350	717	720	p53	GENE-Y	77545
17119350	737	756	phosphorylated FADD	GENE-Y	17119350T23
17119350	757	760	JNK	GENE-N	17119350T24
17119350	762	768	P-FADD	GENE-Y	17119350T25
17119350	769	772	JNK	GENE-N	17119350T26
17119350	864	871	P-Bcl-2	GENE-Y	17119350T27
17119350	1057	1064	P-Bcl-2	GENE-Y	17119350T28
17119350	0	5	Bcl-2	GENE-Y	17119350T29
17119350	331	334	NH2	CHEMICAL	17119350T2
17119350	571	581	paclitaxel	CHEMICAL	17119350T3
17119350	673	681	estrogen	CHEMICAL	17119350T4
17119350	683	695	progesterone	CHEMICAL	17119350T5
17119350	1110	1116	P-FADD	GENE-Y	17119350T6
17119350	1117	1120	JNK	GENE-N	17119350T7
17119350	1128	1135	P-Bcl-2	GENE-Y	17119350T8
17119350	1151	1157	P-FADD	GENE-Y	17119350T9
17119350	CPR:3	17119350T3	17119350T11
17119350	CPR:3	17119350T3	114302
17119350	CPR:3	17119350T3	17119350T13
17119350	CPR:3	17119350T3	17119350T14
17119350	CPR:3	17119350T3	17119350T17
17119350	CPR:3	17119350T3	114302

1712335|t|Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.
1712335|a|The mechanism(s) responsible for arterial vasodilation observed following acute administration of racemic carvedilol, a novel vasodilator/beta adrenoceptor antagonist, has been investigated in rats. In conscious spontaneously hypertensive rats, carvedilol (0.03-3.0 mg/kg, iv) produced a dose-dependent reduction in blood pressure with no significant effect on heart rate. Because cardiac output was relatively unaffected, the antihypertensive response of carvedilol was associated with a dose-dependent reduction in total peripheral vascular resistance. Submaximal antihypertensive doses of carvedilol were chosen for mechanism of action studies in pithed rats. Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the beta 1 adrenoceptor mediated positive chronotropic response to isoproterenol. This same dose of carvedilol also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II. Thus, carvedilol blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the beta 1 adrenoceptor subtype. Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses. Carvedilol had no effect on the pressor response elicited by angiotensin II, indicating a lack of nonspecific vasodilator activity. The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies. In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors. We therefore conclude that carvedilol, at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of calcium channels in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)
1712335	1964	1971	calcium	CHEMICAL	1712335T10
1712335	2004	2014	carvedilol	CHEMICAL	1712335T11
1712335	2046	2056	carvedilol	CHEMICAL	1712335T12
1712335	2067	2074	calcium	CHEMICAL	1712335T13
1712335	2224	2234	carvedilol	CHEMICAL	1712335T14
1712335	2349	2357	prazosin	CHEMICAL	1712335T15
1712335	2424	2435	propranolol	CHEMICAL	1712335T16
1712335	2525	2535	carvedilol	CHEMICAL	1712335T17
1712335	353	363	carvedilol	CHEMICAL	1712335T18
1712335	2631	2641	carvedilol	CHEMICAL	1712335T19
1712335	1165	1175	carvedilol	CHEMICAL	1712335T1
1712335	2745	2752	calcium	CHEMICAL	1712335T20
1712335	564	574	carvedilol	CHEMICAL	1712335T21
1712335	700	710	carvedilol	CHEMICAL	1712335T22
1712335	771	781	Carvedilol	CHEMICAL	1124
1712335	902	915	isoproterenol	CHEMICAL	1712335T24
1712335	935	945	carvedilol	CHEMICAL	1712335T25
1712335	1045	1055	salbutamol	CHEMICAL	1712335T26
1712335	206	224	racemic carvedilol	CHEMICAL	1712335T27
1712335	96	106	carvedilol	CHEMICAL	1712335T28
1712335	1143	1157	angiotensin II	GENE-Y	1712335T29
1712335	1323	1333	Carvedilol	CHEMICAL	1124
1712335	1188	1219	beta 1 and beta 2 adrenoceptors	GENE-N	1712335T30
1712335	1294	1313	beta 1 adrenoceptor	GENE-Y	1712335T31
1712335	1373	1393	alpha 1 adrenoceptor	GENE-N	1712335T32
1712335	1478	1498	alpha 2 adrenoceptor	GENE-Y	1712335T33
1712335	246	263	beta adrenoceptor	GENE-N	1712335T34
1712335	1576	1596	alpha 1 adrenoceptor	GENE-N	1712335T35
1712335	1696	1710	angiotensin II	GENE-Y	1712335T36
1712335	1799	1814	calcium channel	GENE-N	1712335T37
1712335	1879	1913	voltage dependent calcium channels	GENE-N	1712335T38
1712335	2067	2082	calcium channel	GENE-N	1712335T39
1712335	1423	1433	cirazoline	CHEMICAL	1712335T3
1712335	2316	2336	alpha 1 adrenoceptor	GENE-N	1712335T40
1712335	2394	2411	beta adrenoceptor	GENE-N	1712335T41
1712335	2572	2602	beta and alpha 1 adrenoceptors	GENE-N	1712335T42
1712335	2690	2731	beta 1, beta 2, and alpha 1 adrenoceptors	GENE-N	1712335T43
1712335	2745	2761	calcium channels	GENE-N	1712335T44
1712335	839	858	beta 1 adrenoceptor	GENE-Y	1712335T45
1712335	990	1009	beta 2 adrenoceptor	GENE-Y	1712335T46
1712335	1528	1536	B-HT 933	CHEMICAL	1712335T4
1712335	1554	1564	carvedilol	CHEMICAL	1712335T5
1712335	1635	1645	Carvedilol	CHEMICAL	1124
1712335	1799	1806	calcium	CHEMICAL	1712335T7
1712335	1826	1836	BAY-K-8644	CHEMICAL	1712335T8
1712335	1897	1904	calcium	CHEMICAL	1712335T9
1712335	CPR:3	1712335T24	1712335T45
1712335	CPR:3	1712335T8	1712335T37
1712335	CPR:3	1712335T8	1712335T38
1712335	CPR:4	1712335T11	1712335T38
1712335	CPR:4	1712335T1	1712335T31
1712335	CPR:4	1124	1712335T45
1712335	CPR:4	1712335T25	1712335T46
1712335	CPR:4	1124	1712335T32
1712335	CPR:6	1712335T12	1712335T39
1712335	CPR:6	1712335T15	1712335T40
1712335	CPR:6	1712335T16	1712335T41
1712335	CPR:6	1712335T19	1712335T44
1712335	CPR:6	1712335T27	1712335T34
1712335	CPR:6	1712335T5	1712335T35
1712335	CPR:9	1712335T10	1712335T38

17126311|t|Clinical, biochemical and molecular diagnosis of a compound homozygote for the 254 bp deletion-8 bp insertion of the APRT gene suffering from severe renal failure.
17126311|a|OBJECTIVE: To determine the type of mutation in a patient with clinical diagnosis of suspected APRT deficiency. DESIGN AND METHODS: A 51-year-old male patient, with a clinical history of two prior episodes of renal colic with urinary stone excretion (reported as uric acid stones in the first episode and as calcium oxalate stones in the second), was admitted to the hospital with severe non-oliguric renal failure (1.06 mmol/L serum creatinine), severe hyponatremia (114 mmol/L Na(+)), metabolic acidosis (14 mmol/L HCO(3)(-)) and uricemia in the normal range. Abnormalities at renal scan and persistency of severe renal failure required to start haemodialysis. Results of renal biopsy prompted us to undertake a biochemical and molecular biological evaluation of the patient for suspected adenine phosphoribosyltransferase (APRT) deficiency. RESULTS: HPLC analysis of serum and urine, for determining purine derivative profile, showed the pathological presence of adenine in both biological fluids (3.57 micromol/L and 7.11 micromol/mmol creatinine in serum and urine, respectively; not detectable in both fluids in healthy controls). APRT assay in a sample of patient hemolysate showed no detectable activity of the enzyme (25.56+/-9.55 U/L red blood cells in control healthy subjects). Molecular biological analysis of the amplified APRT gene revealed that the patient harboured in exon 3 a homozygous 254 bp deletion-8 bp insertion, previously described only once in a compound heterozygote. Analysis of the patient family showed that heterozygotes for this APRT gene mutation, in spite of a 69% lower APRT enzymatic activity than that of healthy subjects, had no detectable adenine concentrations in both serum and urine. CONCLUSIONS: Results of the first patient harbouring the homozygous 254 bp deletion-8 bp insertion of the APRT gene strongly indicated that definitive diagnosis of APRT deficiency (often under or misdiagnosed) would require a combined clinical, biochemical and molecular biological evaluation.
17126311	1130	1137	adenine	CHEMICAL	17126311T10
17126311	1301	1305	APRT	GENE-Y	106849
17126311	1501	1505	APRT	GENE-Y	106849
17126311	1727	1731	APRT	GENE-Y	106849
17126311	1771	1775	APRT	GENE-Y	106849
17126311	1998	2002	APRT	GENE-Y	106849
17126311	2056	2060	APRT	GENE-Y	106849
17126311	955	988	adenine phosphoribosyltransferase	GENE-Y	17126311T17
17126311	990	994	APRT	GENE-Y	106849
17126311	259	263	APRT	GENE-Y	106849
17126311	1204	1214	creatinine	CHEMICAL	17126311T1
17126311	117	121	APRT	GENE-Y	106849
17126311	1844	1851	adenine	CHEMICAL	17126311T2
17126311	427	436	uric acid	CHEMICAL	17126311T3
17126311	472	487	calcium oxalate	CHEMICAL	17126311T4
17126311	598	608	creatinine	CHEMICAL	17126311T5
17126311	643	648	Na(+)	CHEMICAL	17126311T6
17126311	681	690	HCO(3)(-)	CHEMICAL	17126311T7
17126311	955	962	adenine	CHEMICAL	17126311T8
17126311	1067	1073	purine	CHEMICAL	17126311T9

17128263|t|Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B.
17128263|a|Growth hormone binds to its membrane receptor (GHR), whereby it regulates many cellular functions, including proliferation, differentiation and chemotaxis. However, although the activation of growth hormone-mediated signalling is well understood, the precise mechanism responsible for its regulation has not been elucidated. Here, we demonstrate that phospholipase Cgamma1 (PLCgamma1) modulates the action of growth hormone-mediated signalling by interacting with tyrosine kinase Jak2 (janus kinase 2) in a growth hormone-dependent manner. In the absence of PLCgamma1 (PLCgamma1(-/-)), growth hormone-induced JAK2 and STAT5 phosphorylation significantly increased in mouse embryonic fibroblasts (MEFs). Furthermore, the re-expression of PLCgamma1 reduced growth hormone-induced Jak2 activation. Growth hormone-induced Jak2 phosphorylation was enhanced by siRNA-specific knockdown of PLCgamma1. Interestingly, PLCgamma1 physically linked Jak2 and protein tyrosine phosphatase-1B (PTP-1B) by binding to both using different domains, and this process was implicated in the modulation of cytokine signalling through Jak2. In addition, in PLCgamma1(-/-) MEFs, growth hormone-dependent c-Fos activation was upregulated and growth hormone-induced proliferation was potentiated. These results suggest that PLCgamma1 has a key function in the regulation of growth hormone-mediated signalling by negatively regulating Jak2 activation.
17128263	1362	1376	growth hormone	GENE-Y	17128263T10
17128263	1443	1452	PLCgamma1	GENE-Y	17128263T11
17128263	1493	1507	growth hormone	GENE-Y	17128263T12
17128263	1553	1557	Jak2	GENE-Y	200857|246670
17128263	337	351	growth hormone	GENE-Y	17128263T14
17128263	496	517	phospholipase Cgamma1	GENE-Y	17128263T15
17128263	519	528	PLCgamma1	GENE-Y	17128263T16
17128263	554	568	growth hormone	GENE-Y	17128263T17
17128263	609	629	tyrosine kinase Jak2	GENE-Y	17128263T18
17128263	192	195	GHR	GENE-Y	108957|1172345
17128263	609	617	tyrosine	CHEMICAL	17128263T1
17128263	631	645	janus kinase 2	GENE-Y	17128263T20
17128263	652	666	growth hormone	GENE-Y	17128263T21
17128263	703	712	PLCgamma1	GENE-Y	17128263T22
17128263	714	723	PLCgamma1	GENE-Y	17128263T23
17128263	731	745	growth hormone	GENE-Y	17128263T24
17128263	754	758	JAK2	GENE-Y	109920
17128263	763	768	STAT5	GENE-Y	17128263T26
17128263	882	891	PLCgamma1	GENE-Y	17128263T27
17128263	900	914	growth hormone	GENE-Y	17128263T28
17128263	923	927	Jak2	GENE-Y	200857|246670
17128263	1099	1107	tyrosine	CHEMICAL	17128263T2
17128263	940	954	Growth hormone	GENE-Y	17128263T30
17128263	963	967	Jak2	GENE-Y	200857|246670
17128263	1028	1037	PLCgamma1	GENE-Y	17128263T32
17128263	1054	1063	PLCgamma1	GENE-Y	17128263T33
17128263	1082	1086	Jak2	GENE-Y	200857|246670
17128263	1091	1122	protein tyrosine phosphatase-1B	GENE-N	17128263T35
17128263	1124	1130	PTP-1B	GENE-N	17128263T36
17128263	0	21	Phospholipase Cgamma1	GENE-Y	17128263T37
17128263	103	107	Jak2	GENE-Y	200857|246670
17128263	112	143	protein tyrosine phosphatase-1B	GENE-Y	17128263T39
17128263	120	128	tyrosine	CHEMICAL	17128263T3
17128263	43	57	growth hormone	GENE-Y	17128263T40
17128263	145	159	Growth hormone	GENE-Y	17128263T4
17128263	1229	1237	cytokine	GENE-N	17128263T5
17128263	1257	1261	Jak2	GENE-Y	200857|246670
17128263	1279	1288	PLCgamma1	GENE-Y	17128263T7
17128263	1300	1314	growth hormone	GENE-Y	17128263T8
17128263	1325	1330	c-Fos	GENE-Y	17128263T9

17138606|t|Increased responsiveness of rat colonic splanchnic afferents to 5-HT after inflammation and recovery.
17138606|a|5-Hydroxytryptamine (5-HT) activates colonic splanchnic afferents, a mechanism by which it has been implicated in generating symptoms in postinfectious and postinflammatory states in humans. Here we compared mechanisms of colonic afferent activation by 5-HT and mechanical stimuli in normal and inflamed rat colon, and after recovery from inflammation. Colonic inflammation was induced in rats by dextran sulphate sodium. Single-fibre recordings of colonic lumbar splanchnic afferents revealed that 58% of endings responded to 5-HT (10(-4) m) in controls, 88% in acute inflammation (P<0.05) and 75% after 21 days recovery (P < 0.05 versus control). Maximal responses to 5-HT were also larger, and the estimated EC50 was reduced from 3.2 x 10(-6) to 8 x 10(-7) m in acute inflammation and recovered to 2 x 10(-6) m after recovery. Responsiveness to mechanical stimulation was unaffected. 5-HT3 receptor antagonism with alosetron reduced responses to 5-HT in controls but not during inflammation. Responses to the mast cell degranulator 48/80 mimicked those to 5-HT in inflamed tissue but not in controls, and more 5-HT-containing mast cells were seen close to calcitonin gene-related peptide-containing fibres in inflamed serosa. We conclude that colonic serosal and mesenteric endings exhibit increased sensitivity to 5-HT in inflammation, with both an increase in proportion of responders and an increase in sensitivity, which is maintained after healing of inflammation. This is associated with alterations in the roles of 5-HT3 receptors and mast cells.
17138606	1020	1029	alosetron	CHEMICAL	17138606T10
17138606	1051	1055	5-HT	CHEMICAL	17138606T11
17138606	64	68	5-HT	CHEMICAL	17138606T12
17138606	1261	1292	calcitonin gene-related peptide	GENE-N	17138606T13
17138606	1627	1642	5-HT3 receptors	GENE-Y	17138606T14
17138606	989	1003	5-HT3 receptor	GENE-Y	17138606T15
17138606	102	121	5-Hydroxytryptamine	CHEMICAL	17138606T1
17138606	1161	1165	5-HT	CHEMICAL	17138606T2
17138606	1215	1219	5-HT	CHEMICAL	17138606T3
17138606	1420	1424	5-HT	CHEMICAL	17138606T4
17138606	123	127	5-HT	CHEMICAL	17138606T5
17138606	355	359	5-HT	CHEMICAL	17138606T6
17138606	499	522	dextran sulphate sodium	CHEMICAL	17138606T7
17138606	629	633	5-HT	CHEMICAL	17138606T8
17138606	772	776	5-HT	CHEMICAL	17138606T9
17138606	CPR:6	17138606T10	17138606T15

17138644|t|The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle.
17138644|a|Human progesterone receptor (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor. Here we investigated the role and intracellular location of this nontranscriptional activity of PR. Progestin activation of Src/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear. Breast cancer cells stably expressing wild-type PR-B or PR-B with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of progestin on endogenous target gene expression and cell proliferation. Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src. Progestin induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of progestin on cyclin D1 expression and cell cycle was observed in the presence of PR-A. These results highlight the importance of PR activation of the Src/MAPK signaling pathway for progesterone-induced transcription of select target genes and cell cycle progression.
17138644	46	58	progesterone	CHEMICAL	17138644T10
17138644	81	93	progesterone	CHEMICAL	17138644T11
17138644	144	171	Human progesterone receptor	GENE-Y	17138644T12
17138644	1206	1235	progesterone response element	GENE-N	17138644T13
17138644	1284	1286	PR	GENE-Y	17138644T14
17138644	1301	1304	Src	GENE-Y	203491|249840
17138644	1391	1403	PR-BDeltaSH3	GENE-N	17138644T16
17138644	269	272	Src	GENE-Y	203491|249840
17138644	1435	1444	cyclin D1	GENE-Y	17138644T18
17138644	1503	1507	PR-A	GENE-Y	17138644T19
17138644	1206	1218	progesterone	CHEMICAL	17138644T1
17138644	1551	1553	PR	GENE-Y	17138644T20
17138644	1572	1575	Src	GENE-Y	203491|249840
17138644	1576	1580	MAPK	GENE-N	17138644T22
17138644	288	292	MAPK	GENE-N	17138644T23
17138644	294	302	Erk-1/-2	GENE-N	17138644T24
17138644	173	175	PR	GENE-Y	17138644T25
17138644	465	467	PR	GENE-Y	17138644T26
17138644	493	496	Src	GENE-Y	203491|249840
17138644	497	501	MAPK	GENE-N	17138644T28
17138644	540	555	B isoform of PR	GENE-Y	17138644T29
17138644	1306	1315	Progestin	CHEMICAL	17138644T2
17138644	625	629	PR-A	GENE-Y	17138644T30
17138644	710	714	PR-B	GENE-Y	17138644T31
17138644	718	722	PR-B	GENE-Y	17138644T32
17138644	762	786	SH3 domain binding motif	GENE-N	17138644T33
17138644	788	800	PR-BDeltaSH3	GENE-N	17138644T34
17138644	853	855	PR	GENE-Y	17138644T35
17138644	218	228	SH3 domain	GENE-N	17138644T36
17138644	984	993	cyclin D1	GENE-Y	17138644T37
17138644	1014	1043	progesterone response element	GENE-N	17138644T38
17138644	232	235	Src	GENE-Y	203491|249840
17138644	1422	1431	progestin	CHEMICAL	17138644T3
17138644	1062	1064	PR	GENE-Y	17138644T40
17138644	1083	1086	Src	GENE-Y	203491|249840
17138644	1087	1091	MAPK	GENE-N	17138644T42
17138644	1126	1129	Sgk	GENE-Y	17138644T43
17138644	1131	1172	serum and glucocorticoid regulated kinase	GENE-Y	17138644T44
17138644	46	67	progesterone receptor	GENE-Y	17138644T45
17138644	1603	1615	progesterone	CHEMICAL	17138644T4
17138644	469	478	Progestin	CHEMICAL	17138644T5
17138644	150	162	progesterone	CHEMICAL	17138644T6
17138644	886	895	progestin	CHEMICAL	17138644T7
17138644	957	966	Progestin	CHEMICAL	17138644T8
17138644	1014	1026	progesterone	CHEMICAL	17138644T9
17138644	CPR:3	17138644T4	17138644T20
17138644	CPR:3	17138644T4	203491|249840
17138644	CPR:3	17138644T4	17138644T22
17138644	CPR:3	17138644T5	203491|249840
17138644	CPR:3	17138644T5	17138644T28
17138644	CPR:3	17138644T8	17138644T40
17138644	CPR:3	17138644T8	203491|249840
17138644	CPR:3	17138644T8	17138644T42

17146052|t|Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy.
17146052|a|Selected mutations in the human alpha4 or beta2 neuronal nicotinic acetylcholine receptor subunit genes cosegregate with a partial epilepsy syndrome known as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). To examine possible mechanisms underlying this inherited epilepsy, we engineered two ADNFLE mutations (Chrna4(S252F) and Chrna4(+L264)) in mice. Heterozygous ADNFLE mutant mice show persistent, abnormal cortical electroencephalograms with prominent delta and theta frequencies, exhibit frequent spontaneous seizures, and show an increased sensitivity to the proconvulsant action of nicotine. Relative to WT, electrophysiological recordings from ADNFLE mouse layer II/III cortical pyramidal cells reveal a >20-fold increase in nicotine-evoked inhibitory postsynaptic currents with no effect on excitatory postsynaptic currents. i.p. injection of a subthreshold dose of picrotoxin, a use-dependent gamma-aminobutyric acid receptor antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice. Our studies suggest that the mechanism underlying ADNFLE seizures may involve inhibitory synchronization of cortical networks via activation of mutant alpha4-containing nicotinic acetylcholine receptors located on the presynaptic terminals and somatodendritic compartments of cortical GABAergic interneurons.
17146052	1048	1080	gamma-aminobutyric acid receptor	GENE-N	17146052T10
17146052	734	742	nicotine	CHEMICAL	17146052T1
17146052	878	886	nicotine	CHEMICAL	17146052T2
17146052	1020	1030	picrotoxin	CHEMICAL	17146052T3
17146052	1048	1071	gamma-aminobutyric acid	CHEMICAL	17146052T4
17146052	1371	1422	alpha4-containing nicotinic acetylcholine receptors	GENE-Y	17146052T5
17146052	159	222	human alpha4 or beta2 neuronal nicotinic acetylcholine receptor	GENE-N	17146052T6
17146052	455	461	Chrna4	GENE-Y	197932
17146052	462	467	S252F	GENE-N	17146052T8
17146052	473	479	Chrna4	GENE-Y	197932
17146052	CPR:6	17146052T3	17146052T10

17150756|t|Molecular recognition of histidine tRNA by histidyl-tRNA synthetase from hyperthermophilic archaeon, Aeropyrum pernix K1.
17150756|a|To investigate the recognition sites of histidine tRNA for histidyl-tRNA synthetase from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed histidyl-tRNA synthetase and various histidine tRNA transcripts that were prepared by in vitro transcription system. Results indicated that anticodon was not recognized by the histidyl-tRNA synthetase similar to that of Escherichia coli histidine tRNA recognition system. Discriminator base C73 was weekly recognized and an additional G residue was specifically recognized by the enzyme.
17150756	43	67	histidyl-tRNA synthetase	GENE-Y	17150756T10
17150756	331	339	histidyl	CHEMICAL	17150756T1
17150756	368	377	histidine	CHEMICAL	17150756T2
17150756	507	515	histidyl	CHEMICAL	17150756T3
17150756	162	171	histidine	CHEMICAL	17150756T4
17150756	568	577	histidine	CHEMICAL	17150756T5
17150756	25	34	histidine	CHEMICAL	17150756T6
17150756	331	355	histidyl-tRNA synthetase	GENE-Y	17150756T7
17150756	507	531	histidyl-tRNA synthetase	GENE-Y	17150756T8
17150756	181	205	histidyl-tRNA synthetase	GENE-Y	17150756T9

17154506|t|Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.
17154506|a|2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells. Both 1 and 2 have a high affinity for the SERT (Ki=0.2 nM) and are approximately 160 times more selective for the SERT than the DAT. Compound 2 has a significantly higher affinity for the NET than 1, and this may be a result of the different size and electronegativity of the halogen atoms. MicroPET imaging in nonhuman primates with [11C]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the SERT-rich brain regions and peak uptake being achieved in about 55 min postinjection. Chase studies with citalopram and methylphenidate demonstrated that this uptake is the result of preferential binding to the SERT.
17154506	331	397	2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane	CHEMICAL	17154506T10
17154506	1132	1142	citalopram	CHEMICAL	17154506T11
17154506	1147	1162	methylphenidate	CHEMICAL	17154506T12
17154506	192	201	serotonin	CHEMICAL	17154506T13
17154506	56	140	carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes	CHEMICAL	17154506T14
17154506	461	519	human serotonin, dopamine, and norepinephrine transporters	GENE-N	17154506T15
17154506	521	525	SERT	GENE-Y	17154506T16
17154506	527	530	DAT	GENE-Y	17154506T17
17154506	536	539	NET	GENE-Y	17154506T18
17154506	622	626	SERT	GENE-Y	17154506T19
17154506	249	314	2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane	CHEMICAL	17154506T1
17154506	694	698	SERT	GENE-Y	17154506T20
17154506	708	711	DAT	GENE-Y	17154506T21
17154506	768	771	NET	GENE-Y	17154506T22
17154506	1027	1031	SERT	GENE-N	17154506T23
17154506	1238	1242	SERT	GENE-N	17154506T24
17154506	192	213	serotonin transporter	GENE-Y	17154506T25
17154506	399	406	mZBrENT	CHEMICAL	17154506T2
17154506	467	476	serotonin	CHEMICAL	17154506T3
17154506	478	486	dopamine	CHEMICAL	17154506T4
17154506	492	506	norepinephrine	CHEMICAL	17154506T5
17154506	856	863	halogen	CHEMICAL	17154506T6
17154506	915	918	11C	CHEMICAL	17154506T7
17154506	316	322	mZIENT	CHEMICAL	17154506T8
17154506	926	929	11C	CHEMICAL	17154506T9
17154506	CPR:9	17154506T7	17154506T23
17154506	CPR:9	17154506T9	17154506T23

17163232|t|Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects.
17163232|a|BACKGROUND: Hypertension treatment guidelines recommend combination therapy with diuretics and other antihypertensive agents, including angiotensin II type 1 (AT1) receptor antagonists. This trial investigated the possibility of pharmacokinetic interactions between the AT1 receptor antagonist olmesartan medoxomil and the thiazide diuretic hydrochlorothiazide in healthy subjects. METHODS: Twenty-four healthy normotensive adult male subjects underwent three consecutive 7-day treatment periods (A, B and C, respectively) during which they were randomised to receive: olmesartan medoxomil 20 mg once daily (regimen A), hydrochlorothiazide 25 mg once daily (regimen B), or olmesartan medoxomil 20 mg once daily plus hydrochlorothiazide 25 mg once daily (regimen C). Treatment periods were separated by washouts of 7-14 days. The primary pharmacokinetic parameters evaluated were: the area under the plasma concentration versus time curve at steady state (AUCss,tau), the maximum plasma concentration at steady state (Css,max), and the time at which Css,max occurred (tmax). RESULTS: Complete data sets from 17 subjects were available for pharmacokinetic analyses. Mean concentration versus time profiles were similar for monotherapy and combination treatment for both olmesartan (the active metabolite of olmesartan medoxomil) and hydrochlorothiazide. For olmesartan, comparison of monotherapy with combination therapy showed that for AUCss,tau and Css,max point estimates were close to unity, demonstrating bioequivalence. For hydrochlorothiazide, combination therapy resulted in decreases in AUCss,tau and Css,max of approximately 10% versus monotherapy; nevertheless, since 90% CIs were within the acceptance range, bioequivalence was proven. Median tmax values for olmesartan and hydrochlorothiazide for periods A, B and C were identical, indicating bioequivalence. Both olmesartan medoxomil and hydrochlorothiazide were well tolerated. CONCLUSION: These results show that there is little or no potential for a clinically relevant pharmacokinetic interaction between olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg, and therefore dosage adjustment should not be necessary when they are co-administered.
17163232	1999	2018	hydrochlorothiazide	CHEMICAL	17163232T10
17163232	2170	2190	olmesartan medoxomil	CHEMICAL	17163232T11
17163232	2201	2220	hydrochlorothiazide	CHEMICAL	17163232T12
17163232	393	413	olmesartan medoxomil	CHEMICAL	17163232T13
17163232	422	430	thiazide	CHEMICAL	17163232T14
17163232	440	459	hydrochlorothiazide	CHEMICAL	17163232T15
17163232	668	688	olmesartan medoxomil	CHEMICAL	17163232T16
17163232	719	738	hydrochlorothiazide	CHEMICAL	17163232T17
17163232	772	792	olmesartan medoxomil	CHEMICAL	17163232T18
17163232	815	834	hydrochlorothiazide	CHEMICAL	17163232T19
17163232	1367	1377	olmesartan	CHEMICAL	17163232T1
17163232	20	40	olmesartan medoxomil	CHEMICAL	17163232T20
17163232	46	65	hydrochlorothiazide	CHEMICAL	17163232T21
17163232	235	271	angiotensin II type 1 (AT1) receptor	GENE-Y	17163232T22
17163232	369	381	AT1 receptor	GENE-Y	17163232T23
17163232	1404	1424	olmesartan medoxomil	CHEMICAL	17163232T2
17163232	1430	1449	hydrochlorothiazide	CHEMICAL	17163232T3
17163232	1455	1465	olmesartan	CHEMICAL	17163232T4
17163232	235	249	angiotensin II	CHEMICAL	17163232T5
17163232	1627	1646	hydrochlorothiazide	CHEMICAL	17163232T6
17163232	1868	1878	olmesartan	CHEMICAL	17163232T7
17163232	1883	1902	hydrochlorothiazide	CHEMICAL	17163232T8
17163232	1974	1994	olmesartan medoxomil	CHEMICAL	17163232T9
17163232	CPR:6	17163232T13	17163232T23

17179482|t|Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
17179482|a|BACKGROUND: We previously found that S100P, a member of the S100 protein family, is expressed in more than 90% of pancreatic tumors and is associated with tumor growth and invasion. In the current study, we investigated the ability of the antiallergy drug, cromolyn, to block S100P function. METHODS: Interactions between cromolyn and S100P were investigated using a drug affinity column and by examining cromolyn's effects on coimmunoprecipitation of S100P and receptor for advanced glycation end-products (RAGE). The effects of cromolyn on cell growth, invasion, and nuclear factor-kappaB (NFkappaB) activity of pancreatic cancer cells with (BxPC-3 and MPanc-96) and without (Panc-1) endogenous S100P were investigated by cell proliferation assay, by cell invasion assay, and by luciferase reporter gene assay, respectively. The effects of cromolyn on tumor growth in vivo were investigated in three orthotopic models (n = 20 mice per model) by administration of cromolyn (5 mg/kg body weight, daily) with and without gemcitabine (125 mg/kg body weight, biweekly), the drug currently used to treat pancreatic cancer. Tumor growth was assayed by reporter gene expression. All statistical tests were two-sided. RESULTS: S100P was retained on a cromolyn affinity column. Cromolyn blocked the coimmunoprecipitation of S100P and RAGE. In vitro, cromolyn (100 microM) inhibited S100P-stimulated Panc-1 cell proliferation (S100P, mean = 0.93 U, versus S100P + cromolyn, mean = 0.56 U, difference = 0.37 U; 95% confidence interval [CI] = 0.24 to 0.49 U; P = .001, n = 3), invasion (S100P, mean = 58.0%, versus S100P + cromolyn, mean = 9.4%, difference = 48.6%; 95% CI = 38.8% to 58.8%; P<.001, n = 3), and NFkappaB activity (S100P, mean = 14,460, versus S100P + cromolyn, mean = 7360 photons/s, difference = 7100 photons/s; 95% CI = 3689 to 10 510 photons/s; P = .005, n = 3). In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous S100P (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of gemcitabine (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001). However, cromolyn had no effect on growth of tumors lacking S100P (Panc-1). CONCLUSION: Cromolyn binds S100P, prevents activation of RAGE, inhibits tumor growth, and increases the effectiveness of gemcitabine in experimental models.
17179482	1557	1562	S100P	GENE-Y	112194
17179482	1686	1691	S100P	GENE-Y	112194
17179482	1714	1719	S100P	GENE-Y	112194
17179482	1810	1818	NFkappaB	GENE-N	17179482T13
17179482	1829	1834	S100P	GENE-Y	112194
17179482	1858	1863	S100P	GENE-Y	112194
17179482	2060	2065	S100P	GENE-Y	112194
17179482	386	391	S100P	GENE-Y	112194
17179482	2952	2957	S100P	GENE-Y	112194
17179482	2995	3000	S100P	GENE-Y	112194
17179482	1130	1141	gemcitabine	CHEMICAL	17179482T1
17179482	445	450	S100P	GENE-Y	112194
17179482	147	152	S100P	GENE-Y	112194
17179482	562	567	S100P	GENE-Y	112194
17179482	679	700	nuclear factor-kappaB	GENE-N	17179482T23
17179482	702	710	NFkappaB	GENE-N	17179482T24
17179482	170	174	S100	GENE-N	17179482T25
17179482	807	812	S100P	GENE-Y	112194
17179482	22	27	S100P	GENE-Y	112194
17179482	2492	2503	gemcitabine	CHEMICAL	17179482T2
17179482	2513	2524	gemcitabine	CHEMICAL	17179482T3
17179482	2707	2718	gemcitabine	CHEMICAL	17179482T4
17179482	3089	3100	gemcitabine	CHEMICAL	17179482T5
17179482	1330	1335	S100P	GENE-Y	112194
17179482	1426	1431	S100P	GENE-Y	112194
17179482	1484	1489	S100P	GENE-Y	112194
17179482	1528	1533	S100P	GENE-Y	112194

17181859|t|Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk.
17181859|a|INTRODUCTION: The association between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk remains unclear. Inconsistencies in previously reported findings may be partly due to differences in expression of cyclooxygenase (COX)-2. We hypothesized that genetic polymorphisms (COX-2 .926, COX-2 .5209, and COX-2 .8473) may reduce overall breast cancer risk or risk for subtypes of breast cancer by modulating the inflammatory response and may interact with aspirin or any NSAID use. METHODS: We conducted a population-based, case-control study in which we genotyped 1,067 breast cancer cases and 1,110 control individuals included in the Long Island Breast Cancer Study Project. RESULTS: No major effects of the three COX-2 variant alleles on breast cancer risk were found. A total of eight distinct haplotypes and 18 diplotypes were observed in the population. Overall, no significant associations between COX-2 haplotypes/diplotypes and breast cancer risk were observed. Among women who used aspirin or any NSAID there was little evidence for an interaction with the at-risk COX-2 genotypes, with one exception. Among women with hormone receptor positive breast cancer, the reduced risk for any NSAID use was only evident among those who had at least one variant C allele of COX-2 .8473 (odds ratio = 0.7, 95% confidence interval = 0.5 to 1.0; P for the interaction = 0.02). There was no corresponding interaction for aspirin use, possibly because of limited power. CONCLUSION: These data provide modest evidence that the C allele of COX-2 .8473 may interact with NSAIDs to reduce risk for hormone receptor positive breast cancer.
17181859	29	45	cyclooxygenase-2	GENE-Y	17181859T10
17181859	1218	1223	COX-2	GENE-Y	17181859T1
17181859	1418	1423	COX-2	GENE-Y	17181859T2
17181859	1677	1682	COX-2	GENE-Y	17181859T3
17181859	350	372	cyclooxygenase (COX)-2	GENE-Y	17181859T4
17181859	418	423	COX-2	GENE-Y	17181859T5
17181859	430	435	COX-2	GENE-Y	17181859T6
17181859	447	452	COX-2	GENE-Y	17181859T7
17181859	859	864	COX-2	GENE-Y	17181859T8
17181859	1048	1053	COX-2	GENE-N	17181859T9

17194211|t|Biosynthesis of selenocysteine on its tRNA in eukaryotes.
17194211|a|Selenocysteine (Sec) is cotranslationally inserted into protein in response to UGA codons and is the 21st amino acid in the genetic code. However, the means by which Sec is synthesized in eukaryotes is not known. Herein, comparative genomics and experimental analyses revealed that the mammalian Sec synthase (SecS) is the previously identified pyridoxal phosphate-containing protein known as the soluble liver antigen. SecS required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec). Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS. By identifying the pathway of Sec biosynthesis in mammals, this study not only functionally characterized SecS but also assigned the function of the O-phosphoseryl-tRNA([Ser]Sec) kinase. In addition, we found that selenophosphate synthetase 2 could synthesize monoselenophosphate in vitro but selenophosphate synthetase 1 could not. Conservation of the overall pathway of Sec biosynthesis suggests that this pathway is also active in other eukaryotes and archaea that synthesize selenoproteins.
17194211	512	526	O-phosphoseryl	CHEMICAL	17194211T10
17194211	568	581	selenocysteyl	CHEMICAL	17194211T11
17194211	626	629	Sec	CHEMICAL	17194211T12
17194211	672	680	selenide	CHEMICAL	17194211T13
17194211	682	685	ATP	CHEMICAL	164
17194211	691	697	serine	CHEMICAL	17194211T15
17194211	720	725	seryl	CHEMICAL	17194211T16
17194211	743	757	O-phosphoseryl	CHEMICAL	17194211T17
17194211	781	796	selenophosphate	CHEMICAL	17194211T18
17194211	849	852	Sec	CHEMICAL	17194211T19
17194211	58	72	Selenocysteine	CHEMICAL	2250
17194211	968	982	O-phosphoseryl	CHEMICAL	17194211T20
17194211	1033	1048	selenophosphate	CHEMICAL	17194211T21
17194211	16	30	selenocysteine	CHEMICAL	17194211T22
17194211	1112	1140	selenophosphate synthetase 1	GENE-Y	17194211T23
17194211	1298	1312	selenoproteins	GENE-N	17194211T24
17194211	344	366	mammalian Sec synthase	GENE-Y	17194211T25
17194211	368	372	SecS	GENE-Y	17194211T26
17194211	455	476	soluble liver antigen	GENE-Y	17194211T27
17194211	478	482	SecS	GENE-Y	17194211T28
17194211	626	629	Sec	GENE-Y	17194211T29
17194211	1079	1098	monoselenophosphate	CHEMICAL	17194211T2
17194211	720	741	seryl-tRNA synthetase	GENE-Y	17194211T30
17194211	743	779	O-phosphoseryl-tRNA([Ser]Sec) kinase	GENE-Y	17194211T31
17194211	781	807	selenophosphate synthetase	GENE-N	17194211T32
17194211	813	817	SecS	GENE-Y	17194211T33
17194211	137	140	UGA	GENE-N	17194211T34
17194211	925	929	SecS	GENE-Y	17194211T35
17194211	968	1004	O-phosphoseryl-tRNA([Ser]Sec) kinase	GENE-Y	17194211T36
17194211	1033	1061	selenophosphate synthetase 2	GENE-Y	17194211T37
17194211	1112	1127	selenophosphate	CHEMICAL	17194211T3
17194211	164	174	amino acid	CHEMICAL	17194211T4
17194211	74	77	Sec	CHEMICAL	17194211T5
17194211	224	227	Sec	CHEMICAL	17194211T6
17194211	354	357	Sec	CHEMICAL	17194211T7
17194211	403	422	pyridoxal phosphate	CHEMICAL	17194211T8
17194211	492	507	selenophosphate	CHEMICAL	17194211T9
17194211	CPR:9	17194211T10	17194211T28
17194211	CPR:9	17194211T11	17194211T28
17194211	CPR:9	17194211T2	17194211T37
17194211	CPR:9	17194211T9	17194211T28

17194886|t|Effects of triflusal and aspirin in a rat model of cerebral ischemia.
17194886|a|BACKGROUND AND PURPOSE: Neuroinflammation plays a critical role in the pathogenesis of cerebral ischemia. Triflusal, a selective cyclooxygenase-2, and its active metabolite 3-hydroxy-4-trifluoromethylbenzoic acid may inhibit apoptosis and inflammation after cerebral ischemia. An in vivo model of cerebral ischemia was used to investigate the effects of triflusal and aspirin treatment on infarct volume, and inflammation after cerebral ischemia in the rat. METHODS: Male Wistar rats were subjected to a permanent right-sided middle cerebral artery occlusion. Rats received oral administration of either triflusal or aspirin. After 3 days after surgery, immunostaining was used to detect neuroinflammatory cells and molecules, and infarct volumes were measured. RESULTS: Both triflusal and aspirin at a dose of 30 mg/kg but not 10 mg/kg significantly reduced infarct volume compared with vehicle treatment. Middle cerebral artery occlusion resulted in increased astrocyte and heat shock protein-27 (Hsp27) immunostaining in the ipsilateral cortex. Triflusal (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of GFAP or Hsp27 immunostaining. Triflusal (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion. CONCLUSIONS: The results suggest that triflusal and aspirin appear to be equally neuroprotective against middle cerebral artery occlusion-induced cerebral ischemia. Therefore, strong rationale exists to continue the neuroprotective examination of triflusal in brain injury.
17194886	438	445	aspirin	CHEMICAL	17194886T10
17194886	674	683	triflusal	CHEMICAL	17194886T11
17194886	687	694	aspirin	CHEMICAL	17194886T12
17194886	846	855	triflusal	CHEMICAL	17194886T13
17194886	860	867	aspirin	CHEMICAL	17194886T14
17194886	11	20	triflusal	CHEMICAL	17194886T15
17194886	25	32	aspirin	CHEMICAL	17194886T16
17194886	1200	1204	GFAP	GENE-Y	108938
17194886	1208	1213	Hsp27	GENE-Y	64473
17194886	1302	1310	IL-Ibeta	GENE-Y	17194886T19
17194886	1118	1127	Triflusal	CHEMICAL	7584
17194886	1319	1341	nuclear factor kappa B	GENE-N	17194886T20
17194886	1345	1372	tumor necrosis factor-alpha	GENE-Y	17194886T21
17194886	199	215	cyclooxygenase-2	GENE-Y	17194886T22
17194886	1046	1067	heat shock protein-27	GENE-Y	17194886T23
17194886	1069	1074	Hsp27	GENE-Y	64473
17194886	176	185	Triflusal	CHEMICAL	7584
17194886	1142	1149	aspirin	CHEMICAL	17194886T3
17194886	1230	1239	Triflusal	CHEMICAL	7584
17194886	1478	1487	triflusal	CHEMICAL	17194886T5
17194886	1492	1499	aspirin	CHEMICAL	17194886T6
17194886	1687	1696	triflusal	CHEMICAL	17194886T7
17194886	243	282	3-hydroxy-4-trifluoromethylbenzoic acid	CHEMICAL	17194886T8
17194886	424	433	triflusal	CHEMICAL	17194886T9
17194886	CPR:4	7584	17194886T19

17203585|t|Differential expression of glycans in the hippocampus of rats trained on an inhibitory learning paradigm.
17203585|a|The glycan chains of glycoconjugates play important roles in cell-cell and cell-matrix interactions. In the CNS, previous studies on learning and memory suggest the importance of oligosaccharides attached to glycoconjugates in the modulation of synaptic connections. We studied the hippocampal glycan distribution of rats subject to an inhibitory avoidance task. The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose. Two groups of 10 animals were examined: non-trained (Control) and Trained rats. ECL, sWGA and GSL II were negative for both groups in all the hippocampal subfields studied. For both groups, VVL was negative in CA4 and granular cells of the Dentate Gyrus (DG) and LTL was negative in the CA4 subfield. Expression of alpha/beta GalNAc, alpha-fucose and GlcNAc in other hippocampal subflields was positive, with no differences between groups. However, expression of Man alpha-1,3 was significantly higher in the CA1, CA2, CA3, and CA4 subfields in the Trained group. On the other hand, expression of Gal beta-1,3 GalNAc was significantly low in CA4 and DG in the Trained group. In conclusion, the results here presented indicate that the exposure of rats to an associative behavioral paradigm related to declarative memory, involves some regulatory mechanism/s for the differential patterns of glycan expression.
17203585	1365	1382	alpha/beta GlcNAc	CHEMICAL	17203585T10
17203585	1432	1444	alpha-fucose	CHEMICAL	17203585T11
17203585	1772	1778	GalNAc	CHEMICAL	17203585T12
17203585	1780	1792	alpha-fucose	CHEMICAL	17203585T13
17203585	1797	1803	GlcNAc	CHEMICAL	17203585T14
17203585	1909	1922	Man alpha-1,3	CHEMICAL	17203585T15
17203585	2043	2062	Gal beta-1,3 GalNAc	CHEMICAL	17203585T16
17203585	579	611	alpha/beta N-acetylgalactosamine	CHEMICAL	17203585T17
17203585	613	630	alpha/beta GalNAc	CHEMICAL	17203585T18
17203585	677	694	mannose alpha-1,3	CHEMICAL	17203585T19
17203585	1108	1127	N-acetylglucosamine	CHEMICAL	17203585T1
17203585	696	709	Man alpha-1,3	CHEMICAL	17203585T20
17203585	740	779	galactose beta-1,3N-acetylgalactosamine	CHEMICAL	17203585T21
17203585	781	800	Gal beta-1,3 GalNAc	CHEMICAL	17203585T22
17203585	842	880	galactose beta-1,4 N-acetylglucosamine	CHEMICAL	17203585T23
17203585	882	901	Gal beta-1,4 GlcNAc	CHEMICAL	17203585T24
17203585	936	967	sialic acid alpha-2.6 galactose	CHEMICAL	17203585T25
17203585	969	985	SA alpha-2,6 Gal	CHEMICAL	17203585T26
17203585	1029	1050	sialic acid alpha-2,3	CHEMICAL	17203585T27
17203585	1052	1064	SA alpha-2,3	CHEMICAL	17203585T28
17203585	1277	1310	Griffonia simplicifolia lectin II	GENE-N	17203585T29
17203585	1142	1153	sialic acid	CHEMICAL	17203585T2
17203585	1312	1318	GSL II	GENE-N	17203585T30
17203585	1398	1425	Lotus tetragonolobus lectin	GENE-Y	17203585T31
17203585	1427	1430	LTL	GENE-Y	17203585T32
17203585	1526	1529	ECL	GENE-N	17203585T33
17203585	1531	1535	sWGA	GENE-N	17203585T34
17203585	1540	1546	GSL II	GENE-N	17203585T35
17203585	511	517	lectin	GENE-N	17203585T36
17203585	539	559	Vicia villosa lectin	GENE-N	17203585T37
17203585	561	564	VVL	GENE-N	17203585T38
17203585	633	657	Galanthus nivalus lectin	GENE-Y	17203585T39
17203585	1155	1161	GlcNAc	CHEMICAL	17203585T3
17203585	659	662	GNL	GENE-Y	17203585T40
17203585	712	729	Peanut agglutinin	GENE-Y	17203585T41
17203585	731	734	PNA	GENE-Y	17203585T42
17203585	803	831	Erythrina cristagalli lectin	GENE-Y	17203585T43
17203585	833	836	ECL	GENE-Y	17203585T44
17203585	904	925	Sambucus nigra lectin	GENE-Y	17203585T45
17203585	927	930	SNA	GENE-Y	17203585T46
17203585	988	1015	Maackia amurensis lectin II	GENE-N	17203585T47
17203585	1017	1023	MAL II	GENE-N	17203585T48
17203585	1067	1088	Wheat germ agglutinin	GENE-N	17203585T49
17203585	1165	1167	SA	CHEMICAL	252
17203585	1090	1093	WGA	GENE-N	17203585T50
17203585	1207	1226	N-acetylglucosamine	CHEMICAL	17203585T5
17203585	1235	1246	sialic acid	CHEMICAL	17203585T6
17203585	1257	1263	GlcNAc	CHEMICAL	17203585T7
17203585	1272	1274	SA	CHEMICAL	252
17203585	1333	1363	alpha/beta N-acetylglucosamine	CHEMICAL	17203585T9

17207582|t|Glutamate stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.
17207582|a|The glutamate receptor interacting protein 1 (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins. Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures. Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin. The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist. EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented GRIP1 degradation. Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons. Our results suggest that glutamate induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.
17207582	639	644	MG132	CHEMICAL	9567
17207582	783	789	MK-801	CHEMICAL	17207582T11
17207582	794	814	N-methyl-d-aspartate	CHEMICAL	17207582T12
17207582	816	820	NMDA	CHEMICAL	1209
17207582	854	890	6-cyano-7-nitroquinoxaline-2,3-dione	CHEMICAL	17207582T14
17207582	892	896	CNQX	CHEMICAL	17207582T15
17207582	902	906	AMPA	CHEMICAL	17207582T16
17207582	928	932	EGTA	CHEMICAL	17207582T17
17207582	937	1003	1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis	CHEMICAL	17207582T18
17207582	1005	1010	BAPTA	CHEMICAL	17207582T19
17207582	1306	1315	glutamate	CHEMICAL	17207582T1
17207582	1017	1021	Ca2+	CHEMICAL	17207582T20
17207582	1041	1051	nifedipine	CHEMICAL	1103
17207582	1063	1067	Ca2+	CHEMICAL	17207582T22
17207582	1127	1132	MG132	CHEMICAL	9567
17207582	1143	1152	glutamate	CHEMICAL	17207582T24
17207582	0	9	Glutamate	CHEMICAL	17207582T25
17207582	21	30	glutamate	CHEMICAL	17207582T26
17207582	1195	1200	GluR2	GENE-Y	17207582T27
17207582	1219	1224	GRIP1	GENE-Y	116995
17207582	1241	1246	GRIP1	GENE-Y	116995
17207582	265	269	AMPA	CHEMICAL	17207582T2
17207582	1263	1268	GluR2	GENE-Y	17207582T30
17207582	1324	1329	GRIP1	GENE-Y	116995
17207582	265	279	AMPA receptors	GENE-N	17207582T32
17207582	1345	1355	proteasome	GENE-N	17207582T33
17207582	1367	1380	NMDA receptor	GENE-N	17207582T34
17207582	1403	1408	GRIP1	GENE-Y	116995
17207582	1462	1467	GluR2	GENE-Y	17207582T36
17207582	397	402	GRIP1	GENE-Y	116995
17207582	439	447	(GluR) 1	GENE-Y	17207582T38
17207582	449	454	GluR2	GENE-Y	17207582T39
17207582	1367	1371	NMDA	CHEMICAL	1209
17207582	459	494	protein interacting with C kinase 1	GENE-Y	17207582T40
17207582	496	501	PICK1	GENE-Y	114849|60721
17207582	563	568	GRIP1	GENE-Y	116995
17207582	150	190	glutamate receptor interacting protein 1	GENE-Y	17207582T43
17207582	192	197	GRIP1	GENE-Y	116995
17207582	649	659	proteasome	GENE-N	17207582T45
17207582	691	695	K48R	GENE-N	17207582T46
17207582	696	705	ubiquitin	GENE-N	17207582T47
17207582	735	744	ubiquitin	GENE-N	17207582T48
17207582	750	755	GRIP1	GENE-Y	116995
17207582	1381	1385	Ca2+	CHEMICAL	17207582T4
17207582	794	830	N-methyl-d-aspartate (NMDA) receptor	GENE-N	17207582T50
17207582	902	915	AMPA receptor	GENE-N	17207582T51
17207582	1056	1075	L-type Ca2+ channel	GENE-N	17207582T52
17207582	1095	1100	GRIP1	GENE-Y	116995
17207582	139	144	GluR2	GENE-Y	17207582T54
17207582	21	61	glutamate receptor interacting protein 1	GENE-Y	17207582T55
17207582	77	86	ubiquitin	GENE-N	17207582T56
17207582	87	97	proteasome	GENE-N	17207582T57
17207582	329	338	glutamate	CHEMICAL	17207582T5
17207582	420	429	glutamate	CHEMICAL	17207582T6
17207582	150	159	glutamate	CHEMICAL	17207582T7
17207582	572	581	glutamate	CHEMICAL	17207582T8
17207582	597	637	carbobenzoxyl-leucinyl-leucinyl-leucinal	CHEMICAL	17207582T9
17207582	CPR:3	17207582T11	116995
17207582	CPR:3	17207582T17	116995
17207582	CPR:3	17207582T18	116995
17207582	CPR:3	17207582T19	116995
17207582	CPR:4	9567	17207582T45
17207582	CPR:4	17207582T1	116995
17207582	CPR:4	17207582T1	116995
17207582	CPR:4	1103	17207582T52
17207582	CPR:4	17207582T24	17207582T27
17207582	CPR:4	17207582T25	17207582T55
17207582	CPR:4	17207582T5	116995
17207582	CPR:4	17207582T8	116995
17207582	CPR:4	17207582T9	17207582T45
17207582	CPR:6	17207582T11	17207582T50
17207582	CPR:6	17207582T14	17207582T51
17207582	CPR:6	17207582T15	17207582T51

17207992|t|Transgenic expression of the human Vitamin D receptor (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption.
17207992|a|1,25(OH)(2)D(3) regulates calcium homeostasis through its actions in the intestine, bone, and kidney. These actions are mediated through the VDR. To determine if VDR's actions in the proximal small intestine can sufficiently restore calcium homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of mVDR-null mice by using the adenosine deaminase enhancer (hVDR+/mVDR-null). Unlike wild-type mice, hVDR+/mVDR-null mice express hVDR and VDR target genes only in the proximal small intestine. Despite having functional hVDR in the proximal small intestine, hVDR+/mVDR-null mice were hypocalcaemic when fed a normal rodent diet at weaning, like mVDR-null mice fed the same diet. The hypocalcemia in these mice is prevented if they are given the rescue diet before weaning. However, when 90-day-old rachitic mice were fed a rescue diet, serum calcium improved in hVDR+/mVDR-null mice, but not in mVDR-null mice. In conclusion, transgenic hVDR in the proximal small intestine of hVDR+/mVDR-null mice was transcriptionally active and regulated calcium absorption, but VDR actions elsewhere in the intestine are probably necessary to support adequate calcium homeostasis. In addition, hVDR+/mVDR-null mice responded better to the late rescue diet suggesting that expression of VDR in the proximal small intestine protected the calcium absorbing machinery from age-dependent decline.
17207992	35	44	Vitamin D	CHEMICAL	17207992T10
17207992	1159	1163	hVDR	GENE-Y	17207992T11
17207992	1165	1169	mVDR	GENE-Y	17207992T12
17207992	1247	1250	VDR	GENE-Y	113264|676260
17207992	1363	1367	hVDR	GENE-Y	17207992T14
17207992	1369	1373	mVDR	GENE-Y	17207992T15
17207992	1455	1458	VDR	GENE-Y	113264|676260
17207992	295	298	VDR	GENE-Y	113264|676260
17207992	316	319	VDR	GENE-Y	113264|676260
17207992	448	452	hVDR	GENE-Y	17207992T19
17207992	154	169	1,25(OH)(2)D(3)	CHEMICAL	17207992T1
17207992	484	488	mVDR	GENE-Y	17207992T20
17207992	512	540	adenosine deaminase enhancer	GENE-N	17207992T21
17207992	542	546	hVDR	GENE-Y	17207992T22
17207992	548	552	mVDR	GENE-Y	17207992T23
17207992	583	587	hVDR	GENE-Y	17207992T24
17207992	589	593	mVDR	GENE-Y	17207992T25
17207992	612	616	hVDR	GENE-Y	17207992T26
17207992	621	624	VDR	GENE-Y	113264|676260
17207992	702	706	hVDR	GENE-Y	17207992T28
17207992	740	744	hVDR	GENE-Y	17207992T29
17207992	1223	1230	calcium	CHEMICAL	17207992T2
17207992	746	750	mVDR	GENE-Y	17207992T30
17207992	827	831	mVDR	GENE-Y	17207992T31
17207992	1044	1048	hVDR	GENE-Y	17207992T32
17207992	1050	1054	mVDR	GENE-Y	17207992T33
17207992	1077	1081	mVDR	GENE-Y	17207992T34
17207992	1119	1123	hVDR	GENE-Y	17207992T35
17207992	29	53	human Vitamin D receptor	GENE-Y	17207992T36
17207992	55	59	hVDR	GENE-Y	17207992T37
17207992	80	83	VDR	GENE-Y	113264|676260
17207992	1329	1336	calcium	CHEMICAL	17207992T3
17207992	1505	1512	calcium	CHEMICAL	17207992T4
17207992	387	394	calcium	CHEMICAL	17207992T5
17207992	180	187	calcium	CHEMICAL	17207992T6
17207992	512	521	adenosine	CHEMICAL	17207992T7
17207992	1024	1031	calcium	CHEMICAL	17207992T8
17207992	134	141	calcium	CHEMICAL	17207992T9

17223000|t|The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.
17223000|a|OBJECTIVES: Mucin gene expression and mucin production are markedly increased in inflammatory airway disorders such as asthma, chronic bronchitis and rhinosinusitis. Cytokines, lipopolysaccharides and other inflammatory mediators such as prostaglandin and leukotriene are related to the secretion and production of mucin. However, the relationship of leukotrienes with mucin genes expression is not clear. The aim of this study is to evaluate MUC2/5AC gene expression and mucin secretion by the leukotriene receptor in human airway epithelial cells. METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells. The mRNA levels of MUC2/5AC and the amount of mucin were determined by reverse transcription-polymerase chain reaction (RT-PCR) and immunoassay. RESULTS: Leukotriene D(4) upregulated MUC2/5AC gene expression and mucin secretion in a dose dependent pattern. Pranlukast hydrate (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and mucin secretion. CONCLUSION: These results suggest that the leukotriene receptor system is one of the mechanisms related to MUC2/5AC gene expression and mucin secretion in the human airway epithelium.
17223000	764	775	leukotriene	CHEMICAL	17223000T10
17223000	797	815	pranlukast hydrate	CHEMICAL	17223000T11
17223000	817	825	ONO-1078	CHEMICAL	17223000T12
17223000	1104	1120	Leukotriene D(4)	CHEMICAL	17223000T13
17223000	29	40	leukotriene	CHEMICAL	17223000T14
17223000	64	78	leukotriene D4	CHEMICAL	17223000T15
17223000	1292	1300	MUC2/5AC	GENE-N	17223000T16
17223000	1321	1326	mucin	GENE-N	17223000T17
17223000	1381	1401	leukotriene receptor	GENE-N	17223000T18
17223000	178	183	Mucin	GENE-N	17223000T19
17223000	1207	1225	Pranlukast hydrate	CHEMICAL	17223000T1
17223000	1445	1453	MUC2/5AC	GENE-N	17223000T20
17223000	1474	1479	mucin	GENE-N	17223000T21
17223000	332	341	Cytokines	GENE-N	17223000T22
17223000	481	486	mucin	GENE-N	17223000T23
17223000	535	540	mucin	GENE-N	17223000T24
17223000	204	209	mucin	GENE-N	17223000T25
17223000	609	617	MUC2/5AC	GENE-N	17223000T26
17223000	638	643	mucin	GENE-N	17223000T27
17223000	661	681	leukotriene receptor	GENE-N	17223000T28
17223000	764	784	leukotriene receptor	GENE-N	17223000T29
17223000	1227	1235	ONO-1078	CHEMICAL	17223000T2
17223000	848	856	MUC2/5AC	GENE-N	17223000T30
17223000	877	882	mucin	GENE-N	17223000T31
17223000	969	977	MUC2/5AC	GENE-N	17223000T32
17223000	996	1001	mucin	GENE-N	17223000T33
17223000	1133	1141	MUC2/5AC	GENE-N	17223000T34
17223000	1162	1167	mucin	GENE-N	17223000T35
17223000	116	121	mucin	GENE-N	17223000T36
17223000	29	49	leukotriene receptor	GENE-N	17223000T37
17223000	87	95	MUC2/5AC	GENE-N	17223000T38
17223000	1267	1283	leukotriene D(4)	CHEMICAL	17223000T3
17223000	1381	1392	leukotriene	CHEMICAL	17223000T4
17223000	404	417	prostaglandin	CHEMICAL	17223000T5
17223000	422	433	leukotriene	CHEMICAL	17223000T6
17223000	517	529	leukotrienes	CHEMICAL	17223000T7
17223000	661	672	leukotriene	CHEMICAL	17223000T8
17223000	739	755	leukotriene D(4)	CHEMICAL	17223000T9
17223000	CPR:3	17223000T13	17223000T34
17223000	CPR:3	17223000T13	17223000T35
17223000	CPR:3	17223000T15	17223000T36
17223000	CPR:3	17223000T15	17223000T38
17223000	CPR:3	17223000T3	17223000T16
17223000	CPR:3	17223000T3	17223000T17
17223000	CPR:4	17223000T1	17223000T16
17223000	CPR:4	17223000T1	17223000T17
17223000	CPR:4	17223000T2	17223000T16
17223000	CPR:4	17223000T2	17223000T17
17223000	CPR:6	17223000T11	17223000T29
17223000	CPR:6	17223000T12	17223000T29

17224860|t|Effect of isolated isoflavone supplementation on ABCA1-dependent cholesterol efflux potential in postmenopausal women.
17224860|a|OBJECTIVE: Isoflavones may display beneficial health effects in postmenopausal women. We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- (ABCA1), dependent cholesterol efflux from macrophages. In addition, various serum lipid and lipoprotein parameters were investigated. Furthermore, we separately assessed equol-producing and non-equol-producing women. DESIGN: Postmenopausal women (n=56) were treated with either isoflavone or placebo tablets for 3 months in a crossover design, separated by a 2-month washout period. Fifteen women were classified as equol producers, and 15 women were classified as non-equol producers. Serum samples were collected before and after each treatment period. [H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and ABCA1-dependent cholesterol efflux and serum lipid and lipoprotein levels were assessed. RESULTS: Serum promoted 3.1%+/-1.1% and 3.2%+/-1.1% cholesterol efflux from macrophages after isoflavone and placebo treatment, respectively. Thus, isoflavone supplementation did not affect ABCA1-dependent cholesterol efflux to serum. However, as a novel finding, isoflavone treatment increased a subclass of high-density lipoprotein, the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations. ABCA1-facilitated cholesterol efflux and lipid parameters did not differ between equol-producing and non-equol-producing women. CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.
17224860	1716	1721	equol	CHEMICAL	17224860T10
17224860	1785	1795	isoflavone	CHEMICAL	17224860T11
17224860	1838	1849	cholesterol	CHEMICAL	17224860T12
17224860	319	330	cholesterol	CHEMICAL	17224860T13
17224860	357	379	adenosine triphosphate	CHEMICAL	17224860T14
17224860	420	431	cholesterol	CHEMICAL	17224860T15
17224860	680	690	isoflavone	CHEMICAL	17224860T16
17224860	957	972	[H]-Cholesterol	CHEMICAL	17224860T17
17224860	1095	1106	cholesterol	CHEMICAL	17224860T18
17224860	19	29	isoflavone	CHEMICAL	17224860T19
17224860	1220	1231	cholesterol	CHEMICAL	17224860T1
17224860	65	76	cholesterol	CHEMICAL	17224860T20
17224860	1134	1145	lipoprotein	GENE-N	17224860T21
17224860	1358	1363	ABCA1	GENE-Y	106537|4105
17224860	1477	1501	high-density lipoprotein	GENE-N	17224860T23
17224860	1507	1540	pre-beta high-density lipoprotein	GENE-N	17224860T24
17224860	1611	1616	ABCA1	GENE-Y	106537|4105
17224860	1822	1827	ABCA1	GENE-Y	106537|4105
17224860	1910	1943	pre-beta high-density lipoprotein	GENE-N	17224860T27
17224860	357	399	adenosine triphosphate-binding cassette A1	GENE-Y	17224860T28
17224860	402	407	ABCA1	GENE-Y	106537|4105
17224860	130	141	Isoflavones	CHEMICAL	17224860T2
17224860	494	505	lipoprotein	GENE-N	17224860T30
17224860	1021	1026	ABCA1	GENE-Y	106537|4105
17224860	1079	1084	ABCA1	GENE-Y	106537|4105
17224860	49	54	ABCA1	GENE-Y	106537|4105
17224860	1262	1272	isoflavone	CHEMICAL	17224860T3
17224860	1316	1326	isoflavone	CHEMICAL	17224860T4
17224860	1374	1385	cholesterol	CHEMICAL	17224860T5
17224860	1432	1442	isoflavone	CHEMICAL	17224860T6
17224860	253	263	isoflavone	CHEMICAL	17224860T7
17224860	1629	1640	cholesterol	CHEMICAL	17224860T8
17224860	1692	1697	equol	CHEMICAL	17224860T9
17224860	CPR:3	17224860T11	17224860T27
17224860	CPR:3	17224860T6	17224860T23
17224860	CPR:3	17224860T6	17224860T24
17224860	CPR:9	17224860T12	106537|4105
17224860	CPR:9	17224860T15	17224860T28
17224860	CPR:9	17224860T15	106537|4105
17224860	CPR:9	17224860T18	106537|4105
17224860	CPR:9	17224860T5	106537|4105
17224860	CPR:9	17224860T8	106537|4105

17229632|t|The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
17229632|a|BACKGROUND AND OBJECTIVES: Activated tyrosine kinases are implicated in the pathogenesis of chronic and acute leukemia, and represent attractive targets for therapy. Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families. We investigated the efficacy of sorafenib at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies. DESIGN AND METHODS: We tested the effect of sorafenib on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant. The direct effect of sorafenib on the activity of these kinases and their downstream signaling was tested using phospho-specific antibodies. RESULTS: We show that sorafenib is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors. Sorafenib induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing FLT3 with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines. The imatinib-resistant KIT(D816V) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib. INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of sorafenib for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and FLT3.
17229632	476	484	tyrosine	CHEMICAL	17229632T10
17229632	170	178	tyrosine	CHEMICAL	17229632T11
17229632	648	657	sorafenib	CHEMICAL	17229632T12
17229632	696	704	tyrosine	CHEMICAL	17229632T13
17229632	849	858	sorafenib	CHEMICAL	17229632T14
17229632	1048	1057	sorafenib	CHEMICAL	17229632T15
17229632	15	24	sorafenib	CHEMICAL	17229632T16
17229632	1225	1229	ETV6	GENE-Y	108421
17229632	1230	1239	PDGFRbeta	GENE-Y	17229632T18
17229632	1244	1248	FLT3	GENE-Y	108610
17229632	1139	1146	phospho	CHEMICAL	17229632T1
17229632	1331	1335	FLT3	GENE-Y	108610
17229632	1476	1480	FLT3	GENE-Y	108610
17229632	1621	1624	KIT	GENE-Y	110015
17229632	1625	1630	D816V	GENE-N	17229632T23
17229632	1883	1892	PDGFRbeta	GENE-Y	17229632T24
17229632	1897	1901	FLT3	GENE-Y	108610
17229632	351	356	B-RAF	GENE-Y	17229632T26
17229632	467	492	receptor tyrosine kinases	GENE-N	17229632T27
17229632	502	541	platelet-derived growth factor receptor	GENE-Y	17229632T28
17229632	170	186	tyrosine kinases	GENE-N	17229632T29
17229632	1190	1199	sorafenib	CHEMICAL	17229632T2
17229632	543	548	PDGFR	GENE-Y	17229632T30
17229632	554	597	vascular endothelial growth factor receptor	GENE-N	17229632T31
17229632	599	604	VEGFR	GENE-N	17229632T32
17229632	687	712	receptor tyrosine kinases	GENE-N	17229632T33
17229632	713	722	PDGFRbeta	GENE-Y	17229632T34
17229632	724	727	KIT	GENE-Y	110015
17229632	733	737	FLT3	GENE-Y	108610
17229632	918	922	ETV6	GENE-Y	108421
17229632	923	932	PDGFRbeta	GENE-Y	17229632T38
17229632	934	938	FLT3	GENE-Y	108610
17229632	1348	1357	Sorafenib	CHEMICAL	390
17229632	978	983	D835Y	GENE-N	17229632T40
17229632	1008	1011	KIT	GENE-Y	110015
17229632	1012	1017	D816V	GENE-N	17229632T42
17229632	1083	1090	kinases	GENE-N	17229632T43
17229632	46	55	PDGFRbeta	GENE-Y	17229632T44
17229632	60	64	FLT3	GENE-Y	108610
17229632	1602	1610	imatinib	CHEMICAL	17229632T4
17229632	1708	1717	sorafenib	CHEMICAL	17229632T5
17229632	299	308	Sorafenib	CHEMICAL	390
17229632	1801	1810	sorafenib	CHEMICAL	17229632T7
17229632	310	320	BAY43-9006	CHEMICAL	17229632T8
17229632	322	329	Nexavar	CHEMICAL	17229632T9
17229632	CPR:4	17229632T12	17229632T33
17229632	CPR:4	17229632T12	17229632T34
17229632	CPR:4	17229632T12	110015
17229632	CPR:4	17229632T12	108610
17229632	CPR:4	17229632T16	17229632T44
17229632	CPR:4	17229632T16	108610
17229632	CPR:4	17229632T2	108421
17229632	CPR:4	17229632T2	17229632T18
17229632	CPR:4	17229632T2	108610
17229632	CPR:4	17229632T2	108610
17229632	CPR:4	390	108610
17229632	CPR:4	390	17229632T26
17229632	CPR:4	17229632T7	17229632T24
17229632	CPR:4	17229632T7	108610
17229632	CPR:4	17229632T8	17229632T26
17229632	CPR:4	17229632T9	17229632T26

17251323|t|Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium.
17251323|a|Mammary epithelia produce an isotonic, low-Na(+) fluid that is rich in nutrients. Mechanisms that account for the low electrolyte concentration have not been elucidated, although amiloride-sensitive ion transport has been reported in some situations. We hypothesized that corticosteroid exposure modulates epithelial Na(+) channel (ENaC) expression and/or activity in bovine mammary epithelial cells. BME-UV cells were grown to confluent monolayers on permeable supports with a standard basolateral medium and apical medium of low-electrolyte, high-lactose composition that resembles the ionic composition of milk. Ion transport was assessed in modified Ussing flux chambers. Exposure to glucocorticoids (dexamethasone, cortisol, or prednisolone), but not aldosterone, increased short-circuit current (I(sc)), a sensitive measure of net ion transport, whereas apical exposure to amiloride or benzamil reduced corticosteroid-induced I(sc) close to basal levels. Quantitative RT-PCR indicated a glucocorticoid-induced increase in mRNA for beta- and gamma-ENaC, whereas alpha-ENaC mRNA expression was only mildly affected. Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA. We conclude that Na(+) movement across mammary epithelia is modulated by corticosteroids via a glucocorticoid receptor-mediated mechanism that regulates the expression of the beta- and gamma-subunits of ENaC. ENaC expression and activity could account for the low Na(+) concentration that is typical of milk.
17251323	779	792	dexamethasone	CHEMICAL	17251323T10
17251323	794	802	cortisol	CHEMICAL	17251323T11
17251323	807	819	prednisolone	CHEMICAL	17251323T12
17251323	830	841	aldosterone	CHEMICAL	17251323T13
17251323	953	962	amiloride	CHEMICAL	17251323T14
17251323	966	974	benzamil	CHEMICAL	17251323T15
17251323	1111	1131	beta- and gamma-ENaC	GENE-N	17251323T16
17251323	1141	1151	alpha-ENaC	GENE-Y	17251323T17
17251323	1222	1245	glucocorticoid receptor	GENE-Y	17251323T18
17251323	1285	1311	mineralocorticoid receptor	GENE-N	17251323T19
17251323	1206	1218	mifepristone	CHEMICAL	17251323T1
17251323	1433	1453	beta- and gamma-ENaC	GENE-N	17251323T20
17251323	1555	1578	glucocorticoid receptor	GENE-Y	17251323T21
17251323	1635	1667	beta- and gamma-subunits of ENaC	GENE-N	17251323T22
17251323	1669	1673	ENaC	GENE-N	17251323T23
17251323	380	404	epithelial Na(+) channel	GENE-N	17251323T24
17251323	406	410	ENaC	GENE-N	17251323T25
17251323	26	30	ENaC	GENE-N	17251323T26
17251323	1267	1281	spironolactone	CHEMICAL	17251323T2
17251323	1380	1389	amiloride	CHEMICAL	17251323T3
17251323	1477	1482	Na(+)	CHEMICAL	17251323T4
17251323	1724	1729	Na(+)	CHEMICAL	17251323T5
17251323	253	262	amiloride	CHEMICAL	17251323T6
17251323	391	396	Na(+)	CHEMICAL	17251323T7
17251323	117	122	Na(+)	CHEMICAL	17251323T8
17251323	623	630	lactose	CHEMICAL	17251323T9
17251323	CPR:6	17251323T1	17251323T18
17251323	CPR:6	17251323T2	17251323T19

17259377|t|Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy.
17259377|a|It has been previously reported that aspirin inhibited the development of diabetic retinopathy in diabetic animals, raising the possibility that anti-inflammatory drugs may have beneficial effects on diabetic retinopathy. To further explore this, we compared effects of oral consumption of three different salicylate-based drugs (aspirin, sodium salicylate, and sulfasalazine) on the development of early stages of diabetic retinopathy in rats. These three drugs differ in their ability to inhibit cyclooxygenase but share an ability to inhibit nuclear factor-kappaB (NF-kappaB). Diabetes of 9-10 months duration significantly increased the number of TUNEL (transferase-mediated dUTP nick-end labeling)-positive capillary cells and acellular (degenerate) capillaries in the retinal vasculature, and all three salicylate-based drugs inhibited this cell death and formation of acellular capillaries without altering the severity of hyperglycemia. In short-term diabetes (2-4 months), all three salicylates inhibited the diabetes-induced loss of neuronal cells from the ganglion cell layer. Oral aspirin (as a representative of the salicylate family) inhibited diabetes-induced increase in NF-kappaB DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina. All three salicylates inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections. Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate. Salicylates, in doses administrated in our experiments, inhibited NF-kappaB and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.
17259377	430	447	sodium salicylate	CHEMICAL	17259377T10
17259377	453	466	sulfasalazine	CHEMICAL	17259377T11
17259377	128	135	aspirin	CHEMICAL	17259377T12
17259377	900	910	salicylate	CHEMICAL	17259377T13
17259377	1083	1094	salicylates	CHEMICAL	17259377T14
17259377	0	10	Salicylate	CHEMICAL	17259377T15
17259377	1278	1287	NF-kappaB	GENE-N	17259377T16
17259377	1497	1500	p50	GENE-Y	17259377T17
17259377	1515	1524	NF-kappaB	GENE-N	17259377T18
17259377	1627	1630	p50	GENE-Y	17259377T19
17259377	1184	1191	aspirin	CHEMICAL	17259377T1
17259377	1635	1638	p65	GENE-Y	17259377T20
17259377	1904	1913	NF-kappaB	GENE-N	17259377T21
17259377	1958	1991	intracellular adhesion molecule-1	GENE-Y	17259377T22
17259377	1993	2024	inducible nitric oxide synthase	GENE-Y	17259377T23
17259377	2030	2046	cyclooxygenase-2	GENE-Y	17259377T24
17259377	2138	2146	NF-kappa	GENE-N	17259377T25
17259377	589	603	cyclooxygenase	GENE-N	17259377T26
17259377	636	657	nuclear factor-kappaB	GENE-N	17259377T27
17259377	659	668	NF-kappaB	GENE-N	17259377T28
17259377	1220	1230	salicylate	CHEMICAL	17259377T2
17259377	1437	1448	salicylates	CHEMICAL	17259377T3
17259377	1738	1751	Sulfasalazine	CHEMICAL	785
17259377	1785	1796	salicylates	CHEMICAL	17259377T5
17259377	2003	2015	nitric oxide	CHEMICAL	17259377T6
17259377	2072	2083	Salicylates	CHEMICAL	17259377T7
17259377	397	407	salicylate	CHEMICAL	17259377T8
17259377	421	428	aspirin	CHEMICAL	17259377T9
17259377	CPR:4	17259377T1	17259377T16
17259377	CPR:4	17259377T2	17259377T16
17259377	CPR:4	17259377T3	17259377T17
17259377	CPR:4	17259377T3	17259377T18
17259377	CPR:4	17259377T3	17259377T19
17259377	CPR:4	17259377T3	17259377T20
17259377	CPR:4	785	17259377T21
17259377	CPR:4	785	17259377T22
17259377	CPR:4	785	17259377T23
17259377	CPR:4	785	17259377T24
17259377	CPR:4	17259377T5	17259377T21
17259377	CPR:4	17259377T7	17259377T25

1727721|t|Localization of an 11 beta hydroxysteroid dehydrogenase activity to the distal nephron. Evidence for the existence of two species of dehydrogenase in the rat kidney.
1727721|a|An 11 beta hydroxysteroid dehydrogenase (11 beta HSD) activity has been localized in the rat kidney by a histochemical technique which links steroid metabolism with the production of a color reaction. Oxidation of 11 beta-hydroxyandrostenedione was observed in cortical distal convoluted tubules and in medullary collecting ducts. Carbenoxolone abolished staining, no reaction was obtained with androstenedione hydroxylated at the 17 or 19 position, and oxidation of 11 beta-hydroxyandrostenedione was nicotinamide-adenine dinucleotide (NAD) dependent. These results demonstrate the presence of a dehydrogenase activity separate from the nicotinamide-adenine dinucleotide phosphate (NADP)-dependent 11 beta hydroxysteroid dehydrogenase recently purified and cloned from rat liver. We have named this activity 11 beta HSD2 to distinguish it from the NADP-dependent 11 beta HSD. Histological studies showed that 11 beta HSD2 activity does not correlate with the immunocytochemical localization of the previously defined 11 beta HSD enzyme, but rather the 11 beta HSD2 activity is localized in the distal tubules of the rat kidney. In this respect 11 beta HSD2 colocalizes with the mineralocorticoid receptor. No reaction product was obtained using cortisol or corticosterone as substrate with either NAD or NADP as cofactor. Furthermore incubation of tissue sections with 11 beta androstenedione in the presence of deoxycorticosterone completely inhibited cytochemical staining. We interpret these results as evidence of 20 reductase activity which uses the reduced cofactor at the expense of the color reaction. These results support the crucial role played by an 11 beta hydroxysteroid dehydrogenase in the local protection of type I receptors in mineralocorticoid selective tissues.
1727721	169	191	11 beta hydroxysteroid	CHEMICAL	1727721T10
1727721	497	510	Carbenoxolone	CHEMICAL	2235
1727721	561	576	androstenedione	CHEMICAL	1727721T12
1727721	633	663	11 beta-hydroxyandrostenedione	CHEMICAL	1727721T13
1727721	668	701	nicotinamide-adenine dinucleotide	CHEMICAL	1727721T14
1727721	703	706	NAD	CHEMICAL	1727721T15
1727721	804	847	nicotinamide-adenine dinucleotide phosphate	CHEMICAL	1727721T16
1727721	849	853	NADP	CHEMICAL	1727721T17
1727721	865	887	11 beta hydroxysteroid	CHEMICAL	1727721T18
1727721	1015	1019	NADP	CHEMICAL	1727721T19
1727721	1412	1420	cortisol	CHEMICAL	1727721T1
1727721	19	41	11 beta hydroxysteroid	CHEMICAL	1727721T20
1727721	1184	1195	11 beta HSD	GENE-Y	1727721T21
1727721	1219	1231	11 beta HSD2	GENE-Y	1727721T22
1727721	1311	1323	11 beta HSD2	GENE-Y	1727721T23
1727721	1345	1371	mineralocorticoid receptor	GENE-Y	1727721T24
1727721	1685	1697	20 reductase	GENE-N	1727721T25
1727721	1829	1865	11 beta hydroxysteroid dehydrogenase	GENE-Y	1727721T26
1727721	169	205	11 beta hydroxysteroid dehydrogenase	GENE-Y	1727721T27
1727721	207	218	11 beta HSD	GENE-Y	1727721T28
1727721	763	776	dehydrogenase	GENE-N	1727721T29
1727721	1424	1438	corticosterone	CHEMICAL	1727721T2
1727721	865	901	11 beta hydroxysteroid dehydrogenase	GENE-Y	1727721T30
1727721	975	987	11 beta HSD2	GENE-Y	1727721T31
1727721	1030	1041	11 beta HSD	GENE-Y	1727721T32
1727721	1076	1088	11 beta HSD2	GENE-Y	1727721T33
1727721	133	146	dehydrogenase	GENE-N	1727721T34
1727721	19	55	11 beta hydroxysteroid dehydrogenase	GENE-Y	1727721T35
1727721	1464	1467	NAD	CHEMICAL	1727721T3
1727721	1471	1475	NADP	CHEMICAL	1727721T4
1727721	1536	1559	11 beta androstenedione	CHEMICAL	1727721T5
1727721	307	314	steroid	CHEMICAL	1727721T6
1727721	1579	1598	deoxycorticosterone	CHEMICAL	1727721T7
1727721	1829	1851	11 beta hydroxysteroid	CHEMICAL	1727721T8
1727721	380	410	11 beta-hydroxyandrostenedione	CHEMICAL	1727721T9

17289086|t|Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells.
17289086|a|Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) broadly used in the treatment of human mood disorders and gastrointestinal diseases involving the serotoninergic system. The effectiveness of this therapy depends on repeated long-term treatment. Most of the long-term studies in vivo of SSRI effects on serotoninergic activity have focused on their effects on autoreceptors or postsynaptic receptors. The chronic effect of SSRIs on the activity of the serotonin transporter (SERT) has been less studied and the results have been contradictory. The aim of this study was to determine the specific effect of long-term fluoxetine treatment on human serotonin transporter (hSERT) in vitro, by using the human enterocyte-like cell line Caco-2. Results show that fluoxetine diminished the 5-HT uptake in a concentration-dependent way and that this effect was reversible. Fluoxetine affected mainly the hSERT transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the hSERT mRNA level. These results suggest that the effect of fluoxetine on the expression of hSERT is post-translational and has shown itself to be independent of PKC and PKA activity. This study may be useful to clarify the effect of the long-term fluoxetine therapy in both gastrointestinal and central nervous system disorders.
17289086	970	980	Fluoxetine	CHEMICAL	464
17289086	20	30	fluoxetine	CHEMICAL	17289086T11
17289086	54	63	serotonin	CHEMICAL	17289086T12
17289086	1137	1142	hSERT	GENE-Y	17289086T13
17289086	1166	1171	hSERT	GENE-Y	17289086T14
17289086	1257	1262	hSERT	GENE-Y	17289086T15
17289086	1327	1330	PKC	GENE-N	17289086T16
17289086	1335	1338	PKA	GENE-N	17289086T17
17289086	557	578	serotonin transporter	GENE-Y	17289086T18
17289086	580	584	SERT	GENE-Y	17289086T19
17289086	93	103	Fluoxetine	CHEMICAL	464
17289086	745	772	human serotonin transporter	GENE-Y	17289086T20
17289086	774	779	hSERT	GENE-Y	17289086T21
17289086	1001	1006	hSERT	GENE-Y	17289086T22
17289086	48	75	human serotonin transporter	GENE-Y	17289086T23
17289086	1225	1235	fluoxetine	CHEMICAL	17289086T2
17289086	1413	1423	fluoxetine	CHEMICAL	17289086T3
17289086	119	128	serotonin	CHEMICAL	17289086T4
17289086	557	566	serotonin	CHEMICAL	17289086T5
17289086	721	731	fluoxetine	CHEMICAL	17289086T6
17289086	751	760	serotonin	CHEMICAL	17289086T7
17289086	862	872	fluoxetine	CHEMICAL	17289086T8
17289086	888	892	5-HT	CHEMICAL	17289086T9

17289088|t|Roles played by lymphocyte function-associated antigen-1 in the regulation of lymphocytic cholinergic activity.
17289088|a|Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively). Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of ACh and up-regulates expression of ChAT and M(5) mAChR mRNAs. In addition, activation of protein kinase C and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation. Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity, ACh synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells. The cholesterol-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation. We found that simvastatin abolishes anti-CD11a mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity. Collectively then, these results indicate that LFA-1 contributes to the regulation of lymphocytic cholinergic activity via CD11a-mediated pathways and suggest that simvastatin exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.
17289088	1065	1076	cholesterol	CHEMICAL	17289088T10
17289088	207	210	ACh	CHEMICAL	17289088T11
17289088	1112	1117	LFA-1	GENE-Y	17289088T12
17289088	213	238	choline acetyltransferase	GENE-Y	17289088T13
17289088	1164	1169	CD11a	GENE-Y	17289088T14
17289088	1171	1182	LFA-1 alpha	GENE-Y	17289088T15
17289088	1265	1270	CD11a	GENE-Y	17289088T16
17289088	240	244	ChAT	GENE-Y	17289088T17
17289088	1438	1443	LFA-1	GENE-Y	17289088T18
17289088	1514	1519	CD11a	GENE-Y	17289088T19
17289088	213	220	choline	CHEMICAL	17289088T1
17289088	281	319	muscarinic and nicotinic ACh receptors	GENE-N	17289088T20
17289088	321	327	mAChRs	GENE-N	17289088T21
17289088	332	338	nAChRs	GENE-N	17289088T22
17289088	387	405	phytohemagglutinin	GENE-N	17289088T23
17289088	439	454	T cell receptor	GENE-N	17289088T24
17289088	455	458	CD3	GENE-N	17289088T25
17289088	541	545	ChAT	GENE-Y	17289088T26
17289088	550	560	M(5) mAChR	GENE-Y	17289088T27
17289088	595	611	protein kinase C	GENE-N	17289088T28
17289088	698	738	lymphocyte function associated antigen-1	GENE-Y	17289088T29
17289088	1238	1249	simvastatin	CHEMICAL	17289088T2
17289088	740	745	LFA-1	GENE-Y	17289088T30
17289088	747	752	CD11a	GENE-Y	17289088T31
17289088	753	757	CD18	GENE-Y	17289088T32
17289088	835	840	CD11a	GENE-Y	17289088T33
17289088	892	900	globulin	GENE-N	17289088T34
17289088	931	934	CD2	GENE-Y	107352
17289088	936	939	CD7	GENE-Y	107362
17289088	944	949	CD11a	GENE-Y	17289088T37
17289088	963	967	ChAT	GENE-Y	17289088T38
17289088	1023	1027	ChAT	GENE-Y	17289088T39
17289088	1360	1371	cholesterol	CHEMICAL	17289088T3
17289088	1032	1042	M(5) mAChR	GENE-Y	17289088T40
17289088	16	56	lymphocyte function-associated antigen-1	GENE-Y	17289088T41
17289088	1555	1566	simvastatin	CHEMICAL	17289088T4
17289088	306	309	ACh	CHEMICAL	17289088T5
17289088	506	509	ACh	CHEMICAL	17289088T6
17289088	643	647	cAMP	CHEMICAL	2424
17289088	192	205	acetylcholine	CHEMICAL	17289088T8
17289088	978	981	ACh	CHEMICAL	17289088T9
17289088	CPR:3	2424	17289088T29
17289088	CPR:3	2424	17289088T30
17289088	CPR:3	2424	17289088T31
17289088	CPR:3	2424	17289088T32
17289088	CPR:4	17289088T2	17289088T16
17289088	CPR:9	17289088T11	17289088T13
17289088	CPR:9	17289088T11	17289088T17
17289088	CPR:9	17289088T8	17289088T13
17289088	CPR:9	17289088T8	17289088T17

17341305|t|Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment.
17341305|a|INTRODUCTION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice. We sought to reproduce this MPA cancer model in C57BL/6 mice because of their widespread use in genetic engineering. Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of ER and PR expression in MPA-treated and progesterone-treated mammary glands. Finally, we evaluated whether the differences found between BALB/c and C57BL/6 mouse strains were due to intrinsic differences in epithelial cells. METHODS: The carcinogenic effect of MPA was evaluated in C57BL/6 mice using protocols proven to be carcinogenic in BALB/c mice. In addition, BALB/c and C57BL/6 females were treated with progesterone or MPA for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of ER and PR. Hormone levels were determined by radioimmunoassay. Isolated mammary epithelial cells were transplanted into cleared fat pads of 21-day-old female Swiss nu/nu mice or control congenic animals. RESULTS: MPA failed to induce mammary carcinomas or significant morphologic changes in the mammary glands of C57BL/6 mice. The expression of ER-alpha and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in progestin-treated BALB/c mice (P < 0.05). PR isoform B levels were low in virgin control mice and increased after progestin treatment in both strains. ER-beta expression followed a similar trend. No differences in hormone levels were found between strains. Surprisingly, the transplantation of the epithelial mammary gland cells of both strains into the cleared fat pads of Swiss (nu/nu) mice abolished the mammary gland morphologic differences and the ER and PR differences between strains. CONCLUSION: C57BL/6 mammary glands are resistant to MPA-induced carcinogenesis and to hormone action. MPA and progesterone have different effects on mammary glands. Low ER-alpha and PR-A levels in untreated mammary glands may be associated with a low-risk breast cancer profile. Although we cannot at this time rule out the participation of other, untested factors, our findings implicate the stroma as playing a crucial role in the strain-specific differential hormone receptor expression and hormone responsiveness.
17341305	194	197	MPA	CHEMICAL	593
17341305	587	590	MPA	CHEMICAL	593
17341305	595	607	progesterone	CHEMICAL	17341305T12
17341305	651	654	MPA	CHEMICAL	593
17341305	667	679	progesterone	CHEMICAL	17341305T14
17341305	207	215	estrogen	CHEMICAL	17341305T15
17341305	888	891	MPA	CHEMICAL	593
17341305	1038	1050	progesterone	CHEMICAL	17341305T17
17341305	1054	1057	MPA	CHEMICAL	593
17341305	243	255	progesterone	CHEMICAL	17341305T19
17341305	1404	1407	MPA	CHEMICAL	593
17341305	15	23	estrogen	CHEMICAL	17341305T20
17341305	43	55	progesterone	CHEMICAL	17341305T21
17341305	1191	1193	ER	GENE-Y	16226|2525
17341305	1198	1200	PR	GENE-Y	17341305T23
17341305	266	268	PR	GENE-Y	17341305T24
17341305	1536	1544	ER-alpha	GENE-Y	17341305T25
17341305	1549	1561	PR isoform A	GENE-Y	17341305T26
17341305	1731	1743	PR isoform B	GENE-Y	17341305T27
17341305	1840	1847	ER-beta	GENE-Y	17341305T28
17341305	2142	2144	ER	GENE-Y	16226|2525
17341305	165	192	Medroxyprogesterone acetate	CHEMICAL	593
17341305	2149	2151	PR	GENE-Y	17341305T30
17341305	2350	2358	ER-alpha	GENE-Y	17341305T31
17341305	2363	2367	PR-A	GENE-Y	17341305T32
17341305	2643	2659	hormone receptor	GENE-N	17341305T33
17341305	627	629	ER	GENE-Y	16226|2525
17341305	634	636	PR	GENE-Y	17341305T35
17341305	207	224	estrogen receptor	GENE-Y	17341305T36
17341305	226	228	ER	GENE-Y	16226|2525
17341305	243	264	progesterone receptor	GENE-Y	17341305T38
17341305	15	38	estrogen receptor-alpha	GENE-Y	17341305T39
17341305	1689	1698	progestin	CHEMICAL	17341305T3
17341305	43	64	progesterone receptor	GENE-Y	17341305T40
17341305	1803	1812	progestin	CHEMICAL	17341305T4
17341305	358	361	MPA	CHEMICAL	593
17341305	2233	2236	MPA	CHEMICAL	593
17341305	2283	2286	MPA	CHEMICAL	593
17341305	2291	2303	progesterone	CHEMICAL	17341305T8
17341305	520	523	MPA	CHEMICAL	593
17341305	CPR:3	593	17341305T24
17341305	CPR:3	593	17341305T36
17341305	CPR:3	593	16226|2525
17341305	CPR:3	593	17341305T24
17341305	CPR:3	593	17341305T36
17341305	CPR:3	593	16226|2525
17341305	CPR:3	593	17341305T38
17341305	CPR:3	17341305T4	17341305T27
17341305	CPR:4	17341305T3	17341305T25
17341305	CPR:4	17341305T3	17341305T26

17350061|t|Transplacental exposure to inorganic arsenic at a hepatocarcinogenic dose induces fetal gene expression changes in mice indicative of aberrant estrogen signaling and disrupted steroid metabolism.
17350061|a|Exposure to inorganic arsenic in utero in C3H mice produces hepatocellular carcinoma in male offspring when they reach adulthood. To help define the molecular events associated with the fetal onset of arsenic hepatocarcinogenesis, pregnant C3H mice were given drinking water containing 0 (control) or 85 ppm arsenic from day 8 to 18 of gestation. At the end of the arsenic exposure period, male fetal livers were removed and RNA isolated for microarray analysis using 22K oligo chips. Arsenic exposure in utero produced significant (p<0.001) alterations in expression of 187 genes, with approximately 25% of aberrantly expressed genes related to either estrogen signaling or steroid metabolism. Real-time RT-PCR on selected genes confirmed these changes. Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed. Estrogen-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed. Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production). The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed. Thus, exposure of mouse fetus to inorganic arsenic during a critical period in development significantly alters the expression of various genes encoding estrogen signaling and steroid or methionine metabolism. These alterations could disrupt genetic programming at the very early life stage, which could impact tumor formation much later in adulthood.
17350061	1714	1723	thioether	CHEMICAL	17350061T10
17350061	1724	1725	S	CHEMICAL	127
17350061	1795	1812	inorganic arsenic	CHEMICAL	17350061T12
17350061	1915	1923	estrogen	CHEMICAL	17350061T13
17350061	1938	1945	steroid	CHEMICAL	17350061T14
17350061	1949	1959	methionine	CHEMICAL	17350061T15
17350061	397	404	arsenic	CHEMICAL	17350061T16
17350061	504	511	arsenic	CHEMICAL	17350061T17
17350061	561	568	arsenic	CHEMICAL	17350061T18
17350061	681	688	Arsenic	CHEMICAL	17350061T19
17350061	1305	1312	steroid	CHEMICAL	17350061T1
17350061	849	857	estrogen	CHEMICAL	17350061T20
17350061	871	878	steroid	CHEMICAL	17350061T21
17350061	979	987	estrogen	CHEMICAL	17350061T22
17350061	1101	1108	proline	CHEMICAL	17350061T23
17350061	1160	1168	Estrogen	CHEMICAL	17350061T24
17350061	143	151	estrogen	CHEMICAL	17350061T25
17350061	176	183	steroid	CHEMICAL	17350061T26
17350061	27	44	inorganic arsenic	CHEMICAL	17350061T27
17350061	1216	1222	Cyp2a4	GENE-Y	17350061T28
17350061	1253	1260	Cyp3a25	GENE-Y	207946
17350061	1401	1422	17beta-hydroxysteroid	CHEMICAL	17350061T2
17350061	1401	1438	17beta-hydroxysteroid dehydrogenase-7	GENE-Y	17350061T30
17350061	1440	1450	HSD17beta7	GENE-Y	17350061T31
17350061	1514	1524	HSD17beta5	GENE-Y	17350061T32
17350061	1636	1669	methionine adenosyltransferase-1a	GENE-Y	17350061T33
17350061	1671	1709	betaine-homocysteine methyltransferase	GENE-Y	17350061T34
17350061	1714	1743	thioether S-methyltransferase	GENE-Y	17350061T35
17350061	999	1029	X-inactive-specific transcript	GENE-Y	17350061T36
17350061	1031	1050	anterior gradient-2	GENE-Y	17350061T37
17350061	1052	1068	trefoil factor-1	GENE-Y	17350061T38
17350061	1070	1080	CRP-ductin	GENE-Y	17350061T39
17350061	208	225	inorganic arsenic	CHEMICAL	17350061T3
17350061	1082	1089	ghrelin	GENE-Y	17350061T40
17350061	1095	1124	small proline-rich protein-2A	GENE-Y	17350061T41
17350061	1195	1211	cytokeratin 1-19	GENE-Y	17350061T42
17350061	1464	1473	estradiol	CHEMICAL	17350061T4
17350061	1538	1550	testosterone	CHEMICAL	614
17350061	1605	1615	methionine	CHEMICAL	17350061T6
17350061	1636	1646	methionine	CHEMICAL	17350061T7
17350061	1671	1678	betaine	CHEMICAL	17350061T8
17350061	1679	1691	homocysteine	CHEMICAL	17350061T9
17350061	CPR:3	17350061T22	17350061T36
17350061	CPR:3	17350061T22	17350061T37
17350061	CPR:3	17350061T22	17350061T38
17350061	CPR:3	17350061T22	17350061T39
17350061	CPR:3	17350061T22	17350061T40
17350061	CPR:3	17350061T22	17350061T41
17350061	CPR:3	17350061T24	17350061T28
17350061	CPR:3	17350061T24	17350061T42
17350061	CPR:4	17350061T24	207946
17350061	CPR:9	17350061T4	17350061T30
17350061	CPR:9	17350061T4	17350061T31
17350061	CPR:9	614	17350061T32
17350061	CPR:9	17350061T6	17350061T33
17350061	CPR:9	17350061T6	17350061T34
17350061	CPR:9	17350061T6	17350061T35

17352828|t|A pilot study of IL-1 inhibition by anakinra in acute gout.
17352828|a|Monosodium urate crystals stimulate monocytes and macrophages to release IL-1beta through the NALP3 component of the inflammasome. The effectiveness of IL-1 inhibition in hereditary autoinflammatory syndromes with mutations in the NALP3 protein suggested that IL-1 inhibition might also be effective in relieving the inflammatory manifestations of acute gout. The effectiveness of IL-1 inhibition was first evaluated in a mouse model of monosodium urate crystal-induced inflammation. IL-1 inhibition prevented peritoneal neutrophil accumulation but TNF blockade had no effect. Based on these findings, we performed a pilot, open-labeled study (trial registration number ISRCTN10862635) in 10 patients with gout who could not tolerate or had failed standard antiinflammatory therapies. All patients received 100 mg anakinra daily for 3 days. All 10 patients with acute gout responded rapidly to anakinra. No adverse effects were observed. IL-1 blockade appears to be an effective therapy for acute gouty arthritis. The clinical findings need to be confirmed in a controlled study.
17352828	998	1002	IL-1	GENE-N	17352828T10
17352828	154	159	NALP3	GENE-Y	17352828T11
17352828	17	21	IL-1	GENE-N	17352828T12
17352828	60	76	Monosodium urate	CHEMICAL	17352828T1
17352828	497	513	monosodium urate	CHEMICAL	17352828T2
17352828	212	216	IL-1	GENE-N	17352828T3
17352828	291	296	NALP3	GENE-Y	17352828T4
17352828	320	324	IL-1	GENE-N	17352828T5
17352828	441	445	IL-1	GENE-N	17352828T6
17352828	544	548	IL-1	GENE-N	17352828T7
17352828	609	612	TNF	GENE-Y	112979
17352828	133	141	IL-1beta	GENE-Y	17352828T9
17352828	CPR:3	17352828T1	17352828T9

17355872|t|Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.
17355872|a|Sirtuins are NAD(+)-dependent protein deacetylases and are emerging as molecular targets for the development of pharmaceuticals to treat human metabolic and neurological diseases and cancer. To date, several sirtuin inhibitors and activators have been identified, but the structural mechanisms of how these compounds modulate sirtuin activity have not yet been determined. We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM. To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of SIRT5, one in complex with ADP-ribose, the other bound to suramin. Our structural studies provide a view of a synthetic inhibitory compound in a sirtuin active site revealing that suramin binds into the NAD(+), the product, and the substrate-binding site. Finally, our structures may enable the rational design of more potent inhibitors.
17355872	297	304	sirtuin	GENE-N	17355872T10
17355872	415	422	sirtuin	GENE-N	17355872T11
17355872	512	523	human SIRT5	GENE-Y	17355872T12
17355872	552	586	SIRT5 NAD(+)-dependent deacetylase	GENE-Y	17355872T13
17355872	743	748	SIRT5	GENE-Y	116980
17355872	888	895	sirtuin	GENE-N	17355872T15
17355872	38	76	human NAD+-dependent deacetylase SIRT5	GENE-Y	17355872T16
17355872	102	108	NAD(+)	CHEMICAL	17355872T1
17355872	476	483	suramin	CHEMICAL	17355872T2
17355872	558	564	NAD(+)	CHEMICAL	17355872T3
17355872	770	773	ADP	CHEMICAL	17355872T4
17355872	801	808	suramin	CHEMICAL	17355872T5
17355872	923	930	suramin	CHEMICAL	17355872T6
17355872	946	952	NAD(+)	CHEMICAL	17355872T7
17355872	44	48	NAD+	CHEMICAL	17355872T8
17355872	80	87	suramin	CHEMICAL	17355872T9
17355872	CPR:4	17355872T2	17355872T13
17355872	CPR:4	17355872T9	17355872T16

17369066|t|Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase.
17369066|a|Hyperhomocyst(e)inemia is a metabolic derangement that is linked to the distribution of folate pools, which provide one-carbon units for biosynthesis of purines and thymidylate and for remethylation of homocysteine to form methionine. In humans, methionine synthase deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and thymidylate biosynthesis. Complete ablation of methionine synthase activity in mice results in embryonic lethality. Other mouse models for hyperhomocyst(e)inemia have normal or reduced levels of methyltetrahydrofolate and are not embryonic lethal, although they have decreased ratios of AdoMet/AdoHcy and impaired methylation. We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying methionine synthase reductase, an enzyme essential for the activity of methionine synthase. This model is a hypomorph, with reduced methionine synthase reductase activity, thus avoiding the lethality associated with the absence of methionine synthase activity. Mtrr(gt/gt) mice have increased plasma homocyst(e)ine, decreased plasma methionine, and increased tissue methyltetrahydrofolate. Unexpectedly, Mtrr(gt/gt) mice do not show decreases in the AdoMet/AdoHcy ratio in most tissues. The different metabolite profiles in the various genetic mouse models for hyperhomocyst(e)inemia may be useful in understanding biological effects of elevated homocyst(e)ine.
17369066	275	286	thymidylate	CHEMICAL	17369066T10
17369066	312	324	homocysteine	CHEMICAL	17369066T11
17369066	333	343	methionine	CHEMICAL	17369066T12
17369066	356	366	methionine	CHEMICAL	17369066T13
17369066	418	440	methyltetrahydrofolate	CHEMICAL	17369066T14
17369066	459	465	folate	CHEMICAL	17369066T15
17369066	491	497	purine	CHEMICAL	17369066T16
17369066	502	513	thymidylate	CHEMICAL	17369066T17
17369066	549	559	methionine	CHEMICAL	17369066T18
17369066	697	719	methyltetrahydrofolate	CHEMICAL	17369066T19
17369066	1149	1159	methionine	CHEMICAL	17369066T1
17369066	789	795	AdoMet	CHEMICAL	113
17369066	796	802	AdoHcy	CHEMICAL	17369066T21
17369066	918	928	methionine	CHEMICAL	17369066T22
17369066	989	999	methionine	CHEMICAL	17369066T23
17369066	198	204	folate	CHEMICAL	17369066T24
17369066	1050	1060	methionine	CHEMICAL	17369066T25
17369066	25	35	methionine	CHEMICAL	17369066T26
17369066	40	46	folate	CHEMICAL	17369066T27
17369066	79	89	methionine	CHEMICAL	17369066T28
17369066	1149	1168	methionine synthase	GENE-Y	17369066T29
17369066	1218	1232	homocyst(e)ine	CHEMICAL	17369066T2
17369066	1179	1183	Mtrr	GENE-Y	229121
17369066	1322	1326	Mtrr	GENE-Y	229121
17369066	356	375	methionine synthase	GENE-Y	17369066T32
17369066	549	568	methionine synthase	GENE-Y	17369066T33
17369066	897	901	Mtrr	GENE-Y	229121
17369066	918	947	methionine synthase reductase	GENE-Y	17369066T35
17369066	989	1008	methionine synthase	GENE-Y	17369066T36
17369066	1050	1079	methionine synthase reductase	GENE-Y	17369066T37
17369066	79	108	methionine synthase reductase	GENE-Y	17369066T38
17369066	1251	1261	methionine	CHEMICAL	17369066T3
17369066	1284	1306	methyltetrahydrofolate	CHEMICAL	17369066T4
17369066	230	236	carbon	CHEMICAL	17369066T5
17369066	1368	1374	AdoMet	CHEMICAL	113
17369066	1375	1381	AdoHcy	CHEMICAL	17369066T7
17369066	1564	1578	homocyst(e)ine	CHEMICAL	17369066T8
17369066	263	270	purines	CHEMICAL	17369066T9
17369066	CPR:9	17369066T14	17369066T32

17369473|t|Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration.
17369473|a|AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP). Metformin and phenformin, which are biguanides, have been reported to increase AMPK activity without increasing AMP/ATP. This study tests the hypothesis that these biguanides increase AMPK activity in the heart by increasing cytosolic [AMP]. Groups of isolated rat hearts (n = 5-7 each) were perfused with Krebs-Henseleit buffer with or without 0.2 mM phenformin or 10 mM metformin, and (31)P-NMR-measured phosphocreatine, ATP, and intracellular pH were used to calculate cytosolic [AMP]. At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on acetyl-CoA carboxylase, an AMPK target. In hearts treated with phenformin for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and AMPK activity was elevated at 36 min. In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min. In metformin-treated hearts, HPLC-measured total AMP content and total AMP/ATP did not increase. In summary, phenformin and metformin increase AMPK activity and phosphorylation in the isolated heart. The increase in AMPK activity was always preceded by and correlated with increased cytosolic [AMP]. Total AMP content and total AMP/ATP did not change. Cytosolic [AMP] reported metabolically active AMP, which triggered increased AMPK activity, but measures of total AMP did not.
17369473	1387	1390	ATP	CHEMICAL	164
17369473	1421	1431	phenformin	CHEMICAL	17369473T11
17369473	1436	1445	metformin	CHEMICAL	17369473T12
17369473	252	255	AMP	CHEMICAL	125|407
17369473	259	262	ATP	CHEMICAL	164
17369473	1606	1609	AMP	CHEMICAL	125|407
17369473	1618	1621	AMP	CHEMICAL	125|407
17369473	270	273	AMP	CHEMICAL	125|407
17369473	1640	1643	AMP	CHEMICAL	125|407
17369473	1644	1647	ATP	CHEMICAL	164
17369473	119	122	AMP	CHEMICAL	125|407
17369473	274	277	ATP	CHEMICAL	164
17369473	1675	1678	AMP	CHEMICAL	125|407
17369473	1710	1713	AMP	CHEMICAL	125|407
17369473	280	289	Metformin	CHEMICAL	323
17369473	1778	1781	AMP	CHEMICAL	125|407
17369473	294	304	phenformin	CHEMICAL	17369473T25
17369473	316	326	biguanides	CHEMICAL	17369473T26
17369473	392	395	AMP	CHEMICAL	125|407
17369473	396	399	ATP	CHEMICAL	164
17369473	444	454	biguanides	CHEMICAL	17369473T29
17369473	219	222	AMP	CHEMICAL	125|407
17369473	516	519	AMP	CHEMICAL	125|407
17369473	632	642	phenformin	CHEMICAL	17369473T31
17369473	652	661	metformin	CHEMICAL	17369473T32
17369473	667	672	(31)P	CHEMICAL	17369473T33
17369473	686	701	phosphocreatine	CHEMICAL	17369473T34
17369473	703	706	ATP	CHEMICAL	164
17369473	763	766	AMP	CHEMICAL	125|407
17369473	922	932	acetyl-CoA	CHEMICAL	17369473T37
17369473	985	995	phenformin	CHEMICAL	17369473T38
17369473	1066	1069	AMP	CHEMICAL	125|407
17369473	1164	1173	metformin	CHEMICAL	17369473T3
17369473	0	9	Metformin	CHEMICAL	323
17369473	100	103	AMP	CHEMICAL	125|407
17369473	14	24	phenformin	CHEMICAL	17369473T42
17369473	34	37	AMP	CHEMICAL	125|407
17369473	119	147	AMP-activated protein kinase	GENE-N	17369473T44
17369473	1209	1213	AMPK	GENE-N	17369473T45
17369473	1239	1243	AMPK	GENE-N	17369473T46
17369473	1249	1286	phosphorylated acetyl-CoA carboxylase	GENE-N	17369473T47
17369473	1455	1459	AMPK	GENE-N	17369473T48
17369473	1528	1532	AMPK	GENE-N	17369473T49
17369473	1176	1179	AMP	CHEMICAL	125|407
17369473	1741	1745	AMPK	GENE-N	17369473T50
17369473	359	363	AMPK	GENE-N	17369473T51
17369473	149	153	AMPK	GENE-N	17369473T52
17369473	464	468	AMPK	GENE-N	17369473T53
17369473	830	834	AMPK	GENE-N	17369473T54
17369473	876	886	AMPK-alpha	GENE-N	17369473T55
17369473	922	944	acetyl-CoA carboxylase	GENE-N	17369473T56
17369473	949	953	AMPK	GENE-N	17369473T57
17369473	1103	1107	AMPK	GENE-N	17369473T58
17369473	34	62	AMP-activated protein kinase	GENE-N	17369473T59
17369473	1264	1274	acetyl-CoA	CHEMICAL	17369473T5
17369473	1315	1324	metformin	CHEMICAL	17369473T6
17369473	239	242	AMP	CHEMICAL	125|407
17369473	1361	1364	AMP	CHEMICAL	125|407
17369473	1383	1386	AMP	CHEMICAL	125|407
17369473	CPR:3	17369473T11	17369473T48
17369473	CPR:3	17369473T12	17369473T48
17369473	CPR:3	125|407	17369473T50
17369473	CPR:3	323	17369473T51
17369473	CPR:3	17369473T25	17369473T51
17369473	CPR:3	17369473T26	17369473T51
17369473	CPR:3	17369473T38	17369473T58
17369473	CPR:3	17369473T3	17369473T45
17369473	CPR:3	17369473T3	17369473T46
17369473	CPR:3	17369473T3	17369473T47
17369473	CPR:3	323	17369473T59
17369473	CPR:3	17369473T42	17369473T59

17381051|t|The role of glutathione transferases M1 and T1 in individual susceptibility to bladder cancer in a Tunisian population.
17381051|a|BACKGROUND: Susceptibility to bladder cancer is thought to depend on interplay between genetic factors and environmental chemical carcinogens. AIM: This study seeks to determine the role of the glutathione transferases M1 and T1 null genotypes (GSTM1*0 and GSTT1*0) in individual susceptibility to bladder cancer in a Tunisian population. METHOD: Sixty-two patients with transitional cell carcinoma of the bladder cancer and 79 controls were examined with respect to the frequency of GSTM1 and GSTT1 null genotypes. RESULTS: The frequencies of the GSTT1 null in the total group of bladder cancer cases vs. controls did not differ statistically. The proportion of GSTM1 null genotype in patients was 63% compared to 45% in controls group (OR = 2.03; 95% CI 0.97-4.24; p = 0.04). A significantly higher incidence of GSTM1 deletion genotype was found in smokers with bladder cancer compared to the controls (65.38% vs. 45.5%). Smokers lacking the GSTM1 gene are at an approximately 2.2-fold higher risk of bladder cancer (OR= 2.23, 95% CI 1-5.15; p = 0.03). CONCLUSION: This study suggests that in Tunisian subjects the GSTM1 null genotype may be associated with an increased risk of bladder cancer. This association appears to depend upon smoking status.
17381051	783	788	GSTM1	GENE-Y	109199
17381051	934	939	GSTM1	GENE-Y	109199
17381051	1064	1069	GSTM1	GENE-Y	109199
17381051	12	46	glutathione transferases M1 and T1	GENE-N	17381051T13
17381051	314	325	glutathione	CHEMICAL	17381051T1
17381051	12	23	glutathione	CHEMICAL	17381051T2
17381051	1237	1242	GSTM1	GENE-Y	109199
17381051	314	348	glutathione transferases M1 and T1	GENE-N	17381051T4
17381051	365	370	GSTM1	GENE-Y	109199
17381051	377	382	GSTT1	GENE-Y	19374|109207
17381051	604	609	GSTM1	GENE-Y	109199
17381051	614	619	GSTT1	GENE-Y	19374|109207
17381051	668	673	GSTT1	GENE-Y	19374|109207

1738111|t|Characterization of 5-hydroxytryptamine1B receptors in rat spinal cord via [125I]iodocyanopindolol binding and inhibition of [3H]-5-hydroxytryptamine release.
1738111|a|The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the serotonin (5-HT)1B receptor defined by [125I]iodocyanopindolol [( 125I] ICYP) binding and the 5-HT autoreceptor defined by inhibition of [3H]-5-HT release. In Percoll gradient Fractions 3 and 4 of spinal cord synaptosomes, a single saturable binding site for [125I]ICYP with a maximum binding of 70 and 134 fmol/mg, respectively, was demonstrated in the presence of 30 microM isoproterenol. The Kd of 0.16 nM did not vary between fractions. Competition for [125I]ICYP binding by various 5-HT agonists and antagonists also indicated a single site model based on a Hill coefficient of approximately 1.0. The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites. Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT. Compounds with activity at 5-HT1A, 5-HT1C, 5-HT2 or 5-HT3 sites were inactive. A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193). Although [125I]ICYP binding was unaltered, alpha-2 agonists such as clonidine, norepinephrine and UK 14304 [5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline) as well as the alpha-2 antagonists rauwolscine and yohimbine also decreased the K(+)-stimulated release of [3H]-5-HT and phentolamine, an alpha-2 antagonist increased release. The action of these alpha-2 compounds to alter [3H]-5-HT release suggests the presence of heteroreceptors localized on 5-HT terminals in the spinal cord. These results point out that [125I]ICYP identifies the 5-HT1B receptor, and affinity of compounds for this site predicts action at the 5-HT1B autoreceptor.(ABSTRACT TRUNCATED AT 400 WORDS)
1738111	1540	1544	5-HT	CHEMICAL	1738111T10
1738111	1716	1726	[125I]ICYP	CHEMICAL	1738111T11
1738111	317	340	[125I]iodocyanopindolol	CHEMICAL	1738111T12
1738111	1758	1767	[3H]-5-HT	CHEMICAL	1738111T13
1738111	1850	1854	5-HT	CHEMICAL	1738111T14
1738111	1876	1880	5-HT	CHEMICAL	1738111T15
1738111	1906	1916	[125I]ICYP	CHEMICAL	1738111T16
1738111	341	355	[( 125I] ICYP)	CHEMICAL	1738111T17
1738111	1986	1996	[125I]ICYP	CHEMICAL	1738111T18
1738111	2045	2054	clonidine	CHEMICAL	565
1738111	1346	1356	[125I]ICYP	CHEMICAL	1738111T1
1738111	2056	2070	norepinephrine	CHEMICAL	1738111T20
1738111	2075	2083	UK 14304	CHEMICAL	1738111T21
1738111	2084	2131	[5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline	CHEMICAL	1738111T22
1738111	2168	2179	rauwolscine	CHEMICAL	1738111T23
1738111	2184	2193	yohimbine	CHEMICAL	1738111T24
1738111	2213	2217	K(+)	CHEMICAL	1738111T25
1738111	2240	2249	[3H]-5-HT	CHEMICAL	1738111T26
1738111	2254	2266	phentolamine	CHEMICAL	682
1738111	372	376	5-HT	CHEMICAL	1738111T28
1738111	2356	2365	[3H]-5-HT	CHEMICAL	1738111T29
1738111	278	287	serotonin	CHEMICAL	1738111T2
1738111	2428	2432	5-HT	CHEMICAL	1738111T30
1738111	2492	2502	[125I]ICYP	CHEMICAL	1738111T31
1738111	415	424	[3H]-5-HT	CHEMICAL	1738111T32
1738111	537	547	[125I]ICYP	CHEMICAL	1738111T33
1738111	654	667	isoproterenol	CHEMICAL	1738111T34
1738111	735	745	[125I]ICYP	CHEMICAL	1738111T35
1738111	765	769	5-HT	CHEMICAL	1738111T36
1738111	920	930	[125I]ICYP	CHEMICAL	1738111T37
1738111	944	952	RU 24969	CHEMICAL	1738111T38
1738111	954	1008	5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole	CHEMICAL	1738111T39
1738111	1400	1404	K(+)	CHEMICAL	1738111T3
1738111	1011	1039	5-carboxyamidotryptamine HCl	CHEMICAL	1738111T40
1738111	1041	1060	5-methoxytryptamine	CHEMICAL	1738111T41
1738111	1062	1066	5-HT	CHEMICAL	1738111T42
1738111	1071	1081	CGS 12066B	CHEMICAL	1738111T43
1738111	1083	1146	7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate	CHEMICAL	1738111T44
1738111	1149	1159	[125I]ICYP	CHEMICAL	1738111T45
1738111	125	149	[3H]-5-hydroxytryptamine	CHEMICAL	1738111T46
1738111	75	98	[125I]iodocyanopindolol	CHEMICAL	1738111T47
1738111	1214	1220	5-HT1A	GENE-Y	1738111T48
1738111	1222	1228	5-HT1C	GENE-Y	1738111T49
1738111	1427	1436	[3H]-5-HT	CHEMICAL	1738111T4
1738111	1230	1235	5-HT2	GENE-Y	1738111T50
1738111	1237	1242	5-HT3	GENE-Y	1738111T51
1738111	1324	1329	5HT1B	GENE-Y	1738111T52
1738111	278	305	serotonin (5-HT)1B receptor	GENE-Y	1738111T53
1738111	1573	1579	5-HT1A	GENE-Y	1738111T54
1738111	1581	1587	5-HT1C	GENE-Y	1738111T55
1738111	1589	1594	5-HT2	GENE-Y	1738111T56
1738111	1598	1603	5-HT3	GENE-Y	1738111T57
1738111	1661	1667	5-HT1B	GENE-Y	62857
1738111	1850	1867	5-HT autoreceptor	GENE-Y	1738111T59
1738111	1442	1449	RU24969	CHEMICAL	1738111T5
1738111	1876	1889	5-HT receptor	GENE-Y	1738111T60
1738111	372	389	5-HT autoreceptor	GENE-Y	1738111T61
1738111	2518	2524	5-HT1B	GENE-Y	62857
1738111	2598	2604	5-HT1B	GENE-Y	62857
1738111	20	41	5-hydroxytryptamine1B	GENE-Y	1738111T64
1738111	1452	1476	5-carboxyamidotryptamine	CHEMICAL	1738111T6
1738111	1477	1480	HCl	CHEMICAL	1738111T7
1738111	1483	1493	CGS 12066B	CHEMICAL	1738111T8
1738111	1507	1526	5-methoxytryptamine	CHEMICAL	1738111T9

17382376|t|Histamine H1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine.
17382376|a|Histamine H(1) blockade is one of the more prominent actions of the multi-receptor acting antipsychotic clozapine. It is currently not known how much this H(1) antagonism of clozapine contributes to the therapeutic or adverse side effects of clozapine. The current studies with Sprague-Dawley rats were conducted to determine the participation of histaminergic H(1) receptor subtype in sensorimotor plasticity and memory function affected by clozapine using tests of prepulse inhibition (PPI) and radial-arm maze choice accuracy. The PPI impairment caused by the glutamate antagonist dizocilpine (MK-801) was significantly attenuated by clozapine. In the current project, we found that the selective H(1) antagonist pyrilamine also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse. In the radial-arm maze (RAM), pyrilamine, like clozapine, impaired working memory and caused a significant dose-related slowing of response. Pyrilamine, however, decreased the number of reference memory errors. We have previously shown that nicotine effectively attenuates the clozapine-induced working memory impairment, but in the current study, nicotine did not significantly alter the effects of pyrilamine on the RAM. In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the H(1) antagonist pyrilamine, while pyrilamine had a mixed effect on cognition. Pyrilamine impaired working memory but improved reference memory in rats. Thus, H(1) antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as clozapine.
17382376	1558	1568	Pyrilamine	CHEMICAL	17382376T10
17382376	1736	1745	clozapine	CHEMICAL	17382376T11
17382376	306	315	clozapine	CHEMICAL	17382376T12
17382376	374	383	clozapine	CHEMICAL	17382376T13
17382376	574	583	clozapine	CHEMICAL	17382376T14
17382376	695	704	glutamate	CHEMICAL	17382376T15
17382376	716	727	dizocilpine	CHEMICAL	17382376T16
17382376	729	735	MK-801	CHEMICAL	17382376T17
17382376	769	778	clozapine	CHEMICAL	17382376T18
17382376	848	858	pyrilamine	CHEMICAL	5573
17382376	132	141	Histamine	CHEMICAL	17382376T1
17382376	877	888	dizocilpine	CHEMICAL	17382376T20
17382376	991	1001	pyrilamine	CHEMICAL	5573
17382376	1008	1017	clozapine	CHEMICAL	17382376T22
17382376	1102	1112	Pyrilamine	CHEMICAL	17382376T23
17382376	0	9	Histamine	CHEMICAL	17382376T24
17382376	121	130	clozapine	CHEMICAL	17382376T25
17382376	132	146	Histamine H(1)	GENE-Y	17382376T26
17382376	1480	1484	H(1)	GENE-Y	17382376T27
17382376	1638	1642	H(1)	GENE-Y	17382376T28
17382376	287	291	H(1)	GENE-Y	17382376T29
17382376	236	245	clozapine	CHEMICAL	17382376T2
17382376	479	506	histaminergic H(1) receptor	GENE-Y	17382376T30
17382376	832	836	H(1)	GENE-Y	17382376T31
17382376	0	21	Histamine H1 receptor	GENE-Y	17382376T32
17382376	1202	1210	nicotine	CHEMICAL	17382376T3
17382376	1238	1247	clozapine	CHEMICAL	17382376T4
17382376	1309	1317	nicotine	CHEMICAL	17382376T5
17382376	1361	1371	pyrilamine	CHEMICAL	5573
17382376	1422	1431	clozapine	CHEMICAL	17382376T7
17382376	1496	1506	pyrilamine	CHEMICAL	5573
17382376	1514	1524	pyrilamine	CHEMICAL	5573
17382376	CPR:3	17382376T20	17382376T31
17382376	CPR:4	17382376T2	17382376T26
17382376	CPR:4	17382376T7	17382376T27
17382376	CPR:6	17382376T11	17382376T28
17382376	CPR:6	17382376T12	17382376T29
17382376	CPR:6	5573	17382376T31
17382376	CPR:6	5573	17382376T27
17382376	CPR:6	5573	17382376T27

17387686|t|Inhibition of phosphatidylserine biosynthesis in developing rat brain by maternal exposure to ethanol.
17387686|a|Phosphatidylserine (PtdSer), major acidic phospholipids in neuronal membranes, participate in important cell signaling processes. The PtdSer in brain is highly enriched with docosahexaenoic acid (DHA; 22:6n-3), and the DHA status or ethanol exposure has been shown to influence the PtdSer level. This study shows that ethanol exposure during prenatal and developmental period significantly attenuates microsomal PtdSer biosynthetic activities and reduces PtdSer, particularly 18:0, 22:6-PtdSer, in developing rat brain cortices. Brain microsomes were incubated with deuterium labeled exogenous substrates in vitro and the products formed were detected by reversed phase HPLC-electrospray ionization mass spectrometry (ESI-MS). These in vitro bioassays showed that 1-stearoyl-2-docosahexaenoyl (18:0, 22:6) species is the best substrate for PtdSer synthesis from both phosphatidylcholine (PtdCho) and phosphatidylethanolamine (PtdEtn). The PtdSer biosynthetic activity of brain, especially for 18:0, 22:6-PtdSer production, was hampered significantly by maternal exposure to ethanol. PtdSer levels were consistently reduced significantly in brain cortices of the pups from ethanol-exposed dams, due mainly to the depletion of 18:0, 22:6-PtdSer. The mRNA expression of PtdSer synthase 1 (PSS1) and PtdSer synthase 2 (PSS2) was not reduced by ethanol. Similarly, the PSS1 enzyme level did not change after ethanol exposure but PSS2 could not be probed with the antibody available currently. Degradation of PtdSer by mitochondrial PtdSer decarboxylation was not enhanced but also inhibited. Taken together, attenuated PtdSer biosynthetic activities are largely responsible for the PtdSer reduction observed in developing rat brains after maternal exposure to ethanol.
17387686	421	428	ethanol	CHEMICAL	17387686T10
17387686	669	678	deuterium	CHEMICAL	17387686T11
17387686	867	895	1-stearoyl-2-docosahexaenoyl	CHEMICAL	17387686T12
17387686	970	989	phosphatidylcholine	CHEMICAL	17387686T13
17387686	991	997	PtdCho	CHEMICAL	17387686T14
17387686	1003	1027	phosphatidylethanolamine	CHEMICAL	17387686T15
17387686	1029	1035	PtdEtn	CHEMICAL	17387686T16
17387686	94	101	ethanol	CHEMICAL	17387686T17
17387686	1370	1387	PtdSer synthase 1	GENE-Y	17387686T18
17387686	1389	1393	PSS1	GENE-Y	17387686T19
17387686	1177	1184	ethanol	CHEMICAL	17387686T1
17387686	1399	1416	PtdSer synthase 2	GENE-Y	17387686T20
17387686	1418	1422	PSS2	GENE-Y	17387686T21
17387686	1467	1471	PSS1	GENE-Y	17387686T22
17387686	1527	1531	PSS2	GENE-Y	17387686T23
17387686	1275	1282	ethanol	CHEMICAL	17387686T2
17387686	1443	1450	ethanol	CHEMICAL	17387686T3
17387686	1506	1513	ethanol	CHEMICAL	17387686T4
17387686	277	297	docosahexaenoic acid	CHEMICAL	17387686T5
17387686	1858	1865	ethanol	CHEMICAL	17387686T6
17387686	299	302	DHA	CHEMICAL	17387686T7
17387686	322	325	DHA	CHEMICAL	17387686T8
17387686	336	343	ethanol	CHEMICAL	17387686T9

17403374|t|Regulation of gluconeogenesis by Kruppel-like factor 15.
17403374|a|In the postabsorptive state, certain tissues, including the brain, require glucose as the sole source of energy. After an overnight fast, hepatic glycogen stores are depleted, and gluconeogenesis becomes essential for preventing life-threatening hypoglycemia. Mice with a targeted deletion of KLF15, a member of the Kruppel-like family of transcription factors, display severe hypoglycemia after an overnight (18 hr) fast. We provide evidence that defective amino acid catabolism promotes the development of fasting hypoglycemia in KLF15-/- mice by limiting gluconeogenic substrate availability. KLF15-/- liver and skeletal muscle show markedly reduced mRNA expression of amino acid-degrading enzymes. Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes. Consistent with this observation, intraperitoneal injection of pyruvate, but not alanine, rescues fasting hypoglycemia in KLF15-/- mice. We conclude that KLF15 plays an important role in the regulation of gluconeogenesis.
17403374	1086	1091	KLF15	GENE-Y	118818
17403374	1118	1123	KLF15	GENE-Y	118818
17403374	350	355	KLF15	GENE-Y	118818
17403374	373	385	Kruppel-like	GENE-N	17403374T13
17403374	589	594	KLF15	GENE-Y	118818
17403374	653	658	KLF15	GENE-Y	118818
17403374	798	822	alanine aminotransferase	GENE-N	17403374T16
17403374	824	827	ALT	GENE-N	17403374T17
17403374	942	947	KLF15	GENE-Y	118818
17403374	33	55	Kruppel-like factor 15	GENE-Y	17403374T19
17403374	515	525	amino acid	CHEMICAL	17403374T1
17403374	729	739	amino acid	CHEMICAL	17403374T2
17403374	798	805	alanine	CHEMICAL	17403374T3
17403374	132	139	glucose	CHEMICAL	17403374T4
17403374	872	882	amino acid	CHEMICAL	17403374T5
17403374	883	890	alanine	CHEMICAL	17403374T6
17403374	896	904	pyruvate	CHEMICAL	17403374T7
17403374	1027	1035	pyruvate	CHEMICAL	17403374T8
17403374	1045	1052	alanine	CHEMICAL	17403374T9
17403374	CPR:9	17403374T5	17403374T16
17403374	CPR:9	17403374T5	17403374T17
17403374	CPR:9	17403374T6	17403374T16
17403374	CPR:9	17403374T6	17403374T17
17403374	CPR:9	17403374T7	17403374T16
17403374	CPR:9	17403374T7	17403374T17

17427197|t|D-glucose stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium.
17427197|a|Elevated extracellular D-glucose increases transforming growth factor beta1 (TGF-beta1) release from human umbilical vein endothelium (HUVEC). TGF-beta1, via TGF-beta receptors I (TbetaRI) and TbetaRII, activates Smad2 and mitogen-activated protein kinases p44 and p42 (p42/44(mapk)). We studied whether D-glucose-stimulation of L-arginine transport and nitric oxide synthesis involves TGF-beta1 in primary cultures of HUVEC. TGF-beta1 release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) D-glucose. TGF-beta1 increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport. TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation. TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor). However, TGF-beta1 and high D-glucose were ineffective in cells expressing a truncated, negative dominant TbetaRII. High D-glucose increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC. Thus, TGF-beta1 could play a crucial role under conditions of hyperglycemia, such as gestational diabetes mellitus, which is associated with fetal endothelial dysfunction.
17427197	761	770	D-glucose	CHEMICAL	17427197T10
17427197	792	802	L-arginine	CHEMICAL	17427197T11
17427197	869	878	D-glucose	CHEMICAL	17427197T12
17427197	903	912	D-glucose	CHEMICAL	17427197T13
17427197	923	933	L-arginine	CHEMICAL	17427197T14
17427197	964	973	D-glucose	CHEMICAL	17427197T15
17427197	1072	1090	L-[(3)H]citrulline	CHEMICAL	17427197T16
17427197	1106	1122	L-[(3)H]arginine	CHEMICAL	17427197T17
17427197	1133	1135	NO	CHEMICAL	427
17427197	1163	1165	NO	CHEMICAL	427
17427197	1260	1269	D-glucose	CHEMICAL	17427197T1
17427197	0	9	D-glucose	CHEMICAL	17427197T20
17427197	25	35	L-arginine	CHEMICAL	17427197T21
17427197	50	62	nitric oxide	CHEMICAL	17427197T22
17427197	1241	1250	TGF-beta1	GENE-Y	17427197T23
17427197	1280	1286	p42/44	GENE-N	17427197T24
17427197	1287	1291	mapk	GENE-N	17427197T25
17427197	1297	1302	Smad2	GENE-Y	201275|248011
17427197	1351	1357	MEK1/2	GENE-N	17427197T27
17427197	1379	1388	TGF-beta1	GENE-Y	17427197T28
17427197	1476	1484	TbetaRII	GENE-Y	17427197T29
17427197	1341	1349	PD-98059	CHEMICAL	17427197T2
17427197	1536	1540	eNOS	GENE-Y	17427197T30
17427197	1562	1570	TbetaRII	GENE-Y	17427197T31
17427197	1585	1594	TGF-beta1	GENE-Y	17427197T32
17427197	1605	1611	p42/44	GENE-N	17427197T33
17427197	1612	1616	mapk	GENE-N	17427197T34
17427197	1622	1627	Smad2	GENE-Y	201275|248011
17427197	1644	1653	TGF-beta1	GENE-Y	17427197T36
17427197	379	388	TGF-beta1	GENE-Y	17427197T37
17427197	394	414	TGF-beta receptors I	GENE-Y	17427197T38
17427197	416	423	TbetaRI	GENE-Y	17427197T39
17427197	1398	1407	D-glucose	CHEMICAL	17427197T3
17427197	429	437	TbetaRII	GENE-Y	17427197T40
17427197	449	454	Smad2	GENE-Y	201275|248011
17427197	459	492	mitogen-activated protein kinases	GENE-N	17427197T42
17427197	493	496	p44	GENE-Y	17427197T43
17427197	501	504	p42	GENE-Y	17427197T44
17427197	506	512	p42/44	GENE-N	17427197T45
17427197	513	517	mapk	GENE-N	17427197T46
17427197	622	631	TGF-beta1	GENE-Y	17427197T47
17427197	662	671	TGF-beta1	GENE-Y	17427197T48
17427197	279	311	transforming growth factor beta1	GENE-Y	17427197T49
17427197	1491	1500	D-glucose	CHEMICAL	17427197T4
17427197	772	781	TGF-beta1	GENE-Y	17427197T50
17427197	945	954	TGF-beta1	GENE-Y	17427197T51
17427197	984	990	hCAT-1	GENE-Y	17427197T52
17427197	313	322	TGF-beta1	GENE-Y	17427197T53
17427197	1151	1174	endothelial NO synthase	GENE-Y	17427197T54
17427197	1176	1180	eNOS	GENE-Y	17427197T55
17427197	1219	1223	eNOS	GENE-Y	17427197T56
17427197	100	140	mitogen-activated protein kinases p42/44	GENE-N	17427197T57
17427197	145	150	Smad2	GENE-Y	201275|248011
17427197	172	198	type II TGF-beta receptors	GENE-Y	17427197T59
17427197	1511	1521	L-arginine	CHEMICAL	17427197T5
17427197	259	268	D-glucose	CHEMICAL	17427197T6
17427197	540	549	D-glucose	CHEMICAL	17427197T7
17427197	565	575	L-arginine	CHEMICAL	17427197T8
17427197	590	602	nitric oxide	CHEMICAL	17427197T9
17427197	CPR:3	17427197T10	17427197T48
17427197	CPR:3	17427197T15	17427197T52
17427197	CPR:3	17427197T1	201275|248011
17427197	CPR:3	17427197T20	201275|248011
17427197	CPR:3	17427197T4	17427197T30
17427197	CPR:3	17427197T4	17427197T31
17427197	CPR:3	17427197T4	201275|248011
17427197	CPR:3	17427197T6	17427197T49
17427197	CPR:3	17427197T6	17427197T53
17427197	CPR:4	17427197T2	201275|248011
17427197	CPR:9	427	17427197T54
17427197	CPR:9	427	17427197T55

17459764|t|n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells.
17459764|a|Polyunsaturated fatty acids (PUFA) n-3 inhibit inflammation, in vivo and in vitro in keratinocytes. We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (COX-2), an enzyme pivotal to skin inflammation and reparation. We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (roziglitazone), induced COX-2 expression (protein and mRNA). Moreover stimulation of COX-2 promoter activity was increased by those PUFAs or rosiglitazone. The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction. Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation. These findings demonstrate that n-3 and n-6 PUFA increased PPARgamma activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells. Given the anti-inflammatory properties of EPA, we suggest that induction of COX-2 in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of PUFAs n-3 or n-6.
17459764	344	347	GLA	CHEMICAL	17459764T10
17459764	351	359	n-6 PUFA	CHEMICAL	17459764T11
17459764	365	379	arachidic acid	CHEMICAL	17459764T12
17459764	382	402	saturated fatty acid	CHEMICAL	17459764T13
17459764	557	560	GLA	CHEMICAL	17459764T14
17459764	565	568	EPA	CHEMICAL	153
17459764	592	605	roziglitazone	CHEMICAL	17459764T16
17459764	724	729	PUFAs	CHEMICAL	17459764T17
17459764	733	746	rosiglitazone	CHEMICAL	17459764T18
17459764	774	780	GW9662	CHEMICAL	17459764T19
17459764	131	169	Polyunsaturated fatty acids (PUFA) n-3	CHEMICAL	17459764T1
17459764	785	793	T0070907	CHEMICAL	17459764T20
17459764	888	891	EPA	CHEMICAL	153
17459764	896	899	GLA	CHEMICAL	17459764T22
17459764	988	1017	arachidonyl fluorophosphonate	CHEMICAL	17459764T23
17459764	1030	1034	PUFA	CHEMICAL	17459764T24
17459764	1085	1101	arachidonic acid	CHEMICAL	17459764T25
17459764	0	39	n-3 and n-6 polyunsaturated fatty acids	CHEMICAL	17459764T26
17459764	1159	1163	PPAR	GENE-N	17459764T27
17459764	1235	1244	PPARgamma	GENE-Y	17459764T28
17459764	1275	1280	COX-2	GENE-Y	17459764T29
17459764	1141	1143	AA	CHEMICAL	17459764T2
17459764	1402	1407	COX-2	GENE-Y	17459764T30
17459764	427	443	cyclooxygenase-2	GENE-Y	17459764T31
17459764	445	450	COX-2	GENE-Y	17459764T32
17459764	574	583	PPARgamma	GENE-Y	17459764T33
17459764	616	621	COX-2	GENE-Y	17459764T34
17459764	677	691	COX-2 promoter	GENE-N	17459764T35
17459764	795	804	PPARgamma	GENE-Y	17459764T36
17459764	822	827	COX-2	GENE-Y	17459764T37
17459764	861	875	COX-2 promoter	GENE-N	17459764T38
17459764	913	922	PPARgamma	GENE-Y	17459764T39
17459764	1208	1224	n-3 and n-6 PUFA	CHEMICAL	17459764T3
17459764	940	945	COX-2	GENE-Y	17459764T40
17459764	966	970	PLA2	GENE-Y	17459764T41
17459764	1046	1051	COX-2	GENE-Y	17459764T42
17459764	65	70	COX-2	GENE-Y	17459764T43
17459764	75	84	PPARgamma	GENE-Y	17459764T44
17459764	1368	1371	EPA	CHEMICAL	153
17459764	1505	1514	PUFAs n-3	CHEMICAL	17459764T5
17459764	283	304	eicosapentaenoic acid	CHEMICAL	17459764T6
17459764	306	309	EPA	CHEMICAL	153
17459764	313	321	n-3 PUFA	CHEMICAL	17459764T8
17459764	323	342	gamma-linoleic acid	CHEMICAL	17459764T9
17459764	CPR:3	17459764T14	17459764T34
17459764	CPR:3	153	17459764T34
17459764	CPR:3	17459764T16	17459764T34
17459764	CPR:3	17459764T17	17459764T35
17459764	CPR:3	17459764T18	17459764T35
17459764	CPR:3	17459764T26	17459764T43
17459764	CPR:3	17459764T26	17459764T44
17459764	CPR:3	17459764T2	17459764T27
17459764	CPR:3	17459764T3	17459764T28
17459764	CPR:3	17459764T3	17459764T29
17459764	CPR:3	17459764T5	17459764T30
17459764	CPR:4	17459764T23	17459764T41
17459764	CPR:4	17459764T23	17459764T42
17459764	CPR:6	17459764T19	17459764T36
17459764	CPR:6	17459764T20	17459764T36

17465221|t|Methylation-mediated silencing of genes is not altered by selenium treatment of prostate cancer cells.
17465221|a|BACKGROUND: The role of selenium in reducing the risk of multiple cancers has been described in the literature. Although reports have described the antiproliferative and pro-apoptotic function of selenium by up-regulation of genes in these pathways, information is lacking on the target mechanisms of selenium on specific genes. This study examines whether selenium treatment alters the methylation status of epigenetically silenced genes in prostate cancer cells. MATERIALS AND METHODS: Methylation of glutathione sulfotransferase pi (GSTP1) and Ras associated family 1A (RASSF1A) genes was studied using methylation sensitive PCR (MS-PCR). Gene expression was studied using Reverse Transcriptase PCR and Western Blotting. RESULTS AND CONCLUSION: Treatment of prostate cancer cells with selenium did not alter the expression of genes that were silenced by DNA methylation. Furthermore, the methylation status of these genes remained unaltered after treatment with seleno-DL-methionine.
17465221	639	644	GSTP1	GENE-Y	109205
17465221	650	674	Ras associated family 1A	GENE-Y	17465221T11
17465221	676	683	RASSF1A	GENE-Y	17465221T12
17465221	299	307	selenium	CHEMICAL	17465221T1
17465221	127	135	selenium	CHEMICAL	17465221T2
17465221	404	412	selenium	CHEMICAL	17465221T3
17465221	460	468	selenium	CHEMICAL	17465221T4
17465221	606	617	glutathione	CHEMICAL	17465221T5
17465221	891	899	selenium	CHEMICAL	17465221T6
17465221	1068	1088	seleno-DL-methionine	CHEMICAL	17465221T7
17465221	58	66	selenium	CHEMICAL	17465221T8
17465221	606	637	glutathione sulfotransferase pi	GENE-Y	17465221T9

17472819|t|Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
17472819|a|OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting beta(2)-adrenergic agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD). METHODS: This 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial was conducted at 60 centers across the United States. Male and female patients aged >or=35 years with physician-diagnosed COPD received arformoterol (15 microg BID, 25 microg BID, or 50 microg QD via nebulizer), salmeterol (42 microg BID via metered dose inhaler), or placebo. Pulmonary function was assessed by spirometry; dyspnea, by the Transitional Dyspnea Index (TDI); and health status, by the St. George's Respiratory Questionnaire (SGRQ). Adverse events (AEs) were assessed by site personnel at all clinic visits (screening, first dose at week 0, and at weeks 3, 6, 9, 12, and follow-up). COPD exacerbations were defined as worsening respiratory status requiring a change in medication or an unscheduled provider visit. RESULTS: A total of 717 patients received study medication. The demographic composition of all treatment arms was similar. The mean age was 62.9 years, 58% were men, and mean baseline forced expiratory volume in 1 second (FEV(1)) was 1.2 L (41% predicted). Mean improvement in trough FEV(1) over 12 weeks was significantly greater with all 3 arformoterol doses (15 microg BID, +16.9%; 25 microg BID, +18.9%; 50 microg QD, +14.9%) and for salmeterol (+17.4%) relative to placebo (+6.0%; P < 0.001). There were significantly greater improvements in the mean percentage change in FEV(1) AUC(0-12h) from the predose value over 12 weeks (15 microg BID, 12.7%, 25 microg BID, 13.9%, 50 microg QD, 18.9%; salmeterol, 9.8%) versus placebo (2.7%; P <or= 0.001); all doses of arformoterol were statistically different from salmeterol for this end point (P <or= 0.024). At week 12, TDI focal scores were significantly greater with all arformoterol doses compared with placebo (mean [95% CI]: 15 microg BID, 0.97 [0.25-1.69]; 25 microg BID, 1.08 [0.3-1.86]; 50 microg QD, 1.04 [0.32-1.771), suggesting treatment-associated improvement in dyspnea, however, the difference between salmeterol and placebo was not statistically significant (0.36 [-0.40 to 1.12]). Improvements in health status, as measured using SGRQ total scores, were -2.6 to -3.6 U in the arformoterol groups, -4.4 U for salmeterol, and -1.2 U for placebo; 95% CI of differences versus placebo suggested significant improvement for the arformoterol 25 microg BID and salmeterol groups. There was a similar frequency of AEs and COPD exacerbations across all groups, including placebo. CONCLUSIONS: In this trial, patients with moderate to severe COPD administered nebulized arformoterol over 12 weeks were observed to have significant and sustained improvements in airway function and dyspnea compared with placebo. The results also suggest that all doses of arformoterol, including the lowest dose (15 microg BID), were effective. Overall, nebulized arformoterol was well tolerated.
17472819	286	304	beta(2)-adrenergic	GENE-Y	17472819T10
17472819	1639	1651	arformoterol	CHEMICAL	17472819T1
17472819	1735	1745	salmeterol	CHEMICAL	17472819T2
17472819	325	351	[R,R] isomer of formoterol	CHEMICAL	17472819T3
17472819	1995	2005	salmeterol	CHEMICAL	17472819T4
17472819	357	377	salmeterol xinafoate	CHEMICAL	17472819T5
17472819	705	717	arformoterol	CHEMICAL	17472819T6
17472819	781	791	salmeterol	CHEMICAL	17472819T7
17472819	238	259	arformoterol tartrate	CHEMICAL	17472819T8
17472819	10	22	arformoterol	CHEMICAL	17472819T9
17472819	CPR:5	17472819T3	17472819T10
17472819	CPR:5	17472819T8	17472819T10

17477831|t|Discovery of acetyl-coenzyme A carboxylase 2 inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based ADP Assay for high-throughput screening.
17477831|a|Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in fatty acid biosynthesis and oxidation. Though each isoform differs in tissue and subcellular localization, both catalyze the biotin- and ATP-dependent carboxylation of acetyl-coenzyme A to generate malonyl-coenzyme A, a key metabolite in the control of fatty acid synthesis and oxidation. The cytosolic ACC1 is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in fatty acid biosynthesis. The mitochondrial ACC2 is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of fatty acid oxidation. Inhibitors of ACC enzymes may therefore be useful therapeutics for diabetes, obesity, and metabolic syndrome. Two assay formats for these ATP-utilizing enzymes amenable to high-throughput screening are compared: a fluorescence intensity-based assay to detect inorganic phosphate and a fluorescence polarization-based assay to detect ADP. Acetyl-coenzyme A carboxylase inhibitors were identified by these high-throughput screening methods and were confirmed in a radiometric high performance liquid chromatography assay of malonyl-coenzyme A production.
17477831	561	571	fatty acid	CHEMICAL	17477831T10
17477831	677	695	malonyl-coenzyme A	CHEMICAL	17477831T11
17477831	723	733	fatty acid	CHEMICAL	17477831T12
17477831	866	876	fatty acid	CHEMICAL	17477831T13
17477831	1026	1029	ATP	CHEMICAL	164
17477831	1147	1166	inorganic phosphate	CHEMICAL	17477831T15
17477831	102	111	phosphate	CHEMICAL	17477831T16
17477831	13	30	acetyl-coenzyme A	CHEMICAL	17477831T17
17477831	156	159	ADP	CHEMICAL	17477831T18
17477831	197	226	Acetyl-coenzyme A carboxylase	GENE-N	17477831T19
17477831	197	214	Acetyl-coenzyme A	CHEMICAL	17477831T1
17477831	1226	1255	Acetyl-coenzyme A carboxylase	GENE-N	17477831T20
17477831	228	231	ACC	GENE-N	61622
17477831	611	615	ACC1	GENE-Y	35841|25753|1222782
17477831	766	770	ACC2	GENE-Y	25754
17477831	264	268	ACC1	GENE-Y	35841|25753|1222782
17477831	902	905	ACC	GENE-N	61622
17477831	273	277	ACC2	GENE-Y	25754
17477831	13	44	acetyl-coenzyme A carboxylase 2	GENE-Y	17477831T27
17477831	1221	1224	ADP	CHEMICAL	17477831T2
17477831	1226	1243	Acetyl-coenzyme A	CHEMICAL	17477831T3
17477831	308	318	fatty acid	CHEMICAL	17477831T4
17477831	1410	1428	malonyl-coenzyme A	CHEMICAL	17477831T5
17477831	433	439	biotin	CHEMICAL	17477831T6
17477831	445	448	ATP	CHEMICAL	164
17477831	476	493	acetyl-coenzyme A	CHEMICAL	17477831T8
17477831	506	524	malonyl-coenzyme A	CHEMICAL	17477831T9
17477831	CPR:9	17477831T12	35841|25753|1222782
17477831	CPR:9	17477831T13	25754
17477831	CPR:9	17477831T4	17477831T19
17477831	CPR:9	17477831T4	61622
17477831	CPR:9	17477831T4	35841|25753|1222782
17477831	CPR:9	17477831T4	25754

17486539|t|Retinoic acid is required for specification of the ventral eye field and for Rathke's pouch in the avian embryo.
17486539|a|We have investigated the role of retinoic acid (RA) in eye development using the vitamin A deficient quail model system, which overcomes problems of retinoic acid synthesising enzyme redundancy in the embryo. In the absence of retinoic acid, the ventral optic stalk and ventral retina are missing, whereas the dorsal optic stalk and dorsal retina develop appropriately. Other ocular abnormalities observed were a thinner retina and the lack of differentiation of the lens. In an attempt to explain this, we studied the expression of various dorsally and ventrally expressed genes such as Pax2, Pax6, Tbx6, Vax2, Raldh1 and Raldh3 and noted that they were unchanged in their expression patterns. In contrast, the RA catabolising enzymes Cyp26A1 and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye. At much earlier stages, the expression domain of Shh in the prechordal plate was reduced, as was Nkx2.1 and we suggest a model whereby the eye field is specified according to the concentration of SHH protein that is present. We also describe another organ, Rathke's pouch which fails to develop in the absence of retinoic acid. We attribute this to the down-regulation of Bmp2, Shh and Fgf8 which are known to be involved in the induction of this structure.
17486539	1150	1153	SHH	GENE-Y	112365
17486539	1326	1330	Bmp2	GENE-N	198363
17486539	1332	1335	Shh	GENE-Y	203220
17486539	1340	1344	Fgf8	GENE-N	17486539T13
17486539	701	705	Pax2	GENE-N	202029
17486539	707	711	Pax6	GENE-Y	202033|247541
17486539	713	717	Tbx6	GENE-N	203991
17486539	719	723	Vax2	GENE-N	204905
17486539	725	731	Raldh1	GENE-N	17486539T18
17486539	736	742	Raldh3	GENE-N	17486539T19
17486539	1267	1280	retinoic acid	CHEMICAL	17486539T1
17486539	849	856	Cyp26A1	GENE-N	17486539T20
17486539	861	868	Cyp26B1	GENE-N	17486539T21
17486539	1003	1006	Shh	GENE-Y	203220
17486539	1051	1057	Nkx2.1	GENE-N	17486539T23
17486539	262	275	retinoic acid	CHEMICAL	17486539T2
17486539	340	353	retinoic acid	CHEMICAL	17486539T3
17486539	146	159	retinoic acid	CHEMICAL	17486539T4
17486539	161	163	RA	CHEMICAL	17486539T5
17486539	825	827	RA	CHEMICAL	17486539T6
17486539	891	893	RA	CHEMICAL	17486539T7
17486539	194	203	vitamin A	CHEMICAL	17486539T8
17486539	0	13	Retinoic acid	CHEMICAL	17486539T9
17486539	CPR:9	17486539T6	17486539T20
17486539	CPR:9	17486539T6	17486539T21

17494858|t|Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
17494858|a|Severe congenital neutropenia (SCN) is an inborn disorder of granulopoiesis. Like most other bone marrow failure syndromes, it is associated with a marked propensity to transform into a myelodysplastic syndrome (MDS) or acute leukemia, with a cumulative rate of transformation to MDS/leukemia that exceeds 20%. The genetic (and/or epigenetic) changes that contribute to malignant transformation in SCN are largely unknown. In this study, we performed mutational profiling of 14 genes previously implicated in leukemogenesis using 14 MDS/leukemia samples from patients with SCN. We used high-throughput exon-based resequencing of whole-genome-amplified genomic DNA with a semiautomated method to detect mutations. The sensitivity and specificity of the sequencing pipeline was validated by determining the frequency of mutations in these 14 genes using 188 de novo AML samples. As expected, mutations of tyrosine kinase genes (FLT3, KIT, and JAK2) were common in de novo AML, with a cumulative frequency of 30%. In contrast, no mutations in these genes were detected in the SCN samples; instead, mutations of CSF3R, encoding the G-CSF receptor, were common. These data support the hypothesis that mutations of CSF3R may provide the "activated tyrosine kinase signal" that is thought to be important for leukemogenesis.
17494858	1065	1069	JAK2	GENE-Y	109920
17494858	1366	1374	tyrosine	CHEMICAL	17494858T1
17494858	1027	1035	tyrosine	CHEMICAL	17494858T2
17494858	1232	1237	CSF3R	GENE-Y	107828
17494858	1252	1266	G-CSF receptor	GENE-Y	17494858T4
17494858	1333	1338	CSF3R	GENE-Y	107828
17494858	1366	1381	tyrosine kinase	GENE-N	17494858T6
17494858	1027	1042	tyrosine kinase	GENE-N	17494858T7
17494858	1050	1054	FLT3	GENE-Y	108610
17494858	1056	1059	KIT	GENE-Y	110015

17498508|t|Biology of incretins: GLP-1 and GIP.
17498508|a|This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was reviewed, with emphasis on recent advances in our understanding of the biology of GIP and GLP-1. GIP and GLP-1 are both secreted within minutes of nutrient ingestion and facilitate the rapid disposal of ingested nutrients. Both peptides share common actions on islet beta-cells acting through structurally distinct yet related receptors. Incretin-receptor activation leads to glucose-dependent insulin secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis. GIP also promotes energy storage via direct actions on adipose tissue, and enhances bone formation via stimulation of osteoblast proliferation and inhibition of apoptosis. In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion. GLP-1 also promotes satiety and sustained GLP-1-receptor activation is associated with weight loss in both preclinical and clinical studies. The rapid degradation of both GIP and GLP-1 by the enzyme dipeptidyl peptidase-4 has led to the development of degradation-resistant GLP-1-receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. These agents decrease hemoglobin A1c (HbA1c) safely without weight gain in subjects with type 2 diabetes. GLP-1 and GIP integrate nutrient-derived signals to control food intake, energy absorption, and assimilation. Recently approved therapeutic agents based on potentiation of incretin action provide new physiologically based approaches for the treatment of type 2 diabetes.
17498508	165	173	incretin	GENE-N	17498508T10
17498508	1373	1387	GLP-1-receptor	GENE-Y	17498508T11
17498508	1401	1423	dipeptidyl peptidase-4	GENE-Y	17498508T12
17498508	1495	1509	hemoglobin A1c	GENE-Y	17498508T13
17498508	183	227	glucose-dependent insulinotropic polypeptide	GENE-Y	17498508T14
17498508	1511	1516	HbA1c	GENE-Y	17498508T15
17498508	1579	1584	GLP-1	GENE-Y	17498508T16
17498508	1589	1592	GIP	GENE-Y	108962
17498508	1751	1759	incretin	GENE-N	17498508T18
17498508	229	232	GIP	GENE-Y	108962
17498508	1047	1054	glucose	CHEMICAL	17498508T1
17498508	238	261	glucagon-like peptide-1	GENE-Y	17498508T20
17498508	263	268	GLP-1	GENE-Y	17498508T21
17498508	382	385	GIP	GENE-Y	108962
17498508	390	395	GLP-1	GENE-Y	17498508T23
17498508	397	400	GIP	GENE-Y	108962
17498508	405	410	GLP-1	GENE-Y	17498508T25
17498508	638	655	Incretin-receptor	GENE-N	17498508T26
17498508	694	701	insulin	GENE-Y	17498508T27
17498508	789	792	GIP	GENE-Y	108962
17498508	974	979	GLP-1	GENE-Y	17498508T29
17498508	183	190	glucose	CHEMICAL	17498508T2
17498508	11	20	incretins	GENE-N	17498508T30
17498508	22	27	GLP-1	GENE-Y	17498508T31
17498508	32	35	GIP	GENE-Y	108962
17498508	676	683	glucose	CHEMICAL	17498508T3
17498508	1079	1087	glucagon	GENE-Y	17498508T4
17498508	1099	1104	GLP-1	GENE-Y	17498508T5
17498508	1141	1155	GLP-1-receptor	GENE-N	17498508T6
17498508	1270	1273	GIP	GENE-Y	108962
17498508	1278	1283	GLP-1	GENE-Y	17498508T8
17498508	1298	1320	dipeptidyl peptidase-4	GENE-Y	17498508T9
17498508	CPR:3	17498508T3	17498508T27

17500228|t|[Characteristics of A-interferon-generated dendritic cells in patients with pulmonary tuberculosis].
17500228|a|The phenotype of the dendritic cells (DC) generated from the adhesion fraction of mononuclear cells in the presence of GM-CSF and alpha-interferon was studied in patients with pulmonary tuberculosis. Despite the absence of significant differences in the count of mature CD83+DCs in the groups of patients (n = 38) and healthy donors (n = 30), elevated CD14(+)-monocyte levels and few activated CD25(+)-DCs were indicative of the impaired process of DC maturation/generation in patients with pulmonary tuberculosis, particularly in a subgroup of patients with a low T-cell proliferative response against PPD (PPD-anergy, n = 10). The patients with tuberculosis showed the lower relative levels of CD11c(-)-CD123(+)-DC and the normal levels of myeloid CD11c(+)D123(-)DCs. However, in patients with PPD-anergy, the content of myeloid CD11c(+)CD123(-)-DCs was significantly higher than that in PPD-reactive patients. Moreover, the patients with PPD-anergy were characterized by the elevated peripheral blood levels of CD14+CD16(+)-monocytes, which was associated with the high suppressive activity of monocytes (r(s) = 0.53; p < 0.05). The impaired process of DC generation/maturation in patients with pulmonary tuberculosis is believed to be associated with the changes in the phenotypic and functional properties of monocytes and to be a cause of an inadequate antigen-specific response in tuberculous infection.
17500228	231	247	alpha-interferon	GENE-N	17500228T1
17500228	20	32	A-interferon	GENE-N	17500228T2

17501690|t|Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
17501690|a|Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser. However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole. This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D(2) receptor and does not affect 5-HT receptors at therapeutic doses.
17501690	800	804	5-HT	CHEMICAL	17501690T10
17501690	33	41	dopamine	CHEMICAL	17501690T11
17501690	339	375	dopamine D(2) and 5-HT(1A) receptors	GENE-N	17501690T12
17501690	398	405	5-HT(2)	GENE-Y	17501690T13
17501690	757	779	dopamine D(2) receptor	GENE-Y	17501690T14
17501690	800	814	5-HT receptors	GENE-N	17501690T15
17501690	33	53	dopamine D2 receptor	GENE-Y	17501690T16
17501690	71	83	Aripiprazole	CHEMICAL	1226
17501690	339	347	dopamine	CHEMICAL	17501690T2
17501690	453	465	aripiprazole	CHEMICAL	17501690T3
17501690	479	487	dopamine	CHEMICAL	17501690T4
17501690	493	497	5-HT	CHEMICAL	17501690T5
17501690	566	570	5-HT	CHEMICAL	17501690T6
17501690	618	630	aripiprazole	CHEMICAL	17501690T7
17501690	701	713	aripiprazole	CHEMICAL	17501690T8
17501690	757	765	dopamine	CHEMICAL	17501690T9
17501690	CPR:5	17501690T8	17501690T14

17504182|t|Pharmacological therapy of Cushing's syndrome: drugs and indications.
17504182|a|OBJECTIVE: To review the main pharmacological properties and clinical applications of the drugs used in the medical therapy of Cushing's syndrome. DATA SOURCES: Search for articles were performed in the following dababases: MEDLINE, EMBASE, Cochrane Database of systematic Reviews and The Cochrane Central Register of Controlled Trials (CENTRAL). Search terms included Cushing's syndrome and drug therapy. DATA SYNTHESIS: Available data suggest that neuromodulatory compounds affect corticotropin (ACTH) or ACTH-releasing hormone (CRH) synthesis and release. They include serotonin antagonists, dopaminergic agonists, valproic acid, reserpine, somatostatin analogs and thiazolidinediones. These agents have been effective in a limited number of patients with ACTH-dependent Cushing's syndrome. Inhibitors of steroidogenesis reduce cortisol production by blocking one (metyrapone, trilostane) or several (aminoglutethimide, ketoconazole, fluconazole, etomidate) enzymes involved in steroid biosynthesis. Mitotane is a steroidogenesis inhibitor with adrenolitic properties. Mifepriston'e blocks glucocorticoid receptor activation without modifying cortisol synthesis. CONCLUSION: Agents that inhibit steroidogenesis are useful in all forms of Cushing's syndrome and are effective in about 70% of patients. Main indications for drug therapy include preparation for surgery, persistence or recurrence after surgery, while awaiting for the effect of radiation therapy, occult ectopic ACTH syndrome, severe hypercortisolism and malignancy related hypercortisolism.
17504182	974	991	aminoglutethimide	CHEMICAL	17504182T10
17504182	993	1005	ketoconazole	CHEMICAL	17504182T11
17504182	1007	1018	fluconazole	CHEMICAL	17504182T12
17504182	1020	1029	etomidate	CHEMICAL	285
17504182	1163	1186	glucocorticoid receptor	GENE-Y	17504182T14
17504182	1549	1553	ACTH	GENE-Y	17504182T15
17504182	553	566	corticotropin	GENE-Y	17504182T16
17504182	568	572	ACTH	GENE-Y	17504182T17
17504182	577	599	ACTH-releasing hormone	GENE-Y	17504182T18
17504182	601	604	CRH	GENE-Y	107782
17504182	1073	1081	Mitotane	CHEMICAL	638
17504182	714	726	somatostatin	GENE-Y	17504182T20
17504182	829	833	ACTH	GENE-Y	17504182T21
17504182	1142	1155	Mifepriston'e	CHEMICAL	17504182T2
17504182	1216	1224	cortisol	CHEMICAL	17504182T3
17504182	642	651	serotonin	CHEMICAL	17504182T4
17504182	688	701	valproic acid	CHEMICAL	17504182T5
17504182	703	712	reserpine	CHEMICAL	17504182T6
17504182	739	757	thiazolidinediones	CHEMICAL	17504182T7
17504182	938	948	metyrapone	CHEMICAL	17504182T8
17504182	950	960	trilostane	CHEMICAL	17504182T9
17504182	CPR:4	17504182T2	17504182T14

17507169|t|Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies.
17507169|a|[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective cannabinoid CB1 receptor antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection. This effect is mediated by the release of glutamic acid, which in turn activates central oxytocinergic neurons mediating penile erection. Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. As GABAergic synapses in the PVN impinge directly on oxytocinergic neurons or on excitatory glutamatergic synapses, which also impinge on oxytocinergic neurons, these results suggest that the blockade of CB1 receptors decreases GABA release in the PVN, increasing in turn glutamatergic neurotransmission to activate oxytocinergic neurons mediating penile erection. Autoradiography studies with [(3)H](-)-CP 55,940 show that chronic treatment with SR 141716A for 15 days twice daily (1 mg/kg i.p.) significantly increases the density of CB1 receptors in the PVN. This increase occurs concomitantly with an almost twofold increase in the pro-erectile effect of SR 141716A injected into the PVN as compared with control rats. The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of CB1 receptors by SR 141716A increases the density of these receptors in the PVN. This increase is related to an enhanced pro-erectile effect of SR 141716A, which is still present 3 days after the end of the chronic treatment.
17507169	663	672	glutamate	CHEMICAL	17507169T10
17507169	715	728	glutamic acid	CHEMICAL	17507169T11
17507169	758	766	oxytocin	CHEMICAL	102
17507169	235	245	SR 141716A	CHEMICAL	17507169T13
17507169	1136	1140	GABA	CHEMICAL	17507169T14
17507169	0	11	Cannabinoid	CHEMICAL	17507169T15
17507169	260	284	cannabinoid CB1 receptor	GENE-Y	17507169T16
17507169	1444	1457	CB1 receptors	GENE-Y	17507169T17
17507169	1669	1682	CB1 receptors	GENE-Y	17507169T18
17507169	1888	1901	CB1 receptors	GENE-Y	17507169T19
17507169	260	271	cannabinoid	CHEMICAL	17507169T1
17507169	610	623	CB1 receptors	GENE-Y	17507169T20
17507169	625	651	glutamic acid transporters	GENE-N	17507169T21
17507169	653	693	vesicular glutamate transporters 1 and 2	GENE-N	17507169T22
17507169	695	701	VGlut1	GENE-Y	17507169T23
17507169	706	712	VGlut2	GENE-Y	17507169T24
17507169	715	745	glutamic acid decarboxylase-67	GENE-Y	17507169T25
17507169	747	752	GAD67	GENE-Y	17507169T26
17507169	758	766	oxytocin	GENE-Y	17507169T27
17507169	791	804	CB1 receptors	GENE-Y	17507169T28
17507169	1112	1125	CB1 receptors	GENE-Y	17507169T29
17507169	1302	1321	[(3)H](-)-CP 55,940	CHEMICAL	17507169T2
17507169	0	25	Cannabinoid CB1 receptors	GENE-Y	17507169T30
17507169	1355	1365	SR 141716A	CHEMICAL	17507169T3
17507169	1567	1577	SR 141716A	CHEMICAL	17507169T4
17507169	1905	1915	SR 141716A	CHEMICAL	17507169T5
17507169	159	232	N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide	CHEMICAL	17507169T6
17507169	2032	2042	SR 141716A	CHEMICAL	17507169T7
17507169	446	459	glutamic acid	CHEMICAL	17507169T8
17507169	625	638	glutamic acid	CHEMICAL	17507169T9
17507169	CPR:4	17507169T5	17507169T19
17507169	CPR:6	17507169T13	17507169T16
17507169	CPR:6	17507169T6	17507169T16

17510465|t|Activation of human platelets by misfolded proteins.
17510465|a|OBJECTIVE: Protein misfolding diseases result from the deposition of insoluble protein aggregates that often contain fibrils called amyloid. Amyloids are found in Alzheimer disease, atherosclerosis, diabetes mellitus, and systemic amyloidosis, which are diseases where platelet activation might be implicated. METHODS AND RESULTS: We induced amyloid properties in 6 unrelated proteins and found that all induced platelet aggregation in contrast to fresh controls. Amyloid-induced platelet aggregation was independent of thromboxane A2 formation and ADP secretion but enhanced by feedback stimulation through these pathways. Treatments that raised cAMP (iloprost), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition. Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition. Interference with fibrinogen binding (RGDS) revealed a major contribution of alphaIIb beta3-independent aggregation (agglutination). CONCLUSIONS: Protein misfolding resulting in the appearance of amyloid induces platelet aggregation. Amyloid activates platelets through 2 pathways: one is through CD36, p38(MAPK), thromboxane A2-mediated induction of aggregation; the other is through glycoprotein Ib alpha-mediated aggregation and agglutination. The platelet stimulating properties of amyloid might explain the enhanced platelet activation observed in many diseases accompanied by the appearance of misfolded proteins with amyloid.
17510465	1077	1087	fibrinogen	GENE-N	17510465T10
17510465	1136	1150	alphaIIb beta3	GENE-N	17510465T11
17510465	1255	1262	amyloid	GENE-N	17510465T12
17510465	1293	1300	Amyloid	GENE-N	17510465T13
17510465	1356	1360	CD36	GENE-N	107386
17510465	1362	1365	p38	GENE-N	17510465T15
17510465	1366	1370	MAPK	GENE-N	17510465T16
17510465	185	192	amyloid	GENE-Y	17510465T17
17510465	1444	1465	glycoprotein Ib alpha	GENE-N	17510465T18
17510465	194	202	Amyloids	GENE-Y	17510465T19
17510465	1373	1387	thromboxane A2	CHEMICAL	17510465T1
17510465	395	402	amyloid	GENE-Y	17510465T20
17510465	517	524	Amyloid	GENE-Y	17510465T21
17510465	758	765	amyloid	GENE-Y	17510465T22
17510465	795	828	tissue-type plasminogen activator	GENE-Y	17510465T23
17510465	830	833	tPA	GENE-Y	17510465T24
17510465	902	906	CD36	GENE-N	107386
17510465	923	926	p38	GENE-N	17510465T26
17510465	927	931	MAPK	GENE-N	17510465T27
17510465	945	950	COX-1	GENE-N	17510465T28
17510465	971	992	glycoprotein Ib alpha	GENE-N	17510465T29
17510465	573	587	thromboxane A2	CHEMICAL	17510465T2
17510465	994	1005	Nk-protease	GENE-N	17510465T30
17510465	602	605	ADP	CHEMICAL	17510465T3
17510465	700	704	cAMP	CHEMICAL	2424
17510465	706	714	iloprost	CHEMICAL	17510465T5
17510465	729	733	Ca2+	CHEMICAL	17510465T6
17510465	735	743	BAPTA-AM	CHEMICAL	17510465T7
17510465	934	942	SB203580	CHEMICAL	17510465T8
17510465	952	964	indomethacin	CHEMICAL	17510465T9
17510465	CPR:4	17510465T8	17510465T26
17510465	CPR:4	17510465T8	17510465T27
17510465	CPR:4	17510465T9	17510465T28

17512723|t|RDH12, a retinol dehydrogenase causing Leber's congenital amaurosis, is also involved in steroid metabolism.
17512723|a|Three retinol dehydrogenases (RDHs) were tested for steroid converting abilities: human and murine RDH 12 and human RDH13. RDH12 is involved in retinal degeneration in Leber's congenital amaurosis (LCA). We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that human type 12 RDH reduces dihydrotestosterone to androstanediol, and is thus also involved in steroid metabolism. Furthermore, we analyzed both expression and subcellular localization of these enzymes.
17512723	115	137	retinol dehydrogenases	GENE-N	17512723T10
17512723	191	214	human and murine RDH 12	GENE-N	17512723T11
17512723	0	5	RDH12	GENE-Y	126895
17512723	9	30	retinol dehydrogenase	GENE-N	17512723T13
17512723	466	480	androstanediol	CHEMICAL	17512723T1
17512723	115	122	retinol	CHEMICAL	17512723T2
17512723	9	16	retinol	CHEMICAL	17512723T3
17512723	219	230	human RDH13	GENE-Y	17512723T4
17512723	232	237	RDH12	GENE-Y	126895
17512723	326	338	murine Rdh12	GENE-Y	17512723T6
17512723	343	354	human RDH13	GENE-Y	17512723T7
17512723	139	143	RDHs	GENE-N	17512723T8
17512723	417	434	human type 12 RDH	GENE-Y	17512723T9
17512723	CPR:9	17512723T1	17512723T9

17544870|t|Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
17544870|a|BACKGROUND & AIMS: It is unclear whether weight loss with the noradrenergic (norepinephrine) and serotonergic (5-hydroxytryptamine) reuptake inhibitor, sibutramine, is associated with altered stomach functions and whether genetics influence treatment response. METHODS: Forty-eight overweight and obese but otherwise healthy participants were randomized to placebo or sibutramine (15 mg/day for 12 weeks). At baseline and posttreatment we measured the following: gastric emptying for solids and liquids by scintigraphy, gastric volumes by single-photon emission computed tomography, maximum tolerated volume and 30-minute postnutrient challenge symptoms, and selected gastrointestinal hormones. All participants received structured behavior therapy for weight management. The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated. RESULTS: The overall average weight loss posttreatment was 5.4 +/- 0.8 (SEM) kg with sibutramine and 0.9 +/- 0.9 kg with placebo (P < .001). The sibutramine group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial peptide YY compared with the placebo group. Obese females showed greater effects of sibutramine on weight loss and gastric emptying of solids and liquids. Gastric volumes and postchallenge symptoms were not significantly different in the 2 treatment groups. The LS/SS genotype of the promoter for SLC6A4 was associated with enhanced weight loss with sibutramine. CONCLUSIONS: Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype. The role of genetic variation in SLC6A4 on weight loss in response to sibutramine deserves further study.
17544870	481	492	sibutramine	CHEMICAL	17544870T10
17544870	190	204	norepinephrine	CHEMICAL	17544870T11
17544870	943	957	norepinephrine	CHEMICAL	17544870T12
17544870	962	981	5-hydroxytryptamine	CHEMICAL	17544870T13
17544870	1004	1022	phenylethanolamine	CHEMICAL	17544870T14
17544870	1023	1024	N	CHEMICAL	167
17544870	1044	1062	guanine nucleotide	CHEMICAL	17544870T16
17544870	100	111	sibutramine	CHEMICAL	17544870T17
17544870	1127	1201	solute carrier family 6 [neurotransmitter transporter, serotonin] member 4	GENE-Y	17544870T18
17544870	1218	1224	SLC6A4	GENE-Y	112423
17544870	1182	1191	serotonin	CHEMICAL	17544870T1
17544870	1585	1595	peptide YY	GENE-Y	17544870T20
17544870	1882	1888	SLC6A4	GENE-Y	112423
17544870	2054	2064	peptide YY	GENE-Y	17544870T22
17544870	2102	2108	SLC6A4	GENE-Y	112423
17544870	2152	2158	SLC6A4	GENE-Y	112423
17544870	1044	1097	guanine nucleotide binding protein beta polypeptide 3	GENE-Y	17544870T25
17544870	1099	1121	alpha2A adrenoreceptor	GENE-Y	17544870T26
17544870	224	243	5-hydroxytryptamine	CHEMICAL	17544870T2
17544870	1364	1375	sibutramine	CHEMICAL	17544870T3
17544870	1424	1435	sibutramine	CHEMICAL	17544870T4
17544870	265	276	sibutramine	CHEMICAL	17544870T5
17544870	1669	1680	sibutramine	CHEMICAL	17544870T6
17544870	1935	1946	sibutramine	CHEMICAL	17544870T7
17544870	1983	1994	sibutramine	CHEMICAL	17544870T8
17544870	2189	2200	sibutramine	CHEMICAL	17544870T9
17544870	CPR:3	17544870T4	17544870T20
17544870	CPR:3	17544870T8	17544870T22

17570336|t|Multiple rat brain calpastatin forms are produced by distinct starting points and alternative splicing of the N-terminal exons.
17570336|a|5'-RACE was performed on rat brain calpastatin mRNA and two new translation initiation ATG's were found. The first one is upstream of the previously designed initiation translation site localized in the rat calpastatin L-domain. The deduced protein sequence of this region is highly homologous to the XL-domain of calpastatin type I in other species. The other ATG has not previously been reported and is localized in exon 8, thus originating a calpastatin isoform constituted only by four repetitive inhibitory units without the XL-L-domains. Transcripts from the rat brain calpastatin gene are also subjected to multiple splicing events involving exons 4, 6, 8 in different combinations. A series of recombinant calpastatin forms was produced that differed in the exons present in the L-domain, and all the variants showed comparable inhibitory efficiency against calpain. It was concluded that the presence of the XL-domain in these isoforms is not relevant for the formation of the calpain/calpastatin complex in the absence of calcium, that is the interaction of calpastatin with inactive calpain. Using exon-specific antisera, specific calpastatin protein isoforms containing the XL-domain have been detected in rat brain homogenates.
17570336	442	460	calpastatin type I	GENE-N	17570336T10
17570336	573	584	calpastatin	GENE-Y	17570336T11
17570336	658	670	XL-L-domains	GENE-N	17570336T12
17570336	693	714	rat brain calpastatin	GENE-Y	17570336T13
17570336	842	853	calpastatin	GENE-Y	17570336T14
17570336	915	923	L-domain	GENE-N	17570336T15
17570336	994	1001	calpain	GENE-N	17570336T16
17570336	1045	1054	XL-domain	GENE-N	17570336T17
17570336	1114	1121	calpain	GENE-N	17570336T18
17570336	1122	1133	calpastatin	GENE-Y	17570336T19
17570336	1160	1167	calcium	CHEMICAL	17570336T1
17570336	9	30	rat brain calpastatin	GENE-Y	17570336T20
17570336	110	111	N	CHEMICAL	167
17570336	1196	1207	calpastatin	GENE-Y	17570336T3
17570336	1222	1229	calpain	GENE-N	17570336T4
17570336	1270	1281	calpastatin	GENE-Y	17570336T5
17570336	1314	1323	XL-domain	GENE-N	17570336T6
17570336	331	355	rat calpastatin L-domain	GENE-N	17570336T7
17570336	153	174	rat brain calpastatin	GENE-Y	17570336T8
17570336	429	438	XL-domain	GENE-N	17570336T9

17575572|t|An investigation of the absolute configuration of the potent histamine H3 receptor antagonist GT-2331 using vibrational circular dichroism.
17575572|a|GT-2331 [(+)-1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of histamine by the histamine H3 receptor, and as such, is an important biomarker for pharmaceutical companies conducting research in this field. In addition to overall structural features, the bioactivity of this molecule has also been found to be highly dependent on absolute stereochemistry, making the reliable assignment of this property a necessity. X-ray diffraction studies have provided conflicting data, leaving its three-dimensional structure uncertain. In view of this, its absolute configuration was investigated by vibrational circular dichroism. Results from this study provided independent assignment of this important molecule as the (1S,2S)-enantiomer.
17575572	140	147	GT-2331	CHEMICAL	17575572T1
17575572	273	282	histamine	CHEMICAL	17575572T2
17575572	290	299	histamine	CHEMICAL	17575572T3
17575572	61	70	histamine	CHEMICAL	17575572T4
17575572	94	101	GT-2331	CHEMICAL	17575572T5
17575572	290	311	histamine H3 receptor	GENE-Y	17575572T6
17575572	61	82	histamine H3 receptor	GENE-Y	17575572T7
17575572	CPR:6	17575572T5	17575572T7

17588565|t|Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors.
17588565|a|Neuromuscular blocking drugs produce muscle weakness by interaction with nicotinic-acetylcholine receptors. Cardiovascular side effects have been reported. In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant human muscarinic M2 receptors K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01). These data indicate that vecuronium, gallamine and pancuronium interact with an allosteric site on the muscarinic M2 receptor (located on the heart) and this may explain some of their cardiac side effects.
17588565	692	703	pancuronium	CHEMICAL	17588565T10
17588565	712	720	atropine	CHEMICAL	17588565T11
17588565	780	790	vecuronium	CHEMICAL	17588565T12
17588565	792	801	gallamine	CHEMICAL	17588565T13
17588565	806	817	pancuronium	CHEMICAL	17588565T14
17588565	211	224	acetylcholine	CHEMICAL	17588565T15
17588565	53	63	vecuronium	CHEMICAL	17588565T16
17588565	68	79	pancuronium	CHEMICAL	17588565T17
17588565	515	544	human muscarinic M2 receptors	GENE-Y	17588565T18
17588565	858	880	muscarinic M2 receptor	GENE-Y	17588565T19
17588565	330	340	vecuronium	CHEMICAL	17588565T1
17588565	201	234	nicotinic-acetylcholine receptors	GENE-N	17588565T20
17588565	97	126	human muscarinic M2 receptors	GENE-Y	17588565T21
17588565	358	367	gallamine	CHEMICAL	17588565T2
17588565	372	383	pancuronium	CHEMICAL	17588565T3
17588565	403	411	atropine	CHEMICAL	17588565T4
17588565	420	445	[(3)H]N-methylscopolamine	CHEMICAL	17588565T5
17588565	568	578	vecuronium	CHEMICAL	17588565T6
17588565	589	597	atropine	CHEMICAL	17588565T7
17588565	631	640	gallamine	CHEMICAL	17588565T8
17588565	650	658	atropine	CHEMICAL	17588565T9
17588565	CPR:4	17588565T1	17588565T18
17588565	CPR:4	17588565T2	17588565T18
17588565	CPR:4	17588565T3	17588565T18

17592724|t|Hydrogen peroxide-mediated oxidative stress disrupts calcium binding on calmodulin: more evidence for oxidative stress in vitiligo.
17592724|a|Patients with acute vitiligo have low epidermal catalase expression/activities and accumulate 10(-3) M H(2)O(2). One consequence of this severe oxidative stress is an altered calcium homeostasis in epidermal keratinocytes and melanocytes. Here, we show decreased epidermal calmodulin expression in acute vitiligo. Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined calcium binding to calmodulin in the presence and absence of H(2)O(2) utilising (45)calcium. The results showed that all four calcium atoms exchanged per molecule of calmodulin. Since oxidised calmodulin looses its ability to activate calcium ATPase, enzyme activities were followed in full skin biopsies from lesional skin of patients with acute vitiligo (n=6) and healthy controls (n=6). The results yielded a 4-fold decrease of ATPase activities in the patients. Computer simulation of native and oxidised calmodulin confirmed the loss of all four calcium ions from their specific EF-hand domains. Taken together H(2)O(2)-mediated oxidation affects calcium binding in calmodulin leading to perturbed calcium homeostasis and perturbed l-phenylalanine-uptake in the epidermis of acute vitiligo.
17592724	538	545	calcium	CHEMICAL	17592724T10
17592724	599	607	H(2)O(2)	CHEMICAL	17592724T11
17592724	622	629	calcium	CHEMICAL	17592724T12
17592724	664	671	calcium	CHEMICAL	17592724T13
17592724	773	780	calcium	CHEMICAL	17592724T14
17592724	1089	1096	calcium	CHEMICAL	17592724T15
17592724	0	17	Hydrogen peroxide	CHEMICAL	17592724T16
17592724	53	60	calcium	CHEMICAL	17592724T17
17592724	1209	1219	calmodulin	GENE-Y	17592724T18
17592724	405	415	calmodulin	GENE-Y	17592724T19
17592724	1154	1162	H(2)O(2)	CHEMICAL	17592724T1
17592724	557	567	calmodulin	GENE-Y	17592724T20
17592724	180	188	catalase	GENE-Y	17592724T21
17592724	704	714	calmodulin	GENE-Y	17592724T22
17592724	731	741	calmodulin	GENE-Y	17592724T23
17592724	773	787	calcium ATPase	GENE-N	17592724T24
17592724	1047	1057	calmodulin	GENE-Y	17592724T25
17592724	1122	1137	EF-hand domains	GENE-N	17592724T26
17592724	72	82	calmodulin	GENE-Y	17592724T27
17592724	235	243	H(2)O(2)	CHEMICAL	17592724T2
17592724	1190	1197	calcium	CHEMICAL	17592724T3
17592724	1241	1248	calcium	CHEMICAL	17592724T4
17592724	1275	1290	l-phenylalanine	CHEMICAL	17592724T5
17592724	307	314	calcium	CHEMICAL	17592724T6
17592724	460	468	H(2)O(2)	CHEMICAL	17592724T7
17592724	478	488	methionine	CHEMICAL	17592724T8
17592724	493	503	tryptophan	CHEMICAL	17592724T9
17592724	CPR:9	17592724T2	17592724T21

17596133|t|The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.
17596133|a|BACKGROUND: The efficacy of oral anticoagulant therapy is largely conditioned by both environmental and genetic factors. OBJECTIVES: To attempt to define the genetic profile involved in the response to this treatment. PATIENTS AND METHODS: We selected 100 men younger than 75 years, with non-valvular atrial fibrillation, who started anticoagulation with acenocoumarol following the same protocol: 3 mg for three consecutive days. Then, doses were individually adjusted to achieve a steady International Normalized Ratio (INR). The basal plasma level and the level after 3 days were obtained, and the INR was determined. We studied five functional polymorphisms: FVII -323 Del/Ins, CYP2C*9, VKORC1 c1173t, calumenin (CALU) R4Q and CALU a29809g. The dose required for a steady INR was also recorded. RESULTS: Only the VKORC1 genotype had significant impact on the efficacy of therapy. Carriers of the 1173t allele were significantly more sensitive to therapy for 3 days [INR 2.07 (1.59-2.87) vs. 1.74 (1.30-2.09); P = 0.015] and they needed lower acenocoumarol doses to stabilize their INR (15.8 +/- 5.6 vs. 19.5 +/- 6.0 mg week(-1); P = 0.004). Its effect was exacerbated by combination with the CALU a29809g polymorphism. Carriers of both variants (27% of the sample) achieved the highest INR [2.26 (1.70-3.32)] and required the lowest dose (14.1 +/- 5.1 mg week(-1)). This genetic profile was particularly relevant in patients with INR >or= 3.5 at the start of therapy (P = 0.005; odds ratio = 6.67, 95% confidence interval = 1.32-37.43). CONCLUSIONS: Our results suggest that CALU a29809g might be a new genetic factor involved in the pharmacogenetics of anticoagulant therapy, and confirm that specific genetic profiles defined by different polymorphisms will determine the initial response and dose required to achieve a stable and safe INR.
17596133	840	844	CALU	GENE-Y	107263
17596133	846	849	R4Q	GENE-N	17596133T11
17596133	854	858	CALU	GENE-Y	107263
17596133	859	866	a29809g	GENE-N	17596133T13
17596133	940	946	VKORC1	GENE-Y	122472
17596133	32	38	VKORC1	GENE-Y	122472
17596133	39	45	c1173t	GENE-N	17596133T16
17596133	50	59	calumenin	GENE-Y	17596133T17
17596133	60	67	a29809g	GENE-N	17596133T18
17596133	1319	1323	CALU	GENE-Y	107263
17596133	1324	1331	a29809g	GENE-N	17596133T2
17596133	1702	1706	CALU	GENE-Y	107263
17596133	1707	1714	a29809g	GENE-N	17596133T4
17596133	786	790	FVII	GENE-Y	17596133T5
17596133	805	812	CYP2C*9	GENE-Y	17596133T6
17596133	814	820	VKORC1	GENE-Y	122472
17596133	821	827	c1173t	GENE-N	17596133T8
17596133	829	838	calumenin	GENE-Y	17596133T9

17602574|t|Characterization of the nitrosyl adduct of substrate-bound mouse cysteine dioxygenase by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications.
17602574|a|Mammalian cysteine dioxygenase (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism. The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif. Nitric oxide was used as a spectroscopic probe in investigating the order of substrate-O2 binding by EPR spectroscopy. In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes. Moreover, the CDO active site is essentially unreactive toward NO in the absence of substrate, suggesting an obligate ordered binding of l-cysteine prior to NO. Typically, addition of NO to a mononuclear non-heme iron center results in the formation of an {FeNO}7 (S = 3/2) species characterized by an axial EPR spectrum with gx, gy, and gz values of approximately 4, approximately 4, and approximately 2, respectively. However, upon addition of NO to CDO in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops. Similar {FeNO}7 (S = 1/2) EPR signals have been observed for a variety of octahedral mononuclear iron-nitrosyl synthetic complexes; however, this type of iron-nitrosyl species is not commonly observed for non-heme iron enzymes. Substitution of l-cysteine with isosteric substrate analogues cysteamine, 3-mercaptopropionic acid, and propane thiol did not produce any analogous {FeNO}7 signals (S = 1/2 or 3/2), thus reflecting the high substrate specificity of the enzyme observed by a number of researchers. The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site. DFT computations were performed to further characterize this species. The DFT-predicted geometric parameters for {ES-NO}7 are in good agreement with the crystallographically determined substrate-bound active site configuration of CDO and are consistent with known iron-nitrosyl model complexes. Moreover, the computed EPR parameters (g and A values) are in excellent agreement with experimental results for this CDO species and those obtained from comparable synthetic {FeNO}7 (S = 1/2) iron-nitrosyl complexes.
17602574	1672	1676	iron	CHEMICAL	17602574T10
17602574	1702	1712	l-cysteine	CHEMICAL	17602574T11
17602574	1748	1758	cysteamine	CHEMICAL	17602574T12
17602574	1760	1784	3-mercaptopropionic acid	CHEMICAL	17602574T13
17602574	1790	1803	propane thiol	CHEMICAL	17602574T14
17602574	1835	1839	FeNO	CHEMICAL	17602574T15
17602574	1979	1983	FeNO	CHEMICAL	17602574T16
17602574	2052	2065	iron-nitrosyl	CHEMICAL	17602574T17
17602574	2082	2084	NO	CHEMICAL	427
17602574	2107	2128	bidentate thiol/amine	CHEMICAL	17602574T19
17602574	202	210	cysteine	CHEMICAL	17602574T1
17602574	2145	2155	l-cysteine	CHEMICAL	17602574T20
17602574	2163	2165	NO	CHEMICAL	427
17602574	396	400	iron	CHEMICAL	17602574T22
17602574	2306	2308	NO	CHEMICAL	427
17602574	2453	2466	iron-nitrosyl	CHEMICAL	17602574T24
17602574	2659	2663	FeNO	CHEMICAL	17602574T25
17602574	2676	2689	iron-nitrosyl	CHEMICAL	17602574T26
17602574	456	466	histidines	CHEMICAL	17602574T27
17602574	507	532	2-histidine-1-carboxylate	CHEMICAL	17602574T28
17602574	534	538	2H1C	CHEMICAL	17602574T29
17602574	1295	1297	NO	CHEMICAL	427
17602574	560	572	Nitric oxide	CHEMICAL	427
17602574	647	649	O2	CHEMICAL	17602574T31
17602574	243	247	iron	CHEMICAL	17602574T32
17602574	736	746	l-cysteine	CHEMICAL	17602574T33
17602574	756	758	NO	CHEMICAL	427
17602574	775	777	O2	CHEMICAL	17602574T35
17602574	812	816	2H1C	CHEMICAL	17602574T36
17602574	835	839	iron	CHEMICAL	17602574T37
17602574	912	914	NO	CHEMICAL	427
17602574	986	996	l-cysteine	CHEMICAL	17602574T39
17602574	1334	1344	l-cysteine	CHEMICAL	17602574T3
17602574	1006	1008	NO	CHEMICAL	427
17602574	1033	1035	NO	CHEMICAL	427
17602574	1062	1066	iron	CHEMICAL	17602574T42
17602574	1106	1110	FeNO	CHEMICAL	17602574T43
17602574	24	32	nitrosyl	CHEMICAL	17602574T44
17602574	65	73	cysteine	CHEMICAL	17602574T45
17602574	192	222	Mammalian cysteine dioxygenase	GENE-Y	17602574T46
17602574	1301	1304	CDO	GENE-Y	17602574T47
17602574	368	371	CDO	GENE-Y	17602574T48
17602574	2066	2069	CDO	GENE-Y	17602574T49
17602574	1358	1362	FeNO	CHEMICAL	17602574T4
17602574	2172	2175	CDO	GENE-Y	17602574T50
17602574	2419	2422	CDO	GENE-Y	17602574T51
17602574	2601	2604	CDO	GENE-Y	17602574T52
17602574	507	558	2-histidine-1-carboxylate (2H1C) facial triad motif	GENE-N	17602574T53
17602574	224	227	CDO	GENE-Y	17602574T54
17602574	701	704	CDO	GENE-Y	17602574T55
17602574	812	847	2H1C class of non-heme iron enzymes	GENE-N	17602574T56
17602574	863	866	CDO	GENE-Y	17602574T57
17602574	59	85	mouse cysteine dioxygenase	GENE-Y	17602574T58
17602574	315	323	cysteine	CHEMICAL	17602574T5
17602574	1425	1429	iron	CHEMICAL	17602574T6
17602574	1467	1471	FeNO	CHEMICAL	17602574T7
17602574	1555	1568	iron-nitrosyl	CHEMICAL	17602574T8
17602574	1612	1625	iron-nitrosyl	CHEMICAL	17602574T9
17602574	CPR:9	17602574T3	17602574T47
17602574	CPR:9	17602574T5	17602574T46
17602574	CPR:9	17602574T5	17602574T54

17632107|t|Ligand-dependent transcriptional activities of four torafugu pufferfish Takifugu rubripes peroxisome proliferator-activated receptors.
17632107|a|Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the acyl-CoA oxidase PPAR response element. Although torafugu PPARs showed a high similarity in the primary structure to other vertebrate counterparts, torafugu PPARalpha2 and gamma contained additional sequences of 21 and 28 amino acids, respectively, as in the case of other teleost fish species when compared with African clawed frog counterparts. The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively. The activities of torafugu PPARalpha1 and alpha2 were also enhanced 5.6- and 6.3-fold by ETYA at 1 microM, respectively, but not by Wy-14643 at this concentration. Furthermore, the activities of the two torafugu PPARalphas were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively. On the other hand, the activities of torafugu PPARbeta and gamma were not changed by Wy-14643, ETYA, rosiglitazone, nor PUFAs. These results suggest that the activities of torafugu PPARbeta and gamma require undefined ligands. Alternatively, the molecular mechanisms involved in their activation are different from those of other vertebrates.
17632107	693	704	amino acids	CHEMICAL	17632107T10
17632107	905	913	Wy-14643	CHEMICAL	17632107T11
17632107	918	949	5,8,11,14-eicosatetraynoic acid	CHEMICAL	17632107T12
17632107	951	955	ETYA	CHEMICAL	17632107T13
17632107	244	249	PPARs	GENE-N	17632107T14
17632107	1306	1325	torafugu PPARalphas	GENE-N	17632107T15
17632107	252	262	PPARalpha1	GENE-Y	17632107T16
17632107	264	274	PPARalpha2	GENE-Y	17632107T17
17632107	1539	1566	torafugu PPARbeta and gamma	GENE-N	17632107T18
17632107	276	284	PPARbeta	GENE-Y	17632107T19
17632107	1192	1196	ETYA	CHEMICAL	17632107T1
17632107	1674	1701	torafugu PPARbeta and gamma	GENE-N	17632107T20
17632107	290	299	PPARgamma	GENE-Y	17632107T21
17632107	471	509	acyl-CoA oxidase PPAR response element	GENE-N	17632107T22
17632107	511	534	Although torafugu PPARs	GENE-N	17632107T23
17632107	619	648	torafugu PPARalpha2 and gamma	GENE-N	17632107T24
17632107	199	242	peroxisome proliferator-activated receptors	GENE-N	17632107T25
17632107	859	869	PPARalpha1	GENE-Y	17632107T26
17632107	1006	1016	PPARalpha2	GENE-Y	17632107T27
17632107	1130	1151	PPARalpha1 and alpha2	GENE-N	17632107T28
17632107	90	133	peroxisome proliferator-activated receptors	GENE-N	17632107T29
17632107	1235	1243	Wy-14643	CHEMICAL	17632107T2
17632107	1361	1377	arachidonic acid	CHEMICAL	17632107T3
17632107	1400	1420	docosahexaenoic acid	CHEMICAL	17632107T4
17632107	1447	1468	eicosapentaenoic acid	CHEMICAL	17632107T5
17632107	1587	1595	Wy-14643	CHEMICAL	17632107T6
17632107	1597	1601	ETYA	CHEMICAL	17632107T7
17632107	1603	1616	rosiglitazone	CHEMICAL	17632107T8
17632107	471	479	acyl-CoA	CHEMICAL	17632107T9
17632107	CPR:3	17632107T11	17632107T26
17632107	CPR:3	17632107T11	17632107T27
17632107	CPR:3	17632107T12	17632107T26
17632107	CPR:3	17632107T12	17632107T27
17632107	CPR:3	17632107T13	17632107T26
17632107	CPR:3	17632107T13	17632107T27
17632107	CPR:3	17632107T3	17632107T15
17632107	CPR:3	17632107T4	17632107T15
17632107	CPR:3	17632107T5	17632107T15

17643344|t|Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis.
17643344|a|Drug therapy for late-stage (encephalitic) human African trypanosomiasis (HAT) is currently very unsatisfactory with the most commonly used drug, melarsoprol, having a 5% overall mortality. There is evidence in a mouse model of HAT that Substance P (SP) receptor antagonism reduces the neuroinflammatory reaction to CNS trypanosome infection. In this study we investigated the effects of combination chemotherapy with melarsoprol and a humanised SP receptor antagonist aprepitant (EMEND) in this mouse model. The melarsoprol/aprepitant drug combination did not produce any clinical signs of illness in mice with CNS trypanosome infection. This lack of any additional or unexpected CNS toxicity in the mouse model of CNS HAT provides valuable safety data for the future possible use of this drug combination in patients with late-stage HAT.
17643344	32	43	substance P	CHEMICAL	17643344T10
17643344	65	75	aprepitant	CHEMICAL	663
17643344	81	92	melarsoprol	CHEMICAL	17643344T12
17643344	381	406	Substance P (SP) receptor	GENE-Y	17643344T13
17643344	580	601	humanised SP receptor	GENE-Y	17643344T14
17643344	32	52	substance P receptor	GENE-Y	17643344T15
17643344	290	301	melarsoprol	CHEMICAL	17643344T1
17643344	381	392	Substance P	CHEMICAL	17643344T2
17643344	394	396	SP	CHEMICAL	17643344T3
17643344	562	573	melarsoprol	CHEMICAL	17643344T4
17643344	590	592	SP	CHEMICAL	17643344T5
17643344	613	623	aprepitant	CHEMICAL	663
17643344	625	630	EMEND	CHEMICAL	17643344T7
17643344	657	668	melarsoprol	CHEMICAL	17643344T8
17643344	669	679	aprepitant	CHEMICAL	663
17643344	CPR:6	663	17643344T15
17643344	CPR:6	17643344T12	17643344T15
17643344	CPR:6	663	17643344T14
17643344	CPR:6	17643344T7	17643344T14

17652763|t|Identification of the RLBP1 gene promoter.
17652763|a|PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells. It is thought to play a critical role in the visual cycle by functioning as an acceptor of 11-cis-retinol from the isomerohydrolase reaction. The goal here was to evaluate the functional promoter of this gene. METHODS: 5' RACE analysis, promoter-reporter assays, and semiquantitative PCR with exon-specific primers were performed using human-derived RPE cells (ARPE-19 and D407) in culture to evaluate the 5' sequence flanking the RLBP1 gene. In addition, the murine, bovine, and porcine RLBP1 genes were evaluated in silico to identify likely proximal promoter/exon 1 sequences similar to the human gene. RESULTS: 5' RACE analysis revealed the presence of a previously undescribed exon in the RLBP1 gene. This was confirmed by analysis of the GenBank Human EST database, which revealed the presence of 18 sequences matching exon 1. Exon-specific PCR revealed that most CRALBP transcripts expressed in ARPE-19 cells contain both exon 1 and the final exon, suggesting that the primary promoter of CRALBP exists 5' of the newly identified exon 1. Highly homologous sequences in the murine, bovine, and porcine genes were also identified. Finally, promoter-reporter constructs revealed a minimal sequence necessary for promoter function and indicated significantly greater promoter activity compared with previously described RLBP1 promoters. CONCLUSIONS: The findings presented here suggest that CRALBP transcripts in RPE cells contain a noncoding exon in addition to a newly described promoter and, by definition, an additional intron. This finding sets the stage for a mechanistic understanding of the high degree of cell type-specific expression of RLBP1.
17652763	1914	1919	RLBP1	GENE-Y	111949
17652763	379	395	isomerohydrolase	GENE-N	17652763T11
17652763	92	98	CRALBP	GENE-Y	17652763T12
17652763	695	700	RLBP1	GENE-Y	111949
17652763	724	757	murine, bovine, and porcine RLBP1	GENE-N	17652763T14
17652763	122	127	RLBP1	GENE-Y	111949
17652763	958	963	RLBP1	GENE-Y	111949
17652763	52	90	Cellular retinaldehyde-binding protein	GENE-Y	17652763T17
17652763	139	167	36-kDa water-soluble protein	GENE-N	17652763T18
17652763	22	41	RLBP1 gene promoter	GENE-N	17652763T19
17652763	177	188	amino acids	CHEMICAL	17652763T1
17652763	202	209	retinal	CHEMICAL	17652763T2
17652763	61	74	retinaldehyde	CHEMICAL	17652763T3
17652763	242	249	retinal	CHEMICAL	17652763T4
17652763	355	369	11-cis-retinol	CHEMICAL	17652763T5
17652763	1134	1140	CRALBP	GENE-Y	17652763T6
17652763	1260	1266	CRALBP	GENE-Y	17652763T7
17652763	1587	1602	RLBP1 promoters	GENE-N	17652763T8
17652763	1658	1664	CRALBP	GENE-Y	17652763T9
17652763	CPR:9	17652763T5	17652763T11

17653133|t|Determination of dimethylarginine dimethylaminohydrolase activity in the kidney.
17653133|a|Dimethylarginine dimethylaminohydrolase (DDAH) metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney. We present a new study that optimizes the Prescott-Jones colorimetric assay to measure DDAH-dependent L-citrulline generation in kidney homogenates. We found that the removal of urea with urease is necessary since urea also produces a positive reaction. Deproteinization with sulfosalicylic acid was found to be optimal and that protease inhibitors were not necessary. All assays were conducted in phosphate buffer, since other common additives can create false positive and false negative reactions. Arginase or nitric oxide synthase isoenzymes were not found to influence L-citrulline production. Our optimized L-citrulline production assay to measure DDAH activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption. Using this assay, we found that both superoxide and nitric oxide inhibit renal cortical DDAH activity in vitro.
17653133	856	868	L-citrulline	CHEMICAL	17653133T10
17653133	980	996	dimethylarginine	CHEMICAL	17653133T11
17653133	1047	1057	superoxide	CHEMICAL	17653133T12
17653133	1062	1074	nitric oxide	CHEMICAL	17653133T13
17653133	180	192	L-citrulline	CHEMICAL	17653133T14
17653133	17	33	dimethylarginine	CHEMICAL	17653133T15
17653133	81	120	Dimethylarginine dimethylaminohydrolase	GENE-Y	17653133T16
17653133	1098	1102	DDAH	GENE-Y	17653133T17
17653133	330	334	DDAH	GENE-Y	17653133T18
17653133	431	437	urease	GENE-N	17653133T19
17653133	81	97	Dimethylarginine	CHEMICAL	17653133T1
17653133	122	126	DDAH	GENE-Y	17653133T20
17653133	572	580	protease	GENE-N	17653133T21
17653133	744	752	Arginase	GENE-N	17653133T22
17653133	756	777	nitric oxide synthase	GENE-N	17653133T23
17653133	897	901	DDAH	GENE-Y	17653133T24
17653133	17	56	dimethylarginine dimethylaminohydrolase	GENE-Y	17653133T25
17653133	345	357	L-citrulline	CHEMICAL	17653133T2
17653133	421	425	urea	CHEMICAL	17653133T3
17653133	457	461	urea	CHEMICAL	17653133T4
17653133	519	538	sulfosalicylic acid	CHEMICAL	17653133T5
17653133	641	650	phosphate	CHEMICAL	17653133T6
17653133	756	768	nitric oxide	CHEMICAL	17653133T7
17653133	151	167	dimethylarginine	CHEMICAL	17653133T8
17653133	817	829	L-citrulline	CHEMICAL	17653133T9
17653133	CPR:4	17653133T12	17653133T17
17653133	CPR:4	17653133T13	17653133T17
17653133	CPR:9	17653133T10	17653133T24
17653133	CPR:9	17653133T11	17653133T24
17653133	CPR:9	17653133T14	17653133T16
17653133	CPR:9	17653133T14	17653133T20
17653133	CPR:9	17653133T2	17653133T18
17653133	CPR:9	17653133T3	17653133T19
17653133	CPR:9	17653133T8	17653133T16
17653133	CPR:9	17653133T8	17653133T20

17660958|t|The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
17660958|a|OPINION STATEMENT: Treatment of early stage breast cancer requires a multimodality approach in order to eradicate residual cancer and prevent recurrent disease. Targeting the pathways that promote or sustain cancer cell growth and invasion is critical to the effective treatment of breast and other cancers. Overexpression of the family of HER receptors have been associated with a variety of malignancies; the first and best studied is the association of overexpression of the HER2/neu receptor with a more aggressive breast cancer phenotype and poorer survival. A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel. Additional international and national studies support the significant impact of trastuzumab on both disease free and overall survival in women with this aggressive form of breast cancer. Toxicity includes a low but clear risk of congestive heart failure, and the large phase III trials have helped to determine which patients are at higher risk for this complication. Non-anthracycline containing regimens are an alternative therapy associated with reduced cardiac toxicity. Trastuzumab therapy is now the standard of care for the treatment of early stage, HER2/neu positive breast cancer given in combination with one of several chemotherapy regimens. Ongoing questions include the appropriate duration of trastuzumab treatment as well as the optimal chemotherapy regimen and sequence. The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor (EGFR), lapatinib. Other trials are investigating differences in duration. Studies in the neoadjuvant setting should help to define markers of trastuzumab and lapatinib sensitivity and resistance. Preliminary data combining trastuzumab with the antiangiogenic antibody bevacizumab is encouraging; this combination will be tested in both early stage and late stage disease.
17660958	1881	1885	HER2	GENE-Y	35473
17660958	1886	1889	neu	GENE-Y	17660958T11
17660958	1905	1937	epidermal growth factor receptor	GENE-Y	17660958T12
17660958	1939	1943	EGFR	GENE-Y	108276|3932452|676741
17660958	438	441	HER	GENE-N	17660958T14
17660958	576	580	HER2	GENE-Y	35473
17660958	581	593	neu receptor	GENE-Y	17660958T16
17660958	686	690	HER2	GENE-Y	35473
17660958	691	694	neu	GENE-Y	17660958T18
17660958	763	767	HER2	GENE-Y	35473
17660958	1258	1271	anthracycline	CHEMICAL	17660958T1
17660958	768	771	neu	GENE-Y	17660958T20
17660958	1845	1853	tyrosine	CHEMICAL	17660958T2
17660958	1946	1955	lapatinib	CHEMICAL	17660958T3
17660958	2097	2106	lapatinib	CHEMICAL	17660958T4
17660958	839	850	doxorubicin	CHEMICAL	17660958T5
17660958	852	868	cyclophosphamide	CHEMICAL	17660958T6
17660958	874	884	paclitaxel	CHEMICAL	17660958T7
17660958	1443	1447	HER2	GENE-Y	35473
17660958	1448	1451	neu	GENE-Y	17660958T9
17660958	CPR:4	17660958T3	35473
17660958	CPR:4	17660958T3	17660958T11
17660958	CPR:4	17660958T3	17660958T12
17660958	CPR:4	17660958T3	108276|3932452|676741

17662248|t|Stimulation of N-methyl-D-aspartate receptors modulates Jurkat T cell growth and adhesion to fibronectin.
17662248|a|The aims of this study were to investigate the expression and the functional roles of N-methyl-d-aspartate (NMDA) receptors in leukemic Jurkat T cells. RT-PCR and immunofluorescence/confocal microscopy analysis showed that Jurkat T cells express the NR1 and NR2B subunits of the NMDA receptors. Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin. In conclusion, our results demonstrate that Jurkat T cells express NMDA receptors functionally active in controlling cell growth and adhesion to fibronectin.
17662248	903	907	NMDA	CHEMICAL	1209
17662248	192	212	N-methyl-d-aspartate	CHEMICAL	17662248T11
17662248	15	35	N-methyl-D-aspartate	CHEMICAL	17662248T12
17662248	356	359	NR1	GENE-Y	17662248T13
17662248	364	368	NR2B	GENE-Y	17662248T14
17662248	385	399	NMDA receptors	GENE-N	17662248T15
17662248	589	602	NMDA receptor	GENE-N	17662248T16
17662248	823	834	fibronectin	GENE-Y	17662248T17
17662248	903	917	NMDA receptors	GENE-N	17662248T18
17662248	192	229	N-methyl-d-aspartate (NMDA) receptors	GENE-N	17662248T19
17662248	214	218	NMDA	CHEMICAL	1209
17662248	981	992	fibronectin	GENE-Y	17662248T20
17662248	15	45	N-methyl-D-aspartate receptors	GENE-N	17662248T21
17662248	93	104	fibronectin	GENE-Y	17662248T22
17662248	385	389	NMDA	CHEMICAL	1209
17662248	436	509	(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine	CHEMICAL	17662248T3
17662248	511	521	(+)-MK 801	CHEMICAL	17662248T4
17662248	526	565	D-(-)-2-amino-5-phosphonopentanoic acid	CHEMICAL	17662248T5
17662248	567	572	D-AP5	CHEMICAL	17662248T6
17662248	589	593	NMDA	CHEMICAL	1209
17662248	705	716	l-glutamate	CHEMICAL	17662248T8
17662248	732	736	NMDA	CHEMICAL	1209
17662248	CPR:6	17662248T3	17662248T16
17662248	CPR:6	17662248T4	17662248T16
17662248	CPR:6	17662248T5	17662248T16
17662248	CPR:6	17662248T6	17662248T16

17673606|t|Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.
17673606|a|Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the hNET expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine (NIS) binding. Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine. These differences seem not to arise from preparation-specific perturbations of ligand intrinsic affinity or antagonist-specific surface trafficking but rather from protein conformational alterations that perturb the relationships between distinct hNET binding sites. In an initial search for molecular features that differentially define antagonist binding determinants, we document that Val148 in hNET transmembrane domain 3 selectively disrupts NIS binding but not that of DVS.
17673606	819	822	DVS	CHEMICAL	17673606T10
17673606	830	903	rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol	CHEMICAL	17673606T11
17673606	905	913	WY-46824	CHEMICAL	17673606T12
17673606	916	931	methylphenidate	CHEMICAL	17673606T13
17673606	195	209	norepinephrine	CHEMICAL	17673606T14
17673606	941	948	cocaine	CHEMICAL	17673606T15
17673606	956	1018	3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester	CHEMICAL	17673606T16
17673606	1020	1026	RTI-55	CHEMICAL	17673606T17
17673606	1065	1068	NIS	CHEMICAL	17673606T18
17673606	1070	1078	mazindol	CHEMICAL	17673606T19
17673606	115	139	Desvenlafaxine succinate	CHEMICAL	17673606T1
17673606	1080	1089	tricyclic	CHEMICAL	17673606T20
17673606	214	223	serotonin	CHEMICAL	17673606T21
17673606	1111	1118	cocaine	CHEMICAL	17673606T22
17673606	0	24	Desvenlafaxine succinate	CHEMICAL	17673606T23
17673606	87	101	norepinephrine	CHEMICAL	17673606T24
17673606	238	242	hNET	GENE-Y	17673606T25
17673606	1367	1371	hNET	GENE-Y	17673606T26
17673606	247	252	hSERT	GENE-Y	17673606T27
17673606	1518	1545	hNET transmembrane domain 3	GENE-N	17673606T28
17673606	555	559	hNET	GENE-Y	17673606T29
17673606	1567	1570	NIS	CHEMICAL	17673606T2
17673606	666	670	hNET	GENE-Y	17673606T30
17673606	189	236	human norepinephrine and serotonin transporters	GENE-N	17673606T31
17673606	1039	1043	hNET	GENE-Y	17673606T32
17673606	81	113	human norepinephrine transporter	GENE-Y	17673606T33
17673606	141	144	DVS	CHEMICAL	17673606T3
17673606	463	466	DVS	CHEMICAL	17673606T4
17673606	628	644	[(3)H]nisoxetine	CHEMICAL	17673606T5
17673606	646	649	NIS	CHEMICAL	17673606T6
17673606	751	754	DVS	CHEMICAL	17673606T7
17673606	775	784	[(3)H]NIS	CHEMICAL	17673606T8
17673606	810	813	DVS	CHEMICAL	17673606T9
17673606	CPR:6	17673606T10	17673606T30
17673606	CPR:6	17673606T11	17673606T30
17673606	CPR:6	17673606T12	17673606T30
17673606	CPR:6	17673606T13	17673606T30
17673606	CPR:6	17673606T15	17673606T30
17673606	CPR:6	17673606T16	17673606T30
17673606	CPR:6	17673606T17	17673606T30
17673606	CPR:6	17673606T18	17673606T32
17673606	CPR:6	17673606T19	17673606T32
17673606	CPR:6	17673606T1	17673606T25
17673606	CPR:6	17673606T1	17673606T27
17673606	CPR:6	17673606T20	17673606T32
17673606	CPR:6	17673606T22	17673606T32
17673606	CPR:6	17673606T23	17673606T33
17673606	CPR:6	17673606T3	17673606T25
17673606	CPR:6	17673606T3	17673606T27
17673606	CPR:6	17673606T9	17673606T30

17853709|t|[Lipoprotein(a): a link between thrombogenesis and atherogenesis].
17853709|a|INTRODUCTION: It is well known that numerous mechanisms of thrombogenesis can participate in every stage of atherosclerotic disease. The discovery of Lp(a) lipoprotein and its structural similarity with plasminogen suggests another pathogenic link between atherogenesis and thrombogenesis. SOME CHARACTERISTICS OF LP(A) LIPOPROTEIN: This lipoprotein is present in the whole human population in a wide range of plasma concentrations. It has numerous different isoforms. Its synthesis occurs in the liver, but it is practically metabolically independent from other lipoproteins. Today, Lp(a) lipoprotein is considered to be an independent risk factor for heart and brain ischemic disease. FIBRINOLYTIC MECHANISMS: The primary role of the fibrinolytic mechanism is to prevent thrombus Jormation during circulation and to remove already formed ones. Plasmin has a central role in this process, due to the inactive proenzyme plasminogen. Its basic activators are tissue-type plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA). The most important inhibitors of plasminogen are alpha2-antiplasmin and plasminogen activator inhibitors 1 and 2 (PA-1 and PAI-2). Structural similarity of Lp(a) and plasminogen The apo(a) and plasminogen genes are very closely linked on the long arm of chromosome 6. Because of that they are structuraly very similar and they have a cross immunological reactivity. Their common elements are so-called "kringle" structures. The key difference in structure of Lp(a) and plasminogen is replacement of Arg with Ser at position 560. This prevents splitting of apo(a) by plasminogen activators. LP(A) AND FIBRINOLYSIS: Lp(a) lipoprotein inhibits activation of plasminogen by streptokinase. It is also a competitive inhibitor of plasminogen for its binding to plasminogen receptors. Furthermore, it successfully achieves competitive inhibition of plasminogen for binding to tetranectin and thrombospondin. Also, Lp(a) inhibits activation of transforming growth factor alpha (TGF-alpha). It positively correlates with PAI-1 and it is assumed that it promotes release of tissue factor pathway inhibitor (17FPI) from endothelial cell surfaces. CONCLUSION: In regulation of the hemostatic system via apolipoprotein(a) antifibrinolytic effects, Lp(a) lipoprotein ojfers a molecular solution to the link between thrombogenesis and atherogenesis.
17853709	1266	1271	Lp(a)	GENE-Y	17853709T10
17853709	1276	1287	plasminogen	GENE-Y	17853709T11
17853709	1292	1298	apo(a)	GENE-N	17853709T12
17853709	1303	1314	plasminogen	GENE-Y	17853709T13
17853709	217	222	Lp(a)	GENE-Y	17853709T14
17853709	1569	1574	Lp(a)	GENE-Y	17853709T15
17853709	1579	1590	plasminogen	GENE-Y	17853709T16
17853709	223	234	lipoprotein	GENE-N	17853709T17
17853709	1666	1672	apo(a)	GENE-N	17853709T18
17853709	1676	1698	plasminogen activators	GENE-N	17853709T19
17853709	1609	1612	Arg	CHEMICAL	119
17853709	1700	1705	LP(A)	GENE-Y	17853709T20
17853709	1724	1729	Lp(a)	GENE-Y	17853709T21
17853709	1730	1741	lipoprotein	GENE-N	17853709T22
17853709	1765	1776	plasminogen	GENE-Y	17853709T23
17853709	1780	1793	streptokinase	GENE-N	17853709T24
17853709	1833	1844	plasminogen	GENE-Y	17853709T25
17853709	1864	1885	plasminogen receptors	GENE-N	17853709T26
17853709	1951	1962	plasminogen	GENE-Y	17853709T27
17853709	1978	1989	tetranectin	GENE-Y	17853709T28
17853709	1994	2008	thrombospondin	GENE-Y	17853709T29
17853709	1618	1621	Ser	CHEMICAL	127
17853709	2016	2021	Lp(a)	GENE-Y	17853709T30
17853709	2045	2077	transforming growth factor alpha	GENE-Y	17853709T31
17853709	2079	2088	TGF-alpha	GENE-Y	17853709T32
17853709	270	281	plasminogen	GENE-Y	17853709T33
17853709	2121	2126	PAI-1	GENE-Y	17853709T34
17853709	2173	2186	tissue factor	GENE-Y	17853709T35
17853709	2300	2317	apolipoprotein(a)	GENE-N	17853709T36
17853709	2344	2349	Lp(a)	GENE-Y	17853709T37
17853709	2350	2361	lipoprotein	GENE-N	17853709T38
17853709	381	386	LP(A)	GENE-Y	17853709T39
17853709	1070	1101	urokinase plasminogen activator	GENE-Y	17853709T3
17853709	387	398	LIPOPROTEIN	GENE-N	17853709T40
17853709	630	642	lipoproteins	GENE-N	17853709T41
17853709	651	656	Lp(a)	GENE-Y	17853709T42
17853709	657	668	lipoprotein	GENE-N	17853709T43
17853709	913	920	Plasmin	GENE-Y	17853709T44
17853709	987	998	plasminogen	GENE-Y	17853709T45
17853709	1025	1058	tissue-type plasminogen activator	GENE-Y	17853709T46
17853709	1060	1064	t-PA	GENE-Y	17853709T47
17853709	1	15	Lipoprotein(a)	GENE-Y	17853709T48
17853709	1103	1107	u-PA	GENE-Y	17853709T4
17853709	1143	1154	plasminogen	GENE-Y	17853709T5
17853709	1159	1177	alpha2-antiplasmin	GENE-Y	17853709T6
17853709	1182	1222	plasminogen activator inhibitors 1 and 2	GENE-N	17853709T7
17853709	1224	1228	PA-1	GENE-Y	17853709T8
17853709	1233	1238	PAI-2	GENE-Y	17853709T9

17935273|t|Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
17935273|a|Understanding the alterations in cellular protein interactions and their relations to genetic mutations that cause renal cell carcinoma (RCC) provides a unique opportunity for the development of disease-specific therapy for patients with advanced forms of this disease. There is substantial evidence of an association between mutation on von Hippel-Lindau (VHL) gene and the earliest stages of tumorigenesis of RCC. The main consequence of VHL loss is the upregulation of downstream proangiogenic factors leading to highly vascular tumors. Overexpression of hypoxia inducible factor (HIF) is also caused by the mammalian target of rapamycin (mTOR), a key component of signaling pathways inside the cell, involved in cell proliferation. The inhibition of proangiogenic factors and mTOR was the main idea behind the development of new targeted agents in advanced RCC. Since December 2005, 3 targeted agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced RCC: sorafenib, sunitinib and temsirolimus. Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor. Recent clinical studies form the basis for new guidelines for the treatment of advanced RCC: sorafenib should be used as a second-line treatment, sunitinib as the first-line therapy for good and intermediate-risk patients, and temsirolimus should be considered as first-line treatment for poor-risk patients. Future approaches to targeted therapy should focus on optimizing the use of current active drugs, exploring their combinations or investigating their sequential use. In addition, it is important to define the mechanisms of resistance on their use and to further investigate biomarkers and enhance treatment efficacy for the individual patients. The development of these targeted therapies represents an exciting step forward in the treatment of advanced RCC.
17935273	689	698	rapamycin	CHEMICAL	17935273T10
17935273	0	9	Sunitinib	CHEMICAL	1255
17935273	11	20	sorafenib	CHEMICAL	17935273T12
17935273	1189	1243	vascular endothelial growth factor receptors -2 and -3	GENE-N	17935273T13
17935273	1245	1252	VEGFR-2	GENE-Y	17935273T14
17935273	1254	1261	VEGFR-3	GENE-Y	17935273T15
17935273	1267	1311	platelet-derived growth factor receptor beta	GENE-Y	17935273T16
17935273	1313	1323	PDGFR-beta	GENE-Y	17935273T17
17935273	1351	1355	mTOR	GENE-Y	17935273T18
17935273	396	413	von Hippel-Lindau	GENE-Y	17935273T19
17935273	1064	1073	sorafenib	CHEMICAL	17935273T1
17935273	415	418	VHL	GENE-Y	113269
17935273	498	501	VHL	GENE-Y	113269
17935273	616	640	hypoxia inducible factor	GENE-N	17935273T22
17935273	642	645	HIF	GENE-N	17935273T23
17935273	669	698	mammalian target of rapamycin	GENE-Y	17935273T24
17935273	700	704	mTOR	GENE-Y	17935273T25
17935273	838	842	mTOR	GENE-Y	17935273T26
17935273	25	29	mTOR	GENE-Y	17935273T27
17935273	1075	1084	sunitinib	CHEMICAL	17935273T2
17935273	1089	1101	temsirolimus	CHEMICAL	17935273T3
17935273	1103	1112	Sorafenib	CHEMICAL	390
17935273	1117	1126	sunitinib	CHEMICAL	17935273T5
17935273	1332	1344	temsirolimus	CHEMICAL	17935273T6
17935273	1460	1469	sorafenib	CHEMICAL	17935273T7
17935273	1513	1522	sunitinib	CHEMICAL	17935273T8
17935273	1594	1606	temsirolimus	CHEMICAL	17935273T9
17935273	CPR:4	390	17935273T14
17935273	CPR:4	390	17935273T15
17935273	CPR:4	390	17935273T16
17935273	CPR:4	390	17935273T17
17935273	CPR:4	17935273T5	17935273T14
17935273	CPR:4	17935273T5	17935273T15
17935273	CPR:4	17935273T5	17935273T16
17935273	CPR:4	17935273T5	17935273T17
17935273	CPR:4	17935273T6	17935273T18

18034539|t|Management of psoriasis: the position of retinoid drugs.
18034539|a|Oral synthetic retinoids have been established as effective systemic therapy for psoriasis since their introduction for clinical use in the 1970s; a compound for topical use, tazarotene has been recently marketed. Despite the demonstrated clinical success of retinoid therapy in psoriasis, its mechanism of action has not been fully elucidated, and investigators are confronted with two paradoxes. One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha. The other is that there is already increased formation of retinoic acid in the psoriatic lesion. Answering these questions should result in better use of these drugs in the treatment of psoriasis. Oral administration of acitretin remains one of the first therapeutic choices for severe psoriasis, particularly in association with ultraviolet light therapy, of which it may decrease the carcinogenic risk. Topical tazarotene is suitable for moderate plaque psoriasis. Its efficacy and tolerability can be enhanced by the addition of topical corticosteroids; its irritative potential is counterbalanced by a sustained therapeutic effect after the treatment is stopped.
18034539	855	868	retinoic acid	CHEMICAL	18034539T10
18034539	1017	1026	acitretin	CHEMICAL	451
18034539	41	49	retinoid	CHEMICAL	18034539T12
18034539	503	526	retinoic acid receptors	GENE-N	18034539T13
18034539	528	532	RARs	GENE-N	18034539T14
18034539	626	653	RAR-alpha, -beta and -gamma	GENE-N	18034539T15
18034539	749	768	RAR-beta and -gamma	GENE-N	18034539T16
18034539	786	795	RAR-alpha	GENE-Y	18034539T17
18034539	1210	1220	tazarotene	CHEMICAL	18034539T1
18034539	1337	1352	corticosteroids	CHEMICAL	18034539T2
18034539	72	81	retinoids	CHEMICAL	18034539T3
18034539	232	242	tazarotene	CHEMICAL	18034539T4
18034539	316	324	retinoid	CHEMICAL	18034539T5
18034539	482	491	retinoids	CHEMICAL	18034539T6
18034539	503	516	retinoic acid	CHEMICAL	18034539T7
18034539	577	586	acitretin	CHEMICAL	451
18034539	700	710	tazarotene	CHEMICAL	18034539T9
18034539	CPR:3	18034539T9	18034539T17

18035186|t|Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
18035186|a|BACKGROUND: Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine. Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD). OBJECTIVE: The aim of this study was to review the pharmacology, tolerability, and clinical efficacy of rasagiline in the treatment of PD. METHODS: MEDLINE (1966-April 2007), the Cochrane Database of Systematic Reviews, and International Pharmaceutical Abstracts (1970-April 2007) were searched for original research and review articles published in English. The search terms were monoamine oxidase, neuroprotection, Parkinson disease, propargylamine, rasagiline, and selegiline. The reference lists of articles were also consulted, as was information provided by the manufacturer of rasagiline. RESULTS: Data from 63 clinical and laboratory studies were analyzed. Based on the results from those studies, we concluded that rasagiline PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited MAO-B. Pharmacologically, rasagiline was found to be < or =10-fold more potent than selegiline and was not metabolized to amphetamine derivatives. Rasagiline was effective both as monotherapy in early PD and as adjunctive treatment in patients with advancing PD and motor fluctuations. As monotherapy, rasagiline provided modest yet clinically meaningful benefit. A randomized, double-blind, placebo-controlled study found that, after 26 weeks of treatment, the adjusted effect size for total Unified Parkinson's Disease Rating Scale score was -4.20 (95% CI, -5.66 to -2.73) for rasagiline 1 mg/d versus placebo (P < 0.001). Preliminary long-term data from an open-label study suggest a sustained therapeutic advantage when rasagiline is initiated early (before the need for dopaminergic agents) rather than later. In patients with more advanced disease who received treatment with dopaminergic agents, rasagiline and entacapone were associated with reductions of "off" time significantly greater than placebo (-1.18 and -1.2 vs 0.4 hour; both, P < or = 0.001). Rasagiline was well tolerated in younger (aged <;70 years) and older (aged > or =70 years) patients with early or advanced PD. Pharmacologically, rasagiline has the potential to augment the vasopressor effects of diet-derived tyramine (ie, the "cheese reaction"). However, clinical challenge studies of tyramine have found this unlikely to occur even with ingestion of supraphysiologic amounts of tyramine. In experimental models, rasagiline has been found to have neuroprotective properties that may be independent of MAO-B inhibition. CONCLUSIONS: Based on this review, rasagiline has been found to be well tolerated and effective in the treatment of early PD and as adjunctive treatment in motor fluctuations. Whether rasagiline is associated with clinically significant neuroprotection (ie, disease modification) in PD is the subject of ongoing clinical trials.
18035186	331	358	N-propargyl-l(R)-aminoindan	CHEMICAL	18035186T10
18035186	2327	2337	rasagiline	CHEMICAL	18035186T11
18035186	2342	2352	entacapone	CHEMICAL	18035186T12
18035186	2486	2496	Rasagiline	CHEMICAL	1329
18035186	383	397	propargylamine	CHEMICAL	18035186T14
18035186	2712	2720	tyramine	CHEMICAL	18035186T15
18035186	153	162	monoamine	CHEMICAL	18035186T16
18035186	2789	2797	tyramine	CHEMICAL	18035186T17
18035186	2883	2891	tyramine	CHEMICAL	18035186T18
18035186	2917	2927	rasagiline	CHEMICAL	18035186T19
18035186	1127	1137	rasagiline	CHEMICAL	18035186T1
18035186	3058	3068	rasagiline	CHEMICAL	18035186T20
18035186	647	657	rasagiline	CHEMICAL	18035186T21
18035186	924	933	monoamine	CHEMICAL	18035186T22
18035186	979	993	propargylamine	CHEMICAL	18035186T23
18035186	995	1005	rasagiline	CHEMICAL	18035186T24
18035186	1011	1021	selegiline	CHEMICAL	18035186T25
18035186	24	34	rasagiline	CHEMICAL	18035186T26
18035186	56	65	monoamine	CHEMICAL	18035186T27
18035186	1424	1429	MAO-B	GENE-Y	18035186T28
18035186	153	170	monoamine oxidase	GENE-N	18035186T29
18035186	1267	1277	rasagiline	CHEMICAL	18035186T2
18035186	3005	3010	MAO-B	GENE-Y	18035186T30
18035186	461	466	MAO-B	GENE-Y	18035186T31
18035186	172	175	MAO	GENE-N	18035186T32
18035186	924	941	monoamine oxidase	GENE-N	18035186T33
18035186	214	224	MAO type B	GENE-Y	18035186T34
18035186	226	231	MAO-B	GENE-Y	18035186T35
18035186	56	73	monoamine oxidase	GENE-N	18035186T36
18035186	1450	1460	rasagiline	CHEMICAL	18035186T3
18035186	1508	1518	selegiline	CHEMICAL	18035186T4
18035186	1546	1557	amphetamine	CHEMICAL	18035186T5
18035186	1571	1581	Rasagiline	CHEMICAL	1329
18035186	1726	1736	rasagiline	CHEMICAL	18035186T7
18035186	309	317	dopamine	CHEMICAL	18035186T8
18035186	319	329	Rasagiline	CHEMICAL	1329
18035186	CPR:4	18035186T10	18035186T31
18035186	CPR:4	18035186T14	18035186T31
18035186	CPR:4	18035186T26	18035186T36
18035186	CPR:4	18035186T2	18035186T28
18035186	CPR:4	1329	18035186T31

18056711|t|Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.
18056711|a|DNA topoisomerase I (Top1p) catalyzes the relaxation of supercoiled DNA via a concerted mechanism of DNA strand cleavage and religation. Top1p is the cellular target of the anti-cancer drug camptothecin (CPT), which reversibly stabilizes a covalent enzyme-DNA intermediate. Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket. The physical connection of the linker with the Top1p clamp as well as linker flexibility affect enzyme sensitivity to CPT. Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and C-terminal domains) is at one end of a short alpha-helix, which extends to the active site Tyr covalently linked to the DNA. In the presence of drug, the linker is rigid and this alpha-helix extends to include Gly and the preceding Leu. We report that mutation of this conserved Gly in yeast Top1p alters enzyme sensitivity to CPT. Mutating Gly to Asp, Glu, Asn, Gln, Leu, or Ala enhanced enzyme CPT sensitivity, with the acidic residues inducing the greatest increase in drug sensitivity in vivo and in vitro. By contrast, Val or Phe substituents rendered the enzyme CPT-resistant. Mutation-induced alterations in enzyme architecture preceding the active site Tyr suggest these structural transitions modulate enzyme sensitivity to CPT, while enhancing the rate of DNA cleavage. We postulate that this conserved Gly residue provides a flexible hinge within the Top1p catalytic pocket to facilitate linker dynamics and the structural alterations that accompany drug binding of the covalent enzyme-DNA intermediate.
18056711	1221	1224	CPT	CHEMICAL	18056711T10
18056711	1349	1352	Val	CHEMICAL	155
18056711	1356	1359	Phe	CHEMICAL	115
18056711	1393	1396	CPT	CHEMICAL	18056711T13
18056711	1486	1489	Tyr	CHEMICAL	129
18056711	1558	1561	CPT	CHEMICAL	18056711T15
18056711	1638	1641	Gly	CHEMICAL	139
18056711	294	306	camptothecin	CHEMICAL	18056711T17
18056711	308	311	CPT	CHEMICAL	18056711T18
18056711	431	432	C	CHEMICAL	18056711T19
18056711	1104	1107	Gly	CHEMICAL	139
18056711	538	541	Tyr	CHEMICAL	129
18056711	549	550	C	CHEMICAL	18056711T21
18056711	714	717	CPT	CHEMICAL	18056711T22
18056711	765	768	Gly	CHEMICAL	139
18056711	825	826	C	CHEMICAL	18056711T24
18056711	916	919	Tyr	CHEMICAL	129
18056711	1035	1038	Gly	CHEMICAL	139
18056711	1057	1060	Leu	CHEMICAL	143
18056711	90	102	camptothecin	CHEMICAL	18056711T28
18056711	104	123	DNA topoisomerase I	GENE-Y	18056711T29
18056711	1152	1155	CPT	CHEMICAL	18056711T2
18056711	1111	1122	yeast Top1p	GENE-Y	18056711T30
18056711	241	246	Top1p	GENE-Y	18056711T31
18056711	1687	1692	Top1p	GENE-Y	18056711T32
18056711	125	130	Top1p	GENE-Y	18056711T33
18056711	378	383	Top1p	GENE-Y	18056711T34
18056711	476	489	alpha-helices	GENE-N	18056711T35
18056711	491	504	linker domain	GENE-N	18056711T36
18056711	643	648	Top1p	GENE-Y	18056711T37
18056711	870	881	alpha-helix	GENE-N	18056711T38
18056711	1004	1015	alpha-helix	GENE-N	18056711T39
18056711	1166	1169	Gly	CHEMICAL	139
18056711	26	45	DNA topoisomerase I	GENE-Y	18056711T40
18056711	1173	1176	Asp	CHEMICAL	122
18056711	1178	1181	Glu	CHEMICAL	136
18056711	1183	1186	Asn	CHEMICAL	167
18056711	1188	1191	Gln	CHEMICAL	18056711T7
18056711	1193	1196	Leu	CHEMICAL	143
18056711	1201	1204	Ala	CHEMICAL	18056711T9

18081314|t|Characterization of the substrate mimic bound to engineered prostacyclin synthase in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of prostacyclin.
18081314|a|High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered prostacyclin (PGI2) synthase (PGIS) in solution. The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner. The detailed conformational change and 3D structure of the PGIS-bound U46619 were further demonstrated by 2D 1H NMR experiments using the transferred NOE technique. The distances between the protons H20 and H2, H18 and H2, and H18 and H4 are shorter following their binding to the PGIS in solution-down to within 5 A. These shorter distances resulted in a widely open conformation, where the triangle shape of the unbound U46619 changed to a more compact conformation with an oval shape. The bound conformation of U46619 fits the crystal structure of the PGIS substrate binding pocket considerably better than that of the unbound U46619. The residues important to the substrate binding in the active site pocket of PGIS were also predicted. For example, Trp282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the PGIS-bound form of U46619 and the PGIS crystal structure. These studies have provided the structural information for the interaction of the PGIS with its substrate mimic. The noted conformational changes where the C-6 position is closer to the C-9 position of U46619 provided the first experimental data for understanding the molecular mechanism of the catalytic function of PGIS in the isomerization of PGH2 to prostacyclin.
18081314	2061	2073	prostacyclin	CHEMICAL	18081314T10
18081314	420	426	U46619	CHEMICAL	18081314T11
18081314	555	559	C-11	CHEMICAL	18081314T12
18081314	561	564	H2C	CHEMICAL	18081314T13
18081314	570	573	H20	CHEMICAL	18081314T14
18081314	577	583	U46619	CHEMICAL	18081314T15
18081314	603	609	U46619	CHEMICAL	18081314T16
18081314	748	754	U46619	CHEMICAL	18081314T17
18081314	787	789	1H	CHEMICAL	18081314T18
18081314	877	880	H20	CHEMICAL	18081314T19
18081314	330	336	U46619	CHEMICAL	18081314T1
18081314	885	887	H2	CHEMICAL	18081314T20
18081314	889	892	H18	CHEMICAL	18081314T21
18081314	897	899	H2	CHEMICAL	18081314T22
18081314	905	908	H18	CHEMICAL	18081314T23
18081314	913	915	H4	CHEMICAL	18081314T24
18081314	305	321	prostaglandin H2	CHEMICAL	18081314T25
18081314	1100	1106	U46619	CHEMICAL	18081314T26
18081314	1192	1198	U46619	CHEMICAL	18081314T27
18081314	208	220	prostacyclin	CHEMICAL	18081314T28
18081314	60	72	prostacyclin	CHEMICAL	18081314T29
18081314	1308	1314	U46619	CHEMICAL	18081314T2
18081314	1233	1237	PGIS	GENE-Y	18081314T30
18081314	1393	1397	PGIS	GENE-Y	18081314T31
18081314	356	384	prostacyclin (PGI2) synthase	GENE-Y	18081314T32
18081314	1649	1653	PGIS	GENE-Y	18081314T33
18081314	1683	1687	PGIS	GENE-Y	18081314T34
18081314	1789	1793	PGIS	GENE-Y	18081314T35
18081314	386	390	PGIS	GENE-Y	18081314T36
18081314	2024	2028	PGIS	GENE-Y	18081314T37
18081314	434	438	PGIS	GENE-Y	18081314T38
18081314	636	640	PGIS	GENE-Y	18081314T39
18081314	356	368	prostacyclin	CHEMICAL	18081314T3
18081314	737	741	PGIS	GENE-Y	18081314T40
18081314	959	963	PGIS	GENE-Y	18081314T41
18081314	60	81	prostacyclin synthase	GENE-Y	18081314T42
18081314	1668	1674	U46619	CHEMICAL	18081314T4
18081314	370	374	PGI2	CHEMICAL	1228
18081314	1863	1866	C-6	CHEMICAL	18081314T6
18081314	1893	1896	C-9	CHEMICAL	18081314T7
18081314	1909	1915	U46619	CHEMICAL	18081314T8
18081314	2053	2057	PGH2	CHEMICAL	18081314T9

18220763|t|Type 2 diabetes and oral antihyperglycemic drugs.
18220763|a|Type II diabetes is a heterogeneous disease where environment and genetics are important factors for the expression of the disease. The high cost for treating complications of diabetes is a burden for public health systems and governments worldwide. Type II diabetes has been causing debilitation worldwide for many decades, and a single drug that safely treats the disease has yet to be discovered. Sulfonylureas, biguanides, alpha-glucosidase, meglitinides, DPP-4 inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. In this article we present the pros and cons of the six classes and discuss some of the latest advances towards the development of new drugs for the treatment of Type II diabetes.
18220763	450	463	Sulfonylureas	CHEMICAL	18220763T1
18220763	465	475	biguanides	CHEMICAL	18220763T2
18220763	496	508	meglitinides	CHEMICAL	18220763T3
18220763	510	515	DPP-4	CHEMICAL	18220763T4
18220763	531	549	thiazolidinediones	CHEMICAL	18220763T5
18220763	477	494	alpha-glucosidase	GENE-N	18220763T6
18220763	510	515	DPP-4	GENE-Y	18220763T7

18308814|t|Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
18308814|a|Asenapine is a novel psychopharmacologic agent under development for the treatment of schizophrenia and bipolar disorder. We determined and compared the human receptor binding affinities and functional characteristics of asenapine and several antipsychotic drugs. Compounds were tested under comparable assay conditions using cloned human receptors. In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]). It had much lower affinity (pKi<or=5) for muscarinic receptors and was the only agent with affinity for H2 receptors. Relative to its D2 receptor affinity, asenapine had a higher affinity for 5-HT2C, 5-HT2A, 5-HT2B, 5-HT7, 5-HT6, alpha2B and D3 receptors, suggesting stronger engagement of these targets at therapeutic doses. Asenapine behaved as a potent antagonist (pKB) at 5-HT1A (7.4), 5-HT1B (8.1), 5-HT2A (9.0), 5-HT2B (9.3), 5-HT2C (9.0), 5-HT6 (8.0), 5-HT7 (8.5), D2 (9.1), D3 (9.1), alpha2A (7.3), alpha2B (8.3), alpha2C (6.8) and H1 (8.4) receptors. These functional effects differed from those of risperidone (pKB<5 for 5-HT6) and olanzapine (pKB<5 for 5-HT1A and alpha2). Our results indicate that asenapine has a unique human receptor signature, with binding affinity and antagonistic properties that differ appreciably from those of antipsychotic drugs.
18308814	613	619	5-HT2A	GENE-Y	65794
18308814	628	634	5-HT2B	GENE-Y	18308814T11
18308814	642	648	5-HT2C	GENE-Y	18308814T12
18308814	657	662	5-HT5	GENE-Y	18308814T13
18308814	670	675	5-HT6	GENE-Y	18308814T14
18308814	686	691	5-HT7	GENE-Y	18308814T15
18308814	700	721	adrenoceptors (alpha1	GENE-N	18308814T16
18308814	729	736	alpha2A	GENE-Y	18308814T17
18308814	744	751	alpha2B	GENE-Y	18308814T18
18308814	762	769	alpha2C	GENE-Y	18308814T19
18308814	85	94	Asenapine	CHEMICAL	5533
18308814	778	800	dopamine receptors (D1	GENE-Y	18308814T20
18308814	808	810	D2	GENE-Y	18308814T21
18308814	818	820	D3	GENE-Y	18308814T22
18308814	831	833	D4	GENE-Y	18308814T23
18308814	845	868	histamine receptors (H1	GENE-Y	18308814T24
18308814	879	881	H2	GENE-Y	18308814T25
18308814	306	315	asenapine	CHEMICAL	18308814T2
18308814	564	573	serotonin	CHEMICAL	18308814T3
18308814	778	786	dopamine	CHEMICAL	18308814T4
18308814	845	854	histamine	CHEMICAL	18308814T5
18308814	0	9	Asenapine	CHEMICAL	5533
18308814	564	583	serotonin receptors	GENE-N	18308814T7
18308814	585	591	5-HT1A	GENE-Y	18308814T8
18308814	599	605	5-HT1B	GENE-Y	62857

18393142|t|Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
18393142|a|Indirect systemic and direct oral factor Xa and direct oral factor IIa inhibitors with improved pharmacologic profiles compared with heparins and vitamin K antagonists are currently in clinical development. This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran). Specifically, the results of dose-finding studies for the prevention of venous thromboembolism after elective orthopedic surgery, the results of dose-finding studies for treatment of acute venous thromboembolism including prolonged prophylaxis of recurrent events, and the designs of ongoing clinical trials are reviewed.
18393142	84	94	factor IIa	GENE-Y	18393142T10
18393142	242	251	vitamin K	CHEMICAL	18393142T1
18393142	364	379	pentasaccharide	CHEMICAL	18393142T2
18393142	395	406	idraparinux	CHEMICAL	18393142T3
18393142	469	480	rivaroxaban	CHEMICAL	18393142T4
18393142	485	493	apixaban	CHEMICAL	18393142T5
18393142	504	514	dabigatran	CHEMICAL	18393142T6
18393142	458	467	factor Xa	GENE-Y	18393142T7
18393142	156	166	factor IIa	GENE-Y	18393142T8
18393142	70	79	factor Xa	GENE-Y	18393142T9
18393142	CPR:4	18393142T4	18393142T7
18393142	CPR:4	18393142T5	18393142T7

18423812|t|Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
18423812|a|BACKGROUND: Agents inhibiting the renin-angiotensin-aldosterone (RAAS) system have an important role in slowing the progression of chronic kidney disease. We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade). DESIGN: Randomized open controlled crossover study. SETTING & PARTICIPANTS: 18 whites (7 women, 11 men) from the Outpatient Department of Nephrology with chronic nondiabetic proteinuric kidney diseases, mean age 42.4 +/- 1.9 years (SEM). INTERVENTIONS: In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg. Participants were then randomly assigned to 2 treatment sequences, either the addition of spironolactone (25 mg) (triple RAAS blockade) through 8 weeks followed by double RAAS blockade through 8 weeks (sequence 1) or double RAAS blockade followed by triple RAAS blockade (sequence 2). MAIN OUTCOME MEASURES: 24-hour urine protein excretion (primary end point) and markers of tubular injury and fibrosis (secondary end points). Analysis was performed using analysis of variance for repeated measurements. RESULTS: At baseline, mean serum creatinine level was 1.16 +/- 0.09 mg/dL (103 +/- 8 micromol/L), estimated glomerular filtration rate was 107.8 mL/min (95% confidence interval, 93 to 140.9 [1.8 mL/s; 95% confidence interval, 1.55 to 2.35; Cockcroft-Gault formula), and 24-hour mean proteinuria was 0.97 +/- 0.18 g. Mean urine protein excretion was 0.7 g/24 h (95% confidence interval, 0.48 to 0.92) less after triple RAAS blockade than after double RAAS blockade (P = 0.01), without change in blood pressure. Urine excretion of N-acetyl-beta-d-glucosaminidase (P = 0.02) and amino-terminal propeptide of type III procollagen (P = 0.05) also significantly decreased. Potassium levels increased significantly after triple therapy (P = 0.02). However, no patient was withdrawn because of adverse effects. LIMITATIONS: Absence of blinding, small sample size, short treatment period, absence of histological assessment. CONCLUSIONS: Administration of an aldosterone receptor antagonist in addition to double RAAS blockade with an ACE inhibitor and ARB may slow the progression of chronic kidney disease. Additional studies are necessary to confirm this result.
18423812	57	68	aldosterone	CHEMICAL	18423812T10
18423812	2158	2189	N-acetyl-beta-d-glucosaminidase	GENE-Y	18423812T11
18423812	356	376	aldosterone receptor	GENE-Y	18423812T12
18423812	2234	2254	type III procollagen	GENE-N	18423812T13
18423812	2579	2599	aldosterone receptor	GENE-Y	18423812T14
18423812	394	423	angiotensin-converting enzyme	GENE-Y	18423812T15
18423812	2655	2658	ACE	GENE-Y	108004
18423812	425	428	ACE	GENE-Y	108004
18423812	444	481	angiotensin II type 1 (AT-1) receptor	GENE-Y	18423812T18
18423812	183	188	renin	GENE-Y	18423812T19
18423812	1215	1229	spironolactone	CHEMICAL	18423812T1
18423812	189	200	angiotensin	GENE-Y	18423812T20
18423812	570	573	ACE	GENE-Y	108004
18423812	928	931	ACE	GENE-Y	108004
18423812	39	44	renin	GENE-Y	18423812T23
18423812	45	56	angiotensin	GENE-Y	18423812T24
18423812	356	367	aldosterone	CHEMICAL	18423812T2
18423812	2296	2305	Potassium	CHEMICAL	1310
18423812	2579	2590	aldosterone	CHEMICAL	18423812T4
18423812	444	458	angiotensin II	CHEMICAL	18423812T5
18423812	201	212	aldosterone	CHEMICAL	18423812T6
18423812	942	952	cilazapril	CHEMICAL	1306
18423812	969	979	telmisarta	CHEMICAL	18423812T8
18423812	1007	1026	hydrochlorothiazide	CHEMICAL	18423812T9
18423812	CPR:4	1306	108004

18439678|t|Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod.
18439678|a|Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors (PRR), which are utilized by the innate immune system to recognize microbial components, known as pathogen-associated molecular patterns (PAMP). We cloned and characterized porcine TLR7 and TLR8 genes from pig lymph node tissue. Sequence analysis showed that the aa sequence identities of porcine TLR7 with human, mouse and bovine TLR7 are 85, 78 and 90%, respectively, whereas porcine TLR8 aa sequence identities with human, mouse and bovine TLR8 are 73, 69 and 79%, respectively. Both porcine TLR7 and TLR8 proteins were expressed in cell lines and were N-glycosylated. The stimulatory activity of TLR7 and TLR8 ligands to porcine and human TLR7 and TLR8 in transiently transfected Cos-7 and 293T cells were analyzed using a NF-kappaB reporter assay. Two imidazoquinoline molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands. Therefore, receptor specificity for porcine TLR8 is clearly species specific. We further showed that porcine TLR7 and TLR8 are located intracellularly and are mainly within the endoplasmic reticulum. Moreover, activation of transfected cells and porcine PBMC by TLR7 ligands was inhibited by bafilomycin A(1) indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.
18439678	1215	1227	porcine TLR7	GENE-Y	18439678T10
18439678	1232	1236	TLR8	GENE-Y	119462
18439678	1376	1380	TLR7	GENE-Y	119436
18439678	101	105	TLRs	GENE-N	18439678T13
18439678	368	372	TLR7	GENE-Y	119436
18439678	377	381	TLR8	GENE-Y	119462
18439678	476	488	porcine TLR7	GENE-Y	18439678T16
18439678	494	522	human, mouse and bovine TLR7	GENE-N	18439678T17
18439678	565	577	porcine TLR8	GENE-Y	18439678T18
18439678	606	634	human, mouse and bovine TLR8	GENE-N	18439678T19
18439678	1406	1422	bafilomycin A(1)	CHEMICAL	18439678T1
18439678	674	686	porcine TLR7	GENE-N	18439678T20
18439678	691	695	TLR8	GENE-N	119462
18439678	787	791	TLR7	GENE-Y	119436
18439678	796	800	TLR8	GENE-Y	119462
18439678	812	834	porcine and human TLR7	GENE-N	18439678T24
18439678	839	843	TLR8	GENE-N	119462
18439678	157	186	pattern-recognition receptors	GENE-N	18439678T26
18439678	914	923	NF-kappaB	GENE-N	18439678T27
18439678	1023	1035	porcine TLR7	GENE-Y	18439678T28
18439678	1040	1044	TLR8	GENE-Y	119462
18439678	743	744	N	CHEMICAL	167
18439678	1058	1068	human TLR7	GENE-Y	18439678T30
18439678	1078	1082	TLR8	GENE-Y	119462
18439678	17	21	TLR7	GENE-Y	119436
18439678	56	60	TLR7	GENE-Y	119436
18439678	8	12	TLR8	GENE-Y	119462
18439678	944	960	imidazoquinoline	CHEMICAL	18439678T3
18439678	972	981	imiquimod	CHEMICAL	18439678T4
18439678	986	997	gardiquimod	CHEMICAL	18439678T5
18439678	69	78	imiquimod	CHEMICAL	18439678T6
18439678	80	99	Toll-like receptors	GENE-N	18439678T7
18439678	1150	1162	porcine TLR8	GENE-Y	18439678T8
18439678	188	191	PRR	GENE-N	18439678T9
18439678	CPR:3	18439678T3	18439678T28
18439678	CPR:3	18439678T3	119462
18439678	CPR:3	18439678T3	18439678T30
18439678	CPR:3	18439678T4	18439678T28
18439678	CPR:3	18439678T4	119462
18439678	CPR:3	18439678T4	18439678T30
18439678	CPR:3	18439678T5	18439678T28
18439678	CPR:3	18439678T5	119462
18439678	CPR:3	18439678T5	18439678T30
18439678	CPR:3	18439678T6	119436
18439678	CPR:3	18439678T6	119462
18439678	CPR:4	18439678T1	119436

18574460|t|High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues.
18574460|a|BACKGROUND AND PURPOSE: Voltage-operated sodium channels constitute major target sites for local anaesthetic-like action. The clinical use of local anaesthetics is still limited by severe side effects, in particular, arrhythmias and convulsions. These side effects render the search for new local anaesthetics a matter of high interest. EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293. KEY RESULTS: 4-Iodo-, 4-bromo- and 4-chloropropofol reversibly suppressed depolarization-induced whole-cell sodium inward currents with high potency. The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for 4-chloropropofol in Na(V)1.2. Membrane depolarization inducing inactivation strongly increased the blocking potency of all compounds. Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for 4-chloropropofol in Na(V)1.2. Recovery from fast inactivation was prolonged in the presence of drug leading to an accumulation of block during repetitive stimulation at high frequencies (100 Hz). CONCLUSIONS AND IMPLICATIONS: Halogenated propofol analogues constitute a novel class of sodium channel-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine. Preferential drug binding to inactivated channel states suggests that halogenated propofol analogues might be especially effective in suppressing ectopic discharges in a variety of pathological conditions.
18574460	561	569	propofol	CHEMICAL	18574460T10
18574460	612	618	sodium	CHEMICAL	18574460T11
18574460	671	687	4-chloropropofol	CHEMICAL	18574460T12
18574460	701	707	sodium	CHEMICAL	18574460T13
18574460	807	813	4-Iodo	CHEMICAL	18574460T14
18574460	816	823	4-bromo	CHEMICAL	18574460T15
18574460	829	845	4-chloropropofol	CHEMICAL	18574460T16
18574460	902	908	sodium	CHEMICAL	18574460T17
18574460	1072	1088	4-chloropropofol	CHEMICAL	18574460T18
18574460	72	78	sodium	CHEMICAL	18574460T19
18574460	1300	1314	4-iodopropofol	CHEMICAL	18574460T1
18574460	91	111	halogenated propofol	CHEMICAL	18574460T20
18574460	1356	1364	Na(V)1.4	GENE-Y	18574460T21
18574460	1401	1409	Na(V)1.2	GENE-Y	18574460T22
18574460	1666	1680	sodium channel	GENE-N	18574460T23
18574460	147	179	Voltage-operated sodium channels	GENE-N	18574460T24
18574460	573	627	voltage-operated human skeletal muscle sodium channels	GENE-N	18574460T25
18574460	629	637	Na(V)1.4	GENE-Y	18574460T26
18574460	692	716	neuronal sodium channels	GENE-N	18574460T27
18574460	718	726	Na(V)1.2	GENE-Y	18574460T28
18574460	1028	1036	Na(V)1.4	GENE-Y	18574460T29
18574460	1316	1331	4-bromopropofol	CHEMICAL	18574460T2
18574460	1092	1100	Na(V)1.2	GENE-Y	18574460T30
18574460	26	87	voltage-operated skeletal muscle and neuronal sodium channels	GENE-N	18574460T31
18574460	1336	1352	4-chloropropofol	CHEMICAL	18574460T3
18574460	1381	1397	4-chloropropofol	CHEMICAL	18574460T4
18574460	1607	1627	Halogenated propofol	CHEMICAL	18574460T5
18574460	1666	1672	sodium	CHEMICAL	18574460T6
18574460	1799	1808	lidocaine	CHEMICAL	18574460T7
18574460	1880	1900	halogenated propofol	CHEMICAL	18574460T8
18574460	164	170	sodium	CHEMICAL	18574460T9
18574460	CPR:4	18574460T18	18574460T30
18574460	CPR:4	18574460T1	18574460T21
18574460	CPR:4	18574460T20	18574460T31
18574460	CPR:4	18574460T2	18574460T21
18574460	CPR:4	18574460T3	18574460T21
18574460	CPR:4	18574460T4	18574460T22
18574460	CPR:4	18574460T5	18574460T23

18627212|t|Irbesartan: a review of its use in hypertension and diabetic nephropathy.
18627212|a|Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension. It is also approved in some regions for the treatment of nephropathy in patients with hypertension and type 2 diabetes mellitus. In adults with essential hypertension, irbesartan is effective at reducing blood pressure (BP) over a 24-hour period with once-daily administration. Irbesartan also slows the progression of renal disease in hypertensive patients with type 2 diabetes, with this effect partly independent of its BP-lowering effect. In addition, irbesartan was generally well tolerated in clinical trials. Thus, irbesartan is a useful treatment option for patients with hypertension, including those with type 2 diabetes and nephropathy.
18627212	764	774	irbesartan	CHEMICAL	18627212T10
18627212	0	10	Irbesartan	CHEMICAL	1018
18627212	124	154	angiotensin II receptor type 1	GENE-Y	18627212T12
18627212	74	84	Irbesartan	CHEMICAL	1018
18627212	86	93	Aprovel	CHEMICAL	18627212T2
18627212	95	101	Avapro	CHEMICAL	1018
18627212	103	110	Irbetan	CHEMICAL	18627212T4
18627212	410	420	irbesartan	CHEMICAL	18627212T5
18627212	112	118	Karvea	CHEMICAL	18627212T6
18627212	520	530	Irbesartan	CHEMICAL	1018
18627212	124	138	angiotensin II	CHEMICAL	18627212T8
18627212	698	708	irbesartan	CHEMICAL	18627212T9
18627212	CPR:6	1018	18627212T12
18627212	CPR:6	18627212T2	18627212T12
18627212	CPR:6	1018	18627212T12
18627212	CPR:6	18627212T4	18627212T12
18627212	CPR:6	18627212T6	18627212T12

18773878|t|DNA damage and homologous recombination signaling induced by thymidylate deprivation.
18773878|a|DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of thymidylate synthase (TS), but the types of damage and signaling responses remain incompletely understood. Thymidylate deprivation increases dUTP and uracil in DNA, which is removed by base excision repair (BER). Because BER requires a synthesis step, strand break intermediates presumably accumulate. Thymidylate deprivation also induces cell cycle arrest during replication. Homologous recombination (HR) is a means of repairing persistent BER intermediates and collapsed replication forks. There are also intimate links between HR and S-phase checkpoint pathways. In this study, the goals were to determine the involvement of HR-associated proteins and DNA damage signaling responses to thymidylate deprivation. When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (RTX), which specifically inhibits TS. To our knowledge, this is the first demonstration in mammalian cells that depletion of RAD51 causes sensitivity to thymidylate deprivation. Activation of DNA damage signaling responses was examined following treatment with RTX. Phosphorylation of replication protein A (RPA2 subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of RTX. Induction was much more striking following RTX treatment than with hydroxyurea, which is commonly used to inhibit replication. RTX treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied. Collectively, the results suggest that HR and S-phase checkpoint signaling processes are invoked by thymidylate deprivation and influence cellular resistance to thymidylate deprivation.
18773878	302	313	Thymidylate	CHEMICAL	1580
18773878	345	351	uracil	CHEMICAL	18773878T11
18773878	497	508	Thymidylate	CHEMICAL	1580
18773878	129	140	thymidylate	CHEMICAL	18773878T13
18773878	885	896	thymidylate	CHEMICAL	18773878T14
18773878	1005	1016	raltitrexed	CHEMICAL	18773878T15
18773878	1018	1021	RTX	CHEMICAL	18773878T16
18773878	61	72	thymidylate	CHEMICAL	18773878T17
18773878	1143	1148	RAD51	GENE-Y	111825|36841|17483|676352
18773878	195	215	thymidylate synthase	GENE-Y	18773878T19
18773878	1171	1182	thymidylate	CHEMICAL	18773878T1
18773878	1303	1324	replication protein A	GENE-N	18773878T20
18773878	1326	1330	RPA2	GENE-Y	112038|61322|2337|164551
18773878	217	219	TS	GENE-Y	18773878T22
18773878	1594	1599	RAD51	GENE-Y	111825|36841|17483|676352
18773878	1601	1611	gamma-H2AX	GENE-Y	18773878T24
18773878	1613	1625	phospho-Chk1	GENE-Y	18773878T25
18773878	1631	1643	phospho-NBS1	GENE-Y	18773878T26
18773878	1689	1693	RPA2	GENE-Y	112038|61322|2337|164551
18773878	915	920	RAD51	GENE-Y	111825|36841|17483|676352
18773878	1052	1054	TS	GENE-Y	18773878T29
18773878	195	206	thymidylate	CHEMICAL	18773878T2
18773878	1279	1282	RTX	CHEMICAL	18773878T3
18773878	1427	1430	RTX	CHEMICAL	18773878T4
18773878	1475	1478	RTX	CHEMICAL	18773878T5
18773878	1499	1510	hydroxyurea	CHEMICAL	18773878T6
18773878	1559	1562	RTX	CHEMICAL	18773878T7
18773878	1807	1818	thymidylate	CHEMICAL	18773878T8
18773878	1868	1879	thymidylate	CHEMICAL	18773878T9
18773878	CPR:3	18773878T7	111825|36841|17483|676352
18773878	CPR:3	18773878T7	18773878T24
18773878	CPR:3	18773878T7	18773878T25
18773878	CPR:3	18773878T7	18773878T26
18773878	CPR:4	18773878T16	18773878T29
18773878	CPR:9	18773878T13	18773878T19
18773878	CPR:9	18773878T13	18773878T22

18954704|t|Corticosteroids and human recombinant activated protein C for septic shock.
18954704|a|This article summarizes the current knowledge on the benefit/risk profile from the use of low-dose corticosteroids and activated protein C in treating septic shock. Physicians should consider using low-dose corticosteroids and drotrecogin alpha activated in the treatment of patients who have vasopressor-dependent septic shock with persistent signs of hypoperfusion, organ dysfunction, or hypotension. The optimal timing for initiating these treatments is from 6 to 24 hours from onset of shock. When patients are receiving these drugs, physicians should systematically screen for superinfection and serious bleeding events.
18954704	283	298	corticosteroids	CHEMICAL	18954704T1
18954704	175	190	corticosteroids	CHEMICAL	18954704T2
18954704	0	15	Corticosteroids	CHEMICAL	18954704T3
18954704	195	214	activated protein C	GENE-Y	18954704T4
18954704	303	320	drotrecogin alpha	GENE-Y	18954704T5
18954704	20	57	human recombinant activated protein C	GENE-Y	18954704T6

18996527|t|Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine.
18996527|a|Nicotinamide N-methyltransferase (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions. Here we show that, in addition to the liver, 3T3-L1 adipocytes as well as human and murine adipose tissue explants express high amounts of enzymatically active NNMT. NNMT mRNA levels and enzyme activity increased in 3T3-L1 cells in a differentiation-dependent manner. Homocysteine, the atherogenic product of the NNMT-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures. Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the NNMT inhibitor 1-methylnicotinamide. Nicotinic acid (NA), a widely used drug to lower elevated plasma lipid levels, induced NNMT enzyme activity in white adipose tissue of mice. In tissue culture nicotinamide treatment led to an increase in adipose tissue homocysteine secretion. These data support the concept that adipose tissue NNMT contributes to the increased plasma homocysteine levels in patients treated with NA.
18996527	819	821	NA	CHEMICAL	18996527T10
18996527	165	185	1-methylnicotinamide	CHEMICAL	18996527T11
18996527	962	974	nicotinamide	CHEMICAL	18996527T12
18996527	1022	1034	homocysteine	CHEMICAL	18996527T13
18996527	30	42	nicotinamide	CHEMICAL	18996527T14
18996527	43	44	N	CHEMICAL	167
18996527	67	79	homocysteine	CHEMICAL	18996527T16
18996527	81	113	Nicotinamide N-methyltransferase	GENE-Y	18996527T17
18996527	1097	1101	NNMT	GENE-Y	110900
18996527	411	415	NNMT	GENE-Y	110900
18996527	81	93	Nicotinamide	CHEMICAL	2590
18996527	417	421	NNMT	GENE-Y	110900
18996527	115	119	NNMT	GENE-Y	110900
18996527	564	568	NNMT	GENE-Y	110900
18996527	766	770	NNMT	GENE-Y	110900
18996527	890	894	NNMT	GENE-Y	110900
18996527	30	62	nicotinamide N-methyltransferase	GENE-Y	18996527T25
18996527	1138	1150	homocysteine	CHEMICAL	18996527T2
18996527	1183	1185	NA	CHEMICAL	18996527T3
18996527	94	95	N	CHEMICAL	167
18996527	519	531	Homocysteine	CHEMICAL	18996527T5
18996527	648	660	Homocysteine	CHEMICAL	18996527T6
18996527	149	161	nicotinamide	CHEMICAL	18996527T7
18996527	781	801	1-methylnicotinamide	CHEMICAL	18996527T8
18996527	803	817	Nicotinic acid	CHEMICAL	18996527T9
18996527	CPR:3	18996527T10	110900
18996527	CPR:3	18996527T9	110900
18996527	CPR:4	18996527T8	110900
18996527	CPR:9	18996527T11	18996527T17
18996527	CPR:9	18996527T11	110900
18996527	CPR:9	18996527T2	110900
18996527	CPR:9	18996527T5	110900
18996527	CPR:9	18996527T7	18996527T17
18996527	CPR:9	18996527T7	110900

19029287|t|Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms.
19029287|a|The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain. Recent work implicates Ca(v)1.3 channels as interesting drug targets, but no isoform-selective modulators exist. It is also unknown to what extent Ca(v)1.1 and Ca(v)1.4 contribute to L-type-specific DHP binding activity in brain. To address this question and to determine whether DHPs can discriminate between Ca(v)1.2 and Ca(v)1.3 binding pockets, we combined radioreceptor assays and quantitative polymerase chain reaction (qPCR). We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)]. (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding. Instead, this could be explained by low-affinity binding (127-fold K(d) increase) to the mutated Ca(v)1.2 channels. Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels. This suggests that small differences in their binding pockets may allow development of isoform-selective modulators for LTCCs and that, because of their very low expression, Ca(v)1.1 and Ca(v)1.4 are unlikely to serve as drug targets to treat CNS diseases.
19029287	70	77	calcium	CHEMICAL	19029287T10
19029287	1141	1145	LTCC	GENE-N	19029287T11
19029287	1339	1347	Ca(v)1.2	GENE-Y	19029287T12
19029287	1404	1412	Ca(v)1.2	GENE-Y	19029287T13
19029287	1436	1444	Ca(v)1.3	GENE-Y	19029287T14
19029287	1475	1483	Ca(v)1.2	GENE-Y	19029287T15
19029287	1594	1602	Ca(v)1.2	GENE-Y	19029287T16
19029287	1807	1812	LTCCs	GENE-N	19029287T17
19029287	1861	1869	Ca(v)1.1	GENE-Y	19029287T18
19029287	1874	1882	Ca(v)1.4	GENE-Y	19029287T19
19029287	198	201	DHP	CHEMICAL	19029287T1
19029287	288	296	Ca(v)1.3	GENE-Y	19029287T20
19029287	124	128	LTCC	GENE-N	19029287T21
19029287	412	420	Ca(v)1.1	GENE-Y	19029287T22
19029287	425	433	Ca(v)1.4	GENE-Y	19029287T23
19029287	100	122	L-type calcium channel	GENE-N	19029287T24
19029287	139	147	Ca(v)1.2	GENE-Y	19029287T25
19029287	575	583	Ca(v)1.2	GENE-Y	19029287T26
19029287	588	596	Ca(v)1.3	GENE-Y	19029287T27
19029287	152	160	Ca(v)1.3	GENE-Y	19029287T28
19029287	722	727	Ca(v)	GENE-N	19029287T29
19029287	107	114	calcium	CHEMICAL	19029287T2
19029287	760	768	Ca(v)1.2	GENE-Y	19029287T30
19029287	779	787	Ca(v)1.2	GENE-Y	19029287T31
19029287	837	845	Ca(v)1.3	GENE-Y	19029287T32
19029287	857	865	Ca(v)1.3	GENE-Y	19029287T33
19029287	905	913	Ca(v)1.2	GENE-Y	19029287T34
19029287	926	931	Ca(v)	GENE-N	19029287T35
19029287	1015	1023	Ca(v)1.3	GENE-Y	19029287T36
19029287	1052	1057	LTCCs	GENE-N	19029287T37
19029287	1078	1086	Ca(v)1.1	GENE-Y	19029287T38
19029287	1091	1108	Ca(v)1.4 alpha(1)	GENE-Y	19029287T39
19029287	1372	1392	(+)-[(3)H]isradipine	CHEMICAL	19029287T3
19029287	63	85	L-type calcium channel	GENE-N	19029287T40
19029287	1558	1570	nitrendipine	CHEMICAL	19029287T4
19029287	1575	1585	nifedipine	CHEMICAL	1103
19029287	464	467	DHP	CHEMICAL	19029287T6
19029287	873	893	(+)-[(3)H]isradipine	CHEMICAL	19029287T7
19029287	177	196	1,4-dihydropyridine	CHEMICAL	19029287T8
19029287	15	34	1,4-dihydropyridine	CHEMICAL	19029287T9

19039322|t|Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
19039322|a|The detailed molecular mechanism of action of second-generation BCR-ABL tyrosine kinase inhibitors, including perturbed targets and pathways, should contribute to rationalized therapy in chronic myeloid leukemia (CML) or in other affected diseases. Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel. The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and serine/threonine kinases. We have found clear differences in the target patterns of bosutinib in primary CML cells versus the K562 cell line. A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles. Common among those were the SRC, ABL and TEC family kinases. Bosutinib did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases. Although in vivo bosutinib is inactive against ABL T315I, we found this clinically important mutant to be enzymatically inhibited in the mid-nanomolar range. Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.
19039322	932	941	dasatinib	CHEMICAL	19039322T10
19039322	1090	1099	Bosutinib	CHEMICAL	5562
19039322	46	55	bosutinib	CHEMICAL	19039322T12
19039322	1116	1119	KIT	GENE-Y	110015
19039322	1123	1162	platelet-derived growth factor receptor	GENE-N	19039322T14
19039322	1210	1223	STE20 kinases	GENE-N	19039322T15
19039322	1272	1275	ABL	GENE-Y	19039322T16
19039322	1276	1281	T315I	GENE-N	19039322T17
19039322	1415	1421	kinase	GENE-N	19039322T18
19039322	1448	1454	CAMK2G	GENE-Y	107268
19039322	1242	1251	bosutinib	CHEMICAL	19039322T1
19039322	402	405	SRC	GENE-Y	112592|676691|192317
19039322	406	409	ABL	GENE-Y	19039322T21
19039322	592	598	kinase	GENE-N	19039322T22
19039322	634	640	kinase	GENE-N	19039322T23
19039322	163	166	BCR	GENE-Y	107083
19039322	746	783	tyrosine and serine/threonine kinases	GENE-N	19039322T25
19039322	167	170	ABL	GENE-Y	19039322T26
19039322	171	186	tyrosine kinase	GENE-N	19039322T27
19039322	959	965	kinase	GENE-N	19039322T28
19039322	1057	1060	SRC	GENE-Y	112592|676691|192317
19039322	1392	1401	bosutinib	CHEMICAL	19039322T2
19039322	1062	1065	ABL	GENE-Y	19039322T30
19039322	1070	1073	TEC	GENE-Y	112865
19039322	1081	1088	kinases	GENE-N	19039322T32
19039322	29	35	kinase	GENE-N	19039322T33
19039322	420	429	bosutinib	CHEMICAL	19039322T3
19039322	701	710	bosutinib	CHEMICAL	19039322T4
19039322	746	754	tyrosine	CHEMICAL	19039322T5
19039322	759	765	serine	CHEMICAL	19039322T6
19039322	766	775	threonine	CHEMICAL	19039322T7
19039322	843	852	bosutinib	CHEMICAL	19039322T8
19039322	917	926	bosutinib	CHEMICAL	19039322T9
19039322	CPR:4	19039322T10	19039322T28
19039322	CPR:4	19039322T12	19039322T33
19039322	CPR:4	19039322T2	19039322T18
19039322	CPR:4	19039322T2	107268
19039322	CPR:4	19039322T3	112592|676691|192317
19039322	CPR:4	19039322T3	19039322T21
19039322	CPR:4	19039322T9	19039322T28

1908244|t|The effect of estramustine derivatives on microtubule assembly in vitro depends on the charge of the substituent.
1908244|a|Estramustine, and derivatives of estramustine with a charged substituent at position 17 on the estrogen moiety, have been investigated for their effects on bovine brain microtubules in vitro. The negatively charged estramustine phosphate has been found previously to be a microtubule-associated protein (MAP)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985]. In the present study the binding of estramustine phosphate to MAP2 and tau was investigated. Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains. The Kd for the binding of estramustine phosphate to MAP2 was estimated to be 20 microM at 4 degrees, and for the binding of tau, 200 microM. The rate of dissociation was very low (T1/2 greater than 2 hr), which indicates that the binding of estramustine phosphate may stabilize the protein-drug complex by changing the protein conformation. Two new negatively charged estramustine derivatives, estramustine sulphate and estramustine glucuronide, were found to be similar MAP-dependent microtubule inhibitors. The concentration for 50% inhibition of assembly was 100 microM for the sulphate derivative, the same as found previously for estramustine phosphate, and 250 microM for the more bulky estramustine glucuronide. A positively charged derivative, estramustine sarcosinate, did not inhibit microtubule assembly or alter the composition of the coassembled MAPs. The morphology of the microtubules was, however, affected. The uncharged estramustine bound to both tubulin and MAPs, but no effects were seen on microtubule assembly, the composition of coassembled MAPs or the microtubule morphology. Our results suggest that only negatively charged estramustine derivatives have a MAP-dependent microtubule inhibitory effect. The two new negatively charged derivatives could therefore be valuable tools in the study of tubulin-MAP interactions. The results also confirm that these interactions between tubulin and MAPs are mainly electrostatic.
1908244	1994	2006	estramustine	CHEMICAL	1908244T10
1908244	329	351	estramustine phosphate	CHEMICAL	1908244T11
1908244	147	159	estramustine	CHEMICAL	1908244T12
1908244	556	578	estramustine phosphate	CHEMICAL	1908244T13
1908244	679	701	estramustine phosphate	CHEMICAL	1908244T14
1908244	756	766	amino acid	CHEMICAL	1908244T15
1908244	871	893	estramustine phosphate	CHEMICAL	1908244T16
1908244	209	217	estrogen	CHEMICAL	1908244T17
1908244	1086	1108	estramustine phosphate	CHEMICAL	1908244T18
1908244	14	26	estramustine	CHEMICAL	1908244T19
1908244	114	126	Estramustine	CHEMICAL	1184
1908244	1316	1319	MAP	GENE-N	1908244T20
1908244	1704	1708	MAPs	GENE-N	1908244T21
1908244	1810	1817	tubulin	GENE-N	1908244T22
1908244	1822	1826	MAPs	GENE-N	1908244T23
1908244	1909	1913	MAPs	GENE-N	1908244T24
1908244	2026	2029	MAP	GENE-N	1908244T25
1908244	2164	2171	tubulin	GENE-N	1908244T26
1908244	2172	2175	MAP	GENE-N	1908244T27
1908244	2247	2254	tubulin	GENE-N	1908244T28
1908244	2259	2263	MAPs	GENE-N	1908244T29
1908244	1213	1225	estramustine	CHEMICAL	1908244T2
1908244	386	416	microtubule-associated protein	GENE-N	1908244T30
1908244	418	421	MAP	GENE-N	1908244T31
1908244	582	586	MAP2	GENE-Y	32613|110305
1908244	591	594	tau	GENE-Y	77370
1908244	624	628	MAPs	GENE-N	1908244T34
1908244	784	788	MAPs	GENE-N	1908244T35
1908244	820	827	tubulin	GENE-N	1908244T36
1908244	897	901	MAP2	GENE-N	32613|110305
1908244	1239	1260	estramustine sulphate	CHEMICAL	1908244T3
1908244	1265	1289	estramustine glucuronide	CHEMICAL	1908244T4
1908244	1426	1434	sulphate	CHEMICAL	1908244T5
1908244	1480	1502	estramustine phosphate	CHEMICAL	1908244T6
1908244	1538	1562	estramustine glucuronide	CHEMICAL	1908244T7
1908244	1597	1621	estramustine sarcosinate	CHEMICAL	1908244T8
1908244	1783	1795	estramustine	CHEMICAL	1908244T9

1911436|t|Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog.
1911436|a|3 beta-Hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes. Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the dehydrogenase and isomerase substrate steroids bind at different sites on the same protein. However, the coenzyme, NADH, completely abolishes the alkylation of both enzyme activities by the progestin analog [Thomas J .L., Myers R. P., Rosik L. O. and Strickler R. C., J. Steroid Biochem. 36 (1990) 117-123]. Unlike bacterial 3-keto-5-ene-steroid isomerase, the human isomerase reaction is stimulated by diphosphopyridine nucleotides (NADH, NAD+). The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the dehydrogenase and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM). FSA is a cofactor site-directed reagent that binds with similar affinity as a competitive inhibitor of NAD+ reduction by dehydrogenase (Ki = 162 microM) or as a stimulator of isomerase (Km = 153 microM). Parallel plots derived from Kitz and Wilson analysis indicate that FSA inactivates the two enzyme activities with equal alkylation efficiency (k3/Ki = 1/slope = 0.51/mol-s for both). The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as dehydrogenase from inactivation by FSA. These observations are evidence for a single cofactor binding region which services both enzyme activities.
1911436	626	635	progestin	CHEMICAL	1911436T10
1911436	761	781	3-keto-5-ene-steroid	CHEMICAL	1911436T11
1911436	839	868	diphosphopyridine nucleotides	CHEMICAL	1911436T12
1911436	870	874	NADH	CHEMICAL	151
1911436	876	880	NAD+	CHEMICAL	1911436T14
1911436	905	915	nucleotide	CHEMICAL	1911436T15
1911436	924	963	5'-[p-(fluorosulfonyl)benzoyl]adenosine	CHEMICAL	1911436T16
1911436	965	968	FSA	CHEMICAL	1911436T17
1911436	130	169	5'-[p-(fluorosulfonyl)benzoyl]adenosine	CHEMICAL	1911436T18
1911436	48	76	3 beta-hydroxy-5-ene-steroid	CHEMICAL	1911436T19
1911436	209	237	3 beta-Hydroxy-5-ene-steroid	CHEMICAL	1911436T1
1911436	209	251	3 beta-Hydroxy-5-ene-steroid dehydrogenase	GENE-N	1911436T20
1911436	1293	1306	dehydrogenase	GENE-N	1911436T21
1911436	1640	1653	dehydrogenase	GENE-N	1911436T22
1911436	436	449	dehydrogenase	GENE-N	1911436T23
1911436	256	284	steroid 5----4-ene-isomerase	GENE-N	1911436T24
1911436	761	791	3-keto-5-ene-steroid isomerase	GENE-N	1911436T25
1911436	987	1000	dehydrogenase	GENE-N	1911436T26
1911436	32	90	human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase	GENE-N	1911436T27
1911436	95	123	steroid 5----4-ene-isomerase	GENE-N	1911436T28
1911436	1275	1279	NAD+	CHEMICAL	1911436T2
1911436	1443	1446	FSA	CHEMICAL	1911436T3
1911436	1563	1584	3 beta-hydroxysteroid	CHEMICAL	1911436T4
1911436	1596	1608	pregnenolone	CHEMICAL	1911436T5
1911436	1675	1678	FSA	CHEMICAL	1911436T6
1911436	387	417	alpha-bromoacetoxyprogesterone	CHEMICAL	1911436T7
1911436	474	482	steroids	CHEMICAL	1911436T8
1911436	551	555	NADH	CHEMICAL	151
1911436	CPR:4	1911436T15	1911436T26
1911436	CPR:4	1911436T16	1911436T26
1911436	CPR:4	1911436T17	1911436T26
1911436	CPR:4	1911436T6	1911436T22
1911436	CPR:9	1911436T8	1911436T23

19149483|t|Tyrosine kinase blockers: new hope for successful cancer therapy.
19149483|a|Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the last few years, thorough analysis of the mechanism underlying tyrosine kinase's activity led to novel cancer therapy using TKs blockers. These drugs are remarkably effective in the treatment of various human tumors including head and neck, gastric, prostate and breast cancer and leukemias. The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia. The introduction of STI571 for the treatment of leukemia in clinical oncology has had a dramatic impact on how this disease is currently managed. Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase. The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava). Herein, we discuss the chemistry, biological activity and clinical potential of new drugs with tyrosine kinase blockers for cancer treatment.
19149483	1208	1216	SU 11248	CHEMICAL	19149483T10
19149483	1218	1224	Sutent	CHEMICAL	19149483T11
19149483	1261	1267	AMN107	CHEMICAL	19149483T12
19149483	1269	1278	Nilotinib	CHEMICAL	4668
19149483	1284	1292	INNO-406	CHEMICAL	19149483T14
19149483	1294	1300	NS-187	CHEMICAL	19149483T15
19149483	1422	1431	Lapatinib	CHEMICAL	1246
19149483	1433	1453	Lapatinib ditosylate	CHEMICAL	19149483T17
19149483	1455	1461	Tykerb	CHEMICAL	1246
19149483	1463	1472	GW-572016	CHEMICAL	19149483T19
19149483	66	74	Tyrosine	CHEMICAL	19149483T1
19149483	1475	1485	Canertinib	CHEMICAL	19149483T20
19149483	1487	1494	CI-1033	CHEMICAL	19149483T21
19149483	1497	1504	Zactima	CHEMICAL	19149483T22
19149483	1506	1512	ZD6474	CHEMICAL	19149483T23
19149483	1515	1524	Vatalanib	CHEMICAL	4679
19149483	1526	1532	PTK787	CHEMICAL	19149483T25
19149483	1533	1542	ZK 222584	CHEMICAL	19149483T26
19149483	1545	1554	Sorafenib	CHEMICAL	390
19149483	1556	1567	Bay 43-9006	CHEMICAL	19149483T28
19149483	1569	1576	Nexavar	CHEMICAL	19149483T29
19149483	1071	1080	Dasatinib	CHEMICAL	1242
19149483	1583	1594	Leflunomide	CHEMICAL	1085
19149483	1596	1601	SU101	CHEMICAL	19149483T31
19149483	1603	1608	Arava	CHEMICAL	1085
19149483	1706	1714	tyrosine	CHEMICAL	19149483T33
19149483	424	432	tyrosine	CHEMICAL	19149483T34
19149483	703	711	Imatinib	CHEMICAL	609
19149483	713	730	Imatinib mesylate	CHEMICAL	19149483T36
19149483	732	739	Gleevec	CHEMICAL	19149483T37
19149483	741	747	STI571	CHEMICAL	19149483T38
19149483	880	886	STI571	CHEMICAL	19149483T39
19149483	1082	1092	BMS-354825	CHEMICAL	19149483T3
19149483	0	8	Tyrosine	CHEMICAL	19149483T40
19149483	66	82	Tyrosine kinases	GENE-N	19149483T41
19149483	1107	1110	ABL	GENE-Y	19149483T42
19149483	1111	1142	non-receptor cytoplasmic kinase	GENE-N	19149483T43
19149483	1239	1252	VEGF receptor	GENE-N	19149483T44
19149483	1253	1259	kinase	GENE-N	19149483T45
19149483	1315	1320	c-KIT	GENE-Y	19149483T46
19149483	1343	1345	TK	GENE-N	19149483T47
19149483	1706	1721	tyrosine kinase	GENE-N	19149483T48
19149483	246	249	TKs	GENE-N	19149483T49
19149483	1144	1153	Gefitinib	CHEMICAL	310
19149483	84	87	TKs	GENE-N	19149483T50
19149483	424	439	tyrosine kinase	GENE-N	19149483T51
19149483	485	488	TKs	GENE-N	19149483T52
19149483	684	690	kinase	GENE-N	19149483T53
19149483	767	770	Bcr	GENE-Y	225455|259476
19149483	771	774	Abl	GENE-Y	69904
19149483	0	15	Tyrosine kinase	GENE-N	19149483T56
19149483	1155	1161	Iressa	CHEMICAL	310
19149483	1164	1173	Erlotinib	CHEMICAL	520
19149483	1175	1182	OSI-774	CHEMICAL	520
19149483	1184	1191	Tarceva	CHEMICAL	19149483T8
19149483	1197	1206	Sunitinib	CHEMICAL	1255
19149483	CPR:4	19149483T10	19149483T44
19149483	CPR:4	19149483T10	19149483T45
19149483	CPR:4	19149483T11	19149483T44
19149483	CPR:4	19149483T11	19149483T45
19149483	CPR:4	19149483T12	19149483T46
19149483	CPR:4	4668	19149483T46
19149483	CPR:4	19149483T14	19149483T46
19149483	CPR:4	19149483T15	19149483T46
19149483	CPR:4	1246	19149483T47
19149483	CPR:4	19149483T17	19149483T47
19149483	CPR:4	1246	19149483T47
19149483	CPR:4	19149483T19	19149483T47
19149483	CPR:4	19149483T20	19149483T47
19149483	CPR:4	19149483T21	19149483T47
19149483	CPR:4	19149483T22	19149483T47
19149483	CPR:4	19149483T23	19149483T47
19149483	CPR:4	4679	19149483T47
19149483	CPR:4	19149483T25	19149483T47
19149483	CPR:4	19149483T26	19149483T47
19149483	CPR:4	390	19149483T47
19149483	CPR:4	19149483T28	19149483T47
19149483	CPR:4	19149483T29	19149483T47
19149483	CPR:4	1242	19149483T42
19149483	CPR:4	1242	19149483T43
19149483	CPR:4	1085	19149483T47
19149483	CPR:4	19149483T31	19149483T47
19149483	CPR:4	1085	19149483T47
19149483	CPR:4	609	19149483T53
19149483	CPR:4	609	225455|259476
19149483	CPR:4	609	69904
19149483	CPR:4	19149483T36	19149483T53
19149483	CPR:4	19149483T36	225455|259476
19149483	CPR:4	19149483T36	69904
19149483	CPR:4	19149483T37	19149483T53
19149483	CPR:4	19149483T37	225455|259476
19149483	CPR:4	19149483T37	69904
19149483	CPR:4	19149483T38	19149483T53
19149483	CPR:4	19149483T38	225455|259476
19149483	CPR:4	19149483T38	69904
19149483	CPR:4	19149483T3	19149483T42
19149483	CPR:4	310	19149483T44
19149483	CPR:4	310	19149483T45
19149483	CPR:4	310	19149483T44
19149483	CPR:4	310	19149483T45
19149483	CPR:4	520	19149483T44
19149483	CPR:4	520	19149483T45
19149483	CPR:4	520	19149483T44
19149483	CPR:4	520	19149483T45
19149483	CPR:4	19149483T8	19149483T44
19149483	CPR:4	19149483T8	19149483T45
19149483	CPR:4	1255	19149483T44
19149483	CPR:4	1255	19149483T45

19300583|t|Transdermal selegiline for the treatment of major depressive disorder.
19300583|a|Non-selective inhibition of monoamine oxidase (MAO) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects. In the US, the selegiline transdermal system (STS; EMSAM) is the first antidepressant transdermal delivery system to receive Food and Drug Administration (FDA) approved labeling for the treatment of major depressive disorder (MDD). Currently, the use of orally administered MAO inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary tyramine. The selegiline transdermal system is the only MAOI available in the US for the treatment of MDD that does not require dietary restriction at the clinically effective dose of 6 mg/24 hours. Delivery of selegiline transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic MAO-A activity (ie, reduced risk of tyramine-provoked events) while still providing sufficient levels of selegiline in the brain to produce an antidepressant effect. At dosages of 6-12 mg/24 hours, EMSAM has been shown to improve symptoms of depression, have good tolerability, and have high rates of medication adherence. However, at higher doses of EMSAM (ie, 9 mg/24 hours or more), dietary restriction of tyramine intake is recommended. The introduction of EMSAM overcomes many of the safety concerns affiliated with the conventional oral MAO inhibitors and EMSAM may be considered another strategy for the treatment of MDD, especially in patients who cannot tolerate oral antidepressants, are poorly adherent, who present with atypical depressive symptoms, or have failed other antidepressants.
19300583	739	749	selegiline	CHEMICAL	19300583T10
19300583	12	22	selegiline	CHEMICAL	19300583T11
19300583	1086	1091	MAO-A	GENE-Y	19300583T12
19300583	1629	1632	MAO	GENE-N	19300583T13
19300583	99	116	monoamine oxidase	GENE-N	19300583T14
19300583	508	511	MAO	GENE-N	19300583T15
19300583	118	121	MAO	GENE-N	19300583T16
19300583	1122	1130	tyramine	CHEMICAL	19300583T1
19300583	1191	1201	selegiline	CHEMICAL	19300583T2
19300583	1495	1503	tyramine	CHEMICAL	19300583T3
19300583	249	259	selegiline	CHEMICAL	19300583T4
19300583	99	108	monoamine	CHEMICAL	19300583T5
19300583	543	553	phenelzine	CHEMICAL	19300583T6
19300583	555	570	tranylcypromine	CHEMICAL	19300583T7
19300583	598	606	tyramine	CHEMICAL	19300583T8
19300583	725	733	tyramine	CHEMICAL	19300583T9
19300583	CPR:4	19300583T6	19300583T15
19300583	CPR:4	19300583T7	19300583T15

19445548|t|Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
19445548|a|Atomoxetine (Strattera(R)) is a selective norepinephrine (noradrenaline) reuptake inhibitor that is not classified as a stimulant, and is indicated for use in patients with attention-deficit hyperactivity disorder (ADHD). Atomoxetine is effective and generally well tolerated. It is significantly more effective than placebo and standard current therapy and does not differ significantly from or is noninferior to immediate-release methylphenidate; however, it is significantly less effective than the extended-release methylphenidate formulation OROS(R) methylphenidate (hereafter referred to as osmotically released methylphenidate) and extended-release mixed amfetamine salts. Atomoxetine can be administered either as a single daily dose or split into two evenly divided doses, has a negligible risk of abuse or misuse, and is not a controlled substance in the US. Atomoxetine is particularly useful for patients at risk of substance abuse, as well as those who have co-morbid anxiety or tics, or who do not wish to take a controlled substance. Thus, atomoxetine is a useful option in the treatment of ADHD in children and adolescents. The mechanism of action of atomoxetine is unclear, but is thought to be related to its selective inhibition of presynaptic norepinephrine reuptake in the prefrontal cortex. Atomoxetine has a high affinity and selectivity for norepinephrine transporters, but little or no affinity for various neurotransmitter receptors. Atomoxetine has a demonstrated ability to selectively inhibit norepinephrine uptake in humans and animals, and studies have shown that it preferentially binds to areas of known high distribution of noradrenergic neurons, such as the fronto-cortical subsystem. Atomoxetine was generally associated with statistically, but not clinically, significant increases in both heart rate and blood pressure in pediatric patients with ADHD. While there was an initial loss in expected height and weight among atomoxetine recipients, this eventually returned to normal in the longer term. Data suggest that atomoxetine is unlikely to have any abuse potential. Atomoxetine appeared less likely than methylphenidate to exacerbate disordered sleep in pediatric patients with ADHD. Atomoxetine is rapidly absorbed, and demonstrates dose-proportional increases in plasma exposure. It undergoes extensive biotransformation, which is affected by poor metabolism by cytochrome P450 (CYP) 2D6 in a small percentage of the population; these patients have greater exposure to and slower elimination of atomoxetine than extensive metabolizers. Patients with hepatic insufficiency show an increase in atomoxetine exposure. CYP2D6 inhibitors, such as paroxetine, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers. Once- or twice-daily atomoxetine was effective in the short-term treatment of ADHD in children and adolescents, as observed in several well designed placebo-controlled trials. Atomoxetine also demonstrated efficacy in the longer term treatment of these patients. A single morning dose was shown to be effective into the evening, and discontinuation of atomoxetine was not associated with symptom rebound. Atomoxetine efficacy did not appear to differ between children and adolescents. Stimulant-naive patients also responded well to atomoxetine treatment. Atomoxetine did not differ significantly from or was noninferior to immediate-release methylphenidate in children and adolescents with ADHD with regard to efficacy, and was significantly more effective than standard current therapy (any combination of medicines [excluding atomoxetine] and/or behavioral counseling, or no treatment). However, atomoxetine was significantly less effective than osmotically released methylphenidate and extended-release mixed amfetamine salts. The efficacy of atomoxetine did not appear to be affected by the presence of co-morbid disorders, and symptoms of the co-morbid disorders were not affected or were improved by atomoxetine administration. Health-related quality of life (HR-QOL) appeared to be positively affected by atomoxetine in both short- and long-term studies; atomoxetine also improved HR-QOL to a greater extent than standard current therapy. Atomoxetine was generally well tolerated in children and adolescents with ADHD. Common adverse events included headache, abdominal pain, decreased appetite, vomiting, somnolence, and nausea. The majority of adverse events were mild or moderate; there was a very low incidence of serious adverse events. Few patients discontinued atomoxetine treatment because of adverse events. Atomoxetine discontinuation appeared to be well tolerated, with a low incidence of discontinuation-emergent adverse events. Atomoxetine appeared better tolerated among extensive CYP2D6 metabolizers than among poor metabolizers. Slight differences were evident in the adverse event profiles of atomoxetine and stimulants, both immediate- and extended-release. Somnolence appeared more common among atomoxetine recipients and insomnia appeared more common among stimulant recipients. A black-box warning for suicidal ideation has been published in the US prescribing information, based on findings from a meta-analysis showing that atomoxetine is associated with a significantly higher incidence of suicidal ideation than placebo. Rarely, atomoxetine may also be associated with serious liver injury; postmarketing data show that three patients have had liver-related adverse events deemed probably related to atomoxetine treatment. Treatment algorithms involving the initial use of atomoxetine appear cost effective versus algorithms involving initial methylphenidate (immediate- or extended-release), dexamfetamine, tricyclic antidepressants, or no treatment in stimulant-naive, -failed, and -contraindicated children and adolescents with ADHD. The incremental cost per quality-adjusted life-year is below commonly accepted cost-effectiveness thresholds, as shown in several Markov model analyses conducted from the perspective of various European countries, with a time horizon of 1 year.
19445548	1826	1837	Atomoxetine	CHEMICAL	282
19445548	2064	2075	atomoxetine	CHEMICAL	19445548T11
19445548	2161	2172	atomoxetine	CHEMICAL	19445548T12
19445548	2214	2225	Atomoxetine	CHEMICAL	282
19445548	2252	2267	methylphenidate	CHEMICAL	19445548T14
19445548	328	339	Atomoxetine	CHEMICAL	282
19445548	2332	2343	Atomoxetine	CHEMICAL	282
19445548	2645	2656	atomoxetine	CHEMICAL	19445548T17
19445548	2742	2753	atomoxetine	CHEMICAL	19445548T18
19445548	2791	2801	paroxetine	CHEMICAL	705
19445548	106	117	Atomoxetine	CHEMICAL	282
19445548	2834	2845	atomoxetine	CHEMICAL	19445548T20
19445548	2942	2953	atomoxetine	CHEMICAL	19445548T21
19445548	3097	3108	Atomoxetine	CHEMICAL	282
19445548	3273	3284	atomoxetine	CHEMICAL	19445548T23
19445548	3326	3337	Atomoxetine	CHEMICAL	282
19445548	3454	3465	atomoxetine	CHEMICAL	19445548T25
19445548	3477	3488	Atomoxetine	CHEMICAL	282
19445548	3563	3578	methylphenidate	CHEMICAL	19445548T27
19445548	3750	3761	atomoxetine	CHEMICAL	19445548T28
19445548	3820	3831	atomoxetine	CHEMICAL	19445548T29
19445548	1161	1172	atomoxetine	CHEMICAL	19445548T2
19445548	3891	3906	methylphenidate	CHEMICAL	19445548T30
19445548	3934	3944	amfetamine	CHEMICAL	19445548T31
19445548	3968	3979	atomoxetine	CHEMICAL	19445548T32
19445548	4128	4139	atomoxetine	CHEMICAL	19445548T33
19445548	4234	4245	atomoxetine	CHEMICAL	19445548T34
19445548	4284	4295	atomoxetine	CHEMICAL	19445548T35
19445548	148	162	norepinephrine	CHEMICAL	19445548T36
19445548	4368	4379	Atomoxetine	CHEMICAL	282
19445548	538	553	methylphenidate	CHEMICAL	19445548T38
19445548	4697	4708	atomoxetine	CHEMICAL	19445548T39
19445548	1273	1284	atomoxetine	CHEMICAL	19445548T3
19445548	4746	4757	Atomoxetine	CHEMICAL	282
19445548	4870	4881	Atomoxetine	CHEMICAL	282
19445548	5039	5050	atomoxetine	CHEMICAL	19445548T42
19445548	5143	5154	atomoxetine	CHEMICAL	19445548T43
19445548	625	640	methylphenidate	CHEMICAL	19445548T44
19445548	5376	5387	atomoxetine	CHEMICAL	19445548T45
19445548	5483	5494	atomoxetine	CHEMICAL	19445548T46
19445548	5654	5665	atomoxetine	CHEMICAL	19445548T47
19445548	661	676	methylphenidate	CHEMICAL	19445548T48
19445548	5727	5738	atomoxetine	CHEMICAL	19445548T49
19445548	1369	1383	norepinephrine	CHEMICAL	19445548T4
19445548	5797	5812	methylphenidate	CHEMICAL	19445548T50
19445548	5847	5860	dexamfetamine	CHEMICAL	19445548T51
19445548	5862	5871	tricyclic	CHEMICAL	19445548T52
19445548	164	177	noradrenaline	CHEMICAL	19445548T53
19445548	724	739	methylphenidate	CHEMICAL	19445548T54
19445548	768	778	amfetamine	CHEMICAL	19445548T55
19445548	786	797	Atomoxetine	CHEMICAL	282
19445548	975	986	Atomoxetine	CHEMICAL	282
19445548	0	11	Atomoxetine	CHEMICAL	282
19445548	1471	1498	norepinephrine transporters	GENE-Y	19445548T59
19445548	1419	1430	Atomoxetine	CHEMICAL	282
19445548	1538	1564	neurotransmitter receptors	GENE-N	19445548T60
19445548	2512	2537	cytochrome P450 (CYP) 2D6	GENE-Y	19445548T61
19445548	2764	2770	CYP2D6	GENE-Y	107940
19445548	2900	2906	CYP2D6	GENE-Y	107940
19445548	4924	4930	CYP2D6	GENE-Y	107940
19445548	119	128	Strattera	CHEMICAL	19445548T6
19445548	1471	1485	norepinephrine	CHEMICAL	19445548T7
19445548	1566	1577	Atomoxetine	CHEMICAL	282
19445548	1628	1642	norepinephrine	CHEMICAL	19445548T9
19445548	CPR:4	705	107940
19445548	CPR:9	19445548T17	19445548T61
19445548	CPR:9	19445548T20	107940
19445548	CPR:9	282	107940

19531491|t|Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics.
19531491|a|Mammalian glutamate dehydrogenase (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme. Unlike its counterparts from other animal kingdoms, mammalian GDH is regulated by a host of ligands. The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by GTP causes excessive secretion of insulin. Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate. This was followed by high throughput studies that identified more stable inhibitors, including hexachlorophene, GW5074, and bithionol. Shown here are the structures of GDH complexed with these three compounds. Hexachlorophene forms a ring around the internal cavity in GDH through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves. In contrast, GW5074 and bithionol both bind as pairs of stacked compounds at hexameric 2-fold axes between the dimers of subunits. The internal core of GDH contracts when the catalytic cleft closes during enzymatic turnover. None of the drugs cause conformational changes in the contact residues, but all bind to key interfaces involved in this contraction process. Therefore, it seems likely that the drugs inhibit enzymatic turnover by inhibiting this transition. Indeed, this expansion/contraction process may play a major role in the inter-subunit communication and allosteric regulation observed in GDH.
19531491	840	855	hexachlorophene	CHEMICAL	19531491T10
19531491	857	863	GW5074	CHEMICAL	19531491T11
19531491	869	878	bithionol	CHEMICAL	19531491T12
19531491	955	970	Hexachlorophene	CHEMICAL	746
19531491	32	41	glutamate	CHEMICAL	19531491T14
19531491	111	144	Mammalian glutamate dehydrogenase	GENE-N	19531491T15
19531491	1284	1287	GDH	GENE-Y	19531491T16
19531491	1736	1739	GDH	GENE-Y	19531491T17
19531491	343	356	mammalian GDH	GENE-N	19531491T18
19531491	146	149	GDH	GENE-N	19531491T19
19531491	121	130	glutamate	CHEMICAL	19531491T1
19531491	505	508	GDH	GENE-Y	19531491T20
19531491	546	553	insulin	GENE-Y	19531491T21
19531491	647	650	GDH	GENE-Y	19531491T22
19531491	913	916	GDH	GENE-Y	19531491T23
19531491	1014	1017	GDH	GENE-Y	19531491T24
19531491	1078	1081	GDH	GENE-Y	19531491T25
19531491	32	55	glutamate dehydrogenase	GENE-Y	19531491T26
19531491	1145	1151	GW5074	CHEMICAL	19531491T2
19531491	1156	1165	bithionol	CHEMICAL	19531491T3
19531491	232	243	l-glutamate	CHEMICAL	19531491T4
19531491	247	261	2-oxoglutarate	CHEMICAL	19531491T5
19531491	268	277	NAD(P)(+)	CHEMICAL	19531491T6
19531491	512	515	GTP	CHEMICAL	19531491T7
19531491	695	719	epigallocatechin gallate	CHEMICAL	19531491T8
19531491	724	743	epicatechin gallate	CHEMICAL	19531491T9
19531491	CPR:3	19531491T7	19531491T21
19531491	CPR:4	19531491T8	19531491T22
19531491	CPR:4	19531491T9	19531491T22
19531491	CPR:9	19531491T4	19531491T15
19531491	CPR:9	19531491T4	19531491T19
19531491	CPR:9	19531491T5	19531491T15
19531491	CPR:9	19531491T5	19531491T19

19690271|t|The effect of a peripheral block on inflammation-induced prostaglandin E2 and cyclooxygenase expression in rats.
19690271|a|BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 (PGE2) levels associated with the development of hyperalgesia. In this study, we evaluated the effect of bupivacaine administered via a nerve block or via a systemic route on the spinal expression of PGE2 and COX in a model of peripheral inflammation in rats. METHODS: All rats randomly received three injections: 1) a left subcutaneous hindpaw injection (0.2 mL with either carrageenan 2% w/v or saline), 2) a left sciatic block (0.2 mL with either bupivacaine 0.5% or saline), and 3) a systemic injection (subcutaneous interscapular with 0.2 mL with either bupivacaine 0.5% or saline). Local edema, thermal, and mechanical hyperalgesia as well as cerebrospinal fluid PGE2 concentration and COX-1 and COX-2 expression in the spinal cord in dorsal root ganglions were measured. RESULTS: We confirmed that a bupivacaine block attenuates hyperalgesia and local inflammation in a model of inflammatory pain. This effect was associated with an inhibition of the increase in COX-2 expression induced by peripheral inflammation in dorsal root ganglions and cord. The subsequent production of PGE2 in cerebrospinal fluid was also impaired. Systemic bupivacaine did not modify either the hyperalgesia and local inflammation or COX expression. CONCLUSION: These results constitute a key element strongly suggesting that local anesthetics act at a different level when administered systematically or via a nerve block.
19690271	1092	1103	bupivacaine	CHEMICAL	19690271T10
19690271	57	73	prostaglandin E2	CHEMICAL	19690271T11
19690271	1255	1260	COX-2	GENE-Y	19690271T12
19690271	1504	1507	COX	GENE-N	19690271T13
19690271	494	497	COX	GENE-N	19690271T14
19690271	977	982	COX-1	GENE-Y	19690271T15
19690271	987	992	COX-2	GENE-Y	19690271T16
19690271	204	209	COX-2	GENE-Y	19690271T17
19690271	211	227	cyclooxygenase-2	GENE-Y	19690271T18
19690271	78	92	cyclooxygenase	GENE-N	19690271T19
19690271	1371	1375	PGE2	CHEMICAL	907
19690271	1427	1438	bupivacaine	CHEMICAL	19690271T2
19690271	268	284	prostaglandin E2	CHEMICAL	19690271T3
19690271	286	290	PGE2	CHEMICAL	907
19690271	390	401	bupivacaine	CHEMICAL	19690271T5
19690271	485	489	PGE2	CHEMICAL	907
19690271	735	746	bupivacaine	CHEMICAL	19690271T7
19690271	844	855	bupivacaine	CHEMICAL	19690271T8
19690271	954	958	PGE2	CHEMICAL	907
19690271	CPR:9	19690271T3	19690271T17
19690271	CPR:9	19690271T3	19690271T18
19690271	CPR:9	907	19690271T17
19690271	CPR:9	907	19690271T18

1978244|t|Two pharmacologically distinct alpha 1-adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role.
1978244|a|Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta. The alpha 1-adrenoceptor alkylating agent CEC selectively inhibited the phasic component of the norepinephrine-induced contractile response, with little effect on the tonic component. The alpha 1-adrenoceptor occupancy-response relationship defined by the phenoxybenzamine inactivation method was rectangular hyperbolic for the tonic response, whereas that for the phasic response was linear, indicating the different degree of receptor reserve for the two responses. Radioligand binding studies with the nonselective alpha 1-adrenoceptor antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1). Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites. The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil. However, the Schilod plots for these antagonists against norepinephrine were curvilinear. Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that alpha 1-adrenoceptor populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)
1978244	1648	1659	methoxamine	CHEMICAL	1978244T10
1978244	1787	1793	WB4101	CHEMICAL	1978244T11
1978244	1824	1841	5-methyl-urapidil	CHEMICAL	1978244T12
1978244	1900	1914	norepinephrine	CHEMICAL	1978244T13
1978244	2220	2226	WB4101	CHEMICAL	1978244T14
1978244	2257	2274	5-methyl-urapidil	CHEMICAL	1978244T15
1978244	2378	2384	WB4101	CHEMICAL	1978244T16
1978244	2389	2406	5-methyl-urapidil	CHEMICAL	1978244T17
1978244	519	533	norepinephrine	CHEMICAL	1978244T18
1978244	679	695	phenoxybenzamine	CHEMICAL	1978244T19
1978244	303	320	5-methyl-urapidil	CHEMICAL	1978244T1
1978244	264	283	chlorethylclonidine	CHEMICAL	1978244T20
1978244	985	996	125I-BE2254	CHEMICAL	1978244T21
1978244	285	288	CEC	CHEMICAL	1978244T22
1978244	1057	1060	CEC	CHEMICAL	1978244T23
1978244	291	297	WB4101	CHEMICAL	1978244T24
1978244	1126	1132	WB4101	CHEMICAL	1978244T25
1978244	1153	1169	5-methylurapidil	CHEMICAL	1978244T26
1978244	135	139	Ca2+	CHEMICAL	1978244T27
1978244	213	233	alpha 1-adrenoceptor	GENE-N	1978244T28
1978244	1310	1327	alpha 1 receptors	GENE-N	1978244T29
1978244	1223	1243	phosphatidylinositol	CHEMICAL	1978244T2
1978244	1608	1629	alpha 1a-adrenoceptor	GENE-Y	1978244T30
1978244	373	393	alpha 1-adrenoceptor	GENE-N	1978244T31
1978244	2034	2054	alpha 1-adrenoceptor	GENE-N	1978244T32
1978244	427	447	alpha 1-adrenoceptor	GENE-N	1978244T33
1978244	611	631	alpha 1-adrenoceptor	GENE-N	1978244T34
1978244	941	961	alpha 1-adrenoceptor	GENE-N	1978244T35
1978244	1193	1213	alpha 1-adrenoceptor	GENE-N	1978244T36
1978244	31	51	alpha 1-adrenoceptor	GENE-N	1978244T37
1978244	1245	1247	PI	CHEMICAL	1978244T3
1978244	1264	1267	CEC	CHEMICAL	1978244T4
1978244	1333	1336	CEC	CHEMICAL	1978244T5
1978244	1386	1388	PI	CHEMICAL	1978244T6
1978244	1492	1495	CEC	CHEMICAL	1978244T7
1978244	1571	1577	WB4101	CHEMICAL	1978244T8
1978244	1582	1599	5-methyl-urapidil	CHEMICAL	1978244T9
1978244	CPR:5	1978244T10	1978244T30
1978244	CPR:6	1978244T11	1978244T30
1978244	CPR:6	1978244T12	1978244T30
1978244	CPR:6	1978244T14	1978244T32
1978244	CPR:6	1978244T15	1978244T32
1978244	CPR:6	1978244T1	1978244T28
1978244	CPR:6	1978244T20	1978244T28
1978244	CPR:6	1978244T21	1978244T35
1978244	CPR:6	1978244T22	1978244T28
1978244	CPR:6	1978244T24	1978244T28
1978244	CPR:6	1978244T8	1978244T30
1978244	CPR:6	1978244T9	1978244T30

19920913|t|Ambrisentan for the treatment of pulmonary arterial hypertension.
19920913|a|Ambrisentan is an endothelin receptor antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH). Endothelin (ET) is a potent vasoconstrictor with mitogenic, hypertrophic and pro-inflammatory properties that is upregulated in pulmonary hypertensive diseases. The biologic effects of ET are mediated by 2 cell surface receptors termed ET(A) and ET(B). ET(A) mediates the vasoconstrictor effect of ET on vascular smooth muscle, whereas ET(B) is expressed primarily on vascular endothelial cells where it induces nitric oxide synthesis and acts to clear ET from the circulation. Ambrisentan is the first ET(A) selective ERA approved for use in the US. Recently published clinical trials in patients with PAH demonstrate improvement in functional capacity and pulmonary hemodynamics similar to other ET(A) selective and non-selective ERAs. Its once daily dosing and lower incidence of serum aminotransferase elevation offer potential advantages over other ERAs, but further experience with this agent is needed to fully understand its long-term efficacy and safety. This review discusses the endothelin family of proteins and receptors and their role in the pathophysiology of pulmonary hypertensive diseases. It also examines the development process, safety profile and clinical trials that have resulted in ambrisentan being approved for treatment of PAH.
19920913	389	391	ET	GENE-N	19920913T10
19920913	440	445	ET(A)	GENE-Y	19920913T11
19920913	450	455	ET(B)	GENE-Y	19920913T12
19920913	457	462	ET(A)	GENE-Y	19920913T13
19920913	502	504	ET	GENE-N	19920913T14
19920913	540	545	ET(B)	GENE-Y	19920913T15
19920913	657	659	ET	GENE-N	19920913T16
19920913	707	712	ET(A)	GENE-Y	19920913T17
19920913	902	907	ET(A)	GENE-Y	19920913T18
19920913	993	1009	aminotransferase	GENE-N	19920913T19
19920913	66	77	Ambrisentan	CHEMICAL	8074
19920913	1411	1422	ambrisentan	CHEMICAL	19920913T2
19920913	616	628	nitric oxide	CHEMICAL	19920913T3
19920913	682	693	Ambrisentan	CHEMICAL	8074
19920913	0	11	Ambrisentan	CHEMICAL	8074
19920913	1194	1204	endothelin	GENE-N	19920913T6
19920913	204	214	Endothelin	GENE-N	19920913T7
19920913	216	218	ET	GENE-N	19920913T8
19920913	84	103	endothelin receptor	GENE-N	19920913T9
19920913	CPR:6	8074	19920913T9
19920913	CPR:6	8074	19920913T17

19952416|t|Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug.
19952416|a|A series of 4,5-diaryloxazole analogs were designed and the interaction between oxaprozin and cyclooxygenase-2 studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of oxaprozin. Finally, 3-(4-(4-fluorophenyl)-5-(4-aminosulfonyl-3-fluorophenyl)-oxazole-2-yl) propanoic acid (NC-2142), the best candidate, was selected for synthesis and bioassay based on the screening result. NC-2142 could lower the tumefaction rates of back metatarsus in rats, as well as reduce the writhing times in mice. NC-2142 produced fewer gastric lesions than oxaprozin. After the aminosulfonyl group was introduced into the benzene ring of oxaprozin, its analgesic and anti-inflammatory activities remained unchanged, and it reduced the number of gastric lesions. This provided a feasible method for further structure modification and optimization of oxaprozin.
19952416	782	791	oxaprozin	CHEMICAL	19952416T10
19952416	189	198	oxaprozin	CHEMICAL	19952416T11
19952416	993	1002	oxaprozin	CHEMICAL	19952416T12
19952416	45	62	4,5-diaryloxazole	CHEMICAL	19952416T13
19952416	203	219	cyclooxygenase-2	GENE-Y	19952416T14
19952416	121	138	4,5-diaryloxazole	CHEMICAL	19952416T1
19952416	333	342	oxaprozin	CHEMICAL	19952416T2
19952416	353	438	3-(4-(4-fluorophenyl)-5-(4-aminosulfonyl-3-fluorophenyl)-oxazole-2-yl) propanoic acid	CHEMICAL	19952416T3
19952416	440	447	NC-2142	CHEMICAL	19952416T4
19952416	541	548	NC-2142	CHEMICAL	19952416T5
19952416	657	664	NC-2142	CHEMICAL	19952416T6
19952416	701	710	oxaprozin	CHEMICAL	19952416T7
19952416	722	735	aminosulfonyl	CHEMICAL	19952416T8
19952416	766	773	benzene	CHEMICAL	19952416T9

19962254|t|Breast cancer and steroid metabolizing enzymes: the role of progestogens.
19962254|a|It is well documented that breast tissue, both normal and cancerous, contains all the enzymatic systems necessary for the bioformation and metabolic transformation of estrogens, androgens and progesterone. These include sulfatases, aromatase, hydroxysteroid-dehydrogenases, sulfotransferases, hydroxylases and glucuronidases. The control of these enzymes plays an important role in the development and pathogenesis of hormone-dependent breast cancer. As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities. A possible correlation has been postulated between breast cell proliferation and estrogen sulfotransferase activity. Progesterone is largely transformed in the breast; normal breast produces mainly 4-ene derivatives, whereas 5alpha-derivatives are most common in breast cancer tissue. It has been suggested that this specific conversion of progesterone may be involved in breast carcinogenesis. In conclusion, treatment with anti-aromatases combined with anti-sulfatase or 17beta-hydroxysteroid-dehydrogenase type 1 could provide new therapeutic possibilities in the treatment of patients with hormone-dependent breast cancer.
19962254	650	662	promegestone	CHEMICAL	19962254T10
19962254	664	683	nomegestrol acetate	CHEMICAL	19962254T11
19962254	688	702	norelgestromin	CHEMICAL	19962254T12
19962254	738	747	estradiol	CHEMICAL	19962254T13
19962254	791	812	17beta-hydroxysteroid	CHEMICAL	19962254T14
19962254	927	935	estrogen	CHEMICAL	19962254T15
19962254	963	975	Progesterone	CHEMICAL	388
19962254	18	25	steroid	CHEMICAL	19962254T17
19962254	60	72	progestogens	CHEMICAL	19962254T18
19962254	1306	1315	sulfatase	GENE-N	19962254T19
19962254	1186	1198	progesterone	CHEMICAL	19962254T1
19962254	1319	1361	17beta-hydroxysteroid-dehydrogenase type 1	GENE-Y	19962254T20
19962254	294	304	sulfatases	GENE-N	19962254T21
19962254	306	315	aromatase	GENE-Y	19962254T22
19962254	317	346	hydroxysteroid-dehydrogenases	GENE-N	19962254T23
19962254	348	365	sulfotransferases	GENE-N	19962254T24
19962254	367	379	hydroxylases	GENE-N	19962254T25
19962254	384	398	glucuronidases	GENE-N	19962254T26
19962254	777	786	sulfatase	GENE-N	19962254T27
19962254	791	833	17beta-hydroxysteroid-dehydrogenase type 1	GENE-Y	19962254T28
19962254	927	952	estrogen sulfotransferase	GENE-Y	19962254T29
19962254	1319	1340	17beta-hydroxysteroid	CHEMICAL	19962254T2
19962254	241	250	estrogens	CHEMICAL	19962254T3
19962254	252	261	androgens	CHEMICAL	19962254T4
19962254	266	278	progesterone	CHEMICAL	19962254T5
19962254	317	331	hydroxysteroid	CHEMICAL	19962254T6
19962254	562	574	progestogens	CHEMICAL	19962254T7
19962254	585	599	dydrogesterone	CHEMICAL	19962254T8
19962254	636	648	medrogestone	CHEMICAL	19962254T9
19962254	CPR:4	19962254T10	19962254T27
19962254	CPR:4	19962254T10	19962254T28
19962254	CPR:4	19962254T11	19962254T27
19962254	CPR:4	19962254T11	19962254T28
19962254	CPR:4	19962254T12	19962254T27
19962254	CPR:4	19962254T12	19962254T28
19962254	CPR:4	19962254T7	19962254T27
19962254	CPR:4	19962254T7	19962254T28
19962254	CPR:4	19962254T8	19962254T27
19962254	CPR:4	19962254T8	19962254T28
19962254	CPR:4	19962254T9	19962254T27
19962254	CPR:4	19962254T9	19962254T28
19962254	CPR:9	19962254T13	19962254T27
19962254	CPR:9	19962254T13	19962254T28

20022821|t|Mechanism of right precordial ST-segment elevation in structural heart disease: excitation failure by current-to-load mismatch.
20022821|a|BACKGROUND: The Brugada sign has been associated with mutations in SCN5A and with right ventricular structural abnormalities. Their role in the Brugada sign and the associated ventricular arrhythmias is unknown. OBJECTIVE: The purpose of this study was to delineate the role of structural abnormalities and sodium channel dysfunction in the Brugada sign. METHODS: Activation and repolarization characteristics of the explanted heart of a patient with a loss-of-function mutation in SCN5A (G752R) and dilated cardiomyopathy were determined after induction of right-sided ST-segment elevation by ajmaline. In addition, right ventricular structural discontinuities and sodium channel dysfunction were simulated in a computer model encompassing the heart and thorax. RESULTS: In the explanted heart, disappearance of local activation in unipolar electrograms at the basal right ventricular epicardium was followed by monophasic ST-segment elevation. The local origin of this phenomenon was confirmed by coaxial electrograms. Neither early repolarization nor late activation correlated with ST-segment elevation. At sites of local ST-segment elevation, the subepicardium was interspersed with adipose tissue and contained more fibrous tissue than either the left ventricle or control hearts. In computer simulations entailing right ventricular structural discontinuities, reduction of sodium channel conductance or size of the gaps between introduced barriers resulted in subepicardial excitation failure or delayed activation by current-to-load mismatch and in the Brugada sign on the ECG. CONCLUSION: Right ventricular excitation failure and activation delay by current-to-load mismatch in the subepicardium can cause the Brugada sign. Therefore, current-to-load mismatch may underlie the ventricular arrhythmias in patients with the Brugada sign.
20022821	195	200	SCN5A	GENE-Y	112236|1172535
20022821	1508	1514	sodium	CHEMICAL	20022821T1
20022821	435	441	sodium	CHEMICAL	20022821T2
20022821	722	730	ajmaline	CHEMICAL	20022821T3
20022821	794	800	sodium	CHEMICAL	20022821T4
20022821	1508	1522	sodium channel	GENE-N	20022821T5
20022821	435	449	sodium channel	GENE-N	20022821T6
20022821	610	615	SCN5A	GENE-Y	112236|1172535
20022821	617	622	G752R	GENE-N	20022821T8
20022821	794	808	sodium channel	GENE-N	20022821T9

20025554|t|Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis.
20025554|a|OBJECTIVE: Mitiglinide, a rapid- and short-acting insulinotropic sulfonylurea receptor ligand, exhibits hypoglycemic action unlike other sulfonylureas. The efficacy of the combination of mitiglinide and alpha-glucosidase inhibitors for diabetic patients on hemodialysis (HD) has not been prospectively evaluated; therefore, we evaluated the efficacy and safety of mitiglinide in these patients. RESEARCH DESIGN AND METHODS: We performed an open-label randomized study with 36 type 2 diabetics with poor glycemic control on HD and receiving daily doses of voglibose (0.9 mg). The patients were randomly assigned to two groups: a combination-therapy group (mitiglinide group), mitiglinide initial dose 7.5 - 15 mg titrated to 30 mg daily and constant daily dose 0.9 mg of voglibose, and a monotherapy group (control group), constant daily dose 0.9 mg of voglibose alone. The efficacy of the treatment was determined by monitoring plasma glucose, hemoglobin A1c (Hb(A1c)), and glycated albumin (GA) levels and using homeostasis model assessment of insulin resistance (HOMA-IR). Safety and tolerance were determined by monitoring clinical and laboratory parameters. RESULTS: The final dose of mitiglinide was 22.9 +/- 8.9 (mean +/- s.d.) mg (0.41 mg/kg) daily. Mitiglinide reduced fasting plasma glucose and GA levels after 4 weeks and Hb(A1c) levels after 8 weeks. Triglyceride levels and HOMA-IR values also decreased significantly after mitiglinide treatment. No significant changes in blood pressure levels or serious adverse effects such as hypoglycemia or liver impairment were observed. CONCLUSIONS: This study suggests a combination therapy of mitiglinide and voglibose may have potential for the treatment of diabetics on HD. Due to the small sample size used, further studies should be performed, particularly to assess the safety of mitiglinide treatment.
20025554	1962	1973	mitiglinide	CHEMICAL	20025554T10
20025554	309	320	mitiglinide	CHEMICAL	20025554T11
20025554	486	497	mitiglinide	CHEMICAL	20025554T12
20025554	677	686	voglibose	CHEMICAL	20025554T13
20025554	777	788	mitiglinide	CHEMICAL	20025554T14
20025554	187	199	sulfonylurea	CHEMICAL	20025554T15
20025554	797	808	mitiglinide	CHEMICAL	20025554T16
20025554	892	901	voglibose	CHEMICAL	20025554T17
20025554	974	983	voglibose	CHEMICAL	20025554T18
20025554	1057	1064	glucose	CHEMICAL	20025554T19
20025554	133	144	Mitiglinide	CHEMICAL	1240
20025554	25	36	mitiglinide	CHEMICAL	20025554T20
20025554	41	50	voglibose	CHEMICAL	20025554T21
20025554	1167	1174	insulin	GENE-Y	20025554T22
20025554	1426	1428	GA	GENE-Y	20025554T23
20025554	1454	1461	Hb(A1c)	GENE-Y	20025554T24
20025554	325	342	alpha-glucosidase	GENE-Y	20025554T25
20025554	187	208	sulfonylurea receptor	GENE-N	20025554T26
20025554	1066	1080	hemoglobin A1c	GENE-Y	20025554T27
20025554	1082	1089	Hb(A1c)	GENE-Y	20025554T28
20025554	1096	1112	glycated albumin	GENE-Y	20025554T29
20025554	1311	1322	mitiglinide	CHEMICAL	20025554T2
20025554	1114	1116	GA	GENE-Y	20025554T30
20025554	1379	1390	Mitiglinide	CHEMICAL	1240
20025554	1414	1421	glucose	CHEMICAL	20025554T4
20025554	1484	1496	Triglyceride	CHEMICAL	20025554T5
20025554	259	272	sulfonylureas	CHEMICAL	20025554T6
20025554	1558	1569	mitiglinide	CHEMICAL	20025554T7
20025554	1770	1781	mitiglinide	CHEMICAL	20025554T8
20025554	1786	1795	voglibose	CHEMICAL	20025554T9
20025554	CPR:4	1240	20025554T23
20025554	CPR:4	1240	20025554T24

20083608|t|A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation.
20083608|a|Allosteric modulators have been identified for several G protein-coupled receptors, most notably muscarinic receptors. To study their mechanism of action, we made use of a recently developed technique to generate fluorescence resonance energy transfer (FRET)-based sensors to monitor G protein-coupled receptor activation. Cyan fluorescent protein was fused to the C terminus of the M(2) muscarinic receptor, and a specific binding sequence for the small fluorescent compound fluorescein arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH. We then measured FRET between the donor cyan fluorescent protein and the acceptor FlAsH in intact cells and monitored its changes in real time. Agonists such as acetylcholine and carbachol induced rapid changes in FRET, indicative of agonist-induced conformational changes. Removal of the agonists or addition of an antagonist caused a reversal of this signal with rate constants between 400 and 1100 ms. The allosteric ligands gallamine and dimethyl-W84 caused no changes in FRET when given alone, but increased FRET when given in the presence of an agonist, compatible with an inactivation of the receptors. The kinetics of these effects were very rapid, with rate constants of 80-100 ms and approximately 200 ms for saturating concentrations of gallamine and dimethyl-W84, respectively. Because these speeds are significantly faster than the responses to antagonists, these data indicate that gallamine and dimethyl-W84 are allosteric ligands and actively induce a conformation of the M(2) receptor with a reduced affinity for its agonists.
20083608	944	953	carbachol	CHEMICAL	20083608T10
20083608	1753	1766	M(2) receptor	GENE-Y	20083608T11
20083608	410	436	G protein-coupled receptor	GENE-N	20083608T12
20083608	509	533	M(2) muscarinic receptor	GENE-Y	20083608T13
20083608	181	208	G protein-coupled receptors	GENE-N	20083608T14
20083608	223	243	muscarinic receptors	GENE-N	20083608T15
20083608	47	69	M2 muscarinic receptor	GENE-Y	20083608T16
20083608	1193	1202	gallamine	CHEMICAL	20083608T1
20083608	1207	1219	dimethyl-W84	CHEMICAL	20083608T2
20083608	1513	1522	gallamine	CHEMICAL	20083608T3
20083608	1527	1539	dimethyl-W84	CHEMICAL	20083608T4
20083608	1661	1670	gallamine	CHEMICAL	20083608T5
20083608	1675	1687	dimethyl-W84	CHEMICAL	20083608T6
20083608	491	492	C	CHEMICAL	20083608T7
20083608	602	613	fluorescein	CHEMICAL	20083608T8
20083608	926	939	acetylcholine	CHEMICAL	20083608T9

20089905|t|A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons.
20089905|a|Ibuprofen is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of cyclooxygenases. Recently, we have demonstrated that ibuprofen inhibits intracellular signaling of RhoA and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents. In addition, another study suggests that ibuprofen reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex. The molecular mechanisms by which ibuprofen inhibits the RhoA signal in neurons, however, remain unclear. Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling ibuprofen to RhoA inhibition and subsequent neurite growth promotion in neurons. Ibuprofen activates PPARgamma in neuron-like PC12 and B104 cells. Activation of PPARgamma with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors. Protein knockdown with small interfering RNA specific for PPARgamma blocks RhoA suppression of PPARgamma agonists in PC12 cells. Moreover, the effect of ibuprofen on RhoA activity and neurite growth in neuronal cultures is prevented by selective PPARgamma inhibition. These findings support that PPARgamma plays an essential role in mediating the RhoA-inhibiting effect of ibuprofen. Elucidation of the novel molecular mechanisms linking ibuprofen to RhoA inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.
20089905	893	902	ibuprofen	CHEMICAL	20089905T10
20089905	974	983	Ibuprofen	CHEMICAL	1039
20089905	26	35	ibuprofen	CHEMICAL	20089905T12
20089905	1101	1105	RhoA	GENE-Y	20089905T13
20089905	1327	1336	PPARgamma	GENE-Y	20089905T14
20089905	1344	1348	RhoA	GENE-Y	20089905T15
20089905	1364	1373	PPARgamma	GENE-Y	20089905T16
20089905	205	220	cyclooxygenases	GENE-N	20089905T17
20089905	1435	1439	RhoA	GENE-Y	20089905T18
20089905	1515	1524	PPARgamma	GENE-Y	20089905T19
20089905	73	82	Ibuprofen	CHEMICAL	1039
20089905	1565	1574	PPARgamma	GENE-Y	20089905T20
20089905	1616	1620	RhoA	GENE-Y	20089905T21
20089905	1720	1724	RhoA	GENE-Y	20089905T22
20089905	1813	1817	RhoA	GENE-Y	20089905T23
20089905	304	308	RhoA	GENE-Y	20089905T24
20089905	487	501	amyloid-beta42	GENE-Y	20089905T25
20089905	530	534	RhoA	GENE-Y	20089905T26
20089905	576	590	amyloid-beta42	GENE-Y	20089905T27
20089905	629	652	gamma-secretase complex	GENE-N	20089905T28
20089905	711	715	RhoA	GENE-Y	20089905T29
20089905	1131	1140	ibuprofen	CHEMICAL	20089905T2
20089905	806	854	peroxisome proliferator-activated receptor gamma	GENE-Y	20089905T30
20089905	856	865	PPARgamma	GENE-Y	20089905T31
20089905	906	910	RhoA	GENE-Y	20089905T32
20089905	994	1003	PPARgamma	GENE-Y	20089905T33
20089905	1054	1063	PPARgamma	GENE-Y	20089905T34
20089905	45	49	RhoA	GENE-Y	20089905T35
20089905	1165	1174	ibuprofen	CHEMICAL	20089905T3
20089905	1422	1431	ibuprofen	CHEMICAL	20089905T4
20089905	1642	1651	ibuprofen	CHEMICAL	20089905T5
20089905	1707	1716	ibuprofen	CHEMICAL	20089905T6
20089905	258	267	ibuprofen	CHEMICAL	20089905T7
20089905	455	464	ibuprofen	CHEMICAL	20089905T8
20089905	688	697	ibuprofen	CHEMICAL	20089905T9
20089905	CPR:3	1039	20089905T33
20089905	CPR:3	20089905T8	20089905T27
20089905	CPR:4	20089905T10	20089905T32
20089905	CPR:4	20089905T12	20089905T35
20089905	CPR:4	1039	20089905T17
20089905	CPR:4	20089905T2	20089905T13
20089905	CPR:4	20089905T5	20089905T21
20089905	CPR:4	20089905T6	20089905T22
20089905	CPR:4	20089905T7	20089905T24
20089905	CPR:4	20089905T8	20089905T25
20089905	CPR:4	20089905T8	20089905T26
20089905	CPR:4	20089905T8	20089905T28
20089905	CPR:4	20089905T9	20089905T29

20135071|t|Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
20135071|a|Therapeutic oral anticoagulation is still commonly achieved by administration of warfarin or other vitamin K antagonists that are associated with an untoward pharmacokinetic / pharmacodynamic (PK/PD) profile leading to a high incidence of bleeding complications or therapeutic failure. Hence, there is an unmet medical need of novel easy-to-use oral anticoagulants with improved efficacy and safety. Recent developments include the identification of non-peptidic small-molecules that selectively inhibit certain serine proteases within the coagulation cascade. Of these, the thrombin inhibitor dabigatran and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe. In addition, the factor Xa inhibitor apixaban is in late-stage clinical development. Each drug is prescribed at fixed doses without the need of anticoagulant monitoring. Phase III trials in orthopaedic patients essentially resulted in non-inferior efficacy of dabigatran and superior efficacy of rivaroxaban over enoxaparin without any marked differences of drug safety, while apixaban data is still controversial. However, alterations of rivaroxaban and apixaban pharmacokinetics upon interactions with inhibitors and inducers of CYP3A4 or P-glycoprotein may complicate the use of these compounds in daily practice, whereas dabigatran elimination largely depends on renal function. Hence, this review reports PK/PD, efficacy and safety data of dabigatran, rivaroxaban and apixaban throughout preclinical and clinical development.
20135071	737	747	dabigatran	CHEMICAL	20135071T10
20135071	772	783	rivaroxaban	CHEMICAL	20135071T11
20135071	916	924	apixaban	CHEMICAL	20135071T12
20135071	224	232	warfarin	CHEMICAL	20135071T13
20135071	242	251	vitamin K	CHEMICAL	20135071T14
20135071	1139	1149	dabigatran	CHEMICAL	20135071T15
20135071	65	75	dabigatran	CHEMICAL	20135071T16
20135071	77	88	rivaroxaban	CHEMICAL	20135071T17
20135071	93	101	apixaban	CHEMICAL	20135071T18
20135071	1410	1416	CYP3A4	GENE-Y	107948
20135071	1175	1186	rivaroxaban	CHEMICAL	20135071T1
20135071	1420	1434	P-glycoprotein	GENE-N	20135071T20
20135071	655	671	serine proteases	GENE-N	20135071T21
20135071	718	726	thrombin	GENE-Y	20135071T22
20135071	752	761	factor Xa	GENE-Y	20135071T23
20135071	896	905	factor Xa	GENE-Y	20135071T24
20135071	1256	1264	apixaban	CHEMICAL	20135071T2
20135071	1318	1329	rivaroxaban	CHEMICAL	20135071T3
20135071	1334	1342	apixaban	CHEMICAL	20135071T4
20135071	1504	1514	dabigatran	CHEMICAL	20135071T5
20135071	1624	1634	dabigatran	CHEMICAL	20135071T6
20135071	1636	1647	rivaroxaban	CHEMICAL	20135071T7
20135071	1652	1660	apixaban	CHEMICAL	20135071T8
20135071	655	661	serine	CHEMICAL	20135071T9
20135071	CPR:4	20135071T10	20135071T22
20135071	CPR:4	20135071T11	20135071T23
20135071	CPR:4	20135071T12	20135071T24

20184869|t|Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy.
20184869|a|BACKGROUND: Matrix metalloproteinase (MMP)-2 plays an important role in tissue remodeling related to inflammation during continuous ambulatory peritoneal dialysis (CAPD) therapy. But its inhibitors were not applied clinically. We determined whether an angiotensin-converting enzyme (ACE) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex. METHODS: The inhibitory effect of captopril on MMP-2 activity was measured in peritoneal effluents from 17 patients on CAPD. Molecular models of the MMP-2-captopril complex were simulated by 1000 iterations of random docking and energy minimization. RESULTS: Captopril directly inhibited MMP-2 activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion. CONCLUSION: ACE inhibitors, such as captopril, may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD.
20184869	1143	1148	MMP-2	GENE-Y	20184869T10
20184869	130	162	Matrix metalloproteinase (MMP)-2	GENE-Y	20184869T11
20184869	370	399	angiotensin-converting enzyme	GENE-Y	20184869T12
20184869	401	404	ACE	GENE-Y	108004
20184869	437	442	MMP-2	GENE-Y	20184869T14
20184869	537	542	MMP-2	GENE-Y	20184869T15
20184869	609	614	MMP-2	GENE-Y	20184869T16
20184869	711	716	MMP-2	GENE-Y	20184869T17
20184869	850	855	MMP-2	GENE-Y	20184869T18
20184869	968	973	MMP-2	GENE-Y	20184869T19
20184869	370	381	angiotensin	CHEMICAL	20184869T1
20184869	1066	1069	ACE	GENE-Y	108004
20184869	28	54	matrix metalloproteinase-2	GENE-Y	20184869T21
20184869	417	426	captopril	CHEMICAL	20184869T2
20184869	543	552	captopril	CHEMICAL	20184869T3
20184869	596	605	captopril	CHEMICAL	20184869T4
20184869	717	726	captopril	CHEMICAL	20184869T5
20184869	821	830	Captopril	CHEMICAL	1185
20184869	943	952	captopril	CHEMICAL	20184869T7
20184869	1090	1099	captopril	CHEMICAL	20184869T8
20184869	0	9	Captopril	CHEMICAL	1185
20184869	CPR:4	20184869T2	20184869T12
20184869	CPR:4	20184869T2	108004
20184869	CPR:4	20184869T4	20184869T16
20184869	CPR:4	1185	20184869T18
20184869	CPR:4	20184869T8	20184869T10
20184869	CPR:4	20184869T8	108004
20184869	CPR:4	1185	20184869T21

20188727|t|Phenformin has a direct inhibitory effect on the ATP-sensitive potassium channel.
20188727|a|The biguanides, phenformin and metformin, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating AMPK activity. We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs). Phenformin but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1). However it does not inhibit the current potentially present in cardiac myocytes (Kir6.2/SUR2A). The highest affinity interaction is seen with Kir6.1/SUR2B (IC50=0.55 mM) and it also inhibits the current in native vascular smooth muscle cells. The extent and rate of inhibition are similar to that seen with the known K(ATP) blocker PNU 37883A. Additionally, phenformin inhibited the current elicited through the Kir6.2DeltaC26 (functional without SUR) channel with an IC50 of 1.78 mM. Phenformin reduced the open probability of Kir6.1/SUR2B channels by approximately 90% in inside-out patches. These findings suggest that phenformin interacts directly with the pore-forming Kir6.0 subunit however the sulphonylurea receptor is able to significantly modulate the affinity. It is likely to block from the intracellular side of the channel in a manner analogous to that of PNU 37883A.
20188727	290	298	rubidium	CHEMICAL	20188727T10
20188727	351	354	ATP	CHEMICAL	164
20188727	365	367	K+	CHEMICAL	20188727T12
20188727	377	378	K	CHEMICAL	1310
20188727	379	382	ATP	CHEMICAL	164
20188727	113	122	metformin	CHEMICAL	20188727T15
20188727	446	447	K	CHEMICAL	1310
20188727	448	451	ATP	CHEMICAL	164
20188727	86	96	biguanides	CHEMICAL	20188727T18
20188727	529	539	Phenformin	CHEMICAL	904
20188727	1084	1085	K	CHEMICAL	1310
20188727	548	557	metformin	CHEMICAL	20188727T20
20188727	591	592	K	CHEMICAL	1310
20188727	593	596	ATP	CHEMICAL	164
20188727	0	10	Phenformin	CHEMICAL	904
20188727	49	52	ATP	CHEMICAL	164
20188727	63	72	potassium	CHEMICAL	20188727T25
20188727	1084	1090	K(ATP)	GENE-N	20188727T26
20188727	1179	1193	Kir6.2DeltaC26	GENE-Y	20188727T27
20188727	1214	1217	SUR	GENE-Y	20188727T28
20188727	1295	1301	Kir6.1	GENE-Y	20188727T29
20188727	1086	1089	ATP	CHEMICAL	164
20188727	1302	1307	SUR2B	GENE-Y	20188727T30
20188727	1441	1447	Kir6.0	GENE-N	20188727T31
20188727	1468	1490	sulphonylurea receptor	GENE-Y	20188727T32
20188727	237	241	AMPK	GENE-N	20188727T33
20188727	351	375	ATP-sensitive K+ channel	GENE-N	20188727T34
20188727	377	383	K(ATP)	GENE-N	20188727T35
20188727	446	452	K(ATP)	GENE-N	20188727T36
20188727	591	597	K(ATP)	GENE-N	20188727T37
20188727	695	701	Kir6.1	GENE-Y	20188727T38
20188727	702	707	SUR2B	GENE-Y	20188727T39
20188727	1099	1109	PNU 37883A	CHEMICAL	20188727T3
20188727	712	718	Kir6.2	GENE-Y	20188727T40
20188727	719	724	SUR2B	GENE-Y	20188727T41
20188727	753	759	Kir6.2	GENE-Y	20188727T42
20188727	760	764	SUR1	GENE-Y	36123|1938
20188727	848	854	Kir6.2	GENE-Y	20188727T44
20188727	855	860	SUR2A	GENE-Y	20188727T45
20188727	909	915	Kir6.1	GENE-Y	20188727T46
20188727	916	921	SUR2B	GENE-Y	20188727T47
20188727	49	80	ATP-sensitive potassium channel	GENE-N	20188727T48
20188727	1125	1135	phenformin	CHEMICAL	20188727T4
20188727	1252	1262	Phenformin	CHEMICAL	904
20188727	1389	1399	phenformin	CHEMICAL	20188727T6
20188727	1468	1481	sulphonylurea	CHEMICAL	20188727T7
20188727	1637	1647	PNU 37883A	CHEMICAL	20188727T8
20188727	98	108	phenformin	CHEMICAL	20188727T9
20188727	CPR:4	904	20188727T37
20188727	CPR:4	904	20188727T38
20188727	CPR:4	904	20188727T39
20188727	CPR:4	904	20188727T40
20188727	CPR:4	904	20188727T41
20188727	CPR:4	904	20188727T42
20188727	CPR:4	904	36123|1938
20188727	CPR:4	904	20188727T48
20188727	CPR:4	20188727T3	20188727T26
20188727	CPR:4	20188727T4	20188727T27
20188727	CPR:4	904	20188727T29
20188727	CPR:4	904	20188727T30

20204178|t|Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis.
20204178|a|Vitamin D receptor agonists (VDRAs) directly suppress parathyroid hormone (PTH) mRNA expression. Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR). In this study, we compared the effects of paricalcitol and doxercalciferol on regulating serum Ca and PTH, and also the expression of PTH, VDR, and CaSR mRNA. The 5/6 nephrectomized (NX) Sprague-Dawley rats on a normal or hyperphosphatemia-inducing diet were treated with vehicle, paricalcitol, or doxercalciferol for two weeks. Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol. In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively. The multiple effects of VDRAs on modulating serum Ca, parathyroid cell proliferation, and the expression of CaSR and PTH mRNA reflect the complex involvement of the vitamin D axis in regulating the mineral homeostasis system.
20204178	482	497	doxercalciferol	CHEMICAL	8075
20204178	518	520	Ca	CHEMICAL	20204178T11
20204178	704	716	paricalcitol	CHEMICAL	900
20204178	721	736	doxercalciferol	CHEMICAL	8075
20204178	884	896	paricalcitol	CHEMICAL	900
20204178	930	932	Ca	CHEMICAL	20204178T15
20204178	938	953	doxercalciferol	CHEMICAL	8075
20204178	981	993	paricalcitol	CHEMICAL	900
20204178	1017	1032	doxercalciferol	CHEMICAL	8075
20204178	45	57	paricalcitol	CHEMICAL	900
20204178	126	135	Vitamin D	CHEMICAL	20204178T1
20204178	62	77	doxercalciferol	CHEMICAL	8075
20204178	126	144	Vitamin D receptor	GENE-Y	20204178T21
20204178	1229	1233	CaSR	GENE-Y	20204178T22
20204178	1365	1369	CaSR	GENE-N	20204178T23
20204178	1374	1377	PTH	GENE-N	111713
20204178	329	332	PTH	GENE-Y	111713
20204178	365	368	PTH	GENE-Y	111713
20204178	395	414	Ca-sensing receptor	GENE-Y	20204178T27
20204178	416	420	CaSR	GENE-Y	20204178T28
20204178	525	528	PTH	GENE-Y	111713
20204178	1190	1202	paricalcitol	CHEMICAL	900
20204178	557	560	PTH	GENE-Y	111713
20204178	562	565	VDR	GENE-Y	113264|676260
20204178	571	575	CaSR	GENE-Y	20204178T32
20204178	180	199	parathyroid hormone	GENE-Y	20204178T33
20204178	814	817	PTH	GENE-Y	111713
20204178	844	847	PTH	GENE-Y	111713
20204178	201	204	PTH	GENE-Y	111713
20204178	1041	1044	VDR	GENE-Y	113264|676260
20204178	1107	1110	PTH	GENE-Y	111713
20204178	1307	1309	Ca	CHEMICAL	20204178T3
20204178	1422	1431	vitamin D	CHEMICAL	20204178T4
20204178	287	294	calcium	CHEMICAL	20204178T5
20204178	296	298	Ca	CHEMICAL	20204178T6
20204178	352	354	Ca	CHEMICAL	20204178T7
20204178	395	397	Ca	CHEMICAL	20204178T8
20204178	465	477	paricalcitol	CHEMICAL	900
20204178	CPR:3	900	20204178T22
20204178	CPR:3	20204178T7	111713
20204178	CPR:4	900	111713
20204178	CPR:4	900	111713
20204178	CPR:4	8075	111713
20204178	CPR:4	8075	111713
20204178	CPR:4	900	111713
20204178	CPR:4	8075	111713

20223979|t|Identification of a primary target of thalidomide teratogenicity.
20223979|a|Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing multiple birth defects. Today, thalidomide is still used in the treatment of leprosy and multiple myeloma, although how it causes limb malformation and other developmental defects is unknown. Here, we identified cereblon (CRBN) as a thalidomide-binding protein. CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks. Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the associated ubiquitin ligase activity. This study reveals a basis for thalidomide teratogenicity and may contribute to the development of new thalidomide derivatives without teratogenic activity.
20223979	426	453	thalidomide-binding protein	GENE-N	20223979T10
20223979	455	459	CRBN	GENE-N	119360|677660|1182936
20223979	469	496	E3 ubiquitin ligase complex	GENE-N	20223979T12
20223979	502	531	damaged DNA binding protein 1	GENE-N	20223979T13
20223979	533	537	DDB1	GENE-N	108009
20223979	543	548	Cul4A	GENE-N	20223979T15
20223979	608	632	fibroblast growth factor	GENE-N	20223979T16
20223979	633	637	Fgf8	GENE-N	20223979T17
20223979	723	727	CRBN	GENE-N	119360|677660|1182936
20223979	758	774	ubiquitin ligase	GENE-N	20223979T19
20223979	224	235	thalidomide	CHEMICAL	8562
20223979	86	97	thalidomide	CHEMICAL	8562
20223979	426	437	thalidomide	CHEMICAL	8562
20223979	663	674	Thalidomide	CHEMICAL	1030
20223979	816	827	thalidomide	CHEMICAL	8562
20223979	888	899	thalidomide	CHEMICAL	8562
20223979	38	49	thalidomide	CHEMICAL	8562
20223979	405	413	cereblon	GENE-N	20223979T8
20223979	415	419	CRBN	GENE-N	119360|677660|1182936
20223979	CPR:4	1030	20223979T19

20371872|t|A dilated cardiomyopathy troponin C mutation lowers contractile force by reducing strong myosin-actin binding.
20371872|a|In this study we explore the mechanisms by which a double mutation (E59D/D75Y) in cardiac troponin C (CTnC) associated with dilated cardiomyopathy reduces the Ca(2+)-activated maximal tension of cardiac muscle. Studying the single mutants (i.e. E59D or D75Y) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of CTnC in troponin complex, regulated thin filaments (RTF), and the Ca(2+) sensitivity of contraction and ATPase in cardiac muscle preparations. However, both D75Y and E59D are required to reduce the actomyosin ATPase activity and maximal force in muscle fibers, indicating that E59D enhances the effects of D75Y. Part of the reduction in force/ATPase may be due to a defect in the interactions between CTnC and cardiac troponin T, which are known to be necessary for ATPase activation. An additional mechanism for the reduction in force/ATPase comes from measurements of the binding stoichiometry of myosin subfragment-1 (S-1) to the RTF. Using wild type RTFs, 4.8 mol S-1 was bound per mol filament (seven actins), whereas with E59D/D75Y RTFs, the number of binding sites was reduced by approximately 23% to 3.7. Altogether, these results suggest that the reduction in force and ATPase activation is possibly due to a thin filament conformation that promotes fewer accessible S-1-binding sites. In the absence of any family segregation data, the functional results presented here support the concept that this is likely a dilated cardiomyopathy-causing mutation.
20371872	356	360	E59D	GENE-N	20371872T10
20371872	364	368	D75Y	GENE-N	20371872T11
20371872	385	389	D75Y	GENE-N	20371872T12
20371872	399	403	E59D	GENE-N	20371872T13
20371872	451	455	CTnC	GENE-Y	20371872T14
20371872	459	467	troponin	GENE-N	20371872T15
20371872	477	501	regulated thin filaments	GENE-N	20371872T16
20371872	503	506	RTF	GENE-N	20371872T17
20371872	555	561	ATPase	GENE-N	20371872T18
20371872	608	612	D75Y	GENE-N	20371872T19
20371872	270	276	Ca(2+)	CHEMICAL	20371872T1
20371872	617	621	E59D	GENE-N	20371872T20
20371872	649	659	actomyosin	GENE-N	20371872T21
20371872	660	666	ATPase	GENE-N	20371872T22
20371872	728	732	E59D	GENE-N	20371872T23
20371872	757	761	D75Y	GENE-N	20371872T24
20371872	794	800	ATPase	GENE-N	20371872T25
20371872	179	183	E59D	GENE-N	20371872T26
20371872	184	188	D75Y	GENE-N	20371872T27
20371872	852	856	CTnC	GENE-Y	20371872T28
20371872	861	879	cardiac troponin T	GENE-Y	20371872T29
20371872	517	523	Ca(2+)	CHEMICAL	20371872T2
20371872	917	923	ATPase	GENE-N	20371872T30
20371872	193	211	cardiac troponin C	GENE-Y	20371872T31
20371872	987	993	ATPase	GENE-N	20371872T32
20371872	1050	1070	myosin subfragment-1	GENE-N	20371872T33
20371872	1072	1075	S-1	GENE-N	20371872T34
20371872	1084	1087	RTF	GENE-N	20371872T35
20371872	1105	1109	RTFs	GENE-N	20371872T36
20371872	25	35	troponin C	GENE-Y	20371872T37
20371872	89	95	myosin	GENE-N	20371872T38
20371872	96	101	actin	GENE-N	20371872T39
20371872	1119	1122	S-1	GENE-N	20371872T3
20371872	213	217	CTnC	GENE-Y	20371872T4
20371872	1179	1183	E59D	GENE-N	20371872T5
20371872	1184	1188	D75Y	GENE-N	20371872T6
20371872	1189	1193	RTFs	GENE-N	20371872T7
20371872	1330	1336	ATPase	GENE-N	20371872T8
20371872	1427	1444	S-1-binding sites	GENE-N	20371872T9

20407761|t|Zolmitriptan and human aggression: interaction with alcohol.
20407761|a|RATIONALE: The serotonin 1(B/D) (5-HT1(B/D)) receptor has shown potential as a target for decreasing aggression. The 5-HT1(B/D) agonist zolmitriptan's ability to reduce aggressive behavior in humans and its interaction with the well-known aggression-enhancing drug alcohol were examined. OBJECTIVES: Our objective was to investigate zolmitriptan's potential to modify human aggression in a laboratory paradigm across a range of alcohol doses. Alcohol has been consistently associated with aggression and violence, thus we hoped to expand current understanding of alcohol's role in aggressive behavior via manipulation of the serotonin (5-HT) system. METHODS: Eleven social drinkers, seven male, were recruited to participate in a research study lasting 3-4 weeks. Aggression was measured using the point-subtraction aggression paradigm (PSAP), a laboratory model widely used in human aggression studies. Subjects were administered 5-mg zolmitriptan and placebo capsules along with alcohol doses of 0.0, 0.4 and 0.8 g/kg in a within-subject, counterbalanced dosing design. Data were analyzed as the ratio of aggressive/monetary-earning responses, to account for possible changes in overall motor function due to alcohol. RESULTS: There was a significant alcohol by zolmitriptan interaction on the aggressive/monetary response ratio. Specifically, compared to placebo, zolmitriptan decreased the aggressive/monetary ratio at the 0.4- and 0.8-g/kg alcohol doses. CONCLUSIONS: A 5-mg dose of zolmitriptan effectively reduced alcohol-related aggression in an acute dosing protocol, demonstrating an interaction of 5-HT and alcohol in human aggressive behavior.
20407761	1679	1686	alcohol	CHEMICAL	20407761T10
20407761	326	333	alcohol	CHEMICAL	20407761T11
20407761	489	496	alcohol	CHEMICAL	20407761T12
20407761	504	511	Alcohol	CHEMICAL	888
20407761	686	695	serotonin	CHEMICAL	20407761T14
20407761	697	701	5-HT	CHEMICAL	20407761T15
20407761	997	1009	zolmitriptan	CHEMICAL	20407761T16
20407761	1042	1049	alcohol	CHEMICAL	20407761T17
20407761	0	12	Zolmitriptan	CHEMICAL	308
20407761	52	59	alcohol	CHEMICAL	20407761T19
20407761	1272	1279	alcohol	CHEMICAL	20407761T1
20407761	178	188	5-HT1(B/D)	GENE-N	20407761T20
20407761	76	92	serotonin 1(B/D)	GENE-N	20407761T21
20407761	94	104	5-HT1(B/D)	GENE-N	20407761T22
20407761	1314	1321	alcohol	CHEMICAL	20407761T2
20407761	1325	1337	zolmitriptan	CHEMICAL	20407761T3
20407761	1428	1440	zolmitriptan	CHEMICAL	20407761T4
20407761	1506	1513	alcohol	CHEMICAL	20407761T5
20407761	1549	1561	zolmitriptan	CHEMICAL	20407761T6
20407761	1582	1589	alcohol	CHEMICAL	20407761T7
20407761	76	85	serotonin	CHEMICAL	20407761T8
20407761	1670	1674	5-HT	CHEMICAL	20407761T9

20448797|t|New standards in hypertension and cardiovascular risk management: focus on telmisartan.
20448797|a|Blockade of the renin-angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua. Telmisartan is an angiotensin II receptor blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure. In patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensive agents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval. There is also clinical evidence that telmisartan reduces left ventricular hypertrophy, reduces arterial stiffness and the recurrence of atrial fibrillation, and confers renoprotection. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study has demonstrated that telmisartan has similar cardiovascular protective effects to ramipril in a large, high-risk patient population but was better tolerated. The powerful and sustained blood pressure control apparent in clinical trials, together with cardiovascular protection and tolerability demonstrated in ONTARGET means that telmisartan may be a preferred option for patients with hypertension.
20448797	678	686	losartan	CHEMICAL	20448797T10
20448797	688	696	ramipril	CHEMICAL	20448797T11
20448797	698	709	perindopril	CHEMICAL	20448797T12
20448797	715	723	atenolol	CHEMICAL	20448797T13
20448797	845	856	telmisartan	CHEMICAL	956
20448797	1005	1016	Telmisartan	CHEMICAL	956
20448797	1047	1055	Ramipril	CHEMICAL	171
20448797	75	86	telmisartan	CHEMICAL	956
20448797	104	109	renin	GENE-Y	20448797T18
20448797	274	288	angiotensin II	GENE-Y	20448797T19
20448797	1117	1128	telmisartan	CHEMICAL	956
20448797	110	121	angiotensin	GENE-Y	20448797T20
20448797	357	380	angiotensin II receptor	GENE-N	20448797T21
20448797	1178	1186	ramipril	CHEMICAL	20448797T2
20448797	1426	1437	telmisartan	CHEMICAL	956
20448797	274	288	angiotensin II	CHEMICAL	20448797T4
20448797	110	121	angiotensin	CHEMICAL	20448797T5
20448797	339	350	Telmisartan	CHEMICAL	956
20448797	357	371	angiotensin II	CHEMICAL	20448797T7
20448797	601	612	telmisartan	CHEMICAL	956
20448797	667	676	valsartan	CHEMICAL	20448797T9
20448797	CPR:4	956	20448797T21

20512796|t|Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.
20512796|a|Estrogen receptor-alpha (ER) antagonists have been widely used for breast cancer therapy. Despite initial responsiveness, hormone-sensitive ER-positive cancer cells eventually develop resistance to ER antagonists. It has been shown that in most of these resistant tumor cells, the ER is expressed and continues to regulate tumor growth. Recent studies indicate that tamoxifen initially acts as an antagonist, but later functions as an ER agonist, promoting tumor growth. This suggests that targeted ER degradation may provide an effective therapeutic approach for breast cancers, even those that are resistant to conventional therapies. With this in mind, we previously demonstrated that proteolysis targeting chimeras (PROTACs) effectively induce degradation of the ER as a proof-of-concept experiment. Herein we further refined the PROTAC approach to target the ER for degradation. The ER-targeting PROTACs are composed of an estradiol on one end and a hypoxia-inducing factor 1alpha (HIF-1alpha)-derived synthetic pentapeptide on the other. The pentapeptide is recognized by an E3 ubiquitin ligase called the von Hippel Lindau tumor suppressor protein (pVHL), thereby recruiting the ER to this E3 ligase for ubiquitination and degradation. Specifically, the pentapeptide is attached at three different locations on estradiol to generate three different PROTAC types. With the pentapeptide linked through the C7alpha position of estradiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for the estrogen receptor. This result provides an opportunity to develop a novel type of ER antagonist that may overcome the resistance of breast tumors to conventional drugs such as tamoxifen and fulvestrant (Faslodex).
20512796	67	75	estrogen	CHEMICAL	20512796T10
20512796	104	127	Estrogen receptor-alpha	GENE-N	20512796T11
20512796	1185	1204	E3 ubiquitin ligase	GENE-N	20512796T12
20512796	1216	1258	von Hippel Lindau tumor suppressor protein	GENE-N	20512796T13
20512796	1260	1264	pVHL	GENE-N	20512796T14
20512796	1290	1292	ER	GENE-N	16226|2525
20512796	1301	1310	E3 ligase	GENE-N	20512796T16
20512796	244	246	ER	GENE-N	16226|2525
20512796	1592	1594	ER	GENE-N	16226|2525
20512796	1636	1653	estrogen receptor	GENE-N	20512796T19
20512796	104	112	Estrogen	CHEMICAL	20512796T1
20512796	1718	1720	ER	GENE-N	16226|2525
20512796	302	304	ER	GENE-N	16226|2525
20512796	129	131	ER	GENE-N	16226|2525
20512796	385	387	ER	GENE-N	16226|2525
20512796	539	541	ER	GENE-N	16226|2525
20512796	603	605	ER	GENE-N	16226|2525
20512796	871	873	ER	GENE-N	16226|2525
20512796	968	970	ER	GENE-N	16226|2525
20512796	992	994	ER	GENE-N	16226|2525
20512796	1059	1089	hypoxia-inducing factor 1alpha	GENE-N	20512796T29
20512796	1422	1431	estradiol	CHEMICAL	20512796T2
20512796	1091	1101	HIF-1alpha	GENE-N	20512796T30
20512796	67	84	estrogen receptor	GENE-N	20512796T31
20512796	1535	1544	estradiol	CHEMICAL	20512796T3
20512796	1636	1644	estrogen	CHEMICAL	20512796T4
20512796	1812	1821	tamoxifen	CHEMICAL	20512796T5
20512796	1826	1837	fulvestrant	CHEMICAL	20512796T6
20512796	1839	1847	Faslodex	CHEMICAL	20512796T7
20512796	470	479	tamoxifen	CHEMICAL	20512796T8
20512796	1032	1041	estradiol	CHEMICAL	20512796T9
20512796	CPR:4	20512796T3	16226|2525
20512796	CPR:5	20512796T8	16226|2525
20512796	CPR:6	20512796T8	16226|2525

20589617|t|C677T polymorphism of the methylenetetrahydrofolate reductase gene does not affect folic acid, vitamin B12, and homocysteine serum levels in Turkish children with neural tube defects.
20589617|a|Association between neural tube defects (NTDs) and C677T polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene was suspected, because the MTHFR gene codes for a key enzyme in folate metabolism. Its deficiency usually leads to significant reductions in plasma concentrations of folate, vitamin B(12) and methionine, whereas homocysteine levels are increased. We examined folate, vitamin B(12) and homocysteine serum concentrations and polymorphism of the C677T MTHFR gene in Turkish children with neural tube defects. Thirty-three children with NTDs, 26 mothers and 48 healthy individuals were studied. C677T MTHFR polymorphism was determined by melting curve analyses (LightCycler). The levels of folate, vitamin B(12) and homocysteine serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the MTHFR gene. C677T allele frequencies in NTD children and their mothers were similar to those found in controls. Serum folate and vitamin B(12) concentrations were significantly higher in NTD children than that of controls. Serum homocysteine concentrations were not significantly higher in NTD children and mothers. We concluded that C677T MTHFR gene polymorphism does not affect folic acid, vitamin B(12) and homocysteine metabolism in Turkish children with NTDs. C677T polymorphism of the MTHFR gene cannot be regarded as a major risk factor for NTDs in Turkish children.
20589617	569	575	folate	CHEMICAL	20589617T10
20589617	577	590	vitamin B(12)	CHEMICAL	20589617T11
20589617	595	607	homocysteine	CHEMICAL	20589617T12
20589617	896	902	folate	CHEMICAL	20589617T13
20589617	904	917	vitamin B(12)	CHEMICAL	20589617T14
20589617	922	934	homocysteine	CHEMICAL	20589617T15
20589617	261	286	methylenetetrahydrofolate	CHEMICAL	20589617T16
20589617	1160	1166	folate	CHEMICAL	20589617T17
20589617	1171	1184	vitamin B(12)	CHEMICAL	20589617T18
20589617	112	124	homocysteine	CHEMICAL	20589617T19
20589617	1271	1283	homocysteine	CHEMICAL	20589617T1
20589617	26	51	methylenetetrahydrofolate	CHEMICAL	20589617T20
20589617	83	93	folic acid	CHEMICAL	20589617T21
20589617	95	106	vitamin B12	CHEMICAL	20589617T22
20589617	298	303	MTHFR	GENE-Y	110624
20589617	1376	1381	C677T	GENE-N	20589617T24
20589617	1382	1387	MTHFR	GENE-Y	110624
20589617	1507	1512	C677T	GENE-N	20589617T26
20589617	1533	1538	MTHFR	GENE-Y	110624
20589617	337	342	MTHFR	GENE-Y	110624
20589617	653	658	C677T	GENE-N	20589617T29
20589617	1422	1432	folic acid	CHEMICAL	20589617T2
20589617	659	664	MTHFR	GENE-Y	110624
20589617	235	240	C677T	GENE-N	20589617T31
20589617	801	806	C677T	GENE-N	20589617T32
20589617	807	812	MTHFR	GENE-Y	110624
20589617	261	296	methylenetetrahydrofolate reductase	GENE-Y	20589617T34
20589617	1042	1047	MTHFR	GENE-Y	110624
20589617	1054	1059	C677T	GENE-N	20589617T36
20589617	0	5	C677T	GENE-N	20589617T37
20589617	26	61	methylenetetrahydrofolate reductase	GENE-Y	20589617T38
20589617	1434	1447	vitamin B(12)	CHEMICAL	20589617T3
20589617	1452	1464	homocysteine	CHEMICAL	20589617T4
20589617	374	380	folate	CHEMICAL	20589617T5
20589617	476	482	folate	CHEMICAL	20589617T6
20589617	484	497	vitamin B(12)	CHEMICAL	20589617T7
20589617	502	512	methionine	CHEMICAL	20589617T8
20589617	522	534	homocysteine	CHEMICAL	20589617T9

20590599|t|The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
20590599|a|BACKGROUND AND PURPOSE: There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor-ligand complex to induce a response). Ligands are classified as agonists or antagonists depending on whether or not they have efficacy. In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both. This study examined the affinity and intrinsic efficacy of 31 beta-adrenoceptor agonists at the three human beta-adrenoceptors to determine whether the current agonists are subtype selective because of affinity or intrinsic efficacy. EXPERIMENTAL APPROACH: Stable clonal CHO-K1 cell lines, transfected with either the human beta(1), beta(2) or beta(3)-adrenoceptor, were used, and whole-cell [(3)H]-CGP 12177 radioligand binding and [(3)H]-cAMP accumulation were measured. KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity. However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes. Other ligands (e.g. denopamine for beta(1); clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy. Several ligands appeared to activate two agonist conformations of the beta(1)- and beta(3)-adrenoceptors. CONCLUSIONS AND IMPLICATIONS: There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy. Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.
20590599	1473	1483	salbutamol	CHEMICAL	20590599T10
20590599	941	957	[(3)H]-CGP 12177	CHEMICAL	20590599T11
20590599	982	993	[(3)H]-cAMP	CHEMICAL	20590599T12
20590599	1165	1185	beta(2)-adrenoceptor	GENE-Y	20590599T13
20590599	1195	1202	beta(1)	GENE-Y	20590599T14
20590599	1206	1213	beta(3)	GENE-Y	20590599T15
20590599	1440	1447	beta(1)	GENE-Y	20590599T16
20590599	1488	1495	beta(2)	GENE-Y	20590599T17
20590599	1624	1658	beta(1)- and beta(3)-adrenoceptors	GENE-N	20590599T18
20590599	611	628	beta-adrenoceptor	GENE-N	20590599T19
20590599	1130	1140	salmeterol	CHEMICAL	20590599T1
20590599	651	675	human beta-adrenoceptors	GENE-N	20590599T20
20590599	867	913	human beta(1), beta(2) or beta(3)-adrenoceptor	GENE-N	20590599T21
20590599	19	36	beta-adrenoceptor	GENE-N	20590599T22
20590599	49	93	human beta1-, beta2- and beta3-adrenoceptors	GENE-N	20590599T23
20590599	1145	1155	formoterol	CHEMICAL	20590599T2
20590599	1235	1247	isoprenaline	CHEMICAL	20590599T3
20590599	1317	1327	salmeterol	CHEMICAL	20590599T4
20590599	1329	1339	formoterol	CHEMICAL	20590599T5
20590599	1344	1356	isoprenaline	CHEMICAL	20590599T6
20590599	1425	1435	denopamine	CHEMICAL	20590599T7
20590599	1449	1460	clenbuterol	CHEMICAL	20590599T8
20590599	1462	1471	AZ 40140d	CHEMICAL	20590599T9
20590599	CPR:5	20590599T1	20590599T13
20590599	CPR:5	20590599T1	20590599T14
20590599	CPR:5	20590599T2	20590599T13
20590599	CPR:5	20590599T2	20590599T15
20590599	CPR:5	20590599T3	20590599T13
20590599	CPR:5	20590599T3	20590599T14
20590599	CPR:5	20590599T3	20590599T15

20600573|t|Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
20600573|a|Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD). Its S-isomer, TVP1022 is thousand times less potent as an MAO-B inhibitor. However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins. Novel findings demonstrated that the major metabolite of rasagiline, 1-(R)-aminoindan has antioxidant and neuroprotective capabilities and thus, may contribute to the overt activity of its parent compound, rasagiline. This paper will review the earlier and present studies in the development of rasagiline for treatment of PD and discuss its pharmacology and applicable mechanism of action.
20600573	910	926	1-(R)-aminoindan	CHEMICAL	20600573T10
20600573	180	189	monoamine	CHEMICAL	20600573T11
20600573	1047	1057	rasagiline	CHEMICAL	20600573T12
20600573	0	10	Rasagiline	CHEMICAL	1329
20600573	38	47	monoamine	CHEMICAL	20600573T14
20600573	418	423	MAO-B	GENE-Y	20600573T15
20600573	665	670	MAO-B	GENE-Y	20600573T16
20600573	818	823	Bcl-2	GENE-Y	20600573T17
20600573	180	205	monoamine oxidase (MAO)-B	GENE-Y	20600573T18
20600573	38	57	monoamine oxidase-B	GENE-Y	20600573T19
20600573	99	109	Rasagiline	CHEMICAL	1329
20600573	1136	1146	rasagiline	CHEMICAL	20600573T2
20600573	111	139	N-propargyl-1-(R)-aminoindan	CHEMICAL	20600573T3
20600573	241	251	Rasagiline	CHEMICAL	1329
20600573	294	300	L-Dopa	CHEMICAL	20600573T5
20600573	374	381	TVP1022	CHEMICAL	20600573T6
20600573	621	631	rasagiline	CHEMICAL	20600573T7
20600573	706	717	N-propargyl	CHEMICAL	20600573T8
20600573	898	908	rasagiline	CHEMICAL	20600573T9
20600573	CPR:3	20600573T8	20600573T17
20600573	CPR:4	1329	20600573T19
20600573	CPR:4	1329	20600573T18
20600573	CPR:4	20600573T3	20600573T18
20600573	CPR:4	20600573T6	20600573T15
20600573	CPR:4	20600573T7	20600573T16

20615127|t|Resistance to thyroid hormone due to a novel thyroid hormone receptor mutant in a patient with hypothyroidism secondary to lingual thyroid and functional characterization of the mutant receptor.
20615127|a|BACKGROUND: We describe a rare case of congenital hypothyroidism and an extremely high serum thyrotropin (TSH) level caused by a combination of resistance to thyroid hormone (RTH) and a lingual thyroid. As the RTH mutant, R316C, was new, the optimum dose of levothyroxine was unclear. To aid in assessment of the therapy, we characterized the mutant R316C thyroid hormone receptor (TR) and compared it with a common mutant, R316H, using in vitro studies. SUMMARY: The patient was a newborn female having severe hypothyroidism with a free thyroxine level of 0.36 ng/dL and a serum TSH level of 177 microU/mL. A scintiscan showed ectopic lingual thyroid tissue without a normal thyroid gland. Supplementation with levothyroxine at a dose of >350 microg/day did not normalize the serum TSH level; however, the patient showed normal growth and intelligence at 14 years of age. Consistent with the results of a computer analysis, the binding of R316C to triiodothyronine (T3) was significantly decreased to 38% that of the wild type. Electrophoretic mobility shift assay demonstrated that like R316H, R316C did not form a homodimer, but formed a heterodimer with RXR. However, a glutathione-S-transferase pull-down assay showed reduced binding of R316C with NCoR in the absence of T3 and impaired release in the presence of T3. In addition, transient transfection experiments demonstrated that unlike R316H, R316C had severe impairment of transcriptional activity on genes both positively and negatively regulated by thyroid hormone. It also had a clear dominant negative effect on genes negatively, but not positively, regulated by thyroid hormone, including the TSH-releasing hormone and TSHbeta genes. CONCLUSION: This is the first reported case of a R316C TR mutation. The characteristics of the R316C mutant differed from those of the R316H mutant. Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum TSH level with high dose of levothyroxine might be optimum for normal growth.
20615127	1162	1164	T3	CHEMICAL	272
20615127	301	304	TSH	GENE-N	20615127T11
20615127	1284	1289	R316H	GENE-N	20615127T12
20615127	1291	1296	R316C	GENE-N	20615127T13
20615127	1353	1356	RXR	GENE-N	20615127T14
20615127	1437	1442	R316C	GENE-N	20615127T15
20615127	1448	1452	NCoR	GENE-Y	20615127T16
20615127	1591	1596	R316H	GENE-N	20615127T17
20615127	1598	1603	R316C	GENE-N	20615127T18
20615127	1854	1875	TSH-releasing hormone	GENE-Y	20615127T19
20615127	1369	1380	glutathione	CHEMICAL	20615127T1
20615127	1880	1887	TSHbeta	GENE-Y	20615127T20
20615127	1944	1949	R316C	GENE-N	20615127T21
20615127	1950	1952	TR	GENE-N	20615127T22
20615127	1990	1995	R316C	GENE-N	20615127T23
20615127	2030	2035	R316H	GENE-N	20615127T24
20615127	2070	2075	R316C	GENE-N	20615127T25
20615127	2132	2136	NCoR	GENE-Y	20615127T26
20615127	2226	2229	TSH	GENE-N	20615127T27
20615127	417	422	R316C	GENE-N	20615127T28
20615127	545	550	R316C	GENE-N	20615127T29
20615127	1381	1382	S	CHEMICAL	127
20615127	551	575	thyroid hormone receptor	GENE-N	20615127T30
20615127	577	579	TR	GENE-N	20615127T31
20615127	619	624	R316H	GENE-N	20615127T32
20615127	775	778	TSH	GENE-N	20615127T33
20615127	978	981	TSH	GENE-N	20615127T34
20615127	288	299	thyrotropin	GENE-N	20615127T35
20615127	1135	1140	R316C	GENE-N	20615127T36
20615127	45	69	thyroid hormone receptor	GENE-N	20615127T37
20615127	1471	1473	T3	CHEMICAL	272
20615127	1514	1516	T3	CHEMICAL	272
20615127	2254	2267	levothyroxine	CHEMICAL	20615127T5
20615127	453	466	levothyroxine	CHEMICAL	20615127T6
20615127	733	742	thyroxine	CHEMICAL	20615127T7
20615127	907	920	levothyroxine	CHEMICAL	20615127T8
20615127	1144	1160	triiodothyronine	CHEMICAL	20615127T9
20615127	CPR:3	20615127T5	20615127T27

20624420|t|Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment.
20624420|a|In order to shorten the list of candidate drugs with anticonvulsant potential against nerve agents, critical subreceptors in seizure controlling brain regions should be specified. Epileptiform activity does not spread randomly throughout the brain, but appears to be generated and propagated by specific anatomical routes. Nerve agents evoke seizure activity in the forebrain that progresses to the hind brain resulting in tonic-clonic convulsions. In some recent studies, it was shown that lesion of the area tempestas (AT), medial septum (MS), perirhinal cortex (PRC), or posterior piriform cortex (PPC) produces anticonvulsant effects (prevention of convulsions or delayed onset of convulsions) in rats exposed to soman, whereas damage to nucleus accumbens, nucleus basalis magnocellularis, amygdala, hippocampus, or entorhinal cortex does not cause anticonvulsant impact. These results are in compliance with findings that seizures can be generated in AT, MS, PRC, and PPC by means of nerve agents, chemoconvulsants, or kindling. Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC. Calculation of impact factors for the most potent drugs (percentage of positive effects in the seizure controlling sites) showed that scopolamine and procyclidine were ranking highest (75) followed by muscimol (50), NBQX (33), and caramiphen (33). Potential strategies for prophylactic and post-exposure treatments are discussed.
20624420	836	841	soman	CHEMICAL	20624420T10
20624420	1237	1244	GABA(A)	GENE-N	20624420T11
20624420	1284	1286	M1	GENE-Y	20624420T12
20624420	1287	1289	M5	GENE-Y	20624420T13
20624420	1323	1325	M1	GENE-Y	20624420T14
20624420	1326	1328	M5	GENE-Y	20624420T15
20624420	1395	1397	M1	GENE-Y	20624420T16
20624420	1398	1400	M4	GENE-Y	20624420T17
20624420	1437	1469	metabotropic glutamate receptors	GENE-N	20624420T18
20624420	1471	1477	mGluR5	GENE-Y	20624420T19
20624420	1237	1241	GABA	CHEMICAL	20624420T1
20624420	1479	1487	mGluR2/3	GENE-N	20624420T20
20624420	1525	1527	M1	GENE-Y	20624420T21
20624420	1528	1530	M5	GENE-Y	20624420T22
20624420	1535	1542	GABA(A)	GENE-N	20624420T23
20624420	1361	1365	NMDA	CHEMICAL	1209
20624420	1403	1407	AMPA	CHEMICAL	20624420T3
20624420	1450	1459	glutamate	CHEMICAL	20624420T4
20624420	1693	1704	scopolamine	CHEMICAL	20624420T5
20624420	1709	1721	procyclidine	CHEMICAL	20624420T6
20624420	1760	1768	muscimol	CHEMICAL	20624420T7
20624420	1775	1779	NBQX	CHEMICAL	20624420T8
20624420	1790	1800	caramiphen	CHEMICAL	20624420T9

20724158|t|Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk.
20724158|a|BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (COX-2). METHODS: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk. Between 2003 and 2006, a total of 18,368 incident breast cancer cases were identified in the Ingenix/Lab Rx insurance database, which contains clinical encounter and drug prescription data. Four controls per case were randomly selected, matched on age and time in database. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression. RESULTS: Breast cancer risk was inversely associated with both non-specific NSAID and selective COX-2 inhibitor use. Greater than 12 months' duration of use of Celecoxib at a standard dose (200mg/day) was associated with a 16% decrease in breast cancer risk (OR=0.84, 95% CI=0.73, 0.97). We observed the greatest risk reduction in association with >2 years of rofecoxib exposure (OR=0.54, 95% CI=0.37, 0.80). Acetaminophen, a compound with less biological plausibility for chemoprevention, showed no significant association with the risk of developing breast cancer. CONCLUSION: Consistent with animal models and laboratory investigations, higher doses of selective COX-2 inhibitors were more protective against breast cancer than non-specific NSAIDs. With exposure to rofecoxib, a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.
20724158	1659	1664	COX-2	GENE-Y	20724158T10
20724158	1769	1774	COX-2	GENE-Y	20724158T11
20724158	252	268	cyclooxygenase-2	GENE-Y	20724158T12
20724158	270	275	COX-2	GENE-Y	20724158T13
20724158	366	371	cox-2	GENE-Y	20724158T14
20724158	963	968	COX-2	GENE-Y	20724158T15
20724158	10	26	cyclooxygenase-2	GENE-Y	20724158T16
20724158	28	33	COX-2	GENE-Y	20724158T17
20724158	1227	1236	rofecoxib	CHEMICAL	20724158T1
20724158	1276	1289	Acetaminophen	CHEMICAL	309
20724158	1636	1645	rofecoxib	CHEMICAL	20724158T3
20724158	397	406	celecoxib	CHEMICAL	20724158T4
20724158	408	417	rofecoxib	CHEMICAL	20724158T5
20724158	419	429	valdecoxib	CHEMICAL	20724158T6
20724158	150	159	steroidal	CHEMICAL	20724158T7
20724158	1027	1036	Celecoxib	CHEMICAL	474
20724158	1533	1538	COX-2	GENE-Y	20724158T9
20724158	CPR:4	20724158T3	20724158T10
20724158	CPR:4	20724158T3	20724158T11
20724158	CPR:4	20724158T4	20724158T14
20724158	CPR:4	20724158T5	20724158T14
20724158	CPR:4	20724158T6	20724158T14
20724158	CPR:4	20724158T7	20724158T12
20724158	CPR:4	20724158T7	20724158T13

2087492|t|Barrel rotation in rats induced by SMS 201-995: suppression by ceruletide.
2087492|a|Intracerebroventricular administration of SMS 201-995 (5 micrograms/rat), a somatostatin analogue, induced barrel rotation in rats. Pretreatment with ceruletide (40 micrograms/100 g b. wt., IP) 3 days or 7 days prior to the injection of SMS 201-995 significantly inhibited the response rate of barrel rotation induced by SMS 201-995, but not that induced by arginine-vasopressin (1 microgram/rat, ICV). The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist. Desulfated cerulein did not affect the barrel rotation induced by SMS 201-995. These findings suggest that ceruletide specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through CCK-A receptor.
2087492	802	813	SMS 201-995	CHEMICAL	2087492T10
2087492	151	163	somatostatin	CHEMICAL	2087492T11
2087492	35	46	SMS 201-995	CHEMICAL	2087492T12
2087492	63	73	ceruletide	CHEMICAL	2087492T13
2087492	433	453	arginine-vasopressin	GENE-Y	2087492T14
2087492	597	600	CCK	GENE-Y	107327
2087492	601	617	(CCK-A) receptor	GENE-Y	2087492T16
2087492	151	163	somatostatin	GENE-Y	2087492T17
2087492	863	877	CCK-A receptor	GENE-Y	2087492T18
2087492	225	235	ceruletide	CHEMICAL	2087492T1
2087492	312	323	SMS 201-995	CHEMICAL	2087492T2
2087492	396	407	SMS 201-995	CHEMICAL	2087492T3
2087492	433	453	arginine-vasopressin	CHEMICAL	2087492T4
2087492	117	128	SMS 201-995	CHEMICAL	2087492T5
2087492	504	514	ceruletide	CHEMICAL	2087492T6
2087492	566	572	MK-329	CHEMICAL	2087492T7
2087492	696	707	SMS 201-995	CHEMICAL	2087492T8
2087492	737	747	ceruletide	CHEMICAL	2087492T9
2087492	CPR:4	2087492T6	107327
2087492	CPR:4	2087492T6	2087492T16
2087492	CPR:4	2087492T9	2087492T18
2087492	CPR:6	2087492T7	107327
2087492	CPR:6	2087492T7	2087492T16

21058326|t|Effects of the histamine H1 antagonist chlorcyclizine on rat fetal palate development.
21058326|a|BACKGROUND: The effects of histamine H1 antagonist chlorcyclizine on rat palate development were characterized following in utero exposure. METHODS: To identify the optimum dose for inducing cleft palate, pregnant rats were administered 30, 60, or 90 mg/kg chlorcyclizine on Gestation Days 11 to 14. Fetal palate gene expression was also assessed after 90 mg/kg chlorcyclizine at 8, 15 and 30 hours post-dose on Gestation Day 14 using microarray and qRT-PCR. RESULTS: Rats in the 60- and 90-mg/kg groups exhibited adverse clinical signs and body weight loss. Rats in the 90-mg/kg group also demonstrated increases in late resorptions and decreases in fetal weight. Effects in the low-dose group were limited to decreases in body weight gain. Fetal assessment on Gestation Day 21 revealed that findings were limited to the 60- and 90-mg/kg groups, and included cleft palate (80% of litters for both groups), high arched palate, small nose, micrognathia, high domed head, digits shortened/absent and small limb. The fetal incidence of cleft palate was higher at 90 mg/kg, thus this dose was selected to assess palate gene expression. The altered genes associated with chlorcyclizine-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold). CONCLUSIONS: Expression of several genes involved in palate, limb and digit development was altered in the fetal palate following in utero exposure to chlorcyclizine. The subtle perturbation and interplay of these genes may have profound effects on the dynamics of fetal palate development.
21058326	1305	1309	Bmp2	GENE-Y	198363
21058326	1311	1315	Bmp4	GENE-Y	198364
21058326	1317	1322	Fgf10	GENE-Y	199639
21058326	1324	1329	Fgfr2	GENE-Y	247102|199657
21058326	1331	1335	Msx1	GENE-Y	201536
21058326	1341	1347	Insig1	GENE-Y	21058326T15
21058326	114	126	histamine H1	GENE-Y	21058326T16
21058326	15	27	histamine H1	GENE-Y	21058326T17
21058326	1253	1267	chlorcyclizine	CHEMICAL	21058326T1
21058326	1570	1584	chlorcyclizine	CHEMICAL	21058326T2
21058326	344	358	chlorcyclizine	CHEMICAL	21058326T3
21058326	114	123	histamine	CHEMICAL	21058326T4
21058326	449	463	chlorcyclizine	CHEMICAL	21058326T5
21058326	138	152	chlorcyclizine	CHEMICAL	21058326T6
21058326	15	24	histamine	CHEMICAL	21058326T7
21058326	39	53	chlorcyclizine	CHEMICAL	21058326T8
21058326	1298	1303	Wnt5a	GENE-Y	204577
21058326	CPR:6	21058326T6	21058326T16
21058326	CPR:6	21058326T8	21058326T17

21194017|t|GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation.
21194017|a|PURPOSE: The purpose of this review is to summarize current knowledge of detailed biochemical evidence for the role of gamma-aminobutyric acid type A receptors (GABA(A)-Rs) in the mechanisms of general anesthesia. PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate GABA(A)-R-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of GABA(A)-R subunits of varying sensitivity led to identification of amino acid residues in the transmembrane domain that are critical for the drug actions in vitro. Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane amino acids that were affinity labelled in purified bovine brain GABA(A)-R. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit etomidate binding pocket at the beta/alpha interface. This position would be appropriate for modulation of agonist channel gating. Overall, available information suggests that these two etomidate binding residues are allosterically coupled to sites of action of steroids, barbiturates, volatile agents, and propofol, but not alcohols. Residue alpha/betaM2-15' is probably not a binding site but allosterically coupled to action of volatile agents, alcohols, and intravenous agents, and alpha/betaM1-(-2') is coupled to action of intravenous agents. CONCLUSIONS: Establishment of a coherent and consistent structural model of the GABA(A)-R lends support to the conclusion that general anesthetics can modulate function by binding to appropriate domains on the protein. Genetic engineering of mice with mutation in some of these GABA(A)-R residues are insensitive to general anesthetics in vivo, suggesting that further analysis of these domains could lead to development of more potent and specific drugs.
21194017	805	816	amino acids	CHEMICAL	21194017T10
21194017	1029	1038	etomidate	CHEMICAL	285
21194017	255	295	gamma-aminobutyric acid type A receptors	GENE-N	21194017T12
21194017	1658	1667	GABA(A)-R	GENE-N	21194017T13
21194017	297	307	GABA(A)-Rs	GENE-N	21194017T14
21194017	1856	1865	GABA(A)-R	GENE-N	21194017T15
21194017	438	447	GABA(A)-R	GENE-N	21194017T16
21194017	531	540	GABA(A)-R	GENE-N	21194017T17
21194017	857	879	bovine brain GABA(A)-R	GENE-N	21194017T18
21194017	1016	1053	intersubunit etomidate binding pocket	GENE-N	21194017T19
21194017	1215	1224	etomidate	CHEMICAL	285
21194017	1061	1081	beta/alpha interface	GENE-N	21194017T20
21194017	0	17	GABA(A) receptors	GENE-N	21194017T21
21194017	1291	1299	steroids	CHEMICAL	21194017T2
21194017	1301	1313	barbiturates	CHEMICAL	21194017T3
21194017	255	278	gamma-aminobutyric acid	CHEMICAL	21194017T4
21194017	1336	1344	propofol	CHEMICAL	21194017T5
21194017	1354	1362	alcohols	CHEMICAL	21194017T6
21194017	1477	1485	alcohols	CHEMICAL	21194017T7
21194017	598	608	amino acid	CHEMICAL	21194017T8
21194017	758	771	R(+)etomidate	CHEMICAL	21194017T9

2120879|t|Role of extracellular calcium and calmodulin in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells.
2120879|a|The mechanism by which 30% medium hyposmolarity induces PRL secretion by GH4C1 cells was compared with that induced by 100 nmol/l TRH or 30 mmol/l K+. Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion. The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01). The above drugs also blocked or decreased high K(+)-induced secretion, but had much less effect on TRH-induced secretion. Secretion induced by TRH, hyposmolarity, or high K+ was optimal at pH 7.3-7.65 and was significantly depressed at pH 6.0 or 8.0, indicating that release of hormone induced by all 3 stimuli is due to an active cell process requiring a physiologic extracellular pH and is not produced by nonspecific cell toxicity. The data suggest hyposmolarity and high K+ may share some similarities in their mechanism of stimulating secretion, which is different from that of TRH.
2120879	642	648	Ca2(+)	CHEMICAL	2120879T10
2120879	825	829	K(+)	CHEMICAL	2120879T11
2120879	949	951	K+	CHEMICAL	2120879T12
2120879	134	136	K+	CHEMICAL	2120879T13
2120879	22	29	calcium	CHEMICAL	2120879T14
2120879	1361	1364	TRH	GENE-Y	113051
2120879	283	286	TRH	GENE-Y	113051
2120879	335	348	Ca2+ channels	GENE-N	2120879T17
2120879	390	400	calmodulin	GENE-Y	2120879T18
2120879	649	659	calmodulin	GENE-Y	2120879T19
2120879	1253	1255	K+	CHEMICAL	2120879T1
2120879	705	708	PRL	GENE-Y	111602|13442|1172414
2120879	209	212	PRL	GENE-Y	111602|13442|1172414
2120879	877	880	TRH	GENE-Y	113051
2120879	921	924	TRH	GENE-Y	113051
2120879	34	44	calmodulin	GENE-Y	2120879T24
2120879	48	57	prolactin	GENE-Y	2120879T25
2120879	94	123	thyrotropin-releasing hormone	GENE-Y	2120879T26
2120879	300	302	K+	CHEMICAL	2120879T2
2120879	320	324	Ca2+	CHEMICAL	2120879T3
2120879	335	339	Ca2+	CHEMICAL	2120879T4
2120879	365	374	verapamil	CHEMICAL	2120879T5
2120879	428	443	trifluoperazine	CHEMICAL	2120879T6
2120879	456	470	chlorpromazine	CHEMICAL	2120879T7
2120879	485	493	pimozide	CHEMICAL	2120879T8
2120879	581	584	W-7	CHEMICAL	2120879T9
2120879	CPR:4	2120879T5	2120879T17
2120879	CPR:4	2120879T6	2120879T18
2120879	CPR:4	2120879T7	2120879T18
2120879	CPR:4	2120879T8	2120879T18
2120879	CPR:4	2120879T9	111602|13442|1172414

21318872|t|Use of (Gyro) Gy and spermine synthase transgenic mice to study functions of spermine.
21318872|a|The polyamines putrescine, spermidine, and spermine are essential for mammalian cell growth, -differentiation, and cell death and have important physiological roles in all tissues. Many of the properties of polyamines that can be demonstrated in vitro are common to all three molecules with differences only in potency. Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of spermine) is lethal, but male mice lacking spermine synthase (SpmS) due to a deletion of part of the X chromosome are viable on the B6C3H background. These mice are termed Gyro (Gy) due to their circling behavior. They have a variety of abnormalities including deafness, neurological problems, small size, and a tendency to early death. They can therefore be used to evaluate the physiological function(s) uniquely provided by spermine. They also provide a potential animal model for Snyder-Robinson syndrome (SRS), a rare human inherited disease due to a loss of SpmS activity. An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement spermine and this can be accomplished by breeding with CAG-SMS mice that express SpmS from a ubiquitous promoter. Techniques for identifying, characterizing, and using these mouse strains and limitations of this approach are described in this chapter.
21318872	563	571	spermine	CHEMICAL	21318872T10
21318872	947	955	spermine	CHEMICAL	21318872T11
21318872	21	29	spermine	CHEMICAL	21318872T12
21318872	77	85	spermine	CHEMICAL	21318872T13
21318872	1318	1321	SMS	GENE-Y	112495
21318872	1340	1344	SpmS	GENE-Y	21318872T15
21318872	563	580	spermine synthase	GENE-Y	21318872T16
21318872	582	586	SpmS	GENE-Y	21318872T17
21318872	1084	1088	SpmS	GENE-Y	21318872T18
21318872	21	38	spermine synthase	GENE-Y	21318872T19
21318872	1259	1267	spermine	CHEMICAL	21318872T1
21318872	102	112	putrescine	CHEMICAL	21318872T2
21318872	294	304	polyamines	CHEMICAL	21318872T3
21318872	114	124	spermidine	CHEMICAL	21318872T4
21318872	456	466	putrescine	CHEMICAL	21318872T5
21318872	470	480	spermidine	CHEMICAL	21318872T6
21318872	91	101	polyamines	CHEMICAL	21318872T7
21318872	520	528	spermine	CHEMICAL	21318872T8
21318872	130	138	spermine	CHEMICAL	21318872T9
21318872	CPR:9	21318872T1	112495
21318872	CPR:9	21318872T1	21318872T15

21926191|t|Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
21926191|a|The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression. Dysregulation of the MET/VEGF axis is found in a number of human malignancies and has been associated with tumorigenesis. Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3. Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro. In mouse models, cabozantinib dramatically altered tumor pathology, resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models. Importantly, treatment with cabozantinib did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of VEGF signaling that do not target MET. Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.
21926191	1394	1398	VEGF	GENE-Y	21926191T10
21926191	1428	1431	MET	GENE-Y	110391
21926191	1583	1586	MET	GENE-Y	110391
21926191	1591	1596	VEGFR	GENE-N	21926191T13
21926191	338	342	VEGF	GENE-Y	21926191T14
21926191	155	183	receptor tyrosine kinase MET	GENE-Y	21926191T15
21926191	450	453	MET	GENE-Y	110391
21926191	454	458	VEGF	GENE-Y	21926191T17
21926191	592	598	kinase	GENE-N	21926191T18
21926191	637	640	MET	GENE-Y	110391
21926191	1263	1275	cabozantinib	CHEMICAL	21926191T1
21926191	645	660	VEGF receptor 2	GENE-Y	21926191T20
21926191	662	668	VEGFR2	GENE-Y	21926191T21
21926191	700	725	receptor tyrosine kinases	GENE-N	21926191T22
21926191	790	793	RET	GENE-Y	111911
21926191	795	798	KIT	GENE-Y	110015
21926191	800	803	AXL	GENE-Y	107036|3149
21926191	809	813	FLT3	GENE-Y	108610
21926191	853	856	MET	GENE-Y	110391
21926191	861	867	VEGFR2	GENE-Y	21926191T28
21926191	199	223	hepatocyte growth factor	GENE-Y	21926191T29
21926191	1471	1483	cabozantinib	CHEMICAL	21926191T2
21926191	225	228	HGF	GENE-Y	109330
21926191	30	33	MET	GENE-Y	110391
21926191	38	44	VEGFR2	GENE-Y	21926191T32
21926191	551	563	Cabozantinib	CHEMICAL	7619
21926191	565	570	XL184	CHEMICAL	21926191T4
21926191	709	717	tyrosine	CHEMICAL	21926191T5
21926191	830	842	cabozantinib	CHEMICAL	21926191T6
21926191	999	1011	cabozantinib	CHEMICAL	21926191T7
21926191	0	12	Cabozantinib	CHEMICAL	7619
21926191	14	19	XL184	CHEMICAL	21926191T9
21926191	CPR:4	21926191T1	21926191T10
21926191	CPR:4	21926191T2	110391
21926191	CPR:4	21926191T2	21926191T13
21926191	CPR:4	7619	21926191T18
21926191	CPR:4	7619	110391
21926191	CPR:4	7619	21926191T20
21926191	CPR:4	7619	21926191T21
21926191	CPR:4	7619	21926191T22
21926191	CPR:4	7619	111911
21926191	CPR:4	7619	110015
21926191	CPR:4	7619	107036|3149
21926191	CPR:4	7619	108610
21926191	CPR:4	21926191T4	21926191T18
21926191	CPR:4	21926191T4	110391
21926191	CPR:4	21926191T4	21926191T20
21926191	CPR:4	21926191T4	21926191T21
21926191	CPR:4	21926191T4	21926191T22
21926191	CPR:4	21926191T4	111911
21926191	CPR:4	21926191T4	110015
21926191	CPR:4	21926191T4	107036|3149
21926191	CPR:4	21926191T4	108610
21926191	CPR:4	21926191T6	110391
21926191	CPR:4	21926191T6	21926191T28
21926191	CPR:4	7619	110391
21926191	CPR:4	7619	21926191T32
21926191	CPR:4	21926191T9	110391
21926191	CPR:4	21926191T9	21926191T32

21955206|t|Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.
21955206|a|BACKGROUND AND PURPOSE: Most patients with cancer die not because of the tumour in the primary site, but because it has spread to other sites. Common tumours, such as breast, multiple myeloma, and prostate tumours, frequently metastasize to the bone. To search for an inhibitor of cancer-induced bone loss, we investigated the effect of thiocolchicoside, a semi-synthetic colchicoside derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and tumour cells. EXPERIMENTAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well-established system for osteoclastogenesis, and evaluated the effect of thiocolchicoside on RANKL-induced NF-kappaB signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells. KEY RESULTS: Thiocolchicoside suppressed osteoclastogenesis induced by RANKL, and by breast cancer and multiple myeloma cells. Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB. Furthermore, an inhibitor of the IkappaBalpha kinase gamma or NF-kappaB essential modulator, the regulatory component of the IKK complex, demonstrated that the NF-kappaB signalling pathway is mandatory for osteoclastogenesis induced by RANKL. CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that thiocolchicoside significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the NF-kappaB signalling pathway. Thus, thiocolchicoside, a drug that has been used for almost half a century to treat muscle pain, may also be considered as a new treatment for bone loss.
21955206	1242	1251	NF-kappaB	GENE-N	21955206T10
21955206	1278	1292	IkappaB kinase	GENE-N	21955206T11
21955206	1294	1297	IKK	GENE-N	21955206T12
21955206	1327	1341	NF-kappaBalpha	GENE-Y	21955206T13
21955206	1343	1355	IkappaBalpha	GENE-Y	21955206T14
21955206	1406	1415	NF-kappaB	GENE-N	21955206T15
21955206	1450	1462	IkappaBalpha	GENE-Y	21955206T16
21955206	1463	1469	kinase	GENE-N	21955206T17
21955206	1479	1488	NF-kappaB	GENE-N	21955206T18
21955206	1542	1545	IKK	GENE-N	21955206T19
21955206	1205	1217	colchicoside	CHEMICAL	21955206T1
21955206	1577	1586	NF-kappaB	GENE-N	21955206T20
21955206	1653	1658	RANKL	GENE-Y	21955206T21
21955206	1796	1801	RANKL	GENE-Y	21955206T22
21955206	1827	1836	NF-kappaB	GENE-N	21955206T23
21955206	653	691	receptor activator of NF-kappaB ligand	GENE-Y	21955206T24
21955206	693	698	RANKL	GENE-Y	21955206T25
21955206	884	889	RANKL	GENE-Y	21955206T26
21955206	898	907	NF-kappaB	GENE-N	21955206T27
21955206	1071	1076	RANKL	GENE-Y	21955206T28
21955206	1145	1154	NF-kappaB	GENE-N	21955206T29
21955206	1724	1740	thiocolchicoside	CHEMICAL	21955206T2
21955206	58	63	RANKL	GENE-Y	21955206T30
21955206	1863	1879	thiocolchicoside	CHEMICAL	21955206T3
21955206	490	506	thiocolchicoside	CHEMICAL	21955206T4
21955206	525	537	colchicoside	CHEMICAL	21955206T5
21955206	864	880	thiocolchicoside	CHEMICAL	21955206T6
21955206	1013	1029	Thiocolchicoside	CHEMICAL	8251
21955206	0	16	Thiocolchicoside	CHEMICAL	8251
21955206	1228	1233	RANKL	GENE-Y	21955206T9
21955206	CPR:4	21955206T1	21955206T10
21955206	CPR:4	21955206T1	21955206T11
21955206	CPR:4	21955206T1	21955206T12
21955206	CPR:4	21955206T1	21955206T13
21955206	CPR:4	21955206T1	21955206T14
21955206	CPR:4	21955206T1	21955206T15
21955206	CPR:4	21955206T1	21955206T9
21955206	CPR:4	21955206T2	21955206T22
21955206	CPR:4	21955206T2	21955206T23

22064666|t|Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction.
22064666|a|Erectile dysfunction (ED) is usually treated with sildenafil. Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil. We studied 118 patients; 63 patients had ED secondary to radical prostatectomy (PED) and 55 had organic, clinical ED. eNOS genotypes for three eNOS polymorphisms (T(-786)C, rs2070744; a variable number of tandem repeats (VNTR) in intron 4; and Glu298Asp, rs1799983) were determined, and eNOS haplotypes were estimated using PHASE 2.1. The clinical responses to sildenafil were evaluated and the patients were classified as good responders (GR) or poor responders (PR) when their changes in five-item version of International Index for Erectile Function questionnaire were above or below the median value. The TC/CC genotypes and the C allele for the T(-786)C polymorphism were more common in GR, compared with PR patients with PED. However, the 4b4a/4a4a genotypes and the 4a allele for the VNTR polymorphism in intron 4 were more common in GR, compared with PR patients with clinical ED. The C-4a-Glu haplotype was more common in GR than in PR patients with PED. Conversely, the T-4b-Asp haplotype was less common in GR than in PR patients with PED. No other significant differences were found. Our findings show evidence that eNOS polymorphisms affect the responses of PED and clinical ED patients to sildenafil.
22064666	268	272	eNOS	GENE-Y	22064666T10
22064666	1551	1555	eNOS	GENE-Y	22064666T11
22064666	353	357	eNOS	GENE-Y	22064666T12
22064666	541	545	eNOS	GENE-Y	22064666T13
22064666	566	570	eNOS	GENE-Y	22064666T14
22064666	710	714	eNOS	GENE-Y	22064666T15
22064666	0	33	Endothelial nitric oxide synthase	GENE-Y	22064666T16
22064666	245	257	nitric oxide	CHEMICAL	22064666T1
22064666	1626	1636	sildenafil	CHEMICAL	22064666T2
22064666	301	303	NO	CHEMICAL	427
22064666	411	421	sildenafil	CHEMICAL	22064666T4
22064666	183	193	sildenafil	CHEMICAL	22064666T5
22064666	784	794	sildenafil	CHEMICAL	22064666T6
22064666	12	24	nitric oxide	CHEMICAL	22064666T7
22064666	83	93	sildenafil	CHEMICAL	22064666T8
22064666	233	266	endothelial nitric oxide synthase	GENE-Y	22064666T9
22064666	CPR:9	427	22064666T10
22064666	CPR:9	427	22064666T9

22080037|t|Mercury induces the expression of cyclooxygenase-2 and inducible nitric oxide synthase.
22080037|a|Nuclear factor-B (NF-B) is a transcription factor that mediates the inducible expression of a variety of genes involved in immune and inflammatory responses. NF-B activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS). The divalent heavy metal mercury has been used for thousands of years. Although mercury is clearly toxic to most mammalian organ systems, especially the immune system, exposure has still increased in some areas of the world. However, the underlying toxic mechanism is not clearly identified. Here, we report biochemical evidence that mercury alone induces NF-B activation, resulting in the induced expression of COX-2 and iNOS. The results suggest that mercury can induce inflammatory diseases by lowering host defense.
22080037	107	112	NF-B	GENE-N	22080037T10
22080037	322	331	cytokines	GENE-N	22080037T11
22080037	333	349	cyclooxygenase-2	GENE-Y	22080037T12
22080037	351	356	COX-2	GENE-Y	22080037T13
22080037	363	394	inducible nitric oxide synthase	GENE-Y	22080037T14
22080037	396	400	iNOS	GENE-Y	22080037T15
22080037	759	764	NF-B	GENE-N	22080037T16
22080037	816	821	COX-2	GENE-Y	22080037T17
22080037	826	830	iNOS	GENE-Y	22080037T18
22080037	34	50	cyclooxygenase-2	GENE-Y	22080037T19
22080037	373	385	nitric oxide	CHEMICAL	22080037T1
22080037	55	86	inducible nitric oxide synthase	GENE-Y	22080037T20
22080037	428	435	mercury	CHEMICAL	22080037T2
22080037	483	490	mercury	CHEMICAL	22080037T3
22080037	737	744	mercury	CHEMICAL	22080037T4
22080037	857	864	mercury	CHEMICAL	22080037T5
22080037	0	7	Mercury	CHEMICAL	22080037T6
22080037	65	77	nitric oxide	CHEMICAL	22080037T7
22080037	88	105	Nuclear factor-B	GENE-N	22080037T8
22080037	248	253	NF-B	GENE-N	22080037T9
22080037	CPR:3	22080037T4	22080037T16
22080037	CPR:3	22080037T4	22080037T17
22080037	CPR:3	22080037T4	22080037T18
22080037	CPR:3	22080037T6	22080037T19
22080037	CPR:3	22080037T6	22080037T20

22381584|t|Pharmacological evidence of functional inhibitory metabotrophic glutamate receptors on mouse arousal-related cholinergic laterodorsal tegmental neurons.
22381584|a|Cholinergic neurons of the pontine laterodorsal tegmentum (LDT) are importantly involved in neurobiological mechanisms governing states of arousal such as sleep and wakefulness as well as other appetitive behaviors, such as drug-seeking. Accordingly, mechanisms controlling their excitability are important to elucidate if we are to understand how these LDT neurons generate arousal states. Glutamate mediates the vast majority of excitatory synaptic transmission in the vertebrate CNS and while presence of glutamate input in the LDT has been shown and ionotropic responses to glutamate have been reported in the LDT, characterization of metabotropic responses is lacking. Therefore, electrophysiological responses and changes in levels of intracellular Ca(2+) in mouse cholinergic LDT neurons following application of specific mGluR agonists and antagonists were examined. Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization. Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP. Concurrent Ca(2+)imaging revealed that while CHPG actions did include release of Ca(2+) from CPA/thapsigargin-sensitive intracellular stores, actions of LY did not. Both CHPG- and LY-induced outward currents were mediated by a TEA-sensitive potassium conductance. The large-conductance, Ca(2+)-dependent potassium (BK) channel blocker, iberiotoxin, attenuated CHPG actions. Consistent with actions on the BK conductance, CHPG enhanced the amplitude of the fast component of the after hyperpolarizing potential, concurrent with a reduction in the firing rate. We conclude that stimulation of mGluR(5) and group II (mGluR(2/3)) elicits postsynaptically-mediated outward currents/hyperpolarizations in cholinergic LDT neurons. Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic glutamate receptors and mGluR(1), but also inhibition via actions at mGluR(5) and mGluR(2/3) on these neurons. As these two processes counteract each other, these surprising findings necessitate revision of predictions regarding the net level of excitation generated by glutamate input to cholinergic LDT cells and, by extension, the functional outcome of glutamate transmission on processes which these neurons regulate. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.
22381584	1591	1594	TEA	CHEMICAL	7601
22381584	1605	1614	potassium	CHEMICAL	22381584T11
22381584	1651	1657	Ca(2+)	CHEMICAL	22381584T12
22381584	1668	1677	potassium	CHEMICAL	22381584T13
22381584	1724	1728	CHPG	CHEMICAL	22381584T14
22381584	1785	1789	CHPG	CHEMICAL	22381584T15
22381584	2200	2209	glutamate	CHEMICAL	22381584T16
22381584	2470	2479	glutamate	CHEMICAL	22381584T17
22381584	2556	2565	glutamate	CHEMICAL	22381584T18
22381584	2685	2694	Glutamate	CHEMICAL	22381584T19
22381584	1276	1280	MCPG	CHEMICAL	22381584T1
22381584	544	553	Glutamate	CHEMICAL	22381584T20
22381584	661	670	glutamate	CHEMICAL	22381584T21
22381584	731	740	glutamate	CHEMICAL	22381584T22
22381584	908	914	Ca(2+)	CHEMICAL	22381584T23
22381584	1077	1081	CHPG	CHEMICAL	22381584T24
22381584	1127	1135	LY379268	CHEMICAL	22381584T25
22381584	1152	1155	TTX	CHEMICAL	22381584T26
22381584	64	73	glutamate	CHEMICAL	22381584T27
22381584	1259	1264	mGluR	GENE-N	68663
22381584	1338	1346	mGluR(5)	GENE-Y	22381584T29
22381584	1289	1293	CHPG	CHEMICAL	22381584T2
22381584	1651	1690	Ca(2+)-dependent potassium (BK) channel	GENE-N	22381584T30
22381584	1955	1963	mGluR(5)	GENE-Y	22381584T31
22381584	1978	1988	mGluR(2/3)	GENE-N	22381584T32
22381584	2189	2219	ionotropic glutamate receptors	GENE-N	22381584T33
22381584	2224	2232	mGluR(1)	GENE-Y	22381584T34
22381584	2269	2277	mGluR(5)	GENE-Y	22381584T35
22381584	2282	2292	mGluR(2/3)	GENE-N	22381584T36
22381584	2672	2704	Metabotropic Glutamate Receptors	GENE-N	22381584T37
22381584	982	987	mGluR	GENE-N	68663
22381584	1051	1059	mGluR(5)	GENE-Y	22381584T39
22381584	1358	1362	MTEP	CHEMICAL	22381584T3
22381584	1091	1105	group II mGluR	GENE-N	22381584T40
22381584	1107	1116	mGlu(2/3)	GENE-N	22381584T41
22381584	50	83	metabotrophic glutamate receptors	GENE-N	22381584T42
22381584	1375	1381	Ca(2+)	CHEMICAL	22381584T4
22381584	1409	1413	CHPG	CHEMICAL	22381584T5
22381584	1445	1451	Ca(2+)	CHEMICAL	22381584T6
22381584	1457	1460	CPA	CHEMICAL	22381584T7
22381584	1461	1473	thapsigargin	CHEMICAL	22381584T8
22381584	1534	1538	CHPG	CHEMICAL	22381584T9
22381584	CPR:5	22381584T24	22381584T39
22381584	CPR:5	22381584T25	22381584T40
22381584	CPR:6	22381584T1	68663
22381584	CPR:6	22381584T3	22381584T29

22391562|t|A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress.
22391562|a|There are few effective treatments for metastatic melanoma. Checkpoint kinase 1 (Chk1) inhibitors are being trialled for their efficacy in enhancing conventional chemotherapeutic agents, but their effectiveness as single agents is not known. We have examined the effectiveness of two novel Chk1 selective inhibitors, AR323 and AR678, in a panel of melanoma cell lines and normal cell types. We demonstrate that these drugs display single-agent activity, with IC50s in the low nanomolar range. The drugs produce cytotoxic effects in cell lines that are most sensitive to these drugs, whereas normal cells are only sensitive to these drugs at the higher concentrations where they have cytostatic activity. The cytotoxic effect is the consequence of inhibition of S-phase Chk1, which drives cells prematurely from late S phase into an aberrant mitosis and results in either failure of cytokinesis or cell death through an apoptotic mechanism. The sensitivity to the Chk1 inhibitors was correlated with the level of endogenous DNA damage indicating replicative stress. Chk1 inhibitors are viable single-agent therapies that target melanoma cells with high levels of endogenous DNA damage. This sensitivity suggests that Chk1 is a critical component of an adaptation to replicative stress in these cells. It also suggests that markers of DNA damage may be useful in identifying the melanomas and potentially other tumour types that are more likely to be sensitive to Chk1 inhibitors as single agents.
22391562	1065	1069	Chk1	GENE-Y	22391562T10
22391562	9	13	Chk1	GENE-Y	22391562T11
22391562	419	424	AR323	CHEMICAL	22391562T1
22391562	429	434	AR678	CHEMICAL	22391562T2
22391562	1167	1171	Chk1	GENE-Y	22391562T3
22391562	1318	1322	Chk1	GENE-Y	22391562T4
22391562	1564	1568	Chk1	GENE-Y	22391562T5
22391562	392	396	Chk1	GENE-Y	22391562T6
22391562	162	181	Checkpoint kinase 1	GENE-Y	22391562T7
22391562	871	875	Chk1	GENE-Y	22391562T8
22391562	183	187	Chk1	GENE-Y	22391562T9
22391562	CPR:4	22391562T1	22391562T6
22391562	CPR:4	22391562T2	22391562T6

22406476|t|Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.
22406476|a|BACKGROUND & AIMS: Aspirin reduces the incidence of and mortality from colorectal cancer (CRC) by unknown mechanisms. Cancer cells have defects in signaling via the mechanistic target of rapamycin (mTOR), which regulates proliferation. We investigated whether aspirin affects adenosine monophosphate-activated protein kinase (AMPK) and mTOR signaling in CRC cells. METHODS: The effects of aspirin on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting. Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts. LC3 and ULK1 were used as markers of autophagy. We analyzed rectal mucosa samples from patients given 600 mg aspirin, once daily for 1 week. RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1. Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR. Aspirin induced autophagy, a feature of mTOR inhibition. Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells. Rectal mucosal samples from patients given aspirin had reduced phosphorylation of S6K1 and S6. CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism. These could contribute to its protective effects against development of CRC.
22406476	1502	1511	metformin	CHEMICAL	22406476T10
22406476	1559	1563	mTOR	CHEMICAL	22406476T11
22406476	1651	1658	aspirin	CHEMICAL	22406476T12
22406476	1716	1723	Aspirin	CHEMICAL	935
22406476	1743	1747	mTOR	CHEMICAL	22406476T14
22406476	310	319	rapamycin	CHEMICAL	22406476T15
22406476	142	149	Aspirin	CHEMICAL	935
22406476	321	325	mTOR	CHEMICAL	22406476T17
22406476	383	390	aspirin	CHEMICAL	22406476T18
22406476	399	422	adenosine monophosphate	CHEMICAL	22406476T19
22406476	1152	1156	mTOR	CHEMICAL	22406476T1
22406476	459	463	mTOR	CHEMICAL	22406476T20
22406476	512	519	aspirin	CHEMICAL	22406476T21
22406476	523	527	mTOR	CHEMICAL	22406476T22
22406476	784	791	aspirin	CHEMICAL	22406476T23
22406476	811	815	mTOR	CHEMICAL	22406476T24
22406476	1049	1056	aspirin	CHEMICAL	22406476T25
22406476	1090	1097	Aspirin	CHEMICAL	935
22406476	1106	1110	mTOR	CHEMICAL	22406476T27
22406476	0	7	Aspirin	CHEMICAL	935
22406476	17	21	mTOR	CHEMICAL	22406476T29
22406476	1184	1191	Aspirin	CHEMICAL	935
22406476	43	46	AMP	CHEMICAL	125|407
22406476	1152	1156	mTOR	GENE-Y	22406476T31
22406476	1167	1171	S6K1	GENE-Y	22406476T32
22406476	1176	1182	4E-BP1	GENE-Y	22406476T33
22406476	1232	1236	AMPK	GENE-N	22406476T34
22406476	1251	1255	mTOR	GENE-Y	22406476T35
22406476	1325	1334	AMPKalpha	GENE-N	68705
22406476	1347	1351	AMPK	GENE-N	22406476T37
22406476	1366	1370	AMPK	GENE-N	22406476T38
22406476	1427	1431	mTOR	GENE-Y	22406476T39
22406476	1251	1255	mTOR	CHEMICAL	22406476T3
22406476	1473	1477	mTOR	GENE-Y	22406476T40
22406476	1529	1533	AMPK	GENE-N	22406476T41
22406476	1559	1563	mTOR	GENE-Y	22406476T42
22406476	1568	1571	Akt	GENE-N	22406476T43
22406476	1690	1694	S6K1	GENE-Y	22406476T44
22406476	1699	1701	S6	GENE-Y	22406476T45
22406476	1743	1747	mTOR	GENE-Y	22406476T46
22406476	1768	1772	AMPK	GENE-N	22406476T47
22406476	288	319	mechanistic target of rapamycin	GENE-Y	22406476T48
22406476	321	325	mTOR	GENE-Y	22406476T49
22406476	1279	1286	aspirin	CHEMICAL	22406476T4
22406476	399	447	adenosine monophosphate-activated protein kinase	GENE-N	22406476T50
22406476	449	453	AMPK	GENE-N	22406476T51
22406476	459	463	mTOR	GENE-Y	22406476T52
22406476	523	527	mTOR	GENE-Y	22406476T53
22406476	543	563	ribosomal protein S6	GENE-Y	22406476T54
22406476	565	576	S6 kinase 1	GENE-Y	22406476T55
22406476	578	582	S6K1	GENE-Y	22406476T56
22406476	589	650	eukaryotic translation initiation factor 4E binding protein 1	GENE-Y	22406476T57
22406476	652	658	4E-BP1	GENE-Y	22406476T58
22406476	725	729	AMPK	GENE-N	22406476T59
22406476	1397	1404	aspirin	CHEMICAL	22406476T5
22406476	767	776	AMPKalpha	GENE-N	68705
22406476	811	815	mTOR	GENE-Y	22406476T61
22406476	888	906	AMPK(alpha1/alpha2	GENE-N	22406476T62
22406476	940	943	LC3	GENE-N	22406476T63
22406476	948	952	ULK1	GENE-Y	113996|3945825
22406476	1106	1110	mTOR	GENE-Y	22406476T65
22406476	17	21	mTOR	GENE-Y	22406476T66
22406476	43	71	AMP-activated protein kinase	GENE-N	22406476T67
22406476	1427	1431	mTOR	CHEMICAL	22406476T6
22406476	1433	1440	Aspirin	CHEMICAL	935
22406476	1473	1477	mTOR	CHEMICAL	22406476T8
22406476	1490	1497	Aspirin	CHEMICAL	935
22406476	CPR:3	22406476T10	22406476T41
22406476	CPR:3	935	22406476T47
22406476	CPR:3	935	22406476T67
22406476	CPR:3	935	22406476T34
22406476	CPR:3	935	22406476T41
22406476	CPR:4	22406476T10	22406476T42
22406476	CPR:4	22406476T10	22406476T43
22406476	CPR:4	22406476T12	22406476T44
22406476	CPR:4	22406476T12	22406476T45
22406476	CPR:4	935	22406476T46
22406476	CPR:4	935	22406476T31
22406476	CPR:4	935	22406476T32
22406476	CPR:4	935	22406476T33
22406476	CPR:4	935	22406476T65
22406476	CPR:4	935	22406476T66
22406476	CPR:4	22406476T4	22406476T35
22406476	CPR:4	22406476T5	22406476T39
22406476	CPR:4	935	22406476T40
22406476	CPR:4	935	22406476T42
22406476	CPR:4	935	22406476T43

22410778|t|Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration.
22410778|a|The Warburg effect in cancer cells has been proposed to involve several mechanisms, including adaptation to hypoxia, oncogenes activation or loss of oncosuppressors and impaired mitochondrial function. In previous papers, it has been shown that K-ras transformed mouse cells are much more sensitive as compared with normal cells to glucose withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of mitochondrial complex I. Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/cAMP-dependent protein kinase (cAMP/PKA) pathway, which is known to regulate several mitochondrial functions. Herein, the derangement of the cAMP/PKA pathway and its impact on transformation-linked changes of mitochondrial functions is investigated. Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels. Several of these effects were almost completely prevented by inhibiting the PKA activity. Short-time treatment with compounds favoring mitochondrial fusion strongly decreased the cellular ROS levels especially in transformed cells. These findings support the notion that glucose shortage-induced apoptosis, specific of K-ras-transformed cells, is associated to a derangement of PKA signaling that leads to mitochondrial complex I decrease, reduction of ATP formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.
22410778	871	875	cAMP	CHEMICAL	2424
22410778	1031	1040	forskolin	CHEMICAL	22410778T11
22410778	1112	1119	glucose	CHEMICAL	22410778T12
22410778	65	69	cAMP	CHEMICAL	2424
22410778	86	95	forskolin	CHEMICAL	22410778T14
22410778	1376	1379	PKA	GENE-N	22410778T15
22410778	1619	1624	K-ras	GENE-Y	22410778T16
22410778	1678	1681	PKA	GENE-N	22410778T17
22410778	1706	1729	mitochondrial complex I	GENE-N	22410778T18
22410778	407	412	K-ras	GENE-Y	22410778T19
22410778	1176	1198	adenosine triphosphate	CHEMICAL	22410778T1
22410778	597	620	mitochondrial complex I	GENE-N	22410778T20
22410778	730	759	cAMP-dependent protein kinase	GENE-N	22410778T21
22410778	766	769	PKA	GENE-N	22410778T22
22410778	876	879	PKA	GENE-N	22410778T23
22410778	1005	1008	PKA	GENE-N	22410778T24
22410778	1062	1067	K-ras	GENE-Y	22410778T25
22410778	1142	1151	complex I	GENE-N	22410778T26
22410778	10	15	K-ras	GENE-Y	22410778T27
22410778	70	73	PKA	GENE-N	22410778T28
22410778	1200	1203	ATP	CHEMICAL	164
22410778	1271	1277	oxygen	CHEMICAL	22410778T3
22410778	1571	1578	glucose	CHEMICAL	22410778T4
22410778	1753	1756	ATP	CHEMICAL	164
22410778	494	501	glucose	CHEMICAL	22410778T6
22410778	699	729	cyclic adenosine monophosphate	CHEMICAL	22410778T7
22410778	730	734	cAMP	CHEMICAL	2424
22410778	761	765	cAMP	CHEMICAL	2424
22410778	CPR:3	22410778T11	22410778T24
22410778	CPR:3	22410778T11	22410778T26
22410778	CPR:4	22410778T12	22410778T25

22422627|t|Berberine inhibits myofibroblast differentiation in nasal polyp-derived fibroblasts via the p38 pathway.
22422627|a|The purposes of this study were to determine whether berberine has any effect on phenotype changes and extracellular matrix (ECM) production in nasal polyp-derived fibroblasts (NPDFs) and to investigate the underlying molecular mechanism. NPDFs were pre-treated with berberine prior to induction by transforming growth factor (TGF)-1. The expression of -smooth muscle actin (SMA) and collagen type I mRNA was determined by a reverse transcription-polymerase chain reaction, and the expression of -SMA protein and collagen type I was determined by western blotting and/or immunofluorescent staining. The total soluble collagen production was analysed by the SirCol collagen assay. The expression of several signaling molecules of the TGF-1 pathway was evaluated by western blot analysis. In TGF-1-induced NPDFs, berberine significantly inhibited the expression of -SMA and collagen type I mRNA and reduced -SMA and collagen protein levels. Berberine only suppressed the expression of pp38 among the evaluated signaling molecules. SB203580 (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and -SMA in TGF-1-induced NPDFs. Berberine exerts suppressive effects on phenotype changes and ECM production in NPDFs via p38 signaling pathway interference. The findings provide new therapeutic options for ECM production in nasal polyps.
22422627	1235	1250	collagen type I	GENE-N	22422627T10
22422627	1255	1260	-SMA	GENE-Y	22422627T11
22422627	1264	1270	TGF-1	GENE-Y	22422627T12
22422627	1376	1379	p38	GENE-N	22422627T13
22422627	404	439	transforming growth factor (TGF)-1	GENE-Y	22422627T14
22422627	459	480	-smooth muscle actin	GENE-Y	22422627T15
22422627	482	485	SMA	GENE-Y	22422627T16
22422627	491	506	collagen type I	GENE-N	22422627T17
22422627	603	608	-SMA	GENE-Y	22422627T18
22422627	621	636	collagen type I	GENE-N	22422627T19
22422627	1141	1149	SB203580	CHEMICAL	22422627T1
22422627	725	733	collagen	GENE-N	22422627T20
22422627	841	847	TGF-1	GENE-Y	22422627T21
22422627	899	905	TGF-1	GENE-Y	22422627T22
22422627	973	978	-SMA	GENE-Y	22422627T23
22422627	983	998	collagen type I	GENE-N	22422627T24
22422627	1016	1021	-SMA	GENE-Y	22422627T25
22422627	1026	1034	collagen	GENE-N	22422627T26
22422627	1095	1099	pp38	GENE-N	22422627T27
22422627	92	95	p38	GENE-N	22422627T28
22422627	1286	1295	Berberine	CHEMICAL	3947
22422627	372	381	berberine	CHEMICAL	22422627T3
22422627	158	167	berberine	CHEMICAL	22422627T4
22422627	921	930	berberine	CHEMICAL	22422627T5
22422627	1051	1060	Berberine	CHEMICAL	3947
22422627	0	9	Berberine	CHEMICAL	3947
22422627	1175	1178	p38	GENE-N	22422627T8
22422627	1179	1185	kinase	GENE-N	22422627T9
22422627	CPR:4	22422627T1	22422627T10
22422627	CPR:4	22422627T1	22422627T11
22422627	CPR:4	22422627T1	22422627T12
22422627	CPR:4	22422627T1	22422627T8
22422627	CPR:4	22422627T1	22422627T9
22422627	CPR:4	22422627T5	22422627T22
22422627	CPR:4	22422627T5	22422627T23
22422627	CPR:4	22422627T5	22422627T24
22422627	CPR:4	22422627T5	22422627T25
22422627	CPR:4	22422627T5	22422627T26
22422627	CPR:4	3947	22422627T27

22475014|t|Glaucogenin E, a new C21 steroid from Cynanchum stauntonii.
22475014|a|Glaucogenin E (1), a new C(21) steroid sapogenin, along with three known ones (2-4) were isolated from the rhizomes of Cynanchum stauntonii (Decne.) Schltr. ex Levl. Their structures were established mainly by the spectroscopic analysis, including 2D NMR. All the isolated compounds were evaluated for their cytotoxicity against human cancer cell lines HeLa, Bel-7402, SGC-7901 and BGC-823.
22475014	60	73	Glaucogenin E	CHEMICAL	22475014T1
22475014	85	90	C(21)	CHEMICAL	22475014T2
22475014	91	98	steroid	CHEMICAL	22475014T3
22475014	0	13	Glaucogenin E	CHEMICAL	22475014T4
22475014	21	24	C21	CHEMICAL	22475014T5
22475014	25	32	steroid	CHEMICAL	22475014T6

22493952|t|New triterpenoids from the stem bark of Hypodaphnis zenkeri.
22493952|a|A new pentacyclic triterpenoid and three new derivatives based on the taraxer-14-ene skeleton with a C-28 attached a carboxylic acid group have been isolated from the stem bark of Hypodaphnis zenkeri, together with six known compounds. The new product was identified as 2,3-dihydroxytaraxer-14-en-28-oic acid (1). Its derivatives, 2,3-diacetyltaraxer-14-en-28-oic acid (2), 2,3-di-O-carbonyl-2,3-dihydroxytaraxer-14-en-28-oic acid (3) and 2,3-dipropionyltaraxer-14-en-28-oic acid (4) were obtained by semisynthesis. The known compounds were identified as 3-hydroxytaraxer-14-en-28-oic acid or aleuritolic acid (5) (McPhail, A.T., McPhail, D.R., Wani, M.C., Wall, M.E. & A.W., Nicholas, A.W. (1989). Identity of maprounic acid with aleuritolic acid. Revision of the structure of maprounic acid: X-ray crystal structure of p-bromobenzyl acetylmaprounate. Journal Natural Products, 52, 212), 3-hydroxytaraxer-14-en-28-oic acid or isoaleuritolic acid (6), 3-acetyltaraxer-14-en-28-oic acid acetate or aleuritolic acid acetate (7) (Chaudhuri, S.K., Fullas, F., Brown, D.M., Wani, M.C., Wall, M.E., Cai, L.,  Kinghorn, A.D. (1995). Isolation and structural elucidation of pentacyclic triterpenoids from Maprounea africana. Journal of Natural Products, 58, 1-9), 3-oxo-taraxer-14-ene or taraxerone (8) -sitosterol (9) and stigmasterol (10) (Kamboj & Saluja, 2011), together with fatty acids. Their structures were established on the basis of spectroscopic studies and chemical transformations.
22493952	508	550	2,3-dipropionyltaraxer-14-en-28-oic acid	CHEMICAL	22493952T10
22493952	626	661	3-hydroxytaraxer-14-en-28-oic acid	CHEMICAL	22493952T11
22493952	665	681	aleuritolic acid	CHEMICAL	22493952T12
22493952	67	91	pentacyclic triterpenoid	CHEMICAL	22493952T13
22493952	131	145	taraxer-14-ene	CHEMICAL	22493952T14
22493952	783	797	maprounic acid	CHEMICAL	22493952T15
22493952	803	819	aleuritolic acid	CHEMICAL	22493952T16
22493952	850	864	maprounic acid	CHEMICAL	22493952T17
22493952	893	923	p-bromobenzyl acetylmaprounate	CHEMICAL	22493952T18
22493952	961	996	3-hydroxytaraxer-14-en-28-oic acid	CHEMICAL	22493952T19
22493952	1071	1095	aleuritolic acid acetate	CHEMICAL	22493952T1
22493952	1000	1019	isoaleuritolic acid	CHEMICAL	22493952T20
22493952	1025	1067	3-acetyltaraxer-14-en-28-oic acid acetate	CHEMICAL	22493952T21
22493952	4	17	triterpenoids	CHEMICAL	22493952T22
22493952	178	193	carboxylic acid	CHEMICAL	22493952T2
22493952	1331	1351	3-oxo-taraxer-14-ene	CHEMICAL	22493952T3
22493952	1355	1365	taraxerone	CHEMICAL	22493952T4
22493952	1370	1382	-sitosterol	CHEMICAL	22493952T5
22493952	1391	1403	stigmasterol	CHEMICAL	22493952T6
22493952	331	371	2,3-dihydroxytaraxer-14-en-28-oic acid	CHEMICAL	22493952T7
22493952	394	433	2,3-diacetyltaraxer-14-en-28-oic acid	CHEMICAL	22493952T8
22493952	439	499	2,3-di-O-carbonyl-2,3-dihydroxytaraxer-14-en-28-oic acid	CHEMICAL	22493952T9

22537580|t|Two new C-15 enolic acyl phragmalin-type limonoids from Chukrasia tabularis var. velutina.
22537580|a|Two new C-15 enolic acyl phragmalin-type limonoid orthoesters, chukvelutilide G (1) and chukrasine F (2), were isolated from the stem barks of Chukrasia tabularis var. velutina. Their structures were elucidated by their extensive high resolution-electrospray ionization mass spectrometry (HR-ESI-MS), one- and two-dimensional spectroscopic analysis, including heteronuclear single quantum coherence (HSQC), HMBC and NOESY experiments.
22537580	104	126	enolic acyl phragmalin	CHEMICAL	22537580T1
22537580	132	152	limonoid orthoesters	CHEMICAL	22537580T2
22537580	154	170	chukvelutilide G	CHEMICAL	22537580T3
22537580	179	191	chukrasine F	CHEMICAL	22537580T4
22537580	13	35	enolic acyl phragmalin	CHEMICAL	22537580T5
22537580	41	50	limonoids	CHEMICAL	22537580T6

22552008|t|Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
22552008|a|Thalidomide and the immunomodulatory drug, lenalidomide, are therapeutically active in hematological malignancies. The ubiquitously expressed E3 ligase protein cereblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes. CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells. Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable. Our biophysical, biochemical and gene silencing studies show that CRBN is a proximate, therapeutically important molecular target of lenalidomide and pomalidomide.
22552008	460	472	pomalidomide	CHEMICAL	8560
22552008	167	179	lenalidomide	CHEMICAL	8561
22552008	610	622	lenalidomide	CHEMICAL	8561
22552008	627	639	pomalidomide	CHEMICAL	8560
22552008	669	681	lenalidomide	CHEMICAL	8561
22552008	687	699	pomalidomide	CHEMICAL	8560
22552008	740	752	Lenalidomide	CHEMICAL	472
22552008	757	769	pomalidomide	CHEMICAL	8560
22552008	835	846	thalidomide	CHEMICAL	8562
22552008	889	900	thalidomide	CHEMICAL	8562
22552008	124	135	Thalidomide	CHEMICAL	1030
22552008	1044	1056	pomalidomide	CHEMICAL	8560
22552008	110	122	pomalidomide	CHEMICAL	8560
22552008	93	105	lenalidomide	CHEMICAL	8561
22552008	1127	1132	WAF-1	GENE-Y	22552008T23
22552008	1255	1259	CRBN	GENE-Y	119360|677660|1182936
22552008	1339	1343	CRBN	GENE-Y	119360|677660|1182936
22552008	1436	1440	CRBN	GENE-Y	119360|677660|1182936
22552008	284	292	cereblon	GENE-Y	22552008T27
22552008	294	298	CRBN	GENE-Y	119360|677660|1182936
22552008	491	495	CRBN	GENE-Y	119360|677660|1182936
22552008	1170	1182	lenalidomide	CHEMICAL	8561
22552008	512	516	CRBN	GENE-Y	119360|677660|1182936
22552008	517	545	DNA damage binding protein-1	GENE-Y	22552008T31
22552008	547	551	DDB1	GENE-Y	108009
22552008	564	568	CRBN	GENE-Y	119360|677660|1182936
22552008	708	716	cytokine	GENE-N	22552008T34
22552008	802	806	CRBN	GENE-Y	119360|677660|1182936
22552008	875	879	CRBN	GENE-Y	119360|677660|1182936
22552008	919	923	CRBN	GENE-Y	119360|677660|1182936
22552008	950	954	CRBN	GENE-Y	119360|677660|1182936
22552008	982	986	CRBN	GENE-Y	119360|677660|1182936
22552008	1308	1320	pomalidomide	CHEMICAL	8560
22552008	1080	1085	c-myc	GENE-Y	22552008T40
22552008	1090	1094	IRF4	GENE-Y	109870
22552008	1123	1126	p21	GENE-Y	22552008T42
22552008	0	8	Cereblon	GENE-Y	22552008T43
22552008	1325	1337	lenalidomide	CHEMICAL	8561
22552008	1503	1515	lenalidomide	CHEMICAL	8561
22552008	1520	1532	pomalidomide	CHEMICAL	8560
22552008	357	368	thalidomide	CHEMICAL	8562
22552008	399	410	thalidomide	CHEMICAL	8562
22552008	412	424	lenalidomide	CHEMICAL	8561
22552008	CPR:3	8561	22552008T34
22552008	CPR:3	8560	22552008T34
22552008	CPR:3	8560	22552008T23
22552008	CPR:3	8560	22552008T42
22552008	CPR:4	472	119360|677660|1182936
22552008	CPR:4	472	119360|677660|1182936
22552008	CPR:4	8560	119360|677660|1182936
22552008	CPR:4	8560	119360|677660|1182936
22552008	CPR:4	8560	22552008T40
22552008	CPR:4	8560	109870
22552008	CPR:4	8561	119360|677660|1182936

22566187|t|Evaluation of food-drug interaction of guava leaf tea.
22566187|a|Guava leaf tea (GLT) contains guava leaf polyphenol (Gvpp), which regulates the absorption of dietary carbohydrate from the intestines. Borderline diabetics, who are at high risk of development of diabetes, take GLT to suppress a rapid increase of blood sugar level after meals. However, patients with diabetes in whom diabetic drugs or warfarin as a blood thinner are prescribed also take GLT with the expectation of glycemic control. Therefore, we studied whether GLT had potential for inhibition or induction of cytochrome P450 (CYP) and an influence on the action of warfarin. Extract of guava leaf (GvEx) consists of carbohydrate and polyphenols, which are Gvpp, quercetin, and ellagic acid. These polyphenols, but not GvEx, showed a certain level of inhibition of human-cDNA-expressed CYPs. In a comparison of GLT and grapefruit juice, GLT showed weaker inhibition of CYP activities and of midazolam 1'-hydroxylation than grapefruit juice. Furthermore, neither liver weight nor CYP3A expression in the liver was changed in rats that received GvEx for 90days compared with the control group. When rats were concomitantly treated with GLT and warfarin, the prolongation of clotting time of blood by warfarin was not influenced. These data suggest that GLT is unlikely to interact with drugs.
22566187	723	732	quercetin	CHEMICAL	22566187T10
22566187	738	750	ellagic acid	CHEMICAL	22566187T11
22566187	758	769	polyphenols	CHEMICAL	22566187T12
22566187	951	960	midazolam	CHEMICAL	22566187T13
22566187	570	585	cytochrome P450	GENE-N	22566187T14
22566187	587	590	CYP	GENE-N	22566187T15
22566187	846	850	CYPs	GENE-N	22566187T16
22566187	929	932	CYP	GENE-N	22566187T17
22566187	1039	1044	CYP3A	GENE-N	22566187T18
22566187	157	169	carbohydrate	CHEMICAL	22566187T1
22566187	1203	1211	warfarin	CHEMICAL	22566187T2
22566187	1259	1267	warfarin	CHEMICAL	22566187T3
22566187	309	314	sugar	CHEMICAL	22566187T4
22566187	392	400	warfarin	CHEMICAL	22566187T5
22566187	96	106	polyphenol	CHEMICAL	22566187T6
22566187	626	634	warfarin	CHEMICAL	22566187T7
22566187	677	689	carbohydrate	CHEMICAL	22566187T8
22566187	694	705	polyphenols	CHEMICAL	22566187T9
22566187	CPR:4	22566187T12	22566187T16

22594847|t|Crizotinib in the treatment of non-small-cell lung cancer.
22594847|a|INTRODUCTION: Recent progress in identifying distinct subsets of lung cancer, based on critical driver mutations, has led to increasingly focused efforts in the development of selectively targeted therapies. The fusion oncogene, echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase (EML4-ALK), is present in approximately 5% of non-small-cell lung cancer (NSCLC) tumors. Crizotinib is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK. Emerging data suggest that crizotinib may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the MET oncogene, or translocation of the ROS1 oncogene. AREAS COVERED: This paper gives an overview of the molecular pathogenesis of ALK-associated NSCLC. It also reviews the pharmacokinetic and pharmacodynamic data on crizotinib and outlines the preclinical and clinical studies leading to the approval of crizotinib. In addition, it discusses its role in the treatment of NSCLC expressing ALK. EXPERT OPINION: Crizotinib represents the newest example of a focused strategy for drug development in lung cancer, based on identification and targeted inhibition of critical tumor-specific driver mutations. Crizotinib has demonstrated efficacy against ALK-rearranged NSCLC, and has potential for broader application in select subsets of lung cancer.
22594847	1458	1461	ALK	GENE-Y	106739
22594847	288	336	echinoderm microtubule-associated protein-like 4	GENE-Y	22594847T11
22594847	339	365	anaplastic lymphoma kinase	GENE-Y	22594847T12
22594847	367	371	EML4	GENE-N	118169|148767
22594847	372	375	ALK	GENE-Y	106739
22594847	477	492	tyrosine kinase	GENE-N	22594847T15
22594847	552	555	ALK	GENE-Y	106739
22594847	648	651	ALK	GENE-Y	106739
22594847	811	814	MET	GENE-Y	110391
22594847	849	853	ROS1	GENE-Y	112025
22594847	1115	1125	crizotinib	CHEMICAL	22594847T1
22594847	941	944	ALK	GENE-Y	106739
22594847	1220	1230	Crizotinib	CHEMICAL	7610
22594847	1413	1423	Crizotinib	CHEMICAL	7610
22594847	455	465	Crizotinib	CHEMICAL	7610
22594847	477	485	tyrosine	CHEMICAL	22594847T5
22594847	680	690	crizotinib	CHEMICAL	22594847T6
22594847	1027	1037	crizotinib	CHEMICAL	22594847T7
22594847	0	10	Crizotinib	CHEMICAL	7610
22594847	1199	1202	ALK	GENE-Y	106739
22594847	CPR:4	7610	22594847T15
22594847	CPR:4	7610	106739

2262902|t|Central adenosinergic system involvement in ethanol-induced motor incoordination in mice.
2262902|a|To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod. Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions. Results from R-PIA and N6-(S-phenylisopropyl)adenosine experiments showed nearly a 40-fold greater potency of R-vs. S-diastereoisomer, suggesting predominance of adenosine A1 subtype. However, 5'-(N-cyclopropyl)-carboxamidoadenosine data indicate complexity of the mechanism(s) and point toward an additional involvement of a yet unknown subtype of adenosine A2. No effect of ethanol on blood or brain levels of [3H]R-PIA was noted and sufficient amount of the latter entered the brain to suggest adenosine receptor activation adequate to produce behavioral interaction with ethanol. There was no escape of i.c.v.-administered [3H]R-PIA from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of ethanol-adenosine interaction.(ABSTRACT TRUNCATED AT 250 WORDS)
2262902	261	270	adenosine	CHEMICAL	2262902T10
2262902	1858	1865	ethanol	CHEMICAL	2262902T11
2262902	1866	1875	adenosine	CHEMICAL	2262902T12
2262902	281	312	N6-(R-phenylisopropyl)adenosine	CHEMICAL	2262902T13
2262902	314	319	R-PIA	CHEMICAL	2262902T14
2262902	322	353	N6-(S-phenylisopropyl)adenosine	CHEMICAL	2262902T15
2262902	355	394	5'-(N-cyclopropyl)-carboxamidoadenosine	CHEMICAL	2262902T16
2262902	409	421	theophylline	CHEMICAL	2262902T17
2262902	426	455	8-p-(sulfophenyl)theophylline	CHEMICAL	2262902T18
2262902	467	479	enprofylline	CHEMICAL	2262902T19
2262902	1094	1103	adenosine	CHEMICAL	2262902T1
2262902	483	490	ethanol	CHEMICAL	2262902T20
2262902	553	562	Adenosine	CHEMICAL	630
2262902	139	146	ethanol	CHEMICAL	2262902T22
2262902	647	654	ethanol	CHEMICAL	2262902T23
2262902	151	160	adenosine	CHEMICAL	2262902T24
2262902	727	736	adenosine	CHEMICAL	2262902T25
2262902	766	773	ethanol	CHEMICAL	2262902T26
2262902	818	827	adenosine	CHEMICAL	2262902T27
2262902	869	881	Enprofylline	CHEMICAL	814
2262902	890	899	adenosine	CHEMICAL	2262902T29
2262902	1141	1172	N6-(S-phenylisopropyl)adenosine	CHEMICAL	2262902T2
2262902	935	945	cyclic AMP	CHEMICAL	2262902T30
2262902	1086	1093	ethanol	CHEMICAL	2262902T31
2262902	44	51	ethanol	CHEMICAL	2262902T32
2262902	1094	1103	adenosine	GENE-N	2262902T33
2262902	1280	1292	adenosine A1	GENE-Y	2262902T34
2262902	1467	1479	adenosine A2	GENE-N	2262902T35
2262902	1615	1633	adenosine receptor	GENE-N	2262902T36
2262902	261	270	adenosine	GENE-N	2262902T37
2262902	1866	1875	adenosine	GENE-N	2262902T38
2262902	553	562	Adenosine	GENE-N	2262902T39
2262902	1280	1289	adenosine	CHEMICAL	2262902T3
2262902	151	160	adenosine	GENE-N	2262902T40
2262902	727	736	adenosine	GENE-N	2262902T41
2262902	818	827	adenosine	GENE-N	2262902T42
2262902	890	899	adenosine	GENE-N	2262902T43
2262902	935	963	cyclic AMP phosphodiesterase	GENE-N	2262902T44
2262902	1051	1069	adenosine receptor	GENE-N	2262902T45
2262902	1311	1350	5'-(N-cyclopropyl)-carboxamidoadenosine	CHEMICAL	2262902T4
2262902	1467	1476	adenosine	CHEMICAL	2262902T5
2262902	1530	1539	[3H]R-PIA	CHEMICAL	2262902T6
2262902	1615	1624	adenosine	CHEMICAL	2262902T7
2262902	1693	1700	ethanol	CHEMICAL	2262902T8
2262902	1745	1754	[3H]R-PIA	CHEMICAL	2262902T9
2262902	CPR:4	814	2262902T44
2262902	CPR:5	2262902T13	2262902T37
2262902	CPR:5	2262902T14	2262902T37
2262902	CPR:5	2262902T15	2262902T37
2262902	CPR:5	2262902T16	2262902T37
2262902	CPR:6	2262902T17	2262902T37
2262902	CPR:6	2262902T18	2262902T37
2262902	CPR:6	2262902T19	2262902T37
2262902	CPR:6	814	2262902T43

22641218|t|TGF- and NF-B signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers.
22641218|a|Transforming growth factor-beta (TGF-) has a dual role in epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Attenuation of canonical TGF- signaling enhances de novo tumor development, whereas TGF- overexpression and signaling paradoxically promotes malignant progression. We recently observed that TGF--induced growth arrest response is attenuated, in association with aberrant activation of nuclear factor-B (NF-B), a transcription factor, which promotes malignant progression in HNSCC. However, what role cross-talk between components of the TGF- and NF-B pathways plays in altered activation of these pathways has not been established. Here, we show TGF- receptor II and TGF--activated kinase 1 (TAK1) are predominantly expressed in a subset of HNSCC tumors with nuclear activation of NF-B family member RELA (p65). Further, TGF-1 treatment induced sequential phosphorylation of TAK1, IKK, IB and RELA in human HNSCC lines. TAK1 enhances TGF--induced NF-B activation, as TAK1 siRNA knockdown decreased TGF-1-induced phosphorylation of IKK, IB and RELA, degradation of IB, RELA nuclear translocation and DNA binding, and NF-B-induced reporter and target gene transcription. Functionally, TAK1 siRNA inhibited cell proliferation, migration and invasion. Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-1- and tumor necrosis factor-alpha (TNF-)-induced NF-B reporter gene activity. Celastrol also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and Annexin V markers of apoptosis. Furthermore, TGF- and RELA activation promoted SMAD7 expression. In turn, SMAD7 preferentially suppressed TGF--induced SMAD and NF-B reporters when compared with constitutive or TNF--induced NF-B reporter gene activation. Thus, cross-talk by TGF- via TAK1 and NF-B promotes the malignant phenotype of HNSCC. Moreover, NF-B may contribute to the downstream attenuation of canonical TGF- signaling through increased SMAD7 expression. Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF--NF-B signal pathway.
22641218	1215	1219	RELA	GENE-Y	111902
22641218	1236	1240	IB	GENE-Y	22641218T11
22641218	1242	1246	RELA	GENE-Y	111902
22641218	1290	1295	NF-B	GENE-N	22641218T13
22641218	1358	1362	TAK1	GENE-Y	22641218T14
22641218	1436	1440	TAK1	GENE-Y	22641218T15
22641218	1535	1541	TGF-1	GENE-Y	22641218T16
22641218	1569	1573	TAK1	GENE-Y	22641218T17
22641218	1578	1582	RELA	GENE-Y	111902
22641218	1606	1612	TGF-1	GENE-Y	22641218T19
22641218	1423	1432	Celastrol	CHEMICAL	9878
22641218	1618	1645	tumor necrosis factor-alpha	GENE-Y	22641218T20
22641218	1647	1652	TNF-	GENE-Y	22641218T21
22641218	1662	1667	NF-B	GENE-N	22641218T22
22641218	281	286	TGF-	GENE-Y	22641218T23
22641218	1783	1792	Annexin V	GENE-Y	22641218T24
22641218	1828	1833	TGF-	GENE-Y	22641218T25
22641218	1838	1842	RELA	GENE-Y	111902
22641218	1863	1868	SMAD7	GENE-Y	110267
22641218	1890	1895	SMAD7	GENE-Y	110267
22641218	1922	1927	TGF-	GENE-Y	22641218T29
22641218	1692	1701	Celastrol	CHEMICAL	9878
22641218	1936	1940	SMAD	GENE-N	22641218T30
22641218	1945	1950	NF-B	GENE-N	22641218T31
22641218	1996	2001	TNF-	GENE-Y	22641218T32
22641218	2010	2015	NF-B	GENE-N	22641218T33
22641218	2062	2067	TGF-	GENE-Y	22641218T34
22641218	2072	2076	TAK1	GENE-Y	22641218T35
22641218	2081	2086	NF-B	GENE-N	22641218T36
22641218	2140	2145	NF-B	GENE-N	22641218T37
22641218	2204	2209	TGF-	GENE-Y	22641218T38
22641218	2238	2243	SMAD7	GENE-Y	110267
22641218	2256	2265	Celastrol	CHEMICAL	9878
22641218	2323	2327	TAK1	GENE-Y	22641218T40
22641218	2364	2369	TGF-	GENE-Y	22641218T41
22641218	2370	2375	NF-B	GENE-N	22641218T42
22641218	341	346	TGF-	GENE-Y	22641218T43
22641218	448	453	TGF-	GENE-Y	22641218T44
22641218	148	153	TGF-	GENE-Y	22641218T45
22641218	543	560	nuclear factor-B	GENE-N	22641218T46
22641218	562	567	NF-B	GENE-N	22641218T47
22641218	697	702	TGF-	GENE-Y	22641218T48
22641218	707	712	NF-B	GENE-N	22641218T49
22641218	115	146	Transforming growth factor-beta	GENE-Y	22641218T4
22641218	808	825	TGF- receptor II	GENE-Y	22641218T50
22641218	830	854	TGF--activated kinase 1	GENE-Y	22641218T51
22641218	856	860	TAK1	GENE-Y	22641218T52
22641218	945	950	NF-B	GENE-N	22641218T53
22641218	965	969	RELA	GENE-Y	111902
22641218	971	974	p65	GENE-Y	22641218T55
22641218	986	992	TGF-1	GENE-Y	22641218T56
22641218	1041	1045	TAK1	GENE-Y	22641218T57
22641218	1047	1050	IKK	GENE-N	22641218T58
22641218	1052	1056	IB	GENE-Y	22641218T59
22641218	1116	1121	NF-B	GENE-N	22641218T5
22641218	1061	1065	RELA	GENE-Y	111902
22641218	1088	1092	TAK1	GENE-Y	22641218T61
22641218	1102	1107	TGF-	GENE-Y	22641218T62
22641218	0	5	TGF-	GENE-Y	22641218T63
22641218	10	15	NF-B	GENE-N	22641218T64
22641218	62	66	TAK1	GENE-Y	22641218T65
22641218	71	76	SMAD7	GENE-Y	110267
22641218	1137	1141	TAK1	GENE-Y	22641218T6
22641218	1168	1174	TGF-1	GENE-Y	22641218T7
22641218	1202	1205	IKK	GENE-N	22641218T8
22641218	1207	1210	IB	GENE-Y	22641218T9
22641218	CPR:3	9878	22641218T24
22641218	CPR:4	9878	22641218T15
22641218	CPR:4	9878	22641218T16
22641218	CPR:4	9878	22641218T17
22641218	CPR:4	9878	111902
22641218	CPR:4	9878	22641218T19
22641218	CPR:4	9878	22641218T20
22641218	CPR:4	9878	22641218T22
22641218	CPR:4	9878	22641218T40

22683935|t|Dendritic cell migration assay: a potential prediction model for identification of contact allergens.
22683935|a|This manuscript describes methodology and a prediction model for the MUTZ-LC migration assay. The assay represents the physiological change in Langerhans cell (LC) behavior after exposure to a sensitizing chemical, resulting in LC migration from the epidermis to the dermis. MUTZ-LC are derived from the commercially available MUTZ-3 cell line. Upon exposure to a sensitizer MUTZ-LC migrate preferentially towards CXCL12 whereas upon exposure to a non-sensitizer MUTZ-LC migrate towards CCL5. A CXCL12/CCL5 ratio >1.10 in 2/3 independent experiments is indicative of a sensitizer, whereas a CXCL12/CCL5 ratio 1.10 is indicative of a non-sensitizer. At non cytotoxic chemical concentrations 9 sensitizers (2,4-dinitrochlorobenzene, paraphenylendiamine, cinnamaldehyde, isoeugenol, nickel-sulfate, tetramethylthiuram disulfide, eugenol, cinnamic-alcohol, ammonium-hexachloroplatinate) were distinguished from 4 non sensitizers (sodium lauryl sulfate, salicylic acid, phenol, octanoic acid). Critical points in assay performance are (i) MUTZ-3 passage number after thawing (p6-p40); (ii) cell viability (>80%); (iii) standard curve to optimize correlation of fluorescence with cell number; and (iv) optimization of the concentration of rhCXCL12 and rhCCL5 in transwell. The protocol has been tested in three European laboratories and results suggest that it may provide working conditions for performing the DC migration assay which is aimed at distinguishing sensitizers from non sensitizers.
22683935	1029	1050	sodium lauryl sulfate	CHEMICAL	22683935T10
22683935	1052	1066	salicylic acid	CHEMICAL	22683935T11
22683935	1068	1074	phenol	CHEMICAL	22683935T12
22683935	1076	1089	octanoic acid	CHEMICAL	22683935T13
22683935	1336	1344	rhCXCL12	GENE-Y	22683935T14
22683935	1349	1355	rhCCL5	GENE-Y	22683935T15
22683935	516	522	CXCL12	GENE-Y	112288
22683935	589	593	CCL5	GENE-Y	112255
22683935	597	603	CXCL12	GENE-Y	112288
22683935	604	608	CCL5	GENE-Y	112255
22683935	808	832	2,4-dinitrochlorobenzene	CHEMICAL	22683935T1
22683935	693	699	CXCL12	GENE-Y	112288
22683935	700	704	CCL5	GENE-Y	112255
22683935	834	853	paraphenylendiamine	CHEMICAL	22683935T2
22683935	855	869	cinnamaldehyde	CHEMICAL	22683935T3
22683935	871	881	isoeugenol	CHEMICAL	22683935T4
22683935	883	897	nickel-sulfate	CHEMICAL	22683935T5
22683935	899	927	tetramethylthiuram disulfide	CHEMICAL	22683935T6
22683935	929	936	eugenol	CHEMICAL	22683935T7
22683935	938	954	cinnamic-alcohol	CHEMICAL	22683935T8
22683935	956	984	ammonium-hexachloroplatinate	CHEMICAL	22683935T9

22708686|t|The atypical antidepressant mianserin exhibits agonist activity at kappa-opioid receptors.
22708686|a|BACKGROUND AND PURPOSE: Antidepressants are known to interact with the opioid system through mechanisms not completely understood. We previously reported that tricyclic antidepressants act as agonists at distinct opioid receptors. Here, we investigated the effect of the atypical antidepressant mianserin at cloned and native opioid receptors. EXPERIMENTAL APPROACH: Effects of mianserin were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPgammaS binding and MAPK phosphorylation. KEY RESULTS: Mianserin displayed 12- and 18-fold higher affinity for kappa- than micro- and delta-opioid receptors respectively. In [(35)S]GTPgammaS assays, mianserin selectively activated kappa-opioid receptors. The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI). The mianserin analogue mirtazapine also displayed kappa-opioid agonist activity. Mianserin and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by nor-BNI. In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and dynorphin A. When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A. CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors. Thus, this property appears to be a common feature of different classes of antidepressants.
22708686	1599	1615	[(35)S]GTPgammaS	CHEMICAL	22708686T10
22708686	250	259	tricyclic	CHEMICAL	22708686T11
22708686	1693	1704	dynorphin A	CHEMICAL	22708686T12
22708686	1763	1772	mianserin	CHEMICAL	22708686T13
22708686	386	395	mianserin	CHEMICAL	22708686T14
22708686	469	478	mianserin	CHEMICAL	22708686T15
22708686	672	688	[(35)S]GTPgammaS	CHEMICAL	22708686T16
22708686	736	745	Mianserin	CHEMICAL	5516
22708686	855	871	[(35)S]GTPgammaS	CHEMICAL	22708686T18
22708686	880	889	mianserin	CHEMICAL	22708686T19
22708686	1123	1132	Mianserin	CHEMICAL	5516
22708686	1011	1030	nor-binaltorphimine	CHEMICAL	22708686T20
22708686	1032	1039	nor-BNI	CHEMICAL	22708686T21
22708686	1046	1055	mianserin	CHEMICAL	22708686T22
22708686	1065	1076	mirtazapine	CHEMICAL	22708686T23
22708686	28	37	mianserin	CHEMICAL	22708686T24
22708686	1092	1104	kappa-opioid	GENE-Y	22708686T25
22708686	1159	1165	ERK1/2	GENE-N	22708686T26
22708686	1206	1228	kappa-opioid receptors	GENE-Y	22708686T27
22708686	1453	1465	kappa-opioid	GENE-Y	22708686T28
22708686	1491	1502	dynorphin A	GENE-Y	22708686T29
22708686	1137	1148	mirtazapine	CHEMICAL	22708686T2
22708686	1565	1586	kappa-opioid receptor	GENE-Y	22708686T30
22708686	1654	1657	p38	GENE-N	22708686T31
22708686	1658	1662	MAPK	GENE-N	22708686T32
22708686	1667	1673	ERK1/2	GENE-N	22708686T33
22708686	1693	1704	dynorphin A	GENE-Y	22708686T34
22708686	1792	1814	kappa-opioid receptors	GENE-Y	22708686T35
22708686	304	320	opioid receptors	GENE-N	22708686T36
22708686	417	433	opioid receptors	GENE-N	22708686T37
22708686	523	545	human opioid receptors	GENE-N	22708686T38
22708686	701	705	MAPK	GENE-N	22708686T39
22708686	1281	1288	nor-BNI	CHEMICAL	22708686T3
22708686	792	837	kappa- than micro- and delta-opioid receptors	GENE-N	22708686T40
22708686	912	934	kappa-opioid receptors	GENE-Y	22708686T41
22708686	990	1002	kappa-opioid	GENE-Y	22708686T42
22708686	67	89	kappa-opioid receptors	GENE-Y	22708686T43
22708686	1329	1338	mianserin	CHEMICAL	22708686T4
22708686	1350	1364	[35S]GTPgammaS	CHEMICAL	22708686T5
22708686	1378	1385	nor-BNI	CHEMICAL	22708686T6
22708686	1475	1486	(-)-U50,488	CHEMICAL	22708686T7
22708686	1491	1502	dynorphin A	CHEMICAL	22708686T8
22708686	1519	1528	mianserin	CHEMICAL	22708686T9
22708686	CPR:3	22708686T12	22708686T31
22708686	CPR:3	22708686T12	22708686T32
22708686	CPR:3	22708686T13	22708686T35
22708686	CPR:3	22708686T19	22708686T41
22708686	CPR:4	22708686T20	22708686T42
22708686	CPR:4	22708686T21	22708686T42
22708686	CPR:4	22708686T9	22708686T31
22708686	CPR:4	22708686T9	22708686T32
22708686	CPR:5	22708686T11	22708686T36
22708686	CPR:5	22708686T13	22708686T35
22708686	CPR:5	22708686T22	22708686T25
22708686	CPR:5	22708686T23	22708686T25
22708686	CPR:5	22708686T24	22708686T43
22708686	CPR:5	22708686T7	22708686T28
22708686	CPR:5	22708686T8	22708686T28
22708686	CPR:6	22708686T20	22708686T42
22708686	CPR:6	22708686T21	22708686T42
22708686	CPR:6	22708686T9	22708686T30

22718275|t|Lipid biomarkers of oxidative stress in a genetic mouse model of Smith-Lemli-Opitz syndrome.
22718275|a|7-Dehydrocholesterol (7-DHC) accumulates in tissues and fluids of patients with Smith-Lemli-Opitz syndrome (SLOS), which is caused by mutations in the gene encoding 3-hydroxysterol-(7)-reductase (DHCR7). We recently reported that 7-DHC is the most reactive lipid molecule toward free radical oxidation (lipid peroxidation) and 14 oxysterols have been identified as products of oxidation of 7-DHC in solution. As the high oxidizability of 7-DHC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a Dhcr7-KO mouse model of SLOS, including oxysterols, isoprostanes (IsoPs), and neuroprostanes (NeuroPs) that are formed from the oxidation of 7-DHC, arachidonic acid and docosahexaenoic acid, respectively. In addition to a previously described oxysterol, 3,5-dihydroxycholest-7-en-6-one (DHCEO), we provide evidence for the chemical structures of three new oxysterols in the brain and/or liver tissue of Dhcr7-KO mice, two of which were quantified. We find that levels of IsoPs and NeuroPs are also elevated in brain and/or liver tissues of Dhcr7-KO mice relative to matching WT mice. While IsoPs and NeuroPs have been established as a reliable measurement of lipid peroxidation and oxidative stress in vivo, we show that in this genetic SLOS mouse model, 7-DHC-derived oxysterols are present at much higher levels than IsoPs and NeuroPs and thus are better markers of lipid oxidation and related oxidative stress.
22718275	258	274	3-hydroxysterol	CHEMICAL	22718275T10
22718275	115	120	7-DHC	CHEMICAL	22718275T11
22718275	325	330	7-DHC	CHEMICAL	22718275T12
22718275	425	435	oxysterols	CHEMICAL	22718275T13
22718275	485	490	7-DHC	CHEMICAL	22718275T14
22718275	533	538	7-DHC	CHEMICAL	22718275T15
22718275	692	702	oxysterols	CHEMICAL	22718275T16
22718275	704	716	isoprostanes	CHEMICAL	22718275T17
22718275	718	723	IsoPs	CHEMICAL	22718275T18
22718275	730	744	neuroprostanes	CHEMICAL	22718275T19
22718275	93	113	7-Dehydrocholesterol	CHEMICAL	22718275T1
22718275	746	753	NeuroPs	CHEMICAL	22718275T20
22718275	793	798	7-DHC	CHEMICAL	22718275T21
22718275	800	816	arachidonic acid	CHEMICAL	22718275T22
22718275	821	841	docosahexaenoic acid	CHEMICAL	22718275T23
22718275	895	904	oxysterol	CHEMICAL	22718275T24
22718275	906	939	3,5-dihydroxycholest-7-en-6-one	CHEMICAL	22718275T25
22718275	941	946	DHCEO	CHEMICAL	22718275T26
22718275	1010	1020	oxysterols	CHEMICAL	22718275T27
22718275	1194	1199	Dhcr7	GENE-Y	199217
22718275	258	289	3-hydroxysterol-(7)-reductase	GENE-Y	22718275T29
22718275	1125	1130	IsoPs	CHEMICAL	22718275T2
22718275	291	296	DHCR7	GENE-Y	108063
22718275	652	657	Dhcr7	GENE-Y	199217
22718275	1057	1062	Dhcr7	GENE-Y	199217
22718275	1135	1142	NeuroPs	CHEMICAL	22718275T3
22718275	1244	1249	IsoPs	CHEMICAL	22718275T4
22718275	1254	1261	NeuroPs	CHEMICAL	22718275T5
22718275	1409	1414	7-DHC	CHEMICAL	22718275T6
22718275	1423	1433	oxysterols	CHEMICAL	22718275T7
22718275	1473	1478	IsoPs	CHEMICAL	22718275T8
22718275	1483	1490	NeuroPs	CHEMICAL	22718275T9

22798249|t|Correlation of high urinary Smad1 level with glomerular hyperfiltration in type 2 diabetes mellitus.
22798249|a|The aim of this study was to assess the relationship between urinary Smad1 and glomerular hyperfiltration (GHF) in type 2 diabetes mellitus (T2DM), and to explore the factors related to the urinary Smad1 in T2DM. The reference value of the estimated glomerular filtration rate (eGFR) was determined in 248 healthy individuals. 30 patients with GHF, 58 patients with norm-GFR T2DM, and 24 healthy patients who served as controls were recruited. Urinary Smad1, fasting plasma glucose (FPG), fasting serum C-Peptide (C-P), hemoglobin A1C (HbA1c), cystatin C, and other chemistry laboratory parameters of T2DM participants and controls were measured. Patients with GHF had higher levels of urinary Smad1 than the control group, and those with norm-GFR. For T2DM patients with body mass index, age, and gender adjustments, urinary Smad1 was positively correlated with FPG, HbA1C, and eGFR, but negatively correlated with fasting serum C-P. Multivariate linear regression analysis demonstrated that eGFR, HbA1C, and fasting serum C-P were independently associated with urinary Smad1. High levels of urinary Smad1 were found in GHF patients with T2DM, which may be another potential mechanism of GHF in relation to diabetic nephropathy.
22798249	637	642	HbA1c	GENE-Y	22798249T10
22798249	645	655	cystatin C	GENE-Y	22798249T11
22798249	795	800	Smad1	GENE-Y	201274|247700
22798249	170	175	Smad1	GENE-Y	201274|247700
22798249	927	932	Smad1	GENE-Y	201274|247700
22798249	969	974	HbA1C	GENE-Y	22798249T15
22798249	1031	1034	C-P	GENE-N	22798249T16
22798249	1100	1105	HbA1C	GENE-Y	22798249T17
22798249	28	33	Smad1	GENE-Y	201274|247700
22798249	575	582	glucose	CHEMICAL	22798249T1
22798249	1125	1128	C-P	GENE-Y	22798249T2
22798249	1172	1177	Smad1	GENE-Y	201274|247700
22798249	1202	1207	Smad1	GENE-Y	201274|247700
22798249	299	304	Smad1	GENE-Y	201274|247700
22798249	553	558	Smad1	GENE-Y	201274|247700
22798249	604	613	C-Peptide	GENE-Y	22798249T7
22798249	615	618	C-P	GENE-Y	22798249T8
22798249	621	635	hemoglobin A1C	GENE-Y	22798249T9

22824191|t|Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model.
22824191|a|Ageing is associated with a deterioration of cognitive performance and with increased risk of neurodegenerative disorders. Hypertension is the most-prevalent modifiable risk factor for cardiovascular morbidity and mortality worldwide, and clinical data suggest that hypertension is a risk factor for Alzheimer's disease (AD). In the present study we tested whether propranolol, a -receptor antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8). Propranolol administration (5 mg/kg for 3 weeks) to 6-month-old SAMP8 mice attenuated cognitive memory impairments shown by these mice in the novel object recognition test. In the hippocampus of SAMP8 mice it has been found increases in A(42) levels, the principal constituent of amyloid plaques observed in AD, accompanied by both an increased expression of the cleaving enzyme BACE1 and a decreased expression of the degrading enzyme IDE. All these effects were reversed by propranolol treatment. Tau hyperphosphorylation (PHF-1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of propranolol-treated mice, an effect probably related to a decrease in JNK1 expression. Interestingly, propranolol also phosphorylated Akt in SAMP8 mice, which was associated with an increase of glycogen synthase kinase-3 phosphorylation, contributing therefore to the reductions in Tau hyperphosphorylation. Synaptic pathology in SAMP8 mice, as shown by decreases in synaptophysin and BDNF, was also counteracted by propranolol treatment. Overall, propranolol might be beneficial in age-related brain dysfunction and could be an emerging candidate for the treatment of other neurodegenerative diseases. This article is part of a Special Issue entitled 'Cognitive Enhancers'.
22824191	1202	1205	Tau	GENE-Y	22824191T10
22824191	1386	1390	JNK1	GENE-Y	22824191T11
22824191	1450	1453	Akt	GENE-N	22824191T12
22824191	1510	1537	glycogen synthase kinase-3	GENE-Y	22824191T13
22824191	1599	1602	Tau	GENE-Y	22824191T14
22824191	1684	1697	synaptophysin	GENE-Y	22824191T15
22824191	1702	1706	BDNF	GENE-Y	107096
22824191	502	512	-receptor	GENE-N	22824191T17
22824191	939	945	A(42)	GENE-Y	22824191T18
22824191	983	990	amyloid	GENE-Y	22824191T19
22824191	1179	1190	propranolol	CHEMICAL	22824191T1
22824191	1082	1087	BACE1	GENE-Y	117154
22824191	53	60	amyloid	GENE-Y	22824191T21
22824191	65	68	Tau	GENE-Y	22824191T22
22824191	1316	1327	propranolol	CHEMICAL	22824191T2
22824191	1418	1429	propranolol	CHEMICAL	22824191T3
22824191	1733	1744	propranolol	CHEMICAL	22824191T4
22824191	1765	1776	propranolol	CHEMICAL	22824191T5
22824191	487	498	propranolol	CHEMICAL	22824191T6
22824191	702	713	Propranolol	CHEMICAL	561
22824191	0	11	Propranolol	CHEMICAL	561
22824191	1139	1142	IDE	GENE-Y	109642
22824191	CPR:6	22824191T6	22824191T17

22835278|t|Leydig cell hyperplasia and Leydig cell tumour in postmenopausal women: report of two cases.
22835278|a|Leydig cell hyperplasia and Leydig cell tumours of the ovary are rare. We present two cases in which patients had increased blood levels of testosterone and frank hirsutism. Imaging showed minimal abnormalities. After adrenal disease had been ruled out, they underwent a bilateral oophorectomy. One case showed a Leydig cell hyperplasia, the other a Leydig cell tumour. An androgen producing tumour should be excluded in every woman with evidence of hirsutism or frank virilization and markedly elevated testosterone levels. Adrenal disease with androgen hypersecretion can be suspected by detailed clinical, laboratory and radiologic imaging. Although DHEAS has a good sensitivity in the detection of adrenal origin of hyperandrogenism (and hence a good negative predictive value) it is not specific (specificity ranging from 85 to 98%). Imaging of the ovaries can be helpful but does not rule out ovarian disease if normal. Indeed, diffuse stromal Leydig cell hyperplasia and Leydig cell tumours (usually small) may escape imaging and in some cases diagnosis can only be made on pathology. As these clinical entities represent a diagnostic and therapeutic challenge, oophorectomy should be considered in postmenopausal women with hirsutism and elevated testosterone levels, after the exclusion of adrenal causes. The procedure is relatively safe and effective. Follow-up remains indicated.
22835278	1348	1360	testosterone	CHEMICAL	614
22835278	233	245	testosterone	CHEMICAL	614
22835278	466	474	androgen	CHEMICAL	22835278T3
22835278	597	609	testosterone	CHEMICAL	614
22835278	639	647	androgen	CHEMICAL	22835278T5
22835278	746	751	DHEAS	CHEMICAL	22835278T6

22862926|t|Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele.
22862926|a|We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production. All participants had a 3-h oral glucose tolerance test (OGTT), an intravenous glucose tolerance test and a euglycaemic, hyperinsulinaemic clamp. After adjustment for age and sex, risk T allele carriers had higher haemoglobin A1c levels (p = 0.030), reduced first-phase insulin response (p = 0.048), higher peripheral insulin sensitivity (p = 0.050) and lower fasting GIP concentrations (p = 0.003) than CC allele carriers. The latter was also reflected by lower total GIP secretion during the OGTT (p = 0.018). We found no significant differences in endogenous glucose production, hepatic insulin sensitivity or fasting concentrations of glucose, insulin, glucagon and GLP-1 between the groups. The findings suggest that the effect of TCF7L2 on diabetes risk may include reduced secretion of GIP.
22862926	225	254	transcription factor 7-like 2	GENE-Y	22862926T10
22862926	1253	1256	GIP	GENE-Y	108962
22862926	256	262	TCF7L2	GENE-Y	112795
22862926	292	299	insulin	GENE-Y	22862926T13
22862926	301	309	glucagon	GENE-Y	22862926T14
22862926	311	355	glucose-dependent insulinotropic polypeptide	GENE-Y	22862926T15
22862926	357	360	GIP	GENE-Y	108962
22862926	363	386	glucagon-like peptide-1	GENE-Y	22862926T17
22862926	388	393	GLP-1	GENE-Y	22862926T18
22862926	406	413	insulin	GENE-Y	22862926T19
22862926	311	318	glucose	CHEMICAL	22862926T1
22862926	674	689	haemoglobin A1c	GENE-Y	22862926T20
22862926	730	737	insulin	GENE-Y	22862926T21
22862926	778	785	insulin	GENE-Y	22862926T22
22862926	828	831	GIP	GENE-Y	108962
22862926	929	932	GIP	GENE-Y	108962
22862926	1050	1057	insulin	GENE-Y	22862926T25
22862926	1108	1115	insulin	GENE-Y	22862926T26
22862926	0	8	Incretin	GENE-Y	22862926T27
22862926	84	90	TCF7L2	GENE-Y	112795
22862926	441	448	glucose	CHEMICAL	22862926T2
22862926	493	500	glucose	CHEMICAL	22862926T3
22862926	539	546	glucose	CHEMICAL	22862926T4
22862926	1022	1029	glucose	CHEMICAL	22862926T5
22862926	1099	1106	glucose	CHEMICAL	22862926T6
22862926	1117	1125	glucagon	GENE-Y	22862926T7
22862926	1130	1135	GLP-1	GENE-Y	22862926T8
22862926	1196	1202	TCF7L2	GENE-Y	112795

22876943|t|Anti-inflammatory trends of 1, 3-diphenyl-2-propen-1-one derivatives.
22876943|a|Chalcones (1, 3-Diphenyl-2-propen-1-one) are constituted by a three carbon , -unsaturated carbonyl system. The biosynthesis of flavonoids and isoflavonoids is initiated by chalcones. Notable pharmacological activities of chalcones and its derivatives include anti-inflammatory, antifungal, antibacterial, antimalarial, antituberculosis, antitumor, antimicrobial and antiviral effects respectively. Owing to simplicity of the chemical structures and a huge variety of pharmacological actions exhibited, the entities derived from chalcones are subjected to extensive consideration. This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entities. Effect of chalcones on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.
22876943	777	786	chalcones	CHEMICAL	22876943T10
22876943	810	814	heme	CHEMICAL	22876943T11
22876943	145	170	, -unsaturated carbonyl	CHEMICAL	22876943T12
22876943	878	890	nitric oxide	CHEMICAL	22876943T13
22876943	892	894	NO	CHEMICAL	427
22876943	28	56	1, 3-diphenyl-2-propen-1-one	CHEMICAL	22876943T15
22876943	810	826	heme oxygenase 1	GENE-Y	22876943T16
22876943	827	831	HO-1	GENE-Y	22876943T17
22876943	834	848	cyclooxygenase	GENE-N	22876943T18
22876943	850	853	COX	GENE-N	22876943T19
22876943	70	79	Chalcones	CHEMICAL	22876943T1
22876943	856	869	interleukin 5	GENE-Y	22876943T20
22876943	871	875	IL-5	GENE-Y	22876943T21
22876943	81	109	1, 3-Diphenyl-2-propen-1-one	CHEMICAL	22876943T2
22876943	199	209	flavonoids	CHEMICAL	22876943T3
22876943	214	227	isoflavonoids	CHEMICAL	22876943T4
22876943	244	253	chalcones	CHEMICAL	22876943T5
22876943	293	302	chalcones	CHEMICAL	22876943T6
22876943	600	609	chalcones	CHEMICAL	22876943T7
22876943	731	739	chalcone	CHEMICAL	22876943T8
22876943	138	144	carbon	CHEMICAL	22876943T9

22884520|t|Oxysterol generation and liver X receptor-dependent reverse cholesterol transport: not all roads lead to Rome.
22884520|a|Cell cholesterol metabolism is a tightly regulated process, dependent in part on activation of nuclear liver X receptors (LXRs) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse cholesterol transport pathway. LXRs are thought to be activated predominantly by oxysterols generated enzymatically from cholesterol in different cell organelles. Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation. This block does not appear to be compensated by oxysterol production in other cell compartments. The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by LXR of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.
22884520	888	897	oxysterol	CHEMICAL	22884520T10
22884520	955	966	cholesterol	CHEMICAL	22884520T11
22884520	1009	1020	cholesterol	CHEMICAL	22884520T12
22884520	1077	1086	oxysterol	CHEMICAL	22884520T13
22884520	0	9	Oxysterol	CHEMICAL	22884520T14
22884520	60	71	cholesterol	CHEMICAL	22884520T15
22884520	1116	1119	LXR	GENE-N	22884520T16
22884520	233	237	LXRs	GENE-N	22884520T17
22884520	368	372	LXRs	GENE-N	22884520T18
22884520	601	622	sterol-27-hydroxylase	GENE-Y	22884520T19
22884520	299	310	cholesterol	CHEMICAL	22884520T1
22884520	693	696	LXR	GENE-N	22884520T20
22884520	922	925	LXR	GENE-N	22884520T21
22884520	206	231	nuclear liver X receptors	GENE-N	22884520T22
22884520	25	41	liver X receptor	GENE-N	22884520T23
22884520	337	348	cholesterol	CHEMICAL	22884520T2
22884520	418	428	oxysterols	CHEMICAL	22884520T3
22884520	458	469	cholesterol	CHEMICAL	22884520T4
22884520	539	550	cholesterol	CHEMICAL	22884520T5
22884520	601	607	sterol	CHEMICAL	22884520T6
22884520	116	127	cholesterol	CHEMICAL	22884520T7
22884520	659	668	oxysterol	CHEMICAL	22884520T8
22884520	772	781	oxysterol	CHEMICAL	22884520T9
22884520	CPR:3	22884520T10	22884520T21
22884520	CPR:3	22884520T3	22884520T18
22884520	CPR:9	22884520T8	22884520T19

22898132|t|Assessment of developmental delay in the zebrafish embryo teratogenicity assay.
22898132|a|In this study we analyzed some aspects of the assessment of developmental delay in the zebrafish embryotoxicity/teratogenicity test and explored the suitability of acetylcholinesterase (AChE) activity as a biochemical marker and as a higher throughput alternative to morphological endpoints such as head-trunk angle, tail length and morphological score. Embryos were exposed from 4 to 52 h post-fertilization (hpf) to a selection of known embryotoxic/teratogen compounds (valproic acid, retinoic acid, caffeine, sodium salicylate, glucose, hydroxyurea, methoxyacetic acid, boric acid and paraoxon-methyl) over a concentration range. They were evaluated for AChE activity, head-trunk angle, tail length and several qualitative parameters integrated in a morphological score. In general, the different patterns of the concentration-response curves allowed distinguishing between chemicals that produced growth retardation (valproic and methoxyacetic acid) and chemicals that produced non-growth-delay related malformations. An acceptable correlation between the morphological score, AChE activity and head-trunk angle as markers of developmental delay was observed, being AChE activity particularly sensitive to detect delay in the absence of malformations.
22898132	1001	1032	valproic and methoxyacetic acid	CHEMICAL	22898132T10
22898132	1161	1165	AChE	GENE-Y	22898132T11
22898132	1250	1254	AChE	GENE-Y	22898132T12
22898132	244	264	acetylcholinesterase	GENE-Y	22898132T13
22898132	266	270	AChE	GENE-Y	22898132T14
22898132	737	741	AChE	GENE-Y	22898132T15
22898132	552	565	valproic acid	CHEMICAL	22898132T1
22898132	567	580	retinoic acid	CHEMICAL	22898132T2
22898132	582	590	caffeine	CHEMICAL	22898132T3
22898132	592	609	sodium salicylate	CHEMICAL	22898132T4
22898132	611	618	glucose	CHEMICAL	22898132T5
22898132	620	631	hydroxyurea	CHEMICAL	22898132T6
22898132	633	651	methoxyacetic acid	CHEMICAL	22898132T7
22898132	653	663	boric acid	CHEMICAL	22898132T8
22898132	668	683	paraoxon-methyl	CHEMICAL	22898132T9

22898212|t|Cresyl saligenin phosphate makes multiple adducts on free histidine, but does not form an adduct on histidine 438 of human butyrylcholinesterase.
22898212|a|Cresyl saligenin phosphate (CBDP) is a suspected causative agent of "aerotoxic syndrome", affecting pilots, crew members and passengers. CBDP is produced in vivo from ortho-containing isomers of tricresyl phosphate (TCP), a component of jet engine lubricants and hydraulic fluids. CBDP irreversibly inhibits butyrylcholinesterase (BChE) in human plasma by forming adducts on the active site serine (Ser-198). Inhibited BChE undergoes aging to release saligenin and o-cresol. The active site histidine (His-438) was hypothesized to abstract o-hydroxybenzyl moiety from the initial adduct on Ser-198. Our goal was to test this hypothesis. Mass spectral analysis of CBDP-inhibited BChE digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438. Nevertheless, the nitrogen of the imidazole ring of free l-histidine formed a variety of adducts upon reaction with CBDP, including the o-hydroxybenzyl adduct, suggesting that histidine-CBDP adducts may form on other proteins.
22898212	597	606	saligenin	CHEMICAL	22898212T10
22898212	611	619	o-cresol	CHEMICAL	22898212T11
22898212	637	646	histidine	CHEMICAL	22898212T12
22898212	648	651	His	CHEMICAL	112
22898212	686	701	o-hydroxybenzyl	CHEMICAL	22898212T14
22898212	736	739	Ser	CHEMICAL	127
22898212	809	813	CBDP	CHEMICAL	22898212T16
22898212	843	846	Glu	CHEMICAL	136
22898212	859	874	o-hydroxybenzyl	CHEMICAL	22898212T18
22898212	895	901	lysine	CHEMICAL	22898212T19
22898212	146	172	Cresyl saligenin phosphate	CHEMICAL	22898212T1
22898212	954	957	His	CHEMICAL	112
22898212	981	989	nitrogen	CHEMICAL	22898212T21
22898212	997	1006	imidazole	CHEMICAL	22898212T22
22898212	1020	1031	l-histidine	CHEMICAL	22898212T23
22898212	1079	1083	CBDP	CHEMICAL	22898212T24
22898212	1099	1114	o-hydroxybenzyl	CHEMICAL	22898212T25
22898212	1139	1148	histidine	CHEMICAL	22898212T26
22898212	0	26	Cresyl saligenin phosphate	CHEMICAL	22898212T27
22898212	100	109	histidine	CHEMICAL	22898212T28
22898212	58	67	histidine	CHEMICAL	22898212T29
22898212	1149	1153	CBDP	CHEMICAL	22898212T2
22898212	454	475	butyrylcholinesterase	GENE-Y	22898212T30
22898212	477	481	BChE	GENE-Y	22898212T31
22898212	565	569	BChE	GENE-Y	22898212T32
22898212	824	828	BChE	GENE-Y	22898212T33
22898212	117	144	human butyrylcholinesterase	GENE-Y	22898212T34
22898212	283	287	CBDP	CHEMICAL	22898212T3
22898212	341	360	tricresyl phosphate	CHEMICAL	22898212T4
22898212	362	365	TCP	CHEMICAL	1460
22898212	427	431	CBDP	CHEMICAL	22898212T6
22898212	174	178	CBDP	CHEMICAL	22898212T7
22898212	537	543	serine	CHEMICAL	22898212T8
22898212	545	548	Ser	CHEMICAL	127
22898212	CPR:4	22898212T16	22898212T33
22898212	CPR:4	22898212T6	22898212T30
22898212	CPR:4	22898212T6	22898212T31

22898566|t|The role of long chain omega-3 polyunsaturated fatty acids in reducing lipid peroxidation among elderly patients with mild cognitive impairment: a case-control study.
22898566|a|The present work explores the effect of dietary omega-3 polyunsaturated fatty acids (PUFAs) intake on lipid peroxidation among mild cognitive impairment (MCI) patients. The plasma lipid hydroperoxide (LPO) levels in 67 MCI patients were compared to those of 134 healthy elderly controls. Omega-3 PUFA intake was assessed using an interviewer-administered food frequency questionnaire. Apolipoprotein E genotyping was performed using polymerase chain reaction and restriction enzyme digestion. The association between various confounders and lipid peroxidation was evaluated using regression analysis. The influence of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) intake on LPO level was investigated. The results revealed that LPO levels were significantly higher in the MCI group than in the control group. Inverse correlations were found between DHA and EPA intake and LPO level among the MCI group. LPO levels decreased significantly with increasing DHA and EPA intake. In summary, the findings revealed that DHA and EPA can play a role in alleviating oxidative stress and reducing the risk of neurodegenerative diseases.
22898566	252	257	PUFAs	CHEMICAL	22898566T10
22898566	1029	1032	DHA	CHEMICAL	22898566T11
22898566	1037	1040	EPA	CHEMICAL	153
22898566	1134	1137	DHA	CHEMICAL	22898566T13
22898566	1142	1145	EPA	CHEMICAL	153
22898566	23	58	omega-3 polyunsaturated fatty acids	CHEMICAL	22898566T15
22898566	552	568	Apolipoprotein E	GENE-Y	22898566T16
22898566	1193	1196	DHA	CHEMICAL	22898566T1
22898566	1201	1204	EPA	CHEMICAL	153
22898566	353	366	hydroperoxide	CHEMICAL	22898566T3
22898566	455	467	Omega-3 PUFA	CHEMICAL	22898566T4
22898566	215	250	omega-3 polyunsaturated fatty acids	CHEMICAL	22898566T5
22898566	785	805	docosahexaenoic acid	CHEMICAL	22898566T6
22898566	807	810	DHA	CHEMICAL	22898566T7
22898566	816	837	eicosapentaenoic acid	CHEMICAL	22898566T8
22898566	839	842	EPA	CHEMICAL	153

22902329|t|Vitamin E deficiency impairs the somatostatinergic receptor-effector system and leads to phosphotyrosine phosphatase overactivation and cell death in the rat hippocampus.
22902329|a|Vitamin E plays an essential role in maintaining the structure and function of the nervous system, and its deficiency, commonly associated with fat malabsorption diseases, may reduce neuronal survival. We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by -tocopherol in the rat dentate gyrus, increasing cyclic adenosine monophosphate response element binding protein phosphorylation. To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the somatostatin signaling pathway and neuronal survival in the rat hippocampus. No changes in somatostatin expression were detected in vitamin-E-deficient rats. These rats, however, showed a significant increase in the somatostatin receptor density and dissociation constant, which correlated with a significant increase in the protein levels of somatostatin receptors. Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing Gi protein functionality. Furthermore, vitamin E deficiency significantly increased phosphotyrosine phosphatase activity and PTP expression, as well as PKC activation, and decreased extracellular-signal-regulated kinase phosphorylation. All these changes were accompanied by an increase in neuronal cell death. Subsequent -tocopherol administration partially or completely reversed all these values to control levels. Altogether, our results prove the importance of vitamin E homeostasis in the somatostatin receptor-effector system and suggest a possible mechanism by which this vitamin may regulate the neuronal cell survival in the adult hippocampus.
22902329	1885	1894	vitamin E	CHEMICAL	22902329T10
22902329	1914	1926	somatostatin	CHEMICAL	22902329T11
22902329	496	508	-tocopherol	CHEMICAL	22902329T12
22902329	546	576	cyclic adenosine monophosphate	CHEMICAL	22902329T13
22902329	686	697	tocopherols	CHEMICAL	22902329T14
22902329	725	734	vitamin E	CHEMICAL	22902329T15
22902329	736	748	somatostatin	CHEMICAL	22902329T16
22902329	854	864	tocopherol	CHEMICAL	22902329T17
22902329	872	884	somatostatin	CHEMICAL	22902329T18
22902329	963	975	somatostatin	CHEMICAL	22902329T19
22902329	171	180	Vitamin E	CHEMICAL	157
22902329	1004	1013	vitamin-E	CHEMICAL	22902329T20
22902329	1088	1100	somatostatin	CHEMICAL	22902329T21
22902329	0	9	Vitamin E	CHEMICAL	157
22902329	89	104	phosphotyrosine	CHEMICAL	22902329T23
22902329	1215	1237	somatostatin receptors	GENE-N	22902329T24
22902329	1302	1324	somatostatin receptors	GENE-N	22902329T25
22902329	1373	1400	phosphotyrosine phosphatase	GENE-N	22902329T26
22902329	1416	1426	Gi protein	GENE-N	22902329T27
22902329	1500	1527	phosphotyrosine phosphatase	GENE-N	22902329T28
22902329	1541	1545	PTP	GENE-Y	22902329T29
22902329	1215	1227	somatostatin	CHEMICAL	22902329T2
22902329	1569	1573	PKC	GENE-Y	22902329T30
22902329	1600	1637	extracellular-signal-regulated kinase	GENE-N	22902329T31
22902329	1914	1935	somatostatin receptor	GENE-N	22902329T32
22902329	546	609	cyclic adenosine monophosphate response element binding protein	GENE-N	22902329T33
22902329	736	748	somatostatin	GENE-Y	22902329T34
22902329	872	884	somatostatin	GENE-Y	22902329T35
22902329	963	975	somatostatin	GENE-Y	22902329T36
22902329	1088	1109	somatostatin receptor	GENE-N	22902329T37
22902329	33	59	somatostatinergic receptor	GENE-N	22902329T38
22902329	89	116	phosphotyrosine phosphatase	GENE-N	22902329T39
22902329	1253	1262	vitamin E	CHEMICAL	22902329T3
22902329	1302	1314	somatostatin	CHEMICAL	22902329T4
22902329	1352	1360	adenylyl	CHEMICAL	22902329T5
22902329	1373	1388	phosphotyrosine	CHEMICAL	22902329T6
22902329	1455	1464	vitamin E	CHEMICAL	22902329T7
22902329	1500	1515	phosphotyrosine	CHEMICAL	22902329T8
22902329	1740	1752	-tocopherol	CHEMICAL	22902329T9
22902329	CPR:3	22902329T12	22902329T33

22918703|t|CCAAT/Enhancer-binding protein-homologous protein sensitizes to SU5416 by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.
22918703|a|SU5416, vascular endothelial cell growth factor receptor inhibitor, suppresses hypoxia-induced angiogenesis, growth, proliferation, and metastasis in cancer cells. CCAAT/enhancer-binding protein-homologous protein (CHOP) has pivotal roles in regulation of growth and survival. In the present study, we evaluated the effects of SU5416 on cell survival, p21, and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells. Moreover, we investigated the roles of CHOP in cell survival under condition of SU5416 treatment in FRO ATC cells. After SU5416 treatment, cell viability, PARP-1, and caspase-3 protein levels were not changed. p53 and p27 protein levels decreased while p21 protein levels increased. Phospho-Akt protein levels were not altered. In SU5416-treated situation, cell viability was not different before and after administration of either p21 siRNA or LY294002 whereas it was lessened after co-administration of p21 siRNA and LY294002. Compared to SU5416 treatment alone, cell viability was reduced with CHOP plasmid but it was unchanged with CHOP siRNA. PARP-1 and caspase-3 protein levels with CHOP plasmid were elevated whereas the protein levels with CHOP siRNA were similar. While CHOP plasmid transfection diminished p21 and phospho-Akt protein levels, CHOP siRNA transfection did not alter the protein levels. In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to SU5416 thereby inhibiting cell survival by modulating p21 and PI3K/Akt signal pathway. Furthermore, these findings imply that CHOP may be a possible candidate as the chemosensitizing factor for induction of cytotoxicity in ATC cells exposed to SU5416.
22918703	1039	1047	LY294002	CHEMICAL	22918703T10
22918703	1113	1121	LY294002	CHEMICAL	22918703T11
22918703	1135	1141	SU5416	CHEMICAL	22918703T12
22918703	64	70	SU5416	CHEMICAL	22918703T13
22918703	1191	1195	CHOP	GENE-Y	22918703T14
22918703	1230	1234	CHOP	GENE-Y	22918703T15
22918703	1242	1248	PARP-1	GENE-N	22918703T16
22918703	1253	1262	caspase-3	GENE-N	22918703T17
22918703	1283	1287	CHOP	GENE-Y	22918703T18
22918703	1342	1346	CHOP	GENE-Y	22918703T19
22918703	160	166	SU5416	CHEMICAL	22918703T1
22918703	1373	1377	CHOP	GENE-Y	22918703T20
22918703	1410	1413	p21	GENE-Y	22918703T21
22918703	1418	1429	phospho-Akt	GENE-N	22918703T22
22918703	1446	1450	CHOP	GENE-Y	22918703T23
22918703	1546	1550	CHOP	GENE-Y	22918703T24
22918703	1636	1639	p21	GENE-Y	22918703T25
22918703	1644	1648	PI3K	GENE-N	22918703T26
22918703	1649	1652	Akt	GENE-N	22918703T27
22918703	1708	1712	CHOP	GENE-Y	22918703T28
22918703	324	373	CCAAT/enhancer-binding protein-homologous protein	GENE-Y	22918703T29
22918703	1418	1425	phospho	CHEMICAL	22918703T2
22918703	375	379	CHOP	GENE-Y	22918703T30
22918703	512	515	p21	GENE-Y	22918703T31
22918703	521	525	PI3K	GENE-N	22918703T32
22918703	526	529	Akt	GENE-N	22918703T33
22918703	633	637	CHOP	GENE-Y	22918703T34
22918703	749	755	PARP-1	GENE-Y	22918703T35
22918703	761	770	caspase-3	GENE-Y	22918703T36
22918703	804	807	p53	GENE-Y	77545
22918703	812	815	p27	GENE-Y	22918703T38
22918703	847	850	p21	GENE-Y	22918703T39
22918703	1582	1588	SU5416	CHEMICAL	22918703T3
22918703	877	888	Phospho-Akt	GENE-N	22918703T40
22918703	1026	1029	p21	GENE-Y	22918703T41
22918703	1099	1102	p21	GENE-Y	22918703T42
22918703	0	49	CCAAT/Enhancer-binding protein-homologous protein	GENE-Y	22918703T43
22918703	85	88	p21	GENE-Y	22918703T44
22918703	93	97	PI3K	GENE-N	22918703T45
22918703	98	101	Akt	GENE-N	22918703T46
22918703	1826	1832	SU5416	CHEMICAL	22918703T4
22918703	487	493	SU5416	CHEMICAL	22918703T5
22918703	674	680	SU5416	CHEMICAL	22918703T6
22918703	715	721	SU5416	CHEMICAL	22918703T7
22918703	877	884	Phospho	CHEMICAL	22918703T8
22918703	925	931	SU5416	CHEMICAL	22918703T9

22926699|t|An overview of transcriptional regulation in response to toxicological insult.
22926699|a|The completion of the human genome project and the subsequent advent of DNA microarray and high-throughput sequencing technologies have led to a renaissance in molecular toxicology. Toxicogenomic data sets, from both in vivo and in vitro studies, are growing exponentially, providing a wealth of information on regulation of stress pathways at the transcriptome level. Through such studies, we are now beginning to appreciate the diversity and complexity of biological responses to xenobiotics. In this review, we aim to consolidate and summarise the major toxicologically relevant transcription factor-governed molecular pathways. It is becoming clear that different chemical entities can cause oxidative, genotoxic and proteotoxic stress, which induce cellular responses in an effort to restore homoeostasis. Primary among the response pathways involved are NFE2L2 (Nrf2), NFE2L1 (Nrf1), p53, heat shock factor and the unfolded protein response. Additionally, more specific mechanisms exist where xenobiotics act as ligands, including the aryl hydrocarbon receptor, metal-responsive transcription factor-1 and the nuclear receptor family of transcription factors. Other pathways including the immunomodulatory transcription factors NF-B and STAT together with the hypoxia-inducible transcription factor HIF are also implicated in cellular responses to xenobiotic exposure. A less specific but equally important aspect to cellular injury controlled by transcriptional activity is loss of tissue-specific gene expression, resulting in dedifferentiation of target cells and compromise of tissue function. Here, we review these pathways and the genes they regulate in order to provide an overview of this growing field of molecular toxicology.
22926699	947	951	Nrf2	GENE-Y	22926699T10
22926699	954	960	NFE2L1	GENE-Y	110851
22926699	962	966	Nrf1	GENE-Y	201845
22926699	969	972	p53	GENE-Y	77545
22926699	974	991	heat shock factor	GENE-N	22926699T14
22926699	1120	1136	aryl hydrocarbon	CHEMICAL	22926699T1
22926699	1120	1145	aryl hydrocarbon receptor	GENE-Y	22926699T2
22926699	1147	1186	metal-responsive transcription factor-1	GENE-Y	22926699T3
22926699	1195	1211	nuclear receptor	GENE-N	22926699T4
22926699	1313	1318	NF-B	GENE-N	22926699T5
22926699	1323	1327	STAT	GENE-N	22926699T6
22926699	1346	1384	hypoxia-inducible transcription factor	GENE-N	22926699T7
22926699	1385	1388	HIF	GENE-N	22926699T8
22926699	939	945	NFE2L2	GENE-Y	110852

22931533|t|Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease.
22931533|a|Morphinans have a storied history in medicinal chemistry as pain management drugs but have received attention as modulators of cholinergic signaling for the treatment of Alzheimer's Disease (AD). Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids. The structurally diverse opioids codeine and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development. In accordance with the emerging repurposing trend of evaluating known compounds for novel pharmacological activity, ongoing research on augmentation of cholinergic signaling that has been aided by the use of opioids will be reviewed.
22931533	410	443	nicotinic acetylcholine receptors	GENE-N	22931533T10
22931533	445	450	nAChR	GENE-N	22931533T11
22931533	613	618	nAChR	GENE-N	22931533T12
22931533	665	669	AChE	GENE-Y	22931533T13
22931533	723	728	nAChR	GENE-N	22931533T14
22931533	26	41	opioid receptor	GENE-N	22931533T15
22931533	97	107	Morphinans	CHEMICAL	22931533T1
22931533	293	304	Galantamine	CHEMICAL	664
22931533	420	433	acetylcholine	CHEMICAL	22931533T3
22931533	505	514	morphinan	CHEMICAL	22931533T4
22931533	563	570	codeine	CHEMICAL	22931533T5
22931533	575	584	eseroline	CHEMICAL	22931533T6
22931533	591	602	galantamine	CHEMICAL	22931533T7
22931533	334	354	acetylcholinesterase	GENE-Y	22931533T8
22931533	356	360	AChE	GENE-Y	22931533T9
22931533	CPR:4	664	22931533T8
22931533	CPR:4	664	22931533T9

22931535|t|Adhesion of osteoblasts to a vertically aligned TiO2 nanotube surface.
22931535|a|The adhesion of cells to vertically aligned TiO2 nanotubes is reviewed. The attraction between a negatively charged nanotube surface and a negatively charged osteoblast is facilitated by charged protein-mediators like proteins with a quadrupolar internal charge distribution, fibronectin and vitronectin. It is shown that adhesion and spreading of osteoblasts on vertically aligned TiO2 nanotube surfaces depend on the diameter of the nanotubes. Apparently, a small diameter nanotube surface has on average more sharp convex edges per unit area than a large one, leading to stronger binding affinity on its surface.
22931535	453	457	TiO2	CHEMICAL	22931535T1
22931535	115	119	TiO2	CHEMICAL	22931535T2
22931535	48	52	TiO2	CHEMICAL	22931535T3
22931535	347	358	fibronectin	GENE-Y	22931535T4
22931535	363	374	vitronectin	GENE-Y	22931535T5

22946701|t|Abnormal uterine bleeding and dysfunctional uterine bleeding in pediatric and adolescent gynecology.
22946701|a|Abnormal uterine bleeding (AUB), which is defined as excessively heavy, prolonged and/or frequent bleeding of uterine origin, is a frequent cause of visits to the Emergency Department and/or health care provider. While there are many etiologies of AUB, the one most likely among otherwise healthy adolescents is dysfunctional uterine bleeding (DUB), which is characterizing any AUB when all possible underlying pathologic causes have been previously excluded. The most common cause of DUB in adolescence is anovulation, which is very frequent in the first 2-3 post-menarchal years and is associated with immaturity of the hypothalamic - pituitary - ovarian axis. Management of AUB is based on the underlying etiology and the severity of the bleeding and primary goals are prevention of complications, such as anemia and reestablishment of regular cyclical bleeding, while the management of DUB can in part be directed by the amount of flow, the degree of associated anemia, as well as patient and family comfort with different treatment modalities. Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic), GnRH analogues, Danazol and Levonorgestrel releasing intra uterine system (LNG IUS).
22946701	1218	1230	progestogens	CHEMICAL	22946701T1
22946701	1280	1295	tranexamic acid	CHEMICAL	295
22946701	1317	1321	GnRH	CHEMICAL	634
22946701	1333	1340	Danazol	CHEMICAL	1355
22946701	1345	1359	Levonorgestrel	CHEMICAL	359
22946701	1317	1321	GnRH	GENE-Y	22946701T6

22967140|t|Role of oestrogen receptors on the modulation of NADPH-diaphorase-positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats.
22967140|a|Modulation of the nitric oxide producing system (demonstrated via the NADPH-diaphorase histochemical reaction) by oestradiol has been established in several structures of the rat brain. The present study aimed to explore the possible regulation of NADPH-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ER and ER) in this regulation. Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER agonist-PPT [4,4',4-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol). The number of NADPH-diaphorase positive elements in the SON and the PVN was modulated by both ERs but, depending on the nucleus, ER and ER ligands induced different effects. These results suggest that the regulation of nitrergic system by ERs may play a role in the control of oestrogen-dependent physiological mechanisms regulated by the SON and the PVN.
22967140	816	819	DPN	CHEMICAL	22967140T10
22967140	821	859	2,3-bis(4-hydroxyphenyl)-propionitrile	CHEMICAL	22967140T11
22967140	229	234	NADPH	CHEMICAL	22967140T12
22967140	889	892	MPP	CHEMICAL	22967140T13
22967140	894	960	1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol	CHEMICAL	22967140T14
22967140	962	989	1H-pyrazole dihydrochloride	CHEMICAL	22967140T15
22967140	1021	1026	PHTPP	CHEMICAL	22967140T16
22967140	1028	1100	4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol	CHEMICAL	22967140T17
22967140	1117	1122	NADPH	CHEMICAL	22967140T18
22967140	49	54	NADPH	CHEMICAL	22967140T19
22967140	273	283	oestradiol	CHEMICAL	22967140T1
22967140	8	17	oestrogen	CHEMICAL	22967140T20
22967140	1197	1200	ERs	GENE-Y	22967140T21
22967140	1232	1235	ER	GENE-Y	22967140T22
22967140	1240	1243	ER	GENE-Y	22967140T23
22967140	1344	1347	ERs	GENE-Y	22967140T24
22967140	407	423	NADPH-diaphorase	GENE-N	22967140T25
22967140	532	551	oestrogen receptors	GENE-Y	22967140T26
22967140	553	556	ER	GENE-Y	22967140T27
22967140	561	564	ER	GENE-Y	22967140T28
22967140	718	721	ER	GENE-Y	22967140T29
22967140	1382	1391	oestrogen	CHEMICAL	22967140T2
22967140	804	807	ER	GENE-Y	22967140T30
22967140	229	245	NADPH-diaphorase	GENE-N	22967140T31
22967140	874	877	ER	GENE-Y	22967140T32
22967140	1006	1009	ER	GENE-Y	22967140T33
22967140	1117	1133	NADPH-diaphorase	GENE-N	22967140T34
22967140	49	65	NADPH-diaphorase	GENE-N	22967140T35
22967140	8	27	oestrogen receptors	GENE-Y	22967140T36
22967140	177	189	nitric oxide	CHEMICAL	22967140T3
22967140	407	412	NADPH	CHEMICAL	22967140T4
22967140	436	446	oestradiol	CHEMICAL	22967140T5
22967140	532	541	oestrogen	CHEMICAL	22967140T6
22967140	694	704	oestradiol	CHEMICAL	22967140T7
22967140	730	733	PPT	CHEMICAL	1167
22967140	735	789	4,4',4-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol	CHEMICAL	22967140T9
22967140	CPR:5	22967140T10	22967140T30
22967140	CPR:5	22967140T11	22967140T30
22967140	CPR:5	1167	22967140T29
22967140	CPR:5	22967140T9	22967140T29
22967140	CPR:6	22967140T13	22967140T32
22967140	CPR:6	22967140T14	22967140T32
22967140	CPR:6	22967140T15	22967140T32
22967140	CPR:6	22967140T16	22967140T33
22967140	CPR:6	22967140T17	22967140T33
22967140	CPR:9	22967140T3	22967140T31

22981459|t|Human plasma-derived BuChE as a stoichiometric bioscavenger for treatment of nerve agent poisoning.
22981459|a|Potent organophosphorous (OP) agents, such as VX, are hazardous by absorption through the skin and are resistant to conventional pharmacological antidotal treatments. The residence time of a stoichiometric bioscavenger, human butyrylcholinesterase (huBuChE), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs (oxime, anti-muscarinic, anticonvulsant). Intramuscular (i.m.) huBuChE afforded almost complete protection when administered prior to the onset of observable cholinergic signs of VX poisoning, but once signs of poisoning became evident the efficacy of i.m. huBuChE decreased. A combination of nerve agent therapy drugs (oxime, anti-muscarinic, anticonvulsant) with huBuChE (i.m.) protected 100% (8/8) of guinea-pigs from a lethal dose of VX (0.74mg/kg) to 48h, even when administered on signs of poisoning. Survival was presumed to be due to immediate alleviation of the cholinergic crisis by the conventional pharmacological treatment drugs, in conjunction with bioscavenger that prevented further absorbed agent reaching the AChE targets. Evidence to support this proposed mechanism of action was obtained from PKPD experiments in which multiple blood samples and microdialysate samples were collected from individual conscious ambulatory animals. Plasma concentrations of intramuscularly-administered atropine, diazepam and HI-6 reached a peak within 15min and were eliminated rapidly within 4h. Plasma concentrations of huBuChE administered by the i.m. route took approximately 24h to reach a peak, but were well-maintained over the subsequent 7days. Thus, the pharmacological therapy rapidly treated the initial signs of poisoning, whilst the bioscavenger provided prolonged protection by neutralising further nerve agent entering the bloodstream and preventing it from reaching the target organs.
22981459	349	356	huBuChE	GENE-Y	22981459T10
22981459	526	533	huBuChE	GENE-Y	22981459T11
22981459	720	727	huBuChE	GENE-Y	22981459T12
22981459	828	835	huBuChE	GENE-Y	22981459T13
22981459	0	26	Human plasma-derived BuChE	GENE-Y	22981459T14
22981459	1467	1475	atropine	CHEMICAL	22981459T1
22981459	1477	1485	diazepam	CHEMICAL	22981459T2
22981459	1490	1494	HI-6	CHEMICAL	22981459T3
22981459	464	469	oxime	CHEMICAL	22981459T4
22981459	783	788	oxime	CHEMICAL	22981459T5
22981459	107	124	organophosphorous	CHEMICAL	22981459T6
22981459	1190	1194	AChE	GENE-Y	22981459T7
22981459	1587	1594	huBuChE	GENE-Y	22981459T8
22981459	320	347	human butyrylcholinesterase	GENE-Y	22981459T9

22982206|t|Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2/CHOP-dependent manner.
22982206|a|Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the most promising candidates for new cancer therapeutics. However, resistance to TRAIL in some cancers remains a current problem in recent. The protein-folding compartment of the endoplasmic reticulum (ER) is particularly sensitive to disturbances, which, if severe, may trigger apoptosis. Therefore, we examined whether verrucarin A (VA) sensitize TRAIL-induced apoptosis in cancer cells by induction of ER stress. We first found that VA induces a major molecule of ER stress, CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 induction and subsequently increases TRAIL-induced cleavage of caspases and PARP in TRAIL-resistant Hep3B cells. Importantly, the transient knockdown using siRNA for CHOP abrogated VA-induced DR5 expression and attenuated TRAIL-induced apoptosis. Treatment with VA also increased the levels of phosphorylation of eukaryotic translation initiation factor-2 (eIF2), which is a common cellular response of ER stress. Furthermore, salubrinal, a specific eIF2 phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA. In contrast, transfection of mutant-eIF2 significantly reversed VA-induced apoptosis with downregulation of CHOP-dependent DR5 expression. Therefore, VA-induced eIF2 phosphorylation seemed to be important for CHOP and DR5 upregulation and TRAIL-induced apoptosis. In addition, generation of reactive oxygen species (ROS) is an effector molecular in sensitization of VA-induced ER stress. We concluded that VA triggers TRAIL-induced apoptosis by eIF2/CHOP-dependent DR5 induction via ROS generation.
22982206	1391	1395	CHOP	GENE-Y	22982206T10
22982206	1406	1409	DR5	GENE-Y	22982206T11
22982206	1444	1449	eIF2	GENE-Y	22982206T12
22982206	1493	1497	CHOP	GENE-Y	22982206T13
22982206	1502	1505	DR5	GENE-Y	22982206T14
22982206	1523	1528	TRAIL	GENE-Y	22982206T15
22982206	267	272	TRAIL	GENE-Y	22982206T16
22982206	1702	1707	TRAIL	GENE-Y	22982206T17
22982206	1729	1734	eIF2	GENE-Y	22982206T18
22982206	1735	1739	CHOP	GENE-Y	22982206T19
22982206	1164	1174	salubrinal	CHEMICAL	22982206T1
22982206	1750	1753	DR5	GENE-Y	22982206T20
22982206	535	540	TRAIL	GENE-Y	22982206T21
22982206	664	713	CCAAT/enhancer binding protein homologous protein	GENE-Y	22982206T22
22982206	168	173	TRAIL	GENE-Y	22982206T23
22982206	715	719	CHOP	GENE-Y	22982206T24
22982206	731	734	DR5	GENE-N	22982206T25
22982206	772	777	TRAIL	GENE-Y	22982206T26
22982206	798	806	caspases	GENE-N	22982206T27
22982206	811	815	PARP	GENE-N	22982206T28
22982206	819	824	TRAIL	GENE-Y	22982206T29
22982206	1584	1590	oxygen	CHEMICAL	22982206T2
22982206	901	905	CHOP	GENE-Y	22982206T30
22982206	927	930	DR5	GENE-Y	22982206T31
22982206	957	962	TRAIL	GENE-Y	22982206T32
22982206	1048	1091	eukaryotic translation initiation factor-2	GENE-Y	22982206T33
22982206	1093	1098	eIF2	GENE-Y	22982206T34
22982206	24	29	TRAIL	GENE-Y	22982206T35
22982206	72	75	DR5	GENE-Y	22982206T36
22982206	82	87	eIF2	GENE-Y	22982206T37
22982206	88	92	CHOP	GENE-Y	22982206T38
22982206	507	519	verrucarin A	CHEMICAL	22982206T3
22982206	0	12	Verrucarin A	CHEMICAL	22982206T4
22982206	111	166	Tumor necrosis factor-related apoptosis-inducing ligand	GENE-Y	22982206T5
22982206	1187	1192	eIF2	GENE-Y	22982206T6
22982206	1235	1239	CHOP	GENE-Y	22982206T7
22982206	1244	1247	DR5	GENE-Y	22982206T8
22982206	1318	1323	eIF2	GENE-Y	22982206T9
22982206	CPR:3	22982206T1	22982206T6
22982206	CPR:3	22982206T1	22982206T7
22982206	CPR:3	22982206T1	22982206T8
22982206	CPR:3	22982206T4	22982206T36
22982206	CPR:3	22982206T4	22982206T37
22982206	CPR:3	22982206T4	22982206T38

22991293|t|Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia.
22991293|a|X-linked hypophosphatemia (XLH/HYP)-with renal phosphate wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the zinc-metallopeptidase PHEX gene (phosphate-regulating gene with homologies to endopeptidase on the X chromosome). PHEX is highly expressed by mineralized tissue cells. Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic serine- and aspartate-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand N-linked glycoproteins). Although the latter observation suggests a local, direct matrix effect for PHEX, its physiologically relevant substrate protein(s) have not been identified. Here, we investigated two SIBLING proteins containing the ASARM motif-osteopontin (OPN) and bone sialoprotein (BSP)-as potential substrates for PHEX. Using cleavage assays, gel electrophoresis, and mass spectrometry, we report that OPN is a full-length protein substrate for PHEX. Degradation of OPN was essentially complete, including hydrolysis of the ASARM motif, resulting in only very small residual fragments. Western blotting of Hyp (the murine homolog of human XLH) mouse bone extracts having no PHEX activity clearly showed accumulation of an 35kDa OPN fragment that was not present in wild-type mouse bone. Immunohistochemistry and immunogold labeling (electron microscopy) for OPN in Hyp bone likewise showed an accumulation of OPN and/or its fragments compared with normal wild-type bone. Incubation of Hyp mouse bone extracts with PHEX resulted in the complete degradation of these fragments. In conclusion, these results identify full-length OPN and its fragments as novel, physiologically relevant substrates for PHEX, suggesting that accumulation of mineralization-inhibiting OPN fragments may contribute to the mineralization defect seen in the osteomalacic bone characteristic of XLH/HYP.
22991293	1321	1325	PHEX	GENE-Y	111270
22991293	1342	1345	OPN	GENE-Y	22991293T11
22991293	1400	1411	ASARM motif	GENE-N	22991293T12
22991293	1482	1485	Hyp	GENE-Y	22991293T13
22991293	1509	1518	human XLH	GENE-Y	22991293T14
22991293	1550	1554	PHEX	GENE-Y	111270
22991293	1606	1609	OPN	GENE-Y	22991293T16
22991293	302	323	zinc-metallopeptidase	GENE-N	22991293T17
22991293	1736	1739	OPN	GENE-Y	22991293T18
22991293	1787	1790	OPN	GENE-Y	22991293T19
22991293	302	306	zinc	CHEMICAL	22991293T1
22991293	324	328	PHEX	GENE-Y	111270
22991293	1892	1896	PHEX	GENE-Y	111270
22991293	2004	2007	OPN	GENE-Y	22991293T22
22991293	2076	2080	PHEX	GENE-Y	111270
22991293	2140	2143	OPN	GENE-Y	22991293T24
22991293	380	393	endopeptidase	GENE-N	22991293T25
22991293	416	420	PHEX	GENE-Y	111270
22991293	496	500	PHEX	GENE-Y	111270
22991293	666	705	acidic serine- and aspartate-rich motif	GENE-N	22991293T28
22991293	707	712	ASARM	GENE-N	22991293T29
22991293	335	344	phosphate	CHEMICAL	22991293T2
22991293	817	824	SIBLING	GENE-N	22991293T30
22991293	833	886	small, integrin-binding ligand N-linked glycoproteins	GENE-N	22991293T31
22991293	964	968	PHEX	GENE-Y	111270
22991293	1072	1079	SIBLING	GENE-N	22991293T33
22991293	1104	1115	ASARM motif	GENE-N	22991293T34
22991293	1116	1127	osteopontin	GENE-Y	22991293T35
22991293	1129	1132	OPN	GENE-Y	22991293T36
22991293	1138	1155	bone sialoprotein	GENE-Y	22991293T37
22991293	26	37	osteopontin	GENE-Y	22991293T38
22991293	41	45	PHEX	GENE-Y	111270
22991293	201	210	phosphate	CHEMICAL	22991293T3
22991293	66	77	osteopontin	GENE-Y	22991293T40
22991293	673	679	serine	CHEMICAL	22991293T4
22991293	685	694	aspartate	CHEMICAL	22991293T5
22991293	864	865	N	CHEMICAL	167
22991293	1157	1160	BSP	GENE-Y	22991293T7
22991293	1190	1194	PHEX	GENE-Y	111270
22991293	1278	1281	OPN	GENE-Y	22991293T9

22991447|t|Targeted disruption of inducible nitric oxide synthase protects against aging, S-nitrosation, and insulin resistance in muscle of male mice.
22991447|a|Accumulating evidence has demonstrated that S-nitrosation of proteins plays a critical role in several human diseases. Here, we explored the role of inducible nitric oxide synthase (iNOS) in the S-nitrosation of proteins involved in the early steps of the insulin-signaling pathway and insulin resistance in the skeletal muscle of aged mice. Aging increased iNOS expression and S-nitrosation of major proteins involved in insulin signaling, thereby reducing insulin sensitivity in skeletal muscle. Conversely, aged iNOS-null mice were protected from S-nitrosation-induced insulin resistance. Moreover, pharmacological treatment with an iNOS inhibitor and acute exercise reduced iNOS-induced S-nitrosation and increased insulin sensitivity in the muscle of aged animals. These findings indicate that the insulin resistance observed in aged mice is mainly mediated through the S-nitrosation of the insulin-signaling pathway.
22991447	290	321	inducible nitric oxide synthase	GENE-Y	22991447T10
22991447	323	327	iNOS	GENE-Y	22991447T11
22991447	397	404	insulin	GENE-N	22991447T12
22991447	427	434	insulin	GENE-N	22991447T13
22991447	499	503	iNOS	GENE-Y	22991447T14
22991447	563	570	insulin	GENE-N	22991447T15
22991447	599	606	insulin	GENE-N	22991447T16
22991447	656	660	iNOS	GENE-Y	22991447T17
22991447	713	720	insulin	GENE-N	22991447T18
22991447	777	781	iNOS	GENE-Y	22991447T19
22991447	300	312	nitric oxide	CHEMICAL	22991447T1
22991447	819	823	iNOS	GENE-Y	22991447T20
22991447	860	867	insulin	GENE-N	22991447T21
22991447	944	951	insulin	GENE-N	22991447T22
22991447	1037	1044	insulin	GENE-N	22991447T23
22991447	23	54	inducible nitric oxide synthase	GENE-Y	22991447T24
22991447	98	105	insulin	GENE-N	22991447T25
22991447	336	337	S	CHEMICAL	127
22991447	519	520	S	CHEMICAL	127
22991447	185	186	S	CHEMICAL	127
22991447	691	692	S	CHEMICAL	127
22991447	832	833	S	CHEMICAL	127
22991447	1016	1017	S	CHEMICAL	127
22991447	33	45	nitric oxide	CHEMICAL	22991447T8
22991447	79	80	S	CHEMICAL	127

22992330|t|Genetic correlate of cognitive training response in schizophrenia.
22992330|a|Intensive computerized auditory training results in improved cognition for schizophrenia patients, but participants show variation in their cognitive gains and the biological factors that affect the response to training are unknown. Single nucleotide polymorphisms (SNPs) in the catechol-O-methyltransferase (COMT) gene have been related to cognitive function. Here we asked if functional variation in this gene has an impact on the response of schizophrenia patients to cognitive training. We genotyped 48 schizophrenia patients who completed 50 h of computerized cognitive training and analyzed the association between DNA variants in the COMT gene and the improvement in global cognition. Although conventional analyses did not reveal any significant associations, a set-based analysis examining the aggregate effect of common variation in the COMT gene (42 SNPs) suggested association with improvement in global cognition. Eight SNPs, mostly located in the 3' end of the COMT gene, were nominally associated with improvement in cognition. These data suggest that genotype influences the response to intensive cognitive training in schizophrenia, and may indicate that cognitive training regimens need to be personalized to the underlying biosignatures of each individual patient. This article is part of a Special Issue entitled 'Cognitive Enhancers'.
22992330	346	354	catechol	CHEMICAL	22992330T1
22992330	355	356	O	CHEMICAL	22992330T2
22992330	346	374	catechol-O-methyltransferase	GENE-Y	22992330T3
22992330	376	380	COMT	GENE-Y	107707
22992330	708	712	COMT	GENE-Y	107707
22992330	914	918	COMT	GENE-Y	107707
22992330	1042	1046	COMT	GENE-Y	107707

22996137|t|Microtubule network is required for insulin-induced signal transduction and actin remodeling.
22996137|a|Both microtubule and actin are required for insulin-induced glucose uptake. However, the roles of these two cytoskeletons and their relationship in insulin action still remain unclear. In this work, we examined the morphological change of microtubule/actin and their involvement in insulin signal transduction using rat skeletal muscle cells. Insulin rapidly led to microtubule clustering from ventral to dorsal surface of the cell. Microtubule filaments were rearranged to create space where new actin structures formed. Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake. Though microtubule mediated actin remodeling through PKC, reorganization of microtubule depended on tyrosine phosphorylation of insulin receptor, the mechanism is different from insulin-induced actin remodeling, which relied on the activity of PI3-kinase and PKC. We propose that microtubule network is required for insulin-induced signal transduction and actin remodeling in skeletal muscle cells.
22996137	376	383	insulin	GENE-N	22996137T10
22996137	437	444	Insulin	GENE-N	22996137T11
22996137	138	145	insulin	GENE-Y	22996137T12
22996137	591	596	actin	GENE-N	22996137T13
22996137	652	659	insulin	GENE-N	22996137T14
22996137	668	673	actin	GENE-N	22996137T15
22996137	696	703	insulin	GENE-N	22996137T16
22996137	751	780	glucose transporter isoform 4	GENE-Y	22996137T17
22996137	782	787	GLUT4	GENE-Y	22996137T18
22996137	837	842	actin	GENE-N	22996137T19
22996137	154	161	glucose	CHEMICAL	22996137T1
22996137	862	866	PKC	GENE-Y	22996137T20
22996137	938	954	insulin receptor	GENE-Y	22996137T21
22996137	988	995	insulin	GENE-N	22996137T22
22996137	1004	1009	actin	GENE-N	22996137T23
22996137	1054	1064	PI3-kinase	GENE-N	22996137T24
22996137	1069	1073	PKC	GENE-Y	22996137T25
22996137	36	43	insulin	GENE-Y	22996137T26
22996137	751	758	glucose	CHEMICAL	22996137T2
22996137	793	800	glucose	CHEMICAL	22996137T3
22996137	910	918	tyrosine	CHEMICAL	22996137T4
22996137	1127	1134	insulin	GENE-N	22996137T5
22996137	1167	1172	actin	GENE-N	22996137T6
22996137	242	249	insulin	GENE-Y	22996137T7
22996137	115	120	actin	GENE-N	22996137T8
22996137	345	350	actin	GENE-N	22996137T9
22996137	CPR:9	22996137T3	22996137T17
22996137	CPR:9	22996137T3	22996137T18

23007560|t|The influence of chronic fluorosis on mitochondrial dynamics morphology and distribution in cortical neurons of the rat brain.
23007560|a|The present study was designed to evaluate the effects of chronic fluorosis on the dynamics (including fusion and fission proteins), fragmentation, and distribution of mitochondria in the cortical neurons of the rat brain in an attempt to elucidate molecular mechanisms underlying the brain damage associated with excess accumulation of fluoride. Sixty Sprague-Dawley rats were divided randomly into three groups of 20 each, that is, the untreated control group (drinking water naturally containing <0.5mg fluoride/l, NaF), the low-fluoride group (whose drinking water was supplemented with 10mg fluoride/l) and the high-fluoride group (50mg fluoride/l). After 6months of exposure, the expression of mitofusin-1 (Mfn1), fission-1 (Fis1), and dynamin-related protein-1 (Drp1) at both the protein and mRNA levels were detected by Western blotting, immunohistochemistry, and real-time PCR, respectively. Moreover, mitochondrial morphology and distribution in neurons were observed by transmission electron or fluorescence microscopy. In the cortices of the brains of rats with chronic fluorosis, the level of Mfn1 protein was clearly reduced, whereas the levels of Fis1 and Drp1 were elevated. The alternations of expression of the mRNAs encoding all three of these proteins were almost the same as the corresponding changes at the protein levels. The mitochondria were fragmented and the redistributed away from the axons of the cortical neurons. These findings indicate that chronic fluorosis induces abnormal mitochondrial dynamics, which might in turn result in a high level of oxidative stress.
23007560	1302	1306	Drp1	GENE-Y	59672
23007560	831	842	mitofusin-1	GENE-Y	23007560T11
23007560	844	848	Mfn1	GENE-Y	212170|251419
23007560	851	860	fission-1	GENE-Y	23007560T13
23007560	862	866	Fis1	GENE-Y	72485|211472|252608
23007560	873	898	dynamin-related protein-1	GENE-Y	23007560T15
23007560	900	904	Drp1	GENE-Y	59672
23007560	464	472	fluoride	CHEMICAL	23007560T1
23007560	634	642	fluoride	CHEMICAL	23007560T2
23007560	646	649	NaF	CHEMICAL	23007560T3
23007560	660	668	fluoride	CHEMICAL	23007560T4
23007560	725	733	fluoride	CHEMICAL	23007560T5
23007560	750	758	fluoride	CHEMICAL	23007560T6
23007560	772	780	fluoride	CHEMICAL	23007560T7
23007560	1237	1241	Mfn1	GENE-Y	212170|251419
23007560	1293	1297	Fis1	GENE-Y	72485|211472|252608

23015691|t|Quantitative analysis of the interaction of constitutive androstane receptor with chemicals and steroid receptor coactivator 1 using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse.
23015691|a|The constitutive androstane receptor (CAR) not only displays a high basal transcriptional activity but also acts as a ligand-dependent transcriptional factor. It is known that CAR exhibits different ligand profiles across species. However, the mechanisms underlying CAR activation by chemicals and the species-specific responses are not fully understood. The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and steroid receptor coactivator 1 (SRC1). We developed the surface plasmon resonance (SPR) system to assess quantitatively the interaction of CAR with potential ligands and SRC1. The ligand-binding domain (LBD) of bsCAR and mCAR was synthesized in a wheat germ cell-free system. The purified CAR LBD was then immobilized on the sensor chip for the SPR assay, and the kinetics of direct interaction of CARs with ligand candidates was measured. Androstanol and androstenol, estrone, 17-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both CARs. The CAR-SRC1 interaction was ligand dependent but exhibited a different ligand profile between the seal and the mouse. The results of SRC1 interaction assay accounted for those of our previous in vitro CAR-mediated transactivation assay. In silico analyses also supported the results of CAR-SRC1 interaction; there is little structural difference in the ligand-binding pocket of bsCAR and mCAR, but there is a distinct discrimination in the helix 11 and 12 of these receptors, suggesting that the interaction of ligand-bound CAR and SRC1 is critical for determining species-specific and ligand-dependent transactivation over the basal activity. The SPR assays demonstrated a potential as a high-throughput screening tool of CAR ligands.
23015691	96	103	steroid	CHEMICAL	23015691T10
23015691	1366	1370	CARs	GENE-N	23015691T11
23015691	1376	1379	CAR	GENE-N	23015691T12
23015691	1380	1384	SRC1	GENE-N	35136
23015691	1506	1510	SRC1	GENE-N	35136
23015691	1574	1577	CAR	GENE-N	23015691T15
23015691	1659	1662	CAR	GENE-N	23015691T16
23015691	1663	1667	SRC1	GENE-N	35136
23015691	1751	1756	bsCAR	GENE-Y	23015691T18
23015691	1761	1765	mCAR	GENE-Y	23015691T19
23015691	1253	1264	androstenol	CHEMICAL	23015691T1
23015691	1897	1900	CAR	GENE-N	23015691T20
23015691	1905	1909	SRC1	GENE-N	35136
23015691	417	420	CAR	GENE-Y	23015691T22
23015691	2096	2099	CAR	GENE-N	23015691T23
23015691	507	510	CAR	GENE-Y	23015691T24
23015691	279	282	CAR	GENE-Y	23015691T25
23015691	675	678	CAR	GENE-N	23015691T26
23015691	245	277	constitutive androstane receptor	GENE-Y	23015691T27
23015691	706	709	CAR	GENE-N	23015691T28
23015691	741	746	bsCAR	GENE-Y	23015691T29
23015691	1266	1273	estrone	CHEMICAL	23015691T2
23015691	763	767	mCAR	GENE-Y	23015691T30
23015691	797	827	steroid receptor coactivator 1	GENE-N	23015691T31
23015691	829	833	SRC1	GENE-N	35136
23015691	936	939	CAR	GENE-N	23015691T33
23015691	967	971	SRC1	GENE-N	35136
23015691	1008	1013	bsCAR	GENE-Y	23015691T35
23015691	1018	1022	mCAR	GENE-Y	23015691T36
23015691	1086	1093	CAR LBD	GENE-N	23015691T37
23015691	1195	1199	CARs	GENE-N	23015691T38
23015691	44	76	constitutive androstane receptor	GENE-N	23015691T39
23015691	1275	1288	17-estradiol	CHEMICAL	23015691T3
23015691	96	126	steroid receptor coactivator 1	GENE-N	23015691T40
23015691	1290	1297	TCPOBOP	CHEMICAL	23015691T4
23015691	1303	1308	CITCO	CHEMICAL	23015691T5
23015691	258	268	androstane	CHEMICAL	23015691T6
23015691	797	804	steroid	CHEMICAL	23015691T7
23015691	1237	1248	Androstanol	CHEMICAL	23015691T8
23015691	57	67	androstane	CHEMICAL	23015691T9

23017389|t|Studies on the antioxidant potential of flavones of Allium vineale isolated from its water-soluble fraction.
23017389|a|The aim of this work was to examine the chemical constituents and antioxidant potential of water-soluble fractions from the commonly consumed vegetable, Allium vineale. The water-soluble fraction, containing phenolic compounds, was extracted with ethyl acetate to obtain flavonoids which were separated and purified by repeated column chromatography over Sephadex LH-20, RP C18 and silica gel. The isolated compounds were identified according to their physicochemical properties and spectral data (UV, HPLC-TOF/MS, (1)H NMR, (13)C NMR and 2D NMR). Three flavonoids were isolated and identified as chrysoeriol-7-O-[2-O-E-feruloyl]--d-glucoside (1), chrysoeriol (2), and isorhamnetin-3--d-glucoside (3). Antioxidant studies of the aqueous extract and three isolated compounds, 1, 2, 3, were undertaken and they were found to have significant antioxidant activity. Antioxidant activities were evaluated for total antioxidant activity by the ferric thiocyanate method, ferric ion (Fe(3+)) reducing antioxidant power assay (FRAP), ferrous ion (Fe(2+)) metal chelating activity, and DPPH free radical-scavenging activity. The water-soluble ethyl acetate and methanol extraction methods were also compared using HPLC-TOF/MS.
23017389	634	639	(13)C	CHEMICAL	23017389T10
23017389	706	753	chrysoeriol-7-O-[2-O-E-feruloyl]--d-glucoside	CHEMICAL	23017389T11
23017389	759	770	chrysoeriol	CHEMICAL	23017389T12
23017389	780	808	isorhamnetin-3--d-glucoside	CHEMICAL	23017389T13
23017389	1050	1068	ferric thiocyanate	CHEMICAL	23017389T14
23017389	1077	1083	ferric	CHEMICAL	23017389T15
23017389	1089	1095	Fe(3+)	CHEMICAL	23017389T16
23017389	40	48	flavones	CHEMICAL	23017389T17
23017389	1138	1145	ferrous	CHEMICAL	23017389T1
23017389	1151	1157	Fe(2+)	CHEMICAL	23017389T2
23017389	1189	1193	DPPH	CHEMICAL	23017389T3
23017389	1246	1259	ethyl acetate	CHEMICAL	23017389T4
23017389	1264	1272	methanol	CHEMICAL	23017389T5
23017389	356	369	ethyl acetate	CHEMICAL	23017389T6
23017389	380	390	flavonoids	CHEMICAL	23017389T7
23017389	491	501	silica gel	CHEMICAL	23017389T8
23017389	624	628	(1)H	CHEMICAL	23017389T9

23017415|t|Amino acid composition, antinutrients and allergens in the peanut protein fraction obtained by an aqueous enzymatic process.
23017415|a|Enzyme-assisted aqueous extraction (EAE) of peanut kernel was used to extract oil and protein. The aqueous fraction (AF) obtained by EAE had a better essential amino acid profile than the residues obtained by solvent extraction (Rs) and cold pressing (Rc). No major difference in the trypsin inhibitor activity among AF, Rs and Rc was observed; however, the trypsin inhibitor activity was drastically reduced in the residue obtained after EAE. AF was subjected to MALDI-TOF/MS, revealing it to be rich in peptides (107) with molecular masses from m/z 700 to 2369Da. AF had an extremely low phytate content and was rich in peptides, which could be used as a food supplement. ESI-MS/MS data were used for the identification of major peanut allergens, viz., Ara h1, h3, h6-8. Their allergenic potential needs to be established.
23017415	285	295	amino acid	CHEMICAL	23017415T1
23017415	715	722	phytate	CHEMICAL	23017415T2
23017415	0	10	Amino acid	CHEMICAL	23017415T3
23017415	409	416	trypsin	GENE-N	23017415T4
23017415	483	490	trypsin	GENE-N	23017415T5
23017415	856	872	peanut allergens	GENE-N	23017415T6
23017415	880	896	Ara h1, h3, h6-8	GENE-N	23017415T7

23022398|t|NMDA receptor blockade impairs the muscarinic conversion of sub-threshold transient depression into long-lasting LTD in the hippocampus-prefrontal cortex pathway in vivo: correlation with gamma oscillations.
23022398|a|Cholinergic fibers from the brainstem and basal forebrain innervate the medial prefrontal cortex (mPFC) modulating neuronal activity and synaptic plasticity responses to hippocampal inputs. Here, we investigated the muscarinic and glutamatergic modulation of long-term depression (LTD) in the intact projections from CA1 to mPFC in vivo. Cortical-evoked responses were recorded in urethane-anesthetized rats for 30 min during baseline and 4 h following LTD. In order to test the potentiating effects of pilocarpine (PILO), independent groups of rats received either a microinjection of PILO (40 nmol; i.c.v.) or vehicle, immediately before or 20 min after a sub-threshold LTD protocol (600 pulses, 1 Hz; LFS600). Other groups received either an infusion of the selective NMDA receptor antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900). Our results show that PILO converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that NMDA receptor pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO. In addition, AP7 effectively blocked the long-lasting LTD induced by LFS900. Therefore, our findings suggest that the glutamatergic co-activation of prefrontal neurons is important for the effects of PILO on mPFC synaptic depression, which could play an important role in the control of executive and emotional functions.
23022398	794	798	PILO	CHEMICAL	23022398T10
23022398	979	983	NMDA	CHEMICAL	1209
23022398	1005	1008	AP7	CHEMICAL	23022398T12
23022398	1059	1063	PILO	CHEMICAL	23022398T13
23022398	1175	1179	PILO	CHEMICAL	23022398T14
23022398	0	4	NMDA	CHEMICAL	1209
23022398	1408	1421	NMDA receptor	GENE-N	23022398T16
23022398	979	992	NMDA receptor	GENE-N	23022398T17
23022398	0	13	NMDA receptor	GENE-N	23022398T18
23022398	1310	1314	PILO	CHEMICAL	23022398T1
23022398	1408	1412	NMDA	CHEMICAL	1209
23022398	1515	1518	AP7	CHEMICAL	23022398T3
23022398	1629	1633	PILO	CHEMICAL	23022398T4
23022398	1648	1651	AP7	CHEMICAL	23022398T5
23022398	1835	1839	PILO	CHEMICAL	23022398T6
23022398	589	597	urethane	CHEMICAL	23022398T7
23022398	711	722	pilocarpine	CHEMICAL	1073
23022398	724	728	PILO	CHEMICAL	23022398T9
23022398	CPR:4	23022398T3	23022398T16
23022398	CPR:6	23022398T12	23022398T17

23024204|t|Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
23024204|a|Triethylenetetramine (TETA; Syprine; Merck Rahway, NJ), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine. We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT). The acetylation of TETA is increased in SSAT1-overexpressing mice compared with wild-type mice. However, SSAT1-deficient mice metabolize TETA at the same rate as the wild-type mice, indicating the existence of another N-acetylase respons 2ible for its metabolism in mice. Here, we show that siRNA-mediated knockdown of SSAT2 in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of TETA to MAT. By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes. Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas SpmTrien is primarily acetylated by SSAT1.
23024204	179	183	TETA	CHEMICAL	23024204T10
23024204	401	411	spermidine	CHEMICAL	23024204T11
23024204	412	420	spermine	CHEMICAL	23024204T12
23024204	185	192	Syprine	CHEMICAL	23024204T13
23024204	459	469	thialysine	CHEMICAL	23024204T14
23024204	555	559	TETA	CHEMICAL	23024204T15
23024204	673	677	TETA	CHEMICAL	23024204T16
23024204	972	976	TETA	CHEMICAL	23024204T17
23024204	998	1031	1,12-diamino-3,6,9-triazadodecane	CHEMICAL	23024204T18
23024204	1032	1040	SpmTrien	CHEMICAL	23024204T19
23024204	157	177	Triethylenetetramine	CHEMICAL	23024204T1
23024204	1062	1070	spermine	CHEMICAL	23024204T20
23024204	247	253	copper	CHEMICAL	23024204T21
23024204	127	137	thialysine	CHEMICAL	23024204T22
23024204	14	34	triethylenetetramine	CHEMICAL	23024204T23
23024204	39	72	1,12-diamino-3,6,9-triazadodecane	CHEMICAL	23024204T24
23024204	80	90	spermidine	CHEMICAL	23024204T25
23024204	91	99	spermine	CHEMICAL	23024204T26
23024204	1161	1166	SSAT1	GENE-Y	23024204T27
23024204	1279	1284	SSAT2	GENE-Y	23024204T28
23024204	1361	1366	SSAT1	GENE-Y	23024204T29
23024204	1260	1264	TETA	CHEMICAL	23024204T2
23024204	401	443	spermidine/spermine-N(1)-acetyltransferase	GENE-Y	23024204T30
23024204	445	450	SSAT1	GENE-Y	23024204T31
23024204	459	487	thialysine acetyltransferase	GENE-Y	23024204T32
23024204	489	494	SSAT2	GENE-Y	23024204T33
23024204	576	581	SSAT1	GENE-Y	23024204T34
23024204	641	646	SSAT1	GENE-Y	23024204T35
23024204	754	765	N-acetylase	GENE-N	23024204T36
23024204	855	860	SSAT2	GENE-Y	23024204T37
23024204	912	917	SSAT1	GENE-Y	23024204T38
23024204	1114	1137	human recombinant SSAT2	GENE-Y	23024204T39
23024204	1269	1277	SpmTrien	CHEMICAL	23024204T3
23024204	127	155	thialysine acetyltransferase	GENE-N	23024204T40
23024204	80	122	spermidine/spermine-N(1)-acetyltransferase	GENE-Y	23024204T41
23024204	1311	1315	TETA	CHEMICAL	23024204T4
23024204	1325	1333	SpmTrien	CHEMICAL	23024204T5
23024204	296	305	polyamine	CHEMICAL	23024204T6
23024204	306	316	spermidine	CHEMICAL	23024204T7
23024204	342	346	TETA	CHEMICAL	23024204T8
23024204	374	383	polyamine	CHEMICAL	23024204T9
23024204	CPR:9	23024204T15	23024204T34
23024204	CPR:9	23024204T16	23024204T36
23024204	CPR:9	23024204T17	23024204T37
23024204	CPR:9	23024204T18	23024204T27
23024204	CPR:9	23024204T18	23024204T39
23024204	CPR:9	23024204T19	23024204T27
23024204	CPR:9	23024204T19	23024204T39
23024204	CPR:9	23024204T20	23024204T27
23024204	CPR:9	23024204T20	23024204T39
23024204	CPR:9	23024204T23	23024204T40
23024204	CPR:9	23024204T23	23024204T41
23024204	CPR:9	23024204T24	23024204T40
23024204	CPR:9	23024204T24	23024204T41
23024204	CPR:9	23024204T4	23024204T28
23024204	CPR:9	23024204T5	23024204T29
23024204	CPR:9	23024204T8	23024204T30
23024204	CPR:9	23024204T8	23024204T31
23024204	CPR:9	23024204T8	23024204T32
23024204	CPR:9	23024204T8	23024204T33
23024204	CPR:9	23024204T9	23024204T30
23024204	CPR:9	23024204T9	23024204T31

23030680|t|In vitro metabolism of the 5-hydroxytryptamine1B receptor antagonist elzasonan.
23030680|a|The metabolism of elzasonan has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P450 enzymes (rCYP). Metabolism occurs primarily via oxidative N-demethylation to form M4 and oxidation reactions to form elzasonan N-oxide (M5) and 5-hydroxyelzasonan metabolite (M3). Additionally, elzasonan was shown to be metabolized to the novel cyclized indole metabolite (M6) which undergoes subsequent oxidation to form the iminium ion metabolite (M3a). The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each rCYP in the metabolism of elzasonan. Results demonstrated the involvement of CYP3A4 in the pathways leading to M3a, M3, M5 and M6 and CYP2C8 in the formation of M4. Kinetic constants for the formation of M3 were determined and correlation and inhibition studies suggested that CYP3A4 is primarily responsible for the formation of M3 and CYP2C19 plays a very minor role in its formation. Cytochrome b5 has shown to be an essential component in P450 3A4 catalyzed 5-hydroxyelzasonan formation and provides insights on the disconnect between human liver microsomes data and that of rCYP. Furthermore, rCYP3A4 containing b5 are useful models for predicting the rates for liver microsomes P450-dependent drug oxidations and should be utilized routinely.
23030680	69	78	elzasonan	CHEMICAL	23030680T10
23030680	1104	1117	Cytochrome b5	GENE-Y	23030680T11
23030680	1160	1168	P450 3A4	GENE-Y	23030680T12
23030680	1296	1300	rCYP	GENE-N	23030680T13
23030680	1315	1322	rCYP3A4	GENE-Y	23030680T14
23030680	1401	1405	P450	GENE-N	23030680T15
23030680	212	224	P450 enzymes	GENE-N	23030680T16
23030680	226	230	rCYP	GENE-N	23030680T17
23030680	577	581	rCYP	GENE-N	23030680T18
23030680	633	636	CYP	GENE-N	23030680T19
23030680	1179	1197	5-hydroxyelzasonan	CHEMICAL	23030680T1
23030680	717	721	rCYP	GENE-N	23030680T20
23030680	794	800	CYP3A4	GENE-Y	107948
23030680	851	857	CYP2C8	GENE-Y	107936
23030680	994	1000	CYP3A4	GENE-Y	107948
23030680	1054	1061	CYP2C19	GENE-Y	107935
23030680	27	48	5-hydroxytryptamine1B	GENE-Y	23030680T25
23030680	98	107	elzasonan	CHEMICAL	23030680T2
23030680	275	276	N	CHEMICAL	167
23030680	334	351	elzasonan N-oxide	CHEMICAL	23030680T4
23030680	361	379	5-hydroxyelzasonan	CHEMICAL	23030680T5
23030680	411	420	elzasonan	CHEMICAL	23030680T6
23030680	471	477	indole	CHEMICAL	23030680T7
23030680	543	550	iminium	CHEMICAL	23030680T8
23030680	743	752	elzasonan	CHEMICAL	23030680T9
23030680	CPR:6	23030680T10	23030680T25
23030680	CPR:9	23030680T1	23030680T12
23030680	CPR:9	23030680T9	23030680T20

23030766|t|Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcRIIa affinity and selectivity.
23030766|a|Glycans anchored to residue N297 of the antibody IgG Fc domain are critical in mediating binding toward FcRs to direct both adaptive and innate immune responses. However, using a full length bacterial IgG display system, we have isolated aglycosylated Fc domains with mutations that confer up to a 160-fold increase in the affinity toward the low affinity FcRIIa-R131 allele as well as high selectivity against binding to the remarkably homologous human inhibitory receptor, FcRIIb. The mutant Fc domain (AglycoT-Fc1004) contained a total of 5 amino acid substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:FcRIIb). Incorporation of this engineered Fc into trastuzumab, an anti-Her2 antibody, resulted in a 75% increase in tumor cell phagocytosis by macrophages compared to that of the parental glycosylated trastuzumab with both medium and low Her2-expressing cancer cells. A mathematical model has been developed to help explain how receptor affinity and the A/I ratio relate to improved antibody dependent cell-mediated phagocytosis. Our model provides guidelines for the future engineering of Fc domains with enhanced effector function.
23030766	645	659	AglycoT-Fc1004	GENE-N	23030766T10
23030766	776	783	FcyRIIa	GENE-Y	23030766T11
23030766	789	796	FcRIIb	GENE-Y	23030766T12
23030766	832	834	Fc	GENE-N	23030766T13
23030766	861	865	Her2	GENE-Y	23030766T14
23030766	1028	1032	Her2	GENE-Y	23030766T15
23030766	103	110	FcRIIa	GENE-Y	23030766T16
23030766	30	34	Her2	GENE-Y	23030766T17
23030766	69	86	aglycosylated IgG	GENE-N	23030766T18
23030766	684	694	amino acid	CHEMICAL	23030766T1
23030766	241	246	FcRs	GENE-N	23030766T2
23030766	1280	1290	Fc domains	GENE-N	23030766T3
23030766	329	342	bacterial IgG	GENE-N	23030766T4
23030766	376	400	aglycosylated Fc domains	GENE-N	23030766T5
23030766	494	501	FcRIIa	GENE-Y	23030766T6
23030766	614	621	FcRIIb	GENE-Y	23030766T7
23030766	186	199	IgG Fc domain	GENE-N	23030766T8
23030766	634	643	Fc domain	GENE-N	23030766T9

23042728|t|Exposure to valproic acid inhibits chondrogenesis and osteogenesis in mid-organogenesis mouse limbs.
23042728|a|In utero exposure to valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, causes neural tube, heart, and limb defects. Valpromide (VPD), the amide derivative of VPA, does not inhibit HDAC activity and is a weak teratogen in vivo. The detailed mechanism of action of VPA as a teratogen is not known. The goal of this study was to test the hypothesis that VPA disrupts regulation of the expression of genes that are critical in chondrogenesis and osteogenesis during limb development. Murine gestation day-12 embryonic forelimbs were excised and exposed to VPA or VPD in a limb bud culture system. VPA caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its HDAC inhibitory effect. The signaling of both Sox9 and Runx2, key regulators of chondrogenesis, was downregulated by VPA. In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes. Thus, VPA exposure dysregulated the expression of target genes directly involved in chondrogenesis and osteogenesis in the developing limb. Disturbances in these signaling pathways are likely to be a consequence of HDAC inhibition because VPD did not affect their expressions.
23042728	664	667	VPA	CHEMICAL	306
23042728	671	674	VPD	CHEMICAL	23042728T11
23042728	705	708	VPA	CHEMICAL	306
23042728	934	937	VPA	CHEMICAL	306
23042728	952	955	VPD	CHEMICAL	23042728T14
23042728	1077	1080	VPA	CHEMICAL	306
23042728	12	25	valproic acid	CHEMICAL	23042728T16
23042728	1286	1290	HDAC	GENE-N	23042728T17
23042728	292	296	HDAC	GENE-N	23042728T18
23042728	145	164	histone deacetylase	GENE-N	23042728T19
23042728	1310	1313	VPD	CHEMICAL	23042728T1
23042728	166	170	HDAC	GENE-N	23042728T20
23042728	817	821	HDAC	GENE-N	23042728T21
23042728	863	867	Sox9	GENE-Y	203413|250800
23042728	872	877	Runx2	GENE-Y	266386|198518
23042728	1022	1026	HDAC	GENE-N	23042728T24
23042728	228	238	Valpromide	CHEMICAL	23042728T2
23042728	240	243	VPD	CHEMICAL	23042728T3
23042728	250	255	amide	CHEMICAL	23042728T4
23042728	270	273	VPA	CHEMICAL	306
23042728	122	135	valproic acid	CHEMICAL	23042728T6
23042728	375	378	VPA	CHEMICAL	306
23042728	463	466	VPA	CHEMICAL	306
23042728	137	140	VPA	CHEMICAL	306
23042728	CPR:4	306	23042728T21
23042728	CPR:4	306	203413|250800
23042728	CPR:4	306	266386|198518
23042728	CPR:4	23042728T6	23042728T19
23042728	CPR:4	23042728T6	23042728T20
23042728	CPR:4	306	23042728T19
23042728	CPR:4	306	23042728T20

23042730|t|Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stress.
23042730|a|Amiodarone (AMD), a class III antiarrhythmic drug, causes idiosyncratic hepatotoxicity in human patients. We demonstrated previously that tumor necrosis factor-alpha (TNF-) plays an important role in a rat model of AMD-induced hepatotoxicity under inflammatory stress. In this study, we developed a model in vitro to study the roles of caspase activation and oxidative stress in TNF potentiation of AMD cytotoxicity. AMD caused cell death in Hepa1c1c7 cells, and TNF cotreatment potentiated its toxicity. Activation of caspases 9 and 3/7 was observed in AMD/TNF-cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity. Intracellular reactive oxygen species (ROS) generation and lipid peroxidation were observed after treatment with AMD and were further elevated by TNF cotreatment. Adding water-soluble antioxidants (trolox, N-acetylcysteine, glutathione, or ascorbate) produced only minor attenuation of AMD/TNF-induced cytotoxicity and did not influence the effect of AMD alone. On the other hand, -tocopherol (TOCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/TNF cotreatment. -TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity. In summary, activation of caspases and oxidative stress were observed after AMD/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.
23042730	1601	1604	AMD	CHEMICAL	958
23042730	357	360	AMD	CHEMICAL	958
23042730	541	544	AMD	CHEMICAL	958
23042730	559	562	AMD	CHEMICAL	958
23042730	696	699	AMD	CHEMICAL	958
23042730	812	818	oxygen	CHEMICAL	23042730T15
23042730	902	905	AMD	CHEMICAL	958
23042730	987	993	trolox	CHEMICAL	23042730T17
23042730	995	1011	N-acetylcysteine	CHEMICAL	5519
23042730	1013	1024	glutathione	CHEMICAL	23042730T19
23042730	141	151	Amiodarone	CHEMICAL	1106
23042730	1029	1038	ascorbate	CHEMICAL	23042730T20
23042730	1075	1078	AMD	CHEMICAL	958
23042730	1140	1143	AMD	CHEMICAL	958
23042730	60	70	amiodarone	CHEMICAL	23042730T23
23042730	1324	1327	TNF	GENE-Y	112979
23042730	1355	1365	pancaspase	GENE-N	23042730T25
23042730	1401	1404	TNF	GENE-Y	112979
23042730	1453	1461	caspases	GENE-N	23042730T27
23042730	1507	1510	TNF	GENE-Y	112979
23042730	279	306	tumor necrosis factor-alpha	GENE-Y	23042730T29
23042730	1170	1182	-tocopherol	CHEMICAL	23042730T2
23042730	1528	1535	caspase	GENE-N	23042730T30
23042730	1605	1608	TNF	GENE-N	112979
23042730	308	313	TNF-	GENE-Y	23042730T32
23042730	478	485	caspase	GENE-N	23042730T33
23042730	521	524	TNF	GENE-Y	112979
23042730	605	608	TNF	GENE-Y	112979
23042730	661	679	caspases 9 and 3/7	GENE-N	23042730T36
23042730	700	703	TNF	GENE-Y	112979
23042730	935	938	TNF	GENE-Y	112979
23042730	1079	1082	TNF	GENE-Y	112979
23042730	1184	1188	TOCO	CHEMICAL	23042730T3
23042730	0	27	Tumor necrosis factor-alpha	GENE-Y	23042730T40
23042730	100	107	caspase	GENE-N	23042730T41
23042730	1254	1257	AMD	CHEMICAL	958
23042730	1320	1323	AMD	CHEMICAL	958
23042730	1341	1347	-TOCO	CHEMICAL	23042730T6
23042730	153	156	AMD	CHEMICAL	958
23042730	1397	1400	AMD	CHEMICAL	958
23042730	1503	1506	AMD	CHEMICAL	958
23042730	CPR:3	958	23042730T27
23042730	CPR:4	23042730T6	23042730T25

23044488|t|Amino acid residues at the N- and C-termini are essential for the folding of active human butyrylcholinesterase polypeptide.
23044488|a|Human serum butyrylcholinesterase (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic organophosphate (OP) nerve agents. A dose of 200mg of HuBChE is envisioned as a prophylactic treatment that can protect humans from an exposure of up to 2LD50 of soman. The limited availability and administration of multiple doses of this stoichiometric bioscavenger make this pretreatment difficult. Thus, the goal of this study was to produce a smaller enzymatically active HuBChE polypeptide (HBP) that could bind to nerve agents with high affinity thereby reducing the dose of enzyme. Studies have indicated that the three-dimensional structure and the domains of HuBChE (acyl pocket, lip of the active center gorge, and the anionic substrate-binding domain) that are critical for the binding of substrate are also essential for the selectivity and binding of inhibitors including OPs. Therefore, we designed three HBPs by deleting some N- and C-terminal residues of HuBChE by maintaining the folds of the active site core that includes the three active site residues (S198, E325, and H438). HBP-4 that lacks 45 residues from C-terminus but known to have BChE activity was used as a control. The cDNAs for the HBPs containing signal sequences were synthesized, cloned into different mammalian expression vectors, and recombinant polypeptides were transiently expressed in different cell lines. No BChE activity was detected in the culture media of cells transfected with any of the newly designed HBPs, and the inactive polypeptides remained inside the cells. Only enzymatically active HBP-4 was secreted into the culture medium. These results suggest that residues at the N- and C-termini are required for the folding and/or maintenance of HBP into an active stable, conformation.
23044488	160	166	HuBChE	GENE-Y	23044488T10
23044488	625	631	HuBChE	GENE-Y	23044488T11
23044488	817	823	HuBChE	GENE-Y	23044488T12
23044488	1120	1126	HuBChE	GENE-Y	23044488T13
23044488	84	111	human butyrylcholinesterase	GENE-Y	23044488T14
23044488	248	263	organophosphate	CHEMICAL	23044488T1
23044488	825	829	acyl	CHEMICAL	23044488T2
23044488	0	10	Amino acid	CHEMICAL	23044488T3
23044488	125	158	Human serum butyrylcholinesterase	GENE-Y	23044488T4
23044488	1245	1250	HBP-4	GENE-N	23044488T5
23044488	1308	1312	BChE	GENE-Y	23044488T6
23044488	1550	1554	BChE	GENE-Y	23044488T7
23044488	1739	1744	HBP-4	GENE-N	23044488T8
23044488	302	308	HuBChE	GENE-Y	23044488T9
23044488	CPR:9	23044488T1	23044488T10
23044488	CPR:9	23044488T1	23044488T4

23053666|t|Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
23053666|a|Claudin-3 (CLDN3) and claudin-4 (CLDN4) are the major structural molecules that form tight junctions (TJs) between epithelial cells. We found that knockdown of the expression of either CLDN3 or CLDN4 produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to cisplatin (cDDP). The effect of CLND3 and CLDN4 on cDDP cytotoxicity, cDDP cellular accumulation, and DNA adduct formation was compared in the CLDN3- and CLDN4-expressing parental human ovarian carcinoma 2008 cells and CLDN3 and CLDN4 knockdown sublines (CLDN3KD and CLDN4KD, respectively). Knockdown of CLDN3 or CLDN4 rendered human ovarian carcinoma 2008 cells resistant to cDDP in both in vitro culture and in vivo xenograft model. The net accumulation of platinum (Pt) and the Pt-DNA adduct levels were reduced in CLDN3KD and CLDN4KD cells. The endogenous mRNA levels of copper influx transporter CTR1 were found to be significantly reduced in the knockdown cells, and exogenous expression of CTR1 restored their sensitivity to cDDP. Reexpression of an shRNAi-resistant CLDN3 or CLDN4 up-regulated CTR1 levels, reversed the cDDP resistance, and enhanced TJ formation in the knockdown cells. Baseline copper (Cu) level, Cu uptake, and Cu cytotoxicity were also reduced in CLDN3KD and CLDN4KD cells. Cu-dependent tyrosinase activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA. These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the Cu transporter CTR1.
23053666	911	913	Pt	CHEMICAL	23053666T10
23053666	923	925	Pt	CHEMICAL	23053666T11
23053666	1017	1023	copper	CHEMICAL	23053666T12
23053666	102	111	cisplatin	CHEMICAL	23053666T13
23053666	48	57	cisplatin	CHEMICAL	23053666T14
23053666	91	97	copper	CHEMICAL	23053666T15
23053666	137	146	Claudin-3	GENE-Y	23053666T16
23053666	1139	1143	CTR1	GENE-Y	36292|17024
23053666	1216	1221	CLDN3	GENE-Y	107757
23053666	1225	1230	CLDN4	GENE-Y	107756
23053666	1346	1352	copper	CHEMICAL	23053666T1
23053666	1244	1248	CTR1	GENE-Y	36292|17024
23053666	148	153	CLDN3	GENE-Y	107757
23053666	1417	1422	CLDN3	GENE-Y	107757
23053666	1429	1434	CLDN4	GENE-Y	107756
23053666	1457	1467	tyrosinase	GENE-Y	23053666T24
23053666	1520	1524	CLDN	GENE-N	23053666T25
23053666	1611	1616	CLDN3	GENE-Y	107757
23053666	1621	1626	CLDN4	GENE-Y	107756
23053666	1738	1752	Cu transporter	GENE-N	23053666T28
23053666	1753	1757	CTR1	GENE-Y	36292|17024
23053666	1354	1356	Cu	CHEMICAL	23053666T2
23053666	322	327	CLDN3	GENE-Y	107757
23053666	331	336	CLDN4	GENE-Y	107756
23053666	159	168	claudin-4	GENE-Y	23053666T32
23053666	170	175	CLDN4	GENE-Y	107756
23053666	474	479	CLND3	GENE-Y	23053666T34
23053666	484	489	CLDN4	GENE-Y	107756
23053666	585	590	CLDN3	GENE-Y	107757
23053666	596	601	CLDN4	GENE-Y	107756
23053666	661	666	CLDN3	GENE-Y	107757
23053666	671	676	CLDN4	GENE-Y	107756
23053666	1365	1367	Cu	CHEMICAL	23053666T3
23053666	697	702	CLDN3	GENE-Y	107757
23053666	709	714	CLDN4	GENE-Y	107756
23053666	746	751	CLDN3	GENE-Y	107757
23053666	755	760	CLDN4	GENE-Y	107756
23053666	960	965	CLDN3	GENE-Y	107757
23053666	972	977	CLDN4	GENE-Y	107756
23053666	1017	1042	copper influx transporter	GENE-N	23053666T46
23053666	1043	1047	CTR1	GENE-Y	36292|17024
23053666	0	9	Claudin-3	GENE-Y	23053666T48
23053666	131	135	CTR1	GENE-Y	36292|17024
23053666	1380	1382	Cu	CHEMICAL	23053666T4
23053666	14	23	claudin-4	GENE-Y	23053666T50
23053666	91	130	copper and cisplatin influx transporter	GENE-N	23053666T51
23053666	1444	1446	Cu	CHEMICAL	23053666T5
23053666	1575	1581	l-DOPA	CHEMICAL	23053666T6
23053666	1738	1740	Cu	CHEMICAL	23053666T7
23053666	442	451	cisplatin	CHEMICAL	23053666T8
23053666	901	909	platinum	CHEMICAL	23053666T9
23053666	CPR:9	23053666T6	23053666T24

23055538|t|Regulation of hepatic phase II metabolism in pregnant mice.
23055538|a|Phase II enzymes, including Ugts, Sults, and Gsts, are critical for the disposition and detoxification of endo- and xenobiotics. In this study, the mRNA and protein expression of major phase II enzymes, as well as key regulatory transcription factors, were quantified in livers of time-matched pregnant and virgin control C57BL/6 mice on gestation days (GD) 7, 11, 14, 17, and postnatal days (PND) 1, 15, and 30. Compared with virgin controls, the mRNA expression of Ugt1a1, 1a6, 1a9, 2a3, 2b1, 2b34, and 2b35 decreased 40 to 80% in pregnant dams. Protein expression of Ugt1a6 also decreased and corresponded with reduced in vitro glucuronidation of bisphenol A in S9 fractions from livers of pregnant mice. Similar to Ugts levels, Gsta1 and a4 mRNAs were reduced in pregnant dams in mid to late gestation; however no change in protein expression was observed. Conversely, Sult1a1, 2a1/2, and 3a1 mRNAs increased 100 to 500% at various time points in pregnant and lactating mice and corresponded with enhanced in vitro sulfation of acetaminophen in liver S9 fractions. Coinciding with maximal decreases in Ugts as well as increases in Sults, the expression of transcription factors CAR, PPAR, and PXR and their target genes were downregulated, whereas ER mRNA was upregulated. Collectively, these data demonstrate altered regulation of hepatic phase II metabolism in mice during pregnancy and suggest that CAR, PPAR, PXR, and ER signaling pathways may be candidate signaling pathways responsible for these changes.
23055538	1473	1478	PPAR	GENE-Y	23055538T10
23055538	1480	1483	PXR	GENE-Y	23055538T11
23055538	1489	1492	ER	GENE-Y	23055538T12
23055538	88	92	Ugts	GENE-N	23055538T13
23055538	94	99	Sults	GENE-N	23055538T14
23055538	105	109	Gsts	GENE-N	23055538T15
23055538	527	569	Ugt1a1, 1a6, 1a9, 2a3, 2b1, 2b34, and 2b35	GENE-N	23055538T16
23055538	630	636	Ugt1a6	GENE-Y	23055538T17
23055538	779	783	Ugts	GENE-N	23055538T18
23055538	792	804	Gsta1 and a4	GENE-N	23055538T19
23055538	1092	1105	acetaminophen	CHEMICAL	23055538T1
23055538	933	956	Sult1a1, 2a1/2, and 3a1	GENE-N	23055538T20
23055538	710	721	bisphenol A	CHEMICAL	23055538T2
23055538	1166	1170	Ugts	GENE-N	23055538T3
23055538	1195	1200	Sults	GENE-N	23055538T4
23055538	1242	1245	CAR	GENE-Y	23055538T5
23055538	1247	1252	PPAR	GENE-Y	23055538T6
23055538	1258	1261	PXR	GENE-Y	23055538T7
23055538	1313	1316	ER	GENE-Y	23055538T8
23055538	1468	1471	CAR	GENE-Y	23055538T9
23055538	CPR:4	23055538T2	23055538T17

23056222|t|Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling.
23056222|a|TGF-beta plays a key role in the development of renal fibrosis. Suppressing the TGF-beta signaling pathway is a possible therapeutic approach for preventing this disease, and reports have suggested that Nrf2 protects against renal fibrosis by inhibiting TGF-beta signaling. This study examines whether dimethylfumarate (DMF), which stimulates Nrf2, prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling. Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F). Additionally, DMF and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression. However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF. Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively. In summary, DMF attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.
23056222	591	594	DMF	CHEMICAL	23056222T10
23056222	638	641	DMF	CHEMICAL	23056222T11
23056222	897	900	DMF	CHEMICAL	23056222T12
23056222	0	16	Dimethylfumarate	CHEMICAL	23056222T13
23056222	141	149	TGF-beta	GENE-Y	23056222T14
23056222	1161	1165	NQO1	GENE-Y	108072
23056222	1167	1171	HO-1	GENE-Y	23056222T16
23056222	1176	1201	glutathione S-transferase	GENE-N	23056222T17
23056222	1203	1206	GST	GENE-N	23056222T18
23056222	1256	1264	TGF-beta	GENE-Y	23056222T19
23056222	1176	1187	glutathione	CHEMICAL	23056222T1
23056222	1355	1358	ARE	GENE-N	23056222T20
23056222	1491	1500	alpha-SMA	GENE-Y	23056222T21
23056222	1502	1513	fibronectin	GENE-Y	23056222T22
23056222	1518	1533	type 1 collagen	GENE-N	23056222T23
23056222	1635	1639	Nrf2	GENE-Y	23056222T24
23056222	1644	1657	phospho-Smad3	GENE-Y	23056222T25
23056222	1723	1727	Nrf2	GENE-Y	23056222T26
23056222	1751	1759	TGF-beta	GENE-Y	23056222T27
23056222	1760	1765	Smad3	GENE-Y	201276|247660
23056222	1782	1785	ARE	GENE-N	23056222T29
23056222	1188	1189	S	CHEMICAL	127
23056222	344	348	Nrf2	GENE-Y	23056222T30
23056222	395	403	TGF-beta	GENE-Y	23056222T31
23056222	484	488	Nrf2	GENE-Y	23056222T32
23056222	522	526	Nrf2	GENE-Y	23056222T33
23056222	551	559	TGF-beta	GENE-Y	23056222T34
23056222	623	627	Nrf2	GENE-Y	23056222T35
23056222	684	688	Nrf2	GENE-Y	23056222T36
23056222	693	697	Nrf2	GENE-Y	23056222T37
23056222	709	714	PAI-1	GENE-Y	23056222T38
23056222	716	741	alpha-smooth muscle actin	GENE-Y	23056222T39
23056222	1249	1252	DMF	CHEMICAL	23056222T3
23056222	743	752	alpha-SMA	GENE-Y	23056222T40
23056222	755	766	fibronectin	GENE-Y	23056222T41
23056222	771	786	type 1 collagen	GENE-N	23056222T42
23056222	801	809	TGF-beta	GENE-Y	23056222T43
23056222	908	912	Nrf2	GENE-Y	23056222T44
23056222	923	931	TGF-beta	GENE-Y	23056222T45
23056222	943	948	Smad3	GENE-Y	201276|247660
23056222	221	229	TGF-beta	GENE-Y	23056222T47
23056222	972	977	Smad3	GENE-Y	201276|247660
23056222	1045	1049	Nrf2	GENE-Y	23056222T49
23056222	1397	1400	DMF	CHEMICAL	23056222T4
23056222	1093	1121	antioxidant response element	GENE-N	23056222T50
23056222	1123	1126	ARE	GENE-N	23056222T51
23056222	1135	1139	Nrf2	GENE-Y	23056222T52
23056222	125	129	Smad	GENE-N	23056222T53
23056222	47	69	NF-E2-related factor 2	GENE-Y	23056222T54
23056222	93	124	transforming growth factor-beta	GENE-Y	23056222T55
23056222	1411	1414	DMF	CHEMICAL	23056222T5
23056222	1685	1688	DMF	CHEMICAL	23056222T6
23056222	1822	1825	DMF	CHEMICAL	23056222T7
23056222	443	459	dimethylfumarate	CHEMICAL	23056222T8
23056222	461	464	DMF	CHEMICAL	23056222T9
23056222	CPR:3	23056222T10	23056222T35
23056222	CPR:3	23056222T11	23056222T36
23056222	CPR:3	23056222T5	23056222T24
23056222	CPR:4	23056222T11	23056222T38
23056222	CPR:4	23056222T11	23056222T39
23056222	CPR:4	23056222T11	23056222T40
23056222	CPR:4	23056222T11	23056222T41
23056222	CPR:4	23056222T11	23056222T42
23056222	CPR:4	23056222T12	23056222T45
23056222	CPR:4	23056222T12	201276|247660
23056222	CPR:4	23056222T12	201276|247660
23056222	CPR:4	23056222T13	23056222T53
23056222	CPR:4	23056222T13	23056222T55
23056222	CPR:4	23056222T3	23056222T19
23056222	CPR:4	23056222T5	23056222T21
23056222	CPR:4	23056222T5	23056222T22
23056222	CPR:4	23056222T5	23056222T23
23056222	CPR:4	23056222T5	23056222T25
23056222	CPR:4	23056222T6	23056222T27
23056222	CPR:4	23056222T6	201276|247660

23059626|t|The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.
23059626|a|Bone remodeling is affected by mechanical loading and inflammatory mediators, including chemokines. The chemokine (C-C motif) ligand 3 (CCL3) is involved in bone remodeling by binding to C-C chemokine receptors 1 and 5 (CCR1 and CCR5) expressed on osteoclasts and osteoblasts. Our group has previously demonstrated that CCR5 down-regulates mechanical loading-induced bone resorption. Thus, the present study aimed to investigate the role of CCR1 and CCL3 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice. Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES. Met-RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (MMP13). The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and Met-RANTES-treated mice. Altogether, these findings show that CCR1 is pivotal for bone remodeling induced by mechanical loading during orthodontic tooth movement and these actions depend, at least in part, on CCL3.
23059626	1268	1273	RUNX2	GENE-Y	107308
23059626	1279	1288	periostin	GENE-Y	23059626T11
23059626	1310	1321	osteocalcin	GENE-Y	23059626T12
23059626	1323	1326	OCN	GENE-Y	23059626T13
23059626	1345	1349	CCL3	GENE-Y	112252
23059626	1421	1425	CCR1	GENE-Y	15362|107635
23059626	256	260	CCL3	GENE-Y	112252
23059626	1568	1572	CCL3	GENE-Y	112252
23059626	307	338	C-C chemokine receptors 1 and 5	GENE-N	23059626T18
23059626	340	344	CCR1	GENE-Y	15362|107635
23059626	1359	1362	Met	CHEMICAL	128
23059626	349	353	CCR5	GENE-Y	107639
23059626	440	444	CCR5	GENE-Y	107639
23059626	561	565	CCR1	GENE-Y	15362|107635
23059626	570	574	CCL3	GENE-Y	112252
23059626	738	742	CCL3	GENE-Y	112252
23059626	752	756	CCR1	GENE-Y	15362|107635
23059626	824	828	CCR5	GENE-Y	107639
23059626	833	837	CCR1	GENE-Y	15362|107635
23059626	855	899	receptor activator of nuclear factor kappa-B	GENE-Y	23059626T28
23059626	901	905	RANK	GENE-Y	23059626T29
23059626	795	798	Met	CHEMICAL	128
23059626	919	924	RANKL	GENE-Y	23059626T30
23059626	926	953	tumor necrosis factor alpha	GENE-Y	23059626T31
23059626	955	960	TNF-	GENE-Y	23059626T32
23059626	966	971	RANKL	GENE-Y	23059626T33
23059626	972	987	osteoprotegerin	GENE-Y	23059626T34
23059626	989	992	OPG	GENE-Y	23059626T35
23059626	208	218	chemokines	GENE-N	23059626T36
23059626	1039	1043	CCL3	GENE-Y	112252
23059626	14	18	CCL3	GENE-Y	112252
23059626	23	27	CCR1	GENE-Y	15362|107635
23059626	1084	1087	Met	CHEMICAL	128
23059626	1096	1099	Met	CHEMICAL	128
23059626	1144	1155	cathepsin K	GENE-Y	23059626T5
23059626	1160	1180	metalloproteinase 13	GENE-Y	23059626T6
23059626	224	254	chemokine (C-C motif) ligand 3	GENE-Y	23059626T7
23059626	1182	1187	MMP13	GENE-Y	110465
23059626	1231	1266	runt-related transcription factor 2	GENE-Y	23059626T9
23059626	CPR:3	128	23059626T12
23059626	CPR:3	128	23059626T13
23059626	CPR:4	128	107308
23059626	CPR:4	128	23059626T11
23059626	CPR:4	128	23059626T9
23059626	CPR:4	128	23059626T28
23059626	CPR:4	128	23059626T29
23059626	CPR:4	128	23059626T30
23059626	CPR:4	128	23059626T31
23059626	CPR:4	128	23059626T32
23059626	CPR:4	128	23059626T33
23059626	CPR:4	128	23059626T34
23059626	CPR:4	128	23059626T35
23059626	CPR:4	128	23059626T5
23059626	CPR:4	128	23059626T6
23059626	CPR:4	128	110465
23059626	CPR:6	128	107639
23059626	CPR:6	128	15362|107635

23059655|t|Nano-graphene in biomedicine: theranostic applications.
23059655|a|Owing to their unique physical and chemical properties, graphene and its derivatives such as graphene oxide (GO), reduced graphene oxide (RGO) and GO-nanocomposites have attracted tremendous interest in many different fields including biomedicine in recent years. With every atom exposed on its surface, single-layered graphene shows ultra-high surface area available for efficient molecular loading and bioconjugation, and has been widely explored as novel nano-carriers for drug and gene delivery. Utilizing the intrinsic near-infrared (NIR) optical absorbance, in vivo graphene-based photothermal therapy has been realized, achieving excellent anti-tumor therapeutic efficacy in animal experiments. A variety of inorganic nanoparticles can be grown on the surface of nano-graphene, obtaining functional graphene-based nanocomposites with interesting optical and magnetic properties useful for multi-modal imaging and imaging-guided cancer therapy. Moreover, significant efforts have also been devoted to study the behaviors and toxicology of functionalized nano-graphene in animals. It has been uncovered that both surface chemistry and sizes play key roles in controlling the biodistribution, excretion, and toxicity of nano-graphene. Biocompatibly coated nano-graphene with ultra-small sizes can be cleared out from body after systemic administration, without rendering noticeable toxicity to the treated mice. In this review article, we will summarize the latest progress in this rapidly growing field, and discuss future prospects and challenges of using graphene-based materials for theranostic applications.
23059655	831	839	graphene	CHEMICAL	23059655T10
23059655	862	870	graphene	CHEMICAL	23059655T11
23059655	149	163	graphene oxide	CHEMICAL	23059655T12
23059655	5	13	graphene	CHEMICAL	23059655T13
23059655	1121	1129	graphene	CHEMICAL	23059655T1
23059655	170	192	reduced graphene oxide	CHEMICAL	23059655T2
23059655	1285	1293	graphene	CHEMICAL	23059655T3
23059655	1321	1329	graphene	CHEMICAL	23059655T4
23059655	194	197	RGO	CHEMICAL	23059655T5
23059655	1618	1626	graphene	CHEMICAL	23059655T6
23059655	375	383	graphene	CHEMICAL	23059655T7
23059655	112	120	graphene	CHEMICAL	23059655T8
23059655	628	636	graphene	CHEMICAL	23059655T9

23061466|t|Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
23061466|a|The human ether-a-go-go-related gene (hERG) is a K+ channel protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death. In this present review, we have focused the physicochemical properties responsible for the hERG blocking activity of structurally different compounds. The reported research works showed that the hydrophobicity on the van der Waals (vdW) surface of the molecules (aroused from the aromatic ring) necessary for the hERG blocking activity along with topological and electronic properties. The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity. Acehytisine hydrochloride (previously named Guangfu base A) was isolated from the root of Aconitum coreanum (Levl.), is an anti-arrhythmic drug in phase IV clinical trial. The isoquinoline alkaloid, neferine (Nef) induces a concentration-dependent decrease in current amplitude (IC50 of 7.419 MM). Most of these natural product compounds contain non-flexible aromatic structures but have significant activity due to the presence of optimum hydrophobicity. Recent research works revealed that Eag and hERG channels are expressed by a variety of cancer cell lines and tissues. The Eag channel showed an oncogenic potential while hERG channels are associated with more aggressive tumors and have a role in mediating invasion. This review concluded that the consideration of physicochemical properties necessary for the hERG blocking activity will guide to develop novel drugs with less cardiotoxicity.
23061466	794	801	matrine	CHEMICAL	23061466T10
23061466	842	855	O=C=N-C-C-C-N	CHEMICAL	23061466T11
23061466	926	951	Acehytisine hydrochloride	CHEMICAL	23061466T12
23061466	970	984	Guangfu base A	CHEMICAL	23061466T13
23061466	6	11	ether	CHEMICAL	23061466T14
23061466	1418	1421	Eag	GENE-Y	23061466T15
23061466	1426	1430	hERG	GENE-Y	23061466T16
23061466	1505	1508	Eag	GENE-Y	23061466T17
23061466	1553	1557	hERG	GENE-Y	23061466T18
23061466	1742	1746	hERG	GENE-Y	23061466T19
23061466	1102	1123	isoquinoline alkaloid	CHEMICAL	23061466T1
23061466	402	406	hERG	GENE-Y	23061466T20
23061466	133	137	hERG	GENE-Y	23061466T21
23061466	99	131	human ether-a-go-go-related gene	GENE-Y	23061466T22
23061466	144	154	K+ channel	GENE-N	23061466T23
23061466	624	628	hERG	GENE-Y	23061466T24
23061466	902	906	hERG	GENE-Y	23061466T25
23061466	0	32	Human ether-a-go-go-related gene	GENE-Y	23061466T26
23061466	105	110	ether	CHEMICAL	23061466T2
23061466	1125	1133	neferine	CHEMICAL	23061466T3
23061466	1135	1138	Nef	CHEMICAL	23061466T4
23061466	144	146	K+	CHEMICAL	23061466T5
23061466	701	724	quinolizidine alkaloids	CHEMICAL	23061466T6
23061466	752	762	oxymatrine	CHEMICAL	23061466T7
23061466	764	775	sophoridine	CHEMICAL	23061466T8
23061466	777	789	sophocarpine	CHEMICAL	23061466T9
23061466	CPR:4	23061466T10	23061466T25
23061466	CPR:4	23061466T11	23061466T25
23061466	CPR:4	23061466T6	23061466T25
23061466	CPR:4	23061466T7	23061466T25
23061466	CPR:4	23061466T8	23061466T25
23061466	CPR:4	23061466T9	23061466T25

23063595|t|Multifunctional targets of dietary polyphenols in disease: a case for the chemokine network and energy metabolism.
23063595|a|Chronic, non-acute inflammation is behind conditions that represent most of the disease burden in humans and is clearly linked to immune and metabolic mechanisms. The convergence of pathways involving the immune response, oxidative stress, increased circulating lipids and aberrant insulin signaling results in CCL2-associated macrophage recruitment and altered energy metabolism. The CCL2/CCR2 pathway and the energy sensor AMP-activated protein kinase (AMPK) are attractive therapeutic targets as a part of preventive management of disease. Several effects of polyphenols are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators. Research is currently underway to develop orally active drugs with these effects, but it is convenient to examine more closely what we are eating. If a lack of relevance in terms of toxicity and substantial effectiveness are confirmed, plant-derived components may provide useful druggable components and dietary supplements. We consider therapeutic actions as a combination of synergistic and/or antagonistic interactions in a multi-target strategy. Hence, improvement in food through enrichment with polyphenols with demonstrated activity may represent a major advance in the design of diets with both industrial and sanitary value.
23063595	570	574	AMPK	GENE-Y	23063595T10
23063595	761	770	cytokines	GENE-N	23063595T11
23063595	817	836	histone deacetylase	GENE-N	23063595T12
23063595	849	853	AMPK	GENE-Y	23063595T13
23063595	74	83	chemokine	GENE-N	23063595T14
23063595	1423	1434	polyphenols	CHEMICAL	23063595T1
23063595	540	543	AMP	CHEMICAL	125|407
23063595	677	688	polyphenols	CHEMICAL	23063595T3
23063595	35	46	polyphenols	CHEMICAL	23063595T4
23063595	397	404	insulin	GENE-Y	23063595T5
23063595	426	430	CCL2	GENE-Y	112251
23063595	500	504	CCL2	GENE-Y	112251
23063595	505	509	CCR2	GENE-Y	2058|3841|609634
23063595	540	568	AMP-activated protein kinase	GENE-Y	23063595T9
23063595	CPR:3	23063595T3	23063595T13
23063595	CPR:4	23063595T3	23063595T11
23063595	CPR:4	23063595T3	23063595T12

23064031|t|Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells.
23064031|a|Naphtho[1,2-b]furan-4,5-dione (NFD), a bioactive component of Avicennia marina, has been demonstrated to display anti-cancer activity. Activation of epidermal growth factor receptor (EGFR)-induced signaling pathway has been correlated with cancer metastasis in various tumors, including breast carcinoma. We use EGF as a metastatic inducer of MDA-MB-231 cells to investigate the effect of NFD on cell migration and invasion. NFD suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity. NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt. The specific PI3K inhibitor, wortmannin, blocked significantly EGF-induced cell migration and invasion. Furthermore, the EGFR inhibitor AG1478 inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation. These findings suggest that NFD inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression. These results provide a novel mechanism to explain the role of NFD as a potent anti-metastatic agent in MDA-MB-231 cells.
23064031	1007	1013	AG1478	CHEMICAL	23064031T10
23064031	39	68	naphtho[1,2-b]furan-4,5-dione	CHEMICAL	23064031T11
23064031	1138	1142	PI3K	GENE-N	23064031T12
23064031	1143	1146	Akt	GENE-N	23064031T13
23064031	1178	1182	EGFR	GENE-Y	108276|3932452|676741
23064031	1241	1244	EGF	GENE-Y	108270
23064031	1300	1304	EGFR	GENE-Y	108276|3932452|676741
23064031	1315	1319	PI3K	GENE-N	23064031T17
23064031	1320	1323	Akt	GENE-N	23064031T18
23064031	1369	1374	MMP-9	GENE-Y	23064031T19
23064031	120	149	Naphtho[1,2-b]furan-4,5-dione	CHEMICAL	23064031T1
23064031	269	301	epidermal growth factor receptor	GENE-Y	23064031T20
23064031	303	307	EGFR	GENE-Y	108276|3932452|676741
23064031	432	435	EGF	GENE-Y	108270
23064031	560	563	EGF	GENE-Y	108270
23064031	591	596	c-Jun	GENE-Y	23064031T24
23064031	601	606	c-Fos	GENE-Y	23064031T25
23064031	620	625	MMP-9	GENE-Y	23064031T26
23064031	774	777	EGF	GENE-Y	108270
23064031	805	817	EGF receptor	GENE-Y	23064031T28
23064031	819	823	EGFR	GENE-Y	108276|3932452|676741
23064031	1223	1226	NFD	CHEMICAL	23064031T2
23064031	829	858	phosphatidylinositol 3-kinase	GENE-N	23064031T30
23064031	860	864	PI3K	GENE-N	23064031T31
23064031	866	869	Akt	GENE-N	23064031T32
23064031	884	888	PI3K	GENE-N	23064031T33
23064031	934	937	EGF	GENE-Y	108270
23064031	992	996	EGFR	GENE-Y	108276|3932452|676741
23064031	1024	1027	EGF	GENE-Y	108270
23064031	1036	1041	MMP-9	GENE-Y	23064031T37
23064031	1112	1116	PI3K	GENE-N	23064031T38
23064031	1117	1120	Akt	GENE-N	23064031T39
23064031	1450	1453	NFD	CHEMICAL	23064031T3
23064031	14	17	EGF	GENE-Y	108270
23064031	18	22	EGFR	GENE-Y	108276|3932452|676741
23064031	151	154	NFD	CHEMICAL	23064031T4
23064031	509	512	NFD	CHEMICAL	23064031T5
23064031	545	548	NFD	CHEMICAL	23064031T6
23064031	760	763	NFD	CHEMICAL	23064031T7
23064031	829	849	phosphatidylinositol	CHEMICAL	23064031T8
23064031	900	910	wortmannin	CHEMICAL	23064031T9
23064031	CPR:4	23064031T10	23064031T12
23064031	CPR:4	23064031T10	23064031T13
23064031	CPR:4	23064031T10	108276|3932452|676741
23064031	CPR:4	23064031T10	108276|3932452|676741
23064031	CPR:4	23064031T10	108270
23064031	CPR:4	23064031T10	23064031T37
23064031	CPR:4	23064031T10	23064031T38
23064031	CPR:4	23064031T10	23064031T39
23064031	CPR:4	23064031T11	108270
23064031	CPR:4	23064031T11	108276|3932452|676741
23064031	CPR:4	23064031T2	108270
23064031	CPR:4	23064031T2	108276|3932452|676741
23064031	CPR:4	23064031T2	23064031T17
23064031	CPR:4	23064031T2	23064031T18
23064031	CPR:4	23064031T2	23064031T19
23064031	CPR:4	23064031T6	108270
23064031	CPR:4	23064031T6	23064031T24
23064031	CPR:4	23064031T6	23064031T25
23064031	CPR:4	23064031T6	23064031T26
23064031	CPR:4	23064031T7	108270
23064031	CPR:4	23064031T7	23064031T28
23064031	CPR:4	23064031T7	108276|3932452|676741
23064031	CPR:4	23064031T7	23064031T30
23064031	CPR:4	23064031T7	23064031T31
23064031	CPR:4	23064031T7	23064031T32
23064031	CPR:4	23064031T9	23064031T33
23064031	CPR:4	23064031T9	108270

23066090|t|A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion.
23066090|a|Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP. Identifying pharmacological probes for selectively modulating EPAC activity represents a significant unmet need within the research field. Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic  cells. Using this novel EPAC-specific inhibitor, we have probed the functional roles of overexpression of EPAC1 in pancreatic cancer cells. Our studies show that EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer.
23066090	601	605	EPAC	GENE-Y	23066090T10
23066090	145	174	cAMP-dependent protein kinase	GENE-N	23066090T11
23066090	672	676	EPAC	GENE-Y	23066090T12
23066090	686	690	Rap1	GENE-Y	23066090T13
23066090	706	709	Akt	GENE-N	23066090T14
23066090	738	742	EPAC	GENE-Y	23066090T15
23066090	752	759	insulin	GENE-Y	23066090T16
23066090	810	814	EPAC	GENE-Y	23066090T17
23066090	892	897	EPAC1	GENE-Y	23066090T18
23066090	948	953	EPAC1	GENE-Y	23066090T19
23066090	273	277	cAMP	CHEMICAL	2424
23066090	176	179	PKA	GENE-N	23066090T20
23066090	8	12	EPAC	GENE-Y	23066090T21
23066090	479	561	3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile	CHEMICAL	23066090T2
23066090	129	133	cAMP	CHEMICAL	2424
23066090	563	569	ESI-09	CHEMICAL	23066090T4
23066090	590	600	nucleotide	CHEMICAL	23066090T5
23066090	145	149	cAMP	CHEMICAL	2424
23066090	90	133	Exchange protein directly activated by cAMP	GENE-Y	23066090T7
23066090	341	345	EPAC	GENE-Y	23066090T8
23066090	135	139	EPAC	GENE-Y	23066090T9
23066090	CPR:4	23066090T2	23066090T12
23066090	CPR:4	23066090T2	23066090T13
23066090	CPR:4	23066090T2	23066090T14
23066090	CPR:4	23066090T2	23066090T15
23066090	CPR:4	23066090T2	23066090T16
23066090	CPR:4	23066090T4	23066090T12
23066090	CPR:4	23066090T4	23066090T13
23066090	CPR:4	23066090T4	23066090T14
23066090	CPR:4	23066090T4	23066090T15
23066090	CPR:4	23066090T4	23066090T16
23066090	CPR:4	23066090T5	23066090T12
23066090	CPR:4	23066090T5	23066090T13
23066090	CPR:4	23066090T5	23066090T14
23066090	CPR:4	23066090T5	23066090T15
23066090	CPR:4	23066090T5	23066090T16
23066090	CPR:6	23066090T2	23066090T10
23066090	CPR:6	23066090T4	23066090T10
23066090	CPR:6	23066090T5	23066090T10

23066988|t|Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells.
23066988|a|The antidiabetic drug Metformin causes weight loss in both diabetic and non-diabetic individuals. Metformin treatment is also associated with lower circulating levels of the orexigenic hormone ghrelin. To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined. Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1--D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion. Additionally, ghrelin cells were shown to express AMPK. Finally, Metformin treatment caused a significant increase in the level of phosphorylated (active) AMPK. Our results show that Metformin directly inhibits stomach ghrelin production and secretion through AMPK. This reduction in ghrelin secretion may be one of the key components in Metformin's mechanism of weight loss.
23066988	950	959	Metformin	CHEMICAL	323
23066988	1068	1077	Metformin	CHEMICAL	323
23066988	211	220	Metformin	CHEMICAL	323
23066988	0	9	Metformin	CHEMICAL	323
23066988	54	57	AMP	CHEMICAL	125|407
23066988	1145	1149	AMPK	GENE-Y	23066988T15
23066988	287	305	orexigenic hormone	GENE-N	23066988T16
23066988	306	313	ghrelin	GENE-Y	23066988T17
23066988	358	365	ghrelin	GENE-Y	23066988T18
23066988	445	452	ghrelin	GENE-Y	23066988T19
23066988	1223	1232	Metformin	CHEMICAL	323
23066988	464	474	proghrelin	GENE-Y	23066988T20
23066988	509	557	adenosine monophosphate-activated protein kinase	GENE-Y	23066988T21
23066988	559	563	AMPK	GENE-Y	23066988T22
23066988	612	619	ghrelin	GENE-Y	23066988T23
23066988	634	644	proghrelin	GENE-Y	23066988T24
23066988	723	727	AMPK	GENE-Y	23066988T25
23066988	767	771	AMPK	GENE-Y	23066988T26
23066988	866	873	ghrelin	GENE-Y	23066988T27
23066988	899	906	ghrelin	GENE-Y	23066988T28
23066988	935	939	AMPK	GENE-Y	23066988T29
23066988	331	340	Metformin	CHEMICAL	323
23066988	1016	1044	phosphorylated (active) AMPK	GENE-Y	23066988T30
23066988	1104	1111	ghrelin	GENE-Y	23066988T31
23066988	28	35	ghrelin	GENE-Y	23066988T32
23066988	54	82	AMP-activated protein kinase	GENE-Y	23066988T33
23066988	135	144	Metformin	CHEMICAL	323
23066988	417	426	Metformin	CHEMICAL	323
23066988	509	532	adenosine monophosphate	CHEMICAL	23066988T5
23066988	580	589	Metformin	CHEMICAL	323
23066988	738	748	compound C	CHEMICAL	23066988T7
23066988	782	833	5-amino-1--D-ribofuranosyl-imidazole-4-carboxamide	CHEMICAL	23066988T8
23066988	835	840	AICAR	CHEMICAL	23066988T9
23066988	CPR:3	323	23066988T30
23066988	CPR:3	23066988T7	23066988T23
23066988	CPR:3	23066988T7	23066988T24
23066988	CPR:3	23066988T8	23066988T26
23066988	CPR:3	23066988T9	23066988T26
23066988	CPR:4	323	23066988T31
23066988	CPR:4	323	23066988T16
23066988	CPR:4	323	23066988T17
23066988	CPR:4	323	23066988T32
23066988	CPR:4	323	23066988T23
23066988	CPR:4	323	23066988T24
23066988	CPR:4	23066988T7	23066988T25
23066988	CPR:4	23066988T9	23066988T27

23081912|t|Fungicide prochloraz and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.
23081912|a|The molecular mechanisms by which environmental pollutants including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or widely used imidazole fungicide prochloraz display their toxic effects in vertebrates are still not well understood. Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No. EU570105) from the bovine mammary gland. As these regulatory motifs mediate regulation of target genes by AhR agonists including TCDD and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells. TCDD or prochloraz doubled ABCG2-mediated Hoechst H33342 secretion. This effect was almost completely reversed by specific ABCG2 inhibitor Ko143. In further mechanistic studies, we showed that this induction was due to binding of activated AhR to DRE sequences in the ABCG2 5'-UTR. Receptor binding was significantly reduced by specific AhR antagonist salicyl amide. Induction of AhR by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels. As ABCG2 represents the main mammary transporter for xenobiotics including drugs and toxins, exposure to prevalent AhR agonists may enhance transporter-mediated secretion of potential harmful compounds into milk. Through identification of mammary ABCG2 as a novel target gene of pesticide prochloraz and dioxin, our results may therefore help to improve the protection of breast-feeding infants and the consumer of dairy products.
23081912	513	519	dioxin	CHEMICAL	23081912T10
23081912	757	761	TCDD	CHEMICAL	23081912T11
23081912	766	776	prochloraz	CHEMICAL	23081912T12
23081912	240	275	2,3,7,8-tetrachlorodibenzo-p-dioxin	CHEMICAL	23081912T13
23081912	929	933	TCDD	CHEMICAL	23081912T14
23081912	937	947	prochloraz	CHEMICAL	23081912T15
23081912	971	985	Hoechst H33342	CHEMICAL	23081912T16
23081912	1068	1073	Ko143	CHEMICAL	23081912T17
23081912	10	20	prochloraz	CHEMICAL	23081912T18
23081912	127	142	arylhydrocarbon	CHEMICAL	23081912T19
23081912	277	281	TCDD	CHEMICAL	23081912T1
23081912	49	55	dioxin	CHEMICAL	23081912T20
23081912	1176	1179	DRE	GENE-N	23081912T21
23081912	1197	1202	ABCG2	GENE-Y	114821
23081912	1266	1269	AhR	GENE-Y	23081912T23
23081912	1309	1312	AhR	GENE-Y	23081912T24
23081912	1387	1392	ABCG2	GENE-Y	114821
23081912	1444	1449	ABCG2	GENE-Y	114821
23081912	1556	1559	AhR	GENE-Y	23081912T27
23081912	1688	1693	ABCG2	GENE-Y	114821
23081912	459	484	aryl hydrocarbon receptor	GENE-Y	23081912T29
23081912	1281	1294	salicyl amide	CHEMICAL	23081912T2
23081912	486	489	AhR	GENE-Y	23081912T30
23081912	513	537	dioxin response elements	GENE-N	23081912T31
23081912	540	544	DREs	GENE-N	23081912T32
23081912	588	606	efflux transporter	GENE-N	23081912T33
23081912	607	612	ABCG2	GENE-Y	114821
23081912	628	636	EU570105	GENE-Y	23081912T35
23081912	734	737	AhR	GENE-Y	23081912T36
23081912	860	865	ABCG2	GENE-Y	114821
23081912	956	961	ABCG2	GENE-Y	114821
23081912	1052	1057	ABCG2	GENE-Y	114821
23081912	1316	1320	TCDD	CHEMICAL	23081912T3
23081912	1169	1172	AhR	GENE-Y	23081912T40
23081912	127	151	arylhydrocarbon receptor	GENE-Y	23081912T41
23081912	67	72	ABCG2	GENE-Y	114821
23081912	1325	1335	prochloraz	CHEMICAL	23081912T4
23081912	298	307	imidazole	CHEMICAL	23081912T5
23081912	318	328	prochloraz	CHEMICAL	23081912T6
23081912	1730	1740	prochloraz	CHEMICAL	23081912T7
23081912	1745	1751	dioxin	CHEMICAL	23081912T8
23081912	459	475	aryl hydrocarbon	CHEMICAL	23081912T9
23081912	CPR:3	23081912T18	114821
23081912	CPR:3	23081912T20	114821
23081912	CPR:3	23081912T3	23081912T24
23081912	CPR:3	23081912T3	114821
23081912	CPR:3	23081912T4	23081912T24
23081912	CPR:3	23081912T4	114821
23081912	CPR:4	23081912T17	114821
23081912	CPR:5	23081912T11	23081912T36
23081912	CPR:5	23081912T12	23081912T36
23081912	CPR:6	23081912T2	23081912T23
23081912	CPR:9	23081912T16	114821

23085295|t|Molecular analyses of dinosaur osteocytes support the presence of endogenous molecules.
23085295|a|The discovery of soft, transparent microstructures in dinosaur bone consistent in morphology with osteocytes was controversial. We hypothesize that, if original, these microstructures will have molecular features in common with extant osteocytes. We present immunological and mass spectrometry evidence for preservation of proteins comprising extant osteocytes (Actin, Tubulin, PHEX, Histone H4) in osteocytes recovered from two non-avian dinosaurs. Furthermore, antibodies to DNA show localized binding to these microstructures, which also react positively with DNA intercalating stains propidium iodide (PI) and 4',6'-diamidino-2-phenylindole dihydrochloride (DAPI). Each antibody binds dinosaur cells in patterns similar to extant cells. These data are the first to support preservation of multiple proteins and to present multiple lines of evidence for material consistent with DNA in dinosaurs, supporting the hypothesis that these structures were part of the once living animals. We propose mechanisms for preservation of cells and component molecules, and discuss implications for dinosaurian cellular biology.
23085295	676	692	propidium iodide	CHEMICAL	23085295T1
23085295	702	748	4',6'-diamidino-2-phenylindole dihydrochloride	CHEMICAL	23085295T2
23085295	750	754	DAPI	CHEMICAL	23085295T3
23085295	450	455	Actin	GENE-N	23085295T4
23085295	457	464	Tubulin	GENE-N	23085295T5
23085295	466	470	PHEX	GENE-N	111270
23085295	472	482	Histone H4	GENE-N	23085295T7

23086748|t|Effects of silver nanoparticles on the liver and hepatocytes in vitro.
23086748|a|With the increasing use and incorporation of nanoparticles (NPs) into consumer products, screening for potential toxicity is necessary to ensure customer safety. NPs have been shown to translocate to the bloodstream following inhalation and ingestion, and such studies demonstrate that the liver is an important organ for accumulation. Silver (Ag) NPs are highly relevant for human exposure due to their use in food contact materials, dietary supplements, and antibacterial wound treatments. Due to the large number of different NPs already used in various products and being developed for new applications, it is essential that relevant, quick, and cheap methods of in vitro risk assessment suitable for these new materials are established. Therefore, this study used a simple hepatocytes model combined with an in vivo injection model to simulate the passage of a small amount of NPs into the bloodstream following exposure, e.g., via ingestion or inhalation, and examined the potential of Ag NPs of 20 nm diameter to cause toxicity, inflammation, and oxidative stress in the liver following in vivo exposures of female Wistar rats via iv injection to 50 g of NPs and in vitro exposures using the human hepatocyte cell line C3A. We found that Ag NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 g/cm(2)) and affected hepatocyte homeostasis by reducing albumin release. At sublethal concentrations with normal cell or tissue morphology, Ag NPs were detected in cytoplasm and nuclei of hepatocytes. We observed similar effects of Ag NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor- expression in both models and increased IL-8 protein release in vitro. This article presents evidence of the potential toxicity and inflammogenic potential of Ag NPs in the liver following ingestion. In addition, the similarities between in vitro and in vivo responses are striking and encouraging for future reduction, refinement, and replacement of animal studies by the use of hepatocyte cell lines in particle risk assessment.
23086748	1369	1390	lactate dehydrogenase	GENE-N	23086748T10
23086748	1454	1461	albumin	GENE-Y	23086748T11
23086748	1711	1724	interleukin-8	GENE-Y	23086748T12
23086748	1726	1730	IL-8	GENE-Y	23086748T13
23086748	1732	1765	macrophage inflammatory protein 2	GENE-N	23086748T14
23086748	1767	1773	IL-1RI	GENE-Y	23086748T15
23086748	1779	1802	tumor necrosis factor-	GENE-Y	23086748T16
23086748	1843	1847	IL-8	GENE-Y	23086748T17
23086748	1317	1319	Ag	CHEMICAL	23086748T1
23086748	1369	1376	lactate	CHEMICAL	23086748T2
23086748	1538	1540	Ag	CHEMICAL	23086748T3
23086748	1630	1632	Ag	CHEMICAL	23086748T4
23086748	1962	1964	Ag	CHEMICAL	23086748T5
23086748	407	413	Silver	CHEMICAL	23086748T6
23086748	415	417	Ag	CHEMICAL	23086748T7
23086748	1063	1065	Ag	CHEMICAL	23086748T8
23086748	11	17	silver	CHEMICAL	23086748T9
23086748	CPR:3	23086748T4	23086748T12
23086748	CPR:3	23086748T4	23086748T13
23086748	CPR:3	23086748T4	23086748T14
23086748	CPR:3	23086748T4	23086748T15
23086748	CPR:3	23086748T4	23086748T16
23086748	CPR:3	23086748T4	23086748T17
23086748	CPR:4	23086748T1	23086748T11

23087260|t|Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor.
23087260|a|Unlike the majority of G protein-coupled receptors, the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPS). We report the identification of mutations that confer GTPS sensitivity to agonist binding. Seven point mutations were introduced into the conserved motif in the second extracellular loop (ECII) of EP3, resulting in acquisition of GTP-sensitive agonist binding. One receptor mutation W203A was studied in detail. Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the W203A receptor, conditions where high GTP levels are present; however, high affinity binding [(3)H]PGE(2) was observed in broken cell preparations washed free of GTP. The [(3)H]PGE(2) binding of W203A in broken cell membrane fractions was inhibited by addition of GTPS (IC(50) 21  1.8 nM). Taken together, these results suggest that the wild-type EP3 receptor displays unusual characteristics of the complex coupled equilibria between agonist-receptor and receptor-G protein interaction. Moreover, mutation of ECII can alter this coupled equilibrium from GTP-insensitive agonist binding to more conventional GTP-sensitive binding. This suggests that for the mutant receptors, ECII plays a critical role in linking the agonist bound receptor conformation to the G protein nucleotide bound state.
23087260	821	833	[(3)H]PGE(2)	CHEMICAL	23087260T10
23087260	159	165	PGE(2)	CHEMICAL	23087260T11
23087260	890	893	GTP	CHEMICAL	23087260T12
23087260	899	911	[(3)H]PGE(2)	CHEMICAL	23087260T13
23087260	167	179	E-prostanoid	CHEMICAL	23087260T14
23087260	992	997	GTPS	CHEMICAL	23087260T15
23087260	32	35	GTP	CHEMICAL	23087260T16
23087260	55	68	prostaglandin	CHEMICAL	23087260T17
23087260	1195	1204	G protein	GENE-N	23087260T18
23087260	1240	1244	ECII	GENE-N	23087260T19
23087260	1285	1288	GTP	CHEMICAL	23087260T1
23087260	1406	1410	ECII	GENE-N	23087260T20
23087260	1491	1500	G protein	GENE-N	23087260T21
23087260	106	133	G protein-coupled receptors	GENE-N	23087260T22
23087260	482	507	second extracellular loop	GENE-N	23087260T23
23087260	509	513	ECII	GENE-N	23087260T24
23087260	518	521	EP3	GENE-Y	23087260T25
23087260	604	609	W203A	GENE-N	23087260T26
23087260	139	196	prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor	GENE-Y	23087260T27
23087260	728	733	W203A	GENE-N	23087260T28
23087260	923	928	W203A	GENE-N	23087260T29
23087260	1338	1341	GTP	CHEMICAL	23087260T2
23087260	1077	1080	EP3	GENE-Y	23087260T30
23087260	0	21	Extracellular loop II	GENE-N	23087260T31
23087260	55	81	prostaglandin EP3 receptor	GENE-Y	23087260T32
23087260	1501	1511	nucleotide	CHEMICAL	23087260T3
23087260	269	310	guanosine 5[prime]-O-(3-thio)triphosphate	CHEMICAL	23087260T4
23087260	312	317	GTPS	CHEMICAL	23087260T5
23087260	374	379	GTPS	CHEMICAL	23087260T6
23087260	551	554	GTP	CHEMICAL	23087260T7
23087260	139	157	prostaglandin E(2)	CHEMICAL	23087260T8
23087260	766	769	GTP	CHEMICAL	23087260T9

23091169|t|Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotion.
23091169|a|The molecular events during nongenotoxic carcinogenesis and their temporal order are poorly understood but thought to include long-lasting perturbations of gene expression. Here, we have investigated the temporal sequence of molecular and pathological perturbations at early stages of phenobarbital (PB) mediated liver tumor promotion in vivo. Molecular profiling (mRNA, microRNA [miRNA], DNA methylation, and proteins) of mouse liver during 13 weeks of PB treatment revealed progressive increases in hepatic expression of long noncoding RNAs and miRNAs originating from the Dlk1-Dio3 imprinted gene cluster, a locus that has recently been associated with stem cell pluripotency in mice and various neoplasms in humans. PB induction of the Dlk1-Dio3 cluster noncoding RNA (ncRNA) Meg3 was localized to glutamine synthetase-positive hypertrophic perivenous hepatocytes, suggesting a role for -catenin signaling in the dysregulation of Dlk1-Dio3 ncRNAs. The carcinogenic relevance of Dlk1-Dio3 locus ncRNA induction was further supported by in vivo genetic dependence on constitutive androstane receptor and -catenin pathways. Our data identify Dlk1-Dio3 ncRNAs as novel candidate early biomarkers for mouse liver tumor promotion and provide new opportunities for assessing the carcinogenic potential of novel compounds.
23091169	863	867	Dlk1	GENE-Y	199231
23091169	868	872	Dio3	GENE-Y	23091169T11
23091169	925	945	glutamine synthetase	GENE-N	23091169T12
23091169	1014	1023	-catenin	GENE-N	23091169T13
23091169	1058	1062	Dlk1	GENE-Y	199231
23091169	1063	1067	Dio3	GENE-Y	23091169T15
23091169	1106	1110	Dlk1	GENE-Y	199231
23091169	1111	1115	Dio3	GENE-Y	23091169T17
23091169	18	22	Dlk1	GENE-Y	199231
23091169	23	27	Dio3	GENE-Y	23091169T19
23091169	1206	1216	androstane	CHEMICAL	23091169T1
23091169	408	421	phenobarbital	CHEMICAL	23091169T2
23091169	925	934	glutamine	CHEMICAL	23091169T3
23091169	1193	1225	constitutive androstane receptor	GENE-N	23091169T4
23091169	1230	1239	-catenin	GENE-N	23091169T5
23091169	1268	1272	Dlk1	GENE-Y	199231
23091169	1273	1277	Dio3	GENE-Y	23091169T7
23091169	698	702	Dlk1	GENE-Y	199231
23091169	703	707	Dio3	GENE-Y	23091169T9

23092877|t|GH improves spatial memory and reverses certain anabolic androgenic steroid-induced effects in intact rats.
23092877|a|GH has previously been shown to promote cognitive functions in GH-deficient rodents. In this study we report the effects of GH on learning and memory in intact rats pretreated with the anabolic androgenic steroid nandrolone. Male Wistar rats received nandrolone decanoate (15 mg/kg) or peanut oil every third day for 3 weeks and were subsequently treated with recombinant human GH (1.0 IU/kg) or saline for 10 consecutive days. During the GH/saline treatment spatial learning and memory were tested in the Morris water maze (MWM). Also, plasma levels of IGF1 were assessed and the gene expression of the GH receptors (Ghr), Igf1 and Igf2, in hippocampus and frontal cortex was analyzed. The results demonstrated a significant positive effect of GH on memory functions and increased gene expression of Igf1 in the hippocampus was found in the animals treated with GH. In addition, GH was demonstrated to increase the body weight gain and was able to attenuate the reduced body weight seen in nandrolone-treated animals. In general, the rats treated with nandrolone alone did not exhibit any pronounced alteration in memory compared with controls in the MWM, and in many cases GH did not induce any alteration. Regarding target zone crossings, considered to be associated with spatial memory, the difference between GH- and steroid-treated animals was significant and administration of GH improved this parameter in the latter group. In conclusion, GH improves spatial memory in intact rats and can reverse certain effects induced by anabolic androgenic steroid.
23092877	1422	1424	GH	GENE-Y	23092877T10
23092877	1492	1494	GH	GENE-Y	23092877T11
23092877	1555	1557	GH	GENE-Y	23092877T12
23092877	480	488	human GH	GENE-Y	23092877T13
23092877	547	549	GH	GENE-Y	23092877T14
23092877	662	666	IGF1	GENE-Y	109700
23092877	712	724	GH receptors	GENE-Y	23092877T16
23092877	726	729	Ghr	GENE-Y	247275|199915
23092877	732	736	Igf1	GENE-Y	23092877T18
23092877	741	745	Igf2	GENE-Y	200549
23092877	1161	1171	nandrolone	CHEMICAL	23092877T1
23092877	171	173	GH	GENE-Y	23092877T20
23092877	853	855	GH	GENE-Y	23092877T21
23092877	909	913	Igf1	GENE-Y	23092877T22
23092877	971	973	GH	GENE-Y	23092877T23
23092877	988	990	GH	GENE-Y	23092877T24
23092877	0	2	GH	GENE-Y	23092877T25
23092877	1660	1667	steroid	CHEMICAL	23092877T2
23092877	313	320	steroid	CHEMICAL	23092877T3
23092877	321	331	nandrolone	CHEMICAL	23092877T4
23092877	359	379	nandrolone decanoate	CHEMICAL	23092877T5
23092877	1099	1109	nandrolone	CHEMICAL	23092877T6
23092877	108	110	GH	GENE-Y	23092877T7
23092877	1283	1285	GH	GENE-Y	23092877T8
23092877	232	234	GH	GENE-Y	23092877T9

23093023|t|Phosphoinositide-dependent kinase-1 and protein kinase C contribute to endothelin-1 constriction and elevated blood pressure in intermittent hypoxia.
23093023|a|Obstructive sleep apnea (OSA) is associated with cardiovascular complications including hypertension. Previous findings from our laboratory indicate that exposure to intermittent hypoxia (IH), to mimic sleep apnea, increases blood pressure in rats. IH also increases endothelin-1 (ET-1) constrictor sensitivity in a protein kinase C (PKC) -dependent manner in mesenteric arteries. Because phosphoinositide-dependent kinase-1 (PDK-1) regulates PKC activity, we hypothesized that PDK-1 contributes to the augmented ET-1 constrictor sensitivity and elevated blood pressure following IH. Male Sprague-Dawley rats were exposed to either sham or IH (cycles between 21% O(2)/0% CO(2) and 5% O(2)/5% CO(2)) conditions for 7 h/day for 14 or 21 days. The contribution of PKC and PDK-1 to ET-1-mediated vasoconstriction was assessed in mesenteric arteries using pharmacological inhibitors. Constrictor sensitivity to ET-1 was enhanced in arteries from IH-exposed rats. Inhibition of PKC or PDK-1 blunted ET-1 constriction in arteries from IH but not sham group rats. Western analysis revealed similar levels of total and phosphorylated PDK-1 in arteries from sham and IH group rats but decreased protein-protein interaction between PKC and PDK-1 in arteries from IH- compared with sham-exposed rats. Blood pressure was increased in rats exposed to IH, and treatment with the PDK-1 inhibitor OSU-03012 [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg/day) lowered blood pressure in IH but not sham group rats. Our results suggest that exposure to IH unmasks a role for PDK-1 in regulating ET-1 constrictor sensitivity and blood pressure that is not present under normal conditions. These novel findings suggest that PDK-1 may be a uniquely effective antihypertensive therapy for OSA patients.
23093023	1520	1525	PDK-1	GENE-Y	23093023T10
23093023	1762	1767	PDK-1	GENE-Y	23093023T11
23093023	1782	1786	ET-1	GENE-Y	23093023T12
23093023	1909	1914	PDK-1	GENE-Y	23093023T13
23093023	418	430	endothelin-1	GENE-Y	23093023T14
23093023	432	436	ET-1	GENE-Y	23093023T15
23093023	467	491	protein kinase C (PKC) 	GENE-Y	23093023T16
23093023	541	576	phosphoinositide-dependent kinase-1	GENE-Y	23093023T17
23093023	578	583	PDK-1	GENE-Y	23093023T18
23093023	595	599	PKC	GENE-Y	23093023T19
23093023	1536	1545	OSU-03012	CHEMICAL	23093023T1
23093023	631	636	PDK-1	GENE-Y	23093023T20
23093023	666	670	ET-1	GENE-Y	23093023T21
23093023	914	918	PKC	GENE-Y	23093023T22
23093023	923	928	PDK-1	GENE-Y	23093023T23
23093023	932	936	ET-1	GENE-Y	23093023T24
23093023	1060	1064	ET-1	GENE-Y	23093023T25
23093023	1126	1130	PKC	GENE-Y	23093023T26
23093023	1134	1139	PDK-1	GENE-Y	23093023T27
23093023	1148	1152	ET-1	GENE-Y	23093023T28
23093023	0	35	Phosphoinositide-dependent kinase-1	GENE-Y	23093023T29
23093023	1547	1635	2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide	CHEMICAL	23093023T2
23093023	40	57	protein kinase C	GENE-Y	23093023T30
23093023	72	84	endothelin-1	GENE-Y	23093023T31
23093023	816	820	O(2)	CHEMICAL	23093023T3
23093023	824	829	CO(2)	CHEMICAL	23093023T4
23093023	837	841	O(2)	CHEMICAL	23093023T5
23093023	845	850	CO(2)	CHEMICAL	23093023T6
23093023	1265	1285	phosphorylated PDK-1	GENE-Y	23093023T7
23093023	1376	1380	PKC	GENE-Y	23093023T8
23093023	1385	1390	PDK-1	GENE-Y	23093023T9
23093023	CPR:4	23093023T1	23093023T10
23093023	CPR:4	23093023T2	23093023T10

23097088|t|Intercellular adhesion molecule-2 is involved in apical ectoplasmic specialization dynamics during spermatogenesis in the rat.
23097088|a|In this study, we investigated the role of intercellular adhesion molecule-2 (ICAM2) in the testis. ICAM2 is a cell adhesion protein having important roles in cell migration, especially during inflammation when leukocytes cross the endothelium. Herein, we showed ICAM2 to be expressed by germ and Sertoli cells in the rat testis. When a monospecific antibody was used for immunolocalization experiments, ICAM2 was found to surround the heads of elongating/elongated spermatids in all stages of the seminiferous epithelial cycle. To determine whether ICAM2 is a constituent of apical ectoplasmic specialization (ES), co-immunoprecipitation and dual immunofluorescence staining were performed. Interestingly, ICAM2 was found to associate with 1-integrin, nectin-3, afadin, Src, proline-rich tyrosine kinase 2, annexin II, and actin. Following CdCl treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during CdCl-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring. Taken collectively, these results illustrate that ICAM2 plays an important role in apical ES dynamics during spermatogenesis.
23097088	1403	1408	ICAM2	GENE-Y	109611
23097088	390	395	ICAM2	GENE-Y	109611
23097088	531	536	ICAM2	GENE-Y	109611
23097088	170	203	intercellular adhesion molecule-2	GENE-Y	23097088T13
23097088	677	682	ICAM2	GENE-Y	109611
23097088	834	839	ICAM2	GENE-Y	109611
23097088	868	879	1-integrin	GENE-Y	23097088T16
23097088	881	889	nectin-3	GENE-Y	23097088T17
23097088	891	897	afadin	GENE-Y	23097088T18
23097088	899	902	Src	GENE-Y	203491|249840
23097088	1225	1230	CdCl	CHEMICAL	23097088T1
23097088	904	934	proline-rich tyrosine kinase 2	GENE-Y	23097088T20
23097088	205	210	ICAM2	GENE-Y	109611
23097088	936	946	annexin II	GENE-Y	23097088T22
23097088	952	957	actin	GENE-N	23097088T23
23097088	986	991	ICAM2	GENE-Y	109611
23097088	0	33	Intercellular adhesion molecule-2	GENE-Y	23097088T25
23097088	917	925	tyrosine	CHEMICAL	23097088T2
23097088	969	974	CdCl	CHEMICAL	23097088T3
23097088	227	232	ICAM2	GENE-Y	109611
23097088	1136	1141	ICAM2	GENE-Y	109611
23097088	1203	1208	ICAM2	GENE-Y	109611
23097088	1212	1217	actin	GENE-N	23097088T7
23097088	1281	1286	ICAM2	GENE-Y	109611
23097088	1287	1292	actin	GENE-N	23097088T9
23097088	CPR:3	23097088T3	109611
23097088	CPR:4	23097088T1	23097088T7

23098818|t|The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: an in vitro study.
23098818|a|Brain serotonin has been implicated in the pathophysiology of a wide spectrum of psychiatric disorders, as well as in the mechanism of action of psychotropic drugs. The aim of present study was to identify rat cytochrome P450 (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain. The study was conducted on cDNA-expressed CYPs (rat CYP1A1/2, 2A1/2, 2B1, 2C6/11/13, 2D1/2/4/18, 2E1, 3A2 and human CYP2D6), on rat brain and liver microsomes and on human liver microsomes (the wild-type CYP2D6 or the allelic variant 2D6*4*4). Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6. Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to serotonin. The reaction was inhibited by the specific CYP2D inhibitors quinine and fluoxetine. Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective CYP2D6*4*4 ones. The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain. The results are discussed in the context of their possible physiological and pharmacological significance in vivo.
23098818	438	447	serotonin	CHEMICAL	23098818T10
23098818	501	510	serotonin	CHEMICAL	23098818T11
23098818	138	147	serotonin	CHEMICAL	23098818T12
23098818	884	885	O	CHEMICAL	23098818T13
23098818	903	922	5-methoxytryptamine	CHEMICAL	23098818T14
23098818	926	935	serotonin	CHEMICAL	23098818T15
23098818	1066	1085	5-methoxytryptamine	CHEMICAL	23098818T16
23098818	1089	1098	serotonin	CHEMICAL	23098818T17
23098818	64	73	serotonin	CHEMICAL	23098818T18
23098818	79	98	5-methoxytryptamine	CHEMICAL	23098818T19
23098818	1160	1167	quinine	CHEMICAL	23098818T1
23098818	1143	1148	CYP2D	GENE-N	23098818T20
23098818	1224	1230	CYP2D6	GENE-Y	107940
23098818	1316	1322	CYP2D6	GENE-Y	107940
23098818	1368	1383	rat brain CYP2D	GENE-N	23098818T23
23098818	1497	1502	CYP2D	GENE-N	23098818T24
23098818	338	357	rat cytochrome P450	GENE-N	23098818T25
23098818	359	362	CYP	GENE-N	23098818T26
23098818	592	596	CYPs	GENE-N	23098818T27
23098818	598	655	rat CYP1A1/2, 2A1/2, 2B1, 2C6/11/13, 2D1/2/4/18, 2E1, 3A2	GENE-N	23098818T28
23098818	660	672	human CYP2D6	GENE-Y	23098818T29
23098818	1172	1182	fluoxetine	CHEMICAL	23098818T2
23098818	754	760	CYP2D6	GENE-N	107940
23098818	784	787	2D6	GENE-N	23098818T31
23098818	801	808	rat CYP	GENE-N	23098818T32
23098818	827	832	CYP2D	GENE-N	23098818T33
23098818	975	995	human isoform CYP2D6	GENE-Y	23098818T34
23098818	28	43	cytochrome P450	GENE-N	23098818T35
23098818	1243	1262	5-methoxytryptamine	CHEMICAL	23098818T3
23098818	1266	1275	serotonin	CHEMICAL	23098818T4
23098818	1419	1428	serotonin	CHEMICAL	23098818T5
23098818	1434	1453	5-methoxytryptamine	CHEMICAL	23098818T6
23098818	1514	1523	serotonin	CHEMICAL	23098818T7
23098818	396	397	O	CHEMICAL	23098818T8
23098818	415	434	5-methoxytryptamine	CHEMICAL	23098818T9
23098818	CPR:4	23098818T1	23098818T20
23098818	CPR:4	23098818T2	23098818T20
23098818	CPR:9	23098818T13	23098818T33
23098818	CPR:9	23098818T13	23098818T34
23098818	CPR:9	23098818T14	23098818T33
23098818	CPR:9	23098818T14	23098818T34
23098818	CPR:9	23098818T15	23098818T33
23098818	CPR:9	23098818T15	23098818T34
23098818	CPR:9	23098818T18	23098818T35
23098818	CPR:9	23098818T19	23098818T35
23098818	CPR:9	23098818T3	107940
23098818	CPR:9	23098818T3	107940
23098818	CPR:9	23098818T4	107940
23098818	CPR:9	23098818T4	107940
23098818	CPR:9	23098818T5	23098818T23
23098818	CPR:9	23098818T6	23098818T23
23098818	CPR:9	23098818T7	23098818T24

23103568|t|Estrogen receptor signaling as a target for novel breast cancer therapeutics.
23103568|a|In breast cancer (BC) epithelial cells, the mitogenic action of estradiol is transduced through binding to two receptors, ER and ER, which act as transcription factors. Anti-estrogens (AEs) and aromatase inhibitors (AIs) are used clinically to arrest the estrogen-dependent growth of BC. In the case of AE or AI resistance, Herceptin or lapatinib may be used to inhibit growth factors. Estrogen effects are mediated not only through nuclear ERs but also through cytoplasmic/membrane ERs and G-protein-coupled ERs. These estrogen-binding systems associate with various proteins that direct cell cycle signaling, proliferation and survival. The partners of nuclear ER include SRC1-3, HDACs and ER itself as well as newly identified proteins, such as E6-AP, LKB1, PELP1, PAX-2 and FOXA1. The partners of extra-nuclear ER include PI3K and the tyrosine kinase Src. These various factors are all potential targets for therapeutic intervention. In addition, BC proliferation is enhanced by insulin and EGF, which stimulate signaling through the MAPK and PI3K/AKT pathways by activation of the IGF-1R and EGFR axes, respectively. These pathways are tightly interconnected with ER-activated signaling, and membrane ER forms complexes with Src and PI3K. Chemokine-mediated signaling also modulates the estrogen response. Inhibiting these pathways with specific inhibitors or activating some of the pathways by gene manipulation may be therapeutically valuable for arresting BC cell cycle progression and for inducing apoptosis to antagonize hormone-resistance. Here, we review some newly identified putatively targetable ER partners and highlight the need to develop tumor-targeting drug carrier systems affecting both the tumor cells and the tumor environment.
23103568	1120	1124	MAPK	GENE-N	23103568T10
23103568	1129	1133	PI3K	GENE-N	23103568T11
23103568	1134	1137	AKT	GENE-N	23103568T12
23103568	1168	1174	IGF-1R	GENE-Y	23103568T13
23103568	1179	1183	EGFR	GENE-Y	108276|3932452|676741
23103568	1251	1253	ER	GENE-Y	16226|2525
23103568	1288	1291	ER	GENE-Y	23103568T16
23103568	200	203	ER	GENE-Y	23103568T17
23103568	1313	1316	Src	GENE-Y	203491|249840
23103568	1321	1325	PI3K	GENE-N	23103568T19
23103568	1375	1383	estrogen	CHEMICAL	23103568T1
23103568	1327	1336	Chemokine	GENE-N	23103568T20
23103568	208	211	ER	GENE-Y	23103568T21
23103568	1694	1696	ER	GENE-Y	16226|2525
23103568	274	283	aromatase	GENE-Y	23103568T23
23103568	521	524	ERs	GENE-Y	23103568T24
23103568	563	566	ERs	GENE-Y	23103568T25
23103568	571	580	G-protein	GENE-N	23103568T26
23103568	589	592	ERs	GENE-Y	23103568T27
23103568	743	745	ER	GENE-Y	16226|2525
23103568	754	760	SRC1-3	GENE-N	23103568T29
23103568	254	263	estrogens	CHEMICAL	23103568T2
23103568	762	767	HDACs	GENE-N	23103568T30
23103568	772	775	ER	GENE-Y	23103568T31
23103568	829	834	E6-AP	GENE-Y	23103568T32
23103568	836	840	LKB1	GENE-Y	23103568T33
23103568	842	847	PELP1	GENE-Y	117973
23103568	849	854	PAX-2	GENE-Y	23103568T35
23103568	859	864	FOXA1	GENE-Y	109411
23103568	896	899	ER	GENE-Y	23103568T37
23103568	908	912	PI3K	GENE-N	23103568T38
23103568	921	936	tyrosine kinase	GENE-N	23103568T39
23103568	335	343	estrogen	CHEMICAL	23103568T3
23103568	937	940	Src	GENE-Y	203491|249840
23103568	1065	1072	insulin	GENE-Y	23103568T41
23103568	1077	1080	EGF	GENE-Y	108270
23103568	0	17	Estrogen receptor	GENE-Y	23103568T43
23103568	417	426	lapatinib	CHEMICAL	23103568T4
23103568	466	474	Estrogen	CHEMICAL	23103568T5
23103568	600	608	estrogen	CHEMICAL	23103568T6
23103568	142	151	estradiol	CHEMICAL	23103568T7
23103568	921	929	tyrosine	CHEMICAL	23103568T8
23103568	0	8	Estrogen	CHEMICAL	23103568T9

23111283|t|Toosendanin induces apoptosis through suppression of JNK signaling pathway in HL-60 cells.
23111283|a|Toosendanin (TSN), a triterpenoid isolated from Melia toosendan Sieb. et Zucc., has been found to suppress proliferation and induce apoptosis in a variety of human cancer cells. However, the mechanism how TSN induces apoptosis remains poorly understood. In this study, we examined the effects of TSN on the growth, cell cycle arrest, induction of apoptosis and the involved signaling pathway in human promyelocytic leukemia HL-60 cells. Proliferation of HL-60 cells was inhibited in a dose-dependent manner with the IC(50 (48 h)) of 28 ng/mL. The growth inhibition was due primarily to the S phase arrest and cell apoptosis. Cell apoptosis induced by TSN was confirmed by Annexin V-FITC/propidium iodide staining. The increase of the pro-apoptotic protein Bax, cleaved PARP and caspase-3, and the decrease of anti-apoptotic protein Bcl-2 were observed. Western blot analysis indicated that TSN inhibits the CDC42/MEKK1/JNK pathway. Taken together, our study suggested, for the first time, that the pro-apoptotic effects of TSN on HL-60 cells were mediated through JNK signaling pathway.
23111283	981	984	TSN	CHEMICAL	4124
23111283	0	11	Toosendanin	CHEMICAL	23111283T11
23111283	1155	1158	JNK	GENE-N	23111283T12
23111283	847	850	Bax	GENE-Y	198304|246997
23111283	860	864	PARP	GENE-N	23111283T14
23111283	869	878	caspase-3	GENE-Y	23111283T15
23111283	923	928	Bcl-2	GENE-Y	23111283T16
23111283	998	1003	CDC42	GENE-Y	107433|31499|1229572
23111283	1004	1009	MEKK1	GENE-Y	11709
23111283	1010	1013	JNK	GENE-N	23111283T19
23111283	91	102	Toosendanin	CHEMICAL	23111283T1
23111283	53	56	JNK	GENE-N	23111283T20
23111283	1114	1117	TSN	CHEMICAL	4124
23111283	104	107	TSN	CHEMICAL	4124
23111283	296	299	TSN	CHEMICAL	4124
23111283	112	124	triterpenoid	CHEMICAL	23111283T5
23111283	387	390	TSN	CHEMICAL	4124
23111283	742	745	TSN	CHEMICAL	4124
23111283	773	777	FITC	CHEMICAL	23111283T8
23111283	778	794	propidium iodide	CHEMICAL	23111283T9
23111283	CPR:4	4124	107433|31499|1229572
23111283	CPR:4	4124	11709
23111283	CPR:4	4124	23111283T19
23111283	CPR:4	23111283T11	23111283T20

23115221|t|Novel insights on the effect of nicotine in a murine colitis model.
23115221|a|Studies showed that nicotine has a positive influence on symptoms of ulcerative colitis. In the present study, we explored the effect of nicotine treatment using different routes of administration in the dextran sodium sulfate (DSS) colitis mouse model. We also investigated the effects of cotinine, a major metabolite of nicotine, in the model. C57BL6 adult male mice were given DSS solution freely in the drinking water for seven consecutive days, and tap water was given thereafter. Disease severity, length of the colon, colon tissue histology, and inflammatory markers, including colonic myeloperoxidase activity and colonic tumor necrosis factor- levels, were evaluated. The effect of nicotine and cotinine treatments via various different routes of administration were examined the DSS model. In addition, we measured the plasma levels of nicotine and cotinine in our treatment protocols. Administration of low, but not high, doses of oral nicotine in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of tumor necrosis factor-. However, the anti-inflammatory effect of nicotine was not seen after chronic s.c. or minipump infusion of the drug. Differences in plasma levels of nicotine and cotinine do not seem to account for this lack of effect. Finally, oral cotinine alone failed to show a significant effect in the DSS model of colitis. These results highlight that dose and route of administration play a critical role in the protective effect of nicotine in the DSS mouse colitis model.
23115221	390	398	nicotine	CHEMICAL	23115221T10
23115221	760	768	nicotine	CHEMICAL	23115221T11
23115221	773	781	cotinine	CHEMICAL	23115221T12
23115221	915	923	nicotine	CHEMICAL	23115221T13
23115221	928	936	cotinine	CHEMICAL	23115221T14
23115221	1016	1024	nicotine	CHEMICAL	23115221T15
23115221	32	40	nicotine	CHEMICAL	23115221T16
23115221	1155	1178	tumor necrosis factor-	GENE-Y	23115221T17
23115221	653	676	colonic myeloperoxidase	GENE-Y	23115221T18
23115221	690	721	colonic tumor necrosis factor-	GENE-Y	23115221T19
23115221	1221	1229	nicotine	CHEMICAL	23115221T1
23115221	1328	1336	nicotine	CHEMICAL	23115221T2
23115221	1341	1349	cotinine	CHEMICAL	23115221T3
23115221	1412	1420	cotinine	CHEMICAL	23115221T4
23115221	205	213	nicotine	CHEMICAL	23115221T5
23115221	1603	1611	nicotine	CHEMICAL	23115221T6
23115221	88	96	nicotine	CHEMICAL	23115221T7
23115221	280	294	sodium sulfate	CHEMICAL	23115221T8
23115221	358	366	cotinine	CHEMICAL	23115221T9
23115221	CPR:3	23115221T15	23115221T17

23117207|t|The S349T mutation of SQSTM1 links Keap1/Nrf2 signalling to Paget's disease of bone.
23117207|a|Mutations affecting the Sequestosome 1 (SQSTM1) gene commonly occur in patients with the skeletal disorder Paget's disease of bone (PDB), a condition characterised by defective osteoclast differentiation and function. Whilst most mutations cluster within the ubiquitin-associated (UBA) domain of the SQSTM1 protein, and are associated with dysregulated NFB signalling, several non-UBA domain mutations have also been identified. Keap1 is a SQSTM1-interacting protein that regulates the levels and activity of the Nrf2 transcription factor. This in turn controls the expression of numerous cytoprotective genes that contribute to the cell's capacity to defend itself against chemical and oxidative stress, through binding to the antioxidant response element (ARE). The PDB-associated S349T mutation maps to the Keap1-interacting region (KIR) of SQSTM1, however the effects of PDB mutant SQSTM1 on Keap1 function have not been investigated. Here we show that unlike other SQSTM1 mutations, the S349T mutation results in neither impaired ubiquitin-binding function in pull-down assays, nor dysregulated NFB signalling in luciferase reporter assays. Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical hydrogen bonds required to stabilise the KIR-Keap1 complex. Further, S349T mutant SQSTM1, but not other PDB-associated mutants, showed reduced ability to activate Nrf2 signalling as assessed by ARE-luciferase reporter assays. Thus, SQSTM1-mediated dysregulation of the Keap1-Nrf2 axis, which could potentially lead to aberrant production of oxidative response genes, may contribute to disease aetiology in a subset of PDB patients.
23117207	1531	1536	S349T	GENE-N	23117207T10
23117207	1544	1550	SQSTM1	GENE-Y	114397|160182
23117207	1625	1629	Nrf2	GENE-Y	23117207T12
23117207	1656	1659	ARE	GENE-N	23117207T13
23117207	1694	1700	SQSTM1	GENE-Y	114397|160182
23117207	1731	1736	Keap1	GENE-Y	67102|206135|250741
23117207	1737	1741	Nrf2	GENE-Y	23117207T16
23117207	109	123	Sequestosome 1	GENE-Y	23117207T17
23117207	344	377	ubiquitin-associated (UBA) domain	GENE-N	23117207T18
23117207	385	391	SQSTM1	GENE-Y	114397|160182
23117207	1462	1470	hydrogen	CHEMICAL	23117207T1
23117207	438	442	NFB	GENE-N	23117207T20
23117207	467	477	UBA domain	GENE-N	23117207T21
23117207	125	131	SQSTM1	GENE-Y	114397|160182
23117207	515	520	Keap1	GENE-Y	67102|206135|250741
23117207	526	532	SQSTM1	GENE-Y	114397|160182
23117207	599	603	Nrf2	GENE-Y	23117207T25
23117207	814	842	antioxidant response element	GENE-N	23117207T26
23117207	844	847	ARE	GENE-N	23117207T27
23117207	869	874	S349T	GENE-N	23117207T28
23117207	896	920	Keap1-interacting region	GENE-N	23117207T29
23117207	1121	1130	ubiquitin	GENE-N	23117207T2
23117207	922	925	KIR	GENE-N	23117207T30
23117207	930	936	SQSTM1	GENE-Y	114397|160182
23117207	972	978	SQSTM1	GENE-Y	114397|160182
23117207	982	987	Keap1	GENE-Y	67102|206135|250741
23117207	1056	1062	SQSTM1	GENE-Y	114397|160182
23117207	1078	1083	S349T	GENE-N	23117207T35
23117207	22	28	SQSTM1	GENE-Y	114397|160182
23117207	35	40	Keap1	GENE-Y	67102|206135|250741
23117207	41	45	Nrf2	GENE-Y	23117207T38
23117207	4	9	S349T	GENE-N	23117207T39
23117207	1186	1190	NFB	GENE-N	23117207T3
23117207	1233	1238	Keap1	GENE-Y	67102|206135|250741
23117207	1301	1306	S349T	GENE-N	23117207T5
23117207	1340	1346	SQSTM1	GENE-Y	114397|160182
23117207	1347	1352	Keap1	GENE-Y	67102|206135|250741
23117207	1503	1506	KIR	GENE-N	23117207T8
23117207	1507	1512	Keap1	GENE-Y	67102|206135|250741

23117790|t|Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.
23117790|a|Orexin-A (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism. We previously showed that the development of postischemic glucose intolerance is one of the triggers of ischemic neuronal damage. The aim of this study was to determine whether there was an interaction between orexin-A and BDNF functions in the hypothalamus after cerebral ischemic stress. Male ddY mice were subjected to 2 hours of middle cerebral artery occlusion (MCAO). Neuronal damage was estimated by histologic and behavioral analyses. Expression of protein levels was analyzed by Western blot. Small interfering RNA directed BDNF, orexin-A, and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus. The level of hypothalamic orexin-A, detected by immunohistochemistry, was decreased on day 1 after MCAO. Intrahypothalamic administration of orexin-A (1 or 5 pmol/mouse) significantly and dose-dependently suppressed the development of postischemic glucose intolerance on day 1 and development of neuronal damage on day 3. The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of SB334867 as well as by hypothalamic BDNF knockdown. These results suggest that suppression of postischemic glucose intolerance by orexin-A assists in the prevention of cerebral ischemic neuronal damage. In addition, hypothalamic BDNF may play an important role in this effect of orexin-A.
23117790	129	137	Orexin-A	GENE-Y	23117790T10
23117790	230	234	BDNF	GENE-Y	107096
23117790	1213	1221	orexin-A	GENE-Y	23117790T12
23117790	252	264	neurotrophin	GENE-N	23117790T13
23117790	1423	1439	insulin receptor	GENE-Y	23117790T14
23117790	1524	1532	orexin-A	GENE-Y	23117790T15
23117790	1553	1561	orexin-A	GENE-Y	23117790T16
23117790	1636	1640	BDNF	GENE-Y	107096
23117790	1730	1738	orexin-A	GENE-Y	23117790T18
23117790	1829	1833	BDNF	GENE-Y	107096
23117790	1320	1327	glucose	CHEMICAL	23117790T1
23117790	1879	1887	orexin-A	GENE-Y	23117790T20
23117790	569	577	orexin-A	GENE-Y	23117790T21
23117790	582	586	BDNF	GENE-Y	107096
23117790	195	228	brain-derived neurotrophic factor	GENE-Y	23117790T23
23117790	892	896	BDNF	GENE-Y	107096
23117790	898	906	orexin-A	GENE-Y	23117790T25
23117790	992	1009	orexin-1 receptor	GENE-Y	23117790T26
23117790	1098	1106	orexin-A	GENE-Y	23117790T27
23117790	0	8	Orexin-A	GENE-Y	23117790T28
23117790	94	127	brain-derived neurotrophic factor	GENE-Y	23117790T29
23117790	141	148	glucose	CHEMICAL	23117790T2
23117790	1600	1608	SB334867	CHEMICAL	23117790T3
23117790	1707	1714	glucose	CHEMICAL	23117790T4
23117790	339	346	glucose	CHEMICAL	23117790T5
23117790	417	424	glucose	CHEMICAL	23117790T6
23117790	912	920	SB334867	CHEMICAL	23117790T7
23117790	922	979	N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea	CHEMICAL	23117790T8
23117790	33	40	glucose	CHEMICAL	23117790T9
23117790	CPR:4	23117790T3	23117790T14
23117790	CPR:4	23117790T3	23117790T16
23117790	CPR:6	23117790T7	23117790T26
23117790	CPR:6	23117790T8	23117790T26

23146664|t|Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1.
23146664|a|Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition characterized by chronic inflammation of the colon. Knowledge about the molecular and cellular targets of 5-ASA is limited and a clear understanding of its activity in intestinal homeostasis and interference with neoplastic progression is lacking. We sought to identify molecular pathways interfered by 5-ASA, using CRC cell lines with different genetic background. Microarray was performed for gene expression profile of 5-ASA-treated and untreated cells (HCT116 and HT29). Filtering and analysis of data identified three oncogenic pathways interfered by 5-ASA: MAPK/ERK pathway, cell adhesion and -catenin/Wnt signaling. PAK1 emerged as a consensus target of 5-ASA, orchestrating these pathways. We further investigated the effect of 5-ASA on cell adhesion. 5-ASA increased cell adhesion which was measured by cell adhesion assay and transcellular-resistance measurement. Moreover, 5-ASA treatment restored membranous expression of adhesion molecules E-cadherin and -catenin. Role of PAK1 as a mediator of mesalamine activity was validated in vitro and in vivo. Inhibition of PAK1 by RNA interference also increased cell adhesion. PAK1 expression was elevated in APC(min) polyps and 5-ASA treatment reduced its expression. Our data demonstrates novel pharmacological mechanism of mesalamine in modulation of cell adhesion and role of PAK1 in APC(min) polyposis. We propose that inhibition of PAK1 expression by 5-ASA can impede with neoplastic progression in colorectal carcinogenesis. The mechanism of PAK1 inhibition and induction of membranous translocation of adhesion proteins by 5-ASA might be independent of its known anti-inflammatory action.
23146664	744	749	5-ASA	CHEMICAL	237
23146664	850	855	5-ASA	CHEMICAL	237
23146664	925	930	5-ASA	CHEMICAL	237
23146664	949	954	5-ASA	CHEMICAL	237
23146664	1073	1078	5-ASA	CHEMICAL	237
23146664	0	10	Mesalamine	CHEMICAL	237
23146664	1142	1152	E-cadherin	GENE-Y	23146664T16
23146664	1157	1166	-catenin	GENE-Y	23146664T17
23146664	1176	1180	PAK1	GENE-Y	111095
23146664	1268	1272	PAK1	GENE-Y	111095
23146664	91	101	Mesalamine	CHEMICAL	237
23146664	1323	1327	PAK1	GENE-Y	111095
23146664	1526	1530	PAK1	GENE-Y	111095
23146664	1584	1588	PAK1	GENE-Y	111095
23146664	1695	1699	PAK1	GENE-Y	111095
23146664	751	755	MAPK	GENE-N	23146664T24
23146664	756	759	ERK	GENE-N	23146664T25
23146664	787	796	-catenin	GENE-Y	23146664T26
23146664	797	800	Wnt	GENE-N	23146664T27
23146664	812	816	PAK1	GENE-Y	111095
23146664	66	89	p-21 activated kinase-1	GENE-Y	23146664T29
23146664	103	108	5-ASA	CHEMICAL	237
23146664	1375	1380	5-ASA	CHEMICAL	237
23146664	1472	1482	mesalamine	CHEMICAL	23146664T4
23146664	1603	1608	5-ASA	CHEMICAL	237
23146664	1777	1782	5-ASA	CHEMICAL	237
23146664	294	299	5-ASA	CHEMICAL	237
23146664	491	496	5-ASA	CHEMICAL	237
23146664	610	615	5-ASA	CHEMICAL	237
23146664	CPR:3	237	23146664T16
23146664	CPR:3	237	23146664T17
23146664	CPR:4	237	23146664T29
23146664	CPR:4	237	111095
23146664	CPR:4	237	111095
23146664	CPR:4	237	111095

23146761|t|Cholestatic effect of epigallocatechin gallate in rats is mediated via decreased expression of Mrp2.
23146761|a|Epigallocatechin gallate (EGCG) has been shown to be protective in various experimental models of liver injury, although opposite effects have also been reported. Since its effect on biliary physiology has not been thoroughly investigated, the present study evaluated effect of EGCG on bile flow and bile acid homeostasis in rats. Compared to controls, EGCG treatment decreased bile flow by 23%. Hepatic paracellular permeability and biliary bile acid excretion were not altered by EGCG administration, but biliary glutathione excretion was reduced by 70%. Accordingly, the main glutathione transporter on the hepatocyte canalicular membrane, multidrug resistance-associated protein 2 (Mrp2), was significantly decreased at the protein level. EGCG administration also doubled plasma bile acid levels compared to controls. While protein levels of the main hepatic bile acid transporters were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1, was significantly increased by EGCG. Enhanced bile acid synthesis in these animals was also confirmed by a 2-fold increase in plasma marker 7-hydroxy-4-cholesten-3-one. In contrast, EGCG markedly downregulated major bile acid transporters (Asbt and Ost) and regulatory molecules (Shp and Fgf15) in the ileum. When EGCG was coadministered with ethinylestradiol, a potent cholestatic agent, it did not show any additional effect on the induced cholestasis. This study shows ability of EGCG to raise plasma bile acid concentrations, mainly through Cyp7a1 upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow. In conclusion, our data demonstrate that under certain conditions EGCG may induce cholestasis.
23146761	1699	1708	bile acid	CHEMICAL	23146761T10
23146761	1798	1802	EGCG	CHEMICAL	9892
23146761	127	131	EGCG	CHEMICAL	9892
23146761	379	383	EGCG	CHEMICAL	9892
23146761	401	410	bile acid	CHEMICAL	23146761T14
23146761	454	458	EGCG	CHEMICAL	9892
23146761	543	552	bile acid	CHEMICAL	23146761T16
23146761	583	587	EGCG	CHEMICAL	9892
23146761	616	627	glutathione	CHEMICAL	23146761T18
23146761	680	691	glutathione	CHEMICAL	23146761T19
23146761	101	125	Epigallocatechin gallate	CHEMICAL	9892
23146761	844	848	EGCG	CHEMICAL	9892
23146761	884	893	bile acid	CHEMICAL	23146761T21
23146761	964	973	bile acid	CHEMICAL	23146761T22
23146761	1035	1044	bile acid	CHEMICAL	23146761T23
23146761	1095	1099	EGCG	CHEMICAL	9892
23146761	22	46	epigallocatechin gallate	CHEMICAL	23146761T25
23146761	1281	1303	bile acid transporters	GENE-N	23146761T26
23146761	1305	1309	Asbt	GENE-Y	23146761T27
23146761	1314	1318	Ost	GENE-Y	23146761T28
23146761	1346	1349	Shp	GENE-Y	23146761T29
23146761	1110	1119	bile acid	CHEMICAL	23146761T2
23146761	1354	1359	Fgf15	GENE-Y	23146761T30
23146761	1611	1617	Cyp7a1	GENE-Y	23146761T31
23146761	1685	1689	Mrp2	GENE-Y	23146761T32
23146761	680	703	glutathione transporter	GENE-N	23146761T33
23146761	744	785	multidrug resistance-associated protein 2	GENE-Y	23146761T34
23146761	787	791	Mrp2	GENE-Y	23146761T35
23146761	956	986	hepatic bile acid transporters	GENE-Y	23146761T36
23146761	1056	1062	Cyp7a1	GENE-Y	23146761T37
23146761	95	99	Mrp2	GENE-Y	23146761T38
23146761	1204	1232	7-hydroxy-4-cholesten-3-one	CHEMICAL	23146761T3
23146761	1247	1251	EGCG	CHEMICAL	9892
23146761	1281	1290	bile acid	CHEMICAL	23146761T5
23146761	1380	1384	EGCG	CHEMICAL	9892
23146761	1409	1425	ethinylestradiol	CHEMICAL	23146761T7
23146761	1549	1553	EGCG	CHEMICAL	9892
23146761	1570	1579	bile acid	CHEMICAL	23146761T9
23146761	CPR:3	9892	23146761T31
23146761	CPR:4	9892	23146761T26
23146761	CPR:4	9892	23146761T27
23146761	CPR:4	9892	23146761T28
23146761	CPR:4	9892	23146761T29
23146761	CPR:4	9892	23146761T30

23147987|t|Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada.
23147987|a|Although the presence and distribution of polychlorinated biphenyls (PCBs) in Arctic marine environments has been well documented, the implications for the health of biota are poorly understood. In the present study, multiple lines of evidence, including site-specific effects data, were used to assess PCB-related risks to marine biota at a contaminated military site in Saglek Bay, Labrador, Canada, from 1997 to 1999. Risks were evaluated for three components of the ecosystem: benthic invertebrates, a bottom-feeding fish (shorthorn sculpin, Myoxocephalus scorpius), and a diving seabird (black guillemot, Cepphus grylle). Average sediment PCB concentrations exceeded the Canadian interim sediment quality guideline level by 41-fold. However, sediment toxicity testing and a benthic community survey showed no evidence of adverse effects. In contrast, shorthorn sculpin and black guillemot PCB exposures (measured as sum of 55 congeners) were elevated enough to pose risks to survival or reproduction. Based on the collective evidence, the authors estimated that risks were posed by sediment PCB concentrations greater than 77ng/g dry weight for black guillemots and 750ng/g dry weight for shorthorn sculpins. The present study, along with two parallel studies, provided information to support the management decisions concerning potential remedial action on the contaminated sediments. This ecological risk assessment describes the steps and rationale taken to evaluate the risk posed by an area of PCB-contaminated marine sediments in an otherwise relatively pristine northern coastal environment.
23147987	1221	1224	PCB	CHEMICAL	23147987T1
23147987	1631	1634	PCB	CHEMICAL	23147987T2
23147987	428	431	PCB	CHEMICAL	23147987T3
23147987	167	192	polychlorinated biphenyls	CHEMICAL	23147987T4
23147987	769	772	PCB	CHEMICAL	23147987T5
23147987	194	198	PCBs	CHEMICAL	23147987T6
23147987	1019	1022	PCB	CHEMICAL	23147987T7
23147987	53	77	polychlorinated biphenyl	CHEMICAL	23147987T8

23150495|t|Ablation of Egr2-positive cells in male mouse anterior pituitary leads to atypical isolated GH deficiency.
23150495|a|In this study, we have investigated the expression and function of the transcription factor early growth response factor 2 (Egr2)/Krox20 in the developing anterior pituitary. Egr2 is initially expressed in all differentiating hormonal cells types, but its expression is mostly restricted to the somatotroph lineage after birth. Egr2 knockout results in anterior pituitary hypoplasia. However, the analysis of a conditional mutant demonstrates that this phenotype does not originate from a lack of Egr2 expression in the pituitary. Using an Egr2 allele driving a Cre-activable toxin gene, we performed a genetic ablation of Egr2-positive cells in the pituitary. During the postnatal period, this ablation leads to specific and progressive depletion of the somatotroph population, creating a novel model of early-onset isolated GH deficiency (GHD). Mutant animals were subjected to a complete metabolic analysis, revealing atypical and expected features. Consistent with an adult-onset isolated GHD model, mutant animals are hypoglycemic and display increased insulin sensitivity and glucose clearance. This latter phenotype is in contrast to the glucose intolerance observed in another early-onset GHD model. Surprisingly, increased insulin sensitivity is not accompanied by a modified balance between fat and lean tissues, but by reduced metabolic adaptability between glucose and lipid oxidation conditions. This suggests that the relationship between these metabolic features and insulin sensitivity should be reconsidered. In conclusion, our mutant may be a valuable genetic model with which to study the effects of long-term GH deficiency, in conditions of normal pancreatic function and unaffected balance between fat and glucose metabolism.
23150495	604	608	Egr2	GENE-Y	199405
23150495	647	651	Egr2	GENE-Y	199405
23150495	730	734	Egr2	GENE-Y	199405
23150495	199	229	early growth response factor 2	GENE-Y	23150495T13
23150495	12	16	Egr2	GENE-Y	199405
23150495	1189	1196	glucose	CHEMICAL	23150495T1
23150495	1252	1259	glucose	CHEMICAL	23150495T2
23150495	1476	1483	glucose	CHEMICAL	23150495T3
23150495	1834	1841	glucose	CHEMICAL	23150495T4
23150495	1165	1172	insulin	GENE-N	23150495T5
23150495	231	235	Egr2	GENE-Y	199405
23150495	237	243	Krox20	GENE-Y	23150495T7
23150495	282	286	Egr2	GENE-Y	199405
23150495	435	439	Egr2	GENE-Y	199405

23155201|t|The scintigraphic evaluation and genetic correlation of joint involvements in pediatric patients with familial Mediterranean fever.
23155201|a|Purpose: We aimed to evaluate the articular involvements in pediatric patients with familial Mediterranean fever (FMF) with joint symptoms by bone scintigraphy and to correlate the involved joints with the gene mutations. Materials and methods: A total of 41 newly diagnosed patients in pediatric age group (28 girls and 13 boys; mean age 9.14  2.91 years) with joint involvement symptoms were included in this study. Scintigraphic images were obtained at 5th min (blood pool or early phase) and starting at 3 h (late phase) after (after tracer injection) intravenous administration of technetium-99m (99mTc)-methylendiphosphonate (MDP). Genomic DNA was isolated from leukocytes using standard salting out procedure. The sequencing data were analyzed. Results: Of the 41 patients, arthritis was found in 21 (51.2%) patients. Of the 21 patients, there was single joint involvement in 15 (71.4%) patients and multiple joint involvement in six (28.6%) patients. The mean age of patients with joint involvement (8  2.3 years) were considerably lower than the patients without joint involvement (10.35  3.04 years), and this was statistically significant (p = 0.008). The most commonly involved joints were ankles and knees. Multiple joint involvements were most frequently observed in the M694V and M694I gene mutations (16.7%). Conclusions: We use and recommend the bone scintigraphy in patients with FMF to determine the presence and distribution of arthritis, since bone scintigraphy is inexpensive, noninvasive, easy-to-use, and also is more sensitive in the diagnosis and distribution of arthritis than conventional radiological methods and clinical examination.
23155201	719	733	technetium-99m	CHEMICAL	23155201T1
23155201	735	740	99mTc	CHEMICAL	23155201T2
23155201	742	763	methylendiphosphonate	CHEMICAL	23155201T3
23155201	765	768	MDP	CHEMICAL	23155201T4
23155201	1420	1425	M694V	GENE-N	23155201T5
23155201	1430	1435	M694I	GENE-N	23155201T6

23157629|t|Serotonin receptors of type 6 (5-HT6): from neuroscience to clinical pharmacology.
23157629|a|The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop. A lot of controversies still exist regarding their binding affinity, effects of 5-HT6 ligands on brain catecholamines, behavioral syndromes regulated by them, and brain distribution. In spite of the lack of information on metabolic pattern of the various compounds, some of 5-HT6 receptor ligands entered the clinical development as potential anti-dementia, antipsychotic, antidepressant and anti-obese drugs. The present paper is a comprehensive review on the state of art of the 5-HT6 receptors, while highlighting the potential clinical applications of 5-HT6 receptor agonists/antagonists.
23157629	604	609	5-HT6	GENE-Y	23157629T10
23157629	811	816	5-HT6	GENE-Y	23157629T11
23157629	886	891	5-HT6	GENE-Y	23157629T12
23157629	167	181	5-HT receptors	GENE-N	23157629T13
23157629	0	19	Serotonin receptors	GENE-N	23157629T14
23157629	31	36	5-HT6	GENE-Y	23157629T15
23157629	98	102	5-HT	CHEMICAL	23157629T1
23157629	243	244	C	CHEMICAL	23157629T2
23157629	433	447	catecholamines	CHEMICAL	23157629T3
23157629	87	96	serotonin	CHEMICAL	23157629T4
23157629	167	171	5-HT	CHEMICAL	23157629T5
23157629	0	9	Serotonin	CHEMICAL	23157629T6
23157629	410	415	5-HT6	GENE-Y	23157629T7
23157629	125	130	5-HT6	GENE-Y	23157629T8
23157629	87	113	serotonin (5-HT) receptors	GENE-N	23157629T9

23159887|t|Expression of cAMP-responsive element binding proteins (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (ColQ) of acetylcholinesterase at the rat neuromuscular junction.
23159887|a|The gene encoding the collagen-tailed subunit (ColQ) of acetylcholinesterase (AChE) contains two distinct promoters that drive the production of two ColQ mRNAs, ColQ-1 and ColQ-1a, in slow- and fast-twitch muscles, respectively. ColQ-1a is expressed at the neuromuscular junction (NMJ) in fast-twitch muscle, and this expression depends on trophic factors supplied by motor neurons signaling via a cAMP-dependent pathway in muscle. To further elucidate the molecular basis of ColQ-1a's synaptic expression, here we investigated the expression and localization of cAMP-responsive element binding protein (CREB) at the synaptic and extra-synaptic regions of fast- and slow-twitch muscles from adult rats. The total amount of active, phosphorylated CREB (P-CREB) present in slow-twitch soleus muscle was higher than that in fast-twitch tibialis muscle, but P-CREB was predominantly expressed in the fast-twitch muscle at NMJs. In contrast, P-CREB was detected in both synaptic and extra-synaptic regions of slow-twitch muscle. These results reveal, for the first time, the differential distribution of P-CREB in fast- and slow-twitch muscles, which might support the crucial role of cAMP-dependent signaling in controlling the synapse-specific expression of ColQ-1a in fast-twitch muscles.
23159887	271	294	collagen-tailed subunit	GENE-Y	23159887T10
23159887	478	485	ColQ-1a	GENE-Y	23159887T11
23159887	296	300	ColQ	GENE-Y	23159887T12
23159887	725	734	ColQ-1a's	GENE-Y	23159887T13
23159887	812	851	cAMP-responsive element binding protein	GENE-N	23159887T14
23159887	305	325	acetylcholinesterase	GENE-Y	23159887T15
23159887	853	857	CREB	GENE-N	23159887T16
23159887	980	999	phosphorylated CREB	GENE-N	23159887T17
23159887	1001	1007	P-CREB	GENE-N	23159887T18
23159887	327	331	AChE	GENE-Y	23159887T19
23159887	1429	1433	cAMP	CHEMICAL	2424
23159887	1103	1109	P-CREB	GENE-N	23159887T20
23159887	1186	1192	P-CREB	GENE-N	23159887T21
23159887	14	54	cAMP-responsive element binding proteins	GENE-N	23159887T22
23159887	159	182	collagen-tailed subunit	GENE-Y	23159887T23
23159887	184	188	ColQ	GENE-Y	23159887T24
23159887	193	213	acetylcholinesterase	GENE-Y	23159887T25
23159887	56	61	CREBs	GENE-N	23159887T26
23159887	647	651	cAMP	CHEMICAL	2424
23159887	812	816	cAMP	CHEMICAL	2424
23159887	14	18	cAMP	CHEMICAL	2424
23159887	1348	1354	P-CREB	GENE-N	23159887T5
23159887	1504	1511	ColQ-1a	GENE-Y	23159887T6
23159887	398	402	ColQ	GENE-Y	23159887T7
23159887	410	416	ColQ-1	GENE-Y	23159887T8
23159887	421	428	ColQ-1a	GENE-Y	23159887T9

23159888|t|Analysis of mammalian alcohol dehydrogenase 5 (ADH5): characterisation of rat ADH5 with comparisons to the corresponding human variant.
23159888|a|Alcohol dehydrogenase 5 (ADH5) is a member of the mammalian alcohol dehydrogenase family of yet undefined functions. ADH5 was first identified at the DNA level in human and deer mouse. A rat alcohol dehydrogenase structure of similar type has been isolated at the cDNA level using human ADH5 as a screening probe, where the rat cDNA structure displayed several atypical properties. mRNA for rat ADH5 was found in multiple tissues, especially in the kidney. In vitro translation experiments indicated that rat ADH5 is expressed as efficiently as ADH1 and furthermore, rat ADH5 was readily expressed in COS cells fused to Green Fluorescent Protein. However, no soluble ADH5 protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other mammalian ADHs, including fused to glutathione-S-transferase. Molecular modelling of the enzyme indicated that the protein does not fold in a productive way, which can be the explanation why no stable and active ADH5 has been isolated. These results indicate that ADH5, while readily expressed at the mRNA level, does not behave similarly to other mammalian ADHs investigated. The results, in vitro and in silico, suggest an unstable ADH5 structure, which can explain for why no active and stable protein can be isolated. Further possibilities are conceivable: the ADH5 protein may have to interact with a stabiliser, or the gene is actually a pseudogene.
23159888	1276	1290	mammalian ADHs	GENE-N	23159888T10
23159888	253	257	ADH5	GENE-Y	32844|106640|683353
23159888	1362	1366	ADH5	GENE-Y	32844|106640|683353
23159888	1493	1497	ADH5	GENE-Y	32844|106640|683353
23159888	323	348	rat alcohol dehydrogenase	GENE-N	23159888T14
23159888	161	165	ADH5	GENE-Y	32844|106640|683353
23159888	417	427	human ADH5	GENE-Y	23159888T16
23159888	527	535	rat ADH5	GENE-Y	23159888T17
23159888	641	649	rat ADH5	GENE-Y	23159888T18
23159888	186	217	mammalian alcohol dehydrogenase	GENE-N	23159888T19
23159888	136	143	Alcohol	CHEMICAL	888
23159888	681	685	ADH1	GENE-Y	34317|1219481|29266
23159888	703	711	rat ADH5	GENE-Y	23159888T21
23159888	803	807	ADH5	GENE-Y	32844|106640|683353
23159888	928	942	mammalian ADHs	GENE-N	23159888T23
23159888	12	45	mammalian alcohol dehydrogenase 5	GENE-Y	23159888T24
23159888	47	51	ADH5	GENE-Y	32844|106640|683353
23159888	74	82	rat ADH5	GENE-Y	23159888T26
23159888	327	334	alcohol	CHEMICAL	23159888T2
23159888	196	203	alcohol	CHEMICAL	23159888T3
23159888	963	974	glutathione	CHEMICAL	23159888T4
23159888	975	976	S	CHEMICAL	127
23159888	22	29	alcohol	CHEMICAL	23159888T6
23159888	136	159	Alcohol dehydrogenase 5	GENE-Y	23159888T7
23159888	1140	1144	ADH5	GENE-Y	32844|106640|683353
23159888	1192	1196	ADH5	GENE-Y	32844|106640|683353

23161844|t|Combining quantum mechanical ligand conformation analysis and protein modeling to elucidate GPCR-ligand binding modes.
23161844|a|SAR beyond protein-ligand interactions: By combining structure-affinity relationships, protein-ligand modeling studies, and quantum mechanical calculations, we show that ligand conformational energies and basicity play critical roles in ligand binding to the histamine H4 receptor, a GPCR that plays a key role in inflammation.
23161844	378	387	histamine	CHEMICAL	23161844T1
23161844	378	399	histamine H4 receptor	GENE-Y	23161844T2
23161844	403	407	GPCR	GENE-N	26950
23161844	92	96	GPCR	GENE-N	26950

23164921|t|Catalpol inhibits LPS plus IFN--induced inflammatory response in astrocytes primary cultures.
23164921|a|A large body of evidence suggests that the inflammatory reaction plays an important role in the pathogenesis of neurodegenerative diseases. Our previous studies described the neuroprotective effects of catalpol in lipopolysaccharide (LPS)-induced inflammatory models, in which catalpol was shown to prevent mesencephalic neuron death and ameliorate cognitive ability animals. To further investigate the protective effect and underlying mechanism of catalpol, astrocytes were pretreated with low (0.1mM) and high dose (0.5mM) catalpol for 1h prior to LPS plus interferon- stimulation. Biochemical analyses showed that NO and ROS production and iNOS activity were significantly reduced by catalpol. Data at transcriptional level also demonstrated that catalpol potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and TLR4. In addition, our exploration further revealed that the suppressive action of catalpol on inflammation was mediated via inhibiting nuclear factor-B (NF-B) activation. Collectively, these results suggest that catalpol can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of NF-B could be the major determinant for its anti-inflammatory mechanism. Therefore, catalpol may potentially be a highly effective therapeutic agent in treating neurodegenerative diseases associated with inflammation.
23164921	1025	1033	catalpol	CHEMICAL	23164921T10
23164921	0	8	Catalpol	CHEMICAL	23164921T11
23164921	1097	1102	NF-B	GENE-N	23164921T12
23164921	1263	1268	NF-B	GENE-N	23164921T13
23164921	654	666	interferon-	GENE-Y	23164921T14
23164921	739	743	iNOS	GENE-Y	23164921T15
23164921	926	930	iNOS	GENE-Y	23164921T16
23164921	932	937	COX-2	GENE-Y	23164921T17
23164921	942	946	TLR4	GENE-Y	112954
23164921	1078	1095	nuclear factor-B	GENE-N	23164921T19
23164921	1157	1165	catalpol	CHEMICAL	23164921T1
23164921	27	32	IFN-	GENE-Y	23164921T20
23164921	1348	1356	catalpol	CHEMICAL	23164921T2
23164921	297	305	catalpol	CHEMICAL	23164921T3
23164921	372	380	catalpol	CHEMICAL	23164921T4
23164921	544	552	catalpol	CHEMICAL	23164921T5
23164921	620	628	catalpol	CHEMICAL	23164921T6
23164921	713	715	NO	CHEMICAL	427
23164921	783	791	catalpol	CHEMICAL	23164921T8
23164921	846	854	catalpol	CHEMICAL	23164921T9
23164921	CPR:4	23164921T10	23164921T12
23164921	CPR:4	23164921T10	23164921T19
23164921	CPR:4	23164921T11	23164921T20
23164921	CPR:4	23164921T1	23164921T13
23164921	CPR:4	23164921T8	23164921T15
23164921	CPR:4	23164921T9	23164921T16
23164921	CPR:4	23164921T9	23164921T17
23164921	CPR:4	23164921T9	112954

23172229|t|Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV.
23172229|a|Here, we report for the first time in vitro reconstitution of the respiratory supercomplexes from individual complexes III and IV. Complexes III and IV were purified from Saccharomyces cerevisiae mitochondria. Complex III contained eight molecules of cardiolipin, and complex IV contained two molecules of cardiolipin, as determined by electrospray ionization-mass spectrometry. Complex IV also contained Rcf1p. No supercomplexes were formed upon mixing of the purified complexes, and low amounts of the supercomplex trimer III(2)IV(1) were formed after reconstitution into proteoliposomes containing only phosphatidylcholine and phosphatidylethanolamine. Further addition of cardiolipin to the proteoliposome reconstitution mixture resulted in distinct formation of both the III(2)IV(1) supercomplex trimer and III(2)IV(2) supercomplex tetramer. No other anionic phospholipid was as effective as cardiolipin in supporting tetramer formation. Phospholipase treatment of complex IV prevented trimer formation in the absence of cardiolipin. Both trimer and tetramer formations were restored by cardiolipin. Analysis of the reconstituted tetramer by single particle electron microscopy confirmed native organization of individual complexes within the supercomplex. In conclusion, although some trimer formation occurred dependent only on tightly bound cardiolipin, tetramer formation required additional cardiolipin. This is consistent with the high cardiolipin content in the native tetramer. The dependence on cardiolipin for supercomplex formation suggests that changes in cardiolipin levels resulting from changes in physiological conditions may control the equilibrium between individual respiratory complexes and supercomplexes in vivo.
23172229	734	753	phosphatidylcholine	CHEMICAL	23172229T10
23172229	758	782	phosphatidylethanolamine	CHEMICAL	23172229T11
23172229	1025	1036	cardiolipin	CHEMICAL	23172229T12
23172229	0	11	Cardiolipin	CHEMICAL	3286
23172229	533	538	Rcf1p	GENE-Y	23172229T14
23172229	1071	1084	Phospholipase	GENE-N	23172229T15
23172229	1154	1165	cardiolipin	CHEMICAL	23172229T1
23172229	1220	1231	cardiolipin	CHEMICAL	23172229T2
23172229	1477	1488	cardiolipin	CHEMICAL	23172229T3
23172229	1529	1540	cardiolipin	CHEMICAL	23172229T4
23172229	1575	1586	cardiolipin	CHEMICAL	23172229T5
23172229	1637	1648	cardiolipin	CHEMICAL	23172229T6
23172229	1701	1712	cardiolipin	CHEMICAL	23172229T7
23172229	379	390	cardiolipin	CHEMICAL	23172229T8
23172229	434	445	cardiolipin	CHEMICAL	23172229T9

23177789|t|Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.
23177789|a|Protein tyrosine phosphatase 1B (PTP1B) is an important factor in non-insulin-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity. Therefore, the aim of this study is to investigate the inhibitory activities of constituents (three new together with twelve known triterpenes compounds) isolated from the hydrolyzate of total saponins from Gynostemma pentaphyllum. Their structures were accomplished mainly base on the spectroscopic methods, and then were further confirmed by X-ray crystal diffraction. All the compounds were evaluated for inhibitory activity against PTP1B. Current data suggested that the compounds 1, 3, 12, 13 and 14 were considered to be potential as antidiabetic agents, in which they could significantly inhibit the PTP1B enzyme activity in a dose-dependent manner.
23177789	763	768	PTP1B	GENE-Y	23177789T10
23177789	210	217	insulin	GENE-Y	23177789T11
23177789	934	939	PTP1B	GENE-Y	23177789T12
23177789	0	31	Protein tyrosine phosphatase 1B	GENE-Y	23177789T13
23177789	458	469	triterpenes	CHEMICAL	23177789T1
23177789	520	528	saponins	CHEMICAL	23177789T2
23177789	148	156	tyrosine	CHEMICAL	23177789T3
23177789	130	138	saponins	CHEMICAL	23177789T4
23177789	53	62	dammarane	CHEMICAL	23177789T5
23177789	68	79	triterpenes	CHEMICAL	23177789T6
23177789	8	16	tyrosine	CHEMICAL	23177789T7
23177789	140	171	Protein tyrosine phosphatase 1B	GENE-Y	23177789T8
23177789	173	178	PTP1B	GENE-Y	23177789T9
23177789	CPR:4	23177789T4	23177789T13
23177789	CPR:4	23177789T5	23177789T13
23177789	CPR:4	23177789T6	23177789T13

23182946|t|Disrupted cytoskeletal homeostasis, astrogliosis and apoptotic cell death in the cerebellum of preweaning rats injected with diphenyl ditelluride.
23182946|a|In the present report 15 day-old rats were injected with 0.3mol of diphenyl ditelluride (PhTe)(2)/kg body weight and parameters of neurodegeneration were analyzed in slices from cerebellum 3 and 6 days afterwards. The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities. Also, reactive astrogliosis takes part of the early responses to the insult with (PhTe)(2), evidenced by upregulated GFAP in Western blot, PCR and immunofluorescence analysis. Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death. Moreover, activated caspase 3 suggested apoptotic neuronal death. Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however phospho-GSK-3- (Ser9) was not altered in (PhTe)(2) injected rat. Therefore, the present results show that the earlier cerebellar responses to (PhTe)(2) include disruption of cytoskeletal homeostasis that could be related with MAPK and PKA activation and reactive astrogliosis. Akt inhibition observed at this time could also play a role in the neuronal death evidenced afterwards. The later events of the neurodegenerative process are characterized by persistent astrogliosis and activation of apoptotic neuronal death through caspase 3 mediated mechanisms, which could be related with glutamate excitotoxicity. The progression of these responses are therefore likely to be critical for the outcome of the neurodegeneration provoked by (PhTe)(2) in rat cerebellum.
23182946	850	859	(PhTe)(2)	CHEMICAL	23182946T10
23182946	960	969	(PhTe)(2)	CHEMICAL	23182946T11
23182946	1024	1040	propidium iodide	CHEMICAL	23182946T12
23182946	236	245	(PhTe)(2)	CHEMICAL	23182946T13
23182946	125	145	diphenyl ditelluride	CHEMICAL	23182946T14
23182946	1152	1156	NeuN	GENE-Y	23182946T15
23182946	1258	1267	caspase 3	GENE-Y	23182946T16
23182946	1386	1389	Akt	GENE-N	23182946T17
23182946	1416	1431	phospho-GSK-3-	GENE-Y	23182946T18
23182946	1643	1647	MAPK	GENE-N	23182946T19
23182946	1198	1207	(PhTe)(2)	CHEMICAL	23182946T1
23182946	1652	1655	PKA	GENE-N	23182946T20
23182946	1694	1697	Akt	GENE-N	23182946T21
23182946	1944	1953	caspase 3	GENE-Y	23182946T22
23182946	496	527	glial fibrillary acidic protein	GENE-Y	23182946T23
23182946	530	534	GFAP	GENE-Y	108938
23182946	541	549	vimentin	GENE-Y	23182946T25
23182946	563	625	low-, medium- and high molecular weight neurofilament subunits	GENE-N	23182946T26
23182946	627	631	NF-L	GENE-Y	23182946T27
23182946	633	637	NF-M	GENE-Y	23182946T28
23182946	642	646	NF-H	GENE-Y	23182946T29
23182946	1349	1364	[(3)H]glutamate	CHEMICAL	23182946T2
23182946	659	691	mitogen-activated protein kinase	GENE-N	23182946T30
23182946	693	697	MAPK	GENE-N	23182946T31
23182946	700	703	Erk	GENE-N	23182946T32
23182946	708	715	p38MAPK	GENE-N	23182946T33
23182946	721	750	cAMP-dependent protein kinase	GENE-N	23182946T34
23182946	752	755	PKA	GENE-N	23182946T35
23182946	886	890	GFAP	GENE-Y	108938
23182946	1064	1068	NeuN	GENE-Y	23182946T37
23182946	1433	1436	Ser	CHEMICAL	127
23182946	1458	1467	(PhTe)(2)	CHEMICAL	23182946T4
23182946	1559	1568	(PhTe)(2)	CHEMICAL	23182946T5
23182946	2003	2012	glutamate	CHEMICAL	23182946T6
23182946	2153	2162	(PhTe)(2)	CHEMICAL	23182946T7
23182946	721	725	cAMP	CHEMICAL	2424
23182946	215	235	diphenyl ditelluride	CHEMICAL	23182946T9
23182946	CPR:3	23182946T10	108938
23182946	CPR:3	23182946T5	23182946T19
23182946	CPR:3	23182946T5	23182946T20
23182946	CPR:4	23182946T1	23182946T15
23182946	CPR:4	23182946T4	23182946T17

23194529|t|The presence of D-fagomine in the human diet from buckwheat-based foodstuffs.
23194529|a|Buckwheat (Fagopyrum esculentum Moench) groats contain the iminosugar D-fagomine as a minor component that might contribute to the alleged health benefits of this pseudo-cereal. This study presents analysis of D-fagomine in buckwheat-based foodstuffs by liquid chromatography coupled to mass spectrometry and an estimation of its presence in the human diet based on a published population-based cross-sectional nutrition survey. D-fagomine is present in common buckwheat-based foodstuffs in amounts ranging from 1 to 25 mg/kg or mg/L, it is stable during boiling, baking, frying and fermentation, and it is biosynthesised upon sprouting. The estimated total intake of D-fagomine resulting from a diet that includes such foodstuffs would be between 3 and 17 mg per day (mean for both genders; range from P5 to P95). A diet rich in buckwheat products would provide a daily amount of D-fagomine that may in part explain the beneficial properties traditionally attributed to buckwheat consumption.
23194529	288	298	D-fagomine	CHEMICAL	23194529T1
23194529	507	517	D-fagomine	CHEMICAL	23194529T2
23194529	746	756	D-fagomine	CHEMICAL	23194529T3
23194529	148	158	D-fagomine	CHEMICAL	23194529T4
23194529	959	969	D-fagomine	CHEMICAL	23194529T5
23194529	16	26	D-fagomine	CHEMICAL	23194529T6

23198810|t|Profluorogenic reductase substrate for rapid, selective, and sensitive visualization and detection of human cancer cells that overexpress NQO1.
23198810|a|Achieving the vision of identifying and quantifying cancer-related events and targets for future personalized oncology is predicated on the existence of synthetically accessible and economically viable probe molecules fully able to report the presence of these events and targets in a rapid and highly selective and sensitive fashion. Delineated here are the design and evaluation of a newly synthesized turn-on probe whose intense fluorescent reporter signature is revealed only through probe activation by a specific intracellular enzyme present in tumor cells of multiple origins. Quenching of molecular probe fluorescence is achieved through unique photoinduced electron transfer between the naphthalimide dye reporter and a covalently attached, quinone-based enzyme substrate. Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (hNQO1). Successes of the approach include rapid differentiation of NQO1-expressing and -nonexpressing cancer cell lines via the unaided eye, flow cytometry, fluorescence imaging, and two-photon microscopy. The potential for use of the turn-on probe in longer-term cellular studies is indicated by its lack of influence on cell viability and its in vitro stability.
23198810	1149	1156	quinone	CHEMICAL	23198810T1
23198810	1206	1213	quinone	CHEMICAL	23198810T2
23198810	840	853	naphthalimide	CHEMICAL	23198810T3
23198810	894	901	quinone	CHEMICAL	23198810T4
23198810	996	1003	quinone	CHEMICAL	23198810T5
23198810	1192	1238	human NAD(P)H:quinone oxidoreductase isozyme 1	GENE-Y	23198810T6
23198810	1240	1245	hNQO1	GENE-Y	23198810T7
23198810	1307	1311	NQO1	GENE-Y	108072
23198810	138	142	NQO1	GENE-Y	108072
23198810	CPR:9	23198810T1	23198810T6
23198810	CPR:9	23198810T1	23198810T7

23199028|t|Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo.
23199028|a|Novel glycyrrhizin (GL) derivatives were designed and synthesized by introducing various amine or amino acid residues into the carbohydrate chain and at C-30. Their inhibitory effects on high-mobility group box 1 (HMGB1) were evaluated using a cell-based lipopolysaccharide (LPS) induced tumor necrosis factor  (TNF-) release study. Compounds 10, 12, 18-20, 23, and 24, which had substituents introduced at C-30, demonstrated moderate HMGB1 inhibition with ED values ranging from 337 to 141 M, which are values comparable to that of the leading GL compound (1) (ED = 70 M). Compounds 23 and 24 emerged as novel and interesting HMGB1 inhibitors. These compounds were able to extend the survival of mice with chronic heart failure (CHF) and acute heart failure (AHF), respectively. In addition, molecular modeling studies were performed to support the biological data.
23199028	611	616	HMGB1	GENE-Y	109389|9669
23199028	809	814	HMGB1	GENE-Y	109389|9669
23199028	95	120	high-mobility group box-1	GENE-Y	23199028T12
23199028	301	313	carbohydrate	CHEMICAL	23199028T1
23199028	180	192	glycyrrhizin	CHEMICAL	23199028T2
23199028	263	268	amine	CHEMICAL	23199028T3
23199028	272	282	amino acid	CHEMICAL	23199028T4
23199028	60	72	glycyrrhizin	CHEMICAL	23199028T5
23199028	361	386	high-mobility group box 1	GENE-Y	23199028T6
23199028	388	393	HMGB1	GENE-Y	109389|9669
23199028	462	485	tumor necrosis factor 	GENE-Y	23199028T8
23199028	487	492	TNF-	GENE-Y	23199028T9
23199028	CPR:4	23199028T5	23199028T12

23200253|t|Further exploration of M allosteric agonists: subtle structural changes abolish M allosteric agonism and result in pan-mAChR orthosteric antagonism.
23200253|a|This letter describes the further exploration of two series of M(1) allosteric agonists, TBPB and VU0357017, previously reported from our lab. Within the TPBP scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-mAChR antagonism, which was demonstrated to be mediated via the orthosteric site. Additional SAR around a related M(1) allosteric agonist family (VU0357017) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-mAChR orthosteric antagonism. Therefore, all of these ligands are best classified as bi-topic ligands that possess high affinity binding at an allosteric site to engender selective M(1) activation, but all bind, at higher concentrations, to the orthosteric ACh site, leading to non-selective orthosteric site binding and mAChR antagonism.
23200253	305	309	TPBP	CHEMICAL	23200253T1
23200253	377	387	piperidine	CHEMICAL	23200253T2
23200253	607	616	VU0357017	CHEMICAL	23200253T3
23200253	240	244	TBPB	CHEMICAL	23200253T4
23200253	249	258	VU0357017	CHEMICAL	23200253T5
23200253	461	466	mAChR	GENE-N	23200253T6
23200253	734	739	mAChR	GENE-N	23200253T7
23200253	1055	1060	mAChR	GENE-N	23200253T8
23200253	121	126	mAChR	GENE-N	23200253T9
23200253	CPR:6	23200253T1	23200253T6
23200253	CPR:6	23200253T2	23200253T6
23200253	CPR:6	23200253T3	23200253T7

23205514|t|Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats.
23205514|a|1.The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2.The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3.To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction. When risperidone (6mg/kg) was co-administered with silymarin (40mg/kg) to rats orally, the C(max) of 9-hydroxyrisperidone was significantly increased to1.3-fold (p < 0.05), while the other pharmacokinetic parameters did not show any significant differences. Expanding the experiment where rats were repeatedly administered with silymarin for 5 days prior to giving risperidone, the C(max) of risperidone and 9-hydroxyrisperidone were significantly increased to 2.4-fold (p < 0.001) and 1.7-fold (p < 0.001), respectively, and the AUC(0-t), as well to 1.7-fold (p < 0.05) and 2.1-fold (p < 0.01), respectively. 4.The repeated exposures of silymarin, compared to single administration of silymarin, increased oral bioavailability and affected the pharmacokinetics of risperidone and 9-hydroxyrisperidone, by inhibiting P-gp.
23205514	1103	1114	risperidone	CHEMICAL	23205514T10
23205514	1130	1141	risperidone	CHEMICAL	23205514T11
23205514	116	136	9-hydroxyrisperidone	CHEMICAL	23205514T12
23205514	78	89	risperidone	CHEMICAL	23205514T13
23205514	262	276	P-glycoprotein	GENE-Y	23205514T14
23205514	278	282	P-gp	GENE-Y	23205514T15
23205514	1556	1560	P-gp	GENE-Y	23205514T16
23205514	495	499	P-gp	GENE-Y	23205514T17
23205514	1146	1166	9-hydroxyrisperidone	CHEMICAL	23205514T1
23205514	1504	1515	risperidone	CHEMICAL	23205514T2
23205514	1520	1540	9-hydroxyrisperidone	CHEMICAL	23205514T3
23205514	511	522	risperidone	CHEMICAL	23205514T4
23205514	550	570	9-hydroxyrisperidone	CHEMICAL	23205514T5
23205514	618	629	risperidone	CHEMICAL	23205514T6
23205514	634	654	9-hydroxyrisperidone	CHEMICAL	23205514T7
23205514	741	752	risperidone	CHEMICAL	23205514T8
23205514	839	859	9-hydroxyrisperidone	CHEMICAL	23205514T9
23205514	CPR:9	23205514T4	23205514T17
23205514	CPR:9	23205514T5	23205514T17

23205571|t|Design, synthesis and structure-activity relationship of new arginine vasopressin analogues containing proline derivatives in position 2.
23205571|a|In this study, we present the synthesis and pharmacological properties of new analogues of arginine vasopressin modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid. All the peptides were tested for pressor, antidiuretic and in vitro uterotonic activities. We also determined their binding affinity to the human oxytocin receptor. The Ica(2) substitution resulted in two moderately potent and selective antioxytocic agents: [Mpa(1), Ica(2), D-Arg(8)]VP and [Mpa(1),Ica(2),Val(4),D-Arg(8)]VP (pA(2) = 7.09 and 7.50, respectively). On the other hand, peptides modified with (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid, apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to arginine vasopressin. The results of this study provide useful information about the structure-activity relationship of arginine vasopressin analogues and can help to design compounds with desired biological properties.
23205571	832	895	(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid	CHEMICAL	23205571T10
23205571	1007	1027	arginine vasopressin	CHEMICAL	23205571T11
23205571	229	249	arginine vasopressin	CHEMICAL	23205571T12
23205571	1127	1147	arginine vasopressin	CHEMICAL	23205571T13
23205571	103	110	proline	CHEMICAL	23205571T14
23205571	61	81	arginine vasopressin	CHEMICAL	23205571T15
23205571	566	589	human oxytocin receptor	GENE-Y	23205571T16
23205571	1007	1027	arginine vasopressin	GENE-Y	23205571T17
23205571	229	249	arginine vasopressin	GENE-Y	23205571T18
23205571	1127	1147	arginine vasopressin	GENE-Y	23205571T19
23205571	266	267	N	CHEMICAL	167
23205571	61	81	arginine vasopressin	GENE-Y	23205571T20
23205571	303	310	proline	CHEMICAL	23205571T2
23205571	324	350	indoline-2-carboxylic acid	CHEMICAL	23205571T3
23205571	352	355	Ica	CHEMICAL	23205571T4
23205571	361	424	(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid	CHEMICAL	23205571T5
23205571	572	580	oxytocin	CHEMICAL	102
23205571	595	598	Ica	CHEMICAL	23205571T7
23205571	684	712	[Mpa(1), Ica(2), D-Arg(8)]VP	CHEMICAL	23205571T8
23205571	717	750	[Mpa(1),Ica(2),Val(4),D-Arg(8)]VP	CHEMICAL	23205571T9
23205571	CPR:6	23205571T10	23205571T17

23211426|t|Liver X Receptors and female reproduction: when cholesterol meets fertility!
23211426|a|The role of cholesterol in female reproductive physiology has been suspected for a long time, while the molecular bases were unknown. Cholesterol is the precursor of ovarian steroid biosynthesis and is also essential for fertility. In the uterus, cholesterol is essential to achieve correct contractions at term, but an excessive uterine cholesterol concentration has been associated with contractility defects. Liver X Receptor (LXR)  and LXR  are nuclear receptors activated by oxysterols, oxidized derivatives of cholesterol. Since their discovery, the role of LXR in the control of cholesterol homeostasis has been widely described. Beyond their cholesterol-lowering role, more recent data have linked these nuclear receptors to various physiological processes. In particular, they control ovarian endocrine and exocrine functions, as well as uterine contractility. Their contribution to female reproductive cancers will also be discussed. This review will try to enlighten on the LXR as a molecular link between dietary cholesterol and reproductive diseases in women. In the future, a better comprehension of the various physiological processes regulated by the LXR will help to develop new ligands to prevent or to cure these pathologies in women.
23211426	729	740	cholesterol	CHEMICAL	23211426T10
23211426	48	59	cholesterol	CHEMICAL	23211426T11
23211426	1246	1249	LXR	GENE-N	23211426T12
23211426	489	513	Liver X Receptor (LXR) 	GENE-Y	23211426T13
23211426	518	523	LXR 	GENE-Y	23211426T14
23211426	643	646	LXR	GENE-N	23211426T15
23211426	1064	1067	LXR	GENE-N	23211426T16
23211426	0	17	Liver X Receptors	GENE-N	23211426T17
23211426	1104	1115	cholesterol	CHEMICAL	23211426T1
23211426	89	100	cholesterol	CHEMICAL	23211426T2
23211426	211	222	Cholesterol	CHEMICAL	4350
23211426	251	258	steroid	CHEMICAL	23211426T4
23211426	324	335	cholesterol	CHEMICAL	23211426T5
23211426	415	426	cholesterol	CHEMICAL	23211426T6
23211426	559	569	oxysterols	CHEMICAL	23211426T7
23211426	595	606	cholesterol	CHEMICAL	23211426T8
23211426	665	676	cholesterol	CHEMICAL	23211426T9
23211426	CPR:3	23211426T7	23211426T13
23211426	CPR:3	23211426T7	23211426T14

23211523|t|-catenin regulates GnRH-induced FSH gene expression.
23211523|a|The regulation of gonadotropin synthesis by GnRH plays an essential role in the neuroendocrine control of reproduction. The known signaling mechanisms involved in gonadotropin synthesis have been expanding. For example, involvement of -catenin in LH induction by GnRH has been discovered. We examined the role of -catenin in FSH gene expression in LT2 gonadotrope cells. GnRH caused a sustained increase in nuclear -catenin levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition. Small interfering RNA-mediated knockdown of -catenin mRNA demonstrated that induction of FSH mRNA by GnRH depended on -catenin and that regulation of FSH by -catenin occurred independently of the JNK-c-jun pathway. -Catenin depletion had no impact on FSH mRNA stability. In LT2 cells transfected with FSH promoter luciferase fusion constructs, GnRH responsiveness was conferred by the proximal promoter (-944/-1) and was markedly decreased by -catenin knockdown. However, none of the T-cell factor/lymphoid enhancer factor binding sites in that region were required for promoter activation by GnRH. Chromatin immunoprecipitation further corroborated the absence of direct interaction between -catenin and the 1.8-kb FSH promoter. To elucidate the mechanism for the -catenin effect, we analyzed approximately 1 billion reads of next-generation RNA sequencing -catenin knockdown assays and selected the nuclear cofactor breast cancer metastasis-suppressor 1-like (Brms1L) as one candidate for further study. Subsequent experiments confirmed that Brms1L mRNA expression was decreased by -catenin knockdown as well as by JNK inhibition. Furthermore, knockdown of Brms1L significantly attenuated GnRH-induced FSH expression. Thus, our findings indicate that the expression of Brms1L depends on -catenin activity and contributes to FSH induction by GnRH.
23211523	20	24	GnRH	CHEMICAL	634
23211523	1064	1116	T-cell factor/lymphoid enhancer factor binding sites	GENE-N	23211523T11
23211523	1173	1177	GnRH	GENE-Y	23211523T12
23211523	1272	1281	-catenin	GENE-Y	23211523T13
23211523	1297	1310	FSH promoter	GENE-N	23211523T14
23211523	1347	1356	-catenin	GENE-Y	23211523T15
23211523	1441	1450	-catenin	GENE-Y	23211523T16
23211523	1502	1544	breast cancer metastasis-suppressor 1-like	GENE-Y	23211523T17
23211523	1546	1552	Brms1L	GENE-Y	23211523T18
23211523	1628	1634	Brms1L	GENE-Y	23211523T19
23211523	1173	1177	GnRH	CHEMICAL	634
23211523	1668	1677	-catenin	GENE-Y	23211523T20
23211523	218	230	gonadotropin	GENE-N	23211523T21
23211523	1702	1705	JNK	GENE-N	23211523T22
23211523	1744	1750	Brms1L	GENE-Y	23211523T23
23211523	1776	1780	GnRH	GENE-Y	23211523T24
23211523	1789	1793	FSH	GENE-Y	23211523T25
23211523	1857	1863	Brms1L	GENE-Y	23211523T26
23211523	1875	1884	-catenin	GENE-Y	23211523T27
23211523	73	85	gonadotropin	GENE-N	23211523T28
23211523	1913	1917	FSH	GENE-Y	23211523T29
23211523	1776	1780	GnRH	CHEMICAL	634
23211523	1931	1935	GnRH	GENE-Y	23211523T30
23211523	290	299	-catenin	GENE-Y	23211523T31
23211523	320	324	GnRH	GENE-Y	23211523T32
23211523	370	379	-catenin	GENE-Y	23211523T33
23211523	383	387	FSH	GENE-Y	23211523T34
23211523	431	435	GnRH	GENE-Y	23211523T35
23211523	475	484	-catenin	GENE-Y	23211523T36
23211523	99	103	GnRH	GENE-Y	23211523T37
23211523	528	551	c-Jun N-terminal kinase	GENE-N	23211523T38
23211523	553	556	JNK	GENE-N	23211523T39
23211523	1931	1935	GnRH	CHEMICAL	634
23211523	614	623	-catenin	GENE-Y	23211523T40
23211523	660	664	FSH	GENE-Y	23211523T41
23211523	673	677	GnRH	GENE-Y	23211523T42
23211523	690	699	-catenin	GENE-Y	23211523T43
23211523	723	727	FSH	GENE-Y	23211523T44
23211523	731	740	-catenin	GENE-Y	23211523T45
23211523	771	774	JNK	GENE-N	23211523T46
23211523	775	780	c-jun	GENE-Y	23211523T47
23211523	790	799	-Catenin	GENE-Y	23211523T48
23211523	827	831	FSH	GENE-Y	23211523T49
23211523	320	324	GnRH	CHEMICAL	634
23211523	879	892	FSH promoter	GENE-N	23211523T50
23211523	923	927	GnRH	GENE-Y	23211523T51
23211523	1022	1031	-catenin	GENE-Y	23211523T52
23211523	0	9	-catenin	GENE-Y	23211523T53
23211523	20	24	GnRH	GENE-Y	23211523T54
23211523	33	37	FSH	GENE-Y	23211523T55
23211523	431	435	GnRH	CHEMICAL	634
23211523	99	103	GnRH	CHEMICAL	634
23211523	534	535	N	CHEMICAL	167
23211523	673	677	GnRH	CHEMICAL	634
23211523	923	927	GnRH	CHEMICAL	634
23211523	CPR:3	634	23211523T55
23211523	CPR:3	634	23211523T25
23211523	CPR:3	634	23211523T29
23211523	CPR:3	634	23211523T36
23211523	CPR:3	634	23211523T41

23220037|t|Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells.
23220037|a|P-glycoprotein (P-gp) is an efflux pump belonging to the ATP-binding cassette transporter superfamily expressed in several organs. Considering its potential protective effects, the induction of de novo synthesis of P-gp could be used therapeutically in the treatment of intoxications by its substrates. The herbicide paraquat (PQ) is a P-gp substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote. The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX), a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario. Cytotoxicity was evaluated by the MTT assay and PQ intracellular concentrations were measured by gas chromatography-ion trap-mass spectrometry (GC-IT-MS). Also, the DOX modulatory effect on choline uptake transport system was assessed by measuring the uptake of [H]-choline. The results show that DOX exerts protective effects against PQ cytotoxicity, preventing the intracellular accumulation of the herbicide. These protective effects were not completely prevented by the incubation with the UIC2 antibody, a specific P-gp inhibitor, suggesting the involvement of alternative protection mechanisms. In fact, DOX also efficiently inhibited the choline transport system that influences PQ cellular uptake. In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing P-gp and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.
23220037	131	134	ATP	CHEMICAL	164
23220037	855	858	MTT	CHEMICAL	23220037T11
23220037	986	989	DOX	CHEMICAL	23220037T12
23220037	1011	1018	choline	CHEMICAL	23220037T13
23220037	0	11	Doxorubicin	CHEMICAL	987
23220037	22	30	paraquat	CHEMICAL	23220037T15
23220037	74	88	P-glycoprotein	GENE-N	23220037T16
23220037	1342	1346	P-gp	GENE-N	23220037T17
23220037	1624	1628	P-gp	GENE-N	23220037T18
23220037	1666	1685	choline transporter	GENE-N	23220037T19
23220037	1083	1095	[H]-choline	CHEMICAL	23220037T1
23220037	90	94	P-gp	GENE-N	23220037T20
23220037	289	293	P-gp	GENE-N	23220037T21
23220037	102	113	efflux pump	GENE-N	23220037T22
23220037	410	414	P-gp	GENE-N	23220037T23
23220037	652	656	P-gp	GENE-N	23220037T24
23220037	131	163	ATP-binding cassette transporter	GENE-N	23220037T25
23220037	1119	1122	DOX	CHEMICAL	23220037T2
23220037	1432	1435	DOX	CHEMICAL	23220037T3
23220037	1467	1474	choline	CHEMICAL	23220037T4
23220037	1567	1570	DOX	CHEMICAL	23220037T5
23220037	1666	1673	choline	CHEMICAL	23220037T6
23220037	391	399	paraquat	CHEMICAL	23220037T7
23220037	625	636	doxorubicin	CHEMICAL	23220037T8
23220037	638	641	DOX	CHEMICAL	23220037T9
23220037	CPR:3	23220037T5	23220037T18
23220037	CPR:3	23220037T8	23220037T24
23220037	CPR:3	23220037T9	23220037T24
23220037	CPR:9	23220037T7	23220037T23

23220641|t|Sirtuins as emerging anti-parasitic targets.
23220641|a|Silent information regulator 2 (Sir2) enzymes or sirtuins are a family of NAD(+)-dependent protein N()-acetyl-lysine (AcK) deacetylases. Sirtuins are also evolutionarily conserved proteins that are present in all kingdoms of life ranging from bacteria to humans. Interestingly, it was recently found that the sirtuins found in various human parasites (especially the Plasmodium, Trypanosoma, and Leishmania species) were pro-survival for the parasites under various conditions. Therefore, these parasitic sirtuins have emerged as novel anti-parasitic therapeutic targets. This article reviews the currently available structural, biochemical, pharmacological, and medicinal chemistry studies on these enzymes, and discusses the perspectives of selectively targeting the parasitic sirtuins as a novel therapeutic strategy for the human parasitic diseases.
23220641	119	181	NAD(+)-dependent protein N()-acetyl-lysine (AcK) deacetylases	GENE-N	23220641T10
23220641	815	833	parasitic sirtuins	GENE-N	23220641T11
23220641	0	8	Sirtuins	GENE-N	23220641T12
23220641	164	167	AcK	CHEMICAL	23220641T1
23220641	119	125	NAD(+)	CHEMICAL	23220641T2
23220641	144	162	N()-acetyl-lysine	CHEMICAL	23220641T3
23220641	45	75	Silent information regulator 2	GENE-Y	23220641T4
23220641	183	191	Sirtuins	GENE-N	23220641T5
23220641	355	363	sirtuins	GENE-N	23220641T6
23220641	77	81	Sir2	GENE-Y	60746
23220641	94	102	sirtuins	GENE-N	23220641T8
23220641	541	559	parasitic sirtuins	GENE-N	23220641T9

23220742|t|The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
23220742|a|B-cell receptor (BCR) associated kinases including spleen tyrosine kinase (SYK) contribute to the pathogenesis of B-cell malignancies. SYK is persistently phosphorylated in a subset of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), and SYK inhibition results in abrogation of downstream kinase activity and apoptosis. P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases. We evaluated the preclinical characteristics of P505-15 in models of NHL and CLL. P505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL. Oral dosing in mice prevented BCR-mediated splenomegaly and significantly inhibited NHL tumor growth in a xenograft model. In addition, combination treatment of primary CLL cells with P505-15 plus fludarabine produced synergistic enhancement of activity at nanomolar concentrations. Our findings support the ongoing development of P505-15 as a therapeutic agent for B-cell malignancies. A dose finding study in healthy volunteers has been completed.
23220742	28	35	P505-15	CHEMICAL	23220742T10
23220742	37	46	PRT062607	CHEMICAL	23220742T11
23220742	182	197	B-cell receptor	GENE-N	23220742T12
23220742	317	320	SYK	GENE-Y	112717|686612
23220742	199	202	BCR	GENE-N	107083
23220742	438	441	SYK	GENE-Y	112717|686612
23220742	489	495	kinase	GENE-N	23220742T16
23220742	215	222	kinases	GENE-N	23220742T17
23220742	623	626	SYK	GENE-Y	112717|686612
23220742	638	641	SYK	GENE-Y	112717|686612
23220742	1278	1285	P505-15	CHEMICAL	23220742T1
23220742	667	670	SYK	GENE-Y	112717|686612
23220742	233	255	spleen tyrosine kinase	GENE-Y	23220742T21
23220742	741	748	kinases	GENE-N	23220742T22
23220742	863	866	SYK	GENE-Y	112717|686612
23220742	876	891	B-cell receptor	GENE-N	23220742T24
23220742	257	260	SYK	GENE-Y	112717|686612
23220742	977	980	BCR	GENE-N	107083
23220742	14	17	SYK	GENE-Y	112717|686612
23220742	520	527	P505-15	CHEMICAL	23220742T2
23220742	543	552	PRT062607	CHEMICAL	23220742T3
23220742	240	248	tyrosine	CHEMICAL	23220742T4
23220742	798	805	P505-15	CHEMICAL	23220742T5
23220742	832	839	P505-15	CHEMICAL	23220742T6
23220742	1131	1138	P505-15	CHEMICAL	23220742T7
23220742	1144	1155	fludarabine	CHEMICAL	23220742T8
23220742	137	148	fludarabine	CHEMICAL	23220742T9
23220742	CPR:4	23220742T10	112717|686612
23220742	CPR:4	23220742T11	112717|686612
23220742	CPR:4	23220742T2	112717|686612
23220742	CPR:4	23220742T2	112717|686612
23220742	CPR:4	23220742T2	112717|686612
23220742	CPR:4	23220742T3	112717|686612
23220742	CPR:4	23220742T3	112717|686612
23220742	CPR:4	23220742T3	112717|686612
23220742	CPR:4	23220742T6	112717|686612
23220742	CPR:4	23220742T6	23220742T24

23223234|t|The fidelity of transcription: RPB1 (RPO21) mutations that increase transcriptional slippage in S. cerevisiae.
23223234|a|The fidelity of RNA synthesis depends on both accurate template-mediated nucleotide selection and proper maintenance of register between template and RNA. Loss of register, or transcriptional slippage, is particularly likely on homopolymeric runs in the template. Transcriptional slippage can alter the coding capacity of mRNAs and is used as a regulatory mechanism. Here we describe mutations in the largest subunit of Saccharomyces cerevisiae RNA polymerase II that substantially increase the level of transcriptional slippage. Alleles of RPB1 (RPO21) with elevated slippage rates were identified among 6-azauracil-sensitive mutants and were also isolated using a slippage-dependent reporter gene. Biochemical characterization of polymerase II isolated from these mutants confirms elevated levels of transcriptional slippage.
23223234	716	727	6-azauracil	CHEMICAL	23223234T1
23223234	184	194	nucleotide	CHEMICAL	23223234T2
23223234	531	573	Saccharomyces cerevisiae RNA polymerase II	GENE-N	23223234T3
23223234	652	656	RPB1	GENE-Y	23223234T4
23223234	658	663	RPO21	GENE-Y	31921|1222085
23223234	843	856	polymerase II	GENE-N	23223234T6
23223234	31	35	RPB1	GENE-Y	23223234T7
23223234	37	42	RPO21	GENE-Y	31921|1222085

23223414|t|Effect of nuclear vibrations, temperature, co-adsorbed water, and dye orientation on light absorption, charge injection and recombination conditions in organic dyes on TiO2.
23223414|a|We study the effect of nuclear motions at different temperatures, including the effect of a dye molecule's orientation with respect to the oxide surface, on factors determining the performance of dye sensitized solar cells: light absorption, electron injection, and back-donation. We perform ab initio molecular dynamics simulations of aminophenyl acid dyes NK1 and NK7, differing by the electron donating group, in a vacuum and adsorbed in mono- and bi-dentate modes on a dry and a water-covered anatase (101) surface of TiO(2), at 300 and 350 K. Nuclear vibrations and an increase of temperature cause a red shift in the absorption spectra of free dyes. This effect is preserved in dyes on dry TiO(2) but largely disappears in the presence of water. Averaged over nuclear vibrations, the driving force to injection, G, differs from the static estimate. It depends on the adsorption mode and the presence of H(2)O but is almost the same for 300 and 350 K. Recombination to the dye cation is expected to be much enhanced by the approach of the dye oxidation equivalent hole to the surface during dye wagging around TiO(2). This effect is somewhat mitigated by the co-adsorbed water. The dynamics of G(t) are explained by uncorrelated evolution of the energies of the dye excited state and the conduction band minimum of the oxide due to their respective vibrations, and are almost independent of dye orientation. It may therefore be possible to independently control the conditions of recombination and of injection.
23223414	1084	1089	H(2)O	CHEMICAL	23223414T10
23223414	168	172	TiO2	CHEMICAL	23223414T11
23223414	1290	1296	TiO(2)	CHEMICAL	23223414T1
23223414	1500	1505	oxide	CHEMICAL	23223414T2
23223414	313	318	oxide	CHEMICAL	23223414T3
23223414	510	526	aminophenyl acid	CHEMICAL	23223414T4
23223414	532	535	NK1	CHEMICAL	23223414T5
23223414	540	543	NK7	CHEMICAL	23223414T6
23223414	671	684	anatase (101)	CHEMICAL	23223414T7
23223414	696	702	TiO(2)	CHEMICAL	23223414T8
23223414	870	876	TiO(2)	CHEMICAL	23223414T9

23224291|t|Proteomic and metabolomic responses to connexin43 silencing in primary hepatocyte cultures.
23224291|a|Freshly established cultures of primary hepatocytes progressively adopt a foetal-like phenotype and display increased production of connexin43. The latter is a multifaceted cellular entity with variable subcellular locations, including the mitochondrial compartment. Cx43 forms hemichannels and gap junctions that are involved in a plethora of physiological and pathological processes, such as apoptosis. The present study was conducted with the goal of shedding more light onto the role of connexin43 in primary hepatocyte cultures. Connexin43 expression was suppressed by means of RNA interference technology, and the overall outcome of this treatment on the hepatocellular proteome and metabolome was investigated using tandem mass tag-based differential protein profiling and (1)H NMR spectroscopy, respectively. Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase  2 and cytochrome P450 2C70). At the metabolomic level, connexin43 silencing caused no overt changes, though there was some evidence for a subtle increase in intracellular glycine quantities. Collectively, these data could further substantiate the established existence of a mitochondrial connexin pool and could be reconciled with the previously reported involvement of connexin43 signalling in spontaneously occurring apoptosis in primary hepatocyte cultures.
23224291	1218	1238	cytochrome P450 2C70	GENE-N	23224291T10
23224291	1267	1277	connexin43	GENE-Y	23224291T11
23224291	224	234	connexin43	GENE-Y	23224291T12
23224291	1500	1508	connexin	GENE-N	23224291T13
23224291	1582	1592	connexin43	GENE-N	23224291T14
23224291	359	363	Cx43	GENE-Y	23224291T15
23224291	370	382	hemichannels	GENE-N	23224291T16
23224291	583	593	connexin43	GENE-Y	23224291T17
23224291	626	636	Connexin43	GENE-Y	23224291T18
23224291	970	980	connexin43	GENE-Y	23224291T19
23224291	1126	1148	adenosine triphosphate	CHEMICAL	23224291T1
23224291	1037	1058	heat shock protein 60	GENE-Y	23224291T20
23224291	1060	1088	glucose-regulated protein 75	GENE-Y	23224291T21
23224291	1090	1121	thiosulphate sulphurtransferase	GENE-Y	23224291T22
23224291	39	49	connexin43	GENE-Y	23224291T23
23224291	1184	1195	glutathione	CHEMICAL	23224291T2
23224291	1196	1197	S	CHEMICAL	127
23224291	1383	1390	glycine	CHEMICAL	23224291T4
23224291	872	876	(1)H	CHEMICAL	23224291T5
23224291	1060	1067	glucose	CHEMICAL	23224291T6
23224291	1090	1102	thiosulphate	CHEMICAL	23224291T7
23224291	1126	1157	adenosine triphosphate synthase	GENE-N	23224291T8
23224291	1184	1213	glutathione S-transferase  2	GENE-Y	23224291T9

23229511|t|Aryl hydrocarbon receptor is a target of 17-Allylamino-17-demethoxygeldanamycin and enhances its anticancer activity in lung adenocarcinoma cells.
23229511|a|We have demonstrated that aryl hydrocarbon receptor (AhR) is overexpressed in lung adenocarcinoma (AD). AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials. Here we investigated whether AhR plays a role in 17-AAG-mediated anticancer activity by functioning as a downstream target or by modulating its anticancer efficacy. AhR expression in lung AD cells was modulated by siRNA interference or overexpression. Tumor growth was determined with colony formation in vitro or in vivo. Anticancer activity of 17-AAG was determined by measuring cell viability, cell cycle distribution, and expression of cell cycle regulators. Proteins and mRNA levels were examined by immunoblotting and the real-time reverse transcription-polymerase chain reaction, respectively. In this study, AhR overexpression positively modulated growth of lung AD cells, at least partially, via RelA-dependent mechanisms. Although treatment with 17-AAG reduced AhR levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG. In addition, 17-AAG treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells. NAD(P)H:quinone oxidoreductase (NQO1), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells. Knockdown of NQO1 expression attenuated the reduction of cell cycle regulators by 17-AAG treatment in AhR overexpressed cells. We demonstrated that AhR protein not only functions as a downstream target of 17-AAG, but also enhances anticancer activity of 17-AAG in lung AD cells.
23229511	330	368	17-Allylamino-17-demethoxygeldanamycin	CHEMICAL	23229511T10
23229511	370	376	17-AAG	CHEMICAL	9964
23229511	173	189	aryl hydrocarbon	CHEMICAL	23229511T12
23229511	526	532	17-AAG	CHEMICAL	9964
23229511	823	829	17-AAG	CHEMICAL	9964
23229511	0	16	Aryl hydrocarbon	CHEMICAL	23229511T15
23229511	41	79	17-Allylamino-17-demethoxygeldanamycin	CHEMICAL	23229511T16
23229511	1182	1186	RelA	GENE-Y	23229511T17
23229511	251	254	AhR	GENE-Y	23229511T18
23229511	1248	1251	AhR	GENE-Y	23229511T19
23229511	1233	1239	17-AAG	CHEMICAL	9964
23229511	1263	1266	AhR	GENE-Y	23229511T20
23229511	1311	1314	AhR	GENE-Y	23229511T21
23229511	1421	1425	CDK2	GENE-Y	107452|175836
23229511	1427	1431	CDK4	GENE-Y	107454|167251
23229511	1433	1441	cyclin E	GENE-N	23229511T24
23229511	1443	1452	cyclin D1	GENE-Y	23229511T25
23229511	1458	1475	phosphorylated Rb	GENE-Y	23229511T26
23229511	1486	1489	AhR	GENE-Y	23229511T27
23229511	282	303	heat shock protein 90	GENE-N	23229511T28
23229511	1516	1546	NAD(P)H:quinone oxidoreductase	GENE-Y	23229511T29
23229511	1359	1365	17-AAG	CHEMICAL	9964
23229511	1548	1552	NQO1	GENE-Y	108072
23229511	1577	1580	AhR	GENE-Y	23229511T31
23229511	1657	1661	NQO1	GENE-Y	108072
23229511	305	310	Hsp90	GENE-N	23229511T33
23229511	1746	1749	AhR	GENE-Y	23229511T34
23229511	1792	1795	AhR	GENE-Y	23229511T35
23229511	382	387	Hsp90	GENE-N	23229511T36
23229511	173	198	aryl hydrocarbon receptor	GENE-Y	23229511T37
23229511	506	509	AhR	GENE-Y	23229511T38
23229511	642	645	AhR	GENE-Y	23229511T39
23229511	1380	1386	17-AAG	CHEMICAL	9964
23229511	200	203	AhR	GENE-Y	23229511T40
23229511	1093	1096	AhR	GENE-Y	23229511T41
23229511	0	25	Aryl hydrocarbon receptor	GENE-Y	23229511T42
23229511	1516	1523	NAD(P)H	CHEMICAL	23229511T4
23229511	1524	1531	quinone	CHEMICAL	23229511T5
23229511	1627	1633	17-AAG	CHEMICAL	9964
23229511	1726	1732	17-AAG	CHEMICAL	9964
23229511	1849	1855	17-AAG	CHEMICAL	9964
23229511	1898	1904	17-AAG	CHEMICAL	9964
23229511	CPR:4	23229511T10	23229511T36
23229511	CPR:4	9964	23229511T36
23229511	CPR:4	9964	23229511T19
23229511	CPR:4	9964	23229511T20
23229511	CPR:4	9964	107452|175836
23229511	CPR:4	9964	107454|167251
23229511	CPR:4	9964	23229511T24
23229511	CPR:4	9964	23229511T25
23229511	CPR:4	9964	23229511T26

23230131|t|Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
23230131|a|Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates. All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination. All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05). DCK did not significantly contribute to dFdU monophosphorylation. In conclusion, the Lys27Gln substitution does not significantly modulate CDA activity toward dFdC, and therefore would not contribute to interindividual variability in response to gemcitabine. The higher in vitro catalytic efficiency of DCK24Val toward dFdC monophosphorylation may be relevant to dFdC clinical response. The substrate-dependent alterations in activities of CDA70Thr and DCK24Val in vitro were observed for the first time, and demonstrate that the in vivo consequences of these genetic variations should not be extrapolated from one substrate of these enzymes to another.
23230131	629	634	Ara-C	CHEMICAL	977
23230131	637	641	dFdC	CHEMICAL	23230131T11
23230131	662	688	2',2'-difluorodeoxyuridine	CHEMICAL	23230131T12
23230131	690	694	dFdU	CHEMICAL	23230131T13
23230131	769	774	Ara-C	CHEMICAL	977
23230131	779	783	dFdC	CHEMICAL	23230131T15
23230131	198	206	cytidine	CHEMICAL	23230131T16
23230131	878	883	Ara-C	CHEMICAL	977
23230131	961	966	Ara-C	CHEMICAL	977
23230131	971	975	dFdC	CHEMICAL	23230131T19
23230131	132	143	Gemcitabine	CHEMICAL	433
23230131	227	240	deoxycytidine	CHEMICAL	23230131T20
23230131	1111	1115	dFdC	CHEMICAL	23230131T21
23230131	110	123	deoxycytidine	CHEMICAL	23230131T22
23230131	20	31	gemcitabine	CHEMICAL	23230131T23
23230131	87	95	cytidine	CHEMICAL	23230131T24
23230131	1178	1181	DCK	GENE-Y	108001
23230131	1263	1271	Lys27Gln	GENE-N	23230131T26
23230131	249	252	DCK	GENE-Y	108001
23230131	1317	1320	CDA	GENE-Y	107416
23230131	1481	1484	DCK	GENE-Y	108001
23230131	1218	1222	dFdU	CHEMICAL	23230131T2
23230131	1618	1621	CDA	GENE-Y	107416
23230131	1631	1634	DCK	GENE-Y	108001
23230131	441	444	CDA	GENE-Y	107416
23230131	446	454	Lys27Gln	GENE-N	23230131T33
23230131	459	467	Ala70Thr	GENE-N	23230131T34
23230131	473	476	DCK	GENE-Y	108001
23230131	478	486	Ile24Val	GENE-N	23230131T36
23230131	488	497	Ala119Gly	GENE-N	23230131T37
23230131	503	512	Pro122Ser	GENE-N	23230131T38
23230131	721	724	CDA	GENE-Y	107416
23230131	1337	1341	dFdC	CHEMICAL	23230131T3
23230131	198	216	cytidine deaminase	GENE-Y	23230131T40
23230131	808	811	CDA	GENE-Y	107416
23230131	906	909	DCK	GENE-Y	108001
23230131	218	221	CDA	GENE-Y	107416
23230131	1008	1011	DCK	GENE-Y	108001
23230131	227	247	deoxycytidine kinase	GENE-Y	23230131T45
23230131	110	130	deoxycytidine kinase	GENE-Y	23230131T46
23230131	87	105	cytidine deaminase	GENE-Y	23230131T47
23230131	1424	1435	gemcitabine	CHEMICAL	23230131T4
23230131	145	149	dFdC	CHEMICAL	23230131T5
23230131	1497	1501	dFdC	CHEMICAL	23230131T6
23230131	1541	1545	dFdC	CHEMICAL	23230131T7
23230131	151	178	2',2'-difluorodeoxycytidine	CHEMICAL	23230131T8
23230131	617	627	cytarabine	CHEMICAL	23230131T9
23230131	CPR:9	977	107416
23230131	CPR:9	977	23230131T33
23230131	CPR:9	977	23230131T34
23230131	CPR:9	977	108001
23230131	CPR:9	977	23230131T36
23230131	CPR:9	977	23230131T37
23230131	CPR:9	977	23230131T38
23230131	CPR:9	23230131T11	107416
23230131	CPR:9	23230131T11	23230131T33
23230131	CPR:9	23230131T11	23230131T34
23230131	CPR:9	23230131T11	108001
23230131	CPR:9	23230131T11	23230131T36
23230131	CPR:9	23230131T11	23230131T37
23230131	CPR:9	23230131T11	23230131T38
23230131	CPR:9	23230131T12	107416
23230131	CPR:9	23230131T12	23230131T33
23230131	CPR:9	23230131T12	23230131T34
23230131	CPR:9	23230131T12	108001
23230131	CPR:9	23230131T12	23230131T36
23230131	CPR:9	23230131T12	23230131T37
23230131	CPR:9	23230131T12	23230131T38
23230131	CPR:9	23230131T13	107416
23230131	CPR:9	977	107416
23230131	CPR:9	23230131T15	107416
23230131	CPR:9	977	107416
23230131	CPR:9	977	108001
23230131	CPR:9	23230131T19	108001
23230131	CPR:9	433	108001
23230131	CPR:9	433	23230131T40
23230131	CPR:9	433	107416
23230131	CPR:9	433	23230131T45
23230131	CPR:9	23230131T21	108001
23230131	CPR:9	23230131T3	23230131T26
23230131	CPR:9	23230131T3	107416
23230131	CPR:9	23230131T5	108001
23230131	CPR:9	23230131T5	23230131T40
23230131	CPR:9	23230131T5	107416
23230131	CPR:9	23230131T5	23230131T45
23230131	CPR:9	23230131T6	108001
23230131	CPR:9	23230131T7	108001
23230131	CPR:9	23230131T8	108001
23230131	CPR:9	23230131T8	23230131T40
23230131	CPR:9	23230131T8	107416
23230131	CPR:9	23230131T8	23230131T45
23230131	CPR:9	23230131T9	107416
23230131	CPR:9	23230131T9	23230131T33
23230131	CPR:9	23230131T9	23230131T34
23230131	CPR:9	23230131T9	108001
23230131	CPR:9	23230131T9	23230131T36
23230131	CPR:9	23230131T9	23230131T37
23230131	CPR:9	23230131T9	23230131T38

23232060|t|Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.
23232060|a|A series of compounds based on a 4-phenyl-2-phenylaminopyridine scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (TNIK) activity are described. These compounds were used as tools to test the importance of TNIK kinase activity in signaling and proliferation in Wnt-activated colorectal cancer cells. The results indicate that pharmacological inhibition of TNIK kinase activity has minimal effects on either Wnt/TCF4/-catenin-driven transcription or viability. The findings suggest that the kinase activity of TNIK may be less important to Wnt signaling than other aspects of TNIK function, such as its putative role in stabilizing the TCF4/-catenin transcriptional complex.
23232060	511	514	Wnt	GENE-N	23232060T10
23232060	515	519	TCF4	GENE-Y	112787
23232060	520	529	-catenin	GENE-Y	23232060T12
23232060	595	601	kinase	GENE-N	23232060T13
23232060	614	618	TNIK	GENE-Y	116682
23232060	644	647	Wnt	GENE-N	23232060T15
23232060	680	684	TNIK	GENE-Y	116682
23232060	740	744	TCF4	GENE-Y	112787
23232060	745	754	-catenin	GENE-Y	23232060T18
23232060	50	54	TNIK	GENE-Y	116682
23232060	100	130	4-phenyl-2-phenylaminopyridine	CHEMICAL	23232060T1
23232060	13	43	4-phenyl-2-phenylaminopyridine	CHEMICAL	23232060T2
23232060	184	217	Traf2- and Nck-interacting kinase	GENE-Y	23232060T3
23232060	219	223	TNIK	GENE-Y	116682
23232060	310	314	TNIK	GENE-Y	116682
23232060	315	321	kinase	GENE-N	23232060T6
23232060	365	368	Wnt	GENE-N	23232060T7
23232060	460	464	TNIK	GENE-Y	116682
23232060	465	471	kinase	GENE-N	23232060T9
23232060	CPR:4	23232060T1	23232060T3
23232060	CPR:4	23232060T1	116682
23232060	CPR:4	23232060T2	116682

23234537|t|Hybrid carbon nanotube networks as efficient hole extraction layers for organic photovoltaics.
23234537|a|Transparent, highly percolated networks of regioregular poly(3-hexylthiophene) (rr-P3HT)-wrapped semiconducting single-walled carbon nanotubes (s-SWNTs) are deposited, and the charge transfer processes of these nanohybrids are studied using spectroscopic and electrical measurements. The data disclose hole doping of s-SWNTs by the polymer, challenging the prevalent electron-doping hypothesis. Through controlled fabrication, high- to low-density nanohybrid networks are achieved, with low-density hybrid carbon nanotube networks tested as hole transport layers (HTLs) for bulk heterojunction (BHJ) organic photovoltaics (OPV). OPVs incorporating these rr-P3HT/s-SWNT networks as the HTL demonstrate the best large area (70 mm(2)) carbon nanotube incorporated organic solar cells to date with a power conversion efficiency of 7.6%. This signifies the strong capability of nanohybrids as an efficient hole extraction layer, and we believe that dense nanohybrid networks have the potential to replace expensive and material scarce inorganic transparent electrodes in large area electronics toward the realization of low-cost flexible electronics.
23234537	221	227	carbon	CHEMICAL	23234537T1
23234537	601	607	carbon	CHEMICAL	23234537T2
23234537	151	173	poly(3-hexylthiophene)	CHEMICAL	23234537T3
23234537	752	756	P3HT	CHEMICAL	23234537T4
23234537	827	833	carbon	CHEMICAL	23234537T5
23234537	178	182	P3HT	CHEMICAL	23234537T6
23234537	7	13	carbon	CHEMICAL	23234537T7

23238236|t|Chemical assessment and antioxidant capacity of pepper (Capsicum annuum L.) seeds.
23238236|a|Capsicum annuum L. is reported to be the most widely cultivated species. Recently, waste of vegetable processing, like seeds, has been the subject of many studies as an attempt to find new, alternative and cheap resources of bioactive compounds with application in several industries. Despite their chemical, biological and ecological importance, C. annuum seeds are still poorly studied. To improve the knowledge on the metabolic profile of this matrix, a targeted metabolite analysis was performed in "sweet Italian" and "Reus long pairal" pepper seeds. Sterols, triterpenes, organic acids, fatty acids and volatile compounds were determined by different chromatographic methods. The antioxidant activity was assessed against DPPH(), superoxide and nitric oxide radicals. A concentration-dependent activity was noticed against all radicals. Acetylcholinesterase inhibitory capacity was also evaluated, but no effect was found. Data provide evidence of great similarities between "sweet Italian" and "Reus long pairal" pepper seeds. The present study indicates that C. annuum seeds are a potential source of valuable bioactive compounds that could be used in food industry.
23238236	639	646	Sterols	CHEMICAL	23238236T1
23238236	648	659	triterpenes	CHEMICAL	23238236T2
23238236	676	687	fatty acids	CHEMICAL	23238236T3
23238236	811	818	DPPH()	CHEMICAL	23238236T4
23238236	820	830	superoxide	CHEMICAL	23238236T5
23238236	835	847	nitric oxide	CHEMICAL	23238236T6
23238236	927	947	Acetylcholinesterase	GENE-Y	23238236T7

23239555|t|Boron-based inhibitors of acyl protein thioesterases 1 and 2.
23239555|a|Ras proteins are of importance in cell proliferation, and hence their mutated forms play causative roles in many kinds of cancer in different tissues. Inhibition of the Ras-depalmitoylating enzyme acyl protein thioesterases APT1 and -2 is a new approach to modulating the Ras cycle. Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic APT inhibitors. These compounds were detected by extensive library screening using chemical arrays and turned out to inhibit human APT1 and -2 in a competitive mode. Furthermore, one of the molecules was demonstrated to inhibit Erk1/2 phosphorylation significantly.
23239555	436	439	APT	GENE-N	23239555T10
23239555	561	578	human APT1 and -2	GENE-N	23239555T11
23239555	664	670	Erk1/2	GENE-N	23239555T12
23239555	26	60	acyl protein thioesterases 1 and 2	GENE-N	23239555T13
23239555	259	263	acyl	CHEMICAL	23239555T1
23239555	361	368	boronic	CHEMICAL	23239555T2
23239555	373	385	borinic acid	CHEMICAL	23239555T3
23239555	0	5	Boron	CHEMICAL	23239555T4
23239555	26	30	acyl	CHEMICAL	23239555T5
23239555	62	65	Ras	GENE-N	23239555T6
23239555	231	234	Ras	GENE-N	23239555T7
23239555	259	297	acyl protein thioesterases APT1 and -2	GENE-N	23239555T8
23239555	334	337	Ras	GENE-N	23239555T9
23239555	CPR:4	23239555T2	23239555T10
23239555	CPR:4	23239555T3	23239555T10
23239555	CPR:4	23239555T4	23239555T13

23239592|t|Three-Dimensional CdS-Titanate Composite Nanomaterials for Enhanced Visible-Light-Driven Hydrogen Evolution.
23239592|a|3D Hierarchical echinus-like titanate spheres (HETSs), serving as the supporting material for CdS nanoparticles, are synthesized via a fast one-step hydrothermal method. The obtained 3D CdS-HETS composite materials show enhanced H2 generation under visible light irradiation.
23239592	295	298	CdS	CHEMICAL	23239592T1
23239592	338	340	H2	CHEMICAL	23239592T2
23239592	138	146	titanate	CHEMICAL	23239592T3
23239592	203	206	CdS	CHEMICAL	23239592T4
23239592	18	21	CdS	CHEMICAL	23239592T5
23239592	22	30	Titanate	CHEMICAL	23239592T6
23239592	89	97	Hydrogen	CHEMICAL	23239592T7

23246428|t|UPLC-Q-TOF/HSMS/MS(E)-based metabonomics for adenine-induced changes in metabolic profiles of rat faeces and intervention effects of ergosta-4,6,8(14),22-tetraen-3-one.
23246428|a|Ergosta-4,6,8(14),22-tetraen-3-one (ergone), isolated from the medicinal fungus Polyporus umbellatus, has been proven to prevent the progression of renal injury and the subsequent renal fibrosis. Ultra performance liquid chromatography coupled with quadrupole time-of-flight high-sensitivity mass spectrometry and a novel mass spectrometry(Elevated Energy) (MS(E)) data collection technique was employed to investigate metabonomic characters of chronic renal failure (CRF) induced adenine and the protective effects of ergosta-4,6,8(14),22-tetraen-3-one (ergone). Coupled with blood biochemistry and kidney histopathology results, the significant difference in metabolic profiling between adenine-induced CRF group and ergone-treated CRF group by using pattern recognition analysis indicated that changes in global faecal metabolites were occurred. Seven endogenous metabolites were identified by using metabonomic method combined with multivariate data analysis, the accurate mass, isotopic pattern, MS(E) fragments information and MassLynx i-FIT algorithm. These biochemical changes in faecal metabolites are related to the perturbations of bile acid metabolism and phospholipid metabolism, which may be helpful to further understand the CRF and therapeutic mechanisms of ergone. This research proved that MS(E) can simultaneous acquire precursor ion information and fragment ion data at high and low collision energy in one analytical run, which facilitated the fast structural characterization of metabolites.
23246428	133	167	ergosta-4,6,8(14),22-tetraen-3-one	CHEMICAL	23246428T10
23246428	45	52	adenine	CHEMICAL	23246428T11
23246428	169	203	Ergosta-4,6,8(14),22-tetraen-3-one	CHEMICAL	23246428T1
23246428	1312	1321	bile acid	CHEMICAL	23246428T2
23246428	1443	1449	ergone	CHEMICAL	23246428T3
23246428	205	211	ergone	CHEMICAL	23246428T4
23246428	650	657	adenine	CHEMICAL	23246428T5
23246428	688	722	ergosta-4,6,8(14),22-tetraen-3-one	CHEMICAL	23246428T6
23246428	724	730	ergone	CHEMICAL	23246428T7
23246428	858	865	adenine	CHEMICAL	23246428T8
23246428	888	894	ergone	CHEMICAL	23246428T9

23252799|t|Selective separation of similarly sized proteins with tunable nanoporous block copolymer membranes.
23252799|a|An integral asymmetric membrane was fabricated in a fast and one-step process by combining the self-assembly of an amphiphilic block copolymer (PS-b-P4VP) with nonsolvent-induced phase separation. The structure was found to be composed of a thin layer of densely packed highly ordered cylindrical channels with uniform pore sizes perpendicular to the surface on top of a nonordered sponge-like layer. The as-assembled membrane obtained a water flux of more than 3200 L m(-2) h(-1) bar(-1), which was at least an order of magnitude higher than the water fluxes of commercially available membranes with comparable pore sizes, making this membrane particularly well suited to size-selective and charge-based separation of biomolecules. To test the performance of the membrane, we conducted diffusion experiments at the physiological pH of 7.4 using bovine serum albumin (BSA) and globulin-, two proteins with different diameters but too close in size (2-fold difference in molecular mass) to be efficiently separated via conventional dialysis membrane processes. The diffusion rate differed by a factor of 87, the highest value reported to date. We also analyzed charge-based diffusive transport and separation of two proteins of similar molecular weight (BSA and bovine hemoglobin (BHb)) through the membrane as a function of external pH. The membrane achieved a selectivity of about 10 at pH 4.7, the isoelectric point (pI) of BSA. We then positively charged the membrane to improve the separation selectivity. With the modified membrane BSA was completely blocked when the pH was 7.0, the pI of BHb, while BHb was completely blocked at pH 4.7. Our results demonstrate the potential of our asymmetric membrane to efficiently separate biological substances/pharmaceuticals in bioscience, biotechnology, and biomedicine applications.
23252799	968	971	BSA	GENE-Y	23252799T10
23252799	977	987	globulin-	GENE-N	23252799T11
23252799	244	253	PS-b-P4VP	CHEMICAL	23252799T1
23252799	1354	1357	BSA	GENE-Y	23252799T2
23252799	1362	1379	bovine hemoglobin	GENE-N	23252799T3
23252799	1381	1384	BHb	GENE-N	23252799T4
23252799	1527	1530	BSA	GENE-Y	23252799T5
23252799	1638	1641	BSA	GENE-Y	23252799T6
23252799	1696	1699	BHb	GENE-N	23252799T7
23252799	1707	1710	BHb	GENE-N	23252799T8
23252799	946	966	bovine serum albumin	GENE-Y	23252799T9

23254196|t|Phytoestrogen genistein protects against endothelial barrier dysfunction in vascular endothelial cells through PKA-mediated suppression of RhoA signaling.
23254196|a|The soy-derived phytoestrogen genistein has received attention for its potential to improve vascular function, but its mechanism remains unclear. Here, we report that genistein at physiologically relevant concentrations (0.1-10 M) significantly inhibited thrombin-induced increase in endothelial monolayer permeability. Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs). Genistein had no effect on resting intracellular [Ca(2+)] or thrombin-induced increase in Ca(2+) mobilization. Addition of the inhibitors of endothelial nitric oxide synthase or estrogen receptor did not alter the protective effect of genistein. RhoA is a small GTPase that plays an important role in actin-myosin contraction and endothelial barrier dysfunction. RhoA inhibitor blocked the protective effect of genistein on endothelial permeability and also ablated thrombin-induced MLC-phosphorylation in ECs. Inhibition of PKA significantly attenuated the effect of genistein on thrombin-induced EC permeability, MLC phosphorylation, and RhoA membrane translocation in ECs. Furthermore, thrombin diminished cAMP production in ECs, which were prevented by treatment with genistein. These findings demonstrated that genistein improves thrombin-induced endothelial barrier dysfunction in ECs through PKA-mediated suppression of RhoA signaling.
23254196	665	674	Genistein	CHEMICAL	1582
23254196	715	721	Ca(2+)	CHEMICAL	23254196T11
23254196	755	761	Ca(2+)	CHEMICAL	23254196T12
23254196	818	830	nitric oxide	CHEMICAL	23254196T13
23254196	843	851	estrogen	CHEMICAL	23254196T14
23254196	900	909	genistein	CHEMICAL	23254196T15
23254196	1076	1085	genistein	CHEMICAL	23254196T16
23254196	14	23	genistein	CHEMICAL	23254196T17
23254196	1190	1193	PKA	GENE-N	23254196T18
23254196	1246	1254	thrombin	GENE-Y	23254196T19
23254196	1233	1242	genistein	CHEMICAL	23254196T1
23254196	1280	1283	MLC	GENE-N	23254196T20
23254196	1305	1309	RhoA	GENE-Y	23254196T21
23254196	1354	1362	thrombin	GENE-Y	23254196T22
23254196	1500	1508	thrombin	GENE-Y	23254196T23
23254196	1564	1567	PKA	GENE-N	23254196T24
23254196	1592	1596	RhoA	GENE-Y	23254196T25
23254196	411	419	thrombin	GENE-Y	23254196T26
23254196	533	541	thrombin	GENE-Y	23254196T27
23254196	557	565	thrombin	GENE-Y	23254196T28
23254196	593	611	myosin light chain	GENE-N	23254196T29
23254196	1374	1378	cAMP	CHEMICAL	2424
23254196	613	616	MLC	GENE-N	23254196T30
23254196	726	734	thrombin	GENE-Y	23254196T31
23254196	806	839	endothelial nitric oxide synthase	GENE-Y	23254196T32
23254196	843	860	estrogen receptor	GENE-Y	23254196T33
23254196	911	915	RhoA	GENE-Y	23254196T34
23254196	927	933	GTPase	GENE-N	23254196T35
23254196	966	971	actin	GENE-N	23254196T36
23254196	972	978	myosin	GENE-N	23254196T37
23254196	1028	1032	RhoA	GENE-Y	23254196T38
23254196	1131	1139	thrombin	GENE-Y	23254196T39
23254196	1437	1446	genistein	CHEMICAL	23254196T3
23254196	1148	1151	MLC	GENE-N	23254196T40
23254196	111	114	PKA	GENE-N	23254196T41
23254196	139	143	RhoA	GENE-Y	23254196T42
23254196	1481	1490	genistein	CHEMICAL	23254196T4
23254196	322	331	genistein	CHEMICAL	23254196T5
23254196	185	194	genistein	CHEMICAL	23254196T6
23254196	476	485	Genistein	CHEMICAL	1582
23254196	621	624	Ser	CHEMICAL	127
23254196	629	632	Thr	CHEMICAL	150
23254196	CPR:4	23254196T3	23254196T22
23254196	CPR:4	23254196T5	23254196T26
23254196	CPR:4	1582	23254196T27
23254196	CPR:4	1582	23254196T28
23254196	CPR:4	1582	23254196T29
23254196	CPR:4	1582	23254196T30

23256446|t|Metabolic effects of honey in type 1 diabetes mellitus: a randomized crossover pilot study.
23256446|a|The aim of this study was to evaluate the metabolic effects of 12-week honey consumption on patients suffering from type 1 diabetes mellitus (DM). This was a randomized crossover clinical trial done in the National Institute for Diabetes and Endocrinology, Cairo, Egypt. Twenty patients of both sexes aged 4-18 years with type 1 DM and HbA1C<10% participated in the study. They were randomized into two equal groups (intervention to control and control to intervention). The dietary intervention was 12-week honey consumption in a dose of 0.5 mL/kg body weight per day. The main outcome measures were serum glucose, lipids, and C-peptide, and anthropometric measurements. None of participants were lost in follow-up. The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total cholesterol (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002). As possible long-term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2-h postprandial serum glucose (P=.000), TG (P=.003), and HbA1C (P=.043), and significant increases in FCP (P=.002) and PCP (P=.003) were observed. This small clinical trial suggests that long-term consumption of honey might have positive effects on the metabolic derangements of type 1 DM.
23256446	1461	1464	FCP	GENE-Y	23256446T10
23256446	1478	1481	PCP	GENE-Y	23256446T11
23256446	428	433	HbA1C	GENE-Y	23256446T12
23256446	720	729	C-peptide	GENE-Y	23256446T13
23256446	1016	1039	low-density lipoprotein	GENE-N	23256446T14
23256446	1080	1097	fasting C-peptide	GENE-Y	23256446T15
23256446	1381	1388	glucose	CHEMICAL	23256446T1
23256446	699	706	glucose	CHEMICAL	23256446T2
23256446	925	932	glucose	CHEMICAL	23256446T3
23256446	954	965	cholesterol	CHEMICAL	23256446T4
23256446	983	996	triglycerides	CHEMICAL	23256446T5
23256446	1099	1102	FCP	GENE-Y	23256446T6
23256446	1121	1143	postprandial C-peptide	GENE-Y	23256446T7
23256446	1145	1148	PCP	GENE-Y	23256446T8
23256446	1416	1421	HbA1C	GENE-Y	23256446T9

23256625|t|Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
23256625|a|1.This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2.In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300mg BID) on the pharmacokinetic profile of simvastatin (40mg single dose) and rosuvastatin (10mg single dose). 3.In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 M) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2. However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4.In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4. In contrast, GSK1292263 did not inhibit OATP1B1 based on the lack of changes in simvastatin acid exposure [mean AUC(0-inf) ratio (90% CI) of 1.05 (0.91, 1.21)]. 5.GSK1292263 has a weak drug interaction with simvastatin and rosuvastain. This study provides a mechanistic understanding of the in vivo inhibition of transporters and enzymes by GSK1292263.
23256625	448	458	GSK1292263	CHEMICAL	23256625T10
23256625	506	517	simvastatin	CHEMICAL	23256625T11
23256625	542	554	rosuvastatin	CHEMICAL	23256625T12
23256625	589	599	GSK1292263	CHEMICAL	23256625T13
23256625	184	194	GSK1292263	CHEMICAL	23256625T14
23256625	733	743	GSK1292263	CHEMICAL	23256625T15
23256625	890	901	simvastatin	CHEMICAL	23256625T16
23256625	949	961	rosuvastatin	CHEMICAL	23256625T17
23256625	1045	1055	GSK1292263	CHEMICAL	23256625T18
23256625	35	45	GSK1292263	CHEMICAL	23256625T19
23256625	1147	1157	GSK1292263	CHEMICAL	23256625T1
23256625	1126	1132	CYP3A4	GENE-Y	107948
23256625	1174	1181	OATP1B1	GENE-Y	23256625T21
23256625	229	246	HMG-coA reductase	GENE-Y	23256625T22
23256625	1448	1460	transporters	GENE-N	23256625T23
23256625	339	351	transporters	GENE-N	23256625T24
23256625	356	359	CYP	GENE-N	23256625T25
23256625	665	669	CYPs	GENE-N	23256625T26
23256625	671	677	CYP1A2	GENE-Y	107924
23256625	679	682	2C9	GENE-Y	23256625T28
23256625	684	688	2C19	GENE-Y	23256625T29
23256625	1214	1225	simvastatin	CHEMICAL	23256625T2
23256625	690	693	2D6	GENE-Y	23256625T30
23256625	695	698	3A4	GENE-Y	23256625T31
23256625	701	704	Pgp	GENE-N	23256625T32
23256625	706	713	OATP1B3	GENE-Y	23256625T33
23256625	718	722	OCT2	GENE-Y	23256625T34
23256625	754	758	BCRP	GENE-Y	23256625T35
23256625	763	770	OATP1B1	GENE-Y	23256625T36
23256625	204	210	GPR119	GENE-Y	126586
23256625	1117	1121	BCRP	GENE-Y	23256625T38
23256625	49	55	GPR119	GENE-Y	126586
23256625	1298	1308	GSK1292263	CHEMICAL	23256625T3
23256625	1342	1353	simvastatin	CHEMICAL	23256625T4
23256625	1358	1369	rosuvastain	CHEMICAL	23256625T5
23256625	258	269	simvastatin	CHEMICAL	23256625T6
23256625	1476	1486	GSK1292263	CHEMICAL	23256625T7
23256625	274	286	rosuvastatin	CHEMICAL	23256625T8
23256625	371	381	GSK1292263	CHEMICAL	23256625T9
23256625	CPR:4	23256625T13	23256625T26
23256625	CPR:4	23256625T13	107924
23256625	CPR:4	23256625T13	23256625T28
23256625	CPR:4	23256625T13	23256625T29
23256625	CPR:4	23256625T13	23256625T30
23256625	CPR:4	23256625T13	23256625T31
23256625	CPR:4	23256625T13	23256625T32
23256625	CPR:4	23256625T13	23256625T33
23256625	CPR:4	23256625T13	23256625T34
23256625	CPR:4	23256625T15	23256625T35
23256625	CPR:4	23256625T15	23256625T36
23256625	CPR:4	23256625T18	107948
23256625	CPR:4	23256625T18	23256625T38
23256625	CPR:4	23256625T6	23256625T22
23256625	CPR:4	23256625T7	23256625T23
23256625	CPR:4	23256625T8	23256625T22
23256625	CPR:4	23256625T9	23256625T24
23256625	CPR:4	23256625T9	23256625T25
23256625	CPR:5	23256625T14	126586
23256625	CPR:5	23256625T19	126586

23256719|t|Antioxidants and mucolytics in COPD management: when (if ever) and in whom?
23256719|a|Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Oxidative stress is an important mechanism in the pathogenesis of this disease. The oxidant/ antioxidant imbalance occurring in smokers and patients with COPD is well established. Thus, therapeutic strategies targeting oxidative stress with pharmacological antioxidant agents or boosting the endogenous levels of antioxidants is likely to be beneficial as an adjunctive tool in the treatment of COPD patients. Thiol compounts such as N-acetyl-L-cysteine (NAC), carbocysteine, erdosteine, and fudosteine have been extensively studied. Although some results remain controversial, NAC and carbocysteine seem to have beneficial effect in patients not receiving inhaled corticosteroids who suffer from frequent exacerbations. In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). In this article we review the effectiveness of various antioxidant factors in COPD and their potential beneficial effect in the treatment of the disease.
23256719	762	775	carbocysteine	CHEMICAL	23256719T10
23256719	841	856	corticosteroids	CHEMICAL	23256719T11
23256719	934	944	superoxide	CHEMICAL	23256719T12
23256719	1121	1143	glutathione peroxidase	GENE-N	23256719T13
23256719	1145	1148	GPx	GENE-N	23256719T14
23256719	1163	1174	NO synthase	GENE-N	23256719T15
23256719	1176	1180	iNOS	GENE-Y	23256719T16
23256719	934	954	superoxide dismutase	GENE-N	23256719T17
23256719	956	959	SOD	GENE-N	23256719T18
23256719	974	1017	nuclear factor-erythroid 2 related factor 2	GENE-Y	23256719T19
23256719	1121	1132	glutathione	CHEMICAL	23256719T1
23256719	1019	1023	Nrf2	GENE-Y	23256719T20
23256719	1163	1165	NO	CHEMICAL	427
23256719	586	591	Thiol	CHEMICAL	23256719T3
23256719	610	629	N-acetyl-L-cysteine	CHEMICAL	23256719T4
23256719	631	634	NAC	CHEMICAL	23256719T5
23256719	637	650	carbocysteine	CHEMICAL	23256719T6
23256719	652	662	erdosteine	CHEMICAL	23256719T7
23256719	668	678	fudosteine	CHEMICAL	23256719T8
23256719	754	757	NAC	CHEMICAL	23256719T9

23257178|t|Steroid toxicity and detoxification in ascomycetous fungi.
23257178|a|In the last couple of decades fungal infections have become a significant clinical problem. A major interest into fungal steroid action has been provoked since research has proven that steroid hormones are toxic to fungi and affect the host/fungus relationship. Steroid hormones were found to differ in their antifungal activity in ascomycetous fungi Hortaea werneckii, Saccharomyces cerevisiae and Aspergillus oryzae. Dehydroepiandrosterone was shown to be the strongest inhibitor of growth in all three varieties of fungi followed by androstenedione and testosterone. For their protection, fungi use several mechanisms to lower the toxic effects of steroids. The efficiency of biotransformation in detoxification depended on the microorganism and steroid substrate used. Biotransformation was a relatively slow process as it also depended on the growth phase of the fungus. In addition to biotransformation, steroid extrusion out of the cells contributed to the lowering of the active intracellular steroid concentration. Plasma membrane Pdr5 transporter was found to be the most effective, followed by Snq2 transporter and vacuolar transporters Ybt1 and Ycf1. Proteins Aus1 and Dan1 were not found to be involved in steroid import. The research of possible targets of steroid hormone action in fungi suggests that steroid hormones inhibit ergosterol biosynthesis in S. cerevisiae and H. werneckii. Results of this inhibition caused changes in the sterol content of the cellular membrane. The presence of steroid hormones most probably causes the degradation of the Tat2 permease and impairment of tryptophan import.
23257178	244	251	steroid	CHEMICAL	23257178T10
23257178	321	328	Steroid	CHEMICAL	23257178T11
23257178	595	610	androstenedione	CHEMICAL	23257178T12
23257178	615	627	testosterone	CHEMICAL	614
23257178	710	718	steroids	CHEMICAL	23257178T14
23257178	808	815	steroid	CHEMICAL	23257178T15
23257178	969	976	steroid	CHEMICAL	23257178T16
23257178	0	7	Steroid	CHEMICAL	23257178T17
23257178	1099	1103	Pdr5	GENE-N	23257178T18
23257178	1164	1168	Snq2	GENE-N	23257178T19
23257178	1060	1067	steroid	CHEMICAL	23257178T1
23257178	1207	1211	Ybt1	GENE-N	23257178T20
23257178	1216	1220	Ycf1	GENE-N	23257178T21
23257178	1231	1235	Aus1	GENE-N	23257178T22
23257178	1240	1244	Dan1	GENE-N	23257178T23
23257178	1627	1631	Tat2	GENE-N	23257178T24
23257178	180	187	steroid	CHEMICAL	23257178T2
23257178	1278	1285	steroid	CHEMICAL	23257178T3
23257178	1330	1337	steroid	CHEMICAL	23257178T4
23257178	1376	1383	steroid	CHEMICAL	23257178T5
23257178	1401	1411	ergosterol	CHEMICAL	23257178T6
23257178	1509	1515	sterol	CHEMICAL	23257178T7
23257178	1566	1573	steroid	CHEMICAL	23257178T8
23257178	1659	1669	tryptophan	CHEMICAL	23257178T9
23257178	CPR:4	23257178T8	23257178T24

23261051|t|Cell-cycle and DNA damage regulation of the DNA mismatch repair protein Msh2 occurs at the transcriptional and post-transcriptional level.
23261051|a|DNA mismatch repair during replication is a conserved process essential for maintaining genomic stability. Mismatch repair is also implicated in cell-cycle arrest and apoptosis after DNA damage. Because yeast and human mismatch repair systems are well conserved, we have employed the budding yeast Saccharomyces cerevisiae to understand the regulation and function of the mismatch repair gene MSH2. Using a luciferase-based transcriptional reporter, we defined a 218-bp region upstream of MSH2 that contains cell-cycle and DNA damage responsive elements. The 5' end of the MSH2 transcript was mapped by primer extension and was found to encode a small upstream open reading frame (uORF). Mutagenesis of the uORF start codon or of the uORF stop codon, which creates a continuous reading frame with MSH2, increased Msh2 steady-state protein levels 2-fold. Furthermore, we found that the cell-cycle transcription factors Swi6, Swi4, and Mbp1-along with SCB/MCB cell-cycle binding sites upstream of MSH2-are all required for full basal expression of MSH2. Mutagenesis of the cell-cycle boxes resulted in a minor reduction in basal Msh2 levels and a 3-fold defect in mismatch repair. Disruption of the cell-cycle boxes also affected growth in a DNA polymerase-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent methyl methane sulfonate (MMS). Promoter replacements conferring constitutive expression of MSH2 revealed that the transcriptional induction in response to MMS is required to maintain induced levels of Msh2. Turnover experiments confirmed an elevated rate of degradation in the presence of MMS. Taken together, the data show that the DNA damage regulation of Msh2 occurs at the transcriptional and post-transcriptional levels. The transcriptional and translational control elements identified are conserved in mammalian cells, underscoring the use of yeast as a model system to examine the regulation of MSH2.
23261051	1606	1610	MSH2	GENE-Y	110573|34312|6716
23261051	1716	1720	Msh2	GENE-Y	201525|249587
23261051	1873	1877	Msh2	GENE-Y	201525|249587
23261051	2118	2122	MSH2	GENE-Y	110573|34312|6716
23261051	532	536	MSH2	GENE-Y	110573|34312|6716
23261051	628	632	MSH2	GENE-Y	110573|34312|6716
23261051	647	692	cell-cycle and DNA damage responsive elements	GENE-N	23261051T16
23261051	712	716	MSH2	GENE-Y	110573|34312|6716
23261051	791	818	upstream open reading frame	GENE-N	23261051T18
23261051	820	824	uORF	GENE-N	23261051T19
23261051	1514	1538	methyl methane sulfonate	CHEMICAL	23261051T1
23261051	846	862	uORF start codon	GENE-N	23261051T20
23261051	873	888	uORF stop codon	GENE-N	23261051T21
23261051	936	940	MSH2	GENE-Y	110573|34312|6716
23261051	952	956	Msh2	GENE-Y	201525|249587
23261051	1058	1062	Swi6	GENE-Y	23261051T24
23261051	1064	1068	Swi4	GENE-Y	23261051T25
23261051	1074	1078	Mbp1	GENE-Y	23261051T26
23261051	1090	1121	SCB/MCB cell-cycle binding site	GENE-N	23261051T27
23261051	1135	1139	MSH2	GENE-Y	110573|34312|6716
23261051	44	76	DNA mismatch repair protein Msh2	GENE-Y	23261051T29
23261051	1540	1543	MMS	CHEMICAL	23261051T2
23261051	1670	1673	MMS	CHEMICAL	23261051T3
23261051	1804	1807	MMS	CHEMICAL	23261051T4
23261051	1186	1190	MSH2	GENE-Y	110573|34312|6716
23261051	1211	1227	cell-cycle boxes	GENE-N	23261051T6
23261051	1267	1271	Msh2	GENE-Y	201525|249587
23261051	1337	1353	cell-cycle boxes	GENE-N	23261051T8
23261051	1380	1394	DNA polymerase	GENE-N	23261051T9

23261528|t|Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin.
23261528|a|Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the intestine which involves overproduction of pro-inflammatory cytokines and excessive functions of inflammatory cells. However, current treatments for IBD may have potential adverse effects including steroid dependence, infections and lymphoma. Therefore new therapies or drug candidates for the treatment of IBD are desperately needed. In the present study we found that icariin, a major bioactive compound from plants in Epimedium family, exerted protective effect on intestinal inflammation in mice induced by dextran sulfate sodium. Oral administration of icariin significantly attenuated the disease progression and alleviated the pathological changes of colitis. It also inhibited the production of pro-inflammatory cytokines and expression of p-p65, p-STAT1 and p-STAT3 in colon tissues. Further study showed that icariin dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory cytokine levels of activated T cells. Moreover, icariin treatment inhibited the phosphorylations of STAT1 and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively. Taken together, these results indicate that icariin is a potential therapeutic agent for IBD.
23261528	175	182	icariin	CHEMICAL	23261528T10
23261528	1196	1204	cytokine	GENE-N	23261528T11
23261528	1296	1301	STAT1	GENE-Y	112649
23261528	1306	1311	STAT3	GENE-Y	112651
23261528	319	328	cytokines	GENE-N	23261528T14
23261528	979	988	cytokines	GENE-N	23261528T15
23261528	1007	1012	p-p65	GENE-Y	23261528T16
23261528	1014	1021	p-STAT1	GENE-Y	23261528T17
23261528	1026	1033	p-STAT3	GENE-Y	23261528T18
23261528	52	57	STAT1	GENE-Y	112649
23261528	1244	1251	icariin	CHEMICAL	23261528T1
23261528	62	67	STAT3	GENE-Y	112651
23261528	1451	1458	icariin	CHEMICAL	23261528T2
23261528	457	464	steroid	CHEMICAL	23261528T3
23261528	629	636	icariin	CHEMICAL	23261528T4
23261528	778	785	sulfate	CHEMICAL	23261528T5
23261528	786	792	sodium	CHEMICAL	23261528T6
23261528	817	824	icariin	CHEMICAL	23261528T7
23261528	1078	1085	icariin	CHEMICAL	23261528T8
23261528	155	164	flavonoid	CHEMICAL	23261528T9
23261528	CPR:4	23261528T10	112649
23261528	CPR:4	23261528T10	112651
23261528	CPR:4	23261528T1	112649
23261528	CPR:4	23261528T1	112651
23261528	CPR:4	23261528T8	23261528T11
23261528	CPR:4	23261528T9	112649
23261528	CPR:4	23261528T9	112651

23261705|t|Stimulatory effect of insulin on theca-interstitial cell proliferation and cell cycle regulatory proteins through MTORC1 dependent pathway.
23261705|a|The present study examined the effect of insulin-mediated activation of the mammalian target of rapamycin complex 1 (MTORC1) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells. Our results show that insulin treatment increased proliferation of the T-I cells through the MTORC1-dependent signaling pathway by increasing cell cycle regulatory proteins. Inhibition of ERK1/2 signaling caused partial reduction of insulin-induced phosphorylation of RPS6KB1 and RPS6 whereas inhibition of PI3-kinase signaling completely blocked the insulin response. Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6. These results were further confirmed by demonstrating that knockdown of Mtor using siRNA reduced the insulin-stimulated MTORC1 signaling. Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin. Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.
23261705	591	598	insulin	GENE-Y	23261705T10
23261705	626	633	RPS6KB1	GENE-Y	112112
23261705	638	642	RPS6	GENE-Y	112108|14584
23261705	665	675	PI3-kinase	GENE-N	23261705T13
23261705	709	716	insulin	GENE-Y	23261705T14
23261705	757	763	MTORC1	GENE-N	23261705T15
23261705	793	800	insulin	GENE-Y	23261705T16
23261705	828	836	EIF4EBP1	GENE-Y	108293
23261705	838	845	RPS6KB1	GENE-Y	112112
23261705	875	879	RPS6	GENE-Y	112108|14584
23261705	1169	1178	rapamycin	CHEMICAL	23261705T1
23261705	216	255	mammalian target of rapamycin complex 1	GENE-N	23261705T20
23261705	953	957	Mtor	GENE-Y	62050|248568|208142
23261705	982	989	insulin	GENE-Y	23261705T22
23261705	1001	1007	MTORC1	GENE-N	23261705T23
23261705	1032	1039	insulin	GENE-Y	23261705T24
23261705	1096	1126	cell cycle regulatory proteins	GENE-N	23261705T25
23261705	1127	1131	CDK4	GENE-Y	107454|167251
23261705	1133	1138	CCND3	GENE-Y	107336
23261705	114	120	MTORC1	GENE-N	23261705T28
23261705	22	29	insulin	GENE-Y	23261705T29
23261705	769	778	rapamycin	CHEMICAL	23261705T2
23261705	236	245	rapamycin	CHEMICAL	23261705T3
23261705	1143	1147	PCNA	GENE-Y	111142|62946|172122|675031
23261705	257	263	MTORC1	GENE-N	23261705T5
23261705	1334	1340	MTORC1	GENE-N	23261705T6
23261705	451	457	MTORC1	GENE-N	23261705T7
23261705	546	552	ERK1/2	GENE-N	23261705T8
23261705	181	188	insulin	GENE-Y	23261705T9
23261705	CPR:4	23261705T1	23261705T24
23261705	CPR:4	23261705T1	23261705T25
23261705	CPR:4	23261705T1	107454|167251
23261705	CPR:4	23261705T1	107336
23261705	CPR:4	23261705T1	111142|62946|172122|675031
23261705	CPR:4	23261705T2	23261705T15
23261705	CPR:4	23261705T2	23261705T16
23261705	CPR:4	23261705T2	108293
23261705	CPR:4	23261705T2	112112
23261705	CPR:4	23261705T2	112108|14584

23263989|t|The conserved PHD1-PHD2 domain of ZFP-1/AF10 is a discrete functional module essential for viability in Caenorhabditis elegans.
23263989|a|Plant homeodomain (PHD)-type zinc fingers play an important role in recognizing chromatin modifications and recruiting regulatory proteins to specific genes. A specific module containing a conventional PHD finger followed by an extended PHD finger exists in the mammalian AF10 protein, among a few others. AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the N-terminal PHD fingers of AF10. Although this domain of AF10 is the most conserved region of the protein, its biological significance has not been elucidated. In this study, we used genetic and biochemical approaches to examine the PHD1-PHD2 region of the Caenorhabditis elegans ortholog of AF10, zinc finger protein 1 (ZFP-1). We demonstrate that the PHD1-PHD2 region is essential for viability and that the first PHD finger contributes to the preferred binding of PHD1-PHD2 to lysine 4-methylated histone H3 tails. Moreover, we show that ZFP-1 localization peaks overlap with H3K4 methylation-enriched promoters of actively expressed genes genomewide and that H3K4 methylation is important for ZFP-1 localization to promoters in the embryo. We predict that the essential biological role of the PHD1-PHD2 module of ZFP-1/AF10 is connected to the regulation of actively expressed genes during early development.
23263989	330	340	PHD finger	GENE-N	23263989T10
23263989	365	375	PHD finger	GENE-N	23263989T11
23263989	400	404	AF10	GENE-N	23263989T12
23263989	434	438	AF10	GENE-Y	23263989T13
23263989	494	497	MLL	GENE-Y	23263989T14
23263989	498	502	AF10	GENE-Y	23263989T15
23263989	535	557	N-terminal PHD fingers	GENE-N	23263989T16
23263989	561	565	AF10	GENE-Y	23263989T17
23263989	591	595	AF10	GENE-Y	23263989T18
23263989	767	776	PHD1-PHD2	GENE-N	23263989T19
23263989	157	161	zinc	CHEMICAL	23263989T1
23263989	826	830	AF10	GENE-Y	23263989T20
23263989	832	853	zinc finger protein 1	GENE-Y	23263989T21
23263989	855	860	ZFP-1	GENE-Y	23263989T22
23263989	887	896	PHD1-PHD2	GENE-N	23263989T23
23263989	950	960	PHD finger	GENE-N	23263989T24
23263989	1001	1010	PHD1-PHD2	GENE-N	23263989T25
23263989	1075	1080	ZFP-1	GENE-Y	23263989T26
23263989	14	30	PHD1-PHD2 domain	GENE-N	23263989T27
23263989	34	39	ZFP-1	GENE-Y	23263989T28
23263989	40	44	AF10	GENE-Y	23263989T29
23263989	535	536	N	CHEMICAL	167
23263989	832	836	zinc	CHEMICAL	23263989T3
23263989	1014	1020	lysine	CHEMICAL	23263989T4
23263989	128	169	Plant homeodomain (PHD)-type zinc fingers	GENE-N	23263989T5
23263989	1231	1236	ZFP-1	GENE-Y	23263989T6
23263989	1331	1340	PHD1-PHD2	GENE-N	23263989T7
23263989	1351	1356	ZFP-1	GENE-Y	23263989T8
23263989	1357	1361	AF10	GENE-Y	23263989T9

23265873|t|Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
23265873|a|Two novel series of N(4)-(5-(2/3/4-substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(2-methyl-5-(prop-1-en-2-yl)cyclohex-2-enylidene)semicarbazide and N(4)-(5-(2/3/4-substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(3,7-dimethylocta-3,6-dienylidene)-semicarbazide were synthesized to meet structural prerequisite indispensable for anticonvulsant activity. The anticonvulsant activities of the compounds were investigated using maximal electroshock seizure (MES), subcutaneous pentylenetrtrazole (scPTZ) and subcutaneous strychnine (scSTY) models. The rotorod test was conducted to evaluate neurotoxicity. Some of the selected active compounds were subjected to GABA assay to confirm their mode of action. The outcome of the present investigations proved that the four binding sites pharmacophore model is vital for anticonvulsant activity. The efforts were also made to establish structure-activity relationships among test compounds.
23265873	299	409	N(4)-(5-(2/3/4-substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(3,7-dimethylocta-3,6-dienylidene)-semicarbazide	CHEMICAL	23265873T1
23265873	170	294	N(4)-(5-(2/3/4-substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(2-methyl-5-(prop-1-en-2-yl)cyclohex-2-enylidene)semicarbazide	CHEMICAL	23265873T2
23265873	622	640	pentylenetrtrazole	CHEMICAL	23265873T3
23265873	666	676	strychnine	CHEMICAL	23265873T4
23265873	807	811	GABA	CHEMICAL	23265873T5
23265873	107	121	semicarbazones	CHEMICAL	23265873T6
23265873	19	25	citral	CHEMICAL	23265873T7
23265873	32	67	2,5-disubstituted-1,3,4-oxadiazoles	CHEMICAL	23265873T8
23265873	6	14	limonene	CHEMICAL	23265873T9

23265901|t|Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.
23265901|a|We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety. The introduction of the amino group resulted in not only improved water solubility but also enhanced TLR7 agonistic activity. In particular compound 20 (DSR-6434) indicated an optimal balance between the agonistic potency and high water solubility. It also demonstrated a strong antitumor effect in vivo by intravenous administration in a tumor bearing mice model.
23265901	63	83	Toll-like receptor 7	GENE-Y	23265901T10
23265901	262	277	tertiary amines	CHEMICAL	23265901T1
23265901	287	288	N	CHEMICAL	167
23265901	308	315	adenine	CHEMICAL	23265901T3
23265901	348	353	amino	CHEMICAL	23265901T4
23265901	477	485	DSR-6434	CHEMICAL	23265901T5
23265901	201	214	8-oxoadenines	CHEMICAL	23265901T6
23265901	28	40	8-oxoadenine	CHEMICAL	23265901T7
23265901	425	429	TLR7	GENE-Y	119436
23265901	178	182	TLR7	GENE-Y	119436
23265901	CPR:5	23265901T1	119436
23265901	CPR:5	167	119436
23265901	CPR:5	23265901T3	119436
23265901	CPR:5	23265901T4	119436
23265901	CPR:5	23265901T6	119436
23265901	CPR:5	23265901T7	23265901T10

23265904|t|Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).
23265904|a|Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model. Initial optimization revealed potency preferences for the oxazepine core and benzylic positions, while substituents on the piperidine portions were more tolerant and allowed for tuning of potency and PK properties. After preparation and testing of a range of functional groups on the piperidine nitrogen, three classes of analogs were identified with single digit nanomolar potency: glycine amides, heterocycle-linked amides, and thiazoles. Responding to concerns about target localization and potential mechanism-based side effects, an initial effort was also made to improve liver concentration in an available rat PK model. An advanced compound 17m with a 5-carboxy-2-thiazole substructure appended to the spirocyclic piperidine scaffold was developed which satisfied the in vitro and in vivo requirements for more detailed studies.
23265904	784	790	amides	CHEMICAL	23265904T10
23265904	796	805	thiazoles	CHEMICAL	23265904T11
23265904	159	178	stearoyl-coenzyme A	CHEMICAL	23265904T12
23265904	1025	1045	5-carboxy-2-thiazole	CHEMICAL	23265904T13
23265904	42	54	stearoyl-CoA	CHEMICAL	23265904T14
23265904	199	203	SCD1	GENE-Y	26552
23265904	159	197	stearoyl-coenzyme A (CoA) desaturase 1	GENE-Y	23265904T16
23265904	42	65	stearoyl-CoA desaturase	GENE-Y	23265904T17
23265904	67	71	SCD1	GENE-Y	26552
23265904	1075	1097	spirocyclic piperidine	CHEMICAL	23265904T1
23265904	180	183	CoA	CHEMICAL	1916
23265904	96	129	benzo-fused spirocyclic oxazepine	CHEMICAL	23265904T3
23265904	424	433	oxazepine	CHEMICAL	23265904T4
23265904	443	451	benzylic	CHEMICAL	23265904T5
23265904	489	499	piperidine	CHEMICAL	23265904T6
23265904	650	660	piperidine	CHEMICAL	23265904T7
23265904	661	669	nitrogen	CHEMICAL	23265904T8
23265904	749	763	glycine amides	CHEMICAL	23265904T9
23265904	CPR:4	23265904T3	26552
23265904	CPR:4	23265904T3	23265904T16

23266452|t|N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver.
23266452|a|Due to its efficient and specific gene silencing ability, RNA interference has shown great potential in the treatment of liver diseases. However, achieving in vivo delivery of siRNA to critical liver cells remains the biggest obstacle for this technique to be a real clinic therapeutic modality. Here, we describe a promising liver targeting siRNA delivery system based on N-acetylgalactosamine functionalized mixed micellar nanoparticles (Gal-MNP), which can efficiently deliver siRNA to hepatocytes and silence the target gene expression after systemic administration. The Gal-MNP were assembled in aqueous solution from mixed N-acetylgalactosamine functionalized poly(ethylene glycol)-b-poly(-caprolactone) and cationic poly(-caprolactone)-b-poly(2-aminoethyl ethylene phosphate) (PCL-b-PPEEA); the properties of nanoparticles, including particle size, zeta potential and the density of poly(ethylene glycol) could be easily regulated. The hepatocyte-targeting effect of Gal-MNP was demonstrated by significant enriching of fluorescent siRNA in primary hepatocytes in vitro and in vivo. Successful down-regulation of liver-specific apolipoprotein B (apoB) expression was achieved in mouse liver, at both the transcriptional and protein level, following intravenous injection of Gal-MNP/siapoB to BALB/c mice. Systemic delivery of Gal-MNP/siRNA did not induce the innate immune response or positive hepatotoxicity. The results of this study suggested therapeutic potential for the Gal-MNP/siRNA system in liver disease.
23266452	1400	1404	apoB	GENE-Y	23266452T10
23266452	480	501	N-acetylgalactosamine	CHEMICAL	23266452T1
23266452	736	757	N-acetylgalactosamine	CHEMICAL	23266452T2
23266452	773	817	poly(ethylene glycol)-b-poly(-caprolactone)	CHEMICAL	23266452T3
23266452	831	891	poly(-caprolactone)-b-poly(2-aminoethyl ethylene phosphate)	CHEMICAL	23266452T4
23266452	893	904	PCL-b-PPEEA	CHEMICAL	23266452T5
23266452	999	1020	poly(ethylene glycol)	CHEMICAL	23266452T6
23266452	0	21	N-acetylgalactosamine	CHEMICAL	23266452T7
23266452	1244	1260	apolipoprotein B	GENE-Y	23266452T8
23266452	1262	1266	apoB	GENE-Y	23266452T9

23266732|t|Effects of Yerba Mate tea (Ilex paraguariensis) on vascular endothelial function and liver lipoprotein receptor gene expression in hyperlipidemic rats.
23266732|a|Yerba Mate tea (Mate), an infusion made from the leaves of the tree Ilex paraguariensis, is a widely consumed beverage in South America. This study was performed to investigate the effect of Mate tea on vascular endothelial dysfunction and liver lipoprotein receptor gene expression in hyperlipidemic rats, with the aim of gaining insight into its known lipid-lowering protective mechanisms. Sixty male Sprague-Dawley rats were randomly divided into five groups: a normal control group (NC), a high-fat diet group (HC), and three Mate tea-treated groups. In the NC group, rats were fed with standard diet while in the other groups the rats were fed a high-fat diet for 8weeks. In the Mate tea-treated groups, the rats were fed a high-fat diet supplemented with low, moderate or high concentrations of aqueous Mate tea extract for the final 4weeks. Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1) (6-keto-PGF(1)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1). These findings indicate that Mate tea administration might have a regulatory effect on blood fat and endothelial function in hyperlipidemia rats. The mechanism may involve protecting vascular endothelial cell function and upregulating the expression of LDLR and SR-B1 genes, thereby inhibiting the occurrence of atherosclerosis.
23266732	1462	1466	LDLR	GENE-Y	110141
23266732	1472	1493	scavenger receptor B1	GENE-Y	23266732T11
23266732	1495	1500	SR-B1	GENE-Y	23266732T12
23266732	1756	1760	LDLR	GENE-Y	110141
23266732	1765	1770	SR-B1	GENE-Y	23266732T14
23266732	398	418	lipoprotein receptor	GENE-N	23266732T15
23266732	1073	1083	endothelin	GENE-N	23266732T16
23266732	1085	1087	ET	GENE-N	23266732T17
23266732	91	111	lipoprotein receptor	GENE-N	23266732T18
23266732	1154	1156	NO	CHEMICAL	427
23266732	1162	1188	6-keto prostaglandin F(1)	CHEMICAL	23266732T2
23266732	1190	1204	6-keto-PGF(1)	CHEMICAL	23266732T3
23266732	1093	1109	thromboxane B(2)	CHEMICAL	23266732T4
23266732	1111	1117	TXB(2)	CHEMICAL	23266732T5
23266732	1140	1152	nitric oxide	CHEMICAL	23266732T6
23266732	1300	1333	intercellular adhesion molecule-1	GENE-Y	23266732T7
23266732	1335	1341	ICAM-1	GENE-Y	23266732T8
23266732	1428	1460	low density lipoprotein receptor	GENE-Y	23266732T9

23267767|t|Development of hypoxia-inducible factor (HIF)-1 inhibitors: effect of ortho-carborane substituents on HIF transcriptional activity under hypoxia.
23267767|a|A series of substituted ortho-carboranylphenoxyacetanilides were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay. Among the compounds synthesized, 1g and 1l showed significant inhibition of hypoxia-induced HIF-1 transcriptional activity (IC(50): 1.9  0.4 and 1.4  0.2 M, respectively). Both compounds suppressed HIF-1 accumulation in a concentration-dependent manner. The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited human Hsp60 chaperone activity (IC(50): 6.80  0.25 M) and this inhibition activity was higher than that of ETB (IC(50): 10.9  0.63 M).
23267767	781	787	HIF-1	GENE-Y	23267767T10
23267767	842	876	porcine heart malate dehydrogenase	GENE-N	23267767T11
23267767	878	881	MDH	GENE-N	9226
23267767	935	946	human Hsp60	GENE-Y	23267767T13
23267767	103	106	HIF	GENE-N	23267767T14
23267767	15	48	hypoxia-inducible factor (HIF)-1	GENE-Y	23267767T15
23267767	171	206	ortho-carboranylphenoxyacetanilides	CHEMICAL	23267767T1
23267767	569	572	MTT	CHEMICAL	23267767T2
23267767	856	862	malate	CHEMICAL	23267767T3
23267767	1044	1047	ETB	CHEMICAL	23267767T4
23267767	71	86	ortho-carborane	CHEMICAL	23267767T5
23267767	283	288	HIF-1	GENE-N	23267767T6
23267767	377	380	HRE	GENE-N	23267767T7
23267767	430	433	HRE	GENE-N	23267767T8
23267767	672	677	HIF-1	GENE-N	23267767T9
23267767	CPR:4	23267767T4	23267767T13

23270704|t|Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.
23270704|a|We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. Male Sprague-Dawley rats were exposed to hypoxia (100.5% O2) for 17d and intervened with APO and RS in the last 6d. Histological changes and expression of pro-inflammation factors were evaluated in vivo. Biomarkers in isolated Leydig cells incubated with H2O2 were also assayed in vitro. Hypoxic rats displayed lower serum testosterone and higher LH and FSH. Upregulation of p22/p47(phox), NOX2, MMP9, PERK and p66Shc was associated with downregulation of StAR, 3-HSD and Cx43 in the hypoxia testis, revealed by Western blot and immunohistochemical assay, respectively. APO and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and p66Shc in testes.
23270704	0	8	Apocynin	CHEMICAL	23270704T10
23270704	13	25	raisanberine	CHEMICAL	23270704T11
23270704	98	110	testosterone	CHEMICAL	614
23270704	337	340	NOX	GENE-N	23270704T13
23270704	807	809	LH	GENE-N	23270704T14
23270704	814	817	FSH	GENE-N	23270704T15
23270704	835	848	p22/p47(phox)	GENE-N	23270704T16
23270704	850	854	NOX2	GENE-Y	23270704T17
23270704	856	860	MMP9	GENE-Y	110461
23270704	862	866	PERK	GENE-Y	23270704T19
23270704	306	309	APO	CHEMICAL	23270704T1
23270704	871	877	p66Shc	GENE-Y	23270704T20
23270704	916	920	StAR	GENE-Y	23270704T21
23270704	922	928	3-HSD	GENE-N	23270704T22
23270704	933	937	Cx43	GENE-Y	23270704T23
23270704	274	287	NADPH oxidase	GENE-N	23270704T24
23270704	1134	1140	p66Shc	GENE-Y	23270704T25
23270704	289	292	NOX	GENE-N	23270704T26
23270704	169	175	p66Shc	GENE-Y	23270704T27
23270704	74	78	StAR	GENE-Y	23270704T28
23270704	83	89	3-HSD	GENE-N	23270704T29
23270704	311	319	apocynin	CHEMICAL	23270704T2
23270704	345	357	raisanberine	CHEMICAL	23270704T3
23270704	366	373	calcium	CHEMICAL	23270704T4
23270704	549	552	APO	CHEMICAL	23270704T5
23270704	715	719	H2O2	CHEMICAL	23270704T6
23270704	783	795	testosterone	CHEMICAL	614
23270704	274	279	NADPH	CHEMICAL	23270704T8
23270704	1031	1034	APO	CHEMICAL	23270704T9
23270704	CPR:4	23270704T10	23270704T27
23270704	CPR:4	23270704T11	23270704T27
23270704	CPR:4	23270704T1	23270704T13
23270704	CPR:4	23270704T2	23270704T13
23270704	CPR:4	23270704T9	23270704T25
23270704	CPR:9	23270704T11	23270704T29

23270805|t|Coming full circle: contributions of central and peripheral oxytocin actions to energy balance.
23270805|a|The neuropeptide oxytocin has emerged as an important anorexigen in the regulation of energy balance. Its effects on food intake have largely been attributed to limiting meal size through interactions in key regulatory brain regions such as the hypothalamus and hindbrain. Pharmacologic and pair-feeding studies indicate that its ability to reduce body mass extends beyond that of food intake, affecting multiple factors that determine energy balance such as energy expenditure, lipolysis, and glucose regulation. Systemic administration of oxytocin recapitulates many of its effects when administered centrally, raising the questions of whether and to what extent circulating oxytocin contributes to energy regulation. Its therapeutic potential to treat metabolic conditions remains to be determined, but data from diet-induced and genetically obese rodent models as well as application of oxytocin in humans in other areas of research have revealed promising results thus far.
23270805	773	781	oxytocin	GENE-Y	23270805T10
23270805	987	995	oxytocin	GENE-Y	23270805T11
23270805	60	68	oxytocin	GENE-Y	23270805T12
23270805	113	121	oxytocin	CHEMICAL	102
23270805	590	597	glucose	CHEMICAL	23270805T2
23270805	637	645	oxytocin	CHEMICAL	102
23270805	150	160	anorexigen	CHEMICAL	23270805T4
23270805	773	781	oxytocin	CHEMICAL	102
23270805	987	995	oxytocin	CHEMICAL	102
23270805	60	68	oxytocin	CHEMICAL	102
23270805	113	121	oxytocin	GENE-Y	23270805T8
23270805	637	645	oxytocin	GENE-Y	23270805T9

23271742|t|Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of Np63 protein.
23271742|a|Transcription factor p63, a member of the p53 family, shares a high degree of sequence similarity with p53. Because of transcription from two distinct promoters, the p63 gene encodes two isoforms, TAp63 and Np63. Although TAp63 acts as a tumor suppressor, Np63 functions as an oncogene and is often overexpressed in squamous cell carcinomas. Thus, therapeutic agents targeting Np63 might be used to manage tumors that overexpress Np63. Here we found that arsenic trioxide, a frontline agent for acute promyelocytic leukemia, inhibits Np63 but not TAp63 expression in time- and dose-dependent manners. In addition, we found that arsenic trioxide decreases the stability of Np63 protein via a proteasome-dependent pathway but has little effect on the level of Np63 transcript. Furthermore, we found that arsenic trioxide activates the Pirh2 promoter and consequently induces Pirh2 expression. Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, arsenic-induced degradation of Np63 protein. Importantly, we found that knockdown of Np63 sensitizes, whereas ectopic expression of Np63 inhibits, growth suppression induced by arsenic. Together, these data suggest that arsenic degrades Np63 protein at least in part via Pirh2-dependent proteolysis and that inhibition of Np63 expression facilitates tumor cells to arsenic-induced death.
23271742	197	200	p53	GENE-Y	77545
23271742	1134	1139	Np63	GENE-Y	23271742T11
23271742	1189	1194	Np63	GENE-Y	23271742T12
23271742	1237	1242	Np63	GENE-Y	23271742T13
23271742	1343	1348	Np63	GENE-Y	23271742T14
23271742	1378	1383	Pirh2	GENE-Y	23271742T15
23271742	1429	1434	Np63	GENE-Y	23271742T16
23271742	260	263	p63	GENE-N	23271742T17
23271742	291	296	TAp63	GENE-Y	23271742T18
23271742	301	306	Np63	GENE-Y	23271742T19
23271742	1103	1110	arsenic	CHEMICAL	23271742T1
23271742	317	322	TAp63	GENE-Y	23271742T20
23271742	351	356	Np63	GENE-Y	23271742T21
23271742	473	478	Np63	GENE-Y	23271742T22
23271742	136	139	p53	GENE-Y	77545
23271742	527	532	Np63	GENE-Y	23271742T24
23271742	632	637	Np63	GENE-Y	23271742T25
23271742	646	651	TAp63	GENE-Y	23271742T26
23271742	771	776	Np63	GENE-Y	23271742T27
23271742	791	801	proteasome	GENE-N	23271742T28
23271742	858	863	Np63	GENE-Y	23271742T29
23271742	1283	1290	arsenic	CHEMICAL	23271742T2
23271742	934	948	Pirh2 promoter	GENE-N	23271742T30
23271742	974	979	Pirh2	GENE-Y	23271742T31
23271742	1041	1046	Pirh2	GENE-Y	23271742T32
23271742	1087	1092	Pirh2	GENE-Y	23271742T33
23271742	37	42	Pirh2	GENE-Y	23271742T34
23271742	79	84	Np63	GENE-Y	23271742T35
23271742	1326	1333	arsenic	CHEMICAL	23271742T3
23271742	1473	1480	arsenic	CHEMICAL	23271742T4
23271742	553	569	arsenic trioxide	CHEMICAL	23271742T5
23271742	727	743	arsenic trioxide	CHEMICAL	23271742T6
23271742	903	919	arsenic trioxide	CHEMICAL	23271742T7
23271742	0	7	Arsenic	CHEMICAL	23271742T8
23271742	94	118	Transcription factor p63	GENE-Y	23271742T9
23271742	CPR:3	23271742T7	23271742T30
23271742	CPR:3	23271742T7	23271742T31
23271742	CPR:4	23271742T1	23271742T11
23271742	CPR:4	23271742T3	23271742T14
23271742	CPR:4	23271742T3	23271742T16
23271742	CPR:4	23271742T5	23271742T25
23271742	CPR:4	23271742T6	23271742T27

23274058|t|Jaceosidin, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1/2 activation.
23274058|a|Jaceosidin, a flavonoid derived from Artemisia princeps (Japanese mugwort), has been shown to inhibit the growth of several human cancer cells, However, the exact mechanism for the cytotoxic effect of jaceosidin is not completely understood. In this study, we investigated the molecular mechanism involved in the antiproliferative effect of jaceosidin in human endometrial cancer cells. We demonstrated that jaceosidin is a more potent inhibitor of cell growth than cisplatin in human endometrial cancer cells. In contrast, jaceosidin-induced cytotoxicity in normal endometrial cells was lower than that observed for cisplatin. Jaceosidin induced G2/M phase cell cycle arrest and modulated the levels of cyclin B and p-Cdc2 in Hec1A cells. Knockdown of p21 using specific siRNAs partially abrogated jaceosidin-induced cell growth inhibition. Additional mechanistic studies revealed that jaceosidin treatment resulted in an increase in phosphorylation of Cdc25C and ATM-Chk1/2. Ku55933, an ATM inhibitor, reversed jaceosidin-induced cell growth inhibition, in part. Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the ERK inhibitor, PD98059, attenuated cell growth inhibition by jaceosidin. These data suggest that jaceosidin, isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.
23274058	558	568	jaceosidin	CHEMICAL	23274058T10
23274058	616	625	cisplatin	CHEMICAL	23274058T11
23274058	674	684	jaceosidin	CHEMICAL	23274058T12
23274058	767	776	cisplatin	CHEMICAL	23274058T13
23274058	778	788	Jaceosidin	CHEMICAL	23274058T14
23274058	949	959	jaceosidin	CHEMICAL	23274058T15
23274058	1037	1047	jaceosidin	CHEMICAL	23274058T16
23274058	0	10	Jaceosidin	CHEMICAL	23274058T17
23274058	1277	1280	ERK	GENE-N	23274058T18
23274058	1308	1311	ERK	GENE-N	23274058T19
23274058	150	160	Jaceosidin	CHEMICAL	23274058T1
23274058	1463	1466	ERK	GENE-N	23274058T20
23274058	1467	1470	ATM	GENE-Y	106962|9294
23274058	1471	1477	Chk1/2	GENE-N	23274058T22
23274058	1518	1522	Cdc2	GENE-Y	23274058T23
23274058	1523	1532	cyclin B1	GENE-Y	23274058T24
23274058	854	862	cyclin B	GENE-Y	23274058T25
23274058	867	873	p-Cdc2	GENE-Y	23274058T26
23274058	903	906	p21	GENE-Y	23274058T27
23274058	1104	1110	Cdc25C	GENE-Y	23274058T28
23274058	1115	1118	ATM	GENE-Y	106962|9294
23274058	1163	1173	jaceosidin	CHEMICAL	23274058T2
23274058	1119	1125	Chk1/2	GENE-N	23274058T30
23274058	1139	1142	ATM	GENE-Y	106962|9294
23274058	111	117	cdc25C	GENE-Y	23274058T32
23274058	118	122	cdc2	GENE-Y	60495|276415
23274058	127	130	ATM	GENE-Y	106962|9294
23274058	131	137	Chk1/2	GENE-N	23274058T35
23274058	1225	1235	jaceosidin	CHEMICAL	23274058T3
23274058	1323	1330	PD98059	CHEMICAL	23274058T4
23274058	1369	1379	jaceosidin	CHEMICAL	23274058T5
23274058	1405	1415	jaceosidin	CHEMICAL	23274058T6
23274058	164	173	flavonoid	CHEMICAL	23274058T7
23274058	351	361	jaceosidin	CHEMICAL	23274058T8
23274058	491	501	jaceosidin	CHEMICAL	23274058T9
23274058	CPR:3	23274058T16	23274058T28
23274058	CPR:3	23274058T16	106962|9294
23274058	CPR:3	23274058T17	106962|9294
23274058	CPR:4	23274058T17	23274058T32
23274058	CPR:4	23274058T17	60495|276415
23274058	CPR:4	23274058T4	23274058T19
23274058	CPR:4	23274058T6	23274058T23
23274058	CPR:4	23274058T6	23274058T24

23274893|t|EphA5-EphrinA5 interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local glutamine/glutamate balance during hypoglycemia.
23274893|a|Activation of -cell EphA5 receptors by its ligand ephrinA5 from adjacent -cells has been reported to decrease insulin secretion during hypoglycemia. Given the similarities between islet and ventromedial hypothalamus (VMH) glucose sensing, we tested the hypothesis that the EphA5/ephrinA5 system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well. Counterregulatory responses and glutamine/glutamate concentrations in the VMH were assessed during a hyperinsulinemic-hypoglycemic glucose clamp study in chronically catheterized awake male Sprague-Dawley rats that received an acute VMH microinjection of ephrinA5-Fc, chronic VMH knockdown, or overexpression of ephrinA5 using an adenoassociated viral construct. Local stimulation of VMH EphA5 receptors by ephrinA5-Fc or ephrinA5 overexpression increased, whereas knockdown of VMH ephrinA5 reduced counterregulatory responses during hypoglycemia. Overexpression of VMH ephrinA5 transiently increased local glutamate concentrations, whereas ephrinA5 knockdown produced profound suppression of VMH interstitial fluid glutamine concentrations in the basal state and during hypoglycemia. Changes in ephrinA5/EphA5 interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/glutamine cycling.
23274893	702	709	glucose	CHEMICAL	23274893T10
23274893	119	128	glutamine	CHEMICAL	23274893T11
23274893	129	138	glutamate	CHEMICAL	23274893T12
23274893	1212	1220	ephrinA5	GENE-Y	23274893T13
23274893	1367	1375	ephrinA5	GENE-Y	23274893T14
23274893	1376	1381	EphA5	GENE-Y	23274893T15
23274893	189	204	EphA5 receptors	GENE-Y	23274893T16
23274893	443	448	EphA5	GENE-Y	23274893T17
23274893	449	457	ephrinA5	GENE-Y	23274893T18
23274893	219	227	ephrinA5	GENE-Y	23274893T19
23274893	1178	1187	glutamate	CHEMICAL	23274893T1
23274893	826	834	ephrinA5	GENE-Y	23274893T20
23274893	883	891	ephrinA5	GENE-Y	23274893T21
23274893	959	974	EphA5 receptors	GENE-Y	23274893T22
23274893	978	989	ephrinA5-Fc	GENE-Y	23274893T23
23274893	993	1001	ephrinA5	GENE-Y	23274893T24
23274893	1053	1061	ephrinA5	GENE-Y	23274893T25
23274893	1141	1149	ephrinA5	GENE-Y	23274893T26
23274893	0	5	EphA5	GENE-Y	23274893T27
23274893	6	14	EphrinA5	GENE-Y	23274893T28
23274893	1287	1296	glutamine	CHEMICAL	23274893T2
23274893	1423	1430	glucose	CHEMICAL	23274893T3
23274893	1485	1492	glucose	CHEMICAL	23274893T4
23274893	1598	1607	glutamate	CHEMICAL	23274893T5
23274893	1608	1617	glutamine	CHEMICAL	23274893T6
23274893	392	399	glucose	CHEMICAL	23274893T7
23274893	603	612	glutamine	CHEMICAL	23274893T8
23274893	613	622	glutamate	CHEMICAL	23274893T9

23274898|t|Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3K-Akt-AS160 in Skeletal Muscle Cells.
23274898|a|Skeletal muscle glucose uptake in response to exercise is preserved in insulin-resistant conditions, but the signals involved are debated. ATP is released from skeletal muscle by contractile activity and can autocrinely signal through purinergic receptors, and we hypothesized it may influence glucose uptake. Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin). Electrical stimulation transiently elevated extracellular ATP and caused Akt phosphorylation that was additive to insulin and inhibited by suramin. Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation. ATP-dependent 2-NBDG uptake was also inhibited by the G protein  subunit-interacting peptide ark-ct and by the phosphatidylinositol 3-kinase- (PI3K) inhibitor AS605240. ATP caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or PI3K kinase-dead mutants, and potentiated by myristoylated PI3K. ATP stimulated 2-NBDG uptake in normal and insulin-resistant adult muscle fibers, resembling the reported effect of exercise. Hence, the ATP-induced pathway may be tapped to bypass insulin resistance.
23274898	506	519	2-NBD-Glucose	CHEMICAL	23274898T10
23274898	521	527	2-NBDG	CHEMICAL	23274898T11
23274898	593	596	ATP	CHEMICAL	164
23274898	607	613	2-NBDG	CHEMICAL	23274898T13
23274898	639	658	adenosine-phosphate	CHEMICAL	23274898T14
23274898	708	715	suramin	CHEMICAL	23274898T15
23274898	776	779	ATP	CHEMICAL	164
23274898	857	864	suramin	CHEMICAL	23274898T17
23274898	876	879	ATP	CHEMICAL	164
23274898	1015	1018	ATP	CHEMICAL	164
23274898	1232	1240	AS605240	CHEMICAL	4571
23274898	1029	1035	2-NBDG	CHEMICAL	23274898T20
23274898	1068	1071	ATP	CHEMICAL	164
23274898	1082	1088	2-NBDG	CHEMICAL	23274898T22
23274898	27	30	ATP	CHEMICAL	164
23274898	67	74	Glucose	CHEMICAL	23274898T24
23274898	1182	1213	phosphatidylinositol 3-kinase-	GENE-Y	23274898T25
23274898	1215	1220	PI3K	GENE-Y	23274898T26
23274898	1270	1275	GLUT4	GENE-Y	23274898T27
23274898	1364	1369	AS160	GENE-Y	23274898T28
23274898	1370	1375	Rab8A	GENE-Y	23274898T29
23274898	1242	1245	ATP	CHEMICAL	164
23274898	1405	1408	Akt	GENE-N	23274898T30
23274898	1412	1417	PI3K	GENE-Y	23274898T31
23274898	1418	1424	kinase	GENE-N	23274898T32
23274898	1458	1477	myristoylated PI3K	GENE-Y	23274898T33
23274898	1522	1529	insulin	GENE-Y	23274898T34
23274898	1660	1667	insulin	GENE-Y	23274898T35
23274898	363	383	purinergic receptors	GENE-N	23274898T36
23274898	471	478	insulin	GENE-Y	23274898T37
23274898	639	670	adenosine-phosphate phosphatase	GENE-N	23274898T38
23274898	678	697	purinergic receptor	GENE-N	23274898T39
23274898	1479	1482	ATP	CHEMICAL	164
23274898	791	794	Akt	GENE-N	23274898T40
23274898	832	839	insulin	GENE-Y	23274898T41
23274898	199	206	insulin	GENE-Y	23274898T42
23274898	902	905	Akt	GENE-N	23274898T43
23274898	922	951	phosphatidylinositol 3-kinase	GENE-N	23274898T44
23274898	953	957	PI3K	GENE-N	23274898T45
23274898	962	965	Akt	GENE-N	23274898T46
23274898	995	998	Akt	GENE-N	23274898T47
23274898	1047	1050	Akt	GENE-N	23274898T48
23274898	1122	1134	G protein 	GENE-N	23274898T49
23274898	1494	1500	2-NBDG	CHEMICAL	23274898T4
23274898	43	48	GLUT4	GENE-Y	23274898T50
23274898	86	91	PI3K	GENE-Y	23274898T51
23274898	92	95	Akt	GENE-N	23274898T52
23274898	96	101	AS160	GENE-Y	23274898T53
23274898	267	270	ATP	CHEMICAL	164
23274898	1616	1619	ATP	CHEMICAL	164
23274898	144	151	glucose	CHEMICAL	23274898T7
23274898	422	429	glucose	CHEMICAL	23274898T8
23274898	462	465	ATP	CHEMICAL	164
23274898	CPR:3	164	23274898T43
23274898	CPR:4	23274898T15	23274898T38
23274898	CPR:4	23274898T15	23274898T39
23274898	CPR:4	23274898T17	23274898T40
23274898	CPR:4	4571	23274898T25
23274898	CPR:4	4571	23274898T26
23274898	CPR:9	23274898T24	23274898T50

23275442|t|The COP9 signalosome interacts with and regulates interferon regulatory factor 5 protein stability.
23275442|a|The transcription factor interferon regulatory factor 5 (IRF5) exerts crucial functions in the regulation of host immunity against extracellular pathogens, DNA damage-induced apoptosis, death receptor signaling, and macrophage polarization. Tight regulation of IRF5 is thus warranted for an efficient response toward extracellular stressors and for limiting autoimmune and inflammatory responses. Here we report that the COP9 signalosome (CSN), a general modulator of diverse cellular and developmental processes, associates constitutively with IRF5 and promotes its protein stability. The constitutive CSN/IRF5 interaction was identified using proteomics and confirmed by endogenous immunoprecipitations. The CSN/IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (455-466) was found to significantly reduce IRF5 protein stability. CSN subunit 3 (CSN3) was identified as a direct interacting partner of IRF5, and knockdown of this subunit with small interfering RNAs resulted in enhanced degradation. Degradation was further augmented by knockdown of CSN1 and CSN3 together. The ubiquitin E1 inhibitor UBEI-41 or the proteasome inhibitor MG132 prevented IRF5 degradation, supporting the idea that its stability is regulated by the ubiquitin-proteasome system. Importantly, activation of IRF5 by the death receptor ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resulted in enhanced degradation via loss of the CSN/IRF5 interaction. This study defines CSN to be a new interacting partner of IRF5 that controls its stability.
23275442	1416	1426	proteasome	GENE-N	23275442T10
23275442	1462	1466	IRF5	GENE-Y	109871
23275442	1474	1488	death receptor	GENE-N	23275442T12
23275442	1496	1551	tumor necrosis factor-related apoptosis-inducing ligand	GENE-Y	23275442T13
23275442	1553	1558	TRAIL	GENE-Y	23275442T14
23275442	1609	1612	CSN	GENE-N	23275442T15
23275442	1613	1617	IRF5	GENE-Y	109871
23275442	1650	1653	CSN	GENE-N	23275442T17
23275442	1689	1693	IRF5	GENE-Y	109871
23275442	286	300	death receptor	GENE-N	23275442T19
23275442	847	855	carboxyl	CHEMICAL	23275442T1
23275442	125	155	interferon regulatory factor 5	GENE-Y	23275442T20
23275442	361	365	IRF5	GENE-Y	109871
23275442	521	537	COP9 signalosome	GENE-N	23275442T22
23275442	539	542	CSN	GENE-N	23275442T23
23275442	645	649	IRF5	GENE-Y	109871
23275442	157	161	IRF5	GENE-Y	109871
23275442	703	706	CSN	GENE-N	23275442T26
23275442	707	711	IRF5	GENE-Y	109871
23275442	810	813	CSN	GENE-N	23275442T28
23275442	814	818	IRF5	GENE-Y	109871
23275442	860	865	amino	CHEMICAL	23275442T2
23275442	877	881	IRF5	GENE-Y	109871
23275442	983	987	IRF5	GENE-Y	109871
23275442	1007	1020	CSN subunit 3	GENE-Y	23275442T32
23275442	1022	1026	CSN3	GENE-Y	65565|107835|159044
23275442	1078	1082	IRF5	GENE-Y	109871
23275442	4	20	COP9 signalosome	GENE-N	23275442T35
23275442	50	88	interferon regulatory factor 5 protein	GENE-Y	23275442T36
23275442	915	926	amino acids	CHEMICAL	23275442T3
23275442	1226	1230	CSN1	GENE-Y	23275442T4
23275442	1235	1239	CSN3	GENE-Y	65565|107835|159044
23275442	1254	1266	ubiquitin E1	GENE-N	23275442T6
23275442	1292	1302	proteasome	GENE-N	23275442T7
23275442	1329	1333	IRF5	GENE-Y	109871
23275442	1406	1415	ubiquitin	GENE-N	23275442T9

23279865|t|Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
23279865|a|A series of anthra[1,2-d]imidazole-6,11-dione derivatives were synthesized and evaluated for telomerase inhibition, hTERT expression and suppression of cancer cell growth in vitro. All of the compounds tested, except for compounds 4, 7, 16, 24, 27 and 28 were selected by the NCI screening system. Among them, compounds 16, 39, and 40 repressed hTERT expression without greatly affecting cell growth, suggesting for the selectivity toward hTERT expression. Taken together, our findings indicated that the analysis of cytotoxicity and telomerase inhibition might provide information applicable for further developing potential telomerase and polypharmacological targeting strategy.
23279865	184	217	anthra[1,2-d]imidazole-6,11-dione	CHEMICAL	23279865T1
23279865	58	91	anthra[1,2-d]imidazole-6,11-dione	CHEMICAL	23279865T2
23279865	288	293	hTERT	GENE-Y	23279865T3
23279865	517	522	hTERT	GENE-Y	23279865T4
23279865	611	616	hTERT	GENE-Y	23279865T5
23279865	706	716	telomerase	GENE-Y	23279865T6
23279865	798	808	telomerase	GENE-Y	23279865T7
23279865	265	275	telomerase	GENE-Y	23279865T8
23279865	107	117	telomerase	GENE-Y	23279865T9
23279865	CPR:4	23279865T1	23279865T8
23279865	CPR:4	23279865T2	23279865T9

23282999|t|Zinc sulphate and vitamin E alleviate reproductive toxicity caused by aluminium sulphate in male albino rats.
23282999|a|This study was designed to investigate the reproductive toxicity of aluminium sulphate and the therapeutic effects of administration of zinc sulphate and vitamin E individually or in combination against the toxic effect caused by aluminium (Al) in male albino rats. The animals were divided into five groups: group 1 received distilled water and served as control; group 2 received only aluminium sulphate (50 mg/kg body weight (b.w.)); group 3 received aluminium sulphate (50 mg/kg b.w.) plus zinc sulphate (50 mg/kg b.w.); group 4 received aluminium sulphate (50 mg/kg b.w.) and vitamin E (15 mg/kg b.w.); group 5 received aluminium sulphate plus a combination of zinc sulphate and vitamin E in similar doses as above. Doses were administered orally once daily for 45 consecutive days. The results revealed that aluminium sulphate induced significant decrease in body weight gain and testis weight and significant increase in Al level in both serum and testes of male rats. Biochemical analysis showed significant decrease in serum total protein and phospholipids levels, while serum total lipid was significantly elevated post Al treatment. In addition, significant decrease in total protein, phospholipids and cholesterol levels in the testes of Al-treated rats was recorded. The data also showed significant decrease in the levels of serum testosterone, leutinizing hormone and follicle stimulating hormone and significant increase in the level of serum prolactin in Al-intoxicated rats. Moreover, histological examination showed that aluminium sulphate caused apparent alterations in the testicular structure of the treated animals. Treatment with zinc sulphate and vitamin E individually or in combination ameliorated the harmful effects of Al, which was proved histopathologically by the noticeable improvement in the testicular tissues. We can conclude that the tested dose of aluminium sulphate induced toxic effect on the reproductive system of male albino rats and the treatment with zinc sulphate and/or vitamin E alleviated these toxic effects. In some cases, vitamin E exerted a more potent effect, while in other cases, the more potent effect is related to zinc sulphate and the combination of both at most of the recorded data.
23282999	1782	1791	vitamin E	CHEMICAL	23282999T10
23282999	1858	1860	Al	CHEMICAL	1331
23282999	1996	2014	aluminium sulphate	CHEMICAL	23282999T12
23282999	2106	2119	zinc sulphate	CHEMICAL	23282999T13
23282999	2127	2136	vitamin E	CHEMICAL	23282999T14
23282999	2184	2193	vitamin E	CHEMICAL	23282999T15
23282999	2283	2296	zinc sulphate	CHEMICAL	23282999T16
23282999	340	349	aluminium	CHEMICAL	23282999T17
23282999	351	353	Al	CHEMICAL	1331
23282999	497	515	aluminium sulphate	CHEMICAL	23282999T19
23282999	1240	1242	Al	CHEMICAL	1331
23282999	564	582	aluminium sulphate	CHEMICAL	23282999T20
23282999	604	617	zinc sulphate	CHEMICAL	23282999T21
23282999	652	670	aluminium sulphate	CHEMICAL	23282999T22
23282999	691	700	vitamin E	CHEMICAL	23282999T23
23282999	735	753	aluminium sulphate	CHEMICAL	23282999T24
23282999	776	789	zinc sulphate	CHEMICAL	23282999T25
23282999	794	803	vitamin E	CHEMICAL	23282999T26
23282999	178	196	aluminium sulphate	CHEMICAL	23282999T27
23282999	924	942	aluminium sulphate	CHEMICAL	23282999T28
23282999	1038	1040	Al	CHEMICAL	1331
23282999	1324	1335	cholesterol	CHEMICAL	23282999T2
23282999	0	13	Zinc sulphate	CHEMICAL	23282999T30
23282999	18	27	vitamin E	CHEMICAL	23282999T31
23282999	70	88	aluminium sulphate	CHEMICAL	23282999T32
23282999	1469	1488	leutinizing hormone	GENE-N	23282999T33
23282999	1493	1521	follicle stimulating hormone	GENE-N	23282999T34
23282999	1569	1578	prolactin	GENE-Y	23282999T35
23282999	1360	1362	Al	CHEMICAL	1331
23282999	1455	1467	testosterone	CHEMICAL	614
23282999	246	259	zinc sulphate	CHEMICAL	23282999T5
23282999	1582	1584	Al	CHEMICAL	1331
23282999	1650	1668	aluminium sulphate	CHEMICAL	23282999T7
23282999	264	273	vitamin E	CHEMICAL	23282999T8
23282999	1764	1777	zinc sulphate	CHEMICAL	23282999T9

23284002|t|Trichostatin A inhibits transforming growth factor--induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.
23284002|a|Trichostatin A (TSA) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive oxygen species (ROS) scavenging by TSA on transforming growth factor- (TGF-)-induced myofibroblast differentiation of corneal fibroblasts in vitro. Human immortalized corneal fibroblasts were treated with TGF- in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA. Myofibroblast differentiation was assessed by -smooth muscle actin (-SMA) expression, F-actin bundle formation, and collagen gel contraction. ROS, H(2)O(2), intracellular glutathione (GSH) level, cellular total antioxidant capacity, and the activation of Nrf2-ARE signaling were determined with various assays. Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the TGF--induced myofibroblast differentiation as compared with treatment with DPI or NAC. Furthermore, TSA also decreased cellular ROS and H(2)O(2) accumulation induced by TGF-, whereas it elevated intracellular GSH level and cellular total antioxidant capacity. In addition, TSA induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation. In conclusion, this study provides the first evidence implicating that TSA inhibits TGF--induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling.
23284002	1765	1768	TSA	CHEMICAL	4124
23284002	224	227	TSA	CHEMICAL	4124
23284002	383	386	TSA	CHEMICAL	4124
23284002	580	583	TSA	CHEMICAL	4124
23284002	589	596	NAD(P)H	CHEMICAL	23284002T14
23284002	615	634	diphenyleneiodonium	CHEMICAL	23284002T15
23284002	636	639	DPI	CHEMICAL	23284002T16
23284002	658	675	N-acetyl-cysteine	CHEMICAL	23284002T17
23284002	677	680	NAC	CHEMICAL	23284002T18
23284002	760	772	sulforaphane	CHEMICAL	23284002T19
23284002	208	222	Trichostatin A	CHEMICAL	4124
23284002	949	957	H(2)O(2)	CHEMICAL	23284002T20
23284002	973	984	glutathione	CHEMICAL	23284002T21
23284002	986	989	GSH	CHEMICAL	137
23284002	1128	1131	TSA	CHEMICAL	4124
23284002	0	14	Trichostatin A	CHEMICAL	4124
23284002	70	76	oxygen	CHEMICAL	23284002T25
23284002	1369	1374	TGF-	GENE-Y	23284002T26
23284002	1486	1490	Nrf2	GENE-Y	23284002T27
23284002	1548	1552	Nrf2	GENE-Y	23284002T28
23284002	1553	1556	ARE	GENE-N	23284002T29
23284002	1275	1278	DPI	CHEMICAL	23284002T2
23284002	1595	1599	Nrf2	GENE-Y	23284002T30
23284002	1778	1783	TGF-	GENE-Y	23284002T31
23284002	1856	1860	Nrf2	GENE-Y	23284002T32
23284002	1861	1864	ARE	GENE-N	23284002T33
23284002	390	418	transforming growth factor-	GENE-Y	23284002T34
23284002	420	426	TGF-)	GENE-Y	23284002T35
23284002	555	560	TGF-	GENE-Y	23284002T36
23284002	589	604	NAD(P)H oxidase	GENE-N	23284002T37
23284002	687	709	NF-E2-related factor 2	GENE-Y	23284002T38
23284002	710	738	antioxidant response element	GENE-N	23284002T39
23284002	1282	1285	NAC	CHEMICAL	23284002T3
23284002	740	744	Nrf2	GENE-Y	23284002T40
23284002	745	748	ARE	GENE-N	23284002T41
23284002	846	867	-smooth muscle actin	GENE-Y	23284002T42
23284002	869	874	-SMA	GENE-Y	23284002T43
23284002	888	895	F-actin	GENE-N	23284002T44
23284002	918	926	collagen	GENE-N	23284002T45
23284002	1057	1061	Nrf2	GENE-Y	23284002T46
23284002	1062	1065	ARE	GENE-N	23284002T47
23284002	1140	1144	Nrf2	GENE-Y	23284002T48
23284002	1145	1148	ARE	GENE-N	23284002T49
23284002	1300	1303	TSA	CHEMICAL	4124
23284002	1199	1204	TGF-	GENE-Y	23284002T50
23284002	145	167	NF-E2-related factor 2	GENE-Y	23284002T51
23284002	168	196	antioxidant response element	GENE-N	23284002T52
23284002	24	52	transforming growth factor-	GENE-Y	23284002T53
23284002	1336	1344	H(2)O(2)	CHEMICAL	23284002T5
23284002	1410	1413	GSH	CHEMICAL	137
23284002	1474	1477	TSA	CHEMICAL	4124
23284002	348	354	oxygen	CHEMICAL	23284002T8
23284002	1656	1659	TSA	CHEMICAL	4124
23284002	CPR:3	4124	23284002T32
23284002	CPR:3	4124	23284002T33
23284002	CPR:3	23284002T19	23284002T38
23284002	CPR:3	23284002T19	23284002T39
23284002	CPR:3	23284002T19	23284002T40
23284002	CPR:3	23284002T19	23284002T41
23284002	CPR:3	4124	23284002T51
23284002	CPR:3	4124	23284002T52
23284002	CPR:3	4124	23284002T28
23284002	CPR:3	4124	23284002T29
23284002	CPR:4	4124	23284002T31
23284002	CPR:4	23284002T15	23284002T37
23284002	CPR:4	23284002T16	23284002T37
23284002	CPR:4	4124	23284002T50
23284002	CPR:4	4124	23284002T53
23284002	CPR:4	4124	23284002T26

23287700|t|Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.
23287700|a|Cannabinoid receptor 1 (CB(1)) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications. Recent laboratory studies suggest that the effects of CB(1) neutral antagonists differ from those of such inverse agonists, raising the possibility of improved clinical utility. However, little is known regarding the antagonist properties of neutral antagonists. In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054. Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist (9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054. Schild analyses further show that rimonabant and AM4113 produce highly similar antagonist effects, as evident in comparable pA(2) values (6.9). Taken together with previous studies, the present data suggest that the improved safety profile suggested for CB(1) neutral antagonists over inverse agonists is not accompanied by a loss of antagonist action at CB(1) receptors.
23287700	654	660	AM4113	CHEMICAL	23287700T10
23287700	833	839	AM4054	CHEMICAL	23287700T11
23287700	863	869	AM4054	CHEMICAL	23287700T12
23287700	1006	1031	(9)-tetrahydrocannabinol	CHEMICAL	23287700T13
23287700	1062	1072	rimonabant	CHEMICAL	23287700T14
23287700	0	11	Cannabinoid	CHEMICAL	23287700T15
23287700	92	114	Cannabinoid receptor 1	GENE-N	23287700T16
23287700	1530	1535	CB(1)	GENE-N	23287700T17
23287700	1631	1646	CB(1) receptors	GENE-N	23287700T18
23287700	116	121	CB(1)	GENE-N	23287700T19
23287700	92	103	Cannabinoid	CHEMICAL	23287700T1
23287700	339	344	CB(1)	GENE-N	23287700T20
23287700	576	581	CB(1)	GENE-N	23287700T21
23287700	629	634	CB(1)	GENE-N	23287700T22
23287700	703	717	CB(1) receptor	GENE-N	23287700T23
23287700	814	819	CB(1)	GENE-N	23287700T24
23287700	893	898	CB(1)	GENE-N	23287700T25
23287700	992	997	CB(1)	GENE-N	23287700T26
23287700	45	50	CB(1)	GENE-N	23287700T27
23287700	1100	1106	AM4113	CHEMICAL	23287700T2
23287700	1152	1158	AM4054	CHEMICAL	23287700T3
23287700	1268	1274	AM4054	CHEMICAL	23287700T4
23287700	1310	1320	rimonabant	CHEMICAL	23287700T5
23287700	1325	1331	AM4113	CHEMICAL	23287700T6
23287700	598	607	SR141716A	CHEMICAL	23287700T7
23287700	609	619	rimonabant	CHEMICAL	23287700T8
23287700	147	157	rimonabant	CHEMICAL	23287700T9
23287700	CPR:3	23287700T12	23287700T25
23287700	CPR:5	23287700T11	23287700T24
23287700	CPR:5	23287700T13	23287700T26
23287700	CPR:5	23287700T14	23287700T26
23287700	CPR:5	23287700T3	23287700T26
23287700	CPR:5	23287700T4	23287700T26
23287700	CPR:5	23287700T7	23287700T21
23287700	CPR:5	23287700T8	23287700T21
23287700	CPR:5	23287700T9	23287700T16
23287700	CPR:5	23287700T9	23287700T19
23287700	CPR:6	23287700T10	23287700T22
23287700	CPR:6	23287700T2	23287700T26

23292170|t|Marked decline in beta cell function during pregnancy leads to the development of glucose intolerance in Japanese women.
23292170|a|The aim of this study is to investigate glucose metabolism longitudinally during pregnancy to explore mechanisms underlying gestational diabetes mellitus (GDM). We reviewed a total of 62 pregnant Japanese women who underwent a 75g oral glucose tolerance test (OGTT) twice during pregnancy (median: early, 13; late, 28 weeks' gestation) because of positive GDM screening. All showed normal OGTT results in early pregnancy. Based on late OGTT, 15 had GDM (late-onset GDM) and 47 normal glucose tolerance (NGT). In early pregnancy, there were no significant differences in insulin sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the-glucose-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups. In each group, insulin sensitivity significantly decreased from early to late pregnancy, most in the late-onset GDM group (each p < 0.05). The insulin secretion showed no significant changes with advancing pregnancy in both of the groups, although late-onset GDM showed significantly lower IGI compared with NGT in late OGTT (p < 0.05). When assessed beta cell function by OGTT-derived disposition index (i.e. Insulin Secretion-Sensitivity Index-2 and IGI/fasting insulin), the indices significantly decreased from early to late pregnancy in the both groups (each p < 0.05). Women with late-onset GDM showed significantly lower indices compared with NGT (each p < 0.05). The failure of beta cell to compensate for decreased insulin sensitivity could contribute to the development of the late-onset GDM.
23292170	691	698	insulin	GENE-Y	23292170T10
23292170	712	719	insulin	GENE-Y	23292170T11
23292170	802	809	insulin	GENE-Y	23292170T12
23292170	836	843	insulin	GENE-Y	23292170T13
23292170	891	898	insulin	GENE-Y	23292170T14
23292170	1049	1056	insulin	GENE-Y	23292170T15
23292170	357	364	glucose	CHEMICAL	23292170T1
23292170	161	168	glucose	CHEMICAL	23292170T2
23292170	605	612	glucose	CHEMICAL	23292170T3
23292170	933	940	glucose	CHEMICAL	23292170T4
23292170	82	89	glucose	CHEMICAL	23292170T5
23292170	1177	1184	insulin	GENE-Y	23292170T6
23292170	1444	1451	Insulin	GENE-Y	23292170T7
23292170	1498	1505	insulin	GENE-Y	23292170T8
23292170	1758	1765	insulin	GENE-Y	23292170T9

23292752|t|New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
23292752|a|New oral anticoagulants (OACs) that directly inhibit Factor Xa (FXa) or thrombin have been developed for the long-term prevention of thromboembolic disorders. These novel agents provide numerous benefits over older vitamin K antagonists (VKAs) due to major pharmacological differences. VKAs are economical and very well characterized, but have important limitations that can outweigh these advantages, such as slow onset of action, narrow therapeutic window and unpredictable anticoagulant effect. VKA-associated dietary precautions, monitoring and dosing adjustments to maintain international normalized ratio (INR) within therapeutic range, and bridging therapy, are inconvenient for patients, expensive, and may result in inappropriate use of VKA therapy. This may lead to increased bleeding risk or reduced anticoagulation and increased risk of thrombotic events. The new OACs have rapid onset of action, low potential for food and drug interactions, and predictable anticoagulant effect that removes the need for routine monitoring. FXa inhibitors, e.g. rivaroxaban and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa. Both agents have a rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and display similar pharmacokinetics in different patient populations. Since both are substrates, co-administration of rivaroxaban and apixaban with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers. Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists. Dabigatran etexilate is a low-molecular-weight non-active pro-drug that is administered orally and converted rapidly to its active form, dabigatran--a potent, competitive and reversible DTI. Dabigatran has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin. The reversible binding of dabigatran may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent thrombin inhibitors, e.g. hirudin. Dabigatran shows a very low potential for drug-drug interactions. However, co-administration of dabigatran etexilate with other anticoagulants and antiplatelet agents can increase the bleeding risk. Although the new agents are pharmacologically better than VKAs--particularly in terms of fixed dosing, rapid onset of action, no INR monitoring and lower risk of drug interactions--there are some differences between them: the bioavailability of dabigatran is lower than rivaroxaban and apixaban, and so the dabigatran dosage required is higher; lower protein binding of dabigatran reduces the variability related to albuminaemia. The risk of metabolic drug-drug interactions also appears to differ between OACs: VKAs > rivaroxaban > apixaban > dabigatran. The convenience of the new OACs has translated into improvements in efficacy and safety as shown in phase III randomized trials. The new anticoagulants so far offer the greatest promise and opportunity for the replacement of VKAs.
23292752	2271	2281	Dabigatran	CHEMICAL	5577
23292752	2473	2483	dabigatran	CHEMICAL	23292752T11
23292752	2624	2634	Dabigatran	CHEMICAL	5577
23292752	2720	2740	dabigatran etexilate	CHEMICAL	23292752T13
23292752	3068	3078	dabigatran	CHEMICAL	23292752T14
23292752	3093	3104	rivaroxaban	CHEMICAL	23292752T15
23292752	3109	3117	apixaban	CHEMICAL	23292752T16
23292752	3130	3140	dabigatran	CHEMICAL	23292752T17
23292752	3193	3203	dabigatran	CHEMICAL	23292752T18
23292752	3342	3353	rivaroxaban	CHEMICAL	23292752T19
23292752	1137	1148	rivaroxaban	CHEMICAL	23292752T1
23292752	3356	3364	apixaban	CHEMICAL	23292752T20
23292752	3367	3377	dabigatran	CHEMICAL	23292752T21
23292752	55	64	vitamin K	CHEMICAL	23292752T22
23292752	1116	1119	FXa	GENE-Y	23292752T23
23292752	1201	1215	prothrombinase	GENE-N	23292752T24
23292752	1247	1250	FXa	GENE-Y	23292752T25
23292752	1564	1589	cytochrome P450 (CYP) 3A4	GENE-Y	23292752T26
23292752	1594	1619	permeability glycoprotein	GENE-Y	23292752T27
23292752	1621	1625	P-gp	GENE-Y	23292752T28
23292752	1857	1863	CYP3A4	GENE-Y	107948
23292752	1153	1161	apixaban	CHEMICAL	23292752T2
23292752	1868	1872	P-gp	GENE-Y	23292752T30
23292752	1915	1923	thrombin	GENE-Y	23292752T31
23292752	2058	2066	thrombin	GENE-Y	23292752T32
23292752	2317	2325	thrombin	GENE-Y	23292752T33
23292752	2424	2430	fibrin	GENE-N	23292752T34
23292752	2437	2445	thrombin	GENE-Y	23292752T35
23292752	2589	2597	thrombin	GENE-Y	23292752T36
23292752	131	140	Factor Xa	GENE-Y	23292752T37
23292752	142	145	FXa	GENE-Y	23292752T38
23292752	150	158	thrombin	GENE-Y	23292752T39
23292752	1527	1538	rivaroxaban	CHEMICAL	23292752T3
23292752	1543	1551	apixaban	CHEMICAL	23292752T4
23292752	1951	1961	argatroban	CHEMICAL	271
23292752	2027	2037	dabigatran	CHEMICAL	23292752T6
23292752	2080	2100	Dabigatran etexilate	CHEMICAL	5577
23292752	2217	2227	dabigatran	CHEMICAL	23292752T8
23292752	293	302	vitamin K	CHEMICAL	23292752T9
23292752	CPR:4	5577	23292752T33
23292752	CPR:4	5577	23292752T34
23292752	CPR:4	5577	23292752T35
23292752	CPR:4	23292752T11	23292752T36
23292752	CPR:4	23292752T1	23292752T23
23292752	CPR:4	23292752T1	23292752T24
23292752	CPR:4	23292752T1	23292752T25
23292752	CPR:4	23292752T2	23292752T23
23292752	CPR:4	23292752T2	23292752T24
23292752	CPR:4	23292752T2	23292752T25
23292752	CPR:4	271	23292752T31
23292752	CPR:6	23292752T6	23292752T32

23293126|t|Effects of smoking on the oxidant/antioxidant balance and the blood lipids in pesticide sprayers.
23293126|a|The present study was conducted on 80 pesticide male sprayers (42 nonsmokers and 38 smokers). Our aim was to estimate the smoking effects on blood lipids and oxidant/antioxidant status in pesticide sprayers. Results revealed that cholesterol, low-density lipoprotein (LDL) and glutathion peroxidase (GPx) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers. Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (HDL), superoxide dismutase (SOD) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure. In nonsmokers, LDL and cholesterol were negatively correlated with SOD and correlated with malondialdehyde (MDA), and cholesterol was negatively correlated with Zn. HDL was negatively correlated with MDA in all the sprayers, but was correlated with GPx in smokers and with Zn in nonsmokers. In smokers, LDL was negatively correlated with GPx, HDL was negatively correlated with MDA and triglycerides and very-low-density lipoprotein were negatively correlated with Zn. MDA was negatively correlated with SOD, GPx and Zn. Smoking and pesticide exposure could be responsible for hyperlipidemia and oxidative stress. Therefore, improvement in the antioxidant status is mandatory for pesticide sprayers especially the ones who smoke.
23293126	724	735	cholesterol	CHEMICAL	23293126T10
23293126	792	807	malondialdehyde	CHEMICAL	23293126T11
23293126	809	812	MDA	CHEMICAL	23293126T12
23293126	819	830	cholesterol	CHEMICAL	23293126T13
23293126	862	864	Zn	CHEMICAL	23293126T14
23293126	901	904	MDA	CHEMICAL	23293126T15
23293126	974	976	Zn	CHEMICAL	23293126T16
23293126	1079	1082	MDA	CHEMICAL	23293126T17
23293126	1087	1100	triglycerides	CHEMICAL	23293126T18
23293126	1105	1133	very-low-density lipoprotein	GENE-N	23293126T19
23293126	1166	1168	Zn	CHEMICAL	23293126T1
23293126	1205	1208	SOD	GENE-N	23293126T20
23293126	1210	1213	GPx	GENE-N	23293126T21
23293126	341	364	low-density lipoprotein	GENE-N	23293126T22
23293126	366	369	LDL	GENE-N	23293126T23
23293126	375	396	glutathion peroxidase	GENE-N	23293126T24
23293126	398	401	GPx	GENE-N	23293126T25
23293126	513	516	LDL	GENE-N	23293126T26
23293126	556	580	high-density lipoprotein	GENE-N	23293126T27
23293126	582	585	HDL	GENE-N	23293126T28
23293126	588	608	superoxide dismutase	GENE-N	23293126T29
23293126	1170	1173	MDA	CHEMICAL	23293126T2
23293126	610	613	SOD	GENE-N	23293126T30
23293126	716	719	LDL	GENE-N	23293126T31
23293126	768	771	SOD	GENE-N	23293126T32
23293126	866	869	HDL	GENE-N	23293126T33
23293126	950	953	GPx	GENE-N	23293126T34
23293126	1004	1007	LDL	GENE-N	23293126T35
23293126	1039	1042	GPx	GENE-N	23293126T36
23293126	1044	1047	HDL	GENE-N	23293126T37
23293126	1218	1220	Zn	CHEMICAL	23293126T3
23293126	328	339	cholesterol	CHEMICAL	23293126T4
23293126	375	385	glutathion	CHEMICAL	23293126T5
23293126	497	508	Cholesterol	CHEMICAL	4350
23293126	588	598	superoxide	CHEMICAL	23293126T7
23293126	626	630	zinc	CHEMICAL	23293126T8
23293126	632	634	Zn	CHEMICAL	23293126T9

23295229|t|Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human aldehyde dehydrogenase 1.
23295229|a|Aldehyde dehydrogenase 1 (ALDH1A1) catalyzes the oxidation of toxic aldehydes to carboxylic acids. Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme. By using time-resolved fluorescence spectroscopy, we have resolved the fluorescent lifetimes () of free NADH in solution (=0.4 ns) and two enzyme-bound NADH states (=2.0 ns and =7.7 ns). We used this technique to investigate the effects of Mg(2+) ions on the ALDH1A1-NADH binding characteristics and enzyme catalysis. From the resolved free and bound NADH fluorescence signatures, the KD values for both NADH conformations in ALDH1A1 ranged from about 24 M to 1 M for Mg(2+) ion concentrations of 0-6000 M, respectively. The rate constants for dissociation of the enzyme-NADH complex ranged from 0.03 s(-1) (6000 M Mg(2+)) to 0.30s(-1) (0 M Mg(2+)) as determined by addition of excess NAD(+) to prevent re-association of NADH and resolving the real-time NADH fluorescence signal. During the initial reaction of enzyme with NAD(+) and butyraldehyde, there was an immediate rise in the NADH fluorescence, due to the formation of bound NADH complexes, with a constant steady-state rate of production of free NADH. As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 M Mg(2+)) to 0.050 s(-1) (6000 M Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 M Mg(2+). This shift in conformational population at higher Mg(2+) ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the ALDH1 pocket. The results from monitoring enzyme catalysis in the absence of magnesium suggests that the ALDH1-NADH complex with the shorter fluorescence lifetime is the form initially produced, and the complex with the longer fluorescence lifetime is produced through isomerization.
23295229	1516	1522	Mg(2+)	CHEMICAL	23295229T10
23295229	1618	1622	NADH	CHEMICAL	151
23295229	1701	1710	magnesium	CHEMICAL	23295229T12
23295229	1744	1748	NADH	CHEMICAL	151
23295229	1819	1825	Mg(2+)	CHEMICAL	23295229T14
23295229	1877	1883	Mg(2+)	CHEMICAL	23295229T15
23295229	293	297	NADH	CHEMICAL	151
23295229	1975	1979	NADH	CHEMICAL	151
23295229	2064	2073	magnesium	CHEMICAL	23295229T18
23295229	2098	2102	NADH	CHEMICAL	151
23295229	114	122	Aldehyde	CHEMICAL	23295229T1
23295229	435	439	NADH	CHEMICAL	151
23295229	484	488	NADH	CHEMICAL	151
23295229	574	580	Mg(2+)	CHEMICAL	23295229T22
23295229	601	605	NADH	CHEMICAL	151
23295229	685	689	NADH	CHEMICAL	151
23295229	738	742	NADH	CHEMICAL	151
23295229	182	191	aldehydes	CHEMICAL	23295229T26
23295229	804	810	Mg(2+)	CHEMICAL	23295229T27
23295229	908	912	NADH	CHEMICAL	151
23295229	195	211	carboxylic acids	CHEMICAL	23295229T29
23295229	1162	1168	NAD(+)	CHEMICAL	23295229T2
23295229	953	959	Mg(2+)	CHEMICAL	23295229T30
23295229	980	986	Mg(2+)	CHEMICAL	23295229T31
23295229	1024	1030	NAD(+)	CHEMICAL	23295229T32
23295229	1060	1064	NADH	CHEMICAL	151
23295229	1093	1097	NADH	CHEMICAL	151
23295229	45	54	magnesium	CHEMICAL	23295229T35
23295229	74	78	NADH	CHEMICAL	151
23295229	88	96	aldehyde	CHEMICAL	23295229T37
23295229	114	138	Aldehyde dehydrogenase 1	GENE-Y	23295229T38
23295229	256	261	ALDH1	GENE-Y	23295229T39
23295229	1173	1186	butyraldehyde	CHEMICAL	23295229T3
23295229	1612	1617	ALDH1	GENE-Y	23295229T40
23295229	1738	1743	ALDH1	GENE-Y	23295229T41
23295229	1987	1992	ALDH1	GENE-Y	23295229T42
23295229	2092	2097	ALDH1	GENE-Y	23295229T43
23295229	140	147	ALDH1A1	GENE-Y	106718
23295229	593	600	ALDH1A1	GENE-Y	106718
23295229	760	767	ALDH1A1	GENE-Y	106718
23295229	82	112	human aldehyde dehydrogenase 1	GENE-Y	23295229T47
23295229	1223	1227	NADH	CHEMICAL	151
23295229	1272	1276	NADH	CHEMICAL	151
23295229	235	241	Mg(2+)	CHEMICAL	23295229T6
23295229	1344	1348	NADH	CHEMICAL	151
23295229	1357	1363	Mg(2+)	CHEMICAL	23295229T8
23295229	1484	1490	Mg(2+)	CHEMICAL	23295229T9
23295229	CPR:4	23295229T15	23295229T42
23295229	CPR:4	23295229T6	23295229T39
23295229	CPR:4	23295229T8	23295229T40
23295229	CPR:9	23295229T26	23295229T38
23295229	CPR:9	23295229T26	106718
23295229	CPR:9	23295229T29	23295229T38
23295229	CPR:9	23295229T29	106718

23296102|t|Acrolein induces Alzheimer's disease-like pathologies in vitro and in vivo.
23296102|a|The pathologic mechanisms of Alzheimer's disease (AD) have not been fully uncovered. Acrolein, a ubiquitous dietary pollutant and by-product of oxidative stress, can induce cytotoxicity in neurons, which might play an important role in the etiology of AD. Here, we examined the effects of Acrolein on the AD pathologies in vitro and in vivo. We found Acrolein induced HT22 cells death in concentration- and time-dependent manners. Interestingly, Acrolein increased proteins' levels of amyloid precursor protein (APP), -secretase (BACE-1) and the amyloid -peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels. In vivo, chronic oral exposure to Acrolein (2.5 mg/kg/day by intragastric gavage for 8 weeks) induced mild cognitive declination and pyknosis/atrophy of hippocampal neurons. The activity of superoxide dismutase was down-regulated while the level of malondialdehyde was up-regulated in rat brain. Moreover, Acrolein resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of ADAM-10 in hippocampus and cortex. Taken together, our findings suggest that exposure to Acrolein induces AD-like pathology in vitro and in vivo. Scavenging Acrolein might be beneficial for the therapy of AD.
23296102	1071	1079	Acrolein	CHEMICAL	23296102T10
23296102	0	8	Acrolein	CHEMICAL	23296102T11
23296102	1135	1141	BACE-1	GENE-Y	23296102T12
23296102	1175	1182	ADAM-10	GENE-Y	23296102T13
23296102	561	586	amyloid precursor protein	GENE-Y	23296102T14
23296102	588	591	APP	GENE-Y	106848|1172565
23296102	594	605	-secretase	GENE-N	23296102T16
23296102	607	613	BACE-1	GENE-Y	23296102T17
23296102	623	652	amyloid -peptide transporter	GENE-Y	23296102T18
23296102	653	697	receptor for advanced glycation end products	GENE-Y	23296102T19
23296102	1264	1272	Acrolein	CHEMICAL	23296102T1
23296102	713	756	A-disintegrin and metalloprotease (ADAM) 10	GENE-Y	23296102T20
23296102	955	975	superoxide dismutase	GENE-N	23296102T21
23296102	1332	1340	Acrolein	CHEMICAL	23296102T2
23296102	365	373	Acrolein	CHEMICAL	23296102T3
23296102	427	435	Acrolein	CHEMICAL	23296102T4
23296102	522	530	Acrolein	CHEMICAL	23296102T5
23296102	799	807	Acrolein	CHEMICAL	23296102T6
23296102	161	169	Acrolein	CHEMICAL	23296102T7
23296102	955	965	superoxide	CHEMICAL	23296102T8
23296102	1014	1029	malondialdehyde	CHEMICAL	23296102T9
23296102	CPR:3	23296102T10	23296102T12
23296102	CPR:3	23296102T5	23296102T14
23296102	CPR:3	23296102T5	23296102T16
23296102	CPR:3	23296102T5	23296102T17
23296102	CPR:3	23296102T5	23296102T18
23296102	CPR:3	23296102T5	23296102T19
23296102	CPR:4	23296102T10	23296102T13
23296102	CPR:4	23296102T5	23296102T20

23296142|t|Membrane-initiated estradiol signaling in immortalized hypothalamic N-38 neurons.
23296142|a|Regulation of sexual reproduction by estradiol involves the activation of estrogen receptors (ERs) in the hypothalamus. Of the two classical ERs involved in reproduction, ER appears to be the critical isoform. The role of ER in reproduction has been found to involve a nuclear ER that induces a genomic mechanism of action. More recently, a plasma membrane ER has been shown to trigger signaling pathways involved in reproduction. Mechanisms underlying membrane-initiated estradiol signaling are emerging, including evidence that activation of plasma membrane ER involves receptor trafficking. The present study examined the insertion of ER into the plasma membrane of N-38 neurons, an immortalized murine hypothalamic cell line. We identified, using western blotting and PCR that N-38 neurons express full-length 66kDa ER and a 52kDa ER spliced variant missing the fourth exon - ER4. Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant estradiol elevated plasma membrane ER protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane. Insertion of ER was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS). Downstream membrane-initiated signaling was confirmed by estradiol activation of PKC-theta (PKC) and the release of intracellular calcium. These results indicate that membrane ER levels in N-38 neurons are dynamically autoregulated by estradiol.
23296142	19	28	estradiol	CHEMICAL	23296142T10
23296142	1129	1132	ER	GENE-Y	23296142T11
23296142	1250	1253	ER	GENE-Y	23296142T12
23296142	1273	1275	ER	GENE-Y	16226|2525
23296142	1311	1327	protein kinase C	GENE-N	23296142T14
23296142	1329	1332	PKC	GENE-N	23296142T15
23296142	1460	1469	PKC-theta	GENE-Y	23296142T16
23296142	1471	1475	PKC	GENE-Y	23296142T17
23296142	223	226	ERs	GENE-Y	23296142T18
23296142	1556	1559	ER	GENE-Y	23296142T19
23296142	1094	1103	estradiol	CHEMICAL	23296142T1
23296142	253	256	ER	GENE-Y	23296142T20
23296142	305	308	ER	GENE-Y	23296142T21
23296142	361	364	ER	GENE-Y	23296142T22
23296142	442	445	ER	GENE-Y	23296142T23
23296142	646	649	ER	GENE-Y	23296142T24
23296142	725	728	ER	GENE-Y	23296142T25
23296142	156	174	estrogen receptors	GENE-Y	23296142T26
23296142	908	911	ER	GENE-Y	23296142T27
23296142	924	927	ER	GENE-Y	23296142T28
23296142	970	975	ER4	GENE-Y	23296142T29
23296142	1287	1298	ICI 182,780	CHEMICAL	937
23296142	176	179	ERs	GENE-Y	23296142T30
23296142	1352	1371	bisindolylmaleimide	CHEMICAL	23296142T3
23296142	1373	1376	BIS	CHEMICAL	23296142T4
23296142	1436	1445	estradiol	CHEMICAL	23296142T5
23296142	1616	1625	estradiol	CHEMICAL	23296142T6
23296142	119	128	estradiol	CHEMICAL	23296142T7
23296142	156	164	estrogen	CHEMICAL	23296142T8
23296142	1054	1063	estradiol	CHEMICAL	23296142T9
23296142	CPR:3	23296142T1	23296142T11
23296142	CPR:3	23296142T6	23296142T19
23296142	CPR:3	23296142T7	23296142T26
23296142	CPR:3	23296142T7	23296142T30
23296142	CPR:3	23296142T9	23296142T11
23296142	CPR:4	937	23296142T12
23296142	CPR:4	23296142T3	23296142T12
23296142	CPR:4	23296142T3	23296142T14
23296142	CPR:4	23296142T3	23296142T15
23296142	CPR:4	23296142T4	23296142T12
23296142	CPR:4	23296142T4	23296142T14
23296142	CPR:4	23296142T4	23296142T15
23296142	CPR:6	937	16226|2525

23296837|t|Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.
23296837|a|Consumption of coffee is associated with reduced risk of Parkinson's disease (PD), an effect that has largely been attributed to caffeine. However, coffee contains numerous components that may also be neuroprotective. One of these compounds is eicosanoyl-5-hydroxytryptamide (EHT), which ameliorates the phenotype of -synuclein transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation. Here, we sought to investigate if EHT has an effect in the MPTP model of PD. Mice fed a diet containing EHT for four weeks exhibited dose-dependent preservation of nigral dopaminergic neurons following MPTP challenge compared to animals given control feed. Reductions in striatal dopamine and tyrosine hydroxylase content were also less pronounced with EHT treatment. The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and JNK activation were significantly prevented with EHT. In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFB activation, iNOS induction, and nitric oxide production. EHT also exhibited a robust anti-oxidant activity in vitro. Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT. These findings indicate that the neuroprotective effect of EHT against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of PP2A. Our data, therefore, reveal a strong beneficial effect of a novel component of coffee in multiple endpoints relevant to PD.
23296837	618	621	EHT	CHEMICAL	23296837T10
23296837	643	647	MPTP	CHEMICAL	23296837T11
23296837	688	691	EHT	CHEMICAL	23296837T12
23296837	786	790	MPTP	CHEMICAL	23296837T13
23296837	864	872	dopamine	CHEMICAL	23296837T14
23296837	877	885	tyrosine	CHEMICAL	23296837T15
23296837	937	940	EHT	CHEMICAL	23296837T16
23296837	986	990	MPTP	CHEMICAL	23296837T17
23296837	1101	1104	EHT	CHEMICAL	23296837T18
23296837	78	82	MPTP	CHEMICAL	23296837T19
23296837	1152	1155	EHT	CHEMICAL	23296837T1
23296837	1251	1255	NFB	GENE-N	23296837T20
23296837	1268	1272	iNOS	GENE-Y	23296837T21
23296837	1437	1466	phosphoprotein phosphatase 2A	GENE-N	23296837T22
23296837	1468	1472	PP2A	GENE-N	28554
23296837	1819	1823	PP2A	GENE-N	28554
23296837	430	441	-synuclein	GENE-Y	23296837T25
23296837	877	897	tyrosine hydroxylase	GENE-Y	23296837T26
23296837	1052	1055	JNK	GENE-N	23296837T27
23296837	1288	1300	nitric oxide	CHEMICAL	23296837T2
23296837	1313	1316	EHT	CHEMICAL	23296837T3
23296837	1405	1411	MPP(+)	CHEMICAL	23296837T4
23296837	1576	1579	EHT	CHEMICAL	23296837T5
23296837	1640	1643	EHT	CHEMICAL	23296837T6
23296837	1652	1656	MPTP	CHEMICAL	23296837T7
23296837	357	387	eicosanoyl-5-hydroxytryptamide	CHEMICAL	23296837T8
23296837	389	392	EHT	CHEMICAL	23296837T9
23296837	CPR:3	23296837T16	23296837T26
23296837	CPR:3	23296837T5	23296837T22
23296837	CPR:3	23296837T5	28554
23296837	CPR:4	23296837T18	23296837T27
23296837	CPR:4	23296837T1	23296837T20
23296837	CPR:4	23296837T1	23296837T21
23296837	CPR:4	23296837T4	23296837T22
23296837	CPR:4	23296837T4	28554

23297346|t|Hydrogen sulfide, the next potent preventive and therapeutic agent in aging and age-associated diseases.
23297346|a|Hydrogen sulfide (H(2)S) is the third endogenous signaling gasotransmitter, following nitric oxide and carbon monoxide. It is physiologically generated by cystathionine--lyase, cystathionine--synthase, and 3-mercaptopyruvate sulfurtransferase. H(2)S has been gaining increasing attention as an important endogenous signaling molecule because of its significant effects on the cardiovascular and nervous systems. Substantial evidence shows that H(2)S is involved in aging by inhibiting free-radical reactions, activating SIRT1, and probably interacting with the age-related gene Klotho. Moreover, H(2)S has been shown to have therapeutic potential in age-associated diseases. This article provides an overview of the physiological functions and effects of H(2)S in aging and age-associated diseases, and proposes the potential health and therapeutic benefits of H(2)S.
23297346	862	867	H(2)S	CHEMICAL	23297346T10
23297346	968	973	H(2)S	CHEMICAL	23297346T11
23297346	191	203	nitric oxide	CHEMICAL	23297346T12
23297346	0	16	Hydrogen sulfide	CHEMICAL	23297346T13
23297346	260	281	cystathionine--lyase	GENE-Y	23297346T14
23297346	283	307	cystathionine--synthase	GENE-Y	23297346T15
23297346	313	349	3-mercaptopyruvate sulfurtransferase	GENE-Y	23297346T16
23297346	627	632	SIRT1	GENE-Y	116983
23297346	685	691	Klotho	GENE-Y	23297346T18
23297346	105	121	Hydrogen sulfide	CHEMICAL	23297346T1
23297346	208	223	carbon monoxide	CHEMICAL	23297346T2
23297346	260	273	cystathionine	CHEMICAL	23297346T3
23297346	283	296	cystathionine	CHEMICAL	23297346T4
23297346	123	128	H(2)S	CHEMICAL	23297346T5
23297346	313	331	3-mercaptopyruvate	CHEMICAL	23297346T6
23297346	351	356	H(2)S	CHEMICAL	23297346T7
23297346	551	556	H(2)S	CHEMICAL	23297346T8
23297346	703	708	H(2)S	CHEMICAL	23297346T9
23297346	CPR:3	23297346T8	116983

23298677|t|Induction of HO-1 through p38 MAPK/Nrf2 signaling pathway by ethanol extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.
23298677|a|High mobility group box 1 (HMGB1) plays a crucial mediator in the pathogenesis of many inflammatory diseases. We recently proposed that heme oxygenase-1 (HO-1) negatively regulates HMGB1 in inflammatory conditions. We investigated whether ethanol extract of Inula helenium L. (EIH) activates p38 MAPK/Nrf2/HO-1 pathways in RAW264.7 cells and reduces inflammation in CLP-induced septic mice. EIH induced expression of HO-1 protein in a time- and concentration-dependent manner. EIH significantly diminished HO-1 expression in siNrf2 RNA-transfected cells. As expected, the inhibited expression of iNOS/NO, COX-2/PGE2, HMGB1 release by EIH in LPS-activated RAW264.7 cells was significantly reversed by siHO-1RNA transfection. Furthermore, EIH not only inhibited NF-B luciferase activity, phosphorylation of IB in LPS-activated cells but also significantly suppressed expression of adhesion molecules (ICAM-1 and VCAM-1) in TNF- activated human umbilical vein endothelial cells. The induction of HO-1 by EIH was inhibited by SB203580 but not by SP600125, PD98059, nor LY294002. Most importantly, administration of EIH significantly reduced not only increase in blood HMGB1, ALT, AST, BUN, creatinine levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by ZnPPIX, a HO-1 inhibitor. We concluded that EIH has anti-inflammatory effect via the induction of p38 MAPK-dependent HO-1 signaling pathway.
23298677	1349	1354	HMGB1	GENE-Y	109389|9669
23298677	1356	1360	ALT,	GENE-N	23298677T11
23298677	1361	1364	AST	GENE-N	23298677T12
23298677	1491	1495	HO-1	GENE-Y	23298677T13
23298677	317	333	heme oxygenase-1	GENE-Y	23298677T14
23298677	1579	1582	p38	GENE-N	23298677T15
23298677	1583	1587	MAPK	GENE-N	23298677T16
23298677	1598	1602	HO-1	GENE-Y	23298677T17
23298677	335	339	HO-1	GENE-Y	23298677T18
23298677	362	367	HMGB1	GENE-Y	109389|9669
23298677	1207	1215	SB203580	CHEMICAL	23298677T1
23298677	208	213	HMGB1	GENE-Y	109389|9669
23298677	473	476	p38	GENE-N	23298677T21
23298677	477	481	MAPK	GENE-N	23298677T22
23298677	482	486	Nrf2	GENE-Y	23298677T23
23298677	487	491	HO-1	GENE-Y	23298677T24
23298677	598	602	HO-1	GENE-Y	23298677T25
23298677	687	691	HO-1	GENE-Y	23298677T26
23298677	706	712	siNrf2	GENE-Y	23298677T27
23298677	777	781	iNOS	GENE-Y	23298677T28
23298677	786	791	COX-2	GENE-Y	23298677T29
23298677	1227	1235	SP600125	CHEMICAL	23298677T2
23298677	798	803	HMGB1	GENE-Y	109389|9669
23298677	881	887	siHO-1	GENE-Y	23298677T31
23298677	941	946	NF-B	GENE-N	23298677T32
23298677	987	991	IB	GENE-Y	23298677T33
23298677	1083	1089	ICAM-1	GENE-Y	23298677T34
23298677	1094	1100	VCAM-1	GENE-Y	23298677T35
23298677	1105	1110	TNF-	GENE-Y	23298677T36
23298677	1178	1182	HO-1	GENE-Y	23298677T37
23298677	13	17	HO-1	GENE-Y	23298677T38
23298677	26	29	p38	GENE-N	23298677T39
23298677	1237	1244	PD98059	CHEMICAL	23298677T3
23298677	30	34	MAPK	GENE-N	23298677T40
23298677	35	39	Nrf2	GENE-Y	23298677T41
23298677	1250	1258	LY294002	CHEMICAL	23298677T4
23298677	1371	1381	creatinine	CHEMICAL	23298677T5
23298677	317	321	heme	CHEMICAL	23298677T6
23298677	420	427	ethanol	CHEMICAL	23298677T7
23298677	61	68	ethanol	CHEMICAL	23298677T8
23298677	181	206	High mobility group box 1	GENE-Y	23298677T9
23298677	CPR:3	23298677T8	23298677T38
23298677	CPR:3	23298677T8	23298677T39
23298677	CPR:3	23298677T8	23298677T40
23298677	CPR:4	23298677T1	23298677T37

23307185|t|Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets.
23307185|a|With the recent interest of protease-activated receptors (PAR) 1 and PAR4 as possible targets for the treatment of thrombotic disorders, we compared the efficacy of protease-activated receptor (PAR)1 and PAR4 in the generation of procoagulant phenotypes on platelet membranes. PAR4-activating peptide (AP)-stimulated platelets promoted thrombin generation in plasma up to 5 minutes earlier than PAR1-AP-stimulated platelets. PAR4-AP-mediated factor V (FV) association with the platelet surface was 1.6-fold greater than for PAR1-AP. Moreover, PAR4 stimulation resulted in a 3-fold greater release of microparticles, compared with PAR1 stimulation. More robust FV secretion and microparticle generation with PAR4-AP was attributable to stronger and more sustained phosphorylation of myosin light chain at serine 19 and threonine 18. Inhibition of Rho-kinase reduced PAR4-AP-mediated FV secretion and microparticle generation to PAR1-AP-mediated levels. Thrombin generation assays measuring prothrombinase complex activity demonstrated 1.5-fold higher peak thrombin levels on PAR4-AP-stimulated platelets, compared with PAR1-AP-stimulated platelets. Rho-kinase inhibition reduced PAR4-AP-mediated peak thrombin generation by 25% but had no significant effect on PAR1-AP-mediated thrombin generation. In conclusion, stimulation of PAR4 on platelets leads to faster and more robust thrombin generation, compared with PAR1 stimulation. The greater procoagulant potential is related to more efficient FV release from intracellular stores and microparticle production driven by stronger and more sustained myosin light chain phosphorylation. These data have implications about the role of PAR4 during hemostasis and are clinically relevant in light of recent efforts to develop PAR antagonists to treat thrombotic disorders.
23307185	1439	1443	PAR4	GENE-Y	23307185T10
23307185	1524	1528	PAR1	GENE-Y	4224
23307185	1606	1608	FV	GENE-Y	23307185T12
23307185	276	310	protease-activated receptor (PAR)1	GENE-Y	23307185T13
23307185	1793	1797	PAR4	GENE-Y	23307185T14
23307185	1882	1885	PAR	GENE-N	23307185T15
23307185	315	319	PAR4	GENE-Y	23307185T16
23307185	388	392	PAR4	GENE-Y	23307185T17
23307185	139	175	protease-activated receptors (PAR) 1	GENE-Y	23307185T18
23307185	447	455	thrombin	GENE-Y	23307185T19
23307185	915	921	serine	CHEMICAL	23307185T1
23307185	506	510	PAR1	GENE-Y	4224
23307185	536	540	PAR4	GENE-Y	23307185T21
23307185	553	561	factor V	GENE-Y	23307185T22
23307185	563	565	FV	GENE-Y	23307185T23
23307185	635	639	PAR1	GENE-Y	4224
23307185	654	658	PAR4	GENE-Y	23307185T25
23307185	741	745	PAR1	GENE-Y	4224
23307185	771	773	FV	GENE-Y	23307185T27
23307185	180	184	PAR4	GENE-Y	23307185T28
23307185	818	822	PAR4	GENE-Y	23307185T29
23307185	929	938	threonine	CHEMICAL	23307185T2
23307185	957	967	Rho-kinase	GENE-N	23307185T30
23307185	976	980	PAR4	GENE-Y	23307185T31
23307185	993	995	FV	GENE-Y	23307185T32
23307185	1038	1042	PAR1	GENE-Y	4224
23307185	1063	1071	Thrombin	GENE-Y	23307185T34
23307185	1100	1114	prothrombinase	GENE-N	23307185T35
23307185	0	35	Protease-activated receptor (PAR) 1	GENE-Y	23307185T36
23307185	40	44	PAR4	GENE-Y	23307185T37
23307185	69	77	factor V	GENE-Y	23307185T38
23307185	1166	1174	thrombin	GENE-Y	23307185T3
23307185	1185	1189	PAR4	GENE-Y	23307185T4
23307185	1229	1233	PAR1	GENE-Y	4224
23307185	1259	1269	Rho-kinase	GENE-N	23307185T6
23307185	1289	1293	PAR4	GENE-Y	23307185T7
23307185	1371	1375	PAR1	GENE-Y	4224
23307185	1388	1396	thrombin	GENE-Y	23307185T9

23311608|t|Diels-Alder mediated controlled release from a poly(ethylene glycol) based hydrogel.
23311608|a|A synthetic amino acid bearing a furan functionality was developed and incorporated into peptide sequences using solid phase synthesis. Peptides expressing the furan moiety were attached to poly(ethylene glycol) (PEG) hydrogels through a thermally reversible covalent bond formed by a Diels-Alder reaction. Reactions of thiol and maleimide PEG macromers in an off-stoichiometric Michael addition were performed, such that the maleimide moiety was in excess, to create hydrogel networks with pendant Diels-Alder compatible tethering sites, that is, the maleimide. By making use of the Diels-Alder reaction, it was possible to control the release rate of reversibly bound moieties from the hydrogel by changing the temperature; higher temperatures favor a faster retro-Diels-Alder reaction and, therefore, a faster release from the polymer network. This concept was demonstrated by incorporating a fluorescently labeled furan-RGDS sequence into a hydrogel possessing excess maleimide functionalities and monitoring the subsequent liberation of RGDS at various temperatures, illustrating a Diels-Alder mediated release mechanism. The release profile was quantified at temperatures ranging from physiological (37 C) to 80 C. By changing the temperature, varying extents of release were attained over the time course of several days, ranging from 40% release for lower temperatures to complete release for the highest temperature considered. Further confirmation of a reaction-diffusion controlled release mechanism was obtained through comparison of experimental release data to a reaction-diffusion model of the release. In addition to thermal modulation, tuning of the release rate was accomplished by altering the number of possible Diels-Alder tethering sites present in the hydrogel. Increasing the amount of free maleimide and, therefore, the number of potential Diels-Alder reaction sites, effectively slowed the release of peptide from the polymer. For instance, doubling the amount of maleimide sites present in the hydrogel system decreased the amount of peptide released from approximately 60% to about 40% in the same span of time.
23311608	511	520	maleimide	CHEMICAL	23311608T10
23311608	637	646	maleimide	CHEMICAL	23311608T11
23311608	1003	1008	furan	CHEMICAL	23311608T12
23311608	1057	1066	maleimide	CHEMICAL	23311608T13
23311608	47	68	poly(ethylene glycol)	CHEMICAL	23311608T14
23311608	97	107	amino acid	CHEMICAL	23311608T1
23311608	245	250	furan	CHEMICAL	23311608T2
23311608	1902	1911	maleimide	CHEMICAL	23311608T3
23311608	275	296	poly(ethylene glycol)	CHEMICAL	23311608T4
23311608	2077	2086	maleimide	CHEMICAL	23311608T5
23311608	298	301	PEG	CHEMICAL	23311608T6
23311608	405	410	thiol	CHEMICAL	23311608T7
23311608	415	428	maleimide PEG	CHEMICAL	23311608T8
23311608	118	123	furan	CHEMICAL	23311608T9

23312283|t|Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation.
23312283|a|Circulating trimethylamine-N-oxide (TMAO) levels are strongly associated with atherosclerosis. We now examine genetic, dietary, and hormonal factors regulating TMAO levels. We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO. Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1. FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing FMO3 decreases TMAO levels. In both humans and mice, hepatic FMO3 expression is reduced in males compared to females. In mice, this reduction in FMO3 expression is due primarily to downregulation by androgens. FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor. Analysis of natural genetic variation among inbred strains of mice indicates that FMO3 and TMAO are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis.
23312283	636	640	TMAO	CHEMICAL	23312283T10
23312283	820	829	androgens	CHEMICAL	23312283T11
23312283	869	879	bile acids	CHEMICAL	23312283T12
23312283	943	952	bile acid	CHEMICAL	23312283T13
23312283	1072	1076	TMAO	CHEMICAL	23312283T14
23312283	1111	1115	TMAO	CHEMICAL	23312283T15
23312283	0	22	Trimethylamine-N-oxide	CHEMICAL	23312283T16
23312283	316	337	flavin mono-oxygenase	GENE-N	23312283T17
23312283	354	358	FMO1	GENE-Y	36609|108613|23747
23312283	363	367	FMO3	GENE-Y	108615
23312283	131	153	trimethylamine-N-oxide	CHEMICAL	23312283T1
23312283	476	480	FMO3	GENE-Y	108615
23312283	528	532	FMO1	GENE-Y	36609|108613|23747
23312283	534	538	FMO3	GENE-Y	108615
23312283	621	625	FMO3	GENE-Y	108615
23312283	682	686	FMO3	GENE-Y	108615
23312283	766	770	FMO3	GENE-Y	108615
23312283	831	835	FMO3	GENE-Y	108615
23312283	913	933	farnesoid X receptor	GENE-Y	23312283T27
23312283	935	938	FXR	GENE-Y	23312283T28
23312283	1063	1067	FMO3	GENE-Y	108615
23312283	279	283	TMAO	CHEMICAL	23312283T2
23312283	316	322	flavin	CHEMICAL	23312283T3
23312283	377	391	trimethylamine	CHEMICAL	23312283T4
23312283	393	396	TMA	CHEMICAL	23312283T5
23312283	436	443	choline	CHEMICAL	23312283T6
23312283	448	452	TMAO	CHEMICAL	23312283T7
23312283	155	159	TMAO	CHEMICAL	23312283T8
23312283	593	597	TMAO	CHEMICAL	23312283T9
23312283	CPR:3	23312283T12	108615
23312283	CPR:3	23312283T13	23312283T27
23312283	CPR:3	23312283T13	23312283T28
23312283	CPR:4	23312283T11	108615
23312283	CPR:9	23312283T10	108615
23312283	CPR:9	23312283T14	108615
23312283	CPR:9	23312283T4	23312283T17
23312283	CPR:9	23312283T4	36609|108613|23747
23312283	CPR:9	23312283T4	108615
23312283	CPR:9	23312283T5	23312283T17
23312283	CPR:9	23312283T5	36609|108613|23747
23312283	CPR:9	23312283T5	108615
23312283	CPR:9	23312283T6	23312283T17
23312283	CPR:9	23312283T6	36609|108613|23747
23312283	CPR:9	23312283T6	108615
23312283	CPR:9	23312283T7	23312283T17
23312283	CPR:9	23312283T7	36609|108613|23747
23312283	CPR:9	23312283T7	108615
23312283	CPR:9	23312283T9	108615

23313270|t|Tricycloalternarenes F-H: three new mixed terpenoids produced by an endolichenic fungus Ulocladium sp. using OSMAC method.
23313270|a|Three new mixed terpenoids, tricycloalternarenes (TCAs) F-H (1-3), together with ten known tricycloalternarenes (4-13), were isolated from the Czapek's culture of an endophytic fungus Ulocladium sp. Their structures were identified by extensive spectroscopic experiments (NMR and MS) and comparison with literature data. TCA 1b (5) showed weak activity against the Bacille Calmette-Guerin strain with the MIC of 125g/mL. TCA 9b (10) exhibited strong cytotoxic activity against Hela cell line with IC50 of 8.58M.
23313270	139	149	terpenoids	CHEMICAL	23313270T1
23313270	151	171	tricycloalternarenes	CHEMICAL	23313270T2
23313270	444	447	TCA	CHEMICAL	23313270T3
23313270	545	548	TCA	CHEMICAL	23313270T4
23313270	173	177	TCAs	CHEMICAL	23313270T5
23313270	214	234	tricycloalternarenes	CHEMICAL	23313270T6
23313270	0	24	Tricycloalternarenes F-H	CHEMICAL	23313270T7
23313270	42	52	terpenoids	CHEMICAL	23313270T8

23313336|t|What are the physiological estrogens?
23313336|a|Estradiol (E2) is the principal physiological estrogen in mammals. E2 and its active metabolites, estrone and estriol have a characteristic phenolic A ring, unlike progesterone, testosterone, cortisol and aldosterone, which have an A ring containing a C3-ketone, a (4) bond and a C19 methyl group. Crystal structures of E2 in the estrogen receptor (ER) confirm the importance of the A ring in stabilizing E2 in the ER. However, other steroids, including (5)-androstenediol, 5-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor- (ER) and ER. Moreover, selective estrogen response modulators (SERMs) with diverse structures also regulate transcription of ER and ER. Our understanding of the physiological responses mediated by these "alternative" estrogens is in its infancy. Further studies of the role of these steroids and SERMs in regulating responses mediated by ER and ER a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities.
23313336	473	481	steroids	CHEMICAL	23313336T10
23313336	493	512	(5)-androstenediol	CHEMICAL	23313336T11
23313336	514	531	5-androstanediol	CHEMICAL	23313336T12
23313336	536	557	27-hydroxycholesterol	CHEMICAL	23313336T13
23313336	602	613	3-hydroxyl	CHEMICAL	23313336T14
23313336	624	630	methyl	CHEMICAL	23313336T15
23313336	694	702	estrogen	CHEMICAL	23313336T16
23313336	749	757	estrogen	CHEMICAL	23313336T17
23313336	935	944	estrogens	CHEMICAL	23313336T18
23313336	1001	1009	steroids	CHEMICAL	23313336T19
23313336	38	47	Estradiol	CHEMICAL	773
23313336	136	143	estrone	CHEMICAL	23313336T20
23313336	27	36	estrogens	CHEMICAL	23313336T21
23313336	1056	1059	ER	GENE-Y	23313336T22
23313336	1064	1067	ER	GENE-Y	23313336T23
23313336	369	386	estrogen receptor	GENE-Y	23313336T24
23313336	388	390	ER	GENE-Y	16226|2525
23313336	454	456	ER	GENE-Y	16226|2525
23313336	694	713	estrogen receptor-	GENE-Y	23313336T27
23313336	715	718	ER	GENE-Y	23313336T28
23313336	724	727	ER	GENE-Y	23313336T29
23313336	148	155	estriol	CHEMICAL	23313336T2
23313336	841	844	ER	GENE-Y	23313336T30
23313336	849	852	ER	GENE-Y	23313336T31
23313336	202	214	progesterone	CHEMICAL	23313336T3
23313336	216	228	testosterone	CHEMICAL	614
23313336	230	238	cortisol	CHEMICAL	23313336T5
23313336	243	254	aldosterone	CHEMICAL	23313336T6
23313336	293	299	ketone	CHEMICAL	23313336T7
23313336	323	329	methyl	CHEMICAL	23313336T8
23313336	369	377	estrogen	CHEMICAL	23313336T9

23313637|t|Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
23313637|a|Phosphodiesterase type 5 (PDE5) mediates the degradation of cGMP in a variety of tissues including brain. Recent studies have demonstrated the importance of the nitric oxide/cGMP/cAMP-responsive element-binding protein (CREB) pathway to the process of learning and memory. Thus, PDE5 inhibitors (PDE5Is) are thought to be promising new therapeutic agents for the treatment of Alzheimer's disease (AD), a neurodegenerative disorder characterized by memory loss. To explore this possibility, a series of quinoline derivatives were synthesized and evaluated. We found that compound 7a selectively inhibits PDE5 with an IC(50) of 0.27 nM and readily crosses the blood brain barrier. In an in vivo mouse model of AD, compound 7a rescues synaptic and memory defects. Quinoline-based, CNS-permeant PDE5Is have potential for AD therapeutic development.
23313637	364	368	CREB	GENE-N	23313637T10
23313637	170	174	PDE5	GENE-Y	23313637T11
23313637	423	427	PDE5	GENE-Y	23313637T12
23313637	747	751	PDE5	GENE-Y	23313637T13
23313637	72	91	phosphodiesterase 5	GENE-Y	23313637T14
23313637	305	317	nitric oxide	CHEMICAL	23313637T1
23313637	318	322	cGMP	CHEMICAL	23313637T2
23313637	323	327	cAMP	CHEMICAL	2424
23313637	646	655	quinoline	CHEMICAL	23313637T4
23313637	204	208	cGMP	CHEMICAL	23313637T5
23313637	905	914	Quinoline	CHEMICAL	23313637T6
23313637	13	22	quinoline	CHEMICAL	23313637T7
23313637	144	168	Phosphodiesterase type 5	GENE-Y	23313637T8
23313637	323	362	cAMP-responsive element-binding protein	GENE-N	23313637T9
23313637	CPR:4	23313637T7	23313637T14
23313637	CPR:9	23313637T5	23313637T11
23313637	CPR:9	23313637T5	23313637T8

23314054|t|Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
23314054|a|We have previously reported a nanomolar inhibitor of antiapoptotic Mcl-1 protein, 3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1). S1 plays its function by binding to the BH3 groove of Mcl-1. Basing on this spacial structural characteristic, we developed a novel class of Mcl-1 inhibitor using fragment-based drug discovery approach. By dissecting S1, we identified the compound 4 with a 2-hydroxypyridine core as the starting fragment. In the following molecular growth, we used the ligand efficiency evaluation and fit quality score to assess the fragments. A novel potent compound, N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide (12c), which binds Mcl-1 with an IC(50) value of 54 nM was obtained. Compound 12c demonstrated a better aqueous solubility than S1.
23314054	576	593	2-hydroxypyridine	CHEMICAL	23314054T1
23314054	773	831	N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide	CHEMICAL	23314054T2
23314054	246	312	3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile	CHEMICAL	23314054T3
23314054	63	124	N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide	CHEMICAL	23314054T4
23314054	373	378	Mcl-1	GENE-Y	23314054T5
23314054	460	465	Mcl-1	GENE-Y	23314054T6
23314054	231	236	Mcl-1	GENE-Y	23314054T7
23314054	851	856	Mcl-1	GENE-Y	23314054T8
23314054	146	151	Mcl-1	GENE-N	23314054T9
23314054	CPR:4	23314054T2	23314054T8
23314054	CPR:4	23314054T3	23314054T7
23314054	CPR:4	23314054T4	23314054T9

23315216|t|Transaldolase deficiency: report of 12 new cases and further delineation of the phenotype.
23315216|a|PURPOSE: Transaldolase deficiency is a recently described inborn error of pentose phosphate pathway. We conducted this study to further delineate the associated phenotype. METHODS AND RESULTS: We report on 12 new cases representing six families with this metabolic defect that were observed over an 8year span. None of these cases received the correct diagnosis initially because of significant overlap in the presenting symptoms (growth retardation, dysmorphic features, cutis laxa, congenital heart disease, hepatosplenomegaly, pancytopenia, and bleeding tendency) with a wide range of genetic disorders. However, the consanguineous nature of these families allowed us to pursue autozygome analysis, which highlighted TALDO as the likely candidate gene and sequencing confirmed segregation of a novel homozygous mutation with the disease in all the studied families. Biochemical analysis was also consistent with transaldolase deficiency. CONCLUSION: This study expands the clinical definition of transaldolase deficiency, and adds to its allelic heterogeneity. In addition, we emphasize the diagnostic challenge posed by this rare and pleiotropic metabolic disorder.
23315216	165	182	pentose phosphate	CHEMICAL	23315216T1
23315216	1091	1104	transaldolase	GENE-Y	23315216T2
23315216	812	817	TALDO	GENE-Y	23315216T3
23315216	1007	1020	transaldolase	GENE-Y	23315216T4
23315216	100	113	Transaldolase	GENE-Y	23315216T5
23315216	0	13	Transaldolase	GENE-Y	23315216T6

23317163|t|Cellular signaling crosstalk between multiple receptors for investigation of pathophysiology in multifactorial diseases--what is clinically-relevant crosstalk?
23317163|a|Recently, genomics and proteomics have been utilized as advanced tools for investigation of cellular signaling pathways and molecular interactions, and elucidated promiscuous networks composed of numerous interactions among pathways. However, some of these interactions are considered to be simply contributing to background 'noise' and others are as 'crosstalk' biologically-relevant to cellular physiology, leading to synergy effects more than additive responses in an entire organism. Effort is now required to determine which interactions truly contribute to final physiological output. A receptor is the prime example of connectors among the networks. It functions, not simply as a signaling gateway, but also as an active trader by forming inter-receptor dimers. Furthermore, various receptors can modulate the function of the other receptors by input to common intracellular signaling pathways, establishing functional crosstalk among networks. Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of epidermal growth factor receptor (EGFR) and protease activated receptor-1 (PAR-1) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic acetylcholine receptor (mAChRs) and (2) adrenoceptor ((2)AR) on bronchodilatory response to anticholinergic agents in patients with COPD. These results indicate that these interactions are unlikely to be 'noise' but functionally-relevant 'crosstalk' in a human body. This review attempts to highlight the clinically-relevant 'crosstalk' paradigm in a human body which provides us a novel insight necessary to investigate pathophysiology in common multifactorial diseases and to develop new drugs.
23317163	1478	1491	acetylcholine	CHEMICAL	23317163T1
23317163	1296	1328	epidermal growth factor receptor	GENE-Y	23317163T2
23317163	1330	1334	EGFR	GENE-Y	108276|3932452|676741
23317163	1340	1369	protease activated receptor-1	GENE-Y	23317163T4
23317163	1371	1376	PAR-1	GENE-Y	23317163T5
23317163	1467	1500	muscarinic acetylcholine receptor	GENE-N	23317163T6
23317163	1502	1508	mAChRs	GENE-N	23317163T7
23317163	1514	1531	(2) adrenoceptor	GENE-Y	23317163T8
23317163	1533	1539	(2)AR	GENE-Y	23317163T9

23318685|t|Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration.
23318685|a|Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. Studies were designed to determine the erythropoietic response, pharmacokinetics (PK), tissue distribution, metabolism, and excretion of peginesatide in nonhuman primates following a single i.v. dose. The PK profile of peginesatide (0.1-5 mg/kg) is characterized by low, dose-dependent plasma clearance; small volume of distribution; and long half-life. The peginesatide PK profile following a single i.v. dose is consistent with the sustained erythropoiesis. Biodistribution quantitative whole-body autoradiography demonstrated high peginesatide levels in bone marrow (i.e., primary hematopoietic site) as well as other known hematopoietic sites persisting through at least 3 weeks at 2.1 mg/kg. Microautoradiography analysis at 48 hours postdose revealed uniform and high distribution of radioactivity in the bone marrow and splenic red pulp with less extensive distribution in the renal cortex (glomeruli, associated ducts, interstitial cells). Radioactivity in the kidney was most prominent in the outer medullary and papillary interstitium. At 2 weeks after dosing, cumulative radioactivity recovery in the urine and feces was 60 and 7% of the administered dose, respectively, with most of the radioactivity associated with the parent molecule. In conclusion, the PK characteristics are consistent with a PEGylated peptide of a 45-kDa molecular mass, specifically low volume of distribution and long half-life. Drug was localized principally to hematopoietic sites, and nonspecific tissue retention was not observed. The nonhuman primate data indicate that peginesatide is metabolically stable and primarily excreted in the urine.
23318685	224	247	erythropoietin receptor	GENE-N	23318685T10
23318685	113	125	Peginesatide	CHEMICAL	7638
23318685	129	148	polyethylene glycol	CHEMICAL	23318685T2
23318685	1845	1857	peginesatide	CHEMICAL	23318685T3
23318685	420	432	peginesatide	CHEMICAL	23318685T4
23318685	150	153	PEG	CHEMICAL	23318685T5
23318685	502	514	peginesatide	CHEMICAL	23318685T6
23318685	641	653	peginesatide	CHEMICAL	23318685T7
23318685	817	829	peginesatide	CHEMICAL	23318685T8
23318685	0	12	Peginesatide	CHEMICAL	7638
23318685	CPR:3	7638	23318685T10
23318685	CPR:3	23318685T2	23318685T10
23318685	CPR:3	23318685T5	23318685T10

23319584|t|Comparison of orientation and rotational motion of skeletal muscle cross-bridges containing phosphorylated and dephosphorylated myosin regulatory light chain.
23319584|a|Calcium binding to thin filaments is a major element controlling active force generation in striated muscles. Recent evidence suggests that processes other than Ca(2+) binding, such as phosphorylation of myosin regulatory light chain (RLC) also controls contraction of vertebrate striated muscle (Cooke, R. (2011) Biophys. Rev. 3, 33-45). Electron paramagnetic resonance (EPR) studies using nucleotide analog spin label probes showed that dephosphorylated myosin heads are highly ordered in the relaxed fibers and have very low ATPase activity. This ordered structure of myosin cross-bridges disappears with the phosphorylation of RLC (Stewart, M. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 430-435). The slower ATPase activity in the dephosporylated moiety has been defined as a new super-relaxed state (SRX). It can be observed in both skeletal and cardiac muscle fibers (Hooijman, P., Stewart, M. A., and Cooke, R. (2011) Biophys. J. 100, 1969-1976). Given the importance of the finding that suggests a novel pathway of regulation of skeletal muscle, we aim to examine the effects of phosphorylation on cross-bridge orientation and rotational motion. We find that: (i) relaxed cross-bridges, but not active ones, are statistically better ordered in muscle where the RLC is dephosporylated compared with phosphorylated RLC; (ii) relaxed phosphorylated and dephosphorylated cross-bridges rotate equally slowly; and (iii) active phosphorylated cross-bridges rotate considerably faster than dephosphorylated ones during isometric contraction but the duty cycle remained the same, suggesting that both phosphorylated and dephosphorylated muscles develop the same isometric tension at full Ca(2+) saturation. A simple theory was developed to account for this fact.
23319584	687	693	ATPase	GENE-N	23319584T10
23319584	730	736	myosin	GENE-N	23319584T11
23319584	870	876	ATPase	GENE-N	23319584T12
23319584	92	157	phosphorylated and dephosphorylated myosin regulatory light chain	GENE-Y	23319584T13
23319584	159	166	Calcium	CHEMICAL	1332
23319584	320	326	Ca(2+)	CHEMICAL	23319584T2
23319584	1845	1851	Ca(2+)	CHEMICAL	23319584T3
23319584	550	560	nucleotide	CHEMICAL	23319584T4
23319584	1427	1430	RLC	GENE-Y	23319584T5
23319584	1464	1482	phosphorylated RLC	GENE-Y	23319584T6
23319584	363	392	myosin regulatory light chain	GENE-Y	23319584T7
23319584	394	397	RLC	GENE-Y	23319584T8
23319584	598	621	dephosphorylated myosin	GENE-N	23319584T9

23322166|t|LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.
23322166|a|There has been much recent interest in lysophosphatidic acid (LPA) signaling through one of its receptors, LPA1, in fibrotic diseases, but the mechanisms by which LPA-LPA1 signaling promotes pathological fibrosis remain to be fully elucidated. Using a mouse peritoneal fibrosis model, we demonstrate central roles for LPA and LPA1 in fibroblast proliferation. Genetic deletion or pharmacological antagonism of LPA1 protected mice from peritoneal fibrosis, blunting the increases in peritoneal collagen by 65.4 and 52.9%, respectively, compared to control animals and demonstrated that peritoneal fibroblast proliferation was highly LPA1 dependent. Activation of LPA1 on mesothelial cells induced these cells to express connective tissue growth factor (CTGF), driving fibroblast proliferation in a paracrine fashion. Activation of mesothelial cell LPA1 induced CTGF expression by inducing cytoskeleton reorganization in these cells, causing nuclear translocation of myocardin-related transcription factor (MRTF)-A and MRTF-B. Pharmacological inhibition of MRTF-induced transcription also diminished CTGF expression and fibrosis in the peritoneal fibrosis model, mitigating the increase in peritoneal collagen content by 57.9% compared to controls. LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of LPA by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.
23322166	1305	1313	collagen	GENE-N	23322166T10
23322166	1353	1357	LPA1	GENE-Y	24585
23322166	1522	1526	MRTF	GENE-N	23322166T12
23322166	1537	1541	CTGF	GENE-Y	107872
23322166	1679	1683	LPA1	GENE-Y	24585
23322166	1744	1748	CTGF	GENE-Y	107872
23322166	273	277	LPA1	GENE-Y	24585
23322166	432	436	LPA1	GENE-Y	24585
23322166	516	520	LPA1	GENE-Y	24585
23322166	599	607	collagen	GENE-N	23322166T19
23322166	1507	1510	LPA	CHEMICAL	23322166T1
23322166	738	742	LPA1	GENE-Y	24585
23322166	768	772	LPA1	GENE-Y	24585
23322166	825	856	connective tissue growth factor	GENE-Y	23322166T22
23322166	858	862	CTGF	GENE-Y	107872
23322166	953	957	LPA1	GENE-Y	24585
23322166	966	970	CTGF	GENE-Y	107872
23322166	1071	1118	myocardin-related transcription factor (MRTF)-A	GENE-Y	23322166T26
23322166	0	4	LPA1	GENE-Y	24585
23322166	65	69	CTGF	GENE-Y	107872
23322166	269	272	LPA	CHEMICAL	23322166T2
23322166	424	427	LPA	CHEMICAL	23322166T3
23322166	145	166	lysophosphatidic acid	CHEMICAL	23322166T4
23322166	168	171	LPA	CHEMICAL	23322166T5
23322166	1123	1129	MRTF-B	GENE-Y	23322166T6
23322166	1161	1165	MRTF	GENE-N	23322166T7
23322166	213	217	LPA1	GENE-Y	24585
23322166	1204	1208	CTGF	GENE-Y	107872
23322166	CPR:3	23322166T1	107872

23327532|t|Cooperative effects for CYP2E1 differ between styrene and its metabolites.
23327532|a|Abstract 1. Cooperative interactions are frequently observed in the metabolism of drugs and pollutants by cytochrome P450s; nevertheless, the molecular determinants for cooperativity remain elusive. Previously, we demonstrated that steady-state styrene metabolism by CYP2E1 exhibits positive cooperativity. 2. We hypothesized that styrene metabolites have lower affinity than styrene toward CYP2E1 and limited ability to induce cooperative effects during metabolism. To test the hypothesis, we determined the potency and mechanism of inhibition for styrene and its metabolites toward oxidation of 4-nitrophenol using CYP2E1 Supersomes and human liver microsomes. 3. Styrene inhibited the reaction through a mixed cooperative mechanism with high affinity for the catalytic site (67M) and lower affinity for the cooperative site (1100M), while increasing substrate turnover at high concentrations. Styrene oxide and 4-vinylphenol possessed similar affinity for CYP2E1. Styrene oxide behaved cooperatively like styrene, but 4-vinylphenol decreased turnover at high concentrations. Styrene glycol was a very poor competitive inhibitor. Among all compounds, there was a positive correlation with binding and hydrophobicity. 4. Taken together, these findings for CYP2E1 further validate contributions of cooperative mechanisms to metabolic processes, demonstrate the role of molecular structure on those mechanisms and underscore the potential for heterotropic cooperative effects between different compounds.
23327532	994	1007	4-vinylphenol	CHEMICAL	23327532T10
23327532	1047	1060	Styrene oxide	CHEMICAL	23327532T11
23327532	46	53	styrene	CHEMICAL	23327532T12
23327532	181	197	cytochrome P450s	GENE-N	23327532T13
23327532	1337	1343	CYP2E1	GENE-Y	107944
23327532	342	348	CYP2E1	GENE-Y	107944
23327532	466	472	CYP2E1	GENE-Y	107944
23327532	692	698	CYP2E1	GENE-Y	107944
23327532	1039	1045	CYP2E1	GENE-Y	107944
23327532	24	30	CYP2E1	GENE-Y	107944
23327532	1088	1095	styrene	CHEMICAL	23327532T1
23327532	1101	1114	4-vinylphenol	CHEMICAL	23327532T2
23327532	1158	1172	Styrene glycol	CHEMICAL	23327532T3
23327532	406	413	styrene	CHEMICAL	23327532T4
23327532	451	458	styrene	CHEMICAL	23327532T5
23327532	624	631	styrene	CHEMICAL	23327532T6
23327532	672	685	4-nitrophenol	CHEMICAL	23327532T7
23327532	742	749	Styrene	CHEMICAL	23327532T8
23327532	976	989	Styrene oxide	CHEMICAL	23327532T9

23329465|t|Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
23329465|a|Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder in the Western world. It is commonly associated with insulin resistance, obesity, dyslipidaemia, type 2 diabetes mellitus (T2DM) and cardiovascular disease. Nonalcoholic steatohepatitis (NASH) is characterized by steatosis with necroinflammation and eventual fibrosis, which can lead to end-stage liver disease and hepatocellular carcinoma. Its pathogenesis is complex, and involves a state of 'lipotoxicity' in which insulin resistance, with increased free fatty acid release from adipose tissue to the liver, play a key role in the onset of a 'lipotoxic liver disease' and its progression to NASH. The diagnosis of NASH is challenging, as most affected patients are symptom free and the role of routine screening is not clearly established. A complete medical history is important to rule out other causes of fatty liver disease (alcohol abuse, medications, other). Plasma aminotransferase levels and liver ultrasound are helpful in the diagnosis of NAFLD/NASH, but a liver biopsy is often required for a definitive diagnosis. However, there is an active search for plasma biomarkers and imaging techniques that may non-invasively aid in the diagnosis. The treatment of NASH requires a multifaceted approach. The goal is to reverse obesity-associated lipotoxicity and insulin resistance via lifestyle intervention. Although there is no pharmacological agent approved for the treatment of NAFLD, vitamin E (in patients without T2DM) and the thiazolidinedione pioglitazone (in patients with and without T2DM) have shown the most consistent results in randomized controlled trials. This review concentrates on our current understanding of the disease, with a focus on the existing therapeutic approaches and potential future pharmacological developments for NAFLD and NASH.
23329465	1564	1573	vitamin E	CHEMICAL	23329465T1
23329465	1627	1639	pioglitazone	CHEMICAL	23329465T2
23329465	620	635	free fatty acid	CHEMICAL	23329465T3
23329465	999	1006	alcohol	CHEMICAL	23329465T4
23329465	1437	1444	insulin	GENE-Y	23329465T5
23329465	220	227	insulin	GENE-Y	23329465T6
23329465	585	592	insulin	GENE-Y	23329465T7
23329465	1035	1058	Plasma aminotransferase	GENE-N	23329465T8

23330546|t|Nuclear receptors in bile acid metabolism.
23330546|a|Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism. These xenobiotic/endobiotic-sensing nuclear receptors regulate phase I oxidation, phase II conjugation, and phase III transport in bile acid and drug metabolism in the digestive system. Integration of bile acid metabolism with drug metabolism controls absorption, transport, and metabolism of nutrients and drugs to maintain metabolic homeostasis and also protects against liver injury, inflammation, and related metabolic diseases, such as nonalcoholic fatty liver disease, diabetes, and obesity. Bile-acid-based drugs targeting nuclear receptors are in clinical trials for treating cholestatic liver diseases and fatty liver disease.
23330546	162	194	constitutive androstane receptor	GENE-Y	23330546T10
23330546	200	218	vitamin D receptor	GENE-Y	23330546T11
23330546	317	364	xenobiotic/endobiotic-sensing nuclear receptors	GENE-N	23330546T12
23330546	92	109	nuclear receptors	GENE-N	23330546T13
23330546	119	139	farnesoid X receptor	GENE-Y	23330546T14
23330546	141	160	pregnane X receptor	GENE-Y	23330546T15
23330546	0	17	Nuclear receptors	GENE-N	23330546T16
23330546	43	53	Bile acids	CHEMICAL	23330546T1
23330546	175	185	androstane	CHEMICAL	23330546T2
23330546	200	209	vitamin D	CHEMICAL	23330546T3
23330546	273	280	glucose	CHEMICAL	23330546T4
23330546	442	451	bile acid	CHEMICAL	23330546T5
23330546	512	521	bile acid	CHEMICAL	23330546T6
23330546	809	818	Bile-acid	CHEMICAL	23330546T7
23330546	141	149	pregnane	CHEMICAL	23330546T8
23330546	21	30	bile acid	CHEMICAL	23330546T9
23330546	CPR:3	23330546T1	23330546T10
23330546	CPR:3	23330546T1	23330546T11
23330546	CPR:3	23330546T1	23330546T13
23330546	CPR:3	23330546T1	23330546T14
23330546	CPR:3	23330546T1	23330546T15

23333093|t|Green tea catechin leads to global improvement among Alzheimer's disease-related phenotypes in NSE/hAPP-C105 Tg mice.
23333093|a|Amyloid  () has been reported to be responsible for the functional and structural abnormalities of Alzheimer's disease (AD) through the induction of oxidative stress. The aim of this study was to determine whether or not treatment of transgenic (Tg) mice with green tea catechin (GTC), a radical scavenger, improves AD phenotypes. To test this, 7-month-old Tg mice were treated with a low (1 mg) or high (10 mg) dose of GTC for 6 months. Surprisingly, GTC-treated Tg mice exhibited significant decreases in behavioral impairment, A-42 production, APP-C99/89 expression, -secretase component and Wnt protein levels, -secretase activity and MAPK activation. In contrast, the levels of APP-C83 protein and enzyme activities (-secretase, neprilysin and Pin1) were elevated in the GTC-treated groups. Moreover, GTC-treated groups showed lower levels of total cholesterol and low-density lipoprotein cholesterol, whereas the level of high-density lipoprotein cholesterol increased. These results provide the first experimental evidence that GTC improves AD phenotypes, thereby suggesting that GTC can be used in the prevention of AD or treatment of AD patients.
23333093	673	679	C99/89	GENE-N	23333093T10
23333093	692	703	-secretase	GENE-Y	23333093T11
23333093	718	721	Wnt	GENE-N	23333093T12
23333093	738	749	-secretase	GENE-Y	23333093T13
23333093	763	767	MAPK	GENE-N	23333093T14
23333093	807	810	APP	GENE-Y	106848|1172565
23333093	811	814	C83	GENE-N	23333093T16
23333093	846	857	-secretase	GENE-Y	23333093T17
23333093	859	869	neprilysin	GENE-Y	23333093T18
23333093	874	878	Pin1	GENE-Y	204839|255996
23333093	391	399	catechin	CHEMICAL	23333093T1
23333093	995	1018	low-density lipoprotein	GENE-N	23333093T20
23333093	1053	1077	high-density lipoprotein	GENE-N	23333093T21
23333093	104	108	C105	GENE-N	23333093T22
23333093	95	98	NSE	GENE-Y	23333093T23
23333093	99	103	hAPP	GENE-Y	23333093T24
23333093	979	990	cholesterol	CHEMICAL	23333093T2
23333093	1019	1030	cholesterol	CHEMICAL	23333093T3
23333093	1078	1089	cholesterol	CHEMICAL	23333093T4
23333093	10	18	catechin	CHEMICAL	23333093T5
23333093	118	127	Amyloid 	GENE-Y	23333093T6
23333093	129	131		GENE-Y	23333093T7
23333093	651	656	A-42	GENE-Y	23333093T8
23333093	669	672	APP	GENE-Y	106848|1172565

23333305|t|RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection.
23333305|a|The appropriate execution of DNA double-strand break (DSB) repair is critical for genome stability and tumor avoidance. 53BP1 and BRCA1 directly influence DSB repair pathway choice by regulating 5' end resection, but how this is achieved remains uncertain. Here we report that Rif1(-/-) mice are severely compromised for 53BP1-dependent class switch recombination (CSR) and fusion of dysfunctional telomeres. The inappropriate accumulation of RIF1 at DSBs in S phase is antagonized by BRCA1, and deletion of Rif1 suppresses toxic nonhomologous end joining (NHEJ) induced by PARP inhibition in Brca1-deficient cells. Mechanistically, RIF1 is recruited to DSBs via the N-terminal phospho-SQ/TQ domain of 53BP1, and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of RIF1. Thus, RIF1 and 53BP1 cooperate to block DSB resection to promote NHEJ in G1, which is antagonized by BRCA1 in S phase to ensure a switch of DSB repair mode to homologous recombination.
23333305	692	696	PARP	GENE-N	23333305T10
23333305	711	716	Brca1	GENE-Y	198383
23333305	751	755	RIF1	GENE-Y	32970|120482
23333305	785	816	N-terminal phospho-SQ/TQ domain	GENE-N	23333305T13
23333305	820	825	53BP1	GENE-Y	23333305T14
23333305	918	922	RIF1	GENE-Y	32970|120482
23333305	930	934	RIF1	GENE-Y	32970|120482
23333305	939	944	53BP1	GENE-Y	23333305T17
23333305	1025	1030	BRCA1	GENE-Y	107140|13145|160259
23333305	0	4	RIF1	GENE-Y	32970|120482
23333305	785	786	N	CHEMICAL	167
23333305	22	27	53BP1	GENE-Y	23333305T20
23333305	796	803	phospho	CHEMICAL	23333305T2
23333305	238	243	53BP1	GENE-Y	23333305T3
23333305	248	253	BRCA1	GENE-Y	107140|13145|160259
23333305	395	399	Rif1	GENE-Y	73027|206234
23333305	439	444	53BP1	GENE-Y	23333305T6
23333305	561	565	RIF1	GENE-Y	32970|120482
23333305	603	608	BRCA1	GENE-Y	107140|13145|160259
23333305	626	630	Rif1	GENE-Y	73027|206234

23333834|t|RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-B activation and down regulating inflammatory cytokines.
23333834|a|Peptides designed from osteoprotegerin (OPG) have previously been shown to inhibit receptor activator of NF-B ligand (RANKL) and prevent bone loss without significantly inhibiting inflammation. The objective of this study was to develop a novel peptide with dual inhibitory activity against bone loss and inflammation using site-directed mutagenesis. Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and Leu113-Arg122) available on OPG for RANKL binding, Leu113-Arg122 was used as a template for peptide synthesis. Peptide mutants of the template sequence (112YLEIEFCLKHR122) were synthesized and initially screened for their inhibitory effect on RANK-RANKL binding by competitive ELISA. The most active peptide was further evaluated in vitro for RANKL induced osteoclastogenesis in mouse macrophage cells, and in vivo for Freund's complete adjuvant induced arthritis (AIA) in Lewis rats. The efficacy of the candidate peptide was compared with that of the standard drug celecoxib. The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity. Administration of YR-11 peptide at the dose of 30mg/kg (i.p.) ameliorated both bone loss and inflammation in AIA rats. To elucidate the mechanism for inhibition of inflammation in arthritic rats, serum and tissue cytokines (TNF-, IL-1, and IL-6) were analyzed by ELISA and RT-PCR methods. Results confirmed that YR-11 peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-B. The results obtained in this study substantiate the therapeutic benefit of this novel peptide in the prevention of bone loss and inflammation in rheumatoid arthritis with reduced side effects.
23333834	588	591	Leu	CHEMICAL	143
23333834	595	598	Arg	CHEMICAL	119
23333834	639	642	Leu	CHEMICAL	143
23333834	646	649	Arg	CHEMICAL	119
23333834	1155	1164	celecoxib	CHEMICAL	23333834T14
23333834	1324	1328	RANK	GENE-Y	23333834T15
23333834	1329	1334	RANKL	GENE-Y	23333834T16
23333834	1348	1353	RANKL	GENE-Y	23333834T17
23333834	286	291	RANKL	GENE-Y	23333834T18
23333834	1362	1366	TRAP	GENE-Y	936876
23333834	1178	1183	YR-11	CHEMICAL	23333834T1
23333834	1659	1668	cytokines	GENE-N	23333834T20
23333834	1670	1675	TNF-	GENE-Y	23333834T21
23333834	1677	1682	IL-1	GENE-Y	23333834T22
23333834	1688	1692	IL-6	GENE-Y	23333834T23
23333834	1801	1810	cytokines	GENE-N	23333834T24
23333834	1890	1895	RANKL	GENE-Y	23333834T25
23333834	1929	1934	NF-B	GENE-N	23333834T26
23333834	624	629	RANKL	GENE-Y	23333834T27
23333834	831	835	RANK	GENE-Y	23333834T28
23333834	836	841	RANKL	GENE-Y	23333834T29
23333834	1234	1242	cysteine	CHEMICAL	23333834T2
23333834	931	936	RANKL	GENE-Y	23333834T30
23333834	250	284	receptor activator of NF-B ligand	GENE-Y	23333834T31
23333834	0	5	RANKL	GENE-Y	23333834T32
23333834	106	111	NF-B	GENE-N	23333834T33
23333834	156	165	cytokines	GENE-N	23333834T34
23333834	1250	1256	serine	CHEMICAL	23333834T3
23333834	1464	1469	YR-11	CHEMICAL	23333834T4
23333834	1760	1765	YR-11	CHEMICAL	23333834T5
23333834	558	561	Tyr	CHEMICAL	129
23333834	564	567	Asp	CHEMICAL	122
23333834	571	574	Tyr	CHEMICAL	129
23333834	577	580	Glu	CHEMICAL	136
23333834	CPR:4	23333834T1	23333834T17
23333834	CPR:4	23333834T1	936876
23333834	CPR:4	23333834T2	23333834T17
23333834	CPR:4	23333834T2	936876
23333834	CPR:4	23333834T3	23333834T17
23333834	CPR:4	23333834T3	936876
23333834	CPR:4	23333834T5	23333834T24
23333834	CPR:4	23333834T5	23333834T25
23333834	CPR:4	23333834T5	23333834T26

23333897|t|Activation of Rac1 GTPase by nanoparticulate structures in human macrophages.
23333897|a|Inflammatory activation of alveolar macrophages by ambient particles can be facilitated via Toll-like receptors (TLR). The action of TLR agonists and antagonists has been reported to depend on the formation of nanoparticulate structures. Aim of the present study was to identify the signaling pathways induced by nanoparticulate structures in human macrophages, which might be critical for inflammatory cell activation. METHODS: Studies were performed in primary human alveolar macrophages or in differentiated THP-1 macrophages. Silica nanoparticles were prepared by Stber synthesis and characterized by dynamic light scattering and scanning electron microscopy. Mycobacterial DNA was isolated from Mycobacterium bovis BCG, and nanoparticle formation was assessed by atomic force microscopy and dynamic light scattering. Actin polymerization was measured by phalloidin-TRITC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay (cytokine induction), and pull-down assays (Rho GTPases). RESULTS: In contrast to immune stimulatory sequence ISS 1018, BCG DNA spontaneously formed nanoparticulate structures and induced actin polymerization as did synthetic silica nanoparticles. Co-incubation with silica nanoparticles amplified the responsiveness of macrophages toward the TLR9 ligand ISS 1018. The activation of Rac1 was induced by silica nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation. CONCLUSION: Nanoparticles can induce signaling pathways, which amplify an inflammatory response in macrophages.
23333897	1264	1269	actin	GENE-N	23333897T10
23333897	211	214	TLR	GENE-N	23333897T11
23333897	1419	1423	TLR9	GENE-Y	119902
23333897	1459	1463	Rac1	GENE-Y	202556|264467|63689
23333897	901	906	Actin	GENE-N	23333897T14
23333897	170	189	Toll-like receptors	GENE-N	23333897T15
23333897	1077	1085	cytokine	GENE-N	23333897T16
23333897	14	18	Rac1	GENE-Y	202556|264467|63689
23333897	19	25	GTPase	GENE-N	23333897T18
23333897	1302	1308	silica	CHEMICAL	23333897T1
23333897	1343	1349	silica	CHEMICAL	23333897T2
23333897	1479	1485	silica	CHEMICAL	23333897T3
23333897	608	614	Silica	CHEMICAL	23333897T4
23333897	938	948	phalloidin	CHEMICAL	23333897T5
23333897	949	954	TRITC	CHEMICAL	23333897T6
23333897	1120	1123	Rho	GENE-N	23333897T7
23333897	1124	1131	GTPases	GENE-N	23333897T8
23333897	191	194	TLR	GENE-N	23333897T9
23333897	CPR:3	23333897T3	202556|264467|63689

23336337|t|Enhancing macrocyclic diterpenes as multidrug-resistance reversers: structure-activity studies on jolkinol D derivatives.
23336337|a|The phytochemical study of Euphorbia piscatoria yielded jolkinol D (1) in a large amount, whose derivatization gave rise to 12 ester derivatives (2-13) and hydrolysis to compound 14. The in vitro modulation of P-gp of compounds 1-14 was evaluated through a combination of transport and chemosensitivity assays, using the L5178 mouse T lymphoma cell line transfected with the human MDR1 gene. Apart from jolkinol D, all derivatives (2-14) showed potential as MDR reversal agents. In this small library of novel bioactive macrocyclic lathyrane diterpene derivatives, designed to evaluate structure-activity relationships essential in overcoming multidrug resistance (MDR), some correlations between MDR reversal and molecular weight, accessible solvent areas, and octanol/water partition coefficient were identified that can contribute to the development of new selective P-gp reversal agents.
23336337	992	996	P-gp	GENE-N	23336337T10
23336337	249	254	ester	CHEMICAL	23336337T1
23336337	525	535	jolkinol D	CHEMICAL	23336337T2
23336337	654	673	lathyrane diterpene	CHEMICAL	23336337T3
23336337	178	188	jolkinol D	CHEMICAL	23336337T4
23336337	884	891	octanol	CHEMICAL	23336337T5
23336337	22	32	diterpenes	CHEMICAL	23336337T6
23336337	98	108	jolkinol D	CHEMICAL	23336337T7
23336337	332	336	P-gp	GENE-N	23336337T8
23336337	497	507	human MDR1	GENE-Y	23336337T9

23337567|t|Osteoblasts survive the arsenic trioxide treatment by activation of ATM-mediated pathway.
23337567|a|Arsenic trioxide (ATO) is widely used in tumor treatment, but excessive arsenic exposure can have adverse effects. We recently found that, in primary osteoblasts, ATO produces oxidative stress and causes DNA tailing, but does not induce apoptosis. We further examined the signaling pathway by which osteoblasts survive ATO treatment, and found that they were arrested at G2/M phase of the cell cycle at 30h and overrode the G2/M boundary at 48h. After treatment for 30h, there was increased Cdc2 phosphorylation and expression of Wee1, a Cdc2 kinase, and expression of the cell cycle inhibitor, p21(waf1/cip1), which interacts with Cdc2. Furthermore, levels of the phosphatase Cdc25C, which activates Cdc2, were decreased, while the ratio of its phosphorylated/inactivated form to the total amount was increased. Moreover, phosphorylation/activation of the checkpoint kinases Chk1, Chk2 and p53 levels were increased, as were levels of activated ATM and -H2AX. The cell viability was decreased as an ATM inhibitor was added. Additionally, these effects of ATO on -H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor. These findings suggest that G2/M phase arrest of osteoblasts is mediated by Chk1/Chk2 activation via an ATM-dependent pathway by which osteoblasts survive.
23337567	1162	1166	Chk1	GENE-Y	23337567T10
23337567	1168	1172	Chk2	GENE-Y	23337567T11
23337567	1174	1177	p53	GENE-Y	77545
23337567	1183	1186	p21	GENE-Y	23337567T13
23337567	1187	1191	waf1	GENE-Y	23337567T14
23337567	1192	1196	cip1	GENE-Y	276373
23337567	1217	1220	ATM	GENE-Y	106962|9294
23337567	1308	1312	Chk1	GENE-Y	23337567T17
23337567	1313	1317	Chk2	GENE-Y	23337567T18
23337567	1336	1339	ATM	GENE-Y	106962|9294
23337567	90	106	Arsenic trioxide	CHEMICAL	1157
23337567	581	585	Cdc2	GENE-Y	23337567T20
23337567	620	624	Wee1	GENE-Y	60116|204556
23337567	628	632	Cdc2	GENE-Y	23337567T22
23337567	633	639	kinase	GENE-N	23337567T23
23337567	685	688	p21	GENE-Y	23337567T24
23337567	689	693	waf1	GENE-Y	23337567T25
23337567	694	698	cip1	GENE-Y	276373
23337567	722	726	Cdc2	GENE-Y	23337567T27
23337567	755	773	phosphatase Cdc25C	GENE-Y	23337567T28
23337567	791	795	Cdc2	GENE-Y	23337567T29
23337567	1147	1150	ATO	CHEMICAL	23337567T2
23337567	966	970	Chk1	GENE-Y	23337567T30
23337567	972	976	Chk2	GENE-Y	23337567T31
23337567	981	984	p53	GENE-Y	77545
23337567	1036	1039	ATM	GENE-Y	106962|9294
23337567	1046	1050	H2AX	GENE-Y	23337567T34
23337567	68	71	ATM	GENE-Y	106962|9294
23337567	253	256	ATO	CHEMICAL	23337567T3
23337567	108	111	ATO	CHEMICAL	23337567T4
23337567	409	412	ATO	CHEMICAL	23337567T5
23337567	162	169	arsenic	CHEMICAL	23337567T6
23337567	24	40	arsenic trioxide	CHEMICAL	23337567T7
23337567	1091	1094	ATM	GENE-Y	106962|9294
23337567	1156	1160	H2AX	GENE-Y	23337567T9
23337567	CPR:3	23337567T2	23337567T10
23337567	CPR:3	23337567T2	23337567T11
23337567	CPR:3	23337567T2	77545
23337567	CPR:3	23337567T2	23337567T13
23337567	CPR:3	23337567T2	23337567T14
23337567	CPR:3	23337567T2	276373
23337567	CPR:3	23337567T2	106962|9294
23337567	CPR:3	23337567T2	23337567T9
23337567	CPR:3	23337567T7	106962|9294

23339076|t|Structure prediction of binary pernitride MN2 compounds (M=Ca, Sr, Ba, La, and Ti).
23339076|a|Metal-pernitride compounds belong to a class of chemical systems in which both the complex ions and the non-bonding electrons may play roles in the formation of their modified crystalline structures. To investigate this issue, the energy landscapes of pernitrides of metals with different maximum valence (M=Ca, Sr, Ba, La, and Ti) were globally explored on the ab initio level at standard and high pressures, thereby yielding possible (meta)stable modifications in these systems together with information on how the landscape changed as function of the valence of the metal cation. For all of the systems in which no compounds had been synthesized so far, we predicted the existence of kinetically stable modifications that should, in principle, be experimentally accessible. In particular, TiN2 should crystallize in a new structure type, TiN2-I.
23339076	31	41	pernitride	CHEMICAL	23339076T10
23339076	42	45	MN2	CHEMICAL	23339076T11
23339076	59	61	Ca	CHEMICAL	23339076T12
23339076	63	65	Sr	CHEMICAL	23339076T13
23339076	67	69	Ba	CHEMICAL	23339076T14
23339076	71	73	La	CHEMICAL	23339076T15
23339076	79	81	Ti	CHEMICAL	23339076T16
23339076	84	100	Metal-pernitride	CHEMICAL	23339076T1
23339076	336	347	pernitrides	CHEMICAL	23339076T2
23339076	392	394	Ca	CHEMICAL	23339076T3
23339076	396	398	Sr	CHEMICAL	23339076T4
23339076	400	402	Ba	CHEMICAL	23339076T5
23339076	404	406	La	CHEMICAL	23339076T6
23339076	412	414	Ti	CHEMICAL	23339076T7
23339076	876	880	TiN2	CHEMICAL	23339076T8
23339076	925	929	TiN2	CHEMICAL	23339076T9

23340897|t|25-Hydroxyvitamin D in Obese Youth Across the Spectrum of Glucose Tolerance From Normal to Prediabetes to Type 2 Diabetes.
23340897|a|OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (25[OH]D) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo insulin sensitivity and -cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo insulin sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3  2.1 years and 35.7  5.6 kg/m(2), respectively. BMI, plasma 25(OH)D, and the proportion of vitamin D-deficient and -insufficient children did not differ across the three groups. Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or -cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the glucose tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and -cell function relative to insulin sensitivity in any of the groups. It remains uncertain if enhancement of the vitamin D status could improve pathophysiological mechanisms of prediabetes and type 2 diabetes in obese youth.
23340897	605	612	glucose	CHEMICAL	23340897T10
23340897	179	186	25[OH]D	CHEMICAL	23340897T11
23340897	976	983	25(OH)D	CHEMICAL	23340897T12
23340897	1007	1016	vitamin D	CHEMICAL	23340897T13
23340897	0	19	25-Hydroxyvitamin D	CHEMICAL	23340897T14
23340897	58	65	Glucose	CHEMICAL	23340897T15
23340897	1160	1167	insulin	GENE-Y	23340897T16
23340897	1211	1218	insulin	GENE-Y	23340897T17
23340897	1481	1488	insulin	GENE-Y	23340897T18
23340897	1533	1540	insulin	GENE-Y	23340897T19
23340897	1140	1147	25(OH)D	CHEMICAL	23340897T1
23340897	367	374	insulin	GENE-Y	23340897T20
23340897	679	686	insulin	GENE-Y	23340897T21
23340897	240	247	glucose	CHEMICAL	23340897T2
23340897	1370	1377	25(OH)D	CHEMICAL	23340897T3
23340897	1404	1411	glucose	CHEMICAL	23340897T4
23340897	1461	1468	25(OH)D	CHEMICAL	23340897T5
23340897	1618	1627	vitamin D	CHEMICAL	23340897T6
23340897	347	354	25(OH)D	CHEMICAL	23340897T7
23340897	456	463	25(OH)D	CHEMICAL	23340897T8
23340897	158	177	25-hydroxyvitamin D	CHEMICAL	23340897T9

23343565|t|Binary diffusion coefficients for mixtures of ionic liquids [EMIM][N(CN)2], [EMIM][NTf2], and [HMIM][NTf2] with acetone and ethanol by dynamic light scattering (DLS).
23343565|a|Mutual diffusivities for binary mixtures of the ionic liquids (ILs) [EMIM][N(CN)2] (1-ethyl-3-methylimidazolium dicyanimide), [EMIM][NTf2] (1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide), and [HMIM][NTf2] (1-hexyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide) with acetone and ethanol were studied in dependence on composition in the temperature range from 283.15 to 323.15 K, applying dynamic light scattering (DLS). The influence of experimental parameters on the achievable uncertainties was analyzed to ensure the acquisition of accurate data in adequate measurement times. For all probed systems, increasing binary diffusion coefficients were found for increasing temperatures. The systematic variation of anion and cation of the investigated ILs as well as a comparison with the literature data demonstrates the considerable influence of different ions on the resulting binary diffusion coefficients. Mutual diffusivities were found to be lower for the mixtures with ethanol than for those with acetone, which could be related to the formation of hydrogen bonds between ethanol and the ions. Most of the investigated IL solvent mixtures show increasing binary diffusion coefficients with increasing solvent concentration. For the mixtures of [EMIM][NTf2] with ethanol, however, a minimum of the mutual diffusivities was found in the ethanol mole fraction range from 0.7 to 0.8, which may hint at the vicinity of a critical demixing point. The viscosity of the pure ILs turned out to be no reliable indicator for the mutual diffusivity in mixtures with the same solvent.
23343565	389	450	1-hexyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide	CHEMICAL	23343565T10
23343565	457	464	acetone	CHEMICAL	23343565T11
23343565	469	476	ethanol	CHEMICAL	23343565T12
23343565	235	249	[EMIM][N(CN)2]	CHEMICAL	23343565T13
23343565	251	290	1-ethyl-3-methylimidazolium dicyanimide	CHEMICAL	23343565T14
23343565	1165	1172	ethanol	CHEMICAL	23343565T15
23343565	112	119	acetone	CHEMICAL	23343565T16
23343565	124	131	ethanol	CHEMICAL	23343565T17
23343565	60	74	[EMIM][N(CN)2]	CHEMICAL	23343565T18
23343565	76	88	[EMIM][NTf2]	CHEMICAL	23343565T19
23343565	1193	1200	acetone	CHEMICAL	23343565T1
23343565	94	106	[HMIM][NTf2]	CHEMICAL	23343565T20
23343565	1245	1253	hydrogen	CHEMICAL	23343565T2
23343565	1268	1275	ethanol	CHEMICAL	23343565T3
23343565	293	305	[EMIM][NTf2]	CHEMICAL	23343565T4
23343565	1440	1452	[EMIM][NTf2]	CHEMICAL	23343565T5
23343565	1458	1465	ethanol	CHEMICAL	23343565T6
23343565	1531	1538	ethanol	CHEMICAL	23343565T7
23343565	307	368	1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide	CHEMICAL	23343565T8
23343565	375	387	[HMIM][NTf2]	CHEMICAL	23343565T9

23347547|t|Quercetin-loaded microcapsules ameliorate experimental colitis in mice by anti-inflammatory and antioxidant mechanisms.
23347547|a|Quercetin (1) is an anti-inflammatory and antioxidant flavonoid. However, the oral administration of 1 did not lead to beneficial effects in experimental animal colitis models, which involve cytokines and oxidative stress. A possible explanation is that the absorption profile of 1 prevents its activity. Therefore, it was reasoned that the controlled release of 1 would improve its therapeutic effect. Thus, the therapeutic effect and mechanisms of 1-loaded microcapsules in acetic acid-induced colitis in mice were evaluated. Microcapsules were prepared using pectin/casein polymer and 1. The oral administration of 1-loaded microcapsules decreased neutrophil recruitment, attenuated histological alterations, and reduced macroscopical damage, edema, and IL-1 and IL-33 production in the colon samples. Microcapsules loaded with 1 also prevented the reduction of anti-inflammatory cytokine IL-10 and the antioxidant capacity of the colon. These preclinical data indicate that pectin/casein polymer microcapsules loaded with 1 improved the anti-inflammatory and antioxidant effects of 1 compared to the nonencapsulated drug. Therefore, quercetin seems to be a promising active molecule in inflammatory bowel disease if provided with adequate controlled release.
23347547	1004	1012	cytokine	GENE-N	23347547T10
23347547	1013	1018	IL-10	GENE-Y	23347547T11
23347547	1106	1112	casein	GENE-N	23347547T12
23347547	120	129	Quercetin	CHEMICAL	4044
23347547	1258	1267	quercetin	CHEMICAL	23347547T2
23347547	596	607	acetic acid	CHEMICAL	23347547T3
23347547	174	183	flavonoid	CHEMICAL	23347547T4
23347547	0	9	Quercetin	CHEMICAL	4044
23347547	311	320	cytokines	GENE-N	23347547T6
23347547	689	695	casein	GENE-N	23347547T7
23347547	877	882	IL-1	GENE-Y	23347547T8
23347547	887	892	IL-33	GENE-Y	23347547T9

23348407|t|Dietary relevant mixtures of phytoestrogens inhibit adipocyte differentiation in vitro.
23348407|a|Phytoestrogens (PEs) are naturally occurring plant components, with the ability to induce biological responses in vertebrates by mimicking or modulating the action of endogenous hormones. Single isoflavones have been shown to affect adipocyte differentiation, but knowledge on the effect of dietary relevant mixtures of PEs, including for instance lignans, is lacking. In the current study dietary relevant mixtures of isoflavones and their metabolites, lignans and their metabolites, coumestrol, and a mixture containing all of them, were examined for effects on adipogenesis in 3T3-L1 adipocytes, as well as tested for their PPAR activating abilities. The results showed that mixtures of isoflavonoid parent compounds and metabolites, respectively, a mixture of lignan metabolites, as well as coumestrol concentration-dependently inhibited adipocyte differentiation. Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of isoflavonoid metabolites were found to have PPAR activating abilities. These results suggest that PEs can affect pathways known to play a role in obesity development, and indicate that the inhibitory effect on adipocyte differentiation does not appear to be strictly associated with PPAR activation/inhibition. The current study support the hypothesis that compounds with endocrine activity can affect pathways playing a role in the development obesity and obesity related diseases.
23348407	1316	1321	PPAR	GENE-Y	23348407T10
23348407	715	720	PPAR	GENE-Y	23348407T11
23348407	1076	1081	PPAR	GENE-Y	23348407T12
23348407	283	294	isoflavones	CHEMICAL	23348407T1
23348407	507	518	isoflavones	CHEMICAL	23348407T2
23348407	542	549	lignans	CHEMICAL	23348407T3
23348407	573	583	coumestrol	CHEMICAL	23348407T4
23348407	779	791	isoflavonoid	CHEMICAL	23348407T5
23348407	853	859	lignan	CHEMICAL	23348407T6
23348407	884	894	coumestrol	CHEMICAL	23348407T7
23348407	984	996	isoflavonoid	CHEMICAL	23348407T8
23348407	1032	1044	isoflavonoid	CHEMICAL	23348407T9
23348407	CPR:3	23348407T8	23348407T12
23348407	CPR:3	23348407T9	23348407T12

23348408|t|Anti-inflammatory activity of patchouli alcohol in RAW264.7 and HT-29 cells.
23348408|a|Patchouli alcohol (PA) is a chemical compound extracted from patchouli which belongs to the genus Pogostemon, herb of mint family. Recently, it has been reported that PA inhibits the production of inflammatory mediators. However, the biological mechanisms of PA for anti-inflammatory activities have not been studied. In this study, we investigated whether PA decreases the production of inflammatory mediators through downregulation of the NF-B and ERK pathway. Our data indicated that PA inhibits the over-expression of iNOS and IL-6 in protein and mRNA levels in LPS-stimulated RAW264.7 and TNF- stimulated HT-29 cells. PA inhibited IB- degradation and p65 nuclear translocation, and subsequently suppressed transcriptional activity of NF-B in LPS-stimulated RAW264.7 and TNF--stimulated HT-29 cells. In addition, PA inhibited LPS- or TNF--stimulated ERK1/2 activation by decreasing phosphorylation of ERK1/2. These findings suggest that PA shows anti-inflammatory activities through suppressing ERK-mediated NF-B pathway in mouse macrophage and human colorectal cancer cells.
23348408	715	720	IB-	GENE-N	23348408T10
23348408	737	740	p65	GENE-N	23348408T11
23348408	820	825	NF-B	GENE-N	23348408T12
23348408	857	862	TNF-	GENE-Y	23348408T13
23348408	921	926	TNF-	GENE-Y	23348408T14
23348408	938	944	ERK1/2	GENE-N	23348408T15
23348408	989	995	ERK1/2	GENE-N	23348408T16
23348408	77	94	Patchouli alcohol	CHEMICAL	23348408T1
23348408	30	47	patchouli alcohol	CHEMICAL	23348408T2
23348408	1083	1086	ERK	GENE-N	23348408T3
23348408	1096	1101	NF-B	GENE-N	23348408T4
23348408	518	523	NF-B	GENE-N	23348408T5
23348408	528	531	ERK	GENE-N	23348408T6
23348408	600	604	iNOS	GENE-N	23348408T7
23348408	609	613	IL-6	GENE-N	23348408T8
23348408	672	677	TNF-	GENE-Y	23348408T9

23349208|t|Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells.
23349208|a|Despite their beneficial anti-inflammatory properties, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may increase the infection risk at high doses, likely by generating an immune-depressed state. To assess the contribution of different immune cell populations to the immunomodulatory fatty acid effect, we comparatively investigated several aspects of inflammation in human T-helper (Th) cells and monocytes. Both fatty acids, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells. In monocytes, both EPA and DHA increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)- and IL-6. Cellular incorporation of EPA and DHA occurred mainly at the expense of arachidonic acid. Concomitantly, thromboxane B (TXB)2 and leukotriene B (LTB)4 in supernatants decreased, while levels of TXB3 and LTB5 increased. This increase was independent of activation and in accordance with cyclooxygenase expression patterns in monocytes. Moreover, EPA and DHA gave rise to a variety of mono- and trihydroxy derivatives of highly anti-inflammatory potential, such as resolvins and their precursors. Our results suggest that EPA and DHA do not generally affect immune cell functions in an inhibitory manner but rather promote pro-resolving responses.
23349208	1501	1504	DHA	CHEMICAL	23349208T10
23349208	411	421	fatty acid	CHEMICAL	23349208T11
23349208	541	552	fatty acids	CHEMICAL	23349208T12
23349208	558	561	DHA	CHEMICAL	23349208T13
23349208	595	598	EPA	CHEMICAL	153
23349208	169	190	eicosapentaenoic acid	CHEMICAL	23349208T15
23349208	873	876	EPA	CHEMICAL	153
23349208	881	884	DHA	CHEMICAL	23349208T17
23349208	192	195	EPA	CHEMICAL	153
23349208	201	221	docosahexaenoic acid	CHEMICAL	23349208T19
23349208	1117	1123	(LTB)4	CHEMICAL	23349208T1
23349208	999	1002	EPA	CHEMICAL	153
23349208	1007	1010	DHA	CHEMICAL	23349208T21
23349208	1045	1061	arachidonic acid	CHEMICAL	23349208T22
23349208	1078	1091	thromboxane B	CHEMICAL	23349208T23
23349208	1092	1098	(TXB)2	CHEMICAL	23349208T24
23349208	1103	1116	leukotriene B	CHEMICAL	23349208T25
23349208	55	58	EPA	CHEMICAL	153
23349208	63	66	DHA	CHEMICAL	23349208T27
23349208	1259	1273	cyclooxygenase	GENE-N	23349208T28
23349208	659	667	cytokine	GENE-N	23349208T29
23349208	1167	1171	TXB3	CHEMICAL	23349208T2
23349208	693	743	peroxisome proliferator-activated receptor (PPAR)	GENE-Y	23349208T30
23349208	813	817	CD69	GENE-Y	107407
23349208	895	914	interleukin (IL)-10	GENE-Y	23349208T32
23349208	933	962	tumor necrosis factor (TNF)-	GENE-Y	23349208T33
23349208	967	971	IL-6	GENE-Y	23349208T34
23349208	1176	1180	LTB5	CHEMICAL	23349208T3
23349208	223	226	DHA	CHEMICAL	23349208T4
23349208	1318	1321	EPA	CHEMICAL	153
23349208	1326	1329	DHA	CHEMICAL	23349208T6
23349208	1356	1376	mono- and trihydroxy	CHEMICAL	23349208T7
23349208	1436	1445	resolvins	CHEMICAL	23349208T8
23349208	1493	1496	EPA	CHEMICAL	153
23349208	CPR:3	153	23349208T32
23349208	CPR:3	23349208T17	23349208T32
23349208	CPR:4	23349208T12	23349208T29
23349208	CPR:4	23349208T13	23349208T29
23349208	CPR:4	153	23349208T29

23352910|t|Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection.
23352910|a|Targeted nano-particulate systems hold extraordinary potential for delivery of therapeutics across blood brain barrier (BBB). In this work, we investigated the potential of novel bi-ligand (transferrin-poly-l-arginine) liposomal vector for delivery of desired gene to brain, in vivo. The in vivo evaluation of the delivery vectors is essential for clinical translation. We followed an innovative approach of combining transferrin receptor targeting with enhanced cell penetration to design liposomal vectors for improving the transport of molecules into brain. The biodistribution profile of 1, 1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine iodide(DiR)-labeled liposomes was evaluated in adult rats after single intravenous injection at dose of 15.2moles of phospholipids/kg body weight. We demonstrated that bi-ligand liposomes accumulated in rat brain at significantly (p<0.05) higher concentrations as compared to the single-ligand (transferrin) or plain liposomes. In addition, the bi-ligand liposomes resulted in increased expression of -galactosidase(-gal) plasmid in rat brain tissue in comparison to the single-ligand liposomes. Histological examination of the transfected tissues did not show any signs of tissue necrosis or inflammation. Hemolysis assay further authenticated the biocompatibility of bi-ligand liposomes in blood up to 600 nmoles of phospholipids/1.410(7) erythrocytes. The findings of this study provide important and detailed information regarding the distribution of bi-ligand liposomes in vivo and accentuate their ability to demonstrate improved brain penetration and transfection potential over single-ligand liposomes.
23352910	321	336	poly-l-arginine	CHEMICAL	23352910T1
23352910	711	774	1, 1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine iodide	CHEMICAL	23352910T2
23352910	775	778	DiR	CHEMICAL	23352910T3
23352910	1170	1185	-galactosidase	GENE-Y	23352910T4
23352910	1186	1191	-gal	GENE-Y	23352910T5
23352910	1064	1075	transferrin	GENE-Y	23352910T6

23352911|t|Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties.
23352911|a|Most successful vaccines are able to induce persistent antibody responses that can last a lifetime. Emerging evidences indicate that activation of immune cells through pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) or Nod-like receptors (NLRs) may be critical mechanisms. Among PRRs, the use of TLR ligands as adjuvants is already largely described whereas the use of NLRs ligands remains largely unexplored. As activation of intracytoplasmic NLRs is able to induce proinflammatory molecules, the added value of encapsulation of Nod1 and Nod2 receptor ligands into Poly(Lactic Acid) (PLA) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated. Their ability to induce systemic immune responses in mice was also measured and compared to free ligands and the Alum adjuvant. Nod ligands encapsulated into PLA NPs were efficiently taken up by DCs and subsequently induced a strong up-regulation of maturation markers and the enhancement of proinflammatory cytokine secretion by DCs. Furthermore, co-injection of encapsulated Nod-ligands with PLA particles carrying Gag p24 HIV-1 antigen allowed a 100 fold increase in antibody responses in comparison to Alum. These results suggest that encapsulation of Nod ligands into PLA-NPs could be an effective way to improve vaccine efficiency.
23352911	1417	1420	Nod	GENE-N	23352911T10
23352911	290	319	pattern recognition receptors	GENE-N	23352911T11
23352911	321	325	PRRs	GENE-N	23352911T12
23352911	335	354	Toll-like receptors	GENE-N	23352911T13
23352911	356	360	TLRs	GENE-N	23352911T14
23352911	365	383	Nod-like receptors	GENE-N	23352911T15
23352911	385	389	NLRs	GENE-N	23352911T16
23352911	425	429	PRRs	GENE-N	23352911T17
23352911	442	445	TLR	GENE-N	23352911T18
23352911	515	519	NLRs	GENE-N	23352911T19
23352911	1255	1258	PLA	CHEMICAL	23352911T1
23352911	590	594	NLRs	GENE-N	23352911T20
23352911	676	680	Nod1	GENE-Y	223435
23352911	685	689	Nod2	GENE-Y	232988
23352911	989	992	Nod	GENE-N	23352911T23
23352911	17	21	Nod1	GENE-Y	223435
23352911	26	30	Nod2	GENE-Y	232988
23352911	1434	1437	PLA	CHEMICAL	23352911T2
23352911	712	729	Poly(Lactic Acid)	CHEMICAL	23352911T3
23352911	731	734	PLA	CHEMICAL	23352911T4
23352911	1019	1022	PLA	CHEMICAL	23352911T5
23352911	53	70	poly(lactic acid)	CHEMICAL	23352911T6
23352911	1169	1177	cytokine	GENE-N	23352911T7
23352911	1238	1241	Nod	GENE-N	23352911T8
23352911	1278	1285	Gag p24	GENE-N	23352911T9

23353658|t|In vitro permeability analysis, pharmacokinetic and brain distribution study in mice of imperatorin, isoimperatorin and cnidilin in Radix Angelicae Dahuricae.
23353658|a|Coumarins are important constituents of Radix Angelicae Dahuricae, a well-known traditional Chinese medicine possess several known bioactivities with potentials in the treatment of central nervous system diseases. By using an HPLC-MS/MS method, we analyzed the in vivo plasma and brain pharmacokinetics of three ingredients of coumarins, including imperatorin, isoimperatorin and cnidilin in mice after oral administration of Dahuricae extract at doses of 800mg/kg. The biosamples were prepared using acetonitrile precipitation and the separation was achieved on an XDB-C18 column by gradient elution. The BBB permeability and P-gp-mediated efflux were further examined in Madin Canine kidney cells transfected with full length cDNA for human multidrug resistance gene1 (MDCKII-MDR1). Our results demonstrate that the method has excellent and satisfactory selectivity, sensitivity, linearity, precision, and accuracy for simultaneous determination of imperatorin, isoimperatorin and cnidilin. The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0-t) in plasma (1695.22, 1326.45 and 636.98mg*h/L), the AUC(0-t) in brain (1812.35, 2125.17 and 1145.83ng*h/g) as well as the T1/2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for imperatorin, isoimperatorin and cnidilin, respectively, suggesting that the three coumarins could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the P-gp-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82. All data suggest that these three coumarins have high BBB permeability and have pharmacokinetic potentials for the treatment of central nervous system diseases.
23353658	486	495	coumarins	CHEMICAL	23353658T10
23353658	507	518	imperatorin	CHEMICAL	23353658T11
23353658	520	534	isoimperatorin	CHEMICAL	23353658T12
23353658	539	547	cnidilin	CHEMICAL	23353658T13
23353658	660	672	acetonitrile	CHEMICAL	23353658T14
23353658	1110	1121	imperatorin	CHEMICAL	23353658T15
23353658	1123	1137	isoimperatorin	CHEMICAL	23353658T16
23353658	1142	1150	cnidilin	CHEMICAL	23353658T17
23353658	101	115	isoimperatorin	CHEMICAL	23353658T18
23353658	120	128	cnidilin	CHEMICAL	23353658T19
23353658	159	168	Coumarins	CHEMICAL	23353658T1
23353658	88	99	imperatorin	CHEMICAL	23353658T20
23353658	1678	1682	P-gp	GENE-N	23353658T21
23353658	786	790	P-gp	GENE-N	23353658T22
23353658	896	928	human multidrug resistance gene1	GENE-Y	23353658T23
23353658	937	941	MDR1	GENE-Y	33343|1222221
23353658	1448	1459	imperatorin	CHEMICAL	23353658T2
23353658	1461	1475	isoimperatorin	CHEMICAL	23353658T3
23353658	1480	1488	cnidilin	CHEMICAL	23353658T4
23353658	1530	1539	coumarins	CHEMICAL	23353658T5
23353658	1638	1649	imperatorin	CHEMICAL	23353658T6
23353658	1654	1668	isoimperatorin	CHEMICAL	23353658T7
23353658	1758	1766	cnidilin	CHEMICAL	23353658T8
23353658	1812	1821	coumarins	CHEMICAL	23353658T9
23353658	CPR:9	23353658T6	23353658T21
23353658	CPR:9	23353658T7	23353658T21
23353658	CPR:9	23353658T8	23353658T21

23353701|t|Involvement of Src and the actin cytoskeleton in the antitumorigenic action of adenosine dialdehyde.
23353701|a|Transmethylation is an important reaction that transfers a methyl group in S-adenosylmethionine (SAM) to substrates such as DNA, RNA, and proteins. It is known that transmethylation plays critical roles in various cellular responses. In this study, we examined the effects of transmethylation on tumorigenic responses and its regulatory mechanism using an upregulation strategy of adenosylhomocysteine (SAH) acting as a negative feedback inhibitor. Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner. Through immunoblotting analysis, it was found that AdOx was capable of indirectly diminishing the phosphorylation of oncogenic Src and its kinase activity. Interestingly, AdOx disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/PI3K, which is linked to various tumorigenic responses. In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src. Taken together, these results suggest that SAH/SAHH-mediated transmethylation could be linked to the tumorigenic processes through cross-regulation between the actin cytoskeleton and Src kinase activity.
23353701	639	659	adenosylhomocysteine	CHEMICAL	23353701T10
23353701	661	664	SAH	CHEMICAL	23353701T11
23353701	160	166	methyl	CHEMICAL	23353701T12
23353701	706	709	SAH	CHEMICAL	23353701T13
23353701	176	196	S-adenosylmethionine	CHEMICAL	23353701T14
23353701	986	990	AdOx	CHEMICAL	23353701T15
23353701	198	201	SAM	CHEMICAL	113
23353701	79	99	adenosine dialdehyde	CHEMICAL	23353701T17
23353701	1121	1126	actin	GENE-N	23353701T18
23353701	1250	1253	Src	GENE-Y	203491|249840
23353701	1106	1110	AdOx	CHEMICAL	23353701T1
23353701	1258	1261	p85	GENE-N	23353701T20
23353701	1262	1266	PI3K	GENE-N	23353701T21
23353701	1396	1400	SAHH	GENE-Y	23353701T22
23353701	1547	1550	Src	GENE-Y	203491|249840
23353701	1570	1575	actin	GENE-N	23353701T24
23353701	1641	1646	actin	GENE-N	23353701T25
23353701	1651	1654	Src	GENE-Y	203491|249840
23353701	1703	1707	SAHH	GENE-Y	23353701T27
23353701	1816	1821	actin	GENE-N	23353701T28
23353701	1839	1842	Src	GENE-Y	203491|249840
23353701	1375	1378	SAH	CHEMICAL	23353701T2
23353701	1843	1849	kinase	GENE-N	23353701T30
23353701	639	675	adenosylhomocysteine (SAH) hydrolase	GENE-Y	23353701T31
23353701	677	681	SAHH	GENE-Y	23353701T32
23353701	1062	1065	Src	GENE-Y	203491|249840
23353701	1074	1080	kinase	GENE-N	23353701T34
23353701	15	18	Src	GENE-Y	203491|249840
23353701	27	32	actin	GENE-N	23353701T36
23353701	1449	1465	3-deazaadenosine	CHEMICAL	23353701T3
23353701	1467	1471	DAZA	CHEMICAL	23353701T4
23353701	1699	1702	SAH	CHEMICAL	23353701T5
23353701	482	502	adenosylhomocysteine	CHEMICAL	23353701T6
23353701	504	507	SAH	CHEMICAL	23353701T7
23353701	565	585	adenosine dialdehyde	CHEMICAL	23353701T8
23353701	587	591	AdOx	CHEMICAL	23353701T9
23353701	CPR:4	23353701T15	203491|249840
23353701	CPR:4	23353701T15	23353701T34
23353701	CPR:4	23353701T1	23353701T18
23353701	CPR:4	23353701T1	203491|249840
23353701	CPR:4	23353701T1	23353701T20
23353701	CPR:4	23353701T1	23353701T21
23353701	CPR:4	23353701T2	203491|249840
23353701	CPR:4	23353701T3	23353701T22
23353701	CPR:4	23353701T4	23353701T22
23353701	CPR:4	23353701T8	23353701T31
23353701	CPR:4	23353701T8	23353701T32
23353701	CPR:4	23353701T9	23353701T31
23353701	CPR:4	23353701T9	23353701T32
23353701	CPR:9	23353701T13	23353701T31
23353701	CPR:9	23353701T13	23353701T32

23353736|t|Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).
23353736|a|A series of MMP-1 inhibitors have been identified based upon a methyl rosmarinate scaffold using structure-based drug design methods. The best compound in the series showed an IC50 value of 0.4M. A docking study was conducted for compound (S)-10n in order to investigate its binding interactions with MMP-1. The structure-activity relationships (SAR) were also briefly discussed. Useful SAR was established which provides important guidelines for the design of future generations of potent inhibitors against MMP-1.
23353736	186	204	methyl rosmarinate	CHEMICAL	23353736T1
23353736	28	46	methyl rosmarinate	CHEMICAL	23353736T2
23353736	135	140	MMP-1	GENE-Y	23353736T3
23353736	426	431	MMP-1	GENE-Y	23353736T4
23353736	634	639	MMP-1	GENE-Y	23353736T5
23353736	115	120	MMP-1	GENE-Y	23353736T6
23353736	87	113	matrix metalloproteinase-1	GENE-Y	23353736T7
23353736	CPR:4	23353736T1	23353736T3
23353736	CPR:4	23353736T2	23353736T6
23353736	CPR:4	23353736T2	23353736T7

23353741|t|Synthesis and biological evaluation of some novel resveratrol amide derivatives as potential anti-tumor agents.
23353741|a|Three series of novel resveratrol amide derivatives (1a-q, 2a-h, 3a-l) were synthesized and evaluated for their biological activities. All compounds were characterized by (1)H NMR, (13)C NMR, MS and elemental analysis. Furthermore, compound 3e was also characterized by X-ray crystallography. All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line. Among them, compounds 1c, 1g and 3e displayed the most potent COX-2 inhibitory activity with the IC50 values of 1.02, 1.27 and 1.98M, respectively. Molecular docking studies were performed to position compounds 1c and 3e into the active site of COX-2 to determine the probable binding modes.
23353741	894	899	COX-2	GENE-Y	23353741T10
23353741	283	287	(1)H	CHEMICAL	23353741T1
23353741	293	298	(13)C	CHEMICAL	23353741T2
23353741	134	151	resveratrol amide	CHEMICAL	23353741T3
23353741	561	577	prostaglandin E2	CHEMICAL	23353741T4
23353741	579	583	PGE2	CHEMICAL	907
23353741	50	67	resveratrol amide	CHEMICAL	23353741T6
23353741	528	544	cyclooxygenase-2	GENE-Y	23353741T7
23353741	546	551	COX-2	GENE-Y	23353741T8
23353741	709	714	COX-2	GENE-Y	23353741T9
23353741	CPR:9	23353741T4	23353741T7
23353741	CPR:9	23353741T4	23353741T8
23353741	CPR:9	907	23353741T7
23353741	CPR:9	907	23353741T8

23353821|t|Cystathionase mediates senescence evasion in melanocytes and melanoma cells.
23353821|a|The development of malignant melanoma is a highly complex process, which is still poorly understood. A majority of human melanomas are found to express a few oncogenic proteins, such as mutant RAS and BRAF variants. However, these oncogenes are also found in nevi, and it is now a well-accepted fact that their expression alone leads to senescence. This renders the understanding of senescence escape mechanisms an important point to understand tumor development. Here, we approached the question of senescence evasion by expressing the transcription factor v-myc myelocytomatosis viral oncogene homolog (c-MYC), which is known to act synergistically with many oncogenes, in melanocytes. We observed that MYC drives the evasion of reactive-oxygen stress-induced melanocyte senescence, caused by activated receptor tyrosine kinase signaling. Conversely, MIZ1, the growth suppressing interaction partner of MYC, is involved in mediating melanocyte senescence. Both, MYC overexpression and Miz1 knockdown led to a strong reduction of endogenous reactive-oxygen species (ROS), DNA damage and senescence. We identified the cystathionase (CTH) gene product as mediator of the ROS-related MYC and MIZ1 effects. Blocking CTH enzymatic activity in MYC-overexpressing and Miz1 knockdown cells increased intracellular stress and senescence. Importantly, pharmacological inhibition of CTH in human melanoma cells also reconstituted senescence in the majority of cell lines, and CTH knockdown reduced tumorigenic effects such as proliferation, H(2)O(2) resistance and soft agar growth. Thus, we identified CTH as new MYC target gene with an important function in senescence evasion.Oncogene advance online publication, 28 January 2013; doi:10.1038/onc.2012.641.
23353821	1316	1319	MYC	GENE-Y	110694|681305
23353821	1339	1343	Miz1	GENE-Y	23353821T11
23353821	1450	1453	CTH	GENE-Y	107873
23353821	1543	1546	CTH	GENE-Y	107873
23353821	1670	1673	CTH	GENE-Y	107873
23353821	1681	1684	MYC	GENE-Y	110694|681305
23353821	270	273	RAS	GENE-N	23353821T16
23353821	278	282	BRAF	GENE-Y	107141|676499
23353821	635	680	v-myc myelocytomatosis viral oncogene homolog	GENE-Y	23353821T18
23353821	682	687	c-MYC	GENE-Y	23353821T19
23353821	1128	1134	oxygen	CHEMICAL	23353821T1
23353821	782	785	MYC	GENE-Y	110694|681305
23353821	882	906	receptor tyrosine kinase	GENE-N	23353821T21
23353821	930	934	MIZ1	GENE-Y	23353821T22
23353821	982	985	MYC	GENE-Y	110694|681305
23353821	1041	1044	MYC	GENE-Y	110694|681305
23353821	1064	1068	Miz1	GENE-Y	23353821T25
23353821	0	13	Cystathionase	GENE-Y	23353821T26
23353821	1608	1616	H(2)O(2)	CHEMICAL	23353821T2
23353821	817	823	oxygen	CHEMICAL	23353821T3
23353821	891	899	tyrosine	CHEMICAL	23353821T4
23353821	1195	1208	cystathionase	GENE-Y	23353821T5
23353821	1210	1213	CTH	GENE-Y	107873
23353821	1259	1262	MYC	GENE-Y	110694|681305
23353821	1267	1271	MIZ1	GENE-Y	23353821T8
23353821	1290	1293	CTH	GENE-Y	107873

23354728|t|Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
23354728|a|As the pandemic of type 2 diabetes spreads globally, clinicians face many challenges in treating an increasingly diverse patient population varying in age, comorbidities, and socioeconomic status. Current therapies for type 2 diabetes are often unable to alter the natural course of the disease and provide durable glycemic control, and side effects in the context of individual patient characteristics often limit treatment choices. This often results in the progression to insulin use and complex regimens that are difficult to maintain. Therefore, a number of agents are being developed to better address the pathogenesis of type 2 diabetes and to overcome limitations of current therapies. The hope is to provide more options for glucose lowering and complication reduction with less risk for hypoglycemia and other adverse effects. These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, free fatty acid receptor agonists, 11--hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade. Herein we review these agents that are advancing through clinical trials and describe the rationale behind their use, mechanisms of action, and potential for glucose lowering, as well as what is known of their limitations.
23354728	557	564	insulin	GENE-Y	23354728T10
23354728	946	954	incretin	GENE-N	23354728T11
23354728	975	979	PPAR	GENE-N	23354728T12
23354728	1033	1071	sodium-coupled glucose cotransporter 2	GENE-Y	23354728T13
23354728	1089	1099	fatty acid	CHEMICAL	23354728T1
23354728	1119	1138	11--hydroxysteroid	CHEMICAL	23354728T2
23354728	1423	1430	glucose	CHEMICAL	23354728T3
23354728	816	823	glucose	CHEMICAL	23354728T4
23354728	1033	1039	sodium	CHEMICAL	23354728T5
23354728	1048	1055	glucose	CHEMICAL	23354728T6
23354728	1084	1108	free fatty acid receptor	GENE-N	23354728T7
23354728	1119	1159	11--hydroxysteroid dehydrogenase type 1	GENE-Y	23354728T8
23354728	1172	1183	glucokinase	GENE-Y	23354728T9

23355087|t|3-Methylglutaconic aciduria-lessons from 50 genes and 977 patients.
23355087|a|Elevated urinary excretion of 3-methylglutaconic acid is considered rare in patients suspected of a metabolic disorder. In 3-methylglutaconyl-CoA hydratase deficiency (mutations in AUH), it derives from leucine degradation. In all other disorders with 3-methylglutaconic aciduria the origin is unknown, yet mitochondrial dysfunction is thought to be the common denominator. We investigate the biochemical, clinical and genetic data of 388 patients referred to our centre under suspicion of a metabolic disorder showing 3-methylglutaconic aciduria in routine metabolic screening. Furthermore, we investigate 591 patients with 50 different, genetically proven, mitochondrial disorders for the presence of 3-methylglutaconic aciduria. Three percent of all urine samples of the patients referred showed 3-methylglutaconic aciduria, often in correlation with disorders not reported earlier in association with 3-methylglutaconic aciduria (e.g. organic acidurias, urea cycle disorders, haematological and neuromuscular disorders). In the patient cohort with genetically proven mitochondrial disorders 11% presented 3-methylglutaconic aciduria. It was more frequently seen in ATPase related disorders, with mitochondrial DNA depletion or deletion, but not in patients with single respiratory chain complex deficiencies. Besides, it was a consistent feature of patients with mutations in TAZ, SERAC1, OPA3, DNAJC19 and TMEM70 accounting for mitochondrial membrane related pathology. 3-methylglutaconic aciduria is found quite frequently in patients suspected of a metabolic disorder, and mitochondrial dysfunction is indeed a common denominator. It is only a discriminative feature of patients with mutations in AUH, TAZ, SERAC1, OPA3, DNAJC19 TMEM70. These conditions should therefore be referred to as inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature.
23355087	867	885	3-methylglutaconic	CHEMICAL	23355087T10
23355087	973	991	3-methylglutaconic	CHEMICAL	23355087T11
23355087	1026	1030	urea	CHEMICAL	23355087T12
23355087	0	18	3-Methylglutaconic	CHEMICAL	23355087T13
23355087	1238	1244	ATPase	GENE-N	23355087T14
23355087	191	223	3-methylglutaconyl-CoA hydratase	GENE-Y	23355087T15
23355087	1342	1367	respiratory chain complex	GENE-N	23355087T16
23355087	1449	1452	TAZ	GENE-Y	112764
23355087	1454	1460	SERAC1	GENE-Y	124380
23355087	1462	1466	OPA3	GENE-Y	123176
23355087	1178	1196	3-methylglutaconic	CHEMICAL	23355087T1
23355087	1468	1475	DNAJC19	GENE-Y	126272
23355087	1480	1486	TMEM70	GENE-Y	120305
23355087	1773	1776	AUH	GENE-Y	107030
23355087	1778	1781	TAZ	GENE-Y	112764
23355087	1783	1789	SERAC1	GENE-Y	124380
23355087	1791	1795	OPA3	GENE-Y	123176
23355087	1797	1804	DNAJC19	GENE-Y	126272
23355087	1805	1811	TMEM70	GENE-Y	120305
23355087	249	252	AUH	GENE-Y	107030
23355087	191	213	3-methylglutaconyl-CoA	CHEMICAL	23355087T2
23355087	1544	1562	3-methylglutaconic	CHEMICAL	23355087T3
23355087	1898	1916	3-methylglutaconic	CHEMICAL	23355087T4
23355087	271	278	leucine	CHEMICAL	23355087T5
23355087	320	338	3-methylglutaconic	CHEMICAL	23355087T6
23355087	98	121	3-methylglutaconic acid	CHEMICAL	23355087T7
23355087	587	605	3-methylglutaconic	CHEMICAL	23355087T8
23355087	771	789	3-methylglutaconic	CHEMICAL	23355087T9

23356880|t|Bioactives and nutraceutical phytochemicals naturally occurring in virgin olive oil. The case study of the Nocellara del Belice Italian olive cultivar.
23356880|a|This work reports on the composition and bionutritional value of organic virgin olive oil from the Nocellara del Belice variety, one cultivated in the olive areas of the Sicily region, Italy. Destoned oils obtained by processing olives with a destoning-based procedure were compared with conventional oils. This innovative technique, consisting in removing the stone from fruits prior to processing, strongly enhanced the already high-quality level of the conventional product. An in-depth analytical investigation from 2008 to 2010 showed how this innovative olive extraction process led to an excellent peculiar final product, mainly attributable to the improved biophenol and volatile composition, as well as higher concentrations of the lipophilic and vitamin antioxidants (tocopherols and tocotrienols). It had higher levels of oleocanthal (p-HPEA-EDA), a nutraceutical compound exerting actions against COX1 and COX2 (cycloxygenases). Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a cis-cis-1,4-pentadiene system). Among the other bioactives, we highlight its significant levels of trans--carotene and xanthophylls (lutein, violaxanthin, neoxanthin and other carotenoids). Its enhanced nutritional value was also attributable to the increased intensity of valuable tasting notes.
23356880	985	996	oleocanthal	CHEMICAL	23356880T10
23356880	998	1008	p-HPEA-EDA	CHEMICAL	23356880T11
23356880	1207	1219	lipoxygenase	GENE-N	23356880T12
23356880	1221	1224	LOX	GENE-N	110199
23356880	1061	1065	COX1	GENE-Y	34790|201541|110615|247788|2595062
23356880	1070	1074	COX2	GENE-Y	34812|110616|201542|247791|2595064|57535
23356880	1076	1090	cycloxygenases	GENE-N	23356880T16
23356880	1264	1291	polyunsaturated fatty acids	CHEMICAL	23356880T1
23356880	1305	1327	cis-cis-1,4-pentadiene	CHEMICAL	23356880T2
23356880	1404	1420	trans--carotene	CHEMICAL	23356880T3
23356880	1425	1437	xanthophylls	CHEMICAL	23356880T4
23356880	1439	1445	lutein	CHEMICAL	23356880T5
23356880	1447	1459	violaxanthin	CHEMICAL	23356880T6
23356880	1461	1471	neoxanthin	CHEMICAL	23356880T7
23356880	930	941	tocopherols	CHEMICAL	23356880T8
23356880	946	958	tocotrienols	CHEMICAL	23356880T9
23356880	CPR:9	23356880T1	23356880T12
23356880	CPR:9	23356880T1	110199
23356880	CPR:9	23356880T2	23356880T12
23356880	CPR:9	23356880T2	110199

23358307|t|Synthesis, DNA binding and antitumor evaluation of styelsamine and cystodytin analogues.
23358307|a|A series of N-14 sidechain substituted analogues of styelsamine (pyrido[4,3,2-mn]acridine) and cystodytin (pyrido[4,3,2-mn]acridin-4-one) alkaloids have been prepared and evaluated for their DNA binding affinity and antiproliferative activity towards a panel of human tumor cell lines. Overall it was found that styelsamine analogues were stronger DNA binders, with the natural products styelsamines B and D having particularly high affinity (K(app) 5.33  10(6) and 3.64  10(6) M(-1), respectively). In comparison, the cystodytin iminoquinone alkaloids showed lower affinity for DNA, but were typically just as active as styelsamine analogues at inhibiting proliferation of tumor cells in vitro. Sub-panel selectivity towards non-small cell lung, melanoma and renal cancer cell lines were observed for a number of the analogues. Correlation was observed between whole cell activity and clogP, with the most potent antiproliferative activity being observed for 3-phenylpropanamide analogues 37 and 41 (NCI panel average GI(50) 0.4 M and 0.32 M, respectively) with clogP ~4.0-4.5.
23358307	51	62	styelsamine	CHEMICAL	23358307T10
23358307	67	77	cystodytin	CHEMICAL	23358307T11
23358307	196	225	pyrido[4,3,2-mn]acridin-4-one	CHEMICAL	23358307T1
23358307	401	412	styelsamine	CHEMICAL	23358307T2
23358307	476	496	styelsamines B and D	CHEMICAL	23358307T3
23358307	610	643	cystodytin iminoquinone alkaloids	CHEMICAL	23358307T4
23358307	141	152	styelsamine	CHEMICAL	23358307T5
23358307	712	723	styelsamine	CHEMICAL	23358307T6
23358307	154	178	pyrido[4,3,2-mn]acridine	CHEMICAL	23358307T7
23358307	184	194	cystodytin	CHEMICAL	23358307T8
23358307	1051	1070	3-phenylpropanamide	CHEMICAL	23358307T9

23362838|t|Intercalation pathway in many-particle LiFePO4 electrode revealed by nanoscale state-of-charge mapping.
23362838|a|The intercalation pathway of lithium iron phosphate (LFP) in the positive electrode of a lithium-ion battery was probed at the 40 nm length scale using oxidation-state-sensitive X-ray microscopy. Combined with morphological observations of the same exact locations using transmission electron microscopy, we quantified the local state-of-charge of approximately 450 individual LFP particles over nearly the entire thickness of the porous electrode. With the electrode charged to 50% state-of-charge in 0.5 h, we observed that the overwhelming majority of particles were either almost completely delithiated or lithiated. Specifically, only 2% of individual particles were at an intermediate state-of-charge. From this small fraction of particles that were actively undergoing delithiation, we conclude that the time needed to charge a particle is 1/50 the time needed to charge the entire particle ensemble. Surprisingly, we observed a very weak correlation between the sequence of delithiation and the particle size, contrary to the common expectation that smaller particles delithiate before larger ones. Our quantitative results unambiguously confirm the mosaic (particle-by-particle) pathway of intercalation and suggest that the rate-limiting process of charging is initiating the phase transformation by, for example, a nucleation-like event. Therefore, strategies for further enhancing the performance of LFP electrodes should not focus on increasing the phase-boundary velocity but on the rate of phase-transformation initiation.
23362838	1519	1522	LFP	CHEMICAL	23362838T1
23362838	133	155	lithium iron phosphate	CHEMICAL	23362838T2
23362838	482	485	LFP	CHEMICAL	23362838T3
23362838	157	160	LFP	CHEMICAL	23362838T4
23362838	193	200	lithium	CHEMICAL	23362838T5
23362838	39	46	LiFePO4	CHEMICAL	23362838T6

23363425|t|Silica precipitation by synthetic minicollagens.
23363425|a|Oligomeric Pro-Hyp-Gly- (POG-) peptides, wherein the collagenous triple helix is supported by C-terminal capping, exhibit silica precipitation properties (O, Hyp = (2S,4R)hydroxyproline). As quantified by a molybdate assay, the length of the covalently tethered triple helix (number of POG units) determines the amount of amorphous silica obtained from silicic acid solution. Although lacking charged side chains, the synthetic collagens precipitate large quantities of silicic acid resulting in micrometer-sized spheres of varying surface morphologies as analyzed by scanning electron microscopy. Similar precipitation efficiencies on a fast time scale of less than 10 min were previously described only for biogenic diatom proteins and sponge collagen, respectively, which have a considerably higher structural complexity and limited accessibility. The minicollagens described here provide an unexpected alternative to the widely used precipitation conditions, which generally depend on (poly-)amines in phosphate buffer. Collagen can form intimate connections with inorganic matter. Hence, silica-enclosed collagens have promising perspectives as composite materials.
23363425	143	144	C	CHEMICAL	23363425T10
23363425	1038	1051	(poly-)amines	CHEMICAL	23363425T11
23363425	0	6	Silica	CHEMICAL	23363425T12
23363425	1073	1081	Collagen	GENE-N	23363425T13
23363425	1158	1167	collagens	GENE-N	23363425T14
23363425	311	323	triple helix	GENE-N	23363425T15
23363425	477	486	collagens	GENE-N	23363425T16
23363425	102	126	collagenous triple helix	GENE-N	23363425T17
23363425	787	802	sponge collagen	GENE-N	23363425T18
23363425	1055	1064	phosphate	CHEMICAL	23363425T1
23363425	1142	1148	silica	CHEMICAL	23363425T2
23363425	60	71	Pro-Hyp-Gly	CHEMICAL	23363425T3
23363425	171	177	silica	CHEMICAL	23363425T4
23363425	207	210	Hyp	CHEMICAL	23363425T5
23363425	213	234	(2S,4R)hydroxyproline	CHEMICAL	23363425T6
23363425	381	387	silica	CHEMICAL	23363425T7
23363425	402	414	silicic acid	CHEMICAL	23363425T8
23363425	519	531	silicic acid	CHEMICAL	23363425T9

23368510|t|Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
23368510|a|AIM: Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin. METHODS: In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10g weeks 1-2, then 20g; n=77) or liraglutide QD (0.6mg week 1, 1.2mg week 2, then 1.8mg; n=71) 30min before breakfast. Primary endpoint was change in postprandial plasma glucose (PPG) exposure from baseline to day 28 during a breakfast test meal. RESULTS: Lixisenatide reduced PPG significantly more than liraglutide [mean change in AUC(0) (:30-4:30h) : -12.6 vs. -4.0h/mmol/l, respectively; p<0.0001 (0:30h=start of meal)]. Change in maximum PPG excursion was -3.9mmol/l vs. -1.4mmol/l, respectively (p<0.0001). More lixisenatide-treated patients achieved 2-h PPG <7.8mmol/l (69% vs. 29%). Changes in fasting plasma glucose were greater with liraglutide (-0.3 vs. -1.3mmol/l, p<0.0001). Lixisenatide provided greater decreases in postprandial glucagon (p<0.05), insulin (p<0.0001) and C-peptide (p<0.0001). Mean HbA1c decreased in both treatment groups (from 7.2% to 6.9% with lixisenatide vs. 7.4% to 6.9% with liraglutide) as did body weight (-1.6kg vs. -2.4kg, respectively). Overall incidence of adverse events was lower with lixisenatide (55%) versus liraglutide (65%), with no serious events or hypoglycaemia reported. CONCLUSIONS: Once daily prebreakfast lixisenatide provided a significantly greater reduction in PPG (AUC) during a morning test meal versus prebreakfast liraglutide. Lixisenatide provided significant decreases in postprandial insulin, C-peptide (vs. an increase with liraglutide) and glucagon, and better gastrointestinal tolerability than liraglutide.
23368510	1917	1925	glucagon	GENE-Y	23368510T10
23368510	421	426	HbA1c	GENE-Y	23368510T11
23368510	297	306	metformin	CHEMICAL	23368510T1
23368510	655	662	glucose	CHEMICAL	23368510T2
23368510	151	160	metformin	CHEMICAL	23368510T3
23368510	1243	1251	glucagon	GENE-Y	23368510T4
23368510	1264	1271	insulin	GENE-Y	23368510T5
23368510	1289	1298	C-peptide	GENE-Y	23368510T6
23368510	1318	1323	HbA1c	GENE-N	23368510T7
23368510	1859	1866	insulin	GENE-Y	23368510T8
23368510	1868	1877	C-peptide	GENE-Y	23368510T9

23368735|t|The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway.
23368735|a|Organometallic half-sandwich complexes [M(p-cymene)(azo/imino-pyridine)X](+) where M = Ru(II) or Os(II) and X  Cl or I, exhibit potent antiproliferative activity toward a range of cancer cells. Not only are the iodido complexes more potent than the chlorido analogues, but they are not cross-resistant with the clinical platinum drugs cisplatin and oxaliplatin. They are also more selective for cancer cells versus normal cells (fibroblasts) and show high accumulation in cell membranes. They arrest cell growth in G1 phase in contrast to cisplatin (S phase) with a high incidence of late-stage apoptosis. The iodido complexes retain potency in p53 mutant colon cells. All complexes activate caspase 3. In general, antiproliferative activity is greatly enhanced by low levels of the glutathione synthase inhibitor l-buthionine sulfoxime. The work illustrates how subtle changes to the design of low-spin d(6) metal complexes can lead to major changes in cellular metabolism and to potent complexes with novel mechanisms of anticancer activity.
23368735	750	759	cisplatin	CHEMICAL	23368735T10
23368735	821	827	iodido	CHEMICAL	23368735T11
23368735	994	1005	glutathione	CHEMICAL	23368735T12
23368735	1025	1047	l-buthionine sulfoxime	CHEMICAL	23368735T13
23368735	293	313	M = Ru(II) or Os(II)	CHEMICAL	23368735T14
23368735	28	34	iodido	CHEMICAL	23368735T15
23368735	42	60	chlorido ruthenium	CHEMICAL	23368735T16
23368735	65	101	osmium arene azo- and imino-pyridine	CHEMICAL	23368735T17
23368735	856	859	p53	GENE-Y	77545
23368735	903	912	caspase 3	GENE-Y	23368735T19
23368735	318	329	X  Cl or I	CHEMICAL	23368735T1
23368735	994	1014	glutathione synthase	GENE-Y	23368735T20
23368735	171	174	p53	GENE-Y	77545
23368735	322	324	Cl	CHEMICAL	23368735T2
23368735	328	329	I	CHEMICAL	160
23368735	422	428	iodido	CHEMICAL	23368735T4
23368735	460	468	chlorido	CHEMICAL	23368735T5
23368735	531	539	platinum	CHEMICAL	23368735T6
23368735	546	555	cisplatin	CHEMICAL	23368735T7
23368735	560	571	oxaliplatin	CHEMICAL	23368735T8
23368735	249	286	[M(p-cymene)(azo/imino-pyridine)X](+)	CHEMICAL	23368735T9
23368735	CPR:4	23368735T13	23368735T20

23368743|t|Zinc-dependent lysosomal enlargement in TRPML1-deficient cells involves MTF-1 transcription factor and ZnT4 (Slc30a4) transporter.
23368743|a|Zinc is critical for a multitude of cellular processes, including gene expression, secretion and enzymatic activities. Cellular zinc is controlled by zinc-chelating proteins and by zinc transporters. The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1in zinc transport. In the present study we provide new evidence for such a role and identify additional cellular components responsible for it. In agreement with the previously published data, an acute siRNA (small interfering RNA)-driven TRPML1 KD (knockdown) leads to the build-up of large cytoplasmic vesicles positive for LysoTracker and zinc staining, when cells are exposed to high concentrations of zinc. We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4. TRPML1 KD is associated with a build-up of cytoplasmic zinc and with enhanced transcriptional response of mRNA for MT2a (metallothionein 2a). TRPML1 KD did not suppress lysosomal secretion, but it did delay zinc leak from the lysosomes into the cytoplasm. These results underscore a role for TRPML1in zinc metabolism. Furthermore, they suggest that TRPML1 works in concert with ZnT4 to regulate zinc translocation between the cytoplasm and lysosomes.
23368743	360	364	zinc	CHEMICAL	23368743T10
23368743	487	491	zinc	CHEMICAL	23368743T11
23368743	560	564	zinc	CHEMICAL	23368743T12
23368743	900	904	zinc	CHEMICAL	23368743T13
23368743	964	968	zinc	CHEMICAL	23368743T14
23368743	1013	1017	zinc	CHEMICAL	23368743T15
23368743	1057	1061	zinc	CHEMICAL	23368743T16
23368743	1091	1095	zinc	CHEMICAL	23368743T17
23368743	0	4	Zinc	CHEMICAL	23368743T18
23368743	1134	1189	metal-regulatory-element-binding transcription factor-1	GENE-Y	23368743T19
23368743	131	135	Zinc	CHEMICAL	23368743T1
23368743	1198	1219	zinc transporter ZnT4	GENE-Y	23368743T20
23368743	1221	1227	TRPML1	GENE-Y	23368743T21
23368743	1336	1340	MT2a	GENE-Y	23368743T22
23368743	1342	1360	metallothionein 2a	GENE-Y	23368743T23
23368743	1363	1369	TRPML1	GENE-Y	23368743T24
23368743	1513	1519	TRPML1	GENE-Y	23368743T25
23368743	1571	1577	TRPML1	GENE-Y	23368743T26
23368743	1600	1604	ZnT4	GENE-Y	23368743T27
23368743	281	304	zinc-chelating proteins	GENE-N	23368743T28
23368743	312	329	zinc transporters	GENE-N	23368743T29
23368743	1198	1202	zinc	CHEMICAL	23368743T2
23368743	395	406	ion channel	GENE-N	23368743T30
23368743	407	413	TRPML1	GENE-Y	23368743T31
23368743	415	455	transient receptor potential mucolipin 1	GENE-Y	23368743T32
23368743	521	527	TRPML1	GENE-Y	23368743T33
23368743	550	556	TRPML1	GENE-Y	23368743T34
23368743	796	802	TRPML1	GENE-Y	23368743T35
23368743	1030	1036	TRPML1	GENE-Y	23368743T36
23368743	1091	1126	zinc-sensitive transcription factor	GENE-N	23368743T37
23368743	1127	1132	MTF-1	GENE-Y	64482
23368743	103	107	ZnT4	GENE-Y	23368743T39
23368743	1276	1280	zinc	CHEMICAL	23368743T3
23368743	109	116	Slc30a4	GENE-Y	204706
23368743	40	46	TRPML1	GENE-Y	23368743T41
23368743	72	77	MTF-1	GENE-Y	64482
23368743	259	263	zinc	CHEMICAL	23368743T4
23368743	1428	1432	zinc	CHEMICAL	23368743T5
23368743	1523	1527	zinc	CHEMICAL	23368743T6
23368743	1617	1621	zinc	CHEMICAL	23368743T7
23368743	281	285	zinc	CHEMICAL	23368743T8
23368743	312	316	zinc	CHEMICAL	23368743T9
23368743	CPR:9	23368743T10	23368743T31
23368743	CPR:9	23368743T10	23368743T32
23368743	CPR:9	23368743T12	23368743T34
23368743	CPR:9	23368743T4	23368743T28
23368743	CPR:9	23368743T4	23368743T29
23368743	CPR:9	23368743T6	23368743T25
23368743	CPR:9	23368743T7	23368743T26
23368743	CPR:9	23368743T7	23368743T27

23369343|t|Evaluation of in vivo anti-hyperglycemic and antioxidant potentials of -santalol and sandalwood oil.
23369343|a|Sandalwood finds numerous mentions across diverse traditional medicinal systems in use worldwide. The objective of this study was to evaluate the in vivo anti-hyperglycemic and antioxidant potential of sandalwood oil and its major constituent -santalol. The in vivo anti-hyperglycemic experiment was conducted in alloxan-induced diabetic male Swiss albino mice models. The in vivo antioxidant experiment was performed in d-galactose mediated oxidative stress induced male Swiss albino mice models. Intraperitoneal administration of -santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for an week modulated parameters such as body weight, blood glucose, serum bilirubin, liver glycogen, and lipid peroxides contents to normoglycemic levels in the alloxan-induced diabetic mice. Similarly, intraperitoneal administration of -santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice. Besides, it was observed that the beneficial effects of -santalol were well complimented, differentially by other constituents present in sandalwood oil, thus indicating synergism in biological activity of this traditionally used bioresource.
23369343	635	645	-santalol	CHEMICAL	23369343T10
23369343	750	757	glucose	CHEMICAL	23369343T11
23369343	765	774	bilirubin	CHEMICAL	23369343T12
23369343	802	811	peroxides	CHEMICAL	23369343T13
23369343	852	859	alloxan	CHEMICAL	23369343T14
23369343	928	938	-santalol	CHEMICAL	23369343T15
23369343	1073	1082	bilirubin	CHEMICAL	23369343T16
23369343	1084	1094	superoxide	CHEMICAL	23369343T17
23369343	71	81	-santalol	CHEMICAL	23369343T18
23369343	1106	1114	catalase	GENE-Y	23369343T19
23369343	1121	1131	sulfhydryl	CHEMICAL	23369343T1
23369343	1032	1049	aminotransferases	GENE-N	23369343T20
23369343	1051	1071	alkaline phosphatase	GENE-N	23369343T21
23369343	1084	1104	superoxide dismutase	GENE-N	23369343T22
23369343	1141	1149	carbonyl	CHEMICAL	23369343T2
23369343	1151	1163	nitric oxide	CHEMICAL	23369343T3
23369343	1177	1185	peroxide	CHEMICAL	23369343T4
23369343	1224	1235	d-galactose	CHEMICAL	23369343T5
23369343	1332	1342	-santalol	CHEMICAL	23369343T6
23369343	345	355	-santalol	CHEMICAL	23369343T7
23369343	416	423	alloxan	CHEMICAL	23369343T8
23369343	524	535	d-galactose	CHEMICAL	23369343T9

23370008|t|Serum amyloid A upsurge precedes standard biomarkers of hepatotoxicity in ritodrine-injected mice.
23370008|a|The tocolytic agent ritodrine acts on the 2-adrenoceptor and is an effective treatment option for preterm labor. However, several adverse effects of ritodrine therapy, including liver damage, have been noted. To elucidate the underlying mechanisms of ritodrine-induced adverse effects, development of sensitive biomarkers of these adverse events is necessary. Here, we report the development and analysis of an animal model of ritodrine-induced liver damage. Female mice received daily ritodrine injections for 2 weeks; liver samples were then collected and subjected to DNA microarray analysis. Ritodrine significantly altered the expression of genes related to steroid and lipid metabolism, as well as the metabolism of ritodrine itself. Importantly, expression of the acute-phase reactant serum amyloid A (SAA) significantly increased after ritodrine injection, with values indicating the largest fold-change. This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as aspartate aminotransferase and alanine aminotransferase. The increase in SAA expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin. Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the ritodrine-induced SAA increase. Instead, SAA expression was enhanced by indirect phosphorylation of the signal transducer and activator of transcription-3 (STAT3) mediated by interleukin-6. Therefore, our study provides a method for sensitive and early detection of hepatic injury, and may thus help preclude serious liver damage due to ritodrine use in preterm labor.
23370008	249	258	ritodrine	CHEMICAL	23370008T10
23370008	1842	1851	ritodrine	CHEMICAL	23370008T11
23370008	119	128	ritodrine	CHEMICAL	23370008T12
23370008	351	360	ritodrine	CHEMICAL	23370008T13
23370008	527	536	ritodrine	CHEMICAL	23370008T14
23370008	586	595	ritodrine	CHEMICAL	23370008T15
23370008	696	705	Ritodrine	CHEMICAL	857
23370008	763	770	steroid	CHEMICAL	23370008T17
23370008	822	831	ritodrine	CHEMICAL	23370008T18
23370008	944	953	ritodrine	CHEMICAL	23370008T19
23370008	1131	1140	aspartate	CHEMICAL	23370008T1
23370008	74	83	ritodrine	CHEMICAL	23370008T20
23370008	1131	1157	aspartate aminotransferase	GENE-Y	23370008T21
23370008	1162	1186	alanine aminotransferase	GENE-N	23370008T22
23370008	1204	1207	SAA	GENE-N	23370008T23
23370008	1274	1277	SAA	GENE-N	23370008T24
23370008	1523	1526	SAA	GENE-N	23370008T25
23370008	1546	1549	SAA	GENE-N	23370008T26
23370008	1609	1659	signal transducer and activator of transcription-3	GENE-Y	23370008T27
23370008	1661	1666	STAT3	GENE-Y	112651
23370008	1680	1693	interleukin-6	GENE-Y	23370008T29
23370008	1162	1169	alanine	CHEMICAL	23370008T2
23370008	141	156	2-adrenoceptor	GENE-Y	23370008T30
23370008	892	907	serum amyloid A	GENE-N	23370008T31
23370008	909	912	SAA	GENE-N	23370008T32
23370008	1042	1045	SAA	GENE-N	23370008T33
23370008	0	15	Serum amyloid A	GENE-N	23370008T34
23370008	1234	1243	ritodrine	CHEMICAL	23370008T3
23370008	1340	1353	acetaminophen	CHEMICAL	23370008T4
23370008	1355	1368	valproic acid	CHEMICAL	23370008T5
23370008	1373	1382	metformin	CHEMICAL	23370008T6
23370008	1417	1453	cyclic adenosine 3',5'-monophosphate	CHEMICAL	23370008T7
23370008	1455	1459	cAMP	CHEMICAL	2424
23370008	1505	1514	ritodrine	CHEMICAL	23370008T9
23370008	CPR:3	23370008T19	23370008T31
23370008	CPR:3	23370008T19	23370008T32
23370008	CPR:3	23370008T20	23370008T34
23370008	CPR:3	23370008T3	23370008T23
23370008	CPR:3	23370008T9	23370008T25

23371303|t|Ceftazidime-avibactam: a novel cephalosporin/-lactamase inhibitor combination.
23371303|a|Avibactam (formerly NXL104, AVE1330A) is a synthetic non--lactam, -lactamase inhibitor that inhibits the activities of Ambler class A and C -lactamases and some Ambler class D enzymes. This review summarizes the existing data published for ceftazidime-avibactam, including relevant chemistry, mechanisms of action and resistance, microbiology, pharmacokinetics, pharmacodynamics, and efficacy and safety data from animal and human trials. Although not a -lactam, the chemical structure of avibactam closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to -lactamases. Very little is known about the potential for avibactam to select for resistance. The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of -lactamase enzyme(s). Against Pseudomonas aeruginosa, the addition of avibactam also improves the activity of ceftazidime (~fourfold MIC reduction). Limited data suggest that the addition of avibactam does not improve the activity of ceftazidime versus Acinetobacter species or most anaerobic bacteria (exceptions: Bacteroides fragilis, Clostridium perfringens, Prevotella spp. and Porphyromonas spp.). The pharmacokinetics of avibactam follow a two-compartment model and do not appear to be altered by the co-administration of ceftazidime. The maximum plasma drug concentration (C(max)) and area under the plasma concentration-time curve (AUC) of avibactam increase linearly with doses ranging from 50mg to 2,000mg. The mean volume of distribution and half-life of 22 L (~0.3 L/kg) and ~2 hours, respectively, are similar to ceftazidime. Like ceftazidime, avibactam is primarily renally excreted, and clearance correlates with creatinine clearance. Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus -lactamase-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates. The safety and tolerability of ceftazidime-avibactam has been reported in three phase I pharmacokinetic studies and two phase II clinical studies. Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus -lactamase-producing Gram-negative bacilli. The exact roles for ceftazidime-avibactam will be defined by efficacy and safety data from further clinical trials. Potential future roles for ceftazidime-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum -lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC -lactamases. In addition, ceftazidime-avibactam may be used in combination (with metronidazole) for suspected polymicrobial infections. Finally, the increased activity of ceftazidime-avibactam versus P. aeruginosa may be of clinical benefit in patients with suspected or documented P. aeruginosa infections.
23371303	1868	1877	avibactam	CHEMICAL	23371303T10
23371303	1939	1949	creatinine	CHEMICAL	23371303T11
23371303	1995	2006	ceftazidime	CHEMICAL	23371303T12
23371303	2007	2016	avibactam	CHEMICAL	23371303T13
23371303	100	106	NXL104	CHEMICAL	23371303T14
23371303	2118	2129	ceftazidime	CHEMICAL	23371303T15
23371303	2179	2190	ceftazidime	CHEMICAL	23371303T16
23371303	2191	2200	avibactam	CHEMICAL	23371303T17
23371303	2229	2239	carbapenem	CHEMICAL	23371303T18
23371303	2360	2373	cephalosporin	CHEMICAL	23371303T19
23371303	80	89	Avibactam	CHEMICAL	23371303T1
23371303	2439	2450	ceftazidime	CHEMICAL	23371303T20
23371303	2451	2460	avibactam	CHEMICAL	23371303T21
23371303	323	334	ceftazidime	CHEMICAL	23371303T22
23371303	2555	2566	Ceftazidime	CHEMICAL	430
23371303	2567	2576	avibactam	CHEMICAL	23371303T24
23371303	335	344	avibactam	CHEMICAL	23371303T25
23371303	2749	2758	avibactam	CHEMICAL	23371303T26
23371303	2793	2804	ceftazidime	CHEMICAL	23371303T27
23371303	2877	2888	ceftazidime	CHEMICAL	23371303T28
23371303	2889	2898	avibactam	CHEMICAL	23371303T29
23371303	1119	1130	ceftazidime	CHEMICAL	23371303T2
23371303	108	116	AVE1330A	CHEMICAL	23371303T30
23371303	3000	3011	ceftazidime	CHEMICAL	23371303T31
23371303	3012	3021	avibactam	CHEMICAL	23371303T32
23371303	3255	3266	ceftazidime	CHEMICAL	23371303T33
23371303	3267	3276	avibactam	CHEMICAL	23371303T34
23371303	3310	3323	metronidazole	CHEMICAL	23371303T35
23371303	3400	3411	ceftazidime	CHEMICAL	23371303T36
23371303	3412	3421	avibactam	CHEMICAL	23371303T37
23371303	537	545	-lactam	CHEMICAL	23371303T38
23371303	573	582	avibactam	CHEMICAL	23371303T39
23371303	1200	1209	avibactam	CHEMICAL	23371303T3
23371303	617	623	cephem	CHEMICAL	23371303T40
23371303	650	659	avibactam	CHEMICAL	23371303T41
23371303	137	145	-lactam	CHEMICAL	23371303T42
23371303	756	765	avibactam	CHEMICAL	23371303T43
23371303	808	817	avibactam	CHEMICAL	23371303T44
23371303	914	925	ceftazidime	CHEMICAL	23371303T45
23371303	1079	1088	avibactam	CHEMICAL	23371303T46
23371303	0	11	Ceftazidime	CHEMICAL	430
23371303	12	21	avibactam	CHEMICAL	23371303T48
23371303	31	44	cephalosporin	CHEMICAL	23371303T49
23371303	1243	1254	ceftazidime	CHEMICAL	23371303T4
23371303	201	234	Ambler class A and C -lactamases	GENE-N	23371303T50
23371303	244	258	Ambler class D	GENE-N	23371303T51
23371303	2048	2059	-lactamase	GENE-N	23371303T52
23371303	2812	2823	-lactamase	GENE-N	23371303T53
23371303	3134	3163	extended-spectrum -lactamase	GENE-N	23371303T54
23371303	3165	3169	ESBL	GENE-N	23371303T55
23371303	3172	3208	Klebsiella pneumoniae carbapenemases	GENE-N	23371303T56
23371303	3210	3214	KPCs	GENE-N	23371303T57
23371303	3223	3240	AmpC -lactamases	GENE-N	23371303T58
23371303	697	709	-lactamases	GENE-N	23371303T59
23371303	1436	1445	avibactam	CHEMICAL	23371303T5
23371303	147	158	-lactamase	GENE-N	23371303T60
23371303	1008	1019	-lactamase	GENE-N	23371303T61
23371303	45	56	-lactamase	GENE-N	23371303T62
23371303	1537	1548	ceftazidime	CHEMICAL	23371303T6
23371303	1657	1666	avibactam	CHEMICAL	23371303T7
23371303	1837	1848	ceftazidime	CHEMICAL	23371303T8
23371303	1855	1866	ceftazidime	CHEMICAL	23371303T9
23371303	CPR:4	23371303T12	23371303T52
23371303	CPR:4	23371303T13	23371303T52
23371303	CPR:4	23371303T14	23371303T51
23371303	CPR:4	23371303T14	23371303T60
23371303	CPR:4	23371303T1	23371303T51
23371303	CPR:4	23371303T1	23371303T60
23371303	CPR:4	23371303T26	23371303T53
23371303	CPR:4	23371303T27	23371303T53
23371303	CPR:4	23371303T30	23371303T51
23371303	CPR:4	23371303T30	23371303T60
23371303	CPR:4	23371303T44	23371303T61
23371303	CPR:4	23371303T45	23371303T61
23371303	CPR:4	430	23371303T62
23371303	CPR:4	23371303T48	23371303T62

23371451|t|Increased human dermal microvascular endothelial cell survival induced by cysteamine.
23371451|a|BACKGROUND: Cystinosis is an autosomal recessive disease caused by intralysosomal cystine accumulation, treated with cysteamine. Recently, new adverse effects of cysteamine were reported. Skin biopsies showed microvascular proliferation (angioendotheliomatosis). To examine the mechanism of angioendotheliomatosis associated with cysteamine toxicity, we examined the effect of cysteamine on human dermal microvascular endothelial cells (HDMVEC). METHODS: After cysteamine exposure (range 0-3.0mM) during 24h, cell viability was measured using water soluble tetrazolium salt-1 (WST-1) in both control HDMVEC and fibroblasts. Cell proliferation and apoptosis rate were measured in HDMVEC by bromodeoxyuridine (BrdU) incorporation and caspase 3 and caspase 7 activity, respectively. Intracellular glutathione (GSH) was measured in HDMVEC after cysteamine exposure of 0, 0.1 or 1.0mM. Medium and cysteamine were refreshed every 6h to mimic the in vivo situation. Next, cell viability in HDMVEC was measured after 24h of GSH exposure (range 0-10.0mM). RESULTS: HDMVEC viability and proliferation increased after cysteamine exposure 0.03-3.0mM (p<0.01) and 0.03-1.0mM (p=0.01) respectively; cell viability in fibroblasts was not affected by incubation with cysteamine. Apoptosis remained unaffected by incubation with 0-1.0mM cysteamine, 3.0mM caused increased apoptosis. Intracellular GSH was significantly increased after incubation with cysteamine 0.1mM (p=0.02) and 1.0mM (p<0.01). HDMVEC viability increased after exposure to GSH 1.0-5.0mM (p<0.01). CONCLUSION: Cysteamine concentrations, similar to those described in plasma of cystinosis patients, stimulate HDMVEC viability and proliferation and increase intracellular GSH content. We postulate that this mechanism might underlie angioendotheliomatosis induced by cysteamine.
23371451	248	258	cysteamine	CHEMICAL	23371451T10
23371451	1830	1833	GSH	CHEMICAL	137
23371451	1925	1935	cysteamine	CHEMICAL	23371451T12
23371451	416	426	cysteamine	CHEMICAL	23371451T13
23371451	463	473	cysteamine	CHEMICAL	23371451T14
23371451	547	557	cysteamine	CHEMICAL	23371451T15
23371451	645	663	tetrazolium salt-1	CHEMICAL	23371451T16
23371451	777	794	bromodeoxyuridine	CHEMICAL	23371451T17
23371451	796	800	BrdU	CHEMICAL	23371451T18
23371451	882	893	glutathione	CHEMICAL	23371451T19
23371451	1107	1110	GSH	CHEMICAL	137
23371451	895	898	GSH	CHEMICAL	137
23371451	929	939	cysteamine	CHEMICAL	23371451T21
23371451	981	991	cysteamine	CHEMICAL	23371451T22
23371451	74	84	cysteamine	CHEMICAL	23371451T23
23371451	820	829	caspase 3	GENE-Y	23371451T24
23371451	834	843	caspase 7	GENE-Y	23371451T25
23371451	1199	1209	cysteamine	CHEMICAL	23371451T2
23371451	203	213	cysteamine	CHEMICAL	23371451T3
23371451	1349	1359	cysteamine	CHEMICAL	23371451T4
23371451	1419	1429	cysteamine	CHEMICAL	23371451T5
23371451	1480	1483	GSH	CHEMICAL	137
23371451	1534	1544	cysteamine	CHEMICAL	23371451T7
23371451	1631	1634	GSH	CHEMICAL	137
23371451	1670	1680	Cysteamine	CHEMICAL	837

23372041|t|Novel locus including FGF21 is associated with dietary macronutrient intake.
23372041|a|Dietary intake of macronutrients (carbohydrate, protein, and fat) has been associated with risk of chronic conditions such as obesity and diabetes. Family studies have reported a moderate contribution of genetics to variation in macronutrient intake. In a genome-wide meta-analysis of a population-based discovery cohort (n = 33 533), rs838133 in FGF21 (19q13.33), rs197273 near TRAF family member-associated NF-kappa-B activator (TANK) (2p24.2), and rs10163409 in FTO (16q12.2) were among the top associations (P < 10(-5)) for percentage of total caloric intake from protein and carbohydrate. rs838133 was replicated in silico in an independent sample from the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) Nutrition Working Group (n = 38 360) and attained genome-wide significance in combined analysis (Pjoint = 7.9  10(-9)). A cytokine involved in cellular metabolism, FGF21 is a potential susceptibility gene for obesity and type 2 diabetes. Our results highlight the potential of genetic variation for determining dietary macronutrient intake.
23372041	111	123	carbohydrate	CHEMICAL	23372041T1
23372041	657	669	carbohydrate	CHEMICAL	23372041T2
23372041	424	429	FGF21	GENE-Y	117672
23372041	456	506	TRAF family member-associated NF-kappa-B activator	GENE-Y	23372041T4
23372041	508	512	TANK	GENE-Y	115328
23372041	542	545	FTO	GENE-Y	122520
23372041	943	951	cytokine	GENE-N	23372041T7
23372041	985	990	FGF21	GENE-Y	117672
23372041	22	27	FGF21	GENE-Y	117672

23373677|t|Investigation of astatine(III) hydrolyzed species: experiments and relativistic calculations.
23373677|a|This work aims to resolve some controversies about astatine(III) hydroxide species present in oxidant aqueous solution. AtO(+) is the dominant species existing under oxidizing and acidic pH conditions. This is consistent with high-performance ion-exchange chromatography data showing the existence of one species holding one positive charge. A change in speciation occurs as the pH changes from 1 to 4, while remaining under oxidizing conditions. Dynamic experiments with ion-exchange resins evidence the existence of a neutral species witnessed by its elution in the void volume. Batch-experiments using a competition method show the exchange of one proton indicating the formation of the AtO(OH) species. The hydrolysis thermodynamic constant, extrapolated to zero ionic strength, was determined to be 10(-1.9). This value is supported by two-component relativistic quantum calculations and therefore allows disclosing unambiguously the structure of the formed species.
23373677	214	220	AtO(+)	CHEMICAL	23373677T1
23373677	145	168	astatine(III) hydroxide	CHEMICAL	23373677T2
23373677	784	791	AtO(OH)	CHEMICAL	23373677T3
23373677	17	30	astatine(III)	CHEMICAL	23373677T4

23377542|t|Trim24-repressed VL30 retrotransposons regulate gene expression by producing noncoding RNA.
23377542|a|Trim24 (Tif1) and Trim33 (Tif1) interact to form a co-repressor complex that suppresses murine hepatocellular carcinoma. Here we show that Trim24 and Trim33 cooperatively repress retinoic acid receptor-dependent activity of VL30-class endogenous retroviruses (ERVs) in liver. In Trim24-knockout hepatocytes, VL30 derepression leads to accumulation of reverse-transcribed VL30 cDNA in the cytoplasm that correlates with activation of the viral-defense interferon responses mimicking the preneoplastic inflammatory state seen in human liver following exogenous viral infection. Furthermore, upon derepression, VL30 long terminal repeats (LTRs) act as promoter and enhancer elements deregulating expression of neighboring genes and generating enhancer RNAs that are required for LTR enhancer activity in hepatocytes in vivo. These data reinforce the role of the TRIM family of proteins in retroviral restriction and antiviral defense and provide an example of an ERV-derived oncogenic regulatory network.
23377542	402	406	VL30	GENE-N	23377542T10
23377542	465	469	VL30	GENE-N	23377542T11
23377542	545	555	interferon	GENE-N	23377542T12
23377542	702	728	VL30 long terminal repeats	GENE-N	23377542T13
23377542	730	734	LTRs	GENE-N	23377542T14
23377542	743	773	promoter and enhancer elements	GENE-N	23377542T15
23377542	870	882	LTR enhancer	GENE-N	23377542T16
23377542	100	105	Tif1	GENE-Y	23377542T17
23377542	953	957	TRIM	GENE-N	23377542T18
23377542	0	6	Trim24	GENE-Y	204196|271392
23377542	273	286	retinoic acid	CHEMICAL	23377542T1
23377542	17	38	VL30 retrotransposons	GENE-N	23377542T20
23377542	92	98	Trim24	GENE-Y	204196|271392
23377542	233	239	Trim24	GENE-Y	204196|271392
23377542	244	250	Trim33	GENE-Y	220448|265612
23377542	273	295	retinoic acid receptor	GENE-N	23377542T5
23377542	111	117	Trim33	GENE-Y	220448|265612
23377542	318	322	VL30	GENE-N	23377542T7
23377542	119	124	Tif1	GENE-Y	23377542T8
23377542	373	379	Trim24	GENE-Y	204196|271392

23378608|t|Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity.
23378608|a|Angiogenesis is tightly associated with the outgrowth of adipose tissue, leading to obesity, which is a risk factor for type 2 diabetes and hypertension, mainly because expanding adipose tissue requires an increased nutrient supply from blood vessels. Therefore, induction of vessel abnormality by adipokines has been well studied, whereas how altered vascular function promotes obesity is relatively unexplored. Also, surviving Prox1 heterozygous mice showed abnormal lymphatic patterning and adult-onset obesity, indicating that accumulation of adipocytes could be closely linked with lymphatic function. Here we propose a new anti-obesity strategy based on enhancement of lymphatic and blood vessel integrity with apelin. Apelin-knockout mice given a high-fat diet showed an obese phenotype associated with abnormal lymphatic and blood vessel enlargement. Fatty acids present in the high-fat diet induced hyperpermeability of endothelial cells, causing adipocyte differentiation, whereas apelin promoted vascular stabilization. Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective cyclooxygenase-2 inhibitor, celecoxib, improved vascular function, and also attenuated obesity. Finally, apelin transgenic mice showed decreased subcutaneous adipose tissue owing to inhibition of high-fat-diet-induced hyperpermeability of vessels. These results indicate that apelin inhibits high-fat-diet-induced obesity by enhancing vessel integrity. Apelin could serve as a therapeutic target for treating obesity and related diseases.
23378608	813	819	Apelin	GENE-Y	23378608T10
23378608	0	6	Apelin	GENE-Y	23378608T11
23378608	1226	1235	celecoxib	CHEMICAL	23378608T1
23378608	947	958	Fatty acids	CHEMICAL	23378608T2
23378608	1160	1166	apelin	GENE-Y	23378608T3
23378608	1198	1214	cyclooxygenase-2	GENE-Y	23378608T4
23378608	1303	1309	apelin	GENE-Y	23378608T5
23378608	1551	1557	Apelin	GENE-Y	23378608T6
23378608	386	396	adipokines	GENE-N	23378608T7
23378608	517	522	Prox1	GENE-Y	202396
23378608	805	811	apelin	GENE-Y	23378608T9
23378608	CPR:4	23378608T1	23378608T4

23379481|t|Activation of the anti-cancer agent upamostat by the mARC enzyme system.
23379481|a|Abstract 1. Upamostat (Mesupron) is a new small molecule serine protease inhibitor. The drug candidate was developed to inhibit the urokinase-type plasminogen activator (uPA) system, which plays a major role in tumor invasion and metastasis. Upamostat is currently in clinical development as an anti-metastatic and non-cytotoxic agent against pancreatic and breast cancer. 2. Upamostat is the orally available amidoxime- (i.e. hydroxyamidine-) prodrug of the pharmacologically active form, WX-UK1. In this study, the reductive enzymatic activation of upamostat to its corresponding amidine WX-UK1 was analyzed. 3. The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its electron transport proteins cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs. In vitro biotransformation assays with porcine subcellular fractions and the reconstituted human enzymes demonstrate an mARC-dependent N-reduction of upamostat.
23379481	131	137	serine	CHEMICAL	23379481T10
23379481	664	670	WX-UK1	CHEMICAL	23379481T11
23379481	712	722	molybdenum	CHEMICAL	23379481T12
23379481	745	754	Amidoxime	CHEMICAL	23379481T13
23379481	858	862	NADH	CHEMICAL	151
23379481	906	907	N	CHEMICAL	167
23379481	1066	1067	N	CHEMICAL	167
23379481	36	45	upamostat	CHEMICAL	23379481T17
23379481	206	242	urokinase-type plasminogen activator	GENE-Y	23379481T18
23379481	244	247	uPA	GENE-Y	23379481T19
23379481	1081	1090	upamostat	CHEMICAL	23379481T1
23379481	131	146	serine protease	GENE-N	23379481T20
23379481	731	773	mitochondrial Amidoxime Reducing Component	GENE-N	23379481T21
23379481	776	780	mARC	GENE-N	23379481T22
23379481	810	837	electron transport proteins	GENE-N	23379481T23
23379481	838	853	cytochrome b(5)	GENE-Y	23379481T24
23379481	858	888	NADH cytochrome b(5) reductase	GENE-N	23379481T25
23379481	1051	1055	mARC	GENE-N	23379481T26
23379481	53	57	mARC	GENE-N	23379481T27
23379481	85	94	Upamostat	CHEMICAL	23379481T2
23379481	96	104	Mesupron	CHEMICAL	23379481T3
23379481	316	325	Upamostat	CHEMICAL	23379481T4
23379481	450	459	Upamostat	CHEMICAL	23379481T5
23379481	484	493	amidoxime	CHEMICAL	23379481T6
23379481	501	515	hydroxyamidine	CHEMICAL	23379481T7
23379481	564	570	WX-UK1	CHEMICAL	23379481T8
23379481	625	634	upamostat	CHEMICAL	23379481T9
23379481	CPR:4	23379481T2	23379481T20
23379481	CPR:4	23379481T3	23379481T20

23381641|t|Differential autophagic cell death under stress with ectopic cytoplasmic and mitochondrial-specific PPP2R2B in human neuroblastoma cells.
23381641|a|Protein phosphatase 2A is one of four major classes of serine/threonine phosphatases. Overexpression of brain-specific regulatory subunit PPP2R2 in neuron cells is implicated in pathogenesis. The alternative splicing of PPP2R2B encodes two isoforms. They are subunit of cytoplasmic specific B1 and mitochondria-targeted B2. The two constructs were transfected into human neuroblastoma cells, SK-N-SH, respectively, and the stable clones overexpressing either B1 or B2 established. We have reported that B2 clones are sensitive to reactive oxygen species (ROS) treatment by inducing autophagic cell death. To study more on the onset of neuropathogenesis under strain, both clones were exposed to different environmental stress, e.g. starvation and endoplasmic reticulum (ER) stress. To learn how PPP2R2B overexpression responds to starvation, cells were incubated in Hank's buffered salt solution of deprived nutrient. Cell death was induced in B1 clones after 6h starvation, but not in B2 clones. The pharmacological inhibitor, Bafilomycin A1, rescued the cell death while suppressing autophagy. On the other hand, to assess how cells respond to ER stress, the cells were treated with 0.1M of N-glycosylation inhibitor, tunicamycin (TM). In contrast with B1, the apoptotic cell death appeared in B2 after 48h treatment. The formation of autophagolysosome was detected in B2 following 12h treatment with TM as evidenced by lysotracker and GFP-LC3 staining for fluorescence microscopy analysis. The autophagy inhibitor, 3-methyladenine, salvaged the final apoptosis. The stable cell lines with ectopically transfected PPP2R2B genes encoding isoforms of brain-specific regulatory subunit exhibit distinct apoptosis under different stressors. The induced autophagic apoptotic cell death is related to mitochondrial membrane potential drop and ROS generation. Disturbance of autophagy alleviates the induced cell death. The results promised a good model for understanding the onset in pathogenesis under stress in neuron cells with aberrant PPP2R2B expression.
23381641	1445	1448	B2	GENE-Y	23381641T10
23381641	276	282	PPP2R2	GENE-N	23381641T11
23381641	1522	1525	B2	GENE-N	23381641T12
23381641	1769	1776	PPP2R2B	GENE-Y	111513
23381641	2189	2196	PPP2R2B	GENE-Y	111513
23381641	358	365	PPP2R2B	GENE-Y	111513
23381641	429	432	B1	GENE-Y	23381641T16
23381641	459	462	B2	GENE-Y	23381641T17
23381641	599	602	B1	GENE-Y	23381641T18
23381641	606	609	B2	GENE-Y	23381641T19
23381641	1174	1188	Bafilomycin A1	CHEMICAL	5613
23381641	645	648	B2	GENE-Y	23381641T20
23381641	193	222	serine/threonine phosphatases	GENE-N	23381641T21
23381641	938	945	PPP2R2B	GENE-N	111513
23381641	1087	1090	B1	GENE-Y	23381641T23
23381641	1131	1134	B2	GENE-Y	23381641T24
23381641	100	107	PPP2R2B	GENE-Y	111513
23381641	1341	1342	N	CHEMICAL	167
23381641	1368	1379	tunicamycin	CHEMICAL	23381641T3
23381641	1671	1686	3-methyladenine	CHEMICAL	23381641T4
23381641	682	688	oxygen	CHEMICAL	23381641T5
23381641	193	199	serine	CHEMICAL	23381641T6
23381641	200	209	threonine	CHEMICAL	23381641T7
23381641	138	160	Protein phosphatase 2A	GENE-N	23381641T8
23381641	1403	1406	B1	GENE-Y	23381641T9

23381936|t|Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults.
23381936|a|The population pharmacokinetics (PPK) of atorvastatin and its principal active metabolite, o-hydroxyatorvastatin, were described in 6-17 years old pediatric hypercholesterolemia patients with a 2-compartment model for both parent and metabolite. Informative prior distributions on selected parameters, based on adult data, were required to stabilize the model and were implemented using a Bayesian penalty term on the likelihood function in the nonlinear mixed effects model (NONMEM VI with PRIOR). Concentrations below the limit of quantitation were treated as censored data using a conditional likelihood function. Atorvastatin apparent oral clearance (CL/F) was described as a function of body weight using an allometric equation. Based on the final model, the typical CL/F estimates for a Tanner Stage 1 patient (35kg weight) and Tanner Stage 2 (50kg weight), would be 553 and 543L/hour, respectively. When scaled allometrically, CL/F was similar to values reported for adults. Variability in atorvastatin PK was primarily affected by weight.
23381936	1211	1223	atorvastatin	CHEMICAL	23381936T1
23381936	251	263	atorvastatin	CHEMICAL	23381936T2
23381936	827	839	Atorvastatin	CHEMICAL	1064
23381936	301	322	o-hydroxyatorvastatin	CHEMICAL	23381936T4
23381936	31	43	atorvastatin	CHEMICAL	23381936T5

23382074|t|A high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex.
23382074|a|Although many functions and targets have been attributed to the histone and protein deacetylase SIRT1, a comprehensive analysis of SIRT1 binding proteins yielding a high-confidence interaction map has not been established. Using a comparative statistical analysis of binding partners, we have assembled a high-confidence SIRT1 interactome. Employing this method, we identified the deubiquitinating enzyme ubiquitin-specific protease 22 (USP22), a component of the deubiquitinating module (DUBm) of the SAGA transcriptional coactivating complex, as a SIRT1-interacting partner. We found that this interaction is highly specific, requires the ZnF-UBP domain of USP22, and is disrupted by the inactivating H363Y mutation within SIRT1. Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core SAGA complex. Furthermore, USP22-mediated recruitment of SIRT1 activity promotes the deacetylation of individual SAGA complex components. Our results indicate an important role of SIRT1-mediated deacetylation in regulating the formation of DUBm subcomplexes within the larger SAGA complex.
23382074	444	449	SIRT1	GENE-Y	116983
23382074	528	558	ubiquitin-specific protease 22	GENE-Y	23382074T11
23382074	560	565	USP22	GENE-Y	116914
23382074	625	629	SAGA	GENE-N	23382074T13
23382074	673	678	SIRT1	GENE-Y	116983
23382074	764	778	ZnF-UBP domain	GENE-N	23382074T15
23382074	187	194	histone	GENE-N	23382074T16
23382074	782	787	USP22	GENE-Y	116914
23382074	826	831	H363Y	GENE-N	23382074T18
23382074	848	853	SIRT1	GENE-Y	116983
23382074	764	767	ZnF	CHEMICAL	23382074T1
23382074	878	883	USP22	GENE-Y	116914
23382074	199	218	protein deacetylase	GENE-N	23382074T21
23382074	983	997	ZnF-UBP domain	GENE-N	23382074T22
23382074	1040	1044	DUBm	GENE-N	23382074T23
23382074	1059	1063	SAGA	GENE-N	23382074T24
23382074	219	224	SIRT1	GENE-Y	116983
23382074	1086	1091	USP22	GENE-Y	116914
23382074	1116	1121	SIRT1	GENE-Y	116983
23382074	45	50	SIRT1	GENE-Y	116983
23382074	83	88	USP22	GENE-Y	116914
23382074	910	916	lysine	CHEMICAL	23382074T2
23382074	97	101	SAGA	GENE-N	23382074T30
23382074	958	964	lysine	CHEMICAL	23382074T3
23382074	983	986	ZnF	CHEMICAL	23382074T4
23382074	1172	1176	SAGA	GENE-N	23382074T5
23382074	1239	1244	SIRT1	GENE-Y	116983
23382074	1299	1303	DUBm	GENE-N	23382074T7
23382074	1335	1339	SAGA	GENE-N	23382074T8
23382074	254	259	SIRT1	GENE-Y	116983

23384997|t|Characterization of cytosolic glutathione peroxidase and phospholipid-hydroperoxide glutathione peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure.
23384997|a|Selenium (Se) is an oligonutrient with both essential biological functions and recognized harmful effects. As the selenocysteine (SeCys) amino acid, selenium is integrated in several Se-containing proteins (selenoproteins), many of which are fundamental for cell homeostasis. Nevertheless, selenium may exert toxic effects at levels marginally above those required, mainly through the generation of reactive oxygen species (ROS). The selenium chemical speciation can strongly affect the bioavailability of this metal and its impact on metabolism, dictating the levels that can be beneficial or detrimental towards an organism. Glutathione peroxidase (GPxs) is the largest and the most studied selenoprotein family. Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. In this study we have cloned GPx1 and GPx4 genes in rainbow trout (Oncorhynchus mykiss). The constitutive mRNA expression of these GPx genes was examined in 18 trout tissues and their responsiveness to Se availability was analysed using a rainbow trout liver cell line (RTL). An inorganic (sodium selenite, Na2SeO3) and organic (selenocysteine, Cys-Se-Se-Cys) selenocompound have been used as Se sources. GPx1 activity was also tested to verify the impact of transcript changes on the enzymatic function of these molecules. To understand if the results obtained from the transcript expression analysis were due to Se bioavailability or generation of ROS, the cytoxicity of the two selenocompounds was tested by measuring the impact of Se on cell membrane integrity. Lastly, Se availability was quantified by mass spectrophotometry to determine the amount of Se in the cell culture media, the Se background due to the foetal calf serum supplement and the contribution from the two selenocompounds used in the treatments. Three isoforms of genes for both GPx1 (GPx1a, 1b1 and 1b2) and GPx4 (GPx4a1, a2 and b) have been identified. The discovery of a third gene encoding for GPx1 and GPx4 hints that salmonids may have the biggest selenoproteome amongst all vertebrates. Transcripts of GPx4 genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the GPx1 genes were more responsive to selenium exposure in vitro, especially to the organic form. Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells. Although the different concentrations tested of the two selenocompounds modulate GPx1 transcript expression to various degrees, no significant change of GPx1 enzymatic activity was detectable. Our results lead us to conclude that trout GPx1 transcripts expression level may represent a sensitive biomarker for selenium intake, helping to evaluate if selenium concentration and chemical speciation impact on cell homeostasis.
23384997	341	351	amino acid	CHEMICAL	23384997T10
23384997	353	361	selenium	CHEMICAL	23384997T11
23384997	1762	1764	Se	CHEMICAL	23384997T12
23384997	1883	1885	Se	CHEMICAL	23384997T13
23384997	1922	1924	Se	CHEMICAL	23384997T14
23384997	2006	2008	Se	CHEMICAL	23384997T15
23384997	387	389	Se	CHEMICAL	23384997T16
23384997	2040	2042	Se	CHEMICAL	23384997T17
23384997	2598	2606	selenium	CHEMICAL	23384997T18
23384997	2705	2713	selenium	CHEMICAL	23384997T19
23384997	204	212	Selenium	CHEMICAL	23384997T1
23384997	2817	2825	selenium	CHEMICAL	23384997T20
23384997	3185	3193	selenium	CHEMICAL	23384997T21
23384997	3225	3233	selenium	CHEMICAL	23384997T22
23384997	612	618	oxygen	CHEMICAL	23384997T23
23384997	638	646	selenium	CHEMICAL	23384997T24
23384997	831	842	Glutathione	CHEMICAL	137
23384997	929	940	glutathione	CHEMICAL	23384997T26
23384997	982	995	hydroperoxide	CHEMICAL	23384997T27
23384997	996	1007	glutathione	CHEMICAL	23384997T28
23384997	185	193	selenium	CHEMICAL	23384997T29
23384997	214	216	Se	CHEMICAL	23384997T2
23384997	30	41	glutathione	CHEMICAL	23384997T30
23384997	70	83	hydroperoxide	CHEMICAL	23384997T31
23384997	84	95	glutathione	CHEMICAL	23384997T32
23384997	1279	1282	GPx	GENE-N	23384997T33
23384997	1553	1557	GPx1	GENE-Y	23384997T34
23384997	2201	2205	GPx1	GENE-Y	23384997T35
23384997	2207	2225	GPx1a, 1b1 and 1b2	GENE-N	23384997T36
23384997	2231	2235	GPx4	GENE-N	23384997T37
23384997	2237	2253	GPx4a1, a2 and b	GENE-N	23384997T38
23384997	2320	2324	GPx1	GENE-Y	23384997T39
23384997	318	332	selenocysteine	CHEMICAL	23384997T3
23384997	2329	2333	GPx4	GENE-N	23384997T40
23384997	2431	2435	GPx4	GENE-N	23384997T41
23384997	2563	2567	GPx1	GENE-Y	23384997T42
23384997	2673	2678	GPx1a	GENE-Y	23384997T43
23384997	2764	2770	GPx1b1	GENE-Y	23384997T44
23384997	2775	2781	GPx1b2	GENE-Y	23384997T45
23384997	2956	2960	GPx1	GENE-Y	23384997T46
23384997	3028	3032	GPx1	GENE-Y	23384997T47
23384997	3111	3115	GPx1	GENE-Y	23384997T48
23384997	831	853	Glutathione peroxidase	GENE-N	23384997T49
23384997	1438	1453	sodium selenite	CHEMICAL	23384997T4
23384997	855	859	GPxs	GENE-N	23384997T50
23384997	897	910	selenoprotein	GENE-N	23384997T51
23384997	919	951	Cytosolic glutathione peroxidase	GENE-Y	23384997T52
23384997	953	957	cGPx	GENE-Y	23384997T53
23384997	959	963	GPx1	GENE-Y	23384997T54
23384997	969	1018	phospholipid hydroperoxide glutathione peroxidase	GENE-N	23384997T55
23384997	1020	1025	PHGPx	GENE-N	63909
23384997	1027	1031	GPx4	GENE-N	23384997T57
23384997	1177	1181	GPx1	GENE-Y	23384997T58
23384997	1186	1190	GPx4	GENE-N	23384997T59
23384997	1455	1462	Na2SeO3	CHEMICAL	23384997T5
23384997	20	52	cytosolic glutathione peroxidase	GENE-Y	23384997T60
23384997	57	106	phospholipid-hydroperoxide glutathione peroxidase	GENE-N	23384997T61
23384997	1477	1491	selenocysteine	CHEMICAL	23384997T6
23384997	1493	1506	Cys-Se-Se-Cys	CHEMICAL	23384997T7
23384997	334	339	SeCys	CHEMICAL	23384997T8
23384997	1541	1543	Se	CHEMICAL	23384997T9
23384997	CPR:3	23384997T20	23384997T44
23384997	CPR:3	23384997T20	23384997T45

23385959|t|Manganese-exposed developing rats display motor deficits and striatal oxidative stress that are reversed by Trolox.
23385959|a|While manganese (Mn) is essential for proper central nervous system (CNS) development, excessive Mn exposure may lead to neurotoxicity. Mn preferentially accumulates in the basal ganglia, and in adults it may cause Parkinson's disease-like disorder. Compared to adults, younger individuals accumulate greater Mn levels in the CNS and are more vulnerable to its toxicity. Moreover, the mechanisms mediating developmental Mn-induced neurotoxicity are not completely understood. The present study investigated the developmental neurotoxicity elicited by Mn exposure (5, 10 and 20mg/kg; i.p.) from postnatal day 8 to PN27 in rats. Neurochemical analyses were carried out on PN29, with a particular focus on striatal alterations in intracellular signaling pathways (MAPKs, Akt and DARPP-32), oxidative stress generation and cell death. Motor alterations were evaluated later in life at 3, 4 or 5weeks of age. Mn exposure (20mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation. Mn (10 and 20mg/kg) increased caspase activity and F(2)-isoprostane production (a biological marker of lipid peroxidation). Paralleling the changes in striatal biochemical parameters, Mn (20mg/kg) also caused motor impairment, evidenced by increased falling latency in the rotarod test, decreased distance traveled and motor speed in the open-field test. Notably, the antioxidant Trolox reversed the Mn (20mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20mg/kg)-induced caspase activity and F(2)-isoprostane production. Trolox also reversed the Mn-induced motor coordination deficits. These findings are the first to show that long-term exposure to Mn during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK) phosphorylation and caspase activity in the striatum. Moreover, we establish Trolox as a potential neuroprotective agent given its efficacy in reversing the Mn-induced neurodevelopmental effects.
23385959	1720	1722	Mn	CHEMICAL	23385959T10
23385959	1824	1826	Mn	CHEMICAL	23385959T11
23385959	133	135	Mn	CHEMICAL	23385959T12
23385959	2050	2056	Trolox	CHEMICAL	23385959T13
23385959	2131	2133	Mn	CHEMICAL	23385959T14
23385959	425	427	Mn	CHEMICAL	23385959T15
23385959	536	538	Mn	CHEMICAL	23385959T16
23385959	667	669	Mn	CHEMICAL	23385959T17
23385959	122	131	manganese	CHEMICAL	23385959T18
23385959	1022	1024	Mn	CHEMICAL	23385959T19
23385959	1137	1139	Mn	CHEMICAL	23385959T1
23385959	213	215	Mn	CHEMICAL	23385959T20
23385959	0	9	Manganese	CHEMICAL	23385959T21
23385959	108	114	Trolox	CHEMICAL	23385959T22
23385959	1168	1175	caspase	GENE-N	23385959T23
23385959	1580	1583	p38	GENE-N	23385959T24
23385959	1584	1588	MAPK	GENE-N	23385959T25
23385959	1644	1651	caspase	GENE-N	23385959T26
23385959	1963	1966	p38	GENE-N	23385959T27
23385959	1967	1971	MAPK	GENE-N	23385959T28
23385959	1993	2000	caspase	GENE-N	23385959T29
23385959	1189	1205	F(2)-isoprostane	CHEMICAL	23385959T2
23385959	878	883	MAPKs	GENE-N	23385959T30
23385959	885	888	Akt	GENE-N	23385959T31
23385959	893	901	DARPP-32	GENE-Y	23385959T32
23385959	1055	1058	p38	GENE-N	23385959T33
23385959	1059	1063	MAPK	GENE-N	23385959T34
23385959	1069	1072	Akt	GENE-N	23385959T35
23385959	1104	1112	DARPP-32	GENE-Y	23385959T36
23385959	1322	1324	Mn	CHEMICAL	23385959T3
23385959	252	254	Mn	CHEMICAL	23385959T4
23385959	1519	1525	Trolox	CHEMICAL	23385959T5
23385959	1540	1542	Mn	CHEMICAL	23385959T6
23385959	1622	1624	Mn	CHEMICAL	23385959T7
23385959	1665	1681	F(2)-isoprostane	CHEMICAL	23385959T8
23385959	1694	1700	Trolox	CHEMICAL	23385959T9
23385959	CPR:3	23385959T11	23385959T27
23385959	CPR:3	23385959T11	23385959T28
23385959	CPR:3	23385959T11	23385959T29
23385959	CPR:3	23385959T19	23385959T33
23385959	CPR:3	23385959T19	23385959T34
23385959	CPR:3	23385959T19	23385959T35
23385959	CPR:3	23385959T1	23385959T23
23385959	CPR:3	23385959T6	23385959T24
23385959	CPR:3	23385959T6	23385959T25
23385959	CPR:3	23385959T7	23385959T26
23385959	CPR:4	23385959T19	23385959T36
23385959	CPR:4	23385959T5	23385959T24
23385959	CPR:4	23385959T5	23385959T25
23385959	CPR:4	23385959T5	23385959T26

23386029|t|Nocapyrones H-J, 3,6-Disubstituted -Pyrones from the Marine Actinomycete Nocardiopsis sp. KMF-001.
23386029|a|Three new 3,6-disubstituted -pyrones, nocapyrones H-J (1-3), were isolated from the marine actinomycete Nocardiopsis sp. KMF-001. Their structures were assigned to be 3-alkylated 6-(1-methyl-1-propenyl)-2H-pyran-2-ones on the basis of UV, MS, NMR, and high resolution (HR)-FAB-MS analyses. Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1 (IL-1). Moreover, nocapyrone H showed 5.82% stronger inhibitory effect on NO production than chrysin at a concentration of 10 m in lipopolysaccharide (LPS)-stimulated BV-2 microglial cells.
23386029	589	591	NO	CHEMICAL	427
23386029	0	15	Nocapyrones H-J	CHEMICAL	23386029T11
23386029	17	44	3,6-Disubstituted -Pyrones	CHEMICAL	23386029T12
23386029	499	513	interleukin-1	GENE-Y	23386029T13
23386029	515	520	IL-1	GENE-Y	23386029T14
23386029	110	137	3,6-disubstituted -pyrones	CHEMICAL	23386029T1
23386029	268	319	3-alkylated 6-(1-methyl-1-propenyl)-2H-pyran-2-ones	CHEMICAL	23386029T2
23386029	391	403	Nocapyrone H	CHEMICAL	23386029T3
23386029	452	464	nitric oxide	CHEMICAL	23386029T4
23386029	466	468	NO	CHEMICAL	427
23386029	471	487	prostaglandin E2	CHEMICAL	23386029T6
23386029	489	493	PGE2	CHEMICAL	907
23386029	139	154	nocapyrones H-J	CHEMICAL	23386029T8
23386029	533	545	nocapyrone H	CHEMICAL	23386029T9
23386029	CPR:4	23386029T3	23386029T13
23386029	CPR:4	23386029T3	23386029T14

23386703|t|Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
23386703|a|The study described here investigated the impact of intestinal excretion (IE; excretion of drug directly from circulation to intestinal lumen), enteroenteric recirculation (EER), and renal tubule recirculation (RTR) on apixaban pharmacokinetics and disposition. The experimental approaches involve integrating apixaban elimination pathways with pharmacokinetic profiles obtained from bile duct-cannulated (BDC) rats and dogs receiving i.v. doses together with oral administration of activated charcoal (AC). Additionally, the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in apixaban disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats. Approximately 20-50% of an apixaban i.v. dose was found in feces of BDC rats and dogs, suggesting IE leading to fecal elimination and intestinal clearance (IC). The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual BCRP and P-gp inhibitor). BCRP appeared to play a more important role for absorption and intestinal and renal elimination of apixaban than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species. These data demonstrate that apixaban undergoes IE, EER, and RTR that are facilitated by efflux transporters. Intestinal reabsorption of apixaban could be interrupted by AC even at 3 hours post-drug dose in dogs (late charcoal effect). This study demonstrates that the intestine is an organ for direct clearance and redistribution of apixaban. The IE, EER, and RTR contribute to overall pharmacokinetic profiles of apixaban. IE as a clearance pathway, balanced with metabolism and renal excretion, helps decrease the impacts of intrinsic (renal or hepatic impairment) and extrinsic (drug-drug interactions) factors on apixaban disposition.
23386703	540	548	apixaban	CHEMICAL	23386703T10
23386703	723	731	charcoal	CHEMICAL	23386703T11
23386703	847	855	apixaban	CHEMICAL	23386703T12
23386703	989	997	apixaban	CHEMICAL	23386703T13
23386703	1176	1184	apixaban	CHEMICAL	23386703T14
23386703	49	57	apixaban	CHEMICAL	23386703T15
23386703	1309	1313	BCRP	GENE-Y	23386703T16
23386703	1318	1322	P-gp	GENE-N	23386703T17
23386703	1335	1339	BCRP	GENE-Y	23386703T18
23386703	1448	1452	P-gp	GENE-N	23386703T19
23386703	1291	1300	GF-120918	CHEMICAL	23386703T1
23386703	764	768	P-gp	GENE-Y	23386703T20
23386703	770	784	P-glycoprotein	GENE-Y	23386703T21
23386703	786	791	abcb1	GENE-Y	23386703T22
23386703	797	801	BCRP	GENE-Y	23386703T23
23386703	803	835	breast cancer resistance protein	GENE-Y	23386703T24
23386703	837	842	abcg2	GENE-Y	23386703T25
23386703	61	70	factor Xa	GENE-N	23386703T26
23386703	1434	1442	apixaban	CHEMICAL	23386703T2
23386703	1613	1621	apixaban	CHEMICAL	23386703T3
23386703	1721	1729	apixaban	CHEMICAL	23386703T4
23386703	1802	1810	charcoal	CHEMICAL	23386703T5
23386703	1918	1926	apixaban	CHEMICAL	23386703T6
23386703	1999	2007	apixaban	CHEMICAL	23386703T7
23386703	2202	2210	apixaban	CHEMICAL	23386703T8
23386703	449	457	apixaban	CHEMICAL	23386703T9
23386703	CPR:4	23386703T15	23386703T26
23386703	CPR:4	23386703T1	23386703T16
23386703	CPR:4	23386703T1	23386703T17
23386703	CPR:9	23386703T2	23386703T18
23386703	CPR:9	23386703T2	23386703T19

23391336|t|Cloning, Characterization, and Sulfonamide and Thiol Inhibition Studies of an -Carbonic Anhydrase from Trypanosoma cruzi, the Causative Agent of Chagas Disease.
23391336|a|An -carbonic anhydrase (CA, EC 4.2.1.1) has been identified, cloned, and characterized from the unicellular protozoan Trypanosoma cruzi, the causative agent of Chagas disease. The enzyme (TcCA) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle. A large number of aromatic/heterocyclic sulfonamides and some 5-mercapto-1,3,4-thiadiazoles were investigated as TcCA inhibitors. The aromatic sulfonamides were weak inhibitors (K(I) values of 192 nM to 84 M), whereas some heterocyclic compounds inhibited the enzyme with K(I) values in the range 61.6-93.6 nM. The thiols were the most potent in vitro inhibitors (K(I) values of 21.1-79.0 nM), and some of them also inhibited the epimastigotes growth of two T. cruzi strains in vivo.
23391336	187	189	CA	GENE-Y	23391336T10
23391336	191	201	EC 4.2.1.1	GENE-Y	23391336T11
23391336	477	483	hCA II	GENE-Y	23391336T12
23391336	165	185	-carbonic anhydrase	GENE-Y	23391336T13
23391336	649	653	TcCA	GENE-Y	23391336T14
23391336	78	98	-Carbonic Anhydrase	GENE-Y	23391336T15
23391336	400	405	CO(2)	CHEMICAL	23391336T1
23391336	514	517	His	CHEMICAL	112
23391336	554	588	aromatic/heterocyclic sulfonamides	CHEMICAL	23391336T3
23391336	598	627	5-mercapto-1,3,4-thiadiazoles	CHEMICAL	23391336T4
23391336	670	691	aromatic sulfonamides	CHEMICAL	23391336T5
23391336	852	858	thiols	CHEMICAL	23391336T6
23391336	31	42	Sulfonamide	CHEMICAL	23391336T7
23391336	47	52	Thiol	CHEMICAL	23391336T8
23391336	351	355	TcCA	GENE-Y	23391336T9
23391336	CPR:4	23391336T3	23391336T14
23391336	CPR:4	23391336T4	23391336T14
23391336	CPR:4	23391336T7	23391336T15
23391336	CPR:4	23391336T8	23391336T15
23391336	CPR:9	23391336T1	23391336T12
23391336	CPR:9	23391336T1	23391336T9

23391632|t|The increased number of Leydig cells by di(2-ethylhexyl) phthalate comes from the differentiation of stem cells into Leydig cell lineage in the adult rat testis.
23391632|a|The objective of the present study is to determine whether di(2-ethylhexyl) phthalate (DEHP) exposure at adulthood increases rat Leydig cell number and to investigate the possible mechanism. 90-day-old Long-Evans rats were randomly divided into 3 groups, and were gavaged with the corn oil (control) or 10 or 750mg/kg DEHP daily for 7 days, and then received an intraperitoneal injection of 75mg/kg ethane dimethanesulfonate (EDS) to eliminate Leydig cells. Serum testosterone concentrations were assessed by RIA, and the mRNA levels of Leydig cell genes were measured by qPCR. EDS eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum testosterone level and no 3-hydroxysteroid dehydrogenase positive (3-HSD(pos)) cells in the interstitium. However, in DEHP-treated groups, there were detectable serum testosterone concentrations and some oval-shaped 3-HSD(pos) cells in the interstitium. These 3-HSD(pos) cells were not stained by the antibody against 11-hydroxysteroid dehydrogenase 1 (11-HSD1), a marker for Leydig cells at a more advanced stage. The disappearance of mRNAs of Leydig cell biomarkers including Lhcgr, Cyp11a1, Cyp17a1, Insl3 and Hsd11b1 in the control testis was observed on day 4 post-EDS. However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the DEHP-treated testes, indicating that these 3-HSD(pos) cells were newly formed progenitor Leydig cells. The mRNA level for nestin (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes. The present study suggests that DEHP increases the differentiation of stem cells into progenitor Leydig cells.
23391632	588	591	EDS	CHEMICAL	23391632T10
23391632	626	638	testosterone	CHEMICAL	614
23391632	740	743	EDS	CHEMICAL	23391632T12
23391632	221	247	di(2-ethylhexyl) phthalate	CHEMICAL	23391632T13
23391632	808	811	EDS	CHEMICAL	23391632T14
23391632	845	857	testosterone	CHEMICAL	614
23391632	871	888	3-hydroxysteroid	CHEMICAL	23391632T16
23391632	965	969	DEHP	CHEMICAL	23391632T17
23391632	1014	1026	testosterone	CHEMICAL	614
23391632	249	253	DEHP	CHEMICAL	23391632T19
23391632	1167	1185	11-hydroxysteroid	CHEMICAL	23391632T1
23391632	40	66	di(2-ethylhexyl) phthalate	CHEMICAL	23391632T20
23391632	1167	1201	11-hydroxysteroid dehydrogenase 1	GENE-Y	23391632T21
23391632	1203	1210	11-HSD	GENE-Y	23391632T22
23391632	1475	1480	Lhcgr	GENE-Y	201153
23391632	1482	1489	Cyp11a1	GENE-Y	198997
23391632	1494	1501	Cyp17a1	GENE-Y	198999
23391632	1543	1548	Insl3	GENE-Y	200773
23391632	1550	1557	Hsd17b3	GENE-Y	23391632T27
23391632	1562	1569	Hsd11b1	GENE-Y	23391632T28
23391632	1620	1626	3-HSD	GENE-N	23391632T29
23391632	1421	1424	EDS	CHEMICAL	23391632T2
23391632	1700	1706	nestin	GENE-Y	23391632T30
23391632	1708	1711	Nes	GENE-Y	201730
23391632	1873	1879	nestin	GENE-Y	23391632T32
23391632	871	902	3-hydroxysteroid dehydrogenase	GENE-N	23391632T33
23391632	913	919	3-HSD	GENE-N	23391632T34
23391632	1063	1069	3-HSD	GENE-N	23391632T35
23391632	1108	1114	3-HSD	GENE-N	23391632T36
23391632	1577	1581	DEHP	CHEMICAL	23391632T3
23391632	1810	1813	EDS	CHEMICAL	23391632T4
23391632	1830	1834	DEHP	CHEMICAL	23391632T5
23391632	1956	1960	DEHP	CHEMICAL	23391632T6
23391632	2009	2013	DEHP	CHEMICAL	23391632T7
23391632	480	484	DEHP	CHEMICAL	23391632T8
23391632	561	586	ethane dimethanesulfonate	CHEMICAL	23391632T9
23391632	CPR:3	23391632T4	23391632T30
23391632	CPR:3	23391632T4	201730

23393127|t|GnRH pulse frequency-dependent stimulation of FSH transcription is mediated via activation of PKA and CREB.
23393127|a|Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSH gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood. We hypothesized that CREB is activated by a distinct signaling pathway in response to pulsatile GnRH in a frequency-dependent manner to dictate the FSH transcriptional response. GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89. A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH mRNA and FSHLUC activity, but had little effect on LHLUC activity, indicating relative specificity of this pathway. In perifusion studies, FSH mRNA levels and FSHLUC activities were increased by pulsatile GnRH, with significantly greater increases at low compared with high pulse frequencies. DNPKA markedly reduced these GnRH-stimulated FSH responses at both low and high pulse frequencies. Correlating with FSH activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies. Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSH activation.
23393127	176	180	GnRH	CHEMICAL	634
23393127	792	796	GnRH	CHEMICAL	634
23393127	837	841	GnRH	CHEMICAL	634
23393127	1071	1075	GnRH	CHEMICAL	634
23393127	0	4	GnRH	CHEMICAL	634
23393127	210	247	cAMP response element-binding protein	GENE-N	23393127T15
23393127	1159	1164	DNPKA	GENE-N	23393127T16
23393127	1188	1192	GnRH	GENE-N	23393127T17
23393127	1204	1208	FSH	GENE-Y	23393127T18
23393127	1276	1280	FSH	GENE-Y	23393127T19
23393127	210	214	cAMP	CHEMICAL	2424
23393127	1298	1301	PKA	GENE-N	23393127T20
23393127	1325	1330	pCREB	GENE-N	23393127T21
23393127	1392	1396	GnRH	GENE-N	23393127T22
23393127	1437	1442	pCREB	GENE-N	23393127T23
23393127	1484	1489	DNPKA	GENE-N	23393127T24
23393127	249	253	CREB	GENE-N	23393127T25
23393127	1573	1576	PKA	GENE-N	23393127T26
23393127	1613	1617	GnRH	GENE-N	23393127T27
23393127	1632	1636	CREB	GENE-N	23393127T28
23393127	1726	1730	GnRH	GENE-N	23393127T29
23393127	1188	1192	GnRH	CHEMICAL	634
23393127	1771	1775	FSH	GENE-Y	23393127T30
23393127	296	300	FSH	GENE-Y	23393127T31
23393127	133	136	FSH	GENE-N	23393127T32
23393127	366	370	GnRH	GENE-N	23393127T33
23393127	381	385	CREB	GENE-N	23393127T34
23393127	141	143	LH	GENE-N	23393127T35
23393127	444	448	CREB	GENE-N	23393127T36
23393127	519	523	GnRH	GENE-N	23393127T37
23393127	571	575	FSH	GENE-Y	23393127T38
23393127	602	606	GnRH	GENE-N	23393127T39
23393127	1392	1396	GnRH	CHEMICAL	634
23393127	622	626	CREB	GENE-N	23393127T40
23393127	644	649	pCREB	GENE-N	23393127T41
23393127	713	729	protein kinase A	GENE-N	23393127T42
23393127	731	734	PKA	GENE-N	23393127T43
23393127	754	775	dominant negative PKA	GENE-N	23393127T44
23393127	777	782	DNPKA	GENE-N	23393127T45
23393127	176	180	GnRH	GENE-N	23393127T46
23393127	792	796	GnRH	GENE-N	23393127T47
23393127	808	813	pCREB	GENE-N	23393127T48
23393127	837	841	GnRH	GENE-N	23393127T49
23393127	1613	1617	GnRH	CHEMICAL	634
23393127	857	861	FSH	GENE-Y	23393127T50
23393127	871	875	FSH	GENE-Y	23393127T51
23393127	914	917	LH	GENE-Y	23393127T52
23393127	1003	1007	FSH	GENE-Y	23393127T53
23393127	1024	1028	FSH	GENE-Y	23393127T54
23393127	1071	1075	GnRH	GENE-N	23393127T55
23393127	0	4	GnRH	GENE-N	23393127T56
23393127	103	107	CREB	GENE-N	23393127T57
23393127	46	50	FSH	GENE-Y	23393127T58
23393127	95	98	PKA	GENE-N	23393127T59
23393127	1726	1730	GnRH	CHEMICAL	634
23393127	366	370	GnRH	CHEMICAL	634
23393127	519	523	GnRH	CHEMICAL	634
23393127	602	606	GnRH	CHEMICAL	634
23393127	747	750	H89	CHEMICAL	23393127T9
23393127	CPR:3	634	23393127T48
23393127	CPR:3	634	23393127T50
23393127	CPR:3	634	23393127T51
23393127	CPR:3	634	23393127T53
23393127	CPR:3	634	23393127T54
23393127	CPR:3	634	23393127T57
23393127	CPR:3	634	23393127T58
23393127	CPR:3	634	23393127T59
23393127	CPR:3	634	23393127T18
23393127	CPR:3	634	23393127T19
23393127	CPR:3	634	23393127T20
23393127	CPR:3	634	23393127T21
23393127	CPR:3	634	23393127T23
23393127	CPR:3	634	23393127T28
23393127	CPR:3	634	23393127T30
23393127	CPR:3	634	23393127T34
23393127	CPR:3	634	23393127T36
23393127	CPR:3	634	23393127T40
23393127	CPR:3	634	23393127T41
23393127	CPR:4	23393127T9	23393127T40
23393127	CPR:4	23393127T9	23393127T41
23393127	CPR:4	23393127T9	23393127T42
23393127	CPR:4	23393127T9	23393127T43

23395669|t|Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway.
23395669|a|Sophocarpine, an effective compound derived from foxtail-like sophora herb and seed, has been reported that it can alleviate non-alcoholic steatohepatitis (NASH) in rats and affect adipocytokine synthesis. Meanwhile, adipocytokines could adjust hepatic lipid metabolism through AMPK signaling pathway. In the work presented here, primary hepatocytes were isolated from specific pathogen-free male SD rats and incubated with 200 mol/L oleic acid for 24h to induce steatotic model, then treated with sophocarpine for 72 h. Oil red staining was performed to evaluate steatosis, total RNA and protein of primary hepatocytes were extracted for real-time RT-PCR and western blot analysis. A cluster of aberrances were observed in the model group, including hepatocyte steatosis, increased leptin and decreased adiponectin mRNA expressions. While sophocarpine treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold). Moreover, compared with the model group, sophocarpine could significantly increase P-AMPK (>5.82-fold), AMPK (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4 (<0.20-fold) protein expression. The mRNA expression of Srebp-1c was downregulated significantly simultaneously (<0.68-fold). We concluded that sophocarpine could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of AMPK.
23395669	1243	1246	ACC	GENE-N	61622
23395669	1292	1297	P-ACC	GENE-N	23395669T11
23395669	1315	1321	HNF-4	GENE-Y	23395669T12
23395669	1378	1386	Srebp-1c	GENE-Y	23395669T13
23395669	1588	1592	AMPK	GENE-Y	23395669T14
23395669	269	282	adipocytokine	GENE-N	23395669T15
23395669	305	319	adipocytokines	GENE-N	23395669T16
23395669	366	370	AMPK	GENE-Y	23395669T17
23395669	872	878	leptin	GENE-Y	23395669T18
23395669	893	904	adiponectin	GENE-Y	23395669T19
23395669	88	100	Sophocarpine	CHEMICAL	23395669T1
23395669	1031	1037	leptin	GENE-Y	23395669T20
23395669	1078	1089	adiponectin	GENE-Y	23395669T21
23395669	64	68	AMPK	GENE-Y	23395669T22
23395669	1156	1168	sophocarpine	CHEMICAL	23395669T2
23395669	1466	1478	sophocarpine	CHEMICAL	23395669T3
23395669	523	533	oleic acid	CHEMICAL	23395669T4
23395669	587	599	sophocarpine	CHEMICAL	23395669T5
23395669	929	941	sophocarpine	CHEMICAL	23395669T6
23395669	0	12	Sophocarpine	CHEMICAL	23395669T7
23395669	1198	1205	P-AMPK	GENE-N	23395669T8
23395669	1220	1225	AMPK	GENE-N	23395669T9
23395669	CPR:3	23395669T2	61622
23395669	CPR:3	23395669T2	23395669T8
23395669	CPR:3	23395669T2	23395669T9
23395669	CPR:3	23395669T3	23395669T14
23395669	CPR:3	23395669T6	23395669T21
23395669	CPR:3	23395669T7	23395669T22
23395669	CPR:4	23395669T2	23395669T11
23395669	CPR:4	23395669T2	23395669T12
23395669	CPR:4	23395669T6	23395669T20

23395825|t|Elevation of 4-hydroxynonenal and malondialdehyde modified protein levels in cerebral cortex with cognitive dysfunction in rats exposed to 1-bromopropane.
23395825|a|1-Bromopropane (1-BP), an alternative to ozone-depleting solvents (ODS), exhibits central nervous system (CNS) toxicity in animals and humans. This study was designed to relate CNS damage by Morris water maze (MWM) test and oxidative stress to 1-BP exposure in the rat. Male Wistar rats were randomly divided into 4 groups (n=10), and treated with 0, 200, 400 and 800mg/kgbw 1-BP for consecutive 12 days, respectively. From day 8 to day 12 of the experiment, MWM test was employed to assess the cognitive function of rats. The cerebral cortex of rats was obtained immediately following the 24h after MWM test conclusion. Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured. The obtained results showed that 1-BP led to cognitive dysfunction of rats, which was evidenced by delayed escape latency time and swimming distances in MWM performance. GSH and total-SH content, GSH/GSSG ratio, GR activity significantly decreased in cerebral cortex of rats, coupling with the increase of MDA level. 4-HNE and MDA modified protein levels obviously elevated after 1-BP exposure. GSH-Px activities in cerebral cortex of rats also increased. These data suggested that 1-BP resulted in enhanced lipid peroxidation of brain, which might play an important role in CNS damage induced by 1-BP.
23395825	1453	1456	GSH	CHEMICAL	137
23395825	1540	1544	1-BP	CHEMICAL	23395825T11
23395825	1655	1659	1-BP	CHEMICAL	23395825T12
23395825	171	175	1-BP	CHEMICAL	23395825T13
23395825	399	403	1-BP	CHEMICAL	23395825T14
23395825	530	534	1-BP	CHEMICAL	23395825T15
23395825	196	201	ozone	CHEMICAL	23395825T16
23395825	776	787	Glutathione	CHEMICAL	137
23395825	789	792	GSH	CHEMICAL	137
23395825	795	815	oxidized glutathione	CHEMICAL	23395825T19
23395825	155	169	1-Bromopropane	CHEMICAL	23395825T1
23395825	817	821	GSSG	CHEMICAL	23395825T20
23395825	833	838	thiol	CHEMICAL	23395825T21
23395825	846	848	SH	CHEMICAL	23395825T22
23395825	859	862	GSH	CHEMICAL	137
23395825	882	885	GSH	CHEMICAL	137
23395825	898	901	GSH	CHEMICAL	137
23395825	918	933	malondialdehyde	CHEMICAL	23395825T26
23395825	935	938	MDA	CHEMICAL	23395825T27
23395825	958	974	4-hydroxynonenal	CHEMICAL	23395825T28
23395825	976	981	4-HNE	CHEMICAL	23395825T29
23395825	1228	1231	GSH	CHEMICAL	137
23395825	987	990	MDA	CHEMICAL	23395825T30
23395825	1091	1095	1-BP	CHEMICAL	23395825T31
23395825	13	29	4-hydroxynonenal	CHEMICAL	23395825T32
23395825	139	153	1-bromopropane	CHEMICAL	23395825T33
23395825	34	49	malondialdehyde	CHEMICAL	23395825T34
23395825	1270	1272	GR	GENE-Y	9947
23395825	1453	1459	GSH-Px	GENE-N	23395825T36
23395825	859	872	GSH reductase	GENE-Y	23395825T37
23395825	874	876	GR	GENE-Y	9947
23395825	882	896	GSH peroxidase	GENE-N	23395825T39
23395825	1242	1244	SH	CHEMICAL	23395825T3
23395825	898	904	GSH-Px	GENE-N	23395825T40
23395825	1254	1257	GSH	CHEMICAL	137
23395825	1258	1262	GSSG	CHEMICAL	23395825T5
23395825	1364	1367	MDA	CHEMICAL	23395825T6
23395825	1375	1380	4-HNE	CHEMICAL	23395825T7
23395825	1385	1388	MDA	CHEMICAL	23395825T8
23395825	1438	1442	1-BP	CHEMICAL	23395825T9

23395914|t|Site dependent intestinal absorption of darunavir and its interaction with ketoconazole.
23395914|a|The expression of P-gp increases from proximal to distal parts of the small intestine, whereas for P450 enzymes the expression is reported to be highest in duodenum and jejunum, decreasing to more distal sites. To evaluate to what extent the regional differences in expression of P-gp and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of darunavir across different small intestinal segments (duodenum, proximal jejunum and ileum). Moreover, the effect of ketoconazole on the intestinal absorption of darunavir was explored, since these drugs are commonly co-administered. Performing the rat in situ intestinal perfusion technique with mesenteric blood sampling, we found no significant differences in the transport of darunavir at the different intestinal segments. The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar. In presence of zosuquidar, a 2.2-, 4.2- and 5.7-fold increase in Papp values were measured for duodenum, proximal jejunum and ileum, respectively. Involvement of P450 mediated metabolism in the absorption of darunavir could not be demonstrated in this rat model. Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on P-gp as the main mechanism for the increased transport of darunavir across the small intestine.
23395914	940	949	darunavir	CHEMICAL	23395914T10
23395914	986	995	darunavir	CHEMICAL	23395914T11
23395914	1020	1030	zosuquidar	CHEMICAL	23395914T12
23395914	1047	1057	zosuquidar	CHEMICAL	23395914T13
23395914	40	49	darunavir	CHEMICAL	23395914T14
23395914	75	87	ketoconazole	CHEMICAL	23395914T15
23395914	1194	1198	P450	GENE-N	23395914T16
23395914	1432	1436	P-gp	GENE-N	23395914T17
23395914	107	111	P-gp	GENE-N	23395914T18
23395914	369	373	P-gp	GENE-N	23395914T19
23395914	1240	1249	darunavir	CHEMICAL	23395914T1
23395914	378	390	P450 enzymes	GENE-N	23395914T20
23395914	914	918	P-gp	GENE-N	23395914T21
23395914	1005	1009	P-gp	GENE-N	23395914T22
23395914	188	200	P450 enzymes	GENE-N	23395914T23
23395914	1338	1347	darunavir	CHEMICAL	23395914T2
23395914	1353	1365	ketoconazole	CHEMICAL	23395914T3
23395914	1416	1428	ketoconazole	CHEMICAL	23395914T4
23395914	1490	1499	darunavir	CHEMICAL	23395914T5
23395914	467	476	darunavir	CHEMICAL	23395914T6
23395914	584	596	ketoconazole	CHEMICAL	23395914T7
23395914	629	638	darunavir	CHEMICAL	23395914T8
23395914	847	856	darunavir	CHEMICAL	23395914T9
23395914	CPR:4	23395914T12	23395914T22
23395914	CPR:4	23395914T4	23395914T17
23395914	CPR:9	23395914T10	23395914T21
23395914	CPR:9	23395914T1	23395914T16
23395914	CPR:9	23395914T5	23395914T17
23395914	CPR:9	23395914T6	23395914T19
23395914	CPR:9	23395914T6	23395914T20

23396144|t|Protective effect of Codium fragile against UVB-induced pro-inflammatory and oxidative damages in HaCaT cells and BALB/c mice.
23396144|a|Acute exposure to ultraviolet (UV) radiation causes pro-inflammatory responses via diverse mechanisms including oxidative stress. Codium fragile is a green alga of Codiales family and has been reported to exhibit anti-edema, anti-allergic, anti-protozoal and anti-mycobacterial activities. In this study, we have investigated a novel anti-inflammatory potential of C. fragile using in vitro cell culture as well as in vivo animal models. In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor- (TNF- ). Moreover, CFB, CFE and CLS effectively suppressed UVB-induced production of pro-inflammatory mediators such as prostaglandin E2 (PGE2) and nitric oxide (NO). In another experiment, topical application of CFB, CFE or CLS prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and TNF-. Furthermore, CFB, CFE and CLS suppressed oxidative damages caused by UVB irradiation for example lipid peroxidation and/or protein carbonylation, which seemed to be mediated by up-regulation of antioxidant defense enzymes. These results suggest that C. fragile could be an effective therapeutic agent providing protection against UVB-induced inflammatory and oxidative skin damages.
23396144	1050	1066	prostaglandin E2	CHEMICAL	23396144T10
23396144	1068	1072	PGE2	CHEMICAL	907
23396144	1078	1090	nitric oxide	CHEMICAL	23396144T12
23396144	1092	1094	NO	CHEMICAL	427
23396144	1259	1264	COX-2	GENE-Y	23396144T14
23396144	1266	1270	iNOS	GENE-Y	23396144T15
23396144	1276	1281	TNF-	GENE-Y	23396144T16
23396144	835	851	cyclooxygenase-2	GENE-Y	23396144T17
23396144	853	858	COX-2	GENE-Y	23396144T18
23396144	861	892	inducible nitric oxide synthase	GENE-Y	23396144T19
23396144	1155	1158	CLS	CHEMICAL	1504
23396144	894	898	iNOS	GENE-Y	23396144T20
23396144	905	928	tumor necrosis factor-	GENE-Y	23396144T21
23396144	930	936	TNF- 	GENE-Y	23396144T22
23396144	1309	1312	CLS	CHEMICAL	1504
23396144	581	589	buthanol	CHEMICAL	23396144T3
23396144	594	606	ethylacetate	CHEMICAL	23396144T4
23396144	624	632	methanol	CHEMICAL	23396144T5
23396144	688	699	clerosterol	CHEMICAL	23396144T6
23396144	701	704	CLS	CHEMICAL	1504
23396144	871	883	nitric oxide	CHEMICAL	23396144T8
23396144	962	965	CLS	CHEMICAL	1504
23396144	CPR:4	1504	23396144T14
23396144	CPR:4	1504	23396144T15
23396144	CPR:4	1504	23396144T16
23396144	CPR:4	23396144T3	23396144T17
23396144	CPR:4	23396144T3	23396144T18
23396144	CPR:4	23396144T3	23396144T19
23396144	CPR:4	23396144T3	23396144T20
23396144	CPR:4	23396144T3	23396144T21
23396144	CPR:4	23396144T3	23396144T22
23396144	CPR:4	23396144T4	23396144T17
23396144	CPR:4	23396144T4	23396144T18
23396144	CPR:4	23396144T4	23396144T19
23396144	CPR:4	23396144T4	23396144T20
23396144	CPR:4	23396144T4	23396144T21
23396144	CPR:4	23396144T4	23396144T22
23396144	CPR:4	23396144T5	23396144T17
23396144	CPR:4	23396144T5	23396144T18
23396144	CPR:4	23396144T5	23396144T19
23396144	CPR:4	23396144T5	23396144T20
23396144	CPR:4	23396144T5	23396144T21
23396144	CPR:4	23396144T5	23396144T22
23396144	CPR:4	23396144T6	23396144T17
23396144	CPR:4	23396144T6	23396144T18
23396144	CPR:4	23396144T6	23396144T19
23396144	CPR:4	23396144T6	23396144T20
23396144	CPR:4	23396144T6	23396144T21
23396144	CPR:4	23396144T6	23396144T22
23396144	CPR:4	1504	23396144T17
23396144	CPR:4	1504	23396144T18
23396144	CPR:4	1504	23396144T19
23396144	CPR:4	1504	23396144T20
23396144	CPR:4	1504	23396144T21
23396144	CPR:4	1504	23396144T22

23398572|t|Strong effects of cluster size and air exposure on oxygen reduction and carbon oxidation electrocatalysis by size-selected Pt(n) (n  11) on glassy carbon electrodes.
23398572|a|Model Pt(n)/glassy carbon electrodes (Pt(n)/GCE) were prepared by deposition of mass-selected Pt(n)(+) (n  11) on GCE substrates in ultrahigh vacuum. Electrocatalysis under conditions appropriate for the oxygen reduction reaction (ORR) was studied, for samples both in situ with no exposure to laboratory air and with air exposure prior to electrochemical measurements. Of the small clusters, only a few cluster sizes show the expected ORR activity, and in those cases, the activity per Pt atom is similar to that seen under identical conditions with a conventionally prepared electrode with Pt nanoparticles grown on a GCE. For other small Pt(n) on GCE, any ORR signal is overwhelmed by large oxidative currents attributed to catalysis of carbon oxidation by water. If the samples are exposed to air prior to electrochemistry, both ORR and carbon oxidation signals are absent, and instead only small capacitive currents or currents attributed to redox chemistry of adventitious organic adsorbates are observed, indicating that air exposure results in passivation of the small Pt clusters.
23398572	1009	1015	carbon	CHEMICAL	23398572T10
23398572	261	269	Pt(n)(+)	CHEMICAL	23398572T11
23398572	123	128	Pt(n)	CHEMICAL	23398572T12
23398572	141	154	glassy carbon	CHEMICAL	23398572T13
23398572	51	57	oxygen	CHEMICAL	23398572T14
23398572	72	78	carbon	CHEMICAL	23398572T15
23398572	1245	1247	Pt	CHEMICAL	23398572T1
23398572	179	192	glassy carbon	CHEMICAL	23398572T2
23398572	372	378	oxygen	CHEMICAL	23398572T3
23398572	205	210	Pt(n)	CHEMICAL	23398572T4
23398572	655	657	Pt	CHEMICAL	23398572T5
23398572	760	762	Pt	CHEMICAL	23398572T6
23398572	173	178	Pt(n)	CHEMICAL	23398572T7
23398572	809	814	Pt(n)	CHEMICAL	23398572T8
23398572	908	914	carbon	CHEMICAL	23398572T9

23399323|t|Inhibition of ghrelin O-acyltransferase attenuates food deprivation-induced increases in ingestive behavior.
23399323|a|Ghrelin is an orexigenic hormone produced by the stomach in direct proportion to the time since the last meal and has therefore been called a 'hunger signal'. The octanoylation of ghrelin is critical for its orexigenic functions and is dependent upon ghrelin O-acyltransferase (GOAT) catalyzation. The GOAT inhibitor, GO-CoA-Tat, decreases the circulating concentrations of octanoylated ghrelin and attenuates weight gain on a high fat diet in mice. Unlike rats and mice, Siberian hamsters and humans do not increase food intake after food deprivation, but increase food hoarding after food deprivation. In Siberian hamsters, exogenous ghrelin increases ingestive behaviors similarly to 48-56h food deprivation. Therefore, we tested the necessity of increased ghrelin in food-deprived Siberian hamsters to stimulate ingestive behaviors. To do so we used our simulated natural housing system that allows hamsters to forage for and hoard food. Animals were given an injection of GO-CoA-Tat (i.p., 11mol/kg) every 6h because that is the duration of its effective inhibition of octanoylated ghrelin concentrations during a 48h food deprivation. We found that GO-CoA-Tat attenuated food foraging (0-1h), food intake (0-1 and 2-4h), and food hoarding (0-1h and 2 and 3days) post-refeeding compared with saline treated animals. This suggests that increased octanoylated ghrelin concentrations play a role in the food deprivation-induced increases in ingestive behavior. Therefore, ghrelin is a critical aspect of the multi-faceted mechanisms that stimulate ingestive behaviors, and might be a critical point for a successful clinical intervention scheme in humans.
23399323	387	391	GOAT	GENE-Y	23399323T10
23399323	411	415	GOAT	GENE-Y	23399323T11
23399323	483	503	octanoylated ghrelin	GENE-Y	23399323T12
23399323	745	752	ghrelin	GENE-Y	23399323T13
23399323	869	876	ghrelin	GENE-Y	23399323T14
23399323	14	39	ghrelin O-acyltransferase	GENE-Y	23399323T15
23399323	368	369	O	CHEMICAL	23399323T1
23399323	22	23	O	CHEMICAL	23399323T2
23399323	109	116	Ghrelin	GENE-Y	23399323T3
23399323	1184	1204	octanoylated ghrelin	GENE-N	23399323T4
23399323	1460	1480	octanoylated ghrelin	GENE-N	23399323T5
23399323	123	141	orexigenic hormone	GENE-N	23399323T6
23399323	1584	1591	ghrelin	GENE-Y	23399323T7
23399323	289	296	ghrelin	GENE-Y	23399323T8
23399323	360	385	ghrelin O-acyltransferase	GENE-Y	23399323T9

23400796|t|The accumulation of metal (Co, Cr, Cu, Mn and Zn) in freshwater Ulva (Chlorophyta) and its habitat.
23400796|a|The possibility of using freshwater Ulva (Chlorophyta) as a bioaccumulator of metals (Co, Cr, Cu, Mn and Zn) in lake and river water was examined weekly in the summer of 2010 in three types of samples: the water, the sediment and the thalli of Ulva. Samples of freshwater Ulva were collected from two aqueous ecosystems lie 250 km away from the basin of the Baltic Sea and 53 km from each other. A flow lake located in the centre of the big city was the first water reservoir (ten sites) and second, the suburban river (six sites). The mean metal concentrations in the Ulva tissue from the river and the lake decreased in the following order: Mn > Zn > Cr > Cu > Co and Mn > Cr > Zn > Cu > Co, respectively. Moreover, a negative and statistically significant correlation between Mn concentrations in the Ulva thalli and the river water was observed. Additionally, numerous correlations were noted between the different concentrations of metals within the Ulva thalli, in the water and in the sediment. The great concentrations of Mn and Zn and the smallest of Co were found in thalli of Ulva, irrespective of the type of the ecosystem from which samples of algal thalli originated. Freshwater Ulva populations examined in this study were clearly characterized a dozen or so times by the higher Mn and Cr accumulation than taxa from that genera coming from sea ecosystems. The calculated bioconcentration factor confirm the high potential for freshwater Ulva to be a bioaccumulator of trace metals in freshwater ecosystems.
23400796	758	760	Cu	CHEMICAL	23400796T10
23400796	763	765	Co	CHEMICAL	23400796T11
23400796	770	772	Mn	CHEMICAL	23400796T12
23400796	775	777	Cr	CHEMICAL	23400796T13
23400796	780	782	Zn	CHEMICAL	23400796T14
23400796	785	787	Cu	CHEMICAL	23400796T15
23400796	790	792	Co	CHEMICAL	23400796T16
23400796	879	881	Mn	CHEMICAL	23400796T17
23400796	186	188	Co	CHEMICAL	23400796T18
23400796	190	192	Cr	CHEMICAL	23400796T19
23400796	1130	1132	Mn	CHEMICAL	23400796T1
23400796	194	196	Cu	CHEMICAL	23400796T20
23400796	198	200	Mn	CHEMICAL	23400796T21
23400796	27	29	Co	CHEMICAL	23400796T22
23400796	31	33	Cr	CHEMICAL	23400796T23
23400796	35	37	Cu	CHEMICAL	23400796T24
23400796	39	41	Mn	CHEMICAL	23400796T25
23400796	46	48	Zn	CHEMICAL	23400796T26
23400796	1137	1139	Zn	CHEMICAL	23400796T2
23400796	205	207	Zn	CHEMICAL	23400796T3
23400796	1160	1162	Co	CHEMICAL	23400796T4
23400796	1394	1396	Mn	CHEMICAL	23400796T5
23400796	1401	1403	Cr	CHEMICAL	23400796T6
23400796	743	745	Mn	CHEMICAL	23400796T7
23400796	748	750	Zn	CHEMICAL	23400796T8
23400796	753	755	Cr	CHEMICAL	23400796T9

23401298|t|Exploring the Interplay Between Ligand Derivatisation and Cation Type in the Assembly of Hybrid Polyoxometalate Mn-Andersons.
23401298|a|Herein a library of hybrid Mn-Anderson polyoxometalates anions are presented: 1, [(MnMo(6) O(18) )((OCH(2) )(3) -C-(CH(2) )(7) CHCH(2) )(2) ](3-) ; compound 2, [(MnMo(6) O(18) )((OCH(2) )(3) C-NHCH(2) C(16) H(9) )(2) ](3-) ; compound 3, [(MnMo(6) O(18) )((OCH(2) )(3) C-(CH(2) )(7) CHCH(2) )(1) ((OCH(2) )(3) C-NHCH(2) C(16) H(9) )(1) ](3-) ; compound 4, [(MnMo(6) O(18) )((OCH(2) )(3) C-NHC(O)CH(2) CHCH(2) )(2) ](3-) and compounds 5-9, [(MnMo(6) O(18) )((OCH(2) )(3) C-NHC(O)(CH(2) )(x) CH(3) )(2) ]), where x = 4, 10, 12, 14, and 18 respectively. The compounds resulting from the cation exchange of the anions 1-9 to give TBA (a) and DMDOA (b) salts, and additionally for compounds 1, 2 and 3, tetraphenylphosphonium (PPh(4) ) (c) salts, are explored at the air/water interface using scanning force microscopy, showing a range of architectures including hexagonal structures, nanofibers and other supramolecular forms. Additionally the solid-state structures for compounds 1c, 2c, 4a, 6a, 9a, are presented for the first time and these investigations demonstrate the delicate interplay between the structure of the covalently derivatised hybrid organo-clusters as well as the ion-exchange cation types.
23401298	847	853	PPh(4)	CHEMICAL	23401298T10
23401298	207	271	[(MnMo(6) O(18) )((OCH(2) )(3) -C-(CH(2) )(7) CHCH(2) )(2) ](3-)	CHEMICAL	23401298T11
23401298	112	114	Mn	CHEMICAL	23401298T12
23401298	96	111	Polyoxometalate	CHEMICAL	23401298T13
23401298	286	348	[(MnMo(6) O(18) )((OCH(2) )(3) C-NHCH(2) C(16) H(9) )(2) ](3-)	CHEMICAL	23401298T1
23401298	363	466	[(MnMo(6) O(18) )((OCH(2) )(3) C-(CH(2) )(7) CHCH(2) )(1) ((OCH(2) )(3) C-NHCH(2) C(16) H(9) )(1) ](3-)	CHEMICAL	23401298T2
23401298	153	155	Mn	CHEMICAL	23401298T3
23401298	481	544	[(MnMo(6) O(18) )((OCH(2) )(3) C-NHC(O)CH(2) CHCH(2) )(2) ](3-)	CHEMICAL	23401298T4
23401298	165	181	polyoxometalates	CHEMICAL	23401298T5
23401298	564	627	[(MnMo(6) O(18) )((OCH(2) )(3) C-NHC(O)(CH(2) )(x) CH(3) )(2) ]	CHEMICAL	23401298T6
23401298	751	754	TBA	CHEMICAL	23401298T7
23401298	763	768	DMDOA	CHEMICAL	23401298T8
23401298	823	845	tetraphenylphosphonium	CHEMICAL	23401298T9

23401473|t|Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
23401473|a|Organic anion-transporting polypeptides (OATPs) are multispecific transporters mediating the uptake of endogenous compounds and xenobiotics in tissues that are important for drug absorption and elimination, including the intestine and liver. Silymarin is a popular herbal supplement often used by patients with chronic liver disease; higher oral doses than those customarily used (140 mg three times/day) are being evaluated clinically. The present study examined the effect of silymarin flavonolignans on OATP1B1-, OATP1B3-, and OATP2B1-mediated transport in cell lines stably expressing these transporters and in human hepatocytes. In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated. OATP1B1-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 M, respectively). Furthermore, silymarin, silybin A, and silybin B (100 M) significantly inhibited OATP-mediated estradiol-17-glucuronide and rosuvastatin uptake into human hepatocytes. Calculation of the maximal unbound portal vein concentrations/IC50 values indicated a low risk for silymarin-drug interactions in hepatic uptake with a customary silymarin dose. The extent of silymarin-drug interactions depends on OATP isoform specificity and concentrations of flavonolignans at the site of drug transport. Higher than customary doses of silymarin, or formulations with improved bioavailability, may increase the risk of flavonolignan interactions with OATP substrates in patients.
23401473	780	805	estradiol-17-glucuronide	CHEMICAL	23401473T10
23401473	834	851	estrone-3-sulfate	CHEMICAL	23401473T11
23401473	899	913	flavonolignans	CHEMICAL	23401473T12
23401473	1080	1089	silybin A	CHEMICAL	23401473T13
23401473	25	39	flavonolignans	CHEMICAL	23401473T14
23401473	86	125	Organic anion-transporting polypeptides	GENE-N	23401473T15
23401473	1357	1361	OATP	GENE-N	23401473T16
23401473	1676	1680	OATP	GENE-N	23401473T17
23401473	1915	1919	OATP	GENE-N	23401473T18
23401473	127	132	OATPs	GENE-N	23401473T19
23401473	1142	1151	silybin B	CHEMICAL	23401473T1
23401473	592	599	OATP1B1	GENE-Y	23401473T20
23401473	602	609	OATP1B3	GENE-Y	23401473T21
23401473	138	164	multispecific transporters	GENE-N	23401473T22
23401473	616	623	OATP2B1	GENE-Y	23401473T23
23401473	750	757	OATP1B1	GENE-Y	23401473T24
23401473	763	770	OATP1B3	GENE-Y	23401473T25
23401473	817	824	OATP2B1	GENE-Y	23401473T26
23401473	928	935	OATP1B1	GENE-Y	23401473T27
23401473	938	945	OATP1B3	GENE-Y	23401473T28
23401473	952	959	OATP2B1	GENE-Y	23401473T29
23401473	1208	1220	silychristin	CHEMICAL	23401473T2
23401473	45	84	organic anion-transporting polypeptides	GENE-N	23401473T30
23401473	1299	1308	silybin A	CHEMICAL	23401473T3
23401473	1314	1323	silybin B	CHEMICAL	23401473T4
23401473	1371	1396	estradiol-17-glucuronide	CHEMICAL	23401473T5
23401473	1401	1413	rosuvastatin	CHEMICAL	23401473T6
23401473	1723	1737	flavonolignans	CHEMICAL	23401473T7
23401473	1883	1896	flavonolignan	CHEMICAL	23401473T8
23401473	574	588	flavonolignans	CHEMICAL	23401473T9
23401473	CPR:4	23401473T12	23401473T24
23401473	CPR:4	23401473T12	23401473T25
23401473	CPR:4	23401473T12	23401473T26
23401473	CPR:4	23401473T13	23401473T27
23401473	CPR:4	23401473T13	23401473T28
23401473	CPR:4	23401473T13	23401473T29
23401473	CPR:4	23401473T1	23401473T27
23401473	CPR:4	23401473T1	23401473T28
23401473	CPR:4	23401473T1	23401473T29
23401473	CPR:4	23401473T2	23401473T27
23401473	CPR:4	23401473T2	23401473T28
23401473	CPR:4	23401473T2	23401473T29
23401473	CPR:4	23401473T3	23401473T16
23401473	CPR:4	23401473T4	23401473T16
23401473	CPR:9	23401473T10	23401473T24
23401473	CPR:9	23401473T10	23401473T25
23401473	CPR:9	23401473T11	23401473T26
23401473	CPR:9	23401473T5	23401473T16
23401473	CPR:9	23401473T6	23401473T16

23402628|t|Oxidation of tertiary amine-derivatized surfaces to control protein adhesion.
23402628|a|Selective oxidation of -tertiary amine self-assembled thiol monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins lysozyme and fibrinogen upon them. Efficient preparation of both secondary and tertiary linker amides as judged by X-ray photoelectron spectroscopy (XPS) and water droplet contact angle was achieved with an improved amide bond formation on gold quartz crystal microbalance (QCM) sensors using 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl hexafluorophosphate methanaminium uronium (HATU). Oxidation with hydrogen peroxide was similarly assessed, and adhesion of lysozyme and fibrinogen from phosphate buffered saline was then assayed by QCM and imaged by AFM. Tertiary amine-functionalized sensors adsorbed multilayers of aggregated lysozyme, whereas tertiary amine N-oxides and triethylene glycol-terminated monolayers are consistent with small protein aggregates. The surface containing a dimethylamine N-oxide headgroup and ethyl secondary amide linker showed the largest difference in adsorption of both proteins. Oxidation of tertiary amine decorated surfaces therefore holds the potential for selective deposition of proteins and cells through masking and other patterning techniques.
23402628	725	734	phosphate	CHEMICAL	23402628T10
23402628	794	808	Tertiary amine	CHEMICAL	23402628T11
23402628	153	176	tertiary amine N-oxides	CHEMICAL	23402628T12
23402628	885	908	tertiary amine N-oxides	CHEMICAL	23402628T13
23402628	913	931	triethylene glycol	CHEMICAL	23402628T14
23402628	1025	1046	dimethylamine N-oxide	CHEMICAL	23402628T15
23402628	1061	1082	ethyl secondary amide	CHEMICAL	23402628T16
23402628	13	27	tertiary amine	CHEMICAL	23402628T17
23402628	230	238	lysozyme	GENE-Y	23402628T18
23402628	243	253	fibrinogen	GENE-N	23402628T19
23402628	1165	1179	tertiary amine	CHEMICAL	23402628T1
23402628	696	704	lysozyme	GENE-Y	23402628T20
23402628	709	719	fibrinogen	GENE-N	23402628T21
23402628	867	875	lysozyme	GENE-Y	23402628T22
23402628	295	331	secondary and tertiary linker amides	CHEMICAL	23402628T2
23402628	101	117	-tertiary amine	CHEMICAL	23402628T3
23402628	446	451	amide	CHEMICAL	23402628T4
23402628	475	481	quartz	CHEMICAL	23402628T5
23402628	523	614	2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl hexafluorophosphate methanaminium uronium	CHEMICAL	23402628T6
23402628	616	620	HATU	CHEMICAL	23402628T7
23402628	133	138	thiol	CHEMICAL	23402628T8
23402628	638	655	hydrogen peroxide	CHEMICAL	23402628T9

23403014|t|Stabilisation of amorphous drugs under high humidity using pharmaceutical thin films.
23403014|a|In this study, the stabilization effects of three polymers on four model drugs (felodipine, fenofibrate, carbamazepine, and celecoxib) under saturated humidity were investigated. Three different types of thin films (solid dispersions, drug films with a polymer film coating and drug films laid on top of polymer coated surfaces) were prepared and compared with films containing the drug alone. ATR-FTIR spectroscopy, polarised light microscopy (PLM), scanning electron microscopy (SEM) and nano-thermal analysis (nano-TA) were performed on the model systems after storage under saturated humidity. The recrystallisation tendency of the drug in the drug containing thin films was found to be strongly related to the intrinsic crystallization tendency of the drug film alone and the strength of drug-polymer interactions. Additionally, under high humidity, the glass transition temperature of the polymer is no longer an indicator of its drug stabilization capability. Instead, it is the hygroscobicity of the polymer that appears to be the most important parameter. Amongst the polymers tested in this study, EUDRAGIT E PO was found to have the greatest inhibitory effect on crystallization, whilst PVP K30 was found to have the least protective effect; presumably because of its hygroscopic nature.
23403014	191	204	carbamazepine	CHEMICAL	23403014T1
23403014	1194	1207	EUDRAGIT E PO	CHEMICAL	23403014T2
23403014	1284	1291	PVP K30	CHEMICAL	23403014T3
23403014	210	219	celecoxib	CHEMICAL	23403014T4
23403014	166	176	felodipine	CHEMICAL	23403014T5
23403014	178	189	fenofibrate	CHEMICAL	23403014T6

23403085|t|Neuroprotective effects of mercaptoethylleonurine and mercaptoethylguanidine analogs on hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells.
23403085|a|A series of mercaptoethylleonurine and mercaptoethylguanidine derivatives were designed and synthesized. Their neuroprotective effects toward H2O2-induced apoptosis were investigated in human SH-SY5Y cells. The results from these studies identified several potent compounds, with compound 8k emerging as the most effective. Further investigation demonstrated that 8k reduced H2O2-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2. Moreover, the molecular mechanism underlying the observed neuroprotective effects of 8k was exerted via the Akt and JNK pathways. Compound 8k can be a lead compound for further discovery of neuroprotective medicine.
23403085	766	769	Akt	GENE-N	23403085T10
23403085	774	777	JNK	GENE-N	23403085T11
23403085	169	191	mercaptoethylleonurine	CHEMICAL	23403085T1
23403085	299	303	H2O2	CHEMICAL	23403085T2
23403085	532	536	H2O2	CHEMICAL	23403085T3
23403085	196	218	mercaptoethylguanidine	CHEMICAL	23403085T4
23403085	27	49	mercaptoethylleonurine	CHEMICAL	23403085T5
23403085	54	76	mercaptoethylguanidine	CHEMICAL	23403085T6
23403085	88	105	hydrogen peroxide	CHEMICAL	23403085T7
23403085	615	618	Bax	GENE-N	198304|246997
23403085	651	656	Bcl-2	GENE-N	23403085T9
23403085	CPR:3	23403085T3	198304|246997
23403085	CPR:4	23403085T3	23403085T9

23404443|t|Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control.
23404443|a|AIMS/HYPOTHESIS: We examined the effects of serum insulin levels on vagal control over the heart and tested the hypothesis that higher fasting insulin levels are associated with lower vagal control. We also examined whether experimentally induced increases in insulin by beta cell secretagogues, including glucagon-like peptide-1 (GLP-1), will decrease vagal control. METHODS: Respiration and ECGs were recorded for 130 healthy participants undergoing clamps. Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine). RESULTS: Serum insulin level was positively associated with HR at all time points during the clamps except the first-phase hyperglycaemic clamp. Insulin levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, GLP-1 first and second phases, and arginine). These associations disappeared when adjusted for age, BMI and insulin sensitivity. Administration of the beta cell secretagogues GLP-1 and arginine led to a significant increase in HR, but this was not paired with a significant reduction in HRV measures. CONCLUSION/INTERPRETATION: Experimentally induced hyperinsulinaemia is not correlated with cardiac vagal control or HR when adjusting for age, BMI and insulin sensitivity index. Our findings suggest that exposure to a GLP-1 during hyperglycaemia leads to a small acute increase in HR but not to an acute decrease in cardiac vagal control.
23404443	250	257	insulin	GENE-Y	23404443T10
23404443	1564	1571	insulin	GENE-Y	23404443T11
23404443	1631	1636	GLP-1	GENE-Y	23404443T12
23404443	1908	1915	insulin	GENE-Y	23404443T13
23404443	1975	1980	GLP-1	GENE-Y	23404443T14
23404443	367	374	insulin	GENE-Y	23404443T15
23404443	413	436	glucagon-like peptide-1	GENE-Y	23404443T16
23404443	438	443	GLP-1	GENE-Y	23404443T17
23404443	151	164	serum insulin	GENE-Y	23404443T18
23404443	947	954	insulin	GENE-Y	23404443T19
23404443	1491	1499	arginine	CHEMICAL	23404443T1
23404443	982	989	insulin	GENE-Y	23404443T20
23404443	1030	1035	GLP-1	GENE-Y	23404443T21
23404443	1053	1058	GLP-1	GENE-Y	23404443T22
23404443	1093	1106	Serum insulin	GENE-Y	23404443T23
23404443	1641	1649	arginine	CHEMICAL	23404443T2
23404443	995	1002	glucose	CHEMICAL	23404443T3
23404443	1004	1011	glucose	CHEMICAL	23404443T4
23404443	1018	1025	glucose	CHEMICAL	23404443T5
23404443	1041	1048	glucose	CHEMICAL	23404443T6
23404443	1073	1081	arginine	CHEMICAL	23404443T7
23404443	1229	1236	Insulin	GENE-Y	23404443T8
23404443	1456	1461	GLP-1	GENE-Y	23404443T9
23404443	CPR:3	23404443T3	23404443T19
23404443	CPR:3	23404443T4	23404443T19
23404443	CPR:3	23404443T5	23404443T19
23404443	CPR:3	23404443T6	23404443T19
23404443	CPR:3	23404443T7	23404443T19

23404505|t|The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
23404505|a|VEGF-D is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of N- and C-terminal propeptides. These propeptides flank the central VEGF homology domain, that contains the binding sites for VEGF receptors (VEGFRs), but their biological functions were unclear. Characterization of propeptide function will be important to clarify which forms of VEGF-D are biologically active and therefore clinically relevant. Here we use VEGF-D mutants deficient in either propeptide, and in the capacity to process the remaining propeptide, to monitor the functions of these domains. We report for the first time that VEGF-D binds heparin, and that the C-terminal propeptide significantly enhances this interaction (removal of this propeptide from full-length VEGF-D completely prevents heparin binding). We also show that removal of either the N- or C-terminal propeptide is required for VEGF-D to drive formation of VEGFR-2/VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting. The mature form of VEGF-D, lacking both propeptides, can also promote formation of these receptor heterodimers. In a mouse tumor model, removal of only the C-terminal propeptide from full-length VEGF-D was sufficient to enhance angiogenesis and tumor growth. In contrast, removal of both propeptides is required for high rates of lymph node metastasis. The findings reported here show that the propeptides profoundly influence molecular interactions of VEGF-D with VEGF receptors, co-receptors, and heparin, and its effects on tumor biology.
23404505	1261	1267	VEGF-D	GENE-Y	23404505T10
23404505	1437	1443	VEGF-D	GENE-Y	23404505T11
23404505	1695	1701	VEGF-D	GENE-Y	23404505T12
23404505	1707	1721	VEGF receptors	GENE-N	23404505T13
23404505	366	386	VEGF homology domain	GENE-N	23404505T14
23404505	424	438	VEGF receptors	GENE-N	23404505T15
23404505	440	446	VEGFRs	GENE-N	23404505T16
23404505	578	584	VEGF-D	GENE-Y	23404505T17
23404505	656	662	VEGF-D	GENE-Y	23404505T18
23404505	837	843	VEGF-D	GENE-Y	23404505T19
23404505	1398	1399	C	CHEMICAL	23404505T1
23404505	979	985	VEGF-D	GENE-Y	23404505T20
23404505	1108	1114	VEGF-D	GENE-Y	23404505T21
23404505	19	25	VEGF-D	GENE-Y	23404505T22
23404505	299	300	N	CHEMICAL	167
23404505	306	307	C	CHEMICAL	23404505T3
23404505	872	873	C	CHEMICAL	23404505T4
23404505	1064	1065	N	CHEMICAL	167
23404505	1070	1071	C	CHEMICAL	23404505T6
23404505	112	118	VEGF-D	GENE-Y	23404505T7
23404505	1137	1144	VEGFR-2	GENE-Y	23404505T8
23404505	1145	1152	VEGFR-3	GENE-Y	23404505T9

23406497|t|Switchable Elastin-Like Polypeptides that Respond to Chemical Inducers of Dimerization.
23406497|a|Elastin-like polypeptides (ELPs) are protein polymers that reversibly phase separate in response to increased temperature, pressure, concentration, ionic strength, and molecular weight. If it were possible to engineer their phase separation to respond to specific molecular substrates, ELP fusion proteins might be engineered as biosensors, smart biomaterials, diagnostic imaging agents, and targeted therapies. What has been lacking is a strategy to design ELPs to respond to specific substrates. To address this deficiency, we report that ELP fusion proteins phase separate in response to chemical inducers of dimerization (CID). The rationale is that ELP phase separation depends on molecular weight, concentration, and local hydrophobicity; therefore, processes that affect these properties, including noncovalent dimerization, can be tuned to produce isothermal phase separation. To test this hypothesis, constructs were evaluated consisting of an immunophilin: human FK-506 binding protein 12 (FKBP) attached to an ELP. Under stoichiometric binding of a CID, the fusion protein homodimerizes and triggers phase separation. This dimerization is reversible upon saturation with excess CID or competitive binding of a small lipophilic macrolide to FKBP. By modulating the ELP molecular weight, phase separation was tuned for isothermal response to CID at physiological ionic strength and temperature (37 C). To interpret the relationship between transition temperature and equilibrium binding constants, an empirical mathematical model was employed. To the best of our knowledge, this report is the first demonstration of reversible ELP switching in response to controlled dimerization. Due to its simplicity, this strategy may be useful to design ELP fusion proteins that respond to specific dimeric biological entities.
23406497	546	550	ELPs	GENE-N	23406497T10
23406497	629	632	ELP	GENE-N	23406497T11
23406497	742	745	ELP	GENE-N	23406497T12
23406497	1041	1053	immunophilin	GENE-N	23406497T13
23406497	1055	1086	human FK-506 binding protein 12	GENE-Y	23406497T14
23406497	11	36	Elastin-Like Polypeptides	GENE-N	23406497T15
23406497	1061	1067	FK-506	CHEMICAL	23406497T1
23406497	88	113	Elastin-like polypeptides	GENE-N	23406497T2
23406497	1088	1092	FKBP	GENE-Y	23406497T3
23406497	1109	1112	ELP	GENE-N	23406497T4
23406497	1363	1366	ELP	GENE-N	23406497T5
23406497	1725	1728	ELP	GENE-N	23406497T6
23406497	1840	1843	ELP	GENE-N	23406497T7
23406497	115	119	ELPs	GENE-N	23406497T8
23406497	374	377	ELP	GENE-N	23406497T9

23406956|t|Protective role of L-carnitine and vitamin E on the testis of atherosclerotic rats.
23406956|a|Atherosclerosis is a condition caused by lipid build-up and inflammation in the arteries, so hyperlipidemia is the major reason for atherosclerosis. Testis was found to be negatively affected by hyperlipidemia which leads to its impaired functions. Vitamin E and <sc>l</sc>-carnitine have well-known lipid-lowering and antioxidative activities. Triton WR 1339 is a non-ionic detergent, which induces severe hyperlipidemia by inhibition of lipoprotein lipase. The present study evaluates the protective role of vitamin E and <sc>l</sc>-carnitine on the testis in atherosclerosis and detects the most effective choice for protection against atherosclerosis; vitamin E, <sc>l</sc>-carnitine or a combination of both. A total of 80 albino male rats were divided into eight groups (10 rats for each group): control (G(1)), triton (G(2)), <sc>l</sc>-carnitine (G(3)), triton + <sc>l</sc>-carnitine (G(4)), vitamin E (G(5)), triton + vitamin E (G(6)), <sc>l</sc>-carnitine + vitamin E (G(7)) and triton + <sc>l</sc>-carnitine + vitamin E (G(8)). Data showed a significant increase in the levels of total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), 17 beta hydroxysteroid dehydrogenase (17  HSD), testicular catalase and malondialdehyde (MDA) in G(2) when compared with G(1), whereas high-density lipoprotein cholesterol (HDL-C), serum testosterone, testicular 17 ketosteroid reductase (17 KSR), total thiol and glutathione-S-transferase (GST) data showed a significant decrease in G(2) when compared with G(1). Treatment with <sc>l</sc>-carnitine or/and vitamin E helps in improving the adverse effect of triton; also the histological changes confirm this finding. So the present study recommends all people to include <sc>l</sc>-carnitine and vitamin E in their diet to be protected against atherosclerosis.
23406956	1481	1492	ketosteroid	CHEMICAL	23406956T10
23406956	1519	1524	thiol	CHEMICAL	23406956T11
23406956	1529	1540	glutathione	CHEMICAL	23406956T12
23406956	1541	1542	S	CHEMICAL	127
23406956	1644	1664	<sc>l</sc>-carnitine	CHEMICAL	23406956T14
23406956	1672	1681	vitamin E	CHEMICAL	23406956T15
23406956	1723	1729	triton	CHEMICAL	23406956T16
23406956	1837	1857	<sc>l</sc>-carnitine	CHEMICAL	23406956T17
23406956	1862	1871	vitamin E	CHEMICAL	23406956T18
23406956	333	342	Vitamin E	CHEMICAL	157
23406956	1105	1114	vitamin E	CHEMICAL	23406956T1
23406956	347	367	<sc>l</sc>-carnitine	CHEMICAL	23406956T20
23406956	429	443	Triton WR 1339	CHEMICAL	23406956T21
23406956	594	603	vitamin E	CHEMICAL	23406956T22
23406956	608	628	<sc>l</sc>-carnitine	CHEMICAL	23406956T23
23406956	740	749	vitamin E	CHEMICAL	23406956T24
23406956	751	771	<sc>l</sc>-carnitine	CHEMICAL	23406956T25
23406956	902	908	triton	CHEMICAL	23406956T26
23406956	917	937	<sc>l</sc>-carnitine	CHEMICAL	23406956T27
23406956	946	952	triton	CHEMICAL	23406956T28
23406956	955	975	<sc>l</sc>-carnitine	CHEMICAL	23406956T29
23406956	1181	1192	cholesterol	CHEMICAL	23406956T2
23406956	984	993	vitamin E	CHEMICAL	23406956T30
23406956	1002	1008	triton	CHEMICAL	23406956T31
23406956	1011	1020	vitamin E	CHEMICAL	23406956T32
23406956	1029	1049	<sc>l</sc>-carnitine	CHEMICAL	23406956T33
23406956	1052	1061	vitamin E	CHEMICAL	23406956T34
23406956	1073	1079	triton	CHEMICAL	23406956T35
23406956	1082	1102	<sc>l</sc>-carnitine	CHEMICAL	23406956T36
23406956	19	30	L-carnitine	CHEMICAL	23406956T37
23406956	35	44	vitamin E	CHEMICAL	23406956T38
23406956	1199	1212	triglycerides	CHEMICAL	23406956T3
23406956	1244	1255	cholesterol	CHEMICAL	23406956T4
23406956	1265	1287	17 beta hydroxysteroid	CHEMICAL	23406956T5
23406956	1338	1353	malondialdehyde	CHEMICAL	23406956T6
23406956	1355	1358	MDA	CHEMICAL	23406956T7
23406956	1426	1437	cholesterol	CHEMICAL	23406956T8
23406956	1453	1465	testosterone	CHEMICAL	614

23407783|t|The CRF(1) receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.
23407783|a|RATIONALE: The selective CRF(1) (corticotropin releasing factor type 1) receptor antagonist SSR125543 has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure. Memory disturbances described in post-traumatic stress disorder (PTSD) patients are believed to be associated with changes in neuronal activity, in particular at the level of the hippocampus. OBJECTIVES: The present study aims at investigating whether the effects of SSR125543 (10mg/kg/day for 2weeks) on cognitive impairment induced by traumatic stress exposure are associated with changes in hippocampal excitability. Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10mg/kg/day), and the partial N-methyl-D-aspartate (NMDA) receptor agonist, D-cycloserine (10mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD. METHODS: Mice received two unavoidable electric foot-shocks. Then, 1 or 16days after stress, they were tested for their memory performance using the object recognition test. Neuronal excitability was recorded during the third week post-stress in the CA1 area of the hippocampus. Drugs were administered from day 1 post-stress to the day preceding the electrophysiological study. RESULTS: Application of electric shocks produced cognitive impairment 16, but not 1day after stress, an effect which was associated with a decrease in hippocampal neuronal excitability. Both stress-induced effects were prevented by repeated administration of SSR125543, paroxetine and D-cycloserine. CONCLUSIONS: These findings confirm that the CRF(1) receptor antagonist SSR125543 is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.
23407783	945	949	NMDA	CHEMICAL	1209
23407783	969	982	D-cycloserine	CHEMICAL	23407783T11
23407783	262	271	SSR125543	CHEMICAL	23407783T12
23407783	140	150	paroxetine	CHEMICAL	705
23407783	155	168	D-cycloserine	CHEMICAL	23407783T14
23407783	31	40	SSR125543	CHEMICAL	23407783T15
23407783	1795	1810	CRF(1) receptor	GENE-Y	23407783T16
23407783	195	250	CRF(1) (corticotropin releasing factor type 1) receptor	GENE-Y	23407783T17
23407783	923	959	N-methyl-D-aspartate (NMDA) receptor	GENE-N	23407783T18
23407783	4	19	CRF(1) receptor	GENE-Y	23407783T19
23407783	1709	1718	SSR125543	CHEMICAL	23407783T1
23407783	1720	1730	paroxetine	CHEMICAL	705
23407783	1735	1748	D-cycloserine	CHEMICAL	23407783T3
23407783	1822	1831	SSR125543	CHEMICAL	23407783T4
23407783	649	658	SSR125543	CHEMICAL	23407783T5
23407783	815	824	SSR125543	CHEMICAL	23407783T6
23407783	855	859	5-HT	CHEMICAL	23407783T7
23407783	880	890	paroxetine	CHEMICAL	705
23407783	923	943	N-methyl-D-aspartate	CHEMICAL	23407783T9
23407783	CPR:5	23407783T11	23407783T18
23407783	CPR:6	23407783T12	23407783T17
23407783	CPR:6	23407783T15	23407783T19
23407783	CPR:6	23407783T4	23407783T16

23409871|t|Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
23409871|a|A series of indazole arylsulfonamides were synthesized and examined as human CCR4 antagonists. Methoxy- or hydroxyl-containing groups were the more potent indazole C4 substituents. Only small groups were tolerated at C5, C6, or C7, with the C6 analogues being preferred. The most potent N3-substituent was 5-chlorothiophene-2-sulfonamide. N1 meta-substituted benzyl groups possessing an -amino-3-[(methylamino)acyl]-group were the most potent N1-substituents. Strongly basic amino groups had low oral absorption in vivo. Less basic analogues, such as morpholines, had good oral absorption; however, they also had high clearance. The most potent compound with high absorption in two species was analogue 6 (GSK2239633A), which was selected for further development. Aryl sulfonamide antagonists bind to CCR4 at an intracellular allosteric site denoted site II. X-ray diffraction studies on two indazole sulfonamide fragments suggested the presence of an important intramolecular interaction in the active conformation.
23409871	899	915	Aryl sulfonamide	CHEMICAL	23409871T10
23409871	1027	1047	indazole sulfonamide	CHEMICAL	23409871T11
23409871	229	236	Methoxy	CHEMICAL	23409871T12
23409871	50	75	indazole arylsulfonamides	CHEMICAL	23409871T13
23409871	205	215	human CCR4	GENE-Y	23409871T14
23409871	936	940	CCR4	GENE-Y	31745|107638
23409871	115	119	CCR4	GENE-Y	31745|107638
23409871	90	113	CC-chemokine receptor 4	GENE-Y	23409871T17
23409871	241	249	hydroxyl	CHEMICAL	23409871T1
23409871	146	171	indazole arylsulfonamides	CHEMICAL	23409871T2
23409871	289	297	indazole	CHEMICAL	23409871T3
23409871	440	471	5-chlorothiophene-2-sulfonamide	CHEMICAL	23409871T4
23409871	493	499	benzyl	CHEMICAL	23409871T5
23409871	529	550	3-[(methylamino)acyl]	CHEMICAL	23409871T6
23409871	610	615	amino	CHEMICAL	23409871T7
23409871	686	697	morpholines	CHEMICAL	23409871T8
23409871	841	852	GSK2239633A	CHEMICAL	23409871T9
23409871	CPR:6	23409871T2	23409871T14

23411185|t|Comparative analysis of nutritional compositions of transgenic high iron rice with its non-transgenic counterpart.
23411185|a|Iron is an essential micronutrient for human nutrition and polished rice contains very low amount of iron. Rice with high iron content in seed endosperm has been developed by insertion of soybean ferritin gene under the control of the endosperm specific glutelin promoter into the genome of indica rice line IR68144. The nutritional composition of the brown and milled rice grain has been compared with that of the non-transgenic rice of the same variety. In this study, the nutritional components, as well as the anti-nutrient levels, were measured. Our studies established that apart from the increased level of iron and zinc in transgenic seeds, the nutritional quality of both the brown and milled rice grains from the transgenic line was substantially equivalent to that of the non-transgenic rice plants. The result clearly shows that the measured amounts of the nutritional components are well within the range of values reported for other commercial lines.
23411185	115	119	Iron	CHEMICAL	23411185T1
23411185	216	220	iron	CHEMICAL	23411185T2
23411185	237	241	iron	CHEMICAL	23411185T3
23411185	729	733	iron	CHEMICAL	23411185T4
23411185	738	742	zinc	CHEMICAL	23411185T5
23411185	68	72	iron	CHEMICAL	23411185T6
23411185	303	319	soybean ferritin	GENE-N	23411185T7
23411185	369	386	glutelin promoter	GENE-N	23411185T8

23412396|t|Repeated Low Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects.
23412396|a|The monoacylglycerol lipase (MAGL) inhibitor JZL184 produces antinociceptive and anti-inflammatory effects. However, repeated administration of high dose JZL184 (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacological effects of cannabinoid receptor agonists, and CB(1) receptor downregulation and desensitization. This functional CB(1) receptor tolerance poses a hurdle in the development of MAGL inhibitors for therapeutic use. Consequently, the present study tested whether repeated administration of low dose JZL184 maintains its antinociceptive actions in the chronic constrictive injury (CCI) of the sciatic nerve neuropathic pain model and protective effects in a model of NSAlD-induced gastric hemorrhages. Mice given daily injections of high dose JZL184 (16 mg/kg) for six days displayed decreased CB(1) receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTPS binding assays, respectively. In contrast, normal CB(1) receptor expression and function were maintained following repeated administration of low dose JZL184 (8 mg/kg). Likewise, the antinociceptive and gastroprotective effects of high dose JZL184 underwent tolerance following repeated administration, but these effects were maintained following repeated low dose JZL184 treatment. Consistent with these observations, repeated high dose JZL184, but not repeated low dose JZL184, elicited cross-tolerance to the common pharmacological effects of (9)-tetrahydrocannabinol (THC). This same pattern of effects was found in a rimonabant-precipitated withdrawal model of cannabinoid dependence. Taken together, these results indicate that prolonged, partial MAGL inhibition maintains potentially beneficial antinociceptive and anti-inflammatory effects, without producing functional CB(1) receptor tachyphylaxsis/tolerance or cannabinoid dependence.
23412396	161	177	monoacylglycerol	CHEMICAL	23412396T10
23412396	202	208	JZL184	CHEMICAL	23412396T11
23412396	709	715	JZL184	CHEMICAL	23412396T12
23412396	952	958	JZL184	CHEMICAL	23412396T13
23412396	1065	1080	[(3)H]SR141716A	CHEMICAL	23412396T14
23412396	1093	1101	CP55,940	CHEMICAL	23412396T15
23412396	1114	1119	(35)S	CHEMICAL	23412396T16
23412396	40	56	Monoacylglycerol	CHEMICAL	23412396T17
23412396	74	80	JZL184	CHEMICAL	23412396T18
23412396	1176	1181	CB(1)	GENE-Y	23412396T19
23412396	1277	1283	JZL184	CHEMICAL	23412396T1
23412396	1881	1885	MAGL	GENE-Y	23412396T20
23412396	2006	2011	CB(1)	GENE-Y	23412396T21
23412396	425	445	cannabinoid receptor	GENE-N	23412396T22
23412396	186	190	MAGL	GENE-Y	23412396T23
23412396	460	465	CB(1)	GENE-Y	23412396T24
23412396	527	532	CB(1)	GENE-Y	23412396T25
23412396	161	184	monoacylglycerol lipase	GENE-Y	23412396T26
23412396	589	593	MAGL	GENE-Y	23412396T27
23412396	1004	1009	CB(1)	GENE-Y	23412396T28
23412396	40	63	Monoacylglycerol Lipase	GENE-Y	23412396T29
23412396	1368	1374	JZL184	CHEMICAL	23412396T2
23412396	89	92	CB1	GENE-Y	23412396T30
23412396	1492	1498	JZL184	CHEMICAL	23412396T3
23412396	1565	1571	JZL184	CHEMICAL	23412396T4
23412396	1599	1605	JZL184	CHEMICAL	23412396T5
23412396	1673	1698	(9)-tetrahydrocannabinol	CHEMICAL	23412396T6
23412396	311	317	JZL184	CHEMICAL	23412396T7
23412396	1700	1703	THC	CHEMICAL	23412396T8
23412396	1750	1760	rimonabant	CHEMICAL	23412396T9
23412396	CPR:4	23412396T11	23412396T23
23412396	CPR:4	23412396T11	23412396T26
23412396	CPR:4	23412396T13	23412396T28
23412396	CPR:4	23412396T18	23412396T29

23412922|t|Differential gene expression in ER-positive and ER-negative breast cancer cells upon leptin stimulation.
23412922|a|In postmenopausal women, adipositas represents a serious risk factor for cancer development and progression. White adipose tissue secretes the 16kDa hormone leptin which plays a key role in the regulation of appetite and metabolism. An increasing number of reports indicate that leptin also interferes with signal transduction pathways implicated in the development of breast cancer. In our previous study, we identified the estrogen receptor alpha (ER) as a relevant enhancer of leptin-induced signal transduction leading to transactivation of signal transducer and activator of transcription 3 (Stat3). The purpose of this study is the investigation of specific target gene expression in response to leptin-mediated Stat3 signaling. We performed a comprehensive microarray analysis of ER-positive and ER-negative MDA-MB-231 cells upon leptin treatment and identified 49 genes which showed a significant ER-dependent regulation in leptin-treated MDA-MB-231 cells. There was no intersection with genes which were merely up- or downregulated by ER expression and only 9 and 11 genes overlapping targets which were regulated by leptin stimulation either in ER-expressing or ER-negative MDA-MB-231 cells, respectively. To demonstrate the specificity, expression of three target genes was validated by quantitative real-time PCR. In conclusion, these data imply that leptin can induce a different set of target genes dependent on ER expression, which might contribute to the development and progression of cancer diseases.
23412922	533	556	estrogen receptor alpha	GENE-Y	23412922T10
23412922	558	561	ER	GENE-Y	23412922T11
23412922	589	595	leptin	GENE-Y	23412922T12
23412922	654	704	signal transducer and activator of transcription 3	GENE-Y	23412922T13
23412922	706	711	Stat3	GENE-Y	203523|247196
23412922	811	817	leptin	GENE-Y	23412922T15
23412922	827	832	Stat3	GENE-N	203523|247196
23412922	896	899	ER	GENE-Y	23412922T17
23412922	913	916	ER	GENE-Y	23412922T18
23412922	948	954	leptin	GENE-Y	23412922T19
23412922	533	541	estrogen	CHEMICAL	23412922T1
23412922	1016	1019	ER	GENE-Y	23412922T20
23412922	1044	1050	leptin	GENE-Y	23412922T21
23412922	32	35	ER	GENE-Y	23412922T22
23412922	49	52	ER	GENE-Y	23412922T23
23412922	87	93	leptin	GENE-Y	23412922T24
23412922	1156	1159	ER	GENE-Y	23412922T2
23412922	1239	1245	leptin	GENE-Y	23412922T3
23412922	1268	1271	ER	GENE-Y	23412922T4
23412922	1286	1289	ER	GENE-Y	23412922T5
23412922	1478	1484	leptin	GENE-Y	23412922T6
23412922	1541	1544	ER	GENE-Y	23412922T7
23412922	265	271	leptin	GENE-Y	23412922T8
23412922	387	393	leptin	GENE-Y	23412922T9

23416003|t|Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors.
23416003|a|Bicyclic pyrazinone and pyrimidinone amides were designed and synthesized as potent TF-FVIIa inhibitors. SAR demonstrated that the S2 and S3 pockets of FVIIa prefer to bind small, lipophilic groups. An X-ray crystal structure of optimized compound 9b bound in the active site of FVIIa showed that the bicyclic scaffold provides 5 hydrogen bonding interactions in addition to projecting groups for interactions within the S1, S2 and S3 pockets. Compound 9b showed excellent FVIIa potency, good selectivity against FIXa, Xa, XIa and chymotrypsin, and good clotting activity.
23416003	186	191	FVIIa	GENE-Y	23416003T10
23416003	78	80	TF	GENE-Y	112876|676501
23416003	81	86	FVIIa	GENE-Y	23416003T12
23416003	99	142	Bicyclic pyrazinone and pyrimidinone amides	CHEMICAL	23416003T1
23416003	429	437	hydrogen	CHEMICAL	23416003T2
23416003	24	67	bicyclic pyrazinone and pyrimidinone amides	CHEMICAL	23416003T3
23416003	251	256	FVIIa	GENE-Y	23416003T4
23416003	378	383	FVIIa	GENE-Y	23416003T5
23416003	572	577	FVIIa	GENE-Y	23416003T6
23416003	612	625	FIXa, Xa, XIa	GENE-N	23416003T7
23416003	630	642	chymotrypsin	GENE-N	23416003T8
23416003	183	185	TF	GENE-Y	112876|676501
23416003	CPR:4	23416003T1	23416003T10
23416003	CPR:4	23416003T1	112876|676501
23416003	CPR:4	23416003T3	112876|676501
23416003	CPR:4	23416003T3	23416003T12

23416007|t|A multivalent peptide as an activator of hypoxia inducible factor-1.
23416007|a|Hypoxia inducible factor-1 (HIF-1) is a transcription factor found in mammalian cells under hypoxia. While HIF-1 in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1 is degraded under normoxia, which involves its proline hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex. Previously, peptide inhibitors against this interaction between hydroxylated HIF-1 and VBC have been developed to stabilize the transcriptional activity of HIF-1 by preventing the degradation of the protein even under normoxia. Despite the specific inhibition by these peptides, their poor inhibition potency needs to be improved for further clinical application. In this work, we have designed and prepared a streptavidin-based multivalent peptide inhibitor against the HIF-1-VBC complexation. We have evaluated the potency of the multivalent peptide in terms of stabilization of HIF-1 and the downstream effect. As the result, we have found that the inhibitor showed about 13-fold lowered IC50 value compared with that of the corresponding monovalent peptide, thereby activating HIF-1 and leading to up-regulation of VEGF protein at the cellular level.
23416007	99	105	HIF-1	GENE-N	23416007T10
23416007	427	452	von Hippel-Lindau protein	GENE-Y	23416007T11
23416007	453	462	Elongin B	GENE-Y	23416007T12
23416007	463	471	Elogin C	GENE-Y	23416007T13
23416007	473	476	VBC	GENE-N	23416007T14
23416007	564	570	HIF-1	GENE-Y	23416007T15
23416007	575	578	VBC	GENE-N	23416007T16
23416007	644	650	HIF-1	GENE-Y	23416007T17
23416007	960	966	HIF-1	GENE-Y	23416007T18
23416007	967	970	VBC	GENE-N	23416007T19
23416007	375	382	proline	CHEMICAL	23416007T1
23416007	41	68	hypoxia inducible factor-1	GENE-Y	23416007T20
23416007	70	97	Hypoxia inducible factor-1	GENE-N	23416007T2
23416007	1071	1077	HIF-1	GENE-Y	23416007T3
23416007	179	185	HIF-1	GENE-Y	23416007T4
23416007	1272	1278	HIF-1	GENE-Y	23416007T5
23416007	1311	1315	VEGF	GENE-Y	23416007T6
23416007	273	307	vascular endothelial growth factor	GENE-Y	23416007T7
23416007	309	313	VEGF	GENE-Y	23416007T8
23416007	321	327	HIF-1	GENE-Y	23416007T9

23416070|t|Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism.
23416070|a|Circulating levels of insulin and glucagon reflect the nutritional state of animals and elicit regulatory responses in the liver that maintain glucose and lipid homeostasis. The transcription factor Foxa2 activates lipid metabolism and ketogenesis during fasting and is inhibited via insulin-PI3K-Akt signaling-mediated phosphorylation at Thr156 and nuclear exclusion. Here we show that, in addition, Foxa2 is acetylated at the conserved residue Lys259 following inhibition of histone deacetylases (HDACs) class I-III and the cofactors p300 and SirT1 are involved in Foxa2 acetylation and deacetylation, respectively. Physiologically, fasting states and glucagon stimulation are sufficient to induce Foxa2 acetylation. Introduction of the acetylation-mimicking (K259Q) or -deficient (K259R) mutations promotes or inhibits Foxa2 activity, respectively, and adenoviral expression of Foxa2-K259Q augments expression of genes involved in fatty acid oxidation and ketogenesis. Our study reveals a molecular mechanism by which glucagon signaling activates a fasting response through acetylation of Foxa2.
23416070	108	116	glucagon	GENE-Y	23416070T10
23416070	475	480	Foxa2	GENE-Y	23416070T11
23416070	551	591	histone deacetylases (HDACs) class I-III	GENE-N	23416070T12
23416070	610	614	p300	GENE-Y	23416070T13
23416070	619	624	SirT1	GENE-Y	23416070T14
23416070	641	646	Foxa2	GENE-Y	23416070T15
23416070	728	736	glucagon	GENE-Y	23416070T16
23416070	774	779	Foxa2	GENE-Y	23416070T17
23416070	836	841	K259Q	GENE-N	23416070T18
23416070	858	863	K259R	GENE-N	23416070T19
23416070	217	224	glucose	CHEMICAL	23416070T1
23416070	896	901	Foxa2	GENE-Y	23416070T20
23416070	955	960	Foxa2	GENE-Y	23416070T21
23416070	961	966	K259Q	GENE-N	23416070T22
23416070	0	8	Glucagon	GENE-Y	23416070T23
23416070	32	37	Foxa2	GENE-Y	23416070T24
23416070	1008	1018	fatty acid	CHEMICAL	23416070T2
23416070	1095	1103	glucagon	GENE-Y	23416070T3
23416070	1166	1171	Foxa2	GENE-Y	23416070T4
23416070	273	278	Foxa2	GENE-Y	23416070T5
23416070	96	103	insulin	GENE-Y	23416070T6
23416070	358	365	insulin	GENE-Y	23416070T7
23416070	366	370	PI3K	GENE-N	23416070T8
23416070	371	374	Akt	GENE-N	23416070T9

23416131|t|Antitumor and immunomodulatory activity of a water-soluble low molecular weight polysaccharide from Schisandra chinensis (Turcz.) Baill.
23416131|a|A water-soluble low molecular weight polysaccharide (SCPP11) was extracted and purified using DEAE-cellulose and Sephadex G-100 column from Schisandra chinensis (Turcz.) Baill. Its in vivo and in vitro antitumor and immunomodulatory activity were investigated. The results showed that SCPP11 with a molecular weight of 3.410(3)Da exhibited indirect cyctotoxic activity against tumor cells in vitro, but could significantly inhibit the growth of Heps cells in vivo at dose of 50mg/kg, and its inhibition rate is higher than that in the positive group. Moreover, SCPP11 could ameliorate the hematological and biochemical parameters to almost normal and no significant changes in organ weight, and could increase the body weight. In addition, SCPP11 (at 50mg/kg) could also increased in thymus indexes as well as IL-2 and TNF- levels in serum in vivo and significantly enhance the phagocytosis activity and the productions of NO of RAW264.7 in vitro. The results indicated that antitumor properties of SCPP11 might be achieved by improving immune response. It could be explored as a potential adjuvant against cancer used in the health food and pharmaceutical therapy.
23416131	1062	1064	NO	CHEMICAL	427
23416131	948	952	IL-2	GENE-Y	23416131T2
23416131	957	962	TNF-	GENE-Y	23416131T3

23416191|t|Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.
23416191|a|Fragment-based drug design (FBDD) is a promising approach for the generation of lead molecules with enhanced activity and especially drug-like properties against therapeutic targets. Herein, we report the fragment-based drug design, systematic chemical synthesis and pharmacological evaluation of novel scaffolds as potent anticancer agents by utilizing six privileged fragments from known STAT3 inhibitors. Several new molecules such as compounds 5, 12, and 19 that may act as advanced chemical leads have been identified. The most potent compound 5 (HJC0123) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values. Furthermore, compound 5 significantly suppressed estrogen receptor (ER)-negative breast cancer MDA-MB-231 xenograft tumor growth invivo (p.o.), indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy.
23416191	86	91	STAT3	GENE-Y	112651
23416191	674	681	HJC0123	CHEMICAL	23416191T1
23416191	1007	1015	estrogen	CHEMICAL	23416191T2
23416191	49	56	HJC0123	CHEMICAL	23416191T3
23416191	512	517	STAT3	GENE-Y	112651
23416191	711	725	STAT3 promoter	GENE-N	23416191T5
23416191	768	773	STAT3	GENE-Y	112651
23416191	810	819	caspase-3	GENE-Y	23416191T7
23416191	1007	1024	estrogen receptor	GENE-Y	23416191T8
23416191	1026	1028	ER	GENE-Y	16226|2525
23416191	CPR:3	23416191T1	23416191T7
23416191	CPR:4	23416191T1	23416191T5
23416191	CPR:4	23416191T1	112651
23416191	CPR:4	23416191T3	112651

23416946|t|Transcription forms and remodels supercoiling domains unfolding large-scale chromatin structures.
23416946|a|DNA supercoiling is an inherent consequence of twisting DNA and is critical for regulating gene expression and DNA replication. However, DNA supercoiling at a genomic scale in human cells is uncharacterized. To map supercoiling, we used biotinylated trimethylpsoralen as a DNA structure probe to show that the human genome is organized into supercoiling domains. Domains are formed and remodeled by RNA polymerase and topoisomerase activities and are flanked by GC-AT boundaries and CTCF insulator protein-binding sites. Underwound domains are transcriptionally active and enriched in topoisomerase I, 'open' chromatin fibers and DNase I sites, but they are depleted of topoisomerase II. Furthermore, DNA supercoiling affects additional levels of chromatin compaction as underwound domains are cytologically decondensed, topologically constrained and decompacted by transcription of short RNAs. We suggest that supercoiling domains create a topological environment that facilitates gene activation, providing an evolutionary purpose for clustering genes along chromosomes.
23416946	869	887	underwound domains	GENE-N	23416946T10
23416946	33	53	supercoiling domains	GENE-N	23416946T11
23416946	335	365	biotinylated trimethylpsoralen	CHEMICAL	23416946T1
23416946	439	459	supercoiling domains	GENE-N	23416946T2
23416946	497	511	RNA polymerase	GENE-N	23416946T3
23416946	516	529	topoisomerase	GENE-N	23416946T4
23416946	581	585	CTCF	GENE-Y	64257|115906
23416946	619	637	Underwound domains	GENE-N	23416946T6
23416946	683	698	topoisomerase I	GENE-Y	23416946T7
23416946	728	735	DNase I	GENE-Y	23416946T8
23416946	768	784	topoisomerase II	GENE-Y	23416946T9

23421877|t|Four new eudesmane-type sesquiterpenoid lactones from atractylenolide II by biotransformation of rat hepatic microsomes.
23421877|a|The biotransformation of atractylenolide II, a major bioactive principle of the rhizomes of Atractylodes macrocephala Koidz., was investigated in vitro by incubation with rat hepatic microsomes pretreated with sodium phenobarbital. The biotransformation products were extracted and purified by chromatographic methods. Seven biotransformation products (BP1-BP7) were obtained and their structures were elucidated by NMR and MS data analyses and by comparison with the previously reported values, including four new compounds, namely 4(R),15-epoxy-atractylenolide II (BP1), 4(R),15-epoxy-13-hydroxyatractylenolide II (BP5), 4(R),15-epoxy-1-hydroxyatractylenolide II (BP6), and 4(R),15-dihydroxyatractylenolide II (BP7). The biotransformation pathway of atractylenolide II by hepatic microsomes was deducted based on the structure resolution of the products.
23421877	9	18	eudesmane	CHEMICAL	23421877T10
23421877	331	351	sodium phenobarbital	CHEMICAL	23421877T1
23421877	146	164	atractylenolide II	CHEMICAL	23421877T2
23421877	654	686	4(R),15-epoxy-atractylenolide II	CHEMICAL	23421877T3
23421877	694	736	4(R),15-epoxy-13-hydroxyatractylenolide II	CHEMICAL	23421877T4
23421877	744	786	4(R),15-epoxy-1-hydroxyatractylenolide II	CHEMICAL	23421877T5
23421877	798	833	4(R),15-dihydroxyatractylenolide II	CHEMICAL	23421877T6
23421877	874	892	atractylenolide II	CHEMICAL	23421877T7
23421877	24	48	sesquiterpenoid lactones	CHEMICAL	23421877T8
23421877	54	72	atractylenolide II	CHEMICAL	23421877T9

23427190|t|The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral- electroencephalography study.
23427190|a|Phosphodiesterase type 5 inhibitors (PDE5-Is) improve cognitive performance of rodents, but the few human studies investigating their effects did not systematically investigate cognitive effects and the results have been quite contradictory. Therefore, we examined whether the PDE5-I vardenafil improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults. Participants were selected out of a group of volunteers, based on their performance on a memory screening and they were orally treated with vardenafil (10-20 mg or placebo). Memory and executive functioning were tested while EEG activity was recorded. Additionally, a simple reaction time task and questionnaires addressing various complaints were presented. No prominent effects of vardenafil on cognition were found: participants only made more mistakes on a reaction time task after 20 mg vardenafil. During encoding of words, the P300 was generally smaller after vardenafil treatment. Furthermore, the N400 was larger after vardenafil 10 mg than placebo treatment in a spatial memory task at Fz. Finally, headache and feeling weak were reported more after vardenafil treatment. Vardenafil did not affect cognitive performance of healthy adults and showed only some incidental effects on ERPs. These findings in humans do not corroborate the cognition-enhancing effects of PDE5-Is in healthy animals.
23427190	153	177	Phosphodiesterase type 5	GENE-Y	23427190T10
23427190	1531	1535	PDE5	GENE-Y	23427190T11
23427190	430	434	PDE5	GENE-Y	23427190T12
23427190	190	194	PDE5	GENE-Y	23427190T13
23427190	19	43	phosphodiesterase type 5	GENE-Y	23427190T14
23427190	1183	1193	vardenafil	CHEMICAL	23427190T1
23427190	1315	1325	vardenafil	CHEMICAL	23427190T2
23427190	1337	1347	Vardenafil	CHEMICAL	852
23427190	437	447	vardenafil	CHEMICAL	23427190T4
23427190	695	705	vardenafil	CHEMICAL	23427190T5
23427190	938	948	vardenafil	CHEMICAL	23427190T6
23427190	1047	1057	vardenafil	CHEMICAL	23427190T7
23427190	1122	1132	vardenafil	CHEMICAL	23427190T8
23427190	54	64	vardenafil	CHEMICAL	23427190T9
23427190	CPR:4	23427190T4	23427190T12
23427190	CPR:4	23427190T9	23427190T14

23428346|t|Atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex.
23428346|a|Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting step in cholesterol biosynthesis. Statins effectively prevent and reduce the risk of coronary artery disease through lowering serum cholesterol, and also exert anti-thrombotic, anti-inflammatory and antioxidant effects independently of changes in cholesterol levels. On the other hand, clinical and experimental evidence suggests that abrupt cessation of statin treatment (i.e. statin withdrawal) is associated with a deleterious rebound phenomenon. In fact, statin withdrawal increases the risk of thrombotic vascular events, causes impairment of endothelium-dependent relaxation and facilitates experimental seizures. However, evidence for statin withdrawal-induced detrimental effects to the brain parenchyma is still lacking. In the present study adult male Wistar rats were treated with atorvastatin for seven days (10mg/kg/day) and neurochemical assays were performed in the cerebral cortex 30min (atorvastatin treatment) or 24h (atorvastatin withdrawal) after the last atorvastatin administration. We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex. Catalase, glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity. Immunoprecipitation of mitochondrial SOD followed by analysis of 3-nitrotyrosine revealed increased levels of nitrated mitochondrial SOD, suggesting the mechanism underlying the atorvastatin withdrawal-induced decrease in enzyme activity. Altogether, our results indicate the atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex, and that changes in NADPH oxidase activity and mitochondrial superoxide dismutase activities may underlie such harmful effects.
23428346	1463	1474	glutathione	CHEMICAL	23428346T10
23428346	1475	1476	S	CHEMICAL	127
23428346	1493	1501	xanthine	CHEMICAL	23428346T12
23428346	1541	1553	atorvastatin	CHEMICAL	23428346T13
23428346	1598	1606	carbonyl	CHEMICAL	23428346T14
23428346	1611	1630	4-hydroxy-2-nonenal	CHEMICAL	23428346T15
23428346	1714	1729	3-nitrotyrosine	CHEMICAL	23428346T16
23428346	1827	1839	atorvastatin	CHEMICAL	23428346T17
23428346	1925	1937	atorvastatin	CHEMICAL	23428346T18
23428346	2034	2039	NADPH	CHEMICAL	23428346T19
23428346	1097	1109	atorvastatin	CHEMICAL	23428346T1
23428346	2075	2085	superoxide	CHEMICAL	23428346T20
23428346	325	336	cholesterol	CHEMICAL	23428346T21
23428346	440	451	cholesterol	CHEMICAL	23428346T22
23428346	126	163	3-hydroxy-3-methylglutaryl coenzyme A	CHEMICAL	23428346T23
23428346	985	997	atorvastatin	CHEMICAL	23428346T24
23428346	0	12	Atorvastatin	CHEMICAL	1064
23428346	1273	1307	mitochondrial superoxide dismutase	GENE-Y	23428346T26
23428346	1336	1349	NADPH oxidase	GENE-N	23428346T27
23428346	1453	1461	Catalase	GENE-Y	23428346T28
23428346	1463	1488	glutathione-S-transferase	GENE-N	23428346T29
23428346	1129	1141	atorvastatin	CHEMICAL	23428346T2
23428346	1493	1509	xanthine oxidase	GENE-Y	23428346T30
23428346	1672	1689	mitochondrial SOD	GENE-Y	23428346T31
23428346	1768	1785	mitochondrial SOD	GENE-Y	23428346T32
23428346	2034	2047	NADPH oxidase	GENE-N	23428346T33
23428346	2061	2095	mitochondrial superoxide dismutase	GENE-Y	23428346T34
23428346	126	173	3-hydroxy-3-methylglutaryl coenzyme A reductase	GENE-Y	23428346T35
23428346	1169	1181	atorvastatin	CHEMICAL	23428346T3
23428346	201	212	cholesterol	CHEMICAL	23428346T4
23428346	1212	1224	atorvastatin	CHEMICAL	23428346T5
23428346	1256	1268	nitric oxide	CHEMICAL	23428346T6
23428346	1287	1297	superoxide	CHEMICAL	23428346T7
23428346	1336	1341	NADPH	CHEMICAL	23428346T8
23428346	1413	1428	3-nitrotyrosine	CHEMICAL	23428346T9
23428346	CPR:3	23428346T9	23428346T27
23428346	CPR:9	23428346T4	23428346T35

23428368|t|Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment and energy depletion.
23428368|a|This study elucidates the role of metabolic remodeling in cardiac dysfunction induced by hyperthyroidism. Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8g/100g body weight (BW), i.p.) for 15 days or along with a peroxisome proliferator-activated receptor alpha agonist bezafibrate (Bzf; 30g/100g BW, oral) and were found to improve in the Bzf co-treated condition. Ultrastructure of mitochondria was damaged in T3-treated rat heart, which was prevented by Bzf co-administration. Hyperthyroidism-induced oxidative stress, reduction in cytochrome c oxidase activity, and myocardial ATP concentration were also significantly checked by Bzf. Heart function studied at different time points during the course of T3 treatment shows an initial improvement and then a gradual but progressive decline with time, which is prevented by Bzf co-treatment. In summary, the results demonstrate that hyperthyroidism inflicts structural and functional damage to mitochondria, leading to energy depletion and cardiac dysfunction.
23428368	436	484	peroxisome proliferator-activated receptor alpha	GENE-Y	23428368T10
23428368	761	781	cytochrome c oxidase	GENE-N	23428368T11
23428368	287	297	fatty acid	CHEMICAL	23428368T1
23428368	344	360	triiodothyronine	CHEMICAL	23428368T2
23428368	493	504	bezafibrate	CHEMICAL	23428368T3
23428368	506	509	Bzf	CHEMICAL	23428368T4
23428368	566	569	Bzf	CHEMICAL	23428368T5
23428368	683	686	Bzf	CHEMICAL	23428368T6
23428368	807	810	ATP	CHEMICAL	164
23428368	860	863	Bzf	CHEMICAL	23428368T8
23428368	1052	1055	Bzf	CHEMICAL	23428368T9
23428368	CPR:5	23428368T3	23428368T10
23428368	CPR:5	23428368T4	23428368T10

23429231|t|Endothelial cell response to (co)polymer nanoparticles depending on the inflammatory environment and comonomer ratio.
23429231|a|Endothelial cells lining the lumen of blood vessels serve as a physiological barrier controlling nanoparticle movement from the vasculature into the tissue. For exploring the effect of polymer hydrophilicity on nanoparticle interactions with human umbilical vein endothelial cells (HUVECs) in vitro, a series of monomodal poly[acrylonitrile-co-(N-vinylpyrrolidone)] model nanoparticles with increasing hydrophilicity as related to their increasing content (0-30mol.%) of N-vinylpyrrolidone (NVP) were synthesized by miniemulsion polymerization. Nanoparticles with a low NVP content were rapidly endocytized into all cells independent from the particle dose with toxic effects only observed at high particle concentrations, while only 10-30% of the cells incorporated particles with 20mol.% NVP. Since pathologies are often related to inflammation, an inflammatory HUVEC culture condition with IL-1 stimulation has been introduced and suggested to be widely applied for studying nanocarriers, since cellular uptake in this assay was clearly increased for NVP contents 20mol.%. Importantly, the secretion of functional biological mediators by HUVEC was not relevantly influenced by the nanoparticles for both homeostatic and inflammatory conditions. These findings may motivate concepts for nanocarriers specifically targeted to pathologic regions. Additionally, rapidly endocytized RhodaminB loaded particles with low NVP content may be explored for cell labeling and tracking.
23429231	1174	1177	NVP	CHEMICAL	23429231T1
23429231	1502	1511	RhodaminB	CHEMICAL	23429231T2
23429231	1538	1541	NVP	CHEMICAL	23429231T3
23429231	440	483	poly[acrylonitrile-co-(N-vinylpyrrolidone)]	CHEMICAL	23429231T4
23429231	589	607	N-vinylpyrrolidone	CHEMICAL	23429231T5
23429231	609	612	NVP	CHEMICAL	23429231T6
23429231	688	691	NVP	CHEMICAL	23429231T7
23429231	909	912	NVP	CHEMICAL	23429231T8
23429231	1012	1017	IL-1	GENE-Y	23429231T9

23429911|t|Molecular mechanism regulating 24-hour rhythm of dopamine d3 receptor expression in mouse ventral striatum.
23429911|a|The dopamine D3 receptor (DRD3) in the ventral striatum is thought to influence motivation and motor functions. Although the expression of DRD3 in the ventral striatum has been shown to exhibit 24-hour variations, the mechanisms underlying the variation remain obscure. Here, we demonstrated that molecular components of the circadian clock act as regulators that control the 24-hour variation in the expression of DRD3. The transcription of DRD3 was enhanced by the retinoic acid-related orphan receptor  (ROR), and its activation was inhibited by the orphan receptor REV-ERB, an endogenous antagonist of ROR. The serum or dexamethasone-induced oscillation in the expression of DRD3 in cells was abrogated by the downregulation or overexpression of REV-ERB, suggesting that REV-ERB functions as a regulator of DRD3 oscillations in the cellular autonomous clock. Chromatin immunoprecipitation assays of the DRD3 promoter indicated that the binding of the REV-ERB protein to the DRD3 promoter increased in the early dark phase. DRD3 protein expression varied with higher levels during the dark phase. Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant. These results suggest that ROR and REV-ERB consist of a reciprocating mechanism wherein ROR upregulates the expression of DRD3, whereas REV-ERB periodically suppresses the expression at the time of day when REV-ERB is abundant. Our present findings revealed that a molecular link between the circadian clock and the function of DRD3 in the ventral striatum acts as a modulator of the pharmacological actions of DRD3 agonists/antagonists.
23429911	1429	1433	ROR	GENE-Y	23429911T10
23429911	1438	1446	REV-ERB	GENE-Y	23429911T11
23429911	1492	1496	ROR	GENE-Y	23429911T12
23429911	247	251	DRD3	GENE-Y	108148
23429911	1527	1531	DRD3	GENE-Y	108148
23429911	1541	1549	REV-ERB	GENE-Y	23429911T15
23429911	1613	1621	REV-ERB	GENE-Y	23429911T16
23429911	1735	1739	DRD3	GENE-Y	108148
23429911	1818	1822	DRD3	GENE-Y	108148
23429911	134	138	DRD3	GENE-Y	108148
23429911	1257	1295	7-hydroxy-N,N-dipropyl-2-aminotetralin	CHEMICAL	23429911T1
23429911	523	527	DRD3	GENE-Y	108148
23429911	112	132	dopamine D3 receptor	GENE-Y	23429911T21
23429911	550	554	DRD3	GENE-Y	108148
23429911	575	614	retinoic acid-related orphan receptor 	GENE-Y	23429911T23
23429911	616	620	ROR	GENE-Y	23429911T24
23429911	663	678	orphan receptor	GENE-N	23429911T25
23429911	679	687	REV-ERB	GENE-Y	23429911T26
23429911	717	721	ROR	GENE-Y	23429911T27
23429911	791	795	DRD3	GENE-Y	108148
23429911	862	870	REV-ERB	GENE-Y	23429911T29
23429911	1297	1306	7-OH-DPAT	CHEMICAL	23429911T2
23429911	888	896	REV-ERB	GENE-Y	23429911T30
23429911	925	929	DRD3	GENE-Y	108148
23429911	1021	1034	DRD3 promoter	GENE-N	23429911T32
23429911	1069	1077	REV-ERB	GENE-Y	23429911T33
23429911	1093	1106	DRD3 promoter	GENE-N	23429911T34
23429911	49	69	dopamine d3 receptor	GENE-Y	23429911T35
23429911	112	120	dopamine	CHEMICAL	23429911T3
23429911	575	588	retinoic acid	CHEMICAL	23429911T4
23429911	736	749	dexamethasone	CHEMICAL	23429911T5
23429911	49	57	dopamine	CHEMICAL	23429911T6
23429911	1142	1146	DRD3	GENE-Y	108148
23429911	1244	1248	DRD3	GENE-Y	108148
23429911	1373	1377	DRD3	GENE-Y	108148
23429911	CPR:5	23429911T1	108148
23429911	CPR:5	23429911T1	108148
23429911	CPR:5	23429911T2	108148
23429911	CPR:5	23429911T2	108148

23432124|t|Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor antagonist IKM-159: asymmetric synthesis, neuroactivity, and structural characterization.
23432124|a|IKM-159 was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as AMPA receptor-selective antagonists. However, it was not known which enantiomer of IKM-159 was responsible for its pharmacological activities. Here, we report in vivo and in vitro neuronal activities of both enantiomers of IKM-159 prepared by enantioselective asymmetric synthesis. By employment of (R)-2-amino-2-(4-methoxyphenyl)ethanol as a chiral auxiliary, (2R)-IKM-159 and the (2S)-counterpart were successfully synthesized in 0.70% and 1.5% yields, respectively, over a total of 18 steps. Both behavioral and electrophysiological assays showed that the biological activity observed for the racemic mixture was reproduced only with (2R)-IKM-159, whereas the (2S)-counterpart was inactive in both assays. Racemic IKM-159 was crystallized with the ligand-binding domain of GluA2, and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site. (2R)-IKM-159 locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.
23432124	1128	1140	(2R)-IKM-159	CHEMICAL	23432124T10
23432124	1172	1184	(2R)-IKM-159	CHEMICAL	23432124T11
23432124	103	110	IKM-159	CHEMICAL	23432124T12
23432124	14	75	(S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid	CHEMICAL	23432124T13
23432124	77	81	AMPA	CHEMICAL	23432124T14
23432124	1195	1200	GluA2	GENE-Y	23432124T15
23432124	1288	1302	AMPA receptors	GENE-N	23432124T16
23432124	297	310	AMPA receptor	GENE-N	23432124T17
23432124	1073	1078	GluA2	GENE-Y	23432124T18
23432124	76	91	(AMPA) receptor	GENE-N	23432124T19
23432124	182	189	IKM-159	CHEMICAL	23432124T1
23432124	297	301	AMPA	CHEMICAL	23432124T2
23432124	380	387	IKM-159	CHEMICAL	23432124T3
23432124	520	527	IKM-159	CHEMICAL	23432124T4
23432124	596	634	(R)-2-amino-2-(4-methoxyphenyl)ethanol	CHEMICAL	23432124T5
23432124	658	670	(2R)-IKM-159	CHEMICAL	23432124T6
23432124	934	946	(2R)-IKM-159	CHEMICAL	23432124T7
23432124	1006	1021	Racemic IKM-159	CHEMICAL	23432124T8
23432124	265	274	glutamate	CHEMICAL	23432124T9
23432124	CPR:4	23432124T11	23432124T15
23432124	CPR:6	23432124T11	23432124T16
23432124	CPR:6	23432124T12	23432124T19
23432124	CPR:6	23432124T1	23432124T17
23432124	CPR:6	23432124T9	23432124T17

23432429|t|Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition.
23432429|a|A total of 68 chemicals including derivatives of naphthalene, phenanthrene, fluoranthene, pyrene, biphenyl, and flavone were examined for their abilities to interact with human P450s 2A13 and 2A6. Fifty-one of these 68 chemicals induced stronger Type I binding spectra (iron low- to high-spin state shift) with P450 2A13 than those seen with P450 2A6, i.e., the spectral binding intensities (Amax/Ks ratio) determined with these chemicals were always higher for P450 2A13. In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with P450 2A13. Coumarin 7-hydroxylation, catalyzed by P450 2A13, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values. On the basis of the intensities of the spectral changes and inhibition of P450 2A13, we classified the 68 chemicals into eight groups based on the order of affinities for these chemicals and inhibition of P450 2A13. The metabolism of chemicals by P450 2A13 during the assays explained why some of the chemicals that bound well were poor inhibitors of P450 2A13. Finally, we compared the 68 chemicals for their abilities to induce Type I spectral changes of P450 2A13 with the Reverse Type I binding spectra observed with P450 1B1: 45 chemicals interacted with both P450s 2A13 and 1B1, indicating that the two enzymes have some similarty of structural features regarding these chemicals. Molecular docking analyses suggest similarities at the active sites of these P450 enzymes. These results indicate that P450 2A13, as well as Family 1 P450 enzymes, is able to catalyze many detoxication and activation reactions with chemicals of environmental interest.
23432429	622	634	fluoranthene	CHEMICAL	23432429T10
23432429	636	673	2,3-dihydroxy-2,3-dihydrofluoranthene	CHEMICAL	23432429T11
23432429	675	681	pyrene	CHEMICAL	23432429T12
23432429	683	698	1-hydroxypyrene	CHEMICAL	23432429T13
23432429	700	713	1-nitropyrene	CHEMICAL	23432429T14
23432429	715	729	1-acetylpyrene	CHEMICAL	23432429T15
23432429	731	745	2-acetylpyrene	CHEMICAL	23432429T16
23432429	175	187	phenanthrene	CHEMICAL	23432429T17
23432429	747	776	2,5,2',5'-tetrachlorobiphenyl	CHEMICAL	23432429T18
23432429	778	794	7-hydroxyflavone	CHEMICAL	23432429T19
23432429	1127	1136	flavanone	CHEMICAL	23432429T1
23432429	796	803	chrysin	CHEMICAL	23432429T20
23432429	809	817	galangin	CHEMICAL	23432429T21
23432429	189	201	fluoranthene	CHEMICAL	23432429T22
23432429	885	893	Coumarin	CHEMICAL	23432429T23
23432429	961	992	2'-methoxy-5,7-dihydroxyflavone	CHEMICAL	23432429T24
23432429	994	1014	2-ethynylnaphthalene	CHEMICAL	23432429T25
23432429	1016	1033	2'-methoxyflavone	CHEMICAL	23432429T26
23432429	203	209	pyrene	CHEMICAL	23432429T27
23432429	1035	1066	2-naphththalene propargyl ether	CHEMICAL	23432429T28
23432429	1068	1080	acenaphthene	CHEMICAL	23432429T29
23432429	1138	1145	chrysin	CHEMICAL	23432429T2
23432429	1082	1096	acenaphthylene	CHEMICAL	23432429T30
23432429	211	219	biphenyl	CHEMICAL	23432429T31
23432429	1098	1109	naphthalene	CHEMICAL	23432429T32
23432429	1111	1125	1-acetylpyrene	CHEMICAL	23432429T33
23432429	1343	1352	P450 2A13	GENE-Y	23432429T34
23432429	1474	1483	P450 2A13	GENE-Y	23432429T35
23432429	1516	1525	P450 2A13	GENE-Y	23432429T36
23432429	1620	1629	P450 2A13	GENE-Y	23432429T37
23432429	1726	1735	P450 2A13	GENE-Y	23432429T38
23432429	1790	1798	P450 1B1	GENE-Y	23432429T39
23432429	1147	1168	3-ethynylphenanthrene	CHEMICAL	23432429T3
23432429	284	308	human P450s 2A13 and 2A6	GENE-N	23432429T40
23432429	1834	1852	P450s 2A13 and 1B1	GENE-N	23432429T41
23432429	2033	2045	P450 enzymes	GENE-N	23432429T42
23432429	2075	2084	P450 2A13	GENE-Y	23432429T43
23432429	2106	2118	P450 enzymes	GENE-N	23432429T44
23432429	424	433	P450 2A13	GENE-Y	23432429T45
23432429	455	463	P450 2A6	GENE-N	23432429T46
23432429	576	585	P450 2A13	GENE-Y	23432429T47
23432429	874	883	P450 2A13	GENE-Y	23432429T48
23432429	924	933	P450 2A13	GENE-Y	23432429T49
23432429	1170	1177	flavone	CHEMICAL	23432429T4
23432429	48	89	Human Cytochromes P450 2A13, 2A6, and 1B1	GENE-N	23432429T50
23432429	1183	1199	7-hydroxyflavone	CHEMICAL	23432429T5
23432429	225	232	flavone	CHEMICAL	23432429T6
23432429	383	387	iron	CHEMICAL	23432429T7
23432429	600	620	benzo[c]phenanthrene	CHEMICAL	23432429T8
23432429	162	173	naphthalene	CHEMICAL	23432429T9
23432429	CPR:4	23432429T1	23432429T49
23432429	CPR:4	23432429T24	23432429T49
23432429	CPR:4	23432429T25	23432429T49
23432429	CPR:4	23432429T26	23432429T49
23432429	CPR:4	23432429T28	23432429T49
23432429	CPR:4	23432429T29	23432429T49
23432429	CPR:4	23432429T2	23432429T49
23432429	CPR:4	23432429T30	23432429T49
23432429	CPR:4	23432429T32	23432429T49
23432429	CPR:4	23432429T33	23432429T49
23432429	CPR:4	23432429T3	23432429T49
23432429	CPR:4	23432429T4	23432429T49
23432429	CPR:4	23432429T5	23432429T49
23432429	CPR:9	23432429T23	23432429T49

23432662|t|Discovery of a Novel Selective PPAR Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow.
23432662|a|Full agonists to the peroxisome proliferator-activated receptor (PPAR), such as Rosiglitazone, have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity. Nevertheless, PPAR is involved in the expression of genes that control glucose and lipid metabolism and is an important target for drugs against type 2 diabetes, dyslipidemia, atherosclerosis, and cardiovascular disease. In an effort to identify novel PPAR ligands with an improved pharmacological profile, emphasis has shifted to selective ligands with partial agonist binding properties. Toward this end we applied an integrated in silico/in vitro workflow, based on pharmacophore- and structure-based virtual screening of the ZINC library, coupled with competitive binding and transactivation assays, and adipocyte differentiation and gene expression studies. Hit compound 9 was identified as the most potent ligand (IC50 = 0.3 M) and a relatively poor inducer of adipocyte differentiation. The binding mode of compound 9 was confirmed by molecular dynamics simulation, and the calculated free energy of binding was -8.4 kcal/mol. A novel functional group, the carbonitrile group, was identified to be a key substituent in the ligand-protein interactions. Further studies on the transcriptional regulation properties of compound 9 revealed a gene regulatory profile that was to a large extent unique, however functionally closer to that of a partial agonist.
23432662	1332	1344	carbonitrile	CHEMICAL	23432662T1
23432662	437	444	glucose	CHEMICAL	23432662T2
23432662	209	222	Rosiglitazone	CHEMICAL	404
23432662	149	199	peroxisome proliferator-activated receptor (PPAR)	GENE-Y	23432662T4
23432662	379	384	PPAR	GENE-Y	23432662T5
23432662	618	623	PPAR	GENE-Y	23432662T6
23432662	31	36	PPAR	GENE-Y	23432662T7
23432662	CPR:5	404	23432662T4

23434648|t|Structural Characterization of an LPA1 Second Extracellular Loop Mimetic with a Self-Assembling Coiled-Coil Folding Constraint.
23434648|a|G protein-coupled receptor (GPCR) structures are of interest as a means to understand biological signal transduction and as tools for therapeutic discovery. The growing number of GPCR crystal structures demonstrates that the extracellular loops (EL) connecting the membrane-spanning helices show tremendous structural variability relative to the more structurally-conserved seven transmembrane -helical domains. The EL of the LPA(1) receptor have not yet been conclusively resolved, and bear limited sequence identity to known structures. This study involved development of a peptide to characterize the intrinsic structure of the LPA(1) GPCR second EL. The loop was embedded between two helices that assemble into a coiled-coil, which served as a receptor-mimetic folding constraint (LPA(1)-CC-EL2 peptide). The ensemble of structures from multi-dimensional NMR experiments demonstrated that a robust coiled-coil formed without noticeable deformation due to the EL2 sequence. In contrast, the EL2 sequence showed well-defined structure only near its C-terminal residues. The NMR ensemble was combined with a computational model of the LPA(1) receptor that had previously been validated. The resulting hybrid models were evaluated using docking. Nine different hybrid models interacted with LPA 18:1 as expected, based on prior mutagenesis studies, and one was additionally consistent with antagonist affinity trends.
23434648	353	372	extracellular loops	GENE-N	23434648T10
23434648	374	376	EL	GENE-N	23434648T11
23434648	393	418	membrane-spanning helices	GENE-N	23434648T12
23434648	156	160	GPCR	GENE-N	26950
23434648	522	539	-helical domains	GENE-N	23434648T14
23434648	545	547	EL	GENE-N	23434648T15
23434648	555	561	LPA(1)	GENE-Y	23434648T16
23434648	760	766	LPA(1)	GENE-Y	23434648T17
23434648	767	771	GPCR	GENE-N	26950
23434648	779	781	EL	GENE-N	23434648T19
23434648	1180	1181	C	CHEMICAL	23434648T1
23434648	846	857	coiled-coil	GENE-N	23434648T20
23434648	914	920	LPA(1)	GENE-Y	23434648T21
23434648	924	927	EL2	GENE-N	23434648T22
23434648	1031	1042	coiled-coil	GENE-N	23434648T23
23434648	1092	1095	EL2	GENE-N	23434648T24
23434648	1123	1126	EL2	GENE-N	23434648T25
23434648	34	38	LPA1	GENE-Y	24585
23434648	39	64	Second Extracellular Loop	GENE-N	23434648T27
23434648	96	107	Coiled-Coil	GENE-N	23434648T28
23434648	1265	1268	LPA	CHEMICAL	23434648T2
23434648	1420	1423	LPA	CHEMICAL	23434648T3
23434648	555	558	LPA	CHEMICAL	23434648T4
23434648	760	763	LPA	CHEMICAL	23434648T5
23434648	914	917	LPA	CHEMICAL	23434648T6
23434648	128	154	G protein-coupled receptor	GENE-N	23434648T7
23434648	1265	1271	LPA(1)	GENE-Y	23434648T8
23434648	307	311	GPCR	GENE-N	26950

23435615|t|The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
23435615|a|PURPOSE: Omeprazole has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with cytochrome P450 (CYP) 2C19 genotype groups. The aim of this study was to investigate whether the 1-point, 4-h postdose (R)-omeprazole hydroxylation index (HI) of racemic omeprazole reflects the three CYP2C19 genotype groups in Japanese individuals. METHODS: Ninety healthy Japanese individuals were enrolled and classified into the three different CYP2C19 genotype groups: homozygous extensive metabolizers (hmEMs; n=34), heterozygous EMs (htEMs; n=44), and poor metabolizers (PMs; n=12). Blood samples were drawn 4h after the intake of an oral dose of omeprazole 40mg, and plasma levels of omeprazole and its metabolites were analyzed by high-performance liquid chromatography (HPLC) using a chiral column. RESULTS: Mean plasma concentrations of (R)- and (S)-omeprazole in PMs were significantly higher than those in hmEMs and htEMs, and similar results were obtained in the case of omeprazole sulfone. Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among CYP2C19 genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole. Similarly, (R)-omeprazole HI in hmEMs, htEMs, and PMs were 5.6, 3.1, and 0.3, respectively, which were significantly different, but no significant difference was present in the (S)-omeprazole HI. CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with CYP2C19 genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.
23435615	773	783	omeprazole	CHEMICAL	23435615T10
23435615	812	822	omeprazole	CHEMICAL	23435615T11
23435615	968	991	(R)- and (S)-omeprazole	CHEMICAL	23435615T12
23435615	106	116	Omeprazole	CHEMICAL	330
23435615	4	18	(R)-omeprazole	CHEMICAL	23435615T14
23435615	1232	1239	CYP2C19	GENE-Y	107935
23435615	213	239	cytochrome P450 (CYP) 2C19	GENE-Y	23435615T16
23435615	1621	1628	CYP2C19	GENE-Y	107935
23435615	1742	1749	CYP2C19	GENE-Y	107935
23435615	413	420	CYP2C19	GENE-Y	107935
23435615	1105	1123	omeprazole sulfone	CHEMICAL	23435615T1
23435615	561	568	CYP2C19	GENE-Y	107935
23435615	48	55	CYP2C19	GENE-Y	107935
23435615	1202	1225	(R)-5-hydroxyomeprazole	CHEMICAL	23435615T2
23435615	1317	1340	(S)-5-hydroxyomeprazole	CHEMICAL	23435615T3
23435615	1353	1367	(R)-omeprazole	CHEMICAL	23435615T4
23435615	1519	1533	(S)-omeprazole	CHEMICAL	726
23435615	1580	1594	(R)-omeprazole	CHEMICAL	23435615T6
23435615	1650	1668	racemic-omeprazole	CHEMICAL	23435615T7
23435615	332	346	(R)-omeprazole	CHEMICAL	23435615T8
23435615	375	393	racemic omeprazole	CHEMICAL	23435615T9
23435615	CPR:9	330	23435615T16
23435615	CPR:9	23435615T14	107935
23435615	CPR:9	23435615T2	107935
23435615	CPR:9	23435615T3	107935
23435615	CPR:9	23435615T6	107935
23435615	CPR:9	23435615T7	107935

23439660|t|Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
23439660|a|Perturbations of the expression of transporters and drug-metabolizing enzymes (DMEs) by opioids can be the locus of deleterious drug-drug interactions (DDIs). Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs. The objective of this study was to determine the influence of oxycodone administration (15 mg/kg intraperitoneally twice daily for 8 days) on liver expression of XRs, transporters, and DMEs in rats. Microarray, quantitative real-time polymerase chain reaction and immunoblotting analyses were used to identify significantly regulated genes. Three XRs (e.g., PXR, CAR, and AhR), 27 transporters (e.g., ABCB1 and SLC22A8), and 19 DMEs (e.g., CYP2B2 and CYP3A1) were regulated (P < 0.05) with fold changes ranging from -46.3 to 17.1. Using MetaCore (computational platform), we identified a unique gene-network of transporters and DMEs assembled around PXR, CAR, and AhR. Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by oxycodone or its major metabolites (noroxycodone and oxymorphone). Neither oxycodone nor its metabolites activated PXR, CAR, or AhR. Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that oxycodone alters the expression of many transporters and DMEs (without direct activation of PXR, CAR, and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.
23439660	582	591	oxycodone	CHEMICAL	23439660T10
23439660	82	91	oxycodone	CHEMICAL	23439660T11
23439660	1170	1173	PXR	GENE-Y	23439660T12
23439660	1175	1178	CAR	GENE-Y	23439660T13
23439660	1184	1187	AhR	GENE-Y	23439660T14
23439660	1364	1367	PXR	GENE-Y	23439660T15
23439660	1369	1372	CAR	GENE-Y	23439660T16
23439660	1377	1380	AhR	GENE-Y	23439660T17
23439660	1499	1502	PXR	GENE-Y	23439660T18
23439660	1504	1507	CAR	GENE-Y	23439660T19
23439660	1384	1393	oxycodone	CHEMICAL	23439660T1
23439660	1512	1515	AhR	GENE-Y	23439660T20
23439660	1761	1764	PXR	GENE-Y	23439660T21
23439660	1766	1769	CAR	GENE-Y	23439660T22
23439660	1775	1778	AhR	GENE-Y	23439660T23
23439660	296	316	xenobiotic receptors	GENE-N	23439660T24
23439660	318	321	XRs	GENE-N	23439660T25
23439660	329	348	pregnane X receptor	GENE-Y	23439660T26
23439660	350	353	PXR	GENE-Y	23439660T27
23439660	356	388	constitutive androstane receptor	GENE-Y	23439660T28
23439660	390	393	CAR	GENE-Y	23439660T29
23439660	1420	1432	noroxycodone	CHEMICAL	23439660T2
23439660	400	425	Aryl hydrocarbon receptor	GENE-Y	23439660T30
23439660	427	430	AhR	GENE-Y	23439660T31
23439660	515	518	XRs	GENE-N	23439660T32
23439660	682	685	XRs	GENE-N	23439660T33
23439660	867	870	XRs	GENE-N	23439660T34
23439660	878	881	PXR	GENE-Y	23439660T35
23439660	883	886	CAR	GENE-Y	23439660T36
23439660	892	895	AhR	GENE-Y	23439660T37
23439660	921	926	ABCB1	GENE-Y	3609|111262
23439660	931	938	SLC22A8	GENE-Y	114777
23439660	1437	1448	oxymorphone	CHEMICAL	23439660T3
23439660	960	966	CYP2B2	GENE-Y	23439660T40
23439660	971	977	CYP3A1	GENE-Y	23439660T41
23439660	13	33	xenobiotic receptors	GENE-N	23439660T42
23439660	1459	1468	oxycodone	CHEMICAL	23439660T4
23439660	1615	1624	oxycodone	CHEMICAL	23439660T5
23439660	1669	1678	oxycodone	CHEMICAL	23439660T6
23439660	1887	1896	oxycodone	CHEMICAL	23439660T7
23439660	369	379	androstane	CHEMICAL	23439660T8
23439660	400	416	Aryl hydrocarbon	CHEMICAL	23439660T9

23439872|t|Strain-dependent dysregulation of one-carbon metabolism in male mice is associated with choline- and folate-deficient diet-induced liver injury.
23439872|a|Dysregulation of one-carbon metabolism-related metabolic processes is a major contributor to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). It is well established that genetic and gender-specific variations in one-carbon metabolism contribute to the vulnerability to NAFLD in humans. To examine the role of one-carbon metabolism dysregulation in the pathogenesis and individual susceptibility to NAFLD, we used a "population-based" mouse model where male mice from 7 inbred were fed a choline- and folate-deficient (CFD) diet for 12 wk. Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1 (Mat1a), cystathionine--synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed. These changes were strongly associated with interstrain variability in liver injury (steatosis, necrosis, inflammation, and activation of fibrogenesis) and hyperhomocysteinemia. Mechanistically, the decreased expression of Mat1a, Ahcy, and Mthfd1 was linked to a reduced level and promoter binding of transcription factor CCAAT/enhancer binding protein  (CEBP), which directly regulates their transcription. The strain specificity of diet-induced dysregulation of one-carbon metabolism suggests that interstrain variation in the regulation of one-carbon metabolism may contribute to the differential vulnerability to NFLD and that correcting the imbalance may be considered as preventive and treatment strategies for NAFLD.-Pogribny, I. P., Kutanzi, K., Melnyk, S., de Conti, A., Tryndyak, V., Montgomery, B., Pogribna, M., Muskhelishvili, L., Latendresse, J. R., James, S. J., Beland, F. A., Rusyn, I. Strain-dependent dysregulation of one-carbon metabolism in male mice is associated with choline- and folate-deficient diet-induced liver injury.
23439872	658	664	folate	CHEMICAL	23439872T10
23439872	749	755	carbon	CHEMICAL	23439872T11
23439872	784	794	methionine	CHEMICAL	23439872T12
23439872	827	840	cystathionine	CHEMICAL	23439872T13
23439872	859	884	methylenetetrahydrofolate	CHEMICAL	23439872T14
23439872	904	912	adenosyl	CHEMICAL	23439872T15
23439872	940	965	methylenetetrahydrofolate	CHEMICAL	23439872T16
23439872	101	107	folate	CHEMICAL	23439872T17
23439872	38	44	carbon	CHEMICAL	23439872T18
23439872	88	95	choline	CHEMICAL	23439872T19
23439872	1476	1482	carbon	CHEMICAL	23439872T1
23439872	1229	1234	Mat1a	GENE-Y	247370|198092
23439872	1236	1240	Ahcy	GENE-Y	248089|234644
23439872	1246	1252	Mthfd1	GENE-Y	223871|249015
23439872	1328	1360	CCAAT/enhancer binding protein 	GENE-Y	23439872T23
23439872	1362	1367	CEBP	GENE-Y	23439872T24
23439872	784	817	methionine adenosyltransferase 1	GENE-Y	23439872T25
23439872	819	824	Mat1a	GENE-Y	247370|198092
23439872	827	851	cystathionine--synthase	GENE-Y	23439872T27
23439872	853	856	Cbs	GENE-Y	59367|198533
23439872	859	894	methylenetetrahydrofolate reductase	GENE-Y	23439872T29
23439872	1555	1561	carbon	CHEMICAL	23439872T2
23439872	896	901	Mthfr	GENE-Y	23439872T30
23439872	904	927	adenosyl-homocysteinase	GENE-Y	23439872T31
23439872	929	933	Ahcy	GENE-Y	248089|234644
23439872	940	981	methylenetetrahydrofolate dehydrogenase 1	GENE-Y	23439872T33
23439872	983	989	Mthfd1	GENE-Y	223871|249015
23439872	1949	1955	carbon	CHEMICAL	23439872T3
23439872	1999	2006	choline	CHEMICAL	23439872T4
23439872	2012	2018	folate	CHEMICAL	23439872T5
23439872	166	172	carbon	CHEMICAL	23439872T6
23439872	374	380	carbon	CHEMICAL	23439872T7
23439872	471	477	carbon	CHEMICAL	23439872T8
23439872	645	652	choline	CHEMICAL	23439872T9

23440512|t|Vitamin A and retinoid signaling: genomic and non-genomic effects.
23440512|a|Vitamin A or retinol is arguably the most multifunctional vitamin in the human body as it is essential from embryogenesis to adulthood. The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR/), polymorphic retinoic acid (RA) response elements and multiple coregulators. It also involves extra nuclear and non-transcriptional effects such as the activation of kinase cascades, which are integrated in the nucleus via the phosphorylation of several actors of RA signaling. However, vitamin A itself proved recently to be active and RARs to be present in the cytosol to regulate translation and cell plasticity. All these new concepts expand the scope of the biologic functions of vitamin A and RA.
23440512	0	9	Vitamin A	CHEMICAL	156
23440512	14	22	retinoid	CHEMICAL	23440512T11
23440512	405	422	nuclear receptors	GENE-N	23440512T12
23440512	424	428	RARs	GENE-N	23440512T13
23440512	430	434	RXRs	GENE-N	23440512T14
23440512	439	446	PPAR/	GENE-N	23440512T15
23440512	449	497	polymorphic retinoic acid (RA) response elements	GENE-N	23440512T16
23440512	614	620	kinase	GENE-N	23440512T17
23440512	785	789	RARs	GENE-N	23440512T18
23440512	67	76	Vitamin A	CHEMICAL	156
23440512	80	87	retinol	CHEMICAL	23440512T2
23440512	230	239	vitamin A	CHEMICAL	23440512T3
23440512	285	308	all-trans retinoic acid	CHEMICAL	23440512T4
23440512	310	314	atRA	CHEMICAL	23440512T5
23440512	461	474	retinoic acid	CHEMICAL	23440512T6
23440512	125	132	vitamin	CHEMICAL	23440512T7
23440512	735	744	vitamin A	CHEMICAL	23440512T8
23440512	933	942	vitamin A	CHEMICAL	23440512T9
23440512	CPR:3	23440512T4	23440512T12
23440512	CPR:3	23440512T4	23440512T13
23440512	CPR:3	23440512T4	23440512T14
23440512	CPR:3	23440512T4	23440512T16
23440512	CPR:3	23440512T5	23440512T12
23440512	CPR:3	23440512T5	23440512T13
23440512	CPR:3	23440512T5	23440512T14
23440512	CPR:3	23440512T5	23440512T16

23441017|t|Phase stability and elastic properties of chromium borides with various stoichiometries.
23441017|a|Phase stability is important to the application of materials. By first-principles calculations, we establish the phase stability of chromium borides with various stoichiometries. Moreover, the phases of CrB3 and CrB4 have been predicted by using a newly developed particle swarm optimization (PSO) algorithm. Formation enthalpy-pressure diagrams reveal that the MoB-type structure is more energetically favorable than the TiI-type structure for CrB. For CrB2 , the WB2 -type structure is preferred at zero pressure. The predicted new phase of CrB3 belongs to the hexagonal P-6m2 space group and it transforms into an orthorhombic phase as the pressure exceeds 93 GPa. The predicted CrB4 (space group: Pnnm) phase is more energetically favorable than the previously proposed Immm structure. The mechanical and thermodynamic stabilities of predicted CrB3 and CrB4 are verified by the calculated elastic constants and formation enthalpies. The full phonon dispersion calculations confirm the dynamic stability of WB2 -type CrB2 and predicted CrB3 . The large shear moduli, large Young's moduli, low Poisson ratios, and low bulk and shear modulus ratios of CrB4 PSC and CrB4 PSD indicate that they are potential hard materials. Analyses of Debye temperature, electronic localization function, and electronic structure provide further understanding of the chemical and physical properties of these borides.
23441017	511	514	TiI	CHEMICAL	23441017T10
23441017	534	537	CrB	CHEMICAL	23441017T11
23441017	543	547	CrB2	CHEMICAL	23441017T12
23441017	554	557	WB2	CHEMICAL	23441017T13
23441017	632	636	CrB3	CHEMICAL	23441017T14
23441017	771	775	CrB4	CHEMICAL	23441017T15
23441017	937	941	CrB3	CHEMICAL	23441017T16
23441017	946	950	CrB4	CHEMICAL	23441017T17
23441017	42	58	chromium borides	CHEMICAL	23441017T18
23441017	1099	1102	WB2	CHEMICAL	23441017T1
23441017	1109	1113	CrB2	CHEMICAL	23441017T2
23441017	1128	1132	CrB3	CHEMICAL	23441017T3
23441017	1242	1246	CrB4	CHEMICAL	23441017T4
23441017	1256	1260	CrB4	CHEMICAL	23441017T5
23441017	221	237	chromium borides	CHEMICAL	23441017T6
23441017	292	296	CrB3	CHEMICAL	23441017T7
23441017	301	305	CrB4	CHEMICAL	23441017T8
23441017	451	454	MoB	CHEMICAL	23441017T9

23443810|t|Effect of miR-21 on Renal Fibrosis by Regulating MMP-9 and TIMP1 in kk-ay Diabetic Nephropathy Mice.
23443810|a|MicroRNAs (miRs) play important roles in initiation and progression of many pathologic processes. However, the roles of miRs in diabetic nephropathy remain unclear. This study was to determine whether miR-21 was involved in diabetic nephropathy and to explore the relationship between miR-21 and MMP9/TIMP1 expression in diabetic nephropathy. In situ hybridization studies showed that miR-21 was primarily localized and distributed in cortical glomerular and renal tubular cells in diabetic kk-ay kidney. Real-time quantitative RT-PCR demonstrated that the expression of miR-21 was significantly increased in kk-ay mice, compared with control C57BL mice. Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein. Importantly, antagomir-21 not only ameliorated Ccr and ACR but also decreased TIMP1, ColIV, and FN proteins. In conclusion, our data demonstrate that miR-21 contributes to renal fibrosis by mediating MMP9/TIMP1 and that inhibition of miR-21 may be a novel target for diabetic nephropathy.
23443810	402	407	TIMP1	GENE-Y	112932
23443810	486	492	miR-21	GENE-Y	23443810T11
23443810	672	678	miR-21	GENE-Y	23443810T12
23443810	771	777	miR-21	GENE-Y	23443810T13
23443810	822	829	albumin	GENE-Y	23443810T14
23443810	852	857	TIMP1	GENE-Y	112932
23443810	859	870	collagen IV	GENE-N	23443810T16
23443810	872	877	ColIV	GENE-N	23443810T17
23443810	884	895	fibronectin	GENE-Y	23443810T18
23443810	897	899	FN	GENE-Y	23443810T19
23443810	830	838	creatine	CHEMICAL	23443810T1
23443810	970	975	MMP-9	GENE-Y	23443810T20
23443810	1063	1068	TIMP1	GENE-Y	112932
23443810	1070	1075	ColIV	GENE-N	23443810T22
23443810	1081	1083	FN	GENE-Y	23443810T23
23443810	10	16	miR-21	GENE-Y	23443810T24
23443810	49	54	MMP-9	GENE-Y	23443810T25
23443810	59	64	TIMP1	GENE-Y	112932
23443810	935	943	creatine	CHEMICAL	23443810T2
23443810	1135	1141	miR-21	GENE-Y	23443810T3
23443810	1185	1189	MMP9	GENE-Y	110461
23443810	1190	1195	TIMP1	GENE-Y	112932
23443810	1219	1225	miR-21	GENE-Y	23443810T6
23443810	302	308	miR-21	GENE-Y	23443810T7
23443810	386	392	miR-21	GENE-Y	23443810T8
23443810	397	401	MMP9	GENE-Y	110461
23443810	CPR:3	23443810T1	23443810T13
23443810	CPR:4	23443810T2	23443810T13

23444386|t|Modification of the Catalytic Function of Human Hydroxysteroid Sulfotransferase hSULT2A1 by Formation of Disulfide Bonds.
23444386|a|The human cytosolic sulfotransferase hSULT2A1 catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and bile acids. Reversible modulation of the catalytic activity of this enzyme could play important roles in its physiologic functions. Whereas other mammalian sulfotransferases are known to be reversibly altered by changes in their redox environment, this has not been previously shown for hSULT2A1. We have examined the hypothesis that the formation of disulfide bonds in hSULT2A1 can reversibly regulate the catalytic function of the enzyme. Three thiol oxidants were used as model compounds to investigate their effects on homogeneous preparations of hSULT2A1: glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) (diamide). Examination of the effects of disulfide bond formation with these agents indicated that the activity of the enzyme is reversibly altered. Studies on the kinetics of the hSULT2A1-catalyzed sulfation of dehydroepiandrosterone (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme. The effects of these agents on the binding of substrates and products, liquid chromatography-mass spectrometry identification of the disulfides formed, and structural modeling of the modified enzyme were examined. Our results indicate that conformational changes at cysteines near the nucleotide binding site affect the binding of both the nucleotide and DHEA to the enzyme, with the specific effects dependent on the structure of the resulting disulfide. Thus, the formation of disulfide bonds in hSULT2A1 is a potentially important reversible mechanism for alterations in the rates of sulfation of both endogenous and xenobiotic substrates.
23444386	1630	1634	DHEA	CHEMICAL	1643
23444386	1720	1729	disulfide	CHEMICAL	23444386T11
23444386	1754	1763	disulfide	CHEMICAL	23444386T12
23444386	618	627	disulfide	CHEMICAL	23444386T13
23444386	714	719	thiol	CHEMICAL	23444386T14
23444386	828	849	glutathione disulfide	CHEMICAL	23444386T15
23444386	851	886	5,5'-dithiobis(2-nitrobenzoic acid)	CHEMICAL	23444386T16
23444386	892	925	1,1'-azobis(N,N-dimethylformamide	CHEMICAL	23444386T17
23444386	928	935	diamide	CHEMICAL	23444386T18
23444386	968	977	disulfide	CHEMICAL	23444386T19
23444386	1139	1161	dehydroepiandrosterone	CHEMICAL	23444386T1
23444386	105	114	Disulfide	CHEMICAL	23444386T20
23444386	48	62	Hydroxysteroid	CHEMICAL	23444386T21
23444386	1773	1781	hSULT2A1	GENE-Y	23444386T22
23444386	413	440	mammalian sulfotransferases	GENE-N	23444386T23
23444386	554	562	hSULT2A1	GENE-Y	23444386T24
23444386	126	167	human cytosolic sulfotransferase hSULT2A1	GENE-Y	23444386T25
23444386	637	645	hSULT2A1	GENE-Y	23444386T26
23444386	818	826	hSULT2A1	GENE-Y	23444386T27
23444386	1107	1115	hSULT2A1	GENE-Y	23444386T28
23444386	42	88	Human Hydroxysteroid Sulfotransferase hSULT2A1	GENE-Y	23444386T29
23444386	1163	1167	DHEA	CHEMICAL	1643
23444386	1191	1200	disulfide	CHEMICAL	23444386T3
23444386	247	262	hydroxysteroids	CHEMICAL	23444386T4
23444386	1408	1418	disulfides	CHEMICAL	23444386T5
23444386	1541	1550	cysteines	CHEMICAL	23444386T6
23444386	1560	1570	nucleotide	CHEMICAL	23444386T7
23444386	267	277	bile acids	CHEMICAL	23444386T8
23444386	1615	1625	nucleotide	CHEMICAL	23444386T9
23444386	CPR:9	23444386T1	23444386T28
23444386	CPR:9	1643	23444386T28
23444386	CPR:9	23444386T4	23444386T25
23444386	CPR:9	23444386T8	23444386T25

23448346|t|Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.
23448346|a|Estrogen receptor (ER) antagonists are valuable in the treatment of ER-positive human breast cancer. In this study, we designed and synthesized nine new derivatives of 17-estradiol (E2) with a bulky side chain attached to its C-7 position, and determined their ER antagonistic activity using in vitro bioassays. Four of the derivatives showed a strong inhibition of ER transactivation activity in a luciferase reporter assay and blocked ER interactions with coactivators. Similarly, these derivatives also strongly inhibited the growth of the ER-positive human breast cancer cells. Computational docking analysis was conducted to model the interaction of these antagonists with the human ER and showed that they could tightly bind to the ER in a manner similar to that of ICI-182,780, a pure ER antagonist. These results provide an example that attachment of a bulky side chain to the C-7 position of E2 can produce ER antagonists with ER affinity comparable to that of ICI-182,780.
23448346	581	584	ER	GENE-Y	23448346T10
23448346	688	691	ER	GENE-Y	23448346T11
23448346	209	211	ER	GENE-Y	16226|2525
23448346	828	837	human ER	GENE-Y	23448346T13
23448346	885	888	ER	GENE-N	23448346T14
23448346	940	942	ER	GENE-Y	16226|2525
23448346	1065	1067	ER	GENE-Y	16226|2525
23448346	1085	1087	ER	GENE-Y	16226|2525
23448346	19	36	estrogen receptor	GENE-Y	23448346T18
23448346	141	149	Estrogen	CHEMICAL	23448346T1
23448346	309	322	17-estradiol	CHEMICAL	23448346T2
23448346	920	931	ICI-182,780	CHEMICAL	23448346T3
23448346	1119	1130	ICI-182,780	CHEMICAL	23448346T4
23448346	19	27	estrogen	CHEMICAL	23448346T5
23448346	141	158	Estrogen receptor	GENE-Y	23448346T6
23448346	160	162	ER	GENE-N	16226|2525
23448346	404	406	ER	GENE-Y	16226|2525
23448346	509	512	ER	GENE-Y	23448346T9
23448346	CPR:6	23448346T3	16226|2525
23448346	CPR:6	23448346T4	16226|2525

23449197|t|Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor- type I receptor inhibitor as a topical drug for alopecia.
23449197|a|7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor- (TGF-) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor. Compound 11, a potent and selective ALK5 inhibitor, exhibited good enzyme inhibitory activity (IC50=4.8nM) as well as inhibitory activity against TGF--induced Smad2/3 phosphorylation at a cellular level (IC50=17nM). The introduction of a methoxy group to the benzothiazole ring in 1 and the break up of the planarity between the imidazole ring and the thiazole ring improved the solubility in the lotion base of 11. Furthermore, the topical application of 3% 11 lotion significantly inhibited Smad2 phosphorylation in mouse skin at 8h after application (71% inhibition, compared with vehicle-treated animals).
23449197	414	444	activin receptor-like kinase 5	GENE-Y	23449197T10
23449197	448	452	ALK5	GENE-Y	23449197T11
23449197	501	505	ALK5	GENE-Y	23449197T12
23449197	612	617	TGF-	GENE-Y	23449197T13
23449197	626	649	Smad2/3 phosphorylation	GENE-N	23449197T14
23449197	961	982	Smad2 phosphorylation	GENE-Y	23449197T15
23449197	130	174	transforming growth factor- type I receptor	GENE-Y	23449197T16
23449197	217	295	7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole	CHEMICAL	23449197T1
23449197	706	713	methoxy	CHEMICAL	23449197T2
23449197	727	740	benzothiazole	CHEMICAL	23449197T3
23449197	797	806	imidazole	CHEMICAL	23449197T4
23449197	820	828	thiazole	CHEMICAL	23449197T5
23449197	300	311	TASP0382088	CHEMICAL	23449197T6
23449197	13	91	7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole	CHEMICAL	23449197T7
23449197	93	104	TASP0382088	CHEMICAL	23449197T8
23449197	346	398	transforming growth factor- (TGF-) type I receptor	GENE-Y	23449197T9
23449197	CPR:4	23449197T1	23449197T10
23449197	CPR:4	23449197T1	23449197T11
23449197	CPR:4	23449197T1	23449197T9
23449197	CPR:4	23449197T6	23449197T10
23449197	CPR:4	23449197T6	23449197T11
23449197	CPR:4	23449197T6	23449197T9
23449197	CPR:4	23449197T7	23449197T16
23449197	CPR:4	23449197T8	23449197T16

23449888|t|ARF represses androgen receptor transactivation in prostate cancer.
23449888|a|Androgen receptor (AR) signaling is essential for prostate cancer (PCa) development in humans. The initiation of prostate malignancy and progression to a castration-resistant stage are largely contributed by the modulation of AR activity through its coregulatory proteins. We and others previously reported that p14 alternative reading frame (ARF) expression is positively correlated with the disease progression and severity of PCa. Here, we provide evidence that p14ARF physically interacts with AR and functions as an AR corespressor in both an androgen-dependent and androgen-independent manner. Endogenous ARF (p14ARF in human and p19ARF in mouse) and AR colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of p14ARF in PCa cells significantly attenuates the activities of androgen response region (ARR2)-probasin and prostate-specific antigen (PSA) promoters. The forced expression of p14ARF in cells resulted in a suppression of PSA and NK transcription factor locus 1 (NKX3.1) expression. Conversely, knockdown of endogenous p14ARF in human PCa cells with short hairpin RNA enhanced AR transactivation activities in a dose-dependent and p53-independent manner. Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR. Most importantly, we observed that the expression of PSA is reversely correlated with p14ARF in human prostate tissues. Taken together, our results reveal a novel function of ARF in modulation of AR transactivation in PCa.
23449888	68	85	Androgen receptor	GENE-Y	23449888T10
23449888	1096	1102	NKX3.1	GENE-Y	23449888T11
23449888	1152	1158	p14ARF	GENE-Y	23449888T12
23449888	1210	1212	AR	GENE-Y	106862
23449888	1264	1267	p53	GENE-Y	77545
23449888	1322	1328	p14ARF	GENE-Y	23449888T15
23449888	1398	1400	AR	GENE-Y	106862
23449888	1410	1452	human double minute 2 (HDM2)-binding motif	GENE-N	23449888T17
23449888	1456	1462	p14ARF	GENE-Y	23449888T18
23449888	1498	1504	p14ARF	GENE-Y	23449888T19
23449888	68	76	Androgen	CHEMICAL	23449888T1
23449888	1509	1511	AR	GENE-Y	106862
23449888	1522	1528	p14ARF	GENE-Y	23449888T21
23449888	1612	1614	AR	GENE-Y	106862
23449888	1669	1672	PSA	GENE-Y	23449888T23
23449888	1702	1708	p14ARF	GENE-Y	23449888T24
23449888	1791	1794	ARF	GENE-Y	23449888T25
23449888	1812	1814	AR	GENE-Y	106862
23449888	87	89	AR	GENE-Y	106862
23449888	294	296	AR	GENE-Y	106862
23449888	380	409	p14 alternative reading frame	GENE-Y	23449888T29
23449888	1347	1348	N	CHEMICAL	167
23449888	411	414	ARF	GENE-Y	23449888T30
23449888	533	539	p14ARF	GENE-Y	23449888T31
23449888	566	568	AR	GENE-Y	106862
23449888	589	591	AR	GENE-Y	106862
23449888	679	682	ARF	GENE-Y	23449888T34
23449888	684	690	p14ARF	GENE-Y	23449888T35
23449888	704	710	p19ARF	GENE-Y	23449888T36
23449888	725	727	AR	GENE-Y	106862
23449888	834	840	p14ARF	GENE-Y	23449888T38
23449888	897	921	androgen response region	GENE-N	23449888T39
23449888	1542	1550	androgen	CHEMICAL	23449888T3
23449888	923	927	ARR2	GENE-N	36370
23449888	929	983	probasin and prostate-specific antigen (PSA) promoters	GENE-N	23449888T41
23449888	1010	1016	p14ARF	GENE-Y	23449888T42
23449888	1055	1058	PSA	GENE-Y	23449888T43
23449888	1063	1094	NK transcription factor locus 1	GENE-Y	23449888T44
23449888	14	31	androgen receptor	GENE-Y	23449888T45
23449888	1583	1584	N	CHEMICAL	167
23449888	1598	1599	C	CHEMICAL	23449888T5
23449888	616	624	androgen	CHEMICAL	23449888T6
23449888	639	647	androgen	CHEMICAL	23449888T7
23449888	897	905	androgen	CHEMICAL	23449888T8
23449888	14	22	androgen	CHEMICAL	23449888T9

23454144|t|Role of oxidative stress in chemical allergens induced skin cells activation.
23454144|a|Allergic contact dermatitis (ACD) is an important occupational and environmental disease caused by topical exposure to chemical allergens. It describes the adverse effects that may results when exposure to a chemical elicits a T cell-mediated inflammatory skin disease. The ability of contact sensitizers to induce the oxidative stress pathway in keratinocytes and dendritic cells has been confirmed by several authors. Reactive oxygen species (ROS) can serve as essential second messengers mediating cellular responses resulting in immune cells activation. Oxidative stress may be the starter point, as it leads to the activation of transcription factors and signaling pathways, including NF-kB and p38 MAPK, which leads to the release of cytokines and chemokines. ROS are also involved in the activation of the NLRP3/NALP3 inflammasome, which is required to direct the proteolytic maturation of inflammatory cytokines such as IL-1 and IL-18, which are all integral to the process of dendritic cells mobilization, migration and functional maturation. Moreover, emerging evidence correlates ROS to changes in the constitution of the extracellular microenvironment found to facilitate ACD. The purpose of this review is to provide both conceptual and technical frameworks on the role of oxidative stress in chemical allergy.
23454144	1006	1011	IL-1	GENE-Y	23454144T10
23454144	1016	1021	IL-18	GENE-Y	23454144T11
23454144	507	513	oxygen	CHEMICAL	23454144T1
23454144	768	773	NF-kB	GENE-N	23454144T2
23454144	778	781	p38	GENE-N	23454144T3
23454144	782	786	MAPK	GENE-N	23454144T4
23454144	818	827	cytokines	GENE-N	23454144T5
23454144	832	842	chemokines	GENE-N	23454144T6
23454144	891	896	NLRP3	GENE-Y	125319
23454144	897	902	NALP3	GENE-Y	23454144T8
23454144	988	997	cytokines	GENE-N	23454144T9

23454145|t|Relative expression of cholesterol transport-related proteins and inflammation markers through the induction of 7-ketosterol-mediated stress in Caco-2 cells.
23454145|a|Human diets contain sterol oxidation products that can induce cytotoxic effects, mainly caused by cholesterol oxides. However, phytosterol oxides effects have been less extensively investigated. This study evaluates the production of inflammatory biomarkers (IL-1, IL-8, IL-10, TNF) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells. These effects were linked to intracellular signaling pathways by using several inhibitors. Results showed 7-ketostigmasterol to have a greater proinflammatory potential than 7-ketocholesterol. In non-pre-treated cells, only efflux transporters were down-regulated by 7-ketosterols, showing a greater influence upon ABCG5 expression. Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells. In non-pre-treated cells, HMG-CoA was up-regulated by both 7-ketosterols. However, exposure to inhibitors down-regulated the expression levels, mainly in 7-ketocholesterol-incubated cells. While ACAT expression values in non-pre-treated cells were unchanged, exposure to inhibitors caused down-regulation of mRNA levels. These results suggest that internalization and excretion of 7-ketostigmasterol is probably influenced by [Ca]i, which also could mediate HMGCoA activity in POPs metabolism. However, energetic metabolism and reducing equivalents exert different influences upon the 7-ketosterol internalization.
23454145	178	184	sterol	CHEMICAL	23454145T10
23454145	516	527	cholesterol	CHEMICAL	23454145T11
23454145	572	578	HMGCoA	CHEMICAL	23454145T12
23454145	598	611	7-ketosterols	CHEMICAL	23454145T13
23454145	613	625	stigmasterol	CHEMICAL	23454145T14
23454145	626	637	cholesterol	CHEMICAL	23454145T15
23454145	762	780	7-ketostigmasterol	CHEMICAL	23454145T16
23454145	830	847	7-ketocholesterol	CHEMICAL	23454145T17
23454145	923	936	7-ketosterols	CHEMICAL	23454145T18
23454145	1014	1024	bradykinin	CHEMICAL	23454145T19
23454145	1183	1200	7-ketocholesterol	CHEMICAL	23454145T1
23454145	1073	1091	7-ketostigmasterol	CHEMICAL	23454145T20
23454145	256	274	cholesterol oxides	CHEMICAL	23454145T21
23454145	112	124	7-ketosterol	CHEMICAL	23454145T22
23454145	23	34	cholesterol	CHEMICAL	23454145T23
23454145	1244	1251	HMG-CoA	GENE-Y	23454145T24
23454145	1413	1417	ACAT	GENE-Y	23454145T25
23454145	1676	1682	HMGCoA	GENE-Y	23454145T26
23454145	417	422	IL-1	GENE-Y	23454145T27
23454145	424	428	IL-8	GENE-Y	23454145T28
23454145	430	435	IL-10	GENE-Y	23454145T29
23454145	1244	1251	HMG-CoA	CHEMICAL	23454145T2
23454145	437	441	TNF	GENE-Y	23454145T30
23454145	555	561	NPC1L1	GENE-Y	118936
23454145	563	570	ABCG5/8	GENE-N	23454145T32
23454145	572	578	HMGCoA	GENE-Y	23454145T33
23454145	580	584	ACAT	GENE-Y	23454145T34
23454145	880	899	efflux transporters	GENE-N	23454145T35
23454145	971	976	ABCG5	GENE-Y	122124
23454145	1014	1024	bradykinin	GENE-Y	23454145T37
23454145	1044	1048	ABCG	GENE-N	23454145T38
23454145	1157	1163	NPC1L1	GENE-Y	118936
23454145	1277	1290	7-ketosterols	CHEMICAL	23454145T3
23454145	24	61	holesterol transport-related proteins	GENE-N	23454145T40
23454145	1372	1389	7-ketocholesterol	CHEMICAL	23454145T4
23454145	285	303	phytosterol oxides	CHEMICAL	23454145T5
23454145	1599	1617	7-ketostigmasterol	CHEMICAL	23454145T6
23454145	1645	1647	Ca	CHEMICAL	23454145T7
23454145	1676	1682	HMGCoA	CHEMICAL	23454145T8
23454145	1803	1815	7-ketosterol	CHEMICAL	23454145T9
23454145	CPR:3	23454145T3	23454145T24
23454145	CPR:4	23454145T18	23454145T35
23454145	CPR:4	23454145T1	118936

23454297|t|Caffeic acid treatment alters the extracellular adenine nucleotide hydrolysis in platelets and lymphocytes of adult rats.
23454297|a|This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. Animals were divided into five groups: I (control); II (oil); III (caffeic acid 10mg/kg); IV (caffeic acid 50mg/kg); and V (caffeic acid 100mg/kg). Animals were treated with caffeic acid diluted in oil for 30days. In platelets, caffeic acid decreased the ATP hydrolysis and increased ADP hydrolysis in groups III, IV and V when compared to control (P<0.05). The 5'-nucleotidase activity was decreased, while E-NPP and ADA activities were increased in platelets of rats of groups III, IV and V (P<0.05). Caffeic acid reduced significantly the platelet aggregation in the animals of groups III, IV and V in relation to group I (P<0.05). In lymphocytes, the NTPDase and ADA activities were increased in all groups treated with caffeic acid when compared to control (P<0.05). These findings demonstrated that the enzymes were altered in tissues by caffeic acid and this compound decreased the platelet aggregation suggesting that caffeic acid should be considered a potentially therapeutic agent in disorders related to the purinergic system.
23454297	630	642	caffeic acid	CHEMICAL	23454297T10
23454297	684	696	caffeic acid	CHEMICAL	23454297T11
23454297	711	714	ATP	CHEMICAL	164
23454297	740	743	ADP	CHEMICAL	23454297T13
23454297	959	971	Caffeic acid	CHEMICAL	23454297T14
23454297	219	242	nucleoside triphosphate	CHEMICAL	23454297T15
23454297	0	12	Caffeic acid	CHEMICAL	23454297T16
23454297	48	66	adenine nucleotide	CHEMICAL	23454297T17
23454297	1123	1126	ADA	GENE-Y	106614
23454297	264	319	Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase)	GENE-N	23454297T19
23454297	1180	1192	caffeic acid	CHEMICAL	23454297T1
23454297	321	336	5'-nucleotidase	GENE-Y	23454297T20
23454297	341	360	adenosine deaminase	GENE-Y	23454297T21
23454297	362	365	ADA	GENE-Y	106614
23454297	864	869	E-NPP	GENE-N	23454297T23
23454297	874	877	ADA	GENE-Y	106614
23454297	210	217	NTPDase	GENE-N	23454297T25
23454297	219	261	nucleoside triphosphate diphosphohydrolase	GENE-N	23454297T26
23454297	1111	1118	NTPDase	GENE-N	23454297T27
23454297	1300	1312	caffeic acid	CHEMICAL	23454297T2
23454297	1382	1394	caffeic acid	CHEMICAL	23454297T3
23454297	274	284	nucleotide	CHEMICAL	23454297T4
23454297	341	350	adenosine	CHEMICAL	23454297T5
23454297	158	170	caffeic acid	CHEMICAL	23454297T6
23454297	523	535	caffeic acid	CHEMICAL	23454297T7
23454297	550	562	caffeic acid	CHEMICAL	23454297T8
23454297	580	592	caffeic acid	CHEMICAL	23454297T9
23454297	CPR:3	23454297T1	106614
23454297	CPR:3	23454297T1	23454297T27

23455323|t|Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.
23455323|a|Approximately 50% of melanomas depend on mutant B-RAF for proliferation, metastasis and survival. The inhibition of oncogenic B-RAF with highly targeted compounds has produced remarkable albeit short-lived clinical responses in B-RAF mutant melanoma patients. Reactivation of signaling downstream of B-RAF is frequently associated with acquired resistance to B-RAF inhibitors, and the identification of B-RAF targets may provide new strategies for managing melanoma. Oncogenic B-RAF(V600E) is known to promote the stabilizing phosphorylation of the anti-apoptotic protein Mcl-1, implicated in melanoma survival and chemoresistance. We now show that B-RAF(V600E) signaling also induces the transcription of Mcl-1 in melanocytes and melanoma. We demonstrate that activation of STAT3 serine-727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation. Consequently, suppression of STAT3 activity disrupted B-RAF(V600E)-mediated induction of Mcl-1 and reduced melanoma cell survival. We propose that STAT3 has a central role in the survival and contributes to chemoresistance of B-RAF(V600E) melanoma.Oncogene advance online publication, 4 March 2013; doi:10.1038/onc.2013.45.
23455323	309	314	B-RAF	GENE-Y	23455323T10
23455323	381	386	B-RAF	GENE-Y	23455323T11
23455323	440	445	B-RAF	GENE-Y	23455323T12
23455323	484	489	B-RAF	GENE-Y	23455323T13
23455323	558	563	B-RAF	GENE-Y	23455323T14
23455323	564	569	V600E	GENE-N	23455323T15
23455323	129	134	B-RAF	GENE-Y	23455323T16
23455323	653	658	Mcl-1	GENE-Y	23455323T17
23455323	730	735	B-RAF	GENE-Y	23455323T18
23455323	736	741	V600E	GENE-N	23455323T19
23455323	862	868	serine	CHEMICAL	23455323T1
23455323	787	792	Mcl-1	GENE-Y	23455323T20
23455323	856	861	STAT3	GENE-Y	112651
23455323	922	927	B-RAF	GENE-Y	23455323T22
23455323	928	933	V600E	GENE-N	23455323T23
23455323	957	971	Mcl-1 promoter	GENE-N	23455323T24
23455323	990	994	STAT	GENE-N	23455323T25
23455323	1014	1019	B-RAF	GENE-Y	23455323T26
23455323	1070	1075	STAT3	GENE-Y	112651
23455323	13	18	Mcl-1	GENE-Y	23455323T28
23455323	53	58	STAT3	GENE-Y	112651
23455323	877	885	tyrosine	CHEMICAL	23455323T2
23455323	7	12	B-RAF	GENE-Y	23455323T30
23455323	1095	1100	B-RAF	GENE-Y	23455323T3
23455323	1101	1106	V600E	GENE-N	23455323T4
23455323	1130	1135	Mcl-1	GENE-Y	23455323T5
23455323	1188	1193	STAT3	GENE-Y	112651
23455323	1267	1272	B-RAF	GENE-Y	23455323T7
23455323	1273	1278	V600E	GENE-N	23455323T8
23455323	207	212	B-RAF	GENE-Y	23455323T9

23462233|t|Aldehyde oxidase importance in vivo in xenobiotic metabolism: imidacloprid nitroreduction in mice.
23462233|a|Aldehyde oxidase (AOX) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to cytochrome P450s (CYPs) and other detoxification systems. Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by AOX on reduction of the nitroimino group and by CYPs via oxidation reactions. The goal of this study was to establish the relative importance of AOX and CYPs in vivo using the mouse model. The procedure was to reduce liver AOX activity by providing tungsten or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain. None of these approaches reduced CYP activity measured in vitro with an isozyme nonspecific substrate. Liver AOX activity was reduced by 45% with tungsten and 61% with hydralazine and 81% in AOX-deficient mice relative to controls. When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice. The other IMI nitroreduction metabolite, desnitro-IMI, was decreased by 55%, 65%, and 81% with tungsten, hydralazine, and in the AOX-deficient mice, respectively. Thus, decreasing liver AOX activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of IMI-treated mice. Possible AOX involvement in IMI metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains. This is the first study to establish the in vivo relevance of AOX in neonicotinoid metabolism in mammals and one of the first for xenobiotics in general.
23462233	1602	1605	IMI	CHEMICAL	23462233T10
23462233	1726	1729	IMI	CHEMICAL	23462233T11
23462233	1854	1867	neonicotinoid	CHEMICAL	23462233T12
23462233	324	338	neonicotinoids	CHEMICAL	23462233T13
23462233	398	408	nitroimino	CHEMICAL	23462233T14
23462233	623	631	tungsten	CHEMICAL	23462233T15
23462233	635	646	hydralazine	CHEMICAL	23462233T16
23462233	863	871	tungsten	CHEMICAL	23462233T17
23462233	885	896	hydralazine	CHEMICAL	23462233T18
23462233	1004	1016	imidacloprid	CHEMICAL	23462233T19
23462233	99	107	Aldehyde	CHEMICAL	23462233T1
23462233	1018	1021	IMI	CHEMICAL	23462233T20
23462233	0	8	Aldehyde	CHEMICAL	23462233T21
23462233	62	74	imidacloprid	CHEMICAL	23462233T22
23462233	99	115	Aldehyde oxidase	GENE-N	23462233T23
23462233	1104	1107	AOX	GENE-N	23462233T24
23462233	1221	1224	AOX	GENE-N	23462233T25
23462233	219	235	cytochrome P450s	GENE-N	23462233T26
23462233	1370	1373	AOX	GENE-N	23462233T27
23462233	1427	1430	AOX	GENE-N	23462233T28
23462233	237	241	CYPs	GENE-N	23462233T29
23462233	1118	1134	nitrosoguanidine	CHEMICAL	23462233T2
23462233	1583	1586	AOX	GENE-N	23462233T30
23462233	1648	1651	AOX	GENE-N	23462233T31
23462233	1667	1670	AOX	GENE-N	23462233T32
23462233	1847	1850	AOX	GENE-N	23462233T33
23462233	117	120	AOX	GENE-N	23462233T34
23462233	374	377	AOX	GENE-N	23462233T35
23462233	422	426	CYPs	GENE-N	23462233T36
23462233	519	522	AOX	GENE-N	23462233T37
23462233	527	531	CYPs	GENE-N	23462233T38
23462233	597	600	AOX	GENE-N	23462233T39
23462233	1172	1180	tungsten	CHEMICAL	23462233T3
23462233	683	686	AOX	GENE-N	23462233T40
23462233	750	753	CYP	GENE-N	23462233T41
23462233	826	829	AOX	GENE-N	23462233T42
23462233	908	911	AOX	GENE-N	23462233T43
23462233	1038	1041	CYP	GENE-N	23462233T44
23462233	0	16	Aldehyde oxidase	GENE-N	23462233T45
23462233	1194	1205	hydralazine	CHEMICAL	23462233T4
23462233	1251	1254	IMI	CHEMICAL	23462233T5
23462233	1291	1294	IMI	CHEMICAL	23462233T6
23462233	1336	1344	tungsten	CHEMICAL	23462233T7
23462233	1346	1357	hydralazine	CHEMICAL	23462233T8
23462233	1556	1559	IMI	CHEMICAL	23462233T9
23462233	CPR:4	23462233T15	23462233T39
23462233	CPR:4	23462233T16	23462233T39
23462233	CPR:4	23462233T17	23462233T42
23462233	CPR:4	23462233T18	23462233T42
23462233	CPR:4	23462233T3	23462233T24
23462233	CPR:4	23462233T4	23462233T24
23462233	CPR:9	23462233T10	23462233T30
23462233	CPR:9	23462233T10	23462233T31
23462233	CPR:9	23462233T12	23462233T33
23462233	CPR:9	23462233T13	23462233T35
23462233	CPR:9	23462233T13	23462233T36
23462233	CPR:9	23462233T14	23462233T35
23462233	CPR:9	23462233T2	23462233T24
23462233	CPR:9	23462233T9	23462233T28

23462380|t|Non-front-fanged colubroid snakes: A current evidence-based analysis of medical significance.
23462380|a|Non-front-fanged colubroid snakes (NFFC; formerly and artificially taxonomically assembled as "colubrids") comprise about 70% of extant snake species and include several taxa now known to cause lethal or life threatening envenoming in humans. Although the medical risks of bites by only a handful of species have been documented, a growing number of NFFC are implicated in medically significant bites. The majority of these snakes have oral products (Duvernoy's secretions, or venoms) with unknown biomedical properties and their potential for causing harm in humans is unknown. Increasingly, multiple NFFC species are entering the commercial snake trade posing an uncertain risk. Published case reports describing NFFC bites were assessed for evidence-based value, clinical detail and verified species identification. These data were subjected to meta-analysis and a hazard index was generated for select taxa. Cases on which we consulted or personally treated were included and subjected to the same assessment criteria. Cases involving approximately 120 species met the selection criteria, and a small subset designated Hazard Level 1 (most hazardous), contained 5 species with lethal potential. Recommended management of these cases included antivenom for 3 species, Dispholidus typus, Rhabdophis tiginis, Rhabdophis subminiatus, whereas others in this subset without commercially available antivenoms (Thelotornis spp.) were treated with plasma/erythrocyte replacement therapy and supportive care. Heparin, antifibrinolytics and/or plasmapheresis/exchange transfusion have been used in the management of some Hazard Level 1 envenomings, but evidence-based analysis positively contraindicates the use of any of these interventions. Hazard Level 2/3 species were involved in cases containing mixed quality data that implicated these taxa (e.g. Boiga irregularis, Philodryas olfersii, Malpolon monspessulanus) with bites that caused rare systemic effects. Recommended management may include use of acetylcholinesterase inhibitors (e.g. neostigmine) and wound care on a case-by-case basis. Hazard level 3 species comprised a larger group capable of producing significant local effects only, often associated with a protracted bite (eg Heterodon nasicus, Borikenophis (Alsophis) portoricensis, Platyceps (Coluber) rhodorachis). Management is restricted to wound care. Bites by Hazard level 4 species comprised the majority of surveyed taxa and these showed only minor effects of no clinical importance. This study has produced a comprehensive evidence-based listing of NFFC snakes tabulated against medical significance of bites, together with best-practice management recommendations. This analysis assumes increasing importance, as there is growing exposure to lesser-known NFFC snakes, particularly in captive collections that may uncover further species of significance in the future. Careful and accurate documentation of bites by verified species of NFFC snakes is required to increase the evidence base and establish the best medical management approach for each species.
23462380	2132	2143	neostigmine	CHEMICAL	23462380T1
23462380	2094	2114	acetylcholinesterase	GENE-Y	23462380T2
23462380	CPR:4	23462380T1	23462380T2

23462526|t|Cell cycle arrest, extracellular matrix changes and intrinsic apoptosis in human melanoma cells are induced by Boron Neutron Capture Therapy.
23462526|a|Boron Neutron Capture Therapy (BNCT) involves the selective accumulation of boron carriers in tumor tissue followed by irradiation with a thermal or epithermal neutron beam. This therapy is therefore a cellular irradiation suited to treat tumors that have infiltrated into healthy tissues. BNCT has been used clinically to treat patients with cutaneous melanomas which have a high mortality. Human normal melanocytes and melanoma cells were treated with BNCT at different boronophenylalanine concentrations for signaling pathways analysis. BNCT induced few morphological alterations in normal melanocytes, with a negligible increase in free radical production. Melanoma cells treated with BNCT showed significant extracellular matrix (ECM) changes and a significant cyclin D1 decrease, suggesting cell death by necrosis and apoptosis and cell cycle arrest, respectively. BNCT also induced a significant increase in cleaved caspase-3 and a decrease in the mitochondrial electrical potential with selectivity for melanoma cells. Normal melanocytes had no significant differences due to BNCT treatment, confirming the data from the literature regarding the selectivity of BNCT. The results from this study suggest that some signaling pathways are involved in human melanoma treatment by BNCT, such as cell cycle arrest, ECM changes and intrinsic apoptosis.
23462526	142	147	Boron	CHEMICAL	23462526T1
23462526	614	633	boronophenylalanine	CHEMICAL	23462526T2
23462526	111	116	Boron	CHEMICAL	23462526T3
23462526	908	917	cyclin D1	GENE-Y	23462526T4
23462526	1065	1074	caspase-3	GENE-Y	23462526T5

23465614|t|Anti-adipogenic diarylheptanoids from Alnus hirsuta f. sibirica on 3T3-L1 cells.
23465614|a|A new diarylheptanoid, (5S)-hydroxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-hepta-1E-en-3-one (1), was isolated along with seventeen known diarylheptanoids (2-18) from the methanol extract of Alnus hirsuta f. sibirica leaves using bioactivity-guided fractionation. Among the isolated compounds, compounds 1 and 2 and 4-12 reduced lipid accumulation dose-dependently in 3T3-L1 preadipocytes. Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O--d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor  (PPAR and CCAAT/enhancer binding protein  (C/EBP) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR agonist. It was demonstrated that compound 7 has anti-adipogenic activity mediated by the regulation of PPAR dependent pathways.
23465614	694	726	CCAAT/enhancer binding protein 	GENE-Y	23465614T10
23465614	728	734	C/EBP	GENE-Y	23465614T11
23465614	823	828	PPAR	GENE-Y	23465614T12
23465614	933	938	PPAR	GENE-Y	23465614T13
23465614	224	240	diarylheptanoids	CHEMICAL	23465614T1
23465614	257	265	methanol	CHEMICAL	23465614T2
23465614	104	178	(5S)-hydroxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-hepta-1E-en-3-one	CHEMICAL	23465614T3
23465614	557	594	platyphyllonol-5-O--d-xylopyranoside	CHEMICAL	23465614T4
23465614	87	102	diarylheptanoid	CHEMICAL	23465614T5
23465614	807	819	troglitazone	CHEMICAL	23465614T6
23465614	16	32	diarylheptanoids	CHEMICAL	23465614T7
23465614	638	682	peroxisome proliferator activated receptor 	GENE-Y	23465614T8
23465614	684	689	PPAR	GENE-Y	23465614T9
23465614	CPR:4	23465614T4	23465614T10
23465614	CPR:4	23465614T4	23465614T11
23465614	CPR:4	23465614T4	23465614T8
23465614	CPR:4	23465614T4	23465614T9
23465614	CPR:5	23465614T6	23465614T12

23468189|t|Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors.
23468189|a|The interaction of CXCR4 with CXCL12 (SDF-1) plays a critical role in cancer metastasis by facilitating the homing of tumor cells to metastatic sites. Based on our previously published work on CXCR4 antagonists, we have synthesized a series of aryl sulfonamides that inhibit the CXCR4/CXCL12 interaction. Analogue bioactivities were assessed with binding affinity and Matrigel invasion assays. Computer modeling was employed to evaluate a selection of the new analogues docked into the CXCR4 X-ray structure and to rationalize discrepancies between the affinity and Matrigel in vitro assays. A lead compound displays nanomolar potency in the binding affinity assay (IC(50)=8.0 nM) and the Matrigel invasion assay (100 % blockade of invasion at 10 nM). These data demonstrate that benzenesulfonamides are a unique class of CXCR4 inhibitors with high potency.
23468189	563	568	CXCR4	GENE-Y	113607
23468189	899	904	CXCR4	GENE-Y	113607
23468189	39	64	chemokine receptor type 4	GENE-Y	23468189T12
23468189	321	338	aryl sulfonamides	CHEMICAL	23468189T1
23468189	857	876	benzenesulfonamides	CHEMICAL	23468189T2
23468189	0	19	Benzenesulfonamides	CHEMICAL	23468189T3
23468189	96	101	CXCR4	GENE-Y	113607
23468189	270	275	CXCR4	GENE-Y	113607
23468189	356	361	CXCR4	GENE-Y	113607
23468189	362	368	CXCL12	GENE-Y	112288
23468189	107	113	CXCL12	GENE-Y	112288
23468189	115	120	SDF-1	GENE-Y	23468189T9
23468189	CPR:4	23468189T1	113607
23468189	CPR:4	23468189T1	112288
23468189	CPR:4	23468189T2	113607
23468189	CPR:4	23468189T3	23468189T12

2347042|t|Oncolytic activity and mechanism of action of a novel L-cysteine derivative, L-cysteine, ethyl ester, S-(N-methylcarbamate) monohydrochloride.
2347042|a|A study on the oncolytic activity of the L-cysteine derivative L-cysteine, ethyl ester, S-(N-methylcarbamate) monohydrochloride (NSC 303861), revealed that the drug caused complete regression of the MX-1 human mammary tumor xenograft. The compound also exhibited moderate antitumor activity against murine leukemia P388 (T/C value of 169% at a daily dose of 400 mg/kg) and against M5076 sarcoma (T/C value of 135% at a daily dose of 600 mg/kg). The drug was inactive against B16 melanoma, Lewis lung, colon 38 and CD8F1 mammary carcinomas. The compound exhibited significant cytotoxicity against hepatoma 3924A cells in culture (LC50 = 6 microM). Studies on the mechanism of action revealed that the cytotoxicity of the drug could be partially abrogated by protecting hepatoma 3924A cells in culture with L-glutamine. At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase. Measurement of the nucleotide concentrations further corroborated the actions of the drug on the purine nucleotide biosynthetic enzyme activities. Drug injection (400 mg/kg) in the hepatoma 3924A-bearing rats reduced the concentrations of IMP in the tumor to 52%, those of total adenylates to 52%, those of total guanylates to 57%, and those of NAD to 73%, without significantly perturbing the pyrimidine nucleotide pools. Studies on the mechanism of action of the L-cysteine derivative suggested that the compound behaved as an L-glutamine antagonist, selectively acting on the enzymes of purine nucleotide biosynthesis.
2347042	1601	1618	purine nucleotide	CHEMICAL	2347042T10
2347042	1743	1746	IMP	CHEMICAL	1536
2347042	1783	1793	adenylates	CHEMICAL	2347042T12
2347042	1817	1827	guanylates	CHEMICAL	2347042T13
2347042	1849	1852	NAD	CHEMICAL	2347042T14
2347042	1898	1919	pyrimidine nucleotide	CHEMICAL	2347042T15
2347042	1969	1979	L-cysteine	CHEMICAL	2347042T16
2347042	2033	2044	L-glutamine	CHEMICAL	2347042T17
2347042	2094	2111	purine nucleotide	CHEMICAL	2347042T18
2347042	184	194	L-cysteine	CHEMICAL	2347042T19
2347042	1208	1219	L-glutamine	CHEMICAL	2347042T1
2347042	206	270	L-cysteine, ethyl ester, S-(N-methylcarbamate) monohydrochloride	CHEMICAL	2347042T20
2347042	948	959	L-glutamine	CHEMICAL	2347042T21
2347042	1059	1070	L-glutamine	CHEMICAL	2347042T22
2347042	1075	1086	L-glutamate	CHEMICAL	2347042T23
2347042	54	64	L-cysteine	CHEMICAL	2347042T24
2347042	77	141	L-cysteine, ethyl ester, S-(N-methylcarbamate) monohydrochloride	CHEMICAL	2347042T25
2347042	1273	1303	amidophosphoribosyltransferase	GENE-Y	2347042T26
2347042	1305	1318	FGAM synthase	GENE-Y	2347042T27
2347042	1324	1336	GMP synthase	GENE-Y	2347042T28
2347042	1455	1485	carbamoylphosphate synthase II	GENE-Y	2347042T29
2347042	1241	1258	purine nucleotide	CHEMICAL	2347042T2
2347042	1490	1502	CTP synthase	GENE-Y	2347042T30
2347042	1305	1309	FGAM	CHEMICAL	2347042T3
2347042	1324	1327	GMP	CHEMICAL	2347042T4
2347042	1422	1432	pyrimidine	CHEMICAL	2347042T5
2347042	272	282	NSC 303861	CHEMICAL	2347042T6
2347042	1455	1473	carbamoylphosphate	CHEMICAL	2347042T7
2347042	1490	1493	CTP	CHEMICAL	2347042T8
2347042	1523	1533	nucleotide	CHEMICAL	2347042T9

23470629|t|Measurement of Transport Activities of 3-Hydroxy-(5)-bile Acids in Bile Salt Export Pump and Multidrug Resistance-Associated Proteins Using LC-MS/MS.
23470629|a|A method has been developed for the measurement of transport activities in membrane vesicles obtained from Sf9 cells for 3-hydroxy-(5)-bile acids by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Calibration curves for the bile acids were linear over the range of 10 to 2000pmol/mL, and the detection limit was less than 1pmol/mL for 3-hydroxy-(5)-bile acids using selected reaction monitoring analysis. The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and human bile salt export pump-expressing Sf9 cells for conjugated 3-hydroxy-(5)-bile acids. The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated 3-hydroxy-(5)-bile acids along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.
23470629	39	65	3-Hydroxy-(5)-bile Acids	CHEMICAL	23470629T10
23470629	69	78	Bile Salt	CHEMICAL	23470629T11
23470629	713	764	human multidrug resistance-associated protein 2-, 3	GENE-N	23470629T12
23470629	771	798	human bile salt export pump	GENE-Y	23470629T13
23470629	899	946	human multidrug resistance-associated protein 3	GENE-Y	23470629T14
23470629	69	90	Bile Salt Export Pump	GENE-Y	23470629T15
23470629	95	135	Multidrug Resistance-Associated Proteins	GENE-N	23470629T16
23470629	273	299	3-hydroxy-(5)-bile acids	CHEMICAL	23470629T1
23470629	419	429	bile acids	CHEMICAL	23470629T2
23470629	532	558	3-hydroxy-(5)-bile acids	CHEMICAL	23470629T3
23470629	777	786	bile salt	CHEMICAL	23470629T4
23470629	835	861	3-hydroxy-(5)-bile acids	CHEMICAL	23470629T5
23470629	976	1002	3-hydroxy-(5)-bile acids	CHEMICAL	23470629T6
23470629	1021	1031	bile acids	CHEMICAL	23470629T7
23470629	1040	1056	glycocholic acid	CHEMICAL	23470629T8
23470629	1061	1092	taurolithocholic acid 3-sulfate	CHEMICAL	23470629T9
23470629	CPR:9	23470629T10	23470629T15
23470629	CPR:9	23470629T10	23470629T16
23470629	CPR:9	23470629T5	23470629T13
23470629	CPR:9	23470629T6	23470629T14
23470629	CPR:9	23470629T7	23470629T14
23470629	CPR:9	23470629T8	23470629T14
23470629	CPR:9	23470629T9	23470629T14

23471969|t|An Intracellular Domain Fragment of the p75 Neurotrophin Receptor (p75NTR) Enhances Tropomyosin Receptor Kinase A (TrkA) Receptor Function.
23471969|a|Facilitation of nerve growth factor (NGF) signaling by the p75 neurotrophin receptor (p75(NTR)) is critical for neuronal survival and differentiation. However, the interaction between p75(NTR) and TrkA receptors required for this activity is not understood. Here, we report that a specific 29-amino acid peptide derived from the intracellular domain fragment of p75(NTR) interacts with and potentiates binding of NGF to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and Akt signaling. An endogenous intracellular domain fragment of p75(NTR) (p75(ICD)) containing these 29 amino acids is produced by regulated proteolysis of the full-length receptor. We demonstrate that generation of this fragment is a requirement for p75(NTR) to facilitate TrkA signaling in neurons and propose that the juxtamembrane region of p75(ICD) acts to cause a conformational change within the extracellular domain of TrkA. This finding provides new insight into the mechanism by which p75(NTR) and TrkA interact to enhance neurotrophic signaling.
23471969	553	556	NGF	GENE-Y	110869
23471969	560	564	TrkA	GENE-Y	23471969T11
23471969	669	675	Erk1/2	GENE-N	23471969T12
23471969	680	683	Akt	GENE-N	23471969T13
23471969	199	224	p75 neurotrophin receptor	GENE-Y	23471969T14
23471969	742	750	p75(NTR)	GENE-Y	23471969T15
23471969	752	760	p75(ICD)	GENE-N	23471969T16
23471969	929	937	p75(NTR)	GENE-Y	23471969T17
23471969	952	956	TrkA	GENE-Y	23471969T18
23471969	226	234	p75(NTR)	GENE-Y	23471969T19
23471969	433	443	amino acid	CHEMICAL	23471969T1
23471969	1023	1031	p75(ICD)	GENE-N	23471969T20
23471969	1105	1109	TrkA	GENE-Y	23471969T21
23471969	115	119	TrkA	GENE-Y	23471969T22
23471969	40	65	p75 Neurotrophin Receptor	GENE-Y	23471969T23
23471969	67	73	p75NTR	GENE-Y	23471969T24
23471969	84	113	Tropomyosin Receptor Kinase A	GENE-Y	23471969T25
23471969	782	793	amino acids	CHEMICAL	23471969T2
23471969	1173	1181	p75(NTR)	GENE-Y	23471969T3
23471969	1186	1190	TrkA	GENE-Y	23471969T4
23471969	156	175	nerve growth factor	GENE-Y	23471969T5
23471969	324	332	p75(NTR)	GENE-Y	23471969T6
23471969	337	341	TrkA	GENE-Y	23471969T7
23471969	502	510	p75(NTR)	GENE-Y	23471969T8
23471969	177	180	NGF	GENE-Y	110869

23474389|t|Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents.
23474389|a|A series of substituted 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines has been synthesised and tested in vitro as potential pro-apoptotic Bcl-2-inhibitory anticancer agents. Synthesis of the target compounds was readily accomplished in good yields through a cyclisation reaction between indole-3-carboxylic acid hydrazide and carbon disulfide under basic conditions, followed by S-benzylation. Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub-micromolar IC50 values in Bcl-2 expressing human cancer cell lines. Molecular modelling and ELISA studies further implicated anti-apoptotic Bcl-2 as a candidate molecular target underpinning anticancer activity.
23474389	87	92	Bcl-2	GENE-Y	23474389T10
23474389	147	205	3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines	CHEMICAL	23474389T1
23474389	423	457	indole-3-carboxylic acid hydrazide	CHEMICAL	23474389T2
23474389	462	478	carbon disulfide	CHEMICAL	23474389T3
23474389	515	516	S	CHEMICAL	127
23474389	560	571	nitrobenzyl	CHEMICAL	23474389T5
23474389	28	83	3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines	CHEMICAL	23474389T6
23474389	274	279	Bcl-2	GENE-Y	23474389T7
23474389	637	642	Bcl-2	GENE-Y	23474389T8
23474389	751	756	Bcl-2	GENE-Y	23474389T9
23474389	CPR:4	23474389T1	23474389T7
23474389	CPR:4	23474389T5	23474389T8
23474389	CPR:4	23474389T6	23474389T10

23475432|t|Effect of nicotine pretreatment on arsenic-induced oxidative stress in male Wistar rats.
23475432|a|Humans are commonly exposed to nicotine, one of the most important lifestyle chemicals. The occurrence of high levels of arsenic in the groundwater of the southeast region of Asia has received much attention in the past decade and has become a global health concern. Predominant occurrence of both these chemicals and ease of their human exposure led us to investigate the effect of nicotine, a major tobacco alkaloid, on arsenic toxicity. Adult male rats were pre-exposed to two different doses of nicotine (0.75 and 3mg/kg, intraperitoneally) for 7days followed by 30days of arsenic exposure (50ppm sodium arsenite in drinking water). Nicotine pre-exposure resulted in an increased brain arsenic accumulation and a decreased liver arsenic concentration. Arsenic also caused a significant oxidative stress in the blood, brain and liver of the exposed rats. Glutathione-S-transferase, a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine. Upon nicotine pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (MAO) decreased. The toxic effects of MAO significantly attenuated with nicotine pre-exposure. The present study suggests that nicotine may not be the major contributing factor for the previously reported synergistic toxic interaction between tobacco and arsenic. Nicotine pre-exposure in arsenic-exposed animals revealed interesting toxicokinetics and oxidative stress modulating interactions in the brain and liver of rats, which requires further exploration.
23475432	472	480	nicotine	CHEMICAL	23475432T10
23475432	511	518	arsenic	CHEMICAL	23475432T11
23475432	588	596	nicotine	CHEMICAL	23475432T12
23475432	669	676	arsenic	CHEMICAL	23475432T13
23475432	694	709	sodium arsenite	CHEMICAL	23475432T14
23475432	730	738	Nicotine	CHEMICAL	177
23475432	783	790	arsenic	CHEMICAL	23475432T16
23475432	826	833	arsenic	CHEMICAL	23475432T17
23475432	849	856	Arsenic	CHEMICAL	23475432T18
23475432	951	962	Glutathione	CHEMICAL	137
23475432	1115	1123	nicotine	CHEMICAL	23475432T1
23475432	963	964	S	CHEMICAL	127
23475432	1019	1026	arsenic	CHEMICAL	23475432T21
23475432	1031	1039	nicotine	CHEMICAL	23475432T22
23475432	1076	1083	arsenic	CHEMICAL	23475432T23
23475432	10	18	nicotine	CHEMICAL	23475432T24
23475432	35	42	arsenic	CHEMICAL	23475432T25
23475432	1159	1179	acetylcholinesterase	GENE-Y	23475432T26
23475432	1197	1214	monoamine oxidase	GENE-N	23475432T27
23475432	1216	1219	MAO	GENE-N	23475432T28
23475432	1253	1256	MAO	GENE-N	23475432T29
23475432	1130	1138	nicotine	CHEMICAL	23475432T2
23475432	951	976	Glutathione-S-transferase	GENE-N	23475432T30
23475432	1287	1295	nicotine	CHEMICAL	23475432T3
23475432	210	217	arsenic	CHEMICAL	23475432T4
23475432	1342	1350	nicotine	CHEMICAL	23475432T5
23475432	1470	1477	arsenic	CHEMICAL	23475432T6
23475432	1479	1487	Nicotine	CHEMICAL	177
23475432	1504	1511	arsenic	CHEMICAL	23475432T8
23475432	120	128	nicotine	CHEMICAL	23475432T9
23475432	CPR:3	23475432T2	23475432T26
23475432	CPR:4	23475432T21	23475432T30
23475432	CPR:4	23475432T22	23475432T30
23475432	CPR:4	23475432T2	23475432T27
23475432	CPR:4	23475432T2	23475432T28
23475432	CPR:4	23475432T3	23475432T29

23475784|t|Developing Predictive Approaches to Characterize Adaptive Responses of the Reproductive Endocrine Axis to Aromatase Inhibition: II. Computational Modeling.
23475784|a|Endocrine-disrupting chemicals can affect reproduction and development in humans and wildlife. We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the aromatase inhibitor, fadrozole (FAD). The model describes adaptive responses to endocrine stress involving regulated secretion of a generic gonadotropin (LH/FSH) from the hypothalamic-pituitary complex. For model development, we used plasma 17-estradiol (E2) concentrations and ovarian cytochrome P450 (CYP) 19A aromatase mRNA data from two time-course experiments, each of which included both an exposure and a depuration phase, and plasma E2 data from a third 4-day study. Model parameters were estimated using E2 concentrations for 0, 0.5, and 3 g/l FAD exposure concentrations, and good fits to these data were obtained. The model accurately predicted CYP19A mRNA fold changes for controls and three FAD doses (0, 0.5, and 3 g/l) and plasma E2 dose response from the 4-day study. Comparing the model-predicted DRTC with experimental data provided insight into how the feedback control mechanisms in the HPG axis mediate these changes: specifically, adaptive changes in plasma E2 levels occurring during exposure and "overshoot" occurring postexposure. This study demonstrates the value of mechanistic modeling to examine and predict dynamic behaviors in perturbed systems. As this work progresses, we will obtain a refined understanding of how adaptive responses within the vertebrate HPG axis affect DRTC behaviors for aromatase inhibitors and other types of endocrine-active chemicals and apply that knowledge in support of risk assessments.
23475784	605	608	FSH	GENE-N	23475784T10
23475784	735	770	cytochrome P450 (CYP) 19A aromatase	GENE-Y	23475784T11
23475784	1106	1112	CYP19A	GENE-Y	23475784T12
23475784	106	115	Aromatase	GENE-Y	23475784T13
23475784	469	478	fadrozole	CHEMICAL	23475784T1
23475784	480	483	FAD	CHEMICAL	3015
23475784	689	702	17-estradiol	CHEMICAL	23475784T3
23475784	1003	1006	FAD	CHEMICAL	3015
23475784	1154	1157	FAD	CHEMICAL	3015
23475784	1775	1784	aromatase	GENE-Y	23475784T6
23475784	448	457	aromatase	GENE-Y	23475784T7
23475784	588	600	gonadotropin	GENE-N	23475784T8
23475784	602	604	LH	GENE-N	23475784T9
23475784	CPR:4	23475784T1	23475784T7
23475784	CPR:4	3015	23475784T7

23478802|t|Benzoquinone Reveals a Cysteine-Dependent Desensitization Mechanism of TRPA1.
23478802|a|The transient receptor potential ankyrin 1 (TRPA1) nonselective cation channel has a conserved function as a noxious chemical sensor throughout much of Metazoa. Electrophilic chemicals activate both insect and vertebrate TRPA1 via covalent modification of cysteine residues in the amino-terminal region. Although naturally occurring electrophilic plant compounds, such as mustard oil and cinnamaldehyde, are TRPA1 agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1. We characterized the effects of the electrophilic arthropod defensive compound para-benzoquinone (pBQN) on the human TRPA1 channel. We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted cysteines crucial for electrophile activation (C621S, C641S, C665S). We found that pBQN activates TRPA1 starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline. Activation by pBQN required reactivity with cysteine residues, but ones that are distinct from those previously reported to be the key targets of electrophiles. The current reduction we found at higher pBQN concentrations was a cysteine-dependent desensitization of TRPA1, and did not require prior activation. The cysteines required for desensitization are not accessible to all electrophiles as iodoacetamide and internally applied 2-(trimethylammonium)ethyl methanesulfonate failed to cause desensitization (despite large activation). Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist carvacrol, whereas the triple cysteine mutant TRPA1 retained its full response. Our results suggest that modification of multiple cysteine residues by electrophilic compounds can generate both activation and desensitization of the TRPA1 channel.
23478802	1880	1888	cysteine	CHEMICAL	23478802T10
23478802	334	342	cysteine	CHEMICAL	23478802T11
23478802	359	364	amino	CHEMICAL	23478802T12
23478802	466	480	cinnamaldehyde	CHEMICAL	23478802T13
23478802	662	679	para-benzoquinone	CHEMICAL	23478802T14
23478802	681	685	pBQN	CHEMICAL	23478802T15
23478802	846	852	serine	CHEMICAL	23478802T16
23478802	865	874	cysteines	CHEMICAL	23478802T17
23478802	948	952	pBQN	CHEMICAL	23478802T18
23478802	0	12	Benzoquinone	CHEMICAL	23478802T19
23478802	1098	1102	pBQN	CHEMICAL	23478802T1
23478802	23	31	Cysteine	CHEMICAL	145
23478802	1350	1355	TRPA1	GENE-Y	114471
23478802	1679	1684	TRPA1	GENE-Y	114471
23478802	1796	1801	TRPA1	GENE-Y	114471
23478802	1981	1986	TRPA1	GENE-Y	114471
23478802	299	304	TRPA1	GENE-Y	114471
23478802	486	491	TRPA1	GENE-Y	114471
23478802	82	120	transient receptor potential ankyrin 1	GENE-Y	23478802T27
23478802	122	128	TRPA1)	GENE-Y	23478802T28
23478802	566	581	mammalian TRPA1	GENE-Y	23478802T29
23478802	1128	1136	cysteine	CHEMICAL	23478802T2
23478802	694	705	human TRPA1	GENE-Y	23478802T30
23478802	142	156	cation channel	GENE-N	23478802T31
23478802	820	825	TRPA1	GENE-Y	114471
23478802	829	834	TRPA1	GENE-Y	114471
23478802	912	917	C621S	GENE-N	23478802T34
23478802	919	924	C641S	GENE-N	23478802T35
23478802	926	931	C665S	GENE-N	23478802T36
23478802	963	968	TRPA1	GENE-Y	114471
23478802	71	76	TRPA1	GENE-Y	114471
23478802	1286	1290	pBQN	CHEMICAL	23478802T3
23478802	1399	1408	cysteines	CHEMICAL	23478802T4
23478802	1481	1494	iodoacetamide	CHEMICAL	23478802T5
23478802	1518	1561	2-(trimethylammonium)ethyl methanesulfonate	CHEMICAL	23478802T6
23478802	1647	1651	pBQN	CHEMICAL	23478802T7
23478802	1750	1759	carvacrol	CHEMICAL	23478802T8
23478802	1780	1788	cysteine	CHEMICAL	23478802T9
23478802	CPR:3	23478802T18	114471
23478802	CPR:5	23478802T13	114471
23478802	CPR:5	23478802T8	114471
23478802	CPR:5	23478802T8	114471

23479059|t|A study of parabens and bisphenol A in surface water and fish brain tissue from the Greater Pittsburgh Area.
23479059|a|Pollution from xenoestrogens has been discovered in the aquatic environment of the Greater Pittsburgh Area and is suspected to be caused by the failing sewer system. Personal care products and plasticizers have the potential to enter the water supply though treated and untreated sewage. Many of these compounds are suspected xenoestrogens. Paraben detection in surface waters was as follows: methyl paraben ranged between 2.2 to 17.3ppt; ethyl paraben was not detectable; propyl paraben was detected at 9.2 and 12.0ppt; butyl paraben was detected at 0.2ppt. BPA was detected between 0.6 and 15.4ppt. Estrogenic potential of extracts from fish brain tissue was tested via Bromodeoxyuridine MCF-7 analysis and paired with HPLC-MS to investigate the presence of xenoestrogens. All samples were non-detectable for parabens. BPA was detected in 44 of the 58 samples, with a range from non-detectable to 120pg/g. BCFs were calculated. Results were statistically significant for location of capture (p<0.05) and correlation existed between estrogenicity and BPA.
23479059	785	802	Bromodeoxyuridine	CHEMICAL	23479059T10
23479059	873	886	xenoestrogens	CHEMICAL	23479059T11
23479059	934	937	BPA	CHEMICAL	23479059T12
23479059	11	19	parabens	CHEMICAL	23479059T13
23479059	24	35	bisphenol A	CHEMICAL	23479059T14
23479059	1168	1171	BPA	CHEMICAL	23479059T1
23479059	124	137	xenoestrogens	CHEMICAL	23479059T2
23479059	435	448	xenoestrogens	CHEMICAL	23479059T3
23479059	450	457	Paraben	CHEMICAL	23479059T4
23479059	502	516	methyl paraben	CHEMICAL	23479059T5
23479059	549	562	ethyl paraben	CHEMICAL	23479059T6
23479059	583	597	propyl paraben	CHEMICAL	23479059T7
23479059	632	645	butyl paraben	CHEMICAL	23479059T8
23479059	671	674	BPA	CHEMICAL	23479059T9

23479193|t|Synthesis and in-silico studies of some diaryltriazole derivatives as potential cyclooxygenase inhibitors.
23479193|a|The synthesis of several 4-phenyl-5-pyridin-4-yl-2,3-dihydro-3H-1,2,4-triazole-3-thiones possessing N-2 Mannich bases or S-alkyl substituents, is reported. Several of them exhibited a low nanomolar COX enzyme inhibition activity. Most of the compounds showed inhibition of edema was similar to that evoked by celocoxib in animal model. Molecular docking studies of the compounds into the binding sites of COX-1 and COX-2 allowed us to shed light on the binding mode of these novel COX inhibitors.
23479193	80	94	cyclooxygenase	GENE-N	23479193T10
23479193	211	224	Mannich bases	CHEMICAL	23479193T1
23479193	228	235	S-alkyl	CHEMICAL	23479193T2
23479193	132	195	4-phenyl-5-pyridin-4-yl-2,3-dihydro-3H-1,2,4-triazole-3-thiones	CHEMICAL	23479193T3
23479193	416	425	celocoxib	CHEMICAL	23479193T4
23479193	40	54	diaryltriazole	CHEMICAL	23479193T5
23479193	305	308	COX	GENE-N	23479193T6
23479193	512	517	COX-1	GENE-Y	23479193T7
23479193	522	527	COX-2	GENE-Y	23479193T8
23479193	588	591	COX	GENE-N	23479193T9
23479193	CPR:4	23479193T5	23479193T10

23479738|t|Multilevel regulation of 2-cys peroxiredoxin reaction cycle by s-nitrosylation.
23479738|a|S-Nitrosothiols (SNOs), formed by nitric oxide (NO)-mediated S-nitrosylation, and hydrogen peroxide (H2O2), a prominent reactive oxygen species, are implicated in diverse physiological and pathological processes. Recent research has shown that the cellular action and metabolism of SNOs and H2O2 involve overlapping, thiol-based mechanisms, but how these reactive species may affect each other's fate and function is not well understood. In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases. We found that, both in a cell-free system and in cells, NO/SNO donors such as S-nitrosocysteine and S-nitrosoglutathione readily induced the S-nitrosylation of Prx1, causing structural and functional alterations. In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (Cys-52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of peroxidase activity. A highly potent inhibition of the peroxidase catalytic reaction by NO/SNO was seen in assays employing the coupled Prx-Trx system. In this setting, S-nitrosocysteine (10 m) effectively blocked the Trx-mediated regeneration of oxidized Prx1. This effect appeared to be due to both competition between S-nitrosocysteine and Prx1 for the Trx system and direct modulation by S-nitrosocysteine of Trx reductase activity. Our findings that NO/SNO target both Prx and Trx reductase may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.
23479738	1571	1574	SNO	CHEMICAL	23479738T10
23479738	97	101	SNOs	CHEMICAL	23479738T11
23479738	362	366	SNOs	CHEMICAL	23479738T12
23479738	371	375	H2O2	CHEMICAL	23479738T13
23479738	397	402	thiol	CHEMICAL	23479738T14
23479738	114	126	nitric oxide	CHEMICAL	23479738T15
23479738	552	554	NO	CHEMICAL	427
23479738	555	558	SNO	CHEMICAL	23479738T17
23479738	128	130	NO	CHEMICAL	427
23479738	649	652	Cys	CHEMICAL	145
23479738	80	95	S-Nitrosothiols	CHEMICAL	23479738T1
23479738	141	142	S	CHEMICAL	127
23479738	767	769	NO	CHEMICAL	427
23479738	770	773	SNO	CHEMICAL	23479738T22
23479738	789	806	S-nitrosocysteine	CHEMICAL	23479738T23
23479738	811	831	S-nitrosoglutathione	CHEMICAL	23479738T24
23479738	852	853	S	CHEMICAL	127
23479738	162	179	hydrogen peroxide	CHEMICAL	23479738T26
23479738	962	971	disulfide	CHEMICAL	23479738T27
23479738	1014	1023	cysteines	CHEMICAL	23479738T28
23479738	1025	1028	Cys	CHEMICAL	145
23479738	181	185	H2O2	CHEMICAL	23479738T2
23479738	1036	1039	Cys	CHEMICAL	145
23479738	27	30	cys	CHEMICAL	23479738T31
23479738	1087	1091	Prx1	GENE-Y	23479738T32
23479738	1112	1122	peroxidase	GENE-N	23479738T33
23479738	1167	1177	peroxidase	GENE-N	23479738T34
23479738	1248	1251	Prx	GENE-N	202408
23479738	1252	1255	Trx	GENE-Y	1207479
23479738	1331	1334	Trx	GENE-Y	1207479
23479738	1360	1373	oxidized Prx1	GENE-Y	23479738T38
23479738	1456	1460	Prx1	GENE-Y	23479738T39
23479738	1200	1202	NO	CHEMICAL	427
23479738	1469	1472	Trx	GENE-Y	1207479
23479738	1526	1539	Trx reductase	GENE-N	23479738T41
23479738	1587	1590	Prx	GENE-N	202408
23479738	1595	1608	Trx reductase	GENE-N	23479738T43
23479738	589	614	mammalian peroxiredoxin-1	GENE-Y	23479738T44
23479738	616	620	Prx1	GENE-Y	23479738T45
23479738	647	657	2-Cys Prxs	GENE-N	23479738T46
23479738	670	681	thioredoxin	GENE-Y	23479738T47
23479738	683	686	Trx	GENE-Y	1207479
23479738	698	709	peroxidases	GENE-N	23479738T49
23479738	1203	1206	SNO	CHEMICAL	23479738T4
23479738	871	875	Prx1	GENE-Y	23479738T50
23479738	25	44	2-cys peroxiredoxin	GENE-N	23479738T51
23479738	1281	1298	S-nitrosocysteine	CHEMICAL	23479738T5
23479738	209	215	oxygen	CHEMICAL	23479738T6
23479738	1434	1451	S-nitrosocysteine	CHEMICAL	23479738T7
23479738	1505	1522	S-nitrosocysteine	CHEMICAL	23479738T8
23479738	1568	1570	NO	CHEMICAL	427
23479738	CPR:4	427	23479738T34
23479738	CPR:4	23479738T4	23479738T34
23479738	CPR:4	23479738T5	1207479
23479738	CPR:4	23479738T5	23479738T38

23480597|t|A Novel CUG(exp)MBNL1 Inhibitor with Therapeutic Potential for Myotonic Dystrophy Type 1.
23480597|a|Myotonic dystrophy type 1 (DM1) is caused by an expanded CUG repeat (CUG(exp)) that sequesters muscleblind-like 1 protein (MBNL1), a protein that regulates alternative splicing. CUG(exp) RNA is a validated drug target for this currently untreatable disease. Herein, we develop a bioactive small molecule (1) that targets CUG(exp) RNA and is able to inhibit the CUG(exp)MBNL1 interaction in cells that model DM1. The core of this small molecule is based on ligand 2, which was previously reported to be active in an in vitro assay. A polyamine-derivative side chain was conjugated to this core to make it aqueous-soluble and cell-penetrable. In a DM1 cell model this conjugate was found to disperse CUG(exp) ribonuclear foci, release MBNL1, and partially reverse the mis-splicing of the insulin receptor pre-mRNA. Direct evidence for ribonuclear foci dispersion by this ligand was obtained in a live DM1 cell model using time-lapse confocal microscopy.
23480597	625	634	polyamine	CHEMICAL	23480597T1
23480597	214	219	MBNL1	GENE-Y	110324
23480597	461	466	MBNL1	GENE-Y	110324
23480597	825	830	MBNL1	GENE-Y	110324
23480597	878	894	insulin receptor	GENE-Y	23480597T5
23480597	186	212	muscleblind-like 1 protein	GENE-N	23480597T6
23480597	17	22	MBNL1	GENE-Y	110324

23483103|t|The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(ii) asymmetric complexes.
23483103|a|Four ruthenium(ii) asymmetric complexes, [Ru(bpy)2(PAIDH)](2+) (bpy = 2,2'-bipyridine, PAIDH = 2-pyridyl-1H-anthra[1,2-d]imidazole-6,11-dione, ), [Ru(phen)2(PAIDH)](2+) (phen = 1,10-phenanthroline, ), [Ru(dmp)2(PAIDH)](2+) (dmp = 4,7-dimethyl-1,10-phenanthroline, ) and [Ru(dip)2(PAIDH)](2+) (dip = 4,7-diphenyl-1,10-phenanthroline, ), have been synthesized and characterized. These complexes displayed potent anti-proliferation activity against various cancer cell lines and had high selectivity between tumor cells and normal cells. HeLa cells exhibited the highest sensitivity to complex , accounting for the greatest cellular uptake. Complex was shown to accumulate preferentially in the mitochondria of HeLa cells and induced apoptosis via the mitochondrial pathway, which involved ROS generation, mitochondrial membrane potential depolarisation, and Bcl-2 and caspase family members activation. These results demonstrated that complex induced cancer cell apoptosis by acting on mitochondrial pathways.
23483103	145	166	[Ru(bpy)2(PAIDH)](2+)	CHEMICAL	23483103T10
23483103	109	122	ruthenium(ii)	CHEMICAL	23483103T11
23483103	168	171	bpy	CHEMICAL	23483103T12
23483103	174	189	2,2'-bipyridine	CHEMICAL	23483103T13
23483103	191	196	PAIDH	CHEMICAL	23483103T14
23483103	199	245	2-pyridyl-1H-anthra[1,2-d]imidazole-6,11-dione	CHEMICAL	23483103T15
23483103	68	81	ruthenium(ii)	CHEMICAL	23483103T16
23483103	960	965	Bcl-2	GENE-Y	23483103T17
23483103	970	977	caspase	GENE-N	23483103T18
23483103	250	272	[Ru(phen)2(PAIDH)](2+)	CHEMICAL	23483103T1
23483103	274	278	phen	CHEMICAL	23483103T2
23483103	281	300	1,10-phenanthroline	CHEMICAL	23483103T3
23483103	305	326	[Ru(dmp)2(PAIDH)](2+)	CHEMICAL	23483103T4
23483103	328	331	dmp	CHEMICAL	23483103T5
23483103	334	366	4,7-dimethyl-1,10-phenanthroline	CHEMICAL	23483103T6
23483103	374	395	[Ru(dip)2(PAIDH)](2+)	CHEMICAL	23483103T7
23483103	397	400	dip	CHEMICAL	23483103T8
23483103	403	435	4,7-diphenyl-1,10-phenanthroline	CHEMICAL	23483103T9

23485615|t|Platycodi Radix attenuates dimethylnitrosamine-induced liver fibrosis in rats by inducing Nrf2-mediated antioxidant enzymes.
23485615|a|The purpose of this study was to investigate the anti-fibrotic effects of the aqueous extract of the Platycodi Radix root (Changkil: CK) on dimethylnitrosamine (DMN)-induced liver fibrosis in rats. DMN treatment for 4weeks led to marked liver fibrosis as assessed by serum biochemistry, histopathological examination, and hepatic lipid peroxidation and collagen content. CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content. CK also inhibited DMN-induced reductions in rat body and liver weights. Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor- (TNF-) mRNA, and collagen type I and -smooth muscle actin protein. DMN-induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (NF-B) activation was reduced by CK treatment. Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as -glutamylcysteine synthetase (-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells. These results demonstrated that CK attenuates DMN-induced liver fibrosis through the activation of Nrf2-mediated antioxidant enzymes.
23485615	323	326	DMN	CHEMICAL	23485615T10
23485615	523	526	DMN	CHEMICAL	23485615T11
23485615	554	561	alanine	CHEMICAL	23485615T12
23485615	589	598	aspartate	CHEMICAL	23485615T13
23485615	662	677	malondialdehyde	CHEMICAL	23485615T14
23485615	718	721	DMN	CHEMICAL	23485615T15
23485615	882	885	DMN	CHEMICAL	23485615T16
23485615	1092	1095	DMN	CHEMICAL	23485615T17
23485615	27	46	dimethylnitrosamine	CHEMICAL	23485615T18
23485615	1144	1166	nuclear factor-kappa B	GENE-N	23485615T19
23485615	1334	1352	-glutamylcysteine	CHEMICAL	23485615T1
23485615	1168	1173	NF-B	GENE-N	23485615T20
23485615	1253	1289	nuclear erythroid 2-related factor 2	GENE-Y	23485615T21
23485615	1291	1295	Nrf2	GENE-Y	23485615T22
23485615	1334	1363	-glutamylcysteine synthetase	GENE-Y	23485615T23
23485615	1365	1370	-GCS	GENE-Y	23485615T24
23485615	1373	1389	heme oxygenase-1	GENE-Y	23485615T25
23485615	1391	1395	HO-1	GENE-Y	23485615T26
23485615	1398	1430	NAD(P)H quinone oxidoreductase 1	GENE-Y	23485615T27
23485615	1432	1436	NQO1	GENE-Y	108072
23485615	1443	1468	glutathione-S-transferase	GENE-N	23485615T29
23485615	1373	1377	heme	CHEMICAL	23485615T2
23485615	1470	1473	GST	GENE-N	23485615T30
23485615	1590	1594	Nrf2	GENE-Y	23485615T31
23485615	478	486	collagen	GENE-N	23485615T32
23485615	554	578	alanine aminotransferase	GENE-N	23485615T33
23485615	580	583	ALT	GENE-N	23485615T34
23485615	589	615	aspartate aminotransferase	GENE-N	23485615T35
23485615	617	620	AST	GENE-N	23485615T36
23485615	682	690	collagen	GENE-N	23485615T37
23485615	907	934	matrix metalloproteinase-13	GENE-Y	23485615T38
23485615	936	942	MMP-13	GENE-Y	23485615T39
23485615	1398	1405	NAD(P)H	CHEMICAL	23485615T3
23485615	945	984	tissue inhibitor of metalloproteinase-1	GENE-Y	23485615T40
23485615	986	992	TIMP-1	GENE-Y	23485615T41
23485615	999	1022	tumor necrosis factor-	GENE-Y	23485615T42
23485615	1024	1029	TNF-	GENE-Y	23485615T43
23485615	1041	1056	collagen type I	GENE-N	23485615T44
23485615	1061	1082	-smooth muscle actin	GENE-Y	23485615T45
23485615	1104	1120	cyclooxygenase-2	GENE-Y	23485615T46
23485615	1122	1127	COX-2	GENE-Y	23485615T47
23485615	90	94	Nrf2	GENE-Y	23485615T48
23485615	1406	1413	quinone	CHEMICAL	23485615T4
23485615	1443	1454	glutathione	CHEMICAL	23485615T5
23485615	1455	1456	S	CHEMICAL	127
23485615	265	284	dimethylnitrosamine	CHEMICAL	23485615T7
23485615	1537	1540	DMN	CHEMICAL	23485615T8
23485615	286	289	DMN	CHEMICAL	23485615T9
23485615	CPR:3	23485615T11	23485615T33
23485615	CPR:3	23485615T11	23485615T34
23485615	CPR:3	23485615T11	23485615T35
23485615	CPR:3	23485615T11	23485615T36
23485615	CPR:3	23485615T11	23485615T37
23485615	CPR:3	23485615T16	23485615T38
23485615	CPR:3	23485615T16	23485615T39
23485615	CPR:3	23485615T16	23485615T40
23485615	CPR:3	23485615T16	23485615T41
23485615	CPR:3	23485615T16	23485615T42
23485615	CPR:3	23485615T16	23485615T43
23485615	CPR:3	23485615T16	23485615T44
23485615	CPR:3	23485615T16	23485615T45
23485615	CPR:3	23485615T17	23485615T19
23485615	CPR:3	23485615T17	23485615T20
23485615	CPR:3	23485615T17	23485615T46
23485615	CPR:3	23485615T17	23485615T47

23485651|t|Cadmium telluride quantum dots cause oxidative stress leading to extrinsic and intrinsic apoptosis in hepatocellular carcinoma HepG2 cells.
23485651|a|The mechanisms of toxicity related to human hepatocellular carcinoma HepG2 cell exposures to cadmium telluride quantum dots (CdTe-QDs) were investigated. CdTe-QDs caused cytotoxicity in HepG2 cells in a dose- and time-dependent manner. Treated cells showed an increase in reactive oxygen species (ROS). Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased NF-E2-related Factor 2 (Nrf2) activation. Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed. Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase (PARP) cleavage and phosphatidylserine externalization. Extrinsic apoptotic pathway markers such as Fas levels and caspase-8 activity increased as a result of CdTe-QD exposure. Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun N-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated. Our findings reveal that CdTe-QDs cause oxidative stress, interfere with antioxidant defenses and activate protein kinases, leading to apoptosis via both extrinsic and intrinsic pathways. Since the effects of CdTe-QDs on selected biomarkers were similar or greater compared to those of CdCl2 at equivalent concentrations of cadmium, the study suggests that the toxicity of CdTe-QDs arises from a combination of the effects of cadmium and ROS generated from the NPs.
23485651	504	523	reduced glutathione	CHEMICAL	23485651T10
23485651	525	528	GSH	CHEMICAL	137
23485651	560	571	glutathione	CHEMICAL	23485651T12
23485651	575	595	oxidized glutathione	CHEMICAL	23485651T13
23485651	597	600	GSH	CHEMICAL	137
23485651	601	605	GSSG	CHEMICAL	23485651T15
23485651	692	702	superoxide	CHEMICAL	23485651T16
23485651	768	779	glutathione	CHEMICAL	23485651T17
23485651	780	781	S	CHEMICAL	127
23485651	858	862	CdTe	CHEMICAL	23485651T19
23485651	265	269	CdTe	CHEMICAL	23485651T1
23485651	952	967	poly ADP-ribose	CHEMICAL	23485651T20
23485651	999	1017	phosphatidylserine	CHEMICAL	23485651T21
23485651	233	250	cadmium telluride	CHEMICAL	23485651T22
23485651	1138	1142	CdTe	CHEMICAL	23485651T23
23485651	0	17	Cadmium telluride	CHEMICAL	23485651T24
23485651	1254	1271	B-cell lymphoma 2	GENE-Y	23485651T25
23485651	1273	1277	Bcl2	GENE-Y	198318|246412
23485651	1305	1317	cytochrome c	GENE-Y	23485651T27
23485651	1360	1386	Bcl-2-associated X protein	GENE-Y	23485651T28
23485651	1388	1391	Bax	GENE-Y	198304|246997
23485651	1486	1487	N	CHEMICAL	167
23485651	1407	1419	cytochrome c	GENE-Y	23485651T30
23485651	1430	1463	mitogen-activated protein kinases	GENE-N	23485651T31
23485651	1465	1470	MAPKs	GENE-N	23485651T32
23485651	1480	1504	c-Jun N-terminal kinases	GENE-N	23485651T33
23485651	1506	1509	JNK	GENE-N	23485651T34
23485651	1512	1550	extracellular signal-regulated kinases	GENE-N	23485651T35
23485651	1552	1558	Erk1/2	GENE-N	23485651T36
23485651	1565	1568	p38	GENE-N	23485651T37
23485651	1704	1711	kinases	GENE-N	23485651T38
23485651	624	646	NF-E2-related Factor 2	GENE-Y	23485651T39
23485651	1614	1618	CdTe	CHEMICAL	23485651T3
23485651	648	652	Nrf2	GENE-Y	23485651T40
23485651	692	712	superoxide dismutase	GENE-N	23485651T41
23485651	714	717	SOD	GENE-N	23485651T42
23485651	749	757	catalase	GENE-Y	23485651T43
23485651	759	762	CAT	GENE-Y	107297
23485651	768	793	glutathione-S-transferase	GENE-N	23485651T45
23485651	795	798	GST	GENE-N	23485651T46
23485651	932	941	caspase-3	GENE-Y	23485651T47
23485651	952	978	poly ADP-ribose polymerase	GENE-N	23485651T48
23485651	980	984	PARP	GENE-N	23485651T49
23485651	294	298	CdTe	CHEMICAL	23485651T4
23485651	1079	1082	Fas	GENE-Y	199594
23485651	1094	1103	caspase-8	GENE-Y	23485651T51
23485651	1798	1802	CdTe	CHEMICAL	23485651T5
23485651	1875	1880	CdCl2	CHEMICAL	23485651T6
23485651	1913	1920	cadmium	CHEMICAL	23485651T7
23485651	1962	1966	CdTe	CHEMICAL	23485651T8
23485651	421	427	oxygen	CHEMICAL	23485651T9
23485651	CPR:3	23485651T23	199594
23485651	CPR:3	23485651T23	23485651T51
23485651	CPR:3	23485651T3	23485651T38

23494236|t|Reinforcement enhancing effects of nicotine via smoking.
23494236|a|RATIONALE: In animals, nicotine enhances reinforcement from stimuli unrelated to nicotine intake. Human research is suggestive but has not clearly shown a similar influence of nicotine. OBJECTIVES: We assessed acute effects of nicotine via smoking on enhancement of positive (money, music) or negative (termination of noise) reinforcers, or no "reward" (control). These different rewards determined the generalizability of nicotine effects. MATERIALS AND METHODS: Dependent (n=25) and nondependent (n=27) smokers participated in three sessions, each after overnight abstinence. Using a within-subjects design, sessions involved no smoking or smoking denicotinized (0.05mg) or nicotine (0.6mg) Quest(R) brand cigarettes. For comparison, a fourth session involved no abstinence prior to smoking one's own brand to gauge responses under typical nicotine satiation. Reinforcement was assessed by responses on a simple operant computer task for the rewards, each available singly on a progressive ratio schedule during separate trials. RESULTS: The reinforcing effect of music, but not other rewards, was greater due to the nicotine cigarette, compared to the denicotinized cigarette or no smoking. Reinforcement enhancing effects of nicotine did not differ between dependent and nondependent groups, indicating no influence of withdrawal relief. Responding due to acute nicotine after abstinence was very similar to responding to one's own brand after no abstinence. CONCLUSIONS: Acute nicotine intake per se from smoking after abstinence enhances the reinforcing value of rewards unassociated with smoking, perhaps in a manner comparable to ad lib smoking after no abstinence. Nicotine's reinforcement enhancing effects may be specific to certain rewards, perhaps those sensory in nature.
23494236	738	746	nicotine	CHEMICAL	23494236T10
23494236	138	146	nicotine	CHEMICAL	23494236T11
23494236	905	913	nicotine	CHEMICAL	23494236T12
23494236	35	43	nicotine	CHEMICAL	23494236T13
23494236	1182	1190	nicotine	CHEMICAL	23494236T1
23494236	1292	1300	nicotine	CHEMICAL	23494236T2
23494236	1429	1437	nicotine	CHEMICAL	23494236T3
23494236	1545	1553	nicotine	CHEMICAL	23494236T4
23494236	1737	1745	Nicotine	CHEMICAL	177
23494236	233	241	nicotine	CHEMICAL	23494236T6
23494236	284	292	nicotine	CHEMICAL	23494236T7
23494236	80	88	nicotine	CHEMICAL	23494236T8
23494236	480	488	nicotine	CHEMICAL	23494236T9

23500061|t|Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: Use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier.
23500061|a|The cardiomyocyte apoptosis plays a critical role in the development of myocardial injury after ischemia and reperfusion. Thus, alteration of the major apoptosis-regulatory factors during myocardial ischemia-reperfusion is expected to have favorable cardioprotective effects. Herein, we report ischemic-reperfused myocardial infarction (MI) repair with siRNA against Src homology region 2 domain-containing tyrosine phosphatase-1 (SHP-1), which is known as a key factor involved in regulating the progress of apoptosis in many cell types. A low molecular weight polyethyleneimine modified with deoxycholic acid (PEI1.8-DA)-based delivery strategy was suggested for the cardiac application of SHP-1 siRNA to overcome the poor gene delivery efficiency to myocardium due to the highly charged structures of the compact cardiac muscles. The PEI1.8-DA conjugates formed stable nanocomplexes with SHP-1 siRNA via electrostatic and hydrophobic interactions. The PEI1.8-DA/SHP-1 siRNA polyplexes effectively silenced SHP-1 gene expression in cardiomyocytes, leading to a significant inhibition of cardiomyocyte apoptosis under hypoxia. In comparison to conventional gene carriers, relatively large amounts of siRNA molecules remained after treatment with the PEI1.8-DA/SHP-1 siRNA polyplexes. Cardiac administration of the PEI1.8-DA/SHP-1 siRNA polyplexes resulted in substantial improvement in SHP-1 gene silencing, which can be explained by the enhancement of cardiac delivery efficiency of the PEI1.8-DA conjugates. In addition, in vivo treatment with the PEI1.8-DA/SHP-1 siRNA polyplexes induced a highly significant reduction in myocardial apoptosis and infarct size in rat MI models. These results demonstrate that the PEI1.8-DA/SHP-1 siRNA polyplex formulation is a useful system for efficient gene delivery into the compact myocardium that provides a fundamental advantage in treating ischemic-reperfused MI.
23500061	1762	1767	SHP-1	GENE-Y	23500061T10
23500061	1928	1933	SHP-1	GENE-Y	23500061T11
23500061	568	630	Src homology region 2 domain-containing tyrosine phosphatase-1	GENE-Y	23500061T12
23500061	632	637	SHP-1	GENE-Y	23500061T13
23500061	893	898	SHP-1	GENE-Y	23500061T14
23500061	1092	1097	SHP-1	GENE-Y	23500061T15
23500061	1166	1171	SHP-1	GENE-Y	23500061T16
23500061	43	48	SHP-1	GENE-Y	23500061T17
23500061	608	616	tyrosine	CHEMICAL	23500061T1
23500061	763	780	polyethyleneimine	CHEMICAL	23500061T2
23500061	795	811	deoxycholic acid	CHEMICAL	23500061T3
23500061	108	124	deoxycholic acid	CHEMICAL	23500061T4
23500061	155	172	polyethyleneimine	CHEMICAL	23500061T5
23500061	1210	1215	SHP-1	GENE-Y	23500061T6
23500061	1462	1467	SHP-1	GENE-Y	23500061T7
23500061	1526	1531	SHP-1	GENE-Y	23500061T8
23500061	1588	1593	SHP-1	GENE-Y	23500061T9

23500411|t|Synthesis of C17-OH-north unit of ritterazine G via "Red-Ox" modifications of hecogenin acetate.
23500411|a|The C17-OH-north unit of ritterazine G was prepared in 13 steps from hecogenin acetate. This synthesis features a highly efficient and stereoselective introduction of the C17-OH via E-ring cleavage/F-ring formation, D-ring oxidation, and F-ring cleavage/E-ring formation.
23500411	272	274	OH	CHEMICAL	23500411T1
23500411	122	135	ritterazine G	CHEMICAL	23500411T2
23500411	166	183	hecogenin acetate	CHEMICAL	23500411T3
23500411	105	107	OH	CHEMICAL	23500411T4
23500411	17	19	OH	CHEMICAL	23500411T5
23500411	34	47	ritterazine G	CHEMICAL	23500411T6
23500411	78	95	hecogenin acetate	CHEMICAL	23500411T7

23507868|t|Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.
23507868|a|There is evidence that high-density lipoproteins (HDLs) may regulate platelet function, but disparate results exist regarding the effects of oxidized HDLs on platelets. The objective of our study was to determine the role of in vivo oxidized HDLs on platelet aggregation. Platelet aggregation and redox status were investigated in 5 patients with abetalipoproteinemia (ABLP) or homozygous hypobetalipoproteinemia, two rare metabolic diseases characterized by the absence of apolipoprotein B-containing lipoproteins, compared to 5 control subjects. Platelets isolated from plasma of patients with ABLP aggregated 4 to 10 times more than control platelets, depending on the agonist. By contrast, no differences in the extent of platelet aggregation were observed between ABLP platelet-rich plasma (PRP) and control PRP, suggesting the presence of a protective factor in ABLP plasma. ABLP HDLs inhibited agonist-induced platelet aggregation by binding to SR-BI, while control HDLs had no effect. On the other hand, lipoprotein-deficient plasma from patients with ABLP did not inhibit platelet aggregation. Severe oxidative stress was evidenced in patients with ABLP. Compared to control HDLs, ABLP HDLs showed a 40% decrease of -tocopherol and an 11-fold increased malondialdehyde concentration. These results demonstrate that in vivo oxidized HDLs do not lose their antiaggregatory properties despite oxidation.-Calzada, C., Vricel, E., Colas, R., Guillot, N., El Khoury, G., Drai, J., Sassolas, A., Peretti, N., Ponsin, G., Lagarde, M., Moulin, P. Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.
23507868	163	188	high-density lipoproteins	GENE-N	23507868T10
23507868	614	630	apolipoprotein B	GENE-Y	23507868T11
23507868	642	654	lipoproteins	GENE-N	23507868T12
23507868	190	194	HDLs	GENE-N	23507868T13
23507868	1026	1030	HDLs	GENE-N	23507868T14
23507868	1092	1097	SR-BI	GENE-Y	23507868T15
23507868	1113	1117	HDLs	GENE-N	23507868T16
23507868	30	64	oxidized high-density lipoproteins	GENE-N	23507868T17
23507868	1365	1377	-tocopherol	CHEMICAL	23507868T1
23507868	1403	1418	malondialdehyde	CHEMICAL	23507868T2
23507868	1152	1163	lipoprotein	GENE-N	23507868T3
23507868	1324	1328	HDLs	GENE-N	23507868T4
23507868	1335	1339	HDLs	GENE-N	23507868T5
23507868	1473	1486	oxidized HDLs	GENE-N	23507868T6
23507868	290	294	HDLs	GENE-N	23507868T7
23507868	1719	1753	oxidized high-density lipoproteins	GENE-N	23507868T8
23507868	373	386	oxidized HDLs	GENE-N	23507868T9

23511088|t|Derivatives of Dictyostelium discoideum differentiation-inducing factor-3 suppress the activities of Trypanosoma cruzi in vitro and in vivo.
23511088|a|Chagas disease (human American trypanosomiasis), which is caused by the protozoan parasite Trypanosoma cruzi, is responsible for numerous deaths each year; however, established treatments for the disease are limited. Differentiation-inducing factor-1 (DIF-1) and DIF-3 are chlorinated alkylphenones originally found in the cellular slime mold Dictyostelium discoideum that have been shown to possess pharmacological activities. Here, we investigated the effects of DIF-3 derivatives on the infection rate and growth of T. cruzi by using an in vitro assay system utilizing host human fibrosarcoma HT1080 cells. Certain DIF-3 derivatives, such as butoxy-DIF-3 (Bu-DIF-3), at micro-molar levels strongly suppressed both the infection rate and growth of T. cruzi in HT1080 cells and exhibited little toxicity for HT1080 cells. For example, the IC50 of DIF-3 and Bu-DIF-3 versus the growth of T. cruzi in HT1080 cells were 3.95 and 0.72M, respectively, and the LD50 of the two compounds versus HT1080 cells were both greater than 100M. We also examined the effects of DIF-3 and Bu-DIF-3 on T. cruzi activity in C57BL/6 mice. Intraperitoneally administered Bu-DIF-3 (50mg/kg) significantly suppressed the number of trypomastigotes in blood with no apparent adverse effects. These results strongly suggest that DIF-3 derivatives could be new lead compounds in the development of anti-trypanosomiasis drugs.
23511088	426	439	alkylphenones	CHEMICAL	23511088T1
23511088	786	792	butoxy	CHEMICAL	23511088T2

23512787|t|Neuroprotective Effects of Puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's Disease Model in Mice.
23512787|a|Puerarin, an active component of Pueraria montana var. lobata (Willd.) Sanjappa & Pradeep is well-known for its anti-oxidative and neuroprotective activities. Although anti-Parkinson's disease activity of puerarin was reported in both of in vivo and in vitro model, detailed mechanisms are not clarified. In this study, we addressed that puerarin attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced behavioral deficits, dopaminergic neuronal degeneration and dopamine depletion. Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice. In addition to the effect on ROS, puerarin ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (Lamp 2A) expression. Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression. Copyright  2013 John Wiley & Sons, Ltd.
23512787	658	669	glutathione	CHEMICAL	23512787T10
23512787	671	674	GSH	CHEMICAL	137
23512787	804	808	MPTP	CHEMICAL	23512787T12
23512787	861	867	oxygen	CHEMICAL	23512787T13
23512787	935	943	puerarin	CHEMICAL	23512787T14
23512787	956	960	MPTP	CHEMICAL	23512787T15
23512787	1078	1086	puerarin	CHEMICAL	23512787T16
23512787	1098	1102	MPTP	CHEMICAL	23512787T17
23512787	27	35	Puerarin	CHEMICAL	23512787T18
23512787	39	83	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	CHEMICAL	23512787T19
23512787	127	135	Puerarin	CHEMICAL	23512787T1
23512787	1161	1165	GDNF	GENE-Y	108936
23512787	1178	1182	PI3K	GENE-N	23512787T21
23512787	1183	1186	Akt	GENE-N	23512787T22
23512787	1288	1295	Lamp 2A	GENE-Y	23512787T23
23512787	686	729	glial cell line-derived neurotrophic factor	GENE-Y	23512787T24
23512787	731	735	GDNF	GENE-Y	108936
23512787	752	756	PI3K	GENE-N	23512787T26
23512787	757	760	Akt	GENE-N	23512787T27
23512787	969	1013	lysosome-associated membrane protein type 2A	GENE-Y	23512787T28
23512787	1015	1022	Lamp 2A	GENE-Y	23512787T29
23512787	1199	1202	GSH	CHEMICAL	137
23512787	1245	1249	MPTP	CHEMICAL	23512787T3
23512787	332	340	puerarin	CHEMICAL	23512787T4
23512787	465	473	puerarin	CHEMICAL	23512787T5
23512787	485	529	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	CHEMICAL	23512787T6
23512787	531	535	MPTP	CHEMICAL	23512787T7
23512787	605	613	dopamine	CHEMICAL	23512787T8
23512787	625	633	Puerarin	CHEMICAL	23512787T9
23512787	CPR:3	23512787T9	23512787T24
23512787	CPR:3	23512787T9	108936
23512787	CPR:3	23512787T9	23512787T26
23512787	CPR:3	23512787T9	23512787T27
23512787	CPR:4	23512787T14	23512787T29
23512787	CPR:4	23512787T15	23512787T28
23512787	CPR:4	23512787T15	23512787T29
23512787	CPR:4	23512787T16	23512787T23
23512787	CPR:4	23512787T3	23512787T23

23517729|t|Efficient induction of apoptosis in HeLa cells by a novel cationic porphycene photosensitizer.
23517729|a|In the present study we analyze the photobiological properties of 2,7,12-tris(-pyridinio-p-tolyl)-17-(p-(methoxymethyl)phenyl) porphycene (Py3MeO-TBPo) in Hela cells, in order to assess its potential as a new photosensitizer for photodynamic therapy of cultured tumor cells. Using 0.5M Py3MeO-TBPo, flow cytometry studies demonstrated an increase of intracellular drug levels related to the incubation time, reaching a maximum at 18h. LysoTracker() Green (LTG) and MitoTracker() Green (MTG) probes were used to identify the subcellular localization. Upon exposure to ultraviolet excitation, red porphycene fluorescence was detected as red granules in the cytoplasm that colocalized with LTG. No significant toxic effects were detected for Py3MeO-TBPo in the dark at concentrations below 1M. In contrast, Py3MeO-TBPo combined with red-light irradiation induced concentration- and fluence-dependent HeLa cells inactivation. Besides, all photodynamic protocols assayed induced a clear effect of cell detachment inhibition after trypsin treatment. Both apoptotic and necrotic cell death mechanisms can occur in HeLa cells depending on the experimental protocol. After 18h incubation with 0.5M Py3MeO-TBPo and subsequent red light irradiation (3.6J/cm(2)), a high number of cells die by apoptosis, as evaluated by morphological alterations, immunofluorescent relocalization of Bax from cytosol to mitochondria, and TUNEL assay. Likewise, immunofluorescence techniques showed that cytochrome c is released from mitochondria into cytosol in cells undergoing apoptosis, which occurs immediately after relocation of Bax in mitochondria. The highest amount of apoptosis appeared 24h after treatment (70%) and this cell death occurred without cell detachment to the substrate. In contrast, with 0.75M Py3MeO-TBPo and 3.6J/cm(2) irradiation, morphological changes showed a preferential necrotic cell death. Singlet oxygen was identified as the cytotoxic agent involved in cell photoinactivation. Moreover, cell cultures pre-exposed to the singlet oxygen scavenger sodium azide showed pronounced protection against the loss of viability induced by Py3MeO-TBPo and light. Different changes in distribution and organization of cytoskeletal elements (microtubules and actin microfilaments) as well as the protein vinculin, after apoptotic and necrotic photodynamic treatments have been analyzed. Neither of these two cell death mechanisms (apoptosis or necrosis) induced cell detachment. In summary, Py3MeO-TBPo appears to meet the requirements for further scrutiny as a very good photosensitizer for photodynamic therapy: it is water soluble, has a high absorption in the red spectral region (where light penetration in tissue is higher), and is able to induce effective high apoptotic rate (70%) related to the more widely studied photosensitizers.
23517729	696	706	porphycene	CHEMICAL	23517729T10
23517729	161	233	2,7,12-tris(-pyridinio-p-tolyl)-17-(p-(methoxymethyl)phenyl) porphycene	CHEMICAL	23517729T11
23517729	840	851	Py3MeO-TBPo	CHEMICAL	23517729T12
23517729	907	918	Py3MeO-TBPo	CHEMICAL	23517729T13
23517729	67	77	porphycene	CHEMICAL	23517729T14
23517729	1128	1135	trypsin	GENE-N	23517729T15
23517729	1479	1482	Bax	GENE-Y	198304|246997
23517729	1582	1594	cytochrome c	GENE-Y	23517729T17
23517729	1714	1717	Bax	GENE-Y	198304|246997
23517729	2346	2358	microtubules	GENE-N	23517729T19
23517729	1295	1306	Py3MeO-TBPo	CHEMICAL	23517729T1
23517729	2363	2368	actin	GENE-N	23517729T20
23517729	2408	2416	vinculin	GENE-Y	23517729T21
23517729	235	246	Py3MeO-TBPo	CHEMICAL	23517729T2
23517729	1900	1911	Py3MeO-TBPo	CHEMICAL	23517729T3
23517729	2014	2020	oxygen	CHEMICAL	23517729T4
23517729	2146	2152	oxygen	CHEMICAL	23517729T5
23517729	2163	2175	sodium azide	CHEMICAL	23517729T6
23517729	2246	2257	Py3MeO-TBPo	CHEMICAL	23517729T7
23517729	2595	2606	Py3MeO-TBPo	CHEMICAL	23517729T8
23517729	384	395	Py3MeO-TBPo	CHEMICAL	23517729T9

23522564|t|Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation.
23522564|a|HIV entry is mediated by the envelope glycoproteins gp120 and gp41. The gp41 subunit contains several functional domains: the N-terminal heptad repeat (NHR) domains fold a triple stranded coiled-coil forming a meta-stable prefusion intermediate. C-terminal heptad repeat (CHR) subsequently folds onto the hydrophobic grooves of the NHR coiled-coil to form a stable 6-helix bundle, which juxtaposes the viral and cellular membranes for fusion. The C34 which has 34 amino acid residues is known as the core structure in CHR. A highly anti-HIV peptide inhibitor derived from C34 was designed. An artificial salt bridge was added in the 6-helical bundle by substitution of lysine for Ile646. With a cholesterol modification at C-terminal, the inhibitor containing I646K mutation represented higher anti-viral activity than C34-cholesterol combination without mutation.
23522564	151	179	envelope glycoproteins gp120	GENE-Y	23522564T10
23522564	184	188	gp41	GENE-Y	23522564T11
23522564	194	198	gp41	GENE-Y	23522564T12
23522564	882	887	I646K	GENE-N	23522564T13
23522564	38	47	Ile646Lys	GENE-N	23522564T14
23522564	60	83	gp41 coiled-coil domain	GENE-N	23522564T15
23522564	248	249	N	CHEMICAL	167
23522564	368	369	C	CHEMICAL	23522564T2
23522564	586	596	amino acid	CHEMICAL	23522564T3
23522564	791	797	lysine	CHEMICAL	23522564T4
23522564	802	805	Ile	CHEMICAL	160
23522564	817	828	cholesterol	CHEMICAL	23522564T6
23522564	845	846	C	CHEMICAL	23522564T7
23522564	945	956	cholesterol	CHEMICAL	23522564T8
23522564	248	286	N-terminal heptad repeat (NHR) domains	GENE-N	23522564T9

23523831|t|Cytotoxic mechanism of Piper gaudichaudianum Kunth essential oil and its major compound nerolidol.
23523831|a|Piper gaudichaudianum Kunth is used in popular medicine as anti-inflamatory and against liver disorders. One of the most studied components of the plant is the essential oil for which chemical analysis revealed (E)-nerolidol as major compound. Recently, we have shown that P. gaudichaudianum essential oil possesses strong cytotoxic effects in mammalian V79 cells. The aim of this study was to analyze the cytotoxicity and mutagenicity of P. gaudichaudianum essential oil and nerolidol using Saccharomyces cerevisiae as model study. Treatment of the XV185-14c and N123 strains with essential oil and nerolidol led to cytotoxicity but did not induce mutagenicity. Our results revealed an important role of base excision repair (BER) as the ntg1, ntg2, apn1 and apn2 mutants showed pronounced sensitivity to essential oil and nerolidol. In the absence of superoxide dismutase (in sod1 mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS). The ROS production was confirmed by DCF-DA probing assay in Sod-deficient strains. From this, we conclude that the observed cytotoxicity to P. gaudichaudianum essential oil and nerolidol is mainly related to ROS and DNA single strand breaks generated by the presence of oxidative lesions.
23523831	1084	1093	nerolidol	CHEMICAL	23523831T10
23523831	88	97	nerolidol	CHEMICAL	23523831T11
23523831	1200	1203	Sod	GENE-Y	64623
23523831	838	842	ntg1	GENE-Y	23523831T13
23523831	844	848	ntg2	GENE-Y	23523831T14
23523831	850	854	apn1	GENE-Y	275375
23523831	859	863	apn2	GENE-Y	277204
23523831	952	972	superoxide dismutase	GENE-Y	23523831T17
23523831	977	981	sod1	GENE-Y	278604
23523831	1118	1124	oxygen	CHEMICAL	23523831T1
23523831	1176	1182	DCF-DA	CHEMICAL	23523831T2
23523831	1317	1326	nerolidol	CHEMICAL	23523831T3
23523831	310	323	(E)-nerolidol	CHEMICAL	23523831T4
23523831	575	584	nerolidol	CHEMICAL	23523831T5
23523831	699	708	nerolidol	CHEMICAL	23523831T6
23523831	923	932	nerolidol	CHEMICAL	23523831T7
23523831	952	962	superoxide	CHEMICAL	23523831T8
23523831	1035	1044	nerolidol	CHEMICAL	23523831T9

23524160|t|Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives aspotential antidepressant agents. Part 1.
23524160|a|A series of 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives was synthesized and their biological activity was evaluated. The chemical structures of the newly prepared compounds were confirmed by (1)H NMR, (13)C NMR and ESI-HRMS spectra data. All tested compounds proved to be potent 5-HT1A receptor and serotonin transporter protein (SERT) ligands. Among them, compounds 15, 18, 19 and 30 showed significant affinity for 5-HT1A and SERT. Computer docking simulations carried out for compounds 15, 31 and 32 to models of 5-HT1A receptor and SERT confirm the results of biological tests. Due to high affinity for the 5-HT1A receptor and moderate affinity for SERT, compounds 31, 32, 35, and 37 were evaluated for their affinity for D2L, 5-HT6, 5-HT7 and 5-HT2A receptors. Invivo tests, in turn, resulted in determining the functional activity of compounds 15, 18, 19 and 30 to the 5-HT1A receptor. The results of these tests indicate that all of the ligands possess properties characteristic of 5-HT1A receptor agonists.
23524160	558	562	SERT	GENE-Y	23524160T10
23524160	646	652	5-HT1A	GENE-Y	23524160T11
23524160	666	670	SERT	GENE-Y	23524160T12
23524160	741	747	5-HT1A	GENE-Y	23524160T13
23524160	783	787	SERT	GENE-Y	23524160T14
23524160	856	859	D2L	GENE-Y	23524160T15
23524160	861	866	5-HT6	GENE-Y	23524160T16
23524160	868	873	5-HT7	GENE-Y	23524160T17
23524160	878	884	5-HT2A	GENE-Y	65794
23524160	1006	1012	5-HT1A	GENE-Y	23524160T19
23524160	135	173	3-(1H-indol-3-yl)pyrrolidine-2,5-dione	CHEMICAL	23524160T1
23524160	1120	1126	5-HT1A	GENE-Y	23524160T20
23524160	321	325	(1)H	CHEMICAL	23524160T2
23524160	331	336	(13)C	CHEMICAL	23524160T3
23524160	429	438	serotonin	CHEMICAL	23524160T4
23524160	45	66	pyrrolidine-2,5-dione	CHEMICAL	23524160T5
23524160	409	415	5-HT1A	GENE-Y	23524160T6
23524160	429	458	serotonin transporter protein	GENE-Y	23524160T7
23524160	460	464	SERT	GENE-Y	23524160T8
23524160	547	553	5-HT1A	GENE-Y	23524160T9

23524663|t|Metabolism Studies of Unformulated Internally [3H]-labeled siRNAs in Mice.
23524663|a|Absorption, distribution, metabolism, and excretion properties of two unformulated model siRNAs were determined using a single internal [(3)H]-radiolabeling procedure, where the full-length oligonucleotides were radiolabeled by Br/(3)H-exchange. Tissue distribution, excretion, and mass balance of radioactivity were investigated in male CD-1 mice, following a single intravenous administration of the [(3)H]-siRNAs, at a target dose level of 5 mg/kg. Quantitative whole-body autoradiography (QWBA) and liquid scintillation counting techniques were used to determine tissue distribution. Radiochromatogram profiles were determined in plasma, tissue extracts and urine. Metabolites were separated by liquid chromatography and identified by radiodetection and high-resolution accurate mass spectrometry. In general, there was little difference in the distribution of total radiolabeled components after administration of the two unformulated [(3)H]-siRNAs. The radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [(3)H]-MRP4 and [(3)H]-SSB siRNA, respectively). After an initial rapid decline, concentrations of total radiolabeled components in dried blood declined at a much slower rate. A nearly complete mass balance was obtained for the [(3)H]-SSB siRNA and renal excretion was the main route of elimination (38%). The metabolism of the two model siRNAs was rapid and extensive. Five minutes after administration, no parent compound could be detected in plasma. Instead, radiolabeled nucleosides resulting from nuclease hydrolysis were observed. In the metabolism profiles obtained from various tissues only radiolabeled nucleosides were found, suggesting that siRNAs are rapidly metabolized and that the distribution pattern of total radiolabeled components can be ascribed to small molecular weight metabolites.
23524663	1016	1020	(3)H	CHEMICAL	23524663T10
23524663	47	49	3H	CHEMICAL	23524663T11
23524663	1205	1209	MRP4	GENE-Y	36421|4727
23524663	1700	1708	nuclease	GENE-N	23524663T13
23524663	1199	1203	(3)H	CHEMICAL	23524663T1
23524663	1215	1219	(3)H	CHEMICAL	23524663T2
23524663	1427	1431	(3)H	CHEMICAL	23524663T3
23524663	212	216	(3)H	CHEMICAL	23524663T4
23524663	1673	1684	nucleosides	CHEMICAL	23524663T5
23524663	1810	1821	nucleosides	CHEMICAL	23524663T6
23524663	303	305	Br	CHEMICAL	23524663T7
23524663	306	310	(3)H	CHEMICAL	23524663T8
23524663	478	482	(3)H	CHEMICAL	23524663T9
23524663	CPR:9	23524663T5	23524663T13

23525902|t|Chemical genetic analyses of quantitative changes in Cdk1 activity during the human cell cycle.
23525902|a|Cyclin-dependent kinase 1 (Cdk1) controls cell proliferation and is inhibited by promising anticancer agents, but its mode of action and the consequences of its inhibition are incompletely understood. Cdk1 promotes S- and M-phases during the cell-cycle but also suppresses endoreduplication, which is associated with polyploidy and genome instability. The complexity of Cdk1 regulation has made it difficult to determine whether these different roles require different thresholds of kinase activity and whether the surge of activity as inhibitory phosphates are removed at mitotic onset is essential for cell proliferation. Here, we have used chemical genetics in a human cell line to address these issues. We rescued cells lethally depleted of endogenous Cdk1 with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (RO3306). At no 1NMPP1 concentration was mitosis in rescued clones prevented without also inducing endoreduplication, suggesting that these two key roles for Cdk1 are not simply controlled by different Cdk1 activity thresholds. We also rescued RO3306-resistant clones using exogenous Cdk1 without inhibitory phosphorylation sites, indicating that the mitotic surge of Cdk1 activity is dispensable for cell proliferation. These results suggest that the basic mammalian cycle requires at least some qualitative changes in Cdk1 activity and that quantitative increases in activity need not be rapid. Furthermore, the viability of cells that are unable to undergo rapid Cdk1 activation, and the strong association between endoreduplication and impaired proliferation, may place restrictions on the therapeutic use of a Cdk1 inhibitors.
23525902	1252	1256	Cdk1	GENE-Y	198624|248460
23525902	1336	1340	Cdk1	GENE-Y	198624|248460
23525902	1488	1492	Cdk1	GENE-Y	198624|248460
23525902	1634	1638	Cdk1	GENE-Y	198624|248460
23525902	1783	1787	Cdk1	GENE-Y	198624|248460
23525902	297	301	Cdk1	GENE-Y	198624|248460
23525902	123	127	Cdk1	GENE-Y	198624|248460
23525902	466	470	Cdk1	GENE-Y	198624|248460
23525902	579	585	kinase	GENE-N	23525902T18
23525902	852	856	Cdk1	GENE-Y	198624|248460
23525902	1212	1218	RO3306	CHEMICAL	23525902T1
23525902	875	879	Cdk1	GENE-Y	198624|248460
23525902	53	57	Cdk1	GENE-Y	198624|248460
23525902	643	653	phosphates	CHEMICAL	23525902T2
23525902	910	913	ATP	CHEMICAL	164
23525902	934	940	1NMPP1	CHEMICAL	23525902T4
23525902	969	975	RO3306	CHEMICAL	23525902T5
23525902	984	990	1NMPP1	CHEMICAL	23525902T6
23525902	96	121	Cyclin-dependent kinase 1	GENE-Y	23525902T7
23525902	1126	1130	Cdk1	GENE-Y	198624|248460
23525902	1170	1174	Cdk1	GENE-Y	198624|248460

23526644|t|Inhibition of Ebola Virus Infection: Identification of Niemann-Pick C1 as the Target by Optimization of a Chemical Probe.
23526644|a|A high throughput screen identified adamantane dipeptide 1 as an inhibitor of Ebola virus (EboV) infection. Hit-to-lead optimization to determine the structure-activity relationship (SAR) identified the more potent EboV inhibitor 2 and a photoaffinity labeling agent 3. These anti-viral compounds were employed to identify the target as Niemann-Pick C1 (NPC1), a host protein that binds the EboV glycoprotein and is essential for infection. These studies establish NPC1 as a promising target for anti-viral therapy.
23526644	158	168	adamantane	CHEMICAL	23526644T1
23526644	459	474	Niemann-Pick C1	GENE-Y	23526644T2
23526644	476	480	NPC1	GENE-Y	110925
23526644	513	530	EboV glycoprotein	GENE-N	23526644T4
23526644	587	591	NPC1	GENE-Y	110925
23526644	55	70	Niemann-Pick C1	GENE-Y	23526644T6

23527317|t|Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.
23527317|a|A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the vesicular monoamine transporter and for their inhibition of vesicular [(3)H]dopamine uptake. Compound 19a, which contains an N-1,2(R)-dihydroxypropyl group, had been identified as a potential clinical candidate for the treatment of methamphetamine abuse.
23527317	42	54	nor-lobelane	CHEMICAL	23527317T10
23527317	306	337	vesicular monoamine transporter	GENE-N	23527317T11
23527317	79	84	VMAT2	GENE-Y	23527317T12
23527317	182	183	N	CHEMICAL	167
23527317	316	325	monoamine	CHEMICAL	23527317T2
23527317	376	390	[(3)H]dopamine	CHEMICAL	23527317T3
23527317	431	455	N-1,2(R)-dihydroxypropyl	CHEMICAL	23527317T4
23527317	196	204	lobelane	CHEMICAL	23527317T5
23527317	538	553	methamphetamine	CHEMICAL	23527317T6
23527317	255	281	[(3)H]dihydrotetrabenazine	CHEMICAL	23527317T7
23527317	147	162	methamphetamine	CHEMICAL	23527317T8
23527317	24	25	N	CHEMICAL	167
23527317	CPR:9	23527317T3	23527317T11

23527529|t|The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway.
23527529|a|Abstract 1. IPI-926 is a novel semisynthetic cyclopamine derivative that is a potent and selective Smoothened inhibitor that blocks the hedgehog signal transduction pathway. 2. The in vivo clearance of IPI-926 is low in mouse and dog and moderate in monkey. The volume of distribution is high across species. Oral bioavailability ranges from moderate in monkey to high in mouse and dog. Predicted human clearance using simple allometry is low (24Lh(-1)), predicted volume of distribution is high (469L) and predicted half-life is long (20h). 3. IPI-926 is highly bound to plasma proteins and has minimal interaction with human -1-acid glycoprotein. 4. In vitro metabolic stability ranges from stable to moderately stable. Twelve oxidative metabolites were detected in mouse, rat, dog, monkey and human liver microsome incubations and none were unique to human. 5. IPI-926 is not a potent reversible inhibitor of CYP1A2, 2C8, 2C9 or 3A4 (testosterone). IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 (midazolam) with KI values of 19, 16 and 4.5M, respectively. IPI-926 is both a substrate and inhibitor (IC50=1.9M) of P-glycoprotein. 6. In summary, IPI-926 has desirable pre-clinical absorption, distribution, metabolism and excretion properties.
23527529	1127	1134	IPI-926	CHEMICAL	23527529T10
23527529	82	89	IPI-926	CHEMICAL	23527529T11
23527529	1307	1321	P-glycoprotein	GENE-N	23527529T12
23527529	795	822	human -1-acid glycoprotein	GENE-N	23527529T13
23527529	1087	1110	CYP1A2, 2C8, 2C9 or 3A4	GENE-N	23527529T14
23527529	1162	1182	CYP2C19, 2D6 and 3A4	GENE-N	23527529T15
23527529	1184	1193	midazolam	CHEMICAL	23527529T1
23527529	1246	1253	IPI-926	CHEMICAL	23527529T2
23527529	1338	1345	IPI-926	CHEMICAL	23527529T3
23527529	182	189	IPI-926	CHEMICAL	23527529T4
23527529	372	379	IPI-926	CHEMICAL	23527529T5
23527529	215	226	cyclopamine	CHEMICAL	23527529T6
23527529	719	726	IPI-926	CHEMICAL	23527529T7
23527529	1039	1046	IPI-926	CHEMICAL	23527529T8
23527529	1112	1124	testosterone	CHEMICAL	614
23527529	CPR:4	23527529T2	23527529T12
23527529	CPR:9	23527529T2	23527529T12

23528363|t|Protection of glycyrrhizic acid against AGEs-induced endothelial dysfunction through inhibiting RAGE/NF-B pathway activation in human umbilical vein endothelial cells.
23528363|a|ETHNOPHARMACOLOGICAL RELEVANCE: Licorice (Glycyrrhiza uralensis roots) is used as a traditional medicine for the treatment of diabetes mellitus and its vascular complications. Glycyrrhizic acid (GA, also known as Glycyrrhizin), a triterpenoid saponin glycoside, is considered to be a bioactive component in Licorice and is beneficial to diabetic vascular complications. AIM OF STUDY: The present study was conducted to evaluate the potential protective activities on AGEs-induced endothelial dysfunction, including anti-apoptosis, antioxidant stress and anti-proinflammatory responses, and explore the underlying mechanism. MATERIALS AND METHODS: Human umbilical vein endothelial cells (HUVECs) were incubated and pre-treated with GA (10(-9)-10(-6)M) or RAGE-Ab (5g/ml) in the presence or absence of 200g/ml AGEs. AO/EB fluorescence staining assay was performed to evaluate anti-apoptosis activity. The superoxide dismutase (SOD) activity and malondialdehyde (MDA) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) kit. Immunocytochemistry analysis was designed to determine transforming growth factor beta1(TGF-1) protein expression while immunofluorescence analysis for RAGE and NF-kB. The protein expressions of TGF-1, RAGE and NF-kB were analyzed by Western blot analysis. RESULTS: Pretreatment with GA at a concentration of 10(-8)-10(-6)M significantly reduced the AGEs-induced apoptosis in HUVECs. GA significantly increased antioxidant enzyme SOD activity and decreased peroxide degradation product MDA level in a dose-dependent manner. Furthermore, GA also remarkably inhibited the overgeneration of AGEs-induced ROS. Both immunocytochemistry analysis and western blot analysis showed that GA significantly decreased the protein expression of poinflammatory cytokine TGF-1 in a similar manner which RAGE-Ab did. Additionally, AGEs-induced RAGE and NF-kB protein expressions were down-regulated significantly by the pretreatment with GA or RAGE-Ab. CONCLUSION: These findings provide evidences that GA possesses protective activity on AGEs-induced endothelial dysfunction, including anti-apoptosis, anti-inflammation and antioxidant stress, via inhibiting RAGE/NF-kB pathway. GA might be an alternative for the prevention and treatment of diabetic vascular complications in an appropriate dosage.
23528363	1131	1134	MDA	CHEMICAL	23528363T10
23528363	14	31	glycyrrhizic acid	CHEMICAL	23528363T11
23528363	1377	1409	transforming growth factor beta1	GENE-Y	23528363T12
23528363	1410	1416	TGF-1	GENE-Y	23528363T13
23528363	1475	1479	RAGE	GENE-Y	23528363T14
23528363	1484	1489	NF-kB	GENE-N	23528363T15
23528363	1518	1524	TGF-1	GENE-Y	23528363T16
23528363	1526	1530	RAGE	GENE-Y	23528363T17
23528363	1535	1540	NF-kB	GENE-N	23528363T18
23528363	1754	1757	SOD	GENE-N	23528363T19
23528363	1217	1223	oxygen	CHEMICAL	23528363T1
23528363	2070	2078	cytokine	GENE-N	23528363T20
23528363	2079	2085	TGF-1	GENE-Y	23528363T21
23528363	2112	2116	RAGE	GENE-Y	23528363T22
23528363	2152	2156	RAGE	GENE-Y	23528363T23
23528363	2161	2166	NF-kB	GENE-N	23528363T24
23528363	2252	2256	RAGE	GENE-Y	23528363T25
23528363	2468	2472	RAGE	GENE-Y	23528363T26
23528363	2473	2478	NF-kB	GENE-N	23528363T27
23528363	923	927	RAGE	GENE-Y	23528363T28
23528363	1074	1094	superoxide dismutase	GENE-N	23528363T29
23528363	1267	1306	2,7-dichlorodihydrofluorescin diacetate	CHEMICAL	23528363T2
23528363	1096	1099	SOD	GENE-N	23528363T30
23528363	101	106	NF-B	GENE-N	23528363T31
23528363	96	100	RAGE	GENE-Y	23528363T32
23528363	1308	1315	DCFH-DA	CHEMICAL	23528363T3
23528363	1810	1813	MDA	CHEMICAL	23528363T4
23528363	345	362	Glycyrrhizic acid	CHEMICAL	23528363T5
23528363	382	394	Glycyrrhizin	CHEMICAL	23528363T6
23528363	399	429	triterpenoid saponin glycoside	CHEMICAL	23528363T7
23528363	1074	1084	superoxide	CHEMICAL	23528363T8
23528363	1114	1129	malondialdehyde	CHEMICAL	23528363T9

23529671|t|Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.
23529671|a|The effects of hyperprolactinemia on metabolic parameters are not clear and a few data evaluating adiponectin levels in prolactinoma and idiopathic hyperprolactinemia exist. The aim of this study was to evaluate the effects of hyperprolactinemia on body weight, insulin resistance, beta cell function, and leptin and adiponectin levels in premenopausal women with hyperprolactinemia. Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age-matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma glucose, insulin levels, insulin resistance measured by homeostasis model assessment (HOMA)-insulin resistance index, beta cell function measured by HOMA- index, leptin and adiponectin levels. Plasma insulin levels and HOMA indexes (both insulin resistance and beta indexes) were significantly higher in hyperprolactinemic women. The other parameters were similar between both groups. There was a positive correlation between prolactin levels and fasting plasma glucose in hyperprolactinemic women. The results of this study showed that high prolactin levels may be associated with hyperinsulinemia and insulin resistance in premenopausal women. This effect seems to be independent of body weight, leptin and adiponectin levels. High prolactin levels may directly stimulate insulin secretion from pancreas and directly cause hepatic and whole-body insulin resistance.
23529671	1605	1612	insulin	GENE-Y	23529671T10
23529671	431	437	leptin	GENE-Y	23529671T11
23529671	442	453	adiponectin	GENE-Y	23529671T12
23529671	765	772	insulin	GENE-Y	23529671T13
23529671	781	788	insulin	GENE-Y	23529671T14
23529671	848	855	insulin	GENE-Y	23529671T15
23529671	919	925	leptin	GENE-Y	23529671T16
23529671	930	941	adiponectin	GENE-Y	23529671T17
23529671	957	964	insulin	GENE-Y	23529671T18
23529671	995	1002	insulin	GENE-Y	23529671T19
23529671	1219	1226	glucose	CHEMICAL	23529671T1
23529671	223	234	adiponectin	GENE-Y	23529671T20
23529671	27	34	insulin	GENE-Y	23529671T21
23529671	47	53	leptin	GENE-N	23529671T22
23529671	58	69	adiponectin	GENE-N	23529671T23
23529671	756	763	glucose	CHEMICAL	23529671T2
23529671	1183	1192	prolactin	GENE-Y	23529671T3
23529671	1299	1308	prolactin	GENE-Y	23529671T4
23529671	1360	1367	insulin	GENE-Y	23529671T5
23529671	1455	1461	leptin	GENE-Y	23529671T6
23529671	1466	1477	adiponectin	GENE-Y	23529671T7
23529671	1491	1500	prolactin	GENE-Y	23529671T8
23529671	1531	1538	insulin	GENE-Y	23529671T9

23529825|t|Lorcaserin: a review of its use in chronic weight management.
23529825|a|Oral lorcaserin (BELVIQ()), a selective serotonin 5-HT2C receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes). This article reviews the pharmacological properties, therapeutic efficacy and tolerability of oral lorcaserin in this patient population. In three large randomized, double-blind, multicentre studies, oral lorcaserin was more effective than placebo in the management of obese and overweight adults with or without type 2 diabetes mellitus. Following 12months' therapy, significantly higher proportions of lorcaserin than placebo recipients achieved a 5 and 10% reduction from baseline in their bodyweight and a significant between-group difference favouring lorcaserin over placebo was observed for the change from baseline in bodyweight. Moreover, among patients who had achieved a 5% reduction in their bodyweight after 12months' therapy with lorcaserin, a significantly higher proportion who received lorcaserin for a further 12months than those who switched to placebo maintained 5% weight loss at 24months. In general, oral lorcaserin was well tolerated in clinical studies, with hypoglycaemia and headache the most frequently reported adverse events in those with or without type 2 diabetes, respectively. According to a pooled analysis, the risk of US-FDA-defined valvulopathy with lorcaserin is generally low and not statistically significantly different from placebo. From these and other data, the FDA has concluded that lorcaserin is unlikely to elevate the risk of valvulopathy.
23529825	67	77	lorcaserin	CHEMICAL	23529825T10
23529825	770	780	lorcaserin	CHEMICAL	23529825T11
23529825	926	936	lorcaserin	CHEMICAL	23529825T12
23529825	0	10	Lorcaserin	CHEMICAL	4671
23529825	113	119	5-HT2C	GENE-Y	23529825T14
23529825	1116	1126	lorcaserin	CHEMICAL	23529825T1
23529825	1175	1185	lorcaserin	CHEMICAL	23529825T2
23529825	1304	1314	lorcaserin	CHEMICAL	23529825T3
23529825	1564	1574	lorcaserin	CHEMICAL	23529825T4
23529825	1706	1716	lorcaserin	CHEMICAL	23529825T5
23529825	79	85	BELVIQ	CHEMICAL	23529825T6
23529825	464	474	lorcaserin	CHEMICAL	23529825T7
23529825	103	112	serotonin	CHEMICAL	23529825T8
23529825	570	580	lorcaserin	CHEMICAL	23529825T9
23529825	CPR:5	23529825T10	23529825T14
23529825	CPR:5	23529825T6	23529825T14

23530834|t|Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a 2-Cyanopyrrolidine Moiety as Potent Dipeptidyl Peptidase 4 Inhibitors.
23530834|a|A novel series of (S)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety were designed and synthesized through a rational drug design strategy. Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the cyclopropyl-substituted phenylalanine derivative 11h displayed the most potent DPP-4 inhibitory activity with an IC50 value of 0.247 M. In addition, molecular docking analysis of the representative compounds 11h, 11k, and 15a were performed, which not only revealed the impact of binding modes on DPP-4 inhibitory activity, but also provided additional methodological values for design and optimization.  2013 John Wiley & Sons A/S.
23530834	138	160	Dipeptidyl Peptidase 4	GENE-Y	23530834T10
23530834	191	208	(S)-phenylalanine	CHEMICAL	23530834T1
23530834	454	491	cyclopropyl-substituted phenylalanine	CHEMICAL	23530834T2
23530834	228	246	2-cyanopyrrolidine	CHEMICAL	23530834T3
23530834	102	120	2-Cyanopyrrolidine	CHEMICAL	23530834T4
23530834	65	82	(S)-Phenylalanine	CHEMICAL	23530834T5
23530834	395	417	dipeptidyl peptidase 4	GENE-Y	23530834T6
23530834	419	424	DPP-4	GENE-Y	23530834T7
23530834	533	538	DPP-4	GENE-Y	23530834T8
23530834	752	757	DPP-4	GENE-Y	23530834T9
23530834	CPR:4	23530834T2	23530834T8
23530834	CPR:4	23530834T4	23530834T10
23530834	CPR:4	23530834T5	23530834T10

23532932|t|Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.
23532932|a|The MDR1 gene encodes P-glycoprotein, a transmembrane drug efflux transporter that confers multidrug resistance in cancer cells and affects drug pharmacokinetics by virtue of its expression in the liver, kidney, and colon. Nuclear receptors SXR and CAR are possible master regulators of xenobiotic-inducible MDR1 expression in drug processing organs, but the mechanism of MDR1 regulation has yet to be directly demonstrated in vivo. Moreover, it has previously been impossible to determine the sustained or cumulative effect of repeated doses of xenobiotics on in vivo MDR1 expression. We previously reported a mouse model containing firefly luciferase (fLUC) knocked into the mdr1a genomic locus, allowing non-invasive bioimaging of intestinal mdr1a gene expression in live animals. In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel. All three agents induced mdr1a.fLUC expression (bioluminescence), but only PCN and docetaxel appeared to act primarily via PXR. Luminescence returned to baseline by 24-48 hrs after drug injection and was re-inducible over two additional rounds of drug dosing in pxr(+/+) mice. TCPOBOP, a CAR ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation. Collectively, these results demonstrate that the mdr1a.fLUC bioimaging model can capture changes in mdr1 gene expression under conditions of repeated xenobiotic treatment in vivo and that it can be used to probe the mechanism of gene regulation in response to different xenobiotic agents.
23532932	1243	1246	PXR	GENE-Y	23532932T10
23532932	1382	1385	pxr	GENE-Y	23532932T11
23532932	1408	1411	CAR	GENE-Y	23532932T12
23532932	1437	1442	mdr1a	GENE-Y	23532932T13
23532932	1451	1454	pxr	GENE-Y	23532932T14
23532932	1464	1467	pxr	GENE-Y	23532932T15
23532932	1498	1501	CAR	GENE-Y	23532932T16
23532932	1518	1523	mdr1a	GENE-Y	23532932T17
23532932	1585	1590	mdr1a	GENE-Y	23532932T18
23532932	1636	1640	mdr1	GENE-Y	23532932T19
23532932	1094	1104	paclitaxel	CHEMICAL	23532932T1
23532932	309	326	Nuclear receptors	GENE-N	23532932T20
23532932	108	123	P-glycoprotein,	GENE-Y	23532932T21
23532932	327	330	SXR	GENE-Y	23532932T22
23532932	335	338	CAR	GENE-Y	23532932T23
23532932	394	398	MDR1	GENE-Y	33343|1222221
23532932	458	462	MDR1	GENE-Y	33343|1222221
23532932	126	163	transmembrane drug efflux transporter	GENE-N	23532932T26
23532932	90	94	MDR1	GENE-Y	33343|1222221
23532932	655	659	MDR1	GENE-Y	33343|1222221
23532932	763	768	mdr1a	GENE-Y	23532932T29
23532932	1109	1118	docetaxel	CHEMICAL	23532932T2
23532932	831	836	mdr1a	GENE-Y	23532932T30
23532932	903	908	mdr1a	GENE-Y	23532932T31
23532932	928	931	pxr	GENE-Y	23532932T32
23532932	942	945	pxr	GENE-Y	23532932T33
23532932	1040	1043	PXR	GENE-Y	23532932T34
23532932	21	24	PXR	GENE-Y	23532932T35
23532932	35	40	mdr1a	GENE-Y	23532932T36
23532932	60	65	mdr1a	GENE-Y	23532932T37
23532932	1195	1198	PCN	CHEMICAL	23532932T3
23532932	1203	1212	docetaxel	CHEMICAL	23532932T4
23532932	1397	1404	TCPOBOP	CHEMICAL	23532932T5
23532932	994	1023	pregnenolone-16-carbonitrile	CHEMICAL	23532932T6
23532932	1025	1028	PCN	CHEMICAL	23532932T7
23532932	1085	1092	taxanes	CHEMICAL	23532932T8
23532932	1145	1150	mdr1a	GENE-Y	23532932T9
23532932	CPR:3	23532932T5	23532932T13

23534440|t|Bioinformatics and Molecular Dynamics Simulation Study of L1 Stalk Non-Canonical rRNA Elements: Kink-Turns, Loops, and Tetraloops.
23534440|a|The L1 stalk is a prominent mobile element of the large ribosomal subunit. We explore the structure and dynamics of its non-canonical rRNA elements, which include two kink-turns, an internal loop, and a tetraloop. We use bioinformatics to identify the L1 stalk RNA conservation patterns and carry out over 11.5 s of MD simulations for a set of systems ranging from isolated RNA building blocks up to complexes of L1 stalk rRNA with the L1 protein and tRNA fragment. We show that the L1 stalk tetraloop has an unusual GNNA or UNNG conservation pattern deviating from major GNRA and YNMG RNA tetraloop families. We suggest that this deviation is related to a highly conserved tertiary contact within the L1 stalk. The available X-ray structures contain only UCCG tetraloops which in addition differ in orientation (anti vs syn) of the guanine. Our analysis suggests that the anti orientation might be a mis-refinement, although even the anti interaction would be compatible with the sequence pattern and observed tertiary interaction. Alternatively, the anti conformation may be a real substate whose population could be pH-dependent, since the guanine syn orientation requires protonation of cytosine in the tertiary contact. In absence of structural data, we use molecular modeling to explore the GCCA tetraloop that is dominant in bacteria and suggest that the GCCA tetraloop is structurally similar to the YNMG tetraloop. Kink-turn Kt-77 is unusual due to its 11-nucleotide bulge. The simulations indicate that the long bulge is a stalk-specific eight-nucleotide insertion into consensual kink-turn only subtly modifying its structural dynamics. We discuss a possible evolutionary role of helix H78 and a mechanism of L1 stalk interaction with tRNA. We also assess the simulation methodology. The simulations provide a good description of the studied systems with the latest bsc0OL3 force field showing improved performance. Still, even bsc0OL3 is unable to fully stabilize an essential sugar-edge H-bond between the bulge and non-canonical stem of the kink-turn. Inclusion of Mg(2+) ions may deteriorate the simulations. On the other hand, monovalent ions can in simulations readily occupy experimental Mg(2+) binding sites.
23534440	1429	1433	GCCA	GENE-N	23534440T10
23534440	1434	1443	tetraloop	GENE-N	23534440T11
23534440	1494	1498	GCCA	GENE-N	23534440T12
23534440	1499	1508	tetraloop	GENE-N	23534440T13
23534440	1540	1544	YNMG	GENE-N	23534440T14
23534440	1545	1554	tetraloop	GENE-N	23534440T15
23534440	1556	1571	Kink-turn Kt-77	GENE-N	23534440T16
23534440	1723	1732	kink-turn	GENE-N	23534440T17
23534440	298	308	kink-turns	GENE-N	23534440T18
23534440	1823	1832	helix H78	GENE-N	23534440T19
23534440	1275	1282	guanine	CHEMICAL	23534440T1
23534440	1852	1860	L1 stalk	GENE-N	23534440T20
23534440	313	326	internal loop	GENE-N	23534440T21
23534440	334	343	tetraloop	GENE-N	23534440T22
23534440	2189	2198	kink-turn	GENE-N	23534440T23
23534440	383	391	L1 stalk	GENE-N	23534440T24
23534440	135	143	L1 stalk	GENE-N	23534440T25
23534440	545	553	L1 stalk	GENE-N	23534440T26
23534440	568	578	L1 protein	GENE-Y	23534440T27
23534440	615	633	L1 stalk tetraloop	GENE-N	23534440T28
23534440	649	653	GNNA	GENE-N	23534440T29
23534440	1323	1331	cytosine	CHEMICAL	23534440T2
23534440	657	661	UNNG	GENE-N	23534440T30
23534440	704	708	GNRA	GENE-N	23534440T31
23534440	713	717	YNMG	GENE-N	23534440T32
23534440	718	731	RNA tetraloop	GENE-N	23534440T33
23534440	834	842	L1 stalk	GENE-N	23534440T34
23534440	888	892	UCCG	GENE-N	23534440T35
23534440	893	903	tetraloops	GENE-N	23534440T36
23534440	58	94	L1 Stalk Non-Canonical rRNA Elements	GENE-N	23534440T37
23534440	96	106	Kink-Turns	GENE-N	23534440T38
23534440	1597	1607	nucleotide	CHEMICAL	23534440T3
23534440	1686	1696	nucleotide	CHEMICAL	23534440T4
23534440	2123	2128	sugar	CHEMICAL	23534440T5
23534440	2134	2135	H	CHEMICAL	112
23534440	2213	2219	Mg(2+)	CHEMICAL	23534440T7
23534440	2340	2346	Mg(2+)	CHEMICAL	23534440T8
23534440	965	972	guanine	CHEMICAL	23534440T9

23535185|t|Galangin attenuates mast cell-mediated allergic inflammation.
23535185|a|A great number of people are suffering from allergic inflammatory disease such as asthma, atopic dermatitis, and sinusitis. Therefore discovery of drugs for the treatment of these diseases is an important subject in human health. In this study, we investigated anti-allergic inflammatory effect of galangin and underlying mechanisms of action using in vitro and in vivo models. Galangin inhibited histamine release by the reduction of intracellular calcium in phorbol 12-mystate 13-acetate plus calcium ionophore A23187-stimulated human mast cells (HMC-1). Galangin decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-, interleukin (IL)-6, IL-1, and IL-8. The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-B, and caspase-1. Furthermore, galangin attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue. The inhibitory effects of galangin were more potent than cromolyn, a known anti-allergic drug. Our results showed that galangin down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory cytokines. In light of in vitro and in vivo anti-allergic inflammatory effects, galangin could be a beneficial anti-allergic inflammatory agent.
23535185	522	551	phorbol 12-mystate 13-acetate	CHEMICAL	23535185T10
23535185	557	564	calcium	CHEMICAL	23535185T11
23535185	619	627	Galangin	CHEMICAL	23535185T12
23535185	781	789	galangin	CHEMICAL	23535185T13
23535185	850	851	N	CHEMICAL	167
23535185	959	967	galangin	CHEMICAL	23535185T15
23535185	1044	1053	histamine	CHEMICAL	23535185T16
23535185	0	8	Galangin	CHEMICAL	23535185T17
23535185	1347	1356	cytokines	GENE-N	23535185T18
23535185	669	678	cytokines	GENE-N	23535185T19
23535185	1115	1123	galangin	CHEMICAL	23535185T1
23535185	688	717	tumor necrosis factor (TNF)-	GENE-Y	23535185T20
23535185	719	730	interleukin	GENE-Y	23535185T21
23535185	731	737	(IL)-6	GENE-Y	23535185T22
23535185	739	744	IL-1	GENE-Y	23535185T23
23535185	750	754	IL-8	GENE-Y	23535185T24
23535185	817	826	cytokines	GENE-N	23535185T25
23535185	844	849	c-Jun	GENE-Y	23535185T26
23535185	850	868	N-terminal kinases	GENE-N	23535185T27
23535185	874	877	p38	GENE-N	23535185T28
23535185	878	910	mitogen-activated protein kinase	GENE-N	23535185T29
23535185	1146	1154	cromolyn	CHEMICAL	23535185T2
23535185	912	929	nuclear factor-B	GENE-N	23535185T30
23535185	935	944	caspase-1	GENE-Y	23535185T31
23535185	979	982	IgE	GENE-N	23535185T32
23535185	1044	1064	histamine receptor 1	GENE-Y	23535185T33
23535185	1208	1216	galangin	CHEMICAL	23535185T3
23535185	1294	1303	histamine	CHEMICAL	23535185T4
23535185	1427	1435	galangin	CHEMICAL	23535185T5
23535185	360	368	galangin	CHEMICAL	23535185T6
23535185	440	448	Galangin	CHEMICAL	23535185T7
23535185	459	468	histamine	CHEMICAL	23535185T8
23535185	511	518	calcium	CHEMICAL	23535185T9
23535185	CPR:4	23535185T12	23535185T19
23535185	CPR:4	23535185T12	23535185T20
23535185	CPR:4	23535185T12	23535185T21
23535185	CPR:4	23535185T12	23535185T22
23535185	CPR:4	23535185T12	23535185T23
23535185	CPR:4	23535185T12	23535185T24
23535185	CPR:4	23535185T13	23535185T25
23535185	CPR:4	23535185T15	23535185T32
23535185	CPR:4	23535185T15	23535185T33
23535185	CPR:4	23535185T3	23535185T18

23535288|t|Aberrant activation of M phase proteins by cell proliferation-evoking carcinogens after 28-day administration in rats.
23535288|a|We have previously reported that hepatocarcinogens increase liver cells expressing p21(Cip1), a G1 checkpoint protein and M phase proteins after 28-day treatment in rats. This study aimed to identify early prediction markers of carcinogens available in many target organs after 28-day treatment in rats. Immunohistochemical analysis was performed on Ki-67, p21(Cip1) and M phase proteins [nuclear Cdc2, phospho-Histone H3 (p-Histone H3), Aurora B and heterochromatin protein 1 (HP1)] with carcinogens targeting different organs. Carcinogens targeting thyroid (sulfadimethoxine; SDM), urinary bladder (phenylethyl isothiocyanate), forestomach (butylated hydroxyanisole; BHA), glandular stomach (catechol; CC), and colon (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and chenodeoxycholic acid) were examined using a non-carcinogenic toxicant (caprolactam) and carcinogens targeting other organs as negative controls. All carcinogens increased Ki-67(+), nuclear Cdc2(+), p-Histone H3(+) or Aurora B(+) carcinogenic target cells, except for both colon carcinogens, which did not increase cell proliferation. On the other hand, p21(Cip1+) cells increased with SDM and CC. HP1 responded only to BHA. Results revealed carcinogens evoking cell proliferation concurrently induced cell cycle arrest at M phase or showing chromosomal instability reflecting aberration in cell cycle regulation, irrespective of target organs, after 28-day treatment. Therefore, M phase proteins may be early prediction markers of carcinogens evoking cell proliferation in many target organs.
23535288	965	976	caprolactam	CHEMICAL	23535288T10
23535288	1247	1250	p21	GENE-Y	23535288T11
23535288	1251	1255	Cip1	GENE-Y	23535288T12
23535288	1291	1295	HP1	GENE-Y	23535288T13
23535288	241	257	M phase proteins	GENE-N	23535288T14
23535288	1574	1590	M phase proteins	GENE-N	23535288T15
23535288	469	474	Ki-67	GENE-Y	23535288T16
23535288	476	479	p21	GENE-Y	23535288T17
23535288	480	484	Cip1	GENE-Y	23535288T18
23535288	490	506	M phase proteins	GENE-N	23535288T19
23535288	1314	1317	BHA	CHEMICAL	23535288T1
23535288	516	520	Cdc2	GENE-Y	23535288T20
23535288	522	540	phospho-Histone H3	GENE-N	23535288T21
23535288	542	554	p-Histone H3	GENE-N	23535288T22
23535288	557	565	Aurora B	GENE-Y	23535288T23
23535288	570	596	heterochromatin protein 1	GENE-Y	23535288T24
23535288	598	602	HP1	GENE-Y	23535288T25
23535288	202	205	p21	GENE-Y	23535288T26
23535288	206	210	Cip1	GENE-Y	23535288T27
23535288	1065	1070	Ki-67	GENE-Y	23535288T28
23535288	1083	1087	Cdc2	GENE-Y	23535288T29
23535288	681	697	sulfadimethoxine	CHEMICAL	23535288T2
23535288	1092	1104	p-Histone H3	GENE-N	23535288T30
23535288	1111	1119	Aurora B	GENE-Y	23535288T31
23535288	23	39	M phase proteins	GENE-N	23535288T32
23535288	699	702	SDM	CHEMICAL	23535288T3
23535288	722	748	phenylethyl isothiocyanate	CHEMICAL	23535288T4
23535288	764	788	butylated hydroxyanisole	CHEMICAL	23535288T5
23535288	790	793	BHA	CHEMICAL	23535288T6
23535288	815	823	catechol	CHEMICAL	23535288T7
23535288	841	888	2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine	CHEMICAL	23535288T8
23535288	893	914	chenodeoxycholic acid	CHEMICAL	23535288T9

23537747|t|Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.
23537747|a|Hepatocyte growth factor (HGF), and its receptor, c-Met activation has recently been shown to play important roles in cancer invasion and metastasis in a wide variety of tumor cells. We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis. Among them, nobiletin markedly inhibited HGF-induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations. Data also showed nobiletin inhibited HGF-induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia. Furthermore, nobiletin could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38. Next, nobiletin significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration. In conclusion, nobiletin attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.
23537747	1053	1060	phospho	CHEMICAL	23537747T10
23537747	1070	1077	phospho	CHEMICAL	23537747T11
23537747	0	9	Nobiletin	CHEMICAL	23537747T12
23537747	108	132	Hepatocyte growth factor	GENE-Y	23537747T13
23537747	1227	1230	HGF	GENE-Y	109330
23537747	1277	1280	ERK	GENE-N	23537747T15
23537747	1285	1289	PI3K	GENE-N	23537747T16
23537747	1290	1293	Akt	GENE-N	23537747T17
23537747	298	301	HGF	GENE-Y	109330
23537747	134	137	HGF	GENE-Y	109330
23537747	1206	1215	nobiletin	CHEMICAL	23537747T1
23537747	448	451	HGF	GENE-Y	109330
23537747	452	457	c-Met	GENE-Y	23537747T21
23537747	539	542	HGF	GENE-Y	109330
23537747	158	163	c-Met	GENE-Y	23537747T23
23537747	756	759	HGF	GENE-Y	109330
23537747	882	885	HGF	GENE-Y	109330
23537747	938	943	c-Met	GENE-Y	23537747T26
23537747	945	949	ERK2	GENE-Y	23537747T27
23537747	955	958	Akt	GENE-N	23537747T28
23537747	968	989	phosphorylated JNK1/2	GENE-N	23537747T29
23537747	399	407	apigenin	CHEMICAL	6168
23537747	994	997	p38	GENE-N	23537747T30
23537747	1053	1065	phospho-ERK2	GENE-Y	23537747T31
23537747	1070	1081	phospho-Akt	GENE-N	23537747T32
23537747	1085	1089	ERK2	GENE-Y	23537747T33
23537747	1093	1096	Akt	GENE-N	23537747T34
23537747	41	44	ERK	GENE-N	23537747T35
23537747	49	53	PI3K	GENE-N	23537747T36
23537747	54	57	Akt	GENE-N	23537747T37
23537747	70	73	HGF	GENE-Y	109330
23537747	409	417	tricetin	CHEMICAL	23537747T3
23537747	419	429	tangeretin	CHEMICAL	23537747T4
23537747	435	444	nobiletin	CHEMICAL	23537747T5
23537747	510	519	nobiletin	CHEMICAL	23537747T6
23537747	736	745	nobiletin	CHEMICAL	23537747T7
23537747	858	867	nobiletin	CHEMICAL	23537747T8
23537747	1005	1014	nobiletin	CHEMICAL	23537747T9
23537747	CPR:4	23537747T12	23537747T35
23537747	CPR:4	23537747T12	23537747T36
23537747	CPR:4	23537747T12	23537747T37
23537747	CPR:4	23537747T1	109330
23537747	CPR:4	23537747T1	23537747T15
23537747	CPR:4	23537747T1	23537747T16
23537747	CPR:4	23537747T1	23537747T17
23537747	CPR:4	23537747T6	109330
23537747	CPR:4	23537747T7	109330
23537747	CPR:4	23537747T8	109330
23537747	CPR:4	23537747T8	23537747T26
23537747	CPR:4	23537747T8	23537747T27
23537747	CPR:4	23537747T8	23537747T28
23537747	CPR:4	23537747T9	23537747T31
23537747	CPR:4	23537747T9	23537747T32
23537747	CPR:4	23537747T9	23537747T33
23537747	CPR:4	23537747T9	23537747T34

23539511|t|Cardiac natriuretic Peptide gene expression and plasma concentrations during the first 72 hours of life in piglets.
23539511|a|Plasma measurement of cardiac natriuretic peptides constitutes promising markers of congenital heart disease. However, concentrations change rapidly and dramatically during the first days after delivery even in healthy neonates, which complicates clinical interpretation. It is unknown whether these changes in plasma concentrations are explained by corresponding changes in the cardiac gene expression. We quantified the chamber-specific mRNA levels of ANP (A-type natriuretic peptide) and BNP (B-type natriuretic peptide) and plasma pro-ANP and BNP-32 concentrations in healthy piglets during the first 72 hours of life (from 2 litters, n = 44). Chamber-specific ANP and BNP mRNA levels reflected hemodynamic neonate changes at birth but did not correlate with circulating natriuretic peptide concentrations. However, plasma pro-ANP and creatinine concentrations were closely correlated (P < .0001; r = 0.73). Plasma pro-ANP levels were highest on the day of delivery (5580 pmol/L [4320-6786] decreasing to 2484 pmol/L [1602-2898] after 72 hours, P < .0001). During the 72 hours, gel chromatography suggested that the translational products in circulation and in atrial tissue were immature, ie, unprocessed pro-ANP. In contrast to pro-ANP, BNP-32 plasma concentrations were low at delivery and peaked after 48 hours (12 [10.5-20.6] vs. 88.8 [71.7-101.4] pmol/L, P < .0001). To conclude, ANP and BNP gene expression differs considerably between cardiac chambers in the first 72 hours of life in healthy piglets, resembling the transition from fetal to neonate circulation. However, the cardiac gene expression does not explain plasma concentrations.
23539511	607	610	BNP	GENE-Y	23539511T10
23539511	612	638	B-type natriuretic peptide	GENE-N	23539511T11
23539511	655	658	ANP	GENE-Y	23539511T12
23539511	663	669	BNP-32	GENE-Y	23539511T13
23539511	781	784	ANP	GENE-Y	23539511T14
23539511	789	792	BNP	GENE-Y	23539511T15
23539511	891	910	natriuretic peptide	GENE-N	23539511T16
23539511	947	950	ANP	GENE-Y	23539511T17
23539511	1039	1042	ANP	GENE-Y	23539511T18
23539511	0	27	Cardiac natriuretic Peptide	GENE-N	23539511T19
23539511	955	965	creatinine	CHEMICAL	23539511T1
23539511	1330	1333	ANP	GENE-Y	23539511T2
23539511	1354	1357	ANP	GENE-Y	23539511T3
23539511	1359	1365	BNP-32	GENE-Y	23539511T4
23539511	1506	1509	ANP	GENE-Y	23539511T5
23539511	1514	1517	BNP	GENE-Y	23539511T6
23539511	138	166	cardiac natriuretic peptides	GENE-N	23539511T7
23539511	570	573	ANP	GENE-Y	23539511T8
23539511	575	601	A-type natriuretic peptide	GENE-Y	23539511T9

23541086|t|T-Cells from HLA-B*57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms.
23541086|a|Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different V receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself.
23541086	874	882	abacavir	CHEMICAL	23541086T10
23541086	1073	1081	abacavir	CHEMICAL	23541086T11
23541086	60	68	Abacavir	CHEMICAL	23541086T12
23541086	286	297	HLA-B*57:01	GENE-Y	23541086T13
23541086	1672	1704	major histocompatibility complex	GENE-N	23541086T14
23541086	1706	1709	MHC	GENE-N	23541086T15
23541086	1778	1781	MHC	GENE-N	23541086T16
23541086	1782	1797	T-cell receptor	GENE-N	23541086T17
23541086	1867	1870	MHC	GENE-N	23541086T18
23541086	533	544	HLA-B*57:01	GENE-Y	23541086T19
23541086	1211	1225	glutaraldehyde	CHEMICAL	23541086T1
23541086	727	739	V receptors	GENE-N	23541086T20
23541086	242	284	human leukocyte antigen allele HLA-B*57:01	GENE-Y	23541086T21
23541086	13	24	HLA-B*57:01	GENE-Y	23541086T22
23541086	1337	1345	abacavir	CHEMICAL	23541086T2
23541086	1487	1495	abacavir	CHEMICAL	23541086T3
23541086	1603	1611	abacavir	CHEMICAL	23541086T4
23541086	1739	1747	abacavir	CHEMICAL	23541086T5
23541086	1918	1926	abacavir	CHEMICAL	23541086T6
23541086	1945	1953	abacavir	CHEMICAL	23541086T7
23541086	606	614	abacavir	CHEMICAL	23541086T8
23541086	829	837	abacavir	CHEMICAL	23541086T9

23541982|t|Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid.
23541982|a|The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover. It is reduced in neurodegenerative disease states proportionally to the severity of disease and the degree of brain atrophy. In the early phases of active disease, a higher rate of turnover may result in transitory increases in plasma 24OHC. Less than 1% of the total brain excretion of 24OHC occurs via the cerebrospinal fluid (CSF) whereas almost all 27-hydroxycholesterol (27OHC) excretion is dependent on the function of the blood-cerebrospinal fluid barrier. Iincreased CSF oxysterols were found in patients with neurodegenerative and neuroinflammatory diseases in the presence of barrier dysfunction. In neurodegeneration, free cholesterol released from dying cells may engulf neurons. Cholesterol also increases Amyloid  (A) deposition and tau pathology. ApoE, 24OHC, tau and soluble APP were correlated in Alzheimer disease (AD) samples. Excess of cholesterol converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for A and Tau. In AD this protective mechanism seems to be inefficient, probably due to the presence of high concentrations of 27OHC, microvascular dysfunction and the decreased efficiency of ApoE4 as lipid transporter and A scavenger. 24OHC itself was cytotoxic. Analysis of side chain oxysterols in the CSF is likely to provided useful information about cholesterol metabolism and ApoE function in the pathogenesis of AD.
23541982	121	132	cholesterol	CHEMICAL	23541982T10
23541982	318	323	24OHC	CHEMICAL	23541982T11
23541982	410	421	cholesterol	CHEMICAL	23541982T12
23541982	667	672	24OHC	CHEMICAL	23541982T13
23541982	719	724	24OHC	CHEMICAL	23541982T14
23541982	170	181	cholesterol	CHEMICAL	23541982T15
23541982	785	806	27-hydroxycholesterol	CHEMICAL	23541982T16
23541982	808	813	27OHC	CHEMICAL	23541982T17
23541982	911	921	oxysterols	CHEMICAL	23541982T18
23541982	187	209	24S-hydroxycholesterol	CHEMICAL	23541982T19
23541982	1124	1135	Cholesterol	CHEMICAL	4350
23541982	1066	1077	cholesterol	CHEMICAL	23541982T20
23541982	48	58	oxysterols	CHEMICAL	23541982T21
23541982	1151	1160	Amyloid 	GENE-Y	23541982T22
23541982	1162	1164	A	GENE-Y	23541982T23
23541982	1181	1184	tau	GENE-Y	77370
23541982	1196	1200	ApoE	GENE-Y	23541982T25
23541982	1209	1212	tau	GENE-Y	77370
23541982	1217	1228	soluble APP	GENE-Y	23541982T27
23541982	1339	1343	ApoE	GENE-Y	23541982T28
23541982	1379	1381	A	GENE-Y	23541982T29
23541982	211	216	24OHC	CHEMICAL	23541982T2
23541982	1386	1389	Tau	GENE-Y	23541982T30
23541982	233	249	liver X receptor	GENE-N	23541982T31
23541982	1568	1573	ApoE4	GENE-Y	23541982T32
23541982	251	254	LXR	GENE-N	23541982T33
23541982	1599	1601	A	GENE-Y	23541982T34
23541982	1760	1764	ApoE	GENE-Y	23541982T35
23541982	312	316	ApoE	GENE-Y	23541982T36
23541982	1202	1207	24OHC	CHEMICAL	23541982T3
23541982	1290	1301	cholesterol	CHEMICAL	23541982T4
23541982	1317	1322	24OHC	CHEMICAL	23541982T5
23541982	1503	1508	27OHC	CHEMICAL	23541982T6
23541982	1613	1618	24OHC	CHEMICAL	23541982T7
23541982	1664	1674	oxysterols	CHEMICAL	23541982T8
23541982	1733	1744	cholesterol	CHEMICAL	23541982T9
23541982	CPR:3	23541982T4	23541982T28
23541982	CPR:3	23541982T5	23541982T28
23541982	CPR:4	4350	23541982T22
23541982	CPR:4	4350	23541982T23
23541982	CPR:4	4350	77370

23543737|t|Loss of Calcium/Calmodulin-Dependent Protein Kinase II Activity in Cortical Astrocytes Decreases Glutamate Uptake and Induces Neurotoxic Release of ATP.
23543737|a|The extent of calcium/calmodulin-dependent protein kinase II (CaMKII) inactivation in the brain following ischemia correlates with the extent of damage. We have previously shown that a loss of CaMKII activity in neurons is detrimental to neuronal viability by inducing excitotoxic glutamate release. In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular glutamate is reduced when CaMKII is inhibited. Furthermore, CaMKII inhibition in astrocytes is associated with the rapid onset of intracellular calcium oscillations. Surprisingly, this rapid calcium influx is blocked by the N-type calcium channel antagonist, omega-conotoxin. While the function of N-type calcium channels within astrocytes is controversial, these voltage-gated calcium channels have been linked to calcium-dependent vesicular gliotransmitter release. When extracellular glutamate and ATP levels are measured following CaMKII inhibition within our enriched astrocyte cultures, no alterations in glutamate levels are observed, whereas ATP levels in the extracellular environment significantly increase. Extracellular ATP accumulation associated with CaMKII inhibition contributes both to calcium oscillations within astrocytes and ultimately cortical neuron toxicity. Thus, a loss of CaMKII signaling within astrocytes dysregulates glutamate uptake and supports ATP release, two processes that would compromise neuronal survival following ischemic/excitotoxic insults.
23543737	707	714	calcium	CHEMICAL	23543737T10
23543737	754	761	calcium	CHEMICAL	23543737T11
23543737	787	788	N	CHEMICAL	167
23543737	794	801	calcium	CHEMICAL	23543737T13
23543737	861	862	N	CHEMICAL	167
23543737	868	875	calcium	CHEMICAL	23543737T15
23543737	941	948	calcium	CHEMICAL	23543737T16
23543737	978	985	calcium	CHEMICAL	23543737T17
23543737	1050	1059	glutamate	CHEMICAL	23543737T18
23543737	1064	1067	ATP	CHEMICAL	164
23543737	1174	1183	glutamate	CHEMICAL	23543737T1
23543737	148	151	ATP	CHEMICAL	164
23543737	8	15	Calcium	CHEMICAL	1332
23543737	97	106	Glutamate	CHEMICAL	23543737T22
23543737	1328	1334	CaMKII	GENE-N	68654
23543737	1462	1468	CaMKII	GENE-N	68654
23543737	167	213	calcium/calmodulin-dependent protein kinase II	GENE-N	23543737T25
23543737	346	352	CaMKII	GENE-N	68654
23543737	589	595	CaMKII	GENE-N	68654
23543737	623	629	CaMKII	GENE-N	68654
23543737	215	221	CaMKII	GENE-N	68654
23543737	1213	1216	ATP	CHEMICAL	164
23543737	787	809	N-type calcium channel	GENE-N	23543737T30
23543737	822	837	omega-conotoxin	GENE-N	23543737T31
23543737	861	884	N-type calcium channels	GENE-N	23543737T32
23543737	927	957	voltage-gated calcium channels	GENE-N	23543737T33
23543737	1098	1104	CaMKII	GENE-N	68654
23543737	8	54	Calcium/Calmodulin-Dependent Protein Kinase II	GENE-N	23543737T35
23543737	1295	1298	ATP	CHEMICAL	164
23543737	1366	1373	calcium	CHEMICAL	23543737T4
23543737	1510	1519	glutamate	CHEMICAL	23543737T5
23543737	1540	1543	ATP	CHEMICAL	164
23543737	167	174	calcium	CHEMICAL	23543737T7
23543737	434	443	glutamate	CHEMICAL	23543737T8
23543737	563	572	glutamate	CHEMICAL	23543737T9
23543737	CPR:9	23543737T9	68654

23545568|t|Stable and high-rate overcharge protection for rechargeable lithium batteries.
23545568|a|Rechargeable lithium or lithium-ion cells can be overcharge-protected by an electroactive polymer composite separator. The use of non-woven fibrous membranes instead of conventional microporous membranes as the composite substrates allowed better distribution of the electroactive polymer, which led to improved utilization and a 40-fold increase in sustainable current density. For the first time, stable overcharge protection for hundreds of cycles was demonstrated in several cell chemistries, including LiNi1/3Co1/3Mn1/3O2, LiFePO4, and spinel Li1.05Mn1.95O4 half-cells. Protection at a charging rate as high as 5 C was achieved at a steady state cell potential below 4.85 V.
23545568	92	99	lithium	CHEMICAL	23545568T1
23545568	103	110	lithium	CHEMICAL	23545568T2
23545568	586	591	LiNi1	CHEMICAL	23545568T3
23545568	592	596	3Co1	CHEMICAL	23545568T4
23545568	597	601	3Mn1	CHEMICAL	23545568T5
23545568	602	605	3O2	CHEMICAL	23545568T6
23545568	607	614	LiFePO4	CHEMICAL	23545568T7
23545568	627	641	Li1.05Mn1.95O4	CHEMICAL	23545568T8
23545568	60	67	lithium	CHEMICAL	23545568T9

23547652|t|3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition.
23547652|a|Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date. However, concerns about the pharmacokinetic liabilities of the hydroxamic acid moiety have stimulated research efforts aimed at finding alternative nonhydroxamate ZBGs. We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition. 3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively. Remarkably, 3-HPT gives no inhibition of HDAC 1. Subsequent optimization led to several novel 3HPT-based HDACi that are selective for HDAC 6 and HDAC 8. Furthermore, a subset of these inhibitors induces apoptosis in various cancer cell lines.
23547652	201	220	histone deacetylase	GENE-N	23547652T10
23547652	233	237	HDAC	GENE-N	23547652T11
23547652	510	514	HDAC	GENE-N	23547652T12
23547652	542	548	HDAC 6	GENE-Y	23547652T13
23547652	553	559	HDAC 8	GENE-Y	23547652T14
23547652	648	654	HDAC 1	GENE-Y	23547652T15
23547652	712	716	HDAC	GENE-N	23547652T16
23547652	741	747	HDAC 6	GENE-Y	23547652T17
23547652	752	758	HDAC 8	GENE-Y	23547652T18
23547652	68	87	Histone Deacetylase	GENE-N	23547652T19
23547652	312	327	hydroxamic acid	CHEMICAL	23547652T1
23547652	437	462	3-hydroxypyridin-2-thione	CHEMICAL	23547652T2
23547652	464	469	3-HPT	CHEMICAL	23547652T3
23547652	527	532	3-HPT	CHEMICAL	23547652T4
23547652	147	151	zinc	CHEMICAL	23547652T5
23547652	619	624	3-HPT	CHEMICAL	23547652T6
23547652	701	705	3HPT	CHEMICAL	23547652T7
23547652	0	25	3-Hydroxypyridin-2-thione	CHEMICAL	23547652T8
23547652	35	39	Zinc	CHEMICAL	23547652T9
23547652	CPR:4	23547652T2	23547652T12
23547652	CPR:4	23547652T3	23547652T12
23547652	CPR:4	23547652T4	23547652T13
23547652	CPR:4	23547652T4	23547652T14
23547652	CPR:4	23547652T5	23547652T10
23547652	CPR:4	23547652T5	23547652T11
23547652	CPR:4	23547652T7	23547652T16
23547652	CPR:4	23547652T7	23547652T17
23547652	CPR:4	23547652T7	23547652T18
23547652	CPR:4	23547652T8	23547652T19
23547652	CPR:4	23547652T9	23547652T19

23552260|t|Histological, ultrastructural and immunohistochemical studies on the protective effect of ginger extract against cisplatin-induced nephrotoxicity in male rats.
23552260|a|Cisplatin (CP) is a widely used anticancer drug; however, it has several side effects such as nephrotoxicity. Ginger, the rhizome of Zingiber officinale, consumed since ancient times has numerous health benefits. The objective of this work was to evaluate the protective effect of ginger extract (GE) against CP-induced nephrotoxicity. CP group displayed a marked renal failure characterized by a significant increase in serum creatinine and blood urea nitrogen (BUN) levels in addition to severe histopathological and ultrastructural renal alterations. Also, CP group showed an increase in the immunohistochemical expression of Bax proapoptotic protein. In contrast, GE+CP group showed significant decrease in the elevated serum creatinine and BUN levels and an improvement in the histopathological and ultrastructural renal injury induced by CP. The overexpression of Bax proapoptotic protein was significantly decreased in the GE+CP group. Hence, the present results indicated that GE has a protective effect against CP-induced renal damage in rats. Thereby, such findings recommended the usage of GE to prevent and/or decrease the renal damage induced by CP chemotherapeutic treatment.
23552260	160	169	Cisplatin	CHEMICAL	9929
23552260	587	597	creatinine	CHEMICAL	23552260T2
23552260	608	612	urea	CHEMICAL	23552260T3
23552260	613	621	nitrogen	CHEMICAL	23552260T4
23552260	890	900	creatinine	CHEMICAL	23552260T5
23552260	113	122	cisplatin	CHEMICAL	23552260T6
23552260	789	792	Bax	GENE-Y	198304|246997
23552260	1030	1033	Bax	GENE-Y	198304|246997

23553905|t|An analysis of skeletal development in osteoblast- and chondrocyte-specific Runx2 knockout mice.
23553905|a|Global gene deletion studies in mice and humans have established the pivotal role of runt related transcription factor-2 (Runx2) in both intramembranous and endochondral ossification processes during skeletogenesis. In this study, we for the first time generated mice carrying a conditional Runx2 allele with exon 4, which encodes the Runt domain, flanked by loxP sites. These mice were crossed with 1(I)-collagen-Cre or 1(II)-collagen-Cre transgenic mice to obtain osteoblast- or chondrocyte-specific Runx2 deficient mice, respectively. As seen in Runx2(-/-) mice, perinatal lethality was observed in 1(II)-Cre;Runx2(flox/flox) mice, but this was not the case in animals in which 1(I)-collagen-Cre was used to delete Runx2. When using double staining with Alizarin red for mineralized matrix and Alcian blue for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in Runx2(-/-) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in 1(II)-Cre;Runx2(flox/flox) mice. In newborn 1(II)-Cre;Runx2(flox/flox) mice, mineralization impairment was restricted to skeletal areas undergoing endochondral ossification including long bones and vertebrae. In contrast, no apparent skeletal abnormalities were seen in mutant embryo, newborn, and 3- to 6-week old-mice in which Runx2 had been deleted with the 1(I)-collagen-Cre driver. These results suggest that Runx2 is absolutely required for endochondral ossification during embryonic and postnatal skeletogenesis, but that disrupting its expression in already committed osteoblasts as achieved here with the 1(I)-collagen-Cre driver does not affect overtly intramembranous and endochondral ossification. The Runx2 floxed allele established here is undoubtedly useful for investigating the role of Runx2 in particular cells.  2013 American Society for Bone and Mineral Research.
23553905	1571	1576	Runx2	GENE-Y	266386|198518
23553905	1771	1785	1(I)-collagen	GENE-Y	23553905T11
23553905	1872	1877	Runx2	GENE-Y	266386|198518
23553905	1961	1966	Runx2	GENE-Y	266386|198518
23553905	388	393	Runx2	GENE-Y	266386|198518
23553905	432	443	Runt domain	GENE-N	23553905T15
23553905	456	466	loxP sites	GENE-N	23553905T16
23553905	497	511	1(I)-collagen	GENE-Y	23553905T17
23553905	519	534	1(II)-collagen	GENE-Y	23553905T18
23553905	601	606	Runx2	GENE-Y	266386|198518
23553905	858	870	Alizarin red	CHEMICAL	23553905T1
23553905	648	653	Runx2	GENE-Y	266386|198518
23553905	701	707	1(II)	GENE-Y	23553905T21
23553905	712	717	Runx2	GENE-Y	266386|198518
23553905	781	795	1(I)-collagen	GENE-Y	23553905T23
23553905	819	824	Runx2	GENE-Y	266386|198518
23553905	182	217	runt related transcription factor-2	GENE-Y	23553905T25
23553905	1043	1048	Runx2	GENE-Y	266386|198518
23553905	76	81	Runx2	GENE-Y	266386|198518
23553905	898	909	Alcian blue	CHEMICAL	23553905T2
23553905	1154	1160	1(II)	GENE-Y	23553905T3
23553905	1165	1170	Runx2	GENE-Y	266386|198518
23553905	1199	1205	1(II)	GENE-Y	23553905T5
23553905	1210	1215	Runx2	GENE-Y	266386|198518
23553905	219	224	Runx2	GENE-Y	266386|198518
23553905	1485	1490	Runx2	GENE-Y	266386|198518
23553905	1517	1531	1(I)-collagen	GENE-Y	23553905T9

23554071|t|A Mineral Extract from red Algae Ameliorates Chronic Spontaneous Colitis in IL-10 Deficient Mice in a Mouse Strain Dependent Manner.
23554071|a|Inflammatory bowel disease is an urgent public health problem with a high incidence in developed countries. Alterations of lifestyle or dietary interventions may attenuate the disease progression and increase the efficacy of current therapies. Here we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in calcium (34%), magnesium, phosphorus, selenium and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, interleukin (IL)-10(-/-) mice. The mineral extract was administered in the drinking water of Il10(-/-) mice on C57BL/6J and BALB/c strain backgrounds for 25weeks commencing from 3 to 4weeks of age. The mineral extract ameliorated the spontaneous development of colitis and severity of disease in Il10(-/-) mice on a C57BL/6J background. Mineral extract-treated Il10(-/-) C57BL/6J strain mice had significantly reduced mortality, circulating levels of serum Amyloid A and reduced colonic tissue damage. In contrast, comparable treatment of Il10(-/-) mice on a BALB/c background with the mineral extract did not alter the course of colitis. These data demonstrate that chronic supplementation with a natural mineral extract selectively ameliorates spontaneous mild-moderate colitis in Il10(-/-) mice on a C57BL/6J, but does not attenuate more moderate-severe colitis in BALB/c strain animals. Copyright  2013 John Wiley & Sons, Ltd.
23554071	985	989	Il10	GENE-Y	200603
23554071	1076	1091	serum Amyloid A	GENE-N	23554071T11
23554071	76	81	IL-10	GENE-Y	23554071T12
23554071	485	492	calcium	CHEMICAL	23554071T1
23554071	500	509	magnesium	CHEMICAL	23554071T2
23554071	511	521	phosphorus	CHEMICAL	23554071T3
23554071	523	531	selenium	CHEMICAL	23554071T4
23554071	1164	1168	Il10	GENE-Y	200603
23554071	1408	1412	Il10	GENE-Y	200603
23554071	620	639	interleukin (IL)-10	GENE-Y	23554071T7
23554071	713	717	Il10	GENE-Y	200603
23554071	919	923	Il10	GENE-Y	200603

23554574|t|Neuronal expression of glucosylceramide synthase in central nervous system regulates body weight and energy homeostasis.
23554574|a|Hypothalamic neurons are main regulators of energy homeostasis. Neuronal function essentially depends on plasma membrane-located gangliosides. The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of glucosylceramide synthase (GCS; UDP-glucose:ceramide glucosyltransferase). As a major mechanism of central nervous system (CNS) metabolic control, we demonstrate that GCS-derived gangliosides interacting with leptin receptors (ObR) in the neuronal membrane modulate leptin-stimulated formation of signaling metabolites in hypothalamic neurons. Furthermore, ganglioside-depleted hypothalamic neurons fail to adapt their activity (c-Fos) in response to alterations in peripheral energy signals. Consequently, mice with inducible forebrain neuron-specific deletion of the UDP-glucose:ceramide glucosyltransferase gene (Ugcg) display obesity, hypothermia, and lower sympathetic activity. Recombinant adeno-associated virus (rAAV)-mediated Ugcg delivery to the arcuate nucleus (Arc) significantly ameliorated obesity, specifying gangliosides as seminal components for hypothalamic regulation of body energy homeostasis.
23554574	404	407	GCS	GENE-Y	23554574T10
23554574	409	449	UDP-glucose:ceramide glucosyltransferase	GENE-Y	23554574T11
23554574	544	547	GCS	GENE-Y	23554574T12
23554574	586	602	leptin receptors	GENE-Y	23554574T13
23554574	604	607	ObR	GENE-Y	23554574T14
23554574	643	649	leptin	GENE-Y	23554574T15
23554574	806	811	c-Fos	GENE-Y	23554574T16
23554574	946	986	UDP-glucose:ceramide glucosyltransferase	GENE-Y	23554574T17
23554574	993	997	Ugcg	GENE-Y	204432
23554574	1112	1116	Ugcg	GENE-Y	204432
23554574	377	393	glucosylceramide	CHEMICAL	23554574T1
23554574	23	48	glucosylceramide synthase	GENE-Y	23554574T20
23554574	409	412	UDP	CHEMICAL	23554574T2
23554574	413	420	glucose	CHEMICAL	23554574T3
23554574	421	429	ceramide	CHEMICAL	23554574T4
23554574	946	949	UDP	CHEMICAL	23554574T5
23554574	950	957	glucose	CHEMICAL	23554574T6
23554574	958	966	ceramide	CHEMICAL	23554574T7
23554574	23	39	glucosylceramide	CHEMICAL	23554574T8
23554574	377	402	glucosylceramide synthase	GENE-Y	23554574T9

23557688|t|Environmental pesticide exposure modulates cytokines, arginase and ornithine decarboxylase expression in human placenta.
23557688|a|To evaluate the cytokine balance and enzymatic alterations induced by environmental pesticide exposure during pregnancy, this transversal study explored placentas derived from non-exposed women (control group-CG), and from women living in a rural area (rural group-RG), collected during intensive organophosphate (OP) pesticide spraying season (RG-SS) and during non-spraying season (RG-NSS). The exposure biomarkers blood cholinesterase and placental carboxylesterase (CaE) were significantly decreased in RG-SS. Among the cytokines studied IL-8, IL-6, TNF, IL-10, TGF and IL-13, the expression frequency of IL-13 increased in RG-SS. Arginase and ornithine decarboxylase (ODC) enzymes were induced in syncytiotrophoblast and endothelial cells. Interestingly, the decrease in CaE activity was associated with arginase and ODC activity induction. These findings suggest that environmental pesticide exposure impacts the placenta by increasing the expression frequency of the anti-inflammatory cytokine IL-13, which may be related to the up-regulation of enzymes implicated in tissue repair.
23557688	663	667	IL-8	GENE-Y	23557688T10
23557688	669	673	IL-6	GENE-Y	23557688T11
23557688	675	679	TNF	GENE-Y	23557688T12
23557688	681	686	IL-10	GENE-Y	23557688T13
23557688	688	692	TGF	GENE-Y	23557688T14
23557688	697	702	IL-13	GENE-Y	23557688T15
23557688	732	737	IL-13	GENE-Y	23557688T16
23557688	758	766	Arginase	GENE-N	23557688T17
23557688	771	794	ornithine decarboxylase	GENE-Y	23557688T18
23557688	796	799	ODC	GENE-Y	23557688T19
23557688	418	433	organophosphate	CHEMICAL	23557688T1
23557688	899	902	CaE	GENE-N	23557688T20
23557688	945	948	ODC	GENE-Y	23557688T21
23557688	1115	1123	cytokine	GENE-N	23557688T22
23557688	43	52	cytokines	GENE-N	23557688T23
23557688	54	62	arginase	GENE-N	23557688T24
23557688	67	90	ornithine decarboxylase	GENE-Y	23557688T25
23557688	771	780	ornithine	CHEMICAL	23557688T2
23557688	67	76	ornithine	CHEMICAL	23557688T3
23557688	1124	1129	IL-13	GENE-Y	23557688T4
23557688	137	145	cytokine	GENE-N	23557688T5
23557688	544	558	cholinesterase	GENE-Y	23557688T6
23557688	573	589	carboxylesterase	GENE-N	23557688T7
23557688	591	594	CaE	GENE-N	23557688T8
23557688	645	654	cytokines	GENE-N	23557688T9

23558600|t|Lixisenatide: first global approval.
23558600|a|The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia()) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin secretion in a glucose-dependent manner, as well as suppressing glucagon production and slowing gastric emptying. A once-daily subcutaneous formulation of lixisenatide has been approved in the EU, Iceland, Liechtenstein, Norway and Mexico for the treatment of type 2 diabetes, and is under regulatory review in the USA, Switzerland, Brazil, Canada, Ukraine, South Africa, Japan and Australia. This article summarizes the milestones in the development of lixisenatide, leading to this first approval for use in adults with type 2 diabetes.
23558600	372	379	glucose	CHEMICAL	23558600T1
23558600	261	266	GLP-1	GENE-Y	23558600T2
23558600	318	323	GLP-1	GENE-Y	23558600T3
23558600	332	337	GLP-1	GENE-Y	23558600T4
23558600	349	356	insulin	GENE-Y	23558600T5
23558600	71	111	glucagon-like peptide-1 (GLP-1) receptor	GENE-Y	23558600T6
23558600	421	429	glucagon	GENE-Y	23558600T7

23561088|t|Maqui berry (Aristotelia chilensis) and the constituent delphinidin glycoside inhibit photoreceptor cell death induced by visible light.
23561088|a|The protective effects of maqui berry (Aristotelia chilensis) extract (MBE) and its major anthocyanins [delphinidin 3,5-O-diglucoside (D3G5G) and delphinidin 3-O-sambubioside-5-O-glucoside (D3S5G)] against light-induced murine photoreceptor cells (661W) death were evaluated. Viability of 661W after light treatment for 24h, assessed by the tetrazolium salt (WST-8) assay and Hoechst 33342 nuclear staining, was improved by addition of MBE, D3G5G, and D3S5G. Intracellular radical activation in 661W, evaluated using the reactive oxygen species (ROS)-sensitive probe 5-(and-6)-chloromethyl-2,7-dichlorodihydro fluorescein diacetate acetyl ester (CM-H2DCFDA), was reduced by MBE and its anthocyanins. The anti-apoptosis mechanism of MBE was evaluated by light-induced phosphorylation of p38. MBE significantly suppressed the light-induced phosphorylation of p38. These findings indicate that MBE and its anthocyanidins suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of phosphorylated-p38 may be involved in the underlying mechanism.
23561088	704	781	5-(and-6)-chloromethyl-2,7-dichlorodihydro fluorescein diacetate acetyl ester	CHEMICAL	23561088T10
23561088	783	793	CM-H2DCFDA	CHEMICAL	23561088T11
23561088	823	835	anthocyanins	CHEMICAL	23561088T12
23561088	227	239	anthocyanins	CHEMICAL	23561088T13
23561088	1040	1054	anthocyanidins	CHEMICAL	23561088T14
23561088	56	77	delphinidin glycoside	CHEMICAL	23561088T15
23561088	1171	1189	phosphorylated-p38	GENE-N	23561088T16
23561088	923	926	p38	GENE-N	23561088T17
23561088	994	997	p38	GENE-N	23561088T18
23561088	86	99	photoreceptor	GENE-N	23561088T19
23561088	241	270	delphinidin 3,5-O-diglucoside	CHEMICAL	23561088T1
23561088	272	277	D3G5G	CHEMICAL	23561088T2
23561088	283	325	delphinidin 3-O-sambubioside-5-O-glucoside	CHEMICAL	23561088T3
23561088	327	332	D3S5G	CHEMICAL	23561088T4
23561088	478	489	tetrazolium	CHEMICAL	23561088T5
23561088	513	526	Hoechst 33342	CHEMICAL	23561088T6
23561088	578	583	D3G5G	CHEMICAL	23561088T7
23561088	589	594	D3S5G	CHEMICAL	23561088T8
23561088	667	673	oxygen	CHEMICAL	23561088T9
23561088	CPR:3	23561088T15	23561088T19
23561088	CPR:4	23561088T14	23561088T16

23561115|t|Influence of triterpenoids present in apple peel on inflammatory gene expression associated with inflammatory bowel disease (IBD).
23561115|a|Various ursanic, oleanic and lupanic pentacyclic triterpenoids found in apple peel were studied for anti-inflammatory effects in vitro using T84 colon carcinoma cells. After pretreatment with single triterpenoids, cells were stimulated with pro-inflammatory cytokines (TNF-, INF-, IL-1). Regulation of mRNA expression was analysed for three specific inflammation-associated marker genes (TNF-, IL-8, IP-10) using qRT-PCR. Furthermore, the effects of ursolic acid (UA) and oleanolic acid (OA) on the synthesis of certain pro-inflammatory proteins were examined. IP-10 expression was inhibited in a dose-dependent manner by all the tested compounds at concentrations 25M. The mRNA expression of TNF- was slightly affected and the IL-8 level was increased. At the protein level, UA and OA (25M) reduced the synthesis of IP-10; sICAM-1, IL-23 and GRO were slightly repressed. The TNF- level was not modulated, whereas induction of IL-8 was increased. UA also enhanced the synthesis of IL-1ra, while OA suppressed the level of I-TAC. The present study confirms that triterpenoids present in apple peel and -damascone may be implicated in the anti-inflammatory properties of apple constituents, suggesting that these substances might be helpful in the treatment of IBD as nutrient supplements.
23561115	400	405	TNF-	GENE-Y	23561115T10
23561115	407	412	INF-	GENE-Y	23561115T11
23561115	414	419	IL-1	GENE-Y	23561115T12
23561115	522	527	TNF-	GENE-Y	23561115T13
23561115	529	533	IL-8	GENE-Y	23561115T14
23561115	535	540	IP-10	GENE-Y	23561115T15
23561115	696	701	IP-10	GENE-Y	23561115T16
23561115	830	835	TNF-	GENE-Y	23561115T17
23561115	866	870	IL-8	GENE-Y	23561115T18
23561115	956	961	IP-10	GENE-Y	23561115T19
23561115	1202	1215	triterpenoids	CHEMICAL	23561115T1
23561115	963	970	sICAM-1	GENE-Y	23561115T20
23561115	972	977	IL-23	GENE-Y	23561115T21
23561115	982	986	GRO	GENE-Y	23561115T22
23561115	1016	1021	TNF-	GENE-Y	23561115T23
23561115	1068	1072	IL-8	GENE-Y	23561115T24
23561115	1122	1128	IL-1ra	GENE-Y	23561115T25
23561115	1242	1253	-damascone	CHEMICAL	23561115T2
23561115	330	343	triterpenoids	CHEMICAL	23561115T3
23561115	585	597	ursolic acid	CHEMICAL	23561115T4
23561115	607	621	oleanolic acid	CHEMICAL	23561115T5
23561115	139	193	ursanic, oleanic and lupanic pentacyclic triterpenoids	CHEMICAL	23561115T6
23561115	13	26	triterpenoids	CHEMICAL	23561115T7
23561115	1163	1168	I-TAC	GENE-Y	23561115T8
23561115	389	398	cytokines	GENE-N	23561115T9

23561205|t|Curcumin inhibits invasion and metastasis in K1 papillary thyroid cancer cells.
23561205|a|Curcumin, the active constituent of dietary spice turmeric, possesses a strong potential for cancer prevention and treatment. However, there is no study to address the effects of curcumin on invasion and metastasis of thyroid cancers. Thyroid cancer is the most common malignancy of endocrine organs, and its incidence rates have steadily increased over recent decades. Although most indolent tumours can be effectively managed, metastatic tumours at distant secondary sites behave aggressively and currently there is no effective form of treatment. Here, for the first time it has been reported that curcumin inhibit multiple metastasis steps of K1 papillary thyroid cancer cells. Curcumin dose-dependently suppressed viability of K1 cells as well as its cell attachment, spreading, migration and invasion abilities. Moreover, curcumin could also down-regulate the expression and activity of matrix metalloproteinase-9 (MMP-9). The findings showed that curcumin might be an effective tumouristatic agent for the treatment of aggressive papillary thyroid carcinomas.
23561205	80	88	Curcumin	CHEMICAL	23561205T1
23561205	259	267	curcumin	CHEMICAL	23561205T2
23561205	681	689	curcumin	CHEMICAL	23561205T3
23561205	762	770	Curcumin	CHEMICAL	23561205T4
23561205	908	916	curcumin	CHEMICAL	23561205T5
23561205	1034	1042	curcumin	CHEMICAL	23561205T6
23561205	0	8	Curcumin	CHEMICAL	23561205T7
23561205	973	999	matrix metalloproteinase-9	GENE-Y	23561205T8
23561205	1001	1006	MMP-9	GENE-Y	23561205T9
23561205	CPR:4	23561205T5	23561205T8
23561205	CPR:4	23561205T5	23561205T9

23562365|t|Lignans extracted from Vitex negundo possess cytotoxic activity by G2/M phase cell cycle arrest and apoptosis induction.
23562365|a|Evn-50 is a lignan compounds mixture extracted from Vitex negundo, a widely used herb in traditional Chinese medicine. This study is aimed to define the spectrum of cytotoxic activity of EVn-50, and also to investigate mechanisms underlying the anticancer actions via assessing the influence on cell cycle using EVn-50, and the lignan compound VB1 purified from EVn-50. The cytotoxic effect of EVn-50 and VB1 was determined with SRB assay using a panel of cancer cell lines. Breast cancer cell line MDA-MB-435 and liver cancer cell line SMMC-7721 were selected for further evaluating the effect of EVn-50 or VB1 on cell cycle by flow cytometric analysis. Apoptosis exerted by EVn-50 or VB1 was measured by TUNEL assay and DAPI staining, and Western blot analysis was utilized to assess the influence on expression and phosphorylation of proteins which are closely related to cell cycle and apoptosis. EVn-50 possessed a broad spectrum of in vitro anticancer activity for those tested cancer cells, especially sensitive to MDA-MB-435, SKOV-3, BXPC-3, SMMC-7721, MCF-7, HO-8910, SGC-7901, BEL-7402, HCT-116, and 786-O, with the respective IC50 below 10g/ml. Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c. Moreover, we found that exposure of MDA-MB-435 cells to EVn-50 or VB1 caused obvious apoptosis of MDA-MB-435 cells. Our data show that EVn-50, lignan compounds extracted from Vitex negundo, possesses a broad spectrum cytotoxic effect via arresting cancer cells at G2/M phase cell cycle and subsequently inducing apoptosis.
23562365	1713	1719	lignan	CHEMICAL	23562365T10
23562365	308	314	EVn-50	CHEMICAL	23562365T11
23562365	433	439	EVn-50	CHEMICAL	23562365T12
23562365	449	455	lignan	CHEMICAL	23562365T13
23562365	465	468	VB1	CHEMICAL	23562365T14
23562365	483	489	EVn-50	CHEMICAL	23562365T15
23562365	515	521	EVn-50	CHEMICAL	23562365T16
23562365	526	529	VB1	CHEMICAL	23562365T17
23562365	719	725	EVn-50	CHEMICAL	23562365T18
23562365	729	732	VB1	CHEMICAL	23562365T19
23562365	121	127	Evn-50	CHEMICAL	23562365T1
23562365	797	803	EVn-50	CHEMICAL	23562365T20
23562365	807	810	VB1	CHEMICAL	23562365T21
23562365	1022	1028	EVn-50	CHEMICAL	23562365T22
23562365	0	7	Lignans	CHEMICAL	23562365T23
23562365	1455	1464	Histone 3	GENE-N	23562365T24
23562365	1494	1498	Cdk1	GENE-Y	198624|248460
23562365	1523	1532	cyclin B1	GENE-Y	23562365T26
23562365	1562	1568	Cdc25c	GENE-Y	258742|198623
23562365	1293	1299	EVn-50	CHEMICAL	23562365T2
23562365	1303	1306	VB1	CHEMICAL	23562365T3
23562365	133	139	lignan	CHEMICAL	23562365T4
23562365	1468	1471	Ser	CHEMICAL	127
23562365	1502	1505	Tyr	CHEMICAL	129
23562365	1626	1632	EVn-50	CHEMICAL	23562365T7
23562365	1636	1639	VB1	CHEMICAL	23562365T8
23562365	1705	1711	EVn-50	CHEMICAL	23562365T9
23562365	CPR:3	23562365T2	23562365T24
23562365	CPR:3	23562365T2	198624|248460
23562365	CPR:3	23562365T2	23562365T26
23562365	CPR:3	23562365T3	23562365T24
23562365	CPR:3	23562365T3	198624|248460
23562365	CPR:3	23562365T3	23562365T26
23562365	CPR:4	23562365T2	258742|198623
23562365	CPR:4	23562365T3	258742|198623

23562495|t|TRP and ASIC channels mediate the antinociceptive effect of citronellyl acetate.
23562495|a|Background Citronellyl acetate (CAT), a monoterpene product of the secondary metabolism of plants, has been shown in the literature to possess several different biological activities. However, no antinociceptive abilities have yet been discussed. Here, we used acute pain animal models to describe the antinociceptive action of CAT. Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism. To do so, we induced paw-linking using agonists. Results CAT was administered intragastrically (25, 50, 75, 100 and 200mg/kg), and the two higher doses caused antinociceptive effects in the acetic acid model; the highest dose reduced pain for 4h after it was administered (200mg/kg). In the formalin test, two doses of CAT promoted antinociception in both the early and later phases of the test. The glutamate test showed that its receptors are involved in the antinociceptive mechanism of CAT. Pretreatment with CAT did not alter locomotor activity or motor coordination. In an investigation into the participation of TRP channels and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2g/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98). The results showed that TRPV1, TRPM8 and ASIC, but not TRPA1, are involved in the antinociceptive mechanism. Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of CAT. Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, glutamate receptors, PKC and PKA participate in CAT's antinociceptive mechanism.
23562495	1763	1766	CAT	CHEMICAL	23562495T10
23562495	1871	1874	CAT	CHEMICAL	23562495T11
23562495	1942	1951	glutamate	CHEMICAL	23562495T12
23562495	1990	1993	CAT	CHEMICAL	23562495T13
23562495	113	116	CAT	CHEMICAL	23562495T14
23562495	409	412	CAT	CHEMICAL	23562495T15
23562495	426	437	acetic acid	CHEMICAL	23562495T16
23562495	121	132	monoterpene	CHEMICAL	23562495T17
23562495	522	531	glutamate	CHEMICAL	23562495T18
23562495	536	544	formalin	CHEMICAL	23562495T19
23562495	1116	1125	glutamate	CHEMICAL	23562495T1
23562495	603	606	CAT	CHEMICAL	23562495T20
23562495	773	776	CAT	CHEMICAL	23562495T21
23562495	906	917	acetic acid	CHEMICAL	23562495T22
23562495	1007	1015	formalin	CHEMICAL	23562495T23
23562495	1035	1038	CAT	CHEMICAL	23562495T24
23562495	60	79	citronellyl acetate	CHEMICAL	23562495T25
23562495	1335	1347	TRP channels	GENE-N	23562495T26
23562495	1352	1357	ASICs	GENE-N	23562495T27
23562495	1548	1553	TRPV1	GENE-Y	113281
23562495	1555	1560	TRPM8	GENE-Y	122512
23562495	1206	1209	CAT	CHEMICAL	23562495T2
23562495	1565	1569	ASIC	GENE-N	23562495T30
23562495	1579	1584	TRPA1	GENE-Y	114471
23562495	1661	1664	PKC	GENE-N	23562495T32
23562495	1669	1672	PKA	GENE-N	23562495T33
23562495	1922	1927	TRPV1	GENE-Y	113281
23562495	1929	1934	TRPM8	GENE-Y	122512
23562495	1936	1940	ASIC	GENE-N	23562495T36
23562495	1942	1961	glutamate receptors	GENE-N	23562495T37
23562495	1963	1966	PKC	GENE-N	23562495T38
23562495	1971	1974	PKA	GENE-N	23562495T39
23562495	92	111	Citronellyl acetate	CHEMICAL	23562495T3
23562495	643	646	PKC	GENE-N	23562495T40
23562495	648	651	PKA	GENE-N	23562495T41
23562495	653	658	TRPV1	GENE-Y	113281
23562495	660	665	TRPA1	GENE-Y	114471
23562495	667	672	TRPM8	GENE-Y	122512
23562495	677	681	ASIC	GENE-N	23562495T45
23562495	0	21	TRP and ASIC channels	GENE-N	23562495T46
23562495	1229	1232	CAT	CHEMICAL	23562495T4
23562495	1361	1364	CAT	CHEMICAL	23562495T5
23562495	1402	1411	capsaicin	CHEMICAL	23562495T6
23562495	1425	1439	cinnamaldehyde	CHEMICAL	23562495T7
23562495	1454	1461	menthol	CHEMICAL	23562495T8
23562495	1501	1512	acetic acid	CHEMICAL	23562495T9

23562496|t|2-Hydroxychalcone and xanthohumol inhibit invasion of triple negative breast cancer cells.
23562496|a|Breast cancer is estimated as one of the most common causes of cancer death among women. In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/progesterone receptors (ER/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis. Chalcones, the biosynthetic precursors of flavonoids present in edible plants, exert cytotoxic and chemopreventive activities. Although mounting evidence suggests the anticancer properties of chalcones, limited information is available regarding the inhibitory effects of chalcones on the aggressiveness of breast cancer cells. The present study aimed to investigate the effects of chalcone and its derivatives on the growth and the invasiveness of TNBC cells. Here, we showed that treatment with chalcone, 2-hydroxychalcone, and xanthohumol for 24h inhibited the growth of MDA-MB-231cells with IC50 values of 18.1, 4.6, and 6.7M, respectively. Similarly, Chalcone, 2-hydroxychalcone, and xanthohumol also exerted cytotoxicity in another TNBC cell line, Hs578T. Neohesperidin dihydrochalcone, 4-methoxychalcone, and hesperidin methylchalcone did not show the cytotoxicity on the MDA-MB-231cells. Xanthohumol and 2-hydroxychalcone induced apoptosis by Bcl-2 downregulation. Importantly, 2-hydroxychalcone and xanthohumol exerted more potent inhibitory effects on the proliferation, MMP-9 expression and invasive phenotype of MDA-MB-231 than chalcone. These results suggest a potential application of these chalcones as anticancer agents that can alleviate malignant progression of TNBC.
23562496	1626	1635	chalcones	CHEMICAL	23562496T10
23562496	270	278	estrogen	CHEMICAL	23562496T11
23562496	279	291	progesterone	CHEMICAL	23562496T12
23562496	420	429	Chalcones	CHEMICAL	23562496T13
23562496	462	472	flavonoids	CHEMICAL	23562496T14
23562496	612	621	chalcones	CHEMICAL	23562496T15
23562496	692	701	chalcones	CHEMICAL	23562496T16
23562496	802	810	chalcone	CHEMICAL	23562496T17
23562496	917	925	chalcone	CHEMICAL	23562496T18
23562496	927	944	2-hydroxychalcone	CHEMICAL	23562496T19
23562496	1110	1121	xanthohumol	CHEMICAL	23562496T1
23562496	950	961	xanthohumol	CHEMICAL	23562496T20
23562496	1077	1085	Chalcone	CHEMICAL	23562496T21
23562496	1087	1104	2-hydroxychalcone	CHEMICAL	23562496T22
23562496	0	17	2-Hydroxychalcone	CHEMICAL	23562496T23
23562496	22	33	xanthohumol	CHEMICAL	23562496T24
23562496	1372	1377	Bcl-2	GENE-Y	23562496T25
23562496	1502	1507	MMP-9	GENE-Y	23562496T26
23562496	270	278	estrogen	GENE-Y	23562496T27
23562496	279	301	progesterone receptors	GENE-Y	23562496T28
23562496	303	305	ER	GENE-Y	16226|2525
23562496	1183	1212	Neohesperidin dihydrochalcone	CHEMICAL	23562496T2
23562496	306	308	PR	GENE-Y	23562496T30
23562496	314	354	human epidermal growth factor receptor 2	GENE-Y	23562496T31
23562496	356	360	HER2	GENE-Y	35473
23562496	1214	1231	4-methoxychalcone	CHEMICAL	23562496T3
23562496	1237	1262	hesperidin methylchalcone	CHEMICAL	23562496T4
23562496	1317	1328	Xanthohumol	CHEMICAL	9900
23562496	1333	1350	2-hydroxychalcone	CHEMICAL	23562496T6
23562496	1407	1424	2-hydroxychalcone	CHEMICAL	23562496T7
23562496	1429	1440	xanthohumol	CHEMICAL	23562496T8
23562496	1561	1569	chalcone	CHEMICAL	23562496T9
23562496	CPR:4	9900	23562496T25
23562496	CPR:4	23562496T6	23562496T25
23562496	CPR:4	23562496T7	23562496T26
23562496	CPR:4	23562496T8	23562496T26

23566269|t|4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.
23566269|a|d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor. We identified a series of 4-hydroxypyridazin-3(2H)-one derivatives as novel DAAO inhibitors with high potency and substantial cell permeability using fragment-based drug design. Comparisons of complex structures deposited in the Protein Data Bank as well as those determined with in-house fragment hits revealed that a hydrophobic subpocket was formed perpendicular to the flavin ring by flipping Tyr224 in a ligand-dependent manner. We investigated the ability of the initial fragment hit, 3-hydroxy-pyridine-2(1H)-one, to fill this subpocket with the aid of complex structure information. 3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one exhibited the predicted binding mode and demonstrated high inhibitory activity for human DAAO in enzyme- and cell-based assays. We further designed and synthesized 4-hydroxypyridazin-3(2H)-one derivatives, which are equivalent to the 3-hydroxy-pyridine-2(1H)-one series but lack cell toxicity. 6-[2-(3,5-Difluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one was found to be effective against MK-801-induced cognitive deficit in the Y-maze.
23566269	813	858	3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one	CHEMICAL	23566269T10
23566269	162	170	d-serine	CHEMICAL	23566269T11
23566269	1023	1051	4-hydroxypyridazin-3(2H)-one	CHEMICAL	23566269T12
23566269	0	28	4-Hydroxypyridazin-3(2H)-one	CHEMICAL	23566269T13
23566269	50	62	d-Amino Acid	CHEMICAL	23566269T14
23566269	83	103	d-Amino acid oxidase	GENE-Y	23566269T15
23566269	191	220	N-methyl-d-aspartate receptor	GENE-N	23566269T16
23566269	298	302	DAAO	GENE-Y	23566269T17
23566269	105	109	DAAO	GENE-Y	23566269T18
23566269	942	952	human DAAO	GENE-Y	23566269T19
23566269	83	95	d-Amino acid	CHEMICAL	23566269T1
23566269	50	70	d-Amino Acid Oxidase	GENE-Y	23566269T20
23566269	1093	1121	3-hydroxy-pyridine-2(1H)-one	CHEMICAL	23566269T2
23566269	1153	1213	6-[2-(3,5-Difluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one	CHEMICAL	23566269T3
23566269	191	211	N-methyl-d-aspartate	CHEMICAL	23566269T4
23566269	1248	1254	MK-801	CHEMICAL	23566269T5
23566269	248	276	4-hydroxypyridazin-3(2H)-one	CHEMICAL	23566269T6
23566269	619	622	Tyr	CHEMICAL	129
23566269	138	151	d-amino acids	CHEMICAL	23566269T8
23566269	713	741	3-hydroxy-pyridine-2(1H)-one	CHEMICAL	23566269T9
23566269	CPR:4	23566269T10	23566269T19
23566269	CPR:4	23566269T13	23566269T20
23566269	CPR:4	23566269T6	23566269T17
23566269	CPR:5	23566269T11	23566269T16
23566269	CPR:9	23566269T11	23566269T15
23566269	CPR:9	23566269T11	23566269T18
23566269	CPR:9	23566269T8	23566269T15
23566269	CPR:9	23566269T8	23566269T18

23567241|t|Comparative study on transcriptional activity of 17 parabens mediated by estrogen receptor  and  and androgen receptor.
23567241|a|The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor  (hER), hER and androgen receptor (hAR) were investigated. Fourteen of 17 parabens exhibited hER and/or hER agonistic activity at concentrations of 110(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity. Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER and ER agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12. Most parabens showing estrogenic activity exhibited ER-agonistic activity at lower concentrations than those inducing ER-agonistic activity. The estrogenic activity of butylparaben was markedly decreased by incubation with rat liver microsomes, and the decrease of activity was blocked by a carboxylesterase inhibitor. These results indicate that parabens are selective agonists for ER over ER; their interactions with ER/ are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.
23567241	597	610	heptylparaben	CHEMICAL	23567241T10
23567241	620	633	pentylparaben	CHEMICAL	23567241T11
23567241	860	868	parabens	CHEMICAL	23567241T12
23567241	1025	1037	butylparaben	CHEMICAL	23567241T13
23567241	103	111	androgen	CHEMICAL	23567241T14
23567241	52	60	parabens	CHEMICAL	23567241T15
23567241	73	81	estrogen	CHEMICAL	23567241T16
23567241	1148	1164	carboxylesterase	GENE-N	23567241T17
23567241	1240	1243	ER	GENE-Y	23567241T18
23567241	1249	1252	ER	GENE-Y	23567241T19
23567241	1204	1212	parabens	CHEMICAL	23567241T1
23567241	1278	1283	ER/	GENE-N	23567241T20
23567241	1373	1390	carboxylesterases	GENE-N	23567241T21
23567241	253	278	human estrogen receptor 	GENE-Y	23567241T22
23567241	280	284	hER	GENE-Y	23567241T23
23567241	287	291	hER	GENE-Y	23567241T24
23567241	296	313	androgen receptor	GENE-Y	23567241T25
23567241	315	318	hAR	GENE-Y	23567241T26
23567241	373	377	hER	GENE-Y	23567241T27
23567241	385	389	hER	GENE-Y	23567241T28
23567241	481	483	AR	GENE-Y	106862
23567241	1331	1336	alkyl	CHEMICAL	23567241T2
23567241	662	665	ER	GENE-Y	23567241T30
23567241	670	673	ER	GENE-Y	23567241T31
23567241	907	910	ER	GENE-Y	23567241T32
23567241	974	977	ER	GENE-Y	23567241T33
23567241	103	120	androgen receptor	GENE-Y	23567241T34
23567241	73	98	estrogen receptor  and 	GENE-N	23567241T35
23567241	259	267	estrogen	CHEMICAL	23567241T3
23567241	296	304	androgen	CHEMICAL	23567241T4
23567241	354	362	parabens	CHEMICAL	23567241T5
23567241	465	473	parabens	CHEMICAL	23567241T6
23567241	162	170	parabens	CHEMICAL	23567241T7
23567241	529	537	parabens	CHEMICAL	23567241T8
23567241	550	555	alkyl	CHEMICAL	23567241T9
23567241	CPR:5	23567241T10	23567241T30
23567241	CPR:5	23567241T10	23567241T31
23567241	CPR:5	23567241T11	23567241T30
23567241	CPR:5	23567241T11	23567241T31
23567241	CPR:5	23567241T12	23567241T32
23567241	CPR:5	23567241T12	23567241T33
23567241	CPR:5	23567241T1	23567241T18
23567241	CPR:5	23567241T1	23567241T19
23567241	CPR:5	23567241T5	23567241T27
23567241	CPR:5	23567241T5	23567241T28
23567241	CPR:5	23567241T8	23567241T30
23567241	CPR:5	23567241T8	23567241T31
23567241	CPR:5	23567241T9	23567241T30
23567241	CPR:5	23567241T9	23567241T31
23567241	CPR:9	23567241T1	23567241T21

23567490|t|The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.
23567490|a|Recent evidence indicates a potential prognostic and predictive value for germline polymorphisms in genes involved in cell cycle control. We investigated the effect of cyclin D1 (CCND1) rs9344 G>A in stage II/III colon cancer patients and validated the findings in an independent study cohort. For evaluation and validation set, a total of 264 and 234 patients were included. Patients treated with 5-fluorouracil-based chemotherapy, carrying the CCND1 rs9344 A/A genotype had significantly decreased time-to-tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16-5.29; P=0.019). There was no significant association between CCND1 rs9344 G>A and TTR in patients with curative surgery alone. In the validation set, the A allele of CCND1 rs9344 G>A remained significantly associated with decreased TTR in univariate and multivariate analyses (HR 1.94; 95% CI 1.05-3.58; P=0.035). CCND1 rs9344 G>A may be a predictive and/or prognostic biomarker in stage II/III colon cancer patients, however, prospective trials are warranted to confirm our findings.The Pharmacogenomics Journal advance online publication, 9 April 2013; doi:10.1038/tpj.2013.15.
23567490	949	954	CCND1	GENE-Y	107067
23567490	955	965	rs9344 G>A	GENE-N	23567490T11
23567490	1097	1102	CCND1	GENE-Y	107067
23567490	1103	1113	rs9344 G>A	GENE-N	23567490T13
23567490	15	20	CCND1	GENE-Y	107067
23567490	22	32	rs9344 G>A	GENE-N	23567490T15
23567490	4	13	cyclin D1	GENE-Y	23567490T16
23567490	542	556	5-fluorouracil	CHEMICAL	23567490T1
23567490	119	123	5-FU	CHEMICAL	534
23567490	312	321	cyclin D1	GENE-Y	23567490T3
23567490	323	328	CCND1	GENE-Y	107067
23567490	330	340	rs9344 G>A	GENE-N	23567490T5
23567490	590	595	CCND1	GENE-Y	107067
23567490	596	606	rs9344 A/A	GENE-N	23567490T7
23567490	844	849	CCND1	GENE-Y	107067
23567490	850	860	rs9344 G>A	GENE-N	23567490T9

23567861|t|Evaluation of 7-O-galloyl-d-sedoheptulose, isolated from Corni Fructus, in the adipose tissue of type 2 diabetic db/db mice.
23567861|a|The aim of the present study was to evaluate the beneficial effects of 7-O-galloyl-d-sedoheptulose (GS), isolated from Corni Fructus, using type 2 diabetic mice. GS was orally administered to db/db mice at doses of 20 and 100mg/kg body weight per day for 6weeks, and the effects of GS on biochemical factors in serum and adipose tissue were investigated. To define the underlying mechanism of these effects, protein expressions related to lipid metabolism, inflammation, fibrosis, and apoptosis, were measured. The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment. In addition, the elevated lipid, ROS, and TBARS contents in adipose tissue as well as serum levels in db/db mice were significantly decreased by the oral administration of GS. From protein analysis, the decreased expressions of peroxisome proliferator activated receptor (PPAR), PPAR, and B-cell lymphoma 2 were up-regulated in the adipose tissue of db/db mice. The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-1, Bax, cytochrome c, and caspase-3 expressions. These results suggest that GS acts as a regulator of oxidative stress, inflammation, fibrosis, and apoptosis in the adipose tissue of db/db mice.
23567861	886	897	cholesterol	CHEMICAL	23567861T10
23567861	922	933	cholesterol	CHEMICAL	23567861T11
23567861	944	950	oxygen	CHEMICAL	23567861T12
23567861	970	989	thiobarbituric acid	CHEMICAL	23567861T13
23567861	14	41	7-O-galloyl-d-sedoheptulose	CHEMICAL	23567861T14
23567861	1324	1374	peroxisome proliferator activated receptor (PPAR)	GENE-Y	23567861T15
23567861	1376	1381	PPAR	GENE-Y	23567861T16
23567861	1387	1404	B-cell lymphoma 2	GENE-Y	23567861T17
23567861	1509	1552	sterol regulatory element binding protein-1	GENE-Y	23567861T18
23567861	1554	1574	nuclear factor-kappa	GENE-N	23567861T19
23567861	1509	1515	sterol	CHEMICAL	23567861T1
23567861	1583	1599	cyclooxygenase-2	GENE-Y	23567861T20
23567861	1601	1632	inducible nitric oxide synthase	GENE-Y	23567861T21
23567861	1634	1664	monocyte chemotactic protein-1	GENE-Y	23567861T22
23567861	1666	1699	intracellular adhesion molecule-1	GENE-Y	23567861T23
23567861	1701	1715	phosphor c-Jun	GENE-Y	23567861T24
23567861	1727	1733	kinase	GENE-N	23567861T25
23567861	1735	1754	activator protein-1	GENE-Y	23567861T26
23567861	1756	1785	transforming growth factor-1	GENE-Y	23567861T27
23567861	1787	1790	Bax	GENE-Y	198304|246997
23567861	1792	1804	cytochrome c	GENE-Y	23567861T29
23567861	1611	1623	nitric oxide	CHEMICAL	23567861T2
23567861	1810	1819	caspase-3	GENE-Y	23567861T30
23567861	679	685	leptin	GENE-Y	23567861T31
23567861	687	694	insulin	GENE-N	23567861T32
23567861	696	705	C-peptide	GENE-N	23567861T33
23567861	707	715	resistin	GENE-Y	23567861T34
23567861	717	740	tumor necrosis factor-	GENE-Y	23567861T35
23567861	742	755	interleukin-6	GENE-Y	23567861T36
23567861	819	843	high-density lipoprotein	GENE-N	23567861T37
23567861	862	885	low-density lipoprotein	GENE-N	23567861T38
23567861	898	921	low-density lipoprotein	GENE-N	23567861T39
23567861	1716	1717	N	CHEMICAL	167
23567861	1053	1064	adiponectin	GENE-Y	23567861T40
23567861	670	677	glucose	CHEMICAL	23567861T4
23567861	757	770	triglycerides	CHEMICAL	23567861T5
23567861	778	789	cholesterol	CHEMICAL	23567861T6
23567861	806	817	fatty acids	CHEMICAL	23567861T7
23567861	844	855	cholesterol	CHEMICAL	23567861T8
23567861	196	223	7-O-galloyl-d-sedoheptulose	CHEMICAL	23567861T9

23570615|t|Extracellular Signal-Regulated Kinases (ERK) Inhibitors from Aristolochia yunnanensis.
23570615|a|Six new sesquiterpenoids, aristoyunnolins A-F (1-6), an artifact of isolation [7-O-ethyl madolin W (7)], and 12 known analogues were isolated from stems of Aristolochia yunnanensis. The structures were determined by combined chemical and spectral methods, and the absolute configurations of compounds 2, 3, 5-7, 9, 14, and 17 were determined by the modified Mosher's method and CD analysis. Compounds 1-19 were screened using a bioassay system designed to evaluate the effect on mitogen-activated protein kinases (MAPKs) signaling pathways. Among three MAPKs (ERK1/2, JNK, and p38), compounds 1, 4, 10-13, 16, 18, and 19 exhibited selective inhibition of the phosphorylation of ERK1/2. Compounds 16 and 19 were more active than the positive control PD98059, a known inhibitor of the ERK1/2 signaling pathway.
23570615	664	667	p38	GENE-N	23570615T10
23570615	765	771	ERK1/2	GENE-N	23570615T11
23570615	870	876	ERK1/2	GENE-N	23570615T12
23570615	0	38	Extracellular Signal-Regulated Kinases	GENE-N	23570615T13
23570615	40	43	ERK	GENE-N	23570615T14
23570615	113	132	aristoyunnolins A-F	CHEMICAL	23570615T1
23570615	836	843	PD98059	CHEMICAL	23570615T2
23570615	166	185	7-O-ethyl madolin W	CHEMICAL	23570615T3
23570615	95	111	sesquiterpenoids	CHEMICAL	23570615T4
23570615	566	599	mitogen-activated protein kinases	GENE-N	23570615T5
23570615	601	606	MAPKs	GENE-N	23570615T6
23570615	640	645	MAPKs	GENE-N	23570615T7
23570615	647	653	ERK1/2	GENE-N	23570615T8
23570615	655	658	JNK	GENE-N	23570615T9

23570999|t|In vivo and in vitro anti-inflammatory potential of pentahydroxy-pregn-14-ol, 20-one--d-thevetopyranoside in rats.
23570999|a|Polyhydroxy pregnane glycoside (PPG), a steroidal glycoside was isolated from Wattakaka volubilis Linn. (Stap.f.). PPG was evaluated for in vivo and in vitro anti-inflammatory activity using acute inflammation and chronic model of inflammation in rats and LPS-induced RAW 264.7 macrophage cells. PPG seemed to be responsible for the anti-inflammatory activity in the studied models. PPG at dose level of both 5 and 10mg/kg significantly reduced the edema induced by the carrageenan in acute model of inflammation. It also showed significant anti-proliferative effect (dry pellet weight basis) in chronic model of inflammation. Cellular content of granuloma was measured by assaying activity of N-acetyl glucosaminidase (NAG) and total nucleic acid content. PPG at 5 and 10mg/kg significantly suppressed the cellular infiltration measured by total nucleic acid content. In contrast, NAG activity decreased over a period of 10 days resulting in inhibition of granuloma weight gain. PPG had a more effective response than the reference drug diclofenac sodium in both the models of inflammation. Wattakaka volubilis steroidal glycoside mixture (WVSM) and PPG (1-50M) significantly inhibited the COX-2 and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells. Hence the study supports the traditional use of Wattakaka volubilis and its constituent PPG in treatment of inflammatory disorders.
23570999	156	175	steroidal glycoside	CHEMICAL	23570999T10
23570999	810	818	N-acetyl	CHEMICAL	23570999T11
23570999	873	876	PPG	CHEMICAL	23570999T12
23570999	1096	1099	PPG	CHEMICAL	23570999T13
23570999	52	106	pentahydroxy-pregn-14-ol, 20-one--d-thevetopyranoside	CHEMICAL	23570999T14
23570999	1308	1313	COX-2	GENE-Y	23570999T15
23570999	1318	1322	iNOS	GENE-Y	23570999T16
23570999	116	146	Polyhydroxy pregnane glycoside	CHEMICAL	23570999T1
23570999	1154	1171	diclofenac sodium	CHEMICAL	23570999T2
23570999	1228	1247	steroidal glycoside	CHEMICAL	23570999T3
23570999	1267	1270	PPG	CHEMICAL	23570999T4
23570999	231	234	PPG	CHEMICAL	23570999T5
23570999	1501	1504	PPG	CHEMICAL	23570999T6
23570999	412	415	PPG	CHEMICAL	23570999T7
23570999	148	151	PPG	CHEMICAL	23570999T8
23570999	499	502	PPG	CHEMICAL	23570999T9
23570999	CPR:4	23570999T3	23570999T15
23570999	CPR:4	23570999T3	23570999T16
23570999	CPR:4	23570999T4	23570999T15
23570999	CPR:4	23570999T4	23570999T16

23572389|t|Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer.
23572389|a|Both p16 and p15 proteins are inhibitors of cyclin-dependent kinases that prevent the cell going through the G1/S phase transaction. E-cadherin is a transmembrane glycoprotein that mediates calcium-dependent interactions between adjacent epithelial cells. Two groups of patients were selected: the first group suffered from epithelial serous ovarian tumors and the second group suffered from benign ovarian lesions; ovarian tissue samples from all the subjects (benign and malignant) were subjected to methylation-specific polymerase chain reaction for methylated and unmethylated alleles of the genes (E-cadherin, p15, and p16). Results obtained showed that aberrant methylation of p15 and p16 genes were detected in 64.29 and 50% of ovarian cancer patients, while E-cadherin hypermethylation was detected in 78.57% of ovarian cancer patients. Methylation of E-cadherin was significantly correlated with different stage of disease (p < 0.05). It was found that the risk of E-cadherin hypermethylation was 1.347-fold, while risk of p15 hypermethylation was 1.543-fold and p16 was 1.2-fold among patients with ovarian cancer than that among patients with benign ovarian lesions. In conclusion, Dysfunction of the cell cycle and/or the cell-cell adhesion molecule plays a role in the pathogenesis of ovarian cancer and that the analysis of the methylation of p15 and E-cadherin genes can provide clinically important evidence on which to base the treatment.
23572389	685	688	p15	GENE-Y	23572389T10
23572389	694	697	p16	GENE-Y	23572389T11
23572389	753	756	p15	GENE-Y	23572389T12
23572389	761	764	p16	GENE-Y	23572389T13
23572389	836	846	E-cadherin	GENE-Y	23572389T14
23572389	930	940	E-cadherin	GENE-Y	23572389T15
23572389	1044	1054	E-cadherin	GENE-Y	23572389T16
23572389	20	23	P15	GENE-Y	23572389T17
23572389	25	28	P16	GENE-Y	23572389T18
23572389	34	44	E-cadherin	GENE-Y	23572389T19
23572389	260	267	calcium	CHEMICAL	23572389T1
23572389	1102	1105	p15	GENE-Y	23572389T2
23572389	83	86	p15	GENE-Y	23572389T3
23572389	203	213	E-cadherin	GENE-Y	23572389T4
23572389	1427	1430	p15	GENE-Y	23572389T5
23572389	1435	1445	E-cadherin	GENE-Y	23572389T6
23572389	114	138	cyclin-dependent kinases	GENE-N	23572389T7
23572389	75	78	p16	GENE-Y	23572389T8
23572389	673	683	E-cadherin	GENE-Y	23572389T9

23572405|t|Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism.
23572405|a|Due to stimulated overall metabolism, a state of nutritional inadequacy often ensues, during thyrotoxicosis. We aimed to investigate circulating levels of some major components of the system that regulates energy stores, glucose, and fat metabolism, during thyrotoxicosis compared to euthyroidism. Fasting serum ghrelin, leptin, adiponectin, insulin, glucagon, glucose, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.515.2years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). The same measurements were repeated an average 3months later, when all patients achieved euthyroidism. Compared to euthyroidism, in thyrotoxicosis, patients had lower ghrelin and fat mass; had comparable insulin, HOMA-IR, glucagon, and leptin levels; higher levels of circulating adiponectin. Fasting serum glucose tended to be higher during thyrotoxicosis. The unique correlation of HOMA-IR was with the-glucagon to ghrelin ratio-(r=0.801, p<0.001) in hyperthyrodism, and with glucagon itself in euthyroidism (r=-0.844, p<0.001). Circulating levels of ghrelin are decreased; leptin, insulin, glucagon are unchanged; adiponectin are increased during hyperthyroidism. The fasting HOMA-IR tends to be higher, despite the decreased adiposity in hyperthyroidism. The-glucagon to ghrelin ratio-strongly correlates with fasting HOMA-IR in hyperthyroidism.
23572405	1429	1437	glucagon	GENE-Y	23572405T10
23572405	1441	1448	ghrelin	GENE-Y	23572405T11
23572405	409	416	ghrelin	GENE-Y	23572405T12
23572405	418	424	leptin	GENE-Y	23572405T13
23572405	426	437	adiponectin	GENE-Y	23572405T14
23572405	439	446	insulin	GENE-Y	23572405T15
23572405	448	456	glucagon	GENE-Y	23572405T16
23572405	825	832	ghrelin	GENE-Y	23572405T17
23572405	862	869	insulin	GENE-Y	23572405T18
23572405	880	888	glucagon	GENE-Y	23572405T19
23572405	318	325	glucose	CHEMICAL	23572405T1
23572405	894	900	leptin	GENE-Y	23572405T20
23572405	938	949	adiponectin	GENE-Y	23572405T21
23572405	1063	1071	glucagon	GENE-Y	23572405T22
23572405	1075	1082	ghrelin	GENE-Y	23572405T23
23572405	12	20	glucagon	GENE-Y	23572405T24
23572405	24	31	ghrelin	GENE-Y	23572405T25
23572405	58	65	insulin	GENE-Y	23572405T26
23572405	458	465	glucose	CHEMICAL	23572405T2
23572405	965	972	glucose	CHEMICAL	23572405T3
23572405	1140	1148	glucagon	GENE-Y	23572405T4
23572405	1219	1226	ghrelin	GENE-Y	23572405T5
23572405	1242	1248	leptin	GENE-Y	23572405T6
23572405	1250	1257	insulin	GENE-Y	23572405T7
23572405	1259	1267	glucagon	GENE-Y	23572405T8
23572405	1283	1294	adiponectin	GENE-Y	23572405T9

23574729|t|Proposed diagnostic criteria for subclinical Cushing's syndrome associated with adrenal incidentaloma.
23574729|a|Subclinical Cushing's syndrome (SCS) associated with adrenal incidentaloma is usually characterized by autonomous cortisol secretion without overt symptoms of Cushing's syndrome (CS). Although the diagnostic criteria for SCS differ among countries, the 1 mg dexamethasone suppression test (DST) is essential to confirm the presence and the extent of cortisol overproduction. Since 1995, SCS has been diagnosed in Japan based on serum cortisol levels 3 g/dl (measured by radioimmunoassay [RIA]) after a 1 mg DST. However, the increasing use of enzyme immunoassays (EIA) instead of RIA has hindered the diagnosis of SCS because of the differing sensitivities of commercially available assays, particularly for serum cortisol levels of around 3 g/dl. One way to overcome this problem is to lower the cortisol threshold level after a 1 mg DST. In the present study, we examined the clinical applicability of lowering the cortisol threshold to 1.8 g/dl, similar to the American Endocrine Society's guidelines for CS, by reanalyzing 119 patients with adrenal incidentaloma. Our findings indicate that serum cortisol levels 1.8 g/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level <10 pg/ml (or poor plasma ACTH response to corticotrophin-releasing hormone) and (2) serum cortisol 5 g/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.
23574729	903	911	cortisol	CHEMICAL	23574729T10
23574729	1023	1031	cortisol	CHEMICAL	23574729T11
23574729	1346	1350	ACTH	GENE-Y	23574729T12
23574729	1383	1387	ACTH	GENE-Y	23574729T13
23574729	1400	1432	corticotrophin-releasing hormone	GENE-Y	23574729T14
23574729	1208	1216	cortisol	CHEMICAL	23574729T1
23574729	217	225	cortisol	CHEMICAL	23574729T2
23574729	1448	1456	cortisol	CHEMICAL	23574729T3
23574729	1621	1651	dehydroepiandrosterone sulfate	CHEMICAL	23574729T4
23574729	1671	1679	cortisol	CHEMICAL	23574729T5
23574729	361	374	dexamethasone	CHEMICAL	23574729T6
23574729	453	461	cortisol	CHEMICAL	23574729T7
23574729	537	545	cortisol	CHEMICAL	23574729T8
23574729	819	827	cortisol	CHEMICAL	23574729T9

23577589|t|Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin.
23577589|a|Insulin treatment in type 1 and type 2 diabetes (T1D and T2D) is highly efficacious, but in practice, non-adherence and ineffective dose titration limit its effectiveness. Barriers to more effective insulin treatment are numerous, including hypoglycaemia, fear of hypoglycaemia and concern about weight gain. The regular treatment timing needed with conventional basal insulins [neutral protamine Hagedorn (NPH) insulin and the first-generation analogues glargine and detemir] may also make adherence to these treatments problematic for many patients. Indeed, surveys indicate that the rigidity of this schedule induces some patients with T1D and T2D to omit insulin doses. Degludec is a novel, ultra-long-acting basal insulin analogue that is as effective as insulin glargine, but significantly reduces patients' risk of nocturnal hypoglycaemia. Because of its peakless, extended and highly predictable glucose-lowering effect, once-daily dosing on a flexible schedule may be feasible with degludec. Studies testing this possibility suggest that degludec tolerates day-to-day variation in dose timing while maintaining full efficacy and low risk of nocturnal hypoglycaemia. Degludec would appear to be an appropriate choice for patients being considered for a basal analogue, and it may be particularly well suited to patients with unpredictable social or work schedules, those who travel frequently and those who find rigid scheduling of their insulin injections a burden or barrier to regular treatment.
23577589	78	85	insulin	GENE-Y	23577589T10
23577589	991	998	glucose	CHEMICAL	23577589T1
23577589	87	94	Insulin	GENE-Y	23577589T2
23577589	1533	1540	insulin	GENE-Y	23577589T3
23577589	286	293	insulin	GENE-Y	23577589T4
23577589	456	464	insulins	GENE-Y	23577589T5
23577589	499	506	insulin	GENE-Y	23577589T6
23577589	746	753	insulin	GENE-Y	23577589T7
23577589	806	813	insulin	GENE-Y	23577589T8
23577589	847	854	insulin	GENE-Y	23577589T9

23578968|t|Evaluation of a predictive in vitro Leydig cell assay for anti-androgenicity of phthalate esters in the rat.
23578968|a|An in vitro assay using the rat Leydig cell line R2C was evaluated for its ability to quantitatively predict inhibition of testosterone synthesis. Results obtained for endocrine active phthalates (MEHP, MBP), and inactive phthalates (MMP and MEP) were highly consistent with in vivo results based on tissue and media concentrations. Statistically significant inhibition of testosterone synthesis (p<0.05, 1-way ANOVA) was observed at 1M MBP and 3M MEHP, while MEP and MMP did not affect inhibition of testosterone synthesis until much higher concentrations (100M). Concentrations causing 50% inhibition of testosterone synthesis for MBP and MEHP (3 and 6M respectively), were similar to in vivo values (3 and 7M). The R2C assay was used to determine the relative potency of 14 structurally diverse monoesters and oxidative metabolites of MEHP. Monoesters with alkyl chains 4-5 carbons in length had the highest potency for testosterone inhibition, while 0-2 carbon alkyl chains were least potent. Phase I metabolism did not completely inactivate MEHP, underscoring the need for metabolism data when interpreting in vitro pharmacodynamic data. This steroid inhibition assay provides a predictive in vitro alternative to expensive and timeconsuming developmental rat studies for phthalate-induced antiandrogenicity.
23578968	351	354	MEP	CHEMICAL	23578968T10
23578968	482	494	testosterone	CHEMICAL	614
23578968	547	550	MBP	CHEMICAL	23578968T12
23578968	559	563	MEHP	CHEMICAL	23578968T13
23578968	571	574	MEP	CHEMICAL	23578968T14
23578968	579	582	MMP	CHEMICAL	23578968T15
23578968	612	624	testosterone	CHEMICAL	614
23578968	719	731	testosterone	CHEMICAL	614
23578968	746	749	MBP	CHEMICAL	23578968T18
23578968	754	758	MEHP	CHEMICAL	23578968T19
23578968	1161	1165	MEHP	CHEMICAL	23578968T1
23578968	913	923	monoesters	CHEMICAL	23578968T20
23578968	953	957	MEHP	CHEMICAL	23578968T21
23578968	959	969	Monoesters	CHEMICAL	23578968T22
23578968	992	999	carbons	CHEMICAL	23578968T23
23578968	1038	1050	testosterone	CHEMICAL	614
23578968	1073	1079	carbon	CHEMICAL	23578968T25
23578968	80	96	phthalate esters	CHEMICAL	23578968T26
23578968	1263	1270	steroid	CHEMICAL	23578968T2
23578968	232	244	testosterone	CHEMICAL	614
23578968	1392	1401	phthalate	CHEMICAL	23578968T4
23578968	294	304	phthalates	CHEMICAL	23578968T5
23578968	306	310	MEHP	CHEMICAL	23578968T6
23578968	312	315	MBP	CHEMICAL	23578968T7
23578968	331	341	phthalates	CHEMICAL	23578968T8
23578968	343	346	MMP	CHEMICAL	23578968T9

23583009|t|Quercetin suppressed CYP2E1-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.
23583009|a|Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect. However, the precise mechanism by which quercetin counteracts CYP2E1-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear. To explore the potential mechanism, herein, ethanol (4.0g/kg.bw.) was administrated to rats for 90 days. Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.). Quercetin (100M) induced HO-1 and depleted heme pool when incubated to human hepatocytes. Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation. CO scavenging blocked the suppression of quercetin only on CYP2E1 activity. CO donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger. Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by quercetin through HO-1 induction. Depleted heme pool and CO releasing limited protein synthesis and inhibited enzymatic activity of CYP2E1, respectively.
23583009	388	395	ethanol	CHEMICAL	23583009T10
23583009	502	509	ethanol	CHEMICAL	23583009T11
23583009	592	599	ethanol	CHEMICAL	23583009T12
23583009	158	165	ethanol	CHEMICAL	23583009T13
23583009	718	727	quercetin	CHEMICAL	23583009T14
23583009	744	753	Quercetin	CHEMICAL	4044
23583009	835	842	Ethanol	CHEMICAL	888
23583009	900	909	quercetin	CHEMICAL	23583009T17
23583009	965	969	heme	CHEMICAL	23583009T18
23583009	984	986	CO	CHEMICAL	23583009T19
23583009	1108	1115	ethanol	CHEMICAL	23583009T1
23583009	1025	1034	quercetin	CHEMICAL	23583009T20
23583009	196	200	heme	CHEMICAL	23583009T21
23583009	1060	1062	CO	CHEMICAL	23583009T22
23583009	0	9	Quercetin	CHEMICAL	4044
23583009	38	45	ethanol	CHEMICAL	23583009T24
23583009	99	101	CO	CHEMICAL	23583009T25
23583009	1159	1163	HO-1	GENE-Y	23583009T26
23583009	1211	1217	CYP2E1	GENE-Y	107944
23583009	214	218	HO-1	GENE-Y	23583009T28
23583009	1286	1290	HO-1	GENE-Y	23583009T29
23583009	1191	1193	CO	CHEMICAL	23583009T2
23583009	1400	1406	CYP2E1	GENE-Y	107944
23583009	372	378	CYP2E1	GENE-Y	107944
23583009	419	423	HO-1	GENE-Y	23583009T32
23583009	615	621	CYP2E1	GENE-Y	107944
23583009	637	641	HO-1	GENE-Y	23583009T34
23583009	770	774	HO-1	GENE-Y	23583009T35
23583009	862	868	CYP2E1	GENE-Y	107944
23583009	934	938	HO-1	GENE-Y	23583009T37
23583009	196	212	heme oxygenase-1	GENE-Y	23583009T38
23583009	1043	1049	CYP2E1	GENE-Y	107944
23583009	1227	1234	ethanol	CHEMICAL	23583009T3
23583009	1098	1104	CYP2E1	GENE-Y	107944
23583009	21	27	CYP2E1	GENE-Y	107944
23583009	1268	1277	quercetin	CHEMICAL	23583009T4
23583009	1325	1327	CO	CHEMICAL	23583009T5
23583009	234	249	carbon monoxide	CHEMICAL	23583009T6
23583009	251	253	CO	CHEMICAL	23583009T7
23583009	122	131	quercetin	CHEMICAL	23583009T8
23583009	350	359	quercetin	CHEMICAL	23583009T9
23583009	CPR:3	23583009T12	107944
23583009	CPR:3	4044	23583009T35
23583009	CPR:3	888	107944
23583009	CPR:3	23583009T1	107944
23583009	CPR:3	23583009T4	23583009T29
23583009	CPR:4	23583009T12	23583009T34
23583009	CPR:4	888	23583009T37
23583009	CPR:4	23583009T17	107944
23583009	CPR:4	23583009T19	107944
23583009	CPR:4	23583009T22	107944
23583009	CPR:4	4044	107944
23583009	CPR:4	23583009T2	107944
23583009	CPR:4	23583009T5	107944
23583009	CPR:4	23583009T9	107944
23583009	CPR:9	23583009T18	23583009T37

23583510|t|Novel racemic tetrahydrocurcuminoid dihydropyrimidinone analogues as potent acetylcholinesterase inhibitors.
23583510|a|The synthesis of racemic tetrahydrocurcumin- (THC-), tetrahydrodemethoxycurcumin- (THDC-) and tetrahydrobisdemethoxycurcumin- (THBDC-) dihydropyrimidinone (DHPM) analogues was achieved by utilizing the multi-component Biginelli reaction in the presence of copper sulphate as a catalyst. The evaluation of acetylcholinesterase inhibitors for Alzheimer's disease of these compounds showed that they exhibited higher inhibitory activity than their parent analogues. THBDC-DHPM demonstrated the most potent inhibitory activity with an IC50 value of 1.340.03M which was more active than the approved drug galanthamine (IC50=1.450.04M).
23583510	192	196	THDC	CHEMICAL	23583510T10
23583510	203	233	tetrahydrobisdemethoxycurcumin	CHEMICAL	23583510T11
23583510	14	55	tetrahydrocurcuminoid dihydropyrimidinone	CHEMICAL	23583510T12
23583510	414	434	acetylcholinesterase	GENE-Y	23583510T13
23583510	76	96	acetylcholinesterase	GENE-Y	23583510T14
23583510	236	241	THBDC	CHEMICAL	23583510T1
23583510	244	263	dihydropyrimidinone	CHEMICAL	23583510T2
23583510	265	269	DHPM	CHEMICAL	23583510T3
23583510	134	152	tetrahydrocurcumin	CHEMICAL	23583510T4
23583510	365	380	copper sulphate	CHEMICAL	23583510T5
23583510	572	582	THBDC-DHPM	CHEMICAL	23583510T6
23583510	155	158	THC	CHEMICAL	23583510T7
23583510	162	189	tetrahydrodemethoxycurcumin	CHEMICAL	23583510T8
23583510	711	723	galanthamine	CHEMICAL	23583510T9
23583510	CPR:4	23583510T12	23583510T14

23583603|t|Agonistic activity of ICI 182 780 on activation of GSK 3/AKT pathway in the rat uterus during the estrous cycle.
23583603|a|We examined the ability of ICI 182,780 (ICI) to block uterine cell proliferation via protein kinase b/AKT pathway in the uterus of the rat during the estrous cycle. Intact rats, with regular estrous cycles, received a subcutaneous (s.c.) injection of either vehicle or ICI at 08:00h on the day of proestrus or at 00:00h on the day of estrus and sacrificed at 13:00h of metaestrus. Estradiol (E2) and progesterone (P4) plasma levels were measured by radioimmunoassay. Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ER) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals. Furthermore, we detected that ICI treatment induced glycogen synthase kinase (Gsk3-) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization. However, some differences were observed between the two different time schedules of administration. We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of Akt phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters. The overall results indicate that ICI may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the Akt pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.
23583603	586	589	ICI	CHEMICAL	23583603T10
23583603	653	661	estrogen	CHEMICAL	23583603T11
23583603	717	729	progesterone	CHEMICAL	23583603T12
23583603	936	939	ICI	CHEMICAL	23583603T13
23583603	22	33	ICI 182 780	CHEMICAL	23583603T14
23583603	216	219	AKT	GENE-N	23583603T15
23583603	1365	1368	Akt	GENE-N	23583603T16
23583603	1669	1672	Akt	GENE-N	23583603T17
23583603	653	676	estrogen receptor alpha	GENE-Y	23583603T18
23583603	678	681	ER	GENE-Y	23583603T19
23583603	1208	1211	ICI	CHEMICAL	23583603T1
23583603	717	738	progesterone receptor	GENE-Y	23583603T20
23583603	740	742	PR	GENE-Y	23583603T21
23583603	805	814	cyclin D1	GENE-Y	23583603T22
23583603	958	982	glycogen synthase kinase	GENE-N	23583603T23
23583603	199	215	protein kinase b	GENE-N	23583603T24
23583603	984	990	Gsk3-	GENE-Y	23583603T25
23583603	1037	1046	cyclin D1	GENE-Y	23583603T26
23583603	51	57	GSK 3	GENE-Y	23583603T27
23583603	58	61	AKT	GENE-N	23583603T28
23583603	1388	1391	Ser	CHEMICAL	127
23583603	1444	1447	ICI	CHEMICAL	23583603T3
23583603	1551	1554	ICI	CHEMICAL	23583603T4
23583603	383	386	ICI	CHEMICAL	23583603T5
23583603	141	152	ICI 182,780	CHEMICAL	937
23583603	495	504	Estradiol	CHEMICAL	773
23583603	514	526	progesterone	CHEMICAL	23583603T8
23583603	154	157	ICI	CHEMICAL	23583603T9
23583603	CPR:3	23583603T13	23583603T23
23583603	CPR:3	23583603T13	23583603T25
23583603	CPR:3	23583603T14	23583603T28
23583603	CPR:3	23583603T4	23583603T17
23583603	CPR:4	23583603T10	23583603T18
23583603	CPR:4	23583603T10	23583603T19
23583603	CPR:4	23583603T1	23583603T16
23583603	CPR:5	23583603T14	23583603T27

23583910|t|Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors.
23583910|a|A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone. Screening on OSCs from five different organisms revealed interesting activities and selectivities of some of the compounds. A N,N-dimethylaminopropyl derivative showed promising inhibition of Trypanosoma cruzi OSC in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.
23583910	232	235	OSC	GENE-Y	23583910T10
23583910	343	347	OSCs	GENE-N	23583910T11
23583910	522	543	Trypanosoma cruzi OSC	GENE-Y	23583910T12
23583910	206	230	oxidosqualene cyclase(1)	GENE-Y	23583910T13
23583910	75	96	oxidosqualene cyclase	GENE-Y	23583910T14
23583910	121	139	aminopropylindenes	CHEMICAL	23583910T1
23583910	261	277	2,3-oxidosqualen	CHEMICAL	23583910T2
23583910	281	291	lanosterol	CHEMICAL	23583910T3
23583910	310	328	Grundmann's ketone	CHEMICAL	23583910T4
23583910	456	479	N,N-dimethylaminopropyl	CHEMICAL	23583910T5
23583910	618	629	cholesterol	CHEMICAL	23583910T6
23583910	206	219	oxidosqualene	CHEMICAL	23583910T7
23583910	0	18	Aminopropylindenes	CHEMICAL	23583910T8
23583910	32	50	Grundmann's ketone	CHEMICAL	23583910T9
23583910	CPR:4	23583910T5	23583910T12
23583910	CPR:4	23583910T8	23583910T14
23583910	CPR:4	23583910T9	23583910T14
23583910	CPR:9	23583910T2	23583910T10
23583910	CPR:9	23583910T2	23583910T13
23583910	CPR:9	23583910T3	23583910T10
23583910	CPR:9	23583910T3	23583910T13
23583910	CPR:9	23583910T6	23583910T12

23583931|t|The ATP required for potentiation of skeletal muscle contraction is released via pannexin hemichannels.
23583931|a|During repetitive stimulation of skeletal muscle, extracellular ATP levels raise, activating purinergic receptors, increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation. We found that ATP appears to be released through pannexin1 hemichannels (Panx1 HCs). Immunocytochemical analyses and function were consistent with pannexin1 localization to T-tubules intercalated with dihydropyridine and ryanodine receptors in slow (soleus) and fast (extensor digitorum longus, EDL) muscles. Isolated myofibers took up ethidium (Etd(+)) and released small molecules (as ATP) during electrical stimulation. Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (GLUT4), and blocked by dual blockade. Adult skeletal muscles apparently do not express connexins, making it unlikely that connexin hemichannels contribute to the uptake and release of small molecules. ATP release, Etd(+) uptake, and potentiation induced by repetitive electrical stimulation were blocked by HC blockers and did not occur in muscles of pannexin1 knockout mice. MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles ATP activates P2Y1 but not P2X receptors. Phosphorylation on Ser and Thr residues of pannexin1 was increased during potentiation, possibly mediating HC opening. Opening of Panx1 HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction. This article is part of a Special Issue entitled 'Connexin based channels'.
23583931	511	526	dihydropyridine	CHEMICAL	23583931T10
23583931	531	540	ryanodine	CHEMICAL	23583931T11
23583931	646	654	ethidium	CHEMICAL	23583931T12
23583931	656	662	Etd(+)	CHEMICAL	23583931T13
23583931	697	700	ATP	CHEMICAL	164
23583931	168	171	ATP	CHEMICAL	164
23583931	753	760	glucose	CHEMICAL	23583931T16
23583931	796	802	2-NBDG	CHEMICAL	23583931T17
23583931	818	825	glucose	CHEMICAL	23583931T18
23583931	876	883	glucose	CHEMICAL	23583931T19
23583931	1111	1117	Etd(+)	CHEMICAL	23583931T1
23583931	1098	1101	ATP	CHEMICAL	164
23583931	4	7	ATP	CHEMICAL	164
23583931	1248	1257	pannexin1	GENE-Y	23583931T22
23583931	1284	1289	P2Y1R	GENE-Y	23583931T23
23583931	1400	1404	P2Y1	GENE-Y	23583931T24
23583931	1413	1426	P2X receptors	GENE-N	23583931T25
23583931	1471	1480	pannexin1	GENE-Y	23583931T26
23583931	1558	1563	Panx1	GENE-Y	23583931T27
23583931	1764	1772	Connexin	GENE-N	23583931T28
23583931	359	368	pannexin1	GENE-Y	23583931T29
23583931	230	236	Ca(2+)	CHEMICAL	23583931T2
23583931	383	388	Panx1	GENE-Y	23583931T30
23583931	457	466	pannexin1	GENE-Y	23583931T31
23583931	531	550	ryanodine receptors	GENE-N	23583931T32
23583931	876	895	glucose transporter	GENE-N	23583931T33
23583931	897	902	GLUT4	GENE-Y	23583931T34
23583931	984	993	connexins	GENE-N	23583931T35
23583931	1019	1027	connexin	GENE-N	23583931T36
23583931	197	217	purinergic receptors	GENE-N	23583931T37
23583931	81	89	pannexin	GENE-N	23583931T38
23583931	1386	1389	ATP	CHEMICAL	164
23583931	1447	1450	Ser	CHEMICAL	127
23583931	1455	1458	Thr	CHEMICAL	150
23583931	1614	1617	ATP	CHEMICAL	164
23583931	1629	1636	glucose	CHEMICAL	23583931T7
23583931	1650	1656	Ca(2+)	CHEMICAL	23583931T8
23583931	324	327	ATP	CHEMICAL	164
23583931	CPR:3	164	23583931T37
23583931	CPR:3	164	23583931T24
23583931	CPR:9	23583931T16	23583931T33
23583931	CPR:9	23583931T16	23583931T34
23583931	CPR:9	23583931T17	23583931T33
23583931	CPR:9	23583931T17	23583931T34
23583931	CPR:9	164	23583931T38
23583931	CPR:9	164	23583931T27
23583931	CPR:9	23583931T7	23583931T27
23583931	CPR:9	23583931T8	23583931T27

23585332|t|tert-Butylhydroquinone reduces lipid accumulation in C57BL/6 mice with lower body weight gain.
23585332|a|tert-Butylhydroquinone (tBHQ) is a commonly used antioxidant additive that is approved for human use by both the Food and Agriculture Organization and the World Health Organization (FAO/WHO). In this study, we examined the effect of tBHQ on body weight gain and found that food supplementation with 0.001% (w/w) tBHQ inhibited 61.4% (P<0.01) of body weight gain in high-fat diet (HFD)-induced C57BL/6 mice, and the oral administration of tBHQ (1.5mg/kg) reduced 47.5% (P<0.05) of body weight gain in normal diet fed db/db mice. The HFD increased lipid deposit in adipocytes, but these were reduced significantly by tBHQ treatment in C57BL/6 mice. tBHQ supplementation significantly lowered the plasma triglyceride and total cholesterol, with reduced size of accumulated fat mass. The rate limiting enzyme of beta-oxidation (ACOX1) was significantly over-expressed in the liver with tBHQ treatment. These results indicate that tBHQ suppresses body weight gain in mice, possibly at least related to the up-regulation of ACOX1 gene expression.
23585332	985	989	tBHQ	CHEMICAL	23585332T10
23585332	1029	1033	tBHQ	CHEMICAL	23585332T11
23585332	0	22	tert-Butylhydroquinone	CHEMICAL	23585332T12
23585332	1121	1126	ACOX1	GENE-Y	106567
23585332	927	932	ACOX1	GENE-Y	106567
23585332	95	117	tert-Butylhydroquinone	CHEMICAL	23585332T1
23585332	328	332	tBHQ	CHEMICAL	23585332T2
23585332	119	123	tBHQ	CHEMICAL	23585332T3
23585332	408	412	tBHQ	CHEMICAL	23585332T4
23585332	537	541	tBHQ	CHEMICAL	23585332T5
23585332	718	722	tBHQ	CHEMICAL	23585332T6
23585332	750	754	tBHQ	CHEMICAL	23585332T7
23585332	804	816	triglyceride	CHEMICAL	23585332T8
23585332	827	838	cholesterol	CHEMICAL	23585332T9
23585332	CPR:3	23585332T10	106567
23585332	CPR:3	23585332T11	106567

23585380|t|Dual Growth Factor Delivery Using Biocompatible Core-Shell Microcapsules for Angiogenesis.
23585380|a|An optimized electrodropping system produces homogeneous core-shell microcapsules (C-S MCs) by using poly(L-lactic-co-glycolic acid) (PLGA) and alginate. Fluorescence imaging clearly shows the C-S domain in the MC. For release control, the use of high-molecular-weight PLGA (HMW 270 000) restrains the initial burst release of protein compared to that of low-MW PLGA (LMW 40 000). Layer-by-layer (LBL) assembly of chitosan and alginate on MCs is also useful in controlling the release profile of biomolecules. LBL (7-layer) treatment is effective in suppressing the initial burst release of protein compared to no LBL (0-layer). The difference of cumulative albumin release between HMW (7-layer LBL) and LMW (0-layer LBL) PLGA is determined to be more than 40% on day 5. When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA. As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area. This study demonstrates that the fabrication of biocompatible C-S MCs is possible, and that the release control of biomolecules is adjustable. Furthermore, MC-mediated GFs remain in an active form and can upregulate the angiogenic activity of ECs.
23585380	913	932	platelet-derived GF	GENE-N	23585380T10
23585380	934	938	PDGF	GENE-N	23585380T11
23585380	944	967	vascular endothelial GF	GENE-N	23585380T12
23585380	969	973	VEGF	GENE-N	23585380T13
23585380	1053	1057	VEGF	GENE-N	23585380T14
23585380	192	223	poly(L-lactic-co-glycolic acid)	CHEMICAL	23585380T1
23585380	1218	1222	PLGA	CHEMICAL	23585380T2
23585380	1255	1259	PLGA	CHEMICAL	23585380T3
23585380	225	229	PLGA	CHEMICAL	23585380T4
23585380	360	364	PLGA	CHEMICAL	23585380T5
23585380	453	457	PLGA	CHEMICAL	23585380T6
23585380	813	817	PLGA	CHEMICAL	23585380T7
23585380	1100	1104	PDGF	GENE-N	23585380T8
23585380	1384	1388	CD31	GENE-Y	23585380T9
23585380	CPR:3	23585380T2	23585380T14
23585380	CPR:3	23585380T2	23585380T8
23585380	CPR:3	23585380T3	23585380T14
23585380	CPR:3	23585380T3	23585380T8

23587425|t|Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
23587425|a|Chemistry has been developed to access both imidazo[1,2-a]pyrazines and imidazo[1,2-c]pyrimidines. Small structural modifications in both series led to a switch of potency between two kinases involved in mediating cell cycle checkpoint control, CHK1 and MK2.
23587425	32	35	MK2	GENE-Y	23587425T10
23587425	172	195	imidazo[1,2-a]pyrazines	CHEMICAL	23587425T1
23587425	200	225	imidazo[1,2-c]pyrimidines	CHEMICAL	23587425T2
23587425	50	72	imidazo[1,2-a]pyrazine	CHEMICAL	23587425T3
23587425	78	102	imidazo[1,2-c]pyrimidine	CHEMICAL	23587425T4
23587425	312	319	kinases	GENE-N	23587425T5
23587425	373	377	CHK1	GENE-Y	32969
23587425	382	385	MK2	GENE-Y	23587425T7
23587425	109	115	kinase	GENE-N	23587425T8
23587425	23	27	CHK1	GENE-Y	32969
23587425	CPR:4	23587425T3	23587425T10
23587425	CPR:4	23587425T3	23587425T8
23587425	CPR:4	23587425T3	32969
23587425	CPR:4	23587425T4	23587425T10
23587425	CPR:4	23587425T4	23587425T8
23587425	CPR:4	23587425T4	32969

23589302|t|The Fer tyrosine kinase is important for platelet-derived growth factor-BB-induced Stat3 phosphorylation, colony formation in soft agar and tumor growth in vivo.
23589302|a|Fer is a cytoplasmic tyrosine kinase that is activated in response to platelet-derived growth factor (PDGF) stimulation. In the present report, we show that Fer associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581, Tyr740 and Tyr1021. Using low molecular weight inhibitors, we found that PDGF-BB-induced Fer activation is dependent on PDGFRbeta kinase activity, but not on the enzymatic activity of Src or Jak kinases. In cells in which Fer was downregulated using siRNA, PDGF-BB was unable to induce phosphorylation of Stat3, whereas phosphorylations of Stat5, Erk1/2 and Akt were unaffected. PDGF-BB-induced activation of Stat3 occurred also in cells expressing kinase-dead Fer, suggesting a kinase-independent adaptor role of Fer. Expression of Fer was dispensable for PDGF-BB-induced proliferation and migration, but essential for colony formation in soft agar. Tumor growth in vivo was delayed in cells depleted of Fer expression. Our data suggests a critical role of Fer in PDGF-BB-induced Stat3 activation and cell transformation.
23589302	1213	1220	PDGF-BB	GENE-Y	23589302T10
23589302	1229	1234	Stat3	GENE-Y	203523|247196
23589302	319	322	Fer	GENE-Y	222202
23589302	353	370	PDGFbeta receptor	GENE-Y	23589302T13
23589302	372	381	PDGFRbeta	GENE-Y	23589302T14
23589302	183	198	tyrosine kinase	GENE-N	23589302T15
23589302	521	528	PDGF-BB	GENE-Y	23589302T16
23589302	537	540	Fer	GENE-Y	222202
23589302	568	577	PDGFRbeta	GENE-Y	23589302T18
23589302	578	584	kinase	GENE-N	23589302T19
23589302	183	191	tyrosine	CHEMICAL	23589302T1
23589302	632	635	Src	GENE-Y	203491|249840
23589302	639	642	Jak	GENE-N	23589302T21
23589302	643	650	kinases	GENE-N	23589302T22
23589302	670	673	Fer	GENE-Y	222202
23589302	705	712	PDGF-BB	GENE-Y	23589302T24
23589302	753	758	Stat3	GENE-Y	203523|247196
23589302	788	793	Stat5	GENE-N	23589302T26
23589302	795	801	Erk1/2	GENE-N	23589302T27
23589302	806	809	Akt	GENE-N	23589302T28
23589302	827	834	PDGF-BB	GENE-Y	23589302T29
23589302	432	435	Tyr	CHEMICAL	129
23589302	857	862	Stat3	GENE-Y	203523|247196
23589302	232	262	platelet-derived growth factor	GENE-N	23589302T31
23589302	897	903	kinase	GENE-N	23589302T32
23589302	909	912	Fer	GENE-Y	222202
23589302	927	933	kinase	GENE-N	23589302T34
23589302	962	965	Fer	GENE-Y	222202
23589302	981	984	Fer	GENE-Y	222202
23589302	1005	1012	PDGF-BB	GENE-Y	23589302T37
23589302	1153	1156	Fer	GENE-Y	222202
23589302	41	74	platelet-derived growth factor-BB	GENE-Y	23589302T39
23589302	440	443	Tyr	CHEMICAL	129
23589302	4	7	Fer	GENE-Y	222202
23589302	8	23	tyrosine kinase	GENE-N	23589302T41
23589302	83	88	Stat3	GENE-Y	203523|247196
23589302	448	451	Tyr	CHEMICAL	129
23589302	459	462	Tyr	CHEMICAL	129
23589302	8	16	tyrosine	CHEMICAL	23589302T6
23589302	162	165	Fer	GENE-Y	222202
23589302	264	268	PDGF	GENE-N	23589302T8
23589302	1206	1209	Fer	GENE-Y	222202

23591110|t|Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part I).
23591110|a|A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective histamine H3 receptor (H3R) antagonists. The SAR was explored and the data obtained set up the starting point and foundation for further optimization. The most potent tool compounds, as exemplified by compounds 2l, 5b, 5d, and 5e, displayed antagonism potencies in the subnanomolar range in in vitro human-H3R FLIPR assays and rhesus monkey H3R binding assays.
23591110	64	85	histamine H3 receptor	GENE-Y	23591110T10
23591110	238	247	histamine	CHEMICAL	23591110T1
23591110	168	178	aryl ureas	CHEMICAL	23591110T2
23591110	13	23	aryl ureas	CHEMICAL	23591110T3
23591110	28	39	aryl amides	CHEMICAL	23591110T4
23591110	64	73	histamine	CHEMICAL	23591110T5
23591110	238	259	histamine H3 receptor	GENE-Y	23591110T6
23591110	261	264	H3R	GENE-Y	23591110T7
23591110	538	547	human-H3R	GENE-Y	23591110T8
23591110	565	582	rhesus monkey H3R	GENE-Y	23591110T9
23591110	CPR:6	23591110T2	23591110T6
23591110	CPR:6	23591110T2	23591110T7
23591110	CPR:6	23591110T3	23591110T10
23591110	CPR:6	23591110T4	23591110T10

23591590|t|Structure and energetics of gas phase halogen-bonding in mono-, bi-, and tri-dentate anion receptors as studied by BIRD.
23591590|a|Complexes of mono-, bi- (RB), and tridentate (RT) receptors with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods. Temperature dependent blackbody infrared radiative dissociation (BIRD) experiments were performed on complexes of C8F17I with Br(-) and I(-), RB with I(-), NO3(-), HSO4(-), H2PO4(-), and TsO(-), and RT with I(-), HSO4(-) and TsO(-) and the observed Arrhenius parameters are reported here. Master equation modeling of the BIRD kinetics data was carried out to determine threshold dissociation energies. Geometry optimizations and thermochemistry calculations were performed using the B3LYP/6-31+G(d,p) level of theory. Additional single point energies were calculated using MP2/6-311++G(2d,p). Results were examined in terms of the binding order of various anions as well as the added binding strength from additional halogen bonding (XB) interactions. The relative binding energies of ions were generally consistent with the ordering previously reported from solution phase experiments; however, the relatively strong binding of H2PO4(-) to the bidentate receptor contrasted the solution phase observation of oxoanions having weaker interactions when compared to halides. An increase in the energy required to remove the same anion from the tridentate receptor when compared to the bidentate and monodentate receptors is explained as being due to the increase in halogen bonding interactions. The possibility of mixed halogen and hydrogen bonded complexes were considered.
23591590	1674	1681	halogen	CHEMICAL	23591590T10
23591590	1686	1694	hydrogen	CHEMICAL	23591590T11
23591590	470	476	C8F17I	CHEMICAL	23591590T12
23591590	482	487	Br(-)	CHEMICAL	23591590T13
23591590	492	496	I(-)	CHEMICAL	23591590T14
23591590	506	510	I(-)	CHEMICAL	23591590T15
23591590	512	518	NO3(-)	CHEMICAL	23591590T16
23591590	520	527	HSO4(-)	CHEMICAL	23591590T17
23591590	529	537	H2PO4(-)	CHEMICAL	23591590T18
23591590	543	549	TsO(-)	CHEMICAL	23591590T19
23591590	225	231	NO3(-)	CHEMICAL	23591590T1
23591590	563	567	I(-)	CHEMICAL	23591590T20
23591590	569	576	HSO4(-)	CHEMICAL	23591590T21
23591590	581	587	TsO(-)	CHEMICAL	23591590T22
23591590	205	210	Cl(-)	CHEMICAL	23591590T23
23591590	212	217	Br(-)	CHEMICAL	23591590T24
23591590	1073	1080	halogen	CHEMICAL	23591590T25
23591590	219	223	I(-)	CHEMICAL	23591590T26
23591590	38	45	halogen	CHEMICAL	23591590T27
23591590	134	180	mono-, bi- (RB), and tridentate (RT) receptors	GENE-N	23591590T28
23591590	1497	1516	tridentate receptor	GENE-N	23591590T29
23591590	233	241	H2PO4(-)	CHEMICAL	23591590T2
23591590	1538	1573	bidentate and monodentate receptors	GENE-N	23591590T30
23591590	57	100	mono-, bi-, and tri-dentate anion receptors	GENE-N	23591590T31
23591590	1285	1293	H2PO4(-)	CHEMICAL	23591590T3
23591590	243	250	HSO4(-)	CHEMICAL	23591590T4
23591590	1365	1368	oxo	CHEMICAL	23591590T5
23591590	1419	1426	halides	CHEMICAL	23591590T6
23591590	256	264	tosylate	CHEMICAL	23591590T7
23591590	266	272	TsO(-)	CHEMICAL	23591590T8
23591590	1619	1626	halogen	CHEMICAL	23591590T9

23597506|t|Anandamide deficiency and heightened neuropathic pain in aged mice.
23597506|a|Damaging of peripheral nerves may result in chronic neuropathic pain for which the likelihood is increased in the elderly. We assessed in mice if age-dependent alterations of endocannabinoids contributed to the heightened vulnerability to neuropathic pain at old age. We assessed nociception, endocannabinoids and the therapeutic efficacy of R-flurbiprofen in young and aged mice in the spared nerve injury model of neuropathic pain. R-flurbiprofen was used because it is able to reduce neuropathic pain in young mice in part by increasing anandamide. Aged mice developed stronger nociceptive hypersensitivity after sciatic nerve injury than young mice. This was associated with low anandamide levels in the dorsal root ganglia, spinal cord, thalamus and cortex, which further decreased after nerve injury. In aged mice, R-flurbiprofen had only weak antinociceptive efficacy and it failed to restore normal anandamide levels after nerve injury. In terms of the mechanisms, we found that fatty acid amide hydrolase (FAAH) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences. However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide. This may overwhelm the capacity of R-flurbiprofen to restore anandamide homeostasis and may contribute to the heightened risk for neuropathic pain at old age.
23597506	889	903	R-flurbiprofen	CHEMICAL	23597506T10
23597506	975	985	anandamide	CHEMICAL	23597506T11
23597506	1055	1065	fatty acid	CHEMICAL	23597506T12
23597506	1066	1071	amide	CHEMICAL	23597506T13
23597506	0	10	Anandamide	CHEMICAL	23597506T14
23597506	1083	1087	FAAH	GENE-N	108464
23597506	1325	1341	cyclooxygenase-1	GENE-Y	23597506T16
23597506	1346	1352	Cyp2D6	GENE-N	23597506T17
23597506	1055	1081	fatty acid amide hydrolase	GENE-N	23597506T18
23597506	1104	1114	anandamide	CHEMICAL	23597506T1
23597506	1306	1316	anandamide	CHEMICAL	23597506T2
23597506	1442	1452	anandamide	CHEMICAL	23597506T3
23597506	1489	1503	R-flurbiprofen	CHEMICAL	23597506T4
23597506	1515	1525	anandamide	CHEMICAL	23597506T5
23597506	410	424	R-flurbiprofen	CHEMICAL	23597506T6
23597506	502	516	R-flurbiprofen	CHEMICAL	23597506T7
23597506	608	618	anandamide	CHEMICAL	23597506T8
23597506	751	761	anandamide	CHEMICAL	23597506T9
23597506	CPR:9	23597506T1	108464
23597506	CPR:9	23597506T1	23597506T18
23597506	CPR:9	23597506T2	23597506T16
23597506	CPR:9	23597506T2	23597506T17
23597506	CPR:9	23597506T3	23597506T16
23597506	CPR:9	23597506T3	23597506T17

23600667|t|Polymer-based protein engineering can rationally tune enzyme activity, pH-dependence, and stability.
23600667|a|The attachment of inert polymers, such as polyethyleneglycol, to proteins has driven the emergence of a multibillion dollar biotechnology industry. In all cases, proteins have been stabilized or altered by covalently coupling the pre-existing polymer to the surface of the protein. This approach is inherently limited by a lack of exquisite control of polymer architecture, chain length, site and density of attachment. Using a novel water-soluble atom transfer radical polymerization initiator, we have grown temperature- and pH-responsive polymers from the surface of a model protein, the enzyme chymotrypsin. Poly(2-(dimethylamino)ethyl methacrylate) changes in conformation with altered temperature and pH. Growing the polymer from the surface of chymotrypsin we were able to demonstrate that changes in temperature or pH can change predictably the conformation of the polymer surrounding the enzyme, which in turn enabled the rational tailoring of enzyme activity and stability. Using what we now term "Polymer-Based Protein Engineering" we have increased the activity and stability of chymotrypsin by an order of magnitude at pH's where the enzyme is usually inactive or unstable.
23600667	143	161	polyethyleneglycol	CHEMICAL	23600667T1
23600667	713	754	Poly(2-(dimethylamino)ethyl methacrylate)	CHEMICAL	23600667T2
23600667	1192	1204	chymotrypsin	GENE-N	23600667T3
23600667	699	711	chymotrypsin	GENE-N	23600667T4
23600667	852	864	chymotrypsin	GENE-N	23600667T5

23600914|t|24(S)-hydroxycholesterol is actively eliminated from neuronal cells by ABCA1.
23600914|a|High cholesterol turnover catalyzed by cholesterol 24-hydroxylase is essential for neural functions, especially learning. Because 24(S)-hydroxycholesterol (24-OHC), produced by 24-hydroxylase, induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells. Here, using differentiated SH-SY5Y neuron-like cells as a model, we examined whether 24-OHC is actively eliminated via transporters induced by its accumulation. The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR. When the expression of ABCA1 and ABCG1 was induced, 24-OHC efflux was stimulated in the presence of high density lipoprotein (HDL), whereas apolipoprotein A-I was not an efficient acceptor. The efflux was suppressed by the addition of siRNA against ABCA1, but not by ABCG1 siRNA. To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or ABCG1; we clearly observed 24-OHC efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal. Furthermore, the treatment of primary cerebral neurons with LXR/RXR ligands suppressed the toxicity of 24-OHC. These results suggest that ABCA1 actively eliminates 24-OHC in the presence of HDL as a lipid acceptor and protects neuronal cells. This article is protected by copyright. All rights reserved.
23600914	598	611	retinoic acid	CHEMICAL	23600914T10
23600914	717	723	24-OHC	CHEMICAL	23600914T11
23600914	1071	1077	24-OHC	CHEMICAL	23600914T12
23600914	0	24	24(S)-hydroxycholesterol	CHEMICAL	23600914T13
23600914	1104	1107	HDL	GENE-N	23600914T14
23600914	1143	1161	apolipoprotein A-I	GENE-Y	23600914T15
23600914	1236	1239	LXR	GENE-N	23600914T16
23600914	1240	1243	RXR	GENE-N	23600914T17
23600914	1314	1319	ABCA1	GENE-Y	106537|4105
23600914	1366	1369	HDL	GENE-N	23600914T19
23600914	1279	1285	24-OHC	CHEMICAL	23600914T1
23600914	255	269	24-hydroxylase	GENE-Y	23600914T20
23600914	117	143	cholesterol 24-hydroxylase	GENE-Y	23600914T21
23600914	475	487	transporters	GENE-N	23600914T22
23600914	535	540	ABCA1	GENE-Y	106537|4105
23600914	545	550	ABCG1	GENE-Y	114980
23600914	638	655	nuclear receptors	GENE-N	23600914T25
23600914	656	659	LXR	GENE-N	23600914T26
23600914	660	663	RXR	GENE-N	23600914T27
23600914	688	693	ABCA1	GENE-Y	106537|4105
23600914	698	703	ABCG1	GENE-Y	114980
23600914	1340	1346	24-OHC	CHEMICAL	23600914T2
23600914	765	789	high density lipoprotein	GENE-N	23600914T30
23600914	791	794	HDL	GENE-N	23600914T31
23600914	805	823	apolipoprotein A-I	GENE-Y	23600914T32
23600914	914	919	ABCA1	GENE-Y	106537|4105
23600914	932	937	ABCG1	GENE-Y	114980
23600914	1029	1040	human ABCA1	GENE-Y	23600914T35
23600914	1044	1049	ABCG1	GENE-Y	114980
23600914	71	76	ABCA1	GENE-Y	106537|4105
23600914	208	232	24(S)-hydroxycholesterol	CHEMICAL	23600914T3
23600914	234	240	24-OHC	CHEMICAL	23600914T4
23600914	441	447	24-OHC	CHEMICAL	23600914T5
23600914	117	128	cholesterol	CHEMICAL	23600914T6
23600914	566	572	24-OHC	CHEMICAL	23600914T7
23600914	585	593	TO901317	CHEMICAL	23600914T8
23600914	83	94	cholesterol	CHEMICAL	23600914T9
23600914	CPR:3	23600914T10	106537|4105
23600914	CPR:3	23600914T10	114980
23600914	CPR:3	23600914T7	106537|4105
23600914	CPR:3	23600914T7	114980
23600914	CPR:3	23600914T8	106537|4105
23600914	CPR:3	23600914T8	114980
23600914	CPR:9	23600914T12	23600914T35
23600914	CPR:9	23600914T12	114980
23600914	CPR:9	23600914T13	106537|4105
23600914	CPR:9	23600914T2	106537|4105
23600914	CPR:9	23600914T3	23600914T20
23600914	CPR:9	23600914T4	23600914T20
23600914	CPR:9	23600914T9	23600914T21

23601203|t|Design, Synthesis and biological evaluation of catecholamine vehicle for studying dopaminergic system.
23601203|a|Catecholamine mimetic EDTA-bis(tyramide) was synthesized and characterized by various spectroscopic techniques (NMR, Mass spectroscopy) and em 310 nm for the excitation at 270 nm. Molecular docking studies were performed with Human Serum Albumin (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target. Subsequently binding study with HSA at ex =350 nm found to be 5.847x10(4) M(-1) shows effective quenching effect. Additionally to go more insight AChE binding affinity was investigated, which shows 90% binding affinity for the 10 mM concentration. IC50 value was was found 18.60 M for MAO-B inhibition. Finally, EDTA-bis(tyramide) labeled with (99m) Tc to investigate its in-vivo radiopharmaceutical efficiency, having 97% binding affinity with 98% radiochemical purity. In-vivo studies were carried out for (99m) Tc- EDTA-bis(tyramide) included blood kinetics showed a quick wash out from the circulation via renal route and biodistribution revealed that maximum%ID/g was found in kidney at 1h and its scintigraphy image shows 3.96% brain uptake with respect to whole body. This article is protected by copyright. All rights reserved.
23601203	47	60	catecholamine	CHEMICAL	23601203T10
23601203	330	349	Human Serum Albumin	GENE-Y	23601203T11
23601203	351	354	HSA	GENE-Y	23601203T12
23601203	465	468	HSA	GENE-Y	23601203T13
23601203	850	855	MAO-B	GENE-Y	23601203T14
23601203	103	116	Catecholamine	CHEMICAL	23601203T1
23601203	125	143	EDTA-bis(tyramide)	CHEMICAL	23601203T2
23601203	396	406	amino acid	CHEMICAL	23601203T3
23601203	416	419	Arg	CHEMICAL	119
23601203	424	427	Arg	CHEMICAL	119
23601203	435	438	Lys	CHEMICAL	23601203T6
23601203	877	895	EDTA-bis(tyramide)	CHEMICAL	23601203T7
23601203	909	917	(99m) Tc	CHEMICAL	23601203T8
23601203	1073	1101	(99m) Tc- EDTA-bis(tyramide)	CHEMICAL	23601203T9

23602864|t|Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer-drug conjugates and gold nanorod induced hyperthermia.
23602864|a|In the field of nanomedicine, selective delivery to cancer cells is a common goal, where active targeting strategies are often employed to increase tumor accumulation. In this study, tumor hyperthermia was utilized as a means to increase the active delivery of heat shock protein (HSP) targeted N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates. Following hyperthermia, induced expression of cell surface heat shock protein (HSP) glucose regulated protein 78kDa (GRP78) was utilized for targeted drug therapy. Conjugates bearing the anticancer agents aminohexylgeldanamycin (AHGDM), docetaxel (DOC), or cisplatin and the GRP78 targeting peptide WDLAWMFRLPVG were synthesized and characterized. Binding to cell surface expressed heat shock protein GRP78 on the surface of human prostate cancer DU145 cells was evaluated. HSP targeted AHGDM and DOC conjugates demonstrated active binding comparable to native targeting peptide. They were then assessed in vitro for the ability to synergistically induce cytotoxicity in combination with moderate hyperthermia (43C, 30min). HSP targeted DOC conjugates exhibited high potency against DU145 cells with an IC50 of 2.4nM. HSP targeted AHGDM and DOC conjugates demonstrated synergistic effects in combination with hyperthermia with combination index values of 0.65 and 0.45 respectively. Based on these results, HSP targeted DOC conjugates were selected for in vivo evaluation. In DU145 tumor bearing mice, a single treatment of tumor hyperthermia, induced via gold nanorod mediated plasmonic photothermal therapy, and intravenous administration of HSP targeted HPMA copolymer-docetaxel at 10mg/kg resulted in maintained tumor regression for a period of 30days. These results demonstrate the potential for tumor hyperthermia to increase the delivery of HSP targeted macromolecular chemotherapeutics.
23602864	731	753	aminohexylgeldanamycin	CHEMICAL	23602864T10
23602864	755	760	AHGDM	CHEMICAL	23602864T11
23602864	763	772	docetaxel	CHEMICAL	23602864T12
23602864	774	777	DOC	CHEMICAL	23602864T13
23602864	783	792	cisplatin	CHEMICAL	23602864T14
23602864	1013	1018	AHGDM	CHEMICAL	23602864T15
23602864	1023	1026	DOC	CHEMICAL	23602864T16
23602864	93	97	HPMA	CHEMICAL	23602864T17
23602864	1251	1254	HSP	GENE-N	23602864T18
23602864	1345	1348	HSP	GENE-N	23602864T19
23602864	1264	1267	DOC	CHEMICAL	23602864T1
23602864	1534	1537	HSP	GENE-N	23602864T20
23602864	1771	1774	HSP	GENE-N	23602864T21
23602864	1975	1978	HSP	GENE-N	23602864T22
23602864	424	442	heat shock protein	GENE-N	23602864T23
23602864	444	447	HSP	GENE-N	23602864T24
23602864	585	603	heat shock protein	GENE-N	23602864T25
23602864	605	608	HSP	GENE-N	23602864T26
23602864	610	641	glucose regulated protein 78kDa	GENE-Y	23602864T27
23602864	643	648	GRP78	GENE-Y	23602864T28
23602864	801	806	GRP78	GENE-Y	23602864T29
23602864	1358	1363	AHGDM	CHEMICAL	23602864T2
23602864	908	926	heat shock protein	GENE-N	23602864T30
23602864	927	932	GRP78	GENE-Y	23602864T31
23602864	1000	1003	HSP	GENE-N	23602864T32
23602864	65	83	heat shock protein	GENE-N	23602864T33
23602864	1368	1371	DOC	CHEMICAL	23602864T3
23602864	1547	1550	DOC	CHEMICAL	23602864T4
23602864	1784	1788	HPMA	CHEMICAL	23602864T5
23602864	1799	1808	docetaxel	CHEMICAL	23602864T6
23602864	458	491	N-(2-hydroxypropyl)methacrylamide	CHEMICAL	23602864T7
23602864	493	497	HPMA	CHEMICAL	23602864T8
23602864	610	617	glucose	CHEMICAL	23602864T9

23602989|t|Presynaptic CaMKII modulates dopamine D3 receptor activation in striatonigral terminals of the rat brain in a Ca(2+) dependent manner.
23602989|a|CaMKII is expressed at high density in the nucleus accumbens where it binds to postsynaptic D3 receptors inhibiting their effects. In striatonigral projections, activation of presynaptic D3 receptors potentiates D1 receptor-induced stimulation of cAMP production and GABA release. In this study we examined whether the presynaptic effects of D3 receptor stimulation in the substantia nigra reticulata (SNr) are modulated by Ca(2+) activation of CaMKII. In SNr synaptosomes two procedures that increase cytoplasmic Ca(2+), ionomycin and K(+)-depolarization, blocked the additional stimulation of cAMP accumulation produced by coactivating D3 and D1 dopamine receptors. The selective CaMKII inhibitor KN-62 reversed the blockade produced by ionomycin and K(+)-depolarization. Incubation in either Ca(2) -free solutions or with the selective Ca(2+) blocker nifedipine, also reversed the blocking effects of K(+)-depolarization. Immunoblot studies showed that K(+)-depolarization increased CaMKII phosphorylation in a KN-62 sensitive manner and promoted CaMKII binding to D3 receptors. In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKII was blocked with KN-62. In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4nM. KN-62 also enhanced the effects of dopamine on depolarization induced [(3)H]GABA release. KN-62 changed ED50 for dopamine from 584 to 56nM. KN-62 did not affect D1 and D4 receptor responses. These experiments show that in striatonigral projections, CaMKII inhibits the action of D3 receptors in a Ca(2+) dependent manner blocking their modulatory effects on GABA release. These findings suggest a mechanism through which the frequency of action potential discharge in presynaptic terminals regulates dopamine effects.
23602989	1597	1602	KN-62	CHEMICAL	23602989T10
23602989	1620	1628	dopamine	CHEMICAL	23602989T11
23602989	1648	1653	KN-62	CHEMICAL	23602989T12
23602989	1806	1812	Ca(2+)	CHEMICAL	23602989T13
23602989	1867	1871	GABA	CHEMICAL	23602989T14
23602989	2009	2017	dopamine	CHEMICAL	23602989T15
23602989	561	567	Ca(2+)	CHEMICAL	23602989T16
23602989	652	658	Ca(2+)	CHEMICAL	23602989T17
23602989	660	669	ionomycin	CHEMICAL	23602989T18
23602989	674	678	K(+)	CHEMICAL	23602989T19
23602989	1154	1159	KN-62	CHEMICAL	23602989T1
23602989	733	737	cAMP	CHEMICAL	2424
23602989	786	794	dopamine	CHEMICAL	23602989T21
23602989	838	843	KN-62	CHEMICAL	23602989T22
23602989	878	887	ionomycin	CHEMICAL	23602989T23
23602989	892	896	K(+)	CHEMICAL	23602989T24
23602989	934	939	Ca(2)	CHEMICAL	23602989T25
23602989	978	984	Ca(2+)	CHEMICAL	23602989T26
23602989	993	1003	nifedipine	CHEMICAL	1103
23602989	1043	1047	K(+)	CHEMICAL	23602989T28
23602989	1095	1099	K(+)	CHEMICAL	23602989T29
23602989	1226	1230	K(+)	CHEMICAL	23602989T2
23602989	111	117	Ca(2+)	CHEMICAL	23602989T30
23602989	30	38	dopamine	CHEMICAL	23602989T31
23602989	136	143	CaMKII	GENE-Y	23602989T32
23602989	1190	1197	CaMKII	GENE-Y	23602989T33
23602989	1209	1221	D3 receptors	GENE-Y	23602989T34
23602989	1252	1264	D3 receptors	GENE-Y	23602989T35
23602989	1277	1288	D1 receptor	GENE-N	23602989T36
23602989	1341	1348	CaMKII	GENE-Y	23602989T37
23602989	1422	1424	D3	GENE-Y	23602989T38
23602989	1469	1471	D1	GENE-Y	66262
23602989	1312	1322	[(3)H]GABA	CHEMICAL	23602989T3
23602989	1669	1687	D1 and D4 receptor	GENE-N	23602989T40
23602989	1757	1764	CaMKII	GENE-Y	23602989T41
23602989	1788	1800	D3 receptors	GENE-Y	23602989T42
23602989	324	336	D3 receptors	GENE-Y	23602989T43
23602989	349	360	D1 receptor	GENE-Y	23602989T44
23602989	479	490	D3 receptor	GENE-Y	23602989T45
23602989	582	589	CaMKII	GENE-Y	23602989T46
23602989	776	804	D3 and D1 dopamine receptors	GENE-N	23602989T47
23602989	820	827	CaMKII	GENE-Y	23602989T48
23602989	229	241	D3 receptors	GENE-Y	23602989T49
23602989	1366	1371	KN-62	CHEMICAL	23602989T4
23602989	1125	1132	CaMKII	GENE-Y	23602989T50
23602989	12	19	CaMKII	GENE-Y	23602989T51
23602989	30	50	dopamine D3 receptor	GENE-Y	23602989T52
23602989	1433	1443	PD 128,907	CHEMICAL	23602989T5
23602989	1480	1489	SKF 38393	CHEMICAL	23602989T6
23602989	1507	1512	KN-62	CHEMICAL	23602989T7
23602989	1542	1550	dopamine	CHEMICAL	23602989T8
23602989	1577	1587	[(3)H]GABA	CHEMICAL	23602989T9
23602989	CPR:4	23602989T22	23602989T48
23602989	CPR:4	23602989T23	23602989T48
23602989	CPR:4	23602989T4	23602989T37
23602989	CPR:5	23602989T5	23602989T38
23602989	CPR:5	23602989T6	66262

23603381|t|Ellagic acid attenuates bleomycin and cyclophosphamide-induced pulmonary toxicity in Wistar rats.
23603381|a|Use of bleomycin (BLM) and cyclophosphamide (CP) as chemotherapeutic drugs is associated with side effects including toxicity to respiratory system. Their co-administration may enhance lung toxicity which may subsequently progress to the lung fibrosis. Natural compounds have shown mitigating effects against toxicity of anticancer drugs. Ellagic acid (EA), a polyphenolic compound present in many fruits and nuts in addition to walnut has shown promising protective effect against toxicity of drugs and chemicals. We studied the ameliorative effect of EA on lung toxicity in rats exposed to CP (150mg/kgb.w., i.p.) and BLM (10U/kgb.w., i.t.). EA (15mg/kgb.w., p.o.14days) treatment modulated enhanced hydroxyproline level, lipid peroxidation, myeloperoxidase activity, nitric oxide production and protein carbonyl formation in lungs of rats exposed to toxic anticancer drugs. There was a marked decrease in GSH content and activities of antioxidant enzymes as a result of BLM and CP treatment. Bronchoalveolar lavage fluid showed increased level of cytotoxicity markers in drug treated animals. Treatment with EA attenuated these changes. Histopathological findings also showed protective effects of EA. In conclusion, EA emerged as a natural protectant with an ability to protect lungs from onslaught of pulmonary toxicity of anticancer drugs.
23603381	1072	1075	BLM	CHEMICAL	283
23603381	0	12	Ellagic acid	CHEMICAL	23603381T11
23603381	24	33	bleomycin	CHEMICAL	23603381T12
23603381	38	54	cyclophosphamide	CHEMICAL	23603381T13
23603381	843	858	myeloperoxidase	GENE-Y	23603381T14
23603381	116	119	BLM	CHEMICAL	283
23603381	125	141	cyclophosphamide	CHEMICAL	23603381T2
23603381	437	449	Ellagic acid	CHEMICAL	23603381T3
23603381	718	721	BLM	CHEMICAL	283
23603381	801	815	hydroxyproline	CHEMICAL	23603381T5
23603381	105	114	bleomycin	CHEMICAL	23603381T6
23603381	869	881	nitric oxide	CHEMICAL	23603381T7
23603381	905	913	carbonyl	CHEMICAL	23603381T8
23603381	1007	1010	GSH	CHEMICAL	137

23605050|t|Effects of High Iron and Glucose Concentrations over the Relative Expression of Bcl2, Bax, and Mfn2 in MIN6 Cells.
23605050|a|Type 2 diabetes is characterized by hyperglycemia and oxidative stress. Hyperglycemia is linked to mitochondrial dysfunction and reduced -cell mass due to the reduced expression of genes such as Mfn2 as well as the participation of the Bcl2 gene family, responsible for increased apoptosis. The purpose of this study was to describe the effect of different iron and/or glucose concentrations over Mfn2, Bax, and Bcl2 expressions in a -pancreatic cell line (MIN6 cells). MIN6 cells were pre-incubated with different iron and/or glucose concentrations, and the relative mRNA abundance of the Bcl2/Bax ratio and of Mfn2 genes was measured by qRT-PCR. Heme oxygenase (HO) activity, iron uptake, superoxide dismutase activity, and glutathione content were also determined. The Bcl2/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation. These effects were higher when glucose and iron were incubated together. Additionally, treatment with glucose/iron showed a higher HO activity. Our study revealed that high glucose/Fe concentrations in MIN6 cells induced an increase of the Bcl2/Bax ratio, an indicator of increased cell apoptosis.
23605050	964	971	glucose	CHEMICAL	23605050T10
23605050	1016	1023	glucose	CHEMICAL	23605050T11
23605050	1028	1032	iron	CHEMICAL	23605050T12
23605050	1087	1094	glucose	CHEMICAL	23605050T13
23605050	1095	1099	iron	CHEMICAL	23605050T14
23605050	16	20	Iron	CHEMICAL	23605050T15
23605050	25	32	Glucose	CHEMICAL	23605050T16
23605050	1116	1118	HO	GENE-N	31883
23605050	1225	1229	Bcl2	GENE-Y	198318|246412
23605050	1230	1233	Bax	GENE-Y	198304|246997
23605050	1158	1165	glucose	CHEMICAL	23605050T1
23605050	311	315	Mfn2	GENE-Y	228398
23605050	352	356	Bcl2	GENE-Y	198318|246412
23605050	513	517	Mfn2	GENE-Y	228398
23605050	519	522	Bax	GENE-Y	198304|246997
23605050	528	532	Bcl2	GENE-Y	198318|246412
23605050	707	711	Bcl2	GENE-Y	198318|246412
23605050	712	715	Bax	GENE-Y	198304|246997
23605050	729	733	Mfn2	GENE-Y	228398
23605050	765	779	Heme oxygenase	GENE-N	23605050T28
23605050	781	783	HO	GENE-N	31883
23605050	1166	1168	Fe	CHEMICAL	23605050T2
23605050	808	828	superoxide dismutase	GENE-N	23605050T30
23605050	889	893	Bcl2	GENE-Y	198318|246412
23605050	894	897	Bax	GENE-Y	198304|246997
23605050	918	922	Mfn2	GENE-Y	228398
23605050	80	84	Bcl2	GENE-Y	198318|246412
23605050	86	89	Bax	GENE-Y	198304|246997
23605050	95	99	Mfn2	GENE-Y	228398
23605050	473	477	iron	CHEMICAL	23605050T3
23605050	485	492	glucose	CHEMICAL	23605050T4
23605050	632	636	iron	CHEMICAL	23605050T5
23605050	644	651	glucose	CHEMICAL	23605050T6
23605050	795	799	iron	CHEMICAL	23605050T7
23605050	808	818	superoxide	CHEMICAL	23605050T8
23605050	843	854	glutathione	CHEMICAL	23605050T9
23605050	CPR:3	23605050T10	198318|246412
23605050	CPR:3	23605050T10	198304|246997
23605050	CPR:3	23605050T13	31883
23605050	CPR:3	23605050T14	31883
23605050	CPR:3	23605050T1	198318|246412
23605050	CPR:3	23605050T1	198304|246997
23605050	CPR:3	23605050T2	198318|246412
23605050	CPR:3	23605050T2	198304|246997
23605050	CPR:4	23605050T10	228398

23607523|t|Genetic Insights into Pyralomicin Biosynthesis in Nonomuraea spiralis IMC A-0156.
23607523|a|The biosynthetic gene cluster for the pyralomicin antibiotics has been cloned and sequenced from Nonomuraea spiralis IMC A-0156. The 41 kb gene cluster contains 27 ORFs predicted to encode all of the functions for pyralomicin biosynthesis. This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure. The N-glycosyltransferase is predicted to transfer either glucose or a pseudosugar (cyclitol) to the aglycone. A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs. Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.
23607523	733	741	cyclitol	CHEMICAL	23607523T10
23607523	785	787	C7	CHEMICAL	23607523T11
23607523	788	796	cyclitol	CHEMICAL	23607523T12
23607523	849	867	benzopyranopyrrole	CHEMICAL	23607523T13
23607523	928	929	N	CHEMICAL	167
23607523	967	978	pyralomicin	CHEMICAL	23607523T15
23607523	1068	1073	sugar	CHEMICAL	23607523T16
23607523	1074	1083	phosphate	CHEMICAL	23607523T17
23607523	22	33	Pyralomicin	CHEMICAL	23607523T18
23607523	336	368	nonribosomal peptide synthetases	GENE-N	23607523T19
23607523	1125	1127	C7	CHEMICAL	23607523T1
23607523	370	374	NRPS	GENE-N	23607523T20
23607523	380	400	polyketide synthases	GENE-N	23607523T21
23607523	402	405	PKS	GENE-N	23607523T22
23607523	523	534	halogenases	GENE-N	23607523T23
23607523	539	558	O-methyltransferase	GENE-N	23607523T24
23607523	567	588	N-glycosyltransferase	GENE-N	23607523T25
23607523	653	674	N-glycosyltransferase	GENE-N	23607523T26
23607523	928	949	N-glycosyltransferase	GENE-N	23607523T27
23607523	951	955	prlH	GENE-Y	23607523T28
23607523	1021	1025	PrlA	GENE-Y	23607523T29
23607523	1128	1136	cyclitol	CHEMICAL	23607523T2
23607523	1068	1091	sugar phosphate cyclase	GENE-N	23607523T30
23607523	296	307	pyralomicin	CHEMICAL	23607523T3
23607523	441	459	benzopyranopyrrole	CHEMICAL	23607523T4
23607523	120	131	pyralomicin	CHEMICAL	23607523T5
23607523	539	540	O	CHEMICAL	23607523T6
23607523	567	568	N	CHEMICAL	167
23607523	653	654	N	CHEMICAL	167
23607523	707	714	glucose	CHEMICAL	23607523T9
23607523	CPR:9	23607523T15	23607523T27
23607523	CPR:9	23607523T15	23607523T28
23607523	CPR:9	23607523T1	23607523T29
23607523	CPR:9	23607523T1	23607523T30
23607523	CPR:9	23607523T2	23607523T29
23607523	CPR:9	23607523T2	23607523T30
23607523	CPR:9	23607523T4	23607523T19
23607523	CPR:9	23607523T4	23607523T20
23607523	CPR:9	23607523T4	23607523T21
23607523	CPR:9	23607523T4	23607523T22
23607523	CPR:9	23607523T4	23607523T23
23607523	CPR:9	23607523T4	23607523T24
23607523	CPR:9	23607523T4	23607523T25

23607712|t|Synaptotagmin 1 is required for vesicular Ca(2+) /H(+) -antiport activity.
23607712|a|A low-affinity Ca(2+) /H(+) -antiport was described in the membrane of mammalian brain synaptic vesicles. Electrophysiological studies showed that this antiport contributes to the extreme brevity of excitation-release coupling in rapid synapses. Synaptotagmin-1, a vesicular protein interacting with membranes upon low-affinity Ca(2+) -binding, plays a major role in excitation-release coupling, by synchronizing calcium entry with fast neurotransmitter release. Here, we report that synaptotagmin-1 is necessary for expression of the vesicular Ca(2+) /H(+) -antiport. We measured Ca(2+) /H(+) -antiport activity in vesicles and granules of pheochromocytoma PC12 cells by three methods: (1) Ca(2+) -induced dissipation of the vesicular H(+) -gradient; (2) bafilomycin-sensitive calcium accumulation and (3) pH-jump-induced calcium accumulation. The results were congruent and highly significant: Ca(2+) /H(+) -antiport activity is detectable only in acidic organelles expressing functional synaptotagmin-1. In contrast, synaptotagmin-1-deficient cells - and cells where transgenically encoded synaptotagmin-1 was acutely photo-inactivated - were devoid of any Ca(2+) /H(+) -antiport activity. Therefore, in addition to its previously described functions, synaptotagmin-1 is involved in a rapid vesicular Ca(2+) sequestration through a Ca(2+) /H(+) antiport. This article is protected by copyright. All rights reserved.
23607712	620	626	Ca(2+)	CHEMICAL	23607712T10
23607712	628	632	H(+)	CHEMICAL	23607712T11
23607712	656	662	Ca(2+)	CHEMICAL	23607712T12
23607712	664	668	H(+)	CHEMICAL	23607712T13
23607712	766	772	Ca(2+)	CHEMICAL	23607712T14
23607712	811	815	H(+)	CHEMICAL	23607712T15
23607712	831	842	bafilomycin	CHEMICAL	23607712T16
23607712	853	860	calcium	CHEMICAL	23607712T17
23607712	898	905	calcium	CHEMICAL	23607712T18
23607712	971	977	Ca(2+)	CHEMICAL	23607712T19
23607712	1235	1241	Ca(2+)	CHEMICAL	23607712T1
23607712	979	983	H(+)	CHEMICAL	23607712T20
23607712	42	48	Ca(2+)	CHEMICAL	23607712T21
23607712	50	54	H(+)	CHEMICAL	23607712T22
23607712	1095	1110	synaptotagmin-1	GENE-Y	23607712T23
23607712	1168	1183	synaptotagmin-1	GENE-Y	23607712T24
23607712	1330	1345	synaptotagmin-1	GENE-Y	23607712T25
23607712	321	336	Synaptotagmin-1	GENE-Y	23607712T26
23607712	559	574	synaptotagmin-1	GENE-Y	23607712T27
23607712	1065	1080	synaptotagmin-1	GENE-Y	23607712T28
23607712	0	15	Synaptotagmin 1	GENE-Y	23607712T29
23607712	1243	1247	H(+)	CHEMICAL	23607712T2
23607712	1379	1385	Ca(2+)	CHEMICAL	23607712T3
23607712	1410	1416	Ca(2+)	CHEMICAL	23607712T4
23607712	1418	1422	H(+)	CHEMICAL	23607712T5
23607712	90	96	Ca(2+)	CHEMICAL	23607712T6
23607712	98	102	H(+)	CHEMICAL	23607712T7
23607712	403	409	Ca(2+)	CHEMICAL	23607712T8
23607712	488	495	calcium	CHEMICAL	23607712T9

23608737|t|Estradiol replacement enhances cocaine-stimulated locomotion in female C57BL/6 mice through estrogen receptor alpha.
23608737|a|Psychostimulant effects are enhanced by ovarian hormones in women and female rodents. Estradiol increases behavioral responses to psychostimulants in women and female rats, although the underlying mechanism is unknown. This study utilized mice to investigate the time frame and receptor mediation of estradiol's enhancement of cocaine-induced behavior as mice enable parallel use of genetic, surgical and pharmacological methods. The spontaneous behavior of Sham and Ovariectomized (Ovx) female wildtype (WT) mice was determined during habituation to a novel environment and after cocaine administration. Ovx mice were replaced with vehicle (sesame oil) or 17-estradiol (E2) for 2 days or 30min prior to a cocaine challenge to investigate the time course of E2's effects. To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ER-selective agonist PPT or the ER-selective agonist DPN were compared to Sham mice, and mice lacking either ER (ERKO) or ER (ERKO) were compared to WT littermates. Ovx mice exhibited fewer ambulations during habituation than Sham females. Cocaine-induced increases in behavioral ratings were greater in Sham than in Ovx mice. Two days but not 30min of E2 replacement in Ovx mice increased cocaine responses to Sham levels. PPT replacement also increased the cocaine response relative to vehicle- or DPN- treated Ovx mice. ERKO mice displayed modestly attenuated behavioral responses to novelty and cocaine compared to WT littermates, but no behavioral differences were found between ERKO and WT mice. These results suggest that E2 enhances cocaine-stimulated locomotion in mice predominantly through ER.
23608737	698	705	cocaine	CHEMICAL	23608737T10
23608737	774	787	17-estradiol	CHEMICAL	23608737T11
23608737	825	832	cocaine	CHEMICAL	23608737T12
23608737	924	933	estradiol	CHEMICAL	23608737T13
23608737	203	212	Estradiol	CHEMICAL	773
23608737	1010	1013	PPT	CHEMICAL	1167
23608737	1043	1046	DPN	CHEMICAL	23608737T16
23608737	0	9	Estradiol	CHEMICAL	773
23608737	31	38	cocaine	CHEMICAL	23608737T18
23608737	92	100	estrogen	CHEMICAL	23608737T19
23608737	1234	1241	Cocaine	CHEMICAL	897
23608737	1119	1122	ER	GENE-Y	23608737T20
23608737	1518	1521	ER	GENE-Y	23608737T21
23608737	1681	1684	ER	GENE-Y	23608737T22
23608737	1800	1803	ER	GENE-Y	23608737T23
23608737	988	991	ER	GENE-Y	23608737T24
23608737	1021	1024	ER	GENE-Y	23608737T25
23608737	1099	1102	ER	GENE-Y	23608737T26
23608737	1104	1107	ER	GENE-Y	23608737T27
23608737	1114	1117	ER	GENE-Y	23608737T28
23608737	92	115	estrogen receptor alpha	GENE-Y	23608737T29
23608737	1385	1392	cocaine	CHEMICAL	23608737T2
23608737	1419	1422	PPT	CHEMICAL	1167
23608737	1454	1461	cocaine	CHEMICAL	23608737T4
23608737	1495	1498	DPN	CHEMICAL	23608737T5
23608737	1595	1602	cocaine	CHEMICAL	23608737T6
23608737	1740	1747	cocaine	CHEMICAL	23608737T7
23608737	417	426	estradiol	CHEMICAL	23608737T8
23608737	444	451	cocaine	CHEMICAL	23608737T9
23608737	CPR:5	1167	23608737T24
23608737	CPR:5	23608737T16	23608737T25

23609128|t|Dynamics and structural changes of small water clusters on ionization.
23609128|a|Despite utmost importance in understanding water ionization process, reliable theoretical results of structural changes and molecular dynamics (MD) of water clusters on ionization have hardly been reported yet. Here, we investigate the water cations [(H2 O)n=2-6 (+) ] with density functional theory (DFT), Mller-Plesset second-order perturbation theory (MP2), and coupled cluster theory with single, double, and perturbative triple excitations [CCSD(T)]. The complete basis set limits of interaction energies at the CCSD(T) level are reported, and the geometrical structures, electronic properties, and infrared spectra are investigated. The characteristics of structures and spectra of the water cluster cations reflect the formation of the hydronium cation moiety (H3 O(+) ) and the hydroxyl radical. Although most density functionals fail to predict reasonable energetics of the water cations, some functionals are found to be reliable, in reasonable agreement with high-level ab initio results. To understand the ionization process of water clusters, DFT- and MP2-based Born-Oppenheimer MD (BOMD) simulations are performed on ionization. On ionization, the water clusters tend to have an Eigen-like form with the hydronium cation instead of a Zundel-like form, based on reliable BOMD simulations. For the vertically ionized water hexamer, the relatively stable (H2 O)5 (+) (5sL4A) cluster tends to form with a detached water molecule (H2 O).  2013 Wiley Periodicals, Inc.
23609128	1292	1301	hydronium	CHEMICAL	23609128T1
23609128	1440	1451	(H2 O)5 (+)	CHEMICAL	23609128T2
23609128	1514	1518	H2 O	CHEMICAL	23609128T3
23609128	322	329	(H2 O)n	CHEMICAL	23609128T4
23609128	817	826	hydronium	CHEMICAL	23609128T5
23609128	842	849	H3 O(+)	CHEMICAL	23609128T6
23609128	860	868	hydroxyl	CHEMICAL	23609128T7

23609438|t|The Intermediate-conductance Calcium-activated Potassium Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling.
23609438|a|The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to a variety of cell activation processes in pathologies such as inflammation, carcinogenesis and vascular remodeling. We examined the electrophysiological and transcriptional mechanisms by which KCa3.1 regulates vascular smooth muscle cell (VSMC) proliferation. Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1). This anti-proliferative effect was abolished by elevating [Ca(2+)]i. KCa3.1 overexpression induced VSMC proliferation, and potentiated PDGF-induced proliferation, by inducing CREB phosphorylation, c-fos and NOR-1. Pharmacological stimulation of KCa3.1 unexpectedly suppressed proliferation by inhibiting the rise in [Ca(2+)]i and abolishing the expression and activity of KCa3.1 and PDGF -receptors. The stimulation also attenuated the levels of phosphorylated CREB, c-fos and cyclins expression. After KCa3.1 blockade, the characteristic round shape of VSMCs expressing high l-caldesmon and low calponin-1 (dedifferentiation state) was maintained, whereas KCa3.1 stimulation induced a spindle-shape cellular appearance, with low l-caldesmon and high calponin-1. In conclusion, KCa3.1 plays an important role in VSMC proliferation via controlling Ca(2+)-dependent signaling pathways and its modulation may therefore constitute a new therapeutic target for cell proliferative diseases such as atherosclerosis.
23609438	1021	1027	Ca(2+)	CHEMICAL	23609438T10
23609438	140	147	Calcium	CHEMICAL	1332
23609438	29	36	Calcium	CHEMICAL	1332
23609438	47	56	Potassium	CHEMICAL	1310
23609438	1169	1174	NOR-1	GENE-Y	23609438T14
23609438	1207	1213	KCa3.1	GENE-Y	23609438T15
23609438	1334	1340	KCa3.1	GENE-Y	23609438T16
23609438	1345	1361	PDGF -receptors	GENE-Y	23609438T17
23609438	1409	1428	phosphorylated CREB	GENE-N	23609438T18
23609438	1430	1435	c-fos	GENE-Y	23609438T19
23609438	1279	1285	Ca(2+)	CHEMICAL	23609438T1
23609438	1440	1447	cyclins	GENE-N	23609438T20
23609438	1466	1472	KCa3.1	GENE-Y	23609438T21
23609438	1539	1550	l-caldesmon	GENE-Y	23609438T22
23609438	1559	1569	calponin-1	GENE-Y	23609438T23
23609438	1620	1626	KCa3.1	GENE-Y	23609438T24
23609438	1693	1704	l-caldesmon	GENE-Y	23609438T25
23609438	1714	1724	calponin-1	GENE-Y	23609438T26
23609438	1741	1747	KCa3.1	GENE-Y	23609438T27
23609438	449	455	KCa3.1	GENE-Y	23609438T28
23609438	516	549	Platelet-derived growth factor-BB	GENE-Y	23609438T29
23609438	1810	1816	Ca(2+)	CHEMICAL	23609438T2
23609438	551	555	PDGF	GENE-N	23609438T30
23609438	173	240	intermediate-conductance calcium-activated potassium channel KCa3.1	GENE-Y	23609438T31
23609438	725	731	KCa3.1	GENE-Y	23609438T32
23609438	849	901	phosphorylated cAMP response element binding protein	GENE-N	23609438T33
23609438	903	907	CREB	GENE-N	23609438T34
23609438	910	915	c-fos	GENE-Y	23609438T35
23609438	920	952	neuron-derived orphan receptor-1	GENE-Y	23609438T36
23609438	954	959	NOR-1	GENE-Y	23609438T37
23609438	1031	1037	KCa3.1	GENE-Y	23609438T38
23609438	1097	1101	PDGF	GENE-N	23609438T39
23609438	198	205	calcium	CHEMICAL	23609438T3
23609438	1137	1141	CREB	GENE-N	23609438T40
23609438	1159	1164	c-fos	GENE-Y	23609438T41
23609438	4	71	Intermediate-conductance Calcium-activated Potassium Channel KCa3.1	GENE-Y	23609438T42
23609438	216	225	potassium	CHEMICAL	23609438T4
23609438	651	657	Ca(2+)	CHEMICAL	23609438T5
23609438	674	680	Ca(2+)	CHEMICAL	23609438T6
23609438	715	721	Ca(2+)	CHEMICAL	23609438T7
23609438	806	812	Ca(2+)	CHEMICAL	23609438T8
23609438	864	868	cAMP	CHEMICAL	2424
23609438	CPR:9	1332	23609438T42

23610086|t|Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-b]thiazole-based Inverse Agonists of the Ghrelin Receptor.
23610086|a|The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure. Both compounds underwent oxidative metabolism in NADPH- and glutathione-supplemented human liver microsomes to yield glutathione conjugates, which was consistent with their bioactivation to reactive species. Mass spectral fragmentation and NMR analysis indicated that the site of attachment of the glutathionyl moiety in the thiol conjugates was on the thiazole ring within the bicycle. Two glutathione conjugates were discerned with the imidazo[2,1-b]thiazole derivative 1. One adduct was derived from the Michael addition of glutathione to a putative S-oxide metabolite of 1, whereas, the second adduct was formed via the reaction of a second glutathione molecule with the initial glutathione-S-oxide adduct. In the case of the 2-methylimidazo[2,1-b]thiazole analog 2, glutathione conjugation occurred via an oxidative desulfation mechanism, possibly involving thiazole ring epoxidation as the rate-limiting step. Additional insights into the mechanism were obtained via 18O exchange and trapping studies with potassium cyanide. The mechanistic insights into the bioactivation pathways of 1 and 2 allowed the deployment of a rational chemical intervention strategy that involved replacement of the thiazole ring with a 1,2,4-thiadiazole group to yield -(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)ethanone (3). These structural changes not only abrogated the bioactivation liability but also retained the attractive pharmacological attributes of the prototype agents.
23610086	1807	1941	-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)ethanone	CHEMICAL	23610086T10
23610086	351	476	1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone	CHEMICAL	23610086T11
23610086	501	523	imidazo[2,1-b]thiazole	CHEMICAL	23610086T12
23610086	602	607	NADPH	CHEMICAL	23610086T13
23610086	613	624	glutathione	CHEMICAL	23610086T14
23610086	670	681	glutathione	CHEMICAL	23610086T15
23610086	851	863	glutathionyl	CHEMICAL	23610086T16
23610086	878	883	thiol	CHEMICAL	23610086T17
23610086	906	914	thiazole	CHEMICAL	23610086T18
23610086	944	955	glutathione	CHEMICAL	23610086T19
23610086	1198	1209	glutathione	CHEMICAL	23610086T1
23610086	991	1013	imidazo[2,1-b]thiazole	CHEMICAL	23610086T20
23610086	225	342	1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone	CHEMICAL	23610086T21
23610086	1080	1091	glutathione	CHEMICAL	23610086T22
23610086	1106	1113	S-oxide	CHEMICAL	23610086T23
23610086	40	83	Imidazo- and 2-Methylimidazo[2,1-b]thiazole	CHEMICAL	23610086T24
23610086	190	206	ghrelin receptor	GENE-Y	23610086T25
23610086	114	130	Ghrelin Receptor	GENE-Y	23610086T26
23610086	1236	1255	glutathione-S-oxide	CHEMICAL	23610086T2
23610086	1283	1313	2-methylimidazo[2,1-b]thiazole	CHEMICAL	23610086T3
23610086	1324	1335	glutathione	CHEMICAL	23610086T4
23610086	1416	1424	thiazole	CHEMICAL	23610086T5
23610086	1526	1529	18O	CHEMICAL	23610086T6
23610086	1565	1582	potassium cyanide	CHEMICAL	23610086T7
23610086	1753	1761	thiazole	CHEMICAL	23610086T8
23610086	1774	1791	1,2,4-thiadiazole	CHEMICAL	23610086T9
23610086	CPR:5	23610086T11	23610086T25
23610086	CPR:5	23610086T12	23610086T25
23610086	CPR:5	23610086T21	23610086T25
23610086	CPR:5	23610086T24	23610086T26

23614728|t|Adenovirus-delivered angiopoietin-1 treatment for phosgene-induced acute lung injury.
23614728|a|Abstract Context: Exposure to phosgene can result in an acute lung injury, leading to pulmonary edema and even death. Angiopoietin-1 (Ang1) is a critical factor for vascular stabilization due to its ability to reduce endothelial permeability and inflammation. Objective: In this study, the histopathological changes of the lungs after exposure to phosgene and the effect of Ang1 treatment were examined. Materials and methods: Rats were exposed to phosgene gas at 8.33g/m(3) for 5min. Ang1 overexpressing rats were established by an intravenous injection of adenovirus-Ang1 (Ad/Ang1). The histological changes of the lung were examined by Haematoxylin-Eosin (H&E) staining and fluorescence microscopy. The inferior lobe was used for the determination of the ratio of wet weight to dry weight of the lung. The concentration of cytokines in the serum and bronchoalveolar lavage fluid was determined by enzyme-linked immunosorbent assay. Results: The pathological analysis showed signs of inflammation and edema, evident from a significant increase in the number of leukocytes in bronchoalveolar lavage fluid and the ratio of wet to dry weight of the lungs. The lung injury induced by phosgene was markedly reduced after the injection of Ad/Ang1. The increase of IL-1 and IL-17 and decrease of vascular endothelial growth factor in the serum and bronchoalveolar lavage fluid of phosgene-exposed animals were abolished by the administration of Ad/Ang1. Discussion and conclusions: Ang1 has the beneficial effects on phosgene-induced lung injury. The adenovirus-delivered Ang1 may have the potential as a novel approach for the treatment of the acute lung injury caused by phosgene gas inhalation in humans.
23614728	50	58	phosgene	CHEMICAL	23614728T10
23614728	204	218	Angiopoietin-1	GENE-Y	23614728T11
23614728	1326	1330	Ang1	GENE-Y	23614728T12
23614728	1348	1353	IL-1	GENE-Y	23614728T13
23614728	1358	1363	IL-17	GENE-Y	23614728T14
23614728	1380	1414	vascular endothelial growth factor	GENE-Y	23614728T15
23614728	220	224	Ang1	GENE-Y	23614728T16
23614728	1532	1536	Ang1	GENE-Y	23614728T17
23614728	1566	1570	Ang1	GENE-Y	23614728T18
23614728	1656	1660	Ang1	GENE-Y	23614728T19
23614728	1270	1278	phosgene	CHEMICAL	23614728T1
23614728	460	464	Ang1	GENE-Y	23614728T20
23614728	657	661	Ang1	GENE-Y	23614728T21
23614728	666	670	Ang1	GENE-Y	23614728T22
23614728	914	923	cytokines	GENE-N	23614728T23
23614728	21	35	angiopoietin-1	GENE-Y	23614728T24
23614728	1464	1472	phosgene	CHEMICAL	23614728T2
23614728	1601	1609	phosgene	CHEMICAL	23614728T3
23614728	1757	1765	phosgene	CHEMICAL	23614728T4
23614728	116	124	phosgene	CHEMICAL	23614728T5
23614728	433	441	phosgene	CHEMICAL	23614728T6
23614728	534	542	phosgene	CHEMICAL	23614728T7
23614728	727	739	Haematoxylin	CHEMICAL	23614728T8
23614728	740	745	Eosin	CHEMICAL	23614728T9

23617725|t|Probing the Role of the Vancomycin E-Ring Aryl Chloride: Selective Divergent Synthesis and Evaluation of Alternatively Substituted E-Ring Analogues.
23617725|a|The selective functionalization of a vancomycin aglycon derivative through direct conversion of the E-ring aryl chloride to a reactive boronic acid, and its use in the synthesis of a systematic series of vancomycin E-ring analogues are described. The series of analogues was used to examine the impact of the E-ring chloride in binding D-Ala-D-Ala and on antimicrobial activity. In contrast to the reduced activity of the unsubstituted E-ring derivatives, hydrophobic and relatively non-polar substituents approach or match the chloro substituted vancomycin and was insensitive to the electronic character of the substituent (e.g. Cl vs CN or OMe), whereas highly polar substituents fail to provide the enhancements. Moreover, the active permethylated vancomycin aglycon derivatives examined exhibit VanB VRE antimicrobial activity at levels that approach (typically within 2-fold) their activity against sensitive bacteria. The robust borylation reaction also enabled the selective functionalization of a minimally protected vancomycin aglycon (N-Boc vancomycin aglycon), and provides a direct method for the preparation of previously inaccessible analogues.
23617725	780	782	Cl	CHEMICAL	23617725T10
23617725	786	788	CN	CHEMICAL	23617725T11
23617725	792	795	OMe	CHEMICAL	23617725T12
23617725	901	911	vancomycin	CHEMICAL	502
23617725	949	953	VanB	CHEMICAL	23617725T14
23617725	24	34	Vancomycin	CHEMICAL	502
23617725	42	55	Aryl Chloride	CHEMICAL	23617725T16
23617725	949	953	VanB	GENE-N	23617725T17
23617725	1175	1185	vancomycin	CHEMICAL	502
23617725	1195	1200	N-Boc	CHEMICAL	23617725T2
23617725	1201	1211	vancomycin	CHEMICAL	502
23617725	256	269	aryl chloride	CHEMICAL	23617725T4
23617725	284	296	boronic acid	CHEMICAL	23617725T5
23617725	353	363	vancomycin	CHEMICAL	502
23617725	485	496	D-Ala-D-Ala	CHEMICAL	23617725T7
23617725	186	196	vancomycin	CHEMICAL	502
23617725	677	706	chloro substituted vancomycin	CHEMICAL	23617725T9

23619606|t|Exposure to DEHP decreased four fatty acid levels in plasma of prepartum mice.
23619606|a|Maternal exposure to di(2-ethylhexyl) phthalate (DEHP) decreased the plasma triglyceride in prepartum mice. To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPAR), peroxisome proliferator-activated receptor -null (Ppar-null) and humanized PPAR (hPPAR) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP. Dams were dissected on gestational day 18 together with fetuses, and on postnatal day 2 together with newborns. n-3/n-6 polyunsaturated, saturated, and monounsaturated FAs in maternal plasma and in liver of wild-type offspring, and representative enzymes for FA desaturation and elongation in maternal liver, were measured. The plasma levels of linoleic acid, -linolenic acid, palmitic acid and oleic acid were higher in the pregnant control mPPARa mice than in Ppara-null and hPPARa mice. DEHP exposure significantly decreased the levels of these four FAs only in pregnant mPPAR mice. Plasma levels of many FAs were higher in pregnant mice than in postpartum ones in a genotype-independent manner, while it was lower in the livers of fetuses than pups. DEHP exposure slightly increased hepatic arachidonic acid, -linolenic acid, palmitoleic acid and oleic acid in fetuses, but not in pups. However, DEHP exposure did not clearly influence FA desaturase 1 and 2 nor elongase 2 and 5 expressions in the liver of all maternal mice. Taken together, the levels of plasma four FAs with shorter carbon chains were higher in pregnant mPPAR mice than in other genotypes, and DEHP exposure decreased these specific FA concentrations only in mPPAR mice, similarly to triglyceride levels.
23619606	1742	1754	triglyceride	CHEMICAL	23619606T10
23619606	100	126	di(2-ethylhexyl) phthalate	CHEMICAL	23619606T11
23619606	474	478	DEHP	CHEMICAL	23619606T12
23619606	128	132	DEHP	CHEMICAL	23619606T13
23619606	592	651	n-3/n-6 polyunsaturated, saturated, and monounsaturated FAs	CHEMICAL	23619606T14
23619606	825	838	linoleic acid	CHEMICAL	23619606T15
23619606	840	856	-linolenic acid	CHEMICAL	23619606T16
23619606	155	167	triglyceride	CHEMICAL	23619606T17
23619606	858	871	palmitic acid	CHEMICAL	23619606T18
23619606	876	886	oleic acid	CHEMICAL	23619606T19
23619606	1236	1240	DEHP	CHEMICAL	23619606T1
23619606	971	975	DEHP	CHEMICAL	23619606T20
23619606	12	16	DEHP	CHEMICAL	23619606T21
23619606	32	42	fatty acid	CHEMICAL	23619606T22
23619606	1423	1444	FA desaturase 1 and 2	GENE-N	23619606T23
23619606	1449	1465	elongase 2 and 5	GENE-N	23619606T24
23619606	1610	1616	mPPAR	GENE-Y	23619606T25
23619606	1716	1722	mPPAR	GENE-Y	23619606T26
23619606	308	314	mPPAR	GENE-Y	23619606T27
23619606	317	361	peroxisome proliferator-activated receptor 	GENE-Y	23619606T28
23619606	368	373	Ppar	GENE-Y	23619606T29
23619606	1277	1293	arachidonic acid	CHEMICAL	23619606T2
23619606	384	399	humanized PPAR	GENE-Y	23619606T30
23619606	401	407	hPPAR	GENE-Y	23619606T31
23619606	923	929	mPPARa	GENE-Y	23619606T32
23619606	943	948	Ppara	GENE-Y	202317|247775
23619606	958	964	hPPARa	GENE-Y	23619606T34
23619606	1055	1061	mPPAR	GENE-Y	23619606T35
23619606	1295	1311	-linolenic acid	CHEMICAL	23619606T3
23619606	1313	1329	palmitoleic acid	CHEMICAL	23619606T4
23619606	203	213	fatty acid	CHEMICAL	23619606T5
23619606	1334	1344	oleic acid	CHEMICAL	23619606T6
23619606	1383	1387	DEHP	CHEMICAL	23619606T7
23619606	1572	1578	carbon	CHEMICAL	23619606T8
23619606	1651	1655	DEHP	CHEMICAL	23619606T9

23619613|t|Soluble polysialylated NCAM: a novel player of the innate immune system in the lung.
23619613|a|Posttranslational modification of the neural cell adhesion molecule (NCAM) by polysialic acid (polySia) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity. Here, we describe a novel function of polysialylated NCAM (polySia-NCAM) in innate immunity of the lung. In mature lung tissue of healthy donors, polySia was exclusively attached to the transmembrane isoform NCAM-140 and located to intracellular compartments of epithelial cells. In patients with chronic obstructive pulmonary disease, however, increased polySia levels and processing of the NCAM carrier were observed. Processing of polysialylated NCAM was reproduced in a mouse model by bleomycin administration leading to an activation of the inflammasome and secretion of interleukin (IL)-1. As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1 or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM. Interestingly, polySia chains of secreted NCAM neutralized the cytotoxic activity of extracellular histones as well as DNA/histone-network-containing "neutrophil extracellular traps", which are formed during invasion of microorganisms. Thus, shedding of polySia-NCAM by lung epithelial cells may provide a host-protective mechanism to reduce tissue damage during inflammatory processes.
23619613	180	187	polySia	CHEMICAL	23619613T10
23619613	1096	1101	IL-1	GENE-Y	23619613T11
23619613	1132	1147	metalloprotease	GENE-N	23619613T12
23619613	1157	1167	ectodomain	GENE-N	23619613T13
23619613	1216	1228	polySia-NCAM	GENE-Y	23619613T14
23619613	1272	1276	NCAM	GENE-Y	23619613T15
23619613	1329	1337	histones	GENE-N	23619613T16
23619613	1353	1360	histone	GENE-N	23619613T17
23619613	1484	1496	polySia-NCAM	GENE-Y	23619613T18
23619613	399	418	polysialylated NCAM	GENE-Y	23619613T19
23619613	1216	1223	polySia	CHEMICAL	23619613T1
23619613	420	432	polySia-NCAM	GENE-Y	23619613T20
23619613	123	152	neural cell adhesion molecule	GENE-Y	23619613T21
23619613	569	577	NCAM-140	GENE-Y	23619613T22
23619613	753	757	NCAM	GENE-Y	23619613T23
23619613	154	158	NCAM	GENE-Y	23619613T24
23619613	795	814	polysialylated NCAM	GENE-Y	23619613T25
23619613	937	956	interleukin (IL)-1	GENE-Y	23619613T26
23619613	1000	1008	NCAM-140	GENE-Y	23619613T27
23619613	8	27	polysialylated NCAM	GENE-Y	23619613T28
23619613	1245	1252	polySia	CHEMICAL	23619613T2
23619613	1484	1491	polySia	CHEMICAL	23619613T3
23619613	420	427	polySia	CHEMICAL	23619613T4
23619613	507	514	polySia	CHEMICAL	23619613T5
23619613	716	723	polySia	CHEMICAL	23619613T6
23619613	850	859	bleomycin	CHEMICAL	23619613T7
23619613	163	178	polysialic acid	CHEMICAL	23619613T8
23619613	992	999	polySia	CHEMICAL	23619613T9
23619613	CPR:3	23619613T7	23619613T26

23620256|t|Study of endothelial cell apoptosis using fluorescence resonance energy transfer (FRET) biosensor cell line with hemodynamic microfluidic chip system.
23620256|a|To better understand how hyperglycemia induces endothelial cell dysfunction under the diabetic conditions, a hemodynamic microfluidic chip system was developed. The system combines a caspase-3-based fluorescence resonance energy transfer (FRET) biosensor cell line which can detect endothelial cell apoptosis in real-time, post-treatment effect and with a limited cell sample, by using a microfluidic chip which can mimic the physiological pulsatile flow profile in the blood vessel. The caspase-3-based FRET biosensor endothelial cell line (HUVEC-C3) can produce a FRET-based sensor protein capable of probing caspase-3 activation. When the endothelial cells undergo apoptosis, the color of the sensor cells changes from green to blue, thus sensing apoptosis. A double-labeling fluorescent technique (yo pro-1 and propidium iodide) was used to validate the findings revealed by the FRET-based caspase sensor. The results show high rates of apoptosis and necrosis of endothelial cells when high glucose concentration was applied in our hemodynamic microfluidic chip combined with an exhaustive pulsatile flow profile. The two apoptosis detection techniques (fluorescent method and FRET biosensor) are comparable; but FRET biosensor offers more advantages such as real-time observation and a convenient operating process to generate more accurate and reliable data. Furthermore, the activation of the FRET biosensor also confirms the endothelial cell apoptosis induced by the abnormal pulsatile shear stress and high glucose concentration is through caspase-3 pathway. A 12% apoptotic rate (nearly a 4-fold increase compared to the static condition) was observed when the endothelial cells were exposed to a high glucose concentration of 20 mM under 2 h exhaustive pulsatile shear stress of 30 dyne cm(-2) and followed with another 10 h normal pulsatile shear stress of 15 dyne cm(-2). Therefore, the most important finding of this study is to develop a novel endothelial cell apoptosis detection method, which combines the microfluidic chip system and FRET biosensor. This finding may provide new insight into how glucose causes endothelial cell dysfunction, which is the major cause of diabetes-derived complications.
23620256	762	771	caspase-3	GENE-Y	23620256T10
23620256	1045	1052	caspase	GENE-N	23620256T11
23620256	1667	1674	glucose	CHEMICAL	23620256T1
23620256	1863	1870	glucose	CHEMICAL	23620256T2
23620256	2265	2272	glucose	CHEMICAL	23620256T3
23620256	953	961	yo pro-1	CHEMICAL	23620256T4
23620256	966	982	propidium iodide	CHEMICAL	23620256T5
23620256	1146	1153	glucose	CHEMICAL	23620256T6
23620256	1700	1709	caspase-3	GENE-Y	23620256T7
23620256	334	343	caspase-3	GENE-Y	23620256T8
23620256	639	648	caspase-3	GENE-Y	23620256T9

23620529|t|High salt diets during pregnancy affected fetal and offspring renal renin-angiotensin system.
23620529|a|Intrauterine environments are linked to fetal renal development and postnatal health. Influence of salt diets during pregnancy on renal functions and renin-angiotensin system (RAS) were determined in the ovine fetus and offspring. Pregnant ewes were fed high-salt diet (HSD) or normal-salt diet (NSD) for two months during middle-later gestation. Fetal renal functions, plasma hormones, mRNA and protein expressions of the key elements of renal RAS were measured in the fetus and offspring. Fetal renal excretion of sodium was increased while urine volume decreased in HSD group. Fetal blood urea nitrogen was increased, while kidney/body weight ratio decreased in HSD group. The altered ratio also was observed in the offspring at 15-day-old and 90-day-old. Maternal and fetal plasma antidiuretic hormone was elevated without change in plasma renin activity and Ang I levels, while plasma Ang II was decreased. The key elements of local renal RAS, including angiotensinogen, ACE, ACE2, AT1 and AT2 receptor expression in both mRNA and protein, except renin, were altered following maternal high salt intake. The results suggest that Highintakeofsalt during pregnancy affected fetal renal development associated with an altered expression of the renal key elements of RAS, some alterations of fetal origins remained after birth as possible risks in developing renal or cardiovascular diseases.
23620529	984	990	Ang II	GENE-Y	23620529T10
23620529	1053	1068	angiotensinogen	GENE-Y	23620529T11
23620529	1070	1073	ACE	GENE-Y	108004
23620529	1075	1079	ACE2	GENE-Y	31400|121864|1229088|1173181|3230255|146569|713441|1152036
23620529	1081	1084	AT1	GENE-Y	23620529T14
23620529	1089	1101	AT2 receptor	GENE-Y	23620529T15
23620529	68	73	renin	GENE-Y	23620529T16
23620529	74	85	angiotensin	GENE-Y	23620529T17
23620529	610	616	sodium	CHEMICAL	23620529T1
23620529	686	690	urea	CHEMICAL	23620529T2
23620529	691	699	nitrogen	CHEMICAL	23620529T3
23620529	1146	1151	renin	GENE-Y	23620529T4
23620529	244	249	renin	GENE-Y	23620529T5
23620529	250	261	angiotensin	GENE-Y	23620529T6
23620529	879	899	antidiuretic hormone	GENE-Y	23620529T7
23620529	938	943	renin	GENE-Y	23620529T8
23620529	957	962	Ang I	GENE-Y	23620529T9

23623491|t|Synthesis of pyrazolo[1,5-a]pyrimidine linked aminobenzothiazole conjugates as potential anticancer agents.
23623491|a|A series of pyrazolo[1,5-a]pyrimidine linked 2-aminobenzothizole conjugates (6a-t) were synthesized and evaluated for their anticancer activity against five human cancer cell lines. Among them two compounds 6p and 6m showed significant anticancer activity with IC50 values ranging from 2.01 to 7.07 and 1.94-3.46M, respectively. Moreover, cell cycle arrest in G2/M and reduction in Cdk1 expression level were observed upon treatment of these compounds and they also induced caspase-3 dependent apoptosis. This was further confirmed by staining as well as DNA fragmentation analysis.
23623491	120	145	pyrazolo[1,5-a]pyrimidine	CHEMICAL	23623491T1
23623491	153	172	2-aminobenzothizole	CHEMICAL	23623491T2
23623491	13	38	pyrazolo[1,5-a]pyrimidine	CHEMICAL	23623491T3
23623491	46	64	aminobenzothiazole	CHEMICAL	23623491T4
23623491	491	495	Cdk1	GENE-Y	198624|248460
23623491	583	592	caspase-3	GENE-Y	23623491T6

23624419|t|Evaluation of the positive effects on insulin-resistance and -cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
23624419|a|We evaluated the positive effects of vildagliptin in addition to metformin on glycemic control and -cell function in type 2 diabetic patients. One hundred and seventy-one type 2 diabetic patients were instructed to add vildaglipin 50mg twice a day or placebo to metformin for 12 months. Body mass index (BMI), glycemic control, fasting plasma insulin (FPI), HOMA-IR, HOMA-, fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, vaspin, visfatin, and omentin-1 were evaluated. Before, and after 12 months since the addition of vildagliptin, patients underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation. Vildagliptin+metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and insulin resistance measurements. Vildagliptin+metformin gave also a better increase of HOMA-, and of all -cell parameters after the clamp. We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and omentin-1 obtained with vildagliptin+metformin. Vildagliptin, in addition to metformin, proved to be effective in improving -cell function and in reducing insulin resistance measurements.
23624419	849	857	arginine	CHEMICAL	23624419T10
23624419	871	883	Vildagliptin	CHEMICAL	4676
23624419	884	893	metformin	CHEMICAL	23624419T12
23624419	927	936	metformin	CHEMICAL	23624419T13
23624419	1043	1055	Vildagliptin	CHEMICAL	4676
23624419	1056	1065	metformin	CHEMICAL	23624419T15
23624419	112	121	metformin	CHEMICAL	23624419T16
23624419	84	96	vildagliptin	CHEMICAL	23624419T17
23624419	1239	1245	vaspin	GENE-Y	23624419T18
23624419	1247	1255	visfatin	GENE-Y	23624419T19
23624419	1285	1297	vildagliptin	CHEMICAL	23624419T1
23624419	1261	1270	omentin-1	GENE-Y	23624419T20
23624419	1417	1424	insulin	GENE-Y	23624419T21
23624419	495	502	insulin	GENE-Y	23624419T22
23624419	542	552	proinsulin	GENE-Y	23624419T23
23624419	561	571	proinsulin	GENE-Y	23624419T24
23624419	587	594	insulin	GENE-Y	23624419T25
23624419	617	626	C-peptide	GENE-Y	23624419T26
23624419	628	636	glucagon	GENE-Y	23624419T27
23624419	638	644	vaspin	GENE-Y	23624419T28
23624419	646	654	visfatin	GENE-Y	23624419T29
23624419	1298	1307	metformin	CHEMICAL	23624419T2
23624419	660	669	omentin-1	GENE-Y	23624419T30
23624419	997	1005	glucagon	GENE-Y	23624419T31
23624419	1010	1017	insulin	GENE-Y	23624419T32
23624419	38	45	insulin	GENE-Y	23624419T33
23624419	1309	1321	Vildagliptin	CHEMICAL	4676
23624419	1338	1347	metformin	CHEMICAL	23624419T4
23624419	371	382	vildaglipin	CHEMICAL	23624419T5
23624419	414	423	metformin	CHEMICAL	23624419T6
23624419	188	200	vildagliptin	CHEMICAL	23624419T7
23624419	736	748	vildagliptin	CHEMICAL	23624419T8
23624419	216	225	metformin	CHEMICAL	23624419T9

23624423|t|4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.
23624423|a|Over-expression of cleaved cyclin E in breast tumors is closely associated with tumor progression and resistance to antiestrogens. 17-Estradiol (E2) has been recently shown to induce cyclin E processing in breast cancer cells. Tamoxifen has been used in patients with estrogen-sensitive breast cancer, yet resistance to antiestrogens and recurrence will appear in some of the patients after its continued use. We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor  (ER). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration. OHT-induced cyclin E truncation also occurred in SK-BR-3 cells that express GPR30 and lack ER, but not in MDA-MB-231 cells that express neither GPR30 nor ER. G1, a specific GPR 30 agonist, caused dramatic proteolysis of cyclin E and enhanced migration. Furthermore, OHT-stimulated cleavage of cyclin E and migration were tremendously attenuated by G15, a GPR30 antagonist, or siRNA against GPR30. In addition, inhibitors for EGFR or ERK1/2 remarkably suppressed OHT-induced truncation of cyclin E, suggesting involvement of EGFR signaling. Collectively, our data indicate that OHT contributes to the production of proteolyzed cyclin E via GPR30 with augmented migration in MCF-7 cells.
23624423	838	856	4-Hydroxytamoxifen	CHEMICAL	4282
23624423	858	861	OHT	CHEMICAL	23624423T11
23624423	863	872	tamoxifen	CHEMICAL	23624423T12
23624423	1032	1035	OHT	CHEMICAL	23624423T13
23624423	0	18	4-Hydroxytamoxifen	CHEMICAL	4282
23624423	1177	1182	GPR30	GENE-Y	23624423T15
23624423	1187	1190	ER	GENE-Y	23624423T16
23624423	1207	1213	GPR 30	GENE-Y	23624423T17
23624423	1254	1262	cyclin E	GENE-Y	23624423T18
23624423	1327	1335	cyclin E	GENE-Y	23624423T19
23624423	1300	1303	OHT	CHEMICAL	23624423T1
23624423	1389	1394	GPR30	GENE-Y	23624423T20
23624423	1424	1429	GPR30	GENE-Y	23624423T21
23624423	1459	1463	EGFR	GENE-Y	108276|3932452|676741
23624423	1467	1473	ERK1/2	GENE-N	23624423T23
23624423	1522	1530	cyclin E	GENE-Y	23624423T24
23624423	1558	1562	EGFR	GENE-Y	108276|3932452|676741
23624423	1660	1668	cyclin E	GENE-Y	23624423T26
23624423	1673	1678	GPR30	GENE-Y	23624423T27
23624423	359	367	cyclin E	GENE-Y	23624423T28
23624423	202	210	cyclin E	GENE-Y	23624423T29
23624423	306	319	17-Estradiol	CHEMICAL	23624423T2
23624423	668	676	cyclin E	GENE-Y	23624423T30
23624423	772	806	G protein-coupled protein (GPR) 30	GENE-Y	23624423T31
23624423	811	830	estrogen receptor 	GENE-Y	23624423T32
23624423	832	835	ER	GENE-N	23624423T33
23624423	932	940	cyclin E	GENE-Y	23624423T34
23624423	977	985	cyclin E	GENE-Y	23624423T35
23624423	1044	1052	cyclin E	GENE-Y	23624423T36
23624423	1108	1113	GPR30	GENE-Y	23624423T37
23624423	1123	1126	ER	GENE-Y	23624423T38
23624423	100	106	GPR30)	GENE-Y	23624423T39
23624423	1496	1499	OHT	CHEMICAL	23624423T3
23624423	44	52	cyclin E	GENE-Y	23624423T40
23624423	69	98	G protein-coupled receptor 30	GENE-Y	23624423T41
23624423	1611	1614	OHT	CHEMICAL	23624423T4
23624423	403	412	Tamoxifen	CHEMICAL	665
23624423	444	452	estrogen	CHEMICAL	23624423T6
23624423	629	638	tamoxifen	CHEMICAL	23624423T7
23624423	708	716	estrogen	CHEMICAL	23624423T8
23624423	811	819	estrogen	CHEMICAL	23624423T9
23624423	CPR:3	4282	23624423T40
23624423	CPR:3	23624423T2	23624423T28
23624423	CPR:3	23624423T4	23624423T26

23625804|t|Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of Cu(I) -Loaded hCCS Domain 1 and Analysis of Disulfide-Free hSOD1 Mutants.
23625804|a|Superoxide dismutase 1 (SOD1) maturation within the cell is mainly accomplished with the SOD1-specific chaperone, CCS, a dimeric protein with three distinct domains in each monomer. We recently showed that the first domain of human CCS (hCCSD1) is responsible for copper transfer to its protein partner, human SOD1 (hSOD1). The NMR solution structure of the copper(I)-loaded form of hCCSD1 reported here contributes further to characterization of the copper-transfer mechanism to hSOD1. NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these cysteines during hSOD1 copper acquisition. Together, the information on both hCCS and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the copper-transfer process from hCCS to hSOD1.
23625804	259	262	CCS	GENE-Y	115298|23048
23625804	371	380	human CCS	GENE-Y	23625804T11
23625804	382	388	hCCSD1	GENE-N	23625804T12
23625804	169	173	SOD1	GENE-Y	33860|112530|676211
23625804	449	459	human SOD1	GENE-Y	23625804T14
23625804	461	466	hSOD1	GENE-Y	23625804T15
23625804	528	534	hCCSD1	GENE-N	23625804T16
23625804	625	630	hSOD1	GENE-Y	23625804T17
23625804	678	683	hSOD1	GENE-Y	23625804T18
23625804	692	696	C57A	GENE-N	23625804T19
23625804	145	155	Superoxide	CHEMICAL	23625804T1
23625804	698	703	C146A	GENE-N	23625804T20
23625804	709	713	C57A	GENE-N	23625804T21
23625804	714	719	C146A	GENE-N	23625804T22
23625804	791	795	SOD1	GENE-Y	33860|112530|676211
23625804	856	861	hSOD1	GENE-Y	23625804T24
23625804	916	920	hCCS	GENE-Y	23625804T25
23625804	925	930	hSOD1	GENE-Y	23625804T26
23625804	977	982	CCSD1	GENE-N	23625804T27
23625804	234	257	SOD1-specific chaperone	GENE-Y	23625804T28
23625804	1078	1082	hCCS	GENE-Y	23625804T29
23625804	409	415	copper	CHEMICAL	23625804T2
23625804	1086	1091	hSOD1	GENE-Y	23625804T30
23625804	130	135	hSOD1	GENE-Y	23625804T31
23625804	23	28	hSOD1	GENE-Y	23625804T32
23625804	85	98	hCCS Domain 1	GENE-N	23625804T33
23625804	503	512	copper(I)	CHEMICAL	23625804T3
23625804	773	782	disulfide	CHEMICAL	23625804T4
23625804	839	848	cysteines	CHEMICAL	23625804T5
23625804	1049	1055	copper	CHEMICAL	23625804T6
23625804	115	124	Disulfide	CHEMICAL	23625804T7
23625804	71	76	Cu(I)	CHEMICAL	23625804T8
23625804	145	167	Superoxide dismutase 1	GENE-Y	23625804T9

23626400|t|Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles.
23626400|a|The purpose of this investigation was to design novel pentablock copolymers (polylatide-polycaprolactone-polyethylene glycol- polycaprolactone-polylatide) (PLA-PCL-PEG-PCL-PLA) to prepare nanoparticle formulations which provide continuous delivery of steroids over a longer duration with minimal burst effect. Another purpose was to evaluate the effect of poly (L-lactide) (PLLA) or poly (D, L-lactide) (PDLLA) incorporation on crystallinity of pentablock copolymers and in vitro release profile of triamcinolone acetonide (selected as model drug) from nanoparticles. PLA-PCL-PEG-PCL-PLA copolymers with different block ratio of PCL/PLA segment were synthesized. Release of triamcinolone acetonide from nanoparticles was significantly affected by crystallinity of the copolymers. Burst release of triamcinolone acetonide from nanoparticles was significantly minimized with incorporation of proper ratio of PDLLA in the existing triblock (PCL-PEG-PCL) copolymer. Moreover, pentablock copolymer based nanoparticles exhibited continuous release of triamcinolone acetonide. Pentablock copolymer based nanoparticles can be utilized to achieve continuous near zero-order delivery of corticosteroids from nanoparticles without any burst effect.
23626400	472	480	steroids	CHEMICAL	23626400T10
23626400	577	593	poly (L-lactide)	CHEMICAL	23626400T11
23626400	595	599	PLLA	CHEMICAL	23626400T12
23626400	604	623	poly (D, L-lactide)	CHEMICAL	23626400T13
23626400	625	630	PDLLA	CHEMICAL	23626400T14
23626400	720	743	triamcinolone acetonide	CHEMICAL	23626400T15
23626400	789	792	PLA	CHEMICAL	23626400T16
23626400	793	796	PCL	CHEMICAL	23626400T17
23626400	797	800	PEG	CHEMICAL	23626400T18
23626400	801	804	PCL	CHEMICAL	23626400T19
23626400	1266	1289	triamcinolone acetonide	CHEMICAL	23626400T1
23626400	805	808	PLA	CHEMICAL	23626400T20
23626400	850	853	PCL	CHEMICAL	23626400T21
23626400	854	857	PLA	CHEMICAL	23626400T22
23626400	895	918	triamcinolone acetonide	CHEMICAL	23626400T23
23626400	298	308	polylatide	CHEMICAL	23626400T24
23626400	1018	1041	triamcinolone acetonide	CHEMICAL	23626400T25
23626400	309	325	polycaprolactone	CHEMICAL	23626400T26
23626400	1127	1132	PDLLA	CHEMICAL	23626400T27
23626400	1159	1162	PCL	CHEMICAL	23626400T28
23626400	1163	1166	PEG	CHEMICAL	23626400T29
23626400	326	345	polyethylene glycol	CHEMICAL	23626400T2
23626400	1167	1170	PCL	CHEMICAL	23626400T30
23626400	28	31	PLA	CHEMICAL	23626400T31
23626400	32	35	PCL	CHEMICAL	23626400T32
23626400	36	39	PEG	CHEMICAL	23626400T33
23626400	40	43	PCL	CHEMICAL	23626400T34
23626400	44	47	PLA	CHEMICAL	23626400T35
23626400	347	363	polycaprolactone	CHEMICAL	23626400T3
23626400	364	374	polylatide	CHEMICAL	23626400T4
23626400	377	380	PLA	CHEMICAL	23626400T5
23626400	381	384	PCL	CHEMICAL	23626400T6
23626400	385	388	PEG	CHEMICAL	23626400T7
23626400	389	392	PCL	CHEMICAL	23626400T8
23626400	393	396	PLA	CHEMICAL	23626400T9

23630454|t|PICK1 Deficiency Impairs Secretory Vesicle Biogenesis and Leads to Growth Retardation and Decreased Glucose Tolerance.
23630454|a|Secretory vesicles in endocrine cells store hormones such as growth hormone (GH) and insulin before their release into the bloodstream. The molecular mechanisms governing budding of immature secretory vesicles from the trans-Golgi network (TGN) and their subsequent maturation remain unclear. Here, we identify the lipid binding BAR (Bin/amphiphysin/Rvs) domain protein PICK1 (protein interacting with C kinase 1) as a key component early in the biogenesis of secretory vesicles in GH-producing cells. Both PICK1-deficient Drosophila and mice displayed somatic growth retardation. Growth retardation was rescued in flies by reintroducing PICK1 in neurosecretory cells producing somatotropic peptides. PICK1-deficient mice were characterized by decreased body weight and length, increased fat accumulation, impaired GH secretion, and decreased storage of GH in the pituitary. Decreased GH storage was supported by electron microscopy showing prominent reduction in secretory vesicle number. Evidence was also obtained for impaired insulin secretion associated with decreased glucose tolerance. PICK1 localized in cells to immature secretory vesicles, and the PICK1 BAR domain was shown by live imaging to associate with vesicles budding from the TGN and to possess membrane-sculpting properties in vitro. In mouse pituitary, PICK1 co-localized with the BAR domain protein ICA69, and PICK1 deficiency abolished ICA69 protein expression. In the Drosophila brain, PICK1 and ICA69 co-immunoprecipitated and showed mutually dependent expression. Finally, both in a Drosophila model of type 2 diabetes and in high-fat-diet-induced obese mice, we observed up-regulation of PICK1 mRNA expression. Our findings suggest that PICK1, together with ICA69, is critical during budding of immature secretory vesicles from the TGN and thus for vesicular storage of GH and possibly other hormones. The data link two BAR domain proteins to membrane remodeling processes in the secretory pathway of peptidergic endocrine cells and support an important role of PICK1/ICA69 in maintenance of metabolic homeostasis.
23630454	1579	1584	PICK1	GENE-Y	114849|60721
23630454	1589	1594	ICA69	GENE-Y	23630454T11
23630454	1784	1789	PICK1	GENE-N	114849|60721
23630454	1833	1838	PICK1	GENE-N	114849|60721
23630454	1854	1859	ICA69	GENE-N	23630454T14
23630454	1966	1968	GH	GENE-N	23630454T15
23630454	2016	2035	BAR domain proteins	GENE-N	23630454T16
23630454	2158	2163	PICK1	GENE-Y	114849|60721
23630454	2164	2169	ICA69	GENE-Y	23630454T18
23630454	434	488	lipid binding BAR (Bin/amphiphysin/Rvs) domain protein	GENE-N	23630454T19
23630454	1193	1200	glucose	CHEMICAL	23630454T1
23630454	489	494	PICK1	GENE-Y	114849|60721
23630454	496	531	protein interacting with C kinase 1	GENE-Y	23630454T21
23630454	601	603	GH	GENE-Y	23630454T22
23630454	626	631	PICK1	GENE-N	114849|60721
23630454	180	194	growth hormone	GENE-Y	23630454T24
23630454	757	762	PICK1	GENE-Y	114849|60721
23630454	820	825	PICK1	GENE-Y	114849|60721
23630454	196	198	GH	GENE-Y	23630454T27
23630454	934	936	GH	GENE-Y	23630454T28
23630454	973	975	GH	GENE-Y	23630454T29
23630454	100	107	Glucose	CHEMICAL	23630454T2
23630454	204	211	insulin	GENE-Y	23630454T30
23630454	1004	1006	GH	GENE-Y	23630454T31
23630454	0	5	PICK1	GENE-Y	114849|60721
23630454	1212	1217	PICK1	GENE-Y	114849|60721
23630454	1277	1293	PICK1 BAR domain	GENE-N	23630454T4
23630454	1443	1448	PICK1	GENE-Y	114849|60721
23630454	1471	1489	BAR domain protein	GENE-N	23630454T6
23630454	1490	1495	ICA69	GENE-Y	23630454T7
23630454	1501	1506	PICK1	GENE-Y	114849|60721
23630454	1528	1533	ICA69	GENE-Y	23630454T9

23631463|t|Design, Synthesis and Biological Evaluation of Aminoalkylindole Derivatives as Cannabinoid Receptor Ligands with Potential for Treatment of Alcohol Abuse.
23631463|a|Attenuation of increased endocannabinoid signaling with a CB1R neutral antagonist might offer a new therapeutic direction for treatment of alcohol abuse. We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid JHW-073 (3) exhibits neutral antagonist activity at CB1Rs and thus may serve as a promising lead for the development of novel alcohol abuse therapies. In the current study, we show that systematic modification of an aminoalkylindole scaffold identifies two new compounds with dual CB1R antagonist/CB2R agonist activity. Similar to the CB1R antagonist/inverse agonist rimonabant, analogues 27 and 30 decrease oral alcohol self-administration, without affecting total fluid intake and block the development of alcohol-conditioned place preference. Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.
23631463	140	147	Alcohol	CHEMICAL	888
23631463	47	63	Aminoalkylindole	CHEMICAL	23631463T11
23631463	1158	1162	CB2R	GENE-Y	23631463T12
23631463	469	474	CB1Rs	GENE-Y	23631463T13
23631463	698	702	CB1R	GENE-Y	23631463T14
23631463	714	718	CB2R	GENE-Y	23631463T15
23631463	213	217	CB1R	GENE-Y	23631463T16
23631463	752	756	CB1R	GENE-N	23631463T17
23631463	1142	1146	CB1R	GENE-Y	23631463T18
23631463	79	99	Cannabinoid Receptor	GENE-Y	23631463T19
23631463	1220	1227	alcohol	CHEMICAL	23631463T1
23631463	294	301	alcohol	CHEMICAL	23631463T2
23631463	388	404	aminoalkylindole	CHEMICAL	23631463T3
23631463	417	424	JHW-073	CHEMICAL	23631463T4
23631463	543	550	alcohol	CHEMICAL	23631463T5
23631463	633	649	aminoalkylindole	CHEMICAL	23631463T6
23631463	830	837	alcohol	CHEMICAL	23631463T7
23631463	925	932	alcohol	CHEMICAL	23631463T8
23631463	1051	1068	aminoalkylindoles	CHEMICAL	23631463T9
23631463	CPR:5	23631463T6	23631463T15
23631463	CPR:5	23631463T9	23631463T12
23631463	CPR:6	23631463T3	23631463T13
23631463	CPR:6	23631463T4	23631463T13
23631463	CPR:6	23631463T6	23631463T14
23631463	CPR:6	23631463T9	23631463T18

23632310|t|Immunoregulatory effects of Glycyrrhizic acid exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in ovalbumin-sensitized mice.
23632310|a|ETHNOPHARMACOLOGICAL RELEVANCE: Glycyrrhizic acid (GA) is the main bioactive ingredient of licorice (Glycyrrhiza glabra), and has been found to be associated with multiple therapeutic properties. AIM OF THE STUDY: In this study, we investigated immunoregulatory effects of glycyrrhizic acid on anti-asthmatic effects and underlying mechanisms. MATERIALS AND METHODS: Asthma model was established by ovalbumin-induced. A total of 60 mice were randomly assigned to six experimental groups: control, model, dexamethasone (2mg/kg) and GA (10mg/kg, 20mg/kg, 40mg/kg). Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The hematoxylin and eosin (HE) staining, Th1/Th2 and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the forkhead/winged helix transcription factor (Foxp3) was evaluated by western blotting. RESULTS: Our study demonstrated that, compared with model group, GA inhibited OVA-induced increases in Raw and eosinophil count; interleukin (IL)-4, IL-5, IL-13 levels were recovered in bronchoalveolar lavage fluid compared; increased IFN-level in bronchoalveolar lavage fluid; histological studies demonstrated that GA substantially inhibited OVA-induced eosinophilia in lung tissue and airway tissue compared with model group. Flow cytometry studies demonstrated that GA substantially enhanced Tregs compared with model group. CONCLUSION: These findings suggest that GA may effectively ameliorate the progression of asthma and could be used as a therapy for patients with allergic asthma.
23632310	1345	1350	IL-13	GENE-Y	23632310T10
23632310	1425	1430	IFN-	GENE-Y	23632310T11
23632310	1535	1538	OVA	GENE-Y	23632310T12
23632310	601	610	ovalbumin	GENE-Y	23632310T13
23632310	937	946	cytokines	GENE-N	23632310T14
23632310	1104	1146	forkhead/winged helix transcription factor	GENE-N	23632310T15
23632310	1148	1153	Foxp3	GENE-Y	203183
23632310	102	111	cytokines	GENE-N	23632310T17
23632310	175	184	ovalbumin	GENE-Y	23632310T18
23632310	475	492	glycyrrhizic acid	CHEMICAL	23632310T1
23632310	234	251	Glycyrrhizic acid	CHEMICAL	23632310T2
23632310	706	719	dexamethasone	CHEMICAL	23632310T3
23632310	883	894	hematoxylin	CHEMICAL	23632310T4
23632310	899	904	eosin	CHEMICAL	23632310T5
23632310	28	45	Glycyrrhizic acid	CHEMICAL	23632310T6
23632310	1268	1271	OVA	GENE-Y	23632310T7
23632310	1319	1337	interleukin (IL)-4	GENE-Y	23632310T8
23632310	1339	1343	IL-5	GENE-Y	23632310T9

23636640|t|Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.
23636640|a|AIMS/HYPOTHESIS: Studies have shown that dipeptidyl peptidase-4 (DPP4) inhibitors stimulate insulin secretion and increase beta cell mass in rodents. However, in these models hyperglycaemia has been induced early on in life and the treatment periods have been short. To explore the long-term effects of DPP4 inhibition on insulin secretion and beta cell mass, we have generated a high-fat diet (HFD)-induced-obesity model in mice of advanced age (10months old). METHODS: After 1month of HFD alone, the mice were given the DPP4 inhibitor vildagliptin for a further 11months. At multiple time points throughout the study, OGTTs were performed and beta cell area and long-term survival were evaluated. RESULTS: Beta cell function and glucose tolerance were significantly improved by vildagliptin with both diets. In contrast, in spite of the long treatment period, beta cell area was not significantly different between vildagliptin-treated mice and controls. Mice of advanced age chronically fed an HFD displayed clear and extensive pancreatic inflammation and peri-insulitis, mainly formed by CD3-positive T cells, which were completely prevented by vildagliptin treatment. Chronic vildagliptin treatment also improved survival rates for HFD-fed mice. CONCLUSIONS/INTERPRETATION: In a unique advanced-aged HFD-induced-obesity mouse model, insulin secretion was improved and the extensive peri-insulitis prevented by chronic DPP4 inhibition. The improved survival rates for obese mice chronically treated with vildagliptin suggest that chronic DPP4 inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.
23636640	1616	1620	DPP4	GENE-Y	108137
23636640	1735	1739	DPP4	GENE-Y	108137
23636640	493	497	DPP4	GENE-Y	108137
23636640	512	519	insulin	GENE-N	23636640T13
23636640	231	253	dipeptidyl peptidase-4	GENE-Y	23636640T14
23636640	714	718	DPP4	GENE-Y	108137
23636640	255	259	DPP4	GENE-Y	108137
23636640	282	289	insulin	GENE-N	23636640T17
23636640	90	112	dipeptidyl peptidase-4	GENE-Y	23636640T18
23636640	1342	1354	vildagliptin	CHEMICAL	23636640T1
23636640	1374	1386	vildagliptin	CHEMICAL	23636640T2
23636640	1701	1713	vildagliptin	CHEMICAL	23636640T3
23636640	729	741	vildagliptin	CHEMICAL	23636640T4
23636640	924	931	glucose	CHEMICAL	23636640T5
23636640	973	985	vildagliptin	CHEMICAL	23636640T6
23636640	1110	1122	vildagliptin	CHEMICAL	23636640T7
23636640	123	135	vildagliptin	CHEMICAL	23636640T8
23636640	1531	1538	insulin	GENE-N	23636640T9
23636640	CPR:4	23636640T3	108137
23636640	CPR:4	23636640T4	108137
23636640	CPR:4	23636640T8	23636640T18

23639187|t|Amelioration of palmitate-induced insulin resistance in C2C12 muscle cells by rooibos (Aspalathus linearis).
23639187|a|Increased levels of free fatty acids (FFAs), specifically saturated free fatty acids such as palmitate are associated with insulin resistance of muscle, fat and liver. Skeletal muscle, responsible for up to 80% of the glucose disposal from the peripheral circulation, is particularly vulnerable to increased levels of saturated FFAs. Rooibos (Aspalathus linearis) and its unique dihydrochalcone C-glucoside, aspalathin, shown to reduce hyperglycemia in diabetic rats, could play a role in preventing or ameliorating the development of insulin resistance. This study aims to establish whether rooibos can ameliorate experimentally-induced insulin-resistance in C2C12 skeletal muscle cells. Palmitate-induced insulin resistant C2C12 cells were treated with an aspalathin-enriched green (unfermented) rooibos extract (GRE), previously shown for its blood glucose lowering effect in vitro and in vivo or an aqueous extract of fermented rooibos (FRE). Glucose uptake and mitochondrial activity were measured using 2-deoxy-[(3)H]-d-glucose, MTT and ATP assays, respectively. Expression of proteins relevant to glucose metabolism was analysed by Western blot. GRE contained higher levels of all compounds, except the enolic phenylpyruvic acid-2-O-glucoside and luteolin-7-O-glucoside. Both rooibos extracts increased glucose uptake, mitochondrial activity and ATP production. Compared to FRE, GRE was more effective at increasing glucose uptake and ATP production. At a mechanistic level both extracts down-regulated PKC  activation, which is associated with palmitate-induced insulin resistance. Furthermore, the extracts increased activation of key regulatory proteins (AKT and AMPK) involved in insulin-dependent and non-insulin regulated signalling pathways. Protein levels of the glucose transporter (GLUT4) involved in glucose transport via these two pathways were also increased. This in vitro study therefore confirms that rooibos can ameliorate palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Inhibition of PKC  activation and increased activation of AMPK and AKT offer a plausible mechanistic explanation for this ameliorative effect.
23639187	1551	1554	ATP	CHEMICAL	164
23639187	1662	1671	palmitate	CHEMICAL	23639187T11
23639187	1888	1895	glucose	CHEMICAL	23639187T12
23639187	1928	1935	glucose	CHEMICAL	23639187T13
23639187	2057	2066	palmitate	CHEMICAL	23639187T14
23639187	129	145	free fatty acids	CHEMICAL	23639187T15
23639187	327	334	glucose	CHEMICAL	23639187T16
23639187	437	441	FFAs	CHEMICAL	23639187T17
23639187	488	515	dihydrochalcone C-glucoside	CHEMICAL	23639187T18
23639187	147	151	FFAs	CHEMICAL	23639187T19
23639187	1118	1142	2-deoxy-[(3)H]-d-glucose	CHEMICAL	23639187T1
23639187	517	527	aspalathin	CHEMICAL	23639187T20
23639187	167	193	saturated free fatty acids	CHEMICAL	23639187T21
23639187	798	807	Palmitate	CHEMICAL	3635
23639187	867	877	aspalathin	CHEMICAL	23639187T23
23639187	961	968	glucose	CHEMICAL	23639187T24
23639187	202	211	palmitate	CHEMICAL	23639187T25
23639187	1056	1063	Glucose	CHEMICAL	23639187T26
23639187	16	25	palmitate	CHEMICAL	23639187T27
23639187	232	239	insulin	GENE-Y	23639187T28
23639187	1619	1624	PKC 	GENE-Y	23639187T29
23639187	1144	1147	MTT	CHEMICAL	23639187T2
23639187	1680	1687	insulin	GENE-N	23639187T30
23639187	1775	1778	AKT	GENE-Y	23639187T31
23639187	1783	1787	AMPK	GENE-Y	23639187T32
23639187	1801	1808	insulin	GENE-N	23639187T33
23639187	1827	1834	insulin	GENE-N	23639187T34
23639187	1888	1907	glucose transporter	GENE-N	23639187T35
23639187	1909	1914	GLUT4	GENE-Y	23639187T36
23639187	2075	2082	insulin	GENE-N	23639187T37
23639187	2140	2145	PKC 	GENE-Y	23639187T38
23639187	2185	2189	AMPK	GENE-Y	23639187T39
23639187	1152	1155	ATP	CHEMICAL	164
23639187	2194	2197	AKT	GENE-Y	23639187T40
23639187	644	651	insulin	GENE-N	23639187T41
23639187	747	754	insulin	GENE-N	23639187T42
23639187	34	41	insulin	GENE-N	23639187T43
23639187	1213	1220	glucose	CHEMICAL	23639187T4
23639187	1326	1358	phenylpyruvic acid-2-O-glucoside	CHEMICAL	23639187T5
23639187	1363	1385	luteolin-7-O-glucoside	CHEMICAL	23639187T6
23639187	1419	1426	glucose	CHEMICAL	23639187T7
23639187	1462	1465	ATP	CHEMICAL	164
23639187	1532	1539	glucose	CHEMICAL	23639187T9
23639187	CPR:9	23639187T13	23639187T35
23639187	CPR:9	23639187T13	23639187T36

23639192|t|Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation.
23639192|a|Puerarin, the main isoflavone glycoside found in the Chinese herb radix of Pueraria lobata (Willd.) Ohwi, has received increasing attention because of its possible role in the prevention of osteoporosis. Previously, we showed that puerarin could inhibit the bone absorption of osteoclasts and promote long bone growth in fetal mouse in vitro. Further study confirmed that puerarin stimulated proliferation and differentiation of osteoblasts in rat. However, the mechanisms underlying its actions on human bone cells have not been well defined. Here we show that puerarin increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two estrogen receptor (ER) isoforms. Puerarin promotes proliferation by altering cell cycle distribution whereas puerarin-mediated survival may be associated with up-regulation of Bcl-xL expression. Treatment with the ER antagonist ICI 182,780 abolishes the above actions of puerarin on osteoblast-derived cells. Using small interfering double-stranded RNA technology, we further demonstrate that the effects of puerarin on proliferation, differentiation and survival are mediated by both ER and ER. Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK/ERK and PI3K/Akt signaling. This agent also shows much weaker effect on breast epithelial cell growth than that of estrogen. Therefore, puerarin will be a promising agent that prevents or retards osteoporosis.
23639192	797	806	cisplatin	CHEMICAL	23639192T10
23639192	874	882	estrogen	CHEMICAL	23639192T11
23639192	907	915	Puerarin	CHEMICAL	23639192T12
23639192	983	991	puerarin	CHEMICAL	23639192T13
23639192	1102	1113	ICI 182,780	CHEMICAL	937
23639192	1145	1153	puerarin	CHEMICAL	23639192T15
23639192	0	8	Puerarin	CHEMICAL	23639192T16
23639192	1359	1362	ER	GENE-Y	23639192T17
23639192	1367	1370	ER	GENE-Y	23639192T18
23639192	1467	1470	MEK	GENE-N	23639192T19
23639192	170	178	Puerarin	CHEMICAL	23639192T1
23639192	1471	1474	ERK	GENE-N	23639192T20
23639192	1479	1483	PI3K	GENE-N	23639192T21
23639192	1484	1487	Akt	GENE-N	23639192T22
23639192	874	891	estrogen receptor	GENE-Y	23639192T23
23639192	893	895	ER	GENE-Y	16226|2525
23639192	1050	1056	Bcl-xL	GENE-Y	23639192T25
23639192	1088	1090	ER	GENE-Y	16226|2525
23639192	124	126	ER	GENE-Y	16226|2525
23639192	137	140	MEK	GENE-N	23639192T28
23639192	141	144	ERK	GENE-N	23639192T29
23639192	1282	1290	puerarin	CHEMICAL	23639192T2
23639192	149	153	PI3K	GENE-N	23639192T30
23639192	154	157	Akt	GENE-N	23639192T31
23639192	1407	1415	puerarin	CHEMICAL	23639192T3
23639192	1586	1594	estrogen	CHEMICAL	23639192T4
23639192	1607	1615	puerarin	CHEMICAL	23639192T5
23639192	189	209	isoflavone glycoside	CHEMICAL	23639192T6
23639192	401	409	puerarin	CHEMICAL	23639192T7
23639192	542	550	puerarin	CHEMICAL	23639192T8
23639192	732	740	puerarin	CHEMICAL	23639192T9
23639192	CPR:3	23639192T13	23639192T25
23639192	CPR:3	23639192T16	23639192T28
23639192	CPR:3	23639192T16	23639192T29
23639192	CPR:3	23639192T16	23639192T30
23639192	CPR:3	23639192T16	23639192T31
23639192	CPR:3	23639192T3	23639192T19
23639192	CPR:3	23639192T3	23639192T20
23639192	CPR:3	23639192T3	23639192T21
23639192	CPR:3	23639192T3	23639192T22
23639192	CPR:6	937	16226|2525

23639248|t|Bone Morphogenetic Protein-7 inhibits silica-induced pulmonary fibrosis in rats.
23639248|a|Bone morphogenetic protein-7 (BMP-7) has been shown to inhibit liver and renal fibrosis in in vivo and in vitro studies. There is no study to investigate BMP-7's role in the development of pulmonary fibrosis induced by silica. In the current study, we used the rat model to explore the potential antifibrotic role of BMP-7 and its underlying mechanism in silica-induced pulmonary fibrosis. Sixty Wistar rats were randomly assigned into three groups. Control group received saline, silica group received silica and BMP-7 treated group received silica and BMP-7. BMP-7 was administered to silica-treated rats intraperitoneally at a dose of 300g/kg/injection from day 8 to day 30 every other day. After the animals were sacrificed on day 15 and 30, hydroxyproline levels, the protein expressions of BMP/Smad and TGF-/Smad signaling, and histopathology in lung tissues were analyzed. The hydroxyproline contents in BMP-7 treated groups were significantly lower than the silica groups (P<0.05). Histopathological results showed BMP-7 could reduce the progression of silica induced fibrosis. Furthermore, the expression of p-Smad1/5/8, a marker of BMP/Smad signaling, was significantly up-regulated in BMP-7 treated groups (P<0.05) compared with the silica groups. On the contrary, the expression of p-Smad2/3, a marker for TGF-/Smad signaling, reduced significantly in BMP-7-treated groups compared with silica groups (P<0.05). In conclusion, the pulmonary fibrosis induced by silica in rats was significantly reduced with the therapeutic treatment of BMP-7. The antifibrotic effect of BMP-7 could be related to the activation of BMP/Smad signaling and inhibition of TGF-/Smad pathways.
23639248	668	674	silica	CHEMICAL	23639248T10
23639248	828	842	hydroxyproline	CHEMICAL	23639248T11
23639248	967	981	hydroxyproline	CHEMICAL	23639248T12
23639248	1049	1055	silica	CHEMICAL	23639248T13
23639248	38	44	silica	CHEMICAL	23639248T14
23639248	81	109	Bone morphogenetic protein-7	GENE-Y	23639248T15
23639248	1106	1111	BMP-7	GENE-Y	23639248T16
23639248	1200	1211	p-Smad1/5/8	GENE-N	23639248T17
23639248	1225	1228	BMP	GENE-N	23639248T18
23639248	1229	1233	Smad	GENE-N	23639248T19
23639248	1144	1150	silica	CHEMICAL	23639248T1
23639248	1279	1284	BMP-7	GENE-Y	23639248T20
23639248	1377	1386	p-Smad2/3	GENE-N	23639248T21
23639248	1401	1406	TGF-	GENE-Y	23639248T22
23639248	1407	1411	Smad	GENE-N	23639248T23
23639248	1448	1453	BMP-7	GENE-Y	23639248T24
23639248	235	240	BMP-7	GENE-Y	23639248T25
23639248	1631	1636	BMP-7	GENE-Y	23639248T26
23639248	1665	1670	BMP-7	GENE-Y	23639248T27
23639248	1709	1712	BMP	GENE-N	23639248T28
23639248	1713	1717	Smad	GENE-N	23639248T29
23639248	1327	1333	silica	CHEMICAL	23639248T2
23639248	1746	1751	TGF-	GENE-Y	23639248T30
23639248	1752	1756	Smad	GENE-N	23639248T31
23639248	111	116	BMP-7	GENE-Y	23639248T32
23639248	398	403	BMP-7	GENE-Y	23639248T33
23639248	595	600	BMP-7	GENE-Y	23639248T34
23639248	635	640	BMP-7	GENE-Y	23639248T35
23639248	642	647	BMP-7	GENE-Y	23639248T36
23639248	878	881	BMP	GENE-N	23639248T37
23639248	882	886	Smad	GENE-N	23639248T38
23639248	891	896	TGF-	GENE-Y	23639248T39
23639248	1483	1489	silica	CHEMICAL	23639248T3
23639248	897	901	Smad	GENE-N	23639248T40
23639248	994	999	BMP-7	GENE-Y	23639248T41
23639248	0	28	Bone Morphogenetic Protein-7	GENE-Y	23639248T42
23639248	1556	1562	silica	CHEMICAL	23639248T4
23639248	300	306	silica	CHEMICAL	23639248T5
23639248	436	442	silica	CHEMICAL	23639248T6
23639248	562	568	silica	CHEMICAL	23639248T7
23639248	584	590	silica	CHEMICAL	23639248T8
23639248	624	630	silica	CHEMICAL	23639248T9

23639572|t|The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/Akt signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis.
23639572|a|OBJECTIVE: Increasing evidence suggests that osteocalcin (OC), one of the osteoblast-specific proteins, has been associated with atherosclerosis, but results are conflicting. The aim of this study was to elucidate the independent effect of uncarboxylated osteocalcin (ucOC), an active form of osteocalcin which has been suggested to have an insulin sensitizing effect, on vascular endothelial cells. MATERIALS AND METHODS: We used human aortic endothelial cells and treated them with ucOC. Linoleic acid (LA) was used as a representative free fatty acid. Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and Bcl-xL. The phosphorylations of Akt and endothelial nitric oxide synthase (eNOS) as well as the level of NO were measured to confirm the effect of ucOC on insulin signaling pathway. RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin. Treatment of ucOC (ranged from 0.3 to 30ng/ml) significantly increased the phosphorylation of Akt and eNOS and nitric oxide secretion from endothelial cells in a PI3-kinase dependent manner. CONCLUSIONS: Our study is the first to demonstrate the independent effect of ucOC on vascular endothelial cells. Our results further suggest that ucOC could have beneficial effects on atherosclerosis.
23639572	1149	1151	NO	CHEMICAL	427
23639572	132	152	phosphatidylinositol	CHEMICAL	23639572T11
23639572	60	75	free fatty acid	CHEMICAL	23639572T12
23639572	1251	1255	ucOC	GENE-Y	23639572T13
23639572	1300	1307	insulin	GENE-Y	23639572T14
23639572	1386	1415	phosphatidylinositol 3-kinase	GENE-N	23639572T15
23639572	1417	1427	PI3-kinase	GENE-N	23639572T16
23639572	1465	1469	ucOC	GENE-Y	23639572T17
23639572	1546	1549	Akt	GENE-N	23639572T18
23639572	1554	1558	eNOS	GENE-Y	23639572T19
23639572	1386	1406	phosphatidylinositol	CHEMICAL	23639572T1
23639572	1614	1624	PI3-kinase	GENE-N	23639572T20
23639572	1720	1724	ucOC	GENE-Y	23639572T21
23639572	1789	1793	ucOC	GENE-Y	23639572T22
23639572	479	505	uncarboxylated osteocalcin	GENE-Y	23639572T23
23639572	507	511	ucOC	GENE-Y	23639572T24
23639572	532	543	osteocalcin	GENE-Y	23639572T25
23639572	580	587	insulin	GENE-Y	23639572T26
23639572	284	295	osteocalcin	GENE-Y	23639572T27
23639572	723	727	ucOC	GENE-Y	23639572T28
23639572	297	299	OC	GENE-Y	23639572T29
23639572	1440	1450	wortmannin	CHEMICAL	23639572T2
23639572	861	892	deoxyribonucleotide transferase	GENE-Y	23639572T30
23639572	313	341	osteoblast-specific proteins	GENE-N	23639572T31
23639572	992	1001	caspase 3	GENE-Y	23639572T32
23639572	1011	1039	poly (ADP-ribose) polymerase	GENE-N	23639572T33
23639572	1044	1050	Bcl-xL	GENE-Y	23639572T34
23639572	1076	1079	Akt	GENE-N	23639572T35
23639572	1084	1117	endothelial nitric oxide synthase	GENE-Y	23639572T36
23639572	1119	1123	eNOS	GENE-Y	23639572T37
23639572	1191	1195	ucOC	GENE-Y	23639572T38
23639572	1199	1206	insulin	GENE-Y	23639572T39
23639572	1563	1575	nitric oxide	CHEMICAL	23639572T3
23639572	132	161	phosphatidylinositol 3-kinase	GENE-N	23639572T40
23639572	162	165	Akt	GENE-N	23639572T41
23639572	185	211	Uncarboxylated osteocalcin	GENE-Y	23639572T42
23639572	40	51	osteocalcin	GENE-Y	23639572T43
23639572	729	742	Linoleic acid	CHEMICAL	23639572T4
23639572	777	792	free fatty acid	CHEMICAL	23639572T5
23639572	861	880	deoxyribonucleotide	CHEMICAL	23639572T6
23639572	902	927	deoxyuridine triphosphate	CHEMICAL	23639572T7
23639572	1011	1028	poly (ADP-ribose)	CHEMICAL	23639572T8
23639572	1096	1108	nitric oxide	CHEMICAL	23639572T9
23639572	CPR:4	23639572T2	23639572T15
23639572	CPR:4	23639572T2	23639572T16

23640471|t|Free volume in ionic liquids: a connection of experimentally accessible observables from PALS and PVT experiments with the molecular structure from XRD data.
23640471|a|In the current work, free volume concepts, primarily applied to glass formers in the literature, were transferred to ionic liquids (ILs). A series of 1-butyl-3-methylimidazolium ([C4MIM](+)) based ILs was investigated by Positron Annihilation Lifetime Spectroscopy (PALS). The phase transition and dynamic properties of the ILs [C4MIM][X] with [X](-) = [Cl](-), [BF4](-), [PF6](-), [OTf](-), [NTf2](-) and [B(hfip)4](-) were reported recently (Yu et al., Phys. Chem. Chem. Phys., 2012, 14, 6856-6868). In this subsequent work, attention was paid to the connection of the free volume from PALS (here the mean hole volume, vh) with the molecular structure, represented by volumes derived from X-ray diffraction (XRD) data. These were the scaled molecular volume Vm,scaled and the van der Waals volume Vvdw. Linear correlations of vh at the "knee" temperature (vh(Tk)) with Vm,scaled and Vvdw gave good results for the [C4MIM](+) series. Further relationships between volumes from XRD data with the occupied volume Vocc determined from PALS/PVT (Pressure Volume Temperature) measurements and from Sanchez-Lacombe Equation of State (SL-EOS) fits were elaborated (Vocc(SL-EOS)  1.63 Vvdw, R(2) = 0.981 and Vocc(SL-EOS)  1.12 Vm,scaled, R(2) = 0.980). Finally, the usability of Vm,scaled was justified in terms of the Cohen-Turnbull (CT) free volume theory. Empirical CT type plots of viscosity and electrical conductivity showed a systematic increase in the critical free volume with molecular size. Such correlations allow descriptions of IL properties with the easily accessible quantity Vm,scaled within the context of the free volume.
23640471	1080	1090	[C4MIM](+)	CHEMICAL	23640471T10
23640471	308	335	1-butyl-3-methylimidazolium	CHEMICAL	23640471T1
23640471	337	347	[C4MIM](+)	CHEMICAL	23640471T2
23640471	487	492	C4MIM	CHEMICAL	23640471T3
23640471	511	518	[Cl](-)	CHEMICAL	23640471T4
23640471	520	528	[BF4](-)	CHEMICAL	23640471T5
23640471	530	538	[PF6](-)	CHEMICAL	23640471T6
23640471	540	548	[OTf](-)	CHEMICAL	23640471T7
23640471	550	559	[NTf2](-)	CHEMICAL	23640471T8
23640471	564	577	[B(hfip)4](-)	CHEMICAL	23640471T9

23640884|t|Distinct role of PYK2 in mediating thromboxane generation downstream of both G12/13 and integrin iib in platelets.
23640884|a|Proline-rich tyrosine kinase 2 (Pyk2) is activated by various agonists in platelets. We evaluated the signaling mechanism and the functional role of Pyk2 in platelets by using pharmacological inhibitors and Pyk2-deficient platelets. We found that platelet aggregation and secretion in response to 2-MeSADP and AYPGKF were diminished in the presence of Pyk2 inhibitors or in Pyk2-deficient platelets, suggesting that Pyk2 plays a positive regulatory role in platelet functional responses. It has been shown that ADP-, but not thrombin-, induced thromboxane (TxA2) generation depends on integrin signaling. Unlike ADP, thrombin activates G12/13 pathways, and G12/13 pathways can substitute for integrin signaling for TxA2 generation. We found that Pyk2 was activated downstream of both G12/13 and integrin-mediated pathways, and both 2-MeSADP- and AYPGKF-induced TxA2 generation was significantly diminished in Pyk2-deficient platelets. In addition, TxA2 generation induced by co-stimulation of Gi and Gz pathways, which is dependent on integrin signaling, was inhibited by blocking Pyk2. Furthermore, inhibition of 2-MeSADP-induced TxA2 generation by fibrinogen receptor antagonist was not rescued by co-stimulation of G12/13 pathways in the presence of Pyk2 inhibitor. We conclude that Pyk2 is a common signaling effector downstream of both G12/13 and integrin IIb3 signaling which contributes to thromboxane generation.
23640884	729	732	ADP	CHEMICAL	23640884T10
23640884	832	836	TxA2	CHEMICAL	23640884T11
23640884	949	957	2-MeSADP	CHEMICAL	23640884T12
23640884	978	982	TxA2	CHEMICAL	23640884T13
23640884	1065	1069	TxA2	CHEMICAL	23640884T14
23640884	35	46	thromboxane	CHEMICAL	23640884T15
23640884	117	147	Proline-rich tyrosine kinase 2	GENE-Y	23640884T16
23640884	1117	1119	Gz	GENE-Y	23640884T17
23640884	1152	1160	integrin	GENE-N	23640884T18
23640884	1198	1202	Pyk2	GENE-Y	23640884T19
23640884	117	124	Proline	CHEMICAL	23640884T1
23640884	1267	1286	fibrinogen receptor	GENE-Y	23640884T20
23640884	1335	1341	G12/13	GENE-N	23640884T21
23640884	1370	1374	Pyk2	GENE-Y	23640884T22
23640884	1403	1407	Pyk2	GENE-Y	23640884T23
23640884	1458	1464	G12/13	GENE-N	23640884T24
23640884	1469	1484	integrin IIb3	GENE-Y	23640884T25
23640884	266	270	Pyk2	GENE-Y	23640884T26
23640884	324	328	Pyk2	GENE-Y	23640884T27
23640884	149	153	Pyk2	GENE-Y	23640884T28
23640884	469	473	Pyk2	GENE-Y	23640884T29
23640884	1231	1239	2-MeSADP	CHEMICAL	23640884T2
23640884	491	495	Pyk2	GENE-Y	23640884T30
23640884	533	537	Pyk2	GENE-Y	23640884T31
23640884	642	650	thrombin	GENE-Y	23640884T32
23640884	702	710	integrin	GENE-N	23640884T33
23640884	734	742	thrombin	GENE-Y	23640884T34
23640884	753	759	G12/13	GENE-N	23640884T35
23640884	774	780	G12/13	GENE-N	23640884T36
23640884	809	817	integrin	GENE-N	23640884T37
23640884	863	867	Pyk2	GENE-Y	23640884T38
23640884	901	907	G12/13	GENE-N	23640884T39
23640884	1248	1252	TxA2	CHEMICAL	23640884T3
23640884	912	920	integrin	GENE-N	23640884T40
23640884	1026	1030	Pyk2	GENE-Y	23640884T41
23640884	1110	1112	Gi	GENE-N	23640884T42
23640884	17	21	PYK2	GENE-Y	34732
23640884	77	83	G12/13	GENE-N	23640884T44
23640884	88	102	integrin iib	GENE-Y	23640884T45
23640884	130	138	tyrosine	CHEMICAL	23640884T4
23640884	1516	1527	thromboxane	CHEMICAL	23640884T5
23640884	414	422	2-MeSADP	CHEMICAL	23640884T6
23640884	628	631	ADP	CHEMICAL	23640884T7
23640884	661	672	thromboxane	CHEMICAL	23640884T8
23640884	674	678	TxA2	CHEMICAL	23640884T9

23643725|t|The use of antioxidant enzymes in freshwater biofilms: Temporal variability vs. toxicological responses.
23643725|a|This study aims to investigate the potential of antioxidant enzyme activities (AEA) as biomarkers of oxidative stress in freshwater biofilms. Therefore, biofilms were grown in channels for 38 days and then exposed to different concentrations (0-150gL(-1)) of the herbicide oxyfluorfen for 5 more weeks. Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and glutathione reductase (GR) activities during the slow growth phase. Chronic exposure to oxyfluorfen led to slight variations in AEA, however, the ranges of variability of AEA in controls and exposed communities were similar, highlighting the difficulty of a direct interpretation of AEA values. After 5 weeks of exposure to oxyfluorfen, no clear effects were observed on chl-a concentration or on the composition of other pigments suggesting that algal group composition was not affected. Eukaryotic communities were structured clearly by toxicant concentration and both eukaryotic and bacterial richness were reduced in communities exposed to the highest concentration. In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150gL(-1) oxyfluorfen showed a higher CAT activity than controls. Chronic exposure to oxyfluorfen provoked then structural changes but also functional changes in the capacity of biofilm CAT activity to respond to a sudden increase in concentration, suggesting a selection of species with higher antioxidant capacity. This study highlighted the difficulty of interpretation of AEA values due to their temporal variation and to the absence of absolute threshold value indicative of oxidative stress induced by contaminants. Nevertheless, the determination of AEA pattern throughout acute exposure test is of high interest to compare oxidative stress levels undergone by different biofilm communities and thus determine their antioxidant capacity.
23643725	1621	1624	CAT	GENE-N	107297
23643725	523	543	ascorbate peroxidase	GENE-N	23643725T11
23643725	545	548	APX	GENE-N	23643725T12
23643725	618	626	catalase	GENE-N	23643725T13
23643725	628	631	CAT	GENE-N	107297
23643725	637	658	glutathione reductase	GENE-N	23643725T15
23643725	660	662	GR	GENE-N	9947
23643725	1445	1456	oxyfluorfen	CHEMICAL	23643725T1
23643725	1521	1532	oxyfluorfen	CHEMICAL	23643725T2
23643725	379	390	oxyfluorfen	CHEMICAL	23643725T3
23643725	523	532	ascorbate	CHEMICAL	23643725T4
23643725	637	648	glutathione	CHEMICAL	23643725T5
23643725	725	736	oxyfluorfen	CHEMICAL	23643725T6
23643725	961	972	oxyfluorfen	CHEMICAL	23643725T7
23643725	1008	1013	chl-a	CHEMICAL	23643725T8
23643725	1473	1476	CAT	GENE-N	107297
23643725	CPR:3	23643725T1	107297

23643745|t|Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.
23643745|a|A combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous dopamine to the motor actions of nociceptin/orphanin FQ (N/OFQ) receptor (NOP receptor) ligands. Motor activity was evaluated by a battery of behavioural tests in mice. The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice. Low doses of N/OFQ and NOP receptor antagonists promoted movement whereas higher doses inhibited it. Motor facilitation was selectively prevented by raclopride while motor inhibition was prevented by amisulpride. Amisulpride also attenuated the hypolocomotion induced by the D2/D3 receptor agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it. To dissect out the contribution of pre- and postsynaptic D2 receptors, mice lacking the D2 receptor (D2R(-/-)) or its long isoform (D2L(-/-)) were used. Motor facilitation induced by N/OFQ and NOP receptor antagonists was lost in D2R(-/-) and D2L(-/-) mice whereas motor inhibition induced by NOP receptor antagonists (and pramipexole) was lost in D2R(-/-) but preserved in D2L(-/-) mice. N/OFQ-induced hypolocomotion was observed in both genotypes. We demonstrate that motor actions of NOP receptor ligands rely on the modulation of endogenous dopamine. Motor facilitation induced by NOP receptor antagonists as well as low dose N/OFQ is mediated through D2L postsynaptic receptors whereas motor inhibition observed with higher doses of N/OFQ occurs by direct inhibition of mesencephalic DA neurons. Motor inhibition seen with high doses of NOP receptor antagonists appears to be mediated through the D2 presynaptic autoreceptors. These data confirm that endogenous N/OFQ is a powerful modulator of dopamine transmission in vivo and that the effects of NOP receptor antagonists on motor function reflect the blockade of this endogenous N/OFQ tone.
23643745	919	930	Amisulpride	CHEMICAL	5546
23643745	1004	1015	pramipexole	CHEMICAL	23643745T11
23643745	1020	1028	dopamine	CHEMICAL	23643745T12
23643745	1039	1067	L-3,4-dihydroxyphenylalanine	CHEMICAL	1223
23643745	1077	1087	raclopride	CHEMICAL	23643745T14
23643745	1093	1099	S33084	CHEMICAL	23643745T15
23643745	1171	1183	D2 receptors	GENE-Y	23643745T16
23643745	1202	1213	D2 receptor	GENE-Y	23643745T17
23643745	1215	1218	D2R	GENE-Y	23643745T18
23643745	1246	1249	D2L	GENE-Y	23643745T19
23643745	259	267	dopamine	CHEMICAL	23643745T1
23643745	1297	1302	N/OFQ	GENE-Y	23643745T20
23643745	1307	1319	NOP receptor	GENE-Y	23643745T21
23643745	1344	1347	D2R	GENE-Y	23643745T22
23643745	1357	1360	D2L	GENE-Y	23643745T23
23643745	1407	1419	NOP receptor	GENE-Y	23643745T24
23643745	1462	1465	D2R	GENE-Y	23643745T25
23643745	1488	1491	D2L	GENE-Y	23643745T26
23643745	1503	1508	N/OFQ	GENE-Y	23643745T27
23643745	292	331	nociceptin/orphanin FQ (N/OFQ) receptor	GENE-Y	23643745T28
23643745	1601	1613	NOP receptor	GENE-Y	23643745T29
23643745	1437	1448	pramipexole	CHEMICAL	23643745T2
23643745	1699	1711	NOP receptor	GENE-Y	23643745T30
23643745	1744	1749	N/OFQ	GENE-Y	23643745T31
23643745	1770	1773	D2L	GENE-Y	23643745T32
23643745	1852	1857	N/OFQ	GENE-Y	23643745T33
23643745	1956	1968	NOP receptor	GENE-Y	23643745T34
23643745	333	345	NOP receptor	GENE-Y	23643745T35
23643745	2016	2044	D2 presynaptic autoreceptors	GENE-Y	23643745T36
23643745	2081	2086	N/OFQ	GENE-Y	23643745T37
23643745	2168	2180	NOP receptor	GENE-Y	23643745T38
23643745	2251	2256	N/OFQ	GENE-Y	23643745T39
23643745	1659	1667	dopamine	CHEMICAL	23643745T3
23643745	459	470	DA receptor	GENE-N	23643745T40
23643745	504	509	N/OFQ	GENE-Y	23643745T41
23643745	514	526	NOP receptor	GENE-Y	23643745T42
23643745	578	580	D1	GENE-Y	66262
23643745	581	583	D5	GENE-Y	23643745T44
23643745	596	598	D2	GENE-Y	23643745T45
23643745	599	601	D3	GENE-Y	23643745T46
23643745	632	634	D3	GENE-Y	23643745T47
23643745	679	690	D2 receptor	GENE-Y	23643745T48
23643745	719	724	N/OFQ	GENE-Y	23643745T49
23643745	585	593	SCH23390	CHEMICAL	23643745T4
23643745	729	741	NOP receptor	GENE-Y	23643745T50
23643745	981	995	D2/D3 receptor	GENE-N	23643745T51
23643745	109	140	nociceptin/orphanin FQ receptor	GENE-Y	23643745T52
23643745	63	74	D2 receptor	GENE-Y	23643745T53
23643745	603	613	raclopride	CHEMICAL	23643745T5
23643745	615	626	amisulpride	CHEMICAL	23643745T6
23643745	636	642	S33084	CHEMICAL	23643745T7
23643745	855	865	raclopride	CHEMICAL	23643745T8
23643745	906	917	amisulpride	CHEMICAL	23643745T9
23643745	CPR:6	23643745T4	66262
23643745	CPR:6	23643745T4	23643745T44
23643745	CPR:6	23643745T5	23643745T45
23643745	CPR:6	23643745T5	23643745T46
23643745	CPR:6	23643745T6	23643745T45
23643745	CPR:6	23643745T6	23643745T46
23643745	CPR:6	23643745T7	23643745T47

23643747|t|Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.
23643747|a|The ribosomal protein S6 (rpS6) is a component of the small 40S ribosomal subunit, involved in multiple physiological functions. Here, we examined the effects produced by haloperidol, a typical antipsychotic drug, on the phosphorylation of rpS6 at Ser240/244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders. Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors (D2Rs). This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1). We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1). In line with this observation, incubation of striatal slices with okadaic acid and calyculin A, two inhibitors of PP-1, increased Ser240/244 phosphorylation. These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs. They also indicate that this effect is exerted by suppressing dephosphorylation at Ser240/244, through PKA-dependent activation of DARPP-32 and inhibition of PP-1.
23643747	570	573	Ser	CHEMICAL	127
23643747	619	623	GABA	CHEMICAL	23643747T11
23643747	673	681	dopamine	CHEMICAL	23643747T12
23643747	732	741	rapamycin	CHEMICAL	23643747T13
23643747	783	792	rapamycin	CHEMICAL	23643747T14
23643747	819	827	PF470867	CHEMICAL	23643747T15
23643747	925	936	haloperidol	CHEMICAL	23643747T16
23643747	940	943	Ser	CHEMICAL	127
23643747	1011	1019	dopamine	CHEMICAL	23643747T18
23643747	1025	1029	cAMP	CHEMICAL	2424
23643747	1200	1212	okadaic acid	CHEMICAL	23643747T1
23643747	0	11	Haloperidol	CHEMICAL	494
23643747	82	90	dopamine	CHEMICAL	23643747T21
23643747	96	100	cAMP	CHEMICAL	2424
23643747	1248	1252	PP-1	GENE-N	23643747T23
23643747	1337	1343	mTORC1	GENE-N	23643747T24
23643747	1349	1353	S6K1	GENE-N	23643747T25
23643747	1383	1387	rpS6	GENE-Y	23643747T26
23643747	1450	1454	D2Rs	GENE-Y	23643747T27
23643747	1559	1562	PKA	GENE-N	23643747T28
23643747	1587	1595	DARPP-32	GENE-Y	23643747T29
23643747	1217	1228	calyculin A	CHEMICAL	23643747T2
23643747	1614	1618	PP-1	GENE-N	23643747T30
23643747	417	421	rpS6	GENE-Y	23643747T31
23643747	203	207	rpS6	GENE-Y	23643747T32
23643747	181	201	ribosomal protein S6	GENE-Y	23643747T33
23643747	673	694	dopamine D2 receptors	GENE-Y	23643747T34
23643747	696	700	D2Rs	GENE-Y	23643747T35
23643747	763	802	mammalian target of rapamycin complex 1	GENE-N	23643747T36
23643747	237	258	40S ribosomal subunit	GENE-N	23643747T37
23643747	804	810	mTORC1	GENE-N	23643747T38
23643747	858	883	p70 ribosomal S6 kinase 1	GENE-Y	23643747T39
23643747	1264	1267	Ser	CHEMICAL	127
23643747	885	889	S6K1	GENE-N	23643747T40
23643747	1011	1064	dopamine- and cAMP-regulated phosphoprotein of 32 kDa	GENE-Y	23643747T41
23643747	1066	1074	DARPP-32	GENE-Y	23643747T42
23643747	1104	1125	protein phosphatase-1	GENE-N	23643747T43
23643747	1127	1131	PP-1	GENE-N	23643747T44
23643747	154	175	protein phosphatase-1	GENE-N	23643747T45
23643747	21	27	mTORC1	GENE-N	23643747T46
23643747	57	77	ribosomal protein S6	GENE-Y	23643747T47
23643747	82	135	dopamine- and cAMP-regulated phosphoprotein of 32 kDa	GENE-Y	23643747T48
23643747	1316	1327	haloperidol	CHEMICAL	23643747T4
23643747	1391	1394	Ser	CHEMICAL	127
23643747	1539	1542	Ser	CHEMICAL	127
23643747	348	359	haloperidol	CHEMICAL	23643747T7
23643747	425	428	Ser	CHEMICAL	127
23643747	548	559	haloperidol	CHEMICAL	23643747T9
23643747	CPR:3	494	23643747T47
23643747	CPR:3	23643747T4	23643747T26
23643747	CPR:4	23643747T13	23643747T36
23643747	CPR:4	23643747T13	23643747T38
23643747	CPR:4	23643747T15	23643747T39
23643747	CPR:4	23643747T15	23643747T40
23643747	CPR:4	23643747T1	23643747T23
23643747	CPR:4	494	23643747T45
23643747	CPR:4	23643747T2	23643747T23

23644191|t|Designing, structural elucidation, comparison of DNA binding, cleavage, radical scavenging activity and anticancer activity ofcopper(I) complex with 5-dimethyl-2-phenyl-4-[(pyridin-2-ylmethylene)-amino]-1,2-dihydro-pyrazol-3-one Schiff base ligand.
23644191|a|A novel copper(I) Schiff base complex has been synthesized and fully characterized by spectral, analytical and structural modes. Single crystal X-ray diffraction studies revealed that the copper(I) complex [CuCl(PPh3)L] has a distorted tetrahedral geometry around the central copper(I) ion. The interaction of the ligand and the complex with CT-DNA has been explored by absorption titration method which revealed that the compounds could interact with CT-DNA through intercalation. A gel electrophoresis assay demonstrated the ability of the complex to cleave the pBR322 DNA. The antioxidative properties showed that the copper(I) complex has a strong radical-scavenging potency than ligands. Further the cytotoxic effect of the compounds examined on cancerous cell linesshowed that the complex exhibited substantial anticancer activity.
23644191	438	447	copper(I)	CHEMICAL	23644191T1
23644191	456	469	[CuCl(PPh3)L]	CHEMICAL	23644191T2
23644191	526	535	copper(I)	CHEMICAL	23644191T3
23644191	871	880	copper(I)	CHEMICAL	23644191T4
23644191	258	279	copper(I) Schiff base	CHEMICAL	23644191T5
23644191	127	136	copper(I)	CHEMICAL	23644191T6
23644191	150	229	5-dimethyl-2-phenyl-4-[(pyridin-2-ylmethylene)-amino]-1,2-dihydro-pyrazol-3-one	CHEMICAL	23644191T7
23644191	230	241	Schiff base	CHEMICAL	23644191T8

23644213|t|Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
23644213|a|Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa and fibrinogen GPIIb/IIIa binding (both in the micromolar range). These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity. Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described.
23644213	610	620	fibrinogen	GENE-N	23644213T10
23644213	779	789	GPIIb/IIIa	GENE-Y	23644213T11
23644213	40	49	factor Xa	GENE-Y	23644213T12
23644213	54	64	fibrinogen	GENE-N	23644213T13
23644213	76	86	GPIIb/IIIa	GENE-Y	23644213T14
23644213	548	559	rivaroxaban	CHEMICAL	23644213T1
23644213	580	591	Arg-Gly-Asp	CHEMICAL	23644213T2
23644213	816	841	1,2,4-oxadiazol-5(4H)-one	CHEMICAL	23644213T3
23644213	369	378	factor Xa	GENE-Y	23644213T4
23644213	383	393	fibrinogen	GENE-N	23644213T5
23644213	394	404	GPIIb/IIIa	GENE-Y	23644213T6
23644213	528	537	factor Xa	GENE-Y	23644213T7
23644213	580	591	Arg-Gly-Asp	GENE-N	23644213T8
23644213	593	596	RGD	GENE-N	23644213T9
23644213	CPR:4	23644213T1	23644213T7
23644213	CPR:4	23644213T3	23644213T11

23645211|t|Role of quercetin in cadmium-induced oxidative stress, neuronal damage, and apoptosis in rats.
23645211|a|The present study was carried out to evaluate the neuroprotective effect of quercetin (QE) in protecting the cadmium (Cd)-induced neuronal injury in frontal cortex of rats. A total of 30 adult male Sprague-Dawley rats were randomly divided into three groups of 10 animals each: control, Cd treated and Cd treated with QE. The Cd-treated group was injected subcutaneously with cadmium chloride (CdCl2) dissolved in saline at a dose of 2 ml/kg/day for 30 days, resulting in a dosage of 1 mg/kg Cd. The rats in QE-treated groups were given QE (15 mg/kg body weight) once a day intraperitoneally starting 2 days prior to Cd injection, during the study period. Rats were sacrificed at the end of the study and the frontal cortex tissues were removed for biochemical and histopathological investigation. To date, there is no available information on the effect of QE on neuronal injury after Cd exposure. Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and catalase in the frontal cortex tissue. Administration of QE with Cd significantly diminished the levels of MDA and significantly elevated the levels of enzymatic antioxidants in the frontal cortex tissue. The histopathological studies in the brain of rats also supported that QE markedly reduced the Cd-induced histopathological changes and well preserved the normal histological architecture of the frontal cortex tissue. The caspase-3 immunopositivity was increased in degenerating neurons of the Cd group. Treatment with QE markedly reduced the immunoreactivity of degenerating neurons. In conclusion, the results of the current study suggest that QE may be beneficial in combating the Cd-induced neurotoxicity in the brain of rats. We believe that further preclinical research into the utility of QE may indicate its usefulness as a potential treatment for neurodegeneration after Cd exposure in rats.
23645211	2077	2079	Cd	CHEMICAL	23645211T10
23645211	382	384	Cd	CHEMICAL	23645211T11
23645211	397	399	Cd	CHEMICAL	23645211T12
23645211	421	423	Cd	CHEMICAL	23645211T13
23645211	471	487	cadmium chloride	CHEMICAL	23645211T14
23645211	489	494	CdCl2	CHEMICAL	23645211T15
23645211	587	589	Cd	CHEMICAL	23645211T16
23645211	712	714	Cd	CHEMICAL	23645211T17
23645211	171	180	quercetin	CHEMICAL	23645211T18
23645211	981	983	Cd	CHEMICAL	23645211T19
23645211	1143	1153	superoxide	CHEMICAL	23645211T1
23645211	1016	1018	Cd	CHEMICAL	23645211T20
23645211	1063	1078	malondialdehyde	CHEMICAL	23645211T21
23645211	1080	1083	MDA	CHEMICAL	23645211T22
23645211	21	28	cadmium	CHEMICAL	23645211T23
23645211	8	17	quercetin	CHEMICAL	23645211T24
23645211	1143	1163	superoxide dismutase	GENE-N	23645211T25
23645211	1165	1187	glutathione peroxidase	GENE-N	23645211T26
23645211	1192	1200	catalase	GENE-Y	23645211T27
23645211	1619	1628	caspase-3	GENE-Y	23645211T28
23645211	1165	1176	glutathione	CHEMICAL	23645211T2
23645211	204	211	cadmium	CHEMICAL	23645211T3
23645211	1257	1259	Cd	CHEMICAL	23645211T4
23645211	213	215	Cd	CHEMICAL	23645211T5
23645211	1299	1302	MDA	CHEMICAL	23645211T6
23645211	1492	1494	Cd	CHEMICAL	23645211T7
23645211	1691	1693	Cd	CHEMICAL	23645211T8
23645211	1881	1883	Cd	CHEMICAL	23645211T9
23645211	CPR:3	23645211T8	23645211T28
23645211	CPR:4	23645211T20	23645211T25
23645211	CPR:4	23645211T20	23645211T26
23645211	CPR:4	23645211T20	23645211T27

23645248|t|Oestrogen action on thyroid progenitor cells: relevant for the pathogenesis of thyroid nodules?
23645248|a|Benign and malignant thyroid nodules are more prevalent in females than in men. Experimental data suggest that the proliferative effect of oestrogen rather than polymorphisms is responsible for this gender difference. This study analysed whether both differentiated thyroid cells and thyroid stem and progenitor cells are a target of oestrogen action. In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors. Thyroid stem and progenitor cells expressed oestrogen receptor alpha and beta with an 8 time higher expression level of oestrogen receptor alpha mRNA compared to differentiated thyrocytes. 17beta-oestradiol was a potent stimulator of thyroid stem/ progenitor cell growth. In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the sodium iodide symporter, was significantly inhibited by 17beta-oestradiol.In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells. From these data and based on the concept of cellular heterogeneity, we hypothesize a supportive role of oestrogen in the propagation of thyroid stem/progenitor cells leading to a selection of a progeny of growth-prone cells with a decreased differentiation. These cells may be the origin of hypo- or non-functioning thyroid nodules in females.
23645248	632	649	17beta-oestradiol	CHEMICAL	23645248T10
23645248	771	784	sodium iodide	CHEMICAL	23645248T11
23645248	822	839	17beta-oestradiol	CHEMICAL	23645248T12
23645248	965	974	oestrogen	CHEMICAL	23645248T13
23645248	1041	1050	oestrogen	CHEMICAL	23645248T14
23645248	0	9	Oestrogen	CHEMICAL	23645248T15
23645248	1291	1314	sodium iodide symporter	GENE-Y	23645248T16
23645248	594	613	oestrogen receptors	GENE-Y	23645248T17
23645248	725	737	TSH receptor	GENE-Y	23645248T18
23645248	739	754	thyroperoxidase	GENE-Y	23645248T19
23645248	1110	1127	17beta-oestradiol	CHEMICAL	23645248T1
23645248	756	769	thyroglobulin	GENE-Y	23645248T20
23645248	771	794	sodium iodide symporter	GENE-Y	23645248T21
23645248	965	998	oestrogen receptor alpha and beta	GENE-N	23645248T22
23645248	1041	1065	oestrogen receptor alpha	GENE-N	23645248T23
23645248	1291	1304	sodium iodide	CHEMICAL	23645248T2
23645248	1347	1364	17beta-oestradiol	CHEMICAL	23645248T3
23645248	1380	1389	oestrogen	CHEMICAL	23645248T4
23645248	235	244	oestrogen	CHEMICAL	23645248T5
23645248	1607	1616	oestrogen	CHEMICAL	23645248T6
23645248	430	439	oestrogen	CHEMICAL	23645248T7
23645248	525	542	17beta-oestradiol	CHEMICAL	23645248T8
23645248	594	603	oestrogen	CHEMICAL	23645248T9
23645248	CPR:4	23645248T3	23645248T16

23645360|t|Differential regulation of Arabidopsis plastid gene expression and RNA editing in non-photosynthetic tissues.
23645360|a|RNA editing is one of the post-transcriptional processes that commonly occur in plant plastids and mitochondria. In Arabidopsis, 34 C-to-U RNA editing events, affecting transcripts of 18 plastid genes, have been identified. Here, we examined the editing and expression of these transcripts in different organs, and in green and non-green seedlings (etiolated, cia5-2, ispF and ispG albino mutants, lincomycin-, and norflurazon-treated). The editing efficiency of Arabidopsis plastid transcripts varies from site to site, and may be specifically regulated in different tissues. Steady state levels of plastid transcripts are low or undetectable in etiolated seedlings, but mostediting sites are edited with efficiencies similar to those observed in green seedlings. By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of ndhB-149, ndhB-1255, and ndhD-2 is completely lost in roots and in lincomycin-treated seedlings. The editing of ndhD-2 is also completely lost in albino mutants and norflurazon-treated seedlings. However, matK-640 is completely edited, and accD-794, atpF-92, psbE-214, psbF-77, psbZ-50, and rps14-50 are completely or highly edited in both green and non-green tissues. In addition, the expression of nucleus-encoded RNA polymerase dependent transcripts is specifically induced by lincomycin, and the splicing of ndhB transcripts is significantly reduced in the albino mutants and inhibitor-treated seedlings. Our results indicate that plastid gene expression, and the splicing and editing of plastid transcripts are specifically and differentially regulated in various types of non-green tissues.
23645360	1285	1292	psbF-77	GENE-N	23645360T10
23645360	1294	1301	psbZ-50	GENE-N	23645360T11
23645360	1307	1315	rps14-50	GENE-N	23645360T12
23645360	1432	1446	RNA polymerase	GENE-N	23645360T13
23645360	1528	1532	ndhB	GENE-N	29920
23645360	1651	1658	plastid	GENE-N	23645360T15
23645360	1708	1715	plastid	GENE-N	23645360T16
23645360	297	304	plastid	GENE-N	23645360T17
23645360	573	592	Arabidopsis plastid	GENE-N	23645360T18
23645360	710	717	plastid	GENE-N	23645360T19
23645360	1181	1192	norflurazon	CHEMICAL	23645360T1
23645360	190	204	plant plastids	GENE-N	23645360T20
23645360	1016	1024	ndhB-149	GENE-N	23645360T21
23645360	1026	1035	ndhB-1255	GENE-N	23645360T22
23645360	1041	1047	ndhD-2	GENE-N	23645360T23
23645360	27	46	Arabidopsis plastid	GENE-N	23645360T24
23645360	1496	1506	lincomycin	CHEMICAL	23645360T2
23645360	508	518	lincomycin	CHEMICAL	23645360T3
23645360	525	536	norflurazon	CHEMICAL	23645360T4
23645360	1083	1093	lincomycin	CHEMICAL	23645360T5
23645360	1128	1134	ndhD-2	GENE-N	23645360T6
23645360	1256	1264	accD-794	GENE-N	23645360T7
23645360	1266	1273	atpF-92	GENE-N	23645360T8
23645360	1275	1283	psbE-214	GENE-N	23645360T9

23703578|t|Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.
23703578|a|The HMG-CoA reductase inhibitors are a class of drugs also known as statins. These drugs are effective and widely prescribed for the treatment of hypercholesterolemia and prevention of cardiovascular morbidity and mortality. Seven statins are currently available: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. Although these drugs are generally well tolerated, skeletal muscle abnormalities from myalgia to severe lethal rhabdomyolysis can occur. Factors that increase statin concentrations such as drug-drug interactions can increase the risk of these adverse events. Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this CYP. All statins are substrate of organic anion transporter polypeptide 1B1, an uptake transporter expressed in hepatocyte membrane that may also explain some drug-drug interactions. Many HIV-infected patients have dyslipidemia and comorbidities that may require statin treatment. HIV-protease inhibitors (HIV PIs) are part of recommended antiretroviral treatment in combination with two reverse transcriptase inhibitors. All HIV PIs except nelfinavir are coadministered with a low dose of ritonavir, a potent CYP3A inhibitor to improve their pharmacokinetic properties. Cobicistat is a new potent CYP3A inhibitor that is combined with elvitegravir and will be combined with HIV-PIs in the future. The HCV-PIs boceprevir and telaprevir are both, to different extents, inhibitors of CYP3A. This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions. Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated. Atorvastatin is also a CYP3A substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors. Non-CYP3A-dependent statin concentrations are also affected although to a lesser extent when coadministered with HIV or HCV PIs, mainly through interaction with OATP1B1, and treatment should start with the lowest available statin dose. Effectiveness and occurrence of adverse effects should be monitored at regular time intervals.
23703578	2144	2154	boceprevir	CHEMICAL	23703578T10
23703578	2213	2225	Atorvastatin	CHEMICAL	1064
23703578	369	381	atorvastatin	CHEMICAL	23703578T12
23703578	383	394	fluvastatin	CHEMICAL	1083
23703578	396	406	lovastatin	CHEMICAL	23703578T14
23703578	408	420	pitavastatin	CHEMICAL	23703578T15
23703578	422	433	pravastatin	CHEMICAL	23703578T16
23703578	435	447	rosuvastatin	CHEMICAL	23703578T17
23703578	452	463	simvastatin	CHEMICAL	23703578T18
23703578	109	116	HMG-CoA	CHEMICAL	23703578T19
23703578	1395	1405	nelfinavir	CHEMICAL	23703578T1
23703578	798	809	simvastatin	CHEMICAL	23703578T20
23703578	811	821	lovastatin	CHEMICAL	23703578T21
23703578	826	838	atorvastatin	CHEMICAL	23703578T22
23703578	31	38	HMG-CoA	CHEMICAL	23703578T23
23703578	1235	1247	HIV-protease	GENE-N	23703578T24
23703578	1342	1363	reverse transcriptase	GENE-N	23703578T25
23703578	1464	1469	CYP3A	GENE-N	23703578T26
23703578	1552	1557	CYP3A	GENE-N	23703578T27
23703578	1736	1741	CYP3A	GENE-N	23703578T28
23703578	1961	1966	CYP3A	GENE-N	23703578T29
23703578	1444	1453	ritonavir	CHEMICAL	23703578T2
23703578	2030	2035	CYP3A	GENE-N	23703578T30
23703578	2236	2241	CYP3A	GENE-N	23703578T31
23703578	2316	2321	CYP3A	GENE-N	23703578T32
23703578	2338	2343	CYP3A	GENE-N	23703578T33
23703578	2495	2502	OATP1B1	GENE-Y	23703578T34
23703578	109	126	HMG-CoA reductase	GENE-Y	23703578T35
23703578	863	887	cytochrome P450 (CYP) 3A	GENE-N	23703578T36
23703578	954	957	CYP	GENE-N	23703578T37
23703578	988	1029	organic anion transporter polypeptide 1B1	GENE-Y	23703578T38
23703578	31	48	HMG-CoA reductase	GENE-Y	23703578T39
23703578	1664	1674	boceprevir	CHEMICAL	23703578T3
23703578	84	92	protease	GENE-N	23703578T40
23703578	1679	1689	telaprevir	CHEMICAL	23703578T4
23703578	1914	1925	Simvastatin	CHEMICAL	631
23703578	1930	1940	lovastatin	CHEMICAL	23703578T6
23703578	2055	2064	ritonavir	CHEMICAL	23703578T7
23703578	2069	2079	cobicistat	CHEMICAL	23703578T8
23703578	2130	2140	telaprevir	CHEMICAL	23703578T9
23703578	CPR:4	23703578T10	23703578T30
23703578	CPR:4	23703578T2	23703578T26
23703578	CPR:4	23703578T3	23703578T28
23703578	CPR:4	23703578T4	23703578T28
23703578	CPR:4	23703578T7	23703578T30
23703578	CPR:4	23703578T8	23703578T30
23703578	CPR:4	23703578T9	23703578T30
23703578	CPR:9	1064	23703578T31
23703578	CPR:9	23703578T20	23703578T36
23703578	CPR:9	23703578T21	23703578T36
23703578	CPR:9	23703578T22	23703578T36
23703578	CPR:9	631	23703578T29
23703578	CPR:9	23703578T6	23703578T29

23742252|t|Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.
23742252|a|The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.
23742252	469	475	LDK378	CHEMICAL	23742252T1
23742252	713	719	TAE684	CHEMICAL	23742252T2
23742252	143	259	5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine	CHEMICAL	23742252T3
23742252	261	267	LDK378	CHEMICAL	23742252T4
23742252	427	453	anaplastic lymphoma kinase	GENE-Y	23742252T5
23742252	696	699	ALK	GENE-Y	106739
23742252	841	844	ALK	GENE-Y	106739
23742252	100	126	anaplastic lymphoma kinase	GENE-Y	23742252T8
23742252	128	131	ALK	GENE-Y	106739
23742252	CPR:4	23742252T1	23742252T5
23742252	CPR:4	23742252T2	106739

2450203|t|Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture.
2450203|a|Effects of benzodiazepines (BDZs) and beta carbolines (beta CCs) on sustained repetitive firing at high frequency (SRF) of action potentials of mouse spinal cord neurons in cell culture were examined using intracellular recording techniques. In control medium neurons responded to depolarizing current pulses with SRF. Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations. The limitation of SRF was accompanied by use- and voltage-dependent reduction of maximal rate of rise (Vmax) of sodium-dependent action potentials. Partial agonist and inverse agonist beta CCs did not limit SRF at concentrations up to 200 nM. The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the BDZ receptor, including Ro 15-1788 and the beta CCs. These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation. We propose that the limitation of SRF may contribute to the efficacy of BDZs against generalized tonic-clonic seizures and status epilepticus.
2450203	1425	1431	sodium	CHEMICAL	2450203T10
2450203	1532	1536	BDZs	CHEMICAL	2450203T11
2450203	170	174	BDZs	CHEMICAL	2450203T12
2450203	514	518	BDZs	CHEMICAL	2450203T13
2450203	520	528	diazepam	CHEMICAL	2450203T14
2450203	180	195	beta carbolines	CHEMICAL	2450203T15
2450203	530	540	clonazepam	CHEMICAL	2450203T16
2450203	542	552	nitrazepam	CHEMICAL	2450203T17
2450203	557	566	lorazepam	CHEMICAL	2450203T18
2450203	624	627	BDZ	CHEMICAL	2450203T19
2450203	1143	1146	BDZ	CHEMICAL	2450203T1
2450203	665	668	BDZ	CHEMICAL	2450203T20
2450203	680	689	Ro 5-4864	CHEMICAL	2450203T21
2450203	197	205	beta CCs	CHEMICAL	2450203T22
2450203	733	736	BDZ	CHEMICAL	2450203T23
2450203	768	778	Ro 15-1788	CHEMICAL	2450203T24
2450203	922	928	sodium	CHEMICAL	2450203T25
2450203	1078	1086	diazepam	CHEMICAL	2450203T26
2450203	0	15	Benzodiazepines	CHEMICAL	2450203T27
2450203	25	40	beta carbolines	CHEMICAL	2450203T28
2450203	1143	1155	BDZ receptor	GENE-N	2450203T29
2450203	1167	1177	Ro 15-1788	CHEMICAL	2450203T2
2450203	1296	1329	voltage-dependent sodium channels	GENE-N	2450203T30
2450203	1363	1376	BDZ receptors	GENE-N	2450203T31
2450203	1425	1440	sodium channels	GENE-N	2450203T32
2450203	665	678	BDZ receptors	GENE-N	2450203T33
2450203	733	745	BDZ receptor	GENE-N	2450203T34
2450203	1186	1194	beta CCs	CHEMICAL	2450203T3
2450203	153	168	benzodiazepines	CHEMICAL	2450203T4
2450203	1269	1273	BDZs	CHEMICAL	2450203T5
2450203	1283	1291	beta CCs	CHEMICAL	2450203T6
2450203	1314	1320	sodium	CHEMICAL	2450203T7
2450203	1363	1366	BDZ	CHEMICAL	2450203T8
2450203	1387	1391	BDZs	CHEMICAL	2450203T9
2450203	CPR:3	2450203T9	2450203T32
2450203	CPR:5	2450203T24	2450203T34
2450203	CPR:5	2450203T2	2450203T29
2450203	CPR:5	2450203T3	2450203T29

2521824|t|Androgens directly stimulate proliferation of bone cells in vitro.
2521824|a|This report describes the first observation of a direct mitogenic effect of androgens on isolated osteoblastic cells in serum-free culture. [3H]thymidine incorporation into DNA and cell counts were used as measures of cell proliferation. The percentage of cells that stained for alkaline phosphatase was used as a measure of differentiation. Dihydrotestosterone (DHT) enhanced mouse osteoblastic cell proliferation in a dose dependent manner over a wide range of doses (10(-8) to 10(-11) molar), and was maximally active at 10(-9) M. DHT also stimulated proliferation in human osteoblast cell cultures and in cultures of the human osteosarcoma cell line, TE89. Testosterone, fluoxymesterone (a synthetic androgenic steroid) and methenolone (an anabolic steroid) were also mitogenic in the mouse bone cell system. The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (hydroxyflutamide and cyproterone acetate) which compete for binding to the androgen receptor. In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens. We conclude that androgens can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker ALP, presumably by an androgen receptor mediated mechanism.
2521824	782	789	steroid	CHEMICAL	2521824T10
2521824	795	806	methenolone	CHEMICAL	2521824T11
2521824	820	827	steroid	CHEMICAL	2521824T12
2521824	143	152	androgens	CHEMICAL	2521824T13
2521824	904	907	DHT	CHEMICAL	2781
2521824	954	970	hydroxyflutamide	CHEMICAL	2521824T15
2521824	975	994	cyproterone acetate	CHEMICAL	2521824T16
2521824	1029	1037	androgen	CHEMICAL	2521824T17
2521824	0	9	Androgens	CHEMICAL	2521824T18
2521824	1126	1146	alkaline phosphatase	GENE-N	2521824T19
2521824	1094	1097	DHT	CHEMICAL	2781
2521824	1148	1151	ALP	GENE-N	21402
2521824	1384	1422	osteoblast-line differentiation marker	GENE-N	2521824T21
2521824	1423	1426	ALP	GENE-N	21402
2521824	1445	1462	androgen receptor	GENE-N	2521824T23
2521824	346	366	alkaline phosphatase	GENE-N	2521824T24
2521824	1029	1046	androgen receptor	GENE-N	2521824T25
2521824	1272	1281	androgens	CHEMICAL	2521824T2
2521824	1445	1453	androgen	CHEMICAL	2521824T3
2521824	207	220	[3H]thymidine	CHEMICAL	2521824T4
2521824	409	428	Dihydrotestosterone	CHEMICAL	2781
2521824	430	433	DHT	CHEMICAL	2781
2521824	601	604	DHT	CHEMICAL	2781
2521824	728	740	Testosterone	CHEMICAL	614
2521824	742	757	fluoxymesterone	CHEMICAL	2521824T9
2521824	CPR:3	2781	2521824T19
2521824	CPR:3	2781	21402
2521824	CPR:3	2521824T2	2521824T21
2521824	CPR:3	2521824T2	21402

2569356|t|The effect of histamine-H1 receptor antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma.
2569356|a|Selective histamine-H1 receptor antagonists inhibit adenosine 5'-monophosphate (AMP)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of AMP required to produce a 20% decrease in FEV1 from baseline (PC20). To investigate this further we have determined that, in eight mild atopic asthmatic subjects, terfenadine (180 mg), administered 3 hr pre-challenge, increases the geometric mean PC20 for histamine from 0.4 (range 0.03-3) mg/ml after placebo, to 20.2 (range 0.6-64) mg/ml following active treatment (P less than 0.0001). For AMP, the PC20 increased from 9.3 (range 1.0-113.3) mg/ml after placebo, to 150.2 (range 32.1-1177.7) mg/ml with terfenadine (P less than 0.0001). This 16.2-fold (range, 5.5-47.9) displacement to the right of the AMP concentration-response curve by a selective histamine-H1 receptor antagonist emphasizes the central role of histamine in the airways response to this nucleotide.
2569356	1049	1058	histamine	CHEMICAL	2569356T10
2569356	1113	1122	histamine	CHEMICAL	2569356T11
2569356	14	23	histamine	CHEMICAL	2569356T12
2569356	52	63	terfenadine	CHEMICAL	2569356T13
2569356	89	92	AMP	CHEMICAL	125|407
2569356	142	163	histamine-H1 receptor	GENE-Y	2569356T15
2569356	1049	1070	histamine-H1 receptor	GENE-Y	2569356T16
2569356	14	35	histamine-H1 receptor	GENE-Y	2569356T17
2569356	142	151	histamine	CHEMICAL	2569356T1
2569356	396	399	AMP	CHEMICAL	125|407
2569356	559	570	terfenadine	CHEMICAL	2569356T3
2569356	652	661	histamine	CHEMICAL	2569356T4
2569356	184	210	adenosine 5'-monophosphate	CHEMICAL	2569356T5
2569356	789	792	AMP	CHEMICAL	125|407
2569356	901	912	terfenadine	CHEMICAL	2569356T7
2569356	212	215	AMP	CHEMICAL	125|407
2569356	1001	1004	AMP	CHEMICAL	125|407
2569356	CPR:6	2569356T13	2569356T17

25802231|t|Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
25802231|a|Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK. Oral ibrutinib is indicated for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or TP53 mutation. This article summarizes pharmacological, efficacy and tolerability data relevant to the use of ibrutinib in these indications. In clinical studies, ibrutinib induced a high overall response rate in patients with relapsed/refractory MCL (phase II study). In addition, ibrutinib significantly prolonged progression-free survival and significantly improved the partial response rate and overall survival in patients with relapsed/refractory CLL (RESONATE study), including in those with del 17p, a subgroup with a poor prognosis. Ibrutinib had an acceptable tolerability profile in these studies with <10% of patients discontinuing treatment because of adverse events. Given its efficacy and tolerability, once-daily, oral ibrutinib is an emerging treatment option for patients with relapsed/refractory MCL or CLL and CLL patients with del 17p or TP53 mutation.
25802231	0	9	Ibrutinib	CHEMICAL	7814
25802231	226	229	BTK	GENE-Y	107160
25802231	1392	1396	TP53	GENE-Y	113010|727568|676460|1149408|139788
25802231	245	268	B-cell antigen receptor	GENE-N	25802231T13
25802231	294	297	BTK	GENE-Y	107160
25802231	533	537	TP53	GENE-Y	113010|727568|676460|1149408|139788
25802231	200	224	Bruton's tyrosine kinase	GENE-Y	25802231T16
25802231	103	112	Ibrutinib	CHEMICAL	7814
25802231	209	217	tyrosine	CHEMICAL	25802231T2
25802231	114	126	Imbruvica(R)	CHEMICAL	25802231T3
25802231	1268	1277	ibrutinib	CHEMICAL	25802231T4
25802231	304	313	ibrutinib	CHEMICAL	25802231T5
25802231	643	652	ibrutinib	CHEMICAL	25802231T6
25802231	696	705	ibrutinib	CHEMICAL	25802231T7
25802231	815	824	ibrutinib	CHEMICAL	25802231T8
25802231	1075	1084	Ibrutinib	CHEMICAL	7814
25802231	CPR:4	7814	107160
25802231	CPR:4	7814	25802231T13
25802231	CPR:4	7814	107160
25802231	CPR:4	7814	25802231T16
25802231	CPR:4	25802231T3	107160
25802231	CPR:4	25802231T3	25802231T13
25802231	CPR:4	25802231T3	25802231T16

2859531|t|Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity".
2859531|a|Abrupt withdrawal of beta-adrenoceptor antagonists may lead to "rebound-effects". To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years. Propranolol treatment (4 X 40 mg/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; concomitantly PRA and heart rate were reduced. During treatment beta 2-adrenoceptor density remained elevated. After withdrawal of propranolol PRA reached pre-drug levels rapidly, while heart rate was significantly enhanced. Beta 2-Adrenoceptor density, however, declined slowly being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h. The affinity of ICYP to beta 2-adrenoceptors was not changed during or after treatment. Mepindolol treatment (2 X 5 mg/day) caused a 30% decrease of beta 2-adrenoceptor density and PRA after 2 days; both parameters remained reduced during treatment. After withdrawal, PRA reached rapidly pre-drug levels, whereas beta 2-adrenoceptor density was still after 4 days significantly diminished. The KD-values for ICYP, however, were not changed. During and after treatment heart rate was not affected. Alprenolol treatment (4 X 100 mg/day) led to a rapid fall in PRA, but did not significantly affect beta 2-adrenoceptor density. It is concluded, that the ISA may play an important role in modulating beta 2-adrenoceptor density and hence tissue responsiveness to beta-adrenoceptor stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)
2859531	663	674	Propranolol	CHEMICAL	561
2859531	899	910	propranolol	CHEMICAL	2859531T11
2859531	1106	1117	propranolol	CHEMICAL	2859531T12
2859531	1183	1203	beta 2-adrenoceptors	GENE-Y	2859531T13
2859531	1308	1327	beta 2-adrenoceptor	GENE-Y	2859531T14
2859531	1472	1491	beta 2-adrenoceptor	GENE-Y	2859531T15
2859531	1755	1774	beta 2-adrenoceptor	GENE-Y	2859531T16
2859531	327	344	beta-adrenoceptor	GENE-N	2859531T17
2859531	1855	1874	beta 2-adrenoceptor	GENE-Y	2859531T18
2859531	1918	1935	beta-adrenoceptor	GENE-N	2859531T19
2859531	1175	1179	ICYP	CHEMICAL	2859531T1
2859531	183	200	beta-adrenoceptor	GENE-N	2859531T20
2859531	480	499	beta 2-adrenoceptor	GENE-Y	2859531T21
2859531	579	584	renin	GENE-Y	2859531T22
2859531	726	746	beta 2-adrenoceptors	GENE-Y	2859531T23
2859531	832	851	beta 2-adrenoceptor	GENE-Y	2859531T24
2859531	993	1012	Beta 2-Adrenoceptor	GENE-Y	2859531T25
2859531	11	28	beta-adrenoceptor	GENE-N	2859531T26
2859531	58	77	beta 2-adrenoceptor	GENE-Y	2859531T27
2859531	1247	1257	Mepindolol	CHEMICAL	2859531T2
2859531	1567	1571	ICYP	CHEMICAL	2859531T3
2859531	1656	1666	Alprenolol	CHEMICAL	856
2859531	357	368	propranolol	CHEMICAL	2859531T5
2859531	416	426	alprenolol	CHEMICAL	2859531T6
2859531	442	452	mepindolol	CHEMICAL	2859531T7
2859531	521	551	(+/-)-[125I]-iodocyanopindolol	CHEMICAL	2859531T8
2859531	553	557	ICYP	CHEMICAL	2859531T9
2859531	CPR:3	561	2859531T23
2859531	CPR:4	2859531T2	2859531T14
2859531	CPR:6	2859531T5	2859531T17
2859531	CPR:6	2859531T6	2859531T17
2859531	CPR:6	2859531T7	2859531T17

2882965|t|Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.
2882965|a|The possible effect of sulfasalazine, 5-aminosalicylic acid, and acetyl-5-aminosalicylic acid on endogenous arachidonic acid release and metabolism was studied in human polymorphonuclear leukocytes (PMNs). A new in vitro assay was used by which [1-14C]arachidonic acid is incorporated by purified peripheral PMNs until steady state was obtained (5 hr). After preincubation with the test drugs prior to activation with calcium ionophore A23187, the released eicosanoids were isolated by extraction and thin-layer chromatography (TLC) and quantitated by autoradiography and laser densitometry. Median drug concentrations needed for 50% inhibition of leukotriene B4 and 5-hydroxyeicosatetraenoic acid (5-HETE) release was 4-5 mM (range 1-9 mM) for both sulfasalazine and 5-aminosalicylic acid. The acetylated derivative of 5-aminosalicylic acid was ineffective. The present data suggest that inhibition of arachidonic acid lipoxygenation may be an essential action of sulfasalazine and its active metabolite, 5-aminosalicylic acid. Interference with lipoxygenase enzymes, rather than a steroid-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.
2882965	781	795	leukotriene B4	CHEMICAL	2882965T10
2882965	198	226	acetyl-5-aminosalicylic acid	CHEMICAL	2882965T11
2882965	800	830	5-hydroxyeicosatetraenoic acid	CHEMICAL	2882965T12
2882965	832	838	5-HETE	CHEMICAL	2882965T13
2882965	883	896	sulfasalazine	CHEMICAL	2882965T14
2882965	901	922	5-aminosalicylic acid	CHEMICAL	237
2882965	928	974	acetylated derivative of 5-aminosalicylic acid	CHEMICAL	2882965T16
2882965	1036	1052	arachidonic acid	CHEMICAL	2882965T17
2882965	1098	1111	sulfasalazine	CHEMICAL	2882965T18
2882965	110	131	5-aminosalicylic acid	CHEMICAL	237
2882965	1139	1160	5-aminosalicylic acid	CHEMICAL	237
2882965	40	56	arachidonic acid	CHEMICAL	2882965T20
2882965	92	105	sulfasalazine	CHEMICAL	2882965T21
2882965	1180	1192	lipoxygenase	GENE-N	2882965T22
2882965	14	28	5-lipoxygenase	GENE-Y	2882965T23
2882965	241	257	arachidonic acid	CHEMICAL	2882965T2
2882965	1216	1223	steroid	CHEMICAL	2882965T3
2882965	1243	1259	arachidonic acid	CHEMICAL	2882965T4
2882965	156	169	sulfasalazine	CHEMICAL	2882965T5
2882965	378	401	[1-14C]arachidonic acid	CHEMICAL	2882965T6
2882965	171	192	5-aminosalicylic acid	CHEMICAL	237
2882965	551	575	calcium ionophore A23187	CHEMICAL	2882965T8
2882965	590	601	eicosanoids	CHEMICAL	2882965T9
2882965	CPR:4	237	2882965T23
2882965	CPR:4	2882965T21	2882965T23
2882965	CPR:4	2882965T3	2882965T22
2882965	CPR:9	2882965T20	2882965T23
2882965	CPR:9	2882965T4	2882965T22

2888789|t|Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.
2888789|a|UNLABELLED: Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Some interesting additional properties, such as the absence of the side effect of cold extremities, required investigation, and a great deal of new evidence has been accumulated during the last three years. This new data is consistent with the proposal put forward a couple of years ago that bevantolol interacts with alpha-adrenoceptors. All the available evidence, published and unpublished, has been reviewed and fits into a coherent pattern, here arranged into five sections. Chemistry: affinity for alpha-adrenoceptors. Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. In addition, bevantolol has electrophysiologic effects, including bradycardia by a direct action on the sinus node and a class 1 antiarrhythmic action. Investigations in humans have shown that although bevantolol has a short half-life, good control of hypertension can be achieved on once-a-day dosing. SAFETY: bevantolol has remarkably few side effects, does not cause cold extremities, and does not significantly affect glomerular filtration rate in patients with renal impairment. Evidence has been obtained in man for interaction with alpha-adrenoceptors in the brain; and in the peripheral circulation bevantolol does not, as do other beta blockers, increase peripheral vascular resistance, but reduces it. It is suggested that all the additional actions of bevantolol can be attributed to a partial agonist action on alpha-adrenoceptors.
2888789	105	124	beta-1 adrenoceptor	GENE-Y	2888789T10
2888789	571	590	alpha-adrenoceptors	GENE-N	2888789T11
2888789	757	776	alpha-adrenoceptors	GENE-N	2888789T12
2888789	899	915	beta-1 receptors	GENE-N	2888789T13
2888789	14	33	beta-1 adrenoceptor	GENE-Y	2888789T14
2888789	1119	1129	bevantolol	CHEMICAL	2888789T1
2888789	1228	1238	bevantolol	CHEMICAL	2888789T2
2888789	89	99	Bevantolol	CHEMICAL	1277
2888789	1524	1534	bevantolol	CHEMICAL	2888789T4
2888789	1680	1690	bevantolol	CHEMICAL	2888789T5
2888789	930	940	bevantolol	CHEMICAL	2888789T6
2888789	0	10	Bevantolol	CHEMICAL	1277
2888789	1456	1475	alpha-adrenoceptors	GENE-N	2888789T8
2888789	1740	1759	alpha-adrenoceptors	GENE-N	2888789T9
2888789	CPR:5	2888789T5	2888789T9
2888789	CPR:6	1277	2888789T10
2888789	CPR:6	1277	2888789T14

2889803|t|Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam.
2889803|a|Triazolobenzodiazepines are in clinical use as hypnotics and anxiolytics. We analyzed in vivo receptor binding and brain concentrations of alprazolam, triazolam, and estazolam. Drug concentrations measured in the cerebral cortex 1 h after administration were directly proportional to dose for all three compounds. In vivo receptor binding, as defined by the specific uptake of [3H]Ro15-1788, decreased with increasing doses of estazolam and triazolam, a finding indicating dose-related increases in receptor occupancy due to these compounds. Triazolam was substantially more potent, with an IC50 value of 16 ng/g, compared with 117 ng/g for estazolam. At higher doses of alprazolam (greater than 0.2 mg/kg), receptor binding by [3H]Ro15-1788, likewise decreased with increasing dose of the former drug. However, at lower doses of alprazolam (0.02-0.05 mg/kg), which resulted in cortex concentrations of 2-7 ng/g, receptor binding was increased above control values in cortex, hypothalamus, and hippocampus but not in several other brain regions. Binding returned to control values at doses of greater than or equal to 0.01 mg/kg. Similar results were obtained in time course studies. At 8 and 10 h after a dose of 1 mg/kg i.p., corresponding to cortex concentrations of 2.7-7 ng/g, receptor binding was increased compared with controls. Similarly, at 1, 2, and 3 h after a single dose of 0.05 mg/kg, corresponding to cortex concentrations of 3.7-5.8 ng/g, receptor binding was also increased. The apparent affinity of benzodiazepine receptors for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)
2889803	547	556	estazolam	CHEMICAL	2889803T10
2889803	561	570	triazolam	CHEMICAL	2889803T11
2889803	662	671	Triazolam	CHEMICAL	887
2889803	761	770	estazolam	CHEMICAL	2889803T13
2889803	791	801	alprazolam	CHEMICAL	396
2889803	848	861	[3H]Ro15-1788	CHEMICAL	2889803T15
2889803	950	960	alprazolam	CHEMICAL	396
2889803	0	14	Benzodiazepine	CHEMICAL	2889803T17
2889803	108	118	alprazolam	CHEMICAL	396
2889803	35	58	triazolobenzodiazepines	CHEMICAL	2889803T19
2889803	120	143	Triazolobenzodiazepines	CHEMICAL	2889803T1
2889803	1638	1662	benzodiazepine receptors	GENE-N	2889803T20
2889803	0	23	Benzodiazepine receptor	GENE-N	2889803T21
2889803	259	269	alprazolam	CHEMICAL	396
2889803	271	280	triazolam	CHEMICAL	2889803T3
2889803	1638	1652	benzodiazepine	CHEMICAL	2889803T4
2889803	1667	1677	clonazepam	CHEMICAL	2889803T5
2889803	1696	1706	alprazolam	CHEMICAL	396
2889803	286	295	estazolam	CHEMICAL	2889803T7
2889803	1815	1825	alprazolam	CHEMICAL	396
2889803	497	510	[3H]Ro15-1788	CHEMICAL	2889803T9
2889803	CPR:3	396	2889803T20

2899826|t|Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites.
2899826|a|In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, perphenazine and some of their metabolites for dopamine D2 receptors, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories. The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for histamine H1 receptors in rat brain, using 3H-quinuclidinyl benzilate and 3H-mepyramine as radioligands. Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for muscarinic cholinergic receptors than fluphenazine, perphenazine and their metabolites. Levomepromazine was the most potent and fluphenazine the least potent of the four drugs in histamine H1 receptor binding. 7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in histamine H1 receptor binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system. Their histamine H1 receptor binding affinities indicate that metabolites may contribute to the sedative effects of chlorpromazine and levomepromazine.
2899826	139	151	fluphenazine	CHEMICAL	2899826T10
2899826	582	597	levomepromazine	CHEMICAL	2899826T11
2899826	704	716	fluphenazine	CHEMICAL	2899826T12
2899826	153	168	levomepromazine	CHEMICAL	2899826T13
2899826	718	730	perphenazine	CHEMICAL	2899826T14
2899826	754	769	Levomepromazine	CHEMICAL	1352
2899826	794	806	fluphenazine	CHEMICAL	2899826T16
2899826	845	854	histamine	CHEMICAL	2899826T17
2899826	876	901	7-Hydroxy levomepromazine	CHEMICAL	2899826T18
2899826	170	182	perphenazine	CHEMICAL	2899826T19
2899826	1182	1191	histamine	CHEMICAL	2899826T1
2899826	903	928	3-hydroxy levomepromazine	CHEMICAL	2899826T20
2899826	933	955	7-hydroxy fluphenazine	CHEMICAL	2899826T21
2899826	1006	1015	histamine	CHEMICAL	2899826T22
2899826	1047	1056	7-hydroxy	CHEMICAL	2899826T23
2899826	1072	1086	chlorpromazine	CHEMICAL	2899826T24
2899826	1091	1103	perphenazine	CHEMICAL	2899826T25
2899826	27	36	histamine	CHEMICAL	2899826T26
2899826	60	73	phenothiazine	CHEMICAL	2899826T27
2899826	1182	1203	histamine H1 receptor	GENE-Y	2899826T28
2899826	217	238	dopamine D2 receptors	GENE-Y	2899826T29
2899826	1291	1305	chlorpromazine	CHEMICAL	2899826T2
2899826	240	274	alpha 1- and alpha 2 adrenoceptors	GENE-N	2899826T30
2899826	420	452	muscarinic cholinergic receptors	GENE-N	2899826T31
2899826	461	483	histamine H1 receptors	GENE-Y	2899826T32
2899826	666	698	muscarinic cholinergic receptors	GENE-N	2899826T33
2899826	845	866	histamine H1 receptor	GENE-Y	2899826T34
2899826	1006	1027	histamine H1 receptor	GENE-Y	2899826T35
2899826	27	48	histamine H1 receptor	GENE-Y	2899826T36
2899826	1310	1325	levomepromazine	CHEMICAL	2899826T3
2899826	217	225	dopamine	CHEMICAL	2899826T4
2899826	123	137	chlorpromazine	CHEMICAL	2899826T5
2899826	461	470	histamine	CHEMICAL	2899826T6
2899826	504	530	3H-quinuclidinyl benzilate	CHEMICAL	2899826T7
2899826	535	548	3H-mepyramine	CHEMICAL	2899826T8
2899826	566	580	Chlorpromazine	CHEMICAL	469

2922761|t|Retinoid-induced hemorrhaging and bone toxicity in rats fed diets deficient in vitamin K.
2922761|a|The recent increase in the clinical use of synthetic vitamin A compounds has led to concern of possible side effects. Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on prothrombin times of animals fed the supplemented diet. When menadione was omitted from the diet, however, 4HPR-dosed animals had elevated prothrombin times. This effect was observed as early as Day 7 and was accompanied by one confirmed hemorrhagic death. 13cisRA-dosed animals showed no change in prothrombin times. In the high-dose ROAc group, there was a twofold increase in prothrombin times but only after prolonged dosing. In animals fed the NIH-07 diets, 13cisRA and ROAc induced multiple bone fractures at all dose levels. In contrast, 4HPR administered at the highest dose induced only one fracture in one animal. Animals fed the purified diet lost weight faster and diet sooner than those maintained on the other diets. Bone fractures were not observed in these animals because of early deaths resulting from hemorrhaging. For all retinoid-dosed groups maintained on the purified diet, changes in prothrombin times occured as early as 1 week. The order of effect was 4HPR greater than ROAc greater than 13cisRA, with increases in prothrombin times correlating with increases in hemorrhagic deaths. Hence, the degree of retinoid-induced hemorrhage, but not the incidence of bone fractures, was inversely related to vitamin K levels in the diet. 13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma osteocalcin, an effect that correlated with retinoid-induced bone effects. In contrast, serum alkaline phosphatase was elevated in animals dosed with 13cisRA or 4HPR but not in those dose with ROAc. For this enzyme, the electrophoretic pattern on agarose gel showed a decrease, compared to controls, in the major isozyme in serum of ROAc-dosed animals. Hence, plasma osteocalcin is a better predictor of retinoid-induced bone effects than serum alkaline phosphatase.
2922761	278	287	vitamin K	CHEMICAL	2922761T10
2922761	1991	1998	13cisRA	CHEMICAL	2922761T11
2922761	2003	2007	ROAc	CHEMICAL	2922761T12
2922761	2017	2021	4HPR	CHEMICAL	2922761T13
2922761	2111	2119	retinoid	CHEMICAL	2922761T14
2922761	2217	2224	13cisRA	CHEMICAL	2922761T15
2922761	2228	2232	4HPR	CHEMICAL	2922761T16
2922761	2260	2264	ROAc	CHEMICAL	2922761T17
2922761	2400	2404	ROAc	CHEMICAL	2922761T18
2922761	2471	2479	retinoid	CHEMICAL	2922761T19
2922761	1199	1206	13cisRA	CHEMICAL	2922761T1
2922761	332	352	13-cis-retinoic acid	CHEMICAL	2922761T20
2922761	354	361	13cisRA	CHEMICAL	2922761T21
2922761	364	379	retinyl acetate	CHEMICAL	2922761T22
2922761	381	385	ROAc	CHEMICAL	2922761T23
2922761	392	421	N-(4-hydroxyphenyl)retinamide	CHEMICAL	2922761T24
2922761	423	427	4HPR	CHEMICAL	2922761T25
2922761	508	517	vitamin K	CHEMICAL	2922761T26
2922761	576	585	menadione	CHEMICAL	2922761T27
2922761	595	605	vitamin K3	CHEMICAL	2922761T28
2922761	143	152	vitamin A	CHEMICAL	2922761T29
2922761	1211	1215	ROAc	CHEMICAL	2922761T2
2922761	645	654	menadione	CHEMICAL	2922761T30
2922761	694	703	vitamin K	CHEMICAL	2922761T31
2922761	709	718	retinoids	CHEMICAL	2922761T32
2922761	797	806	menadione	CHEMICAL	2922761T33
2922761	843	847	4HPR	CHEMICAL	2922761T34
2922761	993	1000	13cisRA	CHEMICAL	2922761T35
2922761	1071	1075	ROAc	CHEMICAL	2922761T36
2922761	0	8	Retinoid	CHEMICAL	2922761T37
2922761	79	88	vitamin K	CHEMICAL	2922761T38
2922761	1115	1126	prothrombin	GENE-Y	2922761T39
2922761	1281	1285	4HPR	CHEMICAL	2922761T3
2922761	1644	1655	prothrombin	GENE-Y	2922761T40
2922761	1777	1788	prothrombin	GENE-Y	2922761T41
2922761	2067	2078	osteocalcin	GENE-Y	2922761T42
2922761	2161	2181	alkaline phosphatase	GENE-N	2922761T43
2922761	2434	2445	osteocalcin	GENE-Y	2922761T44
2922761	2512	2532	alkaline phosphatase	GENE-N	2922761T45
2922761	736	747	prothrombin	GENE-Y	2922761T46
2922761	875	886	prothrombin	GENE-Y	2922761T47
2922761	1035	1046	prothrombin	GENE-Y	2922761T48
2922761	1578	1586	retinoid	CHEMICAL	2922761T4
2922761	1714	1718	4HPR	CHEMICAL	2922761T5
2922761	1732	1736	ROAc	CHEMICAL	2922761T6
2922761	1750	1757	13cisRA	CHEMICAL	2922761T7
2922761	1866	1874	retinoid	CHEMICAL	2922761T8
2922761	1961	1970	vitamin K	CHEMICAL	2922761T9
2922761	CPR:3	2922761T15	2922761T43
2922761	CPR:3	2922761T16	2922761T43
2922761	CPR:3	2922761T34	2922761T47
2922761	CPR:3	2922761T36	2922761T39
2922761	CPR:3	2922761T5	2922761T41
2922761	CPR:3	2922761T6	2922761T41
2922761	CPR:3	2922761T7	2922761T41
2922761	CPR:4	2922761T11	2922761T42
2922761	CPR:4	2922761T12	2922761T42
2922761	CPR:4	2922761T13	2922761T42

2982865|t|Multiple affinity states of opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells. Opiate agonist association rate is a function of receptor occupancy.
2982865|a|The existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells has been demonstrated by competition binding studies with tritiated diprenorphine and [D-Ala2, D-Leu5]enkephalin (DADLE). In the presence of 10 mM Mg2+, all receptors exist in a high affinity state with Kd = 1.88 +/- 0.16 nM. Addition of 10 microM guanyl-5'-yl imidodiphosphate (Gpp(NH)p) decreased the affinity of DADLE to Kd = 8.08 +/- 0.93 nM. However, in the presence of 100 mM Na+, which is required for opiate inhibition of adenylate cyclase activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM. Thus, in the presence of sodium, a high affinity complex between receptor (R), GTP binding component (Ni), and ligand (L) was formed which was different from that formed in the absence of sodium. These multiple affinity states of receptor in the hybrid cells are agonist-specific, and the percentage of total opiate receptor in high affinity state is relatively constant in various concentrations of Na+. Multiple affinity states of opiate receptor can be demonstrated further by Scatchard analysis of saturation binding studies with [3H]DADLE. In the presence of Mg2+, or Gpp(NH)p, analysis of [3H]DADLE binding demonstrates that opiate receptor can exist in a single affinity state, with apparent Kd values of [3H]DADLE in 10 mM Mg2+ = 1.75 +/- 0.28 nM and in 10 microM Gpp(NH)p = 0.85 +/- 0.12 nM. There is a reduction of Bmax value from 0.19 +/- 0.02 nM in the presence of Mg2+ to 0.14 +/- 0.03 nM in the presence of Gpp(NH)p. In the presence of 100 mM Na+, Scatchard analysis of saturation binding of [3H]DADLE reveals nonlinear plots; two-site analysis of the curves yields Kd = 0.43 +/- 0.09 and 7.9 +/- 3.2 nM. These Kd values are analogous to that obtained with competition binding studies. Again, this conversion of single site binding Scatchard plots to multiple sites binding plots in the presence of Na+ is restricted to 3H-agonist binding only.(ABSTRACT TRUNCATED AT 400 WORDS)
2982865	1891	1895	Mg2+	CHEMICAL	2982865T10
2982865	1935	1943	Gpp(NH)p	CHEMICAL	2982865T11
2982865	1971	1974	Na+	CHEMICAL	2982865T12
2982865	2020	2029	[3H]DADLE	CHEMICAL	2982865T13
2982865	362	388	[D-Ala2, D-Leu5]enkephalin	CHEMICAL	2982865T14
2982865	2327	2330	Na+	CHEMICAL	2982865T15
2982865	2348	2350	3H	CHEMICAL	2982865T16
2982865	390	395	DADLE	CHEMICAL	2982865T17
2982865	423	427	Mg2+	CHEMICAL	2982865T18
2982865	524	553	guanyl-5'-yl imidodiphosphate	CHEMICAL	2982865T19
2982865	1202	1208	sodium	CHEMICAL	2982865T1
2982865	555	563	Gpp(NH)p	CHEMICAL	2982865T20
2982865	591	596	DADLE	CHEMICAL	2982865T21
2982865	658	661	Na+	CHEMICAL	2982865T22
2982865	706	715	adenylate	CHEMICAL	2982865T23
2982865	1039	1045	sodium	CHEMICAL	2982865T24
2982865	1093	1096	GTP	CHEMICAL	2982865T25
2982865	1323	1338	opiate receptor	GENE-N	2982865T26
2982865	1447	1462	opiate receptor	GENE-N	2982865T27
2982865	378	388	enkephalin	GENE-N	2982865T28
2982865	706	723	adenylate cyclase	GENE-N	2982865T29
2982865	1414	1417	Na+	CHEMICAL	2982865T2
2982865	28	43	opiate receptor	GENE-N	2982865T30
2982865	1548	1557	[3H]DADLE	CHEMICAL	2982865T3
2982865	1578	1582	Mg2+	CHEMICAL	2982865T4
2982865	1587	1595	Gpp(NH)p	CHEMICAL	2982865T5
2982865	1609	1618	[3H]DADLE	CHEMICAL	2982865T6
2982865	1726	1735	[3H]DADLE	CHEMICAL	2982865T7
2982865	1786	1794	Gpp(NH)p	CHEMICAL	2982865T8
2982865	334	357	tritiated diprenorphine	CHEMICAL	2982865T9
2982865	CPR:4	2982865T22	2982865T29

3004501|t|Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor.
3004501|a|Diethylcarbamazine inhibited the formation of sulfidopeptide leukotrienes in rat basophil leukemia (RBL) cells (50% inhibitory concentration, EC50, 3 mM). Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by LTC synthetase, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione. By contrast, the conversion of LTA4 to LTC4 using enzymes from rat liver was at least ten times less sensitive to this inhibitor. The EC50 for inhibition of the leukotriene C synthetase of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4. Kinetic analysis revealed that the inhibition of the leukotriene C synthetase reaction by diethylcarbamazine was competitive with respect to LTA4. In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells. On the other hand, low concentrations of piriprost, which had no demonstrable inhibitory activity on leukotriene formation by themselves, markedly synergized the inhibitory activity of diethylcarbamazine. These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of LTA4 in the leukotriene C synthetase reaction.
3004501	1814	1818	LTA4	CHEMICAL	3004501T10
3004501	1826	1839	leukotriene C	CHEMICAL	3004501T11
3004501	389	403	leukotriene C4	CHEMICAL	3004501T12
3004501	405	409	LTC4	CHEMICAL	3004501T13
3004501	527	531	LTA4	CHEMICAL	3004501T14
3004501	535	546	glutathione	CHEMICAL	3004501T15
3004501	579	583	LTA4	CHEMICAL	3004501T16
3004501	587	591	LTC4	CHEMICAL	3004501T17
3004501	225	252	sulfidopeptide leukotrienes	CHEMICAL	3004501T18
3004501	709	722	leukotriene C	CHEMICAL	3004501T19
3004501	179	197	Diethylcarbamazine	CHEMICAL	701
3004501	780	784	LTA4	CHEMICAL	3004501T20
3004501	852	856	LTA4	CHEMICAL	3004501T21
3004501	885	889	LTA4	CHEMICAL	3004501T22
3004501	944	957	leukotriene C	CHEMICAL	3004501T23
3004501	981	999	diethylcarbamazine	CHEMICAL	3004501T24
3004501	1032	1036	LTA4	CHEMICAL	3004501T25
3004501	1053	1071	diethylcarbamazine	CHEMICAL	3004501T26
3004501	1073	1082	piriprost	CHEMICAL	3004501T27
3004501	1084	1092	U-60,257	CHEMICAL	3004501T28
3004501	1094	1150	6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1	CHEMICAL	3004501T29
3004501	1185	1211	sulfidopeptide leuktrienes	CHEMICAL	3004501T2
3004501	117	135	diethylcarbamazine	CHEMICAL	3004501T30
3004501	140	149	piriprost	CHEMICAL	3004501T31
3004501	18	29	leukotriene	CHEMICAL	3004501T32
3004501	75	93	diethylcarbamazine	CHEMICAL	3004501T33
3004501	1232	1246	5-lipoxygenase	GENE-Y	3004501T34
3004501	1289	1311	leukotriene synthetase	GENE-N	3004501T35
3004501	1826	1850	leukotriene C synthetase	GENE-Y	3004501T36
3004501	414	428	LTC synthetase	GENE-Y	3004501T37
3004501	709	733	leukotriene C synthetase	GENE-Y	3004501T38
3004501	944	968	leukotriene C synthetase	GENE-Y	3004501T39
3004501	1289	1300	leukotriene	CHEMICAL	3004501T3
3004501	153	167	5-lipoxygenase	GENE-Y	3004501T40
3004501	18	40	leukotriene synthetase	GENE-N	3004501T41
3004501	1369	1378	piriprost	CHEMICAL	3004501T4
3004501	1429	1440	leukotriene	CHEMICAL	3004501T5
3004501	1513	1531	diethylcarbamazine	CHEMICAL	3004501T6
3004501	1596	1605	piriprost	CHEMICAL	3004501T7
3004501	1610	1628	diethylcarbamazine	CHEMICAL	3004501T8
3004501	1637	1648	leukotriene	CHEMICAL	3004501T9
3004501	CPR:4	3004501T24	3004501T39
3004501	CPR:4	3004501T26	3004501T34
3004501	CPR:4	3004501T26	3004501T35
3004501	CPR:4	3004501T27	3004501T34
3004501	CPR:4	3004501T28	3004501T34
3004501	CPR:4	3004501T29	3004501T34
3004501	CPR:4	3004501T30	3004501T40
3004501	CPR:4	3004501T31	3004501T40
3004501	CPR:4	3004501T33	3004501T41
3004501	CPR:9	3004501T10	3004501T36
3004501	CPR:9	3004501T12	3004501T37
3004501	CPR:9	3004501T13	3004501T37
3004501	CPR:9	3004501T14	3004501T37
3004501	CPR:9	3004501T20	3004501T38
3004501	CPR:9	3004501T2	3004501T34

3089818|t|Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis assessed simultaneously by non-invasive differential sugar permeation.
3089818|a|Changes in intestinal permeability and lactose hydrolysis have been investigated in three adults and fifteen infants with acute rotaviral gastroenteritis by differential sugar absorption. The method involves chromatographic measurement of urinary lactose, lactulose and L-rhamnose excretion following combined ingestion in an iso-osmolar test solution. All patients had abnormal intestinal permeability indicated by raised urine lactulose/L-rhamnose excretion, ratio of percentages recovered in 5 h, of 0.462 (0.100-1.227) mean and range, compared with 0.027 (0.008-0.052) for healthy controls (P less than 0.001). Ten patients also had urinary lactose/lactulose excretion ratios raised above the normal range (0.014-0.41, mean 0.258) during their acute illness, indicating impaired intestinal lactose hydrolysis. Both indices had become normal 4 weeks after the acute illness, serial investigation of five patients showing that improvement was complete much earlier. Except for the short duration these changes are similar to those associated with villous atrophy in coeliac disease. The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal lactase activity by in vitro assay (R2 = 0.95) in a further group of subjects. Differential lactose/lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal lactase deficiency.
3089818	192	199	lactose	CHEMICAL	3089818T10
3089818	582	591	lactulose	CHEMICAL	3089818T11
3089818	592	602	L-rhamnose	CHEMICAL	3089818T12
3089818	798	805	lactose	CHEMICAL	3089818T13
3089818	806	815	lactulose	CHEMICAL	3089818T14
3089818	947	954	lactose	CHEMICAL	3089818T15
3089818	28	35	lactose	CHEMICAL	3089818T16
3089818	1415	1422	lactase	GENE-Y	3089818T17
3089818	1753	1760	lactase	GENE-Y	3089818T18
3089818	1297	1304	lactose	CHEMICAL	3089818T1
3089818	1363	1370	lactose	CHEMICAL	3089818T2
3089818	1371	1380	lactulose	CHEMICAL	3089818T3
3089818	1507	1514	lactose	CHEMICAL	3089818T4
3089818	1515	1524	lactulose	CHEMICAL	3089818T5
3089818	1525	1535	L-rhamnose	CHEMICAL	3089818T6
3089818	400	407	lactose	CHEMICAL	3089818T7
3089818	409	418	lactulose	CHEMICAL	3089818T8
3089818	423	433	L-rhamnose	CHEMICAL	3089818T9
3089818	CPR:9	3089818T1	3089818T17
3089818	CPR:9	3089818T2	3089818T17
3089818	CPR:9	3089818T3	3089818T17
3089818	CPR:9	3089818T4	3089818T18
3089818	CPR:9	3089818T5	3089818T18
3089818	CPR:9	3089818T6	3089818T18

3134891|t|Characteristics of the binding of phenoxybenzamine to calmodulin.
3134891|a|To determine the factors that influence the interaction between phenoxybenzamine and calmodulin, the binding of phenoxybenzamine to calmodulin was determined by equilibrium dialysis under a variety of experimental conditions. This interaction was found to be similar in some respects to the interaction between phenothiazines and calmodulin. It was saturable, with between 1 and 2 mol of phenoxybenzamine bound to 1 mol of calmodulin. It was also dependent upon temperature, the presence of a divalent cation such as calcium, and on pH, showing maximum binding at pH 6.5 with little binding at pH values below 4.2 or above 8.0. The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin. However, in contrast to the reversible binding of most phenothiazines to calmodulin, phenoxybenzamine bound to calmodulin irreversibly. The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions. In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.
3134891	454	470	phenoxybenzamine	CHEMICAL	3134891T10
3134891	583	590	calcium	CHEMICAL	3134891T11
3134891	712	728	phenoxybenzamine	CHEMICAL	3134891T12
3134891	130	146	phenoxybenzamine	CHEMICAL	3134891T13
3134891	856	867	penfluridol	CHEMICAL	3134891T14
3134891	869	877	pimozide	CHEMICAL	3134891T15
3134891	882	894	spiroperidol	CHEMICAL	3134891T16
3134891	921	937	phenoxybenzamine	CHEMICAL	3134891T17
3134891	1008	1022	phenothiazines	CHEMICAL	3134891T18
3134891	1038	1054	phenoxybenzamine	CHEMICAL	3134891T19
3134891	1104	1120	phenoxybenzamine	CHEMICAL	3134891T1
3134891	34	50	phenoxybenzamine	CHEMICAL	3134891T20
3134891	1124	1134	calmodulin	GENE-N	3134891T21
3134891	1170	1186	alpha-adrenergic	GENE-N	3134891T22
3134891	1254	1264	calmodulin	GENE-N	3134891T23
3134891	198	208	calmodulin	GENE-N	3134891T24
3134891	1402	1415	S-100 protein	GENE-N	3134891T25
3134891	1417	1437	bovine serum albumin	GENE-Y	3134891T26
3134891	1441	1453	cytochrome c	GENE-Y	3134891T27
3134891	1509	1519	calmodulin	GENE-N	3134891T28
3134891	1557	1567	calmodulin	GENE-N	3134891T29
3134891	178	194	phenoxybenzamine	CHEMICAL	3134891T2
3134891	1641	1651	calmodulin	GENE-N	3134891T30
3134891	396	406	calmodulin	GENE-N	3134891T31
3134891	489	499	calmodulin	GENE-N	3134891T32
3134891	738	748	calmodulin	GENE-N	3134891T33
3134891	151	161	calmodulin	GENE-N	3134891T34
3134891	941	951	calmodulin	GENE-N	3134891T35
3134891	1026	1036	calmodulin	GENE-N	3134891T36
3134891	1064	1074	calmodulin	GENE-N	3134891T37
3134891	54	64	calmodulin	GENE-N	3134891T38
3134891	1202	1210	prazosin	CHEMICAL	3134891T3
3134891	1212	1221	yohimbine	CHEMICAL	3134891T4
3134891	1226	1235	clonidine	CHEMICAL	565
3134891	1332	1348	phenoxybenzamine	CHEMICAL	3134891T6
3134891	1369	1376	calcium	CHEMICAL	3134891T7
3134891	1488	1504	phenoxybenzamine	CHEMICAL	3134891T8
3134891	377	391	phenothiazines	CHEMICAL	3134891T9
3134891	CPR:4	3134891T8	3134891T29

3320565|t|Pharmacological and clinical studies of the antiandrogen Anandron.
3320565|a|This paper summarizes the animal and human studies with Anandron available at the time of the meeting. The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the prostatic androgen receptor, antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens. Thus, as shown in 4 different double blind studies performed in stage D2 prostrate cancer patients, the combination of Anandron with surgical or chemical castration enhanced the beneficial effects of castration alone and thus seems a step forward in the hormonal treatment of prostatic carcinoma.
3320565	249	257	Anandron	CHEMICAL	3320565T1
3320565	277	285	androgen	CHEMICAL	3320565T2
3320565	326	338	testosterone	CHEMICAL	614
3320565	424	433	androgens	CHEMICAL	3320565T4
3320565	554	562	Anandron	CHEMICAL	3320565T5
3320565	123	131	Anandron	CHEMICAL	3320565T6
3320565	57	65	Anandron	CHEMICAL	3320565T7
3320565	267	294	prostatic androgen receptor	GENE-N	3320565T8
3320565	398	402	LHRH	GENE-N	3320565T9

3588607|t|Adenosine receptors: development of selective agonists and antagonists.
3588607|a|Adenosine modulates a variety of physiological functions through interaction with A1 and A2 adenosine receptors, where agonists mediate inhibition and stimulation, respectively, of adenylate cyclase. In the cardiovascular system, A2 receptors mediate vasodilation and reduction in blood pressure, while A1 receptors mediate cardiac depression. The involvement of adenylate cyclase in these responses remains unresolved. Adenosine analogs in particular the N6-substituted compounds are more potent at A1 receptors than at A2 receptors. The subregion of the adenosine receptor that interacts with the N6-substituent is different for A1 and A2 receptors, particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity. A series of para-substituted N6-phenyladenosines have been synthesized based on a "functionalized congener" approach in which a chemically reactive group, such as an amine or carboxylic acid, is introduced at the terminus of a chain. From the "functionalized congener" are synthesized a variety of conjugates each containing a common pharmacophore. Certain of the adenosine conjugates are highly selective for A1 receptors. Xanthines are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of adenosine receptors. Caffeine and theophylline are virtually non-selective for A2 and A2 receptors. Replacement of the methyl groups of theophylline with n-propyl or larger alkyl groups yields xanthines with selectivity for A1 receptors, particularly when combined with an 8-phenyl moiety. Most 1,3-dialkyl-8-phenyl xanthines are very insoluble, but incorporation of polar aryl substituents, such as sulfo or carboxy to increase solubility, results in marked reduction in potency and selectivity. A new series of more hydrophilic 1,3-dipropyl-8-phenylxanthines has been synthesized using the "functionalized congener" approach. Certain conjugates of 8-[4-(carboxymethyloxy)phenyl 1]1,3-dipropylxanthine display A1 selectivity in biochemical and cardiovascular models. Certain analogs of caffeine in which the methyl group at the 1- or 7-position is replaced with a propargyl or propyl group display selectivity for A2 receptors. The profile of a series of adenosine analogs or of xanthine antagonists can be used to define the nature of adenosine receptors.
3588607	1518	1526	n-propyl	CHEMICAL	3588607T10
3588607	1537	1542	alkyl	CHEMICAL	3588607T11
3588607	1557	1566	xanthines	CHEMICAL	3588607T12
3588607	1637	1645	8-phenyl	CHEMICAL	3588607T13
3588607	1659	1689	1,3-dialkyl-8-phenyl xanthines	CHEMICAL	3588607T14
3588607	1737	1741	aryl	CHEMICAL	3588607T15
3588607	1764	1769	sulfo	CHEMICAL	3588607T16
3588607	1773	1780	carboxy	CHEMICAL	3588607T17
3588607	253	262	adenylate	CHEMICAL	3588607T18
3588607	1894	1924	1,3-dipropyl-8-phenylxanthines	CHEMICAL	3588607T19
3588607	72	81	Adenosine	CHEMICAL	630
3588607	2014	2066	8-[4-(carboxymethyloxy)phenyl 1]1,3-dipropylxanthine	CHEMICAL	3588607T20
3588607	2151	2159	caffeine	CHEMICAL	3588607T21
3588607	2173	2179	methyl	CHEMICAL	3588607T22
3588607	2242	2248	propyl	CHEMICAL	3588607T23
3588607	2320	2329	adenosine	CHEMICAL	3588607T24
3588607	2344	2352	xanthine	CHEMICAL	3588607T25
3588607	2401	2410	adenosine	CHEMICAL	3588607T26
3588607	435	444	adenylate	CHEMICAL	3588607T27
3588607	492	501	Adenosine	CHEMICAL	630
3588607	528	530	N6	CHEMICAL	3588607T29
3588607	1176	1185	adenosine	CHEMICAL	3588607T2
3588607	628	637	adenosine	CHEMICAL	3588607T30
3588607	671	673	N6	CHEMICAL	3588607T31
3588607	753	759	phenyl	CHEMICAL	3588607T32
3588607	841	860	N6-phenyladenosines	CHEMICAL	3588607T33
3588607	978	983	amine	CHEMICAL	3588607T34
3588607	987	1002	carboxylic acid	CHEMICAL	3588607T35
3588607	164	173	adenosine	CHEMICAL	3588607T36
3588607	0	9	Adenosine	CHEMICAL	630
3588607	1222	1234	A1 receptors	GENE-Y	3588607T38
3588607	1276	1295	adenosine receptors	GENE-N	3588607T39
3588607	1236	1245	Xanthines	CHEMICAL	3588607T3
3588607	1364	1383	adenosine receptors	GENE-N	3588607T40
3588607	1443	1462	A2 and A2 receptors	GENE-N	3588607T41
3588607	1588	1600	A1 receptors	GENE-Y	3588607T42
3588607	253	270	adenylate cyclase	GENE-N	3588607T43
3588607	2279	2291	A2 receptors	GENE-N	3588607T44
3588607	302	314	A2 receptors	GENE-N	3588607T45
3588607	2401	2420	adenosine receptors	GENE-N	3588607T46
3588607	375	387	A1 receptors	GENE-Y	3588607T47
3588607	435	452	adenylate cyclase	GENE-N	3588607T48
3588607	572	584	A1 receptors	GENE-Y	3588607T49
3588607	1276	1285	adenosine	CHEMICAL	3588607T4
3588607	593	605	A2 receptors	GENE-N	3588607T50
3588607	628	646	adenosine receptor	GENE-N	3588607T51
3588607	703	722	A1 and A2 receptors	GENE-N	3588607T52
3588607	154	183	A1 and A2 adenosine receptors	GENE-N	3588607T53
3588607	0	19	Adenosine receptors	GENE-N	3588607T54
3588607	1364	1373	adenosine	CHEMICAL	3588607T5
3588607	1385	1393	Caffeine	CHEMICAL	194
3588607	1398	1410	theophylline	CHEMICAL	3588607T7
3588607	1483	1489	methyl	CHEMICAL	3588607T8
3588607	1500	1512	theophylline	CHEMICAL	3588607T9
3588607	CPR:4	3588607T3	3588607T40
3588607	CPR:6	3588607T3	3588607T39

3735252|t|Inhibition of testicular LDH-X from laboratory animals and man by gossypol and its isomers.
3735252|a|The inhibitory effect of (+)-, (-)-, (+/-)-gossypol and (+/-)-gossypol acetic acid upon testicular cytosolic LDH-X was measured in vitro. Gossypol acetic acid (0-100 mumol/l) inhibited LDH-X prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster. There was no relationship between inhibition and in-vivo antifertility activity. LDH activity measured in vitro in serum of men and hamsters was unaffected by gossypol. Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate. Co-incubation with human serum albumin or poly-L-lysine but not lysine protected human and hamster LDH-X from gossypol.
3735252	944	952	gossypol	CHEMICAL	3735252T10
3735252	66	74	gossypol	CHEMICAL	3735252T11
3735252	201	206	LDH-X	GENE-Y	3735252T12
3735252	277	282	LDH-X	GENE-N	3735252T13
3735252	480	483	LDH	GENE-N	3735252T14
3735252	628	651	human and hamster LDH-X	GENE-N	3735252T15
3735252	713	724	human LDH-X	GENE-Y	3735252T16
3735252	770	783	hamster LDH-X	GENE-Y	3735252T17
3735252	853	872	human serum albumin	GENE-Y	3735252T18
3735252	915	938	human and hamster LDH-X	GENE-N	3735252T19
3735252	230	250	Gossypol acetic acid	CHEMICAL	3735252T1
3735252	25	30	LDH-X	GENE-N	3735252T20
3735252	117	143	(+)-, (-)-, (+/-)-gossypol	CHEMICAL	3735252T2
3735252	558	566	gossypol	CHEMICAL	3735252T3
3735252	568	576	Gossypol	CHEMICAL	9858
3735252	148	174	(+/-)-gossypol acetic acid	CHEMICAL	3735252T5
3735252	681	685	NADH	CHEMICAL	151
3735252	814	832	alpha-ketobutyrate	CHEMICAL	3735252T7
3735252	876	889	poly-L-lysine	CHEMICAL	3735252T8
3735252	898	904	lysine	CHEMICAL	3735252T9
3735252	CPR:4	3735252T11	3735252T20
3735252	CPR:4	3735252T1	3735252T13
3735252	CPR:4	3735252T2	3735252T12
3735252	CPR:4	9858	3735252T15
3735252	CPR:4	3735252T5	3735252T12
3735252	CPR:4	151	3735252T16
3735252	CPR:9	3735252T7	3735252T17

3917545|t|Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone. Requirement for peroxidative metabolism.
3917545|a|Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Most reducing cofactors for the peroxidase protect PHS and prostacyclin synthase from inactivation by hydroperoxides. PB, however, does not protect these enzymes, but rather augments their hydroperoxide-dependent inactivation. Using ram seminal vesicle microsomes as a source of PHS and prostacyclin synthase, we have examined the interaction of PB and exogenous hydroperoxides. Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of PHS is markedly increased in the presence of 100 microM H2O2. This inactivation is a linear function of PB concentration between 10 and 250 microM, with a half-maximal effect in this range at about 100 microM PB. Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously, supporting a direct effect of the treatment on prostacyclin synthase. As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase. Nafazatrom, a competitive inhibitor of PB co-oxygenation, blocks the effects of the PB and H2O2 treatment, supporting our proposal.
3917545	1411	1419	peroxide	CHEMICAL	3917545T10
3917545	1513	1515	PB	CHEMICAL	3917545T11
3917545	1603	1615	prostacyclin	CHEMICAL	3917545T12
3917545	1626	1636	Nafazatrom	CHEMICAL	3917545T13
3917545	1665	1667	PB	CHEMICAL	3917545T14
3917545	1710	1712	PB	CHEMICAL	3917545T15
3917545	1717	1721	H2O2	CHEMICAL	3917545T16
3917545	143	145	PB	CHEMICAL	3917545T17
3917545	343	355	prostacyclin	CHEMICAL	3917545T18
3917545	386	400	hydroperoxides	CHEMICAL	3917545T19
3917545	127	141	Phenylbutazone	CHEMICAL	802
3917545	402	404	PB	CHEMICAL	3917545T20
3917545	473	486	hydroperoxide	CHEMICAL	3917545T21
3917545	571	583	prostacyclin	CHEMICAL	3917545T22
3917545	630	632	PB	CHEMICAL	3917545T23
3917545	647	661	hydroperoxides	CHEMICAL	3917545T24
3917545	709	737	14C-labeled arachidonic acid	CHEMICAL	3917545T25
3917545	767	769	PB	CHEMICAL	3917545T26
3917545	852	856	H2O2	CHEMICAL	3917545T27
3917545	900	902	PB	CHEMICAL	3917545T28
3917545	1009	1021	Prostacyclin	CHEMICAL	1228
3917545	1153	1155	PB	CHEMICAL	3917545T2
3917545	1086	1088	PB	CHEMICAL	3917545T30
3917545	1093	1097	H2O2	CHEMICAL	3917545T31
3917545	16	31	prostaglandin H	CHEMICAL	3917545T32
3917545	45	57	prostacyclin	CHEMICAL	3917545T33
3917545	70	84	phenylbutazone	CHEMICAL	3917545T34
3917545	1372	1393	prostacyclin synthase	GENE-Y	3917545T35
3917545	252	276	prostaglandin H synthase	GENE-N	3917545T36
3917545	1458	1461	PHS	GENE-N	3917545T37
3917545	1595	1598	PHS	GENE-N	3917545T38
3917545	1603	1624	prostacyclin synthase	GENE-Y	3917545T39
3917545	1192	1194	PB	CHEMICAL	3917545T3
3917545	278	281	PHS	GENE-N	3917545T40
3917545	335	338	PHS	GENE-N	3917545T41
3917545	343	364	prostacyclin synthase	GENE-Y	3917545T42
3917545	563	566	PHS	GENE-N	3917545T43
3917545	571	592	prostacyclin synthase	GENE-Y	3917545T44
3917545	796	799	PHS	GENE-N	3917545T45
3917545	1009	1030	Prostacyclin synthase	GENE-Y	3917545T46
3917545	16	40	prostaglandin H synthase	GENE-N	3917545T47
3917545	45	66	prostacyclin synthase	GENE-Y	3917545T48
3917545	1200	1204	H2O2	CHEMICAL	3917545T4
3917545	1252	1256	PGH2	CHEMICAL	3917545T5
3917545	1283	1299	arachidonic acid	CHEMICAL	3917545T6
3917545	1372	1384	prostacyclin	CHEMICAL	3917545T7
3917545	252	267	prostaglandin H	CHEMICAL	3917545T8
3917545	1398	1400	PB	CHEMICAL	3917545T9
3917545	CPR:4	3917545T19	3917545T41
3917545	CPR:4	3917545T19	3917545T42
3917545	CPR:4	3917545T27	3917545T45
3917545	CPR:4	3917545T34	3917545T47
3917545	CPR:4	3917545T34	3917545T48
3917545	CPR:9	3917545T25	3917545T45

3994963|t|Drug-protein interactions: isolation and characterization of covalent adducts of phenoxybenzamine and calmodulin.
3994963|a|Phenoxybenzamine, an alpha-adrenergic antagonist containing a (chloroethyl)amine group, labels calmodulin in the presence of calcium. The covalent interaction is inhibited by chlorpromazine in a concentration-dependent manner. Adducts of calmodulin and phenoxybenzamine were separated by high-performance liquid chromatography into four major fractions: two containing 0.6 and 1.2 mol of drug per mol of protein and two different fractions each containing 2.0 mol/mol. Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct. Isolation and characterization of labeled peptides from phenoxybenzamine-modified calmodulins indicated that peptides encompassing residues 38-75, 107-126, and 127-148 contained phenoxybenzamine label. These studies directly demonstrate the relatedness between the binding activities of two structurally dissimilar calmodulin antagonists, demonstrate that covalent adducts of calmodulin and drugs with equal stoichiometries of labeling can have quantitative differences in activity and sites of modification, and provide direct evidence of distinct drug binding regions in calmodulin located in the amphipathic alpha-helical regions of the second and fourth domains.
3994963	919	935	phenoxybenzamine	CHEMICAL	3994963T10
3994963	1041	1057	phenoxybenzamine	CHEMICAL	3994963T11
3994963	81	97	phenoxybenzamine	CHEMICAL	3994963T12
3994963	1178	1188	calmodulin	GENE-Y	3994963T13
3994963	1239	1249	calmodulin	GENE-Y	3994963T14
3994963	1436	1446	calmodulin	GENE-Y	3994963T15
3994963	352	362	calmodulin	GENE-Y	3994963T16
3994963	629	664	cyclic nucleotide phosphodiesterase	GENE-N	3994963T17
3994963	669	694	myosin light chain kinase	GENE-Y	3994963T18
3994963	762	772	calmodulin	GENE-Y	3994963T19
3994963	114	130	Phenoxybenzamine	CHEMICAL	915
3994963	945	956	calmodulins	GENE-Y	3994963T20
3994963	209	219	calmodulin	GENE-Y	3994963T21
3994963	102	112	calmodulin	GENE-Y	3994963T22
3994963	239	246	calcium	CHEMICAL	3994963T2
3994963	289	303	chlorpromazine	CHEMICAL	3994963T3
3994963	367	383	phenoxybenzamine	CHEMICAL	3994963T4
3994963	629	646	cyclic nucleotide	CHEMICAL	3994963T5
3994963	704	718	chlorpromazine	CHEMICAL	3994963T6
3994963	176	194	(chloroethyl)amine	CHEMICAL	3994963T7
3994963	745	761	phenoxybenzamine	CHEMICAL	3994963T8
3994963	814	830	phenoxybenzamine	CHEMICAL	3994963T9

6150080|t|Amine oxidase activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline-resistant) activity at the fat cell membrane.
6150080|a|Amine oxidase activity, previously described in homogenates of brown adipose tissue of the rat, has now been investigated in preparations of isolated fat cells. It was found that the specific activities of both monoamine oxidase A (MAO) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue. Brown adipocytes therefore represent a major source of both these enzymes. In plasma membranes prepared from these isolated brown fat cells by borate extraction there was a similar enrichment of activity of SSAO and of the plasma membrane marker enzyme, phosphodiesterase I. However in preparations of cell membranes made by binding the cells to polycation-coated beads, enrichment of phosphodiesterase I activity was much greater than that of SSAO. It is suggested that the disposition of the enzyme within the cell membrane may account for the discrepancy in these results, i.e. the sidedness of the membrane may be important. Histochemical visualization of enzyme activity in whole tissue at the ultrastructural level was undertaken. Positive staining of mitochondria was achieved in the presence of the MAO substrate, tryptamine. Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine. Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide. It is not definitely proven that this staining represents sites of enzyme activity but the results are consistent with evidence from other studies indicating that SSAO in brown adipose tissue of the rat may be found predominantly at the fat cell surface.(ABSTRACT TRUNCATED AT 250 WORDS)
6150080	687	693	borate	CHEMICAL	6150080T10
6150080	0	5	Amine	CHEMICAL	6150080T11
6150080	104	114	clorgyline	CHEMICAL	6150080T12
6150080	79	92	semicarbazide	CHEMICAL	6150080T13
6150080	161	174	Amine oxidase	GENE-N	6150080T14
6150080	1351	1354	MAO	GENE-N	6150080T15
6150080	1449	1453	SSAO	GENE-Y	6150080T16
6150080	1591	1595	SSAO	GENE-Y	6150080T17
6150080	1834	1838	SSAO	GENE-Y	6150080T18
6150080	372	391	monoamine oxidase A	GENE-Y	6150080T19
6150080	161	166	Amine	CHEMICAL	6150080T1
6150080	393	396	MAO	GENE-N	6150080T20
6150080	409	467	semicarbazide-sensitive clorgyline-resistant amine oxidase	GENE-Y	6150080T21
6150080	469	473	SSAO	GENE-Y	6150080T22
6150080	751	755	SSAO	GENE-Y	6150080T23
6150080	798	817	phosphodiesterase I	GENE-N	6150080T24
6150080	929	948	phosphodiesterase I	GENE-N	6150080T25
6150080	988	992	SSAO	GENE-Y	6150080T26
6150080	0	13	Amine oxidase	GENE-N	6150080T27
6150080	1366	1376	tryptamine	CHEMICAL	6150080T2
6150080	1466	1474	tyramine	CHEMICAL	6150080T3
6150080	1479	1490	benzylamine	CHEMICAL	6150080T4
6150080	1607	1618	hydralazine	CHEMICAL	6150080T5
6150080	1656	1669	semicarbazide	CHEMICAL	6150080T6
6150080	372	381	monoamine	CHEMICAL	6150080T7
6150080	409	422	semicarbazide	CHEMICAL	6150080T8
6150080	433	443	clorgyline	CHEMICAL	6150080T9
6150080	CPR:3	6150080T10	6150080T23
6150080	CPR:4	6150080T5	6150080T17
6150080	CPR:4	6150080T6	6150080T17
6150080	CPR:9	6150080T2	6150080T15
6150080	CPR:9	6150080T3	6150080T16
6150080	CPR:9	6150080T4	6150080T16

6311012|t|Penicillin-binding proteins and role of amdinocillin in causing bacterial cell death.
6311012|a|The activity of penicillins against bacteria is in large part related to binding to specific receptor proteins involved in cell wall biosynthesis. These proteins have been designated penicillin-binding proteins. They can be separated into distinct entities through the use of acrylamide gel electrophoresis and binding of radioactive 14C-labeled penicillin G. Six major proteins have been defined in the Enterobacteriaceae, penicillin-binding proteins 1 to 6. Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs. Penicillin-binding protein 2 is a murein-elongation initiating enzyme and penicillin-binding protein 3 is a septal murein-synthesizing enzyme. Penicillin-binding proteins 4, 5, and 6 are not essential for bacterial survival. Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments. Amdinocillin is a beta-amidino penicillanic acid derivative that binds specifically to penicillin-binding protein 2. The compound is more beta-lactamase stable than ampicillin and has no major delay in entry into the periplasmic space as do some penicillins. Amdinocillin inhibits most of the Enterobacteriaceae, with the exception of some indole-positive Proteus species, but it does not inhibit gram-positive cocci or Pseudomonas aeruginosa. Amdinocillin produces spherical bacterial cells that eventually lyse. Its activity in vitro is markedly affected by ionic content of media. This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall. Amdinocillin possesses a number of the essentials for effective antimicrobial activity and, by virtue of its enhancement of the activity of other beta-lactams, may prove to be a useful agent in the chemotherapy of certain infections.
6311012	1706	1718	Amdinocillin	CHEMICAL	1151
6311012	102	113	penicillins	CHEMICAL	6311012T11
6311012	1888	1899	penicillins	CHEMICAL	6311012T12
6311012	1909	1919	ampicillin	CHEMICAL	6311012T13
6311012	269	279	penicillin	CHEMICAL	6311012T14
6311012	1921	1934	carbenicillin	CHEMICAL	6311012T15
6311012	1959	1973	cephalosporins	CHEMICAL	6311012T16
6311012	1975	1984	cefazolin	CHEMICAL	6311012T17
6311012	1986	1997	cefamandole	CHEMICAL	6311012T18
6311012	2002	2011	cefoxitin	CHEMICAL	6311012T19
6311012	1142	1152	penicillin	CHEMICAL	6311012T1
6311012	2176	2188	Amdinocillin	CHEMICAL	1151
6311012	2322	2334	beta-lactams	CHEMICAL	6311012T21
6311012	362	372	acrylamide	CHEMICAL	6311012T22
6311012	420	444	14C-labeled penicillin G	CHEMICAL	6311012T23
6311012	510	520	penicillin	CHEMICAL	6311012T24
6311012	618	628	penicillin	CHEMICAL	6311012T25
6311012	670	680	penicillin	CHEMICAL	6311012T26
6311012	738	748	penicillin	CHEMICAL	6311012T27
6311012	801	811	penicillin	CHEMICAL	6311012T28
6311012	833	843	Penicillin	CHEMICAL	6311012T29
6311012	1208	1218	penicillin	CHEMICAL	6311012T2
6311012	907	917	penicillin	CHEMICAL	6311012T30
6311012	976	986	Penicillin	CHEMICAL	6311012T31
6311012	1069	1080	penicillins	CHEMICAL	6311012T32
6311012	1084	1094	penicillin	CHEMICAL	6311012T33
6311012	0	10	Penicillin	CHEMICAL	6311012T34
6311012	40	52	amdinocillin	CHEMICAL	6311012T35
6311012	1142	1170	penicillin-binding protein 2	GENE-N	6311012T36
6311012	1208	1236	penicillin-binding protein 3	GENE-N	6311012T37
6311012	1349	1377	penicillin-binding protein 2	GENE-N	6311012T38
6311012	1400	1414	beta-lactamase	GENE-N	6311012T39
6311012	1262	1274	Amdinocillin	CHEMICAL	1151
6311012	269	296	penicillin-binding proteins	GENE-N	6311012T40
6311012	2134	2147	peptidoglycan	GENE-N	6311012T41
6311012	510	544	penicillin-binding proteins 1 to 6	GENE-N	6311012T42
6311012	618	646	penicillin-binding protein 1	GENE-N	6311012T43
6311012	670	700	penicillin-binding protein 1Bs	GENE-N	6311012T44
6311012	704	732	peptidoglycan transpeptidase	GENE-N	6311012T45
6311012	738	767	penicillin-binding protein 1A	GENE-N	6311012T46
6311012	801	831	penicillin-binding protein 1Bs	GENE-N	6311012T47
6311012	833	861	Penicillin-binding protein 2	GENE-N	6311012T48
6311012	867	873	murein	GENE-N	6311012T49
6311012	1280	1310	beta-amidino penicillanic acid	CHEMICAL	6311012T4
6311012	907	935	penicillin-binding protein 3	GENE-N	6311012T50
6311012	948	954	murein	GENE-N	6311012T51
6311012	976	1015	Penicillin-binding proteins 4, 5, and 6	GENE-N	6311012T52
6311012	1084	1114	penicillin-binding protein 1Bs	GENE-N	6311012T53
6311012	0	27	Penicillin-binding proteins	GENE-N	6311012T54
6311012	1349	1359	penicillin	CHEMICAL	6311012T5
6311012	1427	1437	ampicillin	CHEMICAL	6311012T6
6311012	1508	1519	penicillins	CHEMICAL	6311012T7
6311012	1521	1533	Amdinocillin	CHEMICAL	1151
6311012	1602	1608	indole	CHEMICAL	6311012T9
6311012	CPR:3	6311012T12	6311012T41
6311012	CPR:3	6311012T13	6311012T41
6311012	CPR:3	6311012T15	6311012T41
6311012	CPR:3	6311012T16	6311012T41
6311012	CPR:3	6311012T17	6311012T41
6311012	CPR:3	6311012T18	6311012T41
6311012	CPR:3	6311012T19	6311012T41

6319437|t|Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides.
6319437|a|We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (EGF) in fibroblasts. The loss of alpha 2-macroglobulin receptors is independent of receptor occupancy and is rapidly reversed upon removal of these agents from the culture medium. The extent of EGF receptor loss is less than for alpha 2-macroglobulin, and the EGF receptors do not reappear at the surface when W-7 is removed. Receptor loss was measured as a change in the capacity for binding iodinated ligands; no change in affinity of binding was observed. This receptor loss could reflect inactivation of receptors or internalization. W-7 did not induce a loss of cell surface beta 2-microglobulin, a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of W-7 was specific for membrane receptors and not a result of bulk depletion of plasma membrane. The loss of alpha 2-macroglobulin and EGF receptors occurs at concentrations which do not cause an increase in the pH of endocytic vesicles or the cytoplasm, indicating that these agents act by a mechanism distinct from the effect of other weak bases. Since both TFP and W-7 are potent inhibitors of calmodulin, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors. Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin. These data indicated that cell surface receptor numbers can be regulated by a cellular component that is not cytoplasmic calmodulin but that shares some drug sensitivities with calmodulin.
6319437	2053	2056	W-7	CHEMICAL	6319437T10
6319437	2204	2213	rhodamine	CHEMICAL	6319437T11
6319437	2261	2264	W-7	CHEMICAL	6319437T12
6319437	2510	2519	rhodamine	CHEMICAL	6319437T13
6319437	157	180	naphthalenesulfonamides	CHEMICAL	6319437T14
6319437	701	704	W-7	CHEMICAL	6319437T15
6319437	188	238	N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide	CHEMICAL	6319437T16
6319437	929	932	W-7	CHEMICAL	6319437T17
6319437	1108	1111	W-7	CHEMICAL	6319437T18
6319437	104	128	naphthalene sulfonamides	CHEMICAL	6319437T19
6319437	240	243	W-7	CHEMICAL	6319437T1
6319437	85	99	phenothiazines	CHEMICAL	6319437T20
6319437	1215	1236	alpha 2-macroglobulin	GENE-Y	6319437T21
6319437	1241	1254	EGF receptors	GENE-Y	6319437T22
6319437	1503	1513	calmodulin	GENE-N	6319437T23
6319437	1566	1576	calmodulin	GENE-N	6319437T24
6319437	1657	1667	calmodulin	GENE-N	6319437T25
6319437	1920	1930	calmodulin	GENE-N	6319437T26
6319437	2000	2010	calmodulin	GENE-N	6319437T27
6319437	2130	2140	calmodulin	GENE-N	6319437T28
6319437	2222	2243	alpha 2-macroglobulin	GENE-Y	6319437T29
6319437	250	264	phenothiazines	CHEMICAL	6319437T2
6319437	339	360	alpha 2-macroglobulin	GENE-Y	6319437T30
6319437	2379	2390	calcineurin	GENE-N	6319437T31
6319437	2394	2420	calmodulin-binding protein	GENE-N	6319437T32
6319437	366	389	epidermal growth factor	GENE-Y	6319437T33
6319437	2528	2549	alpha 2-macroglobulin	GENE-Y	6319437T34
6319437	2660	2682	cytoplasmic calmodulin	GENE-N	6319437T35
6319437	2728	2738	calmodulin	GENE-N	6319437T36
6319437	391	394	EGF	GENE-Y	108270
6319437	424	455	alpha 2-macroglobulin receptors	GENE-Y	6319437T38
6319437	585	597	EGF receptor	GENE-Y	6319437T39
6319437	1466	1469	TFP	CHEMICAL	6319437T3
6319437	620	641	alpha 2-macroglobulin	GENE-Y	6319437T40
6319437	651	664	EGF receptors	GENE-Y	6319437T41
6319437	971	991	beta 2-microglobulin	GENE-Y	6319437T42
6319437	34	57	epidermal growth factor	GENE-Y	6319437T43
6319437	8	29	alpha 2-macroglobulin	GENE-Y	6319437T44
6319437	1474	1477	W-7	CHEMICAL	6319437T4
6319437	272	287	trifluoperazine	CHEMICAL	6319437T5
6319437	289	292	TFP	CHEMICAL	6319437T6
6319437	1748	1760	Promethazine	CHEMICAL	1057
6319437	1764	1777	phenothiazine	CHEMICAL	6319437T8
6319437	1844	1847	TFP	CHEMICAL	6319437T9
6319437	CPR:4	6319437T3	6319437T23
6319437	CPR:4	6319437T4	6319437T23
6319437	CPR:4	1057	6319437T26
6319437	CPR:4	6319437T8	6319437T26
6319437	CPR:4	6319437T9	6319437T26

6621777|t|The effect of various amino acids and drugs on the para- and meta-hydroxyphenylacetic acid concentrations in the mouse caudate nucleus.
6621777|a|Injection of L-p-tyrosine (800 mg/kg, 2 h) increased the mouse striatal para-hydroxyphenylacetic acid (p-HPAA) concentrations. A smaller dose of D,L-m-tyrosine (20 mg/kg, 2 h) produced a larger increase in mouse striatal meta-hydroxyphenylacetic acid (m-HPAA) concentrations. The administration of L-phenylalanine to mice caused a slight increase in the p-HPAA concentration in the corpus striatum after 2 h while a larger dose of L-phenylalanine (800 mg/kg) produced a greater increase. Eight hours following L-phenylalanine injection, p-HPAA concentrations were still elevated. With D-phenylalanine a significant increase was observed at eight hours after drug administration. Two drugs which reduce dopamine synthesis, alpha-methyl-para-tyrosine and apomorphine, decreased m-HPAA striatal concentrations without affecting p-HPAA concentrations. From these results, it is proposed that tyrosine hydroxylase activity determines p-HPAA concentrations by regulating p-tyrosine availability. This enzyme may also synthesize m-tyrosine which is subsequently decarboxylated to form m-tyramine and then oxidatively deaminated to form m-HPAA.
6621777	490	496	p-HPAA	CHEMICAL	6621777T10
6621777	567	582	L-phenylalanine	CHEMICAL	6621777T11
6621777	646	661	L-phenylalanine	CHEMICAL	6621777T12
6621777	673	679	p-HPAA	CHEMICAL	6621777T13
6621777	721	736	D-phenylalanine	CHEMICAL	6621777T14
6621777	838	846	dopamine	CHEMICAL	6621777T15
6621777	208	237	para-hydroxyphenylacetic acid	CHEMICAL	6621777T16
6621777	858	884	alpha-methyl-para-tyrosine	CHEMICAL	6621777T17
6621777	889	900	apomorphine	CHEMICAL	6621777T18
6621777	912	918	m-HPAA	CHEMICAL	6621777T19
6621777	1158	1168	m-tyrosine	CHEMICAL	6621777T1
6621777	961	967	p-HPAA	CHEMICAL	6621777T20
6621777	1024	1032	tyrosine	CHEMICAL	6621777T21
6621777	1065	1071	p-HPAA	CHEMICAL	6621777T22
6621777	1101	1111	p-tyrosine	CHEMICAL	6621777T23
6621777	22	33	amino acids	CHEMICAL	6621777T24
6621777	51	90	para- and meta-hydroxyphenylacetic acid	CHEMICAL	6621777T25
6621777	1024	1044	tyrosine hydroxylase	GENE-Y	6621777T26
6621777	239	245	p-HPAA	CHEMICAL	6621777T2
6621777	1214	1224	m-tyramine	CHEMICAL	6621777T3
6621777	1265	1271	m-HPAA	CHEMICAL	6621777T4
6621777	149	161	L-p-tyrosine	CHEMICAL	6621777T5
6621777	281	295	D,L-m-tyrosine	CHEMICAL	6621777T6
6621777	357	386	meta-hydroxyphenylacetic acid	CHEMICAL	6621777T7
6621777	388	394	m-HPAA	CHEMICAL	6621777T8
6621777	434	449	L-phenylalanine	CHEMICAL	6621777T9
6621777	CPR:9	6621777T23	6621777T26

6701456|t|Demonstration of histamine receptors on human platelets by flow cytometry.
6701456|a|Fluoresceinated human albumin conjugated with histamine (FHA-HIS) has been used for the demonstration of histamine receptors on human platelets. Such receptors were demonstrated on 40-63% of peripheral blood platelets in 4 healthy donors. The binding of FHA-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine. The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets. It is concluded that histamine H1 as well as H2 receptors occur on human platelets but the receptors are not equally distributed in the platelet population.
6701456	75	104	Fluoresceinated human albumin	GENE-Y	6701456T10
6701456	180	199	histamine receptors	GENE-N	6701456T11
6701456	329	332	FHA	GENE-Y	6701456T12
6701456	385	406	histamine H1 receptor	GENE-Y	6701456T13
6701456	455	476	histamine H2 receptor	GENE-Y	6701456T14
6701456	511	514	FHA	GENE-Y	6701456T15
6701456	576	588	histamine H1	GENE-Y	6701456T16
6701456	600	612	H2 receptors	GENE-Y	6701456T17
6701456	132	135	FHA	GENE-Y	6701456T18
6701456	17	36	histamine receptors	GENE-N	6701456T19
6701456	180	189	histamine	CHEMICAL	6701456T1
6701456	385	394	histamine	CHEMICAL	6701456T2
6701456	419	434	diphenhydramine	CHEMICAL	6701456T3
6701456	439	449	clemastine	CHEMICAL	6701456T4
6701456	455	464	histamine	CHEMICAL	6701456T5
6701456	488	498	cimetidine	CHEMICAL	6701456T6
6701456	121	130	histamine	CHEMICAL	6701456T7
6701456	576	585	histamine	CHEMICAL	6701456T8
6701456	17	26	histamine	CHEMICAL	6701456T9
6701456	CPR:4	6701456T3	6701456T12
6701456	CPR:4	6701456T4	6701456T12
6701456	CPR:4	6701456T6	6701456T15
6701456	CPR:6	6701456T3	6701456T13
6701456	CPR:6	6701456T4	6701456T13
6701456	CPR:6	6701456T6	6701456T14

6703688|t|The effect of vitamin B6 deficiency on alanine: glyoxylate aminotransferase isoenzymes in rat liver.
6703688|a|Endogenous synthesis of oxalate has been reported to increase in vitamin B6 deficiency probably due to defective transamination of glyoxylate, the direct source of oxalate, to glycine. Alanine:glyoxylate aminotransferase (AGT) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem. J. 127, 155-165). The effects of vitamin B6 deficiency on hepatic AGT isoenzymes, designated AGT 1 and AGT 2, respectively, were examined with male rats; AGT 1 is located both in the peroxisomes and in the mitochondria, and AGT 2 only in the mitochondria. The holo activity of combined peroxisomal and mitochondrial AGT 1 with a low Km for L-alanine rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days). Peroxisomal AGT 1 activity was more affected than the mitochondrial. The holo activity of AGT 2 with a high Km for L-alanine decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days). Urinary excretion of oxalate began to increase in 8-9 days, when AGT 2 remained intact but most of AGT 1 is depleted. When the defect in the glyoxylate transamination in vivo in vitamin B6 deficiency is considered, these findings suggest that it is due to the deficiency of AGT 1. The importance of peroxisomal AGT 1 is discussed, since peroxisomes have been described to be probably the major site of glyoxylate formation.
6703688	125	132	oxalate	CHEMICAL	6703688T10
6703688	363	373	glyoxylate	CHEMICAL	6703688T11
6703688	517	527	vitamin B6	CHEMICAL	6703688T12
6703688	166	176	vitamin B6	CHEMICAL	6703688T13
6703688	824	833	L-alanine	CHEMICAL	6703688T14
6703688	907	917	vitamin B6	CHEMICAL	6703688T15
6703688	1087	1096	L-alanine	CHEMICAL	6703688T16
6703688	14	24	vitamin B6	CHEMICAL	6703688T17
6703688	39	46	alanine	CHEMICAL	6703688T18
6703688	48	58	glyoxylate	CHEMICAL	6703688T19
6703688	1191	1198	oxalate	CHEMICAL	6703688T1
6703688	1124	1129	AGT 1	GENE-Y	6703688T20
6703688	1235	1240	AGT 2	GENE-Y	6703688T21
6703688	1269	1274	AGT 1	GENE-Y	6703688T22
6703688	1444	1449	AGT 1	GENE-Y	6703688T23
6703688	1481	1486	AGT 1	GENE-Y	6703688T24
6703688	286	321	Alanine:glyoxylate aminotransferase	GENE-N	6703688T25
6703688	323	326	AGT	GENE-N	106690|1183
6703688	550	553	AGT	GENE-N	106690|1183
6703688	577	582	AGT 1	GENE-Y	6703688T28
6703688	587	592	AGT 2	GENE-Y	6703688T29
6703688	1311	1321	glyoxylate	CHEMICAL	6703688T2
6703688	638	643	AGT 1	GENE-Y	6703688T30
6703688	708	713	AGT 2	GENE-Y	6703688T31
6703688	800	805	AGT 1	GENE-Y	6703688T32
6703688	984	989	AGT 1	GENE-Y	6703688T33
6703688	1062	1067	AGT 2	GENE-Y	6703688T34
6703688	39	75	alanine: glyoxylate aminotransferase	GENE-N	6703688T35
6703688	1348	1358	vitamin B6	CHEMICAL	6703688T3
6703688	232	242	glyoxylate	CHEMICAL	6703688T4
6703688	1572	1582	glyoxylate	CHEMICAL	6703688T5
6703688	265	272	oxalate	CHEMICAL	6703688T6
6703688	277	284	glycine	CHEMICAL	6703688T7
6703688	286	293	Alanine	CHEMICAL	154
6703688	294	304	glyoxylate	CHEMICAL	6703688T9
6703688	CPR:9	6703688T11	6703688T25
6703688	CPR:9	6703688T11	106690|1183
6703688	CPR:9	6703688T14	6703688T32
6703688	CPR:9	6703688T16	6703688T20
6703688	CPR:9	6703688T16	6703688T34

7499320|t|How do volatile anesthetics inhibit Ca(2+)-ATPases?
7499320|a|Volatile anesthetics at concentrations that are used in clinical practice to induce anesthesia selectively inhibit activity of the plasma membrane Ca(2+)-transport ATPase (Kosk-Kosicka, D., and Roszczynska, G. (1993) Anesthesiology 79, 774-780). We have investigated the mechanism of the inhibitory action of several anesthetics on the purified erythrocyte Ca(2+)-ATPase by employing fluorescence spectroscopy measurements that report changes in the environment of intrinsic tryptophans and of an extrinsic probe attached in the active site of the enzyme. We have shown that the observed inhibition of the Ca(2+)-dependent activation of the enzyme correlates well with the elimination of the Ca(2+)-induced conformation change that is important for the proper function of the enzyme. Analysis of the anesthetics effects on the total tryptophan fluorescence indicates a significant effect on enzyme conformation. Similar changes have been observed in the sarcoplasmic reticulum Ca(2+)-ATPase. We propose that volatile anesthetics inhibit Ca(2+)-ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for myoglobin, hemoglobin, and adenylate kinase (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv. Pharmacol. 5, 1-17; Tilton, R. F., Kuntz, I. D., and Petsko, G. A. (1984) Biochemistry 23, 2849-2857). Such binding is expected to modify conformational substate(s) of the enzyme and perturb its function. We view this process as an example of a general phenomena of interaction of small molecules with internal sites in proteins.
7499320	36	42	Ca(2+)	CHEMICAL	7499320T10
7499320	1089	1102	Ca(2+)-ATPase	GENE-N	7499320T11
7499320	1202	1211	myoglobin	GENE-Y	7499320T12
7499320	1213	1223	hemoglobin	GENE-N	7499320T13
7499320	1229	1245	adenylate kinase	GENE-N	7499320T14
7499320	199	222	Ca(2+)-transport ATPase	GENE-N	7499320T15
7499320	409	422	Ca(2+)-ATPase	GENE-N	7499320T16
7499320	1006	1042	sarcoplasmic reticulum Ca(2+)-ATPase	GENE-N	7499320T17
7499320	36	50	Ca(2+)-ATPases	GENE-N	7499320T18
7499320	1089	1095	Ca(2+)	CHEMICAL	7499320T1
7499320	1229	1238	adenylate	CHEMICAL	7499320T2
7499320	199	205	Ca(2+)	CHEMICAL	7499320T3
7499320	409	415	Ca(2+)	CHEMICAL	7499320T4
7499320	527	538	tryptophans	CHEMICAL	7499320T5
7499320	658	664	Ca(2+)	CHEMICAL	7499320T6
7499320	744	750	Ca(2+)	CHEMICAL	7499320T7
7499320	885	895	tryptophan	CHEMICAL	7499320T8
7499320	1029	1035	Ca(2+)	CHEMICAL	7499320T9

7560228|t|The effect of triclosan on mediators of gingival inflammation.
7560228|a|Triclosan (2,4,4',-trichloro-2'-hydroxydiphenylether) is a well-known and widely used nonionic antibacterial agent which has recently been introduced in toothpastes and mouthrinses. The efficacy of triclosan-containing toothpaste and mouthrinse to reduce both plaque and gingivitis in long-term clinical trials has been well documented. Until recently, it was generally assumed that triclosan's effect on gingival inflammation was due to its antimicrobial and anti-plaque effect. It has now become apparent that triclosan may have a direct anti-inflammatory effect on the gingival tissues. Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of arachidonic acid metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, 5-lipoxygenase and 15-lipoxygenase. These pathways lead to the production of known mediators of inflammation such as the prostaglandins, leukotrienes and lipoxins. Triclosan inhibited both cyclooxygenase 1 and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively. Triclosan also inhibited 5-lipoxygenase with an IC-50 of 43 microM. The 15-lipoxygenase was similarly inhibited by triclosan with an IC-50 of 61 microM. Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy. In cell culture experiments, it was found that triclosan inhibited IL-1 beta induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations. These data, taken together, indicate that triclosan can inhibit formation of several important mediators of gingival inflammation.(ABSTRACT TRUNCATED AT 250 WORDS)
7560228	261	270	triclosan	CHEMICAL	7560228T10
7560228	575	584	triclosan	CHEMICAL	7560228T11
7560228	719	728	triclosan	CHEMICAL	7560228T12
7560228	769	785	arachidonic acid	CHEMICAL	7560228T13
7560228	957	971	prostaglandins	CHEMICAL	7560228T14
7560228	973	985	leukotrienes	CHEMICAL	7560228T15
7560228	990	998	lipoxins	CHEMICAL	7560228T16
7560228	1000	1009	Triclosan	CHEMICAL	7381
7560228	14	23	triclosan	CHEMICAL	7560228T18
7560228	1150	1164	5-lipoxygenase	GENE-Y	7560228T19
7560228	63	72	Triclosan	CHEMICAL	7381
7560228	1197	1212	15-lipoxygenase	GENE-Y	7560228T20
7560228	1331	1346	cyclo-oxygenase	GENE-N	7560228T21
7560228	1351	1363	lipoxygenase	GENE-N	7560228T22
7560228	1494	1503	IL-1 beta	GENE-Y	7560228T23
7560228	798	815	cyclo-oxygenase 1	GENE-Y	7560228T24
7560228	817	834	cyclo-oxygenase 2	GENE-Y	7560228T25
7560228	836	850	5-lipoxygenase	GENE-Y	7560228T26
7560228	855	870	15-lipoxygenase	GENE-Y	7560228T27
7560228	1025	1041	cyclooxygenase 1	GENE-Y	7560228T28
7560228	1046	1063	cyclo-oxygenase 2	GENE-Y	7560228T29
7560228	1125	1134	Triclosan	CHEMICAL	7381
7560228	74	115	2,4,4',-trichloro-2'-hydroxydiphenylether	CHEMICAL	7560228T3
7560228	1240	1249	triclosan	CHEMICAL	7560228T4
7560228	1285	1294	triclosan	CHEMICAL	7560228T5
7560228	1376	1392	arachidonic acid	CHEMICAL	7560228T6
7560228	1474	1483	triclosan	CHEMICAL	7560228T7
7560228	1512	1528	prostaglandin E2	CHEMICAL	7560228T8
7560228	1687	1696	triclosan	CHEMICAL	7560228T9
7560228	CPR:4	7381	7560228T28
7560228	CPR:4	7381	7560228T29
7560228	CPR:4	7381	7560228T19
7560228	CPR:4	7560228T4	7560228T20
7560228	CPR:4	7560228T5	7560228T21
7560228	CPR:4	7560228T5	7560228T22
7560228	CPR:4	7560228T7	7560228T23
7560228	CPR:9	7560228T6	7560228T21
7560228	CPR:9	7560228T6	7560228T22
7560228	CPR:9	7560228T8	7560228T23

7599160|t|The dynamics of cobalamin utilization in L-1210 mouse leukemia cells: a model of cellular cobalamin metabolism.
7599160|a|The uptake and metabolism of cobalamin (Cbl) has been studied in L-1210 murine leukemia cells propagating in vitro. Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to transcobalamin II (transcobalamin, TC). The intracellular pool of free [57Co]Cbl increased during the first 24 h of culture and a substantial fraction of this free pool was effluxed from the cell to the medium. Upon depletion of extracellular TC-[57Co]CN-Cbl, the intracellular concentration of free Cbl decreased as did the efflux of Cbl to the medium. Internalized [57Co]CN-Cbl was converted to hydroxocobalamin (OH-Cbl), methylcobalamin (Me-Cbl) and 5'-deoxyadenosylcobalamin. These Cbl forms were found in both soluble (cytoplasmic) and insoluble (membrane) fractions. Intracellular protein-bound [57Co]Cbl fractionated with methionine synthase (MS) and methylmalonyl-CoA mutase (MU) activity. The major form of Cbl associated with the two enzymes was OH-Cbl. Cells propagated in medium containing N5-methyltetrahydrofolate and homocysteine showed a substantial increase in MS activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.
7599160	404	410	CN-Cbl	CHEMICAL	7599160T10
7599160	141	150	cobalamin	CHEMICAL	7599160T11
7599160	492	501	[57Co]Cbl	CHEMICAL	7599160T12
7599160	152	155	Cbl	CHEMICAL	7599160T13
7599160	664	679	TC-[57Co]CN-Cbl	CHEMICAL	7599160T14
7599160	721	724	Cbl	CHEMICAL	7599160T15
7599160	756	759	Cbl	CHEMICAL	7599160T16
7599160	788	800	[57Co]CN-Cbl	CHEMICAL	7599160T17
7599160	818	834	hydroxocobalamin	CHEMICAL	7599160T18
7599160	836	842	OH-Cbl	CHEMICAL	193
7599160	1137	1140	Cbl	CHEMICAL	7599160T1
7599160	845	860	methylcobalamin	CHEMICAL	7599160T20
7599160	862	868	Me-Cbl	CHEMICAL	7599160T21
7599160	874	899	5'-deoxyadenosylcobalamin	CHEMICAL	7599160T22
7599160	907	910	Cbl	CHEMICAL	7599160T23
7599160	1022	1031	[57Co]Cbl	CHEMICAL	7599160T24
7599160	1050	1060	methionine	CHEMICAL	7599160T25
7599160	1079	1096	methylmalonyl-CoA	CHEMICAL	7599160T26
7599160	16	25	cobalamin	CHEMICAL	7599160T27
7599160	90	99	cobalamin	CHEMICAL	7599160T28
7599160	1299	1301	MS	GENE-Y	7599160T29
7599160	1177	1183	OH-Cbl	CHEMICAL	193
7599160	421	438	transcobalamin II	GENE-Y	7599160T30
7599160	440	454	transcobalamin	GENE-N	7599160T31
7599160	456	458	TC	GENE-N	7599160T32
7599160	1050	1069	methionine synthase	GENE-Y	7599160T33
7599160	1071	1073	MS	GENE-Y	7599160T34
7599160	1079	1103	methylmalonyl-CoA mutase	GENE-Y	7599160T35
7599160	1105	1107	MU	GENE-Y	7599160T36
7599160	1223	1248	N5-methyltetrahydrofolate	CHEMICAL	7599160T3
7599160	1253	1265	homocysteine	CHEMICAL	7599160T4
7599160	1379	1385	Me-Cbl	CHEMICAL	7599160T5
7599160	1394	1397	Cbl	CHEMICAL	7599160T6
7599160	242	245	Cbl	CHEMICAL	7599160T7
7599160	289	292	Cbl	CHEMICAL	7599160T8
7599160	382	402	[57Co]cyanocobalamin	CHEMICAL	7599160T9
7599160	CPR:3	7599160T3	7599160T29
7599160	CPR:3	7599160T4	7599160T29

7665369|t|Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells.
7665369|a|Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated. Ergovaline inhibition of the binding of the D2-specific radioligand, [3H]YM-09151-2, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas dopamine was much less potent (370 +/- 160 nM). Ergot alkaloids were also effective in inhibiting VIP-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively. Inhibition of cyclic AMP production by ergovaline was blocked by the dopamine receptor antagonist, (-)-sulpiride (IC50, 300 +/- 150 nM). Our results indicate that ergot compounds, especially ergovaline, bind to D2 dopamine receptors and elicit second messenger responses similar to that of dopamine. These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including ergovaline, may be due to D2 dopamine receptor activation.
7665369	533	548	Ergot alkaloids	CHEMICAL	7665369T10
7665369	598	608	cyclic AMP	CHEMICAL	7665369T11
7665369	131	139	dopamine	CHEMICAL	7665369T12
7665369	642	652	ergovaline	CHEMICAL	7665369T13
7665369	654	664	ergonovine	CHEMICAL	7665369T14
7665369	666	684	alpha-ergocryptine	CHEMICAL	7665369T15
7665369	686	696	ergotamine	CHEMICAL	7665369T16
7665369	702	710	dopamine	CHEMICAL	7665369T17
7665369	796	806	cyclic AMP	CHEMICAL	7665369T18
7665369	821	831	ergovaline	CHEMICAL	7665369T19
7665369	76	86	Ergovaline	CHEMICAL	7665369T1
7665369	851	859	dopamine	CHEMICAL	7665369T20
7665369	153	167	ergot alkaloid	CHEMICAL	7665369T21
7665369	881	894	(-)-sulpiride	CHEMICAL	7665369T22
7665369	973	983	ergovaline	CHEMICAL	7665369T23
7665369	996	1004	dopamine	CHEMICAL	7665369T24
7665369	1072	1080	dopamine	CHEMICAL	7665369T25
7665369	0	10	Ergovaline	CHEMICAL	7665369T26
7665369	40	48	dopamine	CHEMICAL	7665369T27
7665369	182	211	vasoactive intestinal peptide	GENE-Y	7665369T28
7665369	1267	1287	D2 dopamine receptor	GENE-Y	7665369T29
7665369	1215	1230	ergot alkaloids	CHEMICAL	7665369T2
7665369	213	216	VIP	GENE-Y	113273
7665369	294	318	rat D2 dopamine receptor	GENE-Y	7665369T31
7665369	380	382	D2	GENE-Y	7665369T32
7665369	583	586	VIP	GENE-Y	113273
7665369	128	148	D2 dopamine receptor	GENE-Y	7665369T34
7665369	851	868	dopamine receptor	GENE-N	7665369T35
7665369	993	1014	D2 dopamine receptors	GENE-Y	7665369T36
7665369	37	58	D2 dopamine receptors	GENE-Y	7665369T37
7665369	1241	1251	ergovaline	CHEMICAL	7665369T3
7665369	1270	1278	dopamine	CHEMICAL	7665369T4
7665369	229	239	cyclic AMP	CHEMICAL	7665369T5
7665369	301	309	dopamine	CHEMICAL	7665369T6
7665369	336	346	Ergovaline	CHEMICAL	7665369T7
7665369	405	419	[3H]YM-09151-2	CHEMICAL	7665369T8
7665369	485	493	dopamine	CHEMICAL	7665369T9
7665369	CPR:3	7665369T26	7665369T37
7665369	CPR:3	7665369T2	7665369T29
7665369	CPR:3	7665369T3	7665369T29
7665369	CPR:4	7665369T10	113273
7665369	CPR:4	7665369T13	113273
7665369	CPR:4	7665369T14	113273
7665369	CPR:4	7665369T15	113273
7665369	CPR:4	7665369T16	113273
7665369	CPR:4	7665369T17	113273
7665369	CPR:4	7665369T21	7665369T28
7665369	CPR:4	7665369T21	113273
7665369	CPR:6	7665369T22	7665369T35
7665369	CPR:9	7665369T11	113273
7665369	CPR:9	7665369T5	7665369T28
7665369	CPR:9	7665369T5	113273

7691623|t|Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors.
7691623|a|The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the alpha 1-adrenoceptor. Saturation experiments showed that [3H]prazosin labelled a single population of binding sites in the spleen (alpha 1B) and hippocampus (alpha 1A and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively). Prazosin displaced the radioligand in a monophasic manner in both the spleen and hippocampus whereas 5-methyl-urapidil, phentolamine and WB 4101 displaced the radioligand in a monophasic manner in the spleen but in a biphasic manner in the hippocampus. The affinity of these three compounds for the low affinity site in the hippocampus was similar to that observed in the spleen, suggesting that all three were selective for the alpha 1A-adrenoceptor. Furthermore, the affinities for the alpha 1A- and alpha 1B-adrenoceptors calculated in this manner were in agreement with literature values. With the exception of risperidone, all the antipsychotic drugs tested failed to show selectivity for either of the alpha 1-adrenoceptor subtypes. Risperidone was 120-fold more selective for the alpha 1B-adrenoceptor with respect to the alpha 1A-adrenoceptor (Ki values: 2.3 +/- 1.2 nM and 283.6 +/- 174.1 nM respectively).
7691623	661	673	phentolamine	CHEMICAL	682
7691623	678	685	WB 4101	CHEMICAL	7691623T11
7691623	197	206	clozapine	CHEMICAL	7691623T12
7691623	208	219	haloperidol	CHEMICAL	7691623T13
7691623	221	230	spiperone	CHEMICAL	7691623T14
7691623	72	83	risperidone	CHEMICAL	7691623T15
7691623	1249	1269	alpha 1-adrenoceptor	GENE-N	7691623T16
7691623	1328	1349	alpha 1B-adrenoceptor	GENE-Y	7691623T17
7691623	1370	1391	alpha 1A-adrenoceptor	GENE-Y	7691623T18
7691623	295	315	alpha 1-adrenoceptor	GENE-N	7691623T19
7691623	1156	1167	risperidone	CHEMICAL	7691623T1
7691623	426	434	alpha 1B	GENE-Y	7691623T20
7691623	453	461	alpha 1A	GENE-Y	7691623T21
7691623	466	474	alpha 1B	GENE-Y	7691623T22
7691623	970	991	alpha 1A-adrenoceptor	GENE-Y	7691623T23
7691623	1029	1065	alpha 1A- and alpha 1B-adrenoceptors	GENE-N	7691623T24
7691623	105	127	alpha 1B-adrenoceptors	GENE-Y	7691623T25
7691623	34	70	alpha 1A- and alpha 1B-adrenoceptors	GENE-N	7691623T26
7691623	232	244	thioridazine	CHEMICAL	7691623T2
7691623	1280	1291	Risperidone	CHEMICAL	724
7691623	249	259	YM-09151-2	CHEMICAL	7691623T4
7691623	352	364	[3H]prazosin	CHEMICAL	7691623T5
7691623	168	179	risperidone	CHEMICAL	7691623T6
7691623	541	549	Prazosin	CHEMICAL	449
7691623	642	659	5-methyl-urapidil	CHEMICAL	7691623T8
7691623	181	195	(+)-butaclamol	CHEMICAL	7691623T9

7773533|t|Mediation of noradrenaline-induced contractions of rat aorta by the alpha 1B-adrenoceptor subtype.
7773533|a|1. The subtypes of alpha 1-adrenoceptor mediating contractions to exogenous noradrenaline (NA) in rat aorta have been examined in both biochemical and functional studies. 2. Incubation of rat aortic membranes with the irreversible alpha 1B-adrenoceptor antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax). 3. Contractions of rat aortic strips to NA after CEC (50 microM for 30 min) incubation followed by repetitive washing, showed a marked shift in the potency of NA and a partial reduction in the maximum response. The residual contractions to NA after CEC incubation were not affected by prazosin (10 nM). 4. The competitive antagonists prazosin, terazosin, (R)-YM-12617, phentolamine, 5-methylurapidil and spiperone inhibited contractions to NA with estimated pA2 values of 9.85, 8.54, 9.34, 7.71, 7.64 and 8.41, respectively. 5. The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and phentolamine were confirmed as selective for the alpha 1A-adrenoceptors, whereas spiperone was alpha 1B-selective. 6. A significant correlation was found between the pA2 values of the alpha 1-adrenoceptor antagonists tested and their affinity for the alpha 1B-adrenoceptor subtype, but not for the alpha 1A-subtype. 7. In conclusion, these findings indicate that in rat aorta most of the contraction is mediated by alpha 1B-adrenoceptors, and that the potency (pA2) of an antagonist in this tissue should be related to its antagonistic effect on this subtype of the alpha 1-adrenoceptor population.
7773533	707	709	NA	CHEMICAL	7773533T10
7773533	788	790	NA	CHEMICAL	7773533T11
7773533	797	800	CEC	CHEMICAL	7773533T12
7773533	833	841	prazosin	CHEMICAL	7773533T13
7773533	175	188	noradrenaline	CHEMICAL	7773533T14
7773533	882	890	prazosin	CHEMICAL	7773533T15
7773533	892	901	terazosin	CHEMICAL	7773533T16
7773533	903	915	(R)-YM-12617	CHEMICAL	7773533T17
7773533	917	929	phentolamine	CHEMICAL	682
7773533	931	947	5-methylurapidil	CHEMICAL	7773533T19
7773533	1233	1236	CEC	CHEMICAL	7773533T1
7773533	952	961	spiperone	CHEMICAL	7773533T20
7773533	988	990	NA	CHEMICAL	7773533T21
7773533	190	192	NA	CHEMICAL	7773533T22
7773533	13	26	noradrenaline	CHEMICAL	7773533T23
7773533	1121	1158	alpha 1A- and alpha 1B- adrenoceptors	GENE-N	7773533T24
7773533	1337	1359	alpha 1A-adrenoceptors	GENE-Y	7773533T25
7773533	1472	1492	alpha 1-adrenoceptor	GENE-N	7773533T26
7773533	1539	1560	alpha 1B-adrenoceptor	GENE-Y	7773533T27
7773533	1703	1725	alpha 1B-adrenoceptors	GENE-Y	7773533T28
7773533	1854	1874	alpha 1-adrenoceptor	GENE-N	7773533T29
7773533	1267	1283	5-Methylurapidil	CHEMICAL	7773533T2
7773533	118	138	alpha 1-adrenoceptor	GENE-N	7773533T30
7773533	330	351	alpha 1B-adrenoceptor	GENE-Y	7773533T31
7773533	68	89	alpha 1B-adrenoceptor	GENE-Y	7773533T32
7773533	1288	1300	phentolamine	CHEMICAL	682
7773533	1369	1378	spiperone	CHEMICAL	7773533T4
7773533	364	384	chloroethylclonidine	CHEMICAL	7773533T5
7773533	386	389	CEC	CHEMICAL	7773533T6
7773533	427	440	[3H]-prazosin	CHEMICAL	7773533T7
7773533	588	590	NA	CHEMICAL	7773533T8
7773533	597	600	CEC	CHEMICAL	7773533T9
7773533	CPR:6	7773533T5	7773533T31
7773533	CPR:6	7773533T6	7773533T31

7816863|t|Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice.
7816863|a|The effects of several beta-adrenoceptor antagonists on the desipramine-induced increase in aggressive behavior in long-term isolated mice were examined. Desipramine HCl (10 mg/kg, IP) significantly increased the duration of aggressive behavior in isolated mice but did not significantly change the latency to the first attack consistent with our previous reports. Intraperitoneal administration of (+/- )propranolol HCl (2.5-10 mg/kg), a nonselective beta-adrenoceptor antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses. ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it. Moreover, clenbuterol HCl (0.1-0.5 mg/kg, IP), a lipophilic beta 2-adrenoceptor agonist, significantly increased the duration of basal aggressive behavior. Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.
7816863	53	64	desipramine	CHEMICAL	7816863T10
7816863	1342	1362	alpha 2-adrenoceptor	GENE-N	7816863T11
7816863	1436	1455	beta 2-adrenoceptor	GENE-Y	7816863T12
7816863	151	168	beta-adrenoceptor	GENE-N	7816863T13
7816863	580	597	beta-adrenoceptor	GENE-N	7816863T14
7816863	808	827	beta 2-adrenoceptor	GENE-Y	7816863T15
7816863	998	1017	beta 1-adrenoceptor	GENE-Y	7816863T16
7816863	1109	1128	beta 2-adrenoceptor	GENE-Y	7816863T17
7816863	16	36	beta 1-adrenoceptors	GENE-Y	7816863T18
7816863	1255	1266	desipramine	CHEMICAL	7816863T1
7816863	1328	1337	yohimbine	CHEMICAL	7816863T2
7816863	282	297	Desipramine HCl	CHEMICAL	7816863T3
7816863	527	548	(+/- )propranolol HCl	CHEMICAL	7816863T4
7816863	642	653	desipramine	CHEMICAL	7816863T5
7816863	188	199	desipramine	CHEMICAL	7816863T6
7816863	761	775	ICI118,551 HCl	CHEMICAL	7816863T7
7816863	948	967	metoprolol tartrate	CHEMICAL	7816863T8
7816863	1059	1074	clenbuterol HCl	CHEMICAL	7816863T9
7816863	CPR:5	7816863T9	7816863T17
7816863	CPR:6	7816863T2	7816863T11
7816863	CPR:6	7816863T4	7816863T14
7816863	CPR:6	7816863T7	7816863T15
7816863	CPR:6	7816863T8	7816863T16

7875228|t|Alpha 1-adrenoceptor subtypes mediating the regulation and modulation of Ca2+ sensitization in rabbit thoracic aorta.
7875228|a|Norepinephrine (10 microM), methoxamine (100 microM) and clonidine (100 microM) with guanosine 5'-triphosphate (GTP, 50 microM) or guanosine 5'-O-(3-thiotriphosphate) (GTP gamma-S, 10 microM) all significantly enhanced the contraction induced by 0.3 microM Ca2+ (pCa6.5) in beta-escin-skinned smooth muscle of rabbit thoracic aorta. The enhancement of Ca2+ contraction produced by norepinephrine was greater than that produced by methoxamine or clonidine. In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective alpha 1A-adrenoceptor antagonist WB 4101 (100 nM). The enhancement of Ca2+ contraction produced by methoxamine and clonidine was not affected by chloroethylclonidine pretreatment. The effects of methoxamine, clonidine and norepinephrine in the chloroethylclonidine-pretreated tissue were all inhibited by guanosine 5'-O-(2-thiodiphosphate) (GDP beta-S, 1 mM) and 1-(5-isoquinolinylsulfonyl)-methylpiperazine (H-7, 20 microM). Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than that produced by clonidine. These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the Ca2+ sensitivity of contractile elements, and that the Ca2+ sensitization produced by alpha 1A-subtype receptors is mediated through G-protein and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.
7875228	1581	1585	Ca2+	CHEMICAL	7875228T10
7875228	286	297	GTP gamma-S	CHEMICAL	7875228T11
7875228	375	379	Ca2+	CHEMICAL	7875228T12
7875228	146	157	methoxamine	CHEMICAL	7875228T13
7875228	470	474	Ca2+	CHEMICAL	7875228T14
7875228	499	513	norepinephrine	CHEMICAL	7875228T15
7875228	548	559	methoxamine	CHEMICAL	7875228T16
7875228	563	572	clonidine	CHEMICAL	565
7875228	606	626	chloroethylclonidine	CHEMICAL	7875228T18
7875228	672	676	Ca2+	CHEMICAL	7875228T19
7875228	118	132	Norepinephrine	CHEMICAL	360
7875228	175	184	clonidine	CHEMICAL	565
7875228	701	715	norepinephrine	CHEMICAL	7875228T21
7875228	800	811	methoxamine	CHEMICAL	7875228T22
7875228	815	824	clonidine	CHEMICAL	565
7875228	907	914	WB 4101	CHEMICAL	7875228T24
7875228	944	948	Ca2+	CHEMICAL	7875228T25
7875228	203	228	guanosine 5'-triphosphate	CHEMICAL	7875228T26
7875228	973	984	methoxamine	CHEMICAL	7875228T27
7875228	989	998	clonidine	CHEMICAL	565
7875228	1019	1039	chloroethylclonidine	CHEMICAL	7875228T29
7875228	1118	1138	chloroethylclonidine	CHEMICAL	7875228T2
7875228	1069	1080	methoxamine	CHEMICAL	7875228T30
7875228	1082	1091	clonidine	CHEMICAL	565
7875228	1096	1110	norepinephrine	CHEMICAL	7875228T32
7875228	73	77	Ca2+	CHEMICAL	7875228T33
7875228	1336	1354	myosin light chain	GENE-N	7875228T34
7875228	1459	1511	alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B	GENE-N	7875228T35
7875228	1612	1638	alpha 1A-subtype receptors	GENE-Y	7875228T36
7875228	1659	1668	G-protein	GENE-N	7875228T37
7875228	1673	1689	protein kinase C	GENE-N	7875228T38
7875228	874	895	alpha 1A-adrenoceptor	GENE-Y	7875228T39
7875228	1179	1213	guanosine 5'-O-(2-thiodiphosphate)	CHEMICAL	7875228T3
7875228	0	20	Alpha 1-adrenoceptor	GENE-N	7875228T40
7875228	1215	1225	GDP beta-S	CHEMICAL	7875228T4
7875228	1237	1281	1-(5-isoquinolinylsulfonyl)-methylpiperazine	CHEMICAL	7875228T5
7875228	1367	1381	norepinephrine	CHEMICAL	7875228T6
7875228	1416	1425	clonidine	CHEMICAL	565
7875228	249	284	guanosine 5'-O-(3-thiotriphosphate)	CHEMICAL	7875228T8
7875228	1526	1530	Ca2+	CHEMICAL	7875228T9
7875228	CPR:3	7875228T6	7875228T34
7875228	CPR:3	565	7875228T34
7875228	CPR:6	7875228T24	7875228T39

7926307|t|STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells.
7926307|a|The glucose analog streptozotocin (STZ) has long been used as a tool for creating experimental diabetes because of its relatively specific beta-cell cytotoxic effect, but the mechanism by which systemic injection of STZ causes beta-cell destruction is not well understood. In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or GLUT1 to investigate the role of glucose transporter isoforms in mediating STZ cytotoxicity. The in vivo effects of STZ were evaluated by implantation of RIN cells expressing or lacking GLUT2 into athymic nude rats. The drug had a potent cytotoxic effect on RIN cells expressing GLUT2, but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood glucose levels of treated animals. The preferential cytotoxic effect of STZ on GLUT2-expressing cell lines was confirmed by in vitro analysis of GLUT2-expressing and untransfected RIN cells, as well as GLUT2- and GLUT1-overexpressing AtT-20ins cells. Consistent with these data, only GLUT2-expressing RIN or AtT-20ins cells transported STZ efficiently. We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by STZ, and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.
7926307	878	885	glucose	CHEMICAL	7926307T10
7926307	950	953	STZ	CHEMICAL	7926307T11
7926307	1080	1085	GLUT2	GENE-Y	7926307T12
7926307	1091	1096	GLUT1	GENE-Y	7926307T13
7926307	1162	1167	GLUT2	GENE-Y	7926307T14
7926307	1262	1267	GLUT2	GENE-Y	7926307T15
7926307	1427	1432	GLUT2	GENE-Y	7926307T16
7926307	1441	1446	GLUT1	GENE-Y	7926307T17
7926307	463	468	GLUT2	GENE-Y	7926307T18
7926307	472	477	GLUT1	GENE-Y	7926307T19
7926307	1214	1217	STZ	CHEMICAL	7926307T1
7926307	505	524	glucose transporter	GENE-N	7926307T20
7926307	658	663	GLUT2	GENE-Y	7926307T21
7926307	751	756	GLUT2	GENE-Y	7926307T22
7926307	793	798	GLUT2	GENE-Y	7926307T23
7926307	957	962	GLUT2	GENE-Y	7926307T24
7926307	1023	1028	GLUT2	GENE-Y	7926307T25
7926307	56	61	GLUT2	GENE-Y	7926307T26
7926307	1329	1332	STZ	CHEMICAL	7926307T2
7926307	99	113	streptozotocin	CHEMICAL	7926307T3
7926307	296	299	STZ	CHEMICAL	7926307T4
7926307	115	118	STZ	CHEMICAL	7926307T5
7926307	84	91	glucose	CHEMICAL	7926307T6
7926307	505	512	glucose	CHEMICAL	7926307T7
7926307	547	550	STZ	CHEMICAL	7926307T8
7926307	588	591	STZ	CHEMICAL	7926307T9
7926307	CPR:9	7926307T10	7926307T22
7926307	CPR:9	7926307T1	7926307T14
7926307	CPR:9	7926307T2	7926307T15
7926307	CPR:9	7926307T2	7926307T16

7981624|t|Annexin 1 regulation in human epidermal cells.
7981624|a|Annexin 1 (named p35, lipocortin I or calpactin II), initially described as a glucocorticoid induced protein, belongs to a new characterized family of intracellular proteins. In the skin, the role of annexins has still not been elucidated. In a previous study, we reported the localization of annexin 1 in both freshly isolated human epidermal cells and in cultured keratinocytes using immunofluorescence, FACS analysis and immunoblotting techniques. The protein was characterized by Western blot and immunoprecipitation as a 35 kDa protein. Results from in vivo studies confirmed the presence of annexin 1 in basal and suprabasal layers of normal human skin with modified reactivity patterns in hyperproliferative lesions. In the present study, the role of glucocorticoids in annexin 1 regulation was investigated in epidermal cells by Western blot and immunoprecipation assays. In contrast to other studies, we found that glucocorticoid treatment of epidermal cells led to a decrease in annexin 1 content in the cytoplasm and the membranes of cells. As annexin 1 was not detected in the nucleus of cells, we conclude that there was a down regulation of annexin 1 after glucocorticoid treatments rather than a translocation of the protein to the nucleus. Despite the absence of the signal peptide sequence necessary for protein secretion, annexin 1 was released in the keratinocyte culture medium. We found that the protein was secreted only in low Ca2+ medium (0.15 mM), this process required an active metabolism.
7981624	85	97	calpactin II	GENE-Y	7981624T10
7981624	644	653	annexin 1	GENE-Y	7981624T11
7981624	824	833	annexin 1	GENE-Y	7981624T12
7981624	1036	1045	annexin 1	GENE-Y	7981624T13
7981624	0	9	Annexin 1	GENE-Y	7981624T14
7981624	1497	1501	Ca2+	CHEMICAL	7981624T1
7981624	47	56	Annexin 1	GENE-Y	7981624T2
7981624	1102	1111	annexin 1	GENE-Y	7981624T3
7981624	1202	1211	annexin 1	GENE-Y	7981624T4
7981624	1387	1396	annexin 1	GENE-Y	7981624T5
7981624	64	67	p35	GENE-Y	7981624T6
7981624	247	255	annexins	GENE-N	7981624T7
7981624	69	81	lipocortin I	GENE-Y	7981624T8
7981624	340	349	annexin 1	GENE-Y	7981624T9

8073394|t|Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis.
8073394|a|The lysine analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (t-PA). However, their relative efficacy in inhibiting lysis of clots that have been formed in the presence of exogenous t-PA or that have been formed and then exposed to exogenous t-PA has not been well characterized. The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue. However, their inhibitory effect was markedly reduced if clots were formed in the presence of t-PA and then exposed to either of the lysine analogues. The analogues did not inhibit the initial binding of t-PA to fibrin. They did inhibit binding of plasminogen to fibrin as well as the activation of plasminogen by t-PA in the absence of fibrin. The data suggest that lysine analogues, even at low concentrations, reduce the rate of t-PA induced whole blood clot lysis by several mechanisms.
8073394	821	825	AMCA	CHEMICAL	8073394T10
8073394	840	844	EACA	CHEMICAL	503
8073394	953	959	lysine	CHEMICAL	8073394T12
8073394	1068	1074	lysine	CHEMICAL	8073394T13
8073394	22	28	lysine	CHEMICAL	8073394T14
8073394	1179	1183	t-PA	GENE-Y	8073394T15
8073394	1289	1293	t-PA	GENE-Y	8073394T16
8073394	1297	1303	fibrin	GENE-N	8073394T17
8073394	1333	1344	plasminogen	GENE-Y	8073394T18
8073394	1348	1354	fibrin	GENE-N	8073394T19
8073394	187	191	AMCA	CHEMICAL	8073394T1
8073394	1384	1395	plasminogen	GENE-Y	8073394T20
8073394	1399	1403	t-PA	GENE-Y	8073394T21
8073394	1422	1428	fibrin	GENE-N	8073394T22
8073394	1517	1521	t-PA	GENE-Y	8073394T23
8073394	336	364	tissue plasminogen activator	GENE-Y	8073394T24
8073394	366	370	t-PA	GENE-Y	8073394T25
8073394	486	490	t-PA	GENE-Y	8073394T26
8073394	546	550	t-PA	GENE-Y	8073394T27
8073394	649	659	fibrinogen	GENE-N	8073394T28
8073394	815	819	t-PA	GENE-Y	8073394T29
8073394	1218	1224	lysine	CHEMICAL	8073394T2
8073394	983	987	t-PA	GENE-Y	8073394T30
8073394	1057	1061	t-PA	GENE-Y	8073394T31
8073394	42	46	t-PA	GENE-Y	8073394T32
8073394	1452	1458	lysine	CHEMICAL	8073394T3
8073394	100	125	epsilon-aminocaproic acid	CHEMICAL	8073394T4
8073394	83	89	lysine	CHEMICAL	8073394T5
8073394	127	131	EACA	CHEMICAL	503
8073394	644	648	125I	CHEMICAL	8073394T7
8073394	137	185	trans-4-amino-methyl cyclohexane carboxylic acid	CHEMICAL	8073394T8
8073394	739	745	lysine	CHEMICAL	8073394T9
8073394	CPR:4	8073394T10	8073394T30
8073394	CPR:4	8073394T10	8073394T31
8073394	CPR:4	503	8073394T30
8073394	CPR:4	503	8073394T31
8073394	CPR:4	8073394T14	8073394T32
8073394	CPR:4	8073394T2	8073394T15
8073394	CPR:4	8073394T3	8073394T23
8073394	CPR:4	8073394T9	8073394T29

8098142|t|Histamine enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via H1-receptor activation.
8098142|a|Previous studies have demonstrated that histamine primarily excites unidentified neurons in the rat supraoptic nucleus. We investigated the neuromodulatory effects of histamine on immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus using intracellular recording techniques from the hypothalamo-neurohypophysial explant. Exogenous application of histamine (0.1-100 microM) to vasopressinergic neurons produced a small membrane depolarization accompanied by an increase of up to 100% in the amplitude of the depolarizing afterpotential that follows current-evoked trains of action potentials. The enhancement of the depolarizing afterpotential by histamine did not depend upon the depolarization. Further, histamine enhanced the amplitude of the depolarizing afterpotential when blocking the afterhyperpolarizing potential with d-tubocurarine or apamin, and in the presence of tetrodotoxin and d-tubocurarine or apamin, indicating a postsynaptic action of histamine on the depolarizing afterpotential that is not simply a reflection of a decrease in the afterhyperpolarizing potential. These toxins also had no effect on the histamine-induced depolarization. The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine. In summary, these results show that the excitatory effect of histamine on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the H1-receptor-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.
8098142	332	341	histamine	CHEMICAL	8098142T10
8098142	378	389	vasopressin	CHEMICAL	8098142T11
8098142	541	550	histamine	CHEMICAL	8098142T12
8098142	205	214	histamine	CHEMICAL	8098142T13
8098142	841	850	histamine	CHEMICAL	8098142T14
8098142	900	909	histamine	CHEMICAL	8098142T15
8098142	1022	1036	d-tubocurarine	CHEMICAL	1187
8098142	1071	1083	tetrodotoxin	CHEMICAL	8098142T17
8098142	1088	1102	d-tubocurarine	CHEMICAL	1187
8098142	1150	1159	histamine	CHEMICAL	8098142T19
8098142	1319	1328	histamine	CHEMICAL	8098142T1
8098142	0	9	Histamine	CHEMICAL	8098142T20
8098142	87	98	vasopressin	CHEMICAL	8098142T21
8098142	1437	1458	histamine H1-receptor	GENE-Y	8098142T22
8098142	1523	1534	H1-receptor	GENE-Y	8098142T23
8098142	1614	1635	histamine H2-receptor	GENE-Y	8098142T24
8098142	1835	1846	H1-receptor	GENE-Y	8098142T25
8098142	141	152	H1-receptor	GENE-Y	8098142T26
8098142	1407	1416	histamine	CHEMICAL	8098142T2
8098142	1437	1446	histamine	CHEMICAL	8098142T3
8098142	1467	1488	2-thiazolylethylamine	CHEMICAL	8098142T4
8098142	1546	1558	promethazine	CHEMICAL	8098142T5
8098142	1614	1623	histamine	CHEMICAL	8098142T6
8098142	1648	1658	cimetidine	CHEMICAL	8098142T7
8098142	1721	1730	histamine	CHEMICAL	8098142T8
8098142	1767	1778	vasopressin	CHEMICAL	8098142T9
8098142	CPR:3	8098142T20	8098142T26
8098142	CPR:3	8098142T8	8098142T25
8098142	CPR:5	8098142T4	8098142T22
8098142	CPR:6	8098142T5	8098142T23
8098142	CPR:6	8098142T7	8098142T24

8142113|t|Adapalene, a new chemical entity with retinoid activity.
8142113|a|Adapalene is a novel chemical entity which, in terms of pharmacology, behaves similar to tretinoin, but is chemically and photochemically stable. It has a particular selectivity profile for the known nuclear retinoic acid receptors with low affinity for RAR alpha and no transactivating potential for RXR alpha. This receptor profile could imply that adapalene, in contrast to tretinoin, affects the terminal differentiation pathway of epidermal cells rather than their proliferation. Furthermore, adapalene does not bind to members of the cellular retinoic acid binding protein family. Adapalene has comedolytic activity in the topical rhino mouse model. It exerts a moderate-to-potent anti-inflammatory effect in a series of in vitro and in vivo models. In comparative clinical studies involving 72 acne patients, the efficacy of adapalene was comparable, if not superior, to tretinoin, but adapalene was better tolerated. The data reviewed in this paper indicate that adapalene should be particularly beneficial in the treatment of acne.
8142113	950	959	adapalene	CHEMICAL	8142113T10
8142113	146	155	tretinoin	CHEMICAL	8142113T11
8142113	1028	1037	adapalene	CHEMICAL	8142113T12
8142113	0	9	Adapalene	CHEMICAL	203
8142113	38	46	retinoid	CHEMICAL	8142113T14
8142113	265	288	retinoic acid receptors	GENE-N	8142113T15
8142113	311	320	RAR alpha	GENE-Y	8142113T16
8142113	358	367	RXR alpha	GENE-Y	8142113T17
8142113	606	635	retinoic acid binding protein	GENE-N	8142113T18
8142113	57	66	Adapalene	CHEMICAL	203
8142113	265	278	retinoic acid	CHEMICAL	8142113T2
8142113	408	417	adapalene	CHEMICAL	8142113T3
8142113	434	443	tretinoin	CHEMICAL	8142113T4
8142113	555	564	adapalene	CHEMICAL	8142113T5
8142113	606	619	retinoic acid	CHEMICAL	8142113T6
8142113	644	653	Adapalene	CHEMICAL	203
8142113	889	898	adapalene	CHEMICAL	8142113T8
8142113	935	944	tretinoin	CHEMICAL	8142113T9

8319997|t|Comparative effects of three different potent renin inhibitors in primates.
8319997|a|The goal of the present study was to compare the effects of three potent reference renin inhibitors (remikiren, CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys. In these monkeys, arterial pressure was measured in the conscious state with a telemetry system. Oral and intravenous maximal effective doses of the three renin inhibitors were compared in parallel groups of monkeys. In additional experiments, remikiren was given on top of either CGP 38560A or enalkiren in the same animals. Finally, the three drugs were compared with the angiotensin converting enzyme inhibitor cilazapril. The effects of the three drugs on the plasma components of the renin-angiotensin system (plasma renin activity, immunoreactive renin, and immunoreactive angiotensin II concentrations) were also measured. Our results show that remikiren was as effective as cilazapril and markedly more effective than CGP 38560A or enalkiren in reducing arterial pressure in our monkey model. Interestingly, these differences in arterial pressure could not be explained by differences of in vitro potency or different biochemical changes of the plasma components of the renin-angiotensin system, because the inhibitors all reduced immunoreactive angiotensin II to similarly low levels. One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and enalkiren is able to inhibit renin in a functionally important extraplasmatic compartment.
8319997	679	689	cilazapril	CHEMICAL	1306
8319997	917	926	remikiren	CHEMICAL	8319997T11
8319997	947	957	cilazapril	CHEMICAL	1306
8319997	991	1001	CGP 38560A	CHEMICAL	8319997T13
8319997	1005	1014	enalkiren	CHEMICAL	8319997T14
8319997	1243	1248	renin	GENE-Y	8319997T15
8319997	1249	1260	angiotensin	GENE-Y	8319997T16
8319997	1319	1333	angiotensin II	GENE-Y	8319997T17
8319997	1476	1481	renin	GENE-Y	8319997T18
8319997	420	425	renin	GENE-Y	8319997T19
8319997	177	186	remikiren	CHEMICAL	8319997T1
8319997	639	668	angiotensin converting enzyme	GENE-Y	8319997T20
8319997	754	759	renin	GENE-Y	8319997T21
8319997	760	771	angiotensin	GENE-Y	8319997T22
8319997	787	792	renin	GENE-Y	8319997T23
8319997	818	823	renin	GENE-Y	8319997T24
8319997	844	858	angiotensin II	GENE-Y	8319997T25
8319997	159	164	renin	GENE-Y	8319997T26
8319997	46	51	renin	GENE-N	8319997T27
8319997	188	198	CGP 38560A	CHEMICAL	8319997T2
8319997	204	213	enalkiren	CHEMICAL	8319997T3
8319997	1407	1416	remikiren	CHEMICAL	8319997T4
8319997	1432	1442	CGP 38560A	CHEMICAL	8319997T5
8319997	1447	1456	enalkiren	CHEMICAL	8319997T6
8319997	218	224	sodium	CHEMICAL	8319997T7
8319997	546	556	CGP 38560A	CHEMICAL	8319997T8
8319997	560	569	enalkiren	CHEMICAL	8319997T9
8319997	CPR:4	1306	8319997T20
8319997	CPR:4	8319997T1	8319997T26
8319997	CPR:4	8319997T2	8319997T26
8319997	CPR:4	8319997T3	8319997T26
8319997	CPR:4	8319997T4	8319997T18
8319997	CPR:4	8319997T5	8319997T18
8319997	CPR:4	8319997T6	8319997T18

8384226|t|Inhibition of cytokine-primed eosinophil chemotaxis by nedocromil sodium.
8384226|a|BACKGROUND: Eosinophil influx into the lung tissue is considered to be relevant for the pathogenesis of asthma. Various chemotactic factors may be responsible for this influx. Recently it has been demonstrated that the cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and interleukin-5 (IL-5) are present in the circulation of individuals with allergic asthma. These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (FMLP) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a (C5a). Here the effect of nedocromil sodium on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with GM-CSF or IL-3 toward FMLP, NAF/IL-8 was evaluated. RESULTS: Nedocromil sodium inhibited the chemotactic response toward FMLP and NAF/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L). CONCLUSIONS: The chemotactic responses toward C5a were inhibited by nedocromil sodium at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L). Nedocromil sodium (0.1 mumol/L) was also effective in inhibiting the chemotactic response toward FMLP (10 nmol/L) of eosinophils isolated from the circulation of patients with allergic asthma 3 hours after allergen challenge. These findings might explain in part the antiinflammatory action of nedocromil sodium.
8384226	55	72	nedocromil sodium	CHEMICAL	8384226T10
8384226	1173	1177	IL-3	GENE-Y	8384226T11
8384226	1299	1302	C5a	GENE-Y	8384226T12
8384226	293	302	cytokines	GENE-N	8384226T13
8384226	303	351	granulocyte-macrophage colony-stimulating factor	GENE-Y	8384226T14
8384226	353	359	GM-CSF	GENE-Y	8384226T15
8384226	362	375	interleukin-3	GENE-Y	8384226T16
8384226	377	381	IL-3	GENE-Y	8384226T17
8384226	388	401	interleukin-5	GENE-Y	8384226T18
8384226	403	407	IL-5	GENE-Y	8384226T19
8384226	1321	1338	nedocromil sodium	CHEMICAL	8384226T1
8384226	483	492	cytokines	GENE-N	8384226T20
8384226	645	673	neutrophil-activating factor	GENE-Y	8384226T21
8384226	675	678	NAF	GENE-Y	8384226T22
8384226	680	684	IL-8	GENE-Y	8384226T23
8384226	701	724	complement fragment C5a	GENE-Y	8384226T24
8384226	726	729	C5a	GENE-Y	8384226T25
8384226	889	895	GM-CSF	GENE-Y	8384226T26
8384226	899	903	IL-3	GENE-N	8384226T27
8384226	917	920	NAF	GENE-Y	8384226T28
8384226	921	925	IL-8	GENE-Y	8384226T29
8384226	1445	1462	Nedocromil sodium	CHEMICAL	8384226T2
8384226	1019	1022	NAF	GENE-Y	8384226T30
8384226	1023	1027	IL-8	GENE-Y	8384226T31
8384226	1031	1037	GM-CSF	GENE-Y	8384226T32
8384226	14	22	cytokine	GENE-N	8384226T33
8384226	1542	1546	FMLP	CHEMICAL	8384226T3
8384226	1739	1756	nedocromil sodium	CHEMICAL	8384226T4
8384226	595	632	formyl-methionyl-leucyl-phenylalanine	CHEMICAL	8384226T5
8384226	635	639	FMLP	CHEMICAL	8384226T6
8384226	751	768	nedocromil sodium	CHEMICAL	8384226T7
8384226	950	967	Nedocromil sodium	CHEMICAL	8384226T8
8384226	1010	1014	FMLP	CHEMICAL	8384226T9
8384226	CPR:4	8384226T10	8384226T33
8384226	CPR:4	8384226T1	8384226T12
8384226	CPR:4	8384226T8	8384226T11
8384226	CPR:4	8384226T8	8384226T30
8384226	CPR:4	8384226T8	8384226T31
8384226	CPR:4	8384226T8	8384226T32

8415655|t|Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain.
8415655|a|Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system. In situ hybridization with antisense RNA for the enzyme indicated that mRNA for the enzyme was predominantly expressed in the leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. The findings agree with those obtained by immunohistochemical staining with antibodies against the enzyme. It was further revealed that prostaglandin D synthase activity was considerably greater in the isolated leptomeninges (14.2 nmol per min per mg of protein) and choroid plexus (7.0 nmol per min per mg of protein) than the activity in the whole brain (2.0 nmol per min per mg of protein). These results, taken together, indicate that the enzyme is mainly synthesized and located in the leptomeninges, choroid plexus, and oligodendrocytes in the brain.
8415655	186	214	prostaglandin-H2 D-isomerase	GENE-Y	8415655T10
8415655	745	769	prostaglandin D synthase	GENE-Y	8415655T11
8415655	216	299	(5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase	GENE-Y	8415655T12
8415655	32	56	prostaglandin D synthase	GENE-Y	8415655T13
8415655	136	147	Glutathione	CHEMICAL	137
8415655	359	375	prostaglandin D2	CHEMICAL	8415655T2
8415655	160	175	prostaglandin D	CHEMICAL	8415655T3
8415655	186	202	prostaglandin-H2	CHEMICAL	8415655T4
8415655	745	760	prostaglandin D	CHEMICAL	8415655T5
8415655	216	287	(5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate	CHEMICAL	8415655T6
8415655	32	47	prostaglandin D	CHEMICAL	8415655T7
8415655	301	312	EC 5.3.99.2	GENE-Y	8415655T8
8415655	160	184	prostaglandin D synthase	GENE-Y	8415655T9
8415655	CPR:9	8415655T2	8415655T10
8415655	CPR:9	8415655T2	8415655T12
8415655	CPR:9	8415655T2	8415655T8
8415655	CPR:9	8415655T2	8415655T9

8589992|t|cDNA cloning and functional properties of human glutamate receptor EAA3 (GluR5) in homomeric and heteromeric configuration.
8589992|a|We have isolated a new member of the human glutamate receptor family from a fetal brain cDNA library. This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions. Cell lines stably expressing EAA3a protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA). Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione). Coexpression of EAA3a and human EAA1 cDNAs in HEK 293 cells formed a heteromeric channel with unique properties. Kainate and AMPA activated the heteromeric channel with significantly higher affinities than observed for EAA3a alone. Ligand binding studies with the recombinant EAA3a receptor expressed in mammalian cells indicated a high affinity kainate binding site (Kd = 120 +/- 15.0 nM). The relative potency of compounds in displacing [3H]-kainate binding to EAA3a receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.
8589992	1506	1520	dihydrokainate	CHEMICAL	8589992T10
8589992	1523	1527	NMDA	CHEMICAL	1209
8589992	274	284	nucleotide	CHEMICAL	8589992T12
8589992	396	401	amino	CHEMICAL	8589992T13
8589992	406	413	carboxy	CHEMICAL	8589992T14
8589992	167	176	glutamate	CHEMICAL	8589992T15
8589992	574	581	kainate	CHEMICAL	8589992T16
8589992	583	594	L-glutamate	CHEMICAL	8589992T17
8589992	599	655	(RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate	CHEMICAL	8589992T18
8589992	657	661	AMPA	CHEMICAL	8589992T19
8589992	1265	1272	kainate	CHEMICAL	8589992T1
8589992	664	671	Kainate	CHEMICAL	8589992T20
8589992	785	798	cyclothiazide	CHEMICAL	8589992T21
8589992	826	850	non-N-methyl-D-aspartate	CHEMICAL	8589992T22
8589992	852	856	NMDA	CHEMICAL	1209
8589992	878	882	CNQX	CHEMICAL	8589992T24
8589992	884	916	6-cyano-7-nitro-quinoxalinedione	CHEMICAL	8589992T25
8589992	1032	1039	Kainate	CHEMICAL	8589992T26
8589992	1044	1048	AMPA	CHEMICAL	8589992T27
8589992	48	57	glutamate	CHEMICAL	8589992T28
8589992	1138	1143	EAA3a	GENE-Y	8589992T29
8589992	1358	1370	[3H]-kainate	CHEMICAL	8589992T2
8589992	1195	1200	EAA3a	GENE-Y	8589992T30
8589992	1382	1387	EAA3a	GENE-Y	8589992T31
8589992	254	259	EAA3a	GENE-Y	8589992T32
8589992	323	335	rat GluR5-2b	GENE-Y	8589992T33
8589992	374	388	human GluR5-1d	GENE-Y	8589992T34
8589992	461	466	EAA3a	GENE-Y	8589992T35
8589992	492	517	ligand-gated ion channels	GENE-N	8589992T36
8589992	161	185	human glutamate receptor	GENE-N	8589992T37
8589992	755	769	concanavalin A	GENE-N	8589992T38
8589992	771	775	conA	GENE-N	8589992T39
8589992	1412	1419	kainate	CHEMICAL	8589992T3
8589992	830	866	N-methyl-D-aspartate (NMDA) receptor	GENE-N	8589992T40
8589992	935	940	EAA3a	GENE-Y	8589992T41
8589992	945	955	human EAA1	GENE-Y	8589992T42
8589992	42	66	human glutamate receptor	GENE-N	8589992T43
8589992	67	71	EAA3	GENE-Y	8589992T44
8589992	73	78	GluR5	GENE-Y	8589992T45
8589992	1422	1433	L-glutamate	CHEMICAL	8589992T4
8589992	1436	1447	quisqualate	CHEMICAL	8589992T5
8589992	1450	1482	6,7-dinitroquinoxaline-2,3-dione	CHEMICAL	3601
8589992	1484	1488	DNQX	CHEMICAL	3601
8589992	1492	1496	CNQX	CHEMICAL	8589992T8
8589992	1499	1503	AMPA	CHEMICAL	8589992T9
8589992	CPR:6	8589992T24	8589992T40
8589992	CPR:6	8589992T25	8589992T40

8606397|t|Leukotrienes in the pathogenesis of pulmonary blast injury.
8606397|a|Our previous studies demonstrate a significant increase of sulfidopeptide leukotriene concentrations in animals exposed to a free air blast. The aim of this study was to analyze the role of leukotrienes in the local response of lung tissue as well as in the general response of organisms to blast overpressure. The study was conducted on adult rabbits exposed to moderate blast overpressure (four pulmonary contusions characterized as confluent ecchymoses involving 30 to 60% of the lungs), generated in laboratory conditions. One group of experimental animals was treated with 5-lipoxygenase (5-LO) inhibitor, diethylcarbamazine (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.), immediately before blast. The early posttraumatic period was observed (30 minutes after blast). Hemodynamic parameters (mean arterial pressure, heart rate, blood gases) as well as arterial plasma levels of conjugated dienes were observed. The myeloperoxidase activity, lipid peroxidation products levels, and water contents were measured in the lung tissue of injured rabbits. We observed that 5-LO inhibition reduced edema formation, accumulation of neutrophils, and generation of lipid peroxidation products in injured lungs. In this study, we demonstrated that treatment with DEC inhibits the increased systemic generation of conjugated dienes after blast injury. Although DEC exerts local antioxidant activity with beneficial effects on lung tissue, this 5-LO inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.
8606397	638	652	5-lipoxygenase	GENE-Y	8606397T10
8606397	654	658	5-LO	GENE-Y	8606397T11
8606397	985	1000	myeloperoxidase	GENE-Y	8606397T12
8606397	1321	1324	DEC	CHEMICAL	8606397T1
8606397	1418	1421	DEC	CHEMICAL	8606397T2
8606397	250	262	leukotrienes	CHEMICAL	8606397T3
8606397	671	689	diethylcarbamazine	CHEMICAL	8606397T4
8606397	691	694	DEC	CHEMICAL	8606397T5
8606397	134	145	leukotriene	CHEMICAL	8606397T6
8606397	0	12	Leukotrienes	CHEMICAL	8606397T7
8606397	1136	1140	5-LO	GENE-Y	8606397T8
8606397	1501	1505	5-LO	GENE-Y	8606397T9
8606397	CPR:4	8606397T2	8606397T9
8606397	CPR:4	8606397T4	8606397T10
8606397	CPR:4	8606397T4	8606397T11
8606397	CPR:4	8606397T5	8606397T10
8606397	CPR:4	8606397T5	8606397T11

8647141|t|Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
8647141|a|OBJECTIVE: This meta-analysis of two European studies evaluated the efficacy and safety of modified-release tamsulosin 0.4 mg once daily compared with placebo in patients with benign prostatic enlargement, lower urinary tract symptoms and prostatic obstruction (symptomatic BPH). METHODS: Patients entered a 2-week placebo run-in period, followed by randomization to treatment with tamsulosin (382 patients) or placebo (193 patients) once daily for 12 weeks. RESULTS: Maximum urinary flow rate improved to a greater extent in the tamsulosin group (1.6 ml/s, 16%) than the placebo group (0.6 ml/s, 6%) (p = 0.002). Total Boyarsky symptom score also improved to a greater extent in the tamsulosin group (3.3 points, 35.1% reduction) than the placebo group (2.4 points, 25.5% reduction) (p = 0.002). Significantly more tamsulosin patients (66%) than placebo patients (49%) had a > or = 25% decrease in total symptom score at endpoint (p < 0.001). Twelve weeks of treatment with tamsulosin also produced significant improvements in average urinary flow rate (p = 0.005) and voiding or "obstructive" (p = 0.008) and storage or "irritative' (p = 0.017) symptom scores. The incidence of drug-related adverse events was comparable for the tamsulosin and placebo groups (13 and 12% respectively, p = 0.802). The same applies to the incidence of adverse events commonly attributed to alpha 1-adrenoceptor antagonists, such as dizziness, headache, postural hypotension, syncope, asthenia, somnolence and rhinitis. There were no clinically significant changes in blood pressure or pulse rate in tamsulosin patients compared with placebo patients both in hypertensive and normotensive BPH patients. CONCLUSION: Tamsulosin 0.4 mg once daily is safe, well-tolerated and improves both the symptoms and urinary flow rate in patients with benign prostatic obstruction (symptomatic BPH).
8647141	0	10	Tamsulosin	CHEMICAL	696
8647141	224	234	Tamsulosin	CHEMICAL	696
8647141	1622	1642	alpha 1-adrenoceptor	GENE-Y	8647141T12
8647141	41	62	alpha 1A-adrenoceptor	GENE-Y	8647141T13
8647141	356	366	tamsulosin	CHEMICAL	8647141T1
8647141	1479	1489	tamsulosin	CHEMICAL	8647141T2
8647141	1831	1841	tamsulosin	CHEMICAL	8647141T3
8647141	1946	1956	Tamsulosin	CHEMICAL	696
8647141	630	640	tamsulosin	CHEMICAL	8647141T5
8647141	778	788	tamsulosin	CHEMICAL	8647141T6
8647141	932	942	tamsulosin	CHEMICAL	8647141T7
8647141	1064	1074	tamsulosin	CHEMICAL	8647141T8
8647141	1223	1233	tamsulosin	CHEMICAL	8647141T9
8647141	CPR:6	696	8647141T13

8666140|t|Human prohormone convertase 3 gene: exon-intron organization and molecular scanning for mutations in Japanese subjects with NIDDM.
8666140|a|Proinsulin is converted to insulin by the concerted action of two sequence-specific subtilisin-like proteases termed prohormone convertase 2 (PC2) and prohormone convertase 3 (PC3). PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide. Thus, PC3 plays a key role in regulating insulin biosynthesis. Expressions of insulin and PC3, but not PC2, are coordinately regulated by glucose, consistent with the important role of PC3 in regulating proinsulin processing. NIDDM is associated with increased secretion of proinsulin and proinsulin-like molecules, suggesting that mutations in the PC3 gene may be involved in the development of this disorder. To examine this hypothesis, we have isolated and characterized the human PC3 gene and screened it for mutations in a group of Japanese subjects with NIDDM. The PC3 gene consists of 14 exons spanning more than 35 kb. The exon-intron organization of PC2 and PC3 genes are conserved, consistent with a common evolutionary origin for the prohormone convertase gene family. Single-strand conformational analysis and nucleotide sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population. These data suggest that genetic variation in the PC3 gene is unlikely to be a major contributor to NIDDM susceptibility in Japanese.
8666140	1437	1440	PC3	GENE-Y	8666140T10
8666140	1522	1531	Arg/Gln53	GENE-N	8666140T11
8666140	1541	1551	Gln/Glu638	GENE-N	8666140T12
8666140	273	276	PC2	GENE-Y	8666140T13
8666140	282	305	prohormone convertase 3	GENE-Y	8666140T14
8666140	1666	1669	PC3	GENE-Y	8666140T15
8666140	307	310	PC3	GENE-Y	8666140T16
8666140	313	316	PC3	GENE-Y	8666140T17
8666140	322	357	type I proinsulin-processing enzyme	GENE-N	8666140T18
8666140	402	412	proinsulin	GENE-Y	8666140T19
8666140	1380	1390	nucleotide	CHEMICAL	8666140T1
8666140	158	165	insulin	GENE-Y	8666140T20
8666140	416	423	insulin	GENE-Y	8666140T21
8666140	440	450	proinsulin	GENE-Y	8666140T22
8666140	564	567	PC3	GENE-Y	8666140T23
8666140	599	606	insulin	GENE-Y	8666140T24
8666140	636	643	insulin	GENE-Y	8666140T25
8666140	648	651	PC3	GENE-Y	8666140T26
8666140	661	664	PC2	GENE-Y	8666140T27
8666140	743	746	PC3	GENE-Y	8666140T28
8666140	761	771	proinsulin	GENE-Y	8666140T29
8666140	467	471	COOH	CHEMICAL	8666140T2
8666140	832	842	proinsulin	GENE-Y	8666140T30
8666140	847	857	proinsulin	GENE-Y	8666140T31
8666140	907	910	PC3	GENE-Y	8666140T32
8666140	215	240	subtilisin-like proteases	GENE-N	8666140T33
8666140	1036	1045	human PC3	GENE-Y	8666140T34
8666140	1129	1132	PC3	GENE-Y	8666140T35
8666140	0	29	Human prohormone convertase 3	GENE-Y	8666140T36
8666140	547	548	C	CHEMICAL	8666140T3
8666140	696	703	glucose	CHEMICAL	8666140T4
8666140	131	141	Proinsulin	GENE-Y	8666140T5
8666140	1217	1220	PC2	GENE-Y	8666140T6
8666140	1225	1228	PC3	GENE-Y	8666140T7
8666140	248	271	prohormone convertase 2	GENE-Y	8666140T8
8666140	1303	1324	prohormone convertase	GENE-N	8666140T9
8666140	CPR:3	8666140T4	8666140T25
8666140	CPR:3	8666140T4	8666140T26

8730743|t|Desipramine administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and 5-HT2A binding sites and their relationship to behaviour.
8730743|a|1. The effects of repeated administration of the tricyclic antidepressant drug, desipramine (DMI), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and 5-HT2A receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats. 2. Locomotor activity and rearing were increased in OB rats compared to sham-operated controls. The effect of various doses of DMI (administered orally twice daily for 21 days) on these behavioural measures was examined. A dose of 7.5 mg kg-1 provided optimal reversal of hyperlocomotion and increased rearing in OB rats, without changing these measures in sham-operated controls. 3. The time course of DMI (7.5 mg kg-1) on behavioural and neurochemical measures was examined. locomotion and rearing in OB rats were not significantly altered after 7 days, were significantly attenuated after 14 days and were normalized after 21 days. 4. After 7 days of DMI administration the number of beta-adrenoceptors was lower in frontal and occipital cortex and hippocampus. This reduction was largely restricted to the beta 1-adrenoceptor subtype. Administration of DMI for 14 or 21 days did not further reduce the number of beta-adrenoceptors. The DMI induced reduction in beta-adrenoceptors did not differ in OB and sham-operated control rats. 5. DMI administration for up to 21 days produced a progressive reduction in the number of 5-HT2A receptors in frontal cortex, without significant alterations in occipital cortex. 6. The time course of the reduction in the number of 5-HT2A receptors was similar to that of the DMI-induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different. 7. The present results suggest that the action of DMI in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical 5-HT2A receptors.
8730743	253	256	DMI	CHEMICAL	1139
8730743	1126	1129	DMI	CHEMICAL	1139
8730743	0	11	Desipramine	CHEMICAL	1139
8730743	1282	1301	beta 1-adrenoceptor	GENE-Y	8730743T13
8730743	1388	1406	beta-adrenoceptors	GENE-N	8730743T14
8730743	1437	1455	beta-adrenoceptors	GENE-N	8730743T15
8730743	1599	1605	5-HT2A	GENE-Y	65794
8730743	1741	1747	5-HT2A	GENE-Y	65794
8730743	1851	1869	beta-adrenoceptors	GENE-N	8730743T18
8730743	342	359	beta-adrenoceptor	GENE-N	8730743T19
8730743	1329	1332	DMI	CHEMICAL	1139
8730743	2021	2039	beta-adrenoceptors	GENE-N	8730743T20
8730743	2094	2100	5-HT2A	GENE-Y	65794
8730743	364	370	5-HT2A	GENE-Y	65794
8730743	1159	1177	beta-adrenoceptors	GENE-N	8730743T23
8730743	102	108	5-HT2A	GENE-Y	65794
8730743	80	97	beta-adrenoceptor	GENE-N	8730743T25
8730743	1412	1415	DMI	CHEMICAL	1139
8730743	1512	1515	DMI	CHEMICAL	1139
8730743	1785	1788	DMI	CHEMICAL	1139
8730743	1943	1946	DMI	CHEMICAL	1139
8730743	599	602	DMI	CHEMICAL	1139
8730743	209	218	tricyclic	CHEMICAL	8730743T7
8730743	875	878	DMI	CHEMICAL	1139
8730743	240	251	desipramine	CHEMICAL	8730743T9
8730743	CPR:4	1139	8730743T23
8730743	CPR:4	1139	8730743T15
8730743	CPR:4	1139	65794
8730743	CPR:4	1139	65794
8730743	CPR:4	1139	8730743T18
8730743	CPR:4	1139	8730743T20
8730743	CPR:4	1139	65794

8755512|t|Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.
8755512|a|In addition to its well known sedative and teratogenic effects, thalidomide also possesses potent immunomodulatory and antiinflammatory activities, being most effective against leprosy and chronic graft-versus-host disease. The immunomodulatory activity of thalidomide has been ascribed to the selective inhibition of tumor necrosis factor alpha from monocytes. The molecular mechanism for the immunomodulatory effect of thalidomide remains unknown. To elucidate this mechanism, we synthesized an active photoaffinity label of thalidomide as a probe to identify the molecular target of the drug. Using the probe, we specifically labeled a pair of proteins of 43-45 kDa with high acidity from bovine thymus extract. Purification of these proteins and partial peptide sequence determination revealed them to be alpha1-acid glycoprotein (AGP). We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.
8755512	446	473	tumor necrosis factor alpha	GENE-Y	8755512T10
8755512	937	961	alpha1-acid glycoprotein	GENE-Y	8755512T11
8755512	963	966	AGP	GENE-Y	8755512T12
8755512	1042	1051	human AGP	GENE-N	8755512T13
8755512	26	50	alpha1-acid glycoprotein	GENE-N	8755512T14
8755512	88	115	tumor necrosis factor alpha	GENE-Y	8755512T15
8755512	1330	1341	thalidomide	CHEMICAL	8562
8755512	385	396	thalidomide	CHEMICAL	8562
8755512	549	560	thalidomide	CHEMICAL	8562
8755512	655	666	thalidomide	CHEMICAL	8562
8755512	997	1008	thalidomide	CHEMICAL	8562
8755512	1074	1085	thalidomide	CHEMICAL	8562
8755512	11	22	thalidomide	CHEMICAL	8562
8755512	1208	1235	tumor necrosis factor alpha	GENE-Y	8755512T8
8755512	1274	1277	AGP	GENE-N	8755512T9
8755512	CPR:4	8562	8755512T10
8755512	CPR:4	8562	8755512T8
8755512	CPR:4	8562	8755512T15

8793745|t|AMPA receptor heterogeneity in rat hippocampal neurons revealed by differential sensitivity to cyclothiazide.
8793745|a|1. The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization by glutamate, and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons. Cultures prepared from area CA1 stratum radiatum tended to show weaker modulation by cyclothiazide than cultures prepared from the whole hippocampus. 2. Kinetic analysis of concentration jump responses to glutamate revealed multiple populations of receptors with fast (approximately 400 ms), intermediate (approximately 2-4 s), and slow (> 20 s) time constants for recovery from modulation by cyclothiazide. The amplitudes of these components varied widely between cells, suggesting the existence of at least three populations of AMPA receptor subtypes, the relative density of which varied from cell to cell. 3. The complex patterns of sensitivity to cyclothiazide seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and GluR-B subunits. Recovery from modulation by cyclothiazide was slower for GluR-AiBi and GluR-AoBi than for GluR-AiBo and GluR-AoBo. 4. Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit. However, recovery from modulation by cyclothiazide was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to cyclothiazide. 5. These results demonstrate that AMPA receptors expressed in hippocampal neurons are assembled in a variety of subunit and splice variant combinations that might serve as a mechanism to fine-tune the kinetics of synaptic transmission.
8793745	307	320	cyclothiazide	CHEMICAL	8793745T10
8793745	138	194	alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid	CHEMICAL	8793745T11
8793745	488	501	cyclothiazide	CHEMICAL	8793745T12
8793745	608	617	glutamate	CHEMICAL	8793745T13
8793745	796	809	cyclothiazide	CHEMICAL	8793745T14
8793745	933	937	AMPA	CHEMICAL	8793745T15
8793745	196	200	AMPA	CHEMICAL	8793745T16
8793745	1055	1068	cyclothiazide	CHEMICAL	8793745T17
8793745	0	4	AMPA	CHEMICAL	8793745T18
8793745	95	108	cyclothiazide	CHEMICAL	8793745T19
8793745	1147	1151	AMPA	CHEMICAL	8793745T1
8793745	1147	1160	AMPA receptor	GENE-N	8793745T20
8793745	1249	1255	GluR-A	GENE-Y	8793745T21
8793745	1260	1266	GluR-B	GENE-Y	8793745T22
8793745	1334	1343	GluR-AiBi	GENE-N	8793745T23
8793745	1348	1357	GluR-AoBi	GENE-N	8793745T24
8793745	1367	1376	GluR-AiBo	GENE-N	8793745T25
8793745	1381	1390	GluR-AoBo	GENE-N	8793745T26
8793745	1448	1454	GluR-A	GENE-Y	8793745T27
8793745	1474	1480	GluR-B	GENE-Y	8793745T28
8793745	1508	1522	AMPA receptors	GENE-N	8793745T29
8793745	1305	1318	cyclothiazide	CHEMICAL	8793745T2
8793745	1622	1631	GluR-AoBi	GENE-N	8793745T30
8793745	1635	1644	GluR-AiBo	GENE-N	8793745T31
8793745	1702	1708	GluR-B	GENE-Y	8793745T32
8793745	274	287	AMPA receptor	GENE-N	8793745T33
8793745	1792	1801	GluR-AiBi	GENE-N	8793745T34
8793745	1821	1828	GluR-Ai	GENE-N	8793745T35
8793745	1850	1856	GluR-A	GENE-Y	8793745T36
8793745	1861	1867	GluR-B	GENE-Y	8793745T37
8793745	1988	2002	AMPA receptors	GENE-N	8793745T38
8793745	933	946	AMPA receptor	GENE-N	8793745T39
8793745	230	239	glutamate	CHEMICAL	8793745T3
8793745	195	210	(AMPA) receptor	GENE-N	8793745T40
8793745	0	13	AMPA receptor	GENE-N	8793745T41
8793745	1508	1512	AMPA	CHEMICAL	8793745T4
8793745	1556	1569	cyclothiazide	CHEMICAL	8793745T5
8793745	274	278	AMPA	CHEMICAL	8793745T6
8793745	1755	1768	cyclothiazide	CHEMICAL	8793745T7
8793745	1939	1952	cyclothiazide	CHEMICAL	8793745T8
8793745	1988	1992	AMPA	CHEMICAL	8793745T9

8797532|t|Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users.
8797532|a|Depletion of striatal dopamine (DA) has been hypothesized to explain some of the neurological and psychiatric complications of chronic use of cocaine, including increased risk for neuroleptic-precipitated movement disorders. We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users. Mean DA levels were normal in the putamen, the motor component of the striatum; however 4 of the 12 subjects had DA values below the lower limit of the control range. DA concentrations were significantly reduced in the caudate head (head, -33%; tail, -39%) with a trend for reduction in nucleus accumbens (-27%). Striatal DAT protein (-25 to -46%) and VMAT2 (-17 to -22%) were reduced, whereas DAT determined by [3H]WIN 35,428 binding was normal. In conclusion, our data suggest that chronic cocaine use is associated with modestly reduced levels of striatal DA and the DA transporter in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.
8797532	638	640	DA	CHEMICAL	8797532T10
8797532	692	694	DA	CHEMICAL	8797532T11
8797532	937	951	[3H]WIN 35,428	CHEMICAL	8797532T12
8797532	1017	1024	cocaine	CHEMICAL	8797532T13
8797532	1084	1086	DA	CHEMICAL	8797532T14
8797532	1095	1097	DA	CHEMICAL	8797532T15
8797532	19	27	dopamine	CHEMICAL	8797532T16
8797532	55	64	monoamine	CHEMICAL	8797532T17
8797532	88	95	cocaine	CHEMICAL	8797532T18
8797532	9	17	dopamine	CHEMICAL	8797532T19
8797532	245	252	cocaine	CHEMICAL	8797532T1
8797532	408	422	DA transporter	GENE-Y	8797532T20
8797532	424	427	DAT	GENE-Y	8797532T21
8797532	437	468	vesicular monoamine transporter	GENE-Y	8797532T22
8797532	470	475	VMAT2	GENE-Y	8797532T23
8797532	847	850	DAT	GENE-Y	8797532T24
8797532	877	882	VMAT2	GENE-Y	8797532T25
8797532	919	922	DAT	GENE-Y	8797532T26
8797532	1095	1109	DA transporter	GENE-Y	8797532T27
8797532	19	39	dopamine transporter	GENE-Y	8797532T28
8797532	45	76	vesicular monoamine transporter	GENE-Y	8797532T29
8797532	125	133	dopamine	CHEMICAL	8797532T2
8797532	350	352	DA	CHEMICAL	8797532T3
8797532	369	371	DA	CHEMICAL	8797532T4
8797532	408	410	DA	CHEMICAL	8797532T5
8797532	135	137	DA	CHEMICAL	8797532T6
8797532	447	456	monoamine	CHEMICAL	8797532T7
8797532	510	517	cocaine	CHEMICAL	8797532T8
8797532	530	532	DA	CHEMICAL	8797532T9
8797532	CPR:4	8797532T13	8797532T27

8827452|t|Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator.
8827452|a|A novel hyaluronan-binding protein (PHBP) was purified from human plasma by affinity chromatography on hyaluronan-conjugated Sepharose. The contaminating IgM and albumin in the partially purified preparation were removed with anti-IgG antibody-conjugated Sepharose and anti-albumin antibody-conjugated Sepharose, respectively, and no other contaminant was observed. Finally, 800 micrograms of PHBP was isolated from 500 ml of human plasma. PHBP gave a single 70-kDa band on SDS-PAGE under non-reducing conditions, and 50-kDa and 17-kDa bands under reducing conditions. Thus, PHBP was a heterodimer composed of 50-kDa and 17-kDa subunits, bridged by a disulfide linkage. Both subunits had novel N-terminal amino acid sequences, indicating that PHBP was a novel hyaluronan-binding protein in human plasma. The amino acid sequence deduced from the nucleotide sequence of the cloned PHBP cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA). The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA. The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.
8827452	1268	1272	PHBP	GENE-Y	8827452T10
8827452	1306	1310	PHBP	GENE-Y	8827452T11
8827452	1324	1361	epidermal growth factor (EGF) domains	GENE-N	8827452T12
8827452	1365	1379	kringle domain	GENE-N	8827452T13
8827452	1386	1408	serine protease domain	GENE-N	8827452T14
8827452	1440	1444	HGFA	GENE-Y	8827452T15
8827452	1451	1477	fibronectin type II domain	GENE-N	8827452T16
8827452	1482	1492	EGF domain	GENE-N	8827452T17
8827452	1496	1521	fibronectin type I domain	GENE-N	8827452T18
8827452	1526	1536	EGF domain	GENE-N	8827452T19
8827452	1386	1392	serine	CHEMICAL	8827452T1
8827452	1540	1554	kringle domain	GENE-N	8827452T20
8827452	1562	1584	serine protease domain	GENE-N	8827452T21
8827452	357	360	IgM	GENE-N	8827452T22
8827452	365	372	albumin	GENE-N	8827452T23
8827452	434	437	IgG	GENE-N	8827452T24
8827452	477	484	albumin	GENE-N	8827452T25
8827452	239	243	PHBP	GENE-Y	8827452T26
8827452	596	600	PHBP	GENE-Y	8827452T27
8827452	643	647	PHBP	GENE-Y	8827452T28
8827452	778	782	PHBP	GENE-Y	8827452T29
8827452	1419	1420	N	CHEMICAL	167
8827452	946	950	PHBP	GENE-Y	8827452T30
8827452	211	237	hyaluronan-binding protein	GENE-N	8827452T31
8827452	1082	1086	PHBP	GENE-Y	8827452T32
8827452	1134	1168	hepatocyte growth factor activator	GENE-Y	8827452T33
8827452	1170	1174	HGFA	GENE-Y	8827452T34
8827452	132	154	serine protease domain	GENE-N	8827452T35
8827452	45	71	hyaluronan-binding protein	GENE-N	8827452T36
8827452	73	77	PHBP	GENE-Y	8827452T37
8827452	1562	1568	serine	CHEMICAL	8827452T3
8827452	1595	1596	N	CHEMICAL	167
8827452	854	863	disulfide	CHEMICAL	8827452T5
8827452	897	918	N-terminal amino acid	CHEMICAL	8827452T6
8827452	1011	1021	amino acid	CHEMICAL	8827452T7
8827452	1048	1058	nucleotide	CHEMICAL	8827452T8
8827452	132	138	serine	CHEMICAL	8827452T9

8863950|t|Hypoxemia associated with cimetidine therapy in a newborn infant.
8863950|a|Cimetidine therapy used for the treatment of gastric bleeding due to tolazoline therapy in a newborn infant was temporally associated with episodes of severe hypoxemia. It appears likely that the histamine H2 receptor blocked by cimetidine obviated the pulmonary vasodilator effect of tolazoline therapy.
8863950	66	76	Cimetidine	CHEMICAL	493
8863950	262	271	histamine	CHEMICAL	8863950T2
8863950	295	305	cimetidine	CHEMICAL	8863950T3
8863950	351	361	tolazoline	CHEMICAL	8863950T4
8863950	135	145	tolazoline	CHEMICAL	8863950T5
8863950	26	36	cimetidine	CHEMICAL	8863950T6
8863950	262	283	histamine H2 receptor	GENE-Y	8863950T7
8863950	CPR:4	8863950T3	8863950T7

8882618|t|Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.
8882618|a|1. The 2,3-benzodiazepines GYKI 52466, GYKI 53405 and GYKI 53655 antagonized AMPA-induced currents in cultured superior colliculus neurones in a non use-dependent manner (steady state IC50s: GYKI 52466 9.8 +/- 0.6 microM; GYKI 53405 3.1 +/- 0.6 microM; GYKI 53655 0.8 +/- 0.1 microM). 2. Higher concentrations of all three antagonists slowed the onset kinetics and quickened the offset kinetics of AMPA-induced currents indicative of an allosteric interaction with the AMPA recognition site. 3. Cyclothiazide (3-300 microM) dramatically slowed desensitization of AMPA-induced currents and potentiated steady state currents (EC50 10.0 +/- 2.5 microM) to a much greater degree than peak currents. Both tau on and tau off were also increased by cyclothiazide in a concentration-dependent manner (EC50: tau on 42.1 +/- 4.5 microM; tau off 31.6 +/- 6.6 microM). 4. Cyclothiazide (10-100 microM) shifted the concentration-response curves of the 2,3-benzodiazepines to the right. For example, with 10 microM cyclothiazide the IC50s of GYKI 52466 and GYKI 53405 on steady-state AMPA-induced currents were 57.9 +/- 9.5 and 41.6 +/- 1.5 microM, respectively. 5. GYKI 53405 and GYKI 52466 concentration-dependently reversed the effects of cyclothiazide (100 microM) on offset kinetics (GYKI 53405 IC50 16.6 +/- 4.2 microM). However, the 2,3-benzodiazepines were unable to reintroduce desensitization in the presence of cyclothiazide and even concentration-dependently slowed the onset kinetics of AMPA responses further (GYKI 53405 EC50 8.0 +/- 2.8 microM). 6. GYKI 52466 decreased the peak amplitude of hippocampal area CA1 AMPA receptor-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics. Cyclothiazide prolonged the decay time constant of AMPA receptor-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude. 7. Cyclothiazide (330 microM) shifted the concentration-response curve for the effects of GYKI 52466 on AMPA receptor-mediated e.p.s.c. peak amplitude to the right (GYKI 52466 IC50 26.9 +/- 9.4 microM). Likewise, GYKI 52466 (30-100 microM)) shifted the concentration-response curve for the effects of cyclothiazide on AMPA receptor-mediated e.p.s.c. decay time constants to the right. 8. In conclusion, cyclothiazide and the 2,3-benzodiazepines seem to bind to different sites on AMPA receptors but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site. The interactions of GYKI 52466 and cyclothiazide on AMPA receptor-mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.
8882618	1561	1574	cyclothiazide	CHEMICAL	8882618T10
8882618	1639	1643	AMPA	CHEMICAL	8882618T11
8882618	1663	1673	GYKI 53405	CHEMICAL	8882618T12
8882618	1703	1713	GYKI 52466	CHEMICAL	8882618T13
8882618	1767	1771	AMPA	CHEMICAL	8882618T14
8882618	1907	1920	Cyclothiazide	CHEMICAL	596
8882618	1958	1962	AMPA	CHEMICAL	8882618T16
8882618	344	354	GYKI 52466	CHEMICAL	8882618T17
8882618	2119	2132	Cyclothiazide	CHEMICAL	596
8882618	2206	2216	GYKI 52466	CHEMICAL	8882618T19
8882618	1154	1167	cyclothiazide	CHEMICAL	8882618T1
8882618	2220	2224	AMPA	CHEMICAL	8882618T20
8882618	2281	2291	GYKI 52466	CHEMICAL	8882618T21
8882618	2329	2339	GYKI 52466	CHEMICAL	8882618T22
8882618	375	385	GYKI 53405	CHEMICAL	8882618T23
8882618	2417	2430	cyclothiazide	CHEMICAL	8882618T24
8882618	2434	2438	AMPA	CHEMICAL	8882618T25
8882618	2519	2532	cyclothiazide	CHEMICAL	8882618T26
8882618	2541	2560	2,3-benzodiazepines	CHEMICAL	8882618T27
8882618	2596	2600	AMPA	CHEMICAL	8882618T28
8882618	406	416	GYKI 53655	CHEMICAL	8882618T29
8882618	1181	1191	GYKI 52466	CHEMICAL	8882618T2
8882618	2750	2760	GYKI 52466	CHEMICAL	8882618T30
8882618	2765	2778	cyclothiazide	CHEMICAL	8882618T31
8882618	2782	2786	AMPA	CHEMICAL	8882618T32
8882618	180	190	GYKI 52466	CHEMICAL	8882618T33
8882618	192	202	GYKI 53405	CHEMICAL	8882618T34
8882618	551	555	AMPA	CHEMICAL	8882618T35
8882618	622	626	AMPA	CHEMICAL	8882618T36
8882618	648	661	Cyclothiazide	CHEMICAL	596
8882618	207	217	GYKI 53655	CHEMICAL	8882618T38
8882618	716	720	AMPA	CHEMICAL	8882618T39
8882618	1196	1206	GYKI 53405	CHEMICAL	8882618T3
8882618	160	179	2,3-benzodiazepines	CHEMICAL	8882618T40
8882618	895	908	cyclothiazide	CHEMICAL	8882618T41
8882618	230	234	AMPA	CHEMICAL	8882618T42
8882618	1013	1026	Cyclothiazide	CHEMICAL	596
8882618	1092	1111	2,3-benzodiazepines	CHEMICAL	8882618T44
8882618	16	35	2,3-benzodiazepines	CHEMICAL	8882618T45
8882618	40	53	cyclothiazide	CHEMICAL	8882618T46
8882618	57	61	AMPA	CHEMICAL	8882618T47
8882618	1767	1780	AMPA receptor	GENE-N	8882618T48
8882618	1958	1971	AMPA receptor	GENE-N	8882618T49
8882618	1223	1227	AMPA	CHEMICAL	8882618T4
8882618	2220	2233	AMPA receptor	GENE-N	8882618T50
8882618	2434	2447	AMPA receptor	GENE-N	8882618T51
8882618	2596	2610	AMPA receptors	GENE-N	8882618T52
8882618	2782	2795	AMPA receptor	GENE-N	8882618T53
8882618	57	71	AMPA receptors	GENE-N	8882618T54
8882618	1305	1315	GYKI 53405	CHEMICAL	8882618T5
8882618	1320	1330	GYKI 52466	CHEMICAL	8882618T6
8882618	1381	1394	cyclothiazide	CHEMICAL	8882618T7
8882618	1428	1438	GYKI 53405	CHEMICAL	8882618T8
8882618	1479	1498	2,3-benzodiazepines	CHEMICAL	8882618T9
8882618	CPR:4	8882618T13	8882618T48
8882618	CPR:4	596	8882618T49

8930173|t|Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes.
8930173|a|To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells. Competition curves at the platelet I1-imidazoline binding site were biphasic for most compounds. Only tizanidine and BDF,6143 displayed monophasic I1 competition curves. Agmatine, an endogenous neurotransmitter candidate for the I1-imidazoline receptor, was identified as the most selective agent for a subcomponent of platelet I1 sites. The affinity of agmatine at the high affinity component of platelet I1 sites was 1400-fold selective over alpha-2A adrenoceptors, 5000-fold selective over alpha-2B adrenoceptors and 800-fold selective over alpha-2C adrenoceptors. Moxonidine and tizanidine also displayed selectivities for a high affinity component of the platelet I1 binding sites over alpha-2 adrenoceptors. Naphazoline was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1-midazoline binding sites, respectively. No single selective compound was identified for the alpha-2B adrenoceptor. Norepinephrine displayed, respectively, 18- and 31-fold selectivity for the high affinity state of the alpha-2C adrenoceptor as compared to alpha-2A- or alpha-2B adrenoceptors, and was > 100,000- fold selective over platelet I1-imidazoline sites. Thus, human alpha-2 adrenoceptors and the platelet I1-imidazoline binding site can be clearly discriminated based on their affinities for certain compounds.
8930173	623	633	tizanidine	CHEMICAL	8930173T10
8930173	638	646	BDF,6143	CHEMICAL	8930173T11
8930173	193	204	imidazoline	CHEMICAL	8930173T12
8930173	691	699	Agmatine	CHEMICAL	7602
8930173	753	764	imidazoline	CHEMICAL	8930173T14
8930173	875	883	agmatine	CHEMICAL	8930173T15
8930173	1089	1099	Moxonidine	CHEMICAL	7986
8930173	1104	1114	tizanidine	CHEMICAL	8930173T17
8930173	52	63	imidazoline	CHEMICAL	8930173T18
8930173	1190	1206	I1 binding sites	GENE-N	8930173T19
8930173	1235	1246	Naphazoline	CHEMICAL	5593
8930173	1212	1233	alpha-2 adrenoceptors	GENE-N	8930173T20
8930173	1314	1335	alpha-2A adrenoceptor	GENE-Y	8930173T21
8930173	1388	1396	alpha-2B	GENE-Y	8930173T22
8930173	1398	1406	alpha-2C	GENE-Y	8930173T23
8930173	1420	1447	I1-midazoline binding sites	GENE-N	8930173T24
8930173	1515	1536	alpha-2B adrenoceptor	GENE-Y	8930173T25
8930173	1641	1662	alpha-2C adrenoceptor	GENE-Y	8930173T26
8930173	1678	1686	alpha-2A	GENE-Y	8930173T27
8930173	1691	1713	alpha-2B adrenoceptors	GENE-Y	8930173T28
8930173	1763	1783	I1-imidazoline sites	GENE-N	8930173T29
8930173	254	275	[125I]p-iodoclonidine	CHEMICAL	8930173T2
8930173	1791	1818	human alpha-2 adrenoceptors	GENE-N	8930173T30
8930173	306	349	human platelet I1-imidazoline binding sites	GENE-N	8930173T31
8930173	1836	1863	I1-imidazoline binding site	GENE-N	8930173T32
8930173	389	399	alpha-2 AR	GENE-N	8930173T33
8930173	408	422	human alpha-2A	GENE-Y	8930173T34
8930173	424	432	alpha-2B	GENE-Y	8930173T35
8930173	437	459	alpha-2C adrenoceptors	GENE-Y	8930173T36
8930173	556	583	I1-imidazoline binding site	GENE-N	8930173T37
8930173	190	214	I1-imidazoline receptors	GENE-Y	8930173T38
8930173	750	773	I1-imidazoline receptor	GENE-Y	8930173T39
8930173	1423	1433	midazoline	CHEMICAL	8930173T3
8930173	849	857	I1 sites	GENE-N	8930173T40
8930173	216	218	I1	GENE-Y	8930173T41
8930173	927	935	I1 sites	GENE-N	8930173T42
8930173	965	987	alpha-2A adrenoceptors	GENE-Y	8930173T43
8930173	1014	1036	alpha-2B adrenoceptors	GENE-Y	8930173T44
8930173	1065	1087	alpha-2C adrenoceptors	GENE-Y	8930173T45
8930173	109	129	alpha-2 adrenoceptor	GENE-N	8930173T46
8930173	43	77	human I1-imidazoline binding sites	GENE-N	8930173T47
8930173	1538	1552	Norepinephrine	CHEMICAL	360
8930173	1766	1777	imidazoline	CHEMICAL	8930173T5
8930173	1839	1850	imidazoline	CHEMICAL	8930173T6
8930173	324	335	imidazoline	CHEMICAL	8930173T7
8930173	366	380	norepinephrine	CHEMICAL	8930173T8
8930173	559	570	imidazoline	CHEMICAL	8930173T9

9008235|t|Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect.
9008235|a|Data from the literature indicate that nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, naproxen, piroxicam, or ibuprofen, induce hair loss in vivo. These NSAIDs are well-known inhibitors of both the cytoprotective isoform of prostaglandin endoperoxide synthase-1 (PGHS-1) and of the inducible form (PGHS-2). By immunohistochemical staining, we found that PGHS-1 is the main isoform present in the dermal papilla from normal human hair follicle (either anagen or catagen), whereas PGHS-2 was only faintly and exclusively expressed in anagen dermal papilla. Thus, PGHS-1 might be the primary target of the hair growth-inhibitory effects of NSAIDs. We thus speculated that activation of PGHS-1 might be a mechanism by which minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo. We demonstrate here that minoxidil is a potent activator of purified PGHS-1 (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production. This activation was also evidenced by increased PGE2 production by BALB/c 3T3 fibroblasts and by human dermal papilla fibroblasts in culture. Our findings suggest that minoxidil and its derivatives may have a cytoprotective activity in vivo and that more potent second-generation hair growth-promoting drugs might be designed, based on this mechanism.
9008235	227	239	indomethacin	CHEMICAL	9008235T10
9008235	29	42	prostaglandin	CHEMICAL	9008235T11
9008235	57	66	minoxidil	CHEMICAL	9008235T12
9008235	379	416	prostaglandin endoperoxide synthase-1	GENE-Y	9008235T13
9008235	418	424	PGHS-1	GENE-Y	9008235T14
9008235	453	459	PGHS-2	GENE-Y	9008235T15
9008235	509	515	PGHS-1	GENE-Y	9008235T16
9008235	634	640	PGHS-2	GENE-Y	9008235T17
9008235	716	722	PGHS-1	GENE-Y	9008235T18
9008235	838	844	PGHS-1	GENE-Y	9008235T19
9008235	241	249	naproxen	CHEMICAL	9008235T1
9008235	1031	1037	PGHS-1	GENE-Y	9008235T20
9008235	29	53	prostaglandin synthase-1	GENE-Y	9008235T21
9008235	1280	1289	minoxidil	CHEMICAL	9008235T2
9008235	251	260	piroxicam	CHEMICAL	9008235T3
9008235	265	274	ibuprofen	CHEMICAL	9008235T4
9008235	379	392	prostaglandin	CHEMICAL	9008235T5
9008235	875	884	minoxidil	CHEMICAL	9008235T6
9008235	886	928	2,4-diamino-6-piperidinopyrimidine-3-oxyde	CHEMICAL	9008235T7
9008235	987	996	minoxidil	CHEMICAL	9008235T8
9008235	1072	1078	oxygen	CHEMICAL	9008235T9
9008235	CPR:3	9008235T12	9008235T21
9008235	CPR:3	9008235T6	9008235T19
9008235	CPR:3	9008235T7	9008235T19
9008235	CPR:3	9008235T8	9008235T20

9020367|t|Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
9020367|a|Five patients with non-Hodgkin's lymphoma (NHL) and 4 patients with chronic lymphocytic leukaemia (CLL) were treated with the CDR-grafted (rat x human) monoclonal antibody (mAb) Campath-1H (anti-CD52). Tumour regression was noted preferentially in peripheral blood and in the bone marrow but lymph nodes were less affected. Normal blood B and T cells were profoundly reduced in all patients whereas CD16+ NK cells and CD14+ monocytes decreased marginally. In all responding CLL patients CD52-negative T but not B cells appeared during treatment and persisted for several months (4-19+) during unmaintained follow-up. Clonal T cells defined as a predominance of a single T cell receptor (TCR) V gene usage, in one case verified by TCR CDR3 fragment analysis and nucleotide sequencing, emerged within the CD52-/CD8+ cell population during Campath-1H therapy in 2 CLL patients, both achieving a long-lasting remission. The increase in CD8+ T cell expansions (up to 23-fold) during unmaintained remission and follow-up suggest that the clonal CD8+ cells may represent regulatory T cells controlling the growth of the tumour B cell clone. Clonal T cells might thus be a target for an immune therapeutic intervention in B cell tumours.
9020367	879	889	nucleotide	CHEMICAL	9020367T1
9020367	313	317	CD52	GENE-Y	107473
9020367	605	609	CD52	GENE-Y	107473
9020367	788	811	T cell receptor (TCR) V	GENE-N	9020367T4
9020367	848	851	TCR	GENE-N	9020367T5
9020367	111	115	CD52	GENE-Y	107473

9039330|t|Clinical manifestations of genetic defects affecting gonadotrophins and their receptors.
9039330|a|Raised activity of the LH axis caused by activating mutations of LH receptor gene presents with precocious puberty in boys, analogous to the presentation of LH secreting pituitary adenomas (Faggiano et al., 1983; Ambrosi et al., 1990). LH "hyperactivity' in females appears to have no effect. Hyperactivity of the FSH axis caused by activating mutations of the FSH receptor gene might parallel the presentation of FSH secreting pituitary adenomas with Sertoli cell hypertrophy in men (Heseltine et al., 1989) or reversible premature ovarian failure in women (Moses et al., 1986; Okuda et al., 1989). Indeed the first such case to be described is a male who maintained testicular volume and fertility in the absence of gonadotrophins (Gromoll et al., 1996). Female precocious puberty may require hyperactivity of both gonadotrophin axes because of the "two-cell' arrangement required for ovarian oestrogen production. Mutations of the Gs alpha-subunit gene can mimic this situation in some women with the McCune-Albright syndrome (Malchoff et al., 1994). Lack of LH activity caused by defects in the LH beta molecule causes infertility in men and that resulting from inactivating mutations of the LH receptor gene causes Leydig cell agenesis in men while ovarian development in females is relatively normal. Lack of FSH activity caused by defects in the FSH beta caused infertility in a female, and that caused by inactivating mutations of the FSH receptor gene causes ovarian dysgenesis in women but only variable depression of spermatogenesis in men. Incidentally, this categorization of reproductive disorders may also be applied to the TSH axis. Pituitary adenomas and activating mutations of the TSH receptor gene (Parma et al., 1993) cause hyperthyroidism and TSH beta gene defects (Hayashizaki et al., 1989) and inactivating mutations of the TSH receptor gene (Sunthornthepvarakul et al., 1995) cause hypothyroidism. To complete the analogy with thyroid disorders, it is curious that despite structural similarities with the TSH receptor, neither LH nor FSH receptor autoantibodies have a prominent role in ovarian pathophysiology (Moncayo et al., 1989; Van Weissenbruch et al., 1991; Simoni et al., 1993). Complete gonadotrophin resistance is likely to be very rare, however, so what are we likely to find in partial gonadotrophin resistance? Might the "resistant ovary syndrome' come right in the end, with corresponding minor FSH receptor mutations? Experience with insulin and androgen resistance syndromes suggests that such a scenario is unlikely. Insulin receptor gene mutations are found in extreme Type A insulin resistance but not in moderate forms of insulin resistance (O'Rahilly et al., 1991). Androgen receptor gene mutations are found in nearly all cases of complete androgen insensitivity but rarely in partial forms (Patterson et al., 1994). Mild resistance to hormone action is rarely detectable in relatives who are heterozygous for receptor mutations which are inherited in a recessive pattern. It seems unlikely therefore, that individuals heterozygous for inactivating receptor mutations will manifest symptoms of reproductive disorders and account for common conditions. Thus, while mutation analysis provides new insights into the gender specific role of the gonadotrophins the cause of early gonadal failure in the majority of individuals remains a mystery.
9039330	1789	1801	TSH receptor	GENE-Y	9039330T10
9039330	1854	1862	TSH beta	GENE-Y	9039330T11
9039330	1937	1949	TSH receptor	GENE-Y	9039330T12
9039330	2120	2132	TSH receptor	GENE-Y	9039330T13
9039330	2142	2161	LH nor FSH receptor	GENE-N	9039330T14
9039330	2311	2324	gonadotrophin	GENE-N	9039330T15
9039330	2413	2426	gonadotrophin	GENE-N	9039330T16
9039330	112	114	LH	GENE-N	9039330T17
9039330	325	327	LH	GENE-N	9039330T18
9039330	2524	2536	FSH receptor	GENE-Y	9039330T19
9039330	984	993	oestrogen	CHEMICAL	9039330T1
9039330	2564	2571	insulin	GENE-Y	9039330T20
9039330	2649	2665	Insulin receptor	GENE-Y	9039330T21
9039330	2709	2716	insulin	GENE-Y	9039330T22
9039330	2757	2764	insulin	GENE-Y	9039330T23
9039330	2802	2819	Androgen receptor	GENE-Y	9039330T24
9039330	403	406	FSH	GENE-N	9039330T25
9039330	3378	3392	gonadotrophins	GENE-N	9039330T26
9039330	450	462	FSH receptor	GENE-Y	9039330T27
9039330	503	506	FSH	GENE-N	9039330T28
9039330	154	165	LH receptor	GENE-Y	9039330T29
9039330	1151	1153	LH	GENE-N	9039330T2
9039330	807	821	gonadotrophins	GENE-N	9039330T30
9039330	906	919	gonadotrophin	GENE-N	9039330T31
9039330	1023	1031	Gs alpha	GENE-N	9039330T32
9039330	53	67	gonadotrophins	GENE-N	9039330T33
9039330	1188	1195	LH beta	GENE-Y	9039330T3
9039330	1285	1296	LH receptor	GENE-Y	9039330T4
9039330	1404	1407	FSH	GENE-N	9039330T5
9039330	1442	1450	FSH beta	GENE-Y	9039330T6
9039330	1532	1544	FSH receptor	GENE-Y	9039330T7
9039330	246	248	LH	GENE-N	9039330T8
9039330	1728	1731	TSH	GENE-N	9039330T9

9063462|t|Evolution of the aminoacyl-tRNA synthetase family and the organization of the Drosophila glutamyl-prolyl-tRNA synthetase gene. Intron/exon structure of the gene, control of expression of the two mRNAs, selective advantage of the multienzyme complex.
9063462|a|In Drosophila, glutamyl-prolyl-tRNA synthetase is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. 10, 4267-4277]. The intron/exon organization of the Drosophila gene reveals the presence of six exons among which four are in the 5'-end encoding glutamic acid activity. Only one exon encodes the repeated motifs. A comparison of introns positions, intron classes and intron/exon boundaries in the Drosophila gene and in its human counterpart is compatible with the intron-early hypothesis presiding, at least in part, to the evolution of the synthetases. The full-length fly protein is encoded by a 6.1-kb mRNA which is expressed throughout development. In addition, a shorter transcript encompasses the 3'-end of the cDNA and it is especially abundant in 5-10-h embryos until the first larval stage. Expression of these two mRNAs seems to be controlled by two independent promoters. The 6.1-kb mRNA promoter is probably localized in the 5'-end of the gene. The small mRNA promoter resides in the 4th intron and evidence is provided that the mRNA encodes only the domain corresponding to prolyl-tRNA synthetase and is functional in vivo. Finally, transgenic flies have been established by using constructs corresponding to the three domains of the protein. Overexpression of the repeated motifs leads to a sterility of the flies that suggests a role of these motifs in linking the multienzyme complex to an, as yet, unknown structure of the protein synthesis apparatus.
9063462	1732	1754	prolyl-tRNA synthetase	GENE-Y	9063462T10
9063462	265	296	glutamyl-prolyl-tRNA synthetase	GENE-Y	9063462T11
9063462	1186	1197	synthetases	GENE-N	9063462T12
9063462	17	42	aminoacyl-tRNA synthetase	GENE-N	9063462T13
9063462	89	120	glutamyl-prolyl-tRNA synthetase	GENE-Y	9063462T14
9063462	389	394	amino	CHEMICAL	9063462T1
9063462	1732	1738	prolyl	CHEMICAL	9063462T2
9063462	400	407	carboxy	CHEMICAL	9063462T3
9063462	265	273	glutamyl	CHEMICAL	9063462T4
9063462	456	469	glutamic acid	CHEMICAL	9063462T5
9063462	547	558	amino acids	CHEMICAL	9063462T6
9063462	890	903	glutamic acid	CHEMICAL	9063462T7
9063462	17	26	aminoacyl	CHEMICAL	9063462T8
9063462	89	97	glutamyl	CHEMICAL	9063462T9

9204085|t|Pharmacology and chemistry of adapalene.
9204085|a|BACKGROUND: Retinoid research in the field of dermatology has been influenced by the clinical success of topical tretinoin and oral isotretinoin in the treatment of acne, and by the discovery of high-affinity binding proteins for retinoic acid mediating its action and interaction with other vitamins and hormones. OBJECTIVE: We sought molecules with an optimal balance between stability, efficacy, and local tolerance for topical acne therapy. METHODS: In vitro and in vivo bioassay systems were used to test the ability of retinoids to modulate cell proliferation and differentiation. In addition, antiinflammatory properties were assessed. Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and tretinoin for the nuclear transcription factors, retinoic acid receptors (RARs). RESULTS AND CONCLUSION: Adapalene is a stable naphthoic acid derivative with potent retinoid pharmacology, controlling cell proliferation and differentiation. In addition it has significant antiinflammatory action. The nuclear gene transcription factors RAR beta and RAR gamma mediate the retinoid activity of adapalene.
9204085	799	808	tretinoin	CHEMICAL	9204085T10
9204085	848	861	retinoic acid	CHEMICAL	9204085T11
9204085	904	913	Adapalene	CHEMICAL	203
9204085	926	940	naphthoic acid	CHEMICAL	9204085T13
9204085	964	972	retinoid	CHEMICAL	9204085T14
9204085	30	39	adapalene	CHEMICAL	9204085T15
9204085	1099	1133	nuclear gene transcription factors	GENE-N	9204085T16
9204085	1134	1142	RAR beta	GENE-Y	9204085T17
9204085	1147	1156	RAR gamma	GENE-Y	9204085T18
9204085	817	846	nuclear transcription factors	GENE-N	9204085T19
9204085	1169	1177	retinoid	CHEMICAL	9204085T1
9204085	848	871	retinoic acid receptors	GENE-N	9204085T20
9204085	873	877	RARs	GENE-N	9204085T21
9204085	154	163	tretinoin	CHEMICAL	9204085T2
9204085	1190	1199	adapalene	CHEMICAL	9204085T3
9204085	53	61	Retinoid	CHEMICAL	9204085T4
9204085	173	185	isotretinoin	CHEMICAL	9204085T5
9204085	271	284	retinoic acid	CHEMICAL	9204085T6
9204085	333	341	vitamins	CHEMICAL	9204085T7
9204085	566	575	retinoids	CHEMICAL	9204085T8
9204085	785	794	adapalene	CHEMICAL	9204085T9

9211565|t|Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds.
9211565|a|This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol. Results were compared with those for 5-hydroxytryptamine (5-HT: 10 mg kg-1). The possible involvements of gastric mucus secretion, endogenous prostaglandins (PGs) and sulfhydryl compounds (SH) in the protection mediated by CNT were also examined. Intraperitoneal administration of CNT (0.50 and 1 mg kg-1), 30 min before ethanol, significantly prevented gastric ulceration and increased the hexosamine content of gastric mucus. CNT (1 mg kg-1) also produced a significant increase in gastric mucosal levels of PGE2, but did not induce any significant changes in SH values. On the contrary, pretreatment with 5-HT worsened ethanol-induced erosions, however, did not affect gastric mucus secretion, glycoprotein content or PGE2 levels, although the non-protein SH fraction was significantly decreased. The present results demonstrate that the gastroprotective effects of CNT could be partly explained by a complex PG dependent mechanism. We suggest that 5-HT dependent mechanisms through 5-HT2 receptor blockade and 5-HT1 receptor activation could be also involved.
9211565	553	563	sulfhydryl	CHEMICAL	9211565T10
9211565	575	577	SH	CHEMICAL	9211565T11
9211565	609	612	CNT	CHEMICAL	9211565T12
9211565	667	670	CNT	CHEMICAL	9211565T13
9211565	707	714	ethanol	CHEMICAL	9211565T14
9211565	777	787	hexosamine	CHEMICAL	9211565T15
9211565	814	817	CNT	CHEMICAL	9211565T16
9211565	219	230	cinitapride	CHEMICAL	9211565T17
9211565	896	900	PGE2	CHEMICAL	907
9211565	948	950	SH	CHEMICAL	9211565T19
9211565	257	266	benzamide	CHEMICAL	9211565T1
9211565	994	998	5-HT	CHEMICAL	9211565T20
9211565	232	235	CNT	CHEMICAL	9211565T21
9211565	1008	1015	ethanol	CHEMICAL	9211565T22
9211565	1107	1111	PGE2	CHEMICAL	907
9211565	1145	1147	SH	CHEMICAL	9211565T24
9211565	0	11	Cinitapride	CHEMICAL	7581
9211565	106	120	prostaglandins	CHEMICAL	9211565T26
9211565	125	135	sulfhydryl	CHEMICAL	9211565T27
9211565	29	36	ethanol	CHEMICAL	9211565T28
9211565	85	104	5-hydroxytryptamine	CHEMICAL	9211565T29
9211565	1255	1258	CNT	CHEMICAL	9211565T2
9211565	1372	1377	5-HT2	GENE-N	9211565T30
9211565	1400	1405	5-HT1	GENE-N	9211565T31
9211565	289	294	5-HT4	GENE-Y	9211565T32
9211565	299	304	5-HT1	GENE-N	9211565T33
9211565	319	324	5-HT2	GENE-N	9211565T34
9211565	1083	1095	glycoprotein	GENE-N	9211565T35
9211565	1298	1300	PG	CHEMICAL	1041
9211565	1338	1342	5-HT	CHEMICAL	9211565T4
9211565	377	384	ethanol	CHEMICAL	9211565T5
9211565	423	442	5-hydroxytryptamine	CHEMICAL	9211565T6
9211565	444	448	5-HT	CHEMICAL	9211565T7
9211565	528	542	prostaglandins	CHEMICAL	9211565T8
9211565	544	547	PGs	CHEMICAL	9211565T9
9211565	CPR:5	9211565T17	9211565T32
9211565	CPR:5	9211565T17	9211565T33
9211565	CPR:5	9211565T1	9211565T32
9211565	CPR:5	9211565T1	9211565T33
9211565	CPR:5	9211565T21	9211565T32
9211565	CPR:5	9211565T21	9211565T33
9211565	CPR:6	9211565T17	9211565T34
9211565	CPR:6	9211565T1	9211565T34
9211565	CPR:6	9211565T21	9211565T34

9231703|t|Cloning, characterization, and expression of a calcitonin receptor from guinea pig brain.
9231703|a|A calcitonin receptor was cloned from guinea pig brain by using a degenerate reverse transcription-polymerase chain reaction (RT-PCR) strategy. When the cloned guinea pig calcitonin receptor was transfected into COS 1 cells, salmon calcitonin stimulated intracellular cyclic AMP accumulation with an EC50 of 0.1 nM, whereas human calcitonin was >250-fold less potent (EC50 27.6 nM). Related neuropeptides rat alphaCGRP and rat amylin did not activate the guinea pig calcitonin receptor at physiologic concentrations. Stimulation of the transfected guinea pig calcitonin receptor by salmon calcitonin also resulted in phosphatidylinositol hydrolysis with an EC50 of 2.5 nM. Expression of the calcitonin receptor was mapped by a combination of RT-PCR, northern analysis, and expression in Xenopus oocytes. The guinea pig calcitonin receptor was most highly expressed in diencephalon and a single subtype was detected.
9231703	638	668	guinea pig calcitonin receptor	GENE-Y	9231703T10
9231703	781	800	calcitonin receptor	GENE-Y	9231703T11
9231703	898	928	guinea pig calcitonin receptor	GENE-Y	9231703T12
9231703	47	66	calcitonin receptor	GENE-Y	9231703T13
9231703	358	368	cyclic AMP	CHEMICAL	9231703T1
9231703	707	727	phosphatidylinositol	CHEMICAL	9231703T2
9231703	250	280	guinea pig calcitonin receptor	GENE-Y	9231703T3
9231703	92	111	calcitonin receptor	GENE-Y	9231703T4
9231703	315	332	salmon calcitonin	GENE-N	9231703T5
9231703	414	430	human calcitonin	GENE-Y	9231703T6
9231703	495	508	rat alphaCGRP	GENE-Y	9231703T7
9231703	513	523	rat amylin	GENE-Y	9231703T8
9231703	545	575	guinea pig calcitonin receptor	GENE-Y	9231703T9

9299436|t|Adenosine deaminase is a specific partner for the Grb2 isoform Grb3-3.
9299436|a|Grb3-3 is an isoform of Grb2, thought to arise by alternative splicing, that lacks a functional SH2 domain but retains functional SH3 domains, which allow interaction with other proteins through binding to prolinerich sequences. Several evidences suggest that besides common partners for Grb2 and Grb3-3, specific targets could exist. In order to find specific partners for Grb3-3, we have screened a human cDNA library by the yeast two-hybrid system with Grb3-3 as a bait. We have identified adenosine deaminase, an enzyme involved in purine metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2. This interaction has been confirmed in vitro with GST fusion proteins and in vivo by coimmunoprecipitation experiments in NIH3T3 cells stably transfected with Grb3-3. The functional significance of this finding is discussed.
9299436	527	533	Grb3-3	GENE-Y	9299436T10
9299436	564	583	adenosine deaminase	GENE-Y	9299436T11
9299436	700	706	Grb3-3	GENE-Y	9299436T12
9299436	751	755	Grb2	GENE-Y	200046|249501
9299436	807	810	GST	GENE-N	9299436T14
9299436	916	922	Grb3-3	GENE-Y	9299436T15
9299436	167	177	SH2 domain	GENE-N	9299436T16
9299436	0	19	Adenosine deaminase	GENE-Y	9299436T17
9299436	50	54	Grb2	GENE-Y	200046|249501
9299436	63	69	Grb3-3	GENE-Y	9299436T19
9299436	564	573	adenosine	CHEMICAL	9299436T1
9299436	607	613	purine	CHEMICAL	9299436T2
9299436	0	9	Adenosine	CHEMICAL	630
9299436	71	77	Grb3-3	GENE-Y	9299436T4
9299436	201	212	SH3 domains	GENE-N	9299436T5
9299436	95	99	Grb2	GENE-Y	200046|249501
9299436	359	363	Grb2	GENE-Y	200046|249501
9299436	368	374	Grb3-3	GENE-Y	9299436T8
9299436	445	451	Grb3-3	GENE-Y	9299436T9
9299436	CPR:9	9299436T2	9299436T11

9310349|t|Alendronate inhibition of protein-tyrosine-phosphatase-meg1.
9310349|a|Alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate) is a potent bisphosphonate that inhibits osteoclastic bone resorption and has proven effective for the treatment of osteoporosis. Its molecular mechanism of action, however, has not been defined precisely. Here we report that alendronate is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (PTPmeg1). Two substrates were employed in this study: fluorescein diphosphate and the phosphotyrosyl peptide src-pY527. With either substrate, alendronate was a slow binding inhibitor of PTPmeg1. Among the other bisphosphonates studied, alendronate was more potent and selective for PTPmeg1. The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate. Similarly, with the src-pY527 substrate, alendronate inhibition was also PTP dependent. Alendronate inhibited PTPmeg1 with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM. The alendronate inhibition of these three PTPs and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor. PTP inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition. These observations show substrate- and enzyme-specific PTP inhibition by alendronate and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.
9310349	1783	1794	alendronate	CHEMICAL	9310349T10
9310349	348	359	alendronate	CHEMICAL	9310349T11
9310349	397	405	tyrosine	CHEMICAL	9310349T12
9310349	490	501	diphosphate	CHEMICAL	9310349T13
9310349	567	578	alendronate	CHEMICAL	9310349T14
9310349	636	651	bisphosphonates	CHEMICAL	9310349T15
9310349	661	672	alendronate	CHEMICAL	9310349T16
9310349	746	757	diphosphate	CHEMICAL	9310349T17
9310349	134	148	bisphosphonate	CHEMICAL	9310349T18
9310349	802	813	alendronate	CHEMICAL	9310349T19
9310349	61	72	Alendronate	CHEMICAL	620
9310349	943	954	alendronate	CHEMICAL	9310349T20
9310349	997	1008	alendronate	CHEMICAL	9310349T21
9310349	1044	1055	Alendronate	CHEMICAL	620
9310349	0	11	Alendronate	CHEMICAL	620
9310349	34	42	tyrosine	CHEMICAL	9310349T24
9310349	1066	1073	PTPmeg1	GENE-Y	9310349T25
9310349	1107	1115	PTPsigma	GENE-Y	9310349T26
9310349	1168	1179	PTP epsilon	GENE-Y	9310349T27
9310349	1252	1256	PTPs	GENE-N	9310349T28
9310349	1377	1380	PTP	GENE-N	9310349T29
9310349	1214	1225	alendronate	CHEMICAL	9310349T2
9310349	1671	1674	PTP	GENE-N	9310349T30
9310349	1744	1747	PTP	GENE-N	9310349T31
9310349	389	422	protein-tyrosine-phosphatase-meg1	GENE-Y	9310349T32
9310349	424	431	PTPmeg1	GENE-Y	9310349T33
9310349	533	536	src	GENE-Y	9310349T34
9310349	611	618	PTPmeg1	GENE-Y	9310349T35
9310349	707	714	PTPmeg1	GENE-Y	9310349T36
9310349	761	772	PTP epsilon	GENE-Y	9310349T37
9310349	777	784	PTPmeg1	GENE-Y	9310349T38
9310349	855	863	PTPsigma	GENE-Y	9310349T39
9310349	1395	1410	hisphosphonates	CHEMICAL	9310349T3
9310349	976	979	src	GENE-Y	9310349T40
9310349	1029	1032	PTP	GENE-N	9310349T41
9310349	26	59	protein-tyrosine-phosphatase-meg1	GENE-Y	9310349T42
9310349	1414	1422	vanadate	CHEMICAL	9310349T4
9310349	74	120	4-amino-1-hydroxybutylidene-1,1-bisphosphonate	CHEMICAL	9310349T5
9310349	1467	1471	EDTA	CHEMICAL	9310349T6
9310349	1498	1512	dithiothreitol	CHEMICAL	9310349T7
9310349	1565	1573	cysteine	CHEMICAL	9310349T8
9310349	1689	1700	alendronate	CHEMICAL	9310349T9
9310349	CPR:4	9310349T11	9310349T32
9310349	CPR:4	9310349T11	9310349T33
9310349	CPR:4	9310349T14	9310349T35
9310349	CPR:4	9310349T15	9310349T36
9310349	CPR:4	9310349T16	9310349T36
9310349	CPR:4	9310349T20	9310349T39
9310349	CPR:4	620	9310349T25
9310349	CPR:4	620	9310349T26
9310349	CPR:4	620	9310349T42
9310349	CPR:4	9310349T2	9310349T28
9310349	CPR:4	9310349T3	9310349T29
9310349	CPR:4	9310349T4	9310349T29
9310349	CPR:4	9310349T9	9310349T30
9310349	CPR:9	9310349T17	9310349T37
9310349	CPR:9	9310349T17	9310349T38

9313928|t|Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
9313928|a|1. Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells. Their ligand binding characteristics were examined with thirty two prostanoids and their analogues by determining the Ki values from the displacement curves of radioligand binding to the respective receptors. 2. The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3. The FP receptor bound PGF2 alpha and fluprostenol with Ki values of 3-4 nM. In addition, PGD2, 17-phenyl-PGE2, STA2, I-BOP, PGE2 and M&B-28767 bound to this receptor with Ki values less than 100 nM. 4. The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor. M&B-28767, a putative EP3 agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM. 5. The EP2 and EP4 receptors showed similar binding profiles. They bound 16,16-dimethyl PGE2 and 11-deoxy-PGE1 in addition to PGE2 and PGE1. The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor. 6. The EP3 receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM. In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7. 8-Epi-PGF2 alpha showed only weak binding to the IP, TP, FP, EP2 and EP3 receptor at 10 microM concentration.
9313928	2372	2375	EP3	GENE-Y	9313928T100
9313928	362	365	EP4	GENE-Y	9313928T101
9313928	382	406	prostaglandin E receptor	GENE-N	9313928T102
9313928	172	197	mouse prostanoid receptor	GENE-N	9313928T103
9313928	678	680	DP	GENE-Y	9313928T104
9313928	682	684	IP	GENE-Y	9313928T105
9313928	689	701	TP receptors	GENE-Y	9313928T106
9313928	203	232	prostaglandin D (DP) receptor	GENE-Y	9313928T107
9313928	838	840	DP	GENE-Y	9313928T108
9313928	884	886	IP	GENE-Y	9313928T109
9313928	255	257	FP	CHEMICAL	9313928T10
9313928	922	924	TP	GENE-Y	9313928T110
9313928	933	944	FP receptor	GENE-Y	9313928T111
9313928	1135	1138	EP1	GENE-Y	13705
9313928	68	94	mouse prostanoid receptors	GENE-N	9313928T113
9313928	1383	1392	M&B-28767	CHEMICAL	9313928T11
9313928	1422	1433	misoprostol	CHEMICAL	9313928T12
9313928	273	288	prostaglandin I	CHEMICAL	9313928T13
9313928	1590	1609	16,16-dimethyl PGE2	CHEMICAL	9313928T14
9313928	1614	1627	11-deoxy-PGE1	CHEMICAL	9313928T15
9313928	1643	1647	PGE2	CHEMICAL	907
9313928	1652	1656	PGE1	CHEMICAL	9313928T17
9313928	290	292	IP	CHEMICAL	9313928T18
9313928	1698	1707	butaprost	CHEMICAL	9313928T19
9313928	238	253	prostaglandin F	CHEMICAL	9313928T1
9313928	1709	1717	AH-13205	CHEMICAL	9313928T20
9313928	1722	1729	AH-6809	CHEMICAL	9313928T21
9313928	1797	1806	1-OH-PGE1	CHEMICAL	9313928T22
9313928	308	321	thromboxane A	CHEMICAL	9313928T23
9313928	1925	1936	sulprostone	CHEMICAL	9313928T24
9313928	1938	1947	M&B-28767	CHEMICAL	9313928T25
9313928	1949	1957	GR63799X	CHEMICAL	9313928T26
9313928	1959	1972	11-deoxy-PGE1	CHEMICAL	9313928T27
9313928	1974	1993	16,16-dimethyl-PGE2	CHEMICAL	9313928T28
9313928	1998	2012	17-phenyl-PGE2	CHEMICAL	9313928T29
9313928	1154	1168	17-phenyl-PGE2	CHEMICAL	9313928T2
9313928	323	325	TP	CHEMICAL	9313928T30
9313928	2029	2033	PGE2	CHEMICAL	907
9313928	2038	2042	PGE1	CHEMICAL	9313928T32
9313928	2093	2095	IP	CHEMICAL	9313928T33
9313928	2105	2113	iloprost	CHEMICAL	9313928T34
9313928	2115	2126	carbacyclin	CHEMICAL	9313928T35
9313928	2131	2145	isocarbacyclin	CHEMICAL	9313928T36
9313928	2155	2157	TP	CHEMICAL	9313928T37
9313928	2166	2170	STA2	CHEMICAL	9313928T38
9313928	2265	2267	IP	CHEMICAL	9313928T39
9313928	1170	1181	sulprostone	CHEMICAL	9313928T3
9313928	2272	2274	TP	CHEMICAL	9313928T40
9313928	2300	2313	7. 8-Epi-PGF2	CHEMICAL	9313928T41
9313928	2352	2354	IP	CHEMICAL	9313928T42
9313928	2356	2358	TP	CHEMICAL	9313928T43
9313928	2360	2362	FP	CHEMICAL	9313928T44
9313928	382	397	prostaglandin E	CHEMICAL	9313928T45
9313928	529	540	prostanoids	CHEMICAL	9313928T46
9313928	178	188	prostanoid	CHEMICAL	9313928T47
9313928	678	680	DP	CHEMICAL	9313928T48
9313928	682	684	IP	CHEMICAL	9313928T49
9313928	1186	1194	iloprost	CHEMICAL	9313928T4
9313928	689	691	TP	CHEMICAL	9313928T50
9313928	203	218	prostaglandin D	CHEMICAL	9313928T51
9313928	810	814	PGD2	CHEMICAL	9313928T52
9313928	816	822	BW245C	CHEMICAL	9313928T53
9313928	827	833	BW868C	CHEMICAL	9313928T54
9313928	838	840	DP	CHEMICAL	9313928T55
9313928	842	851	cicaprost	CHEMICAL	9313928T56
9313928	853	861	iloprost	CHEMICAL	9313928T57
9313928	866	879	isocabacyclin	CHEMICAL	9313928T58
9313928	884	886	IP	CHEMICAL	9313928T59
9313928	1210	1214	PGE2	CHEMICAL	907
9313928	892	897	S-145	CHEMICAL	9313928T60
9313928	899	904	I-BOP	CHEMICAL	9313928T61
9313928	909	917	GR 32191	CHEMICAL	9313928T62
9313928	922	924	TP	CHEMICAL	9313928T63
9313928	933	935	FP	CHEMICAL	9313928T64
9313928	951	955	PGF2	CHEMICAL	9313928T65
9313928	966	978	fluprostenol	CHEMICAL	9313928T66
9313928	220	222	DP	CHEMICAL	9313928T67
9313928	1018	1022	PGD2	CHEMICAL	9313928T68
9313928	1024	1038	17-phenyl-PGE2	CHEMICAL	9313928T69
9313928	1219	1223	PGE1	CHEMICAL	9313928T6
9313928	1040	1044	STA2	CHEMICAL	9313928T70
9313928	1046	1051	I-BOP	CHEMICAL	9313928T71
9313928	1053	1057	PGE2	CHEMICAL	907
9313928	1062	1071	M&B-28767	CHEMICAL	9313928T73
9313928	74	84	prostanoid	CHEMICAL	9313928T74
9313928	238	267	prostaglandin F (FP) receptor	GENE-Y	9313928T75
9313928	1290	1293	EP1	GENE-Y	13705
9313928	1405	1408	EP3	GENE-Y	9313928T77
9313928	1446	1449	EP2	GENE-Y	9313928T78
9313928	1450	1453	EP3	GENE-Y	9313928T79
9313928	1253	1272	16,16-dimethyl-PGE2	CHEMICAL	9313928T7
9313928	273	302	prostaglandin I (IP) receptor	GENE-Y	9313928T80
9313928	1524	1527	EP2	GENE-Y	9313928T81
9313928	1532	1535	EP4	GENE-Y	9313928T82
9313928	1748	1751	EP2	GENE-Y	9313928T83
9313928	1776	1779	EP4	GENE-Y	9313928T84
9313928	1825	1828	EP4	GENE-Y	9313928T85
9313928	1844	1847	EP2	GENE-Y	9313928T86
9313928	308	335	thromboxane A (TP) receptor	GENE-Y	9313928T87
9313928	1865	1868	EP3	GENE-Y	9313928T88
9313928	2093	2095	IP	GENE-Y	9313928T89
9313928	1307	1313	AH6809	CHEMICAL	9313928T8
9313928	2155	2157	TP	GENE-Y	9313928T90
9313928	344	347	EP1	GENE-Y	13705
9313928	349	352	EP2	GENE-Y	9313928T92
9313928	2265	2267	IP	GENE-Y	9313928T93
9313928	2272	2284	TP receptors	GENE-Y	9313928T94
9313928	354	357	EP3	GENE-Y	9313928T95
9313928	2352	2354	IP	GENE-Y	9313928T96
9313928	2356	2358	TP	GENE-Y	9313928T97
9313928	2360	2362	FP	GENE-Y	9313928T98
9313928	2364	2367	EP2	GENE-Y	9313928T99
9313928	1318	1326	SC-19220	CHEMICAL	9313928T9
9313928	CPR:5	9313928T11	9313928T77
9313928	CPR:5	9313928T12	9313928T78
9313928	CPR:5	9313928T12	9313928T79
9313928	CPR:6	9313928T8	13705
9313928	CPR:6	9313928T9	13705

9336833|t|The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue.
9336833|a|Thymidine kinase from Herpes simplex virus type 1 (TK) was crystallized in an N-terminally truncated but fully active form. The structures of TK complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively. TK catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of dTMP giving rise to an anhydride. The presented TK structures indicate that there are only small differences between these two modes of action. Glu83 serves as a general base in the ester reaction. Arg163 parks at an internal aspartate during ester formation and binds the alpha-phosphate of dTMP during anhydride formation. The bound deoxythymidine leaves a 35 A3 cavity at position 5 of the base and two sequestered water molecules at position 2. Cavity and water molecules reduce the substrate specificity to such an extent that TK can phosphorylate various substrate analogues useful in pharmaceutical applications. TK is structurally homologous to the well-known nucleoside monophosphate kinases but contains large additional peptide segments.
9336833	361	363	dT	CHEMICAL	9336833T10
9336833	369	393	idoxuridine-5'-phosphate	CHEMICAL	9336833T11
9336833	395	406	5-iodo-dUMP	CHEMICAL	9336833T12
9336833	497	499	TK	CHEMICAL	9336833T13
9336833	533	535	dT	CHEMICAL	9336833T14
9336833	552	557	ester	CHEMICAL	9336833T15
9336833	586	590	dTMP	CHEMICAL	9336833T16
9336833	609	618	anhydride	CHEMICAL	9336833T17
9336833	634	636	TK	CHEMICAL	9336833T18
9336833	768	773	ester	CHEMICAL	9336833T19
9336833	121	130	Thymidine	CHEMICAL	4298
9336833	812	821	aspartate	CHEMICAL	9336833T20
9336833	829	834	ester	CHEMICAL	9336833T21
9336833	859	874	alpha-phosphate	CHEMICAL	9336833T22
9336833	878	882	dTMP	CHEMICAL	9336833T23
9336833	890	899	anhydride	CHEMICAL	9336833T24
9336833	199	200	N	CHEMICAL	167
9336833	921	935	deoxythymidine	CHEMICAL	9336833T26
9336833	1118	1120	TK	CHEMICAL	9336833T27
9336833	18	27	thymidine	CHEMICAL	9336833T28
9336833	121	137	Thymidine kinase	GENE-Y	9336833T29
9336833	1125	1138	phosphorylate	CHEMICAL	9336833T2
9336833	1206	1208	TK	GENE-Y	9336833T30
9336833	1254	1286	nucleoside monophosphate kinases	GENE-N	9336833T31
9336833	263	265	TK	GENE-Y	9336833T32
9336833	497	499	TK	GENE-Y	9336833T33
9336833	634	636	TK	GENE-Y	9336833T34
9336833	172	174	TK	GENE-Y	9336833T35
9336833	1118	1120	TK	GENE-Y	9336833T36
9336833	18	34	thymidine kinase	GENE-Y	9336833T37
9336833	1206	1208	TK	CHEMICAL	9336833T3
9336833	1254	1278	nucleoside monophosphate	CHEMICAL	9336833T4
9336833	281	284	ADP	CHEMICAL	9336833T5
9336833	292	295	ATP	CHEMICAL	164
9336833	305	336	deoxythymidine-5'-monophosphate	CHEMICAL	9336833T7
9336833	338	342	dTMP	CHEMICAL	9336833T8
9336833	345	359	deoxythymidine	CHEMICAL	9336833T9

9374794|t|Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.
9374794|a|Cisapride, a gastrointestinal prokinetic agent, is known to cause long Q-T syndrome and ventricular arrhythmias. The cellular mechanism is not known. The human ether-a-go-go-related gene (HERG), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of cisapride. We tested the hypothesis that cisapride blocks HERG. The whole cell patch-clamp recording technique was used to study HERG channels stably expressed heterologously in HEK293 cells. Under voltage-clamp conditions, cisapride block of HERG is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells). Currents rapidly recovered with drug washout. The onset of block by cisapride required channel activation indicative of open or inactivated state blockage. Block of HERG with cisapride after channel activation was voltage dependent. At -20 mV, 10 nM cisapride reduced HERG tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells). At -20 and + 20 mV, 100 nM cisapride reduced tail-current amplitude by 66 and 90%, respectively. We conclude that cisapride is a potent blocker of HERG channels expressed in HEK293 cells. This effect may account for the clinical occurrence of Q-T prolongation and ventricular arrhythmias observed with cisapride.
9374794	971	980	cisapride	CHEMICAL	9374794T10
9374794	1046	1055	cisapride	CHEMICAL	9374794T11
9374794	35	37	K+	CHEMICAL	9374794T12
9374794	87	96	cisapride	CHEMICAL	9374794T13
9374794	1328	1332	HERG	GENE-Y	9374794T14
9374794	252	284	human ether-a-go-go-related gene	GENE-Y	9374794T15
9374794	286	290	HERG	GENE-Y	9374794T16
9374794	501	505	HERG	GENE-Y	9374794T17
9374794	572	576	HERG	GENE-Y	9374794T18
9374794	686	690	HERG	GENE-Y	9374794T19
9374794	98	107	Cisapride	CHEMICAL	594
9374794	961	965	HERG	GENE-Y	9374794T20
9374794	1064	1068	HERG	GENE-Y	9374794T21
9374794	16	45	HERG human cardiac K+ channel	GENE-Y	9374794T22
9374794	1208	1217	cisapride	CHEMICAL	9374794T2
9374794	1295	1304	cisapride	CHEMICAL	9374794T3
9374794	1483	1492	cisapride	CHEMICAL	9374794T4
9374794	348	350	K+	CHEMICAL	9374794T5
9374794	443	452	cisapride	CHEMICAL	9374794T6
9374794	484	493	cisapride	CHEMICAL	9374794T7
9374794	667	676	cisapride	CHEMICAL	9374794T8
9374794	864	873	cisapride	CHEMICAL	9374794T9
9374794	CPR:4	9374794T10	9374794T20
9374794	CPR:4	9374794T11	9374794T21
9374794	CPR:4	9374794T13	9374794T22
9374794	CPR:4	9374794T3	9374794T14
9374794	CPR:4	9374794T7	9374794T17
9374794	CPR:4	9374794T8	9374794T19

9417820|t|Analysis of NMDA receptors in the human spinal cord.
9417820|a|NMDA receptors in postmortem human spinal cord were analyzed using [3H]MK-801 ligand binding and immunoblotting with NMDA receptor subunit-specific antibodies. The average KD for [3H]MK-801 binding was 1.77 nM with a Bmax of 0.103 pmol/mg. The EC50 for stimulation of -3H-MK-801 binding with L-glutamate was 0.34 microM. None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native NMDA receptors showed that NR1, NR2A, NR2C, and NR2D subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half. Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and NR2D subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord NMDA receptors are heteroligimeric receptors assembled by at least three different receptor subunits. These results provide a basis for the development of drugs selectively aimed at spinal cord NMDA receptors for the future treatment of spinal cord disorders.
9417820	1001	1005	NMDA	CHEMICAL	1209
9417820	12	16	NMDA	CHEMICAL	1209
9417820	53	67	NMDA receptors	GENE-N	9417820T12
9417820	170	183	NMDA receptor	GENE-N	9417820T13
9417820	474	488	NMDA receptors	GENE-N	9417820T14
9417820	501	504	NR1	GENE-Y	9417820T15
9417820	506	510	NR2A	GENE-Y	9417820T16
9417820	512	516	NR2C	GENE-N	9417820T17
9417820	522	526	NR2D	GENE-Y	9417820T18
9417820	589	592	NR1	GENE-Y	9417820T19
9417820	53	57	NMDA	CHEMICAL	1209
9417820	699	702	NR1	GENE-Y	9417820T20
9417820	704	708	NR2C	GENE-N	9417820T21
9417820	714	718	NR2D	GENE-Y	9417820T22
9417820	752	756	NR2A	GENE-Y	9417820T23
9417820	807	821	NMDA receptors	GENE-N	9417820T24
9417820	826	851	heteroligimeric receptors	GENE-N	9417820T25
9417820	1001	1015	NMDA receptors	GENE-N	9417820T26
9417820	12	26	NMDA receptors	GENE-N	9417820T27
9417820	170	174	NMDA	CHEMICAL	1209
9417820	232	242	[3H]MK-801	CHEMICAL	9417820T3
9417820	322	331	3H-MK-801	CHEMICAL	9417820T4
9417820	345	356	L-glutamate	CHEMICAL	9417820T5
9417820	474	478	NMDA	CHEMICAL	1209
9417820	120	130	[3H]MK-801	CHEMICAL	9417820T7
9417820	807	811	NMDA	CHEMICAL	1209
9417820	826	841	heteroligimeric	CHEMICAL	9417820T9

9476974|t|Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine.
9476974|a|Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the dopamine receptor antagonist, SCH 23390. Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response. At nonconvulsant doses, the sodium channel blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP. In rats implanted with telemetric devices, cocaine and its analog, CFT, produced a biphasic pharmacological response that consisted of an initial brief and abrupt behavioral arousal associated with a rapid, large increase in BP followed by prolonged, parallel increases in BP and locomotor activity. Pretreatment with SCH 23390 prevented the prolonged but not the initial rapid and brief pressor and activity responses to both cocaine and CFT administration. The present data suggest that the inhibition of dopamine, norepinephrine, or serotonin transporter functions, either alone or in combination, does not mediate the rapid pressor response to cocaine. The sodium channel-blocking action of cocaine per se does not appear to be involved in the rapid pressor response to cocaine. Finally, the present results confirm previous findings that dopaminergic mechanisms mediate the prolonged increases in BP and locomotor activity produced by cocaine.
9476974	249	257	dopamine	CHEMICAL	9476974T10
9476974	1705	1712	cocaine	CHEMICAL	9476974T11
9476974	1871	1878	cocaine	CHEMICAL	9476974T12
9476974	279	288	SCH 23390	CHEMICAL	9476974T13
9476974	113	120	cocaine	CHEMICAL	9476974T14
9476974	290	299	Monoamine	CHEMICAL	9476974T15
9476974	344	351	cocaine	CHEMICAL	9476974T16
9476974	353	365	cocaethylene	CHEMICAL	9476974T17
9476974	367	370	CFT	CHEMICAL	9476974T18
9476974	372	379	betaCIT	CHEMICAL	9476974T19
9476974	1249	1258	SCH 23390	CHEMICAL	9476974T1
9476974	381	384	CPT	CHEMICAL	9476974T20
9476974	386	397	(+)-cocaine	CHEMICAL	9476974T21
9476974	399	409	norcocaine	CHEMICAL	9476974T22
9476974	415	426	benztropine	CHEMICAL	9476974T23
9476974	533	542	monoamine	CHEMICAL	9476974T24
9476974	570	574	BTCP	CHEMICAL	9476974T25
9476974	576	587	indatraline	CHEMICAL	9476974T26
9476974	589	598	GBR 12935	CHEMICAL	9476974T27
9476974	600	608	mazindol	CHEMICAL	9476974T28
9476974	610	621	nomifensine	CHEMICAL	9476974T29
9476974	1358	1365	cocaine	CHEMICAL	9476974T2
9476974	627	636	zimeldine	CHEMICAL	9476974T30
9476974	757	763	sodium	CHEMICAL	9476974T31
9476974	781	799	acetylprocainamide	CHEMICAL	9476974T32
9476974	801	810	dibucaine	CHEMICAL	9476974T33
9476974	812	821	dyclonine	CHEMICAL	9476974T34
9476974	823	833	prilocaine	CHEMICAL	9476974T35
9476974	835	847	proparacaine	CHEMICAL	9476974T36
9476974	849	858	quinidine	CHEMICAL	9476974T37
9476974	864	874	tetracaine	CHEMICAL	9476974T38
9476974	974	981	cocaine	CHEMICAL	9476974T39
9476974	1370	1373	CFT	CHEMICAL	9476974T3
9476974	998	1001	CFT	CHEMICAL	9476974T40
9476974	0	9	Monoamine	CHEMICAL	9476974T41
9476974	26	32	sodium	CHEMICAL	9476974T42
9476974	85	92	cocaine	CHEMICAL	9476974T43
9476974	1438	1488	dopamine, norepinephrine, or serotonin transporter	GENE-N	9476974T44
9476974	1592	1606	sodium channel	GENE-N	9476974T45
9476974	249	266	dopamine receptor	GENE-N	9476974T46
9476974	533	554	monoamine transporter	GENE-N	9476974T47
9476974	757	771	sodium channel	GENE-N	9476974T48
9476974	0	21	Monoamine transporter	GENE-N	9476974T49
9476974	1438	1446	dopamine	CHEMICAL	9476974T4
9476974	26	40	sodium channel	GENE-N	9476974T50
9476974	1448	1462	norepinephrine	CHEMICAL	9476974T5
9476974	1467	1476	serotonin	CHEMICAL	9476974T6
9476974	1579	1586	cocaine	CHEMICAL	9476974T7
9476974	1592	1598	sodium	CHEMICAL	9476974T8
9476974	1626	1633	cocaine	CHEMICAL	9476974T9
9476974	CPR:4	9476974T25	9476974T47
9476974	CPR:4	9476974T26	9476974T47
9476974	CPR:4	9476974T27	9476974T47
9476974	CPR:4	9476974T28	9476974T47
9476974	CPR:4	9476974T29	9476974T47
9476974	CPR:4	9476974T30	9476974T47
9476974	CPR:4	9476974T32	9476974T48
9476974	CPR:4	9476974T33	9476974T48
9476974	CPR:4	9476974T34	9476974T48
9476974	CPR:4	9476974T35	9476974T48
9476974	CPR:4	9476974T36	9476974T48
9476974	CPR:4	9476974T37	9476974T48
9476974	CPR:4	9476974T38	9476974T48
9476974	CPR:4	9476974T9	9476974T45
9476974	CPR:6	9476974T13	9476974T46

9480897|t|Identification of cDNAs encoding two human alpha class glutathione transferases (GSTA3 and GSTA4) and the heterologous expression of GSTA4-4.
9480897|a|The Expressed Sequence Tag database has been searched for examples of previously undescribed human Alpha class glutathione transferases. An incomplete transcript of the previously described GSTA3 gene was identified in a cDNA library derived from 8-9 week placenta. This indicates that the GSTA3 gene is functional and is possibly under specific developmental regulation. A second cDNA, termed GSTA4, was identified in a brain cDNA library. The encoded GSTA4-4 enzyme was expressed in Escherichia coli and was found to be immunologically distinct from GSTA1-1 and to have high activity with alk-2-enals. Although GSTA4-4 appears to be functionally similar to the mouse GST5.7 and rat GST8-8 Alpha class enzymes, sequence comparisons and phylogenetic analysis suggest that GSTA4-4 may be a member of a distinct Alpha class subgroup.
9480897	822	832	rat GST8-8	GENE-Y	9480897T10
9480897	914	921	GSTA4-4	GENE-Y	9480897T11
9480897	235	277	human Alpha class glutathione transferases	GENE-N	9480897T12
9480897	133	140	GSTA4-4	GENE-Y	9480897T13
9480897	37	79	human alpha class glutathione transferases	GENE-N	9480897T14
9480897	81	86	GSTA3	GENE-Y	109195
9480897	91	96	GSTA4	GENE-Y	109196
9480897	253	264	glutathione	CHEMICAL	9480897T1
9480897	55	66	glutathione	CHEMICAL	9480897T2
9480897	332	337	GSTA3	GENE-Y	109195
9480897	432	437	GSTA3	GENE-Y	109195
9480897	536	541	GSTA4	GENE-Y	109196
9480897	595	602	GSTA4-4	GENE-Y	9480897T6
9480897	694	701	GSTA1-1	GENE-Y	9480897T7
9480897	755	762	GSTA4-4	GENE-Y	9480897T8
9480897	805	817	mouse GST5.7	GENE-Y	9480897T9

9551716|t|Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain.
9551716|a|The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of neurotensin receptors, [3H]SR 142948A (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain. The binding of [3H]SR 142948A in brain membrane homogenates was specific, time-dependent, reversible and saturable. [3H]SR 142948A bound to an apparently homogeneous population of sites, with a Kd of 3.5 nM and a Bmax value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with [3H]neurotensin. [3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and neurotensin. Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). The regional distribution of [3H]SR 142948A binding in the rat brain closely matched the distribution of [125I]neurotensin binding. In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.
9551716	1653	1667	[3H]SR 142948A	CHEMICAL	9551716T10
9551716	1748	1759	neurotensin	CHEMICAL	9551716T11
9551716	276	290	[3H]SR 142948A	CHEMICAL	9551716T12
9551716	1829	1840	neurotensin	CHEMICAL	9551716T13
9551716	292	466	2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride	CHEMICAL	9551716T14
9551716	502	516	[3H]SR 142948A	CHEMICAL	9551716T15
9551716	603	617	[3H]SR 142948A	CHEMICAL	9551716T16
9551716	809	824	[3H]neurotensin	CHEMICAL	9551716T17
9551716	826	840	[3H]SR 142948A	CHEMICAL	9551716T18
9551716	866	876	SR 142948A	CHEMICAL	9551716T19
9551716	1133	1142	histamine	CHEMICAL	9551716T1
9551716	922	930	SR 48692	CHEMICAL	9551716T20
9551716	932	1045	2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid	CHEMICAL	9551716T21
9551716	1051	1062	neurotensin	CHEMICAL	9551716T22
9551716	43	54	neurotensin	CHEMICAL	9551716T23
9551716	76	90	[3H]SR 142948A	CHEMICAL	9551716T24
9551716	1133	1154	histamine H1 receptor	GENE-Y	9551716T25
9551716	1279	1304	neurotensin NT1 receptors	GENE-Y	9551716T26
9551716	1391	1416	neurotensin NT2 receptors	GENE-Y	9551716T27
9551716	253	274	neurotensin receptors	GENE-N	9551716T28
9551716	1748	1763	neurotensin NT1	GENE-Y	9551716T29
9551716	1167	1180	levocabastine	CHEMICAL	9551716T2
9551716	1768	1781	NT2 receptors	GENE-Y	9551716T30
9551716	1829	1850	neurotensin receptors	GENE-N	9551716T31
9551716	1051	1062	neurotensin	GENE-Y	9551716T32
9551716	43	63	neurotensin receptor	GENE-N	9551716T33
9551716	1196	1210	[3H]SR 142948A	CHEMICAL	9551716T3
9551716	1253	1266	levocabastine	CHEMICAL	9551716T4
9551716	1279	1290	neurotensin	CHEMICAL	9551716T5
9551716	1367	1380	levocabastine	CHEMICAL	9551716T6
9551716	1506	1520	[3H]SR 142948A	CHEMICAL	9551716T7
9551716	253	264	neurotensin	CHEMICAL	9551716T8
9551716	1582	1599	[125I]neurotensin	CHEMICAL	9551716T9
9551716	CPR:6	9551716T10	9551716T29
9551716	CPR:6	9551716T10	9551716T30
9551716	CPR:6	9551716T12	9551716T28
9551716	CPR:6	9551716T14	9551716T28
9551716	CPR:6	9551716T24	9551716T33
9551716	CPR:6	9551716T2	9551716T25

9557255|t|A new concept of drug delivery for acne.
9557255|a|Adapalene is a stable naphthoic acid derivative that displays a strong retinoid agonist pharmacology. This drug controls cell proliferation and differentiation, and possesses significant anti-inflammatory action. The retinoid action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and RAR gamma. We describe here how an aqueous gel containing adapalene was selected for the topical treatment of acne.
9557255	375	383	RAR beta	GENE-Y	9557255T10
9557255	388	397	RAR gamma	GENE-Y	9557255T11
9557255	41	50	Adapalene	CHEMICAL	203
9557255	258	266	retinoid	CHEMICAL	9557255T2
9557255	63	77	naphthoic acid	CHEMICAL	9557255T3
9557255	277	286	adapalene	CHEMICAL	9557255T4
9557255	351	364	retinoic acid	CHEMICAL	9557255T5
9557255	446	455	adapalene	CHEMICAL	9557255T6
9557255	112	120	retinoid	CHEMICAL	9557255T7
9557255	307	350	ligand-activated gene transcription factors	GENE-N	9557255T8
9557255	351	374	retinoic acid receptors	GENE-N	9557255T9

9584217|t|Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties.
9584217|a|Dihydropyridines (DHPs) block L-type Ca2+ channels more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state. Nisoldipine (a DHP antagonist) blocks the smooth muscle channel more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels. We examined whether this tissue specificity was attributable to differences of inactivation in the two channel types. We expressed cardiac or smooth muscle alpha1C subunits in combination with beta2a and alpha2/delta subunits in human embryonic kidney cells, and used 2 mM Ca2+ as the permeant ion. This system thus reproduces the in vivo topology and charge carrier of the channels while facilitating comparison of the two alpha1C splice variants. Both voltage-dependent and isoform-specific sensitivity of 10 nM nisoldipine inhibition of the channel were demonstrated, with the use of -100 mV as the holding potential for fully reprimed channels and -65 mV to populate the inactivated state. Under drug-free conditions, we characterized fast inactivation (1-sec prepulses) and slow inactivation (3 min prepulses) in the two isoforms. Inactivation parameters were not statistically different in the two channel isoforms; if anything, cardiac channels tended to inactivate more than the smooth muscle channels at relevant voltages. Likewise, the voltage-dependent activation was identical in the two isoforms. We thus conclude that the more potent nisoldipine inhibition of smooth muscle versus cardiac L-type Ca2+ channels is not attributable to differences in channel inactivation or activation. Intrinsic, gating-independent DHP receptor binding affinity differences must be invoked to explain the isoform-specific sensitivity of the DHP block.
9584217	749	753	Ca2+	CHEMICAL	9584217T10
9584217	990	1001	nisoldipine	CHEMICAL	393
9584217	38	45	calcium	CHEMICAL	9584217T12
9584217	58	74	dihydropyridines	CHEMICAL	9584217T13
9584217	1411	1427	cardiac channels	GENE-N	9584217T14
9584217	1463	1485	smooth muscle channels	GENE-N	9584217T15
9584217	1671	1699	cardiac L-type Ca2+ channels	GENE-N	9584217T16
9584217	1804	1816	DHP receptor	GENE-N	9584217T17
9584217	336	357	smooth muscle channel	GENE-N	9584217T18
9584217	159	179	L-type Ca2+ channels	GENE-N	9584217T19
9584217	129	145	Dihydropyridines	CHEMICAL	9584217T1
9584217	618	639	smooth muscle alpha1C	GENE-Y	9584217T20
9584217	31	54	L-type calcium channels	GENE-N	9584217T21
9584217	1624	1635	nisoldipine	CHEMICAL	393
9584217	1686	1690	Ca2+	CHEMICAL	9584217T3
9584217	294	305	Nisoldipine	CHEMICAL	393
9584217	1804	1807	DHP	CHEMICAL	9584217T5
9584217	1913	1916	DHP	CHEMICAL	9584217T6
9584217	309	312	DHP	CHEMICAL	9584217T7
9584217	147	151	DHPs	CHEMICAL	9584217T8
9584217	166	170	Ca2+	CHEMICAL	9584217T9
9584217	CPR:4	9584217T13	9584217T21
9584217	CPR:4	9584217T1	9584217T19
9584217	CPR:4	393	9584217T16
9584217	CPR:4	393	9584217T18
9584217	CPR:4	9584217T7	9584217T18
9584217	CPR:4	9584217T8	9584217T19

9587031|t|Remethylation defects: guidelines for clinical diagnosis and treatment.
9587031|a|The main remethylation defects include disorders which all have defective methionine synthesis in common. Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis. The clinical presentation is characterized by acute neurological distress in early infancy. In childhood, patients present with progressive encephalopathy with an end-stage which has many signs in common with the adult onset form. In fact, both have more or less severe signs of subacute degeneration of the cord. Cobalamin defective patients must be treated with parenteral supplementation of hydroxocobalamin (1-2 mg per dose). Some methylenetetrahydrofolate patients could be folate responsive and must have a high-dosage folate trial. In addition, oral betaine supplementation (2-9 g per day depending on age) appears an effective means to prevent further neurological deterioration.
9587031	888	904	hydroxocobalamin	CHEMICAL	9587031T10
9587031	929	954	methylenetetrahydrofolate	CHEMICAL	9587031T11
9587031	973	979	folate	CHEMICAL	9587031T12
9587031	1051	1058	betaine	CHEMICAL	9587031T13
9587031	178	213	Methylenetetrahydrofolate reductase	GENE-Y	9587031T14
9587031	407	426	methionine synthase	GENE-Y	9587031T15
9587031	178	203	Methylenetetrahydrofolate	CHEMICAL	9587031T1
9587031	233	255	methyltetrahydrofolate	CHEMICAL	9587031T2
9587031	301	317	hydroxocobalamin	CHEMICAL	9587031T3
9587031	356	362	methyl	CHEMICAL	9587031T4
9587031	368	386	adenosyl cobalamin	CHEMICAL	9587031T5
9587031	407	417	methionine	CHEMICAL	9587031T6
9587031	466	482	methyl cobalamin	CHEMICAL	9587031T7
9587031	808	817	Cobalamin	CHEMICAL	9587031T8
9587031	146	156	methionine	CHEMICAL	9587031T9
9587031	CPR:9	9587031T2	9587031T14
9587031	CPR:9	9587031T7	9587031T15

9614060|t|Increased Cat3-mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines.
9614060|a|Arginine transport is important for a number of biological processes in vertebrates, and its transport may be rate-limiting for the production of nitric oxide. The majority of L-Arg transport is mediated by System y+, although several other carriers have been kinetically defined. System y+ cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3. High affinity L-arginine transport was investigated in embryonic fibroblast cells derived from Cat1 knockout mice that lack functional Cat1. Both wild type and knockout cells transport arginine with comparable Km and Vmax. However, the apparent affinity for lysine transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of Cat3-mediated transport. Northern analysis-documented Cat2 mRNA increased 2-fold, whereas Cat3 mRNA levels increased 11-fold in Cat1(-/-) relative to Cat1(+/+) cells. The low affinity Cat2a mRNA was not detectably expressed in these cells. Even though Cat3 expression is normally limited to adult brain, there was a large increase in the amount of Cat3 protein present at the plasma membrane of Cat1(-/-) embryonic fibroblast cells. These results suggest that Cat3 compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity arginine transport.
9614060	1136	1140	Cat3	GENE-Y	9614060T10
9614060	1232	1236	Cat3	GENE-Y	9614060T11
9614060	1279	1283	Cat1	GENE-Y	9614060T12
9614060	1344	1348	Cat3	GENE-Y	9614060T13
9614060	1388	1392	Cat1	GENE-Y	9614060T14
9614060	1415	1419	Cat1	GENE-Y	9614060T15
9614060	315	324	System y+	GENE-N	9614060T16
9614060	389	398	System y+	GENE-N	9614060T17
9614060	483	487	Cat1	GENE-Y	9614060T18
9614060	489	493	Cat2	GENE-Y	9614060T19
9614060	108	116	Arginine	CHEMICAL	119
9614060	499	503	Cat3	GENE-Y	9614060T20
9614060	600	604	Cat1	GENE-Y	9614060T21
9614060	640	644	Cat1	GENE-Y	9614060T22
9614060	803	807	Cat1	GENE-Y	9614060T23
9614060	884	888	Cat3	GENE-Y	9614060T24
9614060	938	942	Cat2	GENE-Y	9614060T25
9614060	974	978	Cat3	GENE-Y	9614060T26
9614060	1012	1016	Cat1	GENE-Y	9614060T27
9614060	1034	1038	Cat1	GENE-Y	9614060T28
9614060	1068	1073	Cat2a	GENE-N	9614060T29
9614060	1477	1485	arginine	CHEMICAL	9614060T2
9614060	10	14	Cat3	GENE-Y	9614060T30
9614060	82	86	Cat1	GENE-Y	9614060T31
9614060	254	266	nitric oxide	CHEMICAL	9614060T3
9614060	284	289	L-Arg	CHEMICAL	119
9614060	408	418	amino acid	CHEMICAL	9614060T5
9614060	519	529	L-arginine	CHEMICAL	9614060T6
9614060	690	698	arginine	CHEMICAL	9614060T7
9614060	763	769	lysine	CHEMICAL	9614060T8
9614060	33	43	amino acid	CHEMICAL	9614060T9
9614060	CPR:9	9614060T2	9614060T13
9614060	CPR:9	119	9614060T16
9614060	CPR:9	9614060T5	9614060T17
9614060	CPR:9	9614060T5	9614060T18
9614060	CPR:9	9614060T5	9614060T19
9614060	CPR:9	9614060T5	9614060T20
9614060	CPR:9	9614060T8	9614060T24
9614060	CPR:9	9614060T9	9614060T30

9712175|t|Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans.
9712175|a|The role of cholecystokinin (CCK) in the regulation of gastric emptying of physiological meals containing solids and liquids in humans remains controversial. We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent CCK-A receptor antagonist lintitript. Gastric emptying was assessed in nine healthy male volunteers using a randomized, double blind, two-period crossover design with oral lintitript (15 mg 1 h prior to meal intake) or placebo on two different days. After ingestion of a pancake (570 kcal) labelled with 500 microCi of 99mTc-sulfur colloid and 500 ml 10% dextrose containing 80 microCi. 111In-DTPA, subjects were studied in a sitting position, using a dual-headed gamma camera. Plasma CCK and pancreatic polypeptide (PP) were measured by a specific RIA. Lintitript distinctly accelerated gastric emptying of solids, while gastric emptying of liquids was not significantly altered. The lag period was shortened by 20% (P<0.05), AUC and half emptying time of solid emptying were lowered by 12% and 13%, respectively (P<0.03). Lintitript markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo. These data provide further evidence for a significant role of CCK in the regulation of gastric emptying of solids. The study demonstrates for the first time the marked gastrokinetic properties of the new CCK-A receptor antagonist lintitript in humans.
9712175	1329	1331	PP	GENE-Y	13340
9712175	121	136	cholecystokinin	GENE-Y	9712175T11
9712175	1434	1437	CCK	GENE-Y	107327
9712175	1576	1590	CCK-A receptor	GENE-Y	9712175T13
9712175	301	304	CCK	GENE-Y	107327
9712175	394	408	CCK-A receptor	GENE-Y	9712175T15
9712175	138	141	CCK	GENE-Y	107327
9712175	879	882	CCK	GENE-Y	107327
9712175	887	909	pancreatic polypeptide	GENE-Y	9712175T18
9712175	911	913	PP	GENE-Y	13340
9712175	1218	1228	Lintitript	CHEMICAL	4667
9712175	28	42	CCK-A receptor	GENE-Y	9712175T20
9712175	1602	1612	lintitript	CHEMICAL	9712175T2
9712175	420	430	lintitript	CHEMICAL	9712175T3
9712175	566	576	lintitript	CHEMICAL	9712175T4
9712175	713	725	99mTc-sulfur	CHEMICAL	9712175T5
9712175	781	791	111In-DTPA	CHEMICAL	9712175T6
9712175	948	958	Lintitript	CHEMICAL	4667
9712175	10	20	lintitript	CHEMICAL	9712175T8
9712175	1268	1271	CCK	GENE-Y	107327
9712175	CPR:3	4667	107327
9712175	CPR:4	4667	13340
9712175	CPR:6	9712175T2	9712175T13
9712175	CPR:6	9712175T3	9712175T15
9712175	CPR:6	9712175T8	9712175T20

9730867|t|Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype.
9730867|a|Cytokine gene expression in T lymphocytes is a strictly regulated process, involving both stimulatory and inhibitory signals. beta-Adrenoceptor (betaAR) agonists are widely used in the treatment of asthma and are able to induce an inhibitory signal on immunological responses after binding to their specific receptors. In this study, the characterization of betaAR subtype(s) (beta1, beta2, and beta3) involved in the regulation of interleukin (IL)-3, IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon-gamma (IFN-gamma) mRNA accumulation was studied by using various betaAR agonists and antagonists. Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol. IL-4 mRNA accumulation was not susceptible to betaAR stimulation. The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist. The selective beta1AR antagonist atenolol (0.3 x 10(-6) M) did not have any effect. Secretion of GM-CSF protein in the presence of increasing concentrations of isoproterenol followed a similar pattern as observed for GM-CSF mRNA. In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (cAMP) levels. Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist BRL 37344 had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels. These data demonstrate that beta-agonist-induced inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation is solely mediated by beta2-adrenoceptors.
9730867	1171	1182	ICI 118,551	CHEMICAL	9730867T10
9730867	174	182	Cytokine	GENE-N	9730867T11
9730867	1262	1269	beta1AR	GENE-Y	9730867T12
9730867	1345	1351	GM-CSF	GENE-Y	9730867T13
9730867	300	317	beta-Adrenoceptor	GENE-N	9730867T14
9730867	1465	1471	GM-CSF	GENE-Y	9730867T15
9730867	1495	1501	betaAR	GENE-N	9730867T16
9730867	1525	1534	IFN-gamma	GENE-Y	9730867T17
9730867	1536	1542	GM-CSF	GENE-Y	9730867T18
9730867	1548	1552	IL-3	GENE-Y	9730867T19
9730867	1201	1208	timolol	CHEMICAL	9730867T1
9730867	1575	1581	GM-CSF	GENE-Y	9730867T20
9730867	319	325	betaAR	GENE-N	9730867T21
9730867	1705	1712	beta3AR	GENE-Y	9730867T22
9730867	1736	1741	Con A	GENE-N	9730867T23
9730867	1835	1843	cytokine	GENE-N	9730867T24
9730867	1860	1867	beta3AR	GENE-Y	9730867T25
9730867	1935	1943	cytokine	GENE-N	9730867T26
9730867	2069	2078	IFN-gamma	GENE-Y	9730867T27
9730867	2080	2086	GM-CSF	GENE-Y	9730867T28
9730867	2092	2096	IL-3	GENE-Y	9730867T29
9730867	1281	1289	atenolol	CHEMICAL	9730867T2
9730867	2137	2156	beta2-adrenoceptors	GENE-Y	9730867T30
9730867	532	538	betaAR	GENE-N	9730867T31
9730867	606	624	interleukin (IL)-3	GENE-Y	9730867T32
9730867	626	630	IL-4	GENE-Y	9730867T33
9730867	632	680	granulocyte-macrophage colony-stimulating factor	GENE-Y	9730867T34
9730867	682	688	GM-CSF	GENE-Y	9730867T35
9730867	695	711	interferon-gamma	GENE-Y	9730867T36
9730867	713	722	IFN-gamma	GENE-Y	9730867T37
9730867	771	777	betaAR	GENE-N	9730867T38
9730867	804	818	Concanavalin A	GENE-N	9730867T39
9730867	1408	1421	isoproterenol	CHEMICAL	9730867T3
9730867	820	825	Con A	GENE-N	9730867T40
9730867	835	844	IFN-gamma	GENE-Y	9730867T41
9730867	846	852	GM-CSF	GENE-Y	9730867T42
9730867	858	862	IL-3	GENE-Y	9730867T43
9730867	920	926	betaAR	GENE-N	9730867T44
9730867	970	977	beta2AR	GENE-Y	9730867T45
9730867	997	1001	IL-4	GENE-Y	9730867T46
9730867	1043	1049	betaAR	GENE-N	9730867T47
9730867	1090	1099	IFN-gamma	GENE-Y	9730867T48
9730867	1101	1107	GM-CSF	GENE-Y	9730867T49
9730867	1650	1680	cyclic adenosine monophosphate	CHEMICAL	9730867T4
9730867	1113	1117	IL-3	GENE-Y	9730867T50
9730867	1152	1159	beta2AR	GENE-Y	9730867T51
9730867	0	17	Beta-adrenoceptor	GENE-N	9730867T52
9730867	146	164	beta2-adrenoceptor	GENE-Y	9730867T53
9730867	41	50	IFN-gamma	GENE-Y	9730867T54
9730867	52	56	IL-3	GENE-Y	9730867T55
9730867	62	68	GM-CSF	GENE-Y	9730867T56
9730867	1682	1686	cAMP	CHEMICAL	2424
9730867	1876	1885	BRL 37344	CHEMICAL	9730867T6
9730867	1993	1997	cAMP	CHEMICAL	2424
9730867	935	948	isoproterenol	CHEMICAL	9730867T8
9730867	986	995	fenoterol	CHEMICAL	9730867T9
9730867	CPR:3	9730867T10	9730867T48
9730867	CPR:3	9730867T10	9730867T49
9730867	CPR:3	9730867T10	9730867T50
9730867	CPR:3	9730867T1	9730867T48
9730867	CPR:3	9730867T1	9730867T49
9730867	CPR:3	9730867T1	9730867T50
9730867	CPR:3	9730867T3	9730867T13
9730867	CPR:3	9730867T3	9730867T15
9730867	CPR:4	9730867T8	9730867T41
9730867	CPR:4	9730867T8	9730867T42
9730867	CPR:4	9730867T8	9730867T43
9730867	CPR:4	9730867T9	9730867T41
9730867	CPR:4	9730867T9	9730867T42
9730867	CPR:4	9730867T9	9730867T43
9730867	CPR:5	9730867T6	9730867T25
9730867	CPR:5	9730867T8	9730867T44
9730867	CPR:5	9730867T9	9730867T45
9730867	CPR:6	9730867T10	9730867T51
9730867	CPR:6	9730867T1	9730867T51
9730867	CPR:6	9730867T2	9730867T12

9760035|t|Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation.
9760035|a|Metabolites of the analogue 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin (carbetocin) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated. Apart from the parent compound two metabolites were identified namely desGlyNH2-carbetocin (carbetocin metabolite I) and desLeuGlyNH2-carbetocin (carbetocin metabolite II). Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as oxytocin. Carbetocin was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of inositol phosphates, as is the case for oxytocin. However, maximal contractile effect of carbetocin was approximately 50% lower than that of oxytocin (2.70 +/- 0.12 g compared to 5.22 +/- 0.26 g) and EC50 was approximately ten times higher (48.0 +/- 8.20 nM compared to 5.62 +/- 1.22 nM). Neither carbetocin metabolite I nor carbetocin metabolite II were able to contract isolated myometrial tissue. All three compounds displayed antagonistic properties against oxytocin in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81). These results indicate that carbetocin is a partial agonist/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists. All three analogues bound to the myometrial vasopressin V1 receptor, albeit with much lower affinities than to the oxytocin receptor. Carbetocin metabolite II showed the weakest binding affinity of 33.7 +/- 7.34 nM compared to 7.24 +/- 0.29 nM for carbetocin and 9.89 + 2.80 nM for carbetocin metabolite I. Only carbetocin bound to the renal vasopressin V2 receptor though the binding affinity was very low (61.3 +/- 14.6 nM).
9760035	1686	1697	vasopressin	CHEMICAL	9760035T10
9760035	1757	1765	oxytocin	CHEMICAL	102
9760035	1776	1786	Carbetocin	CHEMICAL	1269
9760035	1890	1900	carbetocin	CHEMICAL	9760035T13
9760035	1924	1934	carbetocin	CHEMICAL	9760035T14
9760035	1954	1964	carbetocin	CHEMICAL	9760035T15
9760035	1984	1995	vasopressin	CHEMICAL	9760035T16
9760035	391	400	desGlyNH2	CHEMICAL	9760035T17
9760035	401	411	carbetocin	CHEMICAL	9760035T18
9760035	145	192	1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin	CHEMICAL	9760035T19
9760035	1130	1140	carbetocin	CHEMICAL	9760035T1
9760035	413	423	carbetocin	CHEMICAL	9760035T20
9760035	442	454	desLeuGlyNH2	CHEMICAL	9760035T21
9760035	455	465	carbetocin	CHEMICAL	9760035T22
9760035	467	477	carbetocin	CHEMICAL	9760035T23
9760035	499	509	carbetocin	CHEMICAL	9760035T24
9760035	511	521	carbetocin	CHEMICAL	9760035T25
9760035	539	549	carbetocin	CHEMICAL	9760035T26
9760035	611	619	oxytocin	CHEMICAL	102
9760035	655	663	oxytocin	CHEMICAL	102
9760035	665	675	Carbetocin	CHEMICAL	1269
9760035	1267	1275	oxytocin	CHEMICAL	102
9760035	805	824	inositol phosphates	CHEMICAL	9760035T30
9760035	845	853	oxytocin	CHEMICAL	102
9760035	894	904	carbetocin	CHEMICAL	9760035T32
9760035	194	204	carbetocin	CHEMICAL	9760035T33
9760035	946	954	oxytocin	CHEMICAL	102
9760035	1102	1112	carbetocin	CHEMICAL	9760035T35
9760035	0	8	Oxytocin	CHEMICAL	102
9760035	53	63	carbetocin	CHEMICAL	9760035T37
9760035	1267	1275	oxytocin	GENE-Y	9760035T38
9760035	1523	1540	oxytocin receptor	GENE-Y	9760035T39
9760035	1291	1301	carbetocin	CHEMICAL	9760035T3
9760035	1686	1709	vasopressin V1 receptor	GENE-N	9760035T40
9760035	1757	1774	oxytocin receptor	GENE-Y	9760035T41
9760035	1984	2007	vasopressin V2 receptor	GENE-Y	9760035T42
9760035	611	628	oxytocin receptor	GENE-Y	9760035T43
9760035	655	663	oxytocin	GENE-Y	9760035T44
9760035	184	192	oxytocin	GENE-Y	9760035T45
9760035	845	853	oxytocin	GENE-Y	9760035T46
9760035	946	954	oxytocin	GENE-Y	9760035T47
9760035	0	17	Oxytocin receptor	GENE-Y	9760035T48
9760035	1349	1359	carbetocin	CHEMICAL	9760035T4
9760035	1407	1417	carbetocin	CHEMICAL	9760035T5
9760035	1473	1483	carbetocin	CHEMICAL	9760035T6
9760035	1523	1531	oxytocin	CHEMICAL	102
9760035	1567	1577	carbetocin	CHEMICAL	9760035T8
9760035	1595	1605	carbetocin	CHEMICAL	9760035T9
9760035	CPR:4	9760035T3	9760035T38
9760035	CPR:4	9760035T4	9760035T38
9760035	CPR:4	9760035T5	9760035T38
9760035	CPR:5	9760035T6	9760035T39
9760035	CPR:6	9760035T6	9760035T39
9760035	CPR:6	9760035T8	9760035T39
9760035	CPR:6	9760035T9	9760035T39

9843368|t|Crystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 A resolution.
9843368|a|The aromatic amino acid hydroxylases represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by catechol derivatives. Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase (hPheOH), cocrystallized with various potent and well-known catechol inhibitors and refined at a resolution of 2.0 A. The catechols bind by bidentate coordination to each iron in both subunits of the dimer through the catechol hydroxyl groups, forming a blue-green colored ligand-to-metal charge-transfer complex. In addition, Glu330 and Tyr325 are identified as determinant residues in the recognition of the inhibitors. In particular, the interaction with Glu330 conforms to the structural explanation for the pH dependence of catecholamine binding to PheOH, with a pKa value of 5.1 (20 degreesC). The overall structure of the catechol-bound enzyme is very similar to that of the uncomplexed enzyme (rms difference of 0.2 A for the Calpha atoms). Most striking is the replacement of two iron-bound water molecules with catechol hydroxyl groups. This change is consistent with a change in the ligand field symmetry of the high-spin (S = 5/2) Fe(III) from a rhombic to a nearly axial ligand field symmetry as seen upon noradrenaline binding using EPR spectroscopy [Martinez, A., Andersson, K. K., Haavik, J., and Flatmark, T. (1991) Eur. J. Biochem. 198, 675-682]. Crystallographic comparison with the structurally related rat tyrosine hydroxylase binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4. The comparison demonstrates some structural differences at the active site as the potential basis for the different substrate specificity of the two enzymes.
9843368	138	157	aromatic amino acid	CHEMICAL	9843368T10
9843368	575	584	catechols	CHEMICAL	9843368T11
9843368	624	628	iron	CHEMICAL	9843368T12
9843368	671	688	catechol hydroxyl	CHEMICAL	9843368T13
9843368	982	995	catecholamine	CHEMICAL	9843368T14
9843368	1007	1012	PheOH	CHEMICAL	9843368T15
9843368	1082	1090	catechol	CHEMICAL	9843368T16
9843368	39	52	phenylalanine	CHEMICAL	9843368T17
9843368	93	101	catechol	CHEMICAL	9843368T18
9843368	1676	1700	rat tyrosine hydroxylase	GENE-Y	9843368T19
9843368	1274	1291	catechol hydroxyl	CHEMICAL	9843368T1
9843368	421	452	human phenylalanine hydroxylase	GENE-Y	9843368T20
9843368	454	460	hPheOH	GENE-Y	9843368T21
9843368	138	170	aromatic amino acid hydroxylases	GENE-N	9843368T22
9843368	33	81	human phenylalanine hydroxylase catalytic domain	GENE-N	9843368T23
9843368	1472	1485	noradrenaline	CHEMICAL	9843368T2
9843368	1680	1688	tyrosine	CHEMICAL	9843368T3
9843368	1743	1763	7,8-dihydrobiopterin	CHEMICAL	9843368T4
9843368	1807	1816	catechols	CHEMICAL	9843368T5
9843368	307	315	catechol	CHEMICAL	9843368T6
9843368	1891	1900	catechols	CHEMICAL	9843368T7
9843368	427	440	phenylalanine	CHEMICAL	9843368T8
9843368	513	521	catechol	CHEMICAL	9843368T9
9843368	CPR:4	9843368T18	9843368T23
9843368	CPR:4	9843368T6	9843368T22
9843368	CPR:4	9843368T7	9843368T19
9843368	CPR:4	9843368T9	9843368T20
9843368	CPR:4	9843368T9	9843368T21

9891987|t|Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription.
9891987|a|Glucocorticoids (GCs) influence a great variety of cellular functions by at least three important modes of action: the activation (or repression) of genes controlled by binding sites for the glucocorticoid receptor (GR), the induction of apoptosis in lymphocytes and the recently discovered cross-talk to other transcription factors such as NF-kappaB. In this study we systematically compared various natural and synthetic steroid hormones frequently used as therapeutic agents on their ability to mediate these three modes of action. Betamethasone, triamcinolone, dexamethasone and clobetasol turned out to be the best inducers of gene expression and apoptosis. All GCs including the antagonistic compound RU486 efficiently reduced NF-kappaB-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression. Glucocorticoid treatment of cells did not result in elevated IkappaB-alpha expression, but impaired the tumor necrosis factor (TNF)-alpha-induced degradation of IkappaB-alpha without affecting DNA binding of NF-kappaB. The structural requirements for the various functions of glucocorticoids are discussed.
9891987	351	353	GR	GENE-Y	9947
9891987	476	485	NF-kappaB	GENE-N	9891987T11
9891987	868	877	NF-kappaB	GENE-N	9891987T12
9891987	985	987	GR	GENE-Y	9947
9891987	1084	1097	IkappaB-alpha	GENE-Y	9891987T14
9891987	1127	1160	tumor necrosis factor (TNF)-alpha	GENE-Y	9891987T15
9891987	100	109	NF-kappaB	GENE-N	9891987T16
9891987	558	565	steroid	CHEMICAL	9891987T1
9891987	670	683	Betamethasone	CHEMICAL	435
9891987	685	698	triamcinolone	CHEMICAL	9891987T3
9891987	700	713	dexamethasone	CHEMICAL	9891987T4
9891987	718	728	clobetasol	CHEMICAL	9891987T5
9891987	842	847	RU486	CHEMICAL	824
9891987	1184	1197	IkappaB-alpha	GENE-Y	9891987T7
9891987	1231	1240	NF-kappaB	GENE-N	9891987T8
9891987	326	349	glucocorticoid receptor	GENE-Y	9891987T9
9891987	CPR:4	824	9891987T12

9990013|t|Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide.
9990013|a|The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of glucose-induced insulin secretion. Although electrophysiological studies provide clues to the complex control of KATP channels by ATP, MgADP, and pharmacological agents, the molecular mechanism of KATP-channel regulation remains unclear. The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits. Here, we report that MgATP and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to SUR1. Mutation in the Walker A and B motifs of NBF2 of SUR1 abolished this stabilizing effect of MgADP. These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1. The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner. This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.
9990013	1484	1487	ATP	CHEMICAL	164
9990013	115	124	potassium	CHEMICAL	9990013T11
9990013	330	333	ATP	CHEMICAL	164
9990013	335	340	MgADP	CHEMICAL	9990013T13
9990013	509	512	ATP	CHEMICAL	164
9990013	551	561	nucleotide	CHEMICAL	9990013T15
9990013	101	104	ATP	CHEMICAL	164
9990013	651	656	MgATP	CHEMICAL	9990013T17
9990013	661	666	MgADP	CHEMICAL	9990013T18
9990013	680	682	Mg	CHEMICAL	9990013T19
9990013	200	207	glucose	CHEMICAL	9990013T1
9990013	691	705	gamma-thio-ATP	CHEMICAL	9990013T20
9990013	741	763	8-azido-[alpha-32P]ATP	CHEMICAL	9990013T21
9990013	864	869	MgADP	CHEMICAL	9990013T22
9990013	909	920	8-azido-ATP	CHEMICAL	9990013T23
9990013	947	952	MgADP	CHEMICAL	9990013T24
9990013	1013	1018	MgATP	CHEMICAL	9990013T25
9990013	1048	1059	8-azido-ATP	CHEMICAL	9990013T26
9990013	1081	1107	sulfonylurea glibenclamide	CHEMICAL	9990013T27
9990013	23	26	ATP	CHEMICAL	164
9990013	31	36	MgADP	CHEMICAL	9990013T29
9990013	1135	1157	8-azido-[alpha-32P]ATP	CHEMICAL	9990013T2
9990013	44	56	sulfonylurea	CHEMICAL	9990013T30
9990013	82	95	glibenclamide	CHEMICAL	9990013T31
9990013	1163	1167	SUR1	GENE-Y	36123|1938
9990013	216	223	insulin	GENE-Y	9990013T33
9990013	1332	1336	NBFs	GENE-N	9990013T34
9990013	1340	1344	SUR1	GENE-Y	36123|1938
9990013	1471	1475	NBF2	GENE-N	9990013T36
9990013	1508	1512	NBF1	GENE-N	9990013T37
9990013	313	326	KATP channels	GENE-N	9990013T38
9990013	397	409	KATP-channel	GENE-N	9990013T39
9990013	1187	1192	MgADP	CHEMICAL	9990013T3
9990013	442	454	KATP channel	GENE-N	9990013T40
9990013	488	492	SUR1	GENE-Y	36123|1938
9990013	101	140	ATP-sensitive potassium (KATP) channels	GENE-N	9990013T42
9990013	551	575	nucleotide-binding folds	GENE-N	9990013T43
9990013	577	581	NBF1	GENE-N	9990013T44
9990013	586	590	NBF2	GENE-N	9990013T45
9990013	613	619	Kir6.2	GENE-Y	9990013T46
9990013	767	771	SUR1	GENE-Y	36123|1938
9990013	789	810	Walker A and B motifs	GENE-N	9990013T48
9990013	814	818	NBF2	GENE-N	9990013T49
9990013	1196	1201	MgATP	CHEMICAL	9990013T4
9990013	822	826	SUR1	GENE-Y	36123|1938
9990013	898	902	SUR1	GENE-Y	36123|1938
9990013	933	937	NBF1	GENE-N	9990013T52
9990013	982	986	NBF2	GENE-N	9990013T53
9990013	1022	1026	NBF2	GENE-N	9990013T54
9990013	1071	1075	NBF1	GENE-N	9990013T55
9990013	44	65	sulfonylurea receptor	GENE-N	9990013T56
9990013	1302	1312	nucleotide	CHEMICAL	9990013T5
9990013	1359	1372	glibenclamide	CHEMICAL	9990013T6
9990013	1413	1416	ATP	CHEMICAL	164
9990013	1421	1426	MgADP	CHEMICAL	9990013T8
9990013	1456	1461	MgADP	CHEMICAL	9990013T9
9990013	CPR:3	9990013T1	9990013T33
9990013	CPR:9	9990013T25	9990013T54

